

Informe de la reunión de la Comisión de Normas Biológicas de la OMSA

Original: Inglés (EN)

Del 9 al 13 de septiembre de
2024

París

Introducción y contribución de los Miembros

Este informe presenta el trabajo de la Comisión de Normas Biológicas de la OMSA (denominada en adelante «la Comisión»), que se reunió en París, Francia, del 9 al 13 de septiembre de 2024.

Durante la reunión, se aprobaron 27 capítulos del *Manual de Pruebas de Diagnóstico y Vacunas para los Animales Terrestres* de la OMSA (*Manual Terrestre*) para su distribución a los Miembros para la primera ronda de comentarios, un capítulo para la tercera ronda de comentarios, y también se evaluaron seis solicitudes de Centros de Referencia y ocho candidaturas de expertos sustitutos.

La Comisión desea dar las gracias a los siguientes Miembros por sus comentarios escritos sobre el *Manual de Pruebas de Diagnóstico para los Animales Terrestres* de la OMSA (en adelante, «el *Manual Terrestre*»): Canadá, China (Rep. Pop. de), Japón, Nueva Zelanda, Suiza, Reino Unido (RU), Estados Unidos de América (EE.UU.) y los Estados Miembros de la Unión Europea (UE). La Comisión también desea agradecer el valioso asesoramiento y las contribuciones de numerosos expertos de la red científica de la OMSA.

La Comisión examinó todos los comentarios que se habían presentado antes de la fecha límite y que estaban respaldados por una justificación. La Comisión dio las gracias a los Miembros que presentaron sus comentarios a la [Guía para los Miembros de la OMSA y las Organizaciones Internacionales sobre la presentación de comentarios durante el proceso para la elaboración de Normas Internacionales de la OMSA](#). La Comisión desea subrayar que los comentarios recibidos sobre los textos distribuidos con este informe que no se ajusten a esta Guía no se tendrán en cuenta ni se publicarán. La Comisión ha introducido modificaciones en los borradores, en su caso, de la forma habitual mediante «doble subrayado» y «tachado». En los anexos pertinentes, las enmiendas propuestas en esta reunión se destacan en amarillo para distinguirlas de las realizadas anteriormente.

Como se comunicó en el informe de la Comisión de septiembre de 2023, la Directora General acordó poner en marcha progresivamente un proceso para mejorar la transparencia del proceso de elaboración de normas de la OMSA con el fin de mejorar la documentación y la trazabilidad del proceso.

El primer paso de este proceso fue la publicación, en el sitio web de los Delegados (en abril de 2024), de los comentarios enviados por los Miembros y socios de la OMSA y que fueron examinados por la Comisión en su reunión de febrero de 2024. Los comentarios se cargaron en el sitio web de los delegados al mismo tiempo que la publicación del informe de la Comisión. Los comentarios se publicaron en el idioma en que se presentaron.

El siguiente paso en este proceso es la publicación de los comentarios considerados por la Comisión junto con las respuestas de la Comisión en un anexo específico sólo para información (consulte el [Anexo 4](#)). El Anexo 4 contiene las respuestas de la Comisión a los comentarios de la segunda ronda, realizados por los Miembros, recibidos antes de la Sesión General de mayo. En el futuro, todos los comentarios de los Miembros recibidos sobre un borrador de capítulo se presentarán utilizando el formato de tabla que figura en el [Anexo 4](#). En este anexo, los comentarios considerados se publican en la lengua en la que fueron presentados. Las respuestas de la Comisión se presentan en inglés, francés o español según la versión lingüística. Los comentarios y las respuestas de la Comisión se incluyen en la versión inglesa del texto que se distribuyó para recabar comentarios en febrero de 2024. El texto de referencia se presenta únicamente en inglés para las tres versiones lingüísticas (En, Es y Fr) debido a limitaciones de recursos. Tenga en cuenta que los textos para comentarios se presentan en los tres idiomas para mayor claridad; debemos mencionar que el Anexo 4 sólo se refiere a las respuestas a los comentarios de segunda ronda recibidos antes de la SG, y que en el futuro esta misma tabla se presentará para todos los demás comentarios recibidos a partir de septiembre de 2024 en los [Anexos 5 a 33](#).

Valoramos su participación en el proceso normativo de la OMSA. ¡Gracias por su participación en el proceso!

Anexos

El [Anexo 4](#) se presenta únicamente a título informativo, y expone las observaciones examinadas y las respuestas de la Comisión.

Los textos de los [Anexos 5 a 32](#) se presentan para la primera ronda de comentarios, y el [Anexo 33](#) para la tercera ronda.



Cómo presentar los comentarios

La Comisión de Normas Biológicas anima encarecidamente a los Miembros de la OMSA y a las Organizaciones Internacionales con un Acuerdo de Cooperación con la OMSA a participar en la elaboración de las Normas Internacionales de la OMSA mediante la presentación de comentarios sobre los anexos pertinentes de este informe.

La participación de los Miembros y las organizaciones internacionales en el proceso de elaboración de normas mediante la presentación de comentarios es fundamental para garantizar que las normas tengan una base científica y tomen en consideración los diferentes contextos entre los Miembros y las partes interesadas, y puedan aplicarse. Para garantizar que los comentarios sean tenidos en cuenta, deben presentarse dentro del plazo solicitado y en el formato descrito en la [Guide for WOAH Members and International Organisations on submitting comments during the process for the elaboration of WOAH International Standards](#) (Guía) y el [Standard Operating Procedure for WOAH Members and International Organisations to submit comments during the process for the elaboration of WOAH International Standards](#) (procedimiento operativo estándar, POE) disponibles en la página web de los Delegados y en la parte pública de la web de la OMSA.

Los comentarios que no tengan el formato correcto descrito en la [Guía](#) y en el [POE](#) no serán tenidos en cuenta por la Comisión. Cualquier pregunta sobre los requisitos de formato y presentación de observaciones debe enviarse a BSC.Secretariat@woah.org

Como destacó el Presidente de la Comisión en la Sesión General, el objetivo de la primera ronda de comentarios es que los Miembros presenten revisiones en profundidad, realizadas por sus expertos, que mejoren la precisión científica y la pertinencia de los capítulos. Tras la reunión de febrero, los capítulos se envían para la segunda ronda de comentarios como las versiones que se presentarán para su aprobación. Los comentarios de segunda ronda deben consistir únicamente en modificaciones esenciales que sean cruciales para la actualización.

La Comisión de Normas Biológicas desea subrayar que cuando un debate de la Comisión se basa en las aportaciones de un Grupo *ad hoc*, se anima a los Miembros a examinar el informe del Grupo *ad hoc* pertinente junto con el informe de la Comisión. Los informes de los grupos *ad hoc* pueden consultarse en las páginas web específicas del sitio web de la OMSA en [Grupos ad hoc - OMSA - Organización Mundial de Sanidad Animal](#).

Fecha límite para presentar los comentarios

Los comentarios sobre los textos pertinentes de este informe deben llegar a la Sede antes del [27 de diciembre de 2024](#) para ser examinados por la Comisión de Normas Biológicas.

Dónde enviar los comentarios

Todos los comentarios deben enviarse al Departamento Científico: BSC.Secretariat@woah.org

Fecha de la próxima reunión

La Comisión ha tomado nota de las fechas de su próxima reunión: del [3 al 7 de febrero de 2025](#)

Tabla de Contenidos

1. Bienvenida de las Directoras	6
1.1. Directora General	6
1.2. Directora General Adjunta, Normas Internacionales y Ciencia	6
2. Aprobación del orden del día	7
3. Colaboración con otras Comisiones Especializadas	7
3.1. Temas horizontales entre las Comisiones Especializadas	7
3.1.1. Trabajo sobre los animales hospedadores a los que van dirigidas las normas de la OMSA para una enfermedad de los animales terrestres de la Lista de la OMSA	7
3.2. Comisión Científica para las Enfermedades de los Animales	7
3.2.1. Definiciones de caso: paratuberculosis, artritis/encefalitis caprina y Maedi-visna	7
3.2.2. Evaluación de la lista: enfermedad ovina de Nairobi	7
3.2.3. Recomendaciones del Grupo <i>ad hoc</i> sobre scrapie	8
3.3. Comisión de Normas Sanitarias para los Animales Terrestres	8
3.3.1. Reunión de las Mesas	8
3.4. Comisión de Normas Sanitarias para los Animales Acuáticos	8
4. Programa de Trabajo	8
5. Manual de Pruebas de Diagnóstico y de las Vacunas para los animales terrestres	8
5.1. Formato del informe y sistema de comentarios	8
5.2. Revisión de los borradores de capítulos y su aprobación para la distribución para la primera ronda de comentarios de los Miembros	8
5.3. Respuesta de la Comisión a la segunda ronda de comentarios de los Miembros	34
5.4. Informe sobre un estudio interlaboratorio para seguir validando las pruebas serológicas del muermo	36
5.5. Petición de orientaciones sobre taxonomía y uso de nombres comunes de agentes patógenos	36
5.6. Capítulos suprimidos: ¿se siguen considerando validadas las pruebas según las normas de la OMSA?	36
5.7. Situación del <i>Manual Terrestre</i> : actualización de los capítulos seleccionados para el ciclo de revisión 2025/2026	37
5.8. Actualización sobre el proyecto de herramienta de navegación en línea de las normas de la OMSA	38
6. Centros de Referencia de la OMSA	38
6.1. Solicitudes de estatus de Centro de Referencia de la OMSA	38
6.2. Cambios de expertos en los Centros de Referencia de la OMSA	39
6.3. Revisión de las solicitudes nuevas y pendientes de hermanamiento de laboratorios	39
6.4. Evaluación de los informes anuales de los Centros Colaboradores	40
6.5. Centros de referencia que no cumplen los TdR clave: falta de presentación de un informe anual	40
6.6. Información actualizada sobre el progreso del procedimiento de evaluación de los Centros al final de su mandato quinquenal	40
6.7. Actualización de los avances en la recepción de viñetas de los Centros Colaboradores para el hipervínculo: «Cómo podemos ayudarle»	41
6.8. Necesidades de laboratorio, dar visibilidad de lo que se necesita a nivel mundial, no para establecer prioridades sino para informar y presentar las necesidades en los aspectos globales	41
6.9. Cuestiones relacionadas con los procesos de los Laboratorios de Referencia	41
6.9.1. Proceso del Laboratorio de Referencia de la OMSA: ¿quién debe firmar los formularios CU y DOI: el experto, el director del instituto o ambos?	41

6.9.2. ¿Qué se entiende por sistema de gestión de la calidad «equivalente»?.....	41
6.10. Actualización de las tres redes de Laboratorios de Referencia (PPA, PPR y rabia)	42
6.11. Revisión del título del Laboratorio de Referencia para la Nagana: infecciones por tripanosomas salivares y tripanosomosis (transmitida por la mosca tsetse).....	43
7. Reactivos estándar internacionales aprobados por la OMSA	43
8. Seguimiento a partir de la Sesión General	43
9. Conferencias, Talleres y Reuniones	43
9.1. Información actualizada sobre el seminario de la OMSA que se celebrará durante el Simposio WAVLD en Calgary, Canadá, en 2025.....	43
10. Cuestiones de interés para consideración o información	44
10.1. Información actualizada sobre la peste bovina.....	44
10.2. Actualización del proyecto de biobanco virtual.....	44
10.3. Productos veterinarios de calidad inferior y falsificados	45

Lista de Anexos

Anexo 1. Orden del día aprobado	47
Anexo 2. Lista de Participantes	49
Anexo 3. Programa de Trabajo para la Comisión de Normas Biológicas de la OMSA.....	50
Anexo 4. Punto 5.3. - Respuestas de la Comisión a los comentarios de la segunda vuelta de los Miembros sobre el Capítulo 3.9.1. «Peste porcina africana (infección por el virus de la peste porcina africana)»	53
Anexo 5. Capítulo 1.1.3. Transporte de material biológico.....	102
Anexos 6 a 34 Borradores de capítulos para Comentarios de los Miembros	
Anexo 6. Capítulo 1.1.7. Normas aplicables a la secuenciación de alto rendimiento, la bioinformática y la genómica computacional	127
Anexo 7. Capítulo 1.1.9. Pruebas de esterilidad y ausencia de contaminación en los materiales biológicos de uso veterinario.....	134
Anexo 8. Sección 2.1. Diagnóstico de laboratorio (Capítulo 2.1.1. Métodos de laboratorio para los pruebas de sensibilidad de las bacterias frente a los antimicrobianos).....	152
Anexo 9. Capítulo 2.2.1. Desarrollo y optimización de las pruebas de detección de anticuerpos	170
Anexo 10. Capítulo 2.2.2. Desarrollo y optimización de las pruebas de detección de antígeno.....	186
Anexo 11. Capítulo 2.2.3. Desarrollo y optimización de las pruebas de detección de ácido nucleico	202
Anexo 12. Capítulo 2.2.5. Enfoques estadísticos de la validación.....	220
Anexo 13. Capítulo 2.2.8. Comparabilidad entre pruebas tras aplicar cambios a un método analítico validado.....	230
Anexo 14. Capítulo 3.1.2. Enfermedad de Aujeszky (infección por el virus de la enfermedad de Aujeszky).....	239
Anexo 15. Capítulo 3.1.8. Fiebre aftosa (infección por el virus de la fiebre aftosa)	269
Anexo 16. Capítulo 3.1.9. Cowdriosis	304
Anexo 17. Capítulo 3.1.21. Peste bovina (infección por el virus de la peste bovina).....	320
Anexo 18. Capítulo 3.2.4. Nosemosis de las abejas melíferas	342
Anexo 19. Capítulo 3.2.5. Infestación de las abejas melíferas por <i>Tropilaelaps</i> spp.	363
Anexo 20. Sección 3.3. Aves	383

Anexo 21. Capítulo 3.3.2. Bronquitis infecciosa aviar	402
Anexo 22. Capítulo 3.3.4. Influenza aviar (incluida la infección por los virus de la influenza aviar altamente patógenos)	426
Anexo 23. Capítulo 3.4.9. Leucosis bovina enzoótica.....	508
Anexo 24. Capítulo 3.4.13. Teileriosis en bovinos (infección por <i>Theileria annulata</i> , <i>T. orientalis</i> y <i>T. parva</i>)	524
Anexo 25. Capítulo 3.4.14. Tricomonosis.....	553
Anexo 26. Sección 3.6. Equidae.....	582
Anexo 27. Capítulo 3.6.5. Anemia infecciosa equina	618
Anexo 28. Capítulo 3.8.2. Artritis/encefalitis caprina y Maedi-visna.....	637
Anexo 29. Capítulo 3.8.5. Aborto enzoótico de las ovejas (clamidiosis ovina) (infección por <i>Chlamydia abortus</i>).....	655
Anexo 30. Capítulo 3.8.12. Viruela ovina y viruela caprina.....	671
Anexo 31. Capítulo 3.9.2. Peste porcina clásica (infección por el virus de la peste porcina clásica)	683
Anexo 32. Capítulo 3.9.8. Enfermedad vesicular porcina	703
Anexo 33. Sección 3.9. Suidae.....	715

1. Bienvenida de las Directoras

1.1. Directora General

El 9 de septiembre, la Dra. Emmanuelle Soubeyran, Directora General de la OMSA, y la Dra. Montserrat Arroyo, Directora General Adjunta de Normas Internacionales y Ciencia de la OMSA (DGA de NIC de la OMSA), se reunieron con los miembros de la Comisión de Normas Biológicas, la Comisión Científica para las Enfermedades de los Animales y la Comisión de Normas Sanitarias para los Animales Terrestres para dar la bienvenida oficial al nuevo mandato de las Comisiones Especializadas, tras las elecciones celebradas en la 91ª Sesión General, en mayo de 2024.

La Dra. Soubeyran felicitó a los Miembros por su elección y expresó su agradecimiento a las instituciones empleadoras de los Miembros y a los gobiernos nacionales por su apoyo. La Dra. Soubeyran expuso su visión de la innovación, el desarrollo estratégico y el aumento de la visibilidad de la OMSA, haciendo hincapié en la colaboración, la digitalización y las mejoras de los programas mundiales. La Dra. Soubeyran informó a los miembros de la Comisión de que la OMSA continuará con el proceso en curso de revisión de los *Textos Fundamentales* de la Organización, centrándose en la revisión de su gobernanza, para garantizar la credibilidad de la OMSA entre los Miembros y las partes interesadas.

La Dra. Soubeyran destacó el papel fundamental que desempeñan las Comisiones Especializadas, como líderes de la gobernanza técnica de la Organización, y subrayó la importancia de la experiencia de las Comisiones para la reputación y el reconocimiento de la OMSA. También subrayó la importancia de la colaboración entre las Comisiones Especializadas. La Dra. Soubeyran reiteró su compromiso de promover la inclusión y la transparencia, y señaló que era de suma importancia no sólo promover la participación activa de todos los Miembros en el proceso de elaboración de normas, sino también garantizar que las normas de la OMSA respondan a las necesidades de todos los Miembros y puedan aplicarse de manera global.

La Dra. Soubeyran hizo hincapié en las actividades de la OMSA para mejorar la transparencia mediante la publicación de los comentarios de los Miembros. Además, recordó a la Comisión la digitalización de las normas de la OMSA en forma de herramienta de navegación en línea de las normas de la OMSA para facilitar a los usuarios el acceso y la navegación. La inclusión y la participación de los miembros de la Comisión también se destacaron como elementos esenciales de la gobernanza de la OMSA. La Dra. Soubeyran compartió los planes para aumentar la participación de los Miembros en los procesos de establecimiento de normas e informó de que las próximas Conferencias de las Comisiones regionales incluirán sesiones dedicadas a que los miembros compartan las prioridades de los temas de trabajo para el establecimiento de normas. Para concluir, la Dra. Soubeyran reafirmó el compromiso de la OMSA con la transparencia, la base científica y la inclusión en todas sus operaciones.

La Dra. Arroyo destacó la importancia de un nuevo mandato, señalando la incorporación de nuevos Miembros, el equilibrio geográfico y la mejora de la gestión de la carga de trabajo. También subrayó la importancia de la inclusión, la transparencia y la continuidad en el trabajo de cada una de las Comisiones. Para concluir, la Dra. Arroyo destacó los principales puntos del Marco de Gestión del Rendimiento de las Comisiones Especializadas y subrayó su valor para garantizar la mejora continua del trabajo de la Comisión.

Los miembros de la Comisión agradecieron estas actualizaciones y desearon a la Dra. Soubeyran éxito en su mandato como Directora General.

1.2. Directora General Adjunta, Normas Internacionales y Ciencia

La Dra. Montserrat Arroyo, DGA de NIC de la OMSA, se reunió con la Comisión de Normas Biológicas el 10 de septiembre de 2024 y agradeció a los Miembros nuevos y reelegidos sus continuas contribuciones a esta importante área de trabajo de la OMSA.

Al abordar el tema de los Centros de Referencia y Centros Colaboradores de la OMSA, la Dra. Arroyo subrayó su importancia y valor para la organización. También subrayó la necesidad de que ofrezcan un apoyo coherente tanto a los Miembros como a la Organización, garantizando un nivel uniforme de asistencia en toda la red.

Los miembros de la Comisión expresaron su gratitud a la Dra. Arroyo por el excelente apoyo prestado por la Secretaría de la OMSA.

Tras el discurso de la Dra. Arroyo, la Dra. Gillian Mylrea, Jefa del Departamento de Normas, dirigió una sesión de presentación, dado que se trataba del inicio de un nuevo mandato de las Comisiones Especializadas. Se trataba de la última sesión del programa de iniciación de las Comisiones Especializadas, que también incluía sesiones de

iniciación para los nuevos Miembros de las Comisiones, los Presidentes, y los miembros y Secretarías de las Comisiones, para reunirse y debatir la información pertinente para este nuevo mandato.

2. Aprobación del orden del día

Se presentó y aprobó el orden del día propuesto. Presidió la reunión el Dr. Emmanuel Couacy-Hymann y actuó como ponente la Secretaría de la OMSA. El orden del día y la lista de participantes figuran en los [Anexos 1 y 2](#), respectivamente.

3. Colaboración con otras Comisiones Especializadas

3.1. Temas horizontales entre las Comisiones Especializadas

3.1.1. Trabajo sobre los animales hospedadores a los que van dirigidas las normas de la OMSA para una enfermedad de los animales terrestres de la Lista de la OMSA

En su reunión de septiembre de 2023, la Comisión del Código debatió con la Comisión Científica un plan para desarrollar un enfoque claro y coherente para definir cómo se incluirían en el *Código Terrestre* y el *Manual Terrestre* los animales hospedadores de una enfermedad, infección o infestación de la lista de la OMSA. En la reunión de febrero de 2024, ambas Comisiones consideraron una propuesta de las Secretarías para enfocar este trabajo a través de un grupo de trabajo conjunto en el que participasen miembros de las tres Comisiones.

Durante esta reunión, se presentaron a la Comisión de Normas Biológicas las recomendaciones del grupo operativo, que se reunió en cuatro ocasiones para racionalizar la cobertura de los hospedadores animales de las enfermedades de la lista en las normas de la OMSA para las enfermedades de los animales terrestres. Las recomendaciones también se habían remitido al Presidente del Grupo de Trabajo sobre la Fauna Salvaje para que diera su opinión.

La Comisión de Normas Biológicas estuvo de acuerdo con las recomendaciones del grupo de trabajo en el sentido de que el trabajo de elaboración de normas para enfermedades específicas tanto en el *Manual Terrestre* como en el *Código Terrestre* debería estar bien coordinado. La Comisión convino también en que los capítulos del *Manual Terrestre* dedicados a enfermedades específicas deberían incluir una descripción general de la epidemiología de la enfermedad, incluidos los animales susceptibles, en particular aquellos en los que se dan casos de forma natural. Los capítulos del *Manual Terrestre* también deberían tener en cuenta los animales susceptibles que han sido identificados, las muestras apropiadas que deben tomarse de estos animales y las pruebas de diagnóstico que deben aplicarse.

La Comisión acordó poner a prueba las recomendaciones propuestas por el grupo de trabajo con los expertos encargados de revisar los capítulos específicos de enfermedad del *Manual Terrestre* y proporcionar información al grupo de trabajo.

3.2. Comisión Científica para las Enfermedades de los Animales

3.2.1. Definiciones de caso: paratuberculosis, artritis/encefalitis caprina y Maedi-visna

La Comisión de Normas Biológicas examinó las definiciones de caso de paratuberculosis, artritis/encefalitis caprina y Maedi-visna, y presentó sus recomendaciones a la Comisión Científica. En cuanto a la definición de caso de paratuberculosis, se presentó a la Comisión el proyecto de definición de caso de infección por *Mycobacterium avium* subsp. paratuberculosis (paratuberculosis). La Comisión acordó que la paratuberculosis cumplía el criterio 3: existen medios fiables de detección y diagnóstico, se dispone de una definición de caso precisa para identificar claramente los casos y permitir distinguirlos de otras enfermedades, infecciones o infestaciones. Para obtener más detalles sobre la definición de caso, consulte los puntos 9.3.1. y 9.3.2. del orden del día del informe de la reunión de la Comisión Científica, que tuvo lugar del 9 al 13 de septiembre de 2024.

3.2.2. Evaluación de la lista: enfermedad ovina de Nairobi

Véase el punto 9.2.1 del orden del día del informe de la reunión de la Comisión Científica para las Enfermedades de los Animales, celebrada del 9 al 13 de septiembre de 2024.

3.2.3. Recomendaciones del Grupo *ad hoc* sobre scrapie

Véase el punto 5.1.3 del orden del día del informe de la reunión de la Comisión Científica para las Enfermedades de los Animales, celebrada del 9 al 13 de septiembre de 2024.

3.3. Comisión de Normas Sanitarias para los Animales Terrestres

3.3.1. Reunión de las Mesas

Véase el punto 3.2 del orden del día del informe de la reunión de las Comisiones de Normas Sanitarias para los Animales Terrestres, celebrada del 10 a 19 de septiembre de 2024.

3.4. Comisión de Normas Sanitarias para los Animales Acuáticos

Nada a comentar para esta reunión.

4. Programa de Trabajo

Se acordó el programa de trabajo actualizado, que se puede encontrar en el [Anexo 3](#).

5. Manual de Pruebas de Diagnóstico y de las Vacunas para los animales terrestres

Para este punto del orden del día, la Comisión contó con la presencia del Dr. John Pasick, editor consultor del *Manual Terrestre* de la OMSA.

5.1. Formato del informe y sistema de comentarios

En la reunión de febrero de 2024, la Comisión decidió adoptar el formato de tabla utilizado por la Comisión para los Animales Acuáticos para informar mejor sobre la justificación científica de las modificaciones del *Manual Terrestre*. Los Miembros pueden ver y comprender más fácilmente las decisiones de la Comisión sobre los cambios y la respuesta a los comentarios.

5.2. Revisión de los borradores de capítulos y su aprobación para la distribución para la primera ronda de comentarios de los Miembros

La Comisión examinó 30 proyectos de capítulo y aprobó 29 para su distribución, algunos sujetos a la aclaración de ciertos puntos por parte de los expertos, para una primera ronda de comentarios de los Miembros y una eventual propuesta para su adopción por la Asamblea en mayo de 2025. En cuanto al Capítulo 2.3.2., el papel de los organismos oficiales en la reglamentación internacional de los productos biológicos veterinarios, la Comisión acordó eliminarlo del *Manual Terrestre* debido a que este capítulo no se adecua a los objetivos establecidos del *Manual*. Se debería seguir debatiendo el papel del *Manual Terrestre* en la provisión de una norma sobre la reglamentación de los productos biológicos.

- 1.1.3. "Transporte de materiales biológicos": La BSC revisó el Capítulo 1.1.3. "Transporte de materiales biológicos", que había sido actualizado por un experto del Centro Colaborador de la OMSA. El experto lo actualizó para incluir los cambios a las regulaciones de la IATA que se habían realizado desde que el capítulo se adoptó por última vez en 2018.

El Capítulo 1.1.3. "Transporte de materiales biológicos" revisado se presenta como [Anexo 5](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones incluyen:

Sección/párrafo	Modificación
A.1. El remitente (expedidor, consignatario)	Se añadió un punto sobre la importancia de considerar de antemano cualquier medida para mantener la cadena de frío, cuando sea necesario.
Tabla 1. Resumen de la clasificación, categorización,	Actualización de los requisitos para el triple embalaje en la clasificación 6, división 6.2 de mercancías peligrosas

Sección/párrafo	Modificación
identificación y envasado de sustancias infecciosas	
B.4. Materiales biológicos no sujetos a la reglamentación sobre mercancías peligrosas	Añadida una nota sobre la posible necesidad de evaluar el riesgo de los materiales no sujetos a la normativa sobre mercancías peligrosas.
Tabla 3. Ejemplos indicativos de sustancias infecciosas incluidas en la Categoría A	Se actualizó la lista de microorganismos del número ONU 2814 Sustancias infecciosas que afectan a humanos y del número ONU 2900 Sustancias infecciosas que afectan únicamente a los animales.
C. Embalaje	En caso necesario, se han actualizado las especificaciones de las Naciones Unidas para el envasado.
E. Referencias y lecturas complementarias	Actualizada la lista de referencias

- 1.1.7. “Normas para la secuenciación de alto rendimiento, la bioinformática y la genómica computacional”: la BSC revisó el capítulo 1.1.7., que había sido actualizado por expertos del Centro Colaborador de la OMSA.

El capítulo 1.1.7. “Normas para la secuenciación de alto rendimiento, la bioinformática y la genómica computacional” revisado se presenta como [Anexo 6](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son las siguientes:

Sección/párrafo	Modificación
Introducción	Se ha aclarado la afirmación relativa al «nuevo procedimiento», comparándolo con otros ensayos de diagnóstico estándar.
	Se actualizó la redacción para abordar los plazos, reconociendo que la tecnología de secuenciación está en continuo desarrollo.
A. Consideraciones generales	Se añadió la importancia de una estrecha colaboración con expertos en análisis de datos y el tratamiento adecuado de los mismos.
	Se añadió información sobre los requisitos específicos para la selección de plataformas tecnológicas, incluidas consideraciones sobre la tasa de error inherente a la tecnología, los costes y la infraestructura compatible con las mejores prácticas para el flujo de trabajo de secuenciación.
B. Realización de investigaciones veterinarias que incorporen HTS-BCG	Se eliminó la duplicación con la declaración de la Sección B relativa a la inclusión de veterinarios; se añadió la necesidad de contar con directrices internas de laboratorio.
C.1. Normas para el uso de HTS-BCG	Se añadió más información relativa a las estrategias de enriquecimiento, incluyendo cuándo aplicarlas para aumentar la sensibilidad de la técnica; también se mencionaron las particularidades y precauciones a tener en cuenta con HTS.
	Se suprimió la repetición de información relativa a la separación de las áreas de trabajo para evitar la contaminación cruzada.
	Se añadió información sobre las mejores prácticas, la inclusión del uso del índice

Sección/párrafo	Modificación
C.2. Muestreo e informes	Como las plataformas HTS tienen química y protocolos diferentes, es necesario seguir los principios básicos del control de calidad; se añadió que los diferentes controles positivos y negativos deben cubrir diferentes ubicaciones en la placa multipocillo
	Se suprimió el requisito de determinar el sesgo de GC en el objetivo de una prueba, ya que no está claro cómo puede utilizar el usuario esta información para supervisar el rendimiento de la prueba; se incluyó una métrica de calidad adicional para evaluar el rendimiento analítico de las pruebas basadas en HTS en regiones de baja complejidad; se incluyó una descripción de cómo recortar las lecturas.
C.3. Especímenes y preparación de muestras	Se añadieron detalles sobre la transparencia de directrices claras de gestión de metadatos
	Se revisó para incluir que los sistemas de gestión de datos deben especificar qué datos deben enviarse a archivos o bases de datos nacionales o internacionales, al tiempo que se subraya la importancia de considerar cuidadosamente la selección de plataformas para la integración de datos.
	Añadida la importancia de la dilución de muestras en la misma matriz de muestra
E. Referencias y lecturas complementarias	E. Referencias y lecturas complementarias

- 1.1.9. Pruebas de esterilidad y ausencia de contaminación de los materiales biológicos destinados a uso veterinario": el Comité revisó el capítulo 1.1.9., que había sido actualizado por expertos del Centro Colaborador de la OMSA.

El capítulo 1.1.9. revisado «Pruebas de esterilidad y ausencia de contaminación de materiales biológicos destinados a uso veterinario» se presenta como [Anexo 7](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones incluyen:

Sección/párrafo	Modificación
E. Vacunas parasitarias vivas	Añadida una nueva sección sobre vacunas parasitarias
H.5. Ejemplo de procedimiento para pruebas externas de una vacuna parasitaria viva	Añadida una nueva sección sobre procedimientos para vacunas antiparasitarias

- 2.1.1. Metodologías de laboratorio para las pruebas de susceptibilidad antimicrobiana de las bacterias: el Comité de Normas Biológicas revisó el capítulo 2.1.1., que había sido actualizado mediante consulta a expertos de tres Centros Colaboradores de la OMSA a raíz de una solicitud de la Comisión del Código de revisar el capítulo para determinar si proporciona información suficiente y actualizada sobre el establecimiento de puntos de quiebre clínicos.

El Capítulo 2.1.1. revisado «Metodologías de laboratorio para las pruebas de susceptibilidad antimicrobiana de las bacterias» se presenta como [Anexo 8](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son las siguientes:

Sección/párrafo	Modificación
2. Selección de antimicrobianos para pruebas y notificación	Se actualizó esta sección para incluir más buenas prácticas para la selección de antimicrobianos apropiados para las pruebas de susceptibilidad antimicrobiana (AST, por las siglas en inglés de <i>antimicrobial susceptibility tests</i>).
5.1.1. 5.2. Consideraciones para el uso de la metodología de difusión en disco	Añadidas las desventajas de la metodología de difusión en disco
5.2.1. 5.3. Dilución en caldo	Añadidas las ventajas y desventajas de los métodos de dilución en caldo
5.4. 5.4. Orientaciones futuras en la detección de la susceptibilidad/resistencia a los antimicrobianos	Cambio de nombre de la sección «Detección de la resistencia basada en genes», actualización de la subsección sobre pruebas moleculares y adición de una nueva subsección sobre secuenciación del genoma completo.
6. Puntos de quiebre de susceptibilidad antimicrobiana y zona de inhibición	Se cambió el nombre de la sección «Criterios de interpretación de las pruebas de susceptibilidad a los antimicrobianos» y se actualizó el texto para incluir los factores principales que permiten interpretar los datos de una cepa bacteriana aislada como susceptible, de susceptibilidad intermedia o resistente a un antimicrobiano, de tipo natural o no natural.
Tabla 1. Métodos de ensayo de susceptibilidad fenotípica disponibles y sus características	Renombrado de la Tabla 1. Se actualizó la tabla y se suprimieron las columnas «Uso en las pruebas de sensibilidad con fines terapéuticos», «Puntos de quiebre que pueden aplicarse», «Comparabilidad de los resultados» y «Características».
Referencias	Actualización exhaustiva de la lista de referencias

- 2.2.1. Desarrollo y optimización de los ensayos de detección de anticuerpos": la BSC revisó el capítulo 2.2.1., que había sido actualizado por expertos del Centro Colaborador de la OMSA.

El capítulo 2.2.1. revisado El Capítulo 2.2.1. revisado «Desarrollo y optimización de ensayos de detección de anticuerpos» se presenta como [Anexo 9](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son:

Sección/párrafo	Modificación
Introducción	Se añadió información sobre las normas publicadas y los documentos de orientación disponibles para todas las etapas de validación de las pruebas de diagnóstico y las pruebas de aptitud, y se recordó que los principios subyacentes del desarrollo de ensayos sientan las bases de pruebas de diagnóstico de alta calidad que son aptas para los fines previstos.
A.1. A.2.1.2. Objetivo(s) previsto(s) del ensayo de anticuerpos	Se simplificó el texto añadiendo nuevas referencias y referencias cruzadas para reemplazar parte del texto antiguo y una tabla; se recordó a los usuarios <i>del Manual Terrestre</i> que debían leer primero la Sección B.4. 'Etapas 4 - Aplicación del programa', ya que describe las interrelaciones entre sensibilidad y especificidad diagnósticas, falsos positivos y negativos, y valores predictivos positivos y negativos.
A.2.1.3. Panel de referencia positivo y negativo	Se han incluido recomendaciones sobre la conservación a largo plazo de las muestras de suero y las existencias de muestras de trabajo.

Sección/párrafo	Modificación
B.1.2. Especificidad analítica	Se añadió información sobre las muestras que deben evaluarse para determinar la especificidad analítica.
B.3. Etapa 3 - Estimaciones de reproducibilidad y repetibilidad aumentada	Inserción de nuevas referencias sobre reproducibilidad con ejemplos prácticos de pruebas de aptitud y pruebas comparativas entre laboratorios, un estudio de caso para la selección y el uso de paneles de referencia, y la relevancia de los biobancos virtuales para fines de transparencia con respecto a los reactivos y las muestras utilizados durante el desarrollo y la validación de las pruebas.
B.4.1. B.4.2. Interpretación de los resultados y determinación de los valores predictivos	Se cambió el nombre de la sección «Interpretación de los resultados» y se añadieron referencias para la interpretación de los resultados de las pruebas utilizando el valor predictivo (VP) y la razón de verosimilitud (RV).
B.5. B.5. Seguimiento del ensayo	Se añadió una referencia sobre aspectos de la validación de kits para pruebas utilizadas para el diagnóstico y la vigilancia de enfermedades del ganado: responsabilidades del productor y del usuario final. Se insertó un punto en la lista de elementos a considerar cuando se supervisa el rendimiento de los ensayos en el que se pregunta si existen procedimientos que determinen qué hacer cuando los controles están fuera de los límites de aceptación.
Referencias	Se actualizó la lista de referencias

- 2.2.2. “Desarrollo y optimización de ensayos de detección de antígenos”: la BSC revisó el capítulo 2.2.2., que había sido actualizado por expertos del Centro Colaborador de la OMSA.

El Capítulo 2.2.2. revisado “Desarrollo y optimización de los ensayos de detección de antígenos” se presenta como [Anexo 10](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son:

Sección/párrafo	Modificación
Introducción	Se añadió información sobre las normas publicadas y los documentos de orientación disponibles sobre la validación de las pruebas de diagnóstico y los ensayos de aptitud, incluido el diseño, el análisis y la presentación de informes claros, completos y transparentes de los estudios de validación.
A.1. Objetivo(s) previsto(s) del ensayo de antígenos	Se simplificó el texto añadiendo nuevas referencias y referencias cruzadas para sustituir parte del texto antiguo y una tabla.
A.1.1. Finalidad 1a: Contribuir a la demostración de la ausencia de infección en una población definida a) «Libre» con o sin vacunación	Se añadió un nuevo párrafo en el que se explica cómo minimizar las posibilidades de que se produzcan falsos positivos al diseñar una prueba o un algoritmo de prueba.
A1.1. Propósito 1b Contribuir a la demostración de la ausencia de infección en una población definida b) Restablecimiento de la ausencia de infección después de brotes	Se añadió información sobre las pruebas adaptadas o desarrolladas después de un brote, como ejemplo de prueba de ausencia de enfermedad.
A.1.2. Finalidad 2: Certificar la ausencia de infección o la	Se añadió un párrafo con ejemplos, afirmando que una prueba o una combinación de pruebas que ofrezcan una alta sensibilidad diagnóstica

Sección/párrafo	Modificación
presencia del agente patógeno en animales o productos a efectos de comercio o circulación	(DSe) son preferibles a efectos de movimiento y pueden lograrse mediante pruebas paralelas en las que una muestra se considera positiva si cualquiera de las pruebas da positivo.
A.2.1.1. A.2.1.2. Muestras problema	Se advirtió que el transporte de muestras de tejido en un tampón que contenga glicerol puede afectar a la sensibilidad de las pruebas de detección de antígenos; se recomienda enjuagar las muestras de tejido con solución salina tamponada con fosfato antes de procesarlas para las pruebas, ya que ayuda a evitar la inhibición de la fluorescencia.
A.2.1.3. Paneles de referencia positivos y negativos	Se añadió un texto explicativo y una referencia sobre el desarrollo y la validación de una prueba de detección de antígeno por inmunoperoxidasa para mejorar el diagnóstico de la rabia en Indonesia.
A.2.1.4. Antígenos purificados y crudos para la producción de anticuerpos	Actualización exhaustiva de la información de esta sección para abordar el tema con mayor profundidad.
A.2.1.5. Anticuerpos policlonales y monoclonales para ensayos de detección de antígenos	Se añadió una nueva sección con información sobre este importante tema.
B.1.1. Repetibilidad	Se añadió una nueva sección en la que se explica qué es la repetibilidad y por qué es importante.
B.1.2. B.1.3. Especificidad analítica	Ampliación de esta sección sobre ASp para incluir descripciones de selectividad, exclusividad e inclusividad, todos ellos componentes de ASp.
B.1.4. B.1.5. Comparación del método de ensayo estándar con el método de ensayo candidato	Se cambió el nombre de la sección «Comparación del método de ensayo estándar con el ensayo objeto de evaluación (TUE)» y se añadió una descripción de cómo llevar a cabo comparaciones de métodos de ensayo.
Referencias	Actualización de la lista de referencias

- 2.2.3. “Desarrollo y optimización de ensayos de detección de ácidos nucleicos”: la BSC revisó el capítulo 2.2.3., que había sido actualizado por expertos del Centro Colaborador de la OMSA.

El Capítulo 2.2.3. revisado «Desarrollo y optimización de ensayos de detección de ácidos nucleicos» se presenta como [Anexo 11](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son las siguientes:

Sección/párrafo	Modificación
Introducción	Se añadió información sobre las normas publicadas y los documentos de orientación disponibles sobre una serie de aspectos de la validación de las pruebas de diagnóstico, las pruebas de aptitud y el desarrollo y la optimización de los ensayos de detección de ácidos nucleicos.
A.2.1. Garantía de calidad	Se destacó que los laboratorios deben mantener registros precisos almacenados en bases de datos comunales seguras. Para la acreditación de ensayos, deben prepararse informes completos que describan las muestras utilizadas, las réplicas y los análisis estadísticos de cada fase de validación.
A.2.2. Materiales de referencia	Se subrayó que es importante comprender la biología del agente patógeno en cuestión y los tejidos que se infectarán para seleccionar un tipo de

Sección/párrafo	Modificación
	muestra adecuado; la elección del material de referencia debe reflejar el entorno de diagnóstico probable; se incluyeron ejemplos de muestras no invasivas.
A.2.3.1. A.2.3.1. Elección de la prueba	Se cambió el nombre a «Finalidad de la prueba y secuencia diana» y se amplió la información, incluidas las características críticas de diseño para modelar secuencias diana adecuadas y optimizar el diseño de cebadores y sondas.
A.2.3.2. Pruebas auxiliares o complementarias	Se incluyó esta nueva sección.
A.2.3.3. Pruebas en el punto de atención (POC)	Incluida esta nueva sección.
A.2.4. Estudio de viabilidad	Se hizo hincapié en la importancia de probar diferentes cepas o linajes genéticos del agente patógeno diana, así como agentes patógenos con estrecha relación genética, para determinar la inclusividad y exclusividad preliminares, respectivamente, y se dieron ejemplos.
A.2.5.1. A.2.5.2. Control de la especie hospedadora	Se suprimió esta sección.
A.2.5.3. Control de inhibición	Se actualizó a fondo esta sección y se añadieron dos nuevos puntos: i) Controles internos endógenos y ii) Controles externos endógenos.
B.1. Etapa 1 - Criterios analíticos de funcionamiento	Se actualizó a fondo la información de esta sección, especialmente las subsecciones sobre repetibilidad (Cq o PCR cualitativa convencional), especificidad analítica (ASp) y sensibilidad analítica (ASe).
B.4. Etapa 4 - Ejecución de los programas	Se añadió un párrafo sobre la agrupación de muestras, ya que puede aumentar la eficacia de las pruebas en grandes cantidades.
Referencias	Actualización de la lista de referencias

2.2.5. "Enfoques estadísticos de la validación": la BSC revisó el capítulo 2.2.5., que había sido actualizado por expertos del Centro Colaborador de la OMSA.

El Capítulo 2.2.5. «Enfoques estadísticos de la validación» revisado se presenta como [Anexo 12](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son las siguientes:

Capítulo ampliamente actualizado
Este capítulo ha sido objeto de una amplia actualización, con la actualización o sustitución de la mayor parte del texto existente, así como de las figuras y tablas. También se ha reorganizado el orden de las secciones. El orden de las secciones es el siguiente: Sección A. Sensibilidad analítica; B. Especificidad analítica; C. Repetibilidad; D. Sensibilidad diagnóstica y especificidad diagnóstica; E. Reproducibilidad, en sustitución de: A. Repetibilidad del ensayo dentro de un mismo laboratorio; B. Reproducibilidad del ensayo entre laboratorios; C. Sensibilidad analítica (Ase, sinónimo = límite de detección: LOD); D. Especificidad analítica (Asp); E. Rendimiento diagnóstico del ensayo. La sección de referencia también se actualizó a fondo.

- 2.2.8. “Comparabilidad de los ensayos tras cambios menores en un método de ensayo validado”: la BSC revisó el capítulo 2.2.8., que había sido actualizado por expertos del Centro Colaborador de la OMSAH.

El capítulo 2.2.8. “Comparabilidad de los ensayos tras cambios menores en un método de ensayo validado” revisado se presenta como [Anexo 13](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son las siguientes:

Capítulo ampliamente actualizado
Este capítulo ha sido objeto de una amplia actualización, con la actualización o sustitución de la mayor parte del texto existente, así como de las figuras y tablas. También se ha reorganizado el orden de las secciones. El orden de las secciones es el siguiente Sección A. Determinación de los criterios de evaluación y conclusión; B. Límite de detección; C. Repetibilidad; D. Características diagnósticas; E. Comparación de curvas ROC; F. Discusión; G. Sustitución del análisis de datos: A. Establecimiento de experimentos de comparación; B. Inspección visual; C. Repetibilidad; D. Diagrama de Bland-Altman; E. Experimento de límite de detección (LOD); F. Comparación de curvas ROC; G. Discusión y conclusiones; H. Análisis de datos. La sección de referencias también se actualizó a fondo.

- 3.1.2. “Enfermedad de Aujeszky (infección por el virus de la enfermedad de Aujeszky)”: el Comité de Normas Biológicas revisó el apartado 3.1.2., que había sido actualizado por el experto del Laboratorio de Referencia de la OMSA.

El capítulo 3.1.2. «Enfermedad de Aujeszky (infección por el virus de la enfermedad de Aujeszky)» revisado se presenta como [Anexo 14](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son:

Sección/párrafo	Modificación
Resumen	Se actualizó la taxonomía y se eliminó una frase que afirmaba que es posible distinguir entre los anticuerpos resultantes de la infección natural y los de la vacunación con vacunas con genes suprimidos.
A. Introducción	Se actualizó la taxonomía y se añadieron una declaración y referencias a la encefalitis humana asociada a las nuevas cepas variantes.
Tabla 1. Métodos de prueba disponibles para el diagnóstico de la enfermedad de Aujeszky y su finalidad	Se modificó la clasificación de la prueba de aglutinación en látex y ELISA de «+++» a «++» para el propósito «Estado inmunitario en animales individuales o poblaciones post-vacunación» porque a nivel individual estas pruebas no permiten la cuantificación de anticuerpos; se identificó la ELISA como gB y se añadió una fila sobre la ELISA gE.
B.1.2. B.2.1. Identificación del virus mediante la reacción en cadena de la polimerasa	Se actualizó a fondo esta sección y se añadieron tablas con las secuencias de cebadores/sondas y los parámetros de ciclado para la PCR en tiempo real y la PCR convencional.
B.2.2. C.2.2. Enzimoanálisis	Se actualizaron las referencias de esta sección.
C.2.3. Requisitos para la autorización	Se cambió el nombre de la sección «Requisitos para la aprobación reglamentaria» y se aclaró que las pruebas de reversión a la virulencia deben ser coherentes con VICH GL41 (Examen de vacunas veterinarias vivas en animales diana para detectar la ausencia de reversión a la virulencia, 2008).

Sección/párrafo	Modificación
Referencias	Se actualizó la lista de referencias
Apéndices 1 a 6	Añadidos seis apéndices que justifican la elección de los ensayos y sus calificaciones que figuran en la Tabla 1

- 3.1.8. “Fiebre aftosa (infección por el virus de la fiebre aftosa)”: el Comité de Normas Biológicas revisó el Capítulo 3.1.8., que había sido actualizado por los expertos del Laboratorio de Referencia de la OMSA. Los expertos actualizaron principalmente la sección de pruebas de diagnóstico, y seguirán actualizando el capítulo para revisar las secciones de vacunas y vacunas compatibles, y para añadir las tablas de justificación.

El capítulo 3.1.8. «Fiebre aftosa (infección por el virus de la fiebre aftosa)» revisado se presenta como [Anexo 15](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son las siguientes:

Sección/párrafo	Modificación
A. Introducción	Aclarado que el serotipo C no se ha detectado desde 2004 y ahora se considera extinto.
Tabla 1. Métodos de prueba disponibles para el diagnóstico de la fiebre aftosa y su finalidad	Se suprimió la prueba de fijación del complemento por carecer de sensibilidad.
B. B.1. Pruebas de diagnóstico	Se modificó la composición del medio de transporte y se hizo hincapié en que, cuando no se disponga de él, se puede considerar la posibilidad de transportar las muestras al laboratorio refrigeradas o en hielo sin medio de transporte; se ampliaron las recomendaciones para la recogida de hisopos faríngeos de cerdos y se añadieron matrices de muestra alternativas; se ampliaron las instrucciones sobre el uso de la copa Probang para la toma de muestras de líquido esofágico-faríngeo. Se añadió Senecavirus A en toda esta Sección como virus para el que se recomienda el diagnóstico diferencial.
B.1.1. B.1.2. Aislamiento del virus	Se añadió información sobre la elección de la línea celular y las pruebas rutinarias de sensibilidad de las células.
B.1.2.3. B.1.2.3. Prueba del dispositivo de flujo lateral	Se añadió información sobre el kit LFD que ha sido certificado por la OMSA y se hizo hincapié en que los resultados obtenidos con LFD no certificados deben ser confirmados por ensayos de laboratorio validados.
B.1.2.4. B.1.3.3. Prueba de fijación del complemento	Se suprimió la prueba de fijación del complemento por carecer de sensibilidad.
B.1.3.4. B.1.3.5. Ensayo RT-PCR en tiempo real	Se actualizó el protocolo y se añadieron referencias a métodos que contribuyen a reducir los falsos negativos.
B.1.3.6. Epidemiología molecular	Se añadió un enlace a una lista de cepas prototipo del virus de la fiebre aftosa que pueden constituir los puntos de referencia básicos de un árbol filogenético; se añadió una frase que aclara que en las zonas donde los linajes circulantes del virus de la fiebre aftosa son bien conocidos y donde es difícil acceder a la capacidad de secuenciación, los ensayos RT-PCR en tiempo real específicos de linaje pueden permitir una caracterización rápida a un coste relativamente bajo; se añadieron referencias a métodos para

Sección/párrafo	Modificación
	obtener secuencias completas o parciales del virus de la fiebre aftosa mediante Sanger o secuenciación de alto rendimiento.
B.2. Pruebas serológicas	Confirmación de que las pruebas ELISA de proteínas estructurales (SP) pueden ser reactivas entre serotipos, por lo que debe tenerse precaución cuando se utilicen para la vigilancia en lugares en los que puedan estar circulando múltiples serotipos del virus de la fiebre aftosa.
B.2.1 Prueba de neutralización del virus	Se actualizó el procedimiento de la prueba
B.2.2.1 Enzimoinmunoanálisis de competición en fase sólida	Se ha aclarado cómo se calcula el valor de corte
C.5.3.1. Prueba PD50 y C.5.3.2. D.4.1.3. Prueba PGP (protección contra la fiebre aftosa)	Se corrigió el texto para confirmar que los animales vacunados se consideran no protegidos si muestran lesiones de fiebre aftosa en al menos 1 pata en los 7 días siguientes a la inoculación.
D.4.1.4. Coincidencia de vacunas mediante CFT	Suprimida esta sección.
Referencias	Actualizada la lista de referencias.

- 3.1.9. “Cowdriosis”: la BSC revisó el Capítulo 3.1.9., que había sido actualizado por el experto del Laboratorio de Referencia de la OMSA.

El Capítulo 3.1.9. «Cowdriosis» revisado se presenta como [Anexo 16](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones incluyen:

Sección/párrafo	Modificación
B.3.4. ELISA indirecto para MAP1-B panespecífico	Se añadió un nuevo ELISA indirecto panespecífico.
C.2. Preparados de vacunas atenuadas	Se añadió información y una referencia para una vacuna atenuada contra la cowdriosis administrada por vía intramuscular en bovinos, ovinos y cabras de Angora.
Apéndices 1, 2 y 3	Adición de tres apéndices que justifican la elección de las pruebas y su clasificación en la tabla 1 <i>Métodos de prueba disponibles para el diagnóstico de la cowdriosis y su finalidad.</i>

- 3.1.21. “Peste bovina (infección por el virus de la peste bovina)”: la BSC revisó el Capítulo 3.1.21., que había sido actualizado por los expertos del Laboratorio de Referencia de la OMSA.

El Capítulo 3.1.21. «Peste bovina (infección por el virus de la peste bovina)» revisado se presenta como [Anexo 17](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son las siguientes:

Sección/párrafo	Modificación
Resumen	Se subrayó que todas las pruebas de diagnóstico que utilicen material que contenga el virus de la peste bovina (VPB) deben ser realizadas por un Laboratorio de Referencia de la OMSA, y que debe obtenerse una autorización explícita de la FAO ¹ y de la OMSA antes de que pueda llevarse a cabo cualquier actividad de producción de vacunas y de investigación que utilice el VPB vivo o materiales que contengan el VPB en una instalación de conservación de virus de la peste bovina (RHF, por las siglas en inglés de <i>rinderpest holding facilities</i>) aprobada por la FAO y la OMSA.
Tabla 1. Métodos de prueba disponibles para el diagnóstico de la peste bovina y su finalidad	Se suprimió la inmunodifusión en gel de agar (AGID), ya que no es ni específica ni sensible, y el enzimoanálisis de competición (C-ELISA), ya que el kit ya no está disponible; se añadió la reacción en cadena de la polimerasa con transcriptasa inversa (RT-PCR) convencional; se cambió la clasificación del aislamiento del virus con fines de «confirmación de casos clínicos» de «+++» a «+», ya que su falta de sensibilidad significa que no puede ser la prueba recomendada, y se cambió la clasificación de la neutralización del virus con fines de «población libre de infección», «contribuir a las políticas de erradicación», «prevalencia de la infección - vigilancia» y «estado inmunitario en animales individuales o poblaciones después de la vacunación» de «+++» a «++», ya que está limitada por su dificultad y la casi imposibilidad de realizarla a la escala necesaria para la vigilancia
Nota especial post-erradicación	Se aclara que, para el diagnóstico definitivo, las muestras deben enviarse a uno de los Laboratorios de Referencia de la OMSA para la peste bovina y no a una RHF aprobada por la FAO y la OMSA.
B.1. Detección e identificación del agente	Se aclaró que el aislamiento del virus sólo debe ser realizado por un Laboratorio de Referencia de la OMSA y no por una RHF aprobada por la FAO-OMSA.
B.1.2 Detección del antígeno por inmunodifusión en gel de agar	Se suprimió la AGID.
B.1.2 Métodos de detección y caracterización de ácidos nucleicos	Se enfatizó que los métodos de diagnóstico molecular requieren controles positivos y negativos apropiados durante su ejecución y que es esencial una consideración cuidadosa al interpretar los resultados en ausencia de reacciones de control apropiadas.
B.2.1 Enzimoanálisis de competición	Se suprimió el C-ELISA y se añadió una declaración de que se está desarrollando un nuevo ensayo.
C.1.1. C.2.2. Justificación y uso previsto del producto	Se añadió una declaración en la que se indica que se dispone de una reserva conservada de vacunas tras el permiso explícito de la FAO y la OMSA.
C.2.2.2. C.2.3. Requisitos de los sustratos y los medios	Se aclaró que el suero bovino utilizado debe proceder de países libres de fiebre aftosa y con un riesgo insignificante de encefalopatía espongiforme bovina, debe demostrarse que está libre del virus de la diarrea viral bovina y de cualquier otro virus adventicio y que se recomienda el uso de suero irradiado con rayos gamma.
Referencias	Actualización de la lista de referencias
Apéndices 1 a 6	Se añadieron apéndices que justifican la elección de los ensayos y sus calificaciones que figuran en la tabla 1.

¹ FAO: Organización de las Naciones Unidas para la Agricultura y la Alimentación.

- 3.2.4. “Infestación de las abejas melíferas por *Aethina tumida* (pequeño escarabajo de las colmenas)”: la BSC revisó el Capítulo 3.2.4., que había sido actualizado por los expertos del Laboratorio de Referencia de la OMSA.

El Capítulo 3.2.4. “Infestación de las abejas melíferas por *Aethina tumida* (pequeño escarabajo de la colmena)” revisado se presenta como [Anexo 18](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son las siguientes:

Sección/párrafo	Modificación
Resumen	Se añadió una declaración según la cual, en las zonas con riesgo de nuevas introducciones, se recomienda instalar colmenares centinela que consistan en colonias de abejas melíferas reinas plenamente funcionales para atraer y atrapar a los escarabajos adultos.
A. Introducción	Se añadió información sobre la propagación de <i>Aethina tumida</i> , que ha pasado de ser una plaga de la abeja melífera <i>Apis mellifera</i> a mantenerse y multiplicarse en colonias de la especie de abeja melífera asiática <i>Apis cerana</i> e infestar a otros polinizadores sociales como los abejorros (<i>Hymenoptera: Apidae, Bombini</i>) y las abejas sin aguijón (<i>Hymenoptera: Apidae, Meliponini</i>), que se encuentran en regiones tropicales y subtropicales de América, África y Australia.
A.2. Impacto de la plaga	Se subrayó que el impacto del pequeño escarabajo de la colmena sobre <i>Apis cerana</i> está mal documentado, que su impacto sobre las abejas sin aguijón es aún limitado y que se sabe poco sobre su efecto sobre las abejas melíferas y los abejorros silvestres.
Tabla 1. Métodos de prueba disponibles para el diagnóstico de la infestación por <i>Aethina tumida</i> y su finalidad	Se actualizó la tabla añadiendo «Inspección visual de las colonias».
B.1.3. Inspección visual de las colonias	Se añadió información sobre el uso de colonias centinela en el seguimiento de la presencia y propagación del pequeño escarabajo de la colmena, junto con una descripción de una colmena centinela.
B.1.4. B.2.1. Examen de colonias mediante trampas	Se suprimió una afirmación y referencias de que la tierra de diatomeas se probó con éxito en el laboratorio y demostró ser una trampa eficaz en condiciones norteamericanas; se incluyó información sobre las desventajas de utilizar toallitas de microfibra no tejidas, que pueden contaminar la miel y las abejas con microplásticos.
B.2.2. Identificación morfológica de adultos y larvas	Procedimiento de prueba: incluida una descripción de cómo medir la longitud de los escarabajos adultos.
B.2.2.3. Directrices para la identificación de <i>Aethina tumida</i> B.2.3. Identificación molecular	Forma adulta: se actualizó la lista de características morfológicas y se añadió una nueva figura con una foto y un dibujo de una antena de <i>A. tumida</i> . Forma larvaria: se actualizó la lista de características morfológicas, se añadió una nueva figura que muestra los detalles de los tubérculos dorsales de una larva de <i>A. tumida</i> y se ha indicado que, dado que algunas larvas de otras especies de <i>Nitidulidae</i> son morfológicamente muy similares a <i>A. tumida</i> , se recomienda realizar un análisis PCR de confirmación en caso de duda sobre la identificación.

Sección/párrafo	Modificación
B.2.3.1. Preparación de la muestra, equipo y reactivos	Se actualizó la sección para mencionar que, debido a la aparición de variaciones genéticas tras la dispersión mundial de <i>A. tumida</i> , el método recomendado se adaptó añadiendo un cebador modificado para aumentar el nivel de detección de ciertos especímenes procedentes de países de Asia y de la región del Océano Índico.
Referencias y lecturas complementarias	Se cambió el nombre de la sección a «Método de preparación de la muestra, equipo y reactivos» y se añadió información sobre cómo extraer ADN de la muestra
Apéndice 1	Actualización de la lista de referencias.
Resumen	Se añadió un apéndice que justifica la elección de los ensayos y su clasificación en la Tabla 1.

3.2.5. “Infestación de las abejas melíferas por *Tropilaelaps* spp.”: la BSC revisó el Capítulo 3.2.5., que había sido actualizado por el experto del Laboratorio de Referencia de la OMSA.

El Capítulo 3.2.5. “Infestación de las abejas melíferas por *Tropilaelaps* spp.’ revisado se presenta como [Anexo 19](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son las siguientes:

Sección/párrafo	Modificación
Resumen e introducción	Actualización de la taxonomía del género <i>Tropilaelaps</i> .
A. Introducción	Se añadieron las secciones Naturaleza y clasificación del agente patógeno, Potencial zoonótico y requisitos de bioseguridad y bioprotección y Diagnóstico diferencial, y se actualizaron las secciones Ciclo de vida (incluida la adición de una figura) y Descripción e impacto de la enfermedad.
Tabla 1. Métodos de prueba disponibles para el diagnóstico de la infestación de las abejas melíferas por <i>Tropilaelaps</i> spp. y su finalidad	Se actualizó la tabla añadiendo cuatro nuevos métodos de detección e identificación.
B.1.1 Recolección de ácaros	Se cambió de nombre la sección «Examen de las abejas» y se actualizó la información.
B.1.2. Examen de la colonia y de la cría	Se cambió el nombre de la sección «Examen de la cría en celda operculada» y se actualizó la información.
B.1.3. Bump test	Se añadió una declaración en la que se indica que el método puede provocar una mortalidad significativa de las crías y que no es eficaz para detectar <i>Tropilaelaps</i> .
B.1.4. B.2.1. Examen de la colmena	Se cambió el nombre de la sección «Examen de la colmena» y se actualizó la información.
B.2.2. Identificación morfológica de <i>Tropilaelaps</i> spp.	Se añadieron detalles al procedimiento de prueba para evaluar la relación entre la longitud y la anchura del cuerpo del ácaro.

Sección/párrafo	Modificación
B.2.3. Identificación molecular	Se actualizó la información y se añadieron referencias para los métodos moleculares
Referencias	Actualización de la lista de referencias
Apéndice 1	Se añadió un apéndice que justifica la elección de los ensayos y su clasificación en la tabla 1.

3.3.1. "Clamidiosis aviar": la BSC revisó el Capítulo 3.3.1., que había sido actualizado por los expertos del Laboratorio de Referencia de la OMSA.

El Capítulo 3.3.1. "Clamidiosis aviar" revisado se presenta como [Anexo 20](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones incluyen:

Sección/párrafo	Modificación
Resumen	Se actualizó la taxonomía, se mencionó el potencial zoonótico de <i>Chlamydia psittaci</i> , y se subrayó que la PCR es el método de diagnóstico recomendado.
A.1. Descripción e impacto de la enfermedad	Se actualizó la taxonomía y la información sobre las diferentes especies de <i>Chlamydia</i> y las especies aviarias en las que se han detectado y el efecto sobre estas especies.
A.2. A.3. Naturaleza y clasificación del agente patógeno	Se añadió esta nueva Sección.
A.4. Diagnóstico diferencial	Se añadió esta nueva Sección.
A.5. Tabla 1. Métodos de prueba disponibles para el diagnóstico de la clamidiosis aviar y su finalidad	Se suprimió el ensayo de microarray de ADN y se cambió el orden del ELISA y la CFT.
B.1.1. Métodos moleculares	Se destacó que las técnicas de PCR han reemplazado al aislamiento como el método recomendado para la detección de la clamidiosis aviar; si una prueba de PCR o inmunohistoquímica específica para <i>Chlamydiaceae</i> es positiva, pero una prueba específica para la especie <i>C. psittaci</i> es negativa, se debe considerar la especie de clamidia recientemente descrita. Existen PCR en tiempo real específicas para cada especie para su detección específica, así como para la detección de cepas aviarias de <i>C. abortus</i> .
B.1.1.1 Reacción en cadena de la polimerasa convencional	Se subrayó que no se han desarrollado ensayos de PCR convencionales para detectar las especies aviarias recientemente descritas.
B.1.1.2. PCR en tiempo real	Se incluyó una tabla de ejemplos de ensayos de PCR en tiempo real validados y publicados para el cribado y la identificación de especies de <i>C. psittaci</i> .
B.1.1.3. B.1.1.4. Microarray de ADN	Se suprimió este ensayo.

Sección/párrafo	Modificación
B.1.5. B.2. Detección de antígenos	Se suprimió el enzimoimmunoanálisis de esta sección.
B.2.1. Proteína recombinante mayor de la membrana externa ELISA	Se añadió una declaración de que no se dispone de kits ELISA comerciales para la detección de anticuerpos contra <i>C. psittaci</i> y otras clamidias aviares.
C. Requisitos para las vacunas	Aunque no se dispone de vacunas comerciales, se proporcionó información sobre vacunas candidatas, principalmente plásmidos o proteínas recombinantes.
Referencias	Actualización de la lista de referencias.
Apéndices 1 a 4	Se añadieron cuatro apéndices que justifican la elección de los ensayos y sus calificaciones que figuran en la Tabla 1.

- 3.3.2. “Bronquitis infecciosa aviar”: el Comité revisó el Capítulo 3.3.2., que había sido actualizado por expertos en la enfermedad.

El Capítulo 3.3.2. «Bronquitis infecciosa aviar» revisado se presenta como [Anexo 21](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones incluyen:

Sección/párrafo	Modificación
A. Introducción	Se subrayó la importancia de adoptar un enfoque diagnóstico amplio con diagnóstico diferencial porque las infecciones por el virus de la bronquitis infecciosa aviar (IBV) son inespecíficas.
Tabla 1. Métodos de prueba disponibles para el diagnóstico del virus de la bronquitis infecciosa y su finalidad	Aclaración de las dos RT-PCR existentes: la primera es RT-PCR «convencional» (detección del ARN derivado del virus), la segunda es RT-PCR en tiempo real «(gen conservado)», y se añadió una tercera: RT-PCR en tiempo real (específica de linaje o genotipo).
B.1.5. B.1.5.1. Identificación del genotipo	Se cambió el nombre de la sección a identificación de linaje o genotipo para alinearla con las pruebas de la Tabla 1.
B.1.5.2. Análisis RT-PCR en tiempo real	Se añadió una tabla de secuencias de cebadores/sondas y parámetros de ciclado para un método de RT-PCR en tiempo real.
C.2.1.1. C.2.3. Características biológicas del inóculo primario	Se añadieron una declaración y una referencia sobre la investigación que demuestra que la proteína Beaudette S expresada a partir de un fondo genómico M41 virulento atenúa el virus recombinante y proporciona protección contra el desafío con M41 virulento, lo que indica que el paso múltiple puede no afectar la antigenicidad con respecto a la protección.
C.2.3.2. C.2.3.2. Requisitos de inocuidad	Se ha aclarado que las pruebas de reversión a la virulencia deben ser coherentes con la norma VICH GL41 (Examen de vacunas veterinarias vivas en animales diana para detectar la ausencia de reversión a la virulencia, 2008).
Referencias	Actualización de la lista de referencias.

Sección/párrafo	Modificación
Apéndices 1 a 6	Se añadieron apéndices que justifican la elección de los ensayos y sus calificaciones en la tabla 1.

- 3.3.4. “Influenza aviar (incluida la infección por virus de la influenza aviar de alta patogenicidad)”: la BSC revisó el Capítulo 3.3.4., que había sido actualizado por los expertos del Laboratorio de Referencia de la OMSA.

El Capítulo 3.3.4. “Influenza aviar (incluida la infección por virus de la influenza aviar de alta patogenicidad)” revisado se presenta como [Anexo 22](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son:

Sección/párrafo	Modificación
Resumen	Se actualizó exhaustivamente el resumen, incluyendo la taxonomía, los métodos de detección e identificación y las pruebas serológicas.
A. Introducción	Se actualizó la taxonomía, se aclaró que algunas cepas del virus de la influenza aviar han causado infecciones zoonóticas esporádicas y que algunos subtipos se han destacado como riesgos pandémicos potenciales en caso de que se produzcan mutaciones adicionales que apoyen la transmisión sostenida de persona a persona; que la mutación en el sitio de escisión de la proteína H presenta un riesgo de que los virus H5 o H7 de baja patogenicidad se vuelvan altamente patógenos; y que cuando la presión de infección es alta, se han descrito eventos de propagación a especies no aviares, incluidos mamíferos terrestres y marinos.
Tabla 1. Métodos de prueba disponibles para el diagnóstico de la influenza aviar y su finalidad	Se añadió «(incluidas las manadas vacunadas)» al objetivo «Prevalencia de la infección - vigilancia»; se aumentó la clasificación de la RT-PCR en tiempo real para los objetivos «Población libre de infección», «Contribuir a las políticas de erradicación» y «Prevalencia de la infección - vigilancia» de «++» a «+++»; se añadió la RT-PCR convencional.
B.1.1. B.1.3. Muestras para el aislamiento del virus	Se cambió el nombre de la sección «Muestras para la detección de virus», se incluyó información sobre el uso de muestras ambientales para la vigilancia activa y, dada la capacidad demostrada de ciertos clados para infectar a una amplia gama de mamíferos, se incluyó información sobre los tejidos adecuados para tomar muestras en estas especies. Por último, se añadió un párrafo sobre el uso de tecnologías y reactivos que aumentan la capacidad de detectar y diagnosticar infecciones víricas en zonas remotas donde las instalaciones de laboratorio son limitadas y el mantenimiento de la cadena de frío es difícil, advirtiendo de que los procesos implicados inactivarán la infectividad del virus, impidiendo así la caracterización del virus por aislamiento.
B.1.4. B.1.3. Evaluación de la patogenicidad	Actualización de los métodos y criterios adoptados por la OMSA para determinar la patogenicidad de un virus de la influenza A, incluidas las técnicas de RT-PCR en tiempo real fundamentales para definir rápidamente el patotipo vírico.
B.1.5. B.1.5.1. Captura de antígenos y técnicas moleculares	Se añadió un resumen esquemático de las pruebas de cribado, los ensayos de subtipificación y los métodos de caracterización del virus de la influenza A, así como una tabla de secuencias de cebadores/sondas y parámetros de ciclado para un método de PCR en tiempo real y convencional; dado que las técnicas moleculares se utilizan preferentemente para el diagnóstico, la detección y la caracterización de los virus de la influenza A, se ha subrayado

Sección/párrafo	Modificación
	<p>la importancia de seguir protocolos estrictos para evitar la contaminación cruzada entre muestras clínicas, y que las metodologías de las pruebas de detección del ARN deben validarse conforme a la norma de la OMSA. Esta Sección subraya la importancia de utilizar ensayos y enfoques de diagnóstico diseñados adecuadamente, de mantener herramientas sensibles y específicas para la subtipificación mediante el seguimiento y las actualizaciones rutinarias del diseño de cebadores/sondas para adaptarse a la evolución genética en las regiones génicas a las que se dirigen los ensayos moleculares. Cuando se descarta la presencia de subtipos H5/H7 en muestras clínicas que dan positivo para la influenza A, las investigaciones de diagnóstico deben continuar hasta la identificación del subtipo. Debido a las implicaciones económicas para el sector avícola y al riesgo zoonótico en zonas endémicas, la detección del subtipo H9 suele tener prioridad sobre la de otros subtipos. Debido a las dificultades para mantener herramientas de PCR de subtipado sensibles y específicas, los protocolos que aprovechan la detección de la influenza A seguida de intentos de subtipado son los más adecuados para lograr el mayor éxito. En los laboratorios con escasos recursos, la detección del virus de la influenza aviar puede verse dificultada por la necesidad de mantener una cadena de frío para los reactivos húmedos, junto con el suministro adecuado de reactivos. En tales circunstancias, debería considerarse el uso de reactivos moleculares liofilizados para aumentar la estabilidad térmica y maximizar la capacidad de vigilancia.</p>
<p>B.1.5.4. Epidemiología molecular y filogenética</p>	<p>Se añadió información sobre el desarrollo de criterios para distinguir grupos genéticos específicos del gen de la hemaglutinina (HA) H5 del linaje Gs/GD, incluido un sistema de nomenclatura dinámica para definir subclados dentro de ese linaje. La continua circulación de virus H5N1 de la influenza aviar altamente patógena en aves de corral o silvestres ha dado lugar a la evolución continua de la HA H5 con la aparición de múltiples subclados de HA. El pleno acceso a secuencias genéticas completas y a los metadatos relacionados de los brotes de IA es crucial no sólo para identificar los determinantes de su transmisibilidad y patogenicidad, sino también para reconstruir la dinámica de diseminación de la IAV y seguir la evolución del virus. Dado que existe una necesidad urgente de hacer públicos los datos genómicos durante las epidemias en curso, en caso de dificultades para generar y analizar los datos de la secuencia del genoma completo, debería consultarse a los laboratorios de referencia de la FAO o de la OMSA.</p>
<p>B.2.1. B.2.3. Enzimoimmunoanálisis</p>	<p>Se añadió una declaración en el sentido de que para analizar muestras de suero obtenidas de mamíferos para detectar la exposición a los virus de la influenza aviar, se puede realizar un cribado preliminar con un kit ELISA competitivo multiespecie disponible en el mercado dirigido a anticuerpos específicos para la nucleoproteína (NP) de los virus de la influenza de tipo A, pero su validez en las especies objeto de examen debe evaluarse antes de su uso. Se han desarrollado ensayos serológicos multiplex que ofrecen opciones para mejorar el ancho de banda del diagnóstico, pero se requiere una mayor validación para demostrar que son adecuados para su propósito en entornos de laboratorio de rutina</p>
<p>B.2.3.2. B.2.3.2. Prueba de inhibición de la hemoaglutinación</p>	<p>Se subrayó que cuando los virus de la influenza A de origen aviar emergen en especies no aviarias, puede ser necesaria la detección de anticuerpos contra la influenza aviar en mamíferos: para ello es necesario un pretratamiento de los sueros.</p>
<p>C. Requisitos para las vacunas</p>	<p>Se actualizó la información de referencia, ya que las dos últimas décadas han estado marcadas por un cambio significativo en la dinámica epidemiológica y ecológica de los virus de la IAAP y ha surgido un número cada vez mayor de linajes de IAAP en aves de corral.</p>

Sección/párrafo	Modificación
C.1.1. C.2.2. Justificación y uso previsto del producto	Se cambió el nombre de la sección «Justificación y uso previsto de las vacunas» y se actualizaron el texto y las referencias, incluyendo una lista de las condiciones que determinan las evaluaciones de riesgo sobre la aplicación de la vacunación contra la IAAP en las aves de corral.
C.2.2.4. C.2.3.1. Pruebas del lote de producto final	Potencia de los lotes: se mencionó que, debido a su capacidad para bloquear la adhesión del virus y su entrada en las células del hospedador de los virus de la influenza de tipo A, los anticuerpos contra la proteína HA son reconocidos como los mediadores más potentes de la resistencia a la infección por influenza y se consideran el principal correlato inmunitario de protección
C.2.3.2. Requisitos de eficacia	Para la producción animal: se subrayó que el uso de antígenos apropiados es fundamental para lograr una eficacia adecuada de la vacuna contra los virus de campo y para minimizar los fallos de la vacuna, independientemente de la plataforma de la vacuna.
C.3.1. C.3.1. Vacunas disponibles y sus ventajas	Se actualizó la sección «Vacunas basadas en la biotecnología» con los últimos avances en tecnología de vacunas y estrategias de vacunación de varios Miembros de la OMSA.
C.4. Métodos de vigilancia de la influenza aviar	Se cambió el nombre de la Sección 'Detección de la infección en manadas vacunadas y aves vacunadas' y enfatizó que los métodos moleculares son las herramientas más sensibles utilizadas para monitorear las manadas de aves vacunadas en busca de virus de IA circulantes. Se mencionó que la vigilancia serológica DIVA (diferenciación de animales infectados de vacunados) en aves de corral de larga vida es útil para demostrar retrospectivamente la ausencia de infección en una región, zona o compartimento, ya que demuestra la ausencia de infección en el período precedente. Sin embargo, uno de los problemas de las pruebas serológicas DIVA es la dificultad de interpretar los resultados en un escenario de co-circulación endémica de los virus de la IABP (influenza aviar de baja patogenicidad) en las aves de corral. Por último, subrayó que la aplicación de cualquier plan de vacunación debe ir acompañada de un sistema de vigilancia reforzada, que debe desarrollarse en función del escenario epidemiológico, el contexto socioeconómico y el objetivo de la vacunación.
C.5. Evaluación y actualización continuas de las cepas de inóculos primarios de vacunas para proteger contra las cepas de virus de campo variantes emergentes	Se mencionó la iniciativa OFFLU (OFFLU <i>Avian Influenza Matching</i> - AIM) para proporcionar información mejorada sobre las características antigénicas de los VIA (virus de la influenza aviar) para apoyar los programas de vacunación, en particular con la selección de cepas vacunales. Se publicarán periódicamente actualizaciones globales en el sitio web de la OFFLU para proporcionar información sobre las características antigénicas de los AIV circulantes, incluidos los ensayos de desafío de vacunas, que pueden respaldar las decisiones a la hora de diseñar o modificar los programas de vacunación.
Referencias	Actualización de la lista de referencias
Apéndices 2 a 7	Se añadieron seis apéndices que justifican la elección de los ensayos y sus clasificaciones que figuran en la tabla 1.

- 3.4.9. «Leucosis bovina enzoótica»: la BSC revisó el Capítulo 3.4.9., que había sido actualizado por los expertos del Laboratorio de Referencia de la OMSA.

El Capítulo 3.4.9. «Leucosis bovina enzoótica» revisado se presenta como [Anexo 23](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son las siguientes:

Sección/párrafo	Modificación
Resumen	Se aclaró que la infección es de por vida y provoca una respuesta persistente de anticuerpos.
A. Introducción	Se han creado nuevas secciones: A.1. A.2. «Naturaleza y clasificación del agente patógeno»; A.3. «Potencial zoonótico y bioseguridad»; A.4. «Diagnóstico diferencial»; y se ha trasladado la información sobre la leucosis bovina esporádica, la presencia del virus de la leucosis bovina en células mononucleares de sangre periférica (CMSP) y las infecciones naturales y experimentales a las secciones correspondientes de nueva creación.
Referencias	Actualización de la lista de referencias
Apéndices 1 y 2	Se añadieron dos apéndices que justifican la elección de los ensayos y su clasificación en la Tabla 1.

- 3.4.13. “Theileriosis en bovinos (infección por *Theileria annulata*, *T. orientalis* y *T. parva*)”: la BSC revisó el Capítulo 3.4.13., que había sido actualizado por un experto del Laboratorio de Referencia de la OMSA.

El Capítulo 3.4.13. “Theileriosis en bovinos (infección por *Theileria annulata*, *T. orientalis* y *T. parva*)’ revisado se presenta como [Anexo 24](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son las siguientes:

Sección/párrafo	Modificación
Resumen	Se añadió información sobre <i>Theileria orientalis</i> . Aunque el Código Terrestre establece que <i>Theileria</i> engloba <i>T. annulata</i> , <i>T. orientalis</i> Ikeda, <i>T. orientalis</i> Chitose y <i>T. parva</i> , se aclaró que aún no existen pruebas serológicas para las cepas de <i>T. orientalis</i> Chitose o Ikeda.
A. Introducción	Se aclaró que <i>T. parva</i> causa tres síndromes de enfermedad que difieren en el origen del parásito; se suprimió la información sobre <i>T. lestoquardi</i> y sobre la respuesta inmunitaria a los parásitos theileriae.
Tabla 1. Métodos de prueba disponibles para el diagnóstico de la teileriosis y su finalidad	Modificación de las calificaciones de la PCR para los objetivos «Población libre de infección» y «Prevalencia de la infección - vigilancia» de «+» a «+++» y para el objetivo «Animal individual libre de infección antes del desplazamiento» de «++» a «+++» debido a su sensibilidad, especificidad y capacidad para detectar el parásito; ampliación de la nota a pie de página en la que se indica que la detección del agente y la serología son necesarias conjuntamente para la certificación del desplazamiento de animales para el comercio porque la parasitemia puede fluctuar por debajo de los límites de detección del agente en los animales portadores, mientras que los anticuerpos pueden seguir detectándose utilizando la serología. Por el contrario, en la infección temprana, o en los casos en que un portador no está expuesto al vector y al desafío del parásito, el título de anticuerpos puede caer por debajo del límite de detección, mientras que sigue siendo positivo respecto al agente.

Sección/párrafo	Modificación
B.1.2. B.2.1. Métodos moleculares	Declaró que los ensayos de PCR en tiempo real que utilizan sondas hidrolizadas o específicas de la especie han reemplazado en gran medida los ensayos de PCR convencionales en los laboratorios de diagnóstico debido a su facilidad de uso y para evitar la contaminación y que se ha desarrollado una PCR multiplex en tiempo real que puede detectar y diferenciar las cepas buffeli, Ikeda, chitose y tipo 5; se actualizó la Tabla 2 'Cebadores y sondas de PCR para la detección de <i>Theileria annulata</i> o <i>T. parva</i> ' e incluyó <i>T. orientalis</i>
B.2.2. Enzimoinmunoanálisis	El antígeno PIM muestra reactividad cruzada entre <i>T. parva</i> y <i>T. sp.</i> (búfalo) y debe considerarse como un factor de confusión en caso de contacto entre búfalos africanos y bovinos.
Referencias	Actualización de la lista de referencias.
Apéndice 1	Adición de un apéndice que justifica la elección de las pruebas y su clasificación en la Tabla 1.

- 3.4.14. «Tricomonosis»: la BSC revisó el Capítulo 3.4.14., que había sido actualizado por expertos del Centro Colaborador de la OMSA en consulta con un experto especializado en la enfermedad.

El Capítulo 3.4.14. revisado 'Tricomonosis' revisado se presenta como [Anexo 25](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son las siguientes:

Sección/párrafo	Modificación
Resumen	Se aclaró que las pruebas ELISA desarrolladas para detectar IgG entera, IgG1 e IgG2 en el suero e IgA en el moco vaginal se aplican más comúnmente para confirmar el estado inmunitario en animales individuales o poblaciones post-vacunación. Se aclara que la eficacia de varias vacunas experimentales de células enteras y extractos purificados de membrana de <i>Trichostrongylus axei</i> demuestra que las tasas de eliminación de <i>T. foetus</i> son más cortas en comparación con las novillas no vacunadas, que las vacunas de subunidades son menos eficaces y que no se han desarrollado vacunas recombinantes.
A. Introducción	Se han creado nuevas secciones: A.1. A.1. «Descripción e importancia de la enfermedad»; A.2. «Clasificación taxonómica del agente patógeno». A.2. «Clasificación taxonómica del agente patógeno»; A.3. «Potencial zoonótico y bioseguridad». A.3. «Potencial zoonótico y requisitos de bioseguridad y bioprotección»; A.4. «Diagnóstico diferencial». A.4. «Diagnóstico diferencial»; y se trasladó la información sobre los hospedadores habituales de <i>T. foetus</i> , el riesgo de que los toros viejos sean una fuente permanente de infección, el desarrollo de una protección inmunitaria de corta duración en las vacas y los mecanismos de transmisión a las secciones correspondientes de nueva creación; también se actualizó la información de estas secciones.
B. Técnicas de diagnóstico	Se agregó un párrafo introductorio a esta sección con información sobre los criterios para un diagnóstico tentativo a nivel del rebaño, para la confirmación y sobre las muestras y técnicas de muestreo.

Sección/párrafo	Modificación
Tabla 1. Métodos de prueba disponibles para el diagnóstico de la tricomonosis y su finalidad	Se añadió una fila sobre IgG ELISA (suero) e IgA ELISA (moco vaginal) a la Tabla 1.
B.1.2. B.1.3.1. Transporte	Adición de esta nueva sección en la que se subraya que la elección de las técnicas de muestreo y diagnóstico debe tener en cuenta varios factores, entre ellos las condiciones y posibilidades de transporte y la duración prevista del mismo.
B.1.3.2. Medios de cultivo	Se han incluido las mejores prácticas: utilizar los medios antes de la fecha de caducidad, comprobar la calidad del agua, realizar controles de calidad en todos los lotes de medios, etc. Se actualizó la información sobre el medio Diamond's modificado y el medio <i>T. foetus</i> y se suprimió la sección sobre las características de crecimiento en los distintos medios.
B.1.3.3.2. Criopreservación de cultivos	Se añadió una nueva sección sobre la conservación de los cultivos de <i>T. foetus</i> utilizando una solución de congelación.
B.1.3.4. B.1.4.1. Detección e identificación de <i>Trichomonas foetus</i> al microscopio	Se añadió texto para advertir que el examen de rutina por microscopía puede dar resultados falsos positivos porque varios microorganismos similares a <i>T. foetus</i> también pueden encontrarse en el ganado y son difíciles de distinguir de <i>T. foetus</i> : se recomienda la detección molecular en combinación con el cultivo cuando sea posible.
B.1.4.3. PCR a tiempo real	Actualización completa de esta sección como método recomendado, incluyendo tablas de secuencias de cebadores/sondas y parámetros de ciclado.
B.1.4.4. Amplificación isotérmica mediada por bucle (LAMP)	Se actualizó esta sección para incluir dos ensayos LAMP, pero se advirtió que uno aún no ha sido probado en el terreno y el segundo aún no ha sido probado en muestras positivas de bovinos infectados naturalmente.
C. Requisitos para las vacunas	Añadida una nueva sección sobre los requisitos para las vacunas.
Referencias	Actualización de la lista de referencias.
Resumen	Se añadieron cinco apéndices que justifican la elección de los ensayos y sus clasificaciones en la Tabla 1.

- 3.6.1. 'Peste equina africana (infección por el virus de la peste equina africana)': el BSC revisó el Capítulo 3.6.1., que había sido actualizado por los expertos del Laboratorio de Referencia de la OMSA.

El Capítulo 3.6.1. «Peste equina africana (infección por el virus de la peste equina africana)» revisado se presenta como [Anexo 26](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son las siguientes:

Sección/párrafo	Modificación
Resumen	<u>Detección e identificación del agente</u> : se añadió la RT-PCR como prueba de diagnóstico rápida y muy sensible. Los virus aislados pueden serotipificarse mediante una neutralización del virus específica del tipo o mediante RT-PCR o secuenciación. No se recomiendan las pruebas ELISA debido a su sensibilidad limitada.

Sección/párrafo	Modificación
A.1. Descripción e impacto de la enfermedad	<u>Requisito para las vacunas</u> : se aclaró que anteriormente se utilizaban vacunas inactivadas y que se están evaluando vacunas recombinantes.
A.2. Naturaleza y clasificación del agente patógeno	Se creó esta nueva subsección; eliminada la descripción del agente etiológico y sus detalles moleculares, junto con la sección sobre diagnósticos diferenciales y el párrafo sobre un agente no zoonótico, ya que no son relevantes para esta sección.
A.3. Potencial zoonótico y requisitos de bioseguridad y bioprotección	Se creó esta nueva subsección que incluye una descripción del virus.
A.4. Diagnóstico diferencial	Creada esta nueva subsección detallando las medidas de bioseguridad para manipular muestras contaminadas, específicas para enfermedades potencialmente zoonóticas.
A.4. Diagnóstico diferencial. Métodos de prueba disponibles para el diagnóstico de la peste equina y su finalidad	Se creó esta nueva subsección detallando diferentes diagnósticos diferenciales.
B. Técnicas de diagnóstico	Se aumentó la calificación de la RT-PCR en tiempo real para el propósito «contribuir a las políticas de erradicación» de «+» a «+++»; se aumentó la calificación de la RT-PCR basada en gel de agarosa para el propósito «población libre de infección» de «-» a «+», y para «animal individual libre de infección antes de los desplazamientos» y «contribuir a las políticas de erradicación» de «+» a «++»; se aumentó de «++» a «+++» la calificación de la prueba ELISA para el objetivo «o “animal individual libre de infección antes de los desplazamientos” y se disminuyó de “+++” a “+” la calificación para el objetivo “Confirmación de casos clínicos”; se añadió una nota a pie de página al objetivo “animal individual libre de infección antes de los desplazamientos” sobre la necesidad de muestras pareadas para las pruebas serológicas según lo establecido en el Capítulo 12 <i>del Código Terrestre</i> . 1. «Infección por el virus de la peste equina», Artículo 12.1.7. “Recomendaciones para las importaciones procedentes de países o zonas infectados por la peste equina”.
B.1.1. Cultivo celular	Se actualizaron las normas internacionales para los paneles de virus y de anticuerpos, se proporcionó una breve actualización sobre las pruebas de aptitud y sobre la importancia de la selección de muestras.
B.1.2.1. B.1.2.2. Reacción en cadena de la polimerasa de transcripción inversa	Se incluyó información sobre la interpretación del efecto citopático (ECP) y la importancia de una confirmación cuidadosa mediante RT-PCR en tiempo real.
B.1.2.3. Procedimiento RT-PCR en tiempo real (Agüero <i>et al.</i> , 2008)	Se eliminaron referencias obsoletas.
B.1.2.4. Procedimiento RT-PCR en tiempo real (Guthrie <i>et al.</i> , 2013).	Se actualizó el protocolo y se suprimió la sección sobre características de diagnóstico.
Tabla 2. Comparación de los métodos de RT-PCR en tiempo real de Agüero <i>et al.</i> (2008) y Guthrie <i>et al.</i> (2013)	Se suprimió la sección sobre características de diagnóstico.

Sección/párrafo	Modificación
B.1.3. Tipificación del virus de la peste equina	Se eliminaron las filas sobre sensibilidad analítica (LOD), especificidad diagnóstica y sensibilidad diagnóstica.
B.2. B.2. Pruebas serológicas	Se añadieron los ensayos RT-PCR como método de diagnóstico más rápido.
B.2.1.1. C.1. Procedimiento de la prueba	Se suprimieron las referencias de más de 20 años.
C.1.1. Justificación y uso previsto del producto	Se añadió una descripción de un ejemplo de ELISA de bloqueo.
Referencias	Se añadió una declaración y una referencia de que la detección del genoma vírico en animales vacunados con vacunas vivas atenuadas contra la peste equina se ha descrito hasta 16 semanas después de la vacunación; se añadió un ejemplo de vacunas experimentales de nueva generación.
Apéndices 1 a 6	Actualización de la lista de referencias

3.6.5. "Anemia infecciosa equina": la BSC revisó el Capítulo 3.6.5., que había sido actualizado por los expertos del Laboratorio de Referencia de la OMSA.

El Capítulo 3.6.5. «Anemia infecciosa equina» revisado se presenta como [Anexo 27](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son las siguientes:

Sección/párrafo	Modificación
Resumen	<u>Identificación del agente</u> : se revisaron los criterios para confirmar la infección centrándose en las pruebas serológicas y moleculares, destacando que el virus de la anemia infecciosa equina no puede diferenciarse de otros agentes etiológicos: el diagnóstico depende del laboratorio y se basa en la demostración de una respuesta específica de anticuerpos, el aislamiento del virus o la detección de ácido nucleico vírico.
A.1. Descripción de la enfermedad y etiología	Se añadió información sobre el impacto económico y en la biodiversidad, así como sobre los signos clínicos y la vía de transmisión.
B. Técnicas de diagnóstico	Se añadió información sobre los métodos de diagnóstico del virus de la anemia infecciosa equina, incluidos los antígenos recombinantes para evitar reacciones inespecíficas de inmunodeficiencia adquirida, un ELISA competitivo altamente específico y sensible, y una tira reactiva inmunocromatográfica de oro coloidal (CGICG) para la detección primaria de anticuerpos contra el virus de la anemia infecciosa equina en los puntos de atención.
Tabla 1. Métodos de prueba disponibles para el diagnóstico de la anemia infecciosa equina y su finalidad	Se aumentó la clasificación de la prueba ELISA para los cinco propósitos; supresión de la inmunoelectrotransferencia por no estar disponible comercialmente.
B.1.1. Aislamiento e identificación del virus	Se añadieron detalles sobre las muestras para el aislamiento del virus.

Sección/párrafo	Modificación
B.1.12. Reacción en cadena de la polimerasa	Se añadió información sobre los métodos de PCR en tiempo real y se hizo hincapié en que los métodos de PCR para detectar el ARN vírico y el ADN provírico deberían utilizarse para aumentar la sensibilidad diagnóstica.
B.2. Pruebas serológicas	Se añadió información sobre un algoritmo de diagnóstico eficaz.
B.2.1.1. Preparación del antígeno	Se suprimieron detalles sobre el método de extracción del antígeno.
B.2.3. Prueba de inmunotransferencia	Se añadió información sobre las características de diagnóstico, destacando tanto la alta sensibilidad como la especificidad, y señalando que esta prueba no está disponible comercialmente, razón por la cual se eliminó de la Tabla 1, aunque está disponible en el Laboratorio de Referencia de la OMSA en Italia.
B.2.4. Prueba inmunocromatográfica con oro coloidal	Se añadió un nuevo método de diagnóstico para la detección de anticuerpos contra el virus de la anemia infecciosa equina.
C. Requisitos para las vacunas	Aclaración de que las pruebas de diagnóstico no pueden diferenciar entre anticuerpos de animales vacunados e infectados.
Referencias	Actualización de la lista de referencias
Apéndices 1 a 5	Se añadieron cinco apéndices que justifican la elección de las pruebas y su clasificación en la Tabla 1.

3.8.2. 'Artritis/encefalitis caprina y Maedi-visna': la BSC revisó el Capítulo 3.8.2., que había sido actualizado por un experto en la enfermedad.

El Capítulo 3.8.2. revisado «Artritis/encefalitis caprina y Maedi-visna» se presenta como [Anexo 28](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son:

Sección/párrafo	Modificación
Título	Se cambió el título a «Lentivirus de pequeños rumiantes (artritis/encefalitis caprina y Maedi-visna)».
A. Introducción	Se aclaró que, aunque la artritis/encefalitis caprina y Maedi-visna se clasifican como dos especies víricas diferentes, cada vez hay más consenso en considerarlos como dos genotipos diferentes de un grupo más amplio de virus.
Tabla 1. Métodos de prueba disponibles para el diagnóstico de la artritis/encefalitis caprina y Maedi-visna, y su finalidad	Se suprimió la prueba de fijación del complemento (CFT), la neutralización del virus (VN) y la prueba indirecta de anticuerpos fluorescentes (IFAT) de la tabla; se aumentó la calificación de la PCR y la ELISA a efectos de «Confirmación de casos clínicos» de «++» a «+++» y de «+» a «++», respectivamente; se redujo la calificación de la AGID a efectos de «Animal individual libre de infección antes de los desplazamientos» y «Confirmación de casos clínicos» de «+++» a «++»; se redujo a «-» la calificación de todas las pruebas para los fines de «Estado inmunitario de animales individuales o de la población después de la vacunación», ya que no hay vacuna; se añadió una nota a pie de página en las pruebas AGID y ELISA para los fines de «Ausencia de infección en animales individuales antes del

Sección/párrafo	Modificación
	desplazamiento» y «Contribución a las políticas de erradicación» en la que se indica que las muestras no deben proceder de animales menores de 6 meses debido a la interferencia de los anticuerpos maternos, especialmente si se utiliza calostro tratado térmicamente con fines de erradicación.
B.1.2.1. B.1.2.1. Virus de la artritis/encefalitis caprina y virus del Maedi-visna	Se amplió la actualización del método de recogida de muestras.
B.1.3. B.1.3. Métodos de detección de ácidos nucleicos	Se añadieron dos nuevas tablas de cebadores para la PCR en tiempo real y la PCR convencional.
Referencias	Actualización de la lista de referencias
Apéndices 1 a 5	Se añadieron cinco apéndices que justifican la elección de los ensayos y sus clasificaciones en la Tabla 1.

- 3.8.5. "Aborto enzoótico de las ovejas (clamidiosis ovina) (infección por *Chlamydia abortus*)": la BSC revisó el Capítulo 3.8.5., que había sido actualizado por los expertos del Laboratorio de Referencia de la OMSA.

El Capítulo 3.8.5. «Aborto enzoótico de ovejas (clamidiosis ovina) (infección por *Chlamydia abortus*)» revisado se presenta como [Anexo 29](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son las siguientes:

Sección/párrafo	Modificación
A.1. Descripción e impacto de la enfermedad	Se aclaró que las ovejas infectadas liberan un gran número de <i>C. abortus</i> infecciosos en el momento del aborto o del parto, proporcionando así una fuente de infección; y que las ovejas generalmente abortan sólo una vez debido a esta infección.
A.2. Naturaleza y clasificación del agente patógeno	Se sustituyó la información taxonómica por las características de la familia <i>Chlamydiaceae</i> .
B.2. Pruebas serológicas	Se aclaró que ninguna de las pruebas serológicas disponibles puede diferenciar entre los títulos de vacunación y los resultantes de la infección natural (pruebas DIVA).
B.2.1. ELISA	Se añadió información sobre ELISA específicos para <i>C. abortus</i> basados en proteínas recombinantes que pueden diferenciar animales infectados por <i>C. pecorum</i> .
Referencias	Actualización de la lista de referencias
Apéndices 1 a 6	Se añadieron seis apéndices que justifican la elección de las pruebas y su clasificación en la Tabla 1.

- 3.8.11. 'Viruela ovina y viruela caprina' (sólo sección de vacunas): la BSC revisó el 3.8.11., que había sido actualizado por los expertos del Laboratorio de Referencia de la OMSA en colaboración con expertos en enfermedades y vacunas.

El Capítulo 3.8.11. «Viruela ovina y viruela caprina (sólo la sección de vacunas)» revisado se presenta como [Anexo 30](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son:

Sección ampliamente actualizada: C. Requisitos para las vacunas
Un Laboratorio de Referencia de la OMSA, en colaboración con desarrolladores de vacunas, expertos en la materia y representantes de la comunidad científica, ha actualizado a fondo la Sección C: Requisitos de las vacunas para la fabricación de vacunas puras, potentes, inocuas y eficaces contra la viruela ovina y caprina, incluyendo los criterios clave de rendimiento y calidad de las vacunas; en consecuencia, también se actualizó la lista de referencia.

- 3.9.2. “Peste porcina clásica (infección por el virus de la peste porcina clásica)”: la BSC revisó el Capítulo 3.9.2., que había sido actualizado por los expertos del Laboratorio de Referencia de la OMSA.

El Capítulo 3.9.2. «Peste porcina clásica (infección por el virus de la peste porcina clásica)» revisado se presenta como [Anexo 31](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son:

Sección/párrafo	Modificación
C.1. Antecedentes	Se subrayó que la disponibilidad de vacunas inocuas y eficaces sigue siendo una herramienta importante para el control y la erradicación temprana de la PPC. Proporcionó información sobre nuevas vacunas candidatas.
C.2. Esquema de la producción y requisitos mínimos de las vacunas vivas	Se cambió el nombre de la sección «Esquema de producción y requisitos mínimos para las vacunas vivas convencionales y las vacunas vivas marcadoras modificadas» y se añadió un texto introductorio especificando que el capítulo proporciona los requisitos mínimos para las vacunas vivas, tanto las convencionales como las vivas marcadoras modificadas.
C.2.1.1. C.2.2.2. Características biológicas del inóculo primario	Se añadió información sobre las vacunas vivas marcadoras.
C.2.2.4. C.2.3.1. Potencia del lote/serie del producto final	Se indicó que se requieren pruebas de potencia de lotes/series: el título de liberación apropiado debe correlacionarse con los resultados de los estudios de eficacia de desafío, y debe ser lo suficientemente mayor como para garantizar la eficacia de la vacuna durante toda su vida útil.
C.2.3.2. C.3.3. Requisitos de seguridad	Se aclaró que las pruebas de reversión a la virulencia deben ser coherentes con la norma VICH GL41 (<i>Examination of live veterinary vaccines in target animals for absence of reversion to virulence</i> , 2008); se añadió una sección sobre requisitos especiales para las vacunas vivas marcadoras.
C.4. Otras vacunas basadas en la biotecnología	Inclusión de una nueva sección.
Referencias	Actualización de la lista de referencias.
Apéndices 1 a 5	Adición de cinco apéndices que justifican la elección de los ensayos y sus calificaciones que figuran en la Tabla 1

- 3.9.7. “Enfermedad vesicular porcina”: la BSC revisó el Capítulo 3.9.7., que había sido actualizado por los expertos del Laboratorio de Referencia de la OMSA.

El Capítulo 3.9.7. “Enfermedad vesicular porcina’ revisado se presenta como [Anexo 32](#) para la primera ronda de comentarios de los Miembros.

Las principales modificaciones son:

Sección/párrafo	Modificación
Resumen	Modificación de los criterios de diagnóstico positivo para incluir los resultados tanto de la RT-PCR como del aislamiento del virus.
A. Introducción	Se añadió información sobre la situación epidemiológica de la enfermedad.
B.1. Detección e identificación del agente	Aclaración de que el efecto citopático (ECP) observado en cultivos inoculados debe confirmarse mediante ELISA o RT-PCR para verificar la presencia del VEVV.
B1.2. Aislamiento del virus	Se actualizó la información sobre los procedimientos de aislamiento del virus
B.1.4.1. Reacción en cadena de la polimerasa-transcriptasa inversa	Aclaración de que, para obtener el mejor rendimiento diagnóstico, debe incorporarse a la RT-PCR de un paso un formato en tiempo real con un colorante fluorescente de unión al ADN.
B.1.4.2.1. RT-PCR de un paso	Se cambió el nombre de la sección «RT-PCR de un paso en tiempo real (con un colorante fluorescente de unión al ADN de doble cadena)» y se actualizó el protocolo de ensayo.
Referencias	Actualización de la lista de referencias.
Apéndices 1 a 3	Se añadieron dos apéndices que justifican la elección de los ensayos y su clasificación en la Tabla 1.

5.3. Respuesta de la Comisión a la segunda ronda de comentarios de los Miembros

- 3.9.1. ‘Peste porcina africana (infección por el virus de la peste porcina africana)’ (solo sección sobre vacunas)

Antecedentes

En su reunión de septiembre de 2023, se informó a la Comisión de que un consultor que trabajaba con desarrolladores de vacunas, expertos en la materia, representantes de la comunidad científica, autoridades reguladoras y laboratorios de referencia de la OMSA había actualizado a profundidad la Sección C: Requisitos para las vacunas, del capítulo sobre la PPA relativo a la fabricación de vacunas puras, potentes, inocuas y eficaces contra la PPA, incluyendo criterios clave de rendimiento y calidad de las vacunas. La nueva sección redactada se presentó como [Anexo 16](#) para la primera ronda de comentarios. También se incluyó un apéndice al borrador del capítulo para información que incluía los resultados de la consulta, los parámetros clave, resúmenes de los debates, etc.

En su reunión de febrero de 2024, la Comisión observó que se había recibido un gran número de comentarios sobre la nueva sección de vacunas propuesta. Dado que en algunos Miembros se utilizan vacunas vivas modificadas, la Comisión consideró que era importante disponer de una norma mínima en el *Manual Terrestre* de la OMSA, con el compromiso de revisarla periódicamente a medida que se disponga de pruebas científicas.

El nuevo proyecto de sección sobre vacunas se ha distribuido dos veces para recabar comentarios.

Informes anteriores de la Comisión en los que se debatió este punto

Informe de septiembre de 2023 (punto 5.1., página 9), informe de febrero de 2024 (punto 5.2., páginas 19-26).

Reunión de febrero de 2024

La nueva sección sobre vacunas propuesta ya se había enviado para dos rondas de comentarios de los Miembros, pero su adopción se pospuso en la Sesión General de mayo de 2024 debido al gran número de comentarios recibidos en la segunda ronda. De acuerdo con la nueva política de transparencia de la OMSA, la Comisión abordó todos los comentarios, que pueden consultarse en el [Anexo 4](#).

El Capítulo 3.9.1. «*Peste porcina africana*» revisado (infección por el virus de la peste porcina africana) (sólo la sección sobre vacunas) se presenta en el [Anexo 33](#) para que los Miembros la comenten en tercera ronda.

Capítulos para comentario de los Miembros con este informe y sus correspondientes números de Anexo

	Anexo	Capítulo nº	Título del capítulo
1.	5	1.1.3.	Transporte de materiales biológicos
2.	6	1.1.7.	Normas para la secuenciación de alto rendimiento, la bioinformática y la genómica computacional
3.	7	1.1.9	Pruebas de esterilidad y ausencia de contaminación de materiales biológicos destinados a uso veterinario
4.	8	2.1.1.	Métodos de laboratorio para las pruebas de susceptibilidad antimicrobiana bacteriana
5.	9	2.2.1	Desarrollo y optimización de ensayos de detección de anticuerpos
6.	10	2.2.2	Desarrollo y optimización de ensayos de detección de antígenos
7.	11	2.2.3	Desarrollo y optimización de ensayos de detección de ácidos nucleicos
8.	12	2.2.5	Enfoques estadísticos de la validación
9.	13	2.2.8.	Comparabilidad de los ensayos tras cambios menores en un método de ensayo validado
10.	14	3.1.2.	Enfermedad de Aujeszky (infección por el virus de la enfermedad de Aujeszky)
11.	15	3.1.8.	Fiebre aftosa (infección por el virus de la fiebre aftosa)
12.	16	3.1.9.	Cowdriosis
13.	17	3.1.21.	Peste bovina (infección por el virus de la peste bovina)
14.	18	3.2.4.	Infestación de las abejas melíferas por <i>Aethina tumida</i> (pequeño escarabajo de las colmenas)
15.	19	3.2.5.	Infestación de las abejas melíferas por <i>Tropilaelaps</i> spp.
16.	20	3.3.1.	Clamidiosis aviar
17.	21	3.3.2.	Bronquitis infecciosa aviar
18.	22	3.3.4.	Influenza aviar (incluida la infección por virus de la influenza aviar de alta patogenicidad)
19.	23	3.4.9.	Leucosis bovina enzoótica
20.	24	3.4.13.	Teileriosis bovina (infección por <i>Theileria annulata</i> , <i>T. orientalis</i> y <i>T. parva</i>)
21.	25	3.4.14.	Tricomonosis
22.	26	3.6.1.	Peste equina africana (infección por el virus de la peste equina africana)
23.	27	3.6.5.	Anemia infecciosa equina
24.	28	3.8.2.	Artritis/encefalitis caprina y Maedi-visna
25.	29	3.8.5.	Aborto enzoótico de las ovejas (clamidiosis ovina) (infección por <i>Chlamydia abortus</i>)
26.	30	3.8.11.	Viruela ovina y viruela caprina (sólo en la sección de vacunas)
27.	31	3.9.2.	Peste porcina clásica (infección por el virus de la peste porcina clásica)
28.	32	3.9.7.	Enfermedad vesicular porcina
29.	33	3.9.1.	Peste porcina africana (sólo sección de vacunas)

5.4. Informe sobre un estudio interlaboratorio para seguir validando las pruebas serológicas del muermo

El Laboratorio de Referencia de la OMSA para el muermo de Alemania colaboró en una red internacional para mejorar el diagnóstico serológico del muermo. En 2011, se introdujo la prueba inmunoelctrotransferencia como prueba confirmatoria de los resultados positivos de la prueba de fijación del complemento (CFT), ganando reconocimiento internacional, aunque sigue siendo una prueba compleja y sofisticada. Estudios internacionales posteriores, financiados por la OMSA, compararon métodos alternativos.

En 2019, un estudio demostró que un ELISA basado en proteínas recombinantes tenía un rendimiento comparable o mejor que la CFT en términos de sensibilidad y especificidad. En 2021, se validó un ELISA comercial de doble antígeno, que demostró una sensibilidad y especificidad mejoradas con respecto a la CFT. El protocolo rápido y sencillo de la prueba la hace adecuada para pruebas a gran escala en laboratorios de diagnóstico, y se aprobó su uso en Alemania en 2020.

En octubre de 2021, el capítulo actualizado sobre muermo que incluía esta prueba ELISA de doble antígeno se distribuyó a los Miembros para la primera ronda de comentarios. Los Miembros identificaron dos áreas de preocupación: que había una falta de datos de validación para el rendimiento del kit ELISA basado en doble antígeno recombinante en muestras de mulas y burros; y que había una falta de disponibilidad de sueros de control positivo para permitir que la garantía de calidad externa y el rendimiento de la prueba se llevaran a cabo de manera fiable. Así pues, el capítulo quedó en espera y se solicitó al Laboratorio de Referencia que continuara con la variación de la prueba utilizando una gama más amplia de muestras, tanto en términos de especies como de origen geográfico.

Desde entonces, el Laboratorio de Referencia de la OMSA ha organizado un estudio comparativo interlaboratorio internacional de los dos ensayos: ELISA y CFT. El estudio confirmó la idoneidad de la prueba ELISA de doble antígeno como prueba fiable para identificar a los animales infectados por el muermo y demostrar la ausencia de la enfermedad para el desplazamiento de animales. Sin embargo, la prueba sólo puede considerarse suficientemente validada para los caballos.

La Comisión acordó modificar las calificaciones de la prueba ELISA de antígeno doble en la tabla 1 *Métodos analíticos disponibles para el diagnóstico del muermo y su finalidad* del capítulo 3.6.10 del *Manual Terrestre*. Además, añadió los nuevos anexos que justifican la elección de las pruebas y sus clasificaciones que figuran en la tabla 1. El capítulo será revisado de nuevo por los tres Laboratorios de Referencia y evaluado por la Comisión en la próxima reunión de febrero para su aprobación y envío a la segunda ronda de comentarios de los Miembros.

5.5. Petición de orientaciones sobre taxonomía y uso de nombres comunes de agentes patógenos

La Comisión estudió una solicitud de orientación sobre la incorporación de la nueva taxonomía en el *Manual Terrestre* para dar cabida a la nomenclatura de los virus que ha sido adoptada por el ICTV. Por ejemplo, al adoptar estos nombres binomiales, ¿debería mantenerse el nombre común más familiar junto con la terminología científica actualizada? El debate puso de relieve la necesidad de coherencia en el uso de las últimas clasificaciones taxonómicas, reconociendo al mismo tiempo que los términos comunes siguen siendo ampliamente utilizados por los científicos y los funcionarios encargados de la reglamentación.

La Comisión acordó mantener la práctica actual: utilizar la nueva taxonomía binomial conservando los nombres comunes entre paréntesis para garantizar la claridad y la accesibilidad para todos los usuarios. Este sistema se había aplicado en el capítulo sobre la diarrea vírica bovina (DVB) adoptado en mayo de 2024, que clasifica los virus de la DVB como «*Pestivirus bovis* (comúnmente conocido como DVB de tipo 1), *Pestivirus tauri* (DVB de tipo 2) y *Pestivirus brazilense* (DVB de tipo 3 o pestivirus de tipo Hobi)».

5.6. Capítulos suprimidos: ¿se siguen considerando validadas las pruebas según las normas de la OMSA?

En la reunión de febrero de 2024, la Comisión elaboró y aplicó criterios para mantener capítulos en el *Manual Terrestre* para enfermedades que no figuran en la lista. Tras la supresión de algunos capítulos, un laboratorio que había obtenido la acreditación para un método de detección basándose en que se trata de un método estándar según la OMSA preguntó por su estado de validación ahora que el capítulo ya no figuraba en el *Manual Terrestre*. La Comisión aconsejó que el laboratorio se remitiera a las referencias publicadas de los estudios de validación del método y no al capítulo del *Manual Terrestre*.

Por otra parte, en un futuro próximo se podrá acceder a las versiones históricas del *Manual Terrestre*, pero la versión actual es siempre la versión de referencia con la información más actualizada.

Las versiones anteriores del *Manual Terrestre* están disponibles en el portal de documentos de la OMSA (<https://doc.woah.org/dyn/portal/listalo.xhtml?dos=71&page=listalo&req=121&menu=>); la última edición impresa se

publicó en 2018. Las versiones anteriores de los capítulos aprobados desde entonces pueden solicitarse a la Secretaría de la BSC en: bsc.secretariat@woah.org.

5.7. Situación del *Manual Terrestre*: actualización de los capítulos seleccionados para el ciclo de revisión 2025/2026

La Comisión ha animado a los Laboratorios de Referencia que tienen capítulos pendientes a que los entreguen en el plazo previsto. Se han identificado los siguientes capítulos para su actualización en 2025/2026 (entre paréntesis el año de la última adopción)

- 1.1.2. Obtención, envío y conservación de muestras para diagnóstico (2013)
- 1.1.4. Bioseguridad y bioprotección: Norma para la gestión del riesgo biológico en el laboratorio veterinario y en las instalaciones para animales (2015)
- 2.1.2. Avances biotecnológicos en el diagnóstico de enfermedades infecciosas (2021)
- 2.1.3. Gestión del riesgo biológico: ejemplos de adaptación de las estrategias de gestión de riesgos a los riesgos biológicos evaluados (2014)
- 2.2.7. Validación de pruebas de diagnóstico de enfermedades infecciosas aplicables a la fauna silvestre (2014)
- 2.3.1. Aplicación de la biotecnología al desarrollo de vacunas veterinarias (2010)
- 2.3.3. Requisitos mínimos para la organización y gestión de una instalación de fabricación de vacunas (2016)
- 2.3.5. Requisitos mínimos para la producción aséptica en la fabricación de vacunas (2016)
- 3.1.7. Enfermedad hemorrágica epizootica (infección por el virus de la enfermedad hemorrágica epizootica) (2021)
- 3.1.10. Encefalitis japonesa (2021)
- 3.1.11. Leishmaniosis (2021)
- 3.1.14. Nagana: infecciones por tripanosomosis salivares (excluidos *Trypanosoma evansi* y *T. equiperdum*) (2021)
- 3.1.15. Gusano barrenador del ganado del Nuevo Mundo (*Cochliomyia hominivorax*) y gusano barrenador del ganado del Viejo Mundo (*Chrysomya bezziana*) (2019)
- 3.1.17. Paratuberculosis (enfermedad de Johne) (2021)
- 3.1.18. Fiebre Q (2018)
- 3.1.22. Surra en todas las especies (infección por *Trypanosoma evansi*) (2021)
- 3.1.26. Fiebre del Nilo Occidental (2018)
- 3.3.3. Laringotraqueítis infecciosa aviar (2021)
- 3.3.5. Micoplasmosis aviar (*Mycoplasma gallisepticum*, *M. synoviae*) (2021)
- 3.3.6. Hepatitis por virus del pato (2017)
- 3.3.7. Tifus aviar y enfermedad de Pullorum (2018)
- 3.3.8. Enfermedad infecciosa de la bursitis (enfermedad de Gumboro) (2016)
- 3.3.10. Enfermedad de Newcastle (infección por el virus de la enfermedad de Newcastle) (2021)
- 3.4.2. Babesiosis bovina (2021)
- 3.4.4. Campilobacteriosis genital bovina (2021)
- 3.4.5. Encefalopatía espongiiforme bovina (2021)
- 3.4.8. Pleuroneumonía contagiosa bovina (infección por *Mycoplasma mycoides* subsp. *mycoides*) (2021)
- 3.4.10. Septicemia hemorrágica (*Pasteurella multocida* serotipos 6:b y 6:e) (2021)
- 3.4.11. Rinotraqueítis infecciosa bovina/vulvovaginitis pustulosa infecciosa (2017)
- 3.5.1. Viruela del camello (2021)
- 3.5.2. Síndrome respiratorio de Oriente Medio (infección de dromedarios por coronavirus del síndrome respiratorio de Oriente Medio) (2021)
- 3.6.6. Influenza equina (infección por el virus de la influenza equina) (2019)
- 3.6.7. Piroplasmosis equina (2021)
- 3.6.9. Arteritis viral equina (2013)
- 3.6.10. Muermo y melioidosis (2018)
- 3.8.3. Agalaxia contagiosa (2018)
- 3.8.4. Pleuroneumonía contagiosa caprina (2021)
- 3.8.7. Epididimitis ovina (*Brucella ovis*) (2015)
- 3.8.8. Peste de pequeños rumiantes (infección por morbilivirus de pequeños rumiantes) (2021)
- 3.8.10. Prurigo lumbar (2022)
- 3.9.8. Gastroenteritis transmisible (2008)
- 3.10.2. Cisticercosis (incluida la infección por *Taenia solium*) (2021)
- 3.10.4. *Escherichia coli* verocitotóxica (2008)

5.8. Actualización sobre el proyecto de herramienta de navegación en línea de las normas de la OMSA

La herramienta de navegación en línea por las normas de la OMSA es una plataforma diseñada para simplificar el acceso a las normas de la OMSA. Está en consonancia con la estrategia de digitalización de la OMSA, cuyo objetivo es mejorar la eficiencia y apoyar la toma de decisiones informadas.

El proyecto ofrecerá tres interfases clave. La primera es el sitio web público de la OMSA, que sirve de punto de acceso a las normas. La segunda es una herramienta de Recomendaciones para un Comercio Internacional Seguro por Materias Primas, que permite a los usuarios visualizar las recomendaciones comerciales mediante un sistema de filtrado. Esta función se aplica actualmente al *Código Terrestre*, y podría ampliarse al *Código Acuático*. La tercera interfaz es una herramienta de navegación y búsqueda que ofrece una forma intuitiva de navegar por los códigos y manuales terrestres y acuáticos de la OMSA.

Para uso interno, se está desarrollando una plataforma específica para que el personal de la OMSA gestione y actualice las normas con eficacia. Las interfases públicas ya se han desarrollado y se presentaron con comentarios positivos durante la Sesión General de 2024. Se ha completado la digitalización y verificación de las normas, y hay actualizaciones en curso. La interfaz interna se encuentra en su fase final de desarrollo, y se espera que la herramienta sea plenamente operativa en el segundo semestre de 2024. Durante la reunión se presentó una demostración de la herramienta, en la que se mostraron sus funcionalidades y su potencial futuro.

6. Centros de Referencia de la OMSA

6.1. Solicitudes de estatus de Centro de Referencia de la OMSA

La Comisión recomendó que se aceptaran las siguientes solicitudes de candidatura a Centro de Referencia de la OMSA:

Laboratorio de Referencia de la OMSA para la piroplasmosis equina
ICAR-National Research Centre on Equines (ICAR-NRCE),
(Indian Council of Agricultural Research)
Sirsa Road, Hisar 125 001, Haryana, INDIA
Tel.: (+91) 1662-282503 / (+91) 1662-276217
E-mail: Sanjay.nrce@gmail.com; kumar.sanjay@icar.gov.in
Web: www.nrce.gov.in
Experto designado: Dr. Sanjay Kumar

Centro Colaborador de la OMSA para el comercio y la sanidad de la fauna silvestre
Centre for Wildlife Forensics, National Parks Board, Animal & Plant Health Centre
6 Perahu Road, SINGAPUR 718827
Tel.: (+65) 6471-7808
E-mail: CITES@nparks.gov.sg (General Inquiry) / Anna_wong@nparks.gov.sg
Web: <https://www.nparks.gov.sg/CentreforWildlifeForensics>
Contacto: Dr Anna Wong

Centro Colaborador de la OMSA para la sanidad, vigilancia y epidemiología de la fauna silvestre
Thailand National Wildlife Health Center (Thailand- NWHC), and the Monitoring and
Surveillance Center for Zoonotic Diseases in Wildlife and Exotic Animals (MoZWE), Faculty of Veterinary
Science, Mahidol University
999 Phuttamonthon 4 Rd., Salaya, Phuttamonthon, Nakhon Pathom, 73170, TAILANDIA
Tel: (+66.2) 441-5242-4
E-mail: witthawat.wir@mahidol.ac.th
Web: <https://vs.mahidol.ac.th/thailand-nwhc/en>; <https://vs.mahidol.ac.th/mozwe/en/>
Contacto: Dr. Witthawat Wiriyarat

Se recibieron dos solicitudes de países de la región Asia-Pacífico para su designación como Laboratorios de Referencia para la peste porcina africana (PPA). Si bien un primer solicitante demostró una sólida labor de investigación, la Comisión determinó que la solicitud carecía de suficiente capacidad de diagnóstico y de pruebas de actividades internacionales, incluida la organización de pruebas de aptitud o la participación en ellas. No obstante, la Comisión reconoció el potencial del instituto para contribuir a la red PPA y recomendó que se le invitara a participar como observador en la red de la OMSA para la PPA. El segundo solicitante no cumplía las normas exigidas en cuanto a capacidad de laboratorio y experiencia en PPA. La Comisión consideró que la información facilitada era insuficiente y que el ámbito de trabajo relacionado con la enfermedad no estaba claramente descrito. En consecuencia, la solicitud no fue aceptada.

Por último, también se examinó la solicitud de un país de la región Asia-Pacífico para ser designado Laboratorio de Referencia para el muermo. Aunque la Comisión había solicitado la designación de Laboratorios de Referencia para el muermo en esta región, se consideró que la pericia y experiencia del solicitante no se ajustaban suficientemente a los requisitos y expectativas de un Laboratorio de Referencia de la OMSA. La aplicación carecía de detalles sobre colaboraciones y proyectos internacionales recientes. En general, la Comisión consideró que era prematuro solicitar el estatus de Laboratorio de Referencia de la OMSA y no aceptó la solicitud.

6.2. Cambios de expertos en los Centros de Referencia de la OMSA

Los Delegados de los Miembros interesados habían presentado a la OMSA las siguientes candidaturas para los cambios de experto en los Laboratorios de Referencia de la OMSA. La Comisión recomendó su aceptación:

Enfermedad de Aujeszky

La Dra. Celine Deblanc para sustituir a la Dra. Marie-Frédérique Le Potier en el Laboratorio Ploufragan-Plouzané-Niort de la ANSES (Agencia Francesa de Seguridad Sanitaria de los Alimentos, del Medio Ambiente y del Trabajo), FRANCIA.

Triquinelosis

El Dr. Gianluca Marucci para sustituir a la Dra. María Ángeles Gómez Morales en el Departamento de Enfermedades Infecciosas del *Istituto Superiore di Sanità*, ITALIA.

Influenza aviar y enfermedad de Newcastle

El Dr. Ashley Banyard para sustituir al Dr. Ian Brown en el Laboratorio de Influenza Aviar de la Agencia de Sanidad Animal y Vegetal, REINO UNIDO.

Influenza porcina

La Dra. Helen Everett para sustituir al Dr. Ian Brown en el Departamento de Virología de la Agencia de Sanidad Animal y Vegetal (APHA), REINO UNIDO.

La Comisión examinó otras tres candidaturas para el cambio de experto y, basándose en la información facilitada, consideró que los candidatos no cumplían las expectativas de un experto de la OMSA.

6.3. Revisión de las solicitudes nuevas y pendientes de hermanamiento de laboratorios

En septiembre de 2024, se habían completado 96 proyectos y 14 estaban en marcha. Tres proyectos están pendientes de identificación de financiación antes de comenzar. Catorce laboratorios de referencia de la OMSA y cuatro centros colaboradores de la OMSA han sido designados como resultado de proyectos de hermanamiento de laboratorios.

La evaluación del programa de hermanamiento de laboratorios de la OMSA está a punto de concluir. En el marco de la evaluación, se celebró un taller los días 27 y 28 de junio de 2024 en la sede de la OMSA para recabar la opinión de las partes interesadas en el Programa sobre los temas clave que se desprenden de la evaluación del programa. Se informará a la Comisión de las conclusiones en la reunión de febrero de 2025. Los principales resultados de este proceso serán una nueva guía de hermanamiento, una herramienta de evaluación posterior al proyecto y el informe de evaluación.

Se presentaron tres propuestas de proyectos de hermanamiento de laboratorios para su examen por la Comisión:

- a. **Italia - Uzbekistán** para la gestión de la calidad de los laboratorios y los procedimientos de bioseguridad y bioprotección aplicados a las enfermedades en la interfaz animal y humana: la Comisión apoyó el contenido técnico de esta propuesta de proyecto.
- b. **Italia - Argelia** para el Sistema de bioseguridad y bioprotección de los laboratorios, normalización del funcionamiento de los laboratorios y secuenciación del genoma completo: la Comisión apoyó el contenido técnico de esta propuesta de proyecto.

-
- c. **China - Kazajstán** para la anemia infecciosa equina: la Comisión apoyó el contenido técnico de esta propuesta.

6.4. Evaluación de los informes anuales de los Centros Colaboradores

La Comisión revisó el rendimiento de todos los Centros Colaboradores de la OMSA mediante un análisis en profundidad de los informes anuales de actividades en 2023 para garantizar que cada Centro está cumpliendo los Términos de Referencia (TdR) en beneficio de los Miembros de la OMSA y el criterio de rendimiento de los Procedimientos para la Designación de Centros Colaboradores de la OMSA (los POE: [Centros Colaboradores - OMSA - Organización Mundial de Sanidad Animal](#)).

La Comisión identificó tres Centros Colaboradores que no cumplían los TdR clave. Los Centros Colaboradores afectados serán informados del resultado de la revisión y se les pedirá que proporcionen información y una explicación de su situación y de las posibles razones de la falta de actividad; el Delegado estará en copia de toda la correspondencia. La Comisión también identificó 11 Centros Colaboradores que tienen un bajo nivel de actividades y los incluyó en una lista de vigilancia para un examen de seguimiento en el próximo proceso de revisión del informe anual.

Por falta de tiempo, la Comisión no ha podido evaluar los informes anuales de los Laboratorios de Referencia durante la presente reunión. Estos informes se evaluarán durante una reunión virtual extraordinaria que se celebrará en octubre de 2024. Los resultados se incluirán en el informe de la Comisión de febrero de 2025.

La Comisión expresó su agradecimiento a todos los Centros de Referencia por su puntual presentación de los informes anuales y su continua adhesión a los TdR. La Comisión reconoció además la valiosa contribución de estos Centros a las actividades de la OMSA y alentó a una mayor participación tanto en el proceso de establecimiento de normas como en los esfuerzos más amplios de creación de redes.

6.5. Centros de referencia que no cumplen los TdR clave: falta de presentación de un informe anual

Dos Centros de Referencia no han presentado un informe anual de actividades en 2023, debido a la ausencia de un experto o punto de contacto designado. Se informará al Centro Colaborador de que, si desea mantener su designación, debe proporcionar el nombre de un Punto de Contacto. El Laboratorio de Referencia tendrá una última oportunidad de presentar la candidatura de un nuevo experto para la reunión de febrero de 2025. De conformidad con el punto 9 de los POE ([Laboratorios de Referencia - OMSA - Organización Mundial de Sanidad Animal](#)) «Suspensión de la condición de Laboratorio de Referencia» si un Laboratorio de Referencia es temporalmente incapaz de cumplir sus TdR debido a la ausencia de un experto designado, la Sede de la OMSA, en consulta con la Comisión Especializada pertinente, podrá considerar la suspensión temporal de la condición de Laboratorio de Referencia de la OMSA por un periodo no superior a 2 años. En caso de que el laboratorio siga sin contar con un experto designado tras la reunión de febrero de 2025, podría aplicarse este procedimiento.

6.6. Información actualizada sobre el progreso del procedimiento de evaluación de los Centros al final de su mandato quinquenal

Los Centros Colaboradores son designados por un periodo de 5 años, durante el cual deben ceñirse a un plan de trabajo quinquenal presentado al inicio de su designación. Durante la reunión de la BSC de febrero de 2024, la Comisión elaboró una plantilla para una autoevaluación de sus actividades durante los últimos 5 años en relación con el plan de trabajo quinquenal original. Este informe deberá aportar pruebas de los impactos y logros del Centro, así como de sus contribuciones. Los Centros deberán presentar sus informes anuales periódicos, y ambos documentos serán evaluados por la Comisión.

Los Centros Colaboradores cuyos planes de trabajo quinquenales finalizan en diciembre de 2024 fueron contactados por carta en agosto de 2024, con la expectativa de que los informes de autoevaluación relativos a sus planes de trabajo quinquenales se presentaran antes de noviembre de 2024.

A los Centros Colaboradores cuyos informes finales (autoevaluaciones) hayan sido aceptados se les notificará que su designación es susceptible de renovación, momento en el que se les pedirá que presenten un nuevo plan de trabajo quinquenal. Aquellos Centros Colaboradores cuyos resultados se consideren insatisfactorios dispondrán de un plazo de apelación de 6 meses, tras el cual su designación será evaluada de nuevo en la reunión de septiembre de la Comisión. Esta última evaluación podrá dar lugar a su exclusión de la lista de Centros Colaboradores.

6.7. Actualización de los avances en la recepción de viñetas de los Centros Colaboradores para el hipervínculo: «Cómo podemos ayudarle»

Para aumentar la visibilidad de los Centros Colaboradores, en febrero de 2024, la Comisión propuso solicitar a los Centros que presentaran de tres a cinco viñetas en las que se describieran los servicios que prestan. Estas viñetas se añadirán al perfil de cada Centro en la [página web de la OMSA](#) en un hipervínculo titulado «Cómo podemos ayudarle».

Los centros que estén al final de su plan de trabajo quinquenal tendrán la oportunidad de incluir sus viñetas en la plantilla prevista para el informe final. Los centros que no concluyan su plan de trabajo quinquenal este año serán contactados por separado y se les pedirá que presenten sus propuestas.

6.8. Necesidades de laboratorio, dar visibilidad de lo que se necesita a nivel mundial, no para establecer prioridades sino para informar y presentar las necesidades en los aspectos globales

La Comisión reconoció la necesidad de una estrategia clara para garantizar que las redes de laboratorios de referencia de la OMSA atiendan eficazmente las necesidades de sus miembros. Esto implica no sólo garantizar que las enfermedades designadas reflejen las prioridades regionales, sino también que todos los Centros de Referencia sigan una estrategia preestablecida y coordinada para mejorar los esfuerzos de respuesta a nivel mundial.

La Comisión examinó las enfermedades de la lista de la OMSA y las principales áreas de interés o especialidades para las que se ha detectado la necesidad de designar Centros de Referencia en determinadas regiones o a escala mundial. Estas necesidades derivan de las recomendaciones formuladas durante diversas reuniones de grupos *ad hoc* de la OMSA celebradas en los últimos meses, así como de las aportaciones de los Miembros de la OMSA y del personal de la sede. La Comisión reconoció la importancia de crear una estrategia sólida para adaptar y optimizar la estructura de la red, garantizando que sea eficaz y se ajuste a las necesidades mundiales, sin dejar de incorporar nuevos Centros de Referencia cuando sea necesario.

Los Laboratorios de Referencia de la OMSA desempeñan un papel clave en los conocimientos científicos básicos de la organización y prestan un apoyo inestimable. Por ello, la Comisión propuso llevar a cabo una revisión en profundidad de la situación actual de los Centros Colaboradores y los Laboratorios de Referencia. Esta revisión incluiría un análisis exhaustivo y un ejercicio de cartografía, comparando las capacidades de laboratorio existentes con la epidemiología mundial de las enfermedades enumeradas por la OMSA.

El objetivo será llevar a cabo un análisis exhaustivo que identifique claramente las lagunas en la red actual, proporcionando una imagen bien definida de las necesidades de los laboratorios. Este enfoque contribuirá al desarrollo de una red más eficiente y estratégicamente alineada que siga satisfaciendo las necesidades cambiantes de los Miembros de la OMSA.

6.9. Cuestiones relacionadas con los procesos de los Laboratorios de Referencia

6.9.1. Proceso del Laboratorio de Referencia de la OMSA: ¿quién debe firmar los formularios CU y DOI: el experto, el director del instituto o ambos?

La Comisión determinó que tanto el experto designado como el director del instituto deben firmar los formularios de Compromiso de Confidencialidad (CU) y Declaración de Intereses (DOI). Este requisito se incluirá en la Guía del candidato para garantizar el cumplimiento y la transparencia del proceso de solicitud.

6.9.2. ¿Qué se entiende por sistema de gestión de la calidad «equivalente»?

El requisito de mantener un sistema de gestión de la calidad (SGC) se incluyó en los *Textos Fundamentales* aprobados en 2011. En la Conferencia Mundial de Centros de Referencia celebrada en Seúl en 2014 se anunció que los Laboratorios de Referencia de la OMSA debían estar acreditados conforme a la norma ISO 17025 o equivalente antes de finales de diciembre de 2017, y desde esa fecha la obligación está incluida tanto en los [Laboratorios de Referencia - OMSA - Organización Mundial de Sanidad Animal](#) como en la Guía para los solicitantes del estatus de Laboratorio de Referencia de la OMSA. Esta obligación se controla a través de los informes anuales en los que se pregunta a los Laboratorios de Referencia si disponen de un SGC y si está acreditado.

Al evaluar los informes, la Comisión reconoció la necesidad de proporcionar información sobre lo que constituye un SGC «equivalente». La propuesta inicial es un sistema independiente auditado externamente con pruebas documentadas (certificados) de evaluación con respecto a una norma reconocida.

La Comisión convino en que es necesario seguir debatiendo este asunto y decidió volver a examinar la definición y los criterios de equivalencia en colaboración con la Comisión de Normas Sanitarias para los Animales Acuáticos en la próxima reunión de la Mesa, en febrero de 2025. Mientras tanto, la Comisión examinará detenidamente los informes de los Laboratorios de Referencia que utilizan un SGC equivalente para determinar los detalles de sus sistemas.

Por último, la Comisión revisó el texto del requisito y acordó suprimir la palabra «idealmente» para que la acreditación del Laboratorio de Referencia de la OMSA sea específica para la enfermedad en cuestión. La propuesta es la siguiente:

«Aportar pruebas documentadas (certificados) de acreditación del sistema de gestión de calidad ISO 17025 o equivalente, con las pruebas pertinentes para la enfermedad específica incluida en el ámbito de la acreditación.»

Tras la reunión de la Comisión de Normas Biológicas, la Comisión para los Animales Acuáticos también aceptó este cambio en la Guía para los solicitantes del estatus de Laboratorio de Referencia de la OMSA.

6.10. Actualización de las tres redes de Laboratorios de Referencia (PPA, PPR y rabia)

Peste porcina africana

La Red de la OMSA para la PPA no pudo presentar una actualización sobre el progreso de sus actividades por falta de tiempo. Además, como la Red se reunió en Macedonia del Norte la semana siguiente a la reunión, se decidió aplazar la actualización hasta la reunión prevista para febrero de 2025.

Peste de pequeños rumiantes

La red de la OMSA de Laboratorios de Referencia para la PPR sigue actualizando periódicamente su [sitio web](#) y organizando actividades en apoyo de sus Miembros. Su tercer boletín anual se distribuyó en julio de 2024 y proporciona información actualizada sobre las actividades recientes y futuras de la red, así como sobre las actividades de sus Miembros, incluidas otras redes pertinentes (FAO/OIEA²; Red VETLAB).

La red organizó un taller virtual para sus miembros en diciembre de 2023, así como un curso de formación sobre diagnóstico molecular y serológico de la PPR junto con la FAO, el Organismo Internacional de Energía Atómica (OIEA), la Secretaría del GEP de la PPR de la FAO², y la oficina de la FAO en Nigeria.

Las principales actividades para lo que queda de 2024 incluyen un curso de formación sobre técnicas de diagnóstico de la PPR en el CIRAD³ en noviembre, un seminario web para debatir el papel de los laboratorios de diagnóstico en la aplicación del enfoque episistémico de la PPR para alcanzar los objetivos del PPR-GEP, un ejercicio de comparación interlaboratorios para el diagnóstico de la PPR junto con la Red VETLAB de la FAO/OIEA, así como el taller anual, que tendrá lugar en diciembre de 2024 y será un evento híbrido.

Por último, en la Sesión General de mayo de 2024 se aprobó la creación de un nuevo Laboratorio de Referencia de la OMSA para la PPR en la India, con lo que el número de laboratorios pasará de tres a cuatro.

Rabia

La Red de Laboratorios de Referencia de la OMSA para la rabia (RABLAB) consta ahora de 14 laboratorios, tras la adopción de dos nuevos laboratorios, uno en Italia y otro en Taipei Chino, en la Sesión General de la OMSA de mayo de 2024. Este grupo sigue reuniéndose cada dos meses para compartir información y alinear las actividades OMSA los Laboratorios de Referencia, y se añadió una [nueva pestaña en la página del Laboratorio de Referencia de la OMSA](#) del sitio web de OMSA para aumentar la visibilidad de la RABLAB.

La RABLAB apoya a los miembros de la OMSA en la creación de capacidades de vigilancia, diagnóstico y laboratorio a través de cursos de formación y programas de hermanamiento de laboratorios, y está apoyando la creación de redes de laboratorios para la rabia en el sur de Asia y el sur de África, con apoyo previsto en 2025 para establecer una red de laboratorios para la rabia en el norte de África. La RABLAB también sigue prestando apoyo a los miembros de la OMSA en el desarrollo de planes estratégicos nacionales y estrategias de vacunación masiva de perros.

² GEP: *Global Eradication Programme*

³ CIRAD: *Centre de coopération internationale en recherche agronomique pour le développement* (Francia)

En respuesta a la preocupación suscitada por el uso de vacunas antirrábicas caninas de calidad inferior en algunos países, la [RABLAB ha publicado una declaración de posición](#) en la que subraya la importancia de utilizar vacunas antirrábicas aprobadas y de alta calidad que cumplan las normas internacionales en términos de eficacia, inocuidad y esterilidad.

La RABLAB también ha señalado su preocupación por los países que utilizan la vigilancia serológica para supervisar las campañas de vacunación canina, a pesar de disponer de recursos limitados para comprar vacunas caninas o ampliar la vacunación. La RABLAB recuerda a los Miembros de la OMSA que no se recomienda la vigilancia serológica para supervisar los programas de vacunación canina, ya que es cara y poco fiable ([OMS⁴ TRS, 2018](#)).

La RABLAB sigue desempeñando un papel fundamental en el apoyo al Foro de [Unidos contra la Rabia](#), incluido el pilotaje del programa de Asociación de Países de [Unidos contra la Rabia](#), la mejora de la coordinación y la transparencia de las actividades contra la rabia a través del [Mapa de Asociación de Unidos contra la Rabia](#), y la mejora de la difusión de los conocimientos científicos a través del [Boletín de Vigilancia Científica sobre la rabia](#), y [seminarios web trimestrales de Unidos contra la Rabia](#).

6.11. Revisión del título del Laboratorio de Referencia para la Nagana: infecciones por tripanosomas salivares y tripanosomosis (transmitida por la mosca tsetse)

La Comisión estudió la petición de revisar y simplificar el título del Laboratorio de Referencia para Nagana: infecciones por tripanosomas salivares y tripanosomosis (transmitida por la mosca tse-tsé).

Tras deliberar, la Comisión acordó modificar el título por el de «Nagana (tripanosomiasis animal africana transmitida por la mosca tse-tsé)» para mejorar la claridad y garantizar la coherencia con la terminología establecida para la enfermedad.

La Comisión aprovechó esta oportunidad para recordar a todos los Laboratorios de Referencia que su [mandato](#) incluye la responsabilidad de establecer y mantener una red con otros Laboratorios de Referencia de la OMSA designados para el mismo patógeno o enfermedad, y de organizar periódicamente pruebas de aptitud entre laboratorios para garantizar la comparabilidad de los resultados.

7. Reactivos estándar internacionales aprobados por la OMSA

En la última reunión de febrero de 2024, la Comisión revisó las directrices mínimas presentadas por la red para la PPR para la preparación y validación de materiales de referencia para los métodos de diagnóstico de la PPR, introdujo modificaciones para que las directrices fueran genéricas y propuso compartir el documento con otras redes de enfermedades para recabar más comentarios.

La Comisión examinó y aceptó los comentarios recibidos de las redes de la rabia y la peste porcina africana. La Secretaría distribuirá el documento modificado a la red de la fiebre aftosa para una última ronda de comentarios y aprobación antes de publicarlo en el sitio web de la OMSA. Se espera que estas directrices animen a más laboratorios a solicitar que sus reactivos sean aprobados por la OMSA como reactivos de referencia.

8. Seguimiento a partir de la Sesión General

Se informó a la Comisión de que la presentación a la Asamblea durante la Sesión General de mayo de 2024 fue muy bien acogida por los Delegados y que todas las preguntas fueron abordadas por el Presidente durante su intervención. No hubo que tomar ninguna medida de seguimiento.

9. Conferencias, Talleres y Reuniones

9.1. Información actualizada sobre el seminario de la OMSA que se celebrará durante el Simposio WAVLD en Calgary, Canadá, en 2025

El próximo [Simposio Internacional de la Asociación Mundial de Laboratorios de Diagnóstico Veterinario](#) (ISWAVLD) se celebrará en Calgary, Canadá, del 12 al 14 de junio de 2025 y, paralelamente, la Comisión de Normas Biológicas organizará un seminario de un día que tendrá lugar el 13 de junio de 2025. En la reunión de febrero de 2024, la Comisión pidió a la Secretaría que redactara un orden del día provisional y que se pusiera en contacto con expertos para que presentaran ponencias sobre las últimas tecnologías para el diagnóstico de enfermedades, incluidos temas de las redes específicas de enfermedades de la OMSA sobre PPA, PPR, rabia, fiebre aftosa e influenza aviar. La Secretaría puso al día a la Comisión sobre el estado de las propuestas recibidas de los expertos, que incluyen

⁴ OMS: Organización Mundial de la Salud

presentaciones sobre las tecnologías de secuenciación de nueva generación para el diagnóstico de la influenza aviar, la validación de los ensayos de flujo lateral para el diagnóstico de la rabia, el estado del arte de los diagnósticos de campo y de laboratorio para la PPA, el enfoque «Una sola salud» para el control de la propagación de la encefalitis japonesa en Australia, y una revisión del sistema de tablero de mandos de la fiebre aftosa para el intercambio de información y la colaboración. La Comisión se mostró de acuerdo con estas propuestas y sugirió que se incluyera una sesión de «escaparate» para las redes de enfermedades específicas con el fin de compartir la experiencia de colaboración y los resultados obtenidos mediante el trabajo en red. La Secretaría se pondrá en contacto con más expertos para tratar otros temas de actualidad y propondrá un orden del día completo en la reunión de la Comisión de febrero de 2025 para su debate y aprobación.

10. Cuestiones de interés para consideración o información

10.1. Información actualizada sobre la peste bovina

La Comisión recibió información actualizada sobre las actividades posteriores a la erradicación de la peste bovina. La OMSA sigue trabajando en colaboración con la FAO para reducir las existencias de material con contenido vírico de la peste bovina en todo el mundo, a excepción de los materiales de diagnóstico y las vacunas. Este esfuerzo se traducirá en una reducción del número de instalaciones de categoría A designadas por la FAO y la OMSA para la conservación de material con contenido vírico de la peste bovina, además de la reducción del material con contenido vírico de la peste bovina conservado por los Miembros de la OMSA en centros no autorizados. Actualmente, cinco países poseen material que contiene virus de la peste bovina (MCVR, por las siglas en inglés de *rinderpest virus-containing material*) fuera de IHVR y se han designado siete IHVR de categoría A y B en seis Miembros. De estas siete, tres instalaciones de categoría B poseen vacunas contra la peste bovina para uso mundial. Desafortunadamente, no ha habido ningún progreso en el secuestro o destrucción de MCVR en los cinco Miembros que mantienen estos materiales fuera de las RHF (*rinderpest holding facilities*) designadas por la FAO-OMSA, a pesar de las discusiones en persona mantenidas durante la Sesión General de la OMSA en mayo de 2024.

En marzo de 2024, se confirmó la nueva composición del Comité Consultivo Mixto (CCC) FAO-OMSA para la peste bovina. Posteriormente, la 19ª reunión del CCC se celebró virtualmente el 26 de abril de 2024. La primera mitad de la reunión sirvió para preparar el terreno y garantizar que los nuevos miembros del CCC estuvieran bien informados de las actividades llevadas a cabo por la FAO y la OMSA desde 2012, así como de las prioridades posteriores a la erradicación. Durante la reunión, el CCC aprobó dos propuestas de investigación para proyectos de «secuenciación y destrucción»: en el Instituto Nacional de Sanidad Animal de Japón y en el CIRAD de Francia. Se debatió el concepto de RVCM «esencial» y el CCC emitirá un dictamen oficial al respecto. Durante la reunión se inició la revisión de la lista de comprobación que utilizan los expertos durante la inspección de las RHF. El proceso de revisión fue informado por una reunión de consulta con la OMS en octubre de 2023. Se definieron los puntos de acción para el CCC y la Secretaría de la Peste Bovina, y los avances se evaluarán durante una llamada de seguimiento el 23 de septiembre de 2024. Por último, se habló de la preparación de las re-inspecciones de las instalaciones de conservación de residuos de CIRAD (Francia) e IVDC (República Popular China) en el último trimestre de 2024, y de la primera inspección del ICAR-NIHSAD (India) en el primer semestre de 2025.

10.2. Actualización del proyecto de biobanco virtual

El experto que dirige el Centro Colaborador de Biobancos Virtuales ofreció información actualizada sobre el proyecto de Biobanco Virtual (VB) de la OMSA. El objetivo principal del VB es facilitar el acceso a los recursos biológicos obtenidos y conservados por los Centros de Referencia y los Laboratorios Nacionales de Referencia de la OMSA. Estos recursos son esenciales para desarrollar y estandarizar pruebas de diagnóstico y para controlar las enfermedades incluidas en la lista de la OMSA.

Aprobado inicialmente a finales de 2019, el proyecto se retrasó debido a la pandemia de COVID-19 y comenzó oficialmente en abril de 2023 tras un proceso de licitación de un año para seleccionar una empresa de TI. El proyecto está dirigido por IZSLER, el Centro Colaborador de Biobancos Biológicos Veterinarios, con el apoyo de la red de *Istituti Zooprofilattici Sperimentali* de Italia. Está prevista una fase piloto a principios de 2025.

El experto solicitó orientaciones a la Comisión sobre las siguientes cuestiones:

Elegibilidad de los proveedores: la Comisión recomendó que, en la fase inicial, los Laboratorios de Referencia de la OMSA y los laboratorios nacionales de referencia con normas de calidad establecidas fueran los principales proveedores del VB. La inclusión de otras instituciones con sólidos sistemas de garantía de calidad, como organizaciones gubernamentales de investigación, podría considerarse en fases posteriores del proyecto.

Restricciones en los tipos de materiales: la Comisión debatió los tipos de materiales que podrían incluirse en el catálogo, sugiriendo restricciones para los patógenos de alto riesgo. Debido a los mayores riesgos asociados a estos agentes patógenos, se requerirá una cuidadosa documentación y autorización, garantizando que todos los

proveedores y receptores cumplan estrictas normas de calidad y marcos legales. También se consideró la inclusión de materiales relacionados con enfermedades no incluidas en la lista de la OMSA.

Normas de calidad para los laboratorios: mientras que las certificaciones ISO 9001 e ISO 20387 se recomendaron durante las discusiones iniciales del proyecto en 2017, el experto señaló que solo un número limitado de laboratorios posee actualmente la certificación ISO 20387. La Comisión acordó que podrían ser necesarias directrices adicionales sobre la calidad y la caracterización de los materiales. Estas directrices podrían desarrollarse en colaboración con las instituciones pertinentes para garantizar que todos los laboratorios participantes cumplen las normas requeridas.

Requisitos de documentación: la Comisión debatió si debían establecerse para el proyecto documentos estandarizados, como las autorizaciones para la manipulación de agentes patógenos restringidos, el uso de OMG y las declaraciones de interés para la investigación de doble uso. En la actualidad, sólo se ha estandarizado el *Acuerdo de Transferencia de Material (ATM)*. Se acordó que la responsabilidad legal de la calidad de los materiales recae en el proveedor y el receptor. Los proveedores deben garantizar que los materiales cumplen las normas exigidas e informar al receptor sobre las medidas de control de calidad aplicadas. El receptor garantiza la correcta manipulación del material de acuerdo con la normativa nacional e internacional.

Cumplimiento del Protocolo de Nagoya: el experto aclaró que no habrá intercambio físico de materiales biológicos a través del Biobanco Virtual; los intercambios se producirán directamente entre laboratorios, y la plataforma funcionará únicamente como un catálogo virtual para facilitar el contacto entre el proveedor y el receptor. El cumplimiento del Protocolo de Nagoya es esencial y será responsabilidad de los laboratorios implicados en el intercambio.

Taxonomía controlada para parásitos y hongos: la Comisión destacó la importancia de la taxonomía controlada para parásitos y hongos. Recurrir a los Laboratorios de Referencia para que aporten su experiencia en este ámbito ayudaría a garantizar la exactitud y coherencia de los datos en el seno del BV.

Directrices sobre la calidad de los materiales: la Comisión convino en que la evaluación de la identidad, concentración, pureza y estabilidad de los materiales es esencial para mantener una norma de alta calidad. Es posible que se necesiten más directrices sobre la calidad y caracterización de los materiales para establecer una norma mínima para todos los materiales incluidos en la base de datos virtual.

En general, la Comisión expresó su apoyo al desarrollo continuado del BV y destacó la necesidad de un diálogo permanente para abordar los aspectos jurídicos, técnicos y estratégicos del proyecto.

10.3. Productos veterinarios de calidad inferior y falsificados

La OMSA identificó lagunas en las capacidades de algunos de sus Miembros para gestionar la calidad de los productos veterinarios tras su registro, con ciertas limitaciones para la prevención, detección y respuesta a la presencia de productos veterinarios de calidad inferior y falsificados (PVIF). Sin embargo, aunque existen algunas referencias a los PVIF en algunos capítulos del *Código Terrestre*, actualmente no existen orientaciones específicas.

Para colmar estas lagunas, la OMSA ha puesto en marcha un nuevo programa de apoyo a la prevención, detección y respuesta a los PVIF que tiene en cuenta un enfoque intersectorial y transfronterizo. Dentro de este programa, la actividad más avanzada es el desarrollo del sistema de monitoreo y vigilancia veterinaria de productos veterinarios de calidad inferior y falsificados (V-SAFE), que se inició a raíz de una recomendación de los Delegados en la 2ª Conferencia Mundial de la OMSA sobre Resistencia a los Antimicrobianos en 2018. El V-SAFE es una fase piloto que permite a los Miembros de la OMSA informar sobre sospechas de productos veterinarios falsificados o de calidad inferior observados principalmente a través de sistemas de farmacovigilancia, vigilancia pasiva, monitoreo de la calidad de las vacunas, etc.

La Comisión debatió si esta iniciativa debía integrarse en el *Manual Terrestre* de la OMSA, en el *Código Terrestre* o en ambos. La opinión inicial de la Comisión fue que el ámbito del programa VSAFE va más allá del *Manual Terrestre*, que trata principalmente de los métodos de diagnóstico y del desarrollo de vacunas. La Comisión subrayó que, mientras que el *Manual Terrestre* ofrece recomendaciones para la calidad de las vacunas, el programa VSAFE pretende garantizar que las vacunas sigan siendo de alta calidad sobre el terreno para asegurar su eficacia aprobada mediante, por ejemplo, una vigilancia activa posterior a la comercialización.

Para responder a estas preocupaciones, se propuso modificar el capítulo 1.1.8 del *Manual Terrestre*. “*Principios de producción de vacunas veterinarias*”, para incluir la vigilancia activa post-comercialización en la sección “Supervisión del mercado”. La Comisión apoyó esta enmienda y sugirió posponer la decisión de ampliarla eventualmente para cubrir otros productos farmacéuticos, como los antiparasitarios y los antimicrobianos.

La Comisión expresó su interés por el desarrollo en curso del programa y señaló que se espera que los borradores de los documentos estén disponibles en breve para su revisión. Animaron a proseguir los debates para garantizar la integración efectiva del programa V-SAFE en las normas y directrices de la OMSA.

Se informó a la Comisión de que se va a informar a las demás Comisiones Especializadas, y los comentarios de la Comisión Científica para las Enfermedades de los Animales indicaron que se recomienda incluir definiciones para los términos «subestándar» y «falsificado» en el *Código Terrestre*. Esta recomendación también fue apoyada por la BSC.

.../Anexos

Anexo 1. Orden del día aprobado

REUNIÓN DE LA COMISIÓN DE NORMAS BIOLÓGICAS París, 9–13 de septiembre de 2024

1. **Bienvenida de las Directoras**
 - 1.1. Directora General
 - 1.2. Directora General Adjunta, Normas Internacionales y Ciencia
2. **Aprobación del orden del día**
3. **Colaboración con otras Comisiones Especializadas**
 - 3.1. Temas horizontales entre las Comisiones Especializadas
 - 3.1.1. Trabajo sobre los animales hospedadores a los que van dirigidas las normas de la OMSA para una enfermedad de los animales terrestres de la Lista de la OMSA
 - 3.2. Comisión Científica para las Enfermedades de los Animales
 - 3.2.1. Definiciones de caso: paratuberculosis, artritis/encefalitis caprina y Maedi-visna
 - 3.2.2. Evaluación de la lista: enfermedad ovina de Nairobi
 - 3.2.3. Recomendaciones del Grupo *ad hoc* sobre scrapie
 - 3.3. Comisión de Normas Sanitarias para los Animales Terrestres
 - 3.3.1. Reunión de las Mesas
 - 3.4. Comisión de Normas Sanitarias para los Animales Acuáticos
4. **Programa de Trabajo**
5. **Manual de Pruebas de Diagnóstico y de las Vacunas para los animales terrestres**
 - 5.1. Formato del informe y sistema de comentarios
 - 5.2. Revisión de los borradores de capítulos y su aprobación para la distribución para la primera ronda de comentarios de los Miembros

#	Capítulo nº	Título del capítulo (año de última aprobación)
1.	1.1.3.	Transporte de materiales biológicos (2018)
2.	1.1.7.	Normas para la secuenciación de alto rendimiento, la bioinformática y la genómica computacional (2016)
3.	1.1.9	Pruebas de esterilidad y ausencia de contaminación de materiales biológicos destinados a uso veterinario (2024)
4.	2.1.1.	Metodologías de laboratorio para las pruebas de susceptibilidad antimicrobiana bacteriana (2019)
5.	2.2.1	Desarrollo y optimización de ensayos de detección de anticuerpos (2014)
6.	2.2.2	Desarrollo y optimización de ensayos de detección de antígenos (2014)
7.	2.2.3	Desarrollo y optimización de ensayos de detección de ácidos nucleicos (2014)
8.	2.2.5	Enfoques estadísticos de la validación (2014)
9.	2.2.8.	Comparabilidad de los ensayos tras cambios menores en un método de ensayo validado (2016)
10.	2.3.2.	El papel de los organismos oficiales en la regulación internacional de los productos biológicos veterinarios (2018)
11.	3.1.2.	Enfermedad de Aujeszky (infección por el virus de la enfermedad de Aujeszky) (2018)
12.	3.1.8.	Fiebre aftosa (infección por el virus de la fiebre aftosa) (2021)
13.	3.1.9.	Cowdriosis (2018)
14.	3.1.21.	Peste bovina (infección por el virus de la peste bovina) (2018)
15.	3.2.4.	Infestación de las abejas melíferas por <i>Aethina tumida</i> (pequeño escarabajo de las colmenas) (2018)
16.	3.2.5.	Infestación de las abejas melíferas por <i>Tropilaelaps</i> spp. (2018)
17.	3.3.1.	Clamidiosis aviar (2018)
18.	3.3.2.	Bronquitis infecciosa aviar (2018)

#	Capítulo nº	Título del capítulo (año de última aprobación)
19.	3.3.4.	Influenza aviar (incluida la infección por virus de la influenza aviar de alta patogenicidad) (2021)
20.	3.4.9.	Leucosis bovina enzoótica (2018)
21.	3.4.13.	Teileriosis bovina (infección por <i>Theileria annulata</i> , <i>T. orientalis</i> y <i>T. parva</i>) (2018)
22.	3.4.14.	Tricomonosis (2018)
23.	3.6.1.	Peste equina africana (infección por el virus de la peste equina africana) (2019)
24.	3.6.5.	Anemia infecciosa equina (2019)
25.	3.8.2.	Artritis/encefalitis caprina y Maedi-visna (2017)
26.	3.8.5.	Aborto enzoótico de las ovejas (clamidiosis ovina) (infección por <i>Chlamydia abortus</i>) (2018)
27.	3.8.11.	Viruela ovina y viruela caprina (2024): sección de vacunas
28.	3.9.1.	Peste porcina africana (2021): sección vacunas
29.	3.9.2.	Peste porcina clásica (infección por el virus de la peste porcina clásica) (2022)
30.	3.9.7.	Enfermedad vesicular porcina (2018)

- 5.3. Respuesta de la Comisión a la segunda ronda de comentarios de los Miembros
- 5.4. Informe sobre un estudio interlaboratorio para seguir validando las pruebas serológicas del muermo
- 5.5. Petición de orientaciones sobre taxonomía y uso de nombres comunes de agentes patógenos
- 5.6. Capítulos suprimidos: ¿se siguen considerando validadas las pruebas según las normas de la OMSA?
- 5.7. Situación del *Manual Terrestre*: actualización de los capítulos seleccionados para el ciclo de revisión 2025/2026
- 5.8. Actualización sobre el proyecto de herramienta de navegación en línea de las normas de la OMSA
- 6. Centros de Referencia de la OMSA**
 - 6.1. Solicitudes de estatus de Centro de Referencia de la OMSA
 - 6.2. Cambios de expertos en los Centros de Referencia de la OMSA
 - 6.3. Revisión de las solicitudes nuevas y pendientes de hermanamiento de laboratorios
 - 6.4. Evaluación de los informes anuales de los Centros Colaboradores
 - 6.5. Centros de referencia que no cumplen los TdR clave: falta de presentación de un informe anual
 - 6.6. Información actualizada sobre el progreso del procedimiento de evaluación de los Centros al final de su mandato quinquenal
 - 6.7. Actualización de los avances en la recepción de viñetas de los Centros Colaboradores para el hipervínculo: «Cómo podemos ayudarle»
 - 6.8. Necesidades de laboratorio, dar visibilidad de lo que se necesita a nivel mundial, no para establecer prioridades sino para informar y presentar las necesidades en los aspectos globales
 - 6.9. Cuestiones relacionadas con los procesos de los Laboratorios de Referencia
 - 6.9.1. Proceso del Laboratorio de Referencia de la OMSA: ¿quién debe firmar los formularios CU y DOI: el experto, el director del instituto o ambos?
 - 6.9.2. ¿Qué se entiende por sistema de gestión de la calidad «equivalente»?
 - 6.10. Actualización de las tres redes de Laboratorios de Referencia (PPA, PPR y rabia)
 - 6.11. Revisión del título del Laboratorio de Referencia para la Nagana: infecciones por tripanosomas salivares y tripanosomosis (transmitida por la mosca tsetsé)
- 7. Reactivos estándar internacionales aprobados por la OMSA**
- 8. Seguimiento a partir de la Sesión General**
- 9. Conferencias, Talleres y Reuniones**
 - 9.1. Información actualizada sobre el seminario de la OMSA que se celebrará durante el Simposio WAVLD en Calgary, Canadá, en 2025
- 10. Cuestiones de interés para consideración o información**
 - 10.1. Información actualizada sobre la peste bovina
 - 10.2. Actualización del proyecto de biobanco virtual
 - 10.3. Productos veterinarios de calidad inferior y falsificados
- 11. Revisión de la reunión**

Anexo 2. Lista de Participantes

REUNIÓN DE LA COMISIÓN DE NORMAS BIOLÓGICAS París, 9–13 de septiembre de 2024

MIEMBROS DE LA COMISIÓN

Prof. Emmanuel Couacy-Hymann
(Presidente)
Professor of Virology
CNRA/LIRED
Abiyán
CÔTE D'IVOIRE

Prof. Ann Cullinane
(Vice-Presidente)
Head of Virology Unit
Irish Equine Centre
Naas
IRLANDA

Prof. Chris Oura
(Vice-Presidente)
Professor of Veterinary Virology,
The University of the West Indies,
St-Augustine
TRINIDAD Y TOBAGO

Dr. Joseph S. O'Keefe
(Miembro)
Head of Animal Health Laboratory
Ministry for Primary Industries
Upper Hutt
NUEVA ZELANDA

Dr. Satoko Kawaji
(Miembro)
Principal Scientist, National
Institute of Animal Health, Naro
JAPÓN

Dr. Donald King
(Miembro)
Head of the Vesicular Disease
Reference Laboratory Group,
The Pirbright Institute
REINO UNIDO

EDITOR CONSULTOR DEL MANUAL TERRESTRE

Dr. John Passick
Editor consultor
CANADÁ

SEDE DE LA OMSA

Dr. Gregorio Torres
Jefe del Departamento Científico

Sra. Sara Linnane
Responsable Científico Senior
Departamento Científico

Dra. Mariana Delgado
Responsable de la Secretaría
Científica
Departamento Científico

Dr. Charmaine Chng
Jefe Adjunto del Departamento
Científico

Anexo 3. Programa de Trabajo para la Comisión de Normas Biológicas de la OMSA

REUNIÓN DE LA COMISIÓN DE NORMAS BIOLÓGICAS
París, 9–13 de septiembre de 2024

Asunto	Tema	Estado y Acción
Actualización del Manual Terrestre	1) Distribuir a los Miembros los capítulos aprobados por la BSC para una primera ronda de comentarios.	Para febrero de 2025
	2) Recordar a los autores de los capítulos identificados previamente para su actualización pero aún no recibidos e invitar a los autores de los capítulos identificados recientemente para su actualización.	En curso
	3) Cargar, publicar e informar a los expertos de los Laboratorios de Referencia sobre la base de datos de informes de validación que se publicará en el sitio web de la OMSA para las pruebas recomendadas en el <i>Manual Terrestre</i> .	Realizado
	4) Incluir como apéndices al final de los capítulos específicos de las enfermedades, las tablas que explican las puntuaciones otorgadas a las pruebas en la Tabla 1 <i>Métodos analíticos disponibles y su finalidad</i> . Añadir enlaces a los informes de validación cuando estén disponibles (punto 3 anterior).	Realizado
	5) Pedir a los Centros de Referencia que proporcionen enlaces a vídeos instructivos adecuados para añadirlos al final de los capítulos específicos de las enfermedades. Los vídeos serán revisados por la Comisión cuando el capítulo se someta a revisión.	En curso
	6) Desarrollar criterios para eliminar los capítulos de enfermedades no incluidas en la lista y evaluar dichos capítulos en función de los criterios.	Realizado
	7) Revisar los nuevos desarrollos en enfermedades que causan impactos globales significativos (por ejemplo, influenza aviar, peste porcina africana) y priorizar esos capítulos.	En curso
	8) Iniciar el proceso para atender la solicitud de acceso a las versiones anteriores y a la evolución del <i>Manual Terrestre</i> , como se hizo con el <i>Código Terrestre</i> .	En curso
	9) Incluir la plantilla de la tabla sobre PCR en la Guía para los contribuidores (armonización con el <i>Manual Acuático</i>).	En curso
Centros Colaboradores	1) Aplicación de los POE adoptados:	Realizado
	a) Desarrollar una plantilla para los Centros Colaboradores para el informe de evaluación de su rendimiento en los últimos 5 años para compararlo con su plan de trabajo inicial de 5 años.	Realizado
	b) Enviar la plantilla de evaluación del plan de trabajo quinquenal a los Centros Colaboradores correspondientes.	Para febrero de 2025
	2) Evaluar los comentarios de los Centros que hayan completado los 5 años y valorar la relevancia actual del alcance de sus actividades para la renovación.	En curso
	3) Aumentar la visibilidad de los Centros actuales: pedirles que presenten un máximo de 5 viñetas para añadirlas a	En curso

Asunto	Tema	Estado y Acción
	su entrada en la web bajo el título «¿Cómo podemos ayudar?»	
	4) Explorar mecanismos para mejorar la colaboración reuniendo a los Centros con la misma área de interés principal (actualmente seis): implicación de la industria u otros socios para la financiación.	Septiembre 2025
	5) Elaborar un cuestionario para recabar la opinión de los Centros Colaboradores sobre sus experiencias como CC de la OMSA, similar al de los Laboratorios de Referencia.	En curso
Laboratorios de Referencia	1) Incluir a los laboratorios de bajo rendimiento en la lista de vigilancia y supervisar su rendimiento.	Realizado
	2) Aplicar el nuevo sistema de evaluación de los informes anuales y facilitar la lista de informes asignados a los miembros de la Comisión	Octubre de 2024
	3) Evaluación de los informes anuales	Realizado
	4) Enviar comentarios a la red de laboratorios de referencia sobre el cuestionario	Realizado
	5) Estudiar mejoras en el proceso de elaboración del informe anual: posibilidad de cumplimentar el modelo de informe anual a lo largo del año.	En curso
Redes de Centros Colaboradores	1) Seguimiento con las tres redes de Laboratorios de Referencia (PPA, PPR y rabia) (potencialmente PPC y FA, OFFLU)	Para febrero de 2025
Estandarización/ Armonización	1) Proyecto de ampliación de la lista de reactivos de referencia aprobados por la OMSA	En curso
	a) Preguntar a las otras redes si aceptan el documento de normas mínimas propuesto por la red PPR. Una vez finalizado, cargar el documento para su aplicación	En curso
	2) Proyecto de desarrollo de un estándar internacional de sustitución para la tuberculina bovina y aviar: finalizar el informe y proponer su adopción.	En curso
Grupos ad hoc	1) Contribuir a la revisión del Capítulo 4.7 <i>del Código Terrestre</i> . Recogida y tratamiento de semen de bovinos, pequeños rumiantes y porcinos	En curso
	2) Contribuir al Grupo <i>ad hoc</i> sobre Enfermedades Emergentes y Factores de Emergencia de Enfermedades en los Animales.	En curso
Proyectos	1) Biobancos veterinarios (proyecto)	Realizado
	2) BIO-PREVAİL: Una iniciativa de seguridad sanitaria para laboratorios sostenibles	Junio 2025
Conferencias, Talleres y Reuniones con la participación de Miembros de la BSC	1) Hoja de ruta de la investigación sobre bioseguridad	En curso
	2) Seminario ISWAVLD de la OMSA: desarrollar un tema y un programa y ponentes. Junio de 2025 en Canadá	Después de mayo de 2025
Resultados	1) Comprometerse con los procesos en curso en torno a las cuestiones de rendimiento con los Laboratorios de Referencia	En curso

Asunto	Tema	Estado y Acción
Elaboración de normas de laboratorio para enfermedades emergentes	1) Discutir el capítulo <i>del Código Terrestre</i> una vez adoptado y considerar la introducción de un capítulo correspondiente para el <i>Manual Terrestre</i>	En curso
Definiciones de caso	1) Seguimiento de la aplicación de los procedimientos operativos estándar para la definición de casos.	Realizado

Anexo 4. Punto 5.3. - Respuestas de la Comisión a los comentarios de la segunda vuelta de los Miembros sobre el Capítulo 3.9.1. «Peste porcina africana (infección por el virus de la peste porcina africana)». Peste porcina africana (infección por el virus de la peste porcina africana), distribuido con el informe de febrero de 2024 antes de la Sesión General (NB: este anexo es meramente informativo, no para comentarios. El anexo 33 es la versión actualizada de este capítulo para comentarios en la tercera ronda.)

REUNIÓN DE LA COMISIÓN DE NORMAS BIOLÓGICAS
París, 9–13 de septiembre de 2024

SECTION 3.9.

SUIDAE

CHAPTER 3.9.1.

AFRICAN SWINE FEVER
(INFECTION WITH AFRICAN SWINE FEVER VIRUS)

Reference	Comment	Biological Standards Commission response
3.9.1_1	<p>Category: general</p> <p>Our country thanks the Committee for seriously considering and adopting some of our recommendations. And our country appreciates WOAHA for promoting the development of safe and effective African swine fever vaccines to enhance members' comprehensive prevention and control capabilities against African swine fever. However, we should pay attention to the complex epidemic situation of African swine fever around the world, and the challenges faced by vaccine research and development. In particular, the safety issue of live attenuated vaccines has not been effectively solved, and the data on vaccine field use are insufficient. Under such circumstances, it's hasty to support the use of African swine fever vaccine, which is likely to bring serious risks to the global pig industry. In order to reduce the risk of vaccine and improve vaccine safety, our country suggests that this chapter be revised as follows.</p> <p>First of all, we suppose the safety of the vaccine for sows should be emphasised in the draft. As we know the vaccine will be used in large quantities and may be in wide range after approval. Even if it does not directly immunise sows, it is very likely to infect sows through horizontal transmission. Considering that, our country suggests to add "sow safety" to the minimum requirements for vaccines, and</p>	<p>EN: First point: agreed, due to possible risks from horizontal transmission, to add an extra section on safety testing in pregnant sows similar to the classical swine fever chapter, as the population that is likely to be the most sensitive indicator of any adverse effects (one single dose for pregnant sows). Safety tests for other growth stages could be undertaken as preferred.</p> <p>Second point: Without a better understanding of the frequency of recombination, this kind of recombination evaluation testing would be difficult to introduce. Identifying and monitoring recombination under field conditions is not a trivial undertaking and there is currently insufficient information to expand the section on strain recombination evaluation testing in the field. This should be included in separate guidelines on post-vaccination monitoring that are being developed.</p> <p>Conditional licensing under controlled conditions could be a solution to obtain field data for final decisions on the use of the vaccine to complement national control measures.</p> <p>Prevalence of circulating virus strains should be evaluated prior to commencing vaccination campaigns.</p> <p>Third point: see later in the chapter.</p> <p>FR: Premier point : compte tenu du risque posé par la probabilité d'une transmission horizontale, la Commission accepte la proposition d'ajouter un paragraphe supplémentaire dédié aux essais d'innocuité chez les truies gestantes, similaire à celui qui existe dans le chapitre sur la peste porcine</p>

Reference	Comment	Biological Standards Commission response
	<p>supplement the safety evaluation indicators for sows.</p> <p>Secondly, it might be necessary to add vaccine recombination evaluation test. In view of the pathogenic characteristics of African swine fever, strain recombination is an important factor affecting the safety of live attenuated African swine fever vaccine, therefore recombination evaluation should be run through the whole process from R & D to field use. At current, the revised draft has clarified the risk of strain recombination and ask for post-vaccination surveillance for recombination. On this basis, our country suggests to further supplement the strain recombination evaluation test, specifically including laboratory evaluation and field evaluation.</p> <p>Thirdly, we suppose to improve another two technical indicators (in text).</p>	<p>classique : en effet la sensibilité de cette catégorie d'animaux à d'éventuels effets indésirables en fait un bon indicateur (dose unique pour les truies gestantes). Des essais d'innocuité spécifiques pour d'autres stades de croissance peuvent être effectués suivant les préférences.</p> <p>Deuxième point : tant que la fréquence des recombinaisons n'est pas mieux comprise, il paraît difficile d'introduire des tests de ce type pour déterminer l'existence d'une recombinaison. L'identification et le suivi des recombinaisons dans des conditions de terrain ne sont pas des entreprises anodines et les informations actuellement disponibles sont insuffisantes pour proposer un texte sur les tests visant à déterminer l'existence de recombinaisons entre souches sur le terrain. Cet aspect devrait être traité dans les lignes directrices sur le suivi post-vaccinal qui sont en préparation.</p> <p>La délivrance d'une licence provisoire dans des conditions contrôlées pourrait être une solution afin d'obtenir des données de terrain pour une décision définitive sur l'utilisation du vaccin, en complément des mesures nationales de lutte contre la maladie.</p> <p>La prévalence des souches virales présentes sur le terrain devrait faire l'objet d'une évaluation avant de démarrer les campagnes de vaccination.</p> <p>Troisième point : voir plus loin dans le chapitre.</p> <hr/> <p>ESP: Primer punto: se acuerda, debido a los posibles riesgos de transmisión horizontal, añadir una sección adicional sobre pruebas de seguridad en cerdas gestantes similar al capítulo sobre peste porcina clásica, ya que es la población que probablemente sea el indicador más sensible de cualquier efecto adverso (una sola dosis para cerdas gestantes). Si se prefiere, podrían realizarse pruebas de seguridad para otras fases de crecimiento.</p> <p>Segundo punto: Sin un mejor conocimiento de la frecuencia de la recombinación, sería difícil introducir este tipo de pruebas de evaluación de la recombinación. La identificación y el seguimiento de la recombinación en condiciones de campo no es una tarea trivial y actualmente no hay información suficiente para ampliar la sección sobre las pruebas de campo de evaluación de la recombinación de cepas. Esto debería incluirse en directrices separadas sobre el seguimiento post-vacunación que se están desarrollando.</p> <p>La concesión condicional de licencias en condiciones controladas podría ser una solución para obtener datos de campo para las decisiones finales sobre el uso de la vacuna como complemento de las medidas nacionales de control.</p> <p>La prevalencia de las cepas de virus circulantes debería evaluarse antes de iniciar las campañas de vacunación.</p> <p>Tercer punto: véase más adelante en el capítulo.</p>

Reference	Comment	Biological Standards Commission response
3.9.1_2	<p>Category: general</p> <p>We thank the WOHAI Biological Standards Commission for this work being moved forward. We can in general support this revised chapter. It appears that there are still several points that need to be clarified and we invite the Commission to review them.</p> <p>As a general point, we note that throughout the text reference is sometimes made to either “licensing”, “registration” or “authorisation”. We would recommend to rather use the term “regulatory approval”, which works in all jurisdictions across the world, and has been used systematically in other recently adopted Manual chapters. This would include the title of Section 2.3. “Requirements for authorisation/registration/ licensing” (Line 297), that should be replaced with “Requirements for regulatory approval”.</p>	<p>EN: Agreed, text amended in multiple places for consistency.</p>
		<p>FR: La Commission a souscrit au commentaire ; le texte est modifié à plusieurs endroits pour des raisons de cohérence.</p>
		<p>SP: Aceptado, el texto se modificó en múltiples lugares por coherencia.</p>
3.9.1_3	<p>Category: general</p> <p>This section needs significant proofreading. There are many structural issues that make the ideas hard to follow or the requirements of the chapter unclear.</p> <p>There are many instances of requirements worded as either suggestions (often using the word “should”), or as technical methods (e.g. To obtain individual and group mean baseline temperatures...). These need to be revised for clarity.</p> <p>There is unnecessary repetition and redundancy in the writing.</p> <p>The structure of some sentences/paragraphs makes the intent hard to understand (I have given the first instance of these issues specific comments).</p> <p>There are technical instructions for how to perform tests in the requirements for test compliance, and requirements for test compliance in the instructions for how to perform the tests. These should be kept to their sections.</p>	<p>EN: Agreed, editorial amendments have been made. Some of the repetition is necessary to enable different sections of the text to be read in isolation, but much of the repetition has been removed.</p>
		<p>FR: La Commission a souscrit à ce commentaire et introduit quelques amendements de nature éditoriale. Certaines des répétitions invoquées sont nécessaires car chaque section du texte doit pouvoir être lue de manière autonome ; les répétitions inutiles ont été supprimées.</p>
		<p>SP: De acuerdo, se han introducido modificaciones de redacción. Algunas de las repeticiones son necesarias para permitir la lectura aislada de las diferentes secciones del texto, pero se ha suprimido gran parte de las repeticiones.</p>

SUMMARY

African swine fever (ASF) is an infectious disease of domestic and wild pigs of all breeds and ages, caused by ASF virus (ASFV). The clinical syndromes vary from peracute, acute, subacute to chronic, depending on the virulence of the virus. Acute disease is characterised by high fever, haemorrhages in the reticuloendothelial system, and a high mortality rate. Soft ticks of the Ornithodoros genus, especially O. moubata and O. erraticus, have been shown to be both reservoirs and transmission vectors of ASFV. The virus is present in tick salivary glands and passed to new hosts (domestic or wild suids) when feeding. It can be transmitted sexually between ticks, transovarially to the eggs, or transtadially throughout the tick's life.

ASFV is the only member of the Asfarviridae family, genus Asfivirus.

Laboratory diagnostic procedures for ASF fall into two groups: detection of the virus and serology. The selection of the tests to be carried out depends on the disease situation and laboratory diagnostic capacity in the area or country.

Identification of the agent: Laboratory diagnosis must be directed towards isolation of the virus by inoculation of pig leukocyte or bone marrow cultures, the detection of antigen in smears or cryostat sections of tissues by fluorescent antibody test and/or the detection of genomic DNA by the polymerase chain reaction (PCR) or real-time PCR. The PCRs are excellent, highly sensitive, specific and rapid techniques for ASFV detection and are very useful under a wide range of circumstances. They are especially useful if the tissues are unsuitable for virus isolation and antigen detection. In doubtful cases, the material is passaged in leukocyte cell cultures and the procedures described above are repeated.

Serological tests: Pigs that survive natural infection usually develop antibodies against ASFV from 7–10 days post-infection and these antibodies persist for long periods of time. Where the disease is endemic, or where a primary outbreak is caused by a strain of low or moderate virulence, the investigation of new outbreaks should include the detection of specific antibodies in serum or extracts of the tissues submitted. A variety of methods such as the enzyme-linked immunosorbent assay (ELISA), the indirect fluorescent antibody test (IFAT), the indirect immunoperoxidase test (IPT), and the immunoblotting test (IBT) is available for antibody detection.

Requirements for vaccines: At present, there is no vaccine for ASF. Commercially produced modified live virus vaccines are available and licenced under field evaluation in some countries.

Reference	Comment	Biological Standards Commission response
3.9.1_SUMMARY_1	Category: change Lines 34–35: This text should be updated and aligned with the information given in lines 163–164.	EN: Agreed.
		FR: La Commission a souscrit au commentaire.
		SP: Aceptado.

A. INTRODUCTION

The current distribution of African swine fever (ASF) extends across more than 50 countries in three continents (Africa, Asia and Europe). Several incursions of ASF out of Africa were reported between the 1960s and 1970s. In 2007, ASF was introduced into Georgia, from where it spread to neighbouring countries including the Russian Federation. From there ASF spread to eastern European countries extending westwards and reaching the European Union in 2014. Further westward and southern spread in Europe has occurred since that time. In all these countries, both hosts – domestic pig and wild boar – were affected by the disease. In August 2018, the People’s Republic of China reported its first outbreak of ASF and further spread in Asia has occurred. ASF was identified on the island of Hispaniola (Haiti and the Dominican Republic) in 2021. See WAHIS (<https://wahis.woah.org/#/home>) for recent information on distribution at the country level.

ASF virus (ASFV) is a complex large, enveloped DNA virus with icosahedral morphology. It is currently classified as the only member of the *Asfviridae* family, genus *Asfivirus* (Dixon *et al.*, 2005). More than 60 structural proteins have been identified in intracellular virus particles (200 nm) (Alejo *et al.*, 2018). More than a hundred infection-associated proteins have been identified in infected porcine macrophages, and at least 50 of them react with sera from infected or recovered pigs (Sánchez-Vizcaíno & Arias, 2012). The ASFV double-stranded linear DNA genome comprises between 170 and 193 kilobases (kb) and contains between 150 and 167 open reading frames with a conserved central region of about 125 kb and variable ends. These variable regions encode five multigene families that contribute to the variability of the virus genome. The complete genomes of several ASFV strains have been sequenced (Bishop *et al.*, 2015; Chapman *et al.*, 2011; de Villiers *et al.*, 2010; Portugal *et al.*, 2015). Different strains of ASFV vary in their ability to cause disease, but at present there is only one recognised serotype of the virus detectable by antibody tests.

The molecular epidemiology of the disease is investigated by sequencing of the 3’ terminal end of the B646L open reading frame encoding the p72 protein major capsid protein, which differentiates up to 24 distinct genotypes (Achenbach *et al.*, 2017; Boshoff *et al.*, 2007; Quembo *et al.* 2018). To distinguish subgroups among closely related ASFV, sequence analysis of the tandem repeat sequences (TRS), located in the central variable region (CVR) within the B602L gene (Gallardo *et al.*, 2009; Lubisi *et al.*, 2005; Nix *et al.*, 2006) and in the intergenic region between the I73R and I329L genes, at the right end of the genome (Gallardo *et al.*, 2014), is undertaken. Several

other gene regions such as the E183L encoding p54 protein, the CP204L encoding p30 protein, and the protein encoded by the EP402R gene (CD2v), have been proved as useful tools to analyse ASFVs from different locations and hence track virus spread.

ASF viruses produce a range of syndromes varying from peracute, acute to chronic disease and subclinical infections. Pigs are the only domestic animal species that is naturally infected by ASFV. European wild boar and feral pigs are also susceptible to the disease, exhibiting clinical signs and mortality rates similar to those observed in domestic pigs. In contrast African wild pigs such as warthogs (*Phacochoerus aethiopicus*), bush pigs (*Potamochoerus porcus*) and giant forest hogs (*Hydrochoerus meinertzhageni*) are resistant to the disease and show few or no clinical signs. These species of wild pig act as reservoir hosts of ASFV in Africa (Costard *et al.*, 2013; Sánchez-Vizcaíno *et al.*, 2015).

The incubation period is usually 4–19 days. The more virulent strains produce peracute or acute haemorrhagic disease characterised by high fever, loss of appetite, haemorrhages in the skin and internal organs, and death in 4–10 days, sometimes even before the first clinical signs are observed. Case fatality rates may be as high as 100%. Less virulent strains produce mild clinical signs – slight fever, reduced appetite and depression – which can be readily confused with many other conditions in pigs and may not lead to suspicion of ASF. Moderately virulent strains are recognised that induce variable disease forms, ranging from acute to subacute. Low virulence, non-haemadsorbing strains can produce subclinical non-haemorrhagic infection and seroconversion, but some animals may develop discrete lesions in the lungs or on the skin in areas over bony protrusions and other areas subject to trauma. Animals that have recovered from either acute, subacute or chronic infections may potentially become persistently infected, acting as virus carriers. The biological basis for the persistence of ASFV is still not well understood, nor it is clear what role persistence plays in the epidemiology of the disease.

ASF cannot be differentiated from classical swine fever (CSF) by either clinical or post-mortem examination, and both diseases should be considered in the differential diagnosis of any acute febrile haemorrhagic syndrome of pigs. Bacterial septicaemias may also be confused with ASF and CSF. Laboratory tests are essential to distinguish between these diseases.

In countries free from ASF but suspecting its presence, the laboratory diagnosis must be directed towards isolation of the virus by the inoculation of pig leukocyte or bone marrow cultures, the detection of genomic DNA by polymerase chain reaction (PCR) or the detection of antigen in smears or cryostat sections of tissues by direct fluorescent antibody test (FAT). Currently the PCR is the most sensitive technique and can detect ASFV DNA from a very early stage of infection in tissues, ethylene diamine tetra-acetic acid (EDTA)-blood and serum samples. The PCR is particularly useful if samples submitted are unsuitable for virus isolation and antigen detection because they have undergone putrefaction. Pigs that have recovered from acute, subacute or chronic infections usually exhibit a viraemia for several weeks making the PCR test a very useful tool for the detection of ASFV DNA in pigs infected with low or moderately virulent strains. Virus isolation by the inoculation of pig leukocyte or bone marrow cultures and identification by haemadsorption tests (HAD) are recommended as a confirmatory test when ASF is positive by other methods, particularly in the event of a primary outbreak or a case of ASF.

As no vaccine is available, the presence of ASFV antibodies is indicative of previous infection and, as antibodies are produced from the first week of infection and persist for long periods, they are a good marker for the diagnosis of the disease, particularly in subacute and chronic forms.

Vaccines should be prepared in accordance with Chapter 1.1.8 *Principles of veterinary vaccine production*. Current ASF modified live virus (MLVs) vaccines are based on the live virus that have been naturally attenuated or attenuated by targeted genetic recombination through cell cultures (Gladue & Borca, 2022). MLV production is based on a seed-lot system consistent with the *European Pharmacopoeia* (11th edition) and that has been validated with respect to virus identity, sterility, purity, potency, stability, safety and immunogenicity (including spread), non-transmissibility, stability and immunogenicity. ASF MLV first generation vaccines – defined as those for which peer-reviewed publications are in the public domain – should meet or exceed the minimum standards as described below. Paramount Demonstration of acceptable safety and efficacy against the epidemiologically relevant ASFV field strain(s) circulating in areas where the vaccine is intended for use are is required. At the present time, a variety of mutants (Forth *et al.*, 2023) and recombinants (Zhao *et al.*, 2023) have emerged globally, and the prevalence of these strains is increasing. In addition, there is a risk that vaccine strains will recombine with circulating strains. These conditions should be taken into account in vaccine development. acceptable efficacy should be shown against the B646L (p72) genotype II pandemic virus lineage currently circulating widely in domestic pigs and wild boar.

ASF MLV first generation vaccines allowing the differentiation of infected animals from vaccinated animals (DIVA) by suitable methods (e.g. serology-based tests) are preferred. Demonstration of MLV safety and efficacy in pigs at different growth stages (suckling piglets, nursery pigs, fattening pigs), the safety in breeding-age boars, gilts and pregnant sows, and onset and duration of protective immunity, are also preferred but are not required to meet the minimum standard. Additional data will likely be required by Regulatory Authorities if these categories are included in the indications for the vaccine. Details of the onset of immunity (the interval of time elapsed between vaccination

and challenge if protection is confirmed) and the duration of immunity (the time point at which vaccine-induced immunity begins to decline and provides less protection) are also required to meet minimum standards.

Reference	Comment	Biological Standards Commission response
3.9.1_INTRO_3	<p>Category: change</p> <p><u>ASF MLV first generation vaccines allowing the differentiation of infected animals from vaccinated animals (DIVA) by suitable methods (e.g. serology-based tests) are preferred. Demonstration of MLV safety and efficacy in pigs at target age and safety at different growth stages (suckling piglets, nursery pigs, fattening pigs), the safety in breeding-age boars, gilts and pregnant sows, and onset and duration of protective immunity, are also preferred but are not required to meet the minimum standard.</u></p> <p>Reason: The efficacy in pigs at different growth stages, breeding-age boars, gilts and pregnant sows can be preferred, but not required. Efficacy is required for the targeted pig groups because the vaccine will be used for the animals in this groups. However, the efficacy for non-targeted groups will be benefit for further improvement of the vaccine, but it is not a required condition because the vaccine does not claim to be used for the animals other than the targeted animals. But the safety in pigs at different growth stages, breeding-age boars, gilts and pregnant sows should be a required condition. Due to the evidence of horizontal spread of MLV, it is essential to demonstrate the safety of a MLV in pigs at different growth stages (suckling piglets, nursery pigs, fattening pigs), in breeding-age boars, gilts and pregnant sows, because horizontal transmission could happen from vaccinated pigs to those non-target pigs.</p>	<p>EN: Agreed in part. A section on safety testing in pregnant sows, as the population that is likely to be the most sensitive indicator of any adverse effects (one single dose for pregnant sows) has been added as a minimum standard. Safety tests for other growth stages could be undertaken as preferred.</p> <p>FR: Commentaire accepté en partie. Un paragraphe sur les essais d'innocuité chez les truies gestantes a été ajouté en tant que norme minimale, cette population étant, par sa sensibilité à d'éventuels effets indésirables, un bon indicateur (dose unique pour les truies gestantes). Des essais d'innocuité pour d'autres stades de croissance peuvent être effectués suivant les préférences.</p> <p>SP: Aceptado en parte. Se ha añadido como norma mínima una sección sobre pruebas de seguridad en cerdas gestantes, ya que es la población que probablemente sea el indicador más sensible de cualquier efecto adverso (una sola dosis para cerdas gestantes). Podrían realizarse pruebas de seguridad para otras etapas de crecimiento según se prefiera</p>
3.9.1_INTRO_4	<p>Category: deletion</p> <p>“Demonstration of MLV safety and efficacy in pigs at different growth stages (suckling piglets, nursery pigs, fattening pigs), the safety in breeding-age boars...”</p> <p>Comment: We do not think this is necessary and it is confusing (as tests are recommended in 4-10 week-old piglets, therefore categories mentioned in the brackets could be deleted)</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>
3.9.1_INTRO_5	<p>Category: Editorial</p> <p><u>...if these specific categories are included....</u></p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>
3.9.1_INTRO_6	<p>Category: change</p> <p>“... (the time point at which vaccine-induced immunity begins to decline and provides less protection)....”</p> <p>comment: In our opinion this sentence is not accurate, and we propose to change as follow:</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>

Reference	Comment	Biological Standards Commission response
	" <u>Last</u> time-point at which vaccine-induced immunity begins to decline and provides less protection <u>has been demonstrated.</u> "	

ASF epidemiology is complex with different epidemiological patterns of infection occurring in Africa and Europe. ASF occurs through transmission cycles involving domestic pigs, wild boar, wild African suids, and soft ticks (Sánchez-Vizcaíno *et al.*, 2015). In regions where *Ornithodoros* ~~soft-bodied~~ ticks are present, the detection of ASFV in these reservoirs of infection contributes to a better understanding of the epidemiology of the disease. This is of major importance in establishing effective control and eradication programmes (Costard *et al.*, 2013).

ASF is not a zoonotic disease and does not affect public health (Sánchez-Vizcaíno *et al.*, 2009).

ASFV should be handled with an appropriate level of bio-containment, determined by risk analysis in accordance with Chapter 1.1.4 *Biosafety and biosecurity: Standard for managing biological risk in the veterinary laboratory and animal facilities.*

...

C. REQUIREMENTS FOR VACCINES [UNDER REVIEW]

At present there is no commercially available vaccine for ASF. Commercially produced modified live virus vaccines are being evaluated and licensed for field use.

3.9.1_C_1	<p>Category: editorial</p> <p>Lines 135-136: This text should be aligned with the information given in lines 162-163 about currently authorised vaccines and others under development.</p>	<p>EN: Comment not clear and no rationale provided. Changes have been made that we hope resolve this.</p> <p>FR: Ce commentaire manque de clarté et aucune justification n'est fournie. Des modifications ont été introduites par la Commission dans l'espoir de résoudre la question.</p> <p>SP: Comentario poco claro y sin justificación. Se han introducido cambios que esperamos resuelvan este problema.</p>
-----------	--	---

1. Background

The ASF p72 genotype II strains (ASFV Georgia 2007/1 lineage) (NCBI, 2020) are recognised to be the current highest global threat for domestic pig production worldwide (Penrith *et al.*, 2022). However, genotype I attenuated strains and genotype I/II recombinant strains have been reported to be circulating. In Africa, multiple genotypes are circulating.

Reference	Comment	Biological Standards Commission response
3.9.1_C1_1	<p>Category: change</p> <p><u>However, genotype I low virulent-attenuated strains and genotype I/II recombinant strains have been reported to be circulating. In Africa, multiple genotypes are circulating.</u></p> <p>Reason: The term "attenuated" better applies to a laboratory procedure that weakens a pathogen. The term "low virulent" is better used when referring to a natural product.</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>

Guidelines for the production of veterinary vaccines are given in Chapter 1.1.8 *Principles of Veterinary Vaccine Production*. Varying additional requirements relating to quality (including purity and potency), safety, and efficacy will apply in particular countries or regions for manufacturers to comply with local regulatory requirements.

Wherever live, virulent ASFV or ASF MLVs are stored, handled and disposed, the appropriate biosecurity level, procedures and practices should be used. The ASF MLV vaccine production facility should meet the requirements for containment outlined in Chapter 1.1.4 *Biosafety and biosecurity: Standard for managing biological risk in the veterinary laboratory and animal facilities*.

An optimal ASF MLV first generation vaccine for the target host should have the following general characteristics (minimum standards):

- Safe: demonstrate absence of persistent fever as defined below (see Section 2.3.2) and clinical signs of acute or chronic ASF in vaccinated and in-contact animals, minimal and ideally no vaccine virus transmission, and absence of an increase in virulence (genetic and phenotypic stability);
- Efficacious: protects against mortality, reduces acute disease (fever accompanied by the appearance of clinical signs caused by ASF) and reduces vertical (boar semen and placental) and horizontal disease transmission;

Reference	Comment	Biological Standards Commission response
3.9.1_C1_2	<p>Category: addition</p> <p><u>and reduces vertical (boar semen and placental) and reduces vertical (boar semen and placental) and horizontal disease transmission.</u></p> <p>Reason: The term “attenuated” better applies to a laboratory p This is an important consideration for field use, especially if vaccine virus is transmitted to wild suids. Certain strains of vaccine virus have been shown to revert to virulence and be transmissible to non-vaccinates. If used in a domestic swine population, vaccine virus could theoretically transmit to wild swine populations, revert to virulence, and cause disease where none was present before. In regard to vertical transmission in wild suids, this could present a long-term problem due only to vaccine virus usage. This is a major concern when considering vaccination before an outbreak vs vaccination in response to a natural outbreak. Procedure that weakens a pathogen. The term “low virulent” is better used when referring to a natural product.</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>

- Quality – purity: free from wild-type ASFV and extraneous microorganisms that could adversely affect the safety, potency or efficacy of the product;

Reference	Comment	Biological Standards Commission response
3.9.1_C1_3	<p>Category: deletion</p> <p><i>....that could adversely affect the safety, potency or efficacy of the product:</i></p> <p>Comment: This text is not needed and can be deleted. If left, please delete ‘potency’ because this word is mostly linked to efficacy of the vaccine so using both is redundant.</p>	<p>EN: Agreed to remove “potency”, but maintain the rest of the text because the presence of extraneous microorganisms or wildtype ASFV can impact the efficacy and safety</p> <p>FR: La Commission a accepté la suppression de « <i>potency</i> » (activité), mais le reste de la phrase est maintenu car la présence de micro-organismes adventices ou de souches sauvages du virus de la PPA peut avoir une incidence sur l’efficacité et la sécurité.</p> <p>SP: Se acepta suprimir «potencia», pero mantener el resto del texto, ya que la presencia de microorganismos extraños o de virus de la peste porcina africana de tipo salvaje puede afectar a la eficacia y la seguridad.</p>

- Quality – potent stability: the log₁₀-virus titre maintained throughout the vaccine shelf life that guarantees the efficacy demonstrated by the established minimum immunising (protective) dose.
- Identity–Vaccine matching: based on the capacity to protect against the ASFV B646L (p72) genotype II pandemic strain or other p72 genotypes of recognised epidemiologic importance.

Vaccine production should be carried out using a validated, controlled and consistent manufacturing process.

ASF MLV first generation vaccines must be safe (i.e. an acceptable safety profile) for non-target species and the environment in general.

Ideally, ASF MLV first generation vaccines that meet the minimum standards should also fulfil the following additional general characteristics: i) prevents acute and persistent (carrier state) disease; ii) prevents horizontal and vertical disease transmission; iii) induces rapid protective immunity (e.g. < 2 weeks); and iv) confers stable, life-long immunity.

Furthermore, ASF MLV second and future generation vaccines should meet the minimum safety and efficacy standards as ASF MLV first generation vaccines, and ideally provide additional product profile benefits, including but not limited to: i) contain a negative marker allowing the differentiation of infected from vaccinated animals (DIVA) by reliable discriminatory tests such as serology-based tests; and ii) confer broad range of protection against other p72 genotype field strains of varying virulence (low, moderate, and high).

The majority of ASF global vaccine research groups and companies are currently focused on ASF MLV first generation vaccine candidates that are safe and efficacious against ASF viruses belonging to the ASFV p72 genotype II pandemic strain (ASFV Georgia 2007/1 lineage) (NCBI, 2020). More research is needed to determine whether these genotype II-specific MLVs can effectively protect against newly circulating variants of genotype II and recombinant strains.

Reference	Comment	Biological Standards Commission response
3.9.1_C1_4	<p>Category: deletion</p> <p><u>The majority of ASF global vaccine research groups and companies are currently focused on ASF MLV first generation vaccine candidates that are safe and efficacious against ASF viruses belonging to the ASFV p72 genotype II pandemic strain (ASFV Georgia 2007/1 lineage) (NCBI, 2020).</u></p> <p>Reason: Certain strains of vaccine virus have been shown to revert to virulence and be transmissible to non-vaccinates. The “current focus” is on a strain that was shown to revert to virulence in certain conditions. The deletion makes this chapter more adaptable as further scientific data is generated/published.</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>

Currently, two recombinant gene deleted MLV recombinant vaccines (ASFV-G-ΔI177L and ASFV-G-ΔMGF) have been licenced for field use in Vietnam for use in domestic pigs following supervised field testing to evaluate the safety and effectiveness of several vaccine batches.

There are numerous, promising ASF MLV vaccine candidates targeting the p72 genotype II pandemic strain under development, including:

- A naturally attenuated field strain (Lv17/WB/Rei1) (Barasona *et al.*, 2019) being developed as an oral bait vaccine for wild boars;
- A laboratory thermo-attenuated field strain (ASFV-989) (Bourry *et al.*, 2022);
- Single gene-deleted, recombinant viruses (e.g. SY18ΔI226R, ASFV-G-ΔA137R) (Gladue *et al.*, 2021; Zhang *et al.*, 2021);
- Double gene-deleted, recombinant viruses (e.g. ASFV-G-Δ9GL/AUK; ASFV-SY18-ΔCD2v/UK; Arm-ΔCD2v-ΔA238L) (O’Donnell *et al.*, 2016; Pérez-Núñez *et al.*, 2022; Teklue *et al.*, 2020);

- Multiple gene-deleted, recombinant viruses (ASFV-G-ΔI177L/ΔLVR; ASFV-G-ΔMGF; BA71ACD2; HLJ/18-7GD; ASFVGZΔI177LΔCD2vΔMGF) (Borca *et al.*, 2021; Chen *et al.*, 2020; Kitamura *et al.*, 2023; Liu *et al.*, 2023; Monteagudo *et al.*, 2017; O'Donnell *et al.*, 2015).

Reference	Comment	Biological Standards Commission response
3.9.1_C1_5	<p>Category: addition</p> <p>Multiple gene-deleted, recombinant viruses (ASFV-G-ΔI177L/ΔLVR; ASFV-G-ΔMGF; BA71ACD2; HLJ/18-7GD; ASFVGZΔI177LΔCD2vΔMGF; Arm07ΔMGF) (Borca <i>et al.</i>, 2021; Chen <i>et al.</i>, 2020; Kitamura <i>et al.</i>, 2023; Liu <i>et al.</i>, 2023; Monteagudo <i>et al.</i>, 2017; O'Donnell <i>et al.</i>, 2015)</p> <p>Reason: We request the inclusion of the strain name, which was mistakenly not included in the latest draft despite BSC's previous agreement to include it.</p> <p>Our country's research has led to the development of a vaccine candidate strain with a larger gene deletion than those referenced in the current draft. This strain has shown strong viremia suppression, suggesting higher safety levels than previous strains. We propose adding this strain as an example because the original paper is already referenced.</p> <p>Reference: https://pubmed.ncbi.nlm.nih.gov/36851524/#full-view-affiliation-1</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>

Information regarding many of these MLV vaccine candidates can be found in a recent review publication (Brake, 2022).

Different DIVA strategies using serological methods (e.g. ELISA) or genome detection methods (e.g. differential real-time PCR) are not widely available for these ASF MLV first generation vaccine candidates. Therefore, there is still room for improvement with respect to marker vaccines and their companion diagnostic tests.

Inactivated (non-replicating) whole virus vaccines are not presently available and may be difficult to develop to meet minimum efficacy standards. Recombinant vectored, subunit vaccine candidates that can be produced in scalable vaccine platform expression systems and mRNA-based ASF vaccines are being evaluated in ongoing laboratory research, testing and evaluation in experimental challenge models. The publicly available *Center of Excellence for African Swine Fever Genomics* (ASFV Genomics, 2022¹) that provides the structural protein predictions for all 193 ASFV proteins may help accelerate ASF first and second generation vaccine research and development.

Reference	Comment	Biological Standards Commission response
3.9.1_C1_6	<p>Category: addition</p> <p>As most Members have ratified the Cartagena Protocol on Biosafety, they are required to adhere to its regulations concerning genetically modified organisms (GMOs) handling. Therefore, we request this paragraph include a reference to Chapter 1.1.8 section 7.2.3.2. to highlight that the field use of genetically modified ASFV strains with marker genes, regardless of the presence or degree of its virulence, should be compliant with the Cartagena Protocol's regulations for conserving biodiversity.</p> <p>Rationale: In this section, it is indicated that specific attenuated strains of ASFV, which are genetically modified for use in vaccines, contain inserted exogenous genes coding for fluorescent proteins or enzymes. These genes serve as markers during production and purification of the ASFV strains. It is</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>

¹ <http://asfvgenomics.com>, Accessed 4/4/2023.

	<p>crucial to emphasise that deploying such GMOs in the field without assessing their environmental impact contravenes the Cartagena Protocol on Biosafety, which is designed to protect biodiversity in the environment. Thus, this issue should be highlighted as a significant point to be noted.</p>	
--	--	--

Any future use of vaccine candidates should be based on a thorough risk–benefit assessment considering all safety and efficacy features, as well as the potential vaccination scenario. Fit-for-purpose vaccine use scenarios matched to the intended use in a domestic pig-specific type of production system may require different vaccine product profiles or may influence the focus of essential versus ideal vaccine requirements. Prudent use of ASF MLVs as part of strict, controlled vaccination programmes, especially in the areas where ASF is not prevalent, should be implemented.

Reference	Comment	Biological Standards Commission response
3.9.1_C1_7	<p>Category: addition</p> <p><u>Prudent use of ASF MLVs as part of strict, controlled vaccination programmes, especially in the areas where ASF is not prevalent, should be implemented. Transmission of vaccine virus to non-vaccinates (domestic or wildlife) is particularly problematic in areas where ASF is not present.</u></p> <p>Reason: Certain strains of vaccine virus have been shown to revert to virulence and be transmissible to non-vaccinates. If used in a domestic swine population, vaccine virus could theoretically transmit to wild swine populations, revert to virulence, and cause disease where none was present before. This is a major concern when considering vaccination before an outbreak vs. vaccination in response to a natural outbreak.</p>	<p>EN: Agreed, but changed “is” to “could be”</p> <p>FR: Commentaire accepté, mais en remplaçant « is » (est) par « could be » (pourrait être).</p> <p>SP: Aceptado, pero se ha cambiado «es» por «podría ser».</p>

It is important to know what genotypes of ASFV are circulating in a population before vaccination is introduced. Due to the potential risk of recombination events between circulating low and high virulent field strains with future licensed vaccine strains, and the possibility of reversion to virulence of vaccine strains, strict pharmacovigilance post-vaccination is essential. Field pharmacovigilance data should be collected and analysed during vaccination campaigns using ASF MLV first generation vaccines post-licensing. Active post-vaccination surveillance programmes for the detection of new ASF viruses that may arise from MLV vaccine strains and naturally circulating wild-type virus recombination, as well as revertant vaccine strains, should be implemented. It is also recommended that vaccine manufacturers carry out laboratory experiments to further evaluate the risk of vaccine virus recombination with field and vaccine strains.

Reference	Comment	Biological Standards Commission response
3.9.1_C1_8	<p>Category: addition</p> <p><u>Due to the potential risk of recombination events between circulating low and high virulent field strains with future licensed vaccine strains, and the possibility of reversion to virulence of vaccine strains, strict pharmacovigilance using standard reporting criteria (e.g. any fever is reportable – in contrast to the safety testing criteria below of 3 days of fever) post-vaccination is essential. Field pharmacovigilance data should be collected and analysed during vaccination campaigns using ASF MLV first generation vaccines post-licensing. Active post-vaccination surveillance programmes for the detection of new ASF viruses that may arise from MLV vaccine strains and naturally circulating wild-type virus recombination, as well as revertant vaccine strains, should be implemented. It is also recommended that vaccine manufacturers carry out laboratory experiments to further evaluate the risk of</u></p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>

Reference	Comment	Biological Standards Commission response
	<p>vaccine virus <u>reversion to virulence and/or recombination with field and vaccine strains.</u></p> <p>Reason: Given the looser criteria proposed in other sections of this document for adverse event reporting in licensure studies – e.g. the safety testing criteria – it is worthwhile to note criteria for “strict” pharmacovigilance that is noted as essential to avoid confusion in reporting.</p>	

As with any MLV vaccine, all ASF MLV vaccines should be used according to the label instructions, under the strict control of the country’s Regulatory Authority.

The minimum standards given here and in chapter 1.1.8 are intended to be general in nature and may be supplemented by national, regional, and veterinary international medicinal product harmonised requirements. Minimum data requirements for an authorisation in exceptional circumstances (e.g. unexpected introduction of the virus, sudden outbreaks of the disease) should be considered where applicable.

2. Outline of production and minimum requirements for vaccines

2.1. Characteristics of the seed virus

2.1.1. Biological characteristics of the master seed virus

ASF MLVs are generally produced from ASFV field strains derived from naturally attenuated field isolates or using DNA homologous (genetically targeted) recombination techniques in cell cultures to delete one or more ASFV genes or gene families. These molecular techniques typically involve replacement of the targeted ASFV gene(s) with one or more positive, marker fluorescent (e.g. BFP, eGFP, mCherry) or enzyme-based (e.g. β -glucuronidase) ASFV promoter-reporter gene systems that allow the use of imaging microscopy or flow cytometry to visualise, select, and clone gene-deleted, recombinant, ASF MLVs. MLV production is carried out in cell cultures based on a seed-lot system.

Master seed viruses (MSVs) for MLVs should be selected and produced based on their ease of growth in cell culture, virus yield (\log_{10} infectious titre) and genetic stability over multiple cell passages. Preferably, a continuous well-characterised cell line (e.g. ZMAC-4; PIPEC; IPKM) (Borca *et al.*, 2021; Masujin *et al.*, 2021; Portugal *et al.*, 2020) is used to produce a master cell bank (MCB) on which the MSV and MSV-derived working seed virus (WSV) can be produced. The exact source of the underlying ASFV isolate, the whole genome sequence, and the passage history must be recorded.

2.1.2. Quality criteria (sterility, purity, freedom from extraneous agents)

Only MSVs that have been established as sterile, pure (free of wild-type parental virus and free of extraneous agents as described in Chapter 1.1.9 Tests for sterility and freedom from contamination of biological materials intended for veterinary use, and those listed by the appropriate licensing authorities) and immunogenic, should be used as the vaccine virus (WSV and vaccine batch production). Live vaccines must be shown not to cause disease or other adverse effects in target animals in accordance with chapter 1.1.8, Section 7.1 Safety tests (for live attenuated MSVs), that includes target animal safety tests, increase in virulence tests, assessing the risk to the environment) and if possible, no transmission to other animals.

Identity of the MSV must be confirmed using appropriate methods (e.g. through the use of vaccine strain-specific whole genome detection methods such as next generation sequencing).

Demonstration of MSV stability over several cell passages is necessary, typically through at least five passages (e.g. MSV+5). For those MLV vaccines for which attenuation is linked to specific characteristics (gene deletion, gene mutations, etc.), genetic stability of attenuation throughout the production process should be confirmed by full genome sequencing and confirmation of the vaccine phenotype, for example, by confirming the virus titre obtained by growth in the cell line used for production using suitable methods. Suitable techniques to demonstrate genetic stability may include but are not limited to: genome sequencing, biochemical, proteomic, genotypic (e.g. detection of genetic markers) and phenotypic strain characterisation. If final product yields (infectious titres) are relatively low, as is typically the case with ASFV, demonstration of stability

is required for the maximum passage for use in the final product manufacturing as defined by the producer genetic stability at a minimum of MSV+10 should be demonstrated to allow more flexibility in the outline of production. For example, if MSV+8 is the maximum passage for use in final product manufacturing, demonstration of genetic stability to at least MSV+10 is warranted.

2.1.3. Validation as a vaccine strain

The vaccine derived from the MSV must be shown to be satisfactory with respect to safety and efficacy.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.1.3_1	<p>Category: addition</p> <p><u>The vaccine derived from the MSV must be shown to be satisfactory with respect to safety and efficacy. Live vaccines must be shown not to cause disease or other adverse effects in target animals in accordance with chapter 1.1.8, Section 7.1 Safety tests (for live attenuated MSVs), that includes target animal safety tests, increase in virulence tests, assessing the risk to the environment) and if possible, no transmission to other animals.</u></p> <p>Reason: This text deleted above is appropriate here.</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>

Even if pigs are not known for susceptibility to transmissible spongiform encephalopathy (TSE) agents, consideration should also be given to minimising the risk of TSE transmission by ensuring that animal origin materials from TSE-relevant species, if no alternatives exist for vaccine virus propagation, comply with the measures on minimising the risk of transmission of TSE.

Ideally, the vaccine virus in the final product should generally not differ by more than five passages from the master seed lot.

ASF vaccines should be presented in a suitable pharmaceutical form (e.g. lyophilisate or liquid form).

2.2. Method of manufacture

2.2.1. Procedure

The MLV virus is used to infect swine primary cell cultures obtained from specific-pathogen free pigs, the requirements for which are defined in specific monographs (Chapter 2.3.3 *Minimum requirements for the organisation and management of a vaccine manufacturing facility*, Section 2.4.2). Compared with primary cell cultures, use of a continuous cell line generally allows for more consistency, higher serial volumes in manufacturing and aligns better with a seed lot system. Thus, preferably a master cell bank based on an established, continuous cell line shown to support genetically stable ASFV replication and acceptable titres over several passages should be used.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.2.1_1	<p>Category: addition</p> <p><u>The MLV virus is used to infect swine primary cell cultures obtained from specific-pathogen free pigs, the requirements for which are defined in specific monographs (Chapter 2.3.3 <i>Minimum requirements for the organisation and management of a vaccine manufacturing facility</i>, Section 2.4.2). It should be noted that each donor pig should be considered a different "master cell stock" and be tested for purity and extraneous agents to account for the risk of contamination during cell collection and processing. Similar considerations should apply to collections over</u></p>	<p>EN: Partly agreed: accepted first sentence and modified second sentence for clarity</p> <p>FR: Commentaire retenu en partie : première phrase acceptée, deuxième phrase modifiée pour plus de clarté.</p> <p>SP: Parcialmente aceptado: aceptada la primera frase y</p>

	<p>time at the same time that herd health is closely monitored. Compared...</p> <p>Reason: Good to note limitations of primary cell culture production methods.</p>	<p>modificada la segunda para mayor claridad.</p>
--	--	---

Cell cultures shall comply with the requirements for cell cultures for production of veterinary vaccines in chapter 1.1.8. Regardless of the production method, the substrate should be harvested under aseptic conditions and may be subjected to appropriate methods to release cell-associated virus (e.g. freeze–thaw cycles, detergent lysis). The harvest can be further processed by filtration and other purification methods. A stabiliser or other excipients may be added as appropriate. The vaccine is homogenised to ensure a uniform batch/serial.

2.2.2. Requirements for ingredients

All ingredients used for vaccine production should be in line with requirements in chapter 1.1.8.

2.2.3. In-process controls

In-process controls will depend on the protocol of production; they include virus titration of bulk antigen and sterility tests.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.2.3_1	<p>Category: addition</p> <p>A description of the required biosafety level for handling ASF vaccine strains during in-process quality control should be included in this chapter.</p> <p>Rationale: There is currently no description of the biosafety level in the production process in which the viruses are handled. Given varying national regulations, it may be difficult to specify the biosafety level applicable to all Members. Hence, at least this chapter should provide a guidance on biosafety requirements.</p>	<p>EN: Partly agreed, WOAHP no longer uses biosafety levels. Amended the text to refer to the outcome of biosafety risk assessments in line with WOAHP Standards. Please also see lines 130–132 and 145–148 above.</p> <p>FR: Commentaire accepté en partie, car l'OMSA ne se réfère plus aux niveaux de biosécurité. Le texte a été amendé afin de renvoyer aux résultats des évaluations des risques de biosécurité, conformément aux normes de l'OMSA. Voir également les lignes 130–132 et 145–148 ci-dessus.</p> <p>SP: Parcialmente aceptado, la OMSA ya no utiliza niveles de bioseguridad. Se ha modificado el texto para hacer referencia al resultado de las evaluaciones de riesgos de bioseguridad de acuerdo con las normas de la OMSA. Véanse también las líneas 130–132 y 145–148.</p>

2.2.4. Final product batch tests

i) Sterility

Tests for sterility and freedom from contamination of biological materials intended for veterinary use may be found in chapter 1.1.9.

ii) Identity

Appropriate methods such as specific genome detection methods (e.g. specific differential real-time PCR) should be used for confirmation of the identity of the vaccine virus and differentiation from the parent strain of the virus as a potential contaminant.

iii) Purity

Appropriate methods should be used to ensure that the final product batch does not contain any residual wild-type ASFV.

iv) Safety

Batch safety testing is to be carried out unless consistent safety of the product is demonstrated and approved in the registration dossier and the production process is approved for consistency in accordance with the standard requirements referred to in chapter 1.1.8.

v) Batch/serial potency

Virus titration is a reliable indicator of vaccine potency once a relationship has been established between the vaccine minimum immunising dose (MID) (minimum protective dose) and titre of the modified live vaccine in vitro. In the absence of a demonstrated correlation between the virus titre and protection, an efficacy test will be necessary (Section C.2.3.3 Efficacy requirements, below).

vi) Residual humidity/residual moisture

The test should be carried out consistent with VICH² GL26 (*Biologicals: Testing of Residual Moisture*, 2003³). Required for MLV vaccines presented as lyophilisates **for suspension for injection.**

2.3. Requirements for authorisation/registration/licensing

2.3.1. Manufacturing process

For regulatory approval of a vaccine, all relevant details concerning history of the pre-MSV, preparation of MSV, manufacture of the vaccine and quality control testing (Sections C.2.1 Characteristics of the seed and C.2.2 Method of manufacture) should be submitted to the authorities.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.1_1	Category: deletion <u>For regulatory approval of a vaccine, All relevant details...</u> Reason: WOH chapters should not define acceptance criteria for different regulatory authorities all over the world.	EN: Agreed.
		FR: La Commission a souscrit au commentaire.
		SP: Aceptado.

Information shall be provided from three **preferably** consecutive vaccine batches originating from the same MSV and representative of routine production, with a volume not less than 1/10, and more preferably with a volume not less than 1/3 of the typical industrial batch volume. The in-process controls are part of the manufacturing process.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.1_2	Category: addition Suggest reversing the deletion above as this is a good general guideline. If modification is needed, suggest adding " <u>if volumetric standards cannot be met, explain how scale up will be addressed in production.</u> "	EN: Disagreed to this addition as it is not in line with the VICH guidelines.
		FR: La Commission n'a pas souscrit à cette proposition d'ajout qui n'est pas conforme aux lignes directrices du VICH.
		SP: No aceptado con este añadido ya que no está en consonancia con las directrices de la VICH.

² VICH: International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medical Products

³ https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl26-biologicals-testing-residual-moisture-step-7_en.pdf

2.3.2. Safety requirements

For the purpose of gaining regulatory approval, the following safety tests should be performed satisfactorily.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_1	<p>Category: deletion</p> <p>For the purpose of gaining regulatory approval, the following safety tests should be performed <u>satisfactorily</u>.</p> <p><u>This is tacit and stating that it must be satisfactory weakens the directive to perform the tests.</u></p>	EN: Agreed.
		FR: La Commission a souscrit au commentaire.
		SP: Aceptado.

As a minimum standard, vaccines should be tested for any pathogenic effects on healthy domestic pigs of the target age intended for use. Additional demonstration of MLV safety in breeding age gilts and pregnant sows is preferred but not required as a minimum standard. If in the future a vaccine intended for use in breeding animals is developed, an evaluation of the impact of the vaccine on reproductive performance will be a standard safety requirement.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_2	<p>Category: additions</p> <p>Lines 239-241: This is not clear. Our general requirements (Ph. Eur. 0062) for example are that vaccine production is not undertaken using a virus more than 5 passages from the master seed lot, unless otherwise justified. In any case, demonstration of genetic stability is always required to the maximum passage level used for vaccine production'; therefore, the requirement explained here is a general requirement rather than a special requirement.</p> <p>An alternative wording is proposed: "<u>Genetic stability of attenuation throughout the production process (i.e. to the maximum passage level to be used for vaccine production) should be confirmed by full genome sequencing and confirmation of virus phenotype (e.g. virus yield in cell line used for production)</u>".</p>	EN: Agreed.
		FR: La Commission a souscrit au commentaire.
		SP: Aceptado.
3.9.1_C2.3.2_3	<p>Lines 239-241: "Additional demonstration.....safety requirement".</p> <p>New proposed text: the text below would be preferable for clarity. Also, the existing vaccines in Vietnam could be authorised for use in breeding animals in the future, if relevant supporting safety data are presented to the authorities i.e. use in breeding animals not only for newly developed vaccines)</p> <p>Proposed text:</p> <p>"Additional demonstration of MLV safety in breeding age gilts and pregnant sows is preferred. <u>When the vaccine is recommended for use or may be used but not required as a minimum standard. If in the future a vaccine intended for use in breeding animals is developed,</u> an evaluation of the impact of the vaccine on reproductive performance will be a standard safety requirement.</p>	EN: Agreed.
		FR: La Commission a souscrit au commentaire.
		SP: Aceptado.

i) Safety in young animals

Carry out the test by each recommended route of administration using, in each case, piglets a minimum of 6-4-weeks old and not older than 10-weeks old.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_4	<p>Category: change</p> <p>“...piglets a minimum of 4 weeks old or not older than 10 weeks old”</p> <p>Our requirements for example are for general safety tests to be conducted in the most sensitive category of animals for which the vaccine is recommended, usually animals of the youngest age. Is there any reason as to why a prescriptive age range (4–10 weeks of age) has been defined?</p>	<p>EN: It is stated above that ‘as a minimum standard, vaccines should be tested for any pathogenic effects on healthy domestic pigs of the target age intended for use’. During the consultation process it was agreed by experts and regulatory authorities to provide details here for safety testing in young pigs as this would be the age-group of pigs that would most likely be vaccinated.</p>
		<p>FR: Le texte précise ci-dessus que dans la norme minimale, les vaccins devraient être testés afin de rechercher l’apparition d’un effet pathogène chez des porcs sains appartenant à la classe d’âge visée. Lors du processus de consultation, les experts et les autorités réglementaires ont estimé nécessaire de fournir des informations détaillées concernant les tests d’innocuité chez les porcelets, cette classe d’âge étant celle qui aurait la plus grande probabilité d’être vaccinée.</p>
		<p>SP: Más arriba se afirma que como norma mínima, las vacunas deben probarse para detectar todo posible efecto patógeno en cerdos domésticos sanos de la edad prevista para su uso». Durante el proceso de consulta, los expertos y las autoridades reguladoras acordaron proporcionar detalles para las pruebas de seguridad en cerdos de corta edad, ya que este sería el grupo de edad de los cerdos que con mayor probabilidad serían vacunados.</p>

The test is conducted using no fewer than eight healthy piglets, and preferably no fewer than ten healthy piglets.

Use vaccine virus at the least attenuated passage level that will be present in a batch of the vaccine.

Administer to each piglet a quantity of the vaccine virus equivalent to not less than ten times the maximum virus titre (e.g. 50% haemadsorption dose [HAD₅₀], 50% tissue culture infective dose [TCID₅₀], quantitative PCR, etc.) (maximum release dose) likely to be contained in one dose of the vaccine.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_5	<p>Category: addition</p> <p>Suggest reversing this deletion as some jurisdictions may choose to use qPCR for potency testing.</p>	<p>EN: Disagreed, quantitative PCR does not equate to infectious virus. It is important to look for the presence live virus.</p>
		<p>FR: Le Commission n’a pas souscrit à ce commentaire car une PCR quantitative ne signifie pas virus infectieux. Il est important de rechercher la présence du virus vivant.</p>
		<p>SP: No aceptado, la PCR cuantitativa no equivale a virus infeccioso. Es importante buscar la presencia de virus vivo.</p>
3.9.1_C2.3.2_6	<p>Category: change</p> <p>This sentence is hard to parse. The phrase “equivalent to not less than” is confusing and having two parenthetical statements in the middle of the sentence fragments the ideas it’s trying to relate. We suggest rewording to: “Administer to each piglet a quantity of the vaccine virus equivalent to not less than ten times the maximum virus titre (e.g. 50%</p>	<p>EN: Agreed.</p>
		<p>FR: La Commission a souscrit au commentaire.</p>
		<p>SP: Aceptado.</p>

	<p>haemadsorption dose [HAD₅₀], 50% tissue culture infective dose [TCID₅₀], quantitative PCR, etc.) (maximum release dose) <u>likely to be contained in one dose of the vaccine.</u>” Also suggest either moving the parentheses to the end of the sentence, moving the information in the parentheses into a second sentence, or removing the parenthetical statements altogether.</p>	
--	---	--

To obtain individual and group mean baseline temperatures, the body temperature of each vaccinated piglet is measured on at least the 3 consecutive days preceding administration of the vaccine.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_7	<p>Category: change</p> <p><u>This doesn't flow from the previous sentence at all - there has been no mention of taking temperatures before this point. As written, it is unclear if taking temperature is required, only that if they are taken it must be measured in the prescribed way.</u></p>	<p>EN: Agreed, amended for clarity and moved the sentence.</p> <p>FR: Commentaire accepté ; le texte a été amendé pour plus de clarté et la phrase a été déplacée.</p> <p>SP: Aceptado, modificado para mayor claridad y la frase se ha trasladado.</p>

To confirm the presence or absence of fever accompanied by acute and chronic disease, observe the piglets 4 hours after vaccination and then at least once daily for at least 45 days, preferably 60 days post-vaccination. Carry out the daily observations for signs of acute and chronic disease using a quantitative clinical scoring system adding the values for multiple clinical signs (e.g. Gallardo *et al.*, 2015a). These clinical signs should include fever, anorexia, recumbency, skin haemorrhage or cyanosis, joint swelling and necrotic lesions around the joints, respiratory distress and digestive findings).

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_8	<p>Category: change</p> <p>To confirm the presence or absence of fever accompanied by acute and chronic disease, observe the piglets 4 hours after vaccination and then at least once daily for at least 45 days, preferably 60 days post-vaccination. Carry out the daily observations for signs of acute and chronic disease using a quantitative clinical scoring system adding the values for multiple...</p> <p><u>This is redundant with the start of the next paragraph (which dictates when the piglets should be euthanised). As this paragraph is longer we suggest moving the instruction for the length of observation to the next paragraph.</u></p>	<p>EN: Disagreed, the two paragraphs refer to two different aspects, the first refers to what timepoints the pigs should be monitored for signs of disease/clinical signs using the clinical scoring system. The second paragraph describes when the pigs should be euthanised and checked for pathology.</p> <p>FR: La Commission n'a pas souscrit à cette proposition car les deux paragraphes se réfèrent à deux aspects différents : le premier concerne les moments auxquels il convient d'examiner les porcs pour rechercher d'éventuels signes de maladie/signes cliniques en appliquant le système d'évaluation clinique. Le deuxième paragraphe décrit le moment auquel les porcs devraient être euthanasiés et soumis à un examen anatomopathologique.</p> <p>SP: No aceptado, los dos párrafos se refieren a dos aspectos diferentes, el primero se refiere a qué puntos de tiempo los cerdos deben ser monitoreados para detectar signos de enfermedad/signos clínicos utilizando el sistema de puntuación clínica. El segundo párrafo describe cuándo se debe practicar la eutanasia a los cerdos y comprobar si presentan signos anatomopatológicos.</p>

At a minimum of 45 days post-vaccination, humanely euthanise all vaccinated piglets. Conduct gross pathology on spleen, lung, tonsil, and kidney tissue samples and at least three different lymph nodes (which should include lymph node closest to site of inoculation, gastrohepatic and submandibular nodes).

The vaccine complies with the test if:

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_9	<p>Category: change</p> <p>The vaccine complies with this manual, not the test, reword:</p> <p>"The vaccine <u>is compliant if:</u>" Or "The vaccine <u>is acceptable if:</u>"</p>	<p>EN: Agreed, amended the proposal for clarity.</p> <p>FR: Commentaire accepté ; le texte proposé a été amendé pour plus de clarté.</p> <p>SP: Aceptado, se ha modificado la propuesta para mayor claridad.</p>

- No piglet shows abnormal (local or systemic) reactions or notable signs of disease, or reaches the pre-determined humane endpoint defined in the clinical scoring system or dies from causes attributable to the vaccine:
- The average body temperature increase for all vaccinated piglets (group mean) for the observation period does not exceed 1.5°C above baseline; and no individual piglet shows a temperature rise above baseline greater than 2.5°C for a period exceeding 3 days.
- On each day during the observation period, the maximum increase in body temperature above the baseline observed for each pig will be used to calculate the daily group mean temperature rise. This mean value should not exceed 1.5°C and no individual pig should show a rise in temperature above baseline greater than 1.5°C for a period exceeding 3 consecutive days.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_10	<p>Category: deletion</p> <ul style="list-style-type: none"> • <u>On each day during the observation period, the maximum increase in body temperature above the baseline observed for each pig will be recorded, used to calculate the daily group mean temperature rise. This mean value should not exceed 1.5°C and No individual pig should show a rise in temperature above baseline greater than 1.5°C for a period exceeding 3 consecutive days.</u> <p>Reason: These criteria are set to be acceptable for the current, most developed vaccine strain and are not objectively developed. Additionally, taking the average temperature of the group could mask individual reactions. Minimal temperature rise of 1 day was seen in safety studies - 3 days seems long based on current data. Tran <i>et al.</i>, 2022.</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>
3.9.1_C2.3.2_11	<p>Category: change</p> <p>This is an instruction that should either be included in the previous section that outlined how to collect the temperature data or rephrased to be similar to the struck-through bullet point above.</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>

- No vaccinated pigs show notable signs of disease by gross pathology

ii) Safety test in pregnant sows and test for transplacental transmission

There is limited currently an absence of published information on ASFV pathogenesis in breeding-age gilts and in pregnant sows associated with ASFV transplacental infection and fetus abortion/stillbirth. If a label claim is pursued for use in breeding age gilts and sows, then a safety study in line with VICH GL44 (Guidelines on Target Animal Safety for Veterinary Live and Inactivated Vaccines, Section 2.2. Reproductive Safety Test, 2009⁴) should be completed.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_12	<p>Category: addition</p> <p><u>...VICH GL44 (Guidelines on Target Animal Safety for Veterinary Live and Inactivated Vaccines, Section 2.2. Reproductive Safety Test, 2009) should be completed. The precedent seen with the ASFV-G-Δ9GL single-deletion mutant should be considered when planning and evaluating these studies.</u></p> <p>Reason: Doses of the single deletion mutant similar to that proposed for the current vaccine strains under consideration (10E4 HAD⁵⁰) produced a virulent phenotype in inoculated pigs. O'Donnell et al. 2015 doi:10.1128/JVI.00969-15.</p>	<p>EN: Disagreed, the Commission did not believe that the addition was essential.</p> <p>FR: La Commission n'a pas retenu ce commentaire, estimant que l'ajout proposé ne revêtait pas un caractère essentiel.</p> <p>SP: No aceptado, la Comisión no cree que el añadido sea esencial.</p>
3.9.1_C2.3.2_13	<p>Category: change</p> <p><i>"If a label claim.....should be completed"</i></p> <p>It is suggested to revert the order of the sentences i.e. first the general statement on requirements (if a label claim...) and then the specific info on existing published info.</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>

iii) Horizontal transmission

The test is conducted using no fewer than 12 healthy piglets, a minimum of 6-4-weeks old and not older than 10-weeks old and of the same origin, that do not have antibodies against ASFV, and blood samples are negative on real-time PCR. All piglets are housed together from day 0 and the number of vaccinated animals is the same as the number of naïve, contact animals. Co-mingle equal numbers of vaccinated and naïve, contact piglets from day 0 in the same pen or room.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_14	<p>Category: change</p> <p>The test is conducted using <u>no fewer than 12 a sufficient number of</u> healthy piglets, a minimum of 4-weeks old and not older than 10-weeks old <u>and of the same origin</u>, that do not have antibodies against ASFV, and blood samples are negative on real-time PCR.</p> <p>Rationale: Request to change "no fewer than 12" to "a sufficient number of" as there is no scientific basis for using 12 piglets. The decision to not agree with our proposal for the reason of consistency with CSF chapter in the 2024 February BSC report cannot be justified as a specific number of animals in the efficacy test is not stipulated in many other chapters (Swine Influenza, FMD, PRRS, West Nile Fever etc.). In addition, there is no specification in the VICH</p>	<p>EN: Did not agree to remove the detail of number of piglets as of use to Members, but did agree to remove "of the same origin"</p> <p>FR: La Commission n'a pas retenu la proposition de supprimer l'indication du nombre de porcelets à utiliser mais a accepté de supprimer l'indication suivant laquelle ces porcelets devaient être « de même origine ».</p> <p>SP: No se ha aceptado suprimir el detalle del número de lechones por ser de utilidad para los Miembros, pero sí «del mismo origen».</p>

⁴ https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl44-target-animal-safety-veterinary-live-inactivated-vaccines-step-7_en.pdf

Reference	Comment	Biological Standards Commission response
	<p>guidelines regarding test setting for horizontal transmission, such as number of pigs kept, age, consistency of origin, composition.</p> <p>Furthermore, request to remove the term “the same origin” as its definition is unclear. If intended to mean “same farm,” it is not realistic because animals for experiment would need to be sourced from different farms to have required number of animals. A definition should be provided if the term is used to mean other specific characteristics.</p>	
3.9.1_C2.3.2_15	<p>Category: change</p> <p>The test is conducted using no fewer than 12 healthy piglets, a minimum of 4-weeks old and not older than 10-weeks old and of the same origin, that do not have antibodies against ASFV, and blood samples are negative on real-time PCR.</p> <p><u>This sentence is saying too much and should be split into multiple sentences or a bullet list.</u></p>	<p>EN: Agreed. The sentence has been split up and “of the same origin” has been removed.</p> <p>FR: Commentaire accepté. La phrase a été scindée et l’indication « <i>of the same origin</i> » (de même origine) a été supprimée.</p> <p>SP: Aceptado. Se ha dividido la frase y se ha eliminado «del mismo origen».</p>
3.9.1_C2.3.2_16	<p>Category: change</p> <p>Co-mingle equal numbers of vaccinated and naïve, contact piglets from day 0 in the same pen or room.</p> <p><u>The order that these requirements are listed makes it confusing. At this point it's not clear if equal numbers of vaccinated and naïve piglets – if no fewer than 12 piglets means 12 of each or 12 total (6 of each). The instruction in the next paragraph that no fewer than 6 piglets be vaccinated should be before this statement so that the reader can understand it on the first reading.</u></p>	<p>EN: Agreed and amended the sentence for clarity.</p> <p>FR: Commentaire accepté ; la phrase a été amendée pour plus de clarté.</p> <p>SP: Aceptado y se ha modificado la frase para mayor claridad.</p>

Use vaccine virus at the least attenuated passage level that will be present between the master seed lot and a batch of the vaccine. Administer by each recommended route of administration to no fewer than six piglets a quantity of the vaccine virus equivalent to not less than the maximum virus titre (maximum release dose) likely to be contained in 1 dose of the vaccine.

To obtain individual and group mean baseline temperatures, the body temperature of each naïve, contact piglet is measured on at least the 3 consecutive days preceding co-mingling with vaccinated piglets. The body temperature of each naïve, contact piglet is then measured daily for at least 45 days, preferably 60 days.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_17	<p>Category: deletion</p> <p><u>To obtain individual and group mean baseline temperatures, The body temperature of each naïve, contact piglet is measured on at least the 3 consecutive days preceding co-mingling with vaccinated piglets.</u></p> <p>Reason: These criteria are set to be acceptable for the current, most developed vaccine strain and are not objectively developed. Additionally, taking the average temperature of the group could mask individual</p>	<p>EN: Agreed, amended for clarity and moved the sentence.</p> <p>FR: Commentaire accepté ; la texte a été amendé pour plus de clarté et la phrase a été déplacée.</p> <p>SP: Aceptado, se ha modificado para mayor claridad y se ha trasladado la frase.</p>

Reference	Comment	Biological Standards Commission response
	reactions. Minimal temperature rise of 1 day was seen in safety studies - 3 days seems long based on current data. Tran <i>et al.</i> 2022.	
3.9.1_C2.3.2_18	<p>Category: change</p> <p>We ask to rationalise the sentence “...<i>contact piglet is measured on at least the 3 consecutive days preceding co-mingling with vaccinated piglets. The body temperature of each naïve, contact piglet is then measured daily for at least 45 days, preferably 60 days</i>”.</p>	<p>EN: This has been clarified in the revised text. Temperatures are measured for 3 consecutive days prior to co-mingling with the vaccinated pigs to obtain a baseline temperature for each ‘contact’ pig. This baseline temperature is used to assess temperature rises in each contact pig post-mingling – see below.</p> <p>FR: Ceci est présenté de manière plus claire dans le texte révisé. Un relevé des températures est réalisé pendant trois jours consécutifs avant que les porcs ne soient mélangés aux porcs vaccinés, ce qui permet d’obtenir une température de référence pour chaque porc « contact » (c’est-à-dire exposé). Cette température de référence sert à mesurer toute augmentation de la température chez les porcs exposés après regroupement – voir ci-dessous.</p> <p>SP: Esto se ha aclarado en el texto revisado. Las temperaturas se miden durante 3 días consecutivos antes de la mezcla con los cerdos vacunados para obtener una temperatura de referencia para cada cerdo «de contacto». Esta temperatura de referencia se utiliza para evaluar los aumentos de temperatura en cada cerdo de contacto después de la mezcla (véase más abajo).</p>

To confirm the presence or absence of fever accompanied by disease, observe the naïve, contact piglets daily for at least 45 days, preferably 60 days. On each day during the observation period the maximum increase in body temperature above the baseline observed for each pig will be used to calculate the daily group mean temperature rise. This mean value should not exceed 1.5°C and no individual pig should show a rise in temperature above baseline greater than 1.5°C for a period exceeding 3 consecutive days. Carry out the daily observations for signs of acute and chronic clinical disease using a quantitative clinical scoring system adding the values for multiple clinical signs (e.g. Gallardo *et al.*, 2015a). These clinical signs should include fever, anorexia, recumbency, skin haemorrhage or cyanosis, joint swelling and necrotic lesions around the joints, respiratory distress and digestive findings.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_19	<p>Category: change</p> <p><u>On each day during the observation period the maximum increase in body temperature above the baseline observed for each pig will be recorded, used to calculate the daily group mean temperature rise. This mean value should not exceed 1.5°C and No individual pig should show a rise in temperature above baseline greater than 1.5°C for a period exceeding 3-2 consecutive days.</u></p> <p>Reason: These criteria are set to be acceptable for the current, most developed vaccine strain and are not objectively developed. Additionally, taking the average temperature of the group could mask individual reactions. Minimal temperature rise of 1 day was seen in safety studies - 3 days seems long based on current data. Tran <i>et al.</i>, 2022.</p>	<p>EN: Agreed (see comment 3.9.1_C2.3.2_10above).</p> <p>FR: Commentaire accepté (voir commentaire 3.9.1_C2.3.2_10 ci-dessus).</p> <p>SP: Aceptado (véase el comentario 3.9.1_C2.3.2_10 anterior).</p>
3.9.1_C2.3.2_20	<p>Category: deletion</p> <p>This mean value should not exceed 1.5°C and no individual pig should show a rise in temperature above baseline greater than 1.5°C for a period exceeding 3 consecutive days.</p> <p><u>This is in the section below, it does not need to be written twice and this is not the appropriate location for it.</u></p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>

In addition, Blood should be taken from the naïve contact piglets at least twice a week for the first 21 days post-vaccination and then on a weekly basis. From the blood samples, determine vaccine virus titres by quantitative virus isolation (HAD₅₀/ml, TCID₅₀/ml or other methods, e.g. titration using IPT or FAT detection). Quantitative PCR may be used to detect positive samples, but results should be confirmed by infectious virus titration as described above infectious virus titres by quantitative virus isolation (e.g. HAD₅₀/ml or TCID₅₀/ml) and using a real-time PCR test.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_21	<p>Please rationalise the changes to the following sentence: "<i>Quantitative PCR may be used to detect positive samples, but results should be confirmed by infectious virus titration as described above</i>"</p>	<p>EN: Although PCR can be used to detect positive samples, it is important to confirm PCR results by infectious virus titration to confirm the presence of actual virus in the samples.</p> <p>FR: Bien que la PCR puisse être utilisée pour détecter les échantillons positifs, il est important de confirmer les résultats obtenus par PCR en procédant à un titrage du virus infectieux, ce qui confirme la présence effective du virus dans l'échantillon.</p> <p>SP: Aunque la PCR puede utilizarse para detectar muestras positivas, es importante confirmar los resultados de la PCR mediante una valoración del virus infeccioso para confirmar la presencia de virus real en las muestras.</p>

If the vaccine virus is non-haemadsorbing or does not cause cytopathic effects, a real-time PCR test only may be used.

Collect blood (serum) samples from the naïve contact pigs at least at day 21 and day 28 days and carry out an appropriate test to detect vaccine virus antibodies. At a minimum of 45 days, humanely euthanise all naïve, contact piglets. Conduct gross pathology on spleen, lung, tonsil, and kidney tissue samples and at least three different lymph nodes. Determine virus titres in all collected samples by quantitative virus isolation (HAD₅₀/mg or TCID₅₀/mg) or other appropriate methods (e.g. IPT or FAT detection). Quantitative PCR may be used to detect positive samples, but results should be confirmed by infectious virus titration as described above and real-time(RT)-PCR (see Section B.1. Identification of the agent). If the vaccine virus is non-haemadsorbing or does not cause cytopathic effects, a real-time PCR test or other appropriate method (e.g. titration using IPT or FAT detection) may be used.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_22	<p>Category: change</p> <p><u>Collect blood (serum) and oronasal and fecal swabs samples from the naïve contact pigs at least at day 21 and day 28 days and carry out an appropriate test to detect vaccine virus antibodies.</u></p> <p>Reason: Relevant sample types to evaluate transmission by all possible routes inserted.</p>	<p>EN: Disagreed, this change is not necessary as the text is about looking for evidence of horizontal transmission of vaccine virus between vaccinated and the naïve contact pigs, not onward transmission from the naïve contact pigs.</p> <p>FR: La Commission n'a pas souscrit à ce commentaire : le changement proposé ne s'impose pas car la recherche dont il s'agit est celle d'une transmission horizontale du virus vaccinal entre les porcs vaccinés et les porcs naïfs exposés, et non d'une transmission ultérieure à partir des porcs naïfs exposés.</p> <p>SP: No aceptado, este cambio no es necesario ya que el texto trata sobre la búsqueda de pruebas de transmisión horizontal del virus vacunal entre los cerdos vacunados y los cerdos de contacto nunca antes expuestos, no de la transmisión hacia adelante desde los cerdos de contacto nunca antes expuestos.</p>
3.9.1_C2.3.2_23	<p>Category: change</p> <p>Please rationalise the following sentence: "Collect blood (serum) samples from the naïve contact pigs at least at day 21 and day 28 days and carry out an appropriate test to detect vaccine virus antibodies"</p>	<p>EN: Agreed: this instruction is to look for evidence of horizontal transmission of vaccine virus from the vaccinated pigs to the naïve contact pigs. If the contact pigs are infected, antibodies should appear at around 7–10 days post-infection. The peak of vaccine virus excretion is likely to be around 3–7 days post-vaccination, so timepoints of 21 and 28 days post-mingling with the vaccinated pigs should detect any horizontal transmission in the naïve contact pigs.</p> <p>FR: Commentaire accepté : cette consigne vise à démontrer l'existence d'une transmission horizontale du virus vaccinal des porcs vaccinés aux porcs naïfs exposés. En cas d'infection des porcs exposés, des anticorps devraient apparaître chez ces derniers dans les 7 à 10 jours suivant l'infection. Le niveau maximal de l'excrétion du virus vaccinal se situant entre le 3^e et le 7^e jour après la vaccination, les échéances de 21 jours et de 28 jours après le regroupement des porcs naïfs avec les porcs vaccinés devraient permettre de détecter toute transmission horizontale chez les porcs naïfs exposés.</p> <p>SP: Aceptado: esta instrucción es para buscar evidencia de transmisión horizontal del virus vacunal de los cerdos vacunados a los cerdos de contacto nunca antes expuestos. Si los cerdos de contacto están infectados, los anticuerpos deberían aparecer alrededor de los 7–10 días post-infección. El pico de excreción del virus de la vacuna es probable que sea</p>

Reference	Comment	Biological Standards Commission response
		alrededor de 3–7 días después de la vacunación, por lo que los puntos de tiempo de 21 y 28 días después de la mezcla con los cerdos vacunados deben detectar toda posible transmisión horizontal en los cerdos de contacto nunca antes expuestos.
3.9.1_C2.3.2_24	<p>Category: deletion</p> <p>“samples by quantitative virus isolation (HAD₅₀/mg or TCID₅₀/mg) or other appropriate methods (e.g. IPT or FAT detection). Quantitative PCR may be used to detect positive samples, but results should be confirmed by infectious virus titration as described above”</p> <p><u>This is repeated many times throughout the document word for word, sometimes (as in this case) in two paragraphs one after another. This makes the document very repetitive to read. Consider if this could be defined once early on then referred back to</u></p>	<p>EN: Agreed – but it is important to repeat this in separate sections as sections of the document may be read in isolation. When the same information is repeated in the same section, we have referred to it ‘above’, so it is not repeated.</p> <p>FR: Commentaire accepté – mais il est important que l’information figure dans toutes les sections pertinentes du document, lesquelles doivent pouvoir être consultées séparément. Lorsque la même information est fournie plusieurs fois dans une même section, la formulation « above » (comme ci-dessous) y renvoie, afin d’éviter la répétition.</p> <p>SP: Aceptado, pero es importante repetirlo en secciones separadas, ya que las secciones del documento pueden leerse de forma aislada. Cuando se repite la misma información en la misma sección, nos hemos referido a ella «más arriba», para que no se repita.</p>

The vaccine complies with the test if:

- No vaccinated or naïve contact piglet shows abnormal (local or systemic) reactions or notable signs of disease, reaches the predetermined humane endpoint defined in the clinical scoring system or dies from causes attributable to the vaccine;

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_25	<p>Category: addition</p> <p>Please note that whilst quantitative PCR is mentioned above as optional, then one of the compliance criteria is based on it.</p> <p>Perhaps a more neutral wording could be used here as the suitable testing methods are described above:</p> <p><u>“No or a low percentage of naïve, contact piglets test positive to the vaccine virus and/or to antibodies against the vaccine virus”</u></p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>

- On each day during the observation period the maximum increase in body temperature above the baseline observed for each pig will be used to calculate the daily group mean temperature rise. This mean value should not exceed 1.5°C and no individual pig should show a rise in temperature above baseline greater than 1.5°C for a period exceeding 3 consecutive days. The average body temperature increase for all naïve, contact piglets (group mean) for the observation period does not exceed 1.5°C: above baseline; and no individual piglet shows a temperature rise above baseline greater than 2.5°C for a period exceeding 3 days;

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_26	<p>Category: deletion</p> <p>On each day during the observation period the maximum increase in body temperature above the baseline observed for each pig will be used to calculate the daily group mean temperature rise. This mean value should not exceed 1.5°C and no individual pig should show a rise in temperature above baseline greater than 1.5°C for a period exceeding 3-2 consecutive days</p> <p>Reason: These criteria are set to be acceptable for the <u>current, most developed vaccine strain and are not objectively developed. Additionally, taking the average temperature of the group could mask individual reactions. Minimal temperature rise of 1 day was seen in safety studies - 3 days seems long based on current data. Tran et al. 2022</u></p>	EN: Agreed.
		FR: La Commission a souscrit au commentaire.
		SP: Aceptado.
3.9.1_C2.3.2_27	<p>Category: change</p> <p>On each day during the observation period the maximum increase in body temperature above the baseline observed for each pig will be used to calculate the daily group mean temperature rise.</p> <p><u>As with the safety in young animals section, this should be in the instructions above, not in the requirements for compliance.</u></p>	EN: Agreed.
		FR: La Commission a souscrit au commentaire.
		SP: Aceptado.

- No naïve, contact piglet shows notable signs of disease by gross pathology, and no virus is detected in their blood or tissue samples;
- No or a low percentage of contact piglets test both real-time PCR positive and seropositive ~~No naïve contact pigs test positive for antibodies to the vaccine virus.~~

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_28	<p>Category: deletion</p> <p>No <u>or a low percentage of</u> contact piglets test both real-time PCR positive and seropositive. No naive contact pigs test positive for antibodies to the vaccine virus.</p> <p>Reason: If one piglet positive, it indicates there must be horizontal transmission for the vaccine virus.</p>	<p>EN: Disagreed, as these vaccines are MLVs, some level of horizontal transmission is likely and it is up to regulators to decide whether a vaccine is safe.</p> <p>FR: La Commission est en désaccord avec ce commentaire ; il s'agit de vaccins à virus vivant modifié, de sorte qu'un certain niveau de transmission horizontale est probable. Il revient aux autorités de réglementation de décider si un vaccin est sûr.</p> <p>SP: No aceptado, ya que estas vacunas son MLV, es probable cierto nivel de transmisión horizontal y corresponde a los reguladores decidir si una vacuna es Segura.</p>
3.9.1_C2.3.2_29	<p>Category: deletion</p> <p>No <u>or a low percentage of</u> contact piglets test both real-time PCR positive and seropositive.</p> <p>Reason: This should not be set to meet pre-determined criteria. The test for horizontal transmission should be reported - whether the data are acceptable to individual regulatory authorities is a separate decision.</p>	<p>EN: Disagreed, as these vaccines are MLVs, some level of horizontal transmission is likely and it is up to regulators to decide whether the vaccine is safe.</p> <p>FR: La Commission est en désaccord avec ce commentaire ; il s'agit de vaccins à virus vivant modifié, de sorte qu'un certain niveau de transmission horizontale est probable. Il revient aux autorités de réglementation de décider si le vaccin est sûr.</p> <p>SP: No aceptado, ya que estas vacunas son MLV, es probable cierto nivel de transmisión horizontal y corresponde a los reguladores decidir si la vacuna es segura.</p>
3.9.1_C2.3.2_30	<p>Category: change</p> <p>No or a low percentage of contact piglets test both real-time PCR positive and seropositive</p> <p><u>This should be more clearly defined. If there are 6 contact piglets and one tests positive, 16.7% of the piglets are positive - is that a low percentage?</u></p>	<p>EN: Disagreed, some level of horizontal transmission is likely and it is up to regulators to decide whether the vaccine is safe.</p> <p>FR: La Commission est en désaccord avec ce commentaire ; un certain niveau de transmission horizontale est probable et il revient aux autorités de réglementation de décider si le vaccin est sûr.</p> <p>SP: No aceptado, es probable cierto nivel de transmisión horizontal y corresponde a los reguladores decidir si la vacuna es segura.</p>

iv) Post-vaccination kinetics of viral replication (MLV blood and tissue dissemination) study

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_31	<p>Category: change</p> <p>Line 459: A general, more neutral heading would be preferable as the details are then given in the actual text.</p> <p><i>'Dissemination in the vaccinated animal'</i></p>	<p>EN: Agreed, but slightly modified the proposal</p> <p>FR: Commentaire accepté et proposition légèrement amendée.</p> <p>SP: Aceptado, pero modificando ligeramente la propuesta.</p>

Prior to the reversion to virulence study (Section C2.3.2.v. below), a minimum of one study should be performed to determine the post-vaccination kinetics of virus replication in the blood (viremia), tissues and viral shedding.

The test consists of the administration of the vaccine virus from the master seed lot to no fewer than eight healthy piglets, and preferably ten healthy piglets, a minimum of 6-4-weeks old and not older than 10-weeks old and of the same origin, that do not have antibodies against ASFV, and blood samples are negative on real-time PCR.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_32	Category: change <u>Again, this sentence is too long and says too much, significantly reducing readability. Break it into multiple sentences or bullet points.</u>	EN: Agreed. The sentence has been split up and "of the same origin" has been removed. FR: Commentaire accepté. La phrase a été scindée et les mots « <i>of the same origin</i> » (de la même origine) ont été supprimés. SP: Aceptado. Se ha dividido la frase y se ha eliminado «del mismo origen».

Administer to each piglet, using the recommended route of administration most likely to result in spread (such as the intramuscular route or intranasal route), a quantity of the master seed vaccine virus equivalent to not less than the maximum virus titre (maximum release dose) likely to be contained in 1 dose of the final product of the vaccine.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_33	Category: change Please substitute " <u>final product of the vaccine</u> " with " <u>commercial vaccine</u> ".	EN: Disagreed, the vaccine may not be commercial FR: La Commission n'a pas retenu ce commentaire, car il peut s'agir de vaccins non commerciaux. SP: No aceptado, la vacuna puede no ser comercial.

Record daily body temperatures and observe inoculated animals daily for clinical disease for at least 45 days, preferably 60 days.

Carry out the daily observations for signs of acute and chronic clinical disease using a quantitative clinical scoring system adding the values for multiple clinical signs (e.g. Gallardo *et al.* (2015a). These clinical signs should include fever, anorexia, recumbency, skin haemorrhage or cyanosis, joint swelling and necrotic lesions around the joints, respiratory distress and digestive findings.

Collect blood samples from all the piglets at least two times per week from 3 days post-vaccination for the first 2 weeks, then weekly for the duration of the test. Determine vaccine virus titres by quantitative virus isolation (HAD₅₀/ml or TCID₅₀/ml) or other appropriate methods (e.g. titration using IPT or FAT detection). Quantitative PCR may be used to detect positive samples but results should be confirmed by infectious virus titration as described above and using a real-time PCR test. If the vaccine virus is non-haemadsorbing or does not cause cytopathic effects, a real-time PCR test only may be used.

Determine which blood timepoint(s) should be used in the design of the reversion to virulence study (Section C2.3.2.v. below), for example, specific blood sample(s) at specific timepoints that show the highest titres should be considered for selection and use in the reversion to virulence study.

Collect oral, nasal and faecal swab samples (preferably devoid of blood to minimise assay interference) at least two times per week from 3-days post-vaccination for the first 2 weeks, then weekly for the duration of the test. Test the swabs for the presence of vaccine virus. Determine virus titres in all collected samples by quantitative virus isolation (HAD₅₀/ml or TCID₅₀/ml) or other appropriate methods (e.g. titration using IPT or FAT detection). Quantitative PCR may be used to detect positive samples, but results should be confirmed by infectious virus titration as described above and using a real-time PCR test. If the vaccine

virus is non haemadsorbing or does not cause cytopathic effects, a real time PCR test or other appropriate method (e.g. titration using IPT or FAT detection) may be used.

Euthanise at least two piglets on days 5, 7, 14, 21, and preferably on day 28 (+2 days at each timepoint) and collect spleen, lung, tonsil, kidney tissue samples and at least three different lymph nodes (which should include lymph node closest to site of inoculation, gastrohepatic and submandibular nodes). Determine virus titres in all collected samples by quantitative virus isolation (HAD₅₀/mg or TCID₅₀/mg) or other appropriate methods (e.g. titration using IPT or FAT detection). Quantitative PCR may be used to detect positive samples, but results should be confirmed by infectious virus titration as described above and using real-time PCR test. If the vaccine virus is non-haemadsorbing or does not cause cytopathic effects, a real-time PCR test or other appropriate method (e.g. titration using IPT or FAT detection) may be used.

Determine which tissue(s) and timepoint(s) should be used to aid in the design of the reversion to virulence study (Section C.2.3.2.v), for example, specific tissues at specific timepoints which show the highest titres should be considered for selection and use in the reversion to virulence study.

y) Reversion to virulence

The test carried out should be consistent with VICH GL41 (Examination of live veterinary vaccines in target animals for absence of reversion to virulence, 2008⁵).

The test for increase in virulence consists of the administration of the vaccine master seed virus to healthy piglets of an age (e.g. between 6-4 weeks and 10 weeks old) suitable for recovery of the strain and of the same origin, that do not have antibodies against ASFV, and blood samples that are negative on real-time PCR. This protocol is typically repeated five times.

First passage (p1)

Administer to no fewer than two piglets, and preferably no fewer than four piglets using the intended route of administration for the final product, a quantity of the master seed vaccine virus equivalent to not less than the maximum virus titre (maximum release dose) likely to be contained in 1 dose of the final product of the vaccine. Observe inoculated animals daily for the appearance of at least two and preferably at least three clinical signs and record daily body temperatures using a quantitative clinical scoring system adding the values for multiple clinical signs (e.g. Gallardo *et al.*, 2015a) and record daily body temperatures.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_34	<p>Category: change</p> <p>Administer to no fewer than two piglets, and preferably no fewer than four piglets using the intended route of administration for the final product, a quantity of the master seed vaccine virus equivalent to not less than the maximum virus titre (maximum release dose) likely to be contained in 1 dose of the <u>master seed of the final product of the</u> vaccine.</p> <p>Reason: The International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) defines worldwide standards for veterinary biologics. Guideline 41 specified master seed for this study design as passages of the master seed may be more attenuated, and this evaluation should be on the virus most likely to revert to virulence</p>	<p>EN: Disagreed, proposal not clear and original text conforms to VICH guidelines. It states that the master seed virus should be used equivalent to not less than the maximum virus titre (maximum release dose) likely to be contained in 1 dose of the final product of the vaccine.</p> <p>FR: La Commission n'a pas retenu ce commentaire, car la proposition manque de clarté et le texte original est conforme aux lignes directrices du VICH. Celles-ci indiquent que la semence primaire de virus utilisée doit correspondre à une quantité qui ne peut être inférieure à la titration virale maximale (dose de libération maximale) susceptible</p>

⁵ https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl41-target-animal-safety-examination-live-veterinary-vaccines-target-animals-absence-reversion_en.pdf

Reference	Comment	Biological Standards Commission response
	https://www.vichsec.org/en/index.php?option=com_attachments&view=attachments&task=download&id=321	d'être contenue dans une dose du produit final du vaccin. SP: No aceptado, la propuesta no es clara y el texto original se ajusta a las directrices de la VICH. Establece que el inóculo vírico primario debe utilizarse equivalente a no menos del título máximo del virus (dosis máxima de liberación) que probablemente contenga 1 dosis del producto final de la vacuna.

Based on results from at least one completed post-vaccination kinetics of viral replication (MLV vaccine shed and spread (virus blood and tissue dissemination study (Section C.2.3.2.iv above), collect an appropriate quantity of blood from each piglet on the predetermined single timepoint(s) (day 5-3-13). Determine virus titres in individual blood samples by quantitative virus isolation (HAD₅₀/ml or TCID₅₀/ml) or other appropriate methods (e.g. titration using IPT or FAT detection). Quantitative PCR may be used to detect positive samples, but results should be confirmed by infectious virus titration as described above and by real-time PCR. If the vaccine virus is non-haemadsorbing or does not cause cytopathic effects, a real time PCR test or other appropriate method (e.g. titration using IPT or FAT detection) may be used. Identify the individual blood sample(s) with the highest infectious titre and reserve for the subsequent *in-vivo* passage (second pass, p2).

Based on results from at least one completed vaccine virus-MLV blood and tissue distribution dissemination study (Section C.2.3.2.iv above), euthanise piglets on the predetermined timepoint (i.e. day 5, 7, 14, 21, or 28). Determine infectious virus titres in individual tissue samples by quantitative virus isolation (HAD₅₀/ml or TCID₅₀/ml) or other appropriate methods (e.g. titration using IPT or FAT detection). Quantitative PCR may be used to detect positive samples, but results should be confirmed by infectious virus titration as described above. If the vaccine virus is non-haemadsorbing or does not cause cytopathic effects, a real-time PCR test or other appropriate method (e.g. titration using IPT or FAT detection) may be used. Identify individual tissue-sample type(s) with the highest infectious titre. Pool the tissues with the highest titres from different organs from all each animals with the highest titres and prepare at least a 10% virus suspension to obtain a virus titre within the range used for inoculation in PBS, pH 7.2 kept at 4°C or at -70°C for longer storage.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_35	Category: deletion <u>Pool the tissues with the highest titres from different organs from all each animals with the highest titres and prepare at least a 10% virus suspension to obtain a virus titre within the range used for inoculation in PBS, pH 7.2 kept at 4°C or at -70°C for longer storage.</u> Reason: The International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) defines worldwide standards for veterinary biologics. Guideline 41 specifies "The initial administration and subsequent passages shall be carried out using a recommended route of administration or natural route of infection that is the most likely to lead to reversion to or increase in virulence and result in recovery of the organism following replication in the animal." Diluting the virus to the range used in the initial inoculum instead of passing all recovered virus could decrease the likelihood of detecting a reversion to virulence.	EN: Agreed. FR: La Commission a souscrit au commentaire. SP: Aceptado.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_36	<p>Category: change</p> <p>There is no need to pool tissue samples. Samples with the highest infectious titres should be used for further passage. If appropriate, some tissue samples with the highest infectious titres may be pooled to prepare inoculum for further passages.</p> <p>Rationale:</p> <p>Regarding infectivity, there is only one type of “tissue with the highest infectivity” (except for using more than one types of tissues with identical infectivity) and mixing it with other samples would rather decrease its potency. In other words, it should be made clear that there is no need to pool multiple samples to prepare inoculum for further passages.</p>	<p>EN: Agreed that there is no need to pool. Text has been changed accordingly.</p> <p>FR: La Commission est convenue qu'il n'était pas nécessaire d'assembler les échantillons. Le texte a été modifié en conséquence.</p> <p>SP: Aceptado que no es necesario llevar a cabo una combinación. El texto se ha modificado en consecuencia.</p>

Test each blood and tissue **sample** pool used for inoculation by PCR to confirm the absence of potential viral agent contaminants (i.e. CSFV, FMDV, PRRS, PCV2). Blood and pooled tissue (p1) are used to inoculate 2 ml of positive material **diluted to the maximum release dose likely to be contained in 1 dose of the vaccine** using the intended route of administration for the final product to each of **at least two and ideally at least four further pigs of the same age and origin.**

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_37	<p>Category: deletion</p> <p><u>Blood and pooled tissue (p1) are used to inoculate 2 ml of positive material diluted to the maximum release dose likely to be contained in 1 dose of the vaccine using the intended route of administration for the final product to each of at least two and ideally at least four further pigs of the same age and origin.</u></p> <p>Reason: These should not be diluted or manipulated to increase the chance of detecting reversion to virulence.</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>
3.9.1_C2.3.2_38	<p>Category: deletion</p> <p>Propose to delete the text regarding dilution of samples.</p> <p>Rationale: Samples should not be diluted. The sample with the highest infectious titre should be used as a 10% tissue</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>
3.9.1_C2.3.2_39	<p>Category: change</p> <p>“...release dose...”. Please change to ‘<i>maximum release dose-virus titre</i>’. Dose is mentioned later in the sentence referring to vaccine dose, so it is confusing.</p> <p>After “1 dose of vaccine”, please add: <u>if needed</u>. Indeed, often the titre of the virus recovered after passage is lower than the original virus titre inoculated.</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>

Second pass (p2)

If no virus is found **at passage 1** (p1), repeat the administration by the intended route **once again with the same pooled material (blood and pooled tissue, p1) in another ten healthy piglets of the same age and origin.** If no virus is found **at this point during this second passage (p2) at this point**, end the process here.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_40	<p>Category: change</p> <p>This instruction is confusing. The first sentence seems to say that if no virus is found to move on to passage 2, then the second sentence says that if no virus is found to end the process. Based on the following section it appears that p2 is only required if there is virus so the first sentence doesn't make sense. We suggest a change to make it clearer, but we cannot confidently determine what the intent is to offer suggested wording.</p>	EN: Agreed.
		FR: La Commission a souscrit au commentaire.
		SP: Aceptado.

Second passage (p2)

If ~~however~~ virus is found in p1, carry out a second series of passages by administering 2 ml of positive material diluted to the maximum release dose likely to be contained in 1 dose of the vaccine using the intended route of administration for the final product to each of no fewer than two piglets, and preferably no fewer than four piglets of the same age and origin. Observe inoculated animals daily for the appearance of at least two and preferably at least three clinical signs using a quantitative clinical scoring system adding the values for multiple clinical signs (e.g. Gallardo *et al.*, 2015a), and record daily body temperatures and determine infectious virus titres in individual blood and tissue samples as described for p1 above.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_41	<p>Category: deletion</p> <p>If however virus is found in p1, carry out a second series of passages by administering 2 ml of positive material diluted to the maximum release dose likely to be contained in 1 dose of the vaccine using the intended route of administration for the final product to each of no fewer than two piglets....</p> <p>Reason: These should not be diluted or manipulated to increase the chance of detecting reversion to virulence.</p>	EN: Agreed (see 3.9.1_C2.3.2_37)
		FR: Commentaire accepté (voir 3.9.1_C2.3.2_37)
		SP: Aceptado (véase 3.9.1_C2.3.2_37)

Third and fourth pass (p3 and p4)

If no virus is found at in (p2), repeat the intramuscular administration by the intended route ~~once again with the same pooled material~~ (blood and pooled tissue, p2) in another eight healthy piglets of the same age and origin. If no virus is found at this point, end the process here.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_42	<p>Category: change</p> <p>This has the same issue as the instruction at the end of passage 1. We think the intent is that you repeat passage 2 using the passage 1 material, but this seems to suggest that you used the p2 material, making it essentially a third passage.</p>	EN: Agreed – changes have been made to the text to clarify the use of passage 1 material here.
		FR: Proposition acceptée – texte modifié afin de clarifier que le matériel utilisé est celui du premier passage.
		SP: Aceptado - se han introducido cambios en el texto para aclarar el uso del material del pasaje 1 aquí.

Third and fourth passage (p3 and p4)

If, however, virus is found on p2, carry out this passage operation no fewer than two additional times (p3 and p4) (to each of no fewer than two piglets, and preferably no fewer than four piglets of the same age and origin) and verifying the presence of the virus at each passage in blood and tissues. Observe inoculated animals daily for the appearance of at least two and preferably at least three clinical signs using a quantitative clinical scoring system adding the values for multiple clinical signs (e.g. Gallardo *et al.*, 2015a) and record daily body temperatures.

Fifth passage (p5)

Administer 2 ml of the blood and pooled tissue (p4) to each of at least eight healthy piglets of the same age and origin. Observe inoculated animals daily for at least 28 days post-inoculation for the appearance of at least two and preferably at least three clinical signs using a quantitative clinical scoring system adding the values for multiple clinical signs (e.g. Gallardo *et al.*, 2015a), and record daily body temperature and determine infectious virus titres in individual blood and tissue samples as described above.

The vaccine virus complies with the test if:

- No piglet shows abnormal (local or systemic) reactions, or notable signs of disease, or reaches the pre-determined humane endpoint defined in the clinical scoring system or dies from causes attributable to the vaccine; and

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_43	Category: addition Suggest reversing deletion above given recent data on U.S. select agent exclusion recission. We don't know what clinical signs will be caused by revertant vaccine strains – this consideration should be broad and inclusive (local or systemic reactions and/or notable signs of disease).	EN: Agreed.
		FR: La Commission a souscrit au commentaire.
		SP: Aceptado.

- There is no indication of increasing virulence (as monitored by daily body temperature accompanied by clinical sign observations) of the maximally passaged virus compared with the master seed virus.

At a minimum, a safe MLV vaccine shall demonstrate ALL the following features (minimal standards):

- Absence of fever (on each day during the observation period, the maximum increase in body temperature above the baseline observed for each pig will be used to calculate the daily group mean temperature rise. This mean value should not exceed 1.5°C and no individual pig should show a rise in temperature above baseline greater than 1.5°C (defined as average body temperature increase for all vaccinated piglets (group mean) for the observation period does not exceed 1.5°C above baseline; and no individual piglet shows a temperature rise above baseline greater than 2.5°C for a period exceeding 3 days);

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_44	Category: change Absence of fever (on each day during the observation period, the maximum increase in body temperature above the baseline observed for each pig will be recorded, will be used to calculate the daily group mean temperature rise. This mean value should not exceed 1.5°C and no individual pig should show a rise in temperature above baseline greater than 1.5°C defined as average body temperature increase for all vaccinated piglets (group mean) for the observation period does not exceed 1.5°C above baseline; and no individual piglet shows a temperature rise above baseline greater than 2.5°C for a period exceeding 3-2 days);	EN: Agree (see comment 3.9.1_C2.3.2_10 above)
		FR: Proposition acceptée (voir plus haut le commentaire 3.9.1_C2.3.2_10)
		SP: Aceptado (véase el comentario 3.9.1_C2.3.2_10 anterior)

	Reason: These criteria are set to be acceptable for the current, most developed vaccine strain and are not objectively developed. Additionally, taking the average temperature of the group could mask individual reactions. Minimal temperature rise of 1 day was seen in safety studies - 3 days seems long based on current data. Tran et al. 2022.	
3.9.1_C2.3.2_45	Category: addition In line with the compliance criteria of the safety tests described above the following minimum requirement is missing and should also be added: " Absence of abnormal (local or systemic) reactions " It is understood that the absence of acute/chronic clinical signs/gross pathology are related to ASF. Local/systemic reactions refer to more general observations (injection site reactions, anaphylactic reactions, etc.).	EN: Agreed.
		FR: La Commission a souscrit au commentaire.
		SP: Aceptado.

- Absence of chronic and acute clinical signs and gross pathology over the entire test period or minimal-chronic-mild clinical signs (defined as e.g. mild swollen joints with a low clinical score that resolve within 1 week).
- Minimal (defined as no naïve, contact piglet shows notable signs of disease by clinical signs and gross pathology and no or a low percentage of contact piglets test both real-time PCR positive and seropositive) or no vaccine virus transmission (defined as no naïve, contact piglet shows notable signs of disease by clinical signs and gross pathology and no contact piglets test both real-time PCR positive and seropositive) over the entire test period;

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_46	Category: change This needs to be clarified. As it reads there must be absence of mild clinical signs. Is this the intention? Is it necessary this part? <i>"both real-time PCR positive and seropositive..."</i> Please see the previous comment on this point.	EN: Agreed.
		FR: La Commission a souscrit au commentaire.
		SP: Aceptado.

- Absence of an increase in virulence (genetic and phenotypic stability) (complies with the reversion to virulence test).

In addition, for regulatory approval, ASF MLV the vaccines in their commercial presentation before being authorised for general use should be tested for safety in the under field conditions (see chapter 1.1.8 Section 7.2.3). Additional Field safety studies generally evaluation studies may include measurement of body temperatures, observation of local or systemic reactions and, where appropriate, performance measurements but are not limited to: environmental persistence (e.g. determination of virus recovery from bedding or other surfaces), assessment of immunosuppression, and negative impacts on performance.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.2_47	Category: addition Field safety studies generally evaluation studies may include measurement of body temperatures, observation of local or systemic reactions and, where appropriate, performance measurements such as: environmental persistence (e.g. determination of virus recovery from bedding or other surfaces), assessment of	EN: Agreed.
		FR: La Commission a souscrit au commentaire.
		SP: Aceptado.

Reference	Comment	Biological Standards Commission response
	<p>immunosuppression, and negative impacts on performance.</p> <p>Reason: Suggest reversing deletion above. Environmental persistence is a very relevant criterion for evaluation given recent data our country select agent exclusion recission and the potential for reversion to virulence and spread to wild suids. Other criteria are also valid given the unknown clinical signs that might be seen with revertant viruses and are listed as examples for incorporation.</p>	
3.9.1_C2.3.2_48	<p>Category: deletion</p> <p>Additional—Field safety studies generally evaluation studies...</p> <p>"generally may include..." is redundant.</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>

2.3.3. Efficacy requirements

i) Protective dose

Vaccine efficacy is estimated in immunised animals directly, by evaluating their resistance to live virus challenge. The test consists of a vaccination/challenge trial in piglets a minimum of 6-4-weeks old and not more than 10-weeks old, free of antibodies to ASFV, and negative blood samples by real-time PCR. The test is conducted using no fewer than 15 and preferably no fewer than 24 vaccinated pigs, and no fewer than five non-vaccinated control piglets.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.3_1	<p>Category: addition</p> <p>".....by evaluating their resistance protection against live virus challenge....."</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>

The test is conducted to determine the minimal immunising dose (MID) (also referred to as the minimal protective dose [MPD] or protective fraction); using at least three groups of no fewer than five and preferably not fewer than eight vaccinated piglets per group, and one additional group of no fewer than five non-vaccinated piglets of the same age and origin as controls. Use vaccine containing virus at the highest passage level that will be present in a batch of vaccine.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.3_2	<p>Category: change</p> <p>The test is conducted to determine the minimal immunising dose (MID) (also referred to as the minimal protective dose [MPD] or protective fraction) using at least three groups of no fewer than five and preferably not fewer than eight vaccinated piglets per group, and one additional group of no fewer than five non-vaccinated piglets of the same age and origin as controls. Use vaccine containing virus at the highest passage level that will be present in a batch of vaccine. It may be possible to combine the data obtained by independent experiments</p>	<p>EN: Disagreed: more robust as written originally</p> <p>FR: La Commission n'a pas retenu ce commentaire car le texte est plus solide dans sa rédaction initiale.</p> <p>SP: No aceptado: más robusto tal y como estaba redactado originalmente.</p>

Reference	Comment	Biological Standards Commission response
	<p><u>separately conducted under the same condition due to the limitation of capacity of the facility.</u></p> <p>Rationale: Propose to delete the text that is not in line with the VICH guidelines and to add more feasible recommendation. There is no specification in the VICH guidelines regarding test setting for protective dose such as number of pigs kept, age, consistency of origin, composition.</p> <p>In addition, this description should clearly define "protective dose" (preferably based on PD₅₀) or how to determine the minimum release dose (titre) per vaccine vial.</p> <p>The step described should be performed with MSV but with not each product batches. Hence, the sentence should be deleted at this step.</p>	

Each group of piglets, except the control group, is immunised with a different vaccine virus content in the same vaccine volume. In at least one vaccinated group, piglets are immunised with a vaccine dose containing not more than the minimum virus titre (minimum release dose) likely to be contained in one dose of the vaccine as stated on the label.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.3_3	<p>Category: deletion</p> <p>Please delete <u>(minimum release dose)</u>. Please note that the minimum release titre may be higher than the minimum efficacious titre, to compensate for the potential losses in titre during shelf life (overage).</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>

Twenty-eight days (+2 days) after the single ~~injection dose~~ of vaccine (or if using two ~~injections doses~~ of the vaccine then 28 days [+2 days] following the second ~~injection dose~~), challenge all the piglets by the intramuscular route. If previous studies have demonstrated acceptable efficacy using IM challenge, then a different challenge route (e.g. direct contact, oral or oronasal) may be used. Challenged, vaccinated piglets may be housed in one or more separate pens in the same room or in different rooms. Challenged, naïve controls can be housed in one or more rooms that are separate from challenged, vaccinated piglets.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.3_4	<p>Category: addition</p> <p><u>A suitable challenge model should be developed based on anticipated field usage of the vaccine. As a baseline protocol, 28 days...</u></p> <p>Reason: National Veterinary Joint Stock Company (NAVETCO) updated label claims to allow a single vaccine dose. Suggest this modification to allow different regulatory authorities flexibility to pursue their own criteria for protection.</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>

Carry out the test using an ASFV representative strain of the epidemiologically relevant field strain(s) where the vaccine is intended for use (e.g. ASFV B646L [p72] genotype II pandemic strain and other p72 virulent genotype of recognised epidemiologic importance). For gene deleted, recombinant MLV viruses, if neither challenge virus type is available, then carry out the test with the parental, virulent virus used to generate the MLV recombinant virus. Use a

10e3–10e4 HAD₅₀ (or TCID₅₀ for non-HAD viruses) challenge dose sufficient to cause death or meet the humane endpoint in 100% of the nonvaccinated piglets in less than 21 days. Higher or lower challenge doses can be considered if appropriately justified.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.3_5	<p>Category: change</p> <p>Propose to amend “<u>HAD₅₀ (or TCID₅₀ for non-HAD viruses)</u>” to “<u>HAD₅₀ or TCID₅₀.</u>”</p> <p>Rationale: Regardless of whether the virus is a hemadsorption (HAD) strain or a non-hemadsorption (non-HAD) strain, it is possible to apply HAD₅₀ or TCID₅₀ as units of virus titre as appropriate. Specifically, the titre of non-HAD strains can only be expressed in TCID₅₀, but if it is a HAD strain, it can be expressed in either HAD₅₀ or TCID₅₀, and the values are almost synonymous.</p>	EN: Agreed.
		FR: La Commission a souscrit au commentaire.
		SP: Aceptado.

The rectal temperature of each vaccinated piglet is measured on at least the 3 days preceding administration of the challenge virus, at the time of challenge, 4 hours after challenge, and then daily for the observation period of at least 28-45 days, preferably 35-60 days. Observe the piglets at least daily for at least 28 days, preferably 35 days. Carry out the daily observations for signs of acute and chronic clinical disease using a quantitative clinical scoring system adding the values for multiple clinical signs (e.g. Gallardo *et al.*, 2015). These clinical signs should include fever, anorexia, recumbency, skin haemorrhage or cyanosis, joint swelling and necrotic lesions around the joints, respiratory distress and digestive findings.

Collect oral, nasal, anal and blood samples from the vaccinated challenged piglets at least two times once per week from 3 days post-challenge for at least 28-14 days, then weekly up to 35 days post-challenge and then every 14 days up to the end of the observation period preferably 35 days. From the blood samples, determine infectious virus titres by quantitative virus isolation (HAD₅₀/ml or TCID₅₀/ml) or other appropriate methods (e.g. titration using IPT or FAT detection). Quantitative PCR may be used to detect positive samples, but results should be confirmed by infectious virus titration as described above and using a real-time PCR test. If the vaccine virus is non-haemadsorbing or does not cause cytopathic effects, a real-time PCR test only may be used.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.3_6	<p>Category: addition</p> <p>Collect <u>oral, nasal, and faecal anal swabs and blood samples.</u></p> <p>Reason: Relevant sample types to evaluate transmission by all possible routes inserted.</p>	EN: Agreed.
		FR: La Commission a souscrit au commentaire.
		SP: Aceptado.
3.9.1_C2.3.3_7	<p>Category: change</p> <p>“Collect oral, nasal, anal and blood samples from the vaccinated...”</p> <p>Oral, nasal, and anal samples is open to interpretation - this should specify swabs. Also, there are no clear instructions to use these samples later on in the procedure, so their purpose should be clarified.</p>	EN: Agreed.
		FR: La Commission a souscrit au commentaire.
		SP: Aceptado.

At the end of the test period, humanely euthanise all vaccinated challenged piglets. Conduct gross pathology (and histopathology if considered necessary) on spleen, lung, tonsil, and kidney tissue samples and at least three different lymph nodes (which should include lymph node closest to site of inoculation, gastrohepatic and submandibular nodes). Determine virus titres in all collected samples by quantitative virus isolation (HAD₅₀/mg or TCID₅₀/mg) or other appropriate methods (e.g. titration using IPT or FAT detection). Quantitative PCR

may be used to detect positive samples, but results should be confirmed by infectious virus titration as described above and real-time PCR (see Section B.1. Identification of the agent). If the vaccine virus is non-haemadsorbing or does not cause cytopathic effects, a real-time PCR test or other appropriate method (e.g. titration using IPT or FAT detection) may be used.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.3_8	<p>Category: change</p> <p>The aim of the validity criterion is to validate the suitability of the challenge. It needs to be reminded that one of the key minimum standards for efficacy has been set for protection against mortality. Therefore, it would be expected that the challenge model used is suitable to evaluate such efficacy endpoint.</p> <p>The proposed validity criterion is not considered appropriate: 1) the number of vaccinated piglets dying or reaching the humane endpoint should always be 0 (to fulfil the compliance criterion); 2) it might be challenging to prove statistical significance with the minimum number of animals that can be included per group; 3) even if statistical significance is proven, it may not be meaningful from a biological point of view e.g. 0% mortality in vaccinated vs. 15% mortality in controls might render a statistically significant difference, but it is not considered appropriate to validate a challenge aimed at demonstrating protection against mortality (low severity of the challenge). The severity of the challenge should be suitable to evaluate the efficacy endpoints that are then required as minimum standards. Ideally, a minimum percentage of control piglets dying/reaching humane endpoint should be defined (e.g. minimum 80%, meaning that 1 out of 5 controls may not die or reached the humane endpoint). The experts on the disease may provide advice on which would be a realistic percentage (representative of field conditions).</p> <p>Please also note text in lines 668–670 where validity criterion is also set at 100% mortality in control piglets.</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>
3.9.1_C2.3.3_9	<p>Category: change</p> <p>Considering that it would be nearly impossible to develop a vaccine with 100% protection, this sentence is proposing an excessive high standard in which even a single vaccinated challenged piglet should not die. This type of unfeasible standards should not be included in the <i>Manual</i>. In addition, the current draft text “No vaccinated challenged piglet dies or...” contradicts the earlier statement “The test is invalid if the difference between the number of unvaccinated control piglets infected with the live challenge virus and the number of vaccinated/ challenged piglets that die or reach a humane endpoint is not statistically significant”, thus Japan requests to amend the text to align it with the first statement.</p>	<p>EN: Agreed. The text has been modified, and now refers to challenge with a highly virulent ASFV virus strain, where experts agree that one would expect all the pigs in the unvaccinated control group to die or reach humane endpoints when infected with the live challenge virus for the test to be considered valid.</p> <p>FR: Commentaire accepté. Le texte a été modifié et se réfère désormais à une inoculation d'épreuve avec une souche du virus de la PPA hautement virulente, dont les experts auraient déterminé, afin de fonder la validité du test, que l'inoculation d'épreuve entraînerait chez les porcs non vaccinés du groupe de contrôle soit la mort, soit un état correspondant au point limite imposant d'euthanasier l'animal.</p> <p>SP: Aceptado. El texto ha sido modificado y ahora se refiere al desafío con una cepa altamente</p>

		virulenta del virus de la peste porcina africana, donde los expertos están de acuerdo en que se esperaría que todos los cerdos del grupo de control no vacunado murieran o alcanzaran puntos finales humanitarios cuando se infectaran por el virus vivo de desafío para que la prueba se considerara válida.
--	--	---

The test is invalid if fewer than 100% the difference between in the number of unvaccinated control piglets infected with the live challenge virus and the number of vaccinated/challenged piglets vaccinated with the minimum release dose that die or reach a humane endpoint is not statistically significant.

The vaccine (or a specific vaccine virus dose if conducting a vaccine dose titration study) complies with the test if:

- No vaccinated challenged piglet dies or shows abnormal (local or systemic) reactions, reaches the humane endpoint or dies from causes attributable to ASF;

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.3_10	Category: change Suggest reversing deletion above given recent data our country select agent exclusion recission. We don't know what clinical signs will be caused by revertant vaccine strains – this consideration should be broad and inclusive (local or systemic reactions and/or notable signs of disease)	EN: Agreed.
		FR: La Commission a souscrit au commentaire.
		SP: Aceptado.

- On each day during the observation period the maximum increase in body temperature above the baseline observed for each pig will be used to calculate the daily group mean. This mean value should not exceed 1.5°C and no individual pig should show a rise in temperature above baseline greater than 2.0°C for a period exceeding 2 consecutive days. The average body temperature increase for all vaccinated challenged piglets (group mean) for the observation period does not exceed 2.0°C above baseline; and no individual piglet shows a temperature rise above baseline greater than 2.0°C.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.3_11	Category: change <u>On each day during the observation period the maximum increase in body temperature above the baseline observed for each pig will be recorded, used to calculate the daily group mean. This mean value should not exceed 1.5°C and No individual pig should show a rise in temperature above baseline greater than 2.0-1.5°C for a period exceeding 2 consecutive days</u> Reason: These criteria are set to be acceptable for the current, most developed vaccine strain and are not objectively developed. Additionally, taking the average temperature of the group could mask individual reactions. Minimal temperature rise of 1 day was seen in safety studies - 3 days seems long based on current data. Tran et al. 2022.	EN: Agreed – changes made (see comments: 3.9.1_C2.3.2_10 3.9.1_C2.3.2_19 3.9.1_C2.3.2_44
		FR: Proposition acceptée – les changements ont été introduits. (voir les commentaires : 3.9.1_C2.3.2_10 3.9.1_C2.3.2_19 3.9.1_C2.3.2_44)
		SP: Aceptado - cambios realizados (ver comentarios: 3.9.1_C2.3.2_10 3.9.1_C2.3.2_19 3.9.1_C2.3.2_44

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.3_12	Category: clarification Request to provide the rationale to change the average body temperature increase (group mean) from 2.0°C to 1.5°C? Rationale: For clarity of the scientific grounds.	EN: Group means are no longer measured, so this comment is no longer valid
		FR: Les moyennes du groupe ne sont plus mesurées, ce commentaire n'est donc plus valable
		SP: Ya no se miden las medias de grupo, así que este comentario ya no es válido.
3.9.1_C2.3.3_13	Category: change “On each day during the observation period the maximum increase in body temperature above the baseline observed for each pig will be used to calculate the daily group mean.” As previously, this should be in the instructions for the test, <u>not the compliance requirements.</u>	EN: Agreed.
		FR: La Commission a souscrit au commentaire.
		SP: Aceptado.

- The vaccinated challenged piglets display a reduction or absence of typical acute clinical signs of disease and gross pathology and a reduction or absence of challenge virus levels in blood and tissues.

ii) Assessment for horizontal transmission (challenge virus shed and spread study)

The ASF basic reproduction number, R₀, can be defined as the average number of secondary ASF disease cases caused by a single ASFV infectious pig during its entire infectious period in a fully susceptible population (Hayes *et al.*, 2021). In general, if the ASFV effective reproduction number $Re=R_0 \times (S/N)$ (S= susceptible pigs; N= total number of pigs in a given population) is greater than 1.0, disease is predicted to spread. Ideally, ASF vaccination should reduce Re to less than 1.0 by reducing the number of susceptible, naïve, contact pigs exposed to vaccinated, infected pigs.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.3_14	Category: deletion The ASF basic reproduction number, R₀, can be defined as the average number of secondary ASF disease cases caused by a single ASFV infectious pig during its entire infectious period in a fully susceptible population (Hayes <i>et al.</i>, 2021). In general, if the ASFV effective reproduction number $Re=R_0 \times (S/N)$ (S= susceptible pigs; N= total number of pigs in a given population) is greater than 1.0, disease is predicted to spread. Ideally, ASF vaccination should reduce Re to less than 1.0 by reducing the number of susceptible, naïve, contact pigs exposed to vaccinated, infected pigs. Reason: These are population level statistics and are not valid when calculated with small sample sizes in defined settings.	EN: Agreed.
		FR: La Commission a souscrit au commentaire.
		SP: Aceptado.
3.9.1_C2.3.3_15	Category: change We query why this provision on assessment of horizontal transmission (challenge virus shed and spread study) is included in this chapter. Generally, there are no established protocols for evaluating the inhibitory effect on virus shedding in vaccinated and challenged animals for other veterinary vaccines, and this kind evaluation is not normally	EN: Agreed to delete the section, though the information is useful, it is not required for vaccine registration
		FR: La Commission a accepté de supprimer ce paragraphe ; l'information dont il s'agit, bien

	a part of requirements for authorisation/registration/licensing.	qu'utile, n'est pas nécessaire pour l'enregistrement du vaccin.
		SP: Se acuerda suprimir la sección, aunque la información es útil, no es necesaria para el registro de vacunas.

To evaluate ASF vaccine impact on ASF disease transmission, the test consists of a vaccination/challenge trial in piglets a minimum of 6-4 weeks old and not older than 10-weeks old, free of antibodies to ASFV, and negative blood samples by real-time PCR.

The test is conducted using no fewer than 15 healthy piglets at a ratio comprising twice the number of vaccinated piglets to naïve piglets (e.g. ten vaccinated and five naïve). Use vaccine containing virus at the highest passage level that will be present in a batch of the vaccine.

The quantity of vaccine virus administered to each pig is equivalent to be not less than the minimum virus titre (minimum dose) likely to be contained in one dose of the vaccine as stated on the label. Following immunisation, vaccinated and naïve piglets should continue to be co-mingled.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.3_16	Category: deletion Please delete (minimum dose) . Not necessary and it might be confusing as reference to "dose" is made in the same sentence with a different meaning.	EN: Comment obsolete as the entire Section has been deleted
		FR: Commentaire obsolète car toute la section a été supprimée
		SP: Comentario obsoleto, ya que se ha suprimido toda la sección.

Twenty-eight days (+2 days) after the single injection-dose of vaccine (or if using two injections doses of the vaccine then 28 days [+2 days] following the second injection-dose), temporarily separate [into different pen(s) or room(s)] all vaccinated piglets from naïve piglets. Challenge all vaccinated piglets by the intramuscular or other previously verified route. Carry out the challenge using an ASFV representative strain of the epidemiologically relevant field strain(s) where the vaccine is intended for use (e.g. ASFV B646L [p72] genotype II pandemic strain and other p72 virulent genotype of recognised epidemiological importance). For gene deleted, recombinant MLV viruses, if neither challenge virus type is available, then carry out the test with the parental, virulent virus used to generate the MLV recombinant virus. Use a 10e3–10e4 HAD₅₀ (or TCID₅₀ for non-HAD viruses challenge dose sufficient to cause death or met the humane endpoint in 100% of the nonvaccinated piglets in less than 21 days. Higher or lower challenge doses can be considered if appropriately justified.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.3_17	Category: change "...for TCID.....less than 21 days". This text will need to be revised to align with the final decision on the validity criterion.	EN: Comment obsolete as the entire Section has been deleted
		FR: Commentaire obsolète car toute la section a été supprimée
		SP: Comentario obsoleto, ya que se ha suprimido toda la sección.

Approximately 18–24 hours later, re-introduce naïve piglets to vaccinated, challenged piglets and allow for direct nose to nose contact exposure with vaccinated, challenged piglets. Allow for continuous contact exposure by co-mingling both groups through the end

of the study. If more than one pen or room is used for co-housing, following reintroduction initially maintain a ratio of 2:1 of challenged, vaccinated piglets to contact exposed, naïve piglets.

The rectal temperature of each contact piglet is measured on at least the 3 days preceding administration of the challenge virus to vaccinated pigs, immediately prior to direct contact exposure, 4 hours post-contact exposure, and then daily for at least 28, preferably 35 days and twice a week for at least 60 days. Observe all contact exposed piglets at least daily for at least 28 days, and then twice a week for at least 60 days preferably for at least 35 days.

Carry out the daily observations in each contact piglet for signs of acute and chronic clinical disease using a quantitative clinical scoring system adding the values for multiple clinical signs (e.g. Gallardo *et al.*, 2015a). These clinical signs should include fever, anorexia, recumbency, skin haemorrhage or cyanosis, joint swelling and necrotic lesions around the joints, respiratory distress and digestive findings.

In addition, blood should be taken from the naïve contact piglets at least twice a week from 3-days post-contact exposure for the duration collect blood samples from the contact piglets at least two times per week from 3 days post-contact for at least 14 days, then weekly up to 35 days post-contact exposure and then every 14 days up to the end of the test period. Determine virus titres in all collected samples by quantitative virus isolation (HAD₅₀/mg or TCID₅₀/mg) or other appropriate methods (e.g. titration using IPT or FAT detection). Quantitative PCR may be used to detect positive samples, but results should be confirmed by infectious virus titration as described above. From the blood samples, determine infectious challenge virus titres by quantitative virus isolation (HAD₅₀/ml or TCID₅₀/ml) and using a real-time PCR test. If the vaccine virus is non haemadsorbing or does not cause cytopathic effects, a real-time PCR test only may be used.

Collect blood (serum) samples from the naïve contact pigs at least at day 21 and day 28 (±2 days), and at the end of the test period, and carry out an appropriate test to detect vaccine virus antibodies.

Collect oral, nasal and faecal swab samples (preferably devoid of blood to minimise assay interference) from all contact-exposed naïve piglets at least two times per week from 3-days post-contact exposure for the first 2 weeks, then weekly for the duration of the test and test swabs for the presence of challenge virus. Determine virus titres in all collected samples by quantitative virus isolation (HAD₅₀/mg or TCID₅₀/mg) or other appropriate methods (e.g. titration using IPT or FAT detection). Quantitative PCR may be used to detect positive samples, but results should be confirmed by infectious virus titration as described above. Determine virus titres in all collected samples by quantitative virus isolation (HAD₅₀/ml or TCID₅₀/ml) and using a real-time PCR test. If the vaccine virus is non haemadsorbing or does not cause cytopathic effects, a real-time PCR test or other appropriate method (e.g. titration using IPT or FAT detection) may be used.

At the end of the test period, humanely euthanise all contact piglets. Conduct gross pathology on spleen, lung, tonsil, and kidney tissue samples and at least three different lymph nodes. (which should include lymph node closest to site of inoculation, gastrohepatic and submandibular nodes). Determine virus titres in all collected samples by quantitative virus isolation (HAD₅₀/mg or TCID₅₀/mg) or other appropriate methods (e.g. titration using IPT or FAT detection). Quantitative PCR may be used to detect positive samples, but results should be confirmed by infectious virus titration as described above. Determine virus titres in all collected samples by quantitative virus isolation (HAD₅₀/mg or TCID₅₀/mg) and real-time PCR (see Section B.1. Identification of the agent). If the vaccine virus is non haemadsorbing or does not cause cytopathic effects, a real-time PCR test or other appropriate method (e.g. titration using IPT or FAT detection) may be used.

The test is invalid if the vaccine fails to comply with the compliance criteria described for the protected dose test in vaccinated pigs (Section C.2.3.3.i above).

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.3_18	<p>Category: addition</p> <p><u>The test is invalid if the vaccine fails to comply with the compliance criteria described for the protected dose test in vaccinated pigs (Section C.2.3.3.i above) or evidence of disease is seen in non-vaccinated pigs.</u></p> <p>Reason: This section is evaluation of horizontal transmission and did not include evidence of disease in non-vaccinates as a criteria as the reference is to an efficacy evaluation.</p>	<p>EN: Comment obsolete as the entire Section has been deleted</p> <p>FR: Commentaire obsolète car toute la section a été supprimée</p> <p>SP: Comentario obsoleto, ya que se ha suprimido toda la sección.</p>

If the manufacturer claims that the vaccine induces sterilising immunity, the vaccine complies with the test for a reduction in horizontal disease transmission if all the following conditions are satisfied:

- No naïve, contact exposed piglet shows abnormal (local or systemic) reactions, reaches the defined humane endpoint or dies from causes attributable to ASF.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.3_19	<p>Category: deletion</p> <p><u>“shows abnormal (local or systemic) reactions”</u>. Please delete: Reference to abnormal (local or systemic) reactions is normally used relating safety observations after vaccine administration which is not the case. The point (clinical signs of disease) is covered in the next bullet point.</p>	<p>EN: Comment obsolete as the entire Section has been deleted</p> <p>FR: Commentaire obsolète car toute la section a été supprimée</p> <p>SP: Comentario obsoleto, ya que se ha suprimido toda la sección.</p>

- No naïve, contact exposed piglet displays fever accompanied by typical signs of disease, including gross pathology.

Naïve contact pigs show an absence of challenge virus in blood and tissues.

No naïve contact pigs test positive for antibodies to the challenge virus.

Otherwise, the vaccine complies with the test for a reduction in horizontal disease transmission if:

- Naïve contact pigs show a reduction or absence of challenge virus levels in blood and tissues.
- None of or a reduced number of naïve contact exposed pigs test positive for antibodies to the challenge virus.

At a minimum, an efficacious MLV vaccine shall demonstrate ALL the following features (minimal standards):

- Protects against mortality;
- Reduces acute disease (fever accompanied by a reduction of typical clinical and pathological signs of acute disease)
- Reduces levels of viral shedding and viraemia.
- Reduces horizontal disease transmission (no none of or a reduced number of naïve, contact exposed piglets shows abnormal [local or systemic] reactions, reaches the humane endpoint or dies from causes attributable to ASF, and displays fever accompanied by typical acute disease signs caused by ASF) and test positive for antibodies to the challenge virus.

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.3_20	<p>Category: deletion</p> <p>“(none of or a reduced number of naïve, contact exposed piglets shows abnormal [local or systemic] reactions, reaches the humane endpoint or dies from causes attributable to ASF, displays fever accompanied by typical acute disease signs caused by ASF) and test positive for antibodies to the challenge virus.”</p> <p>We would suggest deleting this part. The key compliance criteria for transmission are already given above and specifically in lines 731-733, so the info would appear redundant and makes reading more difficult.</p>	EN: Comment obsolete as the entire Section has been deleted
		FR: Commentaire obsolète car toute la section a été supprimée
		SP: Comentario obsoleto, ya que se ha suprimido toda la sección.

• ~~Reduces levels of viral shedding and viraemia.~~

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.3_21	<p>Category: change</p> <p>In Section C.2.3.3 of efficacy requirement, it is suggested to add “at least 80% of pigs in the immune group shall have no clinical signs and no viral shedding in mouth, nose and anus” to the minimum requirements for attenuated live vaccine.</p>	EN: Comment obsolete as the entire Section has been deleted
		FR: Commentaire obsolète car toute la section a été supprimée
		SP: Comentario obsoleto, ya que se ha suprimido toda la sección.

~~In general, for regulatory approval, ASF MLV addition, the vaccines in their commercial presentation before being authorised for general use should be tested for efficacy in the under field conditions (see chapter 1.1.8 Section 7.2.3). Additional Field efficacy evaluation studies may generally include but are not limited to: onset of immunity, duration of immunity, and impact on disease transmission measurement of relevant efficacy parameters including but limited to mortality, clinical signs, impact on disease transmission, performance parameters.~~

2.3.4. Duration of immunity

~~Although not included in the guidance for ASF MLV first generation vaccines, manufacturers are encouraged required, as part of the authorisation procedure, to define and demonstrate the duration of immunity of a given vaccine by evaluation of potency at the end of the claimed period of protection.~~

2.3.5. Stability

~~Stability of the vaccine should be demonstrated over the shelf life recommended for the product. Although not included in the standards for first generation MLV ASF vaccines, manufacturers are encouraged required, as part of the authorisation procedure, to generate data supporting the retention of immunogenicity over a defined period of validity time of a lyophilised or other pharmaceutical form of the ASF vaccine as part of the authorisation procedure.~~

Reference	Comment	Biological Standards Commission response
3.9.1_C2.3.5_1	<p>Category: deletion</p> <p>Suggest reversal of all these changes - this should not be required for an initial approval.</p>	EN: Partly agreed, the text has been amended to state that manufacturers are “in general” required...
		FR: Commentaire accepté en partie – le texte a été amendé et indique désormais qu’il est « généralement » demandé aux fabricants etc.

		SP: En parte aceptado, el texto se ha modificado para indicar que «en general» se exige a los fabricantes..
3.9.1_C2.3.5_2	<p>Category: addition</p> <p>“...are required...”. Perhaps to cater for possible differences in different regulatory jurisdictions, “in general” could be added: “Manufacturers are in general required to (...)”</p> <p>Change proposed: The text can be simplified and rationalised as:</p> <p>“Although not included in the standards for first generation MLV ASF vaccines, manufacturers are required, as part of the authorisation procedure, to generate data (including potency) showing that the vaccine remains stable over the shelf life recommended for the product—supporting the retention of immunogenicity over a defined period of validity time of a lyophilised or other pharmaceutical form of the ASF vaccine as part of the authorisation procedure.”</p>	<p>EN: Agreed.</p> <p>FR: La Commission a souscrit au commentaire.</p> <p>SP: Aceptado.</p>

REFERENCES

- ACHENBACH J.E., GALLARDO C., NIETO-PELEGRÍN E., RIVERA-ARROYO B., DEGEFA-NEGI T., ARIAS M., JENBERIE S., MULISA D.D., GIZAW D., GELAYE E., CHIBSSA T.R., BELAYE A., LOITSCH A., FORSA M., YAMI M., DIALLO A., SOLER A., LAMIEN C.E. & SÁNCHEZ-VIZCAÍNO J.M. (2017). Identification of a New Genotype of African Swine Fever Virus in Domestic Pigs from Ethiopia. *Transbound. Emerg. Dis.*, **64**, 1393–1404.
- AGÜERO M., FERNÁNDEZ J., ROMERO L., SANCHEZ C., ARIAS M. & SÁNCHEZ-VIZCAÍNO J.M. (2003). Highly sensitive PCR assay for the routine diagnosis of African swine fever virus in clinical samples, *J. Clin. Microbiol.*, **41**, 4431–4434.
- AGÜERO M., FERNÁNDEZ J., ROMERO L., ZAMORA M.J., SANCHEZ C., BELÁK S., ARIAS M. & SÁNCHEZ-VIZCAÍNO J.M. (2004). A highly sensitive and specific gel-based multiplex RT-PCR assay for the simultaneous and differential diagnosis of African swine fever and Classical swine fever. *Vet. Res.*, **35**, 1–13.
- ALEJO A., MATAMOROS T., GUERRA M. & ANDRÉS G. (2018). A Proteomic Atlas of the African Swine Fever Virus Particle. *J. Virol.*, **92**, pii: e01293-18. doi: 10.1128/JVI.01293-18.
- BARASONA J.A., GALLARDO C., CADENAS-FERNÁNDEZ E., JURADO C., RIVERA B., RODRÍGUEZ-BERTOS A., ARIAS M. & SÁNCHEZ-VIZCAÍNO J.M. (2019). First oral vaccination of Eurasian wild boar against African swine fever virus genotype II. *Front. Vet. Sci.*, **6**, 137. [https://doi: 10.3389/fvets.2019.00137](https://doi.org/10.3389/fvets.2019.00137).
- BASTO A.P., PORTUGAL R.S., NIX R.J., CARTAXEIRO C., BOINAS F., DIXON L.K., LEITAO A. & MARTINS C. (2006). Development of a nested PCR and its internal control for the detection of African swine fever virus (ASFV) in *Ornithodoros erraticus*. *Arch. Virol.*, **151**, 819–826
- BISHOP R.P., FLEISCHAUER C., DE VILLIERS E.P., OKOTH E.A., ARIAS M., GALLARDO C. & UPTON C. (2015). Comparative analysis of the complete genome sequences of Kenyan African swine fever virus isolates within p72 genotypes IX and X. *Virus Genes*, **50**, 303–309.
- BORCA M.V., RALA., RAMÍREZ-MEDINA E., SILVA E., VELAZQUEZ-SALINAS L., VUONO E., PRUITT S., ESPINOZA N. & GLADUE D.P. (2021). A Cell Culture-Adapted Vaccine Virus against the Current African Swine Fever Virus Pandemic Strain. *J. Virol.*, **95**, e0012321. [https://doi: 10.1128/JVI.00123-21](https://doi.org/10.1128/JVI.00123-21).
- BOSHOF C.I., BASTOS A.D., GERBER L.J. & VOSLOO W. (2007). Genetic characterisation of African swine fever viruses from outbreaks in southern Africa (1973–1999). *Vet. Microbiol.*, **121**, 45–55.

BOURRY O., HUTET E., LE DIMNA M., LUCAS P., BLANCHARD Y., CHASTAGNER A., PABOEUF F. & LE POTIER M.F. (2022). Oronasal or Intramuscular Immunization with a Thermo-Attenuated ASFV Strain Provides Full Clinical Protection against Georgia 2007/1 Challenge. *Viruses*, **14**, 2777. doi: 10.3390/v14122777

BRAKE D.A. (2022). African Swine Fever Modified Live Vaccine Candidates: Transitioning from Discovery to Product Development through Harmonized Standards and Guidelines. *Viruses*, **14**, 2619. doi: 10.3390/v14122619

CADENAS-FERNÁNDEZ E., SÁNCHEZ-VIZCAÍNO J.M., KOSOWSKA A., RIVERA B., MAYORAL-ALEGRE F., RODRÍGUEZ-BERTOS A., YAO J., BRAY J., LOKHANDWALA S., MWANGI W. & BARASONA J.A. (2020). Adenovirus-vectored African Swine Fever Virus Antigens Cocktail Is Not Protective against Virulent Arm07 Isolate in Eurasian Wild Boar. *Pathogens*, **9**, 171. doi: 10.3390/pathogens9030171.

CHAPMAN D.A., DARBY A.C., DA SILVA M., UPTON C., RADFORD A.D. & DIXON L.K. (2011). Genomic analysis of highly virulent Georgia 2007/1 isolate of African swine fever virus. *Emerg. Infect. Dis.*, **17**, 599–605.

CHEN W., ZHAO D., HE X., LIU R., WANG Z., ZHANG X., LI F., SHAN D., CHEN H., ZHANG J., WANG L., WEN Z., WANG X., GUAN Y., LIU J. & BU Z. (2020). A seven-gene-deleted African swine fever virus is safe and effective as a live attenuated vaccine in pigs. *Sci. China Life Sci.*, **63**, 623. [https://doi: 10.1007/s11427-020-1657-9](https://doi.org/10.1007/s11427-020-1657-9).

COSTARD S., MUR L., LUBROTH J., SANCHEZ-VIZCAINO J.M. & PFEIFFER D.U. (2013). Epidemiology of African swine fever virus. *Virus Res.*, **173**, 191–197.

DE LEÓN P., BUSTOS M.J. & CARRASCOSA A.L. (2013). Laboratory methods to study African swine fever virus. *Virus Res.*, **173**, 168–179.

DE VILLIER E.P., GALLARDO C., ARIAS M., DA SILVA M., UPTON C., MARTIN R. & BISHOP R.P. (2010). Phylogenomic analysis of 11 complete African swine fever virus genome sequences. *Virology*, **400**, 128–136.

DIXON L.K., ESCRIBANO J.M., MARTINS C., ROCK D.L., SALAS M.L. & WILKINSON P.J. (2005). In: Virus Taxonomy, VIIIth Report of the ICTV, Fauquet C.M., Mayo M.A., Maniloff J, Desselberger U. & Ball L.A., eds. Elsevier/Academic Press, London, UK, 135–143.

ESCRIBANO J.M., PASTOR M.J. & SANCHEZ VIZCAINO J.M. (1989). Antibodies to bovine serum albumin in swine sera: implications for false positive reactions in the sero diagnosis of African swine fever. *Am. J. Vet. Res.*, **50**, 1118–1122.

FERNÁNDEZ-PACHECO P., NIETO R., SIMÓN A., GARCÍA CASTEY T.A., MARTÍN E., ARIAS M. & GALLARDO C. (2016). Comparative evaluation of the performance of six ELISA tests for the detection of antibodies against African swine fever virus (ASFV). EPIZONE 10th Annual Meeting, Madrid, Spain, 27–29 September 2016, p. <https://www.epizone.eu.net/en/Home/Downloads.htm>

FERNÁNDEZ-PINERO J., GALLARDO C., ELIZALDE M., RASMUSSEN T.B., STAHL K., LOEFFEN W., BLOME S., BATTEN C., CROOKE H., LE POTIER M.F., UTTENTHAL Å., LEBLANC N., ALBINA E., KOWALCZYK A., MARKOWSKA-DANIEL I., TIGNON M., DE MIA G.M., GIAMMARIOLI M., ARIAS M. & HOFFMANN B. (2010). EPIZONE ring trial on ASFV real-time PCR. Annual Meeting of National African swine fever Laboratories, 18 May 2010, Pulawy, Poland.

FERNÁNDEZ-PINERO J., GALLARDO C., ELIZALDE M., ROBLES A., GÓMEZ C., BISHOP R., HEATH L., COUACY-HYMAN E., FASINA F.O., PELAYO V., SOLER A & ARIAS M. (2013). Molecular diagnosis of African Swine Fever by a new real-time PCR using universal probe library. *Transbound. Emerg. Dis.*, **60**, 48–58.

FORTH J.H., CALVELAGE S., FISCHER M., HELLERT J., SEHL-EWERT J., ROSZYK H., DEUTSCHMANN P., REICHOLD A., LANGE M., THULKE H.-H., SAUTER-LOUIS C., HÖPER D., MANDYHRA S., SAPACHOVA M., BEER M. & BLOME S. (2023). African swine fever virus - variants on the rise. *Emerg. Microbes infect.*, **12**, 2146537.

GALLARDO C., FERNÁNDEZ-PINERO J., PELAYO V., GAZAEV I., MARKOWSKA-DANIEL I., PRIDOTKAS G., NIETO R., FERNÁNDEZ-PACHECO P., BOKHAN S., NEVOLKO O., DROZHYZHE Z., PÉREZ C., SOLER A., KOLVASOV D. & ARIAS M. (2014). Genetic variation among African swine fever genotype II viruses, eastern and central Europe. *Emerg. Infect. Dis.*, **20**, 1544–1547.

GALLARDO C., MWAENGO D.M., MACHARIA J.M., ARIAS M., TARACHA E.A., SOLER A., OKOTH E., MARTÍN E., KASITI J. & BISHOP R.P. (2009). Enhanced discrimination of African swine fever virus isolates through nucleotide sequencing of the p54, p72, and pB602L (CVR) genes. *Virus Genes*, **38** 85–95.

GALLARDO C., NIETO R., SOLER A., PELAYO V., FERNÁNDEZ-PINERO J., MARKOWSKA-DANIEL I., PRIDOTKAS G., NURMOJA I., GRANTA R., SIMÓN A., PÉREZ C., MARTÍN E., FERNÁNDEZ-PACHECO P. & ARIAS M. (2015b). Assessment of African

swine fever diagnostic techniques as a response to the epidemic outbreaks in Eastern European Union countries: How to improve surveillance and control programs. *J. Clin. Microbiol.*, **53**, 2555–2565.

GALLARDO C., SOLER A., NIETO R., CARRASCOSA A.L., DE MIA G.M., BISHOP R.P., MARTINS C., FASINA F.O., COUACY-HYMMAN E., HEATH L., PELAYO V., MARTIN E., SIMON A., MARTIN R., OKURUT A.R., LEKOLOL I., OKOTH E. & ARIAS M. (2013). Comparative evaluation of novel African swine fever virus (ASF) antibody detection techniques derived from specific ASF viral genotypes with the OIE internationally prescribed serological tests. *Vet. Microbiol.*, **162**, 32–43.

GALLARDO C., SOLER A., NIETO R., SÁNCHEZ M.A.S., MARTINS E., PELAYO V., CARRASCOSA A., REVILLA Y., SIMON A., BRIONES V., SÁNCHEZ-VIZCAÍNO J.M. & ARIAS M. (2015a). Experimental Transmission of African Swine Fever (ASF) Low Virulent Isolate NH/P68 by Surviving Pigs. *Transbound. Emerg. Dis.*, **62**, 612–622.

GLADUE D.P. & BORCA M.V. (2022). Recombinant ASF Live Attenuated Virus Strains as Experimental Vaccine Candidates. *Viruses*, **14**, 878. <http://doi:10.3390/v14050878>.

GLADUE D.P., RAMIREZ-MEDINA E., VUONO E., SILVA E., RAI A., PRUITT S., ESPINOZA N., VELAZQUEZ-SALINAS L. & BORCA M.V. (2021). Deletion of the A137R Gene from the Pandemic Strain of African Swine Fever Virus Attenuates the Strain and Offers Protection against the Virulent Pandemic Virus. *J. Virol.*, **95** (21):e0113921. doi: 10.1128/JVI.01139-21. Epub 2021 Aug 18. PMID: 34406865; PMCID: PMC8513468.

HAINES F.J., HOFMANN M.A., KING D.P., DREW T.W. & CROOKE H.R. (2013). Development and validation of a multiplex, real-time RT PCR assay for the simultaneous detection of classical and African swine fever viruses. *PLoS One*, **8** (7).

HAYES B.H., ANDRAUD M., SALAZAR L.G., ROSE N. & VERGNE T. (2021). Mechanistic modelling of African swine fever: A systematic review. *Prev. Vet. Med.*, **191**, 105358. doi: 10.1016/j.prevetmed.2021.105358.

KITAMURA T., MASUJIN K., YAMAZOE R., KAMEYAMA K.I., WATANABE M., IKEZAWA M., YAMADA M. & KOKUHO T. (2023). A Spontaneously Occurring African Swine Fever Virus with 11 Gene Deletions Partially Protects Pigs Challenged with the Parental Strain. *Viruses*, **15**, 311. doi: 10.3390/v15020311. PMID: 36851524; PMCID: PMC9966947.

KING K., CHAPMAN D., ARGILAGUET J.M., FISHBOURNE E., HUTET E., CARIOLET R., HUTCHINGS G., OURA C.A., NETHERTON C., MOFFAT K., TAYLOR G., LE POTIER M.-F., DIXON L.K. & TAKAMATSU H.-H. (2011). Protection of European domestic pigs from virulent African isolates of African swine fever virus by experimental immunisation. *Vaccine*, **29**, 4593–4600. <https://doi:10.1016/j.vaccine.2011.04.052>

KING D.P., REID S.M., HUTCHINGS G.H., GRIERSON S.S., WILKINSON P.J., DIXON L.K., BASTOS A.D.S. & DREW T.W. (2003). Development of a TaqMan® PCR assay with internal amplification control for the detection of African swine fever virus. *J. Virol. Methods*, **107**, 53–61.

LIU Y., XIE Z., LI Y., SONG Y., DI D., LIU J., GONG L., CHEN Z., WU J., YE Z., LIU J., YU W., LV L., ZHONG Q., TIAN C., SONG Q., WANG H. & CHEN H. (2023). Evaluation of an I177L gene-based five-gene-deleted African swine fever virus as a live attenuated vaccine in pigs. *Emerg. Microbes Infect.*, **12**, 2148560. doi: 10.1080/22221751.2022.2148560. PMID: 36378022; PMCID: PMC9769145.

LUBISI B.A., BASTOS A.D., DWARKA R.M. & VOSLOO W. (2005). Molecular epidemiology of African swine fever in East Africa. *Arch Virol.*, **150**, 2439–2452.

MASUJIN K., KITAMURA K., KAMEYAMA K.I., OKADERA K., NISHI T., TAKENOUCI T., KITANI H. & KOKUHO T. (2021). An immortalized porcine macrophage cell line competent for the isolation of African swine fever virus. *Sci. Rep.*, **11**, 4759. doi.org/10.1038/s41598-021-84237-2.

MONTEAGUDO P.L., LACASTA A., LOPEZ L., BOSCH J., COLLADO J., PINA-PEDRERO S., CORREA-FIZ F., ACCENSI F., NAVAS M.J., VIDAL E., BUSTOS M.J., RODRIGUEZ J.M., GALLEI A., NIKOLIN V., SALAS M.L. & RODRIGUEZ F. (2017). BA71deltaCD2: A new recombinant live attenuated African swine fever virus with cross-protective capabilities. *J. Virol.*, **91**, e1058–e1117. <https://doi:10.1128/JVI.01058-17>.

NCBI (NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION) (2020). <https://www.ncbi.nlm.nih.gov/nuccore/FR682468>. Accessed 4/4/2023.

NIX R.J., GALLARDO C., HUTCHINGS G., BLANCO E. & DIXON L.K. (2006). Molecular epidemiology of African swine fever virus studied by analysis of four variable genome regions. *Arch. Virol.*, **151**, 2475–244.

O'DONNELL V., HOLINKA L.G., GLADUE .DP., SANFORD B., KRUG P.W., LU X., ARZT J., REESE B., CARRILLO C., RISATTI G.R. & BORCA M.V. (2015). African swine fever virus Georgia isolate harboring deletions of MGF360 and MGF505

genes is attenuated in swine and confers protection against challenge with virulent parental virus. *J. Virol.*, **89**, 6048. [https://doi: 10.1128/JVI.00554-15](https://doi.org/10.1128/JVI.00554-15).

O'DONNELL V., RISATTI G.R., HOLINKA L.G., KRUG P.W., CARLSON J., VELAZQUEZ-SALINAS L., AZZINARO P.A., GLADUE D.P. & BORCA M.V. (2016). Simultaneous Deletion of the 9GL and UK Genes from the African Swine Fever Virus Georgia 2007 Isolate Offers In-creased Safety and Protection against Homologous Challenge. *J. Virol.*, **91**, e01760-16. [https://doi: 10.1128/JVI.01760-16](https://doi.org/10.1128/JVI.01760-16).

PASTOR M.J., ARIAS M. & ESCRIBANO J.M. (1990). Comparison of two antigens for use in an enzyme-linked immunosorbent assay to detect African swine fever antibody. *Am. J. Vet. Res.*, **51**, 1540–1543.

PASTOR M.J., LAVIADA M.D., SANCHEZ VIZCAINO J.M. & ESCRIBANO J.M. (1989). Detection of African swine fever virus antibodies by immunoblotting assay. *Can. J. Vet. Res.*, **53**, 105–107.

PENRITH M.L., VAN HEERDEN J., HEATH L., ABWORO E.O. & BASTOS A.D.S. (2022). Review of the Pig-Adapted African Swine Fever Viruses in and Outside Africa. *Pathogens*, **11**, 1190. doi: 10.3390/pathogens11101190.

PÉREZ-NÚÑEZ D., SUNWOO S.-Y., GARCÍA-BELMONTE R., KIM C., VIGARA-ASTILLERO G., RIERA E., KIM D.-M., JEONG J., TARK D., KO Y.-S., YOU Y.-K. & REVILLA Y. (2022). Recombinant African Swine Fever Virus Arm/07/CBM/c2 Lacking CD2v and A238L Is Attenuated and Protects Pigs against Virulent Korean Paju Strain. *Vaccines*, **10**, 1992. <https://doi.org/10.3390/vaccines10121992>.

PORTUGAL R., COELHO J., HÖPER D., LITTLE N.S., SMITHSON C., UPTON C., MARTINS C., LEITÃO A. & KEIL G.M. (2015). Related strains of African swine fever virus with different virulence: genome comparison and analysis. *J. Gen. Virol.*, **96** (Pt 2), 408–419.

PORTUGAL R., GOATLEY L.C., HUSMANN R., ZUCKERMANN F.A. & DIXON L.K. (2020). A porcine macrophage cell line that supports high levels of replication of OURT88/3, an attenuated strain of African swine fever virus. *Emerg. Microbes Infect.*, **9**, 1245–1253. doi.org/10.1080/22221751.2020.1772675.

QUEMBO C.J., JORI F., VOSLOO W. & HEATH L. (2018). Genetic characterization of African swine fever virus isolates from soft ticks at the wildlife/domestic interface in Mozambique and identification of a novel genotype. *Transbound. Emerg. Dis.*, **65**, 420–431.

SÁNCHEZ-VIZCAÍNO J.M. (1987). African swine fever diagnosis. In: African Swine Fever, Becker Y., ed. Martinus Nijhoff, Boston, USA, 63–71.

SÁNCHEZ-VIZCAÍNO J.M. & ARIAS M. (2012). African swine fever. In: Diseases of Swine, tenth Edition, Straw B., D'Allaire S., Mengeling W., Taylor D., eds. Iowa State University, USA, pp.396–404.

SÁNCHEZ-VIZCAÍNO J.M., MARTINEZ-LÓPEZ B., MARTINEZ-AVILÉS M., MARTINS C., BOINAS B., VIAL L., MICHAUD V., JORI F., ETTER E., ALBINA E. & ROGER F. (2009). Scientific Review on African swine fever. CFP/EFSA/AHAW/2007/02, pp: 1–141.

SÁNCHEZ-VIZCAÍNO J.M., MUR L., GOMEZ-VILLAMANDOS J.C. & CARRASCO L. (2015). An update on the epidemiology and pathology of African swine fever. *J. Comp. Pathol.*, **152**, 9–21.

TEKLUE T., WANG T., LUO Y., HU R., SUN Y. & QIU H.J. (2020). Generation and Evaluation of an African Swine Fever Virus Mutant with Deletion of the CD2v and UK Genes. *Vaccines*, **8**, 763. [https://doi:10.3390/vaccines8040763](https://doi.org/10.3390/vaccines8040763).

TIGNON M., GALLARDO C., ISCARO C., HUTET E., VAN DER STEDE Y., KOLBASOV D., DE MIA G.M., LE POTIER M.F., BISHOP R.P., ARIAS M. & KOENEN F. (2011). Development and inter-laboratory validation study of an improved new real-time PCR assay with internal control for detection and laboratory diagnosis of African swine fever virus. *J. Virol. Methods*, **178**, 161–167.

WANG N., ZHAO D., WANG J., ZHANG Y., WANG M., GAO Y., LI F., WANG J., BU Z., RAO Z. & WANG X. (2019). Architecture of African swine fever virus and implications for viral assembly. *Science*, **366**, 640–644. doi: 10.1126/science.aaz1439. Epub 2019 Oct 17

ZHANG Y., KE J., ZHANG J., YANG J., YUE H., ZHOU X., QI Y., ZHU R., MIAO F. & LI Q. (2021). African Swine Fever Virus Bearing an I226R Gene Deletion Elicits Robust Immunity in Pigs to African Swine Fever. *J. Virol.*, **95**, e0119921. [https://doi: 10.1128/JVI.01199-21](https://doi.org/10.1128/JVI.01199-21).

ZHAO D., SUN E., HUANG L., DING L., ZHU Y., ZHANG J., SHEN D., ZHANG X., ZHANG Z., REN T., WANG W., LI F., HE X. & BU Z. (2023). Highly lethal genotype I and II recombinant African swine fever viruses detected in pigs. *Nat. Commun.*, **14**, 3096.

*
* *

NB: There are WOA Reference Laboratories for African swine fever
(please consult the WOA Web site:

<https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>).

Please contact the WOA Reference Laboratories for any further information on
diagnostic tests and reagents for African swine fever

NB: FIRST ADOPTED IN 1990. MOST RECENT UPDATES ADOPTED IN 2021.

4
5 CHAPTER 1.1.3.

6 **TRANSPORT OF BIOLOGICAL MATERIALS**

7 **INTRODUCTION**

8 *The transport of biological materials, including infectious substances, is covered by international,*
9 *regional or national regulations that are updated on a regular basis and are widely accessible via the*
10 *internet, or through commercial and regulatory transportation affiliates. The transport of biological*
11 *materials within a country and between countries will be explained in this chapter.*

12 *The international regulations for the transport of infectious substances by any mode of transport are*
13 *based upon the Recommendations on the Transport of Dangerous Goods made by the*
14 *Subcommittee of Experts on the Transport of Dangerous Goods (UN SCETDG), a subcommittee of*
15 *the United Nations Economic and Social Council. The Recommendations are presented in the form*
16 *of Model Regulations covering air, rail, road, sea and also include international mail. The World Health*
17 *Organization (WHO) guidance document on “Transport of Infectious Substances” summarising the*
18 *different transport regulations is regularly updated. Countries, other international organisations,*
19 *international treaties and conventions such as the International Air Transport Association (IATA), the*
20 *World Customs Organization (WCO), the Convention on International Trade in Endangered Species*
21 *(CITES), and the Convention on Biodiversity (CBD), especially the Nagoya Protocol, provide*
22 *additional guidance and regulations that should be considered in planning the transportation of*
23 *biological materials.*

24 *In the interest of animal and human health, biological materials collected from animals must be*
25 *transported safely, efficiently and legally from the place where they are collected to the place where*
26 *they are analysed, studied or used. The collection of specimens from animals is covered in Chapter*
27 *1.1.2 Collection, submission and storage of diagnostic specimens.*

28 *For the purpose of this chapter, animals are defined as all members of the Kingdom Animalia except*
29 *humans, and biological materials include specimens or samples from animals, cell cultures, zoonotic*
30 *and animal microorganisms and genetically modified or synthetic organisms, and biological products*
31 *such as vaccines and reagents.*

32 *All reasonable precautions have been taken to verify the information contained in this chapter, which*
33 *provides guidance on proper transport of biological materials. However, this text does not replace*
34 *local or global regulations. In no event is WOAH liable for violations that arise from its use. Persons*
35 *should always consult current local and global regulations at the time of transport.*

36 **A. RESPONSIBILITIES**

37 All personnel involved in the packaging, labelling and shipping of biological materials must be appropriately trained,
38 certified, competent and knowledgeable of the relevant national, regional and international regulations.

39 Biological materials should be transported to ensure a rapid and reliable system for delivery to the recipient using
40 individuals such as professional logistics service providers that are trained and competent in the shipping and
41 transportation process.

42 The efficient transport and transfer of biological materials requires co-ordination between the sender (shipper,
43 consignor), the logistic providers, the carrier and the recipient (consignee) to ensure safe transport and arrival on
44 time and in proper condition.

45 The sender (shipper, consignor) is responsible for providing the applicable documentation (e.g. certifications,
46 permits) required by the national authorities of the countries of export, transshipment and import as well as ensuring
47 that the shipment also complies with all other applicable regulations, such as:

48 i) Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from
49 their Utilization to the Convention on Biological Diversity (CBD): Biological material containing genetic
50 resources as defined under the CBD may be subject to Access and Benefit-Sharing legislation in both the
51 country where it is sourced and the country where it is sent.

52 ii) CITES (Convention on International Trade in Endangered Species of Wild Fauna and Flora): All import, export,
53 re-export and introduction from the sea of species covered by the Convention has to be authorised through a
54 licensing system. Resolution Conf. 12.3. (Rev.CoP17) on Permits and Certificates, contains a section XII,
55 regarding the use of simplified procedures to issue permits and certificates ([https://cites-
56 tsp.org/sites/default/files/resources_files/2022-12/E-Res-12-03-R17-min.pdf](https://cites-tsp.org/sites/default/files/resources_files/2022-12/E-Res-12-03-R17-min.pdf)).

57 Procedures for incidents such as spills or theft of materials during transportation and any other realistic and
58 foreseeable emergencies should be part of a risk management system in order to respond adequately to
59 emergencies (for basic principles see Chapter 1.1.4 *Biosafety and biosecurity: Standard for managing biological
60 risk in the veterinary laboratory and animal facilities*).

61 1. The sender (shipper, consignor)

62 i) Before any shipment of biological materials, the sender must be able to:

63 a) Identify and classify, pack (including temperature control), ensure quantity limits, mark and label the
64 package of biological materials,

65 b) Ensure the correct documentation of all biological materials intended for transport,

66 c) Complete and produce a Shipper's Declaration for Dangerous Goods (DGD), when required,

67 d) Ensure biological materials are not forbidden for transport;

68 e) Ensure that the arrival date of the shipment does not fall on a week-end or day off;

69 f) In the event that samples need to be sent under controlled temperature conditions, measures to maintain
70 a cold chain need to be carefully considered throughout the entire shipment (including accommodating
71 any possible delays that may occur).

72 ii) Prepares necessary documentation, including permits, dispatch and shipping documents if necessary;

73 iii) Notifies the recipient of transportation arrangements once these have been made, well in advance of the
74 expected arrival time;

75 iv) The air way bill (AWB) is the standard shipping document for shipping goods by air. While it is common practice
76 for the air carrier or freight forwarder to complete the air waybill, the sender may be required to provide it;

77 v) Makes advance arrangements with the recipient including investigating the need for import/export permits;

78 vi) Makes advance arrangements with the carrier to ensure:

79 a) that the shipment will be accepted for appropriate transport;

80 b) that the shipment is undertaken by the most direct routing, as appropriate.

81 2. The carrier/courier

82 i) The following measures must be taken by the carrier:

83 a) Routing: appropriate routing must be ensured, such as by the shortest or most secure route.

84 b) Transshipment: when transfers are necessary, precautions must be taken to assure special care,
85 expeditious handling and monitoring of the substances in transit for both safety and security purposes.

86 ii) For air transport, the carrier is required by the regulations to use, when applicable, an acceptance checklist to
87 verify that the shipment complies with:

88 a) marking and labelling requirements; and

89 b) documentation requirements.

-
- 90 iii) Provide advice to the sender and assistance regarding the necessary shipping documents and instructions for
91 their completion as well as correct packaging
 - 92 iv) Assists the sender in arranging the most appropriate routing and then confirms the routing and provides, if
93 possible, ways to track the shipment;
 - 94 v) Maintains and archives documentation for shipment and transport.

95 3. The recipient (consignee)

- 96 i) Obtains the necessary authorisation(s) from national authorities for the importation of the material;
- 97 ii) Provides the sender with the required import permit(s), letter(s) of authorisation, or other document(s) required
98 by the national authorities;
- 99 iii) Arranges for the most timely and efficient collection on arrival;
- 100 iv) Should acknowledge receipt to the sender.

101 Shipments should not be dispatched until all the necessary arrangements between the sender, carrier and recipient
102 have been made.

103 The transportation chain involves many more stakeholders with specific roles and responsibilities. These are
104 explained in more details in the framework of aviation security in a joint ICAO (International Civil Aviation
105 Organization) and WCO (World Customs Organization) brochure that can be accessed using the following link:
106 [http://www.wcoomd.org/en/topics/facilitation/instrument-and-](http://www.wcoomd.org/en/topics/facilitation/instrument-and-tools/tools/~/_/media/4B167884A3064E78BCF5D29E29F4E57E.ashx)
107 [tools/tools/~/_/media/4B167884A3064E78BCF5D29E29F4E57E.ashx](http://www.wcoomd.org/en/topics/facilitation/instrument-and-tools/tools/~/_/media/4B167884A3064E78BCF5D29E29F4E57E.ashx).

108 In addition, Material Transfer Agreements (MTA) should be considered because they:

- 109 i) Protect the interests of all involved parties in relation to;
 - 110 a) Intellectual property
 - 111 b) Potential alternative uses
 - 112 c) Commercial aspects
 - 113 d) Liability to third parties
 - 114 e) Potential further transfers/uses
- 115 ii) Help to avoid misunderstandings around the use of materials
- 116 iii) Clarify ownership of property

117 With reference to Article 4 of the “Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable
118 Sharing of Benefits Arising from their Utilization (ABS) to the Convention on Biological Diversity”, the MTA is
119 intended to establish a platform for the open exchange of materials among laboratories and to constitute Prior
120 Informed Consent (PIC) on Mutually Agreeable Terms, while avoiding as much as possible the potential adverse
121 impacts of the Nagoya requirements.

122 Appendix 3 is provided as a generic template for use in transfer of materials. It is intended to be modified and
123 adapted as required to meet individual circumstances.

124 Appendix 3 does not constitute legal advice and users are responsible to ensure it meets their objectives and fulfils
125 requirements of local legislation. Users are encouraged to consult their own legal professionals for advice on use
126 of this template.

127 B. CLASSIFICATION AND CATEGORISATION

128 When transporting biological materials, the certified/ trained sender must determine whether the material should be
129 classified as dangerous goods or not. Dangerous goods (hazardous materials, HAZMAT) are materials that can
130 harm humans, animals and other living organisms, property, or the environment, and their transport is regulated by
131 United Nations (UN) regulations¹. Dangerous goods are assigned a *UN number* and *proper shipping name* based
132 on the classification of the dangerous goods. The transport regulations assign a packing instruction against the UN
133 number and proper shipping name, to specify the packaging/packing method to ensure that the dangerous goods
134 do not pose a hazard in transport. Of the biological materials that are discussed in this Chapter, infectious

¹ http://www.unece.org/trans/danger/publi/unrec/rev13/13nature_e.html;
http://www.unece.org/trans/danger/publi/unrec/rev20/20files_e.html

135 substances are classified as dangerous goods and are assigned to UN 2814, UN 2900, UN 3373, or UN 3291, as
 136 appropriate. In addition, Genetically Modified Microorganisms (GMMOs) and Genetically Modified Organisms
 137 (GMOs) are classified as Class 9 and assigned to UN 3245 if they are not classified as Category A or Category B.

138 Table 1. Summary of classification, categorisation, identification and packaging of infectious substances.

Dangerous goods classifications	Categorisation	Proper shipping name ²	UN number ²	Packing instruction/ packaging requirements
Class 6, Division 6.2	Category A	Infectious substance, affecting humans	UN 2814	P620
		Infectious substance, affecting animals	UN 2900	
Class 6, Division 6.2	Category B	Biological substance, Category B	UN 3373	P650
Class 6, Division 6.2	Exempt human/animal specimens	Exempt human/animal specimens	N/A	Triple packaging to include <u>a leakproof primary container. A leakproof secondary container with absorbent material and outer rigid packaging</u>
not subject to dangerous goods regulations	Biological materials not subject to dangerous goods regulations	N/A	N/A	N/A
Class 9	GMMOs and GMOs that are not classified as Category A or B infectious substances	Genetically modified microorganisms; Genetically modified organisms	UN 3245	P904 (ICAO/IATA PI 959), IBC99

139 If it is likely that microorganisms that are present in the biological materials can cause harm to humans or animals
 140 then they must be assigned either to Category A or B.

141 The proper shipping name (see Table 1) must be supplemented with the technical name (scientific name of the
 142 pathogen) in parenthesis on the transport document, but not on the outer packaging. When the identity of the
 143 infectious substances to be transported are unknown, but are suspected of meeting the criteria for inclusion in
 144 category A, the words “suspected category A infectious substance” must be shown, in parenthesis, following the
 145 proper shipping name on the transport document.

146 1. Category A

147 A Category A substance is an infectious substance which is transported in a form that, when exposure to it occurs,
 148 is capable of causing permanent disability, life-threatening or fatal disease in otherwise healthy humans or animals.
 149 Assignment to UN 2814 or UN 2900 (see Table 1) must be based on the known medical history of the animal(s),
 150 signs and individual circumstances of the specimen source, and endemic local disease conditions, or professional
 151 judgement concerning individual circumstances of the source, human or animal.

152 Some organisms are considered Category A only when in culture form (e.g. *Bacillus anthracis*, foot and mouth
 153 disease virus). Indicative examples of substances that meet these criteria are given in the Table 3. The table is not
 154 exhaustive. Infectious substances, including new or emerging pathogens, that do not appear in the Table but that
 155 meet the same criteria must be assigned to Category A. In addition, if there is doubt as to whether or not a substance
 156 meets the criteria it must be assigned to Category A.

157 Some infectious substances may have a high economic or trade impact on specific countries should there be
 158 release to the environment. Therefore, other infectious substances may be added to the list by individual countries
 159 (e.g. cultures of Newcastle disease virus where the virus is exotic to the country or region).

160 **Medical or clinical waste** containing Category A infectious substances shall be assigned to UN 2814 or UN 2900
 161 as appropriate. **Solid** medical waste containing Category A infectious substances generated from the medical

² Dangerous goods are assigned UN numbers and proper shipping names according to their hazard classification and condition under the Dangerous Goods Regulations. See the Dangerous Goods List at pages 191–304 of the UN Model Regulations http://www.unece.org/fileadmin/DAM/trans/danger/publi/unrec/rev20/Rev20e_Vol1.pdf

162 treatment of humans or veterinary treatment of animals may be assigned to UN 3549. It should be noted that
163 Medical or clinical waste from bioresearch or liquid waste must not be assigned to UN3549.

164 **2. Category B**

165 Biological materials containing pathogens that do not meet the criteria for Category A (i.e. do not cause life-
166 threatening disease to humans or animals) shall be assigned to Category B (UN 3373).

167 Typically, a specimen with a high likelihood to contain pathogenic organisms shipped for disease diagnosis (e.g.
168 confirmatory diagnosis of suspected or clinical cases, specimens for differential diagnosis, such as blood samples
169 for classical swine fever or sheep pox diagnostics or throat samples from chickens for avian influenza) can be
170 assigned to Category B.

171 It is important to note that unlike cultures, *patient specimens* which may contain infectious microorganisms listed as
172 'cultures only' in Table 3 (Category A infectious substances) do not require Category A transport practices. For
173 these specimens Category B transport practice should be applied. In this case, although directly collected
174 specimens (e.g. serum) can be shipped as Category B, pure cultures of the same pathogens must follow the
175 requirements of Category A due to the characteristics of the specific organism. Some examples are classical swine
176 fever virus isolates or sheep pox virus isolates (see Table 3). Specimens from animals intentionally infected with
177 Category A pathogens must be sent as Category A, even if they are assigned to Category A (cultures only).

178 Shipments of cultures of non-category A agents can be assigned to Category B.

179 **Medical or clinical waste** containing Category B infectious substances shall be assigned to UN 3291.

180 **3. Exempt specimens**

181 Animal specimens for which there is minimal likelihood that pathogens are present can be transported as Exempt
182 Specimens. Examples of specimens in the veterinary field which may be transported as exempt include specimens
183 from surveillance studies, export controls of healthy animals (e.g. certification of freedom from classical swine fever)
184 or determination of immune status of individual animals or populations (post-vaccination).

185 These specimens are not subject to dangerous goods regulations if the specimen is transported in a packaging that
186 will prevent any leakage and that is marked appropriately (triple packaging principle, see Section C. *Packaging* and
187 Figure 3-6 of Appendix 1.1.3.2).

188 **4. Biological materials not subject to Dangerous Goods Regulations**

189 Based on the known medical history of the animal(s), signs and individual circumstances of the source of the
190 biological materials, and endemic local disease conditions, the following *are not subject to dangerous goods*
191 *regulations, unless they meet the criteria for inclusion in another class (such as Class 9)*:

- 192 i) biological materials ~~that do~~ known to not contain infectious substances
- 193 ii) biological materials containing microorganisms that are non-pathogenic to humans or animals;
- 194 iii) biological materials in a form in which any pathogens present have been neutralised or inactivated such that
195 they no longer pose a health risk;
- 196 iv) Environmental specimens (including food and water specimens) that are not considered to pose a significant
197 risk of infection;
- 198 v) Dried blood spots, collected by applying a drop of blood onto absorbent material.

199 Note: Materials not subject to dangerous goods regulations may need to be risk assessed before proceeding with
200 their shipment. There may be specific regulations in place in some countries for the shipment, export or import of
201 nucleic acids.

202 **5. Contaminated items**

203 These listed below are also included in infectious substances in the international regulations on transport of
204 dangerous goods, however the details are not discussed in this chapter. For more information see UN Model
205 Regulations, paragraphs 2.6.3.2.3.3 and .9 respectively.

206

207
208

Table 2. Summary of classification, categorisation, identification and packaging of contaminated items with infectious substances.

Dangerous goods classifications	Categorisation	Proper shipping name ³	UN number ³	Package
Class 6, Division 6.2	Category A	Medical* devices or equipment contaminated with or containing infectious substances in Category A	UN2814, UN2900 as appropriate	Must be marked "Used Medical Device" or "Used Medical Equipment"
Class 6, Division 6.2	Exemption when condition is met	Medical* devices, medical equipment	N/A	See UN Model Regulations 2.6.3.2.3.9 and IATA Dangerous Goods Regulations (DGR) 3.6.2.2.3.9
Class 6, Division 6.2	Category A	Medical* waste, Category A, affecting humans, solid ; Medical waste, Category A, affecting animals only, solid	UN 3549	P622, LP622
Class 6, Division 6.2	Category B	Clinical waste, Unspecified, n.o.s. (not otherwise specified); (Bio) medical waste, n.o.s.; Regulated medical waste, n.o.s.	UN3291	P621 (PI622), IBC620, LP621

209 *including veterinary use

210 6. Infectious substances included in Category A

211 Table 3. Indicative examples of infectious substances included in Category A.

UN number and proper shipping name	Microorganism
UN 2814 Infectious substance, affecting humans	<i>Bacillus anthracis</i> (cultures only)
	<i>Brucella abortus</i> (cultures only)
	<i>Brucella melitensis</i> (cultures only)
	<i>Brucella suis</i> (cultures only)
	<i>Burkholderia mallei</i> – <i>Pseudomonas mallei</i> – Glanders (cultures only)
	<i>Burkholderia pseudomallei</i> – <i>Pseudomonas pseudomallei</i> (cultures only)
	<i>Chlamydia psittaci</i> – avian strains (cultures only)
	<i>Clostridium botulinum</i> (cultures only)
	<i>Coccidioides immitis</i> (cultures only)
	<i>Coxiella burnetii</i> (cultures only)
	Crimean–Congo haemorrhagic fever virus
	Dengue virus (cultures only)
	Eastern equine encephalomyelitis virus (cultures only)
<i>Escherichia coli</i> , verotoxigenic (cultures only) ⁴	

³ Dangerous goods are assigned UN numbers and proper shipping names according to their hazard classification and condition under the Dangerous Goods Regulations. See the Dangerous Goods List at pages 191–304 of the UN Model Regulations http://www.unece.org/fileadmin/DAM/trans/danger/publi/unrec/rev20/Rev20e_Vol1.pdf

⁴ For surface transport (ADR) nevertheless, when the cultures are intended for diagnostic or clinical purposes, they may be classified as infectious substances of Category B.

UN number and proper shipping name	Microorganism
	Ebola virus
	Flexal virus
	<i>Francisella tularensis</i> (cultures only)
	Guanarito virus
	Hantaan virus
	Hantaviruses causing haemorrhagic fever with renal syndrome
	Hendra virus
	Hepatitis B virus (cultures only)
	Herpes B virus (cultures only)
	Human immunodeficiency virus (cultures only)
	Highly pathogenic avian influenza virus (cultures only)
	Japanese encephalitis virus (cultures only)
	Junin virus
	Kyasanur Forest disease virus
	Lassa virus
	Machupo virus
	Marburg virus
	Monkeypox virus
	<i>Mycobacterium tuberculosis</i> (cultures only) ¹
	Nipah virus
	Omsk haemorrhagic fever virus
	Poliovirus (cultures only)
	Rabies virus (cultures only)
	<i>Rickettsia prowazekii</i> (cultures only)
	<i>Rickettsia rickettsii</i> (cultures only)
	Rift Valley fever virus (cultures only)
	Russian spring–summer encephalitis virus (cultures only)
	Sabia virus
	<i>Shigella dysenteriae</i> type 1 (cultures only)
	Tick-borne encephalitis virus (cultures only)
	Variola virus
	Venezuelan equine encephalitis virus (cultures only)
	West Nile virus (cultures only)
	Yellow fever virus (cultures only)
	<i>Yersinia pestis</i> (cultures only)
UN 2900 Infectious substance, affecting animals only	African swine fever virus (cultures only)
	Avian paramyxovirus Type 1 – Velogenic Newcastle disease virus (cultures only)
	Classical swine fever virus (cultures only)
	Foot and mouth disease virus (cultures only)
	<u>Goatpox virus (cultures only)</u>

UN number and proper shipping name	Microorganism
	Lumpy skin disease virus (cultures only)
	<i>Mycoplasma mycoides</i> – contagious bovine pleuropneumonia (cultures only)
	Peste des petits ruminants virus (cultures only)
	Rinderpest virus (cultures only) ⁵
	Sheep-pox virus (cultures only)
	Goatpox virus (cultures only)
	Swine vesicular disease virus (cultures only)
	Vesicular stomatitis virus (cultures only)

212

C. PACKAGING

213 1. Principles

214 All biological materials should be packaged and transported in accordance with local, national and international
 215 regulations. The procedures should minimise the risk of exposure for those engaged in transportation and should
 216 protect the environment and susceptible animal populations from potential exposures. Additionally, ineffective
 217 packaging that does not protect specimens or preservatives (e.g. ice) from damage or prevent leakage will likely
 218 delay the delivery of the shipment to the laboratory, delaying or preventing critical laboratory analyses from being
 219 performed. Biological materials should always be packaged and transported to protect the integrity of the
 220 specimens, as well as to avoid cross-contaminating other specimens and environmental contamination. Minimum
 221 requirements for the transport of specimens follow the principle of triple packaging, consisting of three layers as
 222 described below:

- 223 i) a primary leak-proof receptacle;
- 224 ii) a secondary leak-proof packaging with absorbent material;
- 225 iii) an rigid outer packaging;
- 226 of which either the secondary or the outer packaging must be rigid.

227 1.1. Primary receptacle

228 A primary receptacle, leak-proof for liquids or sift-proof for solids containing the specimen. Primary
 229 receptacle(s) must be packed into the secondary packaging with enough absorbent material (e.g.
 230 cellulose wadding, paper towels, household paper, cotton balls) to absorb all fluid in case of breakage.
 231 Even though the regulations do not prohibit glass, primary receptacles should preferably be non-
 232 breakable. In addition, they must not contain any sharps (e.g. vacutainer with needle), particularly when
 233 using soft secondary or outer containers. If screw cap vials are used, they shall be secured by e.g. tape.
 234 A flip-top vial must not be used.

235 1.2. Secondary packaging

236 A second durable, leak-proof packaging to enclose and protect the primary receptacle(s) (e.g. sealed
 237 plastic bag, plastic container, screwcap can).

238 For transport by air, the primary receptacle or the secondary packaging shall be capable of withstanding,
 239 without leakage, an internal pressure of 95 kPa (0.95 bar) in the range of –40°C to +55°C (–40°F to
 240 +130°F).

⁵ Subject to prior approval by the FAO-WOAH rinderpest secretariat

241 **1.3. Outer packaging**

242 Secondary packaging is placed in a rigid outer shipping packaging (e.g. sturdy insulated fibre board box)
243 with suitable cushioning material. Outer packaging protects the contents from outside influences, such
244 as physical damage, while in transit.

245 **2. Category A**

246 Due to the highly hazardous nature of the Category A samples the packaging must meet special requirements. The
247 principle of triple packaging applies here, and the transport containers and outer packaging must meet the criteria
248 defined in the relevant regulations. Category A must only be transported in packaging that meets the United Nations
249 class 6.2 specifications, complies with Packing Instruction P620 and have passed specific tests and with UN
250 specification marking as P620. This ensures that strict performance criteria are met; tests for compliance with these
251 criteria include a 9-metre (29.5 feet) drop test, a puncture test, a pressure test and a stacking test. The packages
252 are labelled to provide information about the contents of the package, the nature of the hazard and the packaging
253 standards applied.

254 Marking and labelling is as follows (see Figure 3 of Appendix 1.1.3.2):

- 255 i) *The delivery address (consignee) and sender's details (shipper), as well as 24/7 emergency contact details*
256 *including named persons with telephone numbers to guarantee safe delivery.*
- 257 ii) *The proper shipping name and the UN number.*

<i>Proper shipping name</i>	<i>UN number</i>
<i>INFECTIOUS SUBSTANCE, AFFECTING HUMANS</i>	<i>UN2814</i>
<i>INFECTIOUS SUBSTANCE, AFFECTING ANIMALS only</i>	<i>UN2900</i>

- 258
- 259 iii) *The Infectious Substance label (Figure 1).*

260 **NB: This label is only for Category A. This label must not be used when shipping Category B.**

261



262
263



264
265
266

Fig. 1. Infectious Substance label for the transport of Category A.

- 267 iv) *UN specification marking for P620 packaging (printed on the box).*
268 v) *Orientation label, Cargo only label, if required (depending on the Net Weight [kg] of the infectious substance*
269 *in a P620 box).*
270 *The exact details can be found in P620 Packing Instruction⁶.*

271 For air transport:

- 272 i) The primary receptacle or secondary packaging must be capable of withstanding, without leakage, an internal
273 pressure of 95 kPa. The primary receptacle or secondary packaging must also be capable of withstanding
274 temperatures in the range of -40°C to $+55^{\circ}\text{C}$;
275 ii) For liquids: the net quantity of infectious substances per one P620 box shall not exceed 50 ml for transport in
276 cargo space of a passenger aircraft; and must not contain more than 4 litres (contain multiple primary
277 receptacles totalling more than 4 litres) for transport on a cargo only aircraft;
278 iii) For solids: the net quantity of infectious substances per one P620 box shall not exceed 50 g for transport in
279 cargo space of a passenger aircraft, and must not contain more than 4 kg (even if containing multiple primary
280 receptacles totalling more than 4 kg) for transport on a cargo only aircraft. This quantity limit doesn't apply for
281 animal parts, organs and whole carcasses.
282 iv) The three triple packaging principle has to be adopted accordingly using appropriate packaging systems;
283 v) The entire package must have been tested and complies with Packing Instruction P620.

284 For further information on marking and labelling of the Category A shipment package, see P620 Packing Instruction
285 for UN Nos 2814 and 2900⁶

286 3. Category B


287 Category B must be transported in a packaging that complies with the requirements of packing instruction P650.
288 The approval of the box by the government is not required, thus UN specification marking is not required.

289 Marking is as follows:

- 290 i) Packages should be clearly labelled with the delivery address and sender's details to guarantee safe delivery
291 in time at the correct destination.

⁶ Page 81 at: http://www.unece.org/fileadmin/DAM/trans/danger/publi/unrec/rev20/Rev20e_Vol2.pdf

- 292 ii) Label with the *proper shipping name* in letters at least 6 mm high: "BIOLOGICAL SUBSTANCE, CATEGORY
293 B" (Figure 2)
- 294 iii) In addition to the proper shipping name, the mark shown below (UN3373 in diamond) is used for shipments
295 of Category B substances. The UN3373 mark must always be visible on the outer packaging.



296 Fig. 2. UN3373 mark for the transport of Category B substances.

297 Additional requirements do apply as for category A for international shipment and air transport. One of the main
298 differences between P650 and P620 is the reduced drop-test to 1.2 metres (4 feet).

299 For air transport:

- 300 i) The primary receptacle or secondary packaging must be capable of withstanding, without leakage, an internal
301 pressure of 95 kPa. The primary receptacle or secondary packaging must also be capable of withstanding
302 temperatures in the range of -40°C to $+55^{\circ}\text{C}$;
- 303 ii) For liquids: no primary receptacle shall exceed 1 litre and the outer packaging must not contain more than
304 4 litres (contain multiple primary receptacles totalling more than 4 litres);
- 305 iii) For solids: the outer packaging must not contain more than 4 kg. This restriction doesn't apply for animal parts,
306 organs and whole carcasses.

307 The exact details can be found in P650 Packing Instruction for UN No. 3373⁷.

308 4. Exempt specimens

309 Biological materials for which there is a minimal likelihood that pathogens are present are not subject to regulation
310 if the specimen is carried in a packaging which will prevent any leakage and which is marked with the words "Exempt
311 animal specimens", as appropriate. The triple packaging system must still be applied.

312 5. Biological materials not subject to Dangerous Goods Regulations

313 This exemption refers to biological materials that do not contain infectious substances and are therefore not subject
314 to dangerous goods regulations (such as class 6.2) and any packaging requirements, *unless they meet the criteria*
315 *for inclusion in another class (such as class 9).*

316 Note: There may be specific regulations in place in some countries for the shipment, export or import of nucleic
317 acids.

318 6. Overpack

319 "Overpack" is the term used when one or more packages are combined to form one unit and sent to the same
320 destination by a single shipper. When refrigerants are used to protect contents, the overpacks may comprise
321 insulated vessels or flasks. Whenever an overpack is used, the required marks and labels shown on the outer

⁷ Page 82 at: http://www.unece.org/fileadmin/DAM/trans/danger/publi/unrec/rev20/Rev20e_Vol2.pdf

322 packaging must be repeated on the outermost layer of the overpack, except for the UN specification marking on
323 P620. This requirement applies to all infectious substances including Categories A and B. Overpacks are also
324 required to be marked with the word “overpack”.

325 Combining different categories of infectious substance in a same overpack is permissible however in this case outer
326 labelling should indicate the highest category included in the package.

327 **7. Cold chain transportation**

328 Refrigerants may be used to stabilise specimens during transport.

329 Ice, ice packs or dry ice shall be placed outside the secondary receptacle. Wet ice shall be placed in a leak-proof
330 container; the outer packaging or overpack shall also be leak-proof.

331 Dry ice (solid carbon dioxide) must not be placed inside the primary or secondary receptacle because of the risk of
332 explosion. A specially designed insulated packaging may be used to contain dry ice, typically a polystyrene or
333 waxed-treated cardboard box to prevent leakage and maintain temperature. The packaging must permit the release
334 of carbon dioxide gas if dry ice is used and the package (the outer packaging or the overpack) shall be marked “UN
335 1845” and “Carbon dioxide, solid as coolant” or “Dry ice as coolant” and the weight of the dry ice in Kilograms should
336 also be indicated on the labelling. The package must also bear the Class 9 – Miscellaneous hazard label.

337 The secondary receptacle shall be secured within the outer package to maintain the original orientation of the inner
338 packages after the refrigerant has melted or dissipated.

339 If liquid nitrogen is used as a refrigerant, additional requirements have to be followed according to the relevant
340 regulations for dangerous goods (Division 2.2, UN 1977). Information on Dry Shipper is available in p19 of WHO
341 Guidance on regulations for the transport of infectious substances 2017–2018⁸.

342 **D. ADDITIONAL CONSIDERATIONS**

343 In addition to the transport regulations described above, other international agreements might be applicable.

344 **1. CITES**

345 The Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) is an international
346 agreement between governments with the aim to ensure that international trade in specimens of wild animals and
347 plants does not threaten their survival. The Convention is in effect in 183 Parties (including one economic integration
348 organisation, the European Union).

349 Some specimens to be transported from one country to another may be derived from species covered by CITES
350 (roughly 5,600 animal species and 30,000 plant species). Depending on the classification of the species in one of
351 the three Appendices of the Convention and the movement involved, a CITES export permit, both an export and
352 import permit, or re-export certificates may be required. The appropriate documents must be obtained from National
353 CITES Management Authorities. Simplified procedures for the issuance of permits and certificates exist to facilitate
354 and expedite trade in biological specimens from CITES-listed species.

355 There may be some variation from one country to another in their CITES trade requirements (some countries take
356 stricter domestic measures and some countries have added additional species requirements for permits in addition
357 to the CITES lists), therefore It is always advisable to check the national legislation that applies.

358 Further information on CITES: <https://cites.org>

359 **2. Nagoya protocol and access and benefit-sharing**

360 “Fair and equitable sharing of benefits arising from the utilisation of genetic resources” (Access and Benefit Sharing,
361 or ABS) is one of the three objectives of the Convention on Biodiversity (CBD). The CBD confirms that States have
362 sovereign rights over their genetic resources, including animals, plants, fungi and microorganisms. Consequently,
363 States may choose to regulate access to these, requiring researchers both within and outside their borders to seek
364 permission. Permission (*Prior Informed Consent* or PIC) will be the responsibility of the State and maybe other

⁸ <http://www.who.int/ihr/publications/WHO-WHE-CPI-2017.8/en/>

365 stakeholders, and the conditions for sharing benefits (*Mutually Agreed Terms* or MAT) may be agreed with a range
366 of actors, including laboratories.

367 In 2014 the *Nagoya Protocol on Access and Benefit Sharing* (NP) was agreed by the Parties of the CBD. Nagoya
368 Protocol requirements have been implemented in a large number of countries. This obliges the Parties to take
369 compliance measures and monitor researchers and others utilising genetic resources (accessed from other Parties)
370 within their jurisdiction. Biological material containing genetic resources as defined under the CBD may be subject
371 to national Access and Benefit-Sharing (ABS) legislation in both the country where it is sourced and the country
372 where it is sent. This may include compliance with the NP if both countries are Party to the NP. To discover whether
373 this is the case, consult the ABS Clearing House (<https://absch.cbd.int/>), and ask the National Focal Point of both
374 countries (contact details on ABS Clearing House). If the source country has ABS legislation it may be necessary
375 to seek a permit (Prior Informed Consent and Mutually Agreed Terms) prior to international transport of the material.

376 Benefits may be monetary or non-monetary. "Utilisation of genetic resources" is defined by the CBD as "means to
377 conduct research and development of the genetic and/or biochemical composition of genetic resources, including
378 through the application of biotechnology as defined in Article 2 of the Convention". Consequently, many activities
379 carried out by WOAH Members and their constituents may be classified as ABS.

380 Compliance will require researchers to produce documentary evidence that genetic resources were accessed with
381 appropriate PIC and MAT, and declaring the type of utilisation being undertaken. This information will be transmitted
382 to the provider country to check if the information accords with their records. There is no exemption for organisms
383 of veterinary importance from ABS provisions in the NP, but countries where they are being accessed may choose
384 to make this distinction and exemption.

385 Article 8 of the Nagoya Protocol states "*In the development and implementation of its access and benefit-sharing*
386 *legislation or regulatory requirements, each Party shall: ... (b) Pay due regard to cases of present or imminent*
387 *emergencies that threaten or damage human, animal or plant health, as determined nationally or internationally.*
388 *Parties may take into consideration the need for expeditious access to genetic resources and expeditious fair and*
389 *equitable sharing of benefits arising out of the use of such genetic resources, including access to affordable*
390 *treatments by those in need, especially in developing countries;".* However, this is not required and countries may
391 choose to take no action. In addition, there is a 90-day grace period allowed to complete required documents after
392 transport of the biological material.

393 If the research or diagnostic work on biological material of veterinary concern is considered 'utilisation' by the
394 country (Party) in which it takes place the researcher will be required to provide information, including:

- 395 i) The Internationally Recognised Certificate of Compliance (number) from the ABS Clearing House, if available;
396 or
- 397 a) ABS Permit reference
398 b) Evidence of Prior Informed Consent
399 c) Evidence of Mutually Agreed Terms
400 d) The entity to whom PIC and MAT was granted
- 401 ii) The Provider Country
402 iii) Date and place of access
403 iv) Description of the Genetic Resources

404 This information should be included in the documents with the transported biological material.

405 Although this documentation is only required if both providing country and recipient country are Party to the Nagoya
406 Protocol the provider may have Access and Benefit-Sharing legislation even if not a Party. This should be respected
407 and any documentation required, including permits, Prior Informed Consent and Mutually Agreed Terms, acquired
408 and dispatched with the material.

409 Further information can be found on:

- 410 i) The ABS Clearing House – <https://absch.cbd.int/>
411 ii) The CBD Website – <https://www.cbd.int/abs/default.shtml>

412

E. REFERENCES AND FURTHER READING

413 WHO Guidance on regulations for the transport of infectious substances 2017–2018: applicable as of 1 January
414 2017, covering transport regulations on national and international and air transport by different means:
415 <http://www.who.int/hr/publications/WHO-WHE-CPI-2017.8/en/> <https://iris.who.int/handle/10665/254788>

416 Swiss Expert Committee on Biosafety on Transport of biological substances, import and export of substances
417 consisting of or containing pathogenic or genetically modified (micro)organisms”; practical explanation on how to
418 transport biological substances according to the specific dangerous goods transport regulations:

419 <http://www.efbs.admin.ch/en/transport/index.html> <https://www.efbs.admin.ch/index.php?id=462&L=3>

420 IATA: <http://www.iata.org/whatwedo/cargo/dgr/Documents/infectious-substance-classification-DGR56-en.pdf>

F. ADDITIONAL INFORMATION ON THE UNITED NATIONS SYSTEM FOR THE TRANSPORT OF DANGEROUS GOODS

423 The United Nations dangerous goods web site provides comprehensive detail concerning the United Nations
424 Recommendations on the Transport of Dangerous Goods. It also provides links to the modal agencies:
425 <http://www.unece.org/trans/danger/danger.html>

426 The site below provides the full text of the United Nations Recommendations on the Transport of Dangerous Goods
427 – Model Regulations, which can be downloaded in PDF format. Readers wishing to see the text relating to the
428 transport of infectious substances should download Part 2, Part 4 and Part 5 of the Recommendations:
429 http://www.unece.org/trans/danger/publi/unrec/rev20/20files_e.html

430 The site below provides the full text of the European Agreement concerning the International Carriage of Dangerous
431 Goods by Road (ADR) of 2017, which entered into force on 1 January 2017, which can be downloaded in PDF
432 format. Readers wishing to study the text relating to the transport of infectious substances should download Part 2
433 (2.2.62), Part 4 (search P620, P650) and Part 5:

434 <http://www.unece.org/trans/danger/publi/adr/adr2017/17contentse0.html> and
435 http://www.unece.org/trans/danger/publi/adn/adn2017/17files_e0.html

436 Contracting parties to the various conventions for the transport of dangerous goods can be found on a number of
437 web sites:

438 **Air** ICAO: <http://www.icao.int/Pages/default.aspx> and
439 <https://www.icao.int/safety/DangerousGoods/Pages/StateVariationPage.aspx>

440 IATA: [http://www.iata.org/whatwedo/cargo/dgr/Documents/infectious-substance-classification-](http://www.iata.org/whatwedo/cargo/dgr/Documents/infectious-substance-classification-DGR56-en.pdf)
441 [DGR56-en.pdf](http://www.iata.org/whatwedo/cargo/dgr/Documents/infectious-substance-classification-DGR56-en.pdf)

442 **Rail** RID (Intergovernmental Organisation for International Carriage by Rail): <http://www.otif.org/>. RID is
443 primarily for the countries of Europe, North Africa and the Middle East. There are a number of
444 countries (mainly Eastern Europe and Asia that apply RID through the Organization for Cooperation
445 of Railways (OSJD); details of RID membership can be found at <http://www.otif.org/en>

446 **Road** ADR: http://www.unece.org/trans/danger/publi/adr/country-info_e.htm <https://unece.org/about-adr>
447 (lists competent authorities)

448 **Sea** IMO (International Maritime Organization): <http://www.imo.org>

449 **Post** UPU (Universal Postal Union): <http://www.upu.int/>

450 **NB:** FIRST ADOPTED IN 1992 AS SAMPLING METHODS.
451 MOST RECENT UPDATES ADOPTED IN 2018.

APPENDIX 1.1.3.1.

DEFINITIONS

The following definitions are for the purposes of this chapter only. For general definitions please see the Glossary.

- **Biological products**

Biological products are those products derived from living organisms which are manufactured and distributed in accordance with the requirements of appropriate national authorities, which may have special licensing requirements, and are used either for prevention, treatment, or diagnosis of disease in humans or animals, or for development, experimental or investigational purposes related thereto. They include, but are not limited to, finished or unfinished products such as vaccines.

- **Cultures**

Cultures are the result of a process by which pathogens are intentionally propagated. This definition does not include human or animal patient specimens as defined below.

- **Infectious substances**

For the purposes of transport, infectious substances are defined as substances which are known or are reasonably expected to contain pathogens. Pathogens are defined as microorganisms (including bacteria, viruses, parasites, fungi) and other agents such as prions, which can cause disease in humans or animals. Infectious substances are further classified according to risk into two categories.

- **Genetically modified microorganisms (GMMOs) and organisms (GMOs)**

Genetically modified microorganisms not meeting the definition of infectious substance are classified in Class 9 (Miscellaneous dangerous substances and articles, including environmentally hazardous substances). GMMOs and GMOs are not subject to dangerous goods regulations when authorised for use by the competent authorities of the countries of origin, transit and destination. Genetically modified live animals shall be transported under terms and conditions of the competent authorities of the countries of origin and destination. DNA, RNA or plasmids are not considered as GMMO and not subject to dangerous goods regulations.

- **Medical or clinical wastes**

Medical or clinical wastes are wastes derived from the veterinary treatment of animals, the medical treatment of humans or from bio-research.

- **Patient specimens**

Patient specimens are those, collected directly from humans or animals, including, but not limited to, excreta, secreta, blood and its components, tissue and tissue fluid swabs, and body parts being transported for purposes such as research, diagnosis, investigational activities, disease treatment and prevention.

*
* *

APPENDIX 1.1.3.2.

EXAMPLE OF THE TRIPLE PACKAGING SYSTEM (IATA RECOMMENDATIONS) FOR THE PACKING AND LABELLING OF DIFFERENT TYPES OF BIOLOGICAL MATERIALS

Fig. 3. Example of triple packaging system for the packaging and labelling of Category A, UN2814 and UN2900 infectious substances (Figure kindly provided by IATA, Montreal, Canada).




Fig. 4. Example of the triple packaging system for the packing and labelling of Category B, UN3373 infectious substances (Figure kindly provided by IATA, Montreal, Canada).




Fig. 5. Example of the triple packaging system for the packing and labelling of Category B, UN3373 infectious substances with non-rigid leakproof secondary packaging (Figure kindly provided by IATA, Montreal, Canada).





Fig. 6. Example of the triple packaging system for the packing and labelling of Exempt specimen (Figure kindly provided by IATA, Montreal, Canada).



APPENDIX 1.1.3.3.

MATERIAL TRANSFER AGREEMENT

MATERIAL TRANSFER AGREEMENT

BETWEEN

PROVIDER

**Organisation:
Address:
Country:**

PROVIDER SCIENTIST

**Title and name:
Organisation:
Address:**

AND

RECIPIENT

**Organisation:
Address:
Country:**

RECIPIENT SCIENTIST

**Title and name:
Organisation:
Address:**

ORIGINAL MATERIAL

Description of the material being transferred

SHIPPING ADDRESS

**Title and name:
Address:**

I. OBJECTIVE AND PURPOSE

[Insert a short statement about the objectives and intended purpose of the agreement and background to the parties to the agreement.]

II. DEFINITIONS

Provider

Organisation providing the *original material*. The name and address of this party will be specified in the first page of this MTA.

Provider scientist

The name and address of this party will be specified in an implementing letter.

Recipient

Organisation receiving the *original material*. The name and address of this party will be specified in an implementing letter.

Recipient scientist

The name and address of this party will be specified in an implementing letter.

Original material

The description of the material being transferred will be specified in an implementing letter.

Material

Original material, progeny, and unmodified derivatives. The *material* shall not include: (a) *modifications*, or (b) other substances created by the *recipient* through the use of the *material* which are not *modifications, progeny, or unmodified derivatives*.

Progeny

Unmodified descendant from the *material*, such as virus from virus, cell from cell, or organism from organism.

Unmodified derivatives

Substances created by the *recipient* which constitute an unmodified functional subunit or product expressed by the *original material*. Some examples include: subclones of unmodified cell lines, purified or fractionated subsets of the *original material*, proteins expressed by DNA/RNA supplied by the *provider*, or monoclonal antibodies secreted by a hybridoma cell line.

Modifications

Substances created by the *recipient* which contain/incorporate the *material*.

Commercial purposes

The sale, lease, license, or other transfer of the *material* or *modifications* to a for-profit organisation. *Commercial purposes* shall also include uses of the *material* or *modifications* by any organisation, including *recipient*, to perform contract research, to screen compound libraries, to produce or manufacture products for general sale, or to conduct research activities that result in any sale, lease, license, or transfer of the *material* or *modifications* to a for-profit organisation. However, industrially sponsored academic research shall not be considered a use of the *material* or *modifications* for *commercial purposes* per se, unless any of the above conditions of this definition are met.

Non-profit organisation(s)

A university or other institution of higher education or an organisation exempt from taxation or any nonprofit scientific or educational organisation qualified under a state nonprofit organisation statute. As used herein, the term also includes government agencies.

Agreement

Material Transfer Agreement (MTA)

III. TERMS AND CONDITIONS OF THIS AGREEMENT

Ownership

The *provider* retains ownership of the *material*, including any *material* contained or incorporated in *modifications*.

The *recipient* retains ownership of:

- (a) *modifications* (except that, the *provider* retains ownership rights to the *material* included therein);
- (b) those substances created through the use of the *material* or *modifications*, but which are not *progeny*, *unmodified derivatives* or *modifications* (i.e., do not contain the *original material*, *progeny*, *unmodified derivatives*). If either 2 (a) or 2 (b) results from the collaborative efforts of the *provider* and the *recipient*, joint ownership may be negotiated.

Non-commercial use

The *recipient* and the *recipient scientist* agree that the *material* is to be used solely for either teaching, non-commercial research or academic research purposes. In this Agreement, non-commercial research purpose and academic research purpose mean that the *material* cannot be used for *commercial purposes*, and the *recipient* may not exploit commercially the results, inventions, discoveries or know-how which incorporates the *materials* for its own benefit nor for a third party, without the consent of the *provider*.

Ownership of the results, inventions, discoveries or know-how generated by the *recipient* using the *material* shall rest with the *recipient*. Nevertheless, any results, inventions, discoveries or know-how which contain or incorporate the *material*, generated by the *recipient* using the *material* ("*modifications*") shall be jointly owned by the *provider* and the *recipient*. However, both the *provider* and the *recipient* agree that should the *recipient* having completed work under this MTA wish to use the *material* or *modifications* for commercial purposes it will be necessary for the *recipient* to negotiate the terms of a license Agreement with the *provider*. No right are given, implied or intended by this Agreement or the material transfer other than those explicitly stated in this Agreement.

Distribution to third parties

This *material* should be considered a property of the *provider*. The *recipient* therefore agrees to retain control over this material, and further agrees not to transfer the *material* to third parties or to personnel of the *recipient* not working under the supervision of the *recipient scientist*. The *recipient* agrees to refer to the *provider* any request for the *material* from anyone other than those persons working under the *recipient scientist's* direct supervision. The *provider* reserves the right to distribute the *material* to others and to use it for its own purposes.

The *recipient* shall have the right, without restrictions, to distribute substances created by the *recipient* through the use of the *original material* only if those substances are not *progeny*, *unmodified derivatives*, or *modifications*.

Under a separate agreement at least as protective of the *provider's* rights, the *recipient* may distribute *modifications* to *non-profit organisation(s)* for non-commercial research purposes and academic research purposes only, subject to prior written notice to the *provider*.

Confidentiality

The *recipient* agrees to treat the *materials* as it would treat its own confidential and proprietary information and at least no less than a reasonable degree of care, and to take all reasonable precautions to prevent unauthorised disclosure to any third party of the *material* which it receives hereunder. The *provider* agrees to keep confidential that the *recipient* is using the *material*.

Publications

This Agreement shall not be interpreted to prevent or delay publication of research findings resulting from the use of the *material* or the *modifications*. The *recipient scientist* agrees to provide appropriate acknowledgement of the source of the *material* in all publications.

Material use liability

The *material* is provided as a service to the research community at large. It is provided without warranty of merchantability or fitness for a particular purpose or any other warranty, express or implied. No indemnification for any damages is intended or provided under this Agreement. Each party should accept liability for their own actions. The parties make no express or implied warranty as to any matter whatsoever, including the conditions of the research or any invention or product, whether tangible or intangible, made, or developed under this Agreement, or the ownership, merchantability, or fitness for a particular purpose of the research or any invention or product. The parties further make no warranty that the use of any invention or other intellectual property or product contributed, made or developed under this Agreement will not infringe any patent or other intellectual property right. In no event, will any party be liable to any other party for compensatory, punitive, exemplary or consequential damages.

Misuse, dual use and biosafety

The *recipient* accepts full responsibility for the safety of the research and warrants that the research will be performed in accordance with all local or national laws, rules and regulations. In particular, this *material* will only be used for research purposes by the *recipient* in its laboratory under suitable containment conditions.

Under the terms of this Agreement, the *material* may not be used in human beings.

Termination of the Agreement

The term of this Agreement is 2 years as of the effective date of termination, unless an extension is mutually agreed by the *provider* and the *recipient*. At the end of this term, the Agreement shall automatically terminate. Upon the effective date of termination, or if requested, the deferred effective date of termination, the *recipient* will discontinue its use of the *material* and will, upon direction of the *provider*, return or destroy any remaining *material*. The cost of return or destruction will be taken by the *recipient*.

Dispute

Any dispute arising under this Agreement instituted against the *recipient* by the *provider* shall be brought in the court of the *recipient's* country of domicile. Any claims and proceedings against the *provider* by the *recipient* shall be brought in the courts of the *provider's* country of domicile.

Modification of the Agreement and signatures

This agreement may not be modified, in whole or in part, except by the written consent of both parties. If any provision of this Agreement may be signed in counterpart, and by the parties hereto or separate counterparts, each of which shall be deemed an original.

This Agreement is effective when signed by all parties. The parties executing it certify that their respective organisations have accepted the terms of this Agreement, and further agree to be bound by the terms, for the transfer specified above.

Recipient responsibility

The Recipient undertakes to use the Material in full compliance with any national and international applicable law, including any disposition and guidelines regarding health and scientific research. In particular, the Material having intrinsic health risk shall be handled in full respect of the specific law and in compliance with all the necessary precautions.

The Recipient represents that within its laboratories:

- Access to the Material, Progeny and Modification will be restricted to personnel capable and qualified to safely handle those substances, using appropriate containment;
- Recipient shall use the utmost precaution to minimise any risk of harm to persons and property and to safeguard them from theft or misuse.

The Recipient also acknowledges that in no event the Material applies directly or indirectly to humans.

The Recipient assumes all liability for any and all third party damages and claims arising out of or relating to this Agreement, including the receipt, use, handling, storage, conservation of the Material. To the extent permitted by applicable law, the Recipient agrees to indemnify, defend and hold harmless the provider against all third party claims, losses, expenses and damages, including reasonable attorney's fees.

The provider shall have no liability towards the Recipient or its employees in the event that the Material and/or Derivatives infringe any intellectual property rights of third parties. The provider makes no warranties for the absence of any third party industrial property rights on the Material.

IV. PAGE OF SIGNATURES

AUTHORISED SIGNATURE OF THE PROVIDER SCIENTIST

Signature:
Title and print name:
Date:


AUTHORISED SIGNATURE OF THE RECIPIENT SCIENTIST

Signature:
Title and print name:
Date:


APPENDIX 1.1.3.4.

DECISION TREES FOR THE TRANSPORT REQUIREMENTS OF BIOLOGICAL MATERIALS


Decision Tree 1:



Decision Tree 2



Decision Tree 3



3 REUNIÓN DE LA COMISIÓN DE NORMAS BIOLÓGICAS
4 París, 9–13 de septiembre de 2024

5
6 CHAPTER 1.1.7.

7 **STANDARDS FOR HIGH THROUGHPUT**
8 **SEQUENCING, BIOINFORMATICS AND**
9 **COMPUTATIONAL GENOMICS**

10 **INTRODUCTION**

11 *High throughput sequencing, bioinformatics and computational genomics (HTS-BCG) in animal*
12 *health and food safety investigations should be used in accordance with standards for laboratory*
13 *testing, just as any other laboratory tool or procedure. As HTS-BCG is a relatively new procedure,*
14 *compared with other standard diagnostic assays, the purpose of this chapter is to assist laboratories*
15 *by defining standards that will allow inclusion of the capability into a laboratory's scope of operations*
16 *in a way in which the users of the results can have confidence.*

17 **A. GENERAL CONSIDERATIONS**

18 Sequence information is playing an increasingly important role in the diagnosis and management of microbial
19 infections, including in the characterisation of infectious agents, their possible phenotypic characteristics and their
20 epidemiology. Consequently, it is incumbent on laboratories to adopt policies and practices for generating, analysing
21 and managing genomic sequence data that are based on accurate information and rigorously interpreted.

22 Increasingly, for full identification and characterisation of a microorganism, there is an expectation that essential
23 features of its genome should be described. For viruses, this may be the whole genome, while for bacteria and
24 parasites, it may be only partial sequences. However as sequencing technology is continually developing ~~so rapidly,~~
25 ~~within a short time~~ whole genome sequences for ~~these~~ larger microorganisms may soon also be routinely generated
26 ~~after suitable bioinformatics procedures have been developed.~~

27 The standards described here apply to the generation of genomic sequence data during investigations of infections
28 of single animals, animal populations and their environment. They also apply to the ~~generation,~~ management and
29 use of such data within the accepted practices of veterinary investigations and within a laboratory's quality
30 assurance system.

31 **B. THE CONDUCT OF VETERINARY INVESTIGATIONS**
32 **INCORPORATING HTS-BCG**

33 Sequence data of microorganisms, such as is generated by high throughput sequencing (HTS) or metagenomics
34 approaches, is only a tool, although a powerful one, to assist in the investigation of ~~issues regarding~~ animal health
35 and food safety. Appropriate experts should perform the processing and analysis of sequence data. The
36 interpretation of ~~that~~ data in relation to the disease investigation should be led by suitably qualified ~~veterinarians~~
37 individuals in close collaboration with data analyses experts, consistent with the standard requirements for diagnosis
38 of animal disease.

39 The sequence and sequence analysis of infections associated with cases, outbreaks and investigations of animal
40 disease and food safety by laboratories should be recorded and analysed together with all other information relating
41 to the reporting and recording of such cases and outbreaks. These data should be considered a necessary part of
42 such reports and records.

43 HTS-BCG (bioinformatics and computational genomics) can be deployed for a range of purposes in the detection
44 of infectious agents and their characterisation, either in biological material such as diagnostic or surveillance
45 specimens or propagated in cultures or as isolates. For primary diagnostic applications, the users of the technology
46 should consider the purposes of their testing in relation to the normal purposes of testing as defined in Chapter
47 1.1.6 *Validation Of diagnostic assays for infectious diseases of terrestrial animals*. HTS-BCG may also be applied
48 as a confirmatory assay for organisms detected in some other primary assay, or to provide additional
49 characterisation of such organisms.

50 Further to these general purposes of testing, HTS-BCG offers specific opportunities for:

- 51 i) The detection, identification and characterisation of previously unidentified microorganisms;
- 52 ii) The improved diagnosis of known diseases;
- 53 iii) The improved diagnosis of emerging or re-emerging diseases with known or unknown aetiology;
- 54 iv) The development of single 'universal' diagnostic assays, able to identify any potential pathogen;
- 55 v) The simultaneous and quick detection of multiple agents in diseases with multifactorial aetiologies;
- 56 vi) The increased capability to study the evolutionary dynamics of pathogens at the farm, local, national and
57 global levels;
- 58 vii) The deeper understanding of the epidemiology of infectious diseases and the phylogeography of infectious
59 agents;
- 60 viii) The enhanced traceability of infectious diseases and modes of pathogen transmission including applications
61 in forensic epidemiology;
- 62 ix) More extensive characterisation of 'populations' of known pathogens (e.g. relevant minority strains, escape
63 mutants) that in turn facilitates the design of better vaccines, antivirals, etc.;
- 64 x) Better links between pathogen genotype and phenotypes enabled through full genome sequence of multiple
65 strains (including reference strains) of a single agent.

66 **C. STANDARDS FOR THE USE OF HTS-BCG**

67 **1. Selection of a technology platform or service**

68 Laboratories may choose to establish a HTS-BCG capability in-house, contract commercial suppliers of services or
69 submit specimens to designated Reference Centres.

70 Where the laboratory establishes its own capability there are a number of commercially available sequencing
71 platforms for the purpose of generating sequence information from test samples. The choice of platform should be
72 based on a consideration of the intended purpose or combination of purposes as outlined in Section B above.

73 Of primary concern is that the technology selected is fit for the intended purpose, that it is appropriate for the
74 production of sequence information from the types of genome intended for study. Other considerations may take
75 into account the time required to conduct a sequencing run, including sample preparation; inherent error rate of the
76 technology; ancillary equipment needed in addition to the actual sequencing device; the capital cost of the purchase
77 and set up of all necessary equipment and the cost of annual licences or service agreements, including
78 manufacturer's recommended maintenance schedule; costs of implementation of technology/workflows, following
79 instrument acquisition; the availability of supporting expertise from the supplier; the cost of reagents for a
80 sequencing run and the likely availability of reagents in the country concerned; the expected sample throughput
81 and consequent cost impact; the requirement of a laboratory infrastructure compatible with best practices for
82 sequencing workflows; staff requirements and training required to operate the equipment and to conduct the
83 associated bioinformatic analyses; access to well maintained server for data storage and analyses; and the data
84 management requirements. Currently available systems have been reviewed (Belák *et al.*, 2013; Granberg *et al.*,

85 2016; Marston et al., 2013; Momoi & Matsuu, 2021; Satam et al., 2023; Suminda et al., 2022), but new models and
86 technologies and computational approaches can be expected to become available frequently and applied to animal
87 health.

88 Where a laboratory or veterinary service contracts an external provider to supply HTS-BCG services, they should
89 ensure that the service provider meets the standards defined in this chapter.

90 **2. Sampling and reporting**

91 HTS-BCG is a relatively new technological tool in the management of diseases of animals and its use should be
92 adopted within the context of tried and accepted processes for the management of animal health and food safety
93 including clinical or epidemiological field investigations and the sampling of animals, animal populations or other
94 epidemiologically relevant situations. The use of the technology should be appropriate to the purpose of the
95 investigation, ~~and~~ The sampling strategy and the specimens taken should be appropriate for that investigation,
96 based on an understanding of the pathogenesis and epidemiology of the infection under study or the likely
97 pathogenesis and epidemiology of any novel infectious agent suspected. ~~Such investigations should be under the~~
98 ~~supervision of appropriately qualified veterinarians.~~

99 In laboratories where HTS-BCG is used it should be managed within the context of the laboratory's quality
100 assurance system. Hence the results of HTS-BCG must be interpreted in the context of the pathogenesis and
101 epidemiology of the infection in the animal species under study. Results should be reported by appropriately
102 qualified veterinary investigators with the authority to make diagnoses of animal diseases under the laboratory's
103 quality assurance system and in the jurisdiction where the investigation is conducted.

104 Laboratories should have clear guidelines to avoid sampling biases for each study type, as well as which
105 sample/veterinary clinical metadata to record.

106 **3. Specimens and sample preparation**

107 Specimens should be collected and submitted to the testing laboratory in accordance with the standards
108 communicated in Chapter 1.1.2 *Collection, submission and storage of diagnostic specimens*. The normal
109 comprehensive information regarding the individual animal, the case or reason for sampling and the relevant
110 epidemiological information should be recorded in the laboratory's accessions processes, as for any submission to
111 the laboratory.

112 As with other laboratory processes, ensuring the integrity of the specimen and the samples to be tested is critical.
113 Nucleic acids, either DNA or RNA, need to be extracted from the samples. In some cases, host depletion or targeted
114 enrichment strategies may be applied during extraction or library preparation to increase the ratio of pathogen to
115 host nucleic acids ~~can be used to~~ and maximise the sensitivity of the technique. However, care must be taken to
116 avoid biasing the outcome in the context of the intended purpose. Precautions to ensure the integrity and quality of
117 nucleic acids must be followed similarly to any other molecular technique (e.g. polymerase chain reaction [PCR])
118 as already described in Chapter 2.1.2 *Biotechnology advances in the diagnosis of infectious diseases*. Those
119 precautions are particularly relevant in HTS applications as they rely on nucleic acid fragment length and
120 microorganism genome coverage for effective pathogen detection and identification, as opposed to PCR assays
121 that amplify only a short fragment of nucleic acid. Once nucleic acids are extracted from the samples, they need to
122 be further manipulated (e.g. reverse transcription of RNA into complementary DNA) in order to be used in HTS.
123 Different technological platforms require specific sets of reagents in order to generate the final material ("libraries")
124 ready for sequencing. Commercial kits are available for this purpose.

125 HTS is an extremely sensitive technology and even few molecules of nucleic acid ~~could~~ can be detected. Hence,
126 precautions to avoid cross-contaminations must be followed as in the case of ~~many~~ other molecular techniques
127 used to detect nucleic acids (e.g. PCR). Separation of work areas and decontamination of working spaces is an
128 essential requirement to avoid cross contamination with nucleic acid ~~from other molecular investigations~~ Separation
129 of work areas from the possibility of cross contamination with nucleic acid from other molecular investigations is an
130 essential requirement. In addition, HTS very frequently involves "multiplexing" of several samples in a single
131 reaction. Individual samples are "tagged" during one of the stages of sample preparation by the use of short index
132 sequences linked to nucleic acid molecules. Best practices should include index usage rotation in benches and
133 sequencers. Index sequences must be of sufficient quality and design to be relied on as a signature for the tagged
134 library for HTS use in order to avoid artefacts during bioinformatics analysis of sequencing data obtained.
135 Furthermore, index misassignment metrics including index hopping should be determined for each workflow and
136 instrument, as well as instrument carryover, when applicable. When available, the amount of the target sequence
137 should be determined by prior analyses to inform sample-batch processing.

138 Every application of HTS-BCG technology should include positive and negative controls appropriate to the
139 investigation and that have been incorporated through the sample preparation processes of the sequencing run as

140 well as the actual run on the technology platform. The use of unique molecules spiked in each sample is highly
141 advisable to monitor intra-batch contamination, mainly in workflows using enrichment methods. Appropriate controls
142 should be used to verify each step of the procedure including nucleic acid quality, library preparation, cross-
143 contamination (including multiplexing) sensitivity and reproducibility.

144 As with any other diagnostic method, confirmation of results ~~would~~ may require resampling of the original specimen,
145 which therefore has to be protected from cross-contamination and be stored appropriately. Validation of HTS results
146 could also be achieved using a different diagnostic method.

147 4. Generation of sequence data

148 While HTS platforms differ widely in their details chemistry and protocols, basic principles of quality control relevant
149 to the technology can be followed, and generic recommendations for acceptable quality metrics can be made.
150 Suitable control measures might include the use of positive, negative and no-template controls run in replicates of
151 the test, iteratively covering different locations in the multiwell plate, and a quality scoring system. Sequencing
152 quality metrics provide suitable parameters for the validation and monitoring of platform performance. Most
153 platforms offer the possibility to spike controls in reagents and to use the control's QC metrics to monitor platform
154 and reagent performance. Additional technology specific performance metrics can be used to monitor platform
155 performance and to identify aberrant sequencing runs. Equally, maintenance of sample handling log files facilitates
156 investigations in case of suspected contaminations that may lead to false positives.

157 Quality metrics for the evaluation of the analytical performance of HTS-based tests, include:

- 158 i) Depth of coverage. This indicates the number of sequence reads providing information about a given
159 nucleotide position. When ongoing quality monitoring shows that the coverage depth at a given nucleotide is
160 below the validated minimum coverage, confirmation should be provided using alternate methods (e.g. Sanger
161 sequencing) or additional sequencing.
- 162 ii) Uniformity of coverage. This parameter describes how the depth of coverage is distributed over the test's
163 target region(s). Coverage across a pathogen genome is rarely uniform. However, deviations of uniformity of
164 coverage from the validated range can potentially indicate errors in the testing process.
- 165 iii) GC bias. The GC content (relative abundance of G and C nucleotides) of a target region affects the efficiency
166 of sequencing reactions and will affect the uniformity of coverage. ~~Where possible, the amount of GC bias in~~
167 ~~the test's target region(s) should be determined during validation and monitored to evaluate test performance.~~
- 168 iv) Low complexity regions. Homopolymer regions and microsatellites in a target region (or close to a target
169 region) may compromise accuracy. This should be determined during validation and if not possible to avoid,
170 carefully assess performance.
- 171 v) Base call quality scores. These are platform-derived reflections of the signal-to noise ratio and reflect the
172 probability that the base call was correct. An acceptable raw base call quality threshold should be established
173 during validation, and incorporated in bioinformatics filters to eliminate poor quality data during analysis.
- 174 vi) Decline in signal intensity or read length. Depending on the exact application, HTS platform and chemistry,
175 sequence reads have a typical distribution of read length and signal intensity. The expected signal intensity
176 across reads (or read length distribution) should be established during validation and monitored for each run.
177 Deviations in the distribution of read lengths may indicate problematic datasets. "Reads "trimming" is usually
178 applied by removing low-quality bases or adapter sequences from raw reads, aiming therefore to balance read
179 retention and read accuracy. The choice on the trimming threshold depends on the diagnostic question and
180 the required read accuracy. For example, identifying a co-infection with two similar viral strains or detecting
181 drug resistance at a sub-consensus level requires higher data quality.
- 182 vii) Mapping quality. This is a measure of uncertainty that a read is mapped properly to a genomic position within
183 the target region. Acceptable values (e.g. proportion of reads mapping to the target) should be established
184 during validation of bioinformatics workflows and the proportion of reads not mapping to the target can be
185 monitored during each run.
- 186 viii) Internal controls. Most platforms offer the possibility to spike an internal control at very low frequency during
187 the sequencing run. The quality metrics of those reads can be compared to previously reported quality metrics.

188 5. Bioinformatics

189 An absolute requirement for any laboratory intending to establish a HTS-BCG capability is the employment (or
190 partnership) of specialised staff with bioinformatics skills. Even if platforms with supporting software for specific
191 analyses in defined clinical situations ~~were to become~~ may be available, the use of such packages would not remove
192 the responsibility of the laboratory to be able to competently analyse its own data.

193 The bioinformatic analysis assembling the pathogen genomic sequence from the raw data and the subsequent
194 secondary analysis are the critical elements in HTS-BCG. Hence the approaches used must be transparent, with
195 clear guidelines on how to record bioinformatic metadata, including a declaration of the software packages, software
196 versions, and reference databases or sequences used should be a component of every report of sequence analysis.
197 Software programs used for these analyses must be readily available (commercially or open access) in order to be
198 evaluated by the international community.

199 As with any laboratory procedure, attention must be given to quality assurance. The test method should include
200 criteria for acceptance or rejection of each run based on the satisfactory analyses of the controls and adequate
201 reference material. Sequencing data must be documented to have satisfied minimum quality scores and coverage
202 for each nucleotide of the assembled final consensus sequence obtained.

203 The appropriateness of chosen bioinformatics software for particular analyses can be evaluated through testing its
204 performance against standard data sets containing data relating to agents expected to be present in the specimens
205 to be tested and by comparing and benchmarking different bioinformatic tools.

206 **6. Data management**

207 The data generated from HTS-BCG operations are essential to reach the diagnosis or other scientific purpose of
208 the investigation, such as agent characterisation, and are an integral component of the process. As such it is an
209 essential requirement of laboratories to have policies, processes and supporting systems to curate, manage and
210 store the data generated.

211 Different HTS technology platforms produce raw data in different formats and stage of pre-analysis, so it is
212 necessary for laboratories to have policies and processes specific to the technology platform in use. Data
213 management systems will include aspects of which data to keep, ~~and~~ the length of time for which they will be kept,
214 and the back-up strategies to protect against accidental loss or deliberate erasure, and submission to national or
215 international archives or databases. Metadata describing the generation and analysis of the sequence data is
216 essential, so that the process itself can be analysed or repeated.

217 Where a sequence analysis leads to an output of animal health significance, especially one of trade or international
218 significance, it is an absolute requirement that the data on which the analysis was performed be kept available for
219 audit or confirmatory analysis for a period of time commensurate with the significance of the animal health finding.
220 This is particularly important where the finding may be disputed. Failure to be able to produce the required data for
221 independent analysis could be taken to invalidate the finding.

222 Sequence data should be stored in a manner in which there is a clear link to the metadata associated with the
223 specimen that was the subject of the analysis. As is standard practice in laboratory investigations, such metadata
224 includes information regarding the animal sampled, its ownership and location, and accompanying clinical and
225 epidemiological information regarding the animal population.

226 Careful consideration should be given to platforms compatible with integration of data from different sources namely
227 sample, clinical and sequencing metadata.

228 **7. Validation of test systems for designated purposes**

229 The concepts of test validation as stated in chapter 1.1.6 are broadly applicable to HTS-BCG (Van Borm *et al.*,
230 2016). All procedures including sample processing (nucleic acid extraction, library preparation, tagging, target
231 enrichment), sequencing, bioinformatics and reporting should be documented in SOPs before validation can start.
232 Stage 1 validation data must be developed to confirm the analytic sensitivity (Se) and specificity (Sp) of the
233 technique, and its repeatability. For sequencing based tests, analytic sensitivity can be defined as the likelihood
234 that the assay will detect the targeted sequence variations, if present, at a given probability (e.g. 95% confidence),
235 while analytical specificity can be defined as the probability that an assay will not detect a sequence variation when
236 none are present at a given probability. Furthermore, each type of specimens has its own characteristics that have
237 to be considered, e.g. nasal swab, sera or faeces. Well described samples with known concentrations of target
238 analyte or non-target analytes and matrix components can be used to assess the analytical performance. This
239 should include, as a minimum, serial dilutions of each type of specimen containing defined organisms to document
240 the limits of detection of designated whole genomes or genetic sequences representative of the type for which the
241 HTS-BCG capability will be used in the laboratory. Care should be used to dilute samples in the same sample matrix
242 containing the normal amount of non-target nucleic acids as detection sensitivity often depends on the ratio of target
243 v. non-target molecules. For viral disease investigations, test specimens could be prepared to contain
244 representative viruses of the full range of viral families from which agents may be present in test specimens of the
245 type to be investigated in routine operations. Documentation of the laboratory's HTS-BCG system to detect these
246 viruses will be established. The same principles apply to genetic markers, bacteria or other organisms for which the
247 HTS-BCG capability will be used in planned routine operations. In all these runs designed to establish sensitivity

248 and specificity, the sample preparation steps should be part of each assessment as these steps are likely to be
249 critical to all aspects of overall test performance.

250 Several factors complicate the validation of NGS tests as primary diagnostic assays including:

- 251 i) The weight of the analytical and diagnostic validation required (chapter 1.1.6);
- 252 ii) The operational cost of the technology;
- 253 iii) The challenges of validation of a data analysis workflow;
- 254 iv) The high need for investment in hardware and expertise;
- 255 v) The time taken to obtain a result (~~currently days~~ compared with ~~hours for specific~~ other molecular diagnostics
256 such as real-time PCR).

257 Confirmatory adjunct or secondary diagnostic assays need to be validated only for their analytical performance,
258 e.g. analytical sensitivity and specificity, and repeatability and initial reproducibility (stage 1) and not to the full
259 diagnostic extent (diagnostic sensitivity and specificity, stage 2).

260 It is recognised that it may not always be practical to produce large data sets on test performance such as would
261 normally allow calculation of test diagnostic sensitivity and specificity, but other aspects of validation such as
262 demonstration of test reproducibility among laboratories conducting similar investigations should be undertaken.

263 8. Quality assurance

264 Testing using HTS-BCG for the purposes of investigations of animal health and food safety should be conducted in
265 accordance with the requirements of the laboratory's quality assurance system, the features of which will meet the
266 standards listed in Chapter 1.1.5 *Quality management in veterinary testing laboratories*. Where the laboratory is
267 accredited, the testing ~~should~~ could be part of the laboratory's scope of accreditation.

268 Standard data sets against which the usefulness of bioinformatics software packages can be verified have been
269 developed. Laboratories using HTS-BCG should ensure that their software packages for bioinformatics meet
270 expected performance criteria against data standards.

271 Where proficiency testing strategies have been developed, laboratories using HTS-BCG should participate.

272 9. Interpretation of results

273 HTS-BCG can be used for a variety of purposes ranging from pathogen discovery to diagnosis or in-depth
274 characterisation of known infectious agents. Consequently, the interpretation of the results obtained will be in the
275 context of the specific clinical and epidemiological situation, reassured by satisfactory performance against all
276 specified controls and quality assurance parameters. As with any other laboratory tests, these considerations are
277 one among a number of parameters to be taken into account.

278 REFERENCES

279 ~~BELÁK S., KARLSSON O.E., LEIJON M. & GRANBERG F. (2013). High-throughput sequencing in veterinary infection biology
280 and diagnostics. *Rev. sci. tech. Off. int. Epiz.*, **32**, 893–915.~~

281 GRANBERG F., BÁLINT A. & BELÁK S. (2016). Novel technologies applied for the nucleotide sequencing and comparative
282 sequence analysis of the genomes of infectious agents in veterinary medicine. *Rev. sci. tech. Off. int. Epiz.*, **35**, 25–
283 41.

284 MARSTON D.A., McELHINNEY L.M., ELLIS R.J., HORTON D.L., WISE E.L., LEECH S.L., DAVID D., DE LAMBALLERIE X. &
285 FOOKS A.R. (2013). Next generation sequencing of viral RNA genomes. *BMC Genomics*, **14**, 444.

286 MOMOI Y. & MATSUU A. (2021). Detection of severe fever with thrombocytopenia syndrome virus and other viruses
287 in cats via unbiased next-generation sequencing. *J. Vet. Diagn. Invest.*, **33**, 279-282.

288 SATAM H., JOSHI K., MANGROLIA U., WAGHOO S., ZAIDI G., RAWOOL S., THAKARE R.P., BANDAY S., MISHRA A.K., DAS G.
289 & MALONIA S.K. (2023). Next-Generation Sequencing Technology: Current Trends and Advancements. *Biology*
290 *(Basel)*, **12**, 997.

291 SUMINDA G.G.D., BHANDARI S., WON Y., GOUTAM U., KANTH PULICHERLA K., SON Y.O. & GHOSH M. (2022). High-
292 throughput sequencing technologies in the detection of livestock pathogens, diagnosis, and zoonotic surveillance.
293 Comput. Struct. Biotechnol. J., 20, 5378–5392.

294 VAN BORM S., WANG J., GRANBERG F. & COLLING A. (2016). Next-generation sequencing workflows in veterinary
295 infection biology: towards validation and quality assurance. *Rev. sci. tech. Off. int. Epiz.*, **35**, 67–81.

296 *
297 * *

298 **NB:** There is a WOAHO Collaborating Centre for Viral Genomics and Bioinformatics
299 (please consult the WOAHO Web site:
300 <https://www.woah.org/en/what-we-offer/expertise-network/collaborating-centres/#ui-id-3>
301 Please contact the WOAHO Collaborating Centre for any further information on HTS-BCG.

302 **NB:** FIRST ADOPTED IN 2016.

5
6 CHAPTER 1.1.9.

7 TESTS FOR STERILITY AND FREEDOM FROM
8 CONTAMINATION OF BIOLOGICAL MATERIALS
9 INTENDED FOR VETERINARY USE

10 INTRODUCTION

11 *The international trade-related movements of biological materials intended for veterinary use are*
12 *subject to restrictions imposed to minimise the spread of animal and human pathogens. Countries*
13 *may impose requirements for proof-of-freedom testing before allowing the regulated importation of*
14 *materials of animal derivation and substances containing such derivatives. Where chemical or*
15 *physical treatments are inappropriate or inefficient, or where evidence of the effectiveness of the*
16 *treatment is lacking, there may be general or specific testing requirements imposed by authorities of*
17 *countries receiving such materials. This chapter provides guidance on the approach to regulated*
18 *testing, particularly as might be applied to the movement of vaccine master seed and master cell*
19 *stocks, and to related biological materials used in manufacturing processes. While the onus for*
20 *ensuring safety of a product remains with the manufacturer and may be regulated by therapeutic*
21 *guidelines, this chapter provides procedures that are designed to minimise the risk of undetected*
22 *contaminants in veterinary therapeutics and biological reagents causing the cross-border spread of*
23 *agents of concern to importing countries. Farsang & Kulcsar (2012) and WHO (2015) describe case*
24 *studies of veterinary and human vaccines contaminated with extraneous agents and findings support*
25 *the need of accurate and validated amplification and detection methods as key elements for effective*
26 *detection and control. Further examples are given in Section G.H. Protocol examples below. Control*
27 *of contamination with transmissible spongiform encephalopathy (TSE) agents is not covered in this*
28 *chapter because standard testing and physical treatments cannot be used to ensure freedom from*
29 *these agents. Detection methods are described in Chapter 3.4.5. Bovine spongiform encephalopathy.*

30 *Sterility is defined as the absence of viable microorganisms, which for the purpose of this chapter,*
31 *includes viruses. It should be achieved using aseptic techniques and validated sterilisation methods,*
32 *including heating, filtration, chemical treatments, and irradiation that fits the intended purpose.*
33 *Freedom from contamination is defined as the absence of specified viable microorganisms. This may*
34 *be achieved by selecting materials from sources shown to be free from specified microorganisms*
35 *and by conducting subsequent procedures aseptically. Adequate assurance of sterility and freedom*
36 *from contaminating microorganisms can only be achieved by proper control of the primary materials*
37 *used and their subsequent processing. Tests on intermediate products are necessary throughout the*
38 *production process to check that this control has been achieved.*

39 *Biological materials subject to contamination that cannot be sterilised before or during use in vaccine*
40 *production, such as ingredients of animal origin, e.g. serum and trypsin, primary and continuous cell*
41 *lines, and viral, ~~or~~ bacterial or parasitic seed stocks, etc., should be tested for viable extraneous*
42 *agents before use. Assays to detect viral contaminants, if present, can be achieved by various culture*
43 *methods, including use of embryonated eggs, which are supported by cytopathic effects (CPE)*
44 *detection/embryo death, fluorescent antibody techniques and suitable (fit for purpose), methods such*

45 as polymerase chain reaction (PCR) and antigen detection ELISA (enzyme-linked immunosorbent
46 assay). As is explained in more detail in this chapter care must be taken when using PCR and ELISA
47 techniques for detection as such tests do not distinguish viable from non-viable agent detection.
48 Specific assays to detect other contaminants, such as fungi, protozoa and bacteria (including
49 rickettsia and mycoplasma) are also described.

50 Testing procedures should be validated and found to be “fit for purpose” following Chapter 1.1.6.
51 Validation of diagnostic assays for infectious diseases of terrestrial animals, where possible.

52 It is a requirement of many regulators, that a laboratory testing report notes the use of validated
53 procedures and describes the validated procedures in detail including acceptance criteria. This gives
54 the regulator transparency in the procedures used in a testing laboratory.

55 The validation assessment of an amplification process in cell culture should include documentation
56 of the history of permissive cell lines used, reference positive controls and culture media products
57 used in the process of excluding adventitious agents, to ensure the process is sound and is not
58 compromised. The validation assessment should give information (published or in-house) of the
59 limitations that may affect test outcomes and an assessment of performance characteristics such as
60 analytical specificity and sensitivity of each cell culture system, using well characterised, reference
61 positive controls.


62 It is the responsibility of the submitter to ensure a representative selection and number of items to be
63 tested. Appendix 1.1.2.1 Epidemiological approaches to sampling: sample size calculations of
64 Chapter 1.1.2 Collection, submission and storage of diagnostic specimens describes the principles
65 to be applied. Chapter 1.1.2 and Chapter 1.1.3 Transport of biological materials describe
66 transportation requirements.

67 A. AN OVERVIEW OF TESTING APPROACHES

68 Although testing is seen as a key component of biosafety in biological products intended for veterinary use, testing
69 is not enough to ensure a given product is free of viable infectious contaminants, and so a holistic, multifaceted
70 approach must be taken. Such an approach includes risk assessment, risk mitigation and management strategies
71 (Barone *et al.*, 2020). In general:

- 72 • Primary materials must be collected from sources shown to be free from contamination and handled in such
73 a way as to minimise contamination and the opportunities for any contaminants to multiply (Figure 1).
- 74 • Materials that are not sterilised and those that are to be processed further after sterilisation must be handled
75 aseptically. Such materials will require further assessment of freedom of contaminants at certain stages of
76 production to assure freedom of adventitious agents.
- 77 • Materials that can be sterilised without their biological activities being affected unduly must be sterilised by a
78 method effective for the pathogens of concern. The method must reduce the level of contamination to be
79 undetectable, as determined by an appropriate sterility test study. If a sterilisation process is used, it shall be
80 validated to demonstrate that it is fit for purpose. Suitable controls will be included in each sterilisation process
81 to monitor efficiency.
- 82 • The environment in which any aseptic handling is carried out must be maintained in a clean state, protected
83 from external sources of contamination, and controlled to prevent internal contamination. Rules governing
84 aseptic preparation of vaccines are documented in Chapter 2.3.3 *Minimum requirements for the organisation
85 and management of a vaccine manufacturing facility*.

86



88

89 Some procedures have been properly validated and found to be fit for purpose, whilst others may have undergone
90 only limited validation studies. For example, methods for bacterial and fungal sterility may have not been formally
91 validated although they have been used for many years. In particular, *in-vivo* and *in-vitro* methods have essentially
92 unknown sensitivity and specificity (Sheets *et al.*, 2012) though there is an accepted theoretical sensitivity, regarding
93 cell culture of 1 plaque-forming unit (PFU). For example, an evaluation of methods to detect bovine and porcine
94 viruses in serum and trypsin based on United States (of America) Code of Federal Regulations, Title 9 (9CFR)
95 revealed gaps in sensitivity, even within virus families (Marcus-Secura *et al.*, 2011). It is therefore important to
96 interpret, and report results in the light of specific conditions of cultures employed and considering sensitivity and
97 specificity of detection systems.

98 Newer, more sensitive methods such as molecular assays may afford the ability to detect contaminants, which may
99 not be successfully amplified in traditional culturing systems. The detection range can be broadened by using family
100 specific primers and probes if designed appropriately. However, most, if not all molecular-based tests are also able
101 to detect evidence for non-infectious contaminants, such as traces of nucleic acid from inactivated contaminants.
102 Note: molecular assays if not designed as fit for purpose may miss detection of contaminating agents or lack
103 sensitivity to do so (Hodinka, 2013).

104 More recently metagenomic high throughput sequencing (HTS) workflows have shown potential for quality control
105 of biological products (van Borm *et al.*, 2013) and vaccines (Baylis *et al.*, 2011; Farsang & Kulcsar, 2012; Neverov
106 & Chumakov, 2010; Onions & Kolman, 2010; Victoria *et al.*, 2010) in particular for the identification and
107 characterisation of unexpected highly divergent pathogen variants (Miller *et al.*, 2010; Rosseel *et al.*, 2011) that
108 may remain undetected using targeted diagnostic tests. Nevertheless, targeted assays, e.g. amplification in cell
109 culture followed by polymerase chain reaction (PCR) may be superior to HTS for specific agent detection (Wang *et al.*,
110 2014) due to lack of sensitivity of HTS at this time. Chapter 1.1.7. gives an overview of the standards for high
111 throughput sequencing, bioinformatics and computational genomics. Similarly, recent improvements in protein and
112 peptide separation efficiencies and highly accurate mass spectrometry have promoted the identification and
113 quantification of proteins in a given sample. Most of these new technologies are broad screening tools, limited by
114 the fact that they cannot distinguish between viable and non-viable organisms.

115 Given the availability of new technologies, there will be future opportunities and challenges to determine presence
116 of extraneous agents in biologicals intended for veterinary use for industry and regulators. Problems can arise when
117 the presence of genome positive results are interpreted as evidence for the presence of contamination (Mackay
118 & Kriz, 2010). When using molecular technologies, it is important to understand the correlation between genome
119 detection and detection of live agent. It cannot be assumed that detection of genome corresponds to the presence
120 of an infectious agent.

121 B. LIVING VIRAL VACCINES FOR ADMINISTRATION BY INJECTION, OR 122 THROUGH DRINKING WATER, SPRAY, OR SKIN SCARIFICATION

- 123 1. Materials of animal origin should be sterilised and obtained from healthy animals that, in so far as is possible,
124 should be shown to be free from pathogens that can be transmitted from the species of origin to the species
125 to be vaccinated, or any species in contact with them by means of extraneous agents testing.
- 126 2. Seed lots of virus, any continuous cell line and biologicals used for virus growth should be shown to be free
127 from bacteria, fungi, mycoplasmas, protozoa, rickettsia, and extraneous viruses that can be transmitted from
128 the species of origin to the species to be vaccinated or any species in contact with them.

129 For production of vaccines in embryonated chicken eggs and the quality control procedures for these vaccines,
130 it is recommended that eggs from specific pathogen-free birds should be used.

131 3. Each batch of vaccine should pass tests for freedom from extraneous agents that are consistent with the
132 importing country's requirements for accepting the vaccine for use. Some examples of published methods that
133 document acceptable testing processes in various countries include:

- 134 • Code of Federal Regulations, Title 9 (9CFR) (of the United States of America) (2015).
- 135 • Department of Agriculture, Forest and Fisheries (Australia) (2013).
- 136 • Department of Agriculture, Forest and Fisheries (Australia) (2021b) Live Veterinary Vaccines.
- 137 • Regulation on Veterinary Drug Administration (China [People's Rep. of]) (2020).
- 138 • European Medicines Agency Sciences Medicines Health (2016).
- 139 • European Pharmacopoeia, 11th Edition (2023).
- 140 • World Health Organization (WHO) (1998; 2013).

141 4. Tests for freedom of contamination should be appropriate to prove that the vaccine is free from viable
142 extraneous viruses, bacteria including rickettsia and mycoplasmas, fungi, and protozoa. Each country will
143 have requirements as to what agents should be tested for and by which procedures. Such tests will include
144 amplification of extraneous agents using cell culture that is susceptible to known viruses of the species of
145 concern, tests in embryonated eggs, bacterial, mycoplasma and fungal culturing techniques and, where there
146 is no alternative, animal inoculation. Use of antisera to 'inactivate' the living virus seed or vaccine prior to
147 exclusion of extraneous agents is recommended to ensure testing in permissive amplification systems
148 (including culture) is sensitive. PCR, fluorescence antibody test (FAT), presence of colonies or cytopathic
149 effects (CPE) and antigen detection ELISA can be used for detection purposes after amplification using
150 culturing techniques to improve specificity and sensitivity. If *in-vitro* or *in-vivo* amplification of the target agent
151 is not possible, direct PCR may be useful if validated for this purpose.

152 C. INACTIVATED VIRAL, AND BACTERIAL AND PARASITIC VACCINES

153 1. Each batch of vaccine shall pass a test for inactivation of the vaccinal seed and should include inactivation
154 studies on representative extraneous agents if the virus, ~~or bacterial~~ or parasitic seed has not already been
155 tested and shown to be free from extraneous agents. An example of a simple *in-vitro* inactivation study could
156 include ~~assessment of the titre of live vaccine before and after inactivation and~~ assessing the log₁₀ drop in titre
157 ~~during in cell culture before and after~~ the inactivation process for a virus vaccine. This would give an indication
158 of the efficacy of the inactivation process. There is evidence that titration tests may not have sufficient
159 sensitivity to ensure complete inactivation. In these circumstances, a specific innocuity test would need to be
160 developed and validated to be fit for increased sensitivity. To increase sensitivity more than one passage
161 would be required depending on the virus, ~~or bacteria~~ or parasite of concern. An example of this approach
162 can be found at:
163 https://www.aphis.usda.gov/animal_health/vet_biologics/publications/memo_800_117.pdf (accessed
164 20/09/2024).

165 2. If studies on representative extraneous agents are required, then spiking inactivated vaccine with live
166 representative agents and following the example of an inactivation study could be useful. The inactivation
167 process and the tests used to detect live agent after inactivation must be validated and shown to be suitable
168 for their intended purpose.

169 In addition, each country may have its own requirements for sourcing or tests for sterility as detailed in Section
170 B above.

171 D. LIVING BACTERIAL VACCINES

172 1. See Section B.

173 2. Seed lots of bacteria shall be shown to be free from other bacteria as well as fungi and mycoplasmas,
174 protozoa, rickettsia, and extraneous viruses. Agents required for exclusion will be dependent on the country
175 accepting the vaccine for use. Use of antibiotics to 'inactivate' the living bacterial seed or vaccine prior to
176 exclusion of ~~viruses and fungi~~ extraneous agents is recommended to ensure testing in permissive amplification
177 systems (including culture) is sensitive. Due to the difficulties and reduced sensitivity in exclusion of
178 extraneous bacteria and some mycoplasma, protozoa, and rickettsia from high-titred seed lots of bacteria, the
179 use of narrow-range antibiotics aimed specifically at reducing seed lot bacteria is useful if antibiotics do not
180 affect the growth of bacteria being excluded. The optimal concentration of antibiotics can be determined in a
181 dilution experiment such as documented in 9CFR Section 113.25(d). Other methods of exclusion of
182 extraneous bacteria from bacterial seeds may include filtering for size exclusion such as removing bacteria

183 seed to look for mycoplasma contamination and use of selective culturing media. Such processes would
184 require verification to ensure the process does not affect the sensitivity of exclusion of extraneous agents of
185 concern.

186 3. Sonication of a living bacterial seed may be useful when excluding specific viral agents. Once again, the
187 inactivation procedure would require a verification process to ensure the adventitious virus being excluded is
188 not affected by the treatment. Use of a suitable reference virus control during the exclusion process would be
189 required.

190 4. Direct PCR techniques may be useful when culturing processes fail to be successful in detecting extraneous
191 bacteria from live bacterial seeds or vaccines.

192 **E. LIVING PARASITIC VACCINES**

193 **1. See Section B.**

194 **2. Seed lots of live parasites shall be shown to be free from other parasites as well as bacteria, fungi and**
195 **mycoplasmas, protozoa, rickettsia and extraneous viruses. Agents required for exclusion will be dependent**
196 **on the country accepting the vaccine for use. Use of antiparasitic agents to 'inactivate' the living parasite seed**
197 **or vaccine prior to exclusion of extraneous agents is recommended to ensure testing in permissive**
198 **amplification systems are sensitive (See Section H.5.5. Test 5. Test for chicken anaemia virus [CAV] for an**
199 **example of a Coccidiosis vaccine).**

200 **E.F. SERA, PLASMA AND DIAGNOSTIC AGENTS FOR**

201 **ADMINISTRATION TO ANIMALS**

202 Some countries require quarantine, health certification, and tests for specific diseases to be completed for all serum
203 and plasma donor animals, for example, 9CFR (2015) and Australian Quarantine Policy and Requirements for the
204 Importation of Live and Novel Veterinary Bulk and Finished Vaccines (1999). For some diseases, for example
205 equine infectious anaemia, the product (plasma) must be stored until the seroconversion period has been exceeded
206 and the donors tested negative.

207 **F.G. EMBRYOS, OVA, SEMEN**

208 Special precautions must be taken with relation to the use of embryos, ova, semen (Hare, 1985). Most countries
209 will have regulatory guidelines for import of these biologicals for veterinary use. Such guidelines can be found at
210 various websites such as the European Commission (2015), FAO and Department of Agriculture Forest and
211 Fisheries (2021a; 2021b), though some guidelines may give more detail in regard to the food safety aspect.

212 **G.H. PROTOCOL EXAMPLES**

213 **1. Introduction**

214 This section provides some examples to illustrate scope and limitations of testing protocols. It is not intended to be
215 prescriptive or exhaustive. Examples are based on standards and published methods to increase the sensitivity for
216 exclusion of live adventitious agents, using general and specific techniques.

217 In principle, proposed testing represents attempted isolation of viable agents in culturing systems normally
218 considered supportive of the growth of each specified agent or group of general agents. After amplification, potential
219 pathogens can be detected further, by sensitive and specific diagnostic tests such as FAT or PCR as required.
220 General detection systems can include haemabsorbance and CPE by immunohistochemistry staining methods.
221 The example procedures for detection of contamination testing and general detection of virus, fungi, protozoa and
222 bacteria (including rickettsia and mycoplasma) described below are derived from standards such as the 9CFR
223 (2015), European Pharmacopoeia, 11th Edition (2023), European Medicines Agency Sciences Medicines Health
224 (2016), Department of Agriculture, Forest and Fisheries (Australia) (2013) and World Health Organization (1998;
225 2012).

226 Individual countries or regions should adopt a holistic, risk-based approach to determine the appropriate testing
227 protocols based on their animal health status. As well as applying general testing procedures documented in

228 national or regional standards as mentioned above, it may be necessary to apply rigorous exclusion testing for
229 specific agents that are exotic to the country or region of concern.

230 General procedures do not necessarily detect all extraneous agents that may be present in biological material;
231 however, they are useful as screening tests. Some examples of agents that may require specific methods for
232 detection in biologicals refer to Table 1 below. Procedures documented in the Review of Published Tests to Detect
233 Pathogens in Veterinary Vaccines Intended for Importation into Australia (2013) available from the Department of
234 Agriculture, Forest and Fisheries are able to address such agents in offering sensitive testing approaches based
235 on reputable publications. A reflection paper published by the Committee of Veterinary Medicinal Products (CVMP)
236 in (2016), lists specific test method approaches for a number of agents that cannot be excluded using general test
237 procedures (Table 1).

238 Exclusion of specific agents requires procedures that maximise sensitivity by providing ideal amplification and
239 detection of the pathogen in question. Extraneous agents, for example, Maedi Visna virus (and other retroviruses),
240 *Trypanosoma evansi* and porcine respiratory coronavirus are difficult to culture even using the most sensitive
241 approaches. In these circumstances, application of molecular assays directly to the biological material, assessing
242 for the presence of nucleic acid from adventitious agents offers an alternative, though detection of the presence of
243 non-viable and host associated agents is also possible.

244 Table 1 gives examples of causative infectious agents that may be present in animal biologicals intended for
245 veterinary use, for example PCV-1 in a rotavirus vaccine (WHO, 2015). BVDV is well known for its presence in
246 many bovine associated biologicals, including cell culture. More recently, non-CPE pestivirus, BVD type 3 (HoBi-
247 like) are found in foetal calf serum and cell culture. Classical Swine fever has contaminated various porcine cell
248 lines used for African swine fever and FMDV diagnosis, and thus the potential for contamination of porcine based
249 vaccines. PEDV is linked to spray-dried porcine plasma used for feed. This is not an exhaustive list of agents of
250 concern or by any means required for exclusion by every country based on risk, they are examples of infectious
251 agents that are not culturable using general culturing procedures and require use of specialised culturing processes
252 and specific detection processes. Notably, some subtypes of an agent type may be detectable by general methods,
253 and some may require specialised testing for detection. For example, bovine adenovirus subgroup 1 (serotypes 1,
254 2, 3 and 9) can be readily isolated using general methods (Vero cells) however bovine adenovirus subgroup 2
255 (serotypes 4, 5, 6, 7, 8 and 10) are not readily isolated and required specialised methods for isolation.

256 Table 1. Examples of infectious agents of veterinary importance
257 that require specialised culturing and detection techniques

Rotaviruses	Pestiviruses (non-CPE)	Turkey rhinotracheitis
Porcine epidemic diarrhoea virus	Bluetongue virus	<i>Brucella abortus</i> (see Section G-H.2.3)
Porcine circoviruses	Swine pox virus	Rickettsias
Swine/equine influenza, some strains	Some adenoviruses	Protozoa
Bovine respiratory syncytial virus	Rhabdoviruses (e.g. rabies virus)	Some fungi (e.g. <i>Histoplasma</i>)

258 2. Example of detection of bacteria and fungi

259 2.1. General procedure for assessing the sterility of viable bacteria and fungi

260 Standard tests for detecting extraneous bacteria and fungi (sterility testing) in raw materials, master cell
261 stocks, or final product are the membrane filtration test or the direct inoculation sterility test.

262 For the membrane filtration technique, a filter having a nominal pore size not greater than 0.45 µm and
263 a diameter of at least 47 mm should be used. Cellulose nitrate filters should be used if the material is
264 aqueous or oily; cellulose acetate filters should be used if the material is strongly alcoholic, oily or oil-
265 adjuvanted. Immediately before the contents of the container or containers to be tested are filtered, the
266 filter is moistened with 20–25 ml of Diluent A or B.

267 2.1.1. Diluent A

268 Diluent A is for aqueous products or materials. Dissolve 1 g peptic digest of animal tissue in water
269 to make 1 litre, filter, or centrifuge to clarify, adjust the pH to 7.1 ± 0.2, dispense into containers
270 in 100 ml quantities, and sterilise by steam.

271 2.1.2. Diluent B

272 Diluent B is for oil-adjuvanted products or materials: Add 1 ml polysorbate 80 to 1 litre Diluent A,
273 adjust the pH to 7.1 ± 0.2, dispense into containers in 100 ml quantities, and sterilise by steam.

274 If the biological being tested has antimicrobial properties, the membrane is washed three times after
 275 sample application with approximately 100 ml of the appropriate diluent (A or B). The membrane is then
 276 transferred to culture media, aseptically cut into equal parts and placed in media, or the media is
 277 transferred to the membrane in the filter apparatus. If the test sample contains merthiolate as a
 278 preservative, FTM (fluid thioglycollate medium) is used in test vessels incubated at both 30–35°C and
 279 20–25°C. Growth should be clearly visible after an appropriate incubation time (see Section H.2.1.3
 280 *Example of growth promotion and test interference*). If the test sample is a killed biological without
 281 merthiolate, or a live bacterial biological, FTM is used at 30–35°C and SCDM (soyabean casein digest
 282 medium) at 20–25°C. If the sample tested is a live viral biological, SCDM is used at both incubation
 283 temperatures. It has been suggested that sulfite-polymyxin-sulfadiazine agar be used to enhance the
 284 detection of *Clostridium* spp. when the membrane filtration technique is used (Tellez *et al.*, 2005).

285 If direct inoculation of culture media is chosen, a sterile pipette or syringe and needle are used to
 286 aseptically transfer the biological material directly into liquid media. If the biological being tested has
 287 antimicrobial properties, the ratio of the inoculum to the volume of culture medium must be determined
 288 before the test is started, for example as explained in 9CFR 113.25(d) and detailed testing procedures
 289 can be found for example in supplemental assay method USDA SAM 903
 290 https://www.aphis.usda.gov/animal_health/vet_biologics/publications/sam903.pdf (accessed
 291 20/09/2024). To determine the correct medium volume to negate antimicrobial activity, 100 CFU of the
 292 control microorganisms listed in Table 2 are used. If the test sample contains merthiolate as a
 293 preservative, or if it is a killed biological without merthiolate or a live bacterial biological, see paragraph
 294 above for recommendations. If the test sample is a live viral biological, SCDM is used at both incubation
 295 temperatures. If the inactivated bacterial vaccine is a clostridial biological, or contains a clostridial
 296 component, the use of FTM with 0.5% added beef extract (FTMB) in place of FTM is preferred. It may
 297 also be desirable to use both FTM and SCDM for all tests.

298 Table 2. Some American Type Culture Collection ¹ (ATCC) strains with their respective
 299 medium and incubation conditions

Medium	Test microorganism	Incubation	
		Temperature (°C)	Conditions
FTM	<i>Bacillus subtilis</i> ATCC # 6633	30–35	Aerobic
FTM	<i>Candida krusei</i> ATCC # 6258	20–25	Aerobic
SCDM	<i>Bacillus subtilis</i> ATCC # 6633	30–35	Aerobic
SCDM	<i>Candida krusei</i> ATCC # 6258	20–25	Aerobic
FTMB	<i>Clostridium sporogenes</i> ATCC # 11437	30–35	Anaerobic
FTMB	<i>Staphylococcus aureus</i> ATCC #6538	30–35	Aerobic
PDA ²	<i>Aspergillus brasiliensis</i> ATCC #16404	20–25	Aerobic
Nutrient agar, nutrient broth	<i>Pseudomonas aeruginosa</i> ATCC #9027	30–35	Aerobic

300 For both membrane filtration and direct inoculation sterility tests, all media are incubated for no fewer
 301 than 14 days. At intervals during incubation, and after 14 days' incubation, the test vessels are examined
 302 for evidence of microbial growth. Microbial growth should be confirmed by subculture and Gram stain.

303 2.1.3. Example of growth promotion and test interference

304 The sterility of the media should be confirmed by incubating representative containers at the
 305 appropriate temperature for the length of time specified for each test.

306 The ability of the culture media to support growth in the presence and absence of product, product
 307 components, cells, seeds, or other test material should be validated for each product to be tested,
 308 and for each new batch or lot of culture media for example as outlined in 9CFR 113.25(b). Detailed
 309 testing procedures can be found for example in USDA SAMs 900-902, See USDA APHIS
 310 [Supplemental Assay Methods – 900 Series (accessed 4 July 2022)].

¹ American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209, USA.

² PDA: potato dextrose agar

311 To test for ability to support growth in the absence of the test material, media should be inoculated
312 with 10–100 viable control organisms of the suggested ATCC strains listed in Table 2 and
313 incubated according to the conditions specified.

314 To test for ability of the culture media to support growth in the presence of the test material,
315 containers should be inoculated simultaneously with both the test material and 10–100 viable
316 control organisms. The number of containers used should be at least one-half the number used
317 to test the product or product component. The test media are satisfactory if clear evidence of
318 growth of the control organisms appears in all inoculated media containers within 7 days. In the
319 event that growth is evident, the organism should be identified to confirm that it is the organism
320 originally added to the medium. The sterility test is considered invalid if any of the media show
321 inadequate growth response, or if the organism recovered, is not the organism used to inoculate
322 the material.

323 If the material being tested renders the medium turbid so that the presence or absence of
324 microbial growth cannot be readily determined by visual examination, 14 days after the beginning
325 of incubation transfer portions (each not less than 1 ml) of the medium to fresh vessels of the
326 same medium and then incubate the original and transfer vessels for not less than 4 days.

327 **2.2. Example of general procedure for testing seed lots of bacteria and live bacterial** 328 **biologicals for purity**

329 Each seed lot of bacteria or batch of live bacterial biological should be tested for purity by inoculation of
330 SCDM, which is incubated at 20–25°C for 14 days, and FTM, which is incubated at 30–35°C for 14 days.
331 Using good practices in sterile technique to avoid laboratory contamination, a sterile pipette or syringe
332 and needle is used to aseptically transfer the quantity of biological directly into the two types of culture
333 medium. The minimum ratio of inoculum to culture medium is 1/15. Both positive and negative controls
334 are set up as well.

335 If the inoculum or growth of the bacterial vaccine renders the medium turbid so that the absence of
336 atypical microbial growth cannot be determined by visual examination, subcultures should be made from
337 all turbid tubes on day 3 through until day 11. Subculturing is done by transferring 0.1–1.0 ml to
338 differential broths and agar and incubating for the balance of the 14-day period. Microscopic examination
339 by Gram stain should also be done.

340 If no atypical growth is found in any of the test vessels when compared with a positive control included
341 in the test, the lot of biological may be considered satisfactory for purity. If atypical growth is found but it
342 can be demonstrated by a negative control that the media or technique were faulty, then the first test
343 should be repeated. If atypical growth is found but there is no evidence invalidating the test, then a retest
344 should be conducted. Twice the number of biological containers and test vessels of the first test are used
345 in the retest. If no atypical growth is found in the retest, the biological could be considered to be
346 satisfactory for purity but the results from both the initial and retest should be reported for assessment
347 by the individual countries relevant regulatory agency if the laboratory is sure that the first test result was
348 not due to in-laboratory contamination. If atypical growth is found in any of the retest vessels, the
349 biological is considered to be unsatisfactory for purity. If, however, it can be demonstrated by controls
350 that the media or technique of the retest were faulty, then the retest should be repeated.

351 **2.3. Example of a specific test procedure for exclusion of *Brucella sp.* including *B. abortus*** 352 **(where general testing is not sufficient)**

353 It should be confirmed that each batch of culture medium supports the growth of *B. abortus* by inoculating
354 plates and flasks of biphasic medium with a known number of cells (around 100) of the fastidious *B.*
355 *abortus* biovar 2. If the media supports the growth of this biotype it will support all other biovars.

356 Inoculate 1.0 ml of prepared master or working live agent or cell seed material (not containing antibiotics)
357 by inoculating 50 µl of the test product into each of 10 flasks containing biphasic medium. At the same
358 time 10 plates of serum dextrose agar (SDA) are inoculated with 50 µl of inoculum and spread with a
359 sterile bent glass Pasteur pipette or hockey stick. An un-inoculated serum dextrose agar plate and a
360 biphasic flask are also set up at the same time as negative controls.

361 For assessment of inhibitory substances 50 µl of previously prepared master or working ~~viral~~ live agent
362 or cell seed material and 10–100 CFU of *B. abortus* are inoculated on to duplicate SDA plates. Positive
363 controls are prepared by inoculating 10–100 CFU of *B. abortus* on to duplicate SDA plates.

364 All plates and flasks are incubated at 37°C in a 5–10% CO₂ environment. Plates are incubated with the
365 agar uppermost and flasks with the agar slope vertical. Flasks are incubated with the cap loose.

366 Plates are checked for growth of colonies at days 4 and 8 of incubation. The biphasic medium is
367 examined every 4 to 7 days for 28 days. After each examination of the flasks, they are tilted so that the
368 liquid phase runs over the solid phase, then righted and returned to the incubator.

369 During the incubation period, SDA plates with positive control and test material are visually compared
370 with plates with the positive control only and if there is no inhibition of growth of the organism in the
371 presence of the test material, the interference testing test is successful, and testing can be assured to
372 be sensitive.

373 Any signs of growth of suspicious contaminating microorganisms on SDA plates, cloudiness or colonies
374 in biphasic flasks require follow-up testing by PCR to confirm whether *B. abortus* is present.

375 **2.4. Example of a general procedure for detection of *Salmonella***

376 Each batch of biological reagents made in eggs should be free from contamination with *Salmonella*. This
377 testing must be done before bacteriostatic or bactericidal agents are added. Five samples of each batch
378 should be tested; 5 ml or one-half of the container contents, whichever is the lesser, of the sample should
379 be used to inoculate 100 ml of tryptose broth and tetrathionate broth. The inoculated broths should be
380 incubated for 18–24 hours at 35–37°C. Transfers from these broths should be made on to MacConkey
381 and *Salmonella*–*Shigella* agar, incubated for 18–24 hours, and examined. If no growth typical of
382 *Salmonella* is noted, the agar plates should be incubated an additional 18–24 hours and again examined.
383 If colonies typical of *Salmonella* are observed, further subculture on to suitable differential media should
384 be made for positive identification. Sensitive PCR tests are available for the detection of *Salmonella*
385 serovars in cultured material. If *Salmonella* is detected, the batch is determined to be unsatisfactory.

386 **3. Example of detection of *Mycoplasma***

387 **3.1. An example of a specific procedure for exclusion of *Mycoplasma mycoides* subsp. 388 *mycoides* (where general testing is not sufficient)**

389 Prior to beginning testing it is necessary to determine that each batch of media promotes the growth of
390 *M. mycoides* subsp. *mycoides* (*Mmm*) type strain PG1. General mycoplasma broth and agar are used
391 but contain porcine serum as a supplement. Each batch of broth and agar is inoculated with 10–100 CFU
392 of *Mmm*. The solid medium is suitable if adequate growth of *Mmm* is found after 3–7 days' incubation at
393 37°C in 5–10% CO₂. The liquid medium is suitable if the growth on the agar plates subcultured from the
394 broth is found by at least the first subculture. If reduced growth occurs another batch of media should be
395 obtained and retested.

396 1 ml of cell or virus seed to be tested is inoculated into 9 ml of the liquid medium and 100 µl on to solid
397 mycoplasma agar. The volume of the product is inoculated so that it is not more than 10% of the volume
398 of the medium. The liquid medium is incubated at 37°C in 5–10% CO₂ and 100 µl of broth is subcultured
399 on to agar at days 7, 14 and 21. The agar plates are incubated at 37°C in 5–10% CO₂ for no fewer than
400 14 days, except those corresponding to day 21 subculture, which are incubated for 7 days. An un-
401 inoculated mycoplasma broth and agar plate are incubated as negative controls. For assessment of
402 inhibitory substances, inoculate 1 ml of sample to be tested into 9 ml of the liquid medium and 100 µl on
403 to solid medium and add 10–100 CFU of *Mmm* to each. Prepare positive control by inoculating 9 ml of
404 mycoplasma broth and a mycoplasma agar plate with 10–100 CFU of *Mmm*. Incubate as for samples
405 and negative controls.

406 During incubation time, visually compare the broth of the positive control with sample present with the
407 positive control broth and, if there is no inhibition of the organism either the product possesses no
408 antimicrobial activity under the conditions of the test, or such activity has been satisfactorily eliminated
409 by dilution. If no growth or reduced growth of *Mmm* is seen in the liquid and solid medium with test sample
410 when compared with the positive control, the product possesses antimicrobial activity, and the test is not
411 satisfactory. Modifications of the conditions to eliminate the antimicrobial activity and repeat test are
412 required.

413 If antimicrobial activity is present it is necessary to dilute the test product further. Repeat the test above
414 using 1.0 ml of sample in 39 ml of mycoplasma broth and then inoculate with 10–100 CFU of *Mmm* and
415 incubate as above. All broths and plates are examined for obvious evidence of growth. Evidence of
416 growth can be determined by comparing the test culture with the negative control, the positive control,
417 and the inhibition control.

418 If evidence of microbial growth is found in the test samples the contaminating bacterium will be identified
419 and confirmed as *Mmm* by specific PCR assay.

420 **3.2 General testing for exclusion of *Mycoplasma* spp.**

421 General testing for exclusion of *Mycoplasma* spp. that are less fastidious may require up to 28 days in
422 culture, using general mycoplasma media. Some mycoplasmas cannot be cultivated, in which case the
423 live biological sample will have to be tested using an indicator cell line such as Vero cells, DNA staining,
424 or PCR methods.

425 Further detailed procedures can be found in Veterinary Medicinal Products, VICH GL34:
426 [https://www.ema.europa.eu/en/vich-gl34-biologicals-testing-detection-mycoplasma-contamination-](https://www.ema.europa.eu/en/vich-gl34-biologicals-testing-detection-mycoplasma-contamination-scientific-guideline)
427 [scientific-guideline](https://www.ema.europa.eu/en/vich-gl34-biologicals-testing-detection-mycoplasma-contamination-scientific-guideline)

428 and

429 USDA SAM 910: https://www.aphis.usda.gov/animal_health/vet_biologics/publications/910.pdf, (both
430 accessed 20/09/2024).

431 **4. Example of detection of rickettsia and protozoa**

432 There are no general test procedures for exclusion of rickettsia or protozoa. Procedures to exclude specific agents
433 of concern such as *Coxiella burnetii* (Q fever), *Ehrlichia canis*, *Trypanosoma evansi* and *Babesia caballi* can be
434 found for example, in the Review of Published Tests to detect pathogens in veterinary vaccines Intended for
435 Importation into Australia (Australian Government Department of Agriculture, Forest and Fisheries (2013)). The
436 review is based on the reading and interpretation of applicable published papers from reputable journals and are
437 regarded as examples of sensitive methods for detection of specified agents.

438 **4.1. Example of a specific test protocol based on published methods for exclusion of** 439 ***Babesia caballi* and *Theileria equi***

440 *Babesia caballi* and *Theileria equi* can be cultured *in vitro* in 10% equine red blood cells (RBC) in
441 supportive medium supplemented with 40% horse serum and in a micro-aerophilic environment. Culture
442 isolation of *T. equi* is more sensitive than for *B. caballi*. Giemsa-stained blood smears are prepared from
443 cultures daily for 7 days (Avarzed *et al.*, 1997; Ikadai *et al.*, 2001). *Babesia caballi* is characterised by
444 paired merozoites connected at one end. *Theileria equi* is characterised by a tetrad formation of
445 merozoites or 'Maltese cross'. Confirmation of the diagnosis is by PCR (see Chapter 2.5.8 *Equine*
446 *piroplasmosis*). Molecular diagnosis is recommended for the testing of biological products that do not
447 contain whole blood or organs. Molecular diagnosis by PCR or loop-mediated isothermal amplification
448 (LAMP) assay are the most sensitive and specific testing methods for detection of the pathogens of
449 equine *piroplasmosis* (Alhassan *et al.*, 2007).

450 **5. Example of a procedure for extraneous testing of a live parasitic vaccine**

451 Live parasitic vaccines can be assessed using testing procedures much the same as those for living viral/bacterial
452 vaccines. The following is an example to exclude avian extraneous agents from a live *Eimeria* spp. vaccine,
453 produced in live chickens and intended for chicken immunisation. Coccidiosis vaccine (live) for chickens is a
454 preparation of sporulated oocysts of a suitable line or lines of species of coccidial parasites (*Eimeria* spp.) and
455 vaccine stocks are produced in specific pathogen free (SPF) chickens. Manufacture and assessment of the vaccine
456 is well described in European Pharmacopoeia (2023). For the exclusion of extraneous agents in live vaccine,
457 reference is made in the specific Monograph *Coccidiosis vaccine (Live) for Chickens* to Monograph 2.6.24: *Avian*
458 *viral vaccines: test for extraneous agents in seed lots*, with the instruction to follow Tests 1 to 6. In using the tests
459 prescribed, the master seed lot must use organisms that are not more than five passages from the master seed lot
460 at the start of the tests.

461 For procedures noted in European Pharmacopoeia Chapter 2.6.24, general provisions a) to d), f) and h) also apply
462 to the assessment of Coccidiosis vaccine. To summarise, chickens, chicken material and cell cultures used for
463 testing must be free from specified pathogens; cell cultures used must be well characterised, a minimum of two
464 replicates for cell culture, although more may be prescribed; test substance must contain at least 10 doses of
465 vaccine in inoculum; reagents used in the exclusion/neutralisation of vaccine seed process must be free of inhibitory
466 substances and extraneous antibodies that may affect exclusion of avian extraneous agents. Nucleic acid
467 amplification techniques can be useful in specific detection of various agents.

468

5.1. Test 1. Test for extraneous agents using embryonated hens' eggs

469 Testing material must be diluted and neutralised accordingly to contain at least 10 doses of vaccine in
470 0.2 ml inoculum. 0.2 ml of neutralised seed is then inoculated into:

471 Pass 1

472 i) 10 x 9- to 11-day-old embryonated eggs into the allantoic cavity, check viability for 7 days

473 ii) 10 x 9- to 11-day-old embryonated eggs onto the chorio-allantoic membrane (CAM), check viability
474 for 7 days

475 iii) 10 x 5- to 6-day-old embryonated eggs into the yolk sac, check viability for 12 days.

476 Any deaths in the first 24 hours are discarded as nonspecific. For validity, at least six of ten embryos
477 must survive past 24 hours. Check macroscopically for abnormalities of all embryos and CAMs that die
478 after 24 hours and survivors at the end of the incubation period. Test all allantoic fluid harvests for the
479 presence of haemagglutinating agents.

480 Pool live embryo material and dead embryo material separately for a further pass in eggs following
481 Pass 1 procedure.

482 Seed lot complies if test embryos/CAMs show no macroscopic abnormalities, embryos do not die from
483 toxicity or test material and HA testing of allantoic fluids are negative.

5.2. Test 2. Test in chicken kidney cells

485 Inoculate 0.1 ml test material (prepared as for Test 1) onto 5 x 25 cm² just confluent chicken kidney
486 monolayers. 2 x 25 cm² monolayers are kept as negative control and treated the same way, but with no
487 test material. Incubate for 1 hour to adsorb prior to addition of maintenance media. Incubate for 7 days
488 with 24- to 48-hour checks for CPE. Freeze-thaw at -80°C once or twice between Pass 1 to 2 to break
489 up cells. Subculture cells into Pass 3 for detection assessment. Monolayers required for detection
490 assessment (from each of the five monolayers) include at least a 10 cm² monolayer for Giemsa or
491 haematoxylin and eosin staining, 25 cm² monolayers for haemadsorption of chicken red blood cells and
492 tissue culture supernatant from each flask for haemagglutination (HA) assessment, using chicken red
493 blood cells.

494 Test validity is based on no signs of extraneous agents in negative cultures. The batch complies if there
495 is no evidence of extraneous agents.

5.3. Test 3. Test for avian leukosis viruses (ALV)

497 Inoculate 0.1 ml test material (prepared as for Test 1) onto 5 x 25 cm², replicate just confluent DF-1 cells.
498 Each replicate is to have a total of 50 cm² area = 10 x 25 cm² total. If available, primary/secondary
499 chicken embryo fibroblast cells can be used but must be produced from the tissues of 9- to 11-day-old
500 SPF embryos that are known to be genetically susceptible to subgroups A, B and J of ALV and support
501 growth of only exogenous ALV: Cells from C/E strain of chickens are suitable. Extra 2 x 25 cm² replicate
502 (x 4) monolayers are used as negative control. Extra 2 x 25 cm² replicate monolayers are infected, each,
503 with a suitable strain of ALV subgroup A, B and J (not more than 10 median cell culture infectious doses
504 [CCID₅₀] in 0.1 ml) for use as positive controls (total of 12 positive control flasks.). Incubate for 1 hour to
505 adsorb prior to addition maintenance media. Incubate for a total of at least 9 days, subculturing at 3- to
506 4-day intervals.

507 Retain cells from each passage and harvest at the end of the incubation period. Pooled cells from each
508 set of replicate flasks are washed and resuspended at a count of 10⁷ cells/ml in barbital-buffered saline.
509 Cells are freeze-thawed three times to release any bound antigen and then tested by a complement
510 fixation test for ALV (COFAL) or by antigen-detection ELISA.

511 The test is valid if group specific antigen is detected in at least five of the six positive control replicate
512 monolayers, negative test monolayers are negative for detection of antigen. If more than one of the test
513 monolayers are inconclusive, further testing of cell lysates are required until they are negative.

514 Batch complies if there is no evidence of ALV antigen.

515 **5.4. Test 4. Test for avian reticuloendotheliosis virus (REV)**

516 Inoculate 0.1 ml test material (prepared as for Test 1) onto 5 × 25 cm² just confluent chicken embryo
517 fibroblast monolayers (produced from the tissues of 9- to 11-day-old SPF embryos). Extra 2 × 25 cm²
518 monolayers are used as negative controls and extra 4 × 25cm² monolayers are infected with a suitable
519 strain of REV (not more than 10 CCID₅₀ in 0.1 ml) for use as positive controls. Incubate for 1 hour to
520 adsorb prior to addition maintenance media. Incubate for a total of 10 days, subculturing at 3- to 4-day
521 intervals.

522 The test is not valid if fewer than four of five test monolayers, fewer than three of the four positive controls
523 or neither of the two negative control monolayers survive after any passage.

524 For the last subculture, subculture each of the 11 × flasks into suitable substrates to obtain at least
525 10 cm² monolayer for each flask. Look for the presence of REV by using immunostaining techniques
526 (FA) for detection of the specific agent.

527 The test is valid if at least three of the four positive controls are positive for REV by FA test. Negative
528 controls and test flasks must not be positive by FA to REV.

529 Batch complies if there is no evidence of REV.

530 **5.5. Test 5. Test for chicken anaemia virus (CAV)**

531 Inoculate 0.1 ml test material (prepared as for Test 1) into 5 × 20 ml of MDCC-MSBI cell suspensions at
532 5 × 10⁵ cell/ml, each suspension is placed in a single 25 cm² flask. Extra 2 × cell suspensions in 25 cm²
533 flasks are used as negative controls and 4 × cell suspensions in 25 cm² flasks are infected with a suitable
534 strain of CAV (not more than 10 CCID₅₀ in 0.1 ml) for use as positive controls. Incubate for a total of
535 24 days, subculturing eight times at 3- to 4-day intervals. During the subculture process, indication of
536 CAV can be seen by metabolic colour changes. Media will become red compared with negative control
537 flasks. CPE will also be detected.

538 With the indication of a positive test result or at the end of the incubation period, harvest cells from each
539 flask, centrifuge at low speed to pellet and resuspend cells at around 1 × 10⁶/ml. Dry 25 µl cell suspension
540 on suitable glass slides and fix ready for immunostaining to detect for CAV.

541 The test is valid if at least three of the four positive controls are positive for CAV. Negative controls and
542 test flasks must not be positive by FA to CAV.

543 Batch complies if there is no evidence of CAV.

544 **5.6. Test 6. Test for extraneous agents using chicks**

545 Inoculate at least 10 × 2-week-old chicks with equivalent of 100 doses of vaccine by the intramuscular
546 route and with the equivalent of 10 does by eye drop. If the dosage used is pathogenic to chickens at
547 this age, then older chickens may be used, if required and can be justified. Repeat the inoculations 2
548 weeks later.

549 Chicks are observed for 5 weeks from the day of inoculation. Antimicrobials and are not to be
550 administered during the test period.

551 Test is valid if more than 80% of chicks survive to the end of the testing period.

552 Collect serum from all chicks at the end of testing and test for serum antibodies selecting a test type from
553 each agent listed in Table 3.

554 Clinical disease other than that attributed to the test material, and detection of antibodies of any agent
555 listed in Table 3 gives evidence of presence of extraneous agent(s).

556
557

Table 3. Detection of antibodies of the following agents by the corresponding tests provides evidence of the presence of extraneous agent(s)

<u>Agent</u>	<u>Type of test</u>
<u>Avian adenoviruses group 1</u>	<u>VNT, ELISA, AGID</u>
<u>Avian encephalomyelitis virus</u>	<u>ELISA, AGID</u>
<u>Avian infectious bronchitis virus</u>	<u>ELISA, HI</u>
<u>Avian infectious laryngotracheitis virus</u>	<u>VNT, ELISA, IS</u>
<u>Avian leukosis viruses</u>	<u>VNT, ELISA</u>
<u>Avian nephritis virus</u>	<u>IS</u>
<u>Avian orthoreoviruses</u>	<u>IS, ELISA</u>
<u>Avian reticuloendotheliosis virus</u>	<u>AGID, IA, ELISA</u>
<u>Chicken anaemia virus</u>	<u>IS, ELISA VNT</u>
<u>Egg drop syndrome</u>	<u>IS, ELISA, VNT</u>
<u>Avian infectious bursal disease virus</u>	<u>Serotype 1: AGID, ELISA, VNT</u>
	<u>Serotype 2: VNT</u>
<u>Influenza A virus</u>	<u>AGID, ELISA, HI</u>
<u>Marek's disease virus</u>	<u>AGID</u>
<u>Newcastle disease virus</u>	<u>HI, ELISA</u>
<u>Avian metapneumovirus</u>	<u>ELISA</u>
<u>Salmonella pullorum</u>	<u>SAT</u>

558 AGID: agar gel immunodiffusion; ELISA: enzyme-linked immunosorbent assay; HI: haemagglutination inhibition; IS: immunostaining (including
559 FA: fluorescent assay); SAT: serum agglutination test; VNT: virus neutralisation test.

560 **5.6. Example of detection of virus**

561 In brief, general testing usually includes the use of continuous and primary cell lines of the source species; cells of
562 known susceptibility to likely viral contaminants, which are inoculated for usually a period of 3–4 weeks with weekly
563 subcultures. Virus seeds also require testing on a primary cell line of the species in which the final product is
564 intended. At Day 21 or 28, assessment of the monolayers is done using appropriate histology staining procedures
565 to assess CPE, and haemadsorption with guinea-pig and chicken RBC to assess the presence of haemadsorbing
566 agents. Note that general testing is useful as a screening tool though not sufficiently sensitive enough to detect all
567 viruses of concern to all countries.

568 Specific testing requires test material to be inoculated on to sensitive, susceptible cells lines for the virus to be
569 excluded; the amplification process in cell culture is usually up to 28 days but depending on the virus, may require
570 longer culturing times. Detection of specific viral contaminants is by recognition of CPE in conjunction with more
571 sensitive antigen detection or molecular tests such as FAT and PCR and ELISA after the amplification process in
572 cell culture is completed.

573 All testing using cell lines to amplify for target viruses is contingent on the sensitivity of the cells for the target agent
574 and the ability to recognise the presence of the agent in the cells. The quality, characteristics, and virus permissibility
575 profile of cell lines in use should be determined as fit for purpose and appropriately maintained.

576 If a virus seed is known to cause cytopathic effect (CPE) in a permissive cell line, the effect must be specifically
577 neutralised without affecting the likelihood of isolation of the target agent. The serum must be shown to be free from
578 antibodies against any agents for which the test is intended to detect. Antiserum should be tested for nonspecific
579 inhibiting affects. For a general test, this can be difficult to ascertain. Serum should be of sufficiently high titre to
580 neutralise the seed virus effectively with the use of an approximately equal volume or less of serum. A microplate
581 block titration is useful to determine the amount of the antiserum required to neutralise a known amount of CPE
582 causing virus seed. This is done in the normal conditions required of each test system (e.g. time, temperature, cell
583 type etc.).

584 If a virus seed is known to be high-titred or difficult to neutralise, antiserum can be added to the growth medium in
585 a test system at a final concentration of 1–2%.

586 Cell seed stocks do not require a neutralisation process.

587 **56.1. Example of general testing procedures for the exclusion of viruses from virus and**
588 **cell seed stocks used in production of veterinary vaccines**

589 **56.1.1 Example of amplification in cell culture**

590 Continuous and primary, 75 cm² area monolayers of the source species (and intended species
591 as applicable) are infected with 1 ml of seed stocks and passaged weekly for up to 21–28-days.
592 Depending on the procedure followed, monolayers can be subcultured between passes or
593 freeze/thawed to disrupt cells. Negative and positive controls should be also set up at each pass
594 using the same cell population. Certain relevant viruses may be selected as indicators for
595 sensitivity and interference (positive controls) but these will not provide validation for the broader
596 range of agents targeted in general testing. The final culture is examined for cytopathology and
597 haemadsorption.

598 **56.1.2 Example of general detection procedures: cytopathology**

599 May–Grünwald–Giemsa or H&E staining procedures are used to assess for cytopathological
600 changes associated with virus growth. Monolayers must have a surface area of at least 6 cm²
601 and can be prepared on appropriate chambered tissue culture slides and incubated for 7 days.
602 The plastic wells of the slides are removed leaving the rubber gasket attached to the slide. The
603 slides are rinsed in Dulbecco's phosphate buffered saline (PBS), fixed in acetone, methanol or
604 formalin depending on the stain used and placed on a staining rack. For May–Grünwald–Giemsa
605 staining: the slides are stained for 15 minutes at room temperature with May–Grünwald stain
606 diluted 1/5 with absolute methanol. The May–Grünwald stain is removed by inverting the slides.
607 The slides are then stained for 20 minutes with Giemsa stain diluted 1/15 in deionised water. The
608 Giemsa stain is removed by inverting the slides and rinsing them in deionised water for 10–
609 20 seconds. The slides are air-dried and mounted with a coverslip using paraffin oil. The May–
610 Grünwald–Giemsa stain differentially stains ribonucleoprotein (RNP); DNA RNP stains red-
611 purple, while RNA RNP stains blue. The monolayers are examined with a conventional
612 microscope for the presence of inclusion bodies, an abnormal number of giant cells, or other
613 cytopathology attributable to a viral contaminant of the test product. The inoculated monolayers
614 are compared with suitable control non-inoculated monolayers. If specific cytopathology
615 attributable to an extraneous virus is found, results are reported, and additional specific testing
616 may be conducted.

617 **56.1.3 Example of general detection procedures: haemadsorption**

618 Testing for haemadsorption requires the use of 75 cm² area monolayers established in tissue
619 culture flasks after the 28-day passage period described above. Guinea-pig, chicken, and any
620 other blood for use in this assay is collected in an equal volume of Alsever's solution and may be
621 stored at 4°C for up to 7 days. Immediately prior to use, the stored erythrocytes are again washed
622 by adding 5 ml of blood in Alsever's solution to 45 ml of calcium and magnesium-free PBS (PBSA)
623 and centrifuging in a 50 ml centrifuge tube at 500 *g* for 10 minutes. The supernatant is aspirated,
624 and the erythrocytes are suspended in PBSA and re-centrifuged. This washing procedure is
625 repeated at least twice until the supernatant is clear. Erythrocytes from each species are
626 combined by adding 0.1 ml of each type of packed blood cells to 100 ml of PBSA. The erythrocytes
627 from different species may be kept separate or combined, as desired. To each flask, add 5 ml of
628 the erythrocyte suspension, and incubate the flasks at 4°C for 30 minutes. Monolayers are
629 washed twice with PBSA and examined for haemadsorption. If no haemadsorption is apparent,
630 5 ml of fresh erythrocyte suspension is added to each flask; the flasks are incubated at 20–25°C
631 (room temperature) for 30 minutes, rinsed as before, and examined for haemadsorption.
632 Separate flasks may be used for each incubation temperature if desired. Monolayers are
633 examined for the presence of haemadsorption using an illuminated light box and microscopically.
634 Non-inoculated monolayers are used as negative controls. The PBSA and fresh erythrocytes
635 should prevent most nonspecific haemadsorption from occurring. If specific haemadsorption
636 attributable to an extraneous agent is found, results are reported, and additional specific testing
637 may be conducted.

638 **56.2. Example of specific agent exclusion testing of biologicals used in the production of**
639 **veterinary vaccines**

640 **56.2.1. Example of porcine epidemic diarrhoea virus (PEDV)**

641 Trypsin presence is required at inoculation and in the culture medium for isolation of porcine
642 epidemic diarrhoea virus (PEDV) in Vero cells (CCL81, ATCC) to ensure the virus can enter host

643 cells. Just confluent monolayers are required as under confluent monolayers (<90%) are more
644 sensitive to the presence of trypsin. An over confluent or aging monolayer will not be sensitive for
645 growth of PEDV. Maintenance media (MM) formulation consists of Earle's MEM (minimal
646 essential medium) (with 5.6 M HEPES [N-2-hydroxyethylpiperazine, N-2-ethanesulphonic acid]
647 and glutamine) + 0.3% Tryptose phosphate broth, 0.02% yeast extract and 4 µg/ml TPCK treated
648 trypsin. The addition of the trypsin into MM should occur on the day the media is to be used.

649 Prior to inoculation, confluent 75 cm² monolayers are washed twice with MM to remove growth
650 media containing FCS. Virus or cell seed (1 ml) is added with 1 ml of MM to each monolayer;
651 incubate at 37°C for 2 hours, then add 30 ml/flask of MM. Negative control monolayers of the
652 same size are set up prior to inoculation of test material. Positive and interference controls are
653 set up last, and where possible, in a separate laboratory to avoid contamination. Assessment for
654 sensitivity and interfering substances requires use of reference virus of known titre. A control for
655 interference using co-inoculation of test sample and PEDV needs only to be set up on the first
656 pass. Positive controls should be set up at every pass to ensure each monolayer used gives
657 expected sensitivity. PEDV virus is titrated in log dilutions starting at 10⁻¹ to 10⁻⁶ in MM (depending
658 on the endpoint titre of reference virus) in duplicate rows of 6 wells of a 24-well tissue culture
659 plate. For the interference test, PEDV is titrated in the same dilution series but using MM spiked
660 with a 10% volume of test material. Decant off the growth media and discard. Wash plates to
661 ensure no FCS is present. Two washes using approximately 400 µl/well MM (with trypsin added)
662 are sufficient.

663 Add 100 µl of diluted virus on to each of two duplicate wells. Rock inoculated plates to distribute
664 the inoculum evenly over the surface of the monolayer. Incubate at 37°C with 5% CO₂ for 2 hours
665 then add a further 1 ml volumes/well of MM.

666 After 7 days, 75 cm² monolayers have cells disrupted using two freeze–thaw cycles at –80°C.
667 Positive control plates are read for end-point titres, and these are compared with virus in the
668 presence of test material to ensure titres are comparable and interference has not occurred.
669 Freeze–thaw lysates are clarified at 2000 *g* for 5 minutes and re-passed on to newly formed
670 monolayers as for the first passage. Passages are repeated until a total of four passages are
671 completed at which point cell lysates are assessed by PCR for detection of PEDV and day 7
672 monolayers in 24-well plates are fixed and stained for FAT. If a seed virus is to be tested and
673 requires neutralisation using antiserum, extra care in the isolation of PEDV needs to be
674 considered. Trypsin is rendered inactive in the presence of serum proteins and without trypsin
675 present, PEDV grows poorly, or not at all. Washing off the inoculum with two MM washes is
676 required after an extended adsorption time of up to 4 hours to ensure acceptable sensitivity.

677 **H. I. INFORMATION TO BE SUBMITTED WHEN** 678 **APPLYING FOR AN IMPORT LICENCE**

679 When undertaking risk analysis for biologicals, Veterinary Authorities should follow the *Terrestrial Code*, and the
680 manufacturer should follow the requirements of the importing country. Requirements for each importing country
681 should be accessible and published online. The manufacturer or the Veterinary Authority of the exporting country
682 should make available detailed information, in confidence as necessary, on the source of the materials used in the
683 manufacture of the product (e.g. substrates). They should make available details of the method of manufacture
684 (and where appropriate inactivation) of the substrates and component materials, the quality assurance procedures
685 for each step in the process, final product testing regimes, and the pharmacopoeia with which the product must
686 conform in the country of origin. They should also make available challenge organisms, their biotypes and reference
687 sera, and other means of appropriate product testing.

688 For detailed examples of a risk-based assessment of veterinary biologicals for import into a country refer to:

- 689 • European Commission (2015). The Rules Governing Medicinal Products in the European Union. Eudralex.
690 Volume 6. Notice to applicants and regulatory guidelines for medicinal products for veterinary use.
- 691 • Department of Agriculture, Forest and Fisheries of Australia (2021b). Live veterinary vaccines Summary of
692 information required for biosecurity risk assessment, Version 6 and Inactivated veterinary vaccines, Version
693 8.
- 694 • Outline of the Regulatory System of Veterinary Drugs in Japan (2015) Assurance of the Quality, Efficacy, and
695 Safety Based on the Law for Ensuring the Quality, Efficacy, and Safety of Drugs and Medical Devices.

696 • Ministry of Agriculture and Rural Affairs, China (People's Rep. of), Regulations on the Administration of
697 Veterinary drugs (revised in 2020).

698 When applying for an import licence other regulatory requirements may need to be addressed depending on the
699 type of sample and if the sample needs to be shipped out of country to a testing laboratory. For example, cell seeds
700 may come under certain requirements for permits such as the Convention for International Trade in Endangered
701 Species of Wild Fauna and Flora (CITES), where a cell line is derived from an endangered species, e.g. the cell
702 line and its derivatives. Applying for such a permit is time consuming and requires input from both the exporting and
703 importing country.

704 Genetically modified organisms (GMOs) are becoming more frequent in use with changes in manufacturing
705 technologies and specialised, time-consuming procedures need to be in place. A laboratory that accepts a GMO
706 product for testing shall follow the procedures of the ~~Office of the Gene Regulator (OGTR)~~ national regulator to
707 allow the GMO to be dealt with.

708 **I. J. RISK ANALYSIS PROCESS**

709 Risk analysis should be as objective and transparent as possible and should be performed in accordance with
710 Section 2 of the *Terrestrial Code*, and certification in line with Section 5 of the *Terrestrial Code*. Of necessity,
711 assessment of the country and commodity factors and risk reduction measures will be based largely on
712 manufacturers' data. These data depend on quality assurance at all stages of manufacture, rather than on testing
713 of the final product alone.

714 Domestic exposure may be influenced by the approved usage of the product. Veterinary Authorities may place
715 limits on usage of some products (e.g. restricting usage to institutions of appropriate biosecurity).

716 **J. K. BIOCONTAINMENT**

717 Suitable biocontainment may be necessary for many forms of biologicals. In particular, the importation of exotic
718 micro-organisms should be carried out in accordance with Chapter 1.1.4 *Biosafety and biosecurity: standard for
719 managing biological risk in the veterinary laboratory and animal facilities*.

720 Laboratories using high risk agents should have well researched and documented risk assessments in place prior
721 to working with such agents to ensure the safety of their staff and laboratory.

722 **REFERENCES**

723 ALHASSAN A., GOVIND Y., TAM N.T., THEKISOE O.M., YOKOYAMA N., INOUE N. & IGARASHI I. (2007). Comparative
724 evaluation of the sensitivity of LAMP, PCR and in vitro culture methods for the diagnosis of equine piro-plasmosis.
725 *Parasitol. Res.*, **100**, 1165–1168.

726 AUSTRALIAN QUARANTINE POLICY AND REQUIREMENTS FOR THE IMPORTATION OF LIVE AND NOVEL VETERINARY BULK AND
727 FINISHED VACCINES (1999). Available online at:
728 [https://www.agriculture.gov.au/sites/default/files/sitecollectiondocuments/ba/memos/1999/animal/99-
729 085acleaned.pdf](https://www.agriculture.gov.au/sites/default/files/sitecollectiondocuments/ba/memos/1999/animal/99-085acleaned.pdf) (Accessed 20/09/2024).

730 AVARZED A., IGARASHI I., KANEMARU T., HIRUMI, K., OMATA T., SAITO Y., OYAMADA A., NAGASAWA H., TOYODA Y. & SUZUKI
731 N. (1997). Improved *in vitro* cultivation of *Babesia caballi*. *J. Vet. Med. Sci.*, **59**, 479–481.

732 BARONE P., WIEBE M.E., LEUNG J.C., HUSSEIN I.T.M., KEUMURIAN F.J., BOURESSA J., BRUSSEL A., CHEN D., CHONG M.,
733 DEGHANI H., GERENTES L., GILBERT J., GOLD D., KISS R., KREIL T.R., LABATUT R., LI Y, MÜLLBERG J., MALLET L.,
734 MENZEL C., MOODY M., MONPOEHO S., MURPHY M., PLAVSIC M., ROTH N.J., ROUSH D., RUFFING M., SCHICHO R., SNYDER
735 R., STARK D., ZHANG C., WOLFRUM J., SINSKEY A.J. & SPRINGS S.L. (2020). Viral contamination in biologic
736 manufacture and implications for emerging therapies. *Nat. Biotechnol.*, **38**, 563–572.

737 BAYLIS S.A., FINSTERBUSCH T., BANNERT N., BLUMEL J. & MANKERTZ A. (2011). Analysis of porcine circovirus type 1
738 detected in Rotarix vaccine. *Vaccine*, **29**, 690–697.

739 CODE OF FEDERAL REGULATIONS (OF THE UNITED STATES OF AMERICA) (CFR) (2015). Subchapter E. Viruses, serums,
740 toxins and analogous products; organisms and vectors. *In: Code of Federal Regulations, Animals and Animal*

-
- 741 Products. Title 9, Parts 101–124. US Government Printing Office, Washington DC, USA. Available online;
742 <https://www.law.cornell.edu/cfr/text/9/part-113> (Accessed 20/09/2024).
- 743 DEPARTMENT OF AGRICULTURE, WATER AND ENVIRONMENT (OF AUSTRALIA) (2013). Review of Published Tests to Detect
744 Pathogens in Veterinary Vaccines Intended for Importation into Australia, Second Edition. CC BY 3.0. Available
745 online at:
746 [https://www.agriculture.gov.au/biosecurity-trade/policy/risk-analysis/animal/review-of-published-tests-to-detect-](https://www.agriculture.gov.au/biosecurity-trade/policy/risk-analysis/animal/review-of-published-tests-to-detect-pathogens)
747 [pathogens](https://www.agriculture.gov.au/biosecurity-trade/policy/risk-analysis/animal/review-of-published-tests-to-detect-pathogens) (Accessed 20/09/2024).
- 748 DEPARTMENT OF AGRICULTURE, WATER AND ENVIRONMENT (OF AUSTRALIA) (2021a). Inactivated veterinary vaccines
749 Summary of information required for biosecurity risk assessment. Version 8. Available online at:
750 [https://www.agriculture.gov.au/sites/default/files/sitecollectiondocuments/aqis/importing/bio-products/vet-](https://www.agriculture.gov.au/sites/default/files/sitecollectiondocuments/aqis/importing/bio-products/vet-vaccines/inact-vet-vacs.pdf)
751 [vaccines/inact-vet-vacs.pdf](https://www.agriculture.gov.au/sites/default/files/sitecollectiondocuments/aqis/importing/bio-products/vet-vaccines/inact-vet-vacs.pdf) (Accessed 20/09/2024).
- 752 DEPARTMENT OF AGRICULTURE, WATER AND ENVIRONMENT (OF AUSTRALIA) (2021b–2023). Live veterinary vaccines.
753 Summary of information required for biosecurity risk assessment. Version 6–9. Available online at:
754 [https://www.agriculture.gov.au/sites/default/files/sitecollectiondocuments/aqis/importing/bio-products/vet-](https://www.agriculture.gov.au/sites/default/files/sitecollectiondocuments/aqis/importing/bio-products/vet-vaccines/live-vet-vaccines.pdf)
755 [vaccines/live-vet-vaccines.pdf](https://www.agriculture.gov.au/sites/default/files/sitecollectiondocuments/aqis/importing/bio-products/vet-vaccines/live-vet-vaccines.pdf) (Accessed 20/09/2024).
- 756 EUROPEAN COMMISSION (2015). The Rules Governing Medicinal Products in the European Union. Eudralex. Volumes
757 4–9. European Commission, DG Health and Food Safety, Public health, EU Pharmaceutical information, Eudralex.
758 Available online at: http://ec.europa.eu/health/documents/eudralex/index_en.htm (accessed 20/09/2024).
- 759 EUROPEAN MEDICINES AGENCY SCIENCES MEDICINES HEALTH (2016). EMA/CVMP/IWP/251741/2015. Reflection paper
760 on methods found suitable within the EU for demonstrating freedom from extraneous agents of the seeds used for
761 the production of immunological veterinary medicinal products. Available online at:
762 [https://www.edqm.eu/en/d/95422?p_l_back_url=%2Fen%2Fsearch-](https://www.edqm.eu/en/d/95422?p_l_back_url=%2Fen%2Fsearch-edqm%3Fq%3DEMA%252FCVMP%252FIWP%252F251741%252F2015%26delta%3D40%26category%3D302281)
763 [edqm%3Fq%3DEMA%252FCVMP%252FIWP%252F251741%252F2015%26delta%3D40%26category%3D3022](https://www.edqm.eu/en/d/95422?p_l_back_url=%2Fen%2Fsearch-edqm%3Fq%3DEMA%252FCVMP%252FIWP%252F251741%252F2015%26delta%3D40%26category%3D302281)
764 [81](https://www.edqm.eu/en/d/95422?p_l_back_url=%2Fen%2Fsearch-edqm%3Fq%3DEMA%252FCVMP%252FIWP%252F251741%252F2015%26delta%3D40%26category%3D302281) (Accessed 20/09/2024).
- 765 EUROPEAN PHARMACOPOEIA (2023). European Directorate for the Quality of Medicines and Health Care (EDQM),
766 Council of Europe, Strasbourg, France. Current version available online at European Pharmacopoeia (Ph. Eur.)
767 11th Edition – European Directorate for the Quality of Medicines & HealthCare (edqm.eu) (accessed 25 July 2023).
- 768 FARSANG A. & KULCSAR G. (2012). Extraneous agent detection in vaccines – a review of technical aspects.
769 *Biologicals*, **40**, 225–230.
- 770 HARE W.C.D. (1985). Diseases Transmissible by Semen and Embryo Transfer Techniques. OIE Technical Series
771 No. 4. World Organisation for Animal Health (OIE), Paris, France.
- 772 HODINKA R.L. (2013). Point: is the era of viral culture over in the clinical microbiology laboratory? *J. Clin. Microbiol.*,
773 **51**, 2–4.
- 774 IKADAI H., MARTIN M.D., NAGASAWA H., FUJISAKI K., SUZUKI N., MIKAMI T., KUDO N., OYAMADA T. & IGARASHI I. (2001).
775 Analysis of a growth-promoting factor for *Babesia caballi* cultivation. *J. Parasitol.*, **87**, 1484–1486.
- 776 MARCUS-SECURA C., RICHARDSON J.C., HARSTON R.K., SANE N. & SHEETS R.L. (2011). Evaluation of the human host
777 range of bovine and porcine viruses that may contaminate bovine serum and porcine trypsin used in the
778 manufacture of biological products. *Biologicals*, **39**, 359–369.
- 779 MACKAY D. & KRIZ N. (2010). Current challenges in viral safety and extraneous agents testing. *Biologicals*, **38**, 335–
780 337.
- 781 MILLER P.J., AFONSO C.L., SPACKMAN E., SCOTT M.A., PEDERSEN J.C., SENNE D.A., BROWN J.D., FULLER C.M., UHART
782 M.M., KARESH W.B., BROWN I.H., ALEXANDER D.J. & SWAYNE D. (2010). Evidence for a new avian paramyxovirus
783 serotype 10 detected in rockhopper penguins from the Falkland Islands. *J. Virol.*, **84**, 11496–11504.
- 784 NEVEROV A. & CHUMAKOV K. (2010). Massively parallel sequencing for monitoring genetic consistency and quality
785 control of live viral vaccines. *Proc. Natl Acad. Sci. USA*, **107**, 20063–20068.
- 786 ONIONS D. & KOLMAN J. (2010). Massively parallel sequencing, a new method for detecting adventitious agents.
787 *Biologicals*, **38**, 377–380.
-

- 788 OUTLINE OF THE REGULATORY SYSTEM OF VETERINARY DRUGS IN JAPAN (2015). Assurance of the Quality, Efficacy, and
789 Safety Based on the Law for Ensuring the Quality, Efficacy, and Safety of Drugs and Medical Devices.
790 https://www.maff.go.jp/nval/english/regulatory/pdf/Outline_RegulatorySystem_VMPs.pdf (Accessed 20/09/2024).
- 791 ROSSEEL T., LAMBRECHT B., VANDENBUSSCHE F., VAN DEN BERG T. & VAN BORM S. (2011). Identification and complete
792 genome sequencing of paramyxoviruses in mallard ducks (*Anas platyrhynchos*) using random access amplification
793 and next generation sequencing technologies. *Viol. J.*, **8**, 463.
- 794 SHEETS R., LOEWER, J., RAYDCHAUDHURI G. & PETRICCIANI J. (2012). Adventitious agents, new technology, and risk
795 assessment, 19–20 May 2011, Baltimore, MD. *Biologicals*, **40**, 162–167.
- 796 TELLEZ S., CASIMIRO R., VELA A.I., FERNANDEZ-GARAYZABAL J.F., EZQUERRA R., LATRE M.V., BRIONES V., GOYACHE J.,
797 BULLIDO R., ARBOIX M. & DOMINGUEZ L. (2005). Unexpected inefficiency of the European pharmacopoeia sterility test
798 for detecting contamination in clostridial vaccines. *Vaccine*, **24**, 1710–1715.
- 799 VAN BORM S., ROSSEEL T., STEENSELS M., VAN DEN BERG T. & LAMBRECHT B. (2013). What's in a strain? Viral
800 metagenomics identifies genetic variation and contaminating circoviruses in laboratory isolates of pigeon
801 paramyxovirus type 1. *Virus Res*, **171**, 186–193.
- 802 VICTORIA J.G., WANG C., JONES M.S., JAING C., MCLOUGHLIN K., GARDNER S. & DELWART E.L. (2010). Viral nucleic
803 acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. *J. Virol.*, **84**, 6033–6040.
- 804 WANG J., LUNT R., MEEHAN B. & COLLING A. (2014). Evaluation of the potential role of next-generation sequencing
805 (NGS) in innocuity testing. Technical Report CSIRO, Australian Animal Health Laboratory.
- 806 WORLD HEALTH ORGANIZATION (WHO) (1998). WHO Expert Committee on Biological Standardization. World Health
807 Organization Technical Report Series, Report No. 858. World Health Organization, Geneva, Switzerland.
- 808 WORLD HEALTH ORGANIZATION (WHO) (2013). WHO Expert Committee on Biological Standardization. World Health
809 Organization Technical Report Series, Report No. 977. World Health Organization, Geneva, Switzerland. Available
810 online at: https://apps.who.int/iris/bitstream/handle/10665/89142/9789241209779_eng.pdf (Accessed 20/09/2024).
- 811 World Health Organisation (WHO) (2015) Expert Committee on Biological Standardization Sixty-fifth report.
812 Technical report series 993, 2015. Annex 2 Scientific principles for regulatory risk evaluation on finding an
813 adventitious agent in a marketed vaccine. Available online at: [https://cdn.who.int/media/docs/default-](https://cdn.who.int/media/docs/default-source/biologicals/cell-substrates/annex2__adventitious_agent_in_marketed_vaccine_eng.pdf?sfvrsn=e5de04a_3&download=true)
814 [source/biologicals/cell-](https://cdn.who.int/media/docs/default-source/biologicals/cell-substrates/annex2__adventitious_agent_in_marketed_vaccine_eng.pdf?sfvrsn=e5de04a_3&download=true)
815 [substrates/annex2__adventitious_agent_in_marketed_vaccine_eng.pdf?sfvrsn=e5de04a_3&download=true](https://cdn.who.int/media/docs/default-source/biologicals/cell-substrates/annex2__adventitious_agent_in_marketed_vaccine_eng.pdf?sfvrsn=e5de04a_3&download=true)
816 (Accessed 20/09/2024)

FURTHER READING

- 817
- 818 Details of methods and culture media can be found in the following books and also in commercial catalogues.
- 819 BARROW G.I. & Feltham R.K.A., eds. (1993). Cowan and Steel's Manual for the Identification of Medical Bacteria,
820 Third Edition. Cambridge University Press, Cambridge, UK.
- 821 COLLINS C.H., LYNE P.M. & GRANGE J.M., eds. (1995). Collins and Lyne's Microbiological Methods, Seventh Edition.
822 Butterworth Heinemann, Oxford, UK.
- 823 MURRAY P.R., ED. (2003). Manual of Clinical Microbiology, Eighth Edition. American Society for Microbiology Press,
824 Washington DC, USA.
- 825 *
826 * *
- 827 **NB:** FIRST ADOPTED IN 1989. MOST RECENT UPDATES ADOPTED IN 2024.

3 REUNIÓN DE LA COMISIÓN DE NORMAS BIOLÓGICAS
4 París, 9–13 de septiembre de 2024

5
6 SECTION 2.1.

7 LABORATORY DIAGNOSTICS

8 CHAPTER 2.1.1.

9 LABORATORY METHODOLOGIES FOR BACTERIAL
10 ANTIMICROBIAL SUSCEPTIBILITY TESTING

11 SUMMARY

12 *With the increase in bacterial resistance to traditionally used antimicrobials, ~~it has become more~~
13 ~~difficult for clinicians to empirically the use of antimicrobial susceptibility testing (AST) has become a~~
14 ~~key element in antimicrobial stewardship as clinicians~~ select an appropriate antimicrobial agent. As
15 a result, in-vitro ~~antimicrobial susceptibility testing (AST)~~ of the relevant bacterial pathogens, from
16 properly collected specimens, should be performed using validated methods. Thus, AST is an
17 important component of prudent antimicrobial use guidelines in animal husbandry worldwide and
18 veterinarians in all countries should have ~~these AST~~ data available for informed decision-making.*

19 *Although a variety of methods exist, the goals of ~~in-vitro antimicrobial susceptibility testing AST~~ are
20 either to provide a reliable predictor of how an ~~organism pathogen~~ is likely to respond to antimicrobial
21 therapy in the infected host or to assess ~~whether there has been a change in susceptibility for a given~~
22 ~~bacterial species over time~~ for surveillance purposes ~~whether there has been development of~~
23 ~~resistance~~. This type of information aids the clinician in selecting the appropriate antimicrobial agent,
24 aids in developing antimicrobial use policy, and provides data for epidemiological surveillance. ~~Such~~
25 ~~epidemiological surveillance data provide a base to choose the appropriate empirical treatment (first-~~
26 ~~line therapy) and to detect the emergence and/or the dissemination of resistant bacterial strains or~~
27 ~~resistance determinants in different bacterial species.~~ The selection of a particular AST method is
28 based on many factors such as validation data, practicality, flexibility, automation, cost, reproducibility,
29 accuracy, standardisation and harmonisation.*

30 *The use of genotypic approaches for detection of antimicrobial resistance genes ~~or mutations~~
31 ~~associated with resistance~~ has also been promoted as a way to increase the speed and ~~accuracy~~
32 ~~resolution~~ of ~~susceptibility testing-resistance surveillance~~. ~~Numerous DNA-based assays are being~~
33 ~~developed to detect bacterial antimicrobial resistance at the genetic level.~~ These methods, when
34 ~~used in conjunction validated~~ with phenotypic analysis, offer the promise of increased sensitivity,
35 specificity, ~~scope~~, and speed in the detection of specific known resistance genes and ~~mutations, and~~
36 ~~can be used in tandem with could in some circumstances replace traditional laboratory AST methods.~~*

INTRODUCTION

38 The spread of multiple antimicrobial-resistant pathogenic bacteria has been recognised by the World Organisation
39 for Animal Health (WOAH), the Food and Agriculture Organization (FAO) and the World Health Organization (WHO)
40 as a serious global human and animal health problem. The development of bacterial antimicrobial resistance is
41 neither an unexpected nor a new phenomenon. It is, however, of increasing concern due to the frequency with
42 which new emerging resistance phenotypes are occurring among many bacterial pathogens and commensal
43 organisms, such as resistance to carbapenems, colistin, linezolid, macrolides, etc.

44 Historically, many infections could be treated successfully according to the clinician's past clinical experience or
45 because susceptibility could be reliably predicted (i.e. empirical therapy)⁴; however, ~~this which~~ is becoming more
46 ~~the exception than the rule challenging~~ (Walker, 2007). Resistance has been observed to essentially all of the
47 antimicrobial agents currently approved for use in humans and veterinary clinical medicine animals. This, combined
48 with the variety of antimicrobial agents currently available, makes the selection of an appropriate agent an
49 increasingly challenging task. This situation has made clinicians more dependent on AST data, from *in-vitro*
50 antimicrobial susceptibility testing, and highlighting the importance of the diagnostic laboratory in clinical practice.

51 In this context, the use of AST allows clinicians to make more informed decisions about the most appropriate
52 antimicrobial agent and provides valuable data to assess susceptibility trends over time for surveillance purposes.

53 ~~A number of antimicrobial susceptibility testing (AST) methods are available to determine bacterial susceptibility to~~
54 ~~antimicrobials. The selection of an AST method is based on many factors such as practicality, flexibility, automation,~~
55 ~~cost, reproducibility, accuracy, accessibility and individual preference. Standardisation and harmonisation of AST~~
56 ~~methodologies, methods and data interpretation used in epidemiological surveillance of antimicrobial drug~~
57 ~~resistance, are critical if data are to be compared among national or international surveillance/monitoring~~
58 ~~programmes of WOAHO Members. It is essential that AST methods provide reproducible results in day-to-day routine~~
59 ~~laboratory use and that the data be comparable with those results obtained by an acknowledged 'gold standard'~~
60 ~~reference method. Currently the reference AST method endorsed by the Clinical and Laboratory Standards Institute~~
61 ~~(CLSI) is the broth micro-dilution method (Humphries *et al.*, 2023)⁴ that determines minimum inhibitory~~
62 ~~concentration (MIC) as described by the ISO (International Organization for Standardization, 2006-2019). In the~~
63 ~~absence of standardised methods or reference procedures, susceptibility results from different laboratories cannot~~
64 ~~be reliably compared. The method used to select samples for inclusion in antimicrobial resistance surveillance~~
65 ~~programmes, as well as the methods laboratory procedures used for primary bacterial isolation and identification,~~
66 ~~are also important factors that should be standardised or harmonised to allow direct comparison of data between~~
67 ~~different regions; consideration of these issues is addressed in a WOAHO, Codex Alimentarius, WHO documents~~
68 ~~(Codex Alimentarius, 2021; Dehaumont 2004; WHO, 2017; WOAHO, 2024).~~

69 ~~As the science of AST has progressed, a greater understanding of the multiple factors that could affect the overall~~
70 ~~outcome of susceptibility testing has become clearer (WHO, 2017). This document chapter provides guidelines and~~
71 ~~guidance for using both standardised AST standardisation for methodologies, and interpretation of antimicrobial~~
72 ~~susceptibility test AST results.~~

73 1. Test requirements

74 The following requirements should be applied to achieve ~~standardisation of AST methods and allow for~~
75 ~~comparability of AST results across national or international surveillance/monitoring programmes of WOAHO~~
76 ~~Members:~~

- 77 i) the use of standardised AST methods is essential to generate accurate and reproducible data, and includes
78 harmonised ~~including the harmonisation~~ of AST test parameters such as media, inoculum, incubation time,
79 quality controls, choice of antimicrobial agents and subsequent interpretive criteria,
- 80 ii) standardised AST methods, including all critical specifications and interpretive criteria, should be clearly
81 defined, documented in detail and used by all participating laboratories,
- 82 ~~iii) all AST methods should generate accurate and reproducible data,~~
- 83 iii) quantitative susceptibility data (e.g. MIC frequencies, zone diameter frequencies) should be reported,
- 84 iv) establishment of national or regional reference laboratories, in cooperation with consensus standards-setting
85 organisations (e.g. European Committee on Antimicrobial Susceptibility Testing [EUCAST], CLSI) is essential
86 for the coordination of AST methodologies, interpretations and appropriate operational techniques used to
87 ensure accuracy and reproducibility (e.g. quality controls),

⁴ <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281161/>

- 88 v) microbiological laboratories should implement and maintain a formal quality management programme (see
89 Chapter 1.1.5 *Quality management in veterinary testing laboratories*),
- 90 vi) laboratories should ~~have acquired be accredited by~~ a third party accreditation that ~~includes covers~~ the AST
91 methodologies to be used within the scope of that accreditation. The accreditation body should meet accepted
92 international Laboratory Accreditation Cooperation (ILAC) standards and guidelines regarding the standards
93 used for the accreditation process. The accreditation standards used should include the requirement for
94 participation in proficiency testing programmes,
- 95 vii) specific bacterial reference strains/quality control strains are essential for determining intra- and inter-
96 laboratory quality control, quality assurance and proficiency testing.

97 2. Selection of antimicrobials for testing and reporting

98 Selecting the appropriate antimicrobials for ~~susceptibility testing AST~~ can be difficult given the vast numbers of
99 agents available. The following ~~guidelines best practices~~ should be noted:

- 100 i) ~~the~~ FAO/WOAH/WHO expert workshop on non-human antimicrobial usage and antimicrobial resistance
101 recommends ~~creating laboratories or programmes create~~ a list of veterinary and human critically important
102 antimicrobials for ~~susceptibility testing routine AST~~ and reporting,
- 103 ii) selection of the most appropriate antimicrobials to test is a decision best made by each WOA Member in
104 consultation with the appropriate bodies and organisations,
- 105 iii) antimicrobials in the same class may have similar *in-vitro* activities against select bacterial pathogens. In these
106 cases, a representative antimicrobial should be selected that predicts susceptibility to other members of the
107 same class,
- 108 iv) certain ~~microorganisms bacteria~~ can be intrinsically resistant to particular antimicrobial classes; therefore it is
109 unnecessary to test and misleading to test report results for certain agents for activity *in vitro*. ~~The type of~~
110 ~~intrinsic resistance has to be determined for these organisms from either the scientific literature or through~~
111 ~~testing. WOA Members may identify intrinsic resistance among tested bacteria from the literature,~~
- 112 v) the number of antimicrobials to be tested should comply with the guideline used (CLSI/EUCAST/ISO) and at
113 least contain class representatives to ensure the relevance and practicality of AST (see also WHO, 2017),
- 114 vi) the panel of antimicrobials tested should depend on the target bacteria, the clinical or epidemiological
115 relevance of these antimicrobials at national or regional level.
- 116 vii) the panel of antimicrobials tested should ideally be harmonised within national surveillance programme(s) to
117 ensure continuity and comparability of data.
- 118 viii) the panel of antimicrobials to be tested may be prioritised based on their higher importance for human health,
119 the national context, or their influence on the selection or co-selection of resistance.

120 Periodic review of ~~microorganisms bacteria~~ that are currently predictably susceptible to certain antimicrobial agents
121 is recommended to ensure that emergent, unexpected resistance is detected and used to update local treatment
122 guidelines. Timely AST can identify emerging resistances before clinical failure is widely observed. Emerging
123 ~~resistance may also be suspected following poor response or treatment failure to a standard antimicrobial treatment~~
124 ~~regime.~~

125 3. Antimicrobial susceptibility testing methodologies

126 The following requirements should be respected:

- 127 i) bacterial isolates subjected to AST must be isolated in derived from a pure culture from the submitted sample,
- 128 ii) standard ~~reference methods laboratory procedures and culture methods~~ should be used for identification so
129 that the subject bacteria are consistently and correctly identified to the genus, ~~and/or species, or serotype~~
130 level, where relevant,
- 131 iii) bacterial isolates considered to be the most important, ~~and other selected isolates, and reference/quality~~
132 control (QC) strains should be stored for future analysis in conditions ensuring an absence in change in the
133 characteristics and purity of the strain (either lyophilisation or cryogenic preservation at -70°C to -80°C).

134 The following factors influencing AST methods should be determined, optimised, and documented in a detailed
135 standard operating procedure:

- 136 i) once ~~the a~~ bacterium has been isolated in pure culture, a standardised concentration of the inoculum must be
137 prepared using a nephelometer or spectrophotometer to ensure a defined number of colony forming units to

-
- 138 obtain accurate and repeatable susceptibility results. Bacteria or other organisms used in AST ~~testing~~ should
139 be from a fresh 24-hour culture,
- 140 ii) the composition and preparation of the agar and broth media used (e.g. pH, cations, thymidine or thymine,
141 use of supplemented media) should comply with ~~guidelines~~ the validated test method (CLSI/EUCAST/ISO).
142 Performance and sterility testing of media lots should also be determined and documented ~~as well as the~~
143 ~~procedures used~~,
- 144 iii) the content, range/interval and concentration of the antimicrobials used (microtitre plates, disk, ~~strip, tablet~~)
145 should follow guidelines (CLSI/EUCAST/ISO) and be relevant to the bacterial species tested,
- 146 iv) composition of solvents and diluents for preparation of antimicrobial stock solutions,
- 147 v) growth and incubation conditions (time, temperature, atmosphere e.g. CO₂),
- 148 vi) agar depth,
- 149 vii) the test controls to be used, including the reference organisms ~~used~~,
- 150 viii) ~~the subsequent~~ interpretive criteria (i.e. clinical breakpoints, epidemiological cut-off values—~~ECOFFs~~).

151 For these reasons, special emphasis has to be placed on the use of documented procedures and validated, well
152 documented methods, as sufficient reproducibility can be attained only through the use of such methodology.

153 **4. Selection of antimicrobial susceptibility testing methodology**

154 The selection of an AST methodology may be influenced by the following factors:

- 155 i) ease of performance,
- 156 ii) flexibility,
- 157 iii) adaptability to automated or semi-automated systems,
- 158 iv) cost,
- 159 v) reproducibility,
- 160 vi) reliability,
- 161 vii) accuracy,
- 162 viii) the organisms and the antimicrobials of interest into that particular WOA Member_±,
- 163 ix) ~~availability of suitable validation data for the range of organisms to be susceptibility tested.~~

164 **5. Antimicrobial susceptibility testing methods**

165 ~~These following three methods have been shown to consistently provide reproducible and repeatable results when~~
166 following standardised procedures followed correctly (Clinical and Laboratory Standards Institute [CLSI], 2008
167 2024a; Walker, 2007):

- 168 i) disk diffusion,
- 169 ii) broth dilution,
- 170 iii) agar dilution_±

171 **5.1 Disk diffusion method**

172 Disk diffusion refers to the diffusion of an antimicrobial agent from a disk ~~or tablet~~ containing a specified
173 ~~concentration~~ amount of the agent ~~tablets~~ (i.e. disk content) into a solid culture medium (normally
174 Mueller–Hinton agar) that has been inoculated on the surface with a pure culture (see Section 3). The
175 disk diffusion test result is determined by measurement of the diameter of the inhibition zone around the
176 disk, the diameter being proportional to the bacterial susceptibility to the antimicrobial present in the disk.

177 The diffusion of the antimicrobial agent into the culture media results in a gradient of the antimicrobial.
178 When the concentration of the antimicrobial becomes so diluted that it can no longer inhibit the growth
179 of the test bacterium, the zone of inhibition is demarcated. ~~The diameter of this zone of inhibition around~~
180 ~~the antimicrobial disk is related to MIC for that particular bacterium/antimicrobial combination; the zone~~
181 ~~of inhibition correlates inversely with the MIC of the test bacterium. Generally, the larger the zone of~~
182 ~~inhibition, the lower the concentration of antimicrobial required to inhibit the growth of the organisms.~~

183 However, this depends on the concentration of antimicrobial agent in the disk and its diffusibility.
184 Antimicrobial agents that are very large molecules (e.g. polymyxins) diffuse poorly in agar making disk
185 diffusion methods unreliable for these compounds. For this reason disk diffusion methods are not
186 recommended for example for the susceptibility testing of colistin/polymyxin (Matuschek *et al.*, 2018).

187 Note: Disk diffusion tests based solely on the presence or absence of a zone of inhibition without regard
188 to the measured size of the zone of inhibition are not acceptable AST methodology.

189 5.1.1. Considerations for the use of the disk diffusion methodology

190 ~~Disk diffusion is easy to perform, reproducible if standardised, and does not require expensive~~
191 ~~equipment. Its main advantages are~~ The advantages of disk diffusion methodology include:

- 192 i) low cost,
- 193 ii) ease in performance.
- 194 iii) ease in modifying test by changing antimicrobial disks when required,
- 195 iv) can be used as a screening test against large numbers of isolates,
- 196 v) can identify a subset of isolates for further testing by other methods, such as ~~determination~~
197 of MICs broth dilution.
- 198 vi) the procedure is controlled by inclusion of appropriate quality control organisms for which a
199 target zone size range is available (or has been derived) for each of the relevant
200 antimicrobial agents being tested in the disk diffusion test procedure.

201 The disadvantages of disk diffusion methodology include:

- 202 i) Availability of antimicrobial agent disks of specific interest to veterinary medicine and at the
203 concentrations needed.
- 204 ii) Limited direct relevance *in vivo* of zones of inhibition measurements as compared to MICs.
- 205 iii) Manual measurement of zones of inhibition may be time-consuming and can be subject to
206 variability by technician.
- 207 iv) Not available for bacteria that require long incubation times (*Mycobacterium* spp., etc.).

208 Automated zone-reading devices are available that can be integrated with laboratory reporting
209 and data-handling systems. The disks should be distributed evenly on the agar surface so that
210 the zones of inhibition around antimicrobial disks in the disk diffusion test do not overlap to such
211 a degree that the zone of inhibition cannot be determined. Generally, this can be accomplished if
212 the disks are no closer than 24 mm from centre to centre, though this is dependent on disk
213 concentration and the ability of the antimicrobial to diffuse in agar. Contamination of culture plates
214 may be harder to detect using automated readers.

215 The diameter of the zone of inhibition obtained in disk diffusion tests is strongly influenced by the
216 density of the bacterial inoculum applied, underlining the requirement to standardise the inoculum
217 density in accordance with guidelines (CLSI, EUCAST, ISO). A denser inoculum than intended
218 will result in reduced zones of inhibition and a sparse inoculum will result in increased zones of
219 inhibition (BSAC [British Society for Antimicrobial Chemotherapy], 2015).

220 5.2. Broth and agar dilution methods

221 The aim of the broth and agar dilution methods is to determine the lowest concentration of the
222 antimicrobial that inhibits the visible growth of the bacterium being tested ~~in either broth or on agar~~ (MIC,
223 usually expressed in µg/ml or mg/litre). ~~The range of concentrations tested in broth and agar dilution~~
224 ~~methods generally includes the breakpoint (clinical or microbiological) with doubling dilutions either side~~
225 ~~of that value as considered appropriate. However, the MIC does not always represent exactly the~~
226 ~~concentration which was tested. The 'true' MIC is a point between the lowest test concentration that~~
227 ~~inhibits the growth of the bacterium and the next lower test concentration. Therefore, MIC determinations~~
228 ~~performed using a dilution series may be considered to have an inherent variation of ±1 dilution.~~

229 Tested antimicrobial concentration ranges should encompass both the ~~interpretive criteria~~ clinical
230 breakpoint and epidemiological cut-off value, when available (susceptible, intermediate and resistant)
231 for a specific bacterium/antimicrobial. The concentration range of each antimicrobial agent should also cover
232 the full range of allowable results for the QC strain(s) used for each antimicrobial agent biotic combination

233 and appropriate quality control reference organisms. Target MIC ranges should be available for each
234 antimicrobial agent being tested.

235 Antimicrobial susceptibility dilution methods are more reproducible than agar disk diffusion which is why
236 broth microdilution is the current reference test method. However, antibiotics are usually tested in
237 doubling dilutions, which can produce inexact MIC data. The continuous range of zone diameter values
238 obtained with disk diffusion can therefore be advantageous in certain circumstances, such as screening
239 large numbers of susceptible isolates.

240 Any laboratory that intends to use a dilution method and set up its own reagents and antibiotic
241 antimicrobial dilutions should have the ability to obtain, prepare and appropriately maintain stock
242 solutions of reagent-grade antimicrobials, to account for the potency of the antimicrobial (supplied by the
243 manufacturer) and to generate complex working dilutions on a regular basis. Published methods should
244 be consulted. It is ~~then~~ essential that such laboratories use quality control organisms (see below) to
245 assure accuracy and standardisation of their procedures.

246 5.2.1. Broth dilution

247 Broth dilution is a technique in which a suspension of a bacterium of a predetermined optimal
248 ~~concentration density~~ is tested against varying concentrations of an antimicrobial agent (usually
249 serial twofold dilutions) in a liquid test medium of predetermined, documented formulation. The
250 broth dilution method can be performed either in tubes containing a minimum volume of 2 ml
251 (~~macro~~dilution) or in smaller volumes using microtitration plates (microdilution). ~~Numerous~~
252 Commercially available microtitre plates containing lyophilised or dried prediluted antibiotic
253 antimicrobials within the wells, ~~are commercially available. The use of the same batches of~~
254 ~~microdilution plates may assist in the minimisation of variation that may arise due to the~~
255 ~~preparation and dilution of the antimicrobials at different laboratories. The use of these plates,~~
256 ~~with a documented test protocol, including specification of appropriate reference organisms, will~~
257 ~~facilitate the comparability of results among laboratories.~~

258 The advantages of broth dilution methods include:

- 259 i) Numerous variations of commercially available plate formats (for microdilution).
- 260 ii) Reduced variability of results and concentration testing ranges using commercially available
261 plate formats (for microdilution).
- 262 iii) Ease in increasing the capacity of testing with commercially available plates (for
263 microdilution).

264 The disadvantages of broth dilution methods include:

- 265 i) Relatively high cost per commercially available plate.
- 266 ii) Specialised equipment is required for automatically reading MICs.
- 267 iii) Limited concentrations range and antimicrobials on commercially available plates.

268 ~~Due to the fact that most broth microdilution antimicrobial test panels are prepared commercially,~~
269 ~~this method is less flexible than agar dilution or disk diffusion in adjusting to the changing needs~~
270 ~~of the surveillance/monitoring programme.~~

271 ~~Because the purchase of antimicrobial plates and associated equipment may be costly, this~~
272 ~~methodology may not be feasible for some laboratories.~~

273 5.2.2. Agar dilution

274 Agar dilution involves the incorporation of varying concentrations of antimicrobial agent into an
275 agar medium, usually using serial twofold dilutions, followed by the precise application of a
276 defined bacterial inoculum to the agar surface of the plate. This method may be considered the
277 most reliable for MIC determination for some antimicrobials (fosfomycin, mecillinam) and for
278 certain bacteria where broth dilution methods are not ~~well established~~ fully validated.

279 The advantages of agar dilution methods include:

- 280 i) the ability to test multiple bacterial isolates (generally 32 to 60), except bacteria that swarm,
281 on the same set of agar plates at the same time,
- 282 ii) the potential to improve the identification of measurement of more precise MICs endpoints
283 and extend the antibiotic concentration range (i.e. test using concentrations that are less

284 than the traditional two-fold dilutions in the concentrations ranges tested, e.g. 3, 2, 1.5, 1,
285 0.75, 0.5, 0.25 µg/ml).

286 iii) the possibility to semi-automate the method using an inoculum-replicating apparatus.
287 Commercially produced inoculum replicators are available and these can transfer with
288 precision between 32 and 60 inocula prepared from different bacterial inocula-isolates onto
289 each agar plate.

290 Agar dilution methods also have certain disadvantages, for example:

291 i) if not automated, they are very laborious and require substantial economic and technical
292 resources,

293 ii) once the plates have been prepared, they normally should be used within 1–3 weeks
294 depending ~~in-on~~ quality control results (or less, depending on the stability of the
295 antimicrobials ~~tested test~~).

296 iii) the endpoints are not always easy to read.

297 Agar dilution is often recommended as a standardised AST method for fastidious organisms
298 (CLSI, 2015-2017), such as anaerobes and *Helicobacter* ~~species spp.~~

299 **5.3. Other bacterial AST and specific antimicrobial resistance tests**

300 Bacterial antimicrobial MICs can also be obtained using commercially available gradient strips that
301 ~~diffuse-contain~~ a predetermined ~~antibiotic-antimicrobial~~ concentration gradient. However, the use of
302 gradient strips can be expensive and MIC discrepancies can be found when testing certain bacteria and
303 antimicrobials-combinations compared with results of other methods (Ge *et al.*, 2002; ~~Rathe et al., 2009~~).
304 Gradient strip methods are not recommended for testing the susceptibility of the antimicrobial agent
305 colistin because of the large size of this molecule and its poor diffusion in agar (Matuschek *et al.*, 2018).
306 An accurate, simple, and practical method for determining colistin MICs is the colistin broth disk elution
307 test (Simner et al., 2019).

308 Regardless of the AST method used, the procedures should be documented in detail to ensure accurate
309 and reproducible results, and appropriate reference and quality control organisms should always be
310 tested ~~every time AST is performed in order~~ to ensure accuracy and validity of the data.

311 The appropriate AST method choice can be dependent on the growth characteristics of the bacterium in
312 question, as well as the objective of testing. In special circumstances, novel test methods and assays
313 may be more appropriate for detection of particular-specific resistance phenotypes. For example,
314 chromogenic cephalosporin-based tests (CLSI, 2018-2024a) (e.g. nitrocefin) may provide more reliable
315 and rapid results for beta-lactamase ~~determination-production~~ in certain bacteria, whereas inducible
316 clindamycin resistance in *Staphylococcus* spp. may be detected using a disk diffusion method employing
317 standard erythromycin and clindamycin disks in adjacent positions and measuring the resultant zones of
318 inhibition (e.g. D-zone or D-test) (Zelazny *et al.*, 2005).

319 Similarly, extended-spectrum beta-lactamase (ESBL) (CLSI, 2018-2024a) activity in certain bacteria can
320 also be detected ~~by~~ using standard disk diffusion ~~susceptibility~~ test methods incorporating specific
321 cephalosporins (cefotaxime and ceftazidime) separately and in combination with a beta-lactamase
322 inhibitor (clavulanic acid) and measuring the resulting zones of inhibition. Penicillin-binding protein 2a
323 (PBP 2a) can also be detected in methicillin resistant staphylococci with a latex agglutination test
324 (Stepanovic *et al.*, 2006). It is essential that testing of known positive and negative control strains occurs
325 alongside clinical isolates to ensure accurate results.

326 Susceptibility testing may also be performed using only concentrations at or near the clinical breakpoint
327 values ~~specifically intended~~ to detect particular mechanisms of ~~bacterial~~ resistance of clinical or public
328 health importance. For example, resistance to the carbapenems, which are ~~used prudently reserved~~ to
329 treat highly-resistant bacterial infections in humans (EUCAST, 2017).

330 ~~Whenever possible, molecular testing may be useful in addressing or confirming inconclusive phenotypic~~
331 ~~results and may be used for the early detection or detection of resistant microorganisms of high public~~
332 ~~health importance.~~

333 **5.4. Future directions in antimicrobial susceptibility/resistance detection – Gene-based**
334 **resistance detection**

335 Whenever possible, molecular testing may be useful in addressing or confirming inconclusive phenotypic
336 results and may be used for the early detection or detection of resistant microorganisms of high public
337 health importance.

338 The use of genotypic approaches for detection of antimicrobial resistance genes has been promoted as
339 a way to increase the rapidity and accuracy of susceptibility testing (Cai *et al.*, 2003; Chen *et al.*, 2005).
340 Numerous DNA-based assays are being developed to detect bacterial resistance at the genetic level.
341 The newest and perhaps most state-of-the-art approach is whole genome sequencing (WGS), which has
342 been shown with a few bacterial pathogens to predict antimicrobial resistance phenotypes via
343 identification and characterisation of known genes that encode resistance mechanisms.

344 **5.4.1. Molecular tests**

345 Methods that employ the use of comparative genomics, genetic probes, microarrays, nucleic acid
346 amplification techniques (e.g. polymerase chain reaction [PCR]), and DNA sequencing offer the
347 promise of increased sensitivity, specificity, and speed in the detection of specific known
348 resistance genes (Cai *et al.*, 2003; Chen *et al.*, 2005; Perreten *et al.*, 2005). Genotypic methods
349 have been successfully applied to supplement traditional AST phenotypic methods for ~~other~~
350 ~~organisms including identifying~~ methicillin-resistant staphylococci, vancomycin-resistant
351 enterococci, and detecting fluoroquinolone resistance mutations (Cai *et al.*, 2003; Chen *et al.*,
352 2005; Perreten *et al.*, 2005). PCR methods have also been described for various antimicrobial
353 resistance genes, including beta-lactamases, aminoglycoside inactivating enzymes, tetracycline
354 efflux genes, and colistin resistance genes (Cai *et al.*, 2003; Chen *et al.*, 2005; Frye *et al.*, 2010;
355 Perreten *et al.*, 2005; Rebelo *et al.*, 2018).

356 Technological innovations in DNA-based diagnostics should allow for the detection of multiple
357 resistance genes and/or variants during the same test. The development of rapid diagnostic
358 identification methods and genotypic resistance testing should help reduce the emergence of
359 antimicrobial resistance, by enabling the use of the most appropriate antimicrobial when therapy
360 is initiated. However, DNA techniques have to be demonstrated to be complementary to AST
361 methods and results.

362 Additionally, new technological advances may facilitate the ability to probe bacterial species for
363 large numbers of antimicrobial resistance genes quickly and cheaply, thereby providing additional
364 relevant data for surveillance and monitoring programmes (Frye *et al.*, 2010). However, despite
365 the new influx of genotypic tests, documented and agreed upon phenotypic AST methods will still
366 be required in the near future to detect emerging resistance mechanisms among bacterial
367 pathogens and to detect and characterise newly discovered mechanisms of resistance for the
368 development and validation of genetic testing. A literature review (Ellington *et al.*, 2017)
369 considered the role of whole genome sequencing (WGS) in antimicrobial susceptibility testing of
370 bacteria and concluded there was insufficient published evidence to support the use of AST via
371 WGS to replace phenotypic AST in clinical settings for all bacterial species, although certain
372 bacteria (e.g. *Salmonella*, *Staphylococcus aureus*) had been well characterised for that purpose.
373 Subsequently several publications have added support to the use of genetic AST (e.g. McDermott
374 *et al.*, 2016, Zhao *et al.*, 2016). The future of genetic testing in the detection of antimicrobial
375 resistance is promising, but phenotypic testing will remain an important mainstay.

376 **5.4.2. Whole genome sequencing**

377 In the past decade, it has become feasible to detect and monitor antimicrobial resistance on a
378 very large scale using genomic approaches (EFSA, 2021; McDermott *et al.*, 2016). With the
379 advent of high-capacity WGS technology, it is relatively inexpensive to quickly determine the
380 genomic sequence of a microorganism (Allard *et al.*, 2019) and to identify the presence and
381 location of antimicrobial resistance (and other) determinants comprehensively, even for
382 compounds not routinely tested using traditional AST methods. A growing body of evidence
383 shows that the presence of known resistance determinants correlates strongly with MICs at or
384 above the 'resistant' clinical breakpoint for most agents in many pathogens and intermediate
385 (decreased susceptibility) for some pathogens (Feldgarden *et al.*, 2019; Tyson *et al.*, 2015; 2017;
386 Zhao *et al.*, 2016). At present, analysis of WGS data requires a high level of technical mastery
387 and bioinformatics skills. Improvements to the technology and a reduction in start-up costs should
388 make WGS more accessible to hospitals and clinics, as well as public health institutions
389 conducting pathogen monitoring.

390 While complexities in WGS data management and interpretation require bioinformatics expertise,
391 this can be supported to a certain extent by national service laboratories or by the international
392 genomics database at the US National Institute of Health (NIH) and others, where bioinformatics
393 is automated for antimicrobial resistance annotation and is freely available to all users.

394 An added benefit of WGS is that it can replace many traditional microbiology methods for
395 characterising organisms that used to require dedicated instrumentation and specialised
396 expertise, such as bacterial speciation, serotyping and pathotyping. It can also greatly improve
397 tracking of antimicrobial resistant strains and determining the antimicrobial resistance source
398 attribution. While many older genetic methods such as multiplex DNA amplification methods can
399 also provide the resistance genotype, the advantages of WGS have obviated these *ad hoc*
400 techniques for most purposes while also detecting new alleles not found by amplicon-based
401 techniques. Furthermore, some studies show the promise of WGS to also predict actual MICs
402 and not just susceptibility phenotype (Nguyen *et al.*, 2019; Tyson *et al.*, 2017), suggesting the
403 possibility that WGS methods may eventually fully complement traditional AST methods across
404 the range of susceptibility phenotypes.

405 Despite the rapidly expanding genetic and genomic data, documented and agreed upon
406 phenotypic AST methods will still be required in the foreseeable future to detect emerging
407 resistance mechanisms among bacterial pathogens and to detect and characterise newly
408 discovered mechanisms of resistance for the development and validation of genetic testing. This
409 process will be used to update canonical resistance gene databases, where artificial intelligence
410 (AI) and machine learning tools can be applied to genome-based AST. The timeline for mature
411 sequence-based AST will depend upon the number and diversity of genomes made available for
412 training AI algorithms, and the possibility that stable signature sequences alone or in combination
413 exist for reliably predicting MICs for major pathogens. Additionally, standardised laboratory
414 methods and bioinformatic pipelines will be needed to harmonise WGS results across
415 international entities.

416 **6. Antimicrobial susceptibility breakpoints and zone of inhibition testing interpretive** 417 **criteria**

418 The primary objective of *in-vitro*-AST is to predict how a bacterial pathogen may respond to an antimicrobial agent
419 *in vivo*. The results generated by bacterial *in-vitro* antimicrobial susceptibility tests, regardless of whether disk
420 diffusion or dilution methods are used, AST are generally interpreted and reported as susceptible (S), intermediate
421 (I), or resistant (R), susceptible or intermediate to the action of a particular antimicrobial by applying clinical
422 breakpoints or as wild-type (WT) or non-wild-type (NWT) by applying epidemiological cut-off values. No single
423 formula for selection of optimal breakpoints has been established. The process involves a review of existing data
424 and is influenced by the methods used to select appropriate breakpoints.

425 Generally, antimicrobial susceptibility clinical breakpoints and epidemiological cut-off values are established by
426 national standard-setting organisations, professional societies or regulatory agencies. The relevant documents
427 should be consulted. However, There can be notable differences in clinical breakpoints for the same antimicrobial
428 agent within and among countries usually due to differences between standards setting organisations and
429 regulatory agencies and because of regional or national differences in drug formulations and dosing regimens in
430 the various jurisdictions (Brown & MacGowan, 2010; de Jong *et al.*, 2009; Kahlmeter *et al.*, 2006).

431 As mentioned previously, antimicrobial susceptibility testing AST results should be recorded quantitatively:

- 432 i) as distribution of MICs in mg/litre or µg/ml,
- 433 ii) or as inhibition zone diameters in millimetres.

434 The following two three primary factors enable a bacterial isolate's data to be interpreted as susceptible or resistant
435 to S, I, R, WT, or NWT for an antimicrobial agent:

- 436 i) The development and establishment of quality control ranges (CLSI, 2015), for disk diffusion or dilution testing,
437 for quality control reference microorganisms.

438 Establishment of quality control ranges for control organisms is essential for validating test to validate results
439 obtained using a specific AST method. The allowable interpretive category ranges for reference control
440 organisms should be established in addition to determining breakpoints for susceptibility or resistance. The
441 use of reference organisms is a quality control and quality assurance activity.

- 442 ii) The determination of the appropriate interpretive criteria regarding establishment availability of clinical
443 breakpoints (CLSI, 2015-2024b).

444 Clinical breakpoints are established by standard setting organisations, professional societies, and regulatory
445 agencies and This involves the generation-integration of three distinct types of data:

-
- 446 a) MIC population distributions of the relevant microorganisms,
447 b) pharmacokinetic parameters and pharmacodynamic indices of the antimicrobial agent, and when
448 available
449 c) results of clinical trials and the outcome of treatment of clinical cases of disease correlated with AST
450 results from pathogenic isolates.
451 iii) The availability of epidemiological cut-off values (CLSI, 2018; EUCAST 2021).

452 Epidemiological cut-off values are established by EUCAST (2021) (abbreviated ECOFFs) and by the CLSI (2018)
453 (abbreviated ECVs). Both bodies evaluate AST data in very similar ways for the purpose of setting these values.
454 The epidemiological cut-off value represents ~~The development of a concept known as ‘microbiological breakpoints’,~~
455 ~~or ‘epidemiological cut-off values’ (the highest MIC value for the bacterium and antimicrobial agent under~~
456 ~~consideration, where the bacterium is devoid of any phenotypically expressed resistance to that antimicrobial~~
457 ~~agent).~~ Application of these values is often ~~may be~~ more appropriate for ~~some~~ antimicrobial resistance surveillance
458 programmes. ~~Epidemiological cut-off~~—These values are derived by statistically examining MIC population
459 distributions for specific bacterial species and antimicrobials performed at several laboratories according to a
460 standardised broth microdilution method (Turnidge *et al.*, 2006). Bacterial isolates that possess any acquired
461 ~~phenotypic~~ resistance (that is, have an MIC above the epidemiological cut-off value) and therefore deviate from the
462 normal ~~wild-type~~—WT fully-susceptible population are designated as ~~non-wild-type~~—NWT. ~~(also termed~~
463 ~~microbiologically resistant) and~~ This approach allows detection of more subtle shifts in susceptibility to the specific
464 antimicrobial/~~bacterium~~ combination ~~can thus be monitored~~ (Kahlmeter, 2015; Kahlmeter *et al.*, 2006; Turnidge *et*
465 *al.*, 2006). There is a great advantage in the recording of quantitative ~~susceptibility~~—AST data, as such ~~in that~~ data
466 may be analysed according to clinical breakpoints ~~as well as by using~~ or epidemiological cut-off values, when
467 available.

468 The development of clinical breakpoints criteria for disk diffusion tests usually involves comparing disk diffusion
469 data against dilution data by creating a scattergram of the bacterial population distribution (representative bacterial
470 isolates), by plotting the zone of inhibition against the logarithm to the base 2 of the MIC for each bacterial isolate
471 for an individual bacterial species. The selection of breakpoints is then based on multiple factors, including
472 regression line analysis that correlates MICs and zone diameters of inhibition, bacterial population distributions,
473 error rate bounding, pharmacokinetics, and ultimately, clinical verification.

474 7. Antimicrobial susceptibility testing guidelines

475 ~~A number of national standards and guidelines are currently available. Internationally harmonised standards and~~
476 ~~guidelines for antimicrobial susceptibility testing and subsequent interpretive criteria throughout the world~~—AST are
477 available through the: Clinical and Laboratory and Standards Institute (CLSI, 2018 CLSI, clsi.org) and the European
478 Committee on Antimicrobial Susceptibility Testing (EUCAST, 2017 eucast.org).

479 ~~At this time, only the CLSI has developed protocols for susceptibility testing of bacteria of animal origin and~~
480 ~~determination of interpretive criteria (CLSI, 2018). A veterinary sub-committee (VETCAST) has also been set up~~
481 ~~under the umbrella of EUCAST. However,~~ Protocols and guidelines are available from a number of standards
482 organisations and professional societies, including those listed above for susceptibility testing for AST of similar
483 bacterial species that cause infections in humans. It is possible that such guidelines methods can be adopted for
484 susceptibility testing for bacteria of animal origin, but each country must evaluate its own AST standards and
485 guidelines any extrapolation of AST data interpretations should be made with caution. Additionally, efforts focusing
486 on both standardisation and harmonisation of susceptibility/resistance breakpoints on an international scale are
487 progressing. These efforts have primarily focused on the adoption of the standards and guidelines of CLSI and
488 EUCAST, which provide laboratories with methods and quality control values enabling comparisons of AST
489 methods and generated data (CLSI, 2018; Kahlmeter *et al.*, 2006). For those WOA Members that do not have
490 standardised AST methods in place, they are encouraged to adoption of either set of CLSI or EUCAST standards
491 would be as an appropriate initial step towards acceptable methods and international harmonisation.

492 Many bacteria that cause disease in aquatic animals require growth conditions (e.g. lower temperatures,
493 supplemented or semisolid media) that may vary considerably as compared to terrestrial bacterial pathogens. This
494 necessitated the need for the development of antimicrobial testing—AST methods for bacteria isolated from aquatic
495 species. Further information with regards to methods for disk diffusion or broth dilution antimicrobial susceptibility
496 testing—AST and interpretive criteria for bacteria isolated from aquatic animals can be referenced in two CLSI
497 documents (CLSI, 2006; 2014b 2020a; 2020b). Further information with regards to Additionally, methods for disk
498 diffusion or and broth dilution antimicrobial susceptibility testing for AST of infrequently isolated or certain fastidious
499 bacteria (e.g. *Campylobacter*, *Pasteurella*) can also be referenced found in the CLSI's VET06 M45-A document
500 supplement (CLSI, 2015 2017). Specific media formulations for a few fastidious pathogens have also been
501 published online by EUCAST (2022).

502 As a first step towards comparability of monitoring and surveillance data, Members should be encouraged to strive
503 for harmonised and standardised ~~programme design~~ AST methods (Brown & MacGowan, 2010; Kahlmeter *et al.*,
504 2006; White *et al.*, 2004). Data from countries using different methods and programme design may otherwise not
505 be directly comparable (Brown & MacGowan, 2010). Notwithstanding this, data collected over time in a given
506 country may at least allow the detection of emergence of antimicrobial resistance or trends in prevalence of
507 susceptibility/resistance in that particular country (Petersen *et al.*, 2003). However, if results achieved with different
508 AST methods are to be compared, then comparability of results must be demonstrated and consensus on
509 interpretation achieved. This will be best accomplished by the use of accurate and reliable documented AST
510 methods used in conjunction with monitoring of AST performance while using well characterised reference
511 microorganisms among participating laboratories.

Table 1. Phenotypic susceptibility testing AST methods available and their features

Susceptibility testing <u>AST</u> method	International standard available?	Published methods available?	Used in national surveillance programmes?	Use in susceptibility testing for therapeutic purposes	Breakpoints that may be applied	Test output	Comparability of outputs	Features
Broth (micro) dilution-MIC determination	Yes (ISO 20776-1), CLSI, EUCAST	Yes (CLSI, EUCAST)	Yes, broth microdilution MIC determination is preferred <u>widely used</u>	Yes	Clinical breakpoints or epidemiological cut-off values (ECOFFs)	MIC	High	Current reference method. Recording MIC values allows interpretation of the test outputs using different breakpoints (e.g. clinical breakpoint or ECOFF), as well as re-evaluation of historical data if changes occur to breakpoints and evaluation of shifts in MIC. Numerous national surveillance programmes adopt this method. The MIC value can sometimes indicate the likely mechanism of resistance (e.g. high-level amikacin resistance and rRNA methylases) or provide an epidemiological marker. Currently, this is the only method suitable for determining susceptibility to colistin.
Agar dilution MIC determination	No	Yes (CLSI, EUCAST)	<u>No</u> , not widely <u>generally</u> used	Yes	Clinical breakpoints or ECOFFs	MIC	Dependent on congruity of methods used	Reference method. The breakpoints appropriate for broth dilution may not be directly applicable to agar dilution. Currently used in particular for testing certain fastidious organisms.
Breakpoint method	No	Yes (scientific literature)	Not widely used	Yes	The test is performed at a set breakpoint	Resistant or susceptible at selected breakpoint	Dependent on congruity of methods used	Changes to breakpoints in this method result in the inability to interpret historical data. Shifts in susceptibility within the S or R categories cannot be detected. The breakpoint method relies on the growth or absence of growth of bacteria in broth or on agar containing an antimicrobial at a single (breakpoint) dilution.
Gradient strip method <u>E-test</u>	No	Yes (manufacturer only)	<u>No</u> , not widely <u>generally</u> used	Yes	Clinical breakpoints or ECOFFs	MIC	High	Provide a convenient alternative method of determining MIC with minimal additional equipment required.
Disk diffusion test	No	Yes (CLSI, EUCAST) A number of different methods are available. These are not in general equivalent.	<u>Yes</u> May be used, but broth microdilution MIC determination is preferred	Yes	Clinical breakpoints (ECOFFs are also available for the EUCAST disc diffusion method).	Diameter of zone of inhibition, interpreted as resistant or susceptible according to test guidelines	Dependent on congruity of methods used	Frequently used to provide an indication of susceptibility for therapeutic purposes. Versatile in that different discs can be used, according to the antimicrobials authorised for treatment. Different methods are not usually equivalent (zone sizes obtained using one method cannot be interpreted using criteria from another, different method). The collection of zone size data can allow shifts in susceptibility to be detected. Disc diffusion methods may be harmonised to a degree with other methods, by using the same breakpoint.

513 The susceptibility testing method selected should provide details of the method, appropriate controls and quality control ranges and breakpoints interpretive criteria. The comparability of outputs
514 obtained in surveillance programmes is not only dependent on the laboratory methodology used but is also dependent on the target population of livestock included in the study and method of
515 sampling.

516 8. Comparability of results

517 To determine the comparability of results originating from different surveillance systems, results obtained from
518 standardised AST should be reported quantitatively including information on the performance of the methods, the
519 reference organisms and clinical breakpoints/epidemiological cut-off values used ~~and the antimicrobial~~.

520 Sample sources, analytical methods, AST methods, and interpretive criteria should be clearly described, and
521 differences transparently explained to show where data may not be directly comparable.

522 AST data, consisting of cumulative and ongoing summaries of susceptibility patterns (antibiograms) ~~among clinically~~
523 ~~important and surveillance microorganisms~~ should be created, recorded and analysed periodically at regular
524 intervals (CLSI, ~~2014a-2022~~). Data must also be presented in a clear and consistent manner so that both new
525 patterns of resistance can be identified and atypical findings confirmed or refuted. This data should be available on
526 a central data bank and published yearly.

527 Cumulative AST data will be useful in monitoring susceptibility/resistance trends in a region over time and assessing
528 the effects of interventions to reduce antimicrobial resistance.

529 9. Quality control (QC) and quality assurance (QA)

530 ~~Quality control/quality assurance~~ QC and QA systems should be established in accordance with chapter 1.1.5 in
531 laboratories performing AST:

532 i) ~~quality control~~ QC refers to the operational techniques that are used to ensure accuracy and reproducibility of
533 AST results,

534 ii) ~~quality assurance~~ QA includes, but is not limited to, monitoring, record keeping, evaluating, taking potential
535 corrective actions if necessary, calibration, and maintenance of equipment, proficiency testing, training and
536 QC. A QA programme helps ensure that testing materials and processes provide consistent quality results.

537 The following components should be determined and monitored:

538 i) precision of the AST procedure,

539 ii) accuracy of the AST procedure,

540 iii) qualifications, competence, and proficiency of the laboratory personnel, as well as the personnel that interpret
541 the results and those that are involved in monitoring of antimicrobial resistance,

542 iv) performance of the appropriate reagents.

543 The following requirements should be respected:

544 i) Strict adherence to specified and documented techniques in conjunction with ~~quality control~~ QC (i.e. assurance
545 of performance and other critical criteria) of media and reagents.

546 ii) Record keeping of:

547 a) lot numbers of all appropriate materials and reagents,

548 b) expiration dates of all appropriate materials and reagents,

549 c) equipment calibration and monitoring,

550 d) critical specifications for AST performance (reference results, time, temperature etc.).

551 iii) The appropriate reference QC microorganism(s) based on availability of QC testing ranges for the
552 antimicrobial(s) tested, should always be used ~~regardless of the AST method employed~~.

553 iv) Reference QC microorganisms are to be obtained from a reliable source ~~for example, from the (e.g. American~~
554 ~~Type Culture Collection (ATCC®), reliable commercial sources, or institutions with demonstrated reliability to~~
555 ~~store and use the organisms correctly.~~

556 ~~v) Reference microorganisms should be catalogued and well characterised, including stable defined~~
557 ~~antimicrobial susceptibility phenotypes. Records regarding these reference organisms should include the~~
558 ~~established resistant and susceptible ranges of the antimicrobials to be assayed, and the reference to the~~
559 ~~method(s) by which these were determined.~~

560 ~~vi) Laboratories involved in AST should use the appropriate reference microorganisms in all AST testing.~~

561 v) Reference QC strains should be kept as stock cultures from which working cultures are derived ~~and should~~
562 ~~be obtained from national or international culture collections.~~ Reference bacterial QC strains should be stored

563 at designated centralised or regional laboratories. Working cultures should not be subcultured from day to day
564 as this introduces contamination and the method of producing working cultures should ensure that stock
565 cultures are rarely used. This may be accomplished with the production of an intermediate stock of cultures
566 derived from the original cultures that are used to create day-to-day working cultures.

567 vi) The preferred method for analysing the overall performance of each laboratory should test the working stock
568 of the appropriate reference QC microorganisms on each day that susceptibility tests are performed.

569 Because this may not always be practical or economical, the frequency of such QC tests may be
570 reduced if the laboratory can demonstrate that the results of QC testing ~~reference microorganisms~~
571 ~~using the selected method~~ are reproducible. If a laboratory can document the reproducibility of the
572 ~~susceptibility testing-AST~~ methods used, testing may be performed on a weekly basis. If concerns
573 regarding accuracy, reproducibility, or method validity emerge, the laboratory has a responsibility to
574 determine the cause(s) and repeat the tests using the reference materials. Depending on the cause(s),
575 daily reference material use and any other corrective action may be re-initiated.

576 vii) Reference ~~microorganisms-QC strains~~ should be tested each time a new batch of media or microtitre plate lot
577 or batch of disks is used, and on a regular basis in parallel with the ~~microorganisms-QC strains~~ to be ~~assayed~~
578 tested.

579 viii) Appropriate biosecurity issues should be addressed in obtaining and dispersing ~~microorganisms-QC strains~~
580 to participating laboratories.

581 10. External proficiency testing

582 Laboratories should participate in external ~~quality assurance-QA~~ and/or proficiency testing programmes in
583 accordance with chapter 1.1.5. Laboratories are also encouraged to participate in international inter-laboratory
584 comparisons (e.g. WHO External Quality Assurance System) (Hendriksen *et al.*, 2009). All bacterial species
585 subjected to AST should be included.

586 National reference laboratories should be designated with responsibility for:

587 i) monitoring the ~~quality assurance-QA~~ programmes of laboratories participating in surveillance and monitoring
588 of antimicrobial resistance,

589 ii) characterising and supplying to those laboratories a set of reference ~~microorganisms-QC strains~~,

590 iii) creating, managing, and distributing samples to be used in external proficiency testing,

591 iv) creating a central database available on the internet (e.g. European Antimicrobial Resistance Surveillance
592 System [EARSS]) that contains the different susceptibility/resistance profiles for each bacterial species under
593 surveillance.

594 11. Conclusion

595 Although a variety of AST methods exist, the goal of ~~*in-vitro* antimicrobial susceptibility testing-AST~~ for clinical
596 veterinary purposes, surveillance and monitoring is the same: to provide a reliable predictor of how a microorganism
597 is likely to respond to antimicrobial therapy in the infected host. This type of information aids the clinician in selecting
598 the appropriate antimicrobial agent, provides data for surveillance, and aids in developing antimicrobial judicious
599 use policies (see [Chapter 6.10](#) of the *Terrestrial Code Manual*).

600 ~~*In-vitro* antimicrobial susceptibility testing-AST~~ can be performed using a variety of formats, the most common being
601 broth microdilution and disk diffusion methods, ~~agar dilution, broth macrodilution, broth microdilution, and a~~
602 ~~concentration gradient test~~. Each of These procedures requires the use of specific testing conditions and methods,
603 including media, incubation conditions and times, and the identification of appropriate ~~quality control-QC~~ organisms
604 along with their specific QC concentration ranges. It is essential that AST methods provide reproducible results in
605 day-to-day laboratory use and that the data be comparable ~~with those results obtained by an acknowledged 'gold~~
606 ~~standard' reference method-across geographical regions and time~~. In the absence of standardised methods or
607 reference procedures, ~~antimicrobial susceptibility/resistance results-AST data~~ from different laboratories cannot be
608 reliably compared.

609 The ~~use-pursuit of using~~ genotypic approaches for detection of antimicrobial resistance genes ~~has also been~~
610 ~~promoted as a way to increase the rapidity and accuracy of susceptibility testing~~. New technological advances in
611 ~~molecular techniques (e.g. microarray) may facilitate the ability to probe bacterial species for large numbers of~~
612 ~~antimicrobial resistance genes quickly and cheaply, thereby providing additional relevant data into surveillance and~~
613 ~~monitoring programs (Ojha & Kostrzynska, 2008; Poxon, 2005) has made significant strides in the past few years,~~
614 becoming more affordable, and offered with a large array of bioinformatics tools to interpret and report the data.
615 While genomics can reliably identify known resistance genes, it has not yet been shown to predict exact MIC values
616 across the range of microbial pathogens. Standardised phenotypic AST methods will still be required to detect novel

617 and emerging resistance mechanisms among bacterial pathogens and to validate their detection via genetic
618 techniques (Ellington *et al.*, 2017).

619 **REFERENCES**

620 ALLARD M.W, STEVENS E.L. & BROWN E.W. (2019) All for one and one for all: the true potential of whole-genome
621 sequencing. *Lancet Infect. Dis.*, **19**, 683–684.

622 ~~BROWN D. & MACGOWAN A. (2010). Harmonization of antimicrobial susceptibility testing breakpoints in Europe:~~
623 ~~implications for reporting intermediate susceptibility. *J. Antimicrob. Chemother.*, **65**, 183–185.~~

624 BRITISH SOCIETY FOR ANTIMICROBIAL CHEMOTHERAPY (BSAC) (2015). BSAC Methods for Antimicrobial Susceptibility
625 Testing Version 14 January 2015 Available at [http://bsac.org.uk/wp-content/uploads/2012/02/BSAC-disc-](http://bsac.org.uk/wp-content/uploads/2012/02/BSAC-disc-susceptibility-testing-method-Jan-2015.pdf)
626 [susceptibility-testing-method-Jan-2015.pdf](http://bsac.org.uk/wp-content/uploads/2012/02/BSAC-disc-susceptibility-testing-method-Jan-2015.pdf) (accessed 16/08/2018).

627 CAI H.Y., ARCHAMBAULT M., GYLES C.L. & PRESCOTT J.F. (2003). Molecular genetic methods in the veterinary clinical
628 bacteriology laboratory: current usage and future applications. *Anim. Health Rev.*, **4**, 73–93.

629 CHEN S., ZHAO S., McDERMOTT P.F., SCHROEDER C.M., WHITE D.G. & MENG J. (2005). A DNA microarray for
630 identification of virulence and antimicrobial resistance genes in *Salmonella* serovars and *Escherichia coli*. *Mol. Cell.*
631 *Probes*, **19**, 195–201.

632 ~~CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI) (2006). Document M42-A, Methods for Antimicrobial Disk~~
633 ~~Susceptibility Testing of Bacteria Isolated from Aquatic Animals; Approved Guideline CLSI, 940 West Valley Road,~~
634 ~~Suite 1400, Wayne, Pennsylvania 19087-1898, USA.~~

635 ~~CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI) (2014a). Document M39-A4. Analysis and Presentation of~~
636 ~~Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline, Fourth Edition. CLSI, 940 West Valley~~
637 ~~Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.~~

638 ~~CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI) (2014b). Document VET 04-A2, Methods for Broth Dilution~~
639 ~~Susceptibility Testing of Bacteria Isolated from Aquatic Animals; Second Edition. Approved Guideline. CLSI, 940~~
640 ~~West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.~~

641 CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI) (2015). Document M45. Methods for Antimicrobial Dilution
642 and Disk Susceptibility of Infrequently Isolated or Fastidious Bacteria; Approved Guideline, Third Edition. CLSI, 940
643 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

644 CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI) (2017). Methods for Antimicrobial Susceptibility Testing of
645 Infrequently Isolated or Fastidious Bacteria Isolated from Animals, First Edition. CLSI supplement VET06. CLSI,
646 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

647 CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI) (2018). Document Vet08. Performance Standards for
648 Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals, Approved Standard, Fourth
649 Edition. CLSI, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

650 CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI) (2020a). Methods for Antimicrobial Broth Dilution and Disk
651 Susceptibility Testing of Bacteria Isolated from Aquatic Animals, Second Edition, CLSI Guideline VET03. CLSI, 940
652 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

653 CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI) (2020b). Performance Standards for Antimicrobial
654 Susceptibility Testing of Bacteria Isolated from Aquatic Animals, Third Edition. CLSI supplement VET04. CLSI, 950
655 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2020.

656 CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI) (2022). Analysis and Presentation of Cumulative
657 Antimicrobial Susceptibility Test Data, Fifth Edition. CLSI guideline M39. CLSI, 940 West Valley Road, Suite 1400,
658 Wayne, Pennsylvania 19087-1898, USA.

659 CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI) (2024a). Performance Standards for Antimicrobial Disk and
660 Dilution Susceptibility Tests for Bacteria Isolated from Animals, Sixth Edition. CLSI standard VET01. CLSI, 940
661 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

- 662 CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI) (2024b). Performance Standards for Antimicrobial Disk and
663 Dilution Susceptibility Tests for Bacteria Isolated from Animals, Seventh Edition. CLSI supplement VET01S. CLSI,
664 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.
- 665 CODEx ALIMENTARIUS (2021) Guidelines on integrated monitoring and surveillance of foodborne antimicrobial
666 resistance and Code of Practice to minimize and contain foodborne antimicrobial resistance. CXG 94-2021.
667 [https://www.fao.org/fao-who-codexalimentarius/sh-](https://www.fao.org/fao-who-codexalimentarius/sh-proxy/en/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252FStandards%252FCXG%2B94-2021%252FCXG_94e.pdf)
668 [proxy/en/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252FStandards%252FCXG%2B94-2021%252FCXG_94e.pdf](https://www.fao.org/fao-who-codexalimentarius/sh-proxy/en/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252FStandards%252FCXG%2B94-2021%252FCXG_94e.pdf)
669
- 670 DEHAUMONT P. (2004). OIE International Standards on Antimicrobial Resistance. *J. Vet. Med. [Series B]*, **51**, 411–
671 444.
- 672 DE JONG A., BYWATER R., BUTTY P., DEROOVER E., GODINHO, K., KLEIN U., MARION H., SIMJEE, S., SMETS, K., THOMAS,
673 V., VALLE, M., & WHEADON A. (2009). A pan-European survey of antimicrobial susceptibility towards human-use
674 antimicrobial drugs among zoonotic and commensal enteric bacteria isolated from healthy food producing animals.
675 *J. Antimicrob. Chemother.*, **63**, 733–744.
- 676 EUROPEAN FOOD SAFETY AUTHORITY (EFSA) (2021). [https://www.efsa.europa.eu/sites/default/files/2021-03/EFSA-](https://www.efsa.europa.eu/sites/default/files/2021-03/EFSA-statement-EFSA-Q-2019-00434.pdf)
677 [statement-EFSA-Q-2019-00434.pdf](https://www.efsa.europa.eu/sites/default/files/2021-03/EFSA-statement-EFSA-Q-2019-00434.pdf)
- 678 ELLINGTON M.J., EKELUND O., AARESTRUP F.M., CANTON R., DOUMITH M., GISKE C., GRUNDMAN H., HASMAN H., HOLDEN
679 M.T.G., HOPKINS K.L., IREDELL J., KAHLMEYER G., KÖSER C.U., MACGOWAN A., MEVIUS D., MULVEY M., NAAS T., PETO
680 T., ROLAIN J-M., SAMUELSON Ø & WOODFORN N (2017). The role of whole genome sequencing in antimicrobial
681 susceptibility testing of bacteria: report from the EUCAST Subcommittee, *Clin. Microbiol. Infect.*, **23**, 2–22.
- 682 EU COMMITTEE ON ANTIMICROBIAL SUSCEPTIBILITY TESTING (EUCAST) (2017). EUCAST guideline for the detection of
683 resistance mechanisms and specific resistances of clinical and/or public health importance v2.0 July 2017.
684 [http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf)
685 [resistance_mechanisms_170711.pdf](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf) (Accessed 18/07/2024).
- 686 EU COMMITTEE ON ANTIMICROBIAL SUSCEPTIBILITY TESTING (EUCAST) (2021). Standard Operating Procedure 10.2
687 MIC distributions and the setting of epidemiological cut-off (ECOFF) values.
688 [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/EUCAST_SOPs/2021/EUCAST_SOP_10.2_MIC](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/EUCAST_SOPs/2021/EUCAST_SOP_10.2_MIC_distributions_and_epidemiological_cut-off_value_ECOFF_setting_20211202.pdf)
689 [distributions_and_epidemiological_cut-off_value_ECOFF_setting_20211202.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/EUCAST_SOPs/2021/EUCAST_SOP_10.2_MIC_distributions_and_epidemiological_cut-off_value_ECOFF_setting_20211202.pdf) (Accessed 18/07/2024).
- 690 EU COMMITTEE ON ANTIMICROBIAL SUSCEPTIBILITY TESTING (EUCAST) (2022). Media preparation for EUCAST disk
691 diffusion testing and for determination of MIC values by the broth microdilution method, Version 7.0.
692 [https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/Media_preparation_v_7.0](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/Media_preparation_v_7.0_EUCAST_AST_2022.pdf)
693 [EUCAST_AST_2022.pdf](https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/Media_preparation_v_7.0_EUCAST_AST_2022.pdf) (Accessed 18/07/2024).
- 694 FELDGARDEN M., BROVER V., HAFT D., PRASAD A.B., TOLSTOY I., TYSON G.H., ZHAO S., HSU C., McDERMOTT P.F.,
695 TADESSE D.A., MORALES C., SIMMONS M., TILLMAN G., WASILENKO J., FOLSTER J.P. & KLIMKE W. (2019). Using the NCBI
696 AMRFinder Tool to Determine Antimicrobial Resistance Genotype-Phenotype Correlations Within a Collection of
697 NARMS Isolates. *Antimicrob. Agents Chemother.*, **63** (11).
- 698 FRYE J.G., LINDSEY R.L., RONDEAU G., PORWOLLIK S., LONG G., McCLELLAND M., JACKSON C.R., ENGLER M.D.,
699 MEINERSMANN R.J., BERRANG M.E., DAVIS J.A., BARRETT J.B., TURPIN J.B., THITARAM S.N. & FEDORKA-CRAY P.J. (2010).
700 Development of a DNA microarray to detect antimicrobial resistance genes identified in the National Center for
701 Biotechnology Information Database. *Microb. Drug Resist.*, **16**, 9–19.
- 702 GE B., BODEIS S., WALKER R.D., WHITE D.G., ZHAO S., McDERMOTT P.F. & MENG J. (2002). Comparison of Etest and
703 agar dilution for in vitro antimicrobial susceptibility testing of *Campylobacter*. *J. Antimicrob. Chemother.*, **50**, 487–
704 494.
- 705 HENDRIKSEN R.S., SEYFARTH A.M., JENSEN A.B., WHICHARD J., KARLSMOSE S., JOYCE K., MIKOLEIT M., DELONG S.M.,
706 WEILL F.X., AIDARA-KANE A., LO FO WONG D.M., ANGULO F.J., WEGENER H.C. & AARESTRUP F.M. (2009). Results of
707 use of WHO Global Salm-Surv external quality assurance system for antimicrobial susceptibility testing of
708 *Salmonella* isolates from 2000 to 2007. *J. Clin. Microbiol.*, **47**, 79–85.
- 709 HUMPHRIES R.M., MILLER L., ZIMMER B., MATUSCHEK E. & HINDLER J.A. (2023). Contemporary Considerations for
710 Establishing Reference Methods for Antibacterial Susceptibility Testing. *J. Clin. Microbiol.*, **61**(6): e01886-22.

- 711 ISO (2006). ISO 20776-1:2006. Clinical laboratory testing and *in vitro* diagnostic test systems— Susceptibility testing
712 of infectious agents and evaluation of performance of antimicrobial susceptibility test devices — Part 1: Reference
713 method for testing the *in vitro* activity of antimicrobial agents against rapidly growing aerobic bacteria involved in
714 infectious diseases. International Organization for Standardization (ISO), www.iso.org.
- 715 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION (ISO) (2019). ISO 20776-1:2019(E). Susceptibility testing of
716 infectious agents and evaluation of performance of antimicrobial susceptibility test devices – Part 1: Broth micro-
717 dilution reference method for testing the *in vitro* activity of antimicrobial agents against rapidly growing aerobic
718 bacteria involved in infectious diseases. International Organization for Standardization (ISO), www.iso.org.
- 719 KAHLMETER G. (2015). The 2014 Garrod Lecture: EUCAST – are we heading towards international agreement? *J.*
720 *Antimicrob. Chemother.*, **70**, 2427-2439.
- 721 KAHLMETER G., BROWN D.F., GOLDSTEIN F.W., MACGOWAN A.P., MOUTON J.W., ODENHOLT I., RODLOFF, A., SOUSSY C.J.,
722 STEINBAKK M., SORIANO F. & STETSIUK. (2006). European committee on antimicrobial susceptibility testing
723 (EUCAST) technical notes on antimicrobial susceptibility testing. *Clin. Microbiol. Infect.*, **12**, 501–503.
- 724 MATUSCHEK E., ÅHMAN J., WEBSTER C. & KAHLMETER G. (2018). Antimicrobial susceptibility testing of colistin –
725 evaluation of seven commercial MIC products against standard broth microdilution for *Escherichia coli*, *Klebsiella*
726 *pneumoniae*, *Pseudomonas aeruginosa* and *Acinetobacter* spp. *Clin. Microbiol. Infect.*, **24**, 865–870.
- 727 McDERMOTT P. F., TYSON G. H., KABERA C., CHEN Y, LI C., FOLSTER J. P., AYERS S. L., LAM C., TATE H. P. & ZHAO S.
728 (2016). Whole-Genome Sequencing for Detecting Antimicrobial Resistance in Nontyphoidal *Salmonella*.
729 *Antimicrob. Agents Chemother.*, **60**, 5515–5520.
- 730 NGUYEN M, LONG W, McDERMOTT PF, OLSEN RJ, TYSON GH, ZHAO S, DAVIS JJ. (2019). In Silico Prediction of Minimum
731 Inhibitory Concentrations for Nontyphoidal Salmonella Genomes. *J. Clin. Microbiol.*, 57(2).
- 732 OJHA S. & KOSTRZYŃSKA M. (2008). Examination of animal and zoonotic pathogens using microarrays. *Vet. Res.*,
733 **39**, 4–26.
- 734 PERRETEŃ V., VORLET-FAWER L., SLICKERS P., EHRLICH R., KUHNERT P. & FREY J. (2005). Microarray-based detection
735 of 90 antibiotic resistance genes of gram-positive bacteria. *J. Clin. Microbiol.*, **43**, 2291–2302.
- 736 PETERSEN A., AARESTRUP F.M., HOFSHAGEN M., SIPILA H., FRANKLIN A. & GUNNARSSON E. (2003). Harmonization of
737 antimicrobial susceptibility testing among veterinary diagnostic laboratories in five Nordic countries. *Microb. Drug*
738 *Resist.*, **9**, 381–388.
- 739 POXTON I.R. (2005). Molecular techniques in the diagnosis and management of infectious diseases: do they have a
740 rôle in bacteriology? *Med. Princ. Pract.*, **14**, 20–26.
- 741 RATHE M., KRISTENSEN L., ELLERMANN-ERIKSEN S., THOMSEN M.K. & SCHUMACHER H. (2009). Vancomycin-resistant
742 *Enterococcus* spp.: validation of susceptibility testing and *in vitro* activity of vancomycin, linezolid, tigecycline and
743 daptomycin. *APMIS*, **118**, 66–73.
- 744 REBELO A.R., BORTOLAI V., KJELDGAARD J.S., PEDERSEN S.K., LEEKITCHAROENPHON P., HANSEN I.M., GUERRA B.,
745 MALORNY B., BOROWIAK M., HAMMERL J.A., BATTISTI A., FRANCO A., ALBA P., PERRIN-GUYOMARD A., GRANIER S.A., DE
746 FRUTOS ESCOBAR C., MALHOTRA-KUMAR S., VILLA L., CARATTOLI A. & HENDRIKSEN R.S. (2018). Multiplex PCR for
747 detection of plasmid-mediated colistin resistance determinants, *mcr-1*, *mcr-2*, *mcr-3*, *mcr-4* and *mcr-5* for
748 surveillance purposes. *Euro Surveill.*, **23**, 17-00672
- 749 SIMNER P.J., BERGMAN Y., TREJO M., ROBERTS A.A., MARAYAN R., TEKLE T., CAMPEAU S., KAZMI A.Q., BELL D.T., LEWIS
750 S., TAMMA P.D., HUMPHRIES R. & HINDLER J.A. (2019). Two-Site Evaluation of the Colistin Broth Disk Elution Test to
751 Determine Colistin *In Vitro* Activity against Gram-Negative Bacilli. *J. Clin. Microbiol.*, **57**, e01163-18.
- 752 STEPANOVIC S., HAUSCHILD T., DAKIC I., AL-DOORI Z., SVABIC-VLAHOVIC M., RANIN L. & MORRISON D. (2006). Evaluation
753 of phenotypic and molecular methods for detection of oxacillin resistance in members of the *Staphylococcus sciuri*
754 group. *J. Clin. Microbiol.*, **44**, 934–937.
- 755 TURNIDGE J., KAHLMETER G., & KRONVALL G. (2006). Statistical characterisation of bacterial wild-type MIC value
756 distributions and the determination of epidemiological cut-off values. *Clin. Microbiol. Infect.* **12**:418-425.

757 TYSON G.H., McDERMOTT P.F., LI C., CHEN Y., TADESSE D.A., MUKHERJEE S., BODEIS-JONES S., KABERA C., GAINES
758 S.A., LONERAGAN G.H., EDRINGTON T.S., TORRENCE M., HARHAY D.M. & ZHAO S. (2015). Whole-Genome Sequencing
759 Effectively Predicts Antimicrobial Resistance in *Escherichia coli*. *J. Antimicrob. Chemother.*, **70**, 2763–2769.

760 TYSON G., ZHAO S., LI C., AYERS S., SABO J., LAM C., MILLER R. & McDERMOTT P. (2017). Establishing Genotypic Cutoff
761 Values to Measure Antimicrobial Resistance in *Salmonella*. *Antimicrob. Agents Chemother.*, **61**(3): e02140-16.

762 WALKER R.D. (2007). Antimicrobial susceptibility testing and interpretation of results. *In: Antimicrobial Therapy in*
763 *Veterinary Medicine*, Giguere S., Prescott J.F., Baggot J.D., Walker R.D., Dowling P.M. eds. Ames, IA, Blackwell
764 Publishing.

765 WHITE D.G., ACAR J., ANTHONY F., FRANKLIN A., GUPTA R., NICHOLLS T., TAMURA Y., THOMPSON S., THRELFALL J.E.,
766 VOSE D., VAN VUUREN M., WEGENER H. & COSTARRICA L. (2001). Standardisation and harmonisation of laboratory
767 methodologies for the detection and quantification of antimicrobial resistance. *Rev. Sci. Tech. Off. int. Epiz.*, **20**,
768 849–858.

769 WORLD HEALTH ORGANIZATION (WHO) (2017). Integrated surveillance of antimicrobial resistance in foodborne
770 bacteria: application of a one health approach: guidance from the WHO Advisory Group on Integrated Surveillanc
771 of Antimicrobial Resistance (AGISAR). WHO, Geneva, Switzerland, pp 76. ISBN: 978-92-4-151241-4
772 <https://www.who.int/publications/i/item/9789241512411>

773 WORLD ORGANIZATION FOR ANIMAL HEALTH (WOAH) (2024). Chapter 6.8. Harmonization of National Antimicrobial
774 Resistance Surveillance and Monitoring Programs. *In: Terrestrial Animal Health Code*. WOAH, Paris, France.
775 [https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/?id=169&L=1&htmlfile=chapitre_antibio_harmonisation.htm)
776 [access/?id=169&L=1&htmlfile=chapitre_antibio_harmonisation.htm](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/?id=169&L=1&htmlfile=chapitre_antibio_harmonisation.htm)

777 ZELAZNY A.M., FERRARO M.J., GLENNEN A., HINDLER J.F., MANN L.M., MUNRO S., MURRAY P.R., RELLER L.B., TENOVER
778 F.C. & JORGENSEN J.H. (2005). Selection of strains for quality assessment of the disk induction method for detection
779 of inducible clindamycin resistance in staphylococci: a CLSI collaborative study. *J. Clin. Microbiol.*, **43**, 2613–2615.

780 ZHAO S., TYSON G.H., CHEN Y., MUKHERJEE S., YOUNG S., LAM C., FOLSTER J.P., WHICHARD J.M. & McDERMOTT P.F.
781 (2016). Whole-Genome Sequencing Analysis Accurately Predicts Antimicrobial Resistance Phenotypes in
782 *Campylobacter* spp. *Appl. Environ. Microbiol.*, **82**, 459–466.

783 *

784 * *

785 **NB:** There is a WOAH Reference Laboratory ([https://www.woah.org/en/what-we-offer/expertise-](https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3)
786 [network/reference-laboratories/#ui-id-3](https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3)) and WOAH Collaborating Centres that cover antimicrobial resistance
787 (<https://www.woah.org/en/what-we-offer/expertise-network/collaborating-centres/#ui-id-3>).
788 Please contact the WOAH Reference Centres for any further information on antimicrobial resistance

789 **NB:** FIRST ADOPTED IN 2004. MOST RECENT UPDATES ADOPTED IN 2019.

REUNIÓN DE LA COMISIÓN DE NORMAS BIOLÓGICAS
París, 9–13 de septiembre de 2024

CHAPTER 2.2.1.

DEVELOPMENT AND OPTIMISATION OF ANTIBODY DETECTION ASSAYS

INTRODUCTION

The WOAH Validation Recommendations in Section 2.2 Validation of diagnostic tests of this Terrestrial Manual provide detailed information and examples in support of the WOAH Validation Standard that is published as Chapter 1.1.6 Validation of diagnostic assays for infectious diseases of terrestrial animals. The Term “WOAH Validation Standard” in this chapter should be taken as referring to that chapter. An up-to-date compilation of the relevant validation standards (WOAH and non-WOAH) and guidance documents for all stages of diagnostic test validation and proficiency testing, including design, analysis as well as clear, complete and transparent reporting of validation studies with case studies is provided in Colling & Gardner (2021). Published standards for peer-reviewed reporting of accuracy studies (STARD) are available for infectious diseases of humans (Bossuyt et al., 2015), and terrestrial animals (Gardner et al., 2011; 2019; Kostoulas et al., 2017; 2021). In their review of WOAH recommended diagnostic tests, Cullinane & Garvey (2021) concluded that enzyme-linked immunosorbent assay (ELISA) and molecular assays were the most widely used WOAH-recommended tests and further examples for these methods can be found in Mayo et al. (2021).

Detection of antibodies that are elicited in response to infectious agents constitutes an indirect means of laboratory-based disease diagnosis. The most common antibody detection methods are enzyme-linked immunosorbent assay (ELISA), classical virus neutralisation test (VNT), enzyme-linked immunosorbent assay (ELISA), haemagglutination inhibition (HAI) and the complement fixation test (CFT). Other, less common, antibody detection tests are the agar gel immunodiffusion (AGID), the indirect fluorescent antibody test (IFAT), the serum agglutination test (SAT), the latex agglutination test (LAT), and the microscopic agglutination test (MAT). More recent novel methods include biosensors, bioluminometry, fluorescence polarisation, chemoluminescence and lateral flow devices also known as point of care or pen-side tests. Other immunological assays that use antibodies in antigen detection tests are described in Chapter 2.2.2.

When considering a candidate an assay type for disease diagnosis, one should include antibody detection assays because of their practicality, ease of sample collection and preparation, generally good diagnostic performance characteristics including the possibility to detect antibodies for long periods of time after infection, suitability for automation (high-throughput), low cost and fast turn-around time. They are particularly useful for processing large numbers of samples in epidemiological and population studies, or for mass diagnosis and surveillance programmes. Antibody assays are also widely used for export, import and trade of animals, and still represent the majority of WOAH recommended tests for international trade.

Comprehensive and well-designed experiments are required to develop and optimise assays with favourable analytical characteristics. The underlying principles are broadly applicable to all assay types and, when conducted with appropriate rigour, provide the foundations for high-quality diagnostic tests that are fit for their intended purpose(s) (Bowden et al., 2021). A characteristic of antibody assays is their capacity to indicate prior exposure to an infectious agent in the absence of detectable organisms or their analytes. They are also adaptable to a variety of matrices, such as serum, plasma, whole blood, milk, lacrimal secretions

43 and saliva. Immunoglobulin isotype or subclass-specific test systems may selectively target early or late
 44 immune responses, e.g. IgM and IgG, respectively. Specifically designed detection systems allow
 45 differentiation between responses to vaccine and field strains and are available as commercial kits, e.g. the
 46 detection of antibodies to classical swine fever virus in pigs. Competitive or blocking formats allow use of
 47 the same basic assay for a variety of animal species while other formats are species specific. Many types
 48 of chemical or physical indicators are used to indicate the presence of specific antibody in a specimen
 49 (chromogens, fluorochromes, agglutinins, among many others). Because of the large number of antibody
 50 detection methods available, it is not possible to describe the best practices for validation of each of these
 51 assay types in this chapter. ~~The most widely used antibody detection system, the ELISA, will therefore be~~
 52 ~~used as an example for application of best practices in antibody assays.~~ Most of the basic processes used
 53 to validate other types of assay systems will become evident by extension of those used to validate ELISAs.

54 A. ANTIBODY DETECTION ASSAY DEVELOPMENT PATHWAY

55 1. Intended purpose(s) of the antibody assay

56 The first consideration in assay development is to define clearly the specific purpose and application of the test to be
 57 developed. Many decisions in developing assays will be based on these first considerations. For antibody detection assays
 58 (hereafter in this chapter designated as “antibody assays”) such as ELISA, such knowledge will guide the selection of the
 59 most appropriate type of antibody detection system to achieve the intended purpose. Many factors related to the assay’s
 60 intended purpose, use, and suitability need to be taken into account ~~(see the WOAHS Validation Standard for other possible~~
 61 ~~purposes).~~ An example-based overview for the purpose-oriented use of diagnostic tests is provided in Gardner *et al.* (2021),
 62 Chapter 1.1.6 *Validation of diagnostic assays for infectious diseases of terrestrial animals*. Table 1 highlights the relevance of
 63 assay parameters such as diagnostic sensitivity and specificity, predictive value and likelihood ratios for individual purposes.

64 The six basic intended purposes for diagnostic assays relevant in the WOAHS context are stated in Chapter 1.1.6 and the
 65 WOAHS Validation Standard, and listed in the footnote to Table 1 below. Because antibody assays have such a broad range
 66 of applications, and can be configured for very specific purposes, it is useful to consider and evaluate several parameters
 67 when establishing the specific purpose(s) for the candidate assay. Table 1 summarises characteristics of antibody assays
 68 when applied for different purposes. Consideration of these characteristics will provide guidance in establishing the specific
 69 purposes for which the candidate assay will be fit.

70 ~~Note—The reader is advised to read Section B.4. Programme implementation, as a primer for the following discussions.~~
 71 ~~That section describes the inter-relationships between diagnostic sensitivity and specificity, false positive and negative test~~
 72 ~~errors, and positive and negative predictive values. For a more in-depth discussion of predictive values as a function of~~
 73 ~~prevalence, see Jacobson, 1998.~~

74 **Table 1. Determinants of an antibody assay’s fitness for its intended purpose**

Assay characteristics	Determinants of fitness for purpose						
	1*		2*	3*	4*	5*	6*
	a	b					
Diagnostic sensitivity (DSe)	+++	+++	+++	+++	+++	+	+
Diagnostic specificity (DSp)	+	+	+	+	+++	+	+++
Positive predictive value (PPV)	+	+	+	+	+++	+	+++
Negative predictive value (NPV)	+++	+++	+++	+++	+++	+	+
Throughput capacity	+	+++	++	+	–	++	++
Turn-around time of test	+	+	+	+	+++	–	+
QA capability	+++	+++	+++	+++	+++	+++	+++
Reproducibility	+++	+++	+++	+++	+++	+++	+++
Repeatability	+++	+++	+++	+++	+++	+++	+++

75 Other characteristics such as the technical sophistication of the assay, and the skill required
 76 for interpretation will be related to the disease or infection under investigation.

77 **Symbols:** +++ = essential; ++ = of less importance; + = of less importance; – = not important.

78 *Basic purposes for which an assay may be deemed fit: 1.

79 include: 1. Contribute to the demonstration of freedom from infection in a defined population a) 'Free' with or without
80 vaccination, b) Re-establishment of freedom after outbreaks. 2. Certify freedom from infection or presence of the agent in
81 individual animals or products for trade/movement purposes; 3. Contribute to the eradication of disease or elimination of
82 infection from defined populations; 4. Confirmatory diagnosis of clinical cases (includes confirmation of positive screening
83 test); 5. Estimate prevalence of infection or exposure to facilitate risk
84 analysis; 6. Determine immune status in individual animals or
85 populations (post-vaccination). An example-based overview of
86 diagnostic tests for each of the six purposes is provided in Gardner et
87 al. (2021), and chapter 1.1.6 highlights the relevance of assay
88 characteristics for each purpose.

89 Note – The reader is advised to read Section B.4. Stage 4 – Programme
90 implementation, as a primer for the following discussions. That Section
91 describes the inter-relationships between diagnostic sensitivity and
92 specificity, false positive and negative test errors, and positive and
93 negative predictive values. For a more in-depth discussion of predictive
94 values as a function of prevalence, see Jacobson (1998).

Designing the method

- Has the design been shaped by the intended purpose of the assay?
- What is the specific application?
- What are the types and statistically relevant numbers of samples to be tested? (See Chapter 2.2.5)
- Will the test be field or laboratory based?

95 **1.1. Purpose 1: Contribute to the demonstration of freedom from infection in a defined population**

96 For disease freedom categories as given in purposes 1a and 1b (Table 1), ~~antibody screening tests of tests or~~
97 ~~test algorithms favouring a high diagnostic sensitivity (DSe) specificity (DSp) are the tests of choice generally~~
98 ~~considered as fit for purpose.~~ As indicated in the purposes above, these tests would be applied to populations
99 that have an apparent prevalence of zero. Tests of high DSe-DSp demonstrate low false negative (FN) ~~positive~~
100 ~~(FP) rates and when applied to low prevalence populations, the negative predictive value (NPV) is at its highest~~
101 ~~level. However, DSe-DSp and diagnostic specificity (DSp) sensitivity (DSe) are usually inversely related and as~~
102 ~~such, a decrease in DSp-DSe will result in an elevated false positive (FP) negative (FN) rate. Other~~
103 ~~considerations, if this is to involve a continuous volume of surveillance samples, would include high throughput,~~
104 ~~low cost and technical simplicity. All screening test positive results should be subjected to some form of~~
105 ~~confirmatory testing to evaluate their true status. Confirmatory tests characteristically have high DSp and~~
106 ~~therefore a low FP rate. These tests are often more sophisticated, more costly and may require enhanced~~
107 ~~interpretive skills.~~

108 If demonstration of freedom from infection is to be achieved after an outbreak (1b), in which vaccination has
109 been used for disease control, then screening of massive numbers of sera is often required. In addition to the
110 considerations above, this also necessitates an antibody detection test which is able to distinguish between
111 infected and vaccinated animals (i.e. a DIVA [differentiation of infected from vaccinated animals] test). At the
112 same time an antigen or nucleic acid detection test may be warranted in some situations to prove that shedding
113 and/or circulation of the infectious agent has ceased.

114 **1.2. Purpose 2: Certify freedom from infection or presence of the agent in individual animals or** 115 **products for trade/movement purposes**

116 If the purpose is to qualify individual animals for international movement, antibody screening tests of high DSe
117 are ~~again~~ the tests of choice. The same rationale as stated above applies with respect to the NPV. Again, all
118 positive reactors will need to be subjected to some form of confirmatory testing to evaluate their true status or
119 may be excluded from shipment without further testing. In cases where borderline positives are observed, it may
120 be wise to request a repeat sampling of the animal(s) at a suitable time interval to ensure that herd/flock has
121 not been very recently infected.

122 **1.3. Purpose 3: Contribute to the eradication of disease or elimination of infection from defined** 123 **populations**

124 If the purpose of the test is the eradication of disease or elimination of infection from defined populations,
125 antibody screening tests of moderate to high DSe are the tests of choice. However, the rationale is slightly
126 different in that the testing will likely be done at herd or compartment level. At the beginning of the campaign,
127 when the disease prevalence is high, moderate DSe and DSp are suitable as both FP and FN rates are less
128 relevant at this juncture and a moderate level of test error is tolerable. Depending on the nature of the disease
129 and rapidity of spread, high throughput and fast turn-around-times may become critical. Usually, decisions are
130 made without confirmatory testing at this point.

131 In the latter stages of the campaign, a higher DSe is warranted as the FN rate becomes the more critical factor.
132 Much like Purposes 1 and 2, positive reactors will need to be subjected to some form of confirmatory testing to

133 evaluate their true status. In these latter stages, antibody detection tests are often applied in conjunction with
134 antigen and/or nucleic acid detection systems to detect subclinical cases and possibly, latent carriers.

135 **1.4. Purpose 4: Confirmatory diagnosis of clinical cases (includes confirmation of positive**
136 **screening test)**

137 For the confirmatory diagnosis of clinical cases, antibody tests of high DSp are the tests of choice. In these
138 cases, the idea is to minimise the FP rate and enhance the PPV of the test. As a general rule, infection is well
139 established and the immune response is usually well underway. In some situations it may be preferable to carry
140 out a screening test of high DSe but a lower DSp, then following up positives with a high DSp confirmatory
141 test. For some clinical cases, e.g. vesicular diseases in terrestrial animals, several tests may be required to rule
142 out select pathogens that present similar clinical signs. In some cases, antigen and/or nucleic acid detection
143 tests may be a better choice for confirmation of clinical cases provided that they offer a fast turn-around-time. A
144 prime example would be highly pathogenic avian influenza infections where mortality may occur before an
145 immune response is even detectable.

146 **1.5. Purpose 5: Estimate prevalence of infection or exposure to facilitate risk analysis**

147 For estimates of prevalence of infection or exposure to facilitate risk analysis, e.g. for health surveys, herd health
148 status and to monitor disease control measures, antibody tests of moderate DSe & DSp are the tests of choice.
149 In general, this would balance both FN & FP rates and result in a more accurate estimate of the true prevalence
150 of infection in the target population. However, if accurate estimates of both DSe and DSp have been established,
151 statistical approaches can be used to minimise bias attributable to FN & FP rates (see Chapter 2.2.5 *Statistical*
152 *approaches to validation*).

153 **1.6. Purpose 6: Determine immune status in individual animals or populations (post-vaccination)**

154 For the determination of the immune status in individual animals or populations, e.g. post-vaccination, antibody
155 tests of high DSp are required. Such tests have very low FP rates and as such provide a high degree of
156 confidence in the PPV of the result. For use in individual animals, the use of virus neutralisation (VN) tests in
157 cell culture for the detection of vaccine-induced neutralising antibodies against rabies virus in dogs and cats
158 would be a prime example of a test with high DSp used for expression of titres in international units. However,
159 these tests are technically sophisticated, expensive to maintain and run, and require strict biosafety procedures.
160 For larger volume applications, such as monitoring regional vaccination programmes, ELISA-based tests would
161 be more applicable, given their simplicity, cost effectiveness and high throughput. The same DSp considerations
162 should be applied to these types of tests.

163 The experience of laboratory diagnosticians is not only essential in the choice of an appropriate test that will achieve the
164 desired purpose, but is also required to determine reliably the scientific limitations of an assay and practical considerations
165 such as cost, equipment and reagent availability, throughput capacity of the laboratory and test turn-around-times.

166 **2. Assay development – experimentation**

167 **2.1. Reference materials, reagents and controls**

168 **2.1.1. Test samples**

169 Samples to be tested in antibody assays should be
170 handled as described in Chapter 1.1.2 *Collection,*
171 *submission and storage of diagnostic specimens*. The
172 sample matrix in which antibodies are usually
173 detected is serum, but may also include plasma,
174 whole blood, milk, meat juice, egg yoke, lacrimal
175 secretions and saliva.

Designing the method

- Has the design been shaped by the intended purpose of the assay?
- What is the specific application?
- What are the types and statistically relevant numbers of samples to be tested? (See Chapter 2.2.5)
- Will the test be field or lab based?

176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193

2.1.2. Reference Standards

Antisera directed against the reference strain of a pathogen are known as reference sera or reference standards (Wright *et al.*, 1993; ~~WOAH Validation Standard~~ Chapter 1.1.6; Section 1.4 of Chapter 2.2.6 *Selection and use of reference samples and panels*). Such sera containing antibody of known concentration/activity are useful in the initial development of an assay. For a number of WOAHL listed diseases, (e.g. avian influenza, foot and mouth disease, classical swine fever, etc.) international reference standards are available through WOAHL Reference Laboratories and Collaborating Centres. When not available from other sources, it may be necessary to produce in-house reference standards against which working standards (process or quality controls) are calibrated.

Critical points to be addressed:

- Have you considered that concentrations of analyte in matrix significantly impact the lower limit of antibody detection and the operating range of the assay?
- Are the required antibody reagents (mono/polyclonal) available?
- Is available antigen sufficiently purified?
- Are reagents commercially available? If not, is it practical to produce them in-house?
- Are reference standard reagents available? If not, how are you going to resolve this deficiency? (See Chapter 1.1.6, Section A.2.6.)

194

2.1.3. Positive and negative reference panel

These sera, containing concentrations of antibody over the intended operating range, (also known as dynamic range) of the assay, should be used throughout the development and standardisation of an antibody assay. It is recommended that they be prepared in sufficient quantities so that they may be used in various aspects of validation. These samples should represent known infected and uninfected animals from the population that eventually will become the target of the validated assay. They should preferably be derived from individual animals, but they may represent pools of samples from several animals (Chapter 2.2.6). Sera samples have to be stored below -20°C for long-term storage and as pools/aliquots of manageable size and volume. The working stock must be in lower volumes so as to avoid repeated freeze-thaw cycles.

204

2.1.4. Monoclonal antibody reagents

The advent of monoclonal antibodies has greatly enhanced ~~enzyme~~ immunoassays. Whereas polyclonal anti-immunoglobulin conjugates are used in most indirect ELISAs, monoclonal antibody conjugates can be directed to specific immunoglobulin isotypes. Depending on the immunoglobulin epitope targeted, many of these monoclonals can be effectively used to detect antibodies in related species, e.g. ruminants. Using monoclonal conjugates to either light or heavy chain epitopes can effectively modulate the DSP and DSe of the indirect ELISA.

211
212
213

Monoclonal antibodies are best known for their application in competitive or blocking ELISAs. In this case, the monoclonal specificity is directed to epitopes on the pathogen in question. Depending on the epitope targeted, the analytical specificity of the assay can be modulated.

214
215
216
217

Monoclonal antibodies can also be used in sandwich ELISAs, either for trapping antigen to the plate or for subsequently detecting antigens that have been trapped. Depending on the size and complexity of the antigen in question, it is sometimes preferable to use a polyclonal antibody preparation for trapping as they generally contain antibodies of high binding affinity.

218

2.1.5. Antigens.

Antigens used in ELISAs are of critical importance to diagnostic performance given a particular application. Antigens expressing highly conserved epitopes, such as those found in some viral matrix or nucleoproteins, are generally useful in group-specific assays, such as ELISAs for the detection of responses to all Influenza A viruses. Other antigen epitopes can be used to restrict detection to certain serotypes. The choice of antigen must be carefully researched and considered.

Aspects affecting choice of test

- Is the assay to be used for screening or confirmatory purposes, or both?
- Will it be used for one or more species? Which ones?
- Is the test intended for detection of early or late infection?
- Will the test be used to measure serotype- or subtype-specific antibodies?
- Will the assay be used to confirm sero-conversion after vaccination?
- Will it be a DIVA assay (differentiation of infected from vaccinated animals)?
- Will the test be applied to trade?

231
232
233
234
235

Crude antigen preparations like cell lysates have had widespread use in the past, and are still deployed for some assays. However, antigens improved greatly as purification techniques advanced, e.g. affinity chromatography. Further improvements were achieved through the application of molecular cloning. Recombinant antigen technologies have greatly enhanced all aspects of ELISA performance, from analytical through diagnostic characteristics.

236

2.2. Design of test method

237
238
239
240
241
242
243
244
245
246
247
248

In designing a test, its intended application will influence the choice of assay format that is best suited for the task. For example, if its use is primarily for surveillance, then the type of ELISA needs to be conducive to achieving high DSe, as described in the 'Purposes' above. If, however, the screening assay's DSe is set so high that it generates many false positives, then a companion confirmatory test should also be considered at the same time. Many ELISA formats are available, each with their advantages and disadvantages that allow customisation of assays for very specific purposes (Table 2).

Practical matters in selecting an assay format

- Is high-throughput essential? Will it be automated?
- What is the anticipated turnaround time? Is that suitable?
- What level of sophistication is needed to run the assay?
- What skills are required to interpret the test?
- Will that assay be feasible for use in my laboratory?
- Will it be easily transferrable to other laboratories?

249
250
251
252
253
254
255
256
257
258
259
260
261
262
263

Important factors that influence the choice of an antibody assay format are availability of reagents and likely continuity of supply, not only for the design and optimisation stage but for operational scale application of the test. A limitation may be the unavailability of relevant antibody reagents for a particular format, e.g. competitive or blocking formats generally require antigen-specific monoclonal antibodies. Another example would be the need for an effective capturing antigen: a rather crude antigen may be acceptable for use in a sandwich-based ELISA screening assay, whereas a purified antigen would be necessary for a confirmatory assay. Other important considerations for choosing a particular ELISA format are which antibody isotypes, concentrations, avidities and antigenic specificities are diagnostically relevant; which antigen, and in particular which epitopes are relevant; and what is the desired operating range of the assay. All will play a large role in selecting a particular type of ELISA (Table 2-1). If it is anticipated that the test will be used in different species, including wildlife, a competitive/blocking format may be useful (Berguido *et al.*, 2016; 2021; Soubrier *et al.*, 2022). Deciding on an assay format also requires that application of the assay be considered. Questions that should be addressed are detailed in the box above on "Practical matters in selecting an assay format" and practical questions in the boxes below Table 2-1. It is essential to deal with such questions at this point in assay development as they are essential to a positive outcome and application.

264

Table 2-1. ELISA formats: advantages and disadvantages*

Type of ELISA	Advantage	Disadvantage
Indirect – bound Ab detected by anti-species conjugate or by Protein A/G conjugates.	Use and availability of high variety of antispecies-specific conjugates often targeting particular antibody subsets, such as anti IgM, IgG1, IgG2, etc. Protein A and Protein G conjugates have a wide species specificity and may give lower background signals than anti-Ig reagents. Wide use for screening large numbers of samples.	Variation in degree of nonspecific binding in individual sera. To compensate for this problem high starting dilutions are required. This can lead to a decrease in DSe in comparison to competitive/blocking formats. Can only be used for one or a few species at a time.
Sandwich – Ag presented on a solid-bound-phase capture antibody.	The capture antibody on the solid phase can help to orient the antigenic molecule, which improves the chance that the sample antibody will bind. Unpurified antigen preparations can be used because capture antibody selectively binds crude antigen. Pre-coating with capture antibody can reduce the potential for subsequent binding of nonspecific proteins during the test.	Antigens must have at least two antigenic sites or epitopes which limits this type to relatively large antigenic complexes or more complex proteins. Size and spatial relationship of epitopes can affect the assay.

Type of ELISA	Advantage	Disadvantage
Competition (indirect and sandwich types) – Test antibody in sample mixed with pre-titrated detection antibody, then added to wells coated with capture antigen, either in direct or inhibition/blocking format.	<p><u>Can be used in different species for which no species-specific conjugated antibodies exist.</u></p> <p>Easy adaptation for use as antibody detection tests.</p> <p>When highly specific MAbs are used the antigen does not have to be highly purified.</p> <p>Can be used in different species for which no conjugated antibodies exist</p> <p>Advantage of competitive/blocking sandwich type relies on antigen capture.</p> <p>Sera can be tested in low dilutions without risk of interference due to non-specific antibodies binding. This may contribute to a higher sensitivity of this format.</p> <p>Different antibody concentrations can be used to favour either analytical sensitivity or specificity. This is particularly relevant for assays using polyclonal antibodies which are much more affected through the use of different dilutions of sera.</p>	<p>Generally more steps and more optimisation may be needed, e.g. pre-titration and optimisation for liquid and solid phase reagents.</p> <p>Higher level of technical sophistication required.</p>

265 *Primary source is Crowther (2001).

266 2.3. Proof of concept experiments (feasibility studies)

267 After choice of an ELISA format, initial experiments
 268 are designed to determine if the proposed assay is
 269 viable. A reference panel such as described in
 270 Section A.2.1.3 should be tested in the prototype
 271 assay. If a reference standard is to be used for
 272 normalisation of test data, it should be selected and
 273 incorporated at this point in assay development. To
 274 provide continuity in data assessment throughout,
 275 both the reference panel and any reference
 276 standards should be included in all remaining
 277 aspects of the validation studies. The reference panel used in the feasibility study should span the entire
 278 anticipated operating range of ~~the candidate assay~~ test under evaluation (TUE) and be run in replicates as a
 279 quick check for repeatability.

Proof of concept

- Was the feasibility study conducted with at least 4 to 5 samples spanning the operating range of the assay?
- Did you include one or more reference standards if required for data normalisation?
- Was separation of results between negative, low positive and high positive samples adequate?

280 The assay should achieve good separation in OD values, spanning the operating range of antibody activity.
 281 Adequate separation is particularly important between the negative and low positive samples. The lower OD
 282 range should be 0.1 or less for the negative control in indirect ELISAs, or for the strong positive control in
 283 competitive/blocking ELISAs. OD values at the upper end of the operating range should not exceed 2.0, as
 284 above this value plate readers become rather inaccurate. If the assay appears promising, optimisation is the
 285 next step.

286 2.4. Samples and data expression

287 2.4.1. Preparation and storage serum panels for optimisation studies

288 A best practice for antibody assays to select several (a minimum of four to five) serum samples that
 289 range from negative to high levels of antibodies against the infectious agent in question. These samples
 290 are initially used in experiments designed to demonstrate proof of concept. A large volume (e.g. a
 291 minimum of 10 ml) of each serum sample is acquired and divided it into 0.1 ml aliquots for storage at or
 292 below –20°C. One aliquot of each sample is thawed, used for experiments, and ideally then discarded.
 293 If it is impractical to discard the aliquot, it may be held at 4°C between experiments for up to about 2
 294 weeks; however, there is a possibility of sample deterioration under these circumstances. Then, another
 295 aliquot is thawed for further experimentation. This method provides the same source of serum with the
 296 same number of freeze–thaw cycles for all experiments (repeated freezing and thawing of serum can
 297 denature antibodies so should be avoided, Chapter 1.1.2). Also, variation is reduced when the
 298 experimenter uses the same source of serum for all experiments rather than switching among various
 299 sera between experiments. This approach has the added advantage of generating a data trail for the
 300 repeatedly run samples.

301 After the initial stages of assay validation are completed, one or more of the samples may be suitable as
302 a reference standard for data expression and the entire panel may be used for repeatability assessments
303 both within and between runs of the assay (Jacobson, 1998). They may also serve as in-house working
304 standards, i.e. quality or process controls given that their reactivity has been well characterised; such
305 controls provide assurance that runs of the assay are producing accurate data (Wright *et al.*, 1993).

306 **2.4.2. Normalisation of results and their expression**

307 An optical density (OD) reading in ELISA is a measurement of colour development that is a function of the
308 amount of antibody present in a sample. Because colour development is a function of a reaction of
309 enzyme and substrate in the presence of a chromogen, results from day to day are subject to variation
310 attributable to external factors such as temperature, reaction time, etc. Comparison of OD results for the
311 same samples between runs of an assay in the same laboratory, or between laboratories, lacks precision
312 because of variation in results of reference standards included in each run of the assay. Therefore, OD
313 results of test samples need to be adjusted as a function of the OD(s) of one or more reference standards
314 in a specific assay run. This process is known as “normalisation” of ELISA results (see ~~the WOA
315 Validation Standard Chapter 1.1.6~~, Section A.2.7 for details). The method of normalisation and
316 expression of data should be determined, preferably no later than at the end of the feasibility studies.

317 OD values may be expressed in several ways (Wright *et al.*, 1993). A simple method is to express all OD
318 values as a percentage of a single high-positive serum control that is included on each plate. For such
319 calculations, this control must yield results that are in the linear segment of the operating range of the
320 assay. A more rigorous normalisation procedure is to calculate results from a standard curve generated
321 by plotting observed OD values against concentration (or dilution) of antibody for several serum controls
322 that span the range of antibody activity of the assay. It requires a more sophisticated algorithm, such as
323 linear regression, log-logit, or 4 or 5 parameter logistic regression analysis, among others. This approach
324 is more precise because it does not rely on only one high-positive control sample for data normalisation,
325 but rather uses several serum controls, adjusted to expected values, to plot a standard curve from which
326 the sample value is extrapolated. This method also allows for exclusion of a control value that may fall
327 outside expected confidence limits.

328 **2.5. Optimisation**

329 For ELISAs, the most important variables that need to be optimised are concentration/dilution of antigen
330 adsorbed to the solid phase, test serum working dilution, enzyme molarity, antibody-conjugate dilution,
331 and substrate solution concentration. These are evaluated through checkerboard assessments (each
332 variable compared against all other variables within one run of an assay that is repeated several times). Other
333 variables that need consideration are pH and ionicity of reagents, molecular factors such as valency and
334 epitope density of antigens, isotype of targeted antibody and antibody affinity (Bowden *et al.*, 2021).
335 Precision of test results can be graphically depicted or expressed numerically by various statistical methods
336 (Crowther, 2001). ELISA studies require that instrumentation (plate washers and readers, etc.) must be properly
337 calibrated prior to use – part of the laboratory’s quality control programme.

Optimisation and standardisation

- Have all critical reagents been tested against each other in checkerboard titrations?
- Did you find optimal concentration/dilutions for each reagent?
- Did you incorporate quality or process control procedures and reagents?
- Did you incorporate methods for normalisation of test data?

344 **2.6. Inhibitory factors in sample matrix**

345 Although ELISA antibody detection systems are rather resistant to inhibitory factors, ~~the WOA
346 Validation Standard Chapter 1.1.6~~, Section A.2.4, and Greiner *et al.* (1997) provide descriptions of the type of inhibitors
347 that could affect the assay. These references should be reviewed carefully to assure that all inhibitory factors
348 are accounted for and controlled.

349 **2.7. Calibration to reference standard sera**

350 If international, national, or other-source reference sera are available, the assay should be calibrated to match
351 the analytical sensitivity in terms of the metrological units ascribed to the calibration sera (Wright, 1998).

B. ASSAY VALIDATION PATHWAY

352

353 1. Stage 1 – Analytical performance characteristics

354 Factors that affect the analytical characteristics of diagnostic assays are numerous and may vary according to each assay
355 type, for examples, the main factors affecting the analytical characteristics of serological tests are described in Bowden *et*
356 *al.* (2021).

357 1.1. Repeatability

358 Repeatability is the level of agreement between results
359 of replicates of a sample, both within and between runs
360 of the same method in one laboratory. The same or
361 similar panel of samples used in the feasibility study is
362 adequate. No less than three (preferably 5) samples
363 covering the operating range of the assay, and of
364 sufficient quantity for at least 20 runs of the assay over
365 several days. Specifics of how the samples should be
366 prepared and handled are provided in Chapters 2.2.6
367 and ~~in the WOH Validation Standard 1.1.6~~, Section
368 B.1.1. It is valuable to include at least one reference
369 sample in an indirect ELISA (a positive serum control)
370 to which the test samples can be normalised by per
371 cent of the positive control. The within run variation can
372 be determined by the mean OD and coefficient of variation (CV) of the replicates of each sample. The CV should
373 not exceed about 45%–20% (Jacobson, 1998) (with the possible exception of negative and very low positive
374 samples which may have higher (and meaningless CVs). If all of the samples have previously been calibrated
375 to reference standards, and their expected ODs are thus known, the observed ODs for each sample in each run
376 can normalised as a function of their expected ODs in linear regression analysis. This provides a correlation
377 coefficient as evidence of closeness of fit to the expected value, and allows for normalised values to be plotted
378 in control charts (Crowther, 2001).

Analytical performance characteristics

- Has repeatability been established for a range of positive and negative samples within and between runs of the assay?
- Have upper and lower control limits of the assay been established?
- Have you defined ASe and ASp for this assay?
- Does the TUE compare favourably with a standard test method, based on objective quantitative and qualitative criteria?

379 1.2. Analytical specificity

380 Analytical specificity (ASp) is determined by testing sera from animals that are known to have been
381 infected/exposed to all species/strains that the test should detect (Chapter 2.2.6, Section B.1). Cross reactivity
382 with sera from animals infected with related species is used to evaluate the ASp. ELISAs are also subject to
383 false positive results attributable to exogenous factors, such as nonspecific binding of serum or conjugate to the
384 plastic surface that may require use of blocking agents (selectivity). Care must be taken to eliminate this source
385 of error. Blocking and competitive ELISAs may also suffer specificity problems due to steric hindrance
386 preventing proteins binding to their target sites.

387 Analytical specificity in antibody detection assays, which can be further characterised according to selectivity,
388 exclusivity and inclusivity, is assessed using well-characterised samples and should include (Bowden *et al.*,
389 2021):

- 390 i) Sera from animals of known exposure status, including:
- 391 a) non-infected and non-vaccinated animals
- 392 b) non-infected and vaccinated animals
- 393 c) infected and non-vaccinated animals
- 394 d) infected and vaccinated animals
- 395 ii) Details of the source of the material, including species, breed, age, sex, reproductive status,
396 vaccination history, herd history, experimental or field origin, geographical region and the presence
397 or absence of clinical signs
- 398 iii) Sera from animals known to have been infected with the species/strains that the test should detect
- 399 iv) Sera from animals infected with related organisms and pathogens that cause similar clinical signs
400 and which may cause cross-reactions.

401

1.3. Analytical sensitivity

402
403
404
405
406

Analytical sensitivity (ASe) is synonymous with the lower limit of detection (LOD) of antibody concentration in a sample. The different types of antibody assays vary considerably in their inherent limit in antibody detection. For instance, LODs for eight different types of antibody assays range from 1000 ng/ml (radial immunodiffusion) to 0.01 ng/ml (chemiluminescence) (Nielsen *et al.*, 1996). LODs are usually determined by endpoint dilution in which replicates (preferably 10) of each dilution in a log₂ dilution series are run in the assay.

407

1.4. Standard test method comparison with the ~~candidate test method~~ under evaluation (TUE)

408
409
410
411
412

The ~~candidate test method~~ TUE should be run in parallel with an WOA or other accepted reference test method, using the same panel of samples on both, to determine whether the ~~candidate method~~ TUE exhibits the same quantitative and qualitative characteristics as the standard method. Favourable comparability lends strength to the belief that ~~candidate method~~ the TUE will be a successful substitute for the reference method (see also methods comparison studies, Chapter 2.2.5-8).

413

2. Stage 2 – Diagnostic performance characteristics

414
415
416
417
418
419
420

DSe and DSp are the primary performance indicators of the validation process. Antibody assays are subject to the same general procedures to achieve estimates of DSe and DSp as required of all other assay types (see ~~the WOA Validation Standard Chapter 1.1.6~~, Section B.2 for essential details). The number of samples needed to establish these estimates for a particular antibody assay require a sampling design that considers many variables. This includes creation of a sample panel that is tailored particularly for the intended purpose of the assay (e.g. a screening versus confirmatory test). It also requires predetermined desired levels of DSe and DSp (indicating acceptable levels of false negative and false positive results), allowable error in the estimates of such DSe and DSp, and the confidence level required for these estimates.

421
422
423
424
425
426
427
428
429

The number of animals required to establish acceptable DSe and DSp estimates is a function of the level of confidence desired in DSe and DSp estimates and the accepted allowable error. For instance, for a pathogenic disease like FMD, it is necessary to reduce the likelihood that infected animals will be misclassified as uninfected, which reduces allowable error in the test result which, in turn, increases the number of samples needed to establish a high level of confidence in the DSe estimates. Alternatively, for a confirmatory assay it is desirable to reduce the likelihood that uninfected animals will be classified as infected. A high DSp is then desired with minimal allowable error, requiring a larger sample size of uninfected animals. All of these general issues related to sample size, confidence intervals and allowable error in the DSe and DSp estimates are described in ~~the WOA Validation Standard Chapter 1.1.6~~, Section B.2, Table 2 with additional detail and tables of sample numbers required available elsewhere (Jacobson, 1998).

430
431
432
433
434
435
436

It is often challenging to obtain a sufficient number of well characterised sera to achieve estimates of DSe and DSp that are sufficient for the intended purpose of the assay. Initially, it may be a compromise between what is statistically meaningful and practically feasible, resulting in an assay that is provisionally recognised (~~WOAH Validation Standard, Section B.2.6~~) Chapter 1.1.6, Section B.2.6). Colling *et al.* (2018) describe a network approach for provisional recognition of an antibody ELISA for Hendra virus when only low sample numbers from infected animals are available. However, over time, with accumulation of more well characterised samples, the estimates of DSe and DSp may be strengthened (see Chapter 1.1.6, Section 5.4 below).

437

2.1. The challenge in establishing accurate estimates of DSe and DSp for antibody assays

438
439
440
441
442
443
444
445
446
447
448
449

Antibody assays undergoing validation pose unique problems when attempting to assemble known positive and known negative samples in sufficient quantity to establish assay performance characteristics. Antibody is an indirect indicator of the presence of, or prior exposure to, an infectious agent or its components. Inferences from detection of antibody (or the lack thereof) depend on the host's qualitative and quantitative responses to the organism. Factors that affect the concentration and composition of specific antibody in serum samples are inherent to the host (e.g. age, sex, breed, nutritional status, pregnancy, immunological responsiveness) or acquired (e.g. passively acquired antibody, or active immunity elicited by vaccination or infection). Theoretically, samples from animals that represent all of these variables should be included in the panels used for establishing DSe and DSp estimates. Clearly, this becomes a daunting, if not impossible task. To surmount this problem, the initial sample panels should be representative of the majority of animals in the target population to achieve initial estimates of DSe and DSp. In reality, it is necessary to enhance DSe and DSp estimates after the assay has been implemented as more well characterised samples become available (see Section 5.4, below).

450 Because it is often desirable to stretch the application of
451 antibody detection assays to a huge number of animals
452 spanning large geographical areas (e.g. as in screening
453 assays for an entire continent), assembly of fully
454 representative sample panels for such a large diagnostic
455 window of variables may be nearly impossible. A useful
456 alternative is to first establish DSe and DSp estimates for a
457 rather homogeneous population of animals. If the assay is
458 destined for use in disparate populations of animals, which
459 may harbour a different infectious agent profile (with
460 possibility of cross reactions not seen in the original targeted
461 population), a reassessment of DSe and DSp may be
462 necessary, drawing from data acquired using new sample
463 panels that are representative of the population(s) targeted.

Diagnostic performance characteristics

- Are the criteria used to determine the positive and negative reference populations legitimate?
- Do the reference samples fully represent the population targeted by the assay?
- Were there difficulties in obtaining a sufficient number of samples? If so, how was the problem addressed?

464 2.2. Reference animal populations

465 2.2.1. Animals of “known infection status”

466 Reference animals of known infected and known uninfected status are the ideal source of samples for
467 determining DSe and DSp. However, such samples are rare and difficult to establish. The most familiar
468 term for reference animals or samples used in establishing DSe and DSp is the so called “gold standard”,
469 a misnomer commonly used to classify almost any reference animal as infected/exposed or uninfected,
470 with samples from such animals classified as positive or negative (see the WOAH Validation Standard,
471 Chapter 1.1.6, Section B.2.1–2–3).

472 Assay developers should be aware of the advantages, and particularly the pitfalls, associated with
473 various methods that are used to classify reference animals as infected or uninfected. The samples from
474 such animals are deemed either positive or negative, and collectively become the *reference standard*
475 upon which the ~~candidate assay’s TUE’s~~ DSe and DSp are based. It is, therefore, crucial to carefully
476 consider the validity of various reference standards as exemplified in the following four examples:

477 i) An unequivocal reference standard: presence of the agent in the host or evidence of definitive
478 (pathognomonic) histopathology

479 If an infectious agent or definitive histopathological criterion is detected in an animal, this generally
480 constitutes an unequivocal reference standard for that animal. Serum samples derived from such
481 animals usually are considered to be unequivocal serum reference standards for determining DSe
482 and DSp of the ~~candidate assay TUE~~. However, such samples may have their limitations. At the
483 population level, a pathogen may be unequivocally present in some animals, but if the serum
484 sample was taken from the animal early in the infection process, the immune response may not yet
485 have produced detectable antibody. In this case, such serum samples used as reference standards
486 would have been FN for the subset of animals in an early stage of infection. In contrast, for more
487 chronic types of infection, using only reference animals that have confirmatory culture or
488 histopathology may produce higher estimates of DSe than are realistic for the population targeted
489 by the assay because the immune response will always be well established.

490 ii) A composite reference standard: verification of uninfected or unexposed animals

491 This standard is achieved by selecting reference animals from geographical areas where herd
492 histories, clinical profiles, prior testing results and other parameters provide evidence suggesting
493 the absence of the pathogen, and thus no specific host antibody response to the pathogen targeted
494 by the ~~candidate assay TUE~~. These types of reference materials, their strengths and limitations are
495 described elsewhere (Jacobson, 1998), and must be considered carefully when using samples from
496 such sources for establishing DSe and DSp for a ~~candidate assay TUE~~.

497 iii) A relative reference standard: comparative serology

498 This standard is characterised by reference animals that have been classified for their infection
499 status by comparison with the test results of another serological assay on the same samples. It
500 often is the only practical source of reference material available for evaluation of a new serological
501 test. If results of such a reference test are chosen as the standard for determining diagnostic
502 performance characteristics of the ~~candidate assay TUE~~, the resultant estimates of DSe and DSp
503 are useful only insofar as the reference test has documentable, established and acceptable
504 performance characteristics. A deficiency of relative reference standards is that they have their own
505 established levels of FP and FN test results, which are sources of error that will be compounded in

506 estimates of DSe and DSp for the new assay. Generally, however, the use of other well described
507 test methods is regarded as good practice to determine the status of reference animals, but only if
508 the inherent bias introduced by the relative reference standard is accounted for.

509 iv) *An adjunct reference standard: experimental infection or vaccination*

510 (See ~~the WOA Validation Standard, Chapter 1.1.6~~, Section B.2.3 for significant limitations of this
511 type of standard.) In some cases, the only way to obtain positive samples is by experimental
512 infection. This approach is highly suitable to model the dynamics of the infection and to determine
513 the 'diagnostic window' with the new assay. For example, it is possible to get estimates of the time
514 interval between exposure to a pathogen and when antibody is first detectable, or when 25, 50, 75
515 and 100% of the infected animals return a positive test result. Nevertheless, there are pitfalls in use
516 of time-series data that must be avoided. Data representing repeated observations from the same
517 animals cannot be used in calculation of DSe and DSp because the statistical models used to
518 establish DSe and DSp require independent observations (only one sample from each anima). For
519 statistically legitimate time-course studies, or when single samples are used from each of many
520 experimental animals, the strain of cultured organism, route and dose of exposure, infection with
521 other related, cross-reactive and non-related, non-cross-reactive organisms are variables which
522 may produce quantitatively and qualitatively atypical responses which are not found in natural
523 infections in the target population. Experimental conditions typically lead to an overestimation of
524 sensitivity and specificity for example by artificially high challenge doses and by using specific
525 pathogen free animals as negative controls.

526 The time point of sample collection (days post-infection) must be indicated. Sources and history of
527 experimental animals should be described. The validation should not be based solely on
528 experimental animals as they do not represent natural populations of animals subject to pathogens
529 by natural exposure.

530 v) Heuer & Stevenson (2021) describe procedures for diagnostic test validation studies when there is
531 a perfect reference standard available for either positive or negative animals or both.

532 2.2.2. Latent-class models for estimation of DSe and DSp

533 For a discussion of this approach for estimation of diagnostic performance, see ~~the WOA Validation~~
534 ~~Standard Chapter 1.1.6~~, Section B.2.5 and, Chapter 2.2.5, Cheung *et al.* (2021).

535 2.3. Threshold (cut-off) determination

536 The procedures for establishing the cut-off between negative and positive results of antibody assays are as
537 described in ~~the WOA Validation Standard Chapter 1.1.6~~, Section B.2.4.

538 3. Stage 3 – Reproducibility and augmented repeatability estimates

539 Reproducibility is the measure of precision of an assay when used in several laboratories located in distinct regions or
540 countries using the identical assay (protocol, reagents and controls) to test the same panel of samples. Factors affecting
541 testing reproducibility among laboratories and practical examples of proficiency testing and interlaboratory comparison
542 testing are provided by Johnson & Cabuang (2021) and Waugh & Clark (2021). A case study with FMD for selection and
543 use of reference panels is presented in Ludi *et al.* (2021). The relevance of virtual biobanks for transparency purposes with
544 respect to reagents and samples used during test development and validation is reported by Watson *et al.* (2021).
545 Reproducibility assessments for antibody assays are not uniquely different from similar assessments for any other type of
546 assay. Therefore, the reader is directed to ~~the WOA Validation Standard Chapter 1.1.6~~, Section 3, for details on
547 reproducibility analysis and for reference samples and panels to Chapter 2.2.6.

548 4. Stage 4 – Programme implementation

549 4.1. Interpretation of results and determination of predictive values

550 Best practices for programme implementation are general to all assay types (~~WOA Validation Standard,~~
551 ~~Section B.4~~). However, as Ab-ELISA is often the assay of choice for surveillance programs to affirm absence of
552 disease, or for eradication of disease or elimination of infection from defined populations, the issue of false
553 positive results can become a significant problem when the disease prevalence drops, e.g. during proof-of-
554 freedom testing after an outbreak even if the diagnostic specificity is very high. For the interpretation of test
555 results, the predictive value (PV) and likelihood ratio (LR) are widely used. Depending solely on the combined

556 DSe and DSp the LR has the advantage of being prevalence independent (Chapter 1.1.6, Section B.4.2.,
557 Caraguel & Colling, 2021; Jacobson, 1998).

558 A common misperception is that a test with 99% DSp and DSe will only mis-classify animals as FP or FN 1% of
559 the time. The FN and FP rates vary depending on the prevalence of infection in the targeted population. False
560 positive reactions in a disease eradication campaign can vary significantly from the beginning of the campaign
561 when prevalence is relatively high (for example, 10%) to near the end of the campaign when it has decreased
562 to 0.1%. The predictive values of test results then become very important. Predictive values are probabilities
563 that a test result is truly positive or truly negative. In our example using an assay with 99% DSe and DSp for
564 testing a population of animals with a 10% prevalence of disease, the predictive value of a positive test result
565 (PPV) is 91.7%, meaning that there is a 91.7% probability that the animal is truly infected. The predictive value
566 of a negative test result (NPV) is 99.9. When the prevalence drops to 5%, the PPV and NPV are 83.9% and
567 99.9%, respectively. However, if the prevalence drops further to 0.1%, by successfully removing infected
568 animals from the population, the same test will produce a PPV of 9% and a NPV of 99.9%, meaning that there
569 is only a 9% chance that a positive test result is detecting a truly infected animal (of 1000 animals tested, only
570 about 1 in 10 positive test results is indicative of an infected animal – the other 9 are false positive). So, if the
571 test is intended for the purpose of eradication of a disease or elimination of infection from a population, the test
572 developer is advised to consider moving the assay to a second cut-off that yields a higher DSp late in the
573 campaign to reduce the probability of false positive reactions. It is instructive to examine a predictive value chart
574 for assays of varying DSe and DSp, to visualise the effects of reduced prevalence on predictive values of an
575 assay (WOAH Validation Standard, Table 2, and Jacobson, 1998).

576 **5. Monitoring assay performance**

577 **5.1. Monitoring the assay**

578 Once the assay is in routine use, internal quality control is
579 accomplished by consistently monitoring the assay using
580 quality control charts for assessment of repeatability and
581 accuracy. Charts representing at least 30 runs will reveal
582 trends or shifts in values of controls and standards. Lines
583 representing the mean value of a control sample in at least
584 30 runs, plus/minus 3 standard deviations, are useful
585 decision criteria for inclusion or exclusion of a run of the
586 assay. The run is rejected if one control/standard exceeds
587 ± 3 standard deviations (STD) or if 2 controls (or more)
588 exceed ± 2 STD (Crowther, 2001). Decision criteria may
589 need to be customised for a given assay because of inherent
590 differences between assays attributable to the host
591 pathogen system. Chapter 2.2.4 provides an example of how
592 to apply measurement uncertainty for an antibody ELISA
593 using a positive internal control sample.

594 Reproducibility of test results between laboratories should
595 be assessed by External Quality Assurance at least once per
596 year and is an essential requirement of ISO 17025
597 accredited laboratories. Membership in a consortium of
598 laboratories that are interested in evaluating their output is
599 valuable.

600 Crowther et al. (2006) provides a critical review of aspects of
601 kit validation for tests used for the diagnosis and surveillance of livestock diseases: producer and end-user
602 responsibilities.

603 **5.2. Minor modifications of the assay – replacement of depleted reagents (Chapter 2.2.8)**

604 When quality or process control samples are nearing depletion, it is essential to prepare and repeatedly test the
605 replacement samples. The replacement samples should be included in at least 10 routine runs of the assay,
606 with their results normalised against the existing reference standard. The activity of the replacement control
607 should be comparable to the replaced control. If the reference standard requires replacement, care must be
608 taken to select a replacement that matches all of the original serum characteristics as closely as possible, thus
609 allowing use of the replacement to normalise test results with comparable outcomes (see also Chapter 2.2.8
610 Comparability of assays after changes in a validated test method-, Kirkland & Newberry (2021) provide an

Monitoring assay performance

- Has the purpose of the assay changed?
- Has the epidemiology of the disease in question changed, e.g. prevalence, new serotypes or strains, etc.?
- Have critical reagents been changed, and if so, was comparability of the new reagents assessed?
- Are performance indicators included in day to day use of the assay (control charts, basic statistics)?
- Are upper and lower limits in control charts updated periodically as more experience with the control samples is achieved?
- Are procedures in place that determine what to do when controls are outside acceptance limits?
- Are test panels shared with other laboratories to assess reproducibility?
- Is proficiency testing included as part of continuing evaluation of the assay?

611 example-based review of verification studies of diagnostic tests and Reising *et al.* (2021) describe comparability
612 studies of assays after minor changes in a validated test method.

613 When other reagents such as antigen for capture of antibody, must be replaced they should be produced or
614 procured using the same protocols or criteria as used for the original reagents. They need to be assessed using
615 sera from routine submissions in 5–10 parallel runs that include the current and the new reagent(s). A panel of
616 representative samples, such as a proficiency panel, is also a useful tool for assessing the comparability of the
617 reagents (Chapter 2.2.6).

618 **5.3. Major modifications of the assay – changing to a new ELISA type or geographical region**

619 If the assay is to be changed from, say, a sandwich ELISA to a competitive/blocking format, the assay will
620 require revalidation because of the many variables that may affect the performance characteristics of the new
621 assay. For an assay considered for implementation in another geographic region, e.g. from the northern to the
622 southern hemisphere, it is essential to verify and potentially revalidate the assay by subjecting it to sera from
623 populations of animals that reside under local conditions. Evaluation of reference sera that represent those
624 populations ~~is done by using stages 3–5 in Figure 1 in the WOAHS Validation Standard.~~ It is the only way to
625 assure that the assay is valid for populations that are of different composition compared with the original
626 population targeted by the assay.

627 **5.4. Enhancing confidence in validation criteria**

628 Due to the extensive set of variables that have an impact on the performance of serodiagnostic assays, it is
629 useful to expand the number of reference sera wherever possible, recognising the principle that error is reduced
630 with increasing sample size. An expanded reference serum bank should be accumulated with well characterised
631 sera, and used periodically to update estimates for DSe and DSp for the population targeted by the assay.

632 **REFERENCES**

633 BERGUIDO, F.J., BODJO S.C., LOITSCH A. & DIALLO A. (2016). Specific detection of peste des petits ruminants virus antibodies
634 in sheep and goat sera by the luciferase immunoprecipitation system. *J. Virol. Methods*, **227**, 40–46. doi:
635 10.1016/j.jviromet.2015.10.008.

636 BERGUIDO F.J., BURBELO P.D., BORTOLAMI A., BONFANTE F., WERNIKE K., HOFFMANN D., BALKEMA-BUSCHMANN A., BEER M.,
637 DUNDON W.G., LAMIEN C.E. & CATTOLI G. (2021). Serological Detection of SARS-CoV-2 Antibodies in Naturally-Infected
638 Mink and Other Experimentally-Infected Animals. *Viruses*, **13**, 1649. doi: 10.3390/v13081649.

639 BOSSUYT P.M., REITSMA J.B., BRUNS D.E., GATSONIS C.A., GLASZIOU P.P., IRWIG L., LIJMER J.G. MOHER D., RENNIE D., DE VET
640 H.C.W., KRESSEL H.Y., RIFAI N., GOLUB R.M., ALTMAN D.G., HOOFT L., KOREVAAR D.A., COHEN J.F. & STARD (STANDARDS FOR
641 REPORTING DIAGNOSTIC ACCURACY GROUP (2015). STARD 2015: an updated list of essential items for reporting diagnostic
642 accuracy studies. *BJM*, **351**:h5527. doi: 10.1136/bmj.h5527

643 BOWDEN T.R., CROWTHER J.R. & WANG J. (2021). Review of critical factors affecting analytical characteristics of serological
644 and molecular assays. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 53–73. doi:10.20506/rst.40.1.3208.

645 CARAGUEL C.G.B. & COLLING A. (2021). Diagnostic likelihood ratio – the next generation of diagnostic test accuracy
646 measurement. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 299–309. doi:10.20506/rst.40.1.3226.

647 CHEUNG A., DUFOUR S., JONES G., KOSTOULAS P., STEVENSON M.A., SINGANALLUR N.B. & FIRESTONE S.M. (2021). Bayesian
648 latent class analysis when there is an imperfect reference test. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 271–286.
649 doi:10.20506/rst.40.1.3224.

650 COLLING A. & GARDNER I.A. (EDS). (2021). Diagnostic test validation science: a key element for effective detection and control
651 of infectious animal diseases. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**. The Special Issue is available at:
652 [https://doc.woah.org/dyn/portal/index.xhtml?page=alo&alold=41245&req=21&cid=1e3ba84f-604f-47b7-bec3-](https://doc.woah.org/dyn/portal/index.xhtml?page=alo&alold=41245&req=21&cid=1e3ba84f-604f-47b7-bec3-927e54e04b42)
653 [927e54e04b42](https://doc.woah.org/dyn/portal/index.xhtml?page=alo&alold=41245&req=21&cid=1e3ba84f-604f-47b7-bec3-927e54e04b42)

654 COLLING A., LUNT R., BERGFELD J., HALPIN K., McNABB L., JUZVA S., NEWBERRY K., MORRISSY C., HLAING LOH M., CARLILE G.,
655 WAUGH C., WRIGHT L., WATSON J., EAGLES D., LOOMES C., WARNER S., DIALLO I., KIRKLAND P., BRODER C., ZUELKE K.,
656 McCULLOUGH S. & DANIELS P. (2018). A network approach for provisional assay recognition of a Hendra virus antibody

- 657 ELISA: test validation with low sample numbers from infected horses. *J. Vet. Diag. Invest.*, **30**, 362–369.
658 <https://doi.org/10.1177/1040638718760102>
- 659 CROWTHER J.R. (2001). The ELISA guidebook. In: Methods in Molecular Biology. Humana Press, Totowa, NJ, USA, 1–
660 421.
- 661 CROWTHER J.R., UNGER H. & VILJOEN G.J. (2006). Aspects of kit validation for tests used for the diagnosis and surveillance
662 of livestock diseases: producer and end-user responsibilities. *Rev. sci. tech. Off. int. Epiz.*, **25**, 913–935.
663 [doi:10.20506/rst.25.3.1706](https://doi.org/10.20506/rst.25.3.1706)
- 664 CULLINANE A. & GARVEY M. (2021). A review of diagnostic tests recommended by the World Organisation for Animal Health
665 *Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 75–89.
666 <https://doi.org/10.20506/rst.40.1.3209>.
- 667 GARDNER I.A., COLLING A., CARAGUEL C.G., CROWTHER J.R., JONES G., FIRESTONE S.M. & HEUER C. (2021). Introduction:
668 validation of tests for OIE-listed diseases as fit-for-purpose in a world of evolving diagnostic technologies. *Rev. Sci. Tec.*
669 *Off. Int. Epiz.*, **40**, 19–28. [doi:10.20506/rst.40.1.3207](https://doi.org/10.20506/rst.40.1.3207).
- 670 GARDNER I.A., COLLING A. & GREINER M. (2019). Design, statistical analysis and reporting standards for test accuracy studies
671 for infectious diseases in animals: Progress, challenges and recommendations. *Prev. Vet. Med.*, **162**, 46–55.
672 [doi:10.1016/j.prevetmed.2018.10.023](https://doi.org/10.1016/j.prevetmed.2018.10.023).
- 673 GARDNER I.A., NIELSEN S.S., WHITTINGTON R.J., COLLINS M.T., BAKKER D., HARRIS B., SREEVATSAN S., LOMBARD J.E., SWEENEY
674 R., SMITH D.R., GAVALCHIN J. & EDA S. (2011). Consensus-based reporting standards for diagnostic test accuracy studies
675 for paratuberculosis in ruminants. *Prev. Vet. Med.*, **101**, 18–34. PMID: 21601933.
- 676 GREINER M., BHAT T.S., PATZELT R.J., KAKAIRE D., SCHARES G., DIETZ E., BÖHNING D., ZESSIN K.H. & MEHLITZ D. (1997). Impact
677 of biological factors on the interpretation of bovine trypanosomosis serology. *Prev. Vet. Med.*, **30**, 61–73.
- 678 HEUER C. & STEVENSON M.A. (2021). Diagnostic test validation studies when there is a perfect reference standard. In
679 Diagnostic test validation science: a key element for effective detection and control of infectious animal diseases. *Rev. Sci.*
680 *Tech. Off. Int. Epiz.*, **40**, 261–270. [doi:10.20506/rst.40.1.3223](https://doi.org/10.20506/rst.40.1.3223).
- 681 JACOBSON R.H. (1998). Validation of serological assays for diagnosis of infectious diseases. *Rev. sci. tech. Off. int. Epiz.*,
682 **17**, 469–486.
- 683 JOHNSON P. & CABUANG L. (2021). Proficiency testing and ring trials. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 189–203.
684 <https://doi.org/10.20506/rst.40.1.3217>
- 685 KIRKLAND P.D. & NEWBERRY K.M. (2021). Your assay has changed – is it still ‘fit for purpose’? What evaluation is required?
686 *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 205–215. <https://doi.org/10.20506/rst.40.1.3218>
- 687 KOSTOULAS P., GARDNER I.A., ELSCHNER M.C., DENWOOD M.J., MELETIS E. & NIELSEN S.S. (2021). Examples of proper
688 reporting for evaluation (Stage 2 validation) of diagnostic tests for diseases listed by the World Organisation for Animal
689 Health. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 287–298. [doi:10.20506/rst.40.1.3225](https://doi.org/10.20506/rst.40.1.3225)
- 690 KOSTOULAS P., NIELSEN S.S., BRANSCUM A., JOHNSON W.O., DENDUKURI N., DHAND N., TOFT N. & GARDNER I.A. (2017).
691 STARD–BLCM: standards for the reporting of diagnostic accuracy studies that use Bayesian latent class models. *Prev.*
692 *Vet. Med.*, **138**, 37–47. [doi:10.1016/j.prevetmed.2017.01.006](https://doi.org/10.1016/j.prevetmed.2017.01.006)
- 693 LUDI A.B., MIOULET V., BAKKALI KASSIMI L., LEFFEBVRE D.J., DE CLERCQ K., CHITSUNGO E., NWANKPA N., VOSLOO W., PATON D.J.
694 & KING D.P. (2021). Selection and use of reference panels: a case study highlighting current gaps in the materials available
695 for foot and mouth disease. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 239–251. [doi:10.20506/rst.40.1.3221](https://doi.org/10.20506/rst.40.1.3221)
- 696 MAYO C.E., WEYER C.T., CARPENTER M.J., REED K.J., RODGERS C.P., LOVETT K.M., GUTHRIE A.J., MULLENS B.A., BARKER C.M.,
697 REISEN W.K. & MACLACHLAN N.J. (2021). Diagnostic applications of molecular and serological assays for bluetongue and
698 African horse sickness. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 91–104. [doi:10.20506/rst.40.1.3210](https://doi.org/10.20506/rst.40.1.3210).
- 699 NIELSEN K., GALL D., KELLY W., VIGLIOCCO A., HENNING D. & GARCIA M. (1996). Immunoassay Development: Application to
700 Enzyme Immunoassay for the Diagnosis of Brucellosis, Copyright, Agriculture and Agri-Food Canada.

701 REISING M.M., TONG C., HARRIS B., TOOHEY-KURTH K.L., CROSSLEY B., MULROONEY D., TALLMADGE R.L., SCHUMANN K.R., LOCK,
702 A.B. & LOIACONO C.M. (2021). A review of guidelines for evaluating a minor modification to a validated assay. *Rev. Sci.*
703 *Tech. Off. Int. Epiz.*, **40**, 217–226. doi:10.20506/rst.40.1.3219.

704 SOUBRIER H., BANGURA U., HOFFMANN C., OLAYEMI A., ADESINA A.S., GÜNTHER S., OESTEREICH L., FICHET-CALVET E. (2022)
705 *Detection of Lassa Virus-Reactive IgG Antibodies in Wild Rodents: Validation of a Capture Enzyme-Linked Immunological*
706 *Assay. Viruses*, **14**, 993. doi: [10.3390/v14050993](https://doi.org/10.3390/v14050993)

707 WATSON J.W., CLARK G.A. & WILLIAMS D.T. (2021). The value of virtual biobanks for transparency purposes with respect to
708 reagents and samples used during test development and validation. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 253–259.
709 doi:10.20506/rst.40.1.3222.

710 WAUGH C. & CLARK G. (2021). Factors affecting test reproducibility among laboratories. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**,
711 131–143. doi:10.20506/rst.40.1.3213.

712 WRIGHT P.F. (1998). International standards for test methods and reference sera for diagnostic tests for antibody detection.
713 *Rev. sci. tech. Off. int. Epiz.*, **17**, 527–533.

714 WRIGHT P.F., NILSSON E., VAN ROOIJ E.M., LELENTA M. & JEGGO M.H. (1993). Standardization and validation of enzyme linked
715 immunosorbent assay techniques for the detection of antibody in infectious disease diagnosis. *Rev. sci. tech. Off. int. Epiz.*,
716 **12**, 435–450.

717 *
718 * *

719 **NB: FIRST ADOPTED IN 2014.**

4
5 CHAPTER 2.2.2.

6 DEVELOPMENT AND OPTIMISATION
7 OF ANTIGEN DETECTION ASSAYS

8 INTRODUCTION

9 *The WOAAH Validation Recommendations in Section 2.2 Validation of diagnostic tests of this Terrestrial*
10 *Manual provide detailed information and examples in support of the WOAAH Validation Standard that is*
11 *published as Chapter 1.1.6 Validation of diagnostic assays for infectious diseases of terrestrial animals. The*
12 *Term “WOAH Validation Standard” in this chapter should be taken as referring to that chapter. An up-to-date*
13 *compilation of the relevant validation standards (WOAH and non-WOAH) and guidance documents for all*
14 *stages of diagnostic test validation and proficiency testing, including design, analysis, as well as clear,*
15 *complete and transparent reporting of validation studies with case studies is provided in Colling & Gardner*
16 *(2021). Published standards for peer-reviewed reporting of accuracy studies (STARD) are available for*
17 *infectious diseases of humans (Bossuyt et al., 2015), and terrestrial animals (Gardner et al., 2011; 2019,*
18 *Kostoulas et al., 2017; 2021)*

19 *The detection and identification of an agent is*
20 *confirmatory evidence of either infection with or*
21 *disease caused by a particular pathogen. There are*
22 *many ~~different~~ diverse direct and indirect test*
23 *methodologies available. Classical direct¹ agent*
24 *detection assays include electron microscopy, light*
25 *microscopy (e.g. observation of unique*
26 *histopathological or pathognomonic features,*
27 *identification of parasites in situ, etc.), virus*
28 *isolation, bacterial culture and parasitic digestion*
29 *techniques. Many direct techniques require*
30 *secondary procedures to assist in the*
31 *characterisation and identification of these agents*
32 *(e.g. haemagglutination inhibition or virus*
33 *neutralisation tests, special bacteria or fungal*
34 *stains, etc.). Representatives of indirect agent and*
35 *in particular, antigen (Ag) detection tests include*
36 *enzyme linked immunosorbent assays (ELISA),*
37 *immunofluorescence or immunoperoxidase assays,*
38 *western blotting techniques, micro-arrays, fluorescence activated cell sorting (FACS) and biosensors. Often*

Practical matters in selecting an assay format

- Is high-throughput essential? Will the test be automated?
- Will the test be used as a herd test or for testing individuals?
- What is the anticipated turnaround time? Is that suitable?
- What level of sophistication is needed to run the assay?
- What skills are required to interpret test results?
- Will the assay be feasible for use in my laboratory?
- Will it be easily transferrable to other laboratories?
- What are the costs to run the assay?
- What is the level of acceptance in the scientific & regulatory community?

¹ Definitions: In the context of direct and indirect detection of an analyte, the term “direct” is relevant to the organism or its antigens, e.g. direct detection by microscopy. The term “indirect” is relevant to the host response to the organism, (e.g., indirect detection inferred by detection of antibodies to the organism). In the context of diagnostic methods that are used to detect infection, microscopy is a means of direct observation of the organism, whereas using a reagent that infers the presence of the agent (such as an enzyme conjugated to a purified antibody that is specific for the agent) is an indirect method.

39 direct and indirect methods are used ~~in tandem~~ complementary, for example a direct technique may be used
40 to isolate, enrich and/or extract the organism followed by indirect techniques to characterise and identify the
41 agent.

42 The examples given above vary widely in terms of laboratory requirements. ~~Pen-side~~ Point-of-Care tests
43 (PoCT) including lateral flow devices may also be antigen detection tests. They are easy to use and were
44 developed for testing of animals in the field but may have applications in laboratories. ~~Cost~~ (Halpin et al.,
45 2021; Hobbs, 2020). Specific validation requirements of PoCT are given in Fig. 1 in Halpin et al. (2021) and
46 Chapter 1.1.6, Fig.1, laboratory infrastructure, biocontainment/safety, technical sophistication, interpretation
47 skills, turn-around time, throughput capacity, diagnostic performance characteristics, repeatability and
48 reproducibility are important parameters which need consideration when selecting the most appropriate
49 assay. They also vary with respect to suitability for different diagnostic applications.

50 In contrast to ~~serological~~ or antibody detection tests, Ag detection tests depend heavily on the time of clinical
51 onset and pathogenesis of the disease and the concentration of the pathogen in certain tissues and/or fluids.
52 Successful diagnosis depends on appropriate timing and selection of the sampling site (affected
53 tissue/lesions, scrapings, swabs, blood, and other body fluids), storage conditions and specimen integrity
54 during transport (Chapter 1.1.2 Collection, submission and storage of diagnostic specimens and Chapter
55 1.1.3 Transport of biological materials). For certain applications, the testing of individual animals and/or
56 samples may be appropriate (e.g. confirmatory testing); while for other purposes (e.g. screening), pooling of
57 animals may be efficient and effective. Selection of the appropriate specimen requires good understanding
58 of the disease and the effect of the sample matrix on the pathogen (e.g. cloacal or tracheal swabs for avian
59 influenza).

60 Nucleic acid detection (NAD) tests and more recently high throughput sequencing (HTS) are increasingly
61 replacing classical antigen detection systems. For development and optimisation of NADs, please refer to
62 Chapter 2.2.3 Development and optimisation of nucleic acid detection assays and for HTS to Chapter 1.1.7
63 Standards for high throughput sequencing, bioinformatics and computational genomics, and van Borm et al.
64 (2016). ~~Although these~~ NAD tests may seem to be the tests of choice for many applications, they are not
65 always the most practical or efficient. In most cases it is still necessary and prudent, at least for an index
66 case, to culture the agent on selective media or in susceptible cell lines or eggs to facilitate further
67 characterisation and identification. While genotyping is an important consideration, especially in molecular
68 epidemiology, other means of agent characterisation such as serotyping, pathotyping or biotyping are also
69 important and provide valuable information on the antigenic properties of the target agent. Cultured and
70 preserved agents have tremendous historical value and are also an important source of reference materials,
71 which can be used for future assay validation, specificity testing and pathogenesis trials for new and
72 emerging agents (Watson et al., 2021).

73 In their review of WOA recommended diagnostic tests, Cullinane & Garvey (2021) concluded that ELISA
74 and molecular assays were the most widely used WOA-recommended tests. Due to its worldwide
75 application, the Ag ELISA is used as an example for application of best practices in antigen detection assays
76 in this chapter. Most of the basic processes used to validate other types of antigen detection assays will
77 become evident by extension of those used to validate ELISAs. Because of the many conceptual similarities
78 between antigen and antibody detection assays this chapter frequently cross-refers to Chapter 2.2.1
79 Development and optimisation of antibody detection assays.

80 A. ANTIGEN DETECTION ASSAY DEVELOPMENT PATHWAY

81 1. Intended purpose(s) of the antigen assay

82 The intended purpose of ~~the a~~ a test is a key factor which will guide decisions in the selection ~~and~~ and early development and
83 validation of a test, the candidate assay. Given the WOA defined 'fitness for purpose' categories in Table 1, Ag detection
84 systems may be appropriate for certain applications. Support for disease eradication or surveillance programmes generally
85 require testing of high numbers of samples, with an emphasis on diagnostic sensitivity and throughput capacity. In contrast,
86 confirmation of clinical cases does not entail high numbers to be tested, but diagnostic specificity and turn-around times
87 become very important. At the outset, the questions posed in the text box, above, should be carefully considered.

Table 1. Determinants of an antigen assay's fitness for its purpose

Assay characteristics	Determinants of fitness for purpose						
	1*		2*	3*	4*	5*	6*
	a	b					
Diagnostic sensitivity (DSe)		+++	+++	+++	+++		
Diagnostic specificity (DSp)		+	+	+	+++		
Positive predictive value (PPV)		+	+	+	+++		
Negative predictive value (NPV)		+++	+++	+++	+++		
Throughput capacity		+++	++	+	-		
Turn-around time of test		+	+	+	+++		
QA capability		+++	+++	+++	+++		
Reproducibility		+++	+++	+++	+++		
Repeatability		+++	+++	+++	+++		

Other characteristics such as the technical sophistication of the assay, and the skill required for interpretation will be related to the disease or infection under investigation.

NB NAD tests may also be used for agent detection, and are considered in Chapter 2.2.3.

Symbols: +++ = essential; ++ = of less importance; - = not important.

89
90
91
92

93 *Basic. The six basic intended purposes for which an assay may be deemed fit: 1- diagnostic assays relevant in the WOAH
94 context are stated in Chapter 1.1.6 and include: 1. Contribute to the demonstration of freedom from infection in a defined
95 population: a) 'Free' with or without vaccination, b) Re-establishment of freedom after outbreaks. 2. Certify freedom from
96 infection or presence of the agent in individual animals or products for trade/movement purposes; 3. Contribute to the
97 eradication of disease or elimination of infection from defined populations; 4. Confirmatory diagnosis of clinical cases
98 (includes confirmation of positive screening test); 5. Estimate prevalence of infection or exposure to facilitate risk analysis;
99 6. Determine immune status in individual animals or populations (post-vaccination). An example-based overview for the
100 purpose-oriented use of diagnostic tests is provided in Gardner *et al.* (2021). Table 1 of Chapter 1.1.6 highlights the
101 relevance of assay parameters such as diagnostic sensitivity and specificity, predictive value and likelihood ratios for
102 individual purposes.

103 **1.1. Purpose 1a: Contribute to the demonstration of freedom from infection in a defined**
104 **population a) 'Free' with or without vaccination**

105 In a population that is historically free of a particular disease/pathogen, the prevalence is zero (or close to zero).
106 To be fit for purpose, the test or test algorithm aims to minimise the chances of false-positive results and ideally
107 requires high DSp, high positive predictive value (PV+) and high positive likelihood ratios (LR+). This can be
108 achieved by a single test with a high DSp or serial testing. In most countries, active surveillance at abattoirs and
109 the screening of fallen stock identifies preclinical cases and cases in which there may have been unrecognised
110 clinical signs. To detect the modified prion protein (PrP) in bovine spongiform encephalopathy in the brain,
111 immunochemical methods including immunohistochemical (IHC) techniques, western immunoblot methods, and
112 rapid test methods such as lateral flow assays and enzyme linked immunosorbent assays (ELISA) are used.
113 Histopathology is no longer the diagnostic method of choice for investigation of animals or the screening of
114 healthy populations. No diagnostic test is currently available for live animals.

115 **Purpose 1b Contribute to the demonstration of freedom from infection in a defined**
116 **population b) Re-establishment of freedom after outbreaks**

117 For disease freedom categories re-establishing freedom after outbreaks as given in purpose (Table 1), 1b,
118 antibody screening tests of high diagnostic sensitivity (DSe) specificity (DSp) are usually the tests of choice
119 provided that a detectable immune response is a significant indicator of infection. However, there may be certain
120 disease situations where the humoral immune response can be misleading and pathogen detection may be

121 more appropriate (e.g. mycobacterial or trypanosomal infections). In these cases, Ag detection tests may be
122 more effective. The antigen screening test testing algorithm should demonstrate favour a high DSe. Tests DSp,
123 Algorithms of high DSe-DSp and high LR+ demonstrate low false negative (FN-positive (FP) rates, which is
124 needed in populations where and when applied to low prevalence is low populations, the NPV is at its highest
125 level. As DSe-DSp and diagnostic specificity (DSp-sensitivity (DSe) are usually inversely related, selection of a
126 more sensitive test may lead to a decrease in DSp, which will result in an elevated false positive (FP) rate.
127 Therefore, all screening test positive results should be subjected to some form of confirmatory testing to evaluate
128 their true status. Confirmatory tests characteristically have high DSp and therefore a low FP rate. These tests
129 are often more sophisticated and require enhanced interpretive skills. A common approach to demonstration of
130 freedom is to use highly sensitive screening tests and then subject positive results samples to some form of
131 confirmatory testing to evaluate their true status. Confirmatory tests characteristically have high DSp and
132 therefore a low FP rate. These tests are often more sophisticated and require enhanced interpretive skills,
133 laboratory environment and highly skilled staff. Provided an appropriate confirmatory assay is selected, such
134 serial testing approaches may present a more economical approach to surveillance testing, however maintaining
135 high DSe in the testing algorithm is necessary to ensure adequate positive predictive values in low to zero
136 prevalence populations.

137 **1.2. Purpose 2: Certify freedom from infection or presence of the agent in individual animals or** 138 **products for trade/movement purposes**

139 For a number of diseases included in the *Terrestrial Manual*, agent identification is listed as the preferred test
140 method for the purpose of determining "Individual animal freedom from infection prior to movement". Although
141 in many cases this involves culture of the organism or detection of nucleic acid, there may be situations where
142 an antigen detection test is appropriate for this purpose. To avoid risk of disease spread through trade, a test
143 offering high DSe is to be preferred. For example, for ASF the antigen detection ELISA is described in Chapter
144 3.9.1. *African swine fever (infection with African swine fever virus)* as "recommended but with limitations". It may
145 perform satisfactorily as an alternative method but, as its sensitivity is much lower than that of the molecular
146 tests, it should not be used as the only method for virus detection and results should be confirmed by polymerase
147 chain reaction (PCR). To avoid risk of disease spread through trade, a test or a combination of tests offering
148 high DSe is to be preferred. This can be achieved through parallel testing where a sample is considered positive
149 if any of the tests are positive. Therefore, parallel testing increases DSe but decreases DSp, when considering
150 laboratory diagnosis within an epidemiological unit.

151 **1.3. Purpose 3: Contribute to the eradication of disease or elimination of infection from defined** 152 **populations**

153 If the purpose of the test is the eradication of disease or elimination of infection from defined populations, antigen
154 screening tests, like and antibody screening tests, of moderate to high DSe-DSp, are the tests of choice.
155 However, the rationale is slightly different in that the testing will likely be done at the herd or compartment level.
156 At the beginning of the eradication campaign, when the disease prevalence is high, moderate DSe and DSp are
157 suitable as both FP and FN rates are less relevant at this juncture and a moderate level of error is tolerable.
158 Depending on the nature of the disease and rapidity of spread, high throughput and fast turn-around times may
159 become critical. Usually decisions are made without confirmatory testing at this point.

160 In the latter stages of the campaign, a higher DSe-DSp is warranted as the FN-FP rate becomes the more critical
161 factor. Much like Purpose 1, positive reactors will need to be subjected to some form of confirmatory testing to
162 evaluate their true infection status. In these latter stages, antigen and/or nucleic acid detection systems are
163 critical in the detection of sub-clinical cases, shedders and possibly, latent carriers.

164 **1.4. Purpose 4: Confirmatory diagnosis of clinical cases (includes confirmation of positive** 165 **screening test)**

166 Although antibody tests of high DSp are often the tests of choice for confirmatory diagnosis of clinical cases,
167 antibody tests confirmation of a positive result from a screening test, they may not always be the tests of choice
168 ideal to confirm a clinical case, especially if clinical signs appear before an immune response is mounted. A,
169 e.g. a prime example would be highly pathogenic avian influenza infections where mortality may occur before
170 an immune response is even detectable. Antigen Under these circumstances antigen or nucleic acid detection
171 tests are usually a better choice for confirmation of clinical cases provided that they offer a fast turn-around-
172 time. In these cases, the idea is to maximise DSp and thereby minimise any potential FP reactions. For some
173 clinical cases, e.g. vesicular diseases in terrestrial animals, several tests may be required to quickly rule out
174 select pathogens that present similar clinical signs. In this category of test, fast turn-around-times are extremely
175 critical in identifying potential outbreaks. An example of a confirmatory diagnosis would be a hydrolysis probe
176 positive avian influenza (AI) virus swab and haemagglutinin (HA) and neuraminidase (NA) testing (including
177 pathotyping/sequencing).

178 **1.5. Purpose 5: Estimate prevalence of infection or exposure to facilitate risk analysis**

179 For estimates of prevalence of infection and/or shedding to facilitate risk analysis, e.g. for health surveys, herd
180 health status and to monitor disease control measures, antigen detection tests of moderate DSe and DSp are
181 the tests of choice. In general, this would balance both FN and FP rates and result in a more accurate estimate
182 of the true prevalence in the target population. However, if accurate estimates of both DSe and DSp have been
183 established, statistical approaches can be used to minimise bias attributable to FN and FP rates (see Chapter
184 2.2.5 *Statistical approaches to validation*).

185 **1.6. Purpose 6: Determine immune status in individual animals or populations (post-vaccination)**

186 This purpose is not applicable to antigen detection assays.

187 **2. Assay development – experimentation**

188 **2.1. Reference materials, reagents and controls**

189 **2.1.1. Test samples**

190 Samples required for antigen detection assays should be handled as described in Chapter 1.1.2
191 *Collection, submission and storage of diagnostic specimens*. Sample matrixes for antigen detection
192 assays can be very heterogeneous (e.g. blood, faeces, milk, skin, semen, saliva, blisters, vesicles or
193 swabs from affected tissues such as oropharynx (Probang), trachea, genitals, cloaca, oesophagus, etc.).
194 The ideal specimen is the one that is easy to obtain and with a high concentration of the analyte. In many
195 cases blood or swabs are the specimens of choice but depending on the pathogen, other tissues or fluids
196 are needed, e.g. skin, organs such as brain (rabies, transmissible spongiform encephalopathies [TSE]),
197 lymphatic organs, such as spleen and lymph nodes (classical swine fever), kidney, liver, heart, parts of
198 respiratory tract (avian influenza), digestive tract (parvovirus), milk, faeces, semen, saliva, tumour
199 material (enzootic bovine leukosis), etc.

200 As stated in Chapter 1.1.2, the usual considerations apply to limit bacterial and fungal contamination of
201 specimens. The use of preservatives and fixatives is not usually recommended and samples should be
202 sent with minimal delay and under refrigeration to a diagnostic laboratory. During transport and storage
203 it is important to be aware of the physical and chemical requirements of the pathogen (e.g. foot and
204 mouth disease [FMD] virus is highly labile at low pH and requires equal amounts of glycerol and
205 phosphate buffer to maintain a pH over 7). Transporting tissue samples in glycerol containing buffer may
206 have an effect on the sensitivity of antigen detection assays, e.g. the rabies fluorescent antibody test.
207 Rinsing tissue samples with phosphate-buffered saline before processing for testing is recommended as
208 it helps to prevent inhibition of the fluorescence (Chapter 3.1.19 *Rabies*).

209 If samples are to be tested as pools, experiments need to be undertaken to demonstrate that the assay
210 is fit for that purpose (e.g. that the analytical sensitivity is sufficiently high to detect one infected animal
211 e.g. in a pool of 5, 10, 50 or more samples from uninfected animals) (Chapter 2.2.6 *Selection and use of
212 reference samples and panels*).

213 **2.1.2. Reference Standards**

214 See Chapters 1.1.6 *Validation of diagnostic assays for infectious diseases of terrestrial animals*, 2.2.1
215 *Development and optimisation of antibody detection assays* and 2.2.6 *Selection and use of reference
216 samples and panels* and Watson et al. (2021).

217 **2.1.3. Positive and negative reference panels**

218 Samples, containing concentrations of antigen over the intended operating range of the assay, should
219 be used as controls during the development and standardisation of an antigen detection assay. They
220 may be obtained from field specimens ~~or produced in~~ the laboratory as a result of animal trials or as
221 spiked samples (see Chapter 2.2.6). Negative samples should be obtained from known uninfected
222 animals and this same matrix should be used when spiked samples are produced. Rahmadane et al.
223 (2017) describes the development and validation of an immunoperoxidase antigen detection test for
224 improved diagnosis of rabies in Indonesia, where 116 dog brains from animals exhibiting signs of rabies
225 involved in human bite cases and 110 brains collected as part of government control measures thought
226 to be rabies free were tested for the exclusion of rabies virus.

227

2.1.4. Purified and crude antigens for antibody production

228
229
230
231

In general, antigens to be used for the production of immunological reagents should be as natural as possible in terms of conformation to ensure that the presentation of epitopes mimics the orientation on the live organism. Therefore, isolation and/or purification methods used should preserve the antigenic integrity of the agent as much as possible.

232
233

For very large pathogens such as poxviruses, bacteria and protozoal parasites, protein microarrays may be useful to identify and select antigens which elicit strong immune responses.

234

2.1.5. Monoclonal and polyclonal antibodies for indirect antigen detection assays

235
236
237
238
239
240

Monoclonal antibodies demonstrate unique analytical specificities and are very useful in the detection of agent-specific epitopes at the group, strain or sub-strain levels. As such, they need to be considered carefully with respect to the application at hand and the desired specificity of the assay. Polyclonal antibodies, by nature, tend to demonstrate a broader range of specificities. Purified or semi-purified polyclonal antibodies are often the reagent of choice for trapping complex antigens because they usually demonstrate higher affinities than their monoclonal counterparts.

241
242
243
244
245
246
247
248
249
250
251

Antigens used to produce antibodies for use as immunological reagents will ideally match their naturally occurring form with regards to their structural conformation and any post-translational modifications. This ensures that the epitopes presented to the host's (the species chosen for antibody production) immune system mimic those presented by the live pathogen, which in turn provides the best chance of producing antibodies relevant to their diagnostic application. Therefore, regardless of whether a crude or purified antigen preparation is to be used, antigen isolation or purification methods should be designed to preserve the antigenic integrity of the target agent. To determine whether a crude or purified antigen preparation is required, it is important to understand the final diagnostic application of the antibodies and whether polyclonal or monoclonal antibodies (MAbs) will be used (see Section A.2.1.5 Polyclonal and monoclonal antibodies for antigen detection assays below). Failing to carefully consider these factors may detrimentally affect the specificity of the assay.

252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268

Preparations of antigen used to generate polyclonal immune sera or MAbs range from crude preparations of a complete pathogen (e.g. virions in tissue culture medium) to highly purified individual protein constituents derived from the pathogen (e.g. structural or non-structural proteins), and even purified subunits of such proteins (e.g. synthetic peptides). Crude preparations containing the pathogen of interest and other irrelevant antigenic elements will produce a multifaceted antibody response that may negatively affect the specificity of the final assay. Using the example of a crude preparation of virus in tissue culture medium containing fetal bovine serum (FBS), the immune response would be expected to produce antibodies specific to the virus and to the antigenic constituents of FBS, assuming the antiserum is raised in a non-bovine species, such as rabbits or mice, as is typically the case. Application of this antiserum to an immunohistochemical (IHC) examination of a clinical sample of bovine tissue for the presence of the virus of interest would produce confounding results due the nonspecific staining caused by anti-bovine antibodies present in the antiserum. It is worth noting here that this specificity limitation, caused by using a crude antigen preparation, is dependent on the application and may not be a problem where, for example, the IHC examination is of tissue from a non-bovine species. It is also only an issue where polyclonal antisera are used. Although hybridomas produced from mice immunised with crude antigen preparations will produce the same range of virus-specific and nonspecific MAbs, only hybridomas producing the virus-specific MAbs are selected for antibody production.

269
270
271
272
273
274
275

The use of purified antigen preparations in the generation of antibodies avoids the specificity problems associated with crude antigens by presenting only a single relevant immunogenic antigen or population of antigens to the host's immune system. Purified antigens may take the form of purified pathogen (e.g. purified virus or bacteria preparations), fractions of a pathogen (e.g. a cell wall preparation), individual protein components of a pathogen (e.g. a nucleoprotein preparation) or peptide fragments of such proteins. Techniques for purifying antigens range from differential and density gradient centrifugation to various chromatographic techniques.

276
277
278
279
280
281
282

Antigens must be immunogenic to generate antibodies. Typically, whole pathogens or full-length proteins derived of pathogens are inherently immunogenic; however, individual peptide fragments of proteins or synthetic peptides may not be. These non-immunogenic peptides are referred to as haptens and must be coupled to larger carrier molecules (e.g. keyhole limpet hemocyanin [KLH]) to make them immunogenic. The immunogenicity of an antigen may be increased using adjuvants, resulting in higher antibody titres. Repeated periodic exposure of a host to the immunogen will further increase the antibody titre. A typical immunisation schedule for the purpose of antibody generation might involve subcutaneous

283 immunisation of a mouse or rabbit with an immunogenic antigen in adjuvant followed by second and
284 often third immunisations given at approximately 3-week intervals. High titre antiserum is collected
285 approximately 2–3 weeks after the last immunisation (Rahmadane *et al.*, 2017; Shiell *et al.*, 2020.).

286 Other important considerations when choosing an appropriate antigen for use in the production of
287 antibodies for detection of antigen are surface presentation and epitope immunodominance. Antibodies
288 targeting antigens that appear on the surface of a pathogen will have the widest diagnostic applicability,
289 being suitable for standard indirect antigen detection ELISAs, antigen capture/sandwich assays and
290 immunohistological assays. Using antigens containing immunodominant epitopes will likely ensure
291 robust seroconversion in the antibody-producing host, resulting in antisera of high titre and assay
292 relevance, especially where the assay has a competition format. Where no information exists regarding
293 an appropriate immunodominant antigen, protein or peptide microarrays probed with immune sera from
294 animals exposed to the pathogen may be useful to identify antigens most likely to elicit strong immune
295 responses.

296 **2.1.5. Polyclonal and monoclonal antibodies for antigen detection assays**

297 Polyclonal antibodies (PABs) for antigen detection assays are typically used in the form of unpurified
298 hyperimmune antisera, produced by harvesting serum from an animal that is successively immunised
299 with an antigen of interest until sufficient specific titre is achieved. Polyclonal antisera are therefore
300 constituted by the polyclonal population of antibodies targeting the antigen of interest, pre-existing host
301 antibodies and all naturally occurring serum proteins. While it is possible to affinity isolate the target
302 antibody away from the host's pre-existing antibodies (or vice versa), this requires complicated
303 chromatographic techniques and should be unnecessary where careful assay design is employed.

304 Where complex antigenic preparations (e.g. inactivated virus or multimeric protein complexes) are used
305 to raise the antisera, antibodies within the polyclonal population will target multiple proteins and multiple
306 epitopes within each protein in the preparation. For these reasons, when compared with antigen
307 detection assays developed using MAbs, PABs demonstrate: i) a broader range of specificities, ii)
308 generally higher avidities, iii) potential for greater sensitivity; iv) broader cross-reactivity with similar
309 targets, and v) greater potential for background signal due to nonspecific binding.

310 Several of these properties of PABs make them the preferred option for assays that trap complex
311 antigens; namely, their broader range of specificity and high avidity, which contribute to higher
312 sensitivities in these types of assays by trapping more antigen. Their ability to bind a broader range of
313 targets on a pathogen of interest gives PABs an advantage where genus-, species- or group-specific
314 assays are desired, i.e. where specific strain or variant information is deemed unimportant for the
315 diagnostic application. While consideration must be given to the greater propensity of polyclonal antisera
316 to bind nonspecifically in assays, this issue is often able to be overcome using suitable assay parameters
317 such as, for example, more stringent washes, suitable controls, or competition formats. It should be noted
318 that MAbs can also be used in trapping assays and may present advantages where a sandwich-type
319 assay format is chosen since two MAbs targeting different epitopes will not compete for binding sites.

320 MAbs for antigen detection assays are typically used as purified preparations due to their ease of
321 purification using simple affinity chromatography methods. Being purified and mono-specific, MAbs tend
322 to produce lower levels of assay background. However, they are also commonly used as crude tissue
323 culture supernatant preparations that contain the secreted MAb and the constituents of the hybridoma
324 culture medium, which may increase background. Current ethical guidelines have led to the elimination
325 of MAbs produced in ascitic fluid as a detection reagent.

326 MAbs differ from PABs in their ability to target one specific epitope. For this reason, they are favoured in
327 assays where detection of a single specific antigen or antigenic epitope is desired. For example, where
328 the serotype or subtype of a pathogenic species is determined by epitopic differences in one of its
329 constituent proteins, MAbs may be developed to target each of the different epitopes, thereby providing
330 typing capability. Of course, where an immunodominant epitope is represented more generally across a
331 genus or species, an MAb may also be useful in higher order (e.g. pan-genotype) diagnostic assays.

332 Recombinant antibodies may be thought of as MAbs that can take many forms and offer a range of
333 advantages, and while not as commonly used as traditional polyclonal and MAbs, they have been
334 incorporated into several assays. Material required for production of recombinant antibodies can be
335 stored virtually as a coding sequence data file (if gene synthesis capability is available) or physically as
336 expression plasmids containing the antibody coding sequence. This eliminates the need for expensive
337 storage of hybridomas in liquid nitrogen and the risk of loss where storage systems fail. Recombinant

338 antibodies are expressed in transformed/transfected cultured cells (bacterial, mammalian, etc.). They
339 may be expressed in a range of forms from full-length IgG to various subunit forms such as single chain
340 variable domain (scFv) or nanobodies. These smaller forms may be advantageous in diagnostic
341 applications where permeation is a factor e.g. immunohistochemical examination of formalin-fixed
342 paraffin-embedded tissue sections.

343 Recombinant antibodies may be modified using standard molecular biological cloning techniques to
344 create antibody fusions with protein/peptide tags (e.g. HA or strep tags) or labels (e.g. green fluorescent
345 protein [GFP] or alkaline phosphatase). Tags may be used to facilitate purification or as a target for
346 secondary antibodies in indirect format assays, while the addition of labels allows for development of
347 direct antigen detection, eliminating the need for a secondary antibody step. It should be noted that
348 MABs, once purified, are able to be chemically modified with tags or labels, however the nature of
349 chemical coupling reactions means placement of the tag/label is random and may interfere with binding.
350 Chemical coupling is also less efficient as it requires additional processing, expertise, time and cost.

351 Additional benefits of recombinant MABs lie in the ability to customise the antibody's species (e.g. from
352 mouse to rabbit or human IgG) or isotype (e.g. from IgG1 to IgG2a or IgE) by swapping determinant
353 sequences within the antibody's constant heavy and light chains. Switching species or isotype provides
354 greater flexibility in assay design and applicability by enabling the use of alternative secondary detection
355 reagents. A practical application might be to switch the species of a recombinant MAB from mouse to
356 rabbit to develop an immunohistochemical assay designed to detect antigen in mouse tissue. Using the
357 rabbit version of the recombinant MAB would increase assay specificity by reducing background staining
358 that would be evident where an anti-mouse secondary antibody conjugate would otherwise be required.

359 When designing assays using PABs, MABs or recombinant antibodies to detect antigens, careful
360 consideration must first be given to the desired output of the assay in terms of diagnostic sensitivity and
361 specificity. Within this context, informed decisions on assay format and the choice of antibody type will
362 be pertinent to successful assay development.

363 2.2. Design of test method

364 2.2.1. Choice of test

365 The prologue to a proper test design requires
366 careful consideration of many variables in the
367 context of performance requirements. The
368 choice of assay must be coupled with its
369 intended application, which usually
370 necessitates consensus between the assay
371 developer, statisticians, and other
372 stakeholders such as epidemiologists and
373 regulatory bodies. The role and capacity of the
374 laboratory may influence the test type chosen.
375 If the purpose is to develop a screening test
376 (e.g. during a post-outbreak surveillance
377 period) the emphasis will be on high DSe, high
378 throughput, low cost, technical simplicity, low
379 interpretative skill, etc. If the purpose is to
380 develop a confirmatory test (e.g. for the
381 confirmation of clinical cases or confirmation of positive screening test reactors), a different set of
382 priorities will come into play including high DSp, fast turn-around-times, technical sophistication and
383 interpretative skills. Further purposes and related parameters are available in chapter 1.1.6, Table 1.
384 There are a growing number of point-of-care or pen-side tests that have their own set of additional
385 robustness and ruggedness requirements given the variable conditions of the environment in which they
386 will be used and the skill level of the operator who will performing and interpreting the test.

Aspects affecting choice of test

- Laboratory resources
- Is the assay to be used for screening or confirmatory purposes, or both?
- Will the assay be used as a laboratory or field-based test?
- Will it be used for one or more species? Which ones?
- What are the preferred specimens?
- Will the test be used for typing organisms to group, serotype or strain-specific levels?
- Will the test be applied nationally or internationally?

387 The antigen ELISA is conceptually the same method employed for the antibody ELISA (Chapter 2.2.1),
388 with the exception that antigen is the targeted analyte, and antibodies are the primary reagents used for
389 capture and detection of antigens. Depending on whether the antigen is adsorbed directly on the
390 microplate or captured by antibodies on a solid phase, along with subsequent detection steps, different
391 formats are available.

392 It is not always apparent which assay format should be used to best fit the intended purpose. Availability
393 of reagents and the limit of detection of the assay for a particular application may be significant factors

394 in limiting the choice. Since many of the systems now target highly specific antigens, the choice of
395 antibody for both trapping and/or detection becomes critical.

396 Preparation of the test sample is also a critical consideration depending on the test format being used.
397 The use of trapping or capture antibody in sandwich-type assays enhances selectivity and reduces
398 potential matrix effects. For assays requiring direct application of the analyte to the solid phase,
399 preparatory extraction, centrifugation or filtration methods may be necessary to remove extraneous
400 material. For a more in-depth discussion of these different assay formats, please see Crowther (2001).

401 Of critical importance is the size and complexity of antigen and the availability of relevant reagents, such
402 as capture antibodies (e.g. antigens to be detected in sandwich assays must have at least two unfettered
403 epitopes) which limits this assay type to relatively large antigens or whole pathogens. The affinities of
404 the immunological reagents come into play as the stability of the resulting antibody-antigen complexes
405 in the microplate or on beads will affect the performance characteristics of the assay.

406 Practical concerns are availability and use of antigen standards for quality control and assurance
407 purposes, repeatability, reproducibility, throughput capacity, turn-around-time of a test result, cost and
408 technical sophistication and interpretation skills.

409 Working with exotic and/or zoonotic agents requires particular attention to biosafety and biosecurity
410 regulations (see also Chapter 1.1.4 *Biosafety and biosecurity: Standard for managing biological risk in
411 the veterinary laboratory and animal facilities*) and will inform the laboratory what personal protective
412 equipment or biosafety level should be employed to ensure operators are kept safe during the testing.

413 2.3. Proof of concept experiments (feasibility studies)

414 The same types of experiments used in antibody detection tests are required for antigen detection tests (see
415 Chapter 2.2.1).

416 2.4. Samples and data expression

417 2.4.1. Selection, storage and use of control samples for test development and validation studies

418 It is important to assess and monitor
419 sensitivity and specificity of the test
420 during development and validation. This
421 is achieved by selecting several
422 samples (4–5 is adequate) that range
423 from negative to high levels of antigen
424 of the analyte in question. These
425 samples are used in experiments
426 designed to optimise the assay. To
427 achieve continuity of evidence requires
428 care and forethought in preparation and
429 storage of samples. A large volume
430 (e.g. 10 ml) of each control sample is
431 acquired and divided into 0.1 ml
432 aliquots for storage at or below –80°C
433 (Chapter 1.1.2.). One aliquot of each
434 sample is thawed, used for
435 experiments, and ideally then
436 discarded. If it is impractical to discard
437 the aliquot, it may be held at 4°C
438 between experiments for up to about
439 2 weeks; however, there is a possibility
440 of sample deterioration under these
441 circumstances, which will vary with
442 sample and antigen types. Then,
443 another aliquot is thawed for further
444 experimentation. This method provides
445 the same source of sample with the
446 same number of freeze–thaw cycles for all experiments (repeated freezing and thawing of samples can
447 denature antigen and/or facilitates the growth of other unwanted microorganisms and should be
448 avoided). Also, variation is reduced when the experimenter uses the same source of sample for all

Optimisation and standardisation

- Is the test able to distinguish between samples with and without the analyte (what is the limit of detection = analytical sensitivity?)
- Does the test cross-react with non-target antigen in the sample or sample matrix (analytical specificity)?
- What is the noise or background activity in a negative sample?
- Has the repeatability been assessed for a range of control samples over a number of days?
- Are sufficient positive and negative samples on hand to carry out the experiments for optimisation and validation?
- If yes, are reference and control samples dispensed and stored properly to avoid introduction of sample related bias (sample deterioration)?
- Have all critical reagents been run against each other in checkerboard titrations?
- ~~Did you find~~ Were optimal concentration/dilutions established for each reagent?
- ~~Did you include~~ Were reference reagents and working standards/controls included and did normalised the-OD data to achieve the best possible comparative results?
- Are the controls in the same matrix as the test samples?

449 experiments rather than switching among various samples between experiments. This approach has the
450 added advantage of generating a data trail for the repeatedly run samples. After the initial stages of
451 assay validation are completed, one or more of the samples can become reference reagent(s) that are
452 the basis for data expression and repeatability assessments both within and between runs of the assay
453 (Jacobson, 1998). They may also serve as in-house working standards if their activity has been
454 predetermined; such standards provide assurance that runs of the assay are producing accurate data
455 (Wright, 1998).

456 2.4.2. Normalisation of results and their expression

457 The same normalisation procedures as used for antibody detection assays are applicable to antigen
458 detection assays (see Chapter 2.2.1 for details).

459 2.5. Optimisation

460 The aim of this stage is to finalise test parameters related to reagents, consumables and equipment that will
461 lead to a fixed protocol and will be used during the assay validation pathway Part B. (for details, see Chapter
462 2.2.1).

463 2.6. Inhibitory factors in sample matrix

464 Due to a higher variety and complexity of specimens, antigen detection assays are more likely to be influenced
465 by matrix factors than antibody detection assays, which normally detect antibodies in serum. Inhibitory
466 substances are frequently found in complex matrixes such as pus, semen, tracheal/nasal/cloacal swabs and
467 may have an impact on the test result. ELISA antigen detection systems are rather resistant to inhibitory factors,
468 please see the ~~WOAH Validation Standard, Chapter 1.1.6~~, Section A.2.4, and B1.2 and Greiner *et al.* (1997) for
469 descriptions of the type of inhibitors that could affect the assay. These references should be reviewed carefully
470 to assure that all inhibitory factors are accounted for and controlled.

471 2.7. Calibration to reference sample and comparison to standard test method

472 Chapter 2.2.1 contains information relevant to this procedure.

473 B. ASSAY VALIDATION PATHWAY

474 1. Stage 1 – Analytical performance characteristics

475 Factors that influence the analytical characteristics of diagnostic assays are numerous and may vary according to each
476 assay type, e.g. the main factors affecting the analytical characteristics of serological (Chapter 2.2.1.) and molecular assays
477 are described in Bowden *et al.* (2021).

478 1.1. Repeatability

479 ~~Chapter 2.2.1.~~

480 Repeatability of an assay over time and when run by
481 different operators is of vital importance to the validation
482 pathway. For ELISAs, raw absorbance values are
483 usually used at this early stage. To obtain preliminary
484 estimates of repeatability it is recommended to perform
485 three to four replicates of each control sample, run in at
486 least five plates on five separate occasions. Coefficients
487 of variation (CV) (SD of replicates divided by mean of
488 replicates) of less than 20% are considered to be
489 acceptable (Jacobson, 1998, Chapter 1.1.6. A2.5., B1.1.
490 and Bowden *et al.*, 2021). Assessing the inter-operator
491 variation is important if the test will be performed by
492 different staff and provides information about
493 robustness and fitness for purpose in a laboratory as a
494 diagnostic assay.

Analytical performance characteristics

- Has repeatability been established for a range of positive and negative samples within and between runs of the assay?
- Have upper and lower control limits of the assay been established and is an alternative procedure in place if results fall outside limits?
- Has ASe and ASp for the assay been defined?
- Does the test under evaluation compare favourably with a standard test method, based on objective quantitative and qualitative criteria?

495

1.2. Analytical specificity

496 Analytical specificity (ASp) is defined as the degree to which the assay distinguishes between the target analyte
497 and other components that may be detected in the sample matrix (see Chapter 2.2.6, Section B.1). The higher
498 the ASp, the lower the number of false positive results. Selectivity, exclusivity and inclusivity are components of
499 ASp (Chapter B1.2). **Selectivity** refers to the extent to which an antigen detection method can accurately
500 quantify the targeted analyte in the presence of: 1) interferences such as matrix components (e.g. inhibitors of
501 enzymes in the reaction mix; 2) degradants (e.g. toxic factors) and 3) nonspecific binding of reactants to a solid
502 phase (e.g. conjugate of an ELISA adsorbed to well of microtiter plate). One way of establishing if there are
503 inhibitory factors in a sample is to test a dilution series. For antigen ELISAs, the resulting optical density value
504 will increase due to the dilution of the inhibitory substance. **Exclusivity** ASp should be determined by testing
505 well characterised samples from similar or related pathogens, which produce similar lesions as the target
506 pathogen or are frequently found in samples containing the target pathogen. For example, to assess the ASp of
507 an FMD antigen detection-ELISA for one particular serotype (e.g. that detects serotype O₁), it is necessary to
508 assess its reactivity of all sub-strains within this serotype (e.g. O Campos, O Manisa, etc.) to assess inclusivity.
509 At the same time it is important to show that the test does not cross-react with other serotypes such as A, Asia
510 1, C, SAT 1, 2 and 3. Finally, there is also a need to assess whether the test cross-reacts with agents from
511 diseases which may produce similar signs, e.g. a lack of cross-reaction with vesicular stomatitis, swine vesicular
512 disease and swine vesicular exanthema would be an example of exclusivity testing. Another example is that the
513 same test does not cross-react with other FMD serotypes such as A, Asia 1, C, SAT 1, 2 and 3. This would also
514 define a confirmatory assay. **Inclusivity** can be assessed for one particular serotype e.g. serotype O by testing
515 the assay's reactivity of sub-strains within this serotype, e.g. O Campos, O Manisa, etc. Another example for
516 ASp is an ELISA designed to detect avian influenza virus: as a screening test the assay should detect the
517 nucleoprotein or matrix antigen of all subtypes, e.g. H1-H16 and N1-N9 (inclusivity). However it should not cross-
518 react with viruses which cause similar clinical signs such as Newcastle disease or infectious bursal disease
519 (diagnostic specificity-**Exclusivity**) or with other non-specific components present in the matrix or on the solid
520 phase. Some ELISAs may be subject to false positive results attributable to non-specific factors, (**Selectivity**).
521 Blocking agents such as bovine serum albumin and the use of detergents, for example Tween 20 in the wash
522 buffer assist in the prevention of non-specific binding of antibody conjugates to the plastic surface and may
523 require use of blocking agents and background reactivity. Care must be taken to eliminate these types of errors
524 effects.

525

1.3. Analytical sensitivity

526 Analytical sensitivity (ASe) is synonymous with the lower limit of detection (LOD) of antigen concentration in a
527 sample. LODs are usually determined by endpoint dilution in which replicates (preferably 10) of each dilution in
528 a log₂ dilution series are run in the assay. The larger the number of replicates, the more precise the
529 determination of the dilution at which the antigen is no longer detectable. Further information on LODs and ASe
530 is given in the WOA Validation Standard and in Chapter 2.2.5 or below the cut-off respectively (Chapter 1.1.6,
531 B1.3.).

532 Screening assays or assays which are designed to detect sub-clinical infections or carriers should have a ~~very~~
533 high ASe. In these cases it may be difficult to obtain suitable samples and to determine the comparative ASe
534 by running a panel of samples on the candidate assay test under evaluation (TUE) and on another independent
535 assay. If available, serial samples from experimentally infected animals could provide temporal information
536 about the assay's capacity to detect antigen over the course of infection. Further information about LOD and
537 ASe experiments is given in Bowden *et al.* (2021), Chapter 1.1.6., Chapter 2.2.5. and Chapter 2.2.8
538 Comparability of assays after changes in a validated test method.

539

1.4. Standard test method comparison with the candidate test method under evaluation (TUE)

540

~~Chapter 2.2.1.~~

541 The TUE should be run in parallel with a WOA or other accepted reference test method, using the same panel
542 of samples on both, to determine whether the TUE exhibits the same quantitative and qualitative characteristics
543 as the standard method. Favourable comparability lends strength to the belief that the TUE will be a successful
544 substitute for the reference method (see also methods comparison studies, Chapter 2.2.8 and Reising *et al.*,
545 2021).

546

2. Stage 2 – Diagnostic performance characteristics

547

See also Chapter 2.2.1. and Chapter 1.1.6. B stage 2.

548
549

2.1. The challenge in establishing accurate estimates of DSe and DSp for antigen assays

550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567

For all antigen detection assays including ELISAs, particular consideration must be given to the timing when the sample is taken as the probability of detecting antigen or the pathogen itself is very closely linked to the stage of infection. The diagnostic window will likely be much smaller in antigen/pathogen detection assays than in antibody detection tests as immune responses can normally be measured over an extended period of time. Dynamics of infection, e.g. acute, persistent, sub-acute, chronic or carrier-state are important determinants for sampling recommendations. For example, during an acute viral infection, the sample should be taken as early as possible after the onset of clinical signs. In persistent, sub-acute, chronic or carrier animals there is a balanced relation between the pathogen and the host and the agent may be present in minute concentrations which may be very difficult to detect. During the course of pathogenesis, other organ systems may become involved and different tissues or fluids may be more appropriate target tissues for sampling as the disease progresses. This information is provided in the disease-specific chapters of this WOAH *Terrestrial Manual*.

Diagnostic performance characteristics

- Are the criteria used to determine the positive and negative reference populations legitimate?
- Do the reference samples with which the assay was validated fully represent the population targeted by population where the assay will be applied?
- Were there difficulties in obtaining a sufficient number of samples? If so, how was the problem addressed?
- Were the samples collected and stored appropriately to minimise deterioration?

568

2.2. Reference animal populations

569

2.2.1. Animals of “known infection status”

570
571
572
573
574
575
576
577
578
579
580
581
582

Depending on the composition of positive and negative reference samples, the same test may have different estimates for DSe and DSp. Ideally the composition of reference samples and animals should match as closely as possible the samples which are expected from the target population for which the test was developed. It is important to have a clear case definition. This is a set of criteria used to decide whether an individual or group of animals is infected or not. The reference status must relate to the purpose of the testing. For example, if the purpose of the assay is to be used as a screening test to detect early infection of FMD (e.g. in free-ranging cattle with vesicles), then the majority of samples to determine DSe and DSp should be taken from this target population. Relevant information should be collected and summarised for all animals involved at this stage of validation (e.g. species, age, sex, breed), and information on other factors that are known to influence DSe and DSp (e.g. date and place of sampling, immunological status, vaccination and disease history, pathognomonic and surrogate tests used to define status of animals, prevalence within population and description how the reference status was derived).

583
584
585
586
587
588
589
590
591
592
593

A sample from a negative reference animal refers to lack of exposure to or infection with the agent in question. For example, a classical swine fever negative population could be defined as a region with pig herds without confirmed clinical cases of the disease in recent years, supported by negative serological tests and negative virological test results of suspected cases. Samples from these animals fulfil the status of negative reference samples. The negative reference population should be chosen with care so as to ensure that it is representative and matches the positive reference population (e.g. as to the breed and exposure to environmental challenge). Another source of negative reference animal samples depending on the sample type is sample collection pre-inoculation for animal trials; numbers for these sample types may be limited. If vaccination is carried out, it may interfere with antigen detection (e.g. vaccination with modified live viral vaccines). Samples from these animals should not qualify as negative reference samples.

594
595
596
597
598
599

The types and limitations of reference standards commonly used for evaluation of the performance characteristics of a new assay are listed here. An expanded description of each reference standard is provided in Chapter 2.2.1, Section B.2.2.1 and in Jacobson (1998). The strengths and limitations of these reference standards must be considered carefully when using samples, derived from animals that fall into any of the following four categories, as sources for establishing DSe and DSp for a ~~candidate assay~~ TUE (Jacobson, 1998).

600

i) An unequivocal reference standard

601
602

An unequivocal reference standard: presence of the agent in the host or evidence of definitive (pathognomonic) histopathology.

603

ii) A composite reference standard

-
- 604 A composite reference standard: verification of uninfected or unexposed animals.
- 605 iii) A relative reference standard
- 606 A relative reference standard: reference animals that have been classified for their infection status
607 by comparison with the test results of another assay for antigen or nucleic acid detection on the
608 same samples. As with antibody assays, the estimates of DSe and DSp are useful only insofar as
609 the reference test has documented, established and acceptable performance characteristics. A
610 deficiency of relative reference standards is that they have their own established levels of FP and
611 FN test results, which are sources of error that will be compounded in estimates of DSe and DSp
612 for the new assay. Generally, however, the use of other well described test methods is regarded as
613 good practice to determine the status of reference animals, but only if the inherent bias introduced
614 by the relative reference standard is accounted for.
- 615 iv) An adjunct reference standard: experimental infection or vaccination
- 616 See ~~the WOA Validation Standard Chapter 1.1.6~~, Section B.2.3 for significant limitations of this
617 type of standard. Note: In the context of antigen detection, “comparative” tests should include
618 pathogen detection by isolation, culture, NAD tests or histopathology or other *in-situ* techniques.
- 619 v) Heuer & Stevenson (2021) describes procedures for diagnostic test validation studies when there
620 is a perfect reference standard available for either positive or negative animals or both.

621 **2.2.2. Latent-class models for ~~sample selection of DSe and DSp~~**

622 For a discussion of this approach ~~to sample selection~~, see ~~the WOA Validation Standard Chapter 1.1.6~~,
623 Section B.2.5 ~~and~~, Chapter 2.2.6 ~~and~~ Cheung *et al.* (2021).

624 **2.3. Threshold (cut-off) determination**

625 It is important to clearly describe the method and the samples used for selecting a cut-off. It is strongly
626 recommended to conduct a receiver operating characteristic (ROC) analysis to show the potential performance
627 of the test in other epidemiological settings (Chapter 1.1.6., section B.2.4.).

628 **3. Stage 3 – Reproducibility and augmented repeatability estimates**

629 Reproducibility assessments for antigen detection assays are not uniquely different from similar assessments for any
630 other type of assay. Therefore, the reader is directed to ~~the WOA Validation Standard, Chapter 1.1.6~~, Section 3 ~~and~~ for
631 details on reproducibility analysis and for reference samples and panels to Chapter 2.2.6 ~~WOAH provides guidelines.~~
632 Further information about reproducibility is available from Johnson & Cabuang (2021) and Waugh & Clark (2021).
633 Samples provided from Proficiency Test rounds can be used for laboratory proficiency comparability testing
634 (<https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-5>) of a reference test and TUE
635 (Johnson & Cabuang, 2021; Waugh & Clark, 2021).

636 **4. Stage 4 – Programme implementation**

637 **4.1. Interpretation of results**

638 See the Chapter 2.2.1, Section B.4.1.

639 **5. Monitoring assay performance**

640 **5.1. Monitoring the assay**

641 After performance characteristics of the ~~new test TUE~~ have been established, on-going monitoring, maintenance
642 and enhancement are required. It is important to continue monitoring the repeatability and reproducibility of the
643 assay over time, on a per run basis, quality control samples have to fall within pre-established limits. If not, the
644 test result is not valid and ~~has established alternative procedures have~~ to be ~~repeated followed~~. Monitoring the
645 assay controls' performance over time is an important way to detect changes or trends in the assay. Simple
646 analysis of results, e.g. statistical assessment of mean values, standard deviation and coefficient of variation
647 are useful in this process and results can be plotted in a control chart. Participation in external quality control or
648 proficiency testing programs is a requirement of ISO 17025 and useful to identify random and systematic errors
649 and provide credibility in test results. Further information about this topic can be obtained from Crowther *et al.*

650 (2006) and in the Chapter 2.2.1, Section B.5.1. This also provides valuable information on the stability of assay
651 reagents over a time period.

652 **5.2. Minor modifications of the assay – replacement of depleted reagents**

653 Over time changes in the test protocol may be necessary due to better or less costly reagents or because the
654 target analyte has changed. Batch-to-batch variation of biological reagents is considered a major contributor to
655 test variation. When reagents such as antibodies or antigen must be replaced they should be produced or
656 procured using the same protocols or criteria as used for the original reagents. New biological reagents (e.g.
657 control samples, antigen, capture or detection antibodies, conjugate, chemicals or consumables) need to be
658 assessed for comparability. Chapter 2.2.8 *Comparability of assays after changes in a validated test method*
659 gives an overview of acceptable comparability studies. A ground rule is never to change more than one reagent
660 at a time in order to avoid the compound problem of evaluating more than one variable concurrently (see also
661 Chapter 2.2.1, Section B.5.2, Chapter 2.2.8. and Reising *et al.*, 2021).

662 **5.3. Major modifications of the assay – changing to a new ELISA type**

663 It is a major challenge of laboratory diagnosis to keep up with the evolving nature of infectious pathogens. Over
664 time pathogens may change their antigenic characteristics and new strains may emerge, e.g. the emergence of
665 Bluetongue virus serotype 8 in northern Europe in 2009. This change necessitates a full test development and
666 validation study. Another major change is the use of a test in a different species than that for which it was
667 originally validated, e.g. there may be a requirement to use an FMD Ag detection ELISA, validated in cattle, for
668 testing camelids or buffalo in different geographical and climatic regions (Kirkland & Newberry, 2021). Evaluation
669 of reference samples that represent those populations of Stage 2 in Figure 1 of the WOAH Validation Standard
670 Chapter 1.1.6 will accomplish this requirement (see also Chapter 2.2.1, Section B.5.3).

671 **5.4. Enhancing confidence in validation criteria**

672 Due to the extensive set of variables that have an impact on the performance of antigen detection assays, it is
673 useful to expand the number of reference samples when possible, due to the principle that error is reduced with
674 increasing sample size (see also Chapter 2.2.1, Section B.5.4).

675 **Acknowledgements**

676 The contributors wish to thank Dr Grant Peck (ACDP, CSIRO Geelong, Australia) for providing detailed advice for the
677 section about purified and crude antigens for antibody production and Andrea Certoma (ACDP, CSIRO Geelong, Australia)
678 for sharing experimental data.

679 **REFERENCES**

680 BOSSUYT P.M., REITSMA J.B., BRUNS D.E., GATSONIS C.A., GLASZIOU P.P., IRWIG L., LIJMER J.G. MOHER D., RENNIE D., DE VET
681 H.C.W., KRESSEL H.Y., RIFAI N., GOLUB R.M., ALTMAN D.G., HOOFT L., KOREVAAR D.A., COHEN J.F. & STARD (STANDARDS FOR
682 REPORTING DIAGNOSTIC ACCURACY GROUP (2015). STARD 2015: an updated list of essential items for reporting diagnostic
683 accuracy studies. *BJM*, **351**:h5527. doi: 10.1136/bmj.h5527

684 BOWDEN T.R., CROWTHER J.R. & WANG J. (2021). Review of critical factors affecting analytical characteristics of serological
685 and molecular assays. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 53–73. doi:10.20506/rst.40.1.3208.

686 CHEUNG A., DUFOUR S., JONES G., KOSTOULAS P., STEVENSON M.A., SINGANALLUR N.B. & FIRESTONE S.M. (2021). – Bayesian
687 latent class analysis when there is an imperfect reference test. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 271–286.
688 doi:10.20506/rst.40.1.3224.

689 COLLING A. & GARDNER I.A. (EDS). (2021). Diagnostic test validation science: a key element for effective detection and control
690 of infectious animal diseases. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**. The Special Issue is available at:
691 [https://doc.woah.org/dyn/portal/index.xhtml?page=alo&alold=41245&req=21&cid=1e3ba84f-604f-47b7-bec3-](https://doc.woah.org/dyn/portal/index.xhtml?page=alo&alold=41245&req=21&cid=1e3ba84f-604f-47b7-bec3-927e54e04b42)
692 927e54e04b42

693 CROWTHER J.R. (2001). The ELISA guidebook. In: Methods in Molecular Biology. Humana Press, Totowa, NJ, USA, 1–
694 421.

-
- 695 CROWTHER J.R., UNGER H. & VILJOEN G.J. (2006). Aspects of kit validation for tests used for the diagnosis and surveillance
696 of livestock diseases: producer and end-user responsibilities. *Rev. sci. tech. Off. int. Epiz.*, **25**, 913–935.
- 697 CULLINANE A. & GARVEY M. (2021). A review of diagnostic tests recommended by the World Organisation for Animal Health
698 Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 75–89.
699 <https://doi.org/10.20506/rst.40.1.3209>
- 700 JOHNSON P. & CABUANG L. (2021). Proficiency testing and ring trials. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 189–203.
701 <https://doi.org/10.20506/rst.40.1.3217>
- 702 GARDNER I.A., COLLING A., CARAGUEL C.G., CROWTHER J.R., JONES G., FIRESTONE S.M. & HEUER C. (2021). Introduction:
703 validation of tests for OIE-listed diseases as fit-for-purpose in a world of evolving diagnostic technologies. *Rev. Sci. Tech.*
704 *Off. Int. Epiz.*, **40**, 19–28. doi:10.20506/rst.40.1.3207.
- 705 GARDNER I.A., COLLING A. & GREINER M. (2019). Design, statistical analysis and reporting standards for test accuracy studies
706 for infectious diseases in animals: Progress, challenges and recommendations. *Prev. Vet. Med.*, **162**, 46–55.
707 [doi:10.1016/j.prevetmed.2018.10.023](https://doi.org/10.1016/j.prevetmed.2018.10.023)
- 708 GARDNER I.A., NIELSEN S.S., WHITTINGTON R.J., COLLINS M.T., BAKKER D., HARRIS B., SREEVATSAN S., LOMBARD J.E., SWEENEY
709 R., SMITH D.R., GAVALCHIN J. & EDA S. (2011). Consensus-based reporting standards for diagnostic test accuracy studies
710 for paratuberculosis in ruminants. *Prev. Vet. Med.*, **101**, 18–34. PMID: 21601933.
- 711 GREINER M., BHAT T.S., PATZELT R.J., KAKAIRE D., SCHARES G., DIETZ E., BÖHNING D., ZESSIN K.H. & MEHLITZ D. (1997). Impact
712 of biological factors on the interpretation of bovine trypanosomosis serology. *Prev. Vet. Med.*, **30**, 61–73.
- 713 HALPIN K., TRIBOLET L., HOBBS E.C. & SINGANALLUR N.B. (2021). Perspectives and challenges in validating new diagnostic
714 technologies. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 145–157. doi:10.20506/rst.40.1.3214.
- 715 HEUER C. & STEVENSON M.A. (2021). Diagnostic test validation studies when there is a perfect reference standard. *Rev. Sci.*
716 *Tech. Off. Int. Epiz.*, **40**, 261–270. doi:10.20506/rst.40.1.3223
- 717 HOBBS E., COLLING A., GURUNG R. & ALLEN J. (2020). The potential of diagnostic point-of-care tests (POCTs) for infectious
718 and zoonotic animal diseases in developing countries: technical, regulatory and sociocultural considerations. *Transbound.*
719 *Emerg. Dis.*, **68**, 1835–1849.
- 720 JACOBSON R.H. (1998). Validation of serological assays for diagnosis of infectious diseases. *Rev. sci. tech. Off. int. Epiz.*,
721 **17**, 469–486.
- 722 KIRKLAND P.D. & NEWBERRY K.M. (2021). Your assay has changed – is it still ‘fit for purpose’? What evaluation is required?
723 *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 205–215. doi:10.20506/rst.40.1.3218
- 724 KOSTOULAS P., GARDNER I.A., ELSCHNER M.C., DENWOOD M.J., MELETIS E. & NIELSEN S.S. (2021). Examples of proper
725 reporting for evaluation (Stage 2 validation) of diagnostic tests for diseases listed by the World Organisation for Animal
726 Health. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 287–298. doi:10.20506/rst.40.1.3225
- 727 KOSTOULAS P., NIELSEN S.S., BRANSCUM A., JOHNSON W.O., DENDUKURI N., DHAND N., TOFT N. & GARDNER I.A. (2017).
728 STAR-D-BLCM: standards for the reporting of diagnostic accuracy studies that use Bayesian latent class models. *Prev.*
729 *Vet. Med.*, **138**, 37–47. doi:10.1016/j.prevetmed.2017.01.006
- 730 RAHMADANE I., CERTOMA A.F., PECK G.R., FITRIA Y., PAYNE J., COLLING A., SHIELL B.J., BEDDOME G., WILSON S., YU M.,
731 MORRISSY C., MICHALSKI W.P., BINGHAM J., GARDNER I.A. & ALLEN J.D. (2017). Development and validation of an
732 immunoperoxidase antigen detection test for improved diagnosis of rabies in Indonesia. *PLoS Negl. Trop. Dis.*,
733 **11**(11):e0006079. doi: 10.1371/journal.pntd.0006079.
- 734 REISING M.M., TONG C., HARRIS B., TOOHEY-KURTH K.L., CROSSLEY B., MULROONEY D., TALLMADGE R.L., SCHUMANN K.R., LOCK,
735 A.B. & LOIACONO C.M. (2021). A review of guidelines for evaluating a minor modification to a validated assay. *Rev. Sci.*
736 *Tech. Off. Int. Epiz.*, **40**, 217–226. doi:10.20506/rst.40.1.3219.
- 737 SHIELL B.J., S. YE, HARPER J.A., VAN DER HEIDE B., BEDDOME G., FOORD A.J., MICHALSKI W.P., BINGHAM J. & PECK G.R. (2020).
738 Reagents for detection of Rift Valley fever virus infection in sheep. *J. Vet. Diagn. Invest.*, **32**, 577–580. doi:
739 [10.1177/1040638720926476](https://doi.org/10.1177/1040638720926476).
-

740 VAN BORM S., WANG J., GRANBERG F. & COLLING A. (2016). Next-generation sequencing workflows in veterinary infection
741 biology: Towards validation and quality assurance. *Rev. Sci. Tech. Off. Int. Epiz.*, **35**, 67–81.

742 WATSON J.W., CLARK G.A. & WILLIAMS D.T. (2021). The value of virtual biobanks for transparency purposes with respect to
743 reagents and samples used during test development and validation. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 253–259.
744 doi:10.20506/rst.40.1.3222.

745 WAUGH C. & CLARK G. (2021). Factors affecting test reproducibility among laboratories. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**,
746 131–143. doi:10.20506/rst.40.1.3213.

747 WRIGHT P.F. (1998). International standards for test methods and reference sera for diagnostic tests for antibody detection.
748 *Rev. sci. tech. Off. int. Epiz.*, **17**, 527–533.

749
750

*
* *

751 **NB:** FIRST ADOPTED IN 2014.

CHAPTER 2.2.3.

DEVELOPMENT AND OPTIMISATION OF NUCLEIC ACID DETECTION ASSAYS

INTRODUCTION

The WOAH Validation Recommendations in Section 2.2 Validation of diagnostic tests of this Terrestrial Manual provide detailed information and examples in support of the WOAH Validation Standard that is published as Chapter 1.1.6 Validation of diagnostic assays for infectious diseases of terrestrial animals. The term “WOAH Validation Standard” in this chapter should be taken as referring to that chapter. An up-to-date compilation of the relevant validation standards (WOAH and non-WOAH) and guidance documents for all stages of diagnostic test validation and proficiency testing, including design, analysis as well as clear, case studies are provided in the WOAH Scientific and Technical Review issue *Diagnostic Test Validation Science* (Colling & Gardner, 2021). Published standards for peer-reviewed reporting of accuracy studies (STARD) are available for infectious diseases of humans and terrestrial animals (paratuberculosis, Bayesian latent class model) (Bossuyt et al., 2015; Gardner et al., 2011; Kostoulas et al., 2017).

An ever increasing number of Nucleic acid detection (NAD) tests are now being used a primary diagnostic tool for diagnosis—the detection of infectious diseases in various species of animals and man. The most common methods are the Polymerase chain reaction (PCR), of which there are a number of variations and is the method of choice in the veterinary clinical laboratory with point-of-care (POC) devices and technologies, such as isothermal amplification methods (such as loop-mediated isothermal amplification), gaining traction in field studies. In addition, solid-phase or liquid phase microarrays are appearing as new useful tools of biotechnology-based diagnosis for screening changes in gene expression. The amplification techniques employed in these assays provide them with often result in high analytical sensitivity. The products of the amplification reaction can be detected in a number of ways, for example, by visualisation in agarose gels, or by using DNA-binding dyes, or labelled probes (e.g. Taqman hydrolysis probes), by the detection of the accumulation of the products in real time or by using arrays where specific probes are captured on a for real-time (rt)PCR, and solid-surface matrix or on-beads for microarrays), (Lauerman, 2004; Viljoen et al., 2005). Different PCR assays can be multiplexed together in a single reaction well to detect several targets in one tube or to combine targeted analytes and controls that generate different amplification products, all in one reaction vessel. Whilst this has obvious advantages, great care must be taken during it also requires significant optimisation and validation to ensure that assay performance is not compromised. Similarly, a multiple outcome PCR can be created using one set of primers, but employing and tagged probes, which that bind to different target sequences in the represented by different species or strains detected by the PCR (Wakeley et al., 2005; 2006).

NAD amplification techniques are usually based on the principle that there is an exponential amplification of the specific sequence targeted in the reaction. This provides a NAD with high analytical sensitivity and specificity. Due to this characteristic high level of sensitivity reached with NAD, special care, but also requires uni-directional workflows and indeed special precautionary steps have to be taken to prevent NAD amplicon contamination to of the environment and subsequent sample analyses. This Contamination is more likely to be a problem where reaction tubes are opened in the laboratory for further processing, for example, to run

44 gels or to perform nested assays. To avoid such contamination, strict laboratory protocols should be
45 employed involving separate rooms or cabinets for particular stages of the assays, changes of laboratory
46 gowns and gloves, and stringent cleaning programmes (Viljoen et al., 2005; Subcommittee of Animal Health
47 Laboratory Standards). For these reasons, tests based on closed tube systems are generally more suitable
48 for diagnostic assays (Sawyer et al., 2006). As with all assays, it is important to use appropriate controls to
49 prove that the assay is performing as expected. All samples used in assay development should have well
50 established provenance and ~~the assay~~ development and validation should be carried out within the
51 framework of a quality system to ensure appropriate levels of training, equipment maintenance and
52 monitoring, etc. (Burkhardt, 2000).

53 A. ASSAY DEVELOPMENT PATHWAY

54 1. Definition of the intended purpose(s) for an assay

Purpose of the assay:

- Is it for a screening or confirmatory test, or both?
- Is it for detection of a group of pathogens?
- Is it for detecting a single disease agent?
- Is it for discriminating between vaccinated and infected animals?

The first consideration in assay development is to define clearly the specific purpose and application of the test to be developed. ~~The purpose and to understand how it application will be applied because this~~ informs many of the decisions of the development pathway. For example ~~one might choose~~, to develop a screening test to detect all avian influenza (AI) subtypes or variants in birds ~~for which~~, an inclusive and broadly reactive test is necessary, ~~or~~, In contrast, to determine the haemagglutinin type, ~~in which case~~ a more specific test is needed. ~~For~~ Some tests ~~the requirement is~~ are designed to detect a group of viruses, e.g. the pan-Pestivirus PCR that detects bovine viral diarrhoea (BVD), border disease (BD) and classical swine fever (CSF) viruses. ~~For other tests, the requirement may be~~, whereas others are designed to detect a single agent, or ~~sometimes even~~ to allow a particular immune status using a DIVA (differentiating infected from vaccinated animals) approach. ~~An~~ Examples of such a ~~method is~~

67 methods include the recently published real-time RT-PCR assays for CSF virus ~~which was developed for the genetic~~
68 differentiation of naturally, and lumpy skin disease (LSD) virus, which are able to differentiate animals infected from with
69 wild type viruses and vaccinated wild bear animals (Agianniotaki et al., 2017; Liu et al., 2009; Wolff et al., 2021).

72 2. Assay development – experimentation

73 2.1. Quality assurance

74 It is important that assays are developed in laboratories where high standards of quality assurance and control
75 are employed (see Chapter 1.1.5 *Quality management in veterinary testing laboratories*). The validation data
76 for test performance and accuracy determined during the development and validation phase must be robust as
77 it will form the basis for interpretation of disease status and consequent actions when the assay is routinely
78 used. Laboratories should keep accurate records of samples, reagents and methods used in test validation and
79 store summary data and reports in secure, communal databases for ready access and review. Where assays
80 are to undergo accreditation with national agencies, comprehensive reports should be prepared describing
81 samples used, replicates and statistical analyses for each validation stage.

82 2.2. Reference materials

83 Sample selection (see Chapter 1.1.2 *Collection, submission and storage of diagnostic specimens*). For
84 further information on biobanks and selection and use
85 of reference samples please see Watson et al. (2021)
86 and Chapter 2.2.6. Selection and use of reference
87 samples and panels, respectively.

89 For most diseases, the samples required for NAD
90 assays are likely to be similar to those used for ~~current~~
91 other detection methods ~~such as bacterial cultivation or~~
92 virus isolation, for example, detection of AI by real-time
93 RT-PCR and virus isolation use the same samples.

94 Recently Wherever possible, reference samples that will be used to develop and assess the sensitivity and

- What kinds of samples will be used from the target population?
- What are the predilection sites for the agent in the host
- ~~Will samples be single or pooled?~~
- What sample collection, storage and transport methods are anticipated and what are the possible effects on results?
- Will samples in the validation panel be representative of the target population?

95 specificity of the assay should resemble the type of sample that will be used in the diagnostic setting. Therefore,
96 it is important to understand the biology of the pathogen concerned and the tissues that will be infected to select
97 an appropriate sample type. For assay validation, the choice of reference material must reflect the likely
98 diagnostic setting and include consideration of: sample type, sample matrix, presence and effect of inhibitory
99 substances, type of collection device, sample buffers and transport/storage conditions, target
100 population/species and whether the assay will be performed in the laboratory or field/pen-side. Recent trends
101 in sampling techniques to minimise or eliminate invasive methods must be considered when choosing reference
102 materials. These changes in sampling have several benefits including improving ease of, and access to,
103 sampling sites for the field practitioner, reduction in biohazard risks, such as tissue homogenisation and aerosol
104 generation and minimising sample processing times in the laboratory and field. Examples include swabbing of
105 fresh cuts in organ samples proved to be a practical approach, replacing the laborious rather than
106 homogenisation of organ samples. Similarly, there is a trend to use samples, which can be obtained by non-
107 invasive methods, such as (Errington *et al.*, 2014), use of saliva for detection of porcine reproductive and
108 respiratory syndrome (PRRS) in pigs (Prickett *et al.*, 2008), or collection of oral fluids using cotton ropes for
109 detections of foot and mouth disease virus (FMDV) and African swine fever virus (ASFV) (Goonewardene *et al.*,
110 2021; Mouchantat *et al.*, 2014; Vosloo *et al.*, 2015) and bulk milk samples for determination of herd BVD status.
111 Prior to the selection of pooled samples, such as bulk milk, test developers need to consider and assess the
112 implications of dilution of the target analyte on diagnostic sensitivity and incorporate this into the validation plan
113 (see below). Faecal samples are widely used for detection of different viruses associated with gastrointestinal
114 diseases and hair samples can be used for detection of some viruses e.g. border disease virus (Kalaiyarasu *et*
115 *al.*, 2019) and bovine viral diarrhoea virus (Singh *et al.*, 2011; Zoccola *et al.*, 2017).

116 It is important to understand the biology of the pathogen concerned and the nature of the sample collection
117 devices. As in the case of AI, different subtypes or variants of the viruses have different predilection sites in host
118 birds. For example cloacal samples are appropriate for some subtypes, whereas buccal samples are acceptable
119 for others. Therefore, a test for use in a surveillance programme would need to incorporate both sampling sites
120 and be validated using both types of sample. Another significant factor is the matrix in which the analyte resides
121 in the host. Cloacal samples are more likely to contain PCR inhibitors than buccal samples. Another potential
122 confounding factor is the type of swab used to collect the samples; some contain materials that inhibit PCR
123 assays. Therefore, it is very important to specify precisely the preferred sample material and to describe fully
124 the swabs and swabbing protocol, including the preferred buffers or transport media and storage conditions.

125 Consideration also should be given to whether samples should be tested singly or in pools and whether pools
126 should be of different samples from a single or multiple animals. Any pooling strategy should be precisely defined
127 and validated prior to use. Finally, if the target population is “birds”, the validation study should cover a large
128 representative population of different species to demonstrate that the assay is widely applicable, whilst
129 concentrating on the most prevalent species or those used as sentinels of infection.

130 2.3. Design of test method (fitness for purposes)

131 2.3.1. Choice Purpose of test and target sequence

132 The purpose of the test under evaluation (TUE) will
133 largely determine the choice of nucleic acid (NA) target
134 sequence. For emerging animal disease surveillance
135 usually activities large numbers of samples may be
136 tested first by a broad screening assay. In the above
137 example for AI, the screening assay described must
138 detect all known subtypes or variants of Influenza A,
139 either in a particular region or throughout the world.
140 The test must be highly sensitive so it does not miss
141 true positive samples, and analytically specific
142 (inclusive) for detection of all viruses in the Influenza
143 A group followed by specific agent characterisation
144 assays. Where broad screening strategies are
145 necessary, consideration must be given to whether
146 these will be conducted in a laboratory with automation
147 to achieve high throughput, or without, or in the field
148 using a pen-side assay.

- Is the test for use only in a particular region or world-wide?
- Is it sufficiently sensitive and is the analytical target inclusive enough to not miss positive samples?
- Consider the impact of a high proportion of false positive results that cannot be confirmed.
- Are rapid results possible and/or necessary?
- Will confirmatory tests (an analytical tool) be used to determine/confirm pathogen pathotype (strain)?
- Will determination of the strain have important bearing on the action taken?

149 Using AI as an example, the screening assay must detect all known subtypes or variants of influenza A,
150 either in a particular region or throughout the world. The test must be highly sensitive and analytically
151 specific (inclusive) for detection of all viruses in the Influenza A group. Avian Influenza is a high profile
152 disease. If a new test should it should not, however, generate a high proportion of false positive results
153 that cannot otherwise be confirmed, as this may make the infection status of the birds would be difficult

154 to resolve. Exclusion of closely related agents that are not of interest within the context of the intended
155 purpose of the assay is therefore essential.

156 To continue with the AI screening example, it is also important for the test to produce rapid results so
157 that disease control measures can be swiftly applied. So, for the detection of avian influenza, the logical
158 choice of tests would be a real time PCR using TaqMan probes or a field based assay. For an AI
159 screening assay, the primers and probes are likely to be based upon the Matrix (M) gene which is known
160 to be present in all influenza type A isolates. Dependent on the assigned fitness for purpose, the
161 scientists may choose to develop an additional assay for use in conjunction with the screening test to
162 determine which particular strain of AI is present and whether the strain is highly pathogenic, because
163 this has an important bearing on the notification requirements and control measures that may follow.
164 Some test methods may qualify as secondary analytic tools that are applied to the analyte detected in
165 the primary assays, and may be used to further characterise the product detected in the screening assay
166 (see the WOAHI Validation Standard, Section B.1.4). An example of such an analytic method would
167 include sequence analysis of the matrix PCR amplicon detected during AI screening. Development of
168 paired confirmatory assays such as real-time PCR assays that target other genes, such as the AI
169 haemagglutinin or neuraminidase to identify subtype or pathotype, would require that those assays also
170 undergo all steps of development, optimisation and validation. Recently a novel, plexus primers-based
171 PCR assay was developed at the WOAHI Collaborating Centre for the Biotechnology-based Diagnosis
172 of Infectious Diseases in Uppsala, Sweden. This assay allows the simple and rapid determination of
173 various RNA virus pathotypes. For example, avian influenza viruses and Newcastle disease viruses can
174 be detected and evaluated with low cost equipment (PCR machine) and in a very short period of time
175 (less than three hours), in simply equipped laboratories or even on site, in the field, during outbreak
176 situations (Leijon *et al.*, 2011; Yacoub *et al.*, 2012). This indicates a very rapid development and
177 simplification in the field of NAD tests in diagnostics towards field/on-site applications.

178 2.3.2. Method design

179 The method should be carefully designed to fulfil the
180 purpose that was defined at the outset. Important
181 factors to consider will include application, types, and
182 numbers of samples to be tested. This, in turn, leads
183 to logistical and practical considerations for the
184 candidate assay, such as whether it will be conducted
185 in a laboratory, with or without automation to achieve
186 high throughput, or in the field using a pen-side assay.

- Was the assay first evaluated on a small sample panel (six to eight samples) to assess viability of the approach?
- Was there good separation between test results of negative and positive samples?
- Was a preliminary test made on a dilution series in matrix to assess preliminary relative analytical sensitivity?

187 All available information such as publications,
188 sequences deposited in databases and in-house
189 sequence data should be used. Sophisticated
190 software is available to optimise primer and probe design; computer modelling of probable sequences
191 for use in the assay is a first step: for target sequence design. Software is available to model suitable
192 target sequences and optimise primer and probe design. The critical design features are target
193 identification; primer/probe characterisation; and assay optimisation. The first two steps are carried out
194 by *in-silico* analysis, and the third by experimental investigation. For further information refer to Bustin &
195 Huggett, 2017; Rodriguez *et al.*, 2015; Thornton & Basu, 2015; and Guide to PCR Qiagen¹. The main
196 features of the steps are:

- 197 i) Target identification – use the purpose of the TUE and *in-silico* alignments of representative isolates
198 to determine the appropriate sequence target of the pathogen
- 199 ii) Primer and probe characterisation:
 - 200 a) Melting temperature (T_m) – to obtain best performance for standard hydrolysis probe PCR assay,
201 the T_m of the probe is normally 8–10°C higher than that of primers, and the T_ms of the primers
202 differs by less than 1°C;
 - 203 b) Primer and probe length between 15 and 30 bp; PCR amplicon length is between 50 and 150 bp
204 (optimum <80 bp).
 - 205 c) Avoid formation of primer-dimer and hairpins within and between primers and probe.
 - 206 d) Where degenerate nucleotides are used, avoid degeneracy in the three nucleotides at the 3' end;
207 and try to design primers with less than four-fold degeneracy at any given position

¹ <https://www.qiagen.com/us/knowledge-and-support/knowledge-hub/bench-guide/pcr/introduction/guidelines-for-pcr>

- 208 iii) Assay optimisation via experimental methods of:
- 209 a) Primer and probe concentration, and combination
- 210 b) Annealing/extension temperature of PCR reaction
- 211 c) Concentration of Mg²⁺ and all enzymes (e.g. reverse transcriptase [if applicable] and DNA
- 212 polymerase)
- 213 d) PCR additives and enhancers (e.g. dimethyl sulfoxide [DMSO], bovine serum album [BSA] and
- 214 glycerol) for specific target sequences (e.g. GC rich).

215 **2.3.2 Ancillary or supplementary tests**

216 Ancillary or supplementary tests may be used in conjunction with the screening test to assist with agent

217 characterisation, because this has an important bearing on the notification requirements and control

218 measures that may follow (see Chapter 1.1.6, Section B.1.4). Examples include sequence analysis of

219 the matrix PCR amplicon detected during AI screening and real-time PCR assays for haemagglutinin or

220 neuraminidase. Ancillary assays that provide additional agent characterisation also require development,

221 optimisation, and limited validation to determine fitness-for-purpose.

222 **2.3.3 Point of care (POC) tests**

223 During the last few years, POC (penside) testing has gained

224 popularity for use in veterinary diagnostics (Halpin *et al.*, 2021;

225 Hobbs *et al.*, 2020) because of its advantages such as (1)

226 portability and ease of use, (2) rapid turnaround time for

227 results; and (3) no need to ship samples to central laboratories

228 (reviewed by Chander, 2023). The rapid rise in the

229 development of POC tests reflects the desire of veterinarians,

230 regulators, and producers to make timely decisions about

231 animal health to instigate appropriate controls if needed.

- Optimal location? Use a clean room or cabinet system to minimise risk of contamination.
- Standardise sample extraction for manual and/or by automated preparation.
- Optimal method of sample extraction to prepare samples? Done manually or by automation?

232 Isothermal amplification-based techniques, such as LAMP,

233 helicase-dependent amplification (HAD) and recombinase

234 polymerase amplification (RPA), have been applied as POC

235 tests for a variety of agents (Bath *et al.*, 2020; Hassan *et al.*, 2022; Velayudhan & Naikare, 2022). Care

236 must be exercised in the interpretation of negative results in suspect animals, to avoid false negatives

237 being reported where viral loads are below the sensitivity threshold of the POC test. Where POC tests

238 are supported by laboratory-based assays, comparative studies of both assays using, where possible,

239 identical reference and diagnostic samples, should be conducted to fully appreciate any differences in

240 sensitivity or specificity.

241 **2.4. Feasibility study**

242 Before embarking on the validation of a newly developed

243 prototype assay, a feasibility study should be carried out

244 using a small panel of approximately six or eight well-

245 characterised samples, covering the operational range of

246 the assay, to assess whether the system is viable. The

247 panel should consist of samples distributed across the

248 operating range of the assay, i.e. include at least two

249 negatives, at least two unambiguous positives, and ideally

250 samples falling mid-range. Ideally these samples should

251 come from different animals. Samples from experimentally

252 infected animals or viral isolates can add value to the

253 feasibility study. The assay should achieve as wide-as-possible separation of test results for the high-strong

254 positive and negative samples in this the panel. It may be useful to test a dilution series (analyte diluted in

255 matrix) at this point to assess relative analytical sensitivity, particularly if the test is a potential replacement for

256 another an existing method where sensitivity is an important criterion (see Chapter 2.2.8 Comparability of assays

257 after changes in a validated test method). It is important to test different genetic strains/lineages of the target

258 pathogen as well as genetically closely related pathogens to determine preliminary inclusivity and exclusivity,

259 respectively. For example, a well-established PCR assay detected all known isolates for many years (Smith *et*

260 *al.*, 2001) but failed on a recent novel variant (HeV-g2) (Annand *et al.*, 2022; Bowden *et al.*, 2021). Toohey-

261 *Kurth et al.* (2020) describe guidelines for validation, verification and comparison of real-time PCR assays in

262 *veterinary diagnostic testing laboratories.*

- Evaluate the assay on a small sample panel (six to eight samples) to assess viability of the approach.
- Is there good separation between test results of negative and positive samples?
- Use a dilution series in matrix to obtain preliminary relative analytical sensitivity.

263

2.5. Development and optimisation

264
265
266
267
268

The aim of this stage is to define and optimise the method that will be used to carry out the test in future routine testing. This includes description of appropriate facilities to carry out the assay. It is important to consider both the method of sample extraction required to prepare samples for the test and the assay procedure. For any PCR assay, ~~definition of clean room protocols is~~ are required to minimise contamination. If large numbers of samples are anticipated, selection of an automated extraction procedure may be essential (Jungkind, 2001).

269
270
271
272
273
274
275
276
277
278
279
280
281

Usually, it is necessary to assess a number of different test methodologies and vary concentrations of reagents, template additions and reaction times to optimise the extraction and the assay. It is important to ~~either~~ change only one variable at a time or use a multi-factorial design and analysis strategy (see the WOA Validation Standard, Section A.2.5 on Robustness). ~~It is important to identify which~~ Factors that have only a narrow range of optimal activity must be identified, as these are critical points in the assay procedure and may affect an assay's robustness. Generally, the assay stages are relatively simple to optimise, but care needs to be taken to ensure a robust nucleic acid extraction, and that all assay reagents, and procedural steps are optimised and suitable for routine laboratory application (Burkhardt, 2000).

- Optimise reagent concentrations and PCR cycling conditions.
- ~~Have concentrations of reagents been tested for optimal reactivity?~~
- ~~Has extraction been optimised?~~
- ~~What are the template additions and reaction times to optimise the assay?~~
- Which factors have a narrow range in which they perform optimally?
- Has that range been defined?

282
283
284

Controls for PCR are many and varied. It is important to include appropriate controls to show that the assay is performing as expected. The various controls that should be considered include:

285

2.5.1. A host-species control

286
287
288
289
290
291
292
293
294
295
296
297
298
299

~~This control demonstrates that the target species has been appropriately sampled. In the AI screening assay example, the control verifies that the sample swab had been in contact with a target species and that the sample contained "bird" nucleic acid, which is available for extraction using the defined protocol. A possible target for this control is a housekeeping gene such as beta actin, which is present in the target host species. This is relatively simple if the host species is a single species e.g. chickens, but it will be more challenging to find a suitable target for all "bird" samples. A host-species control may not be required if a sample is added directly to the extraction process, such as a piece of tissue or blood. It is highly recommended for "indirect" samples such as those collected on swabs; where the host-species control should be used for every sample tested.~~

Have you included all necessary controls to prove the assay is performing as expected?

- ~~Template control?~~
- ~~Inhibition control?~~
- ~~Positive sample control?~~
- ~~For RNA assay—reverse transcription control?~~

300

2.5.1. Analyte-positive control

301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317

This positive control, having a real-time PCR quantification cycle threshold (Ct-Cq) activity within the ~~defined operating moderate to weak~~ range of the assay, is used on each plate. ~~A suitable choice for this control may be a plasmid containing the target sequence, which It can be used to check for the expected level of amplification in the assay. However, this does not assess the efficacy of the either an extraction process, which requires control prepared from a known field sample or its equivalent (such as a sample from an experimental infection) or a plasmid or in-vitro transcribed RNA containing the target sequence.~~ The extraction control has the advantage of testing the entire sample processing pipeline, whereas a plasmid control tests only the DNA amplification step. Whichever is selected for use, positive controls should be prepared as a large batch, aliquoted into single-use vials and tested for homogeneity, to ensure suitable reactivity in the assay. The positive control batch then provides progressive monitoring of assay performance particularly during the optimisation steps.

- Has a large batch of quality-assured positive control material been prepared and aliquoted in single use vials to provide progressive monitoring of the TUE during optimisation and validation?
- Have both the advantages and disadvantages of including an internal control been considered?
- Is the purpose and application of the inhibition control clearly specified in the assay protocol?

318

319

2.5.2. No-template control (NTC)

320
321
322
323
324
325

The NTC consists of a well containing master-mix alone without addition of NA template. This control reveals whether contamination of the sample-master-mix has occurred, resulting in amplified product when no amplified product should be present, as in a sample containing no target. Consideration should be given to the number and placement of no template controls-NTCs in the assay set up template. Generally, a number (approximately 5% of wells) of no template controls-NTCs are distributed randomly within the assay or over the plate when 96 and 386 well-plate formats are used.

326

2.5.3. Inhibition control

327
328
329
330
331
332
333
334
335

~~This control is needed to detect possible inhibitors of the PCR reaction. If an inhibition control yields a negative result, this infers that the sample contains inhibitory substances and that a negative test result for the test sample cannot be interpreted as “negative” because the assay did not perform correctly. Certain samples such as faeces and semen often contain inhibitors whereas this may be less of a problem when testing blood samples or cultured organisms (Ballagi-Pordány & Belák, 1996). Data collected during the validation process concerning assay performance using the sample matrices being targeted will allow for a risk-based decision as to whether an inhibition control should be included for each sample or whether the test system is unlikely to be affected by inhibition. If inhibitory substances are a significant problem an inhibition control must be included for each test sample.~~

336
337

~~There is considerable debate about the most suitable and effective inhibition control. Examples include the following:~~

338
339
340
341
342
343
344
345
346
347
348

~~i) — An artificial target, such as a length of DNA contained in a plasmid, which is added to the extracted sample and amplified with the same primers as the test target, but is of a different size or contains a different internal sequence so that it is identified as the internal control when the detection method is applied (Sawyer et al., 2006). The advantage of this approach is that it utilises the same primers employed in the test, and the control can be added at precise concentrations. Because the target for the assay and for the control is the WOAH Terrestrial Manual 2024-5 Chapter 2.2.3. — Development and optimisation of nucleic acid detection assays same, competition for the primer and dNTPs may reduce the analytic performance of the assay. Care must be taken during assay optimisation, so that the analytical sensitivity of the assay is not detrimentally affected. Another disadvantage is that as an added component, this control only verifies the assay stage of the test and does not act as a control for the extraction stage.~~

349
350
351
352
353
354
355
356
357
358
359
360

~~ii) — ii) An alternative strategy for an inhibition control is to amplify a housekeeping or structural gene such as β -actin which always is present in the target tissue, and thus the sample. If the housekeeping gene has been inhibited by substances in the sample, the inference is that amplification of the gene targeted by the test may also be inhibited. This conclusion is not always warranted. Housekeeping genes are often present in abundance, so sometimes can be detected even in the presence of inhibitory substances while the more limited amounts of the assay's targeted sequences may be inhibited from amplification. In this case, the amplified and detected housekeeping gene was not a sufficient control for inhibitors, resulting in significant risk of a false negative inference for the test result. However, with knowledge of the risk associated with housekeeping genes, which are naturally present in the sample housekeeping genes can be a useful control for inhibitors for the whole assay including sampling, storage and extraction.~~

361
362
363
364
365

Many common diagnostic samples, such as faeces, milk and blood, contain naturally occurring substances that inhibit NA amplification. Anticoagulants and transport media used for sample collection may also cause inhibition of NA amplification (Yan *et al.*, 2020). If an inhibition control yields a negative result, this indicates that the sample contains inhibitory substances, the assay is compromised and a negative test result for a diagnostic sample may not be reliable.

366
367
368
369
370

During validation studies, data assessing the effects of sample matrix on assay performance will guide a risk-based approach to the need for inhibition controls. If inhibitory substances are a significant problem, an inhibition control must be included for each test sample. In a recent review of inhibition monitoring in the veterinary setting, Yan *et al.* (2020) describe two categories of internal controls that can be used to detect inhibitory substances in the PCR reaction:

371

i) Endogenous internal controls

372
373

A common choice of inhibition control is an endogenous gene target, such as house-keeping or structural genes present in multiple species. This control also demonstrates that the target species

374 has been appropriately sampled and that NA extraction has been successful. Examples of
375 endogenous controls include 18S ribosomal RNA (18S rRNA, all eukaryotes), 16S ribosomal RNA
376 (16S rRNA, all prokaryotes), beta actin (ACTB, avian, bovine, porcine), glyceraldehyde-3-
377 phosphate dehydrogenase (GAPDH, equine, bovine, canine, apidae), etc.

378 Caution is required with interpreting results for endogenous genes as these are often present in
379 high copy number, so may be detected even in the presence of inhibitory substances, while the
380 more limited copies of the assay's targeted sequences may be inhibited from amplification.
381 Endogenous internal controls may carry a significant risk of a false negative inference for the test
382 result. However, with knowledge of the risk associated with endogenous genes, which are naturally
383 present in the sample, endogenous genes can be a useful control for detection of inhibitors and for
384 confirmation of successful sampling, storage and extraction (whole assay approach).

385 ii) Exogenous internal controls

386 An exogeneous internal control is an artificial target, such as a length of DNA contained in a plasmid
387 or *in-vitro* transcribed RNA, which is usually spiked into lysis buffer in a defined concentration, prior
388 to extraction. This provides a more stable, and standardised control to assess PCR
389 amplification/inhibition. Exogeneous internal controls can be designed as homologous or
390 heterologous templates.

391 a) Homologous exogeneous internal controls are synthetic templates containing identical primer
392 binding sites as the test target, but when amplified produce an amplicon of a different size or use a
393 specific probe to discriminate it from the pathogen target (Hoorfar *et al.*, 2004; Sawyer *et al.*, 2006;
394 Schrader *et al.*, 2012). The advantages of this approach are that it utilises the same primers
395 employed in the test, and the control can be added at precise concentrations. The disadvantages
396 are that competition for the primer and dNTPs may reduce the analytic performance of the assay.
397 Care must be taken during assay optimisation, so that the analytical sensitivity of the assay is not
398 detrimentally affected.

399 b) Heterologous exogenous internal controls are designed using primers and probes unique and
400 specific for the construct (Hoorfar *et al.*, 2004; Schrader *et al.*, 2012). Like homologous internal
401 controls, optimisation is required to limit the competition for reagents used in PCR reaction.
402 Heterologous exogenous internal controls are commonly used in the diagnostic laboratories
403 providing efficient deployment for different animal species and matrices (Yan *et al.*, 2020).

404 **2.6. Inhibitory factors in the sample matrix**

405 Generally for NAD methods, pure cultures, blood and most tissues are the preferred samples because extraction
406 and recovery of amplifiable NA is generally successful. Faecal samples, semen and autolysed tissue can be
407 more challenging because they generally contain more inhibitors for NAD assays. It is vital to have a robust and
408 repeatable sample extraction procedure, which is appropriate for the numbers of samples to be handled
409 (automated if necessary) and to utilise inhibition controls as necessary (see section above).

410 **2.6. Operating range of the assay**

411 The operating analytical range of the PCR assay
412 should ~~can~~ be determined by ~~diluting a strong~~
413 positive sample and plotting the range of results
414 obtained versus known amounts of nucleic acid
415 (concentration, dilution, number of genomic
416 copies, etc.). This titration of a reference sample
417 must be, such as a synthetic construct of known
418 copy number or whole virus of known infectious
419 dose (e.g. TCID₅₀). This reference sample must be diluted in the same matrix as the test sample, i.e. it is not
420 appropriate to determine the operating range of a sample diluted out-in buffer, if the usual matrix is blood. Each
421 dilution in the titration series should be tested in replicate and resulting Cq values plotted against the reference
422 sample concentration (TCID₅₀, dilution, number of genomic copies, etc.). Once the analytical range of the assay
423 is known, titration of strong diagnostic positives can be used to provide a practical guide to the operating range
424 and end-point Cq values. This data will define interpretation criteria for the positive, negative and suspect range
425 of the assay.

- For determining the operating range of the assay, were samples diluted in the matrix for which the test is intended?
- Does the operating range of the assay conform with the expected norms for such an assay?

426

427

2.7. Robustness

428

429

430

431

432

433

434

435

436

437

~~An~~ To provide reproducible results, when deployed in multiple laboratories, an assay should tolerate small changes in concentrations of reagents and/or slight variations in processing times and temperatures used for different stages of the assay in order to be effectively deployed and provide reproducible results when used in multiple laboratories. This can be determined during assay optimisation when Critical procedural steps, reagents, and equipment are identified. ~~Such~~ during assay optimisation. The critical factors that when not adhered to cause unacceptable variability and their acceptable range of use should be well described in the assay protocol so that particularly exacting processes are assured for carrying them out. This is a laborious process that ultimately is monitored for to minimise assay variability. Ultimately, the precision and accuracy by of the assay are assessed through the preparation and use of quality assured internal and external quality control samples run-controls prepared in bulk and progressively monitored every time the assay is performed.

438

2.8. Calibration verification of the assay to reference samples

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

In calibration verification, known quantities of a material are measured by the assay and results are compared to the known true value of the material (Burd, 2010). Calibration verification and quality control procedures are required to ensure that the expected performance of the assay is maintained throughout the life of the test (Burd, 2010). Ideally, international or national reference standards should be used to calibrate or verify the calibration of the assay. However, these are not always available so it may be necessary to create an in-house reference standard (see Chapter 2.2.6). A working standard(s), for inclusion in all runs of the assay, needs to be created, aliquoted, and stored in sufficient quantities for use in every run of the validation process and for routine use after the validation has been completed. The working standard(s) could be multiple aliquots of a particular sample, which can be used within each assay run. They could also consist of a plasmid containing the sequence of interest, spiked into sample matrix. Use of the latter allows the test developer to determine the number of genome copies that can be detected by the assay. In some instances, test sample results are “normalised” by comparison to the working standard sample(s) included in each run of the assay. This allows direct comparison of data between runs (Huggett *et al.*, 2005; and Chapter 1.1.6).

- Have you verified the calibration of the assay to external reference standards?
- If external reference standards not available, have you created an in-house reference standard?
- Have you made working reference standards in sufficient amounts for use in all development and validation experiments?

457

B. ASSAY VALIDATION PATHWAY

458

459

460

461

462

463

Once the protocol for the assay has been developed and optimised, it must be fixed and held constant while being evaluated through the stages of the validation pathway and during routine use. Some countries have validation templates specifically designed for molecular assays which assists in the standardisation, evaluation and transparency of the validation process (SCAHLs, 2008). Minor changes to a validated assay can be addressed using comparison studies to document that the assay continues to perform as originally defined (Chapter 2.2.8 *Comparability of assays after changes in a validated test method*).

464

1. Stage 1 – Analytical performance criteria

465

1.1. Repeatability (C_t-C_q or qualitative conventional PCR)

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

Repeatability of the assay is a measure of agreement between results (within and between runs) using the same samples and test method in one laboratory. ~~Usually ideally, a small panel of three (preferably five) samples covering batches of samples that are unequivocally positive and, cover~~ the operating range of the assay ~~is selected, are prepared~~ and tested using the entire assay procedure (including nucleic acid extraction). Each batch must be prepared to ensure homogeneity during preparation and aliquoting and contain enough single-use vials to permit repeated testing over several days/weeks by two or more operators. Within assay (intra-assay) variation is determined using multiple (at least five) replicates of each sample in ~~this~~ the panel in one assay run. Between run (inter-assay) variations are determined by testing these samples over several days, using several operators and at least 20 runs. The repeatability panel should be tested treating all samples and each of their replicates exactly like individual diagnostic samples, subjected to every step from sample preparation to data analysis. Accordingly, every replicate of every sample is subjected to an independent

- Has intra- and inter-assay repeatability been determined?
- Is repeatability within the accepted range of coefficient of variation (CV) limits?

481 extraction. This mimics the future use of the assay when implemented for diagnostic use and allows for robust
482 determination of repeatability, both within and between runs of the assay that mimic future runs of the assay
483 when implemented for diagnostic use. Minimal variation in repeatability is important, particularly near the cut-
484 off(s) that establish positive, inconclusive, and negative ranges, because higher variability (especially at the cut-
485 offs) can result in incorrect interpretations (see Chapter 2.2.4 *Measurement uncertainty*). The assay should be
486 designed so that the decision point (cycle quantification, Cq) lies on the steepest part of the amplification curve
487 and is standardised for the assay (automated settings on the PCR cycler cannot be used). Standardisation of
488 the assay threshold will ensure consistency of data analysis between runs and that repeatability will be optimal
489 at the critical point of the assay.

490 The variation observed in repeated measurements (repeatability) can be expressed in several forms including
491 standard deviation (SD), a percentage change or as a coefficient of variation (CV) defined as the ratio of the
492 standard deviation to the mean or relative standard deviation (see Chapter 2.2.5 *Statistical approaches to*
493 validation). Because the CV is independent of the measurement unit, it can be used to compare variability
494 between data sets with different means. The SD, by contrast, is always dependent on the mean of the data. It
495 is worth noting that when the analyte concentration is low (as in weak positives) the CV may be greater than
496 that for strong positives because weak samples (near the negative threshold or cut-off point) often exhibit greater
497 variability in Cq value and thus have a larger SD. Burd *et al.* (2010) suggest the use of precision profiles, plotting
498 the SD or CV as a function of analyte concentration, to map changes in precision.

499 Currently, there are no specific recommendations for acceptable CV values when assessing real-time PCR
500 repeatability in clinical, veterinary or food microbial detection. Accumulated data from the proficiency testing
501 (PT) provider at the authors location indicates that CV<5% using PCR for repeated testing of PT batches,
502 prepared in compliance with ISO 17043, is an indicator of homogeneous, stable samples and reliable repeated
503 testing (unpublished data). However, if the quantitative PCR test is required, the CV should be based on
504 template copy numbers (Bustin, 2009). In fields, such as for genetically modified organisms (GMO) and
505 environmental microbial detection, CV values of up to 25–50% are considered acceptable, particularly when
506 template copy numbers are fewer than 100 (Bowden *et al.*, 2021; Broeders *et al.*, 2014; European Network of
507 GMO Laboratories [ENGL], 2015; Kralik & Ricchi, 2017).

508 Consideration should be given to whether samples are tested individually, in duplicate, or more replicates. Poor
509 precision will affect the linearity of an assay therefore, it is important to assess repeatability (precision) as part
510 of the linearity study (Chapter 1.1.6). In brief, to do this, batches of analyte are prepared covering the operating
511 range of the assay (strong, moderate and weak positive), are aliquoted into single use tubes and are tested in
512 replicate by two or more operators over multiple runs. Consultation with a statistician may be necessary to
513 ensure suitable replicates and number of runs for the expected imprecision of the assay (CLSI, 2003) and use
514 of appropriate result interpretation and statistical analysis.

515 Repeatability can be expressed as a coefficient of variation (see Chapter 2.2.5 *Statistical approaches to*
516 validation). The assay should be designed so that the decision point (cut-off) lies on the steepest part of the
517 real-time PCR Ct curve. If this is achieved, repeatability will be optimal at the critical point of the assay. (Larger
518 CVs at the clearly negative and highly positive ends of the operating range of the assay do occur and have little
519 impact on test result interpretation).

520 1.2. Analytical specificity (ASp)

521 Depending upon the intended purpose of an assay, its analytical specificity is determined by the selected genetic
522 sequence(s) of organism(s) targeted by the assay. The assay can be designed to be highly selective, with
523 analytical specificity for a single genetic sequence that is known not to be present in other organisms or strains
524 of the targeted organism. Such an assay is said to exhibit **exclusivity** and connotes a confirmatory assay of
525 high ASp.

526 Alternatively, the assay may be designed to target a conserved genetic sequence that is common to several
527 strains of a given species, or several species of a genus. Such an assay has an ASp that exhibits **inclusivity**,
528 making it useful as a screening test. For an inclusive screening assay, the analytical specificity should be
529 determined by testing all lineages, strains, species, etc., that the assay is expected to detect. The assay should
530 then be evaluated for its capacity to exclude related organisms such as non-pathogenic strains that are not of
531 interest to the intended purpose of the candidate assay TUE.

532 In the example of an AI screening test, the assay should be
533 evaluated, for inclusivity, against as many well-characterised
534 isolates of AI virus as are available to assure that all detection
535 of strains from a variety of geographical areas (Asia, Europe,
536 North America) and hosts are detected (i.e. to demonstrate
537 inclusivity). This is generally done using laboratory (chickens,
538 migratory and non-migratory birds) Laboratory strains/cultures
539 of AI or extracted nucleic acid. For AI, different lineages may
540 be used for this purpose. The purpose of the virus exist such
541 as Asian, European and North American. It is important to
542 consider how assay, including the assay will be used and in
543 which geographical regions. That area in which it will be used,
544 will aid in determining determine whether it is necessary to
545 evaluate some or all of these lineages. This important
546 requirement is clearly was demonstrated with the recently developed in a cooperative study by various WOA
547 Collaborating Centres to assess a rapid and simple RNA-virus pathotyping assays, which were tested on a large
548 collection of AI and Newcastle disease viruses, originating both from the Eastern and from the Western
549 hemispheres (Leijon *et al.*, 2011; Yacoub *et al.*, 2012), in a collaboration between various WOA
550 Collaborating Centres. Another). For screening assays, it is important factor is to note that viruses can change-evolve
551 rapidly and the resultant mutations can render a diagnostic test sub-optimal. An example of this is the appearance of
552 the 2009 pandemic strain of Influenza A H1N1 and the 2013 low pathogenic AI H7N9 outbreak in Southern
553 China. The analytical sensitivity of the PCR for the traditional M gene was impaired for this strain because due
554 to mutation in the target sequence that rendered the assay specific had mutated. In most countries new primers
555 have been introduced and used either as a new test or in combination with the traditional M gene primers as a
556 combination test (Harmon *et al.*, 2010; Hatchette *et al.*, 2013; Shu *et al.*, 2011; Spackman *et al.*, 2002; WHO,
557 2013).

- Has a panel of as many well-characterised isolates of the target pathogen as possible, including isolates from a variety of geographical areas and hosts, been tested?
- Have related organisms and pathogens, which cause similar clinical syndromes, been tested?
- Have exclusivity, inclusivity and selectivity been assessed?

558 The To demonstrate **exclusivity** the discriminatory power of the assay should be checked by testing organisms
559 related to the AI virus. These would include pathogens which cause similar clinical syndromes such as
560 Newcastle disease, infectious bursal disease, etc., and other organisms, which are likely to be found in the
561 target sample (i.e. to demonstrate exclusivity).

562 **Selectivity** is the extent to which a method can detect and quantify the target analyte in the presence of specific
563 reactants, such as interferences and degradants (e.g. matrix components, inhibitors of enzymes in the reaction
564 mix). Selectivity is essentially the test for detection in the presence of inhibitors. Sample matrix variation is one
565 of the most important factors contributing to interference, but may be among the least acknowledged sources
566 of error in analytical measurements. Assessment of ASp should use matrices relevant to the intended purpose,
567 such as solid tissue, whole blood and swabs, nasal versus cloacal. Interfering substances (inhibitors) can
568 originate from the samples, e.g. haemoglobin, from the environment, or from sample collection and transport
569 media (e.g. media and anticoagulants) (Yan *et al.*, 2020).

570 To assess multiplexed assays, samples containing each target organism should be used, not only to establish
571 assay characteristics for that particular pathogen but also to rule out cross-reactivity or interference between
572 the pathogen and the primers/probes designed to detect the other pathogens in the assay (Bowden *et al.*, 2021).

573 1.3. Analytical sensitivity (ASe)

574 The analytical sensitivity (or limit of detection, LOD) is the lowest concentration at which an analyte can be
575 detected within statistical limits, i.e. 95%. There are two common approaches to assessing analytical sensitivity,
576 also known as the limit of detection. The first is to: comparative sensitivity or quantitative sensitivity. Both
577 approaches use a dilution series of the target pathogen (in this case AI virus) diluted in sample matrix and not
578 buffer. The To perform a comparative sensitivity study the dilution series is usually tested using the assay under
579 validation-TUE and an existing standard method. For AI, the standard method could be virus isolation or another
580 in-house standard method of detection. This approach yields a comparative measure of the two methods (see
581 Chapter 2.2.5). The second-In the quantitative approach is to use, a target of known concentration, such as a
582 plasmid construct or in-vitro transcribed RNA, containing the target sequence and test this as a dilution series
583 of known copy number or virus of known TCID₅₀, is serially diluted in sample matrix. In this manner, and
584 assessed in the TUE to yield the smallest concentration quantifiable e.g. the number of genome copies
585 detectable by the test method can be estimated (or number of virulent particles).

586 Genetic variants (e.g. different lineages, genotypes/subtypes/strains of pathogen) may not have the same ASe
587 in an assay, due to differences in the avidity of primer/probe binding and amplification efficiency. For example,
588 when assessing an ASFV real-time PCR assay using several genotypes, variations in ASe (measured as viral
589 genomic copies) were found between different genotypes (Bowden *et al.*, 2021). Ideally, evaluation of ASe

590 should include all pathogen variants or, at a minimum, the genotypes/lineages prevalent in the region where the
591 test is intended to be applied.

592 **1.4. Standard test method for comparison with the ~~candidate test method~~ TUE**

593 On some occasions it is not possible to complete a full
594 validation exercise either because samples of known
595 analyte status are scarce (e.g. exotic diseases) or, an
596 emergency situation arises, and the assay is required for
597 use before it can be fully validated. Provisional recognition
598 can be achieved ~~provided that where~~ results through Stage
599 1 of the validation process compare favourably with results
600 of a standard test method or a known established, and
601 preferably published, method. ~~Another choice for a standard~~
602 ~~method is the one used routinely in the laboratory.~~ It is
603 important to recognise that different methods identify
604 different morphological or functional entities of the organism. It is therefore possible that comparison between a
605 standard culture-based method and a new NAD technique will give rise to discrepant results (see Section B.2,
606 Stage 2, below, for discussion on resolution of discrepancies). The choice of assessment panel is very important
607 and it should be as extensive as possible (see Chapter 2.2.6). If only a small panel of samples is available for
608 evaluation, it is useful to determine if the assay passes reproducibility expectation, i.e. withstands the rigors of
609 use in other laboratories. This requires that both laboratories use the same protocol, and same reagents, same
610 panel of samples and similar (if not identical) equipment.

- Has the new test performed in a satisfactory manner compared to a standard method of comparison?
- Is preliminary reproducibility data acceptable
- Does the assay merit proceeding to studies on full validation (Stages 2–4)?

611 ~~If lack of samples prevents continuing through the next stage of the validation pathway (Diagnostic Performance~~
612 ~~of the assay).~~ It is acceptable to use an NAD assay that has been provisionally accepted by ~~having been~~
613 ~~thoroughly validated through satisfactory completion of~~ Stage 1 of validation (~~see the WOAH if lack of samples~~
614 ~~prevents continuing through the next stage of the validation pathway (Chapter 1.1.6, Validation Standard of~~
615 ~~diagnostic assays for infectious diseases of terrestrial animals, Section B.2.6). Acceptance of provisional~~
616 ~~validation is fully dependent upon approval by local authorities, or through bilateral agreements between~~
617 ~~countries.~~

618 **1.5. Analytical accuracy of supplementary tests or procedures**

619 ~~Analytical tools, designed to provide information~~ Supplementary tests, used to characterise samples that are
620 detected using a screening assay, only require validation of their analytical performance characteristics. ~~See,~~
621 ~~there (Chapter 1.1.6., B.1.4. Analytical accuracy of adjunct tests or procedures).~~ It is ~~no requirement not~~
622 ~~necessary~~ to determine diagnostic sensitivity or diagnostic specificity ~~in of~~ such ~~cases tests~~. Examples of such
623 approaches include PCR H-typing PCR assays ~~to determine whether of~~ a matrix-positive influenza A strain is
624 H5 or H7, or methods ~~to determine and determination of~~ antibiotic resistance which are only applied ~~to of~~
625 cultured bacteria. A nucleic acid based ~~technology employed for technologies~~ such tests includes ~~as~~ nano-array
626 based methods, which introduce their own challenges due to the large amount of data generated for each
627 sample tested. Before implementing such assays, consideration should be given to how this analysis can be
628 accomplished. A simpler approach is to compare the results of a new analytical tool to a standard tool and permit
629 its use as long as the results of the new and existing techniques compare favourably (Anjum *et al.*, 2007;
630 Batchelor *et al.*, 2008).

631 **2. Stage 2 – Diagnostic performance criteria**

632 **2.1. Diagnostic sensitivity and diagnostic specificity**

633 Diagnostic sensitivity (DSe) and specificity (DSp) provide the principal performance indicators for use of a
634 diagnostic assay. ~~When determining these estimates it is vital to select sufficient and require adequate~~ numbers
635 of samples ~~which represent representing~~ the target population for the test under assessment. It can be difficult
636 to obtain large numbers of samples (particularly positive samples) for some exotic diseases, and negative
637 samples for endemic diseases. In such cases, with few samples available, the amount of error allowed in
638 estimates of DSe and DSp, of necessity, may be rather large (see the WOAH Validation Standard, Section B.2,
639 Table 2). Employing an appropriate sampling design and different, independent test methods to test the
640 samples, it is possible to obtain estimates of DSe and DSp by using Bayesian methods (latent class models)
641 (Chapter 2.2.5 and Cheung *et al.*, 2021). Negative reference samples are often selected from animals living in
642 regions where the disease is not present, while positive samples are usually obtained from animals with clinical
643 signs which have been confirmed in the laboratory. This can lead to overly optimistic estimates of DSe and DSp
644 because the samples do not represent the whole spectrum of the disease process, ranging from non-clinical

645 animals which may have pathogen loads that are much different from animals experiencing fulminant or chronic
646 disease.

647 Samples are often categorised as positive or negative
648 using ~~current test-classical~~ methods such as virus
649 isolation (VI) or bacterial culture. However, this can be
650 problematic when validating new molecular tests,
651 because the basis of the two test systems is different.
652 For example, a positive bacterial culture is dependent
653 upon the presence of a viable organism whereas
654 ~~nucleic acid-based~~ molecular methods detect
655 genomic sequences of both live and dead organisms
656 ~~as long as the nucleic acid is still present in the~~
657 ~~sample~~. VI methods can be particularly susceptible to inhibitors and contaminants present in the sample matrix,
658 leading to an underestimate of “true positives”. This can result in apparent discrepancies where samples are
659 positive using the new molecular test and negative by traditional methods. Various strategies for resolving such
660 anomalies include, but are not limited to, sequencing (which can demonstrate that the pathogen of interest was
661 present in a particular sample), or testing using another molecular approach.

- **Cut-off** is the test (Ct) value selected for distinguishing between negative and positive results on a continuous scale of test values.
- **Indeterminate, intermediate, suspicious, borderline, grey zone or equivocal** are terms used synonymously for a zone of test values falling between the positive and negative cut-offs.

662 To calculate DSe and DSp estimates of the ~~candidate assay-TUE~~, the test results first must be reduced to
663 categorical (positive, negative, or indeterminate) status (Chapter 2.2.5). This is accomplished by insertion of
664 one or two cut-off points (decision limits) in the continuous scale of test results. The cut-off points are determined
665 by several factors in the assay pipeline and may differ with target pathogen and/or test purpose. For example,
666 in some circumstances it is appropriate to use a cut-off for a real time PCR assay in the region of 35 ~~Ct-Cq~~,
667 which means that some samples that produce a higher ~~Ct-Cq~~ value are categorised as negative or inconclusive.
668 For a different PCR assay, however, any sample which merely registers a ~~Ct-Cq~~ and a typical amplification
669 curve, may be categorised as positive. The performance of a particular real-time PCR, comparative validation
670 data, the ultimate application of the results generated, and any relevant veterinary information should be taken
671 into account when considering the use of a cut-off.

672 3. Stage 3 – Reproducibility and augmented repeatability estimates

673 Reproducibility is a measure of the agreement between results obtained in different laboratories using the same protocol,
674 similar (preferably the same) equipment and the same panel of samples. Ideally the panel would consist of 20–30 samples,
675 including a few ~~which are present as quadruplicates. The panel should consist of samples,~~ that cover the dynamic range
676 of the test ~~with and several that have activity with reactivity~~ close to, and on either side of, the test-cut-off(s). The same
677 panel used for determination of repeatability could be used for this evaluation, but with enhanced numbers of replicates.
678 Measurements of precision can be estimated for both the repeatability and reproducibility data (see Chapter 2.2.4 for
679 further explanation of this topic and its application). Chapter 2.2.6 provides further information about the selection and use
680 of reference panels. See also Johnson & Cabuang (2021) about proficiency testing and ring trials and Waugh & Clark
681 (2021) about factors affecting test reproducibility among laboratories.

682 4. Stage 4 – Programme implementation

683 4.1. Interpretation of test results

684 Best practices for programme implementation are general to all assay types (~~see WOAHS Standard Chapter~~
685 1.1.6). For NADs, an inherent advantage is the possibility of follow-up genomic sequencing to characterise
686 pathogens and resolve apparent false positive results. ~~Assays including PCRs are often validated. The~~
687 advantage of network validation studies is that they can provide a preliminary evaluation of molecular assays
688 when used in different laboratories using similar numbers of positive and negative a panel of well characterised
689 samples. However, in surveillance programs, assay results are often applied to affirm the absence of the disease
690 in question in locales where disease prevalence is very low and often approaching zero. In such circumstances,
691 false positive results can be a significant problem even if the diagnostic specificity of a particular assay is high.
692 If the DSp of an assay is 99.5% this means that one in 200 test-positive results will be false if the prevalence is
693 close to zero. If a large number of samples are tested from a population of zero or very low prevalence, such
694 false positive results can significantly out-number true positive results (see the WOAHS Validation Standard
695 Chapter 1.1.6, Section B.4.2 for further explanation of predictive values of test results as a function of disease
696 prevalence). Likelihood ratios offer a convenient advantage because they depend solely on the combined
697 diagnostic sensitivity of the test and therefore do not vary with prevalence (Caraguel & Colling 2021). For NAD
698 assays used in such circumstances, it would be good practise to confirm PCR-positive results by sequencing.
699 This approach is problematic for weak positive samples with high Cq values because DNA sequencing is less
700 sensitive than real-time PCR and may not yield sequence data. In this case additional sampling, and further

701 testing using other independent tests may assist with a confirmatory result (e.g. real-time targeting different
702 genomic region of the same pathogen).

703 Pooling of samples may be appropriate to increase the efficiency of testing large numbers, for example for
704 prevalence studies. Where pooled samples yield positive results, it may be useful to test each sample from the
705 pool individually to identify diseased animals. Whether pools are different samples from a single or multiple
706 animals, any pooling strategy should be precisely defined and validated prior to use to minimise loss of
707 sensitivity.

708 **5. Monitoring of assay performance after initial validation**

709 **5.1. Monitoring the assay and continued fitness for purpose**

710 Monitoring of repeatability by charting the C_t - C_q values obtained for working standard control samples provides
711 re-assurance that the assay is performing as expected. Similarly, participation in proficiency testing schemes
712 issued by external providers of quality assurance samples provides evidence of on-going reproducibility ~~and~~
713 ~~also allows comparison of test accuracy if a reference standard(s) are included in each run for “normalisation”~~
714 ~~of data, assay performance and overall laboratory competence.~~ Re-testing of a proportion (usually in the range
715 of 1–5% depending on throughput) of retained samples is also employed by some laboratories to demonstrate
716 that the assay is performing consistently between runs.

717 In time it may be necessary to modify the assay because the target analyte has changed, e.g. if the assay for
718 avian influenza is to be applied in another part of the world or if new strains or lineages of a virus have emerged
719 (see Section B.1.2, above, on the evolution of the new pandemic lineage of H1N1). RNA viruses evolve rapidly
720 and point mutations can occur, so it is advisable to regularly confirm the nucleotide sequences of the primer and
721 probe sites to ensure that they remain appropriate. Verification is required when an assay is used in a new
722 environment (Kirkland & Newberry, 2021).

723 **5.2. Minor modification of an existing validated assay**

724 **5.2.1. Technical modifications**

725 Modifications of an assay are likely to be required, over time. For example, use of different equipment,
726 use of a different extraction protocol or automation of particular stages will minimally require comparison
727 of the original validated assay with the modified version (see Chapter 2.2.8). If results of the modified
728 version fall outside of the operating range or performance expectation of the original assay, a revalidation
729 may be necessary.

730 **5.2.2. Replacement of depleted reagents**

731 It is important to assign unique identification numbers to all batches of reagents and to record the
732 components used for particular assays. The most critical components in PCR based assays are the
733 probes, the primers and the enzymes. Current and new batches of critical reagents should be tested in
734 parallel prior to their introduction. However, for other reagents such as buffers and nucleotides it is usually
735 sufficient to monitor batches to inform troubleshooting, should that become a necessity.

736 **5.3. Major change in assay requiring re-validation**

737 Upon occasion, application of the assay may need to be extended beyond the scope of the original intended
738 purpose of the assay. Examples are inclusion of another host species or a population of animals from a different
739 geographical area. In such cases it is important to revalidate the assay because of new biological considerations
740 with their many associated variables. The precise details will depend on the extent of the change. Moving the
741 assay into a new geographical area might mean that the analytical characteristics of the assay are still valid but
742 that the diagnostic criteria need to be re-defined. Similarly modifications may be made to PCR primer or probe
743 sequences to allow detection of new strains. It will then be necessary to demonstrate how the new reagents
744 behave in terms of analytical and diagnostic accuracy compared with the previous version of the assay.

745

- 747 AGIANNIOTAKI E.I., CHAINTOUTIS S.C., HAEGEMAN A., TASIYOUDI K.E., DE LEEUW I., KATSOULOS P.D., SACHPATZIDIS A., DE CLERCO
 748 K., ALEXANDROPOULOS T., POLIZOPOULOU Z.S., CHONDROKOUKI E.D. & DOVAS, C.I. (2017). Development and validation of a
 749 TagMan probe-based real-time PCR method for the differentiation of wild type lumpy skin disease virus from vaccine virus
 750 strains. *J. Virol. Methods*, **249**, 48–57. doi:10.1016/j.jviromet.2017.08.011.
- 751 ANJUM M.F., MAFURA M., SLICKERS P., BALLMER K., KUHNERT P., WOODWARD M.J. & EHRLICH R. (2007). Pathotyping of
 752 *Escherichia coli* by using miniaturized DNA microarrays. *App. Environ. Microbiol.*, **73**, 5692–5697.
- 753 ANNAND E.J., HORSBURGH B.A., XU K., REID P.A., POOLE B., DE KANTZOW M.C., BROWN N., TWEEDIE A., MICHIE M., GREWAR
 754 J.D., JACKSON A.E., SINGANALLUR N.B., PLAIN K.M., KIM K., TACHEDJIAN M., VAN DER HEIDE B., CRAMERI S., WILLIAMS D.T.,
 755 SECOMBE C., LAING E.D., STERLING S., YAN L., JACKSON L., JONES C., PLOWRIGHT R.K., PEEL A.J., BREED A.C., DIALLO I., DHAND
 756 N.K., BRITTON P.N., BRODER C.C., SMITH I & EDEN J.S. (2022). Novel Hendra Virus Variant Detected by Sentinel Surveillance
 757 of Horses in Australia. *Emerg. Infect. Dis.*, **28**, 693–704. doi:10.3201/eid2803.211245.
- 758 BALLAGI PORDÁNY A. & BELÁK S. (1996). The use of mimics as internal standards to avoid false negatives in diagnostic PCR.
 759 *Mol. Cell. Probes*, **10**, 159–164.
- 760 BATCHELOR M., HOPKINS K.L., LIEBANA E., SLICKERS P., EHRLICH R., MAFURA M., AERESTRUP F., MEVIUS D., CLIFTON-HADLEY
 761 F.A., WOODWARD M.J., DAVIES R.H., THRELFALL E.J. & ANJUM M.F. (2008). Development of a miniaturised microarray based
 762 assay for the rapid identification of antimicrobial resistance genes in Gram-negative bacteria. *Int. J. Antimicrob. Agents*,
 763 **31**, 440–451.
- 764 BATH C., SCOTT M., SHARMA P.M., GURUNG R.B., PHUENTSHOK Y., PEFANIS S., COLLING A., SINGANALLUR N., FIRESTONE S.M.,
 765 UNGVANIJBAN S., RATTHANOPHART J., ALLEN J., RAWLIN G., FEGAN M. & RODONI B. (2020). Further development of a reverse-
 766 transcription loop-mediated isothermal amplification (RT-LAMP) assay for the detection of Foot-and-Mouth Disease Virus
 767 and validation in the field with use of an internal positive control. *Transbound. Emerg. Dis.*, **67**, 2494–2506.
 768 doi.org/10.1111/tbed.13589
- 769 BOSSUYT P.M., REITSMA J.B., BRUNS D.E., GATSONIS C.A., GLASZIOU P.P., IRWIG L., LIJMER J.G. MOHER D., RENNIE D., DE VET
 770 H.C.W., KRESSEL H.Y., RIFAI N., GOLUB R.M., ALTMAN D.G., HOOFT L., KOREVAAR D.A., COHEN J.F. & STARD (STANDARDS FOR
 771 REPORTING DIAGNOSTIC ACCURACY GROUP (2015). STARD 2015: an updated list of essential items for reporting diagnostic
 772 accuracy studies. *BJM*, **351**:h5527. doi: 10.1136/bmj.h5527
- 773 BOWDEN T.R., CROWTHER J.R. & WANG J. (2021). Review of critical factors affecting analytical characteristics of serological
 774 and molecular assays. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 53–73. doi:10.20506/rst.40.1.3208.
- 775 BROEDERS S., HUBER I., GROHMANN L., BERBEN G., TAVERNIERS I., MAZZARA M., ROOSENS N. & MORISSET D. (2014) Guidelines
 776 for validation of qualitative real-time PCR methods. *Trends Food Sci. Technol.*, **37**, 115–126.
 777 doi.org/10.1016/j.tifs.2014.03.008.
- 778 BURD E.M. (2010). Validation of laboratory-developed molecular assays for infectious diseases. *Clin. Microbiol. Rev.*, **32**,
 779 550–576.
- 780 BURKHARDT H.J. (2000). Standardization and quality control of PCR analyses. *Clin. Chem. Lab. Med.*, **38**, 87–91.
- 781 BUSTIN S.A., BENES V., GARSON J.A., HELLEMANS J., HUGGETT J., KUBISTA M., MUELLER R., NOLAN T., PFAFFL M.W., SHIPLEY
 782 G.L., VANDESOMPELE J. & WITTWER C.T. (2009). The MIQE guidelines: minimum information for publication of quantitative
 783 real-time PCR experiments. *Clin. Chem.*, **55**, 611–622. doi:10.1373/clinchem.2008.112797.
- 784 BUSTIN S.A. & HUGGETT J. (2017). qPCR primer design revisited. *Biomol. Detect. Quantif.*, **14**, 19–28.
- 785 CARAGUEL C.G.B. & COLLING A. (2021). Diagnostic likelihood ratio – the next generation of diagnostic test accuracy
 786 measurement. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 299–309. doi:10.20506/rst.40.1.3226.
- 787 CHANDER Y. (2023). Editorial: Point-of-care diagnostics for veterinary use. *Front. Vet. Sci.*, **10**, 1206117. doi:
 788 10.3389/fvets.2023.1206117
- 789 CHEUNG A., DUFOUR S., JONES G., KOSTOULAS P., STEVENSON M.A., SINGANALLUR N.B. & FIRESTONE S.M. (2021). Bayesian
 790 latent class analysis when there is an imperfect reference test. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 271–286.
 791 doi:10.20506/rst.40.1.3224.

- 792 CLINICAL AND LABORATORY STANDARDS INSTITUTE (CLSI) (2003). Evaluation of the Linearity of Quantitative Measurement
793 Procedures: A Statistical Approach; Approved Guideline. CLSI document EP6-A. CLSI, 940 West Valley Road, Suite
794 1400, Wayne, Pennsylvania 19087-1898, USA.
- 795 COLLING A. & GARDNER I.A. (EDS). (2021). Diagnostic test validation science: a key element for effective detection and control
796 of infectious animal diseases. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**. The Special Issue is available at:
797 [https://doc.woah.org/dyn/portal/index.xhtml?page=alo&aloid=41245&req=21&cid=1e3ba84f-604f-47b7-bec3-](https://doc.woah.org/dyn/portal/index.xhtml?page=alo&aloid=41245&req=21&cid=1e3ba84f-604f-47b7-bec3-927e54e04b42)
798 [927e54e04b42](https://doc.woah.org/dyn/portal/index.xhtml?page=alo&aloid=41245&req=21&cid=1e3ba84f-604f-47b7-bec3-927e54e04b42)
- 799 ERRINGTON J., JONES R.M. & SAWYER J. (2014). Use of tissue swabbing as an alternative to tissue dissection and lysis prior
800 to nucleic acid extraction and real-time polymerase chain reaction detection of Bovine viral diarrhoea virus and Porcine
801 reproductive and respiratory syndrome virus. *J. Vet. Diagn. Invest.*, **26**, 418–422 doi:10.1177/1040638714532925
- 802 EUROPEAN NETWORK OF GMO LABORATORIES (ENGL) (2015). Definition of Minimum Performance Requirements for
803 Analytical Methods of GMO Testing, April 2015. doi:10.13140/RG.2.1.2060.5608
- 804 GARDNER I.A., NIELSEN S.S., WHITTINGTON R.J., COLLINS M.T., BAKKER D., HARRIS B., SREEVATSAN S., LOMBARD J.E., SWEENEY
805 R., SMITH D.R., GAVALCHIN J. & EDA S. (2011). Consensus-based reporting standards for diagnostic test accuracy studies
806 for paratuberculosis in ruminants. *Prev. Vet. Med.*, **101**, 18–34. PMID: 21601933
- 807 GOONEWARDENE K.B., CHUNG C.J., GOOLIA M., BLAKEMORE L., FABIAN A., MOHAMED F., NFOR C., CLAVIJO A., DODD K.A. &
808 AMBAGALA A. (2021). Evaluation of oral fluid as an aggregate sample for early detection of African swine fever virus using
809 four independent pen-based experimental studies. *Transbound. Emerg. Dis.*, **65**, 2867–2877. doi.org/10.1111/tbed.14175
- 810 HALPIN K., TRIBOLET L., HOBBS E.C. & SINGANALLUR N.B. (2021). Perspectives and challenges in validating new diagnostic
811 technologies. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 145–157. doi:10.20506/rst.40.1.3214.
- 812 HARMON K., BOWER L., KIM W.I., PENNELLA M. & YOON K.J. (2010). A matrix gene-based multiplex real-time RT-PCR for
813 detection and differentiation of 2009 pandemic H1N1 and other influenza A viruses in North America. *Influenza Other*
814 *Respir. Viruses*, **4**, 405–410. doi:10.1111/j.1750-2659.2010.00153.x.
- 815 HASSAN M.M., GRIST L.F., POIRIER A.C. & LA RAGIONE R.M. (2022). JMM profile: Loop-mediated isothermal amplification
816 (LAMP): for the rapid detection of nucleic acid targets in resource limited settings. *J. Med. Microbiol.*, **71**,
817 doi:10.1099/jmm.0.001522
- 818 HATCHETTE T.F., DREWS S.J., BASTIEN N., LI Y., GERMAN G., ANTONISHYN N., CHAREST H., MAZZULLI T., FONSECA K., KRAJDEN
819 M., PETRIC M., DUST K. & LEBLANC J.J. (2013). Detection of Influenza H7N9 Virus: All Molecular Tests Are Not Equal. *J. Clin*
820 *Microbiol.*, **51**. doi.org/10.1128/jcm.01808-13
- 821 HOBBS E., COLLING A., GURUNG R. & ALLEN J. (2020). The potential of diagnostic point-of-care tests (POCTs) for infectious
822 and zoonotic animal diseases in developing countries: technical, regulatory and sociocultural considerations. *Transbound.*
823 *Emerg. Dis.*, **68**, 1835–1849.
- 824 HOORFAR J., MALORNY B., ABDULMAWJOOD A., COOK N., WAGNER M. & FACH P. (2004). Practical considerations in design of
825 internal amplification controls for diagnostic PCR assays. *J. Clin. Microbiol.*, **42**, 1863–1868. doi: 10.1128/JCM.42.5.1863-
826 1868.2004.
- 827 HUGGETT J., DHEDA A.K., BUSTIN S. & ZUMLA A. (2005). Real-time RT-PCR normalisation; strategies and considerations.
828 *Genes Immun.*, **6**, 279–284 (Review).
- 829 JOHNSON P. & CABUANG L. (2021). Proficiency testing and ring trials. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 189–203.
830 <https://doi.org/10.20506/rst.40.1.3217>
- 831 JUNGKIND D. (2001). Automation of laboratory testing for infectious diseases using the polymerase chain reaction – our
832 past, our present, our future. *J. Clin. Virol.*, **20**, 1–6.
- 833 KALAIYARASU S., MISHRA N., RAJUKUMAR K., BEHERA S.P., JHADE S.K. & SINGH V.P. (2019). Development and evaluation of
834 real-time RT-PCR using ear hair for specific detection of sheep persistently infected with border disease virus (BDV). *J.*
835 *Viral. Methods*, **269**, 55–63. doi: 10.1016/j.jviromet.2019.04.003.
- 836 KIRKLAND P.D. & NEWBERRY K.M. (2021). Your assay has changed – is it still ‘fit for purpose’? What evaluation is required?
837 *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 205–215. doi.org/10.20506/rst.40.1.3218.

-
- 838 KOSTOULAS P., NIELSEN S.S., BRANSCUM A.J., JOHNSON W.O., DENDUKURI N., DHAND N.K., TOFT N. & GARDNER I.A. (2017).
839 STARD-BLCM: Standards for the Reporting of Diagnostic accuracy studies that use Bayesian Latent Class Models. *Prev*
840 *Vet. Med.*, **138**, 37–47.
- 841 KRALIK P. & RICCHI M. (2017). A Basic Guide to Real Time PCR in Microbial Diagnostics: Definitions, Parameters, and
842 Everything. *Front. Microbiol.*, **8**, 108. doi: 10.3389/fmicb.2017.00108.
- 843 LAUERMAN L.H. (2004). Advances in PCR technology. *Anim. Health Res. Rev.*, **5**, 247–248 (Review).
- 844 LEIJON M., ULLMAN K., THYSELIUS S., ZOHARI S., PEDERSEN J.C., HANNA A., MAHMOOD S., BANKS J., SLOMKA M.J. & BELÁK S.
845 (2011). Rapid PCR-based molecular pathotyping of H5 and H7 avian influenza viruses. *J. Clin. Microbiol.*, **49**, 3860–3873.
- 846 LIU L., HOFFMANN B., BAULE C., BEER M., BELÁK S. & WIDÉN F. (2009). Two real-time RT-PCR assays of classical swine fever
847 virus, developed for the genetic differentiation of naturally infected from vaccinated wild boars. *J. Virol. Methods*, **159**,
848 131–133.
- 849 MOUCHANTAT S., GLOBIG A., BOEHLE W., PETROV A., STREBELOW H.G., METTENLEITER T.C. & DEPNER K. (2014). Novel rope-
850 based sampling of classical swine fever shedding in a group of wild boar showing low contagiousity upon experimental
851 infection with a classical swine fever field strain of genotype 2.3. *Vet. Microbiol.*, **170**, 425–429.
- 852 PRICKETT J., CHRISTOPHER-HENNINGS J., YOON K.-J., EVANS R.B. & ZIMMERMAN J.J. (2008). Detection of porcine reproductive
853 and respiratory syndrome virus infection in porcine oral fluid samples: a longitudinal study under experimental conditions.
854 *J. Vet. Diagn. Invest.*, **20**, 156–163.
- 855 RODRIGUEZ A., RODRÍGUEZ M., CÓRDOBA J.J. & ANDRADE M.J. (2015). Design of primers and probes for quantitative real-time
856 PCR methods. *Methods Mol. Biol.*, **1275**, 31–56.
- 857 SAWYER J., WAKELEY P., WEST D., FEARNLEY C., ANDERSON S., FLOWERS M., WEBSTER K., ERINGTON J. & WILLIAMS R. (2006).
858 Practical experiences of moving molecular diagnostics into routine use at the Veterinary Laboratories Agency. *Dev. Biol.*
859 (Basel) **126**, 89–97.
- 860 SCHRADER C., SCHIELKE A., ELLERBROEK L. & JOHNE R. (2012). PCR inhibitors – occurrence, properties and removal. *J. Appl.*
861 *Microbiol.*, **113**, 1014–1026. doi: 10.1111/j.1365-2672.2012.05384.x
- 862 SHU B., WU K., EMERY S., VILLANUEVA J., JOHNSON R., GUTHRIE E., BERMAN L., WARNES C., BARNES N., KLIMOV A. & LINDSTROM
863 S. (2011). Design and Performance of the CDC Real-Time Reverse Transcriptase PCR Swine Flu Panel for Detection of
864 2009 A (H1N1) Pandemic Influenza Virus. *J. Clin. Microbiol.*, **49**. doi.org/10.1128/jcm.02636-10
- 865 SINGH K., MILLER M., KOHRT L., SCHERBA G., GARRETT E. & FREDRICKSON R. (2011). Development of a novel diagnostic test
866 for detection of bovine viral diarrhea persistently infected animals using hair. *J. Vet. Sci.*, **12**, 295–297. doi:
867 10.4142/jvs.2011.12.3.295.
- 868 SMITH I.L., HALPIN K., WARRILOW D. & SMITH G.A. (2001). Development of a fluorogenic RT-PCR assay (TaqMan) for the
869 detection of Hendra virus. *J. Virol. Methods*, **98**, 33–40. doi: 10.1016/s0166-0934(01)00354-8.
- 870 SPACKMAN E., SENNE D.A., MYERS T.J., BULAGA L.L., GARBER L.P., PERDUE M.L., LOHMAN K., DAUM L.T. & SUAREZ D.L. (2002).
871 Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian H5 and H7
872 hemagglutinin subtypes. *J. Clin. Microbiol.*, **40**, 3256–3260. doi: 10.1128/JCM.40.9.3256-3260.2002.
- 873 SUBCOMMITTEE OF ANIMAL HEALTH LABORATORY STANDARDS (SCAHLs) (2008). Veterinary Laboratory Guidelines for nucleic
874 acid detection techniques (http://www.scahls.org.au/procedures/other_procedures).
- 875 THORNTON B. & BASU C. (2015). Rapid and simple method of qPCR primer design. *Methods Mol. Biol.*, **1275**, 173–179. doi:
876 10.1007/978-1-4939-2365-6_13.
- 877 TOOHEY-KURTH K., REISING M., TALLMADGE R.L., GOODMAN L.B., BAI J., BOLIN S.R., PEDERSEN J.C., BOUNPHENG M.A.,
878 POGRANICHNIY R.M., CHRISTOPHER-HENNINGS J., KILLIAN M.L., MULROONEY D.M., MAES R., SINGH S. & CROSSLEY B.M. (2020).
879 Suggested guidelines for validation of real-time PCR assays in veterinary diagnostic laboratories. *J. Vet. Diagn. Invest.*,
880 **32**, 802–814. doi: 10.1177/1040638720960829. Velayudhan B.T. & NAIKARE H.K. (2022). Point-of-care testing in companion
881 and food animal disease diagnostics. *Front. Vet. Sci.*, **9**, 1056440. doi: 10.3389/fvets.2022.1056440
-

-
- 882 VILJOEN G.J., NELL H. & CROWTHER J.R. (2005). *Molecular Diagnostic PCR Handbook*. IAEA-FAO, Springer, Dordrecht, The
883 Netherlands.
- 884 VOSLOO W., MORRIS J., DAVIS A., GILES M., WANG J., NGUYEN H.T.T., KIM P.V., QUACH N.V., LE P.T.T., NGUYEN P.H.N., DANG
885 H., TRAN H. X., VU P.P., HUNG V.V., LE Q. T., TRAN T.M., MAI T.M.T., LE Q.T.V. & SINGANALLUR N.B. (2015). Collection of Oral
886 Fluids Using Cotton Ropes as a Sampling Method to Detect Foot-and-Mouth Disease Virus Infection in Pigs. *Transbound.*
887 *Emerg. Dis.*, **62**(5):e71-5. doi: 10.1111/tbed.12196.
- 888 **WAKELEY P.R., ERRINGTON J., HANNON S., ROEST H.I., CARSON T., HUNT B., SAWYER J. & HEATH P.** (2006). Development of
889 a real time PCR for the detection of *Taylorella equigenitalis* directly from genital swabs and discrimination from *Taylorella*
890 *asinigenitalis*. *Vet. Microbiol.*, **118**, 247–254.
- 891 **WAKELEY P.R., JOHNSON N., McELHINNEY L.M., MARSTON D., SAWYER J. & FOOKS A.R.** (2005). Development of a real-time,
892 TaqMan reverse transcription-PCR assay for detection and differentiation of lyssavirus genotypes 1, 5, and 6. *J. Clin.*
893 *Microbiol.*, **43**, 2786–2792.
- 894 WATSON J.W., CLARK G.A. & WILLIAMS D.T. (2021). The value of virtual biobanks for transparency purposes with respect to
895 reagents and samples used during test development and validation. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 253–259.
896 doi:10.20506/rst.40.1.3222.
- 897 WAUGH C. & CLARK G. (2021). Factors affecting test reproducibility among laboratories. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**,
898 131–143. doi:10.20506/rst.40.1.3213
- 899 WOLFF J., BEER M. & HOFFMANN B. (2021). Probe-Based Real-Time qPCR Assays for a Reliable Differentiation of Capripox
900 Virus Species. *Microorganisms*, **9**, 765. <https://doi.org/10.3390/microorganisms9040765>.
- 901 WORLD HEALTH ORGANIZATION (WHO) (2013). Real-time RT-PCR Protocol for the Detection of Avian Influenza A(H7N9)
902 Virus [https://cdn.who.int/media/docs/default-source/influenza/global-influenza-surveillance-and-response-system/related-](https://cdn.who.int/media/docs/default-source/influenza/global-influenza-surveillance-and-response-system/related-documents/cnic_realttime_rt_pcr_protocol_a_h7n9.pdf)
903 [documents/cnic_realttime_rt_pcr_protocol_a_h7n9.pdf](https://cdn.who.int/media/docs/default-source/influenza/global-influenza-surveillance-and-response-system/related-documents/cnic_realttime_rt_pcr_protocol_a_h7n9.pdf)
- 904 YACOB A., LEIJON M., MCMENAMY M.J., ULLMAN K., MCKILLEN J., ALLAN G. & BELÁK S. (2012). Development of a novel real-
905 time PCR-based strategy for simple and rapid molecular pathotyping of Newcastle disease virus. *Arch. Virol.*, **157**, 833–
906 844.
- 907 YAN L., TOOHEY-KURTH K.L., CROSSLEY B.M., BAL J., GLASER A.L., TALLMADGE R.L. & GOODMAN L.B. (2020). Inhibition
908 monitoring in veterinary molecular testing. *J. Vet. Diagn. Invest.*, **32**, 758–766. doi: 10.1177/1040638719889315.
- 909 ZOCCOLA R., MAZZEI M., CARROZZA M.L., RICCI E., FORZAN M., PIZZURRO F., GIAMMARIOLI M., BANDECCHI P. & TOLARI F. (2017).
910 A newly developed BVDV-1 RT-qPCR Taqman assay based on Italian isolates: evaluation as a diagnostic tool. *Folia*
911 *Microbiol.*, **62**, 279–286. doi: 10.1007/s12223-017-0497-8.

912 Further reading

- 913 BELÁK S., THORÉN P., LEBLANC N. & VILJOEN G. (2009). Advances in viral disease diagnostic and molecular epidemiological
914 techniques. *Exp. Rev. Molec. Diagn.*, **9**, 367–381.

915
916

*
* *

917

NB: FIRST ADOPTED IN 2014.

1 Anexo 12. Capítulo 2.2.5. Enfoques estadísticos de la validación

2 (Este capítulo ha sido ampliamente revisado y actualizado con respecto a la versión anterior, adoptada en 2014. Aunque se han
3 incorporado algunas partes del texto existente, en aras de la claridad no se ha marcado el texto nuevo ni el suprimido.)

4 REUNIÓN DE LA COMISIÓN DE NORMAS BIOLÓGICAS 5 París, 9–13 de septiembre de 2024

6 CHAPTER 2.2.5.

7 STATISTICAL APPROACHES TO VALIDATION

9 INTRODUCTION

10 *The statistical methods used to analyse data collected from diagnostic tests are determined based on the*
11 *design of the study and the nature of the data (binary, ordinal, or continuous). Design considerations include*
12 *whether the data are paired or independent and whether there is an infallible reference method (gold*
13 *standard) available for comparison (Wilks, 2001).*

14 *While analysis occurs after data collection, it is*
15 *imperative that studies are properly designed so*
16 *that analysis can be conducted (Gardner et al.,*
17 *2019). Consultation with a statistician should be*
18 *done during the design phase prior to*
19 *commencement of the validation studies.*

20 *This chapter presents some commonly used*
21 *statistical approaches but does not consider all*
22 *methods that may be used in practice. Design*
23 *considerations, analysis methods, and examples will*
24 *be presented for assessing repeatability/precision,*
25 *analytical sensitivity, analytical specificity, and for*
26 *diagnostic sensitivity and diagnostic specificity. Analysis methods for direct comparison after a modification is*
27 *made to a validated assay are discussed in detail in Chapter 2.2.8 Comparability of assays after changes in a*
28 *validated test method. Such methods are also discussed by Reising et al. (2021).*

29 *When reporting the results of experiments conducted to assess the diagnostic performance of a test, it is*
30 *imperative to report both the design of the studies and the results in an accurate and complete manner. The*
31 *Standards for Report of Diagnostic Accuracy (STARD) statement was published in 2003 (Bossuyt et al., 2003a;*
32 *2003b) and updated in 2015 (Bossuyt et al., 2015). The update includes a checklist of items to include when*
33 *presenting diagnostic accuracy studies. An updated version, STARD-BLCM for reporting diagnostic accuracy*
34 *studies that use latent class models and Bayesian methods was published by Kostoulas et al. in 2017.*

Definitions of scales of measurement:

Binary (dichotomous): Either positive or negative because that is how the test result is presented, or positive/negative at a selected threshold (cut-off) value when results are measured on an ordinal or continuous scale.

Ordinal: Measured on a scale with discrete values where higher values typically indicate more analyte, e.g. serum virus neutralisation titres.

Continuous: An infinite number of measured values are theoretically possible, depending on the measurement system, e.g. enzyme-linked immunosorbent assay optical density values, cycle-to-threshold values in real-time polymerase chain reaction assays.

35 A. ANALYTICAL SENSITIVITY

36 Analytical sensitivity is synonymous with limit of detection (LOD). Chapter 1.1.6 *Validation of diagnostic assays for*
37 *infectious diseases of terrestrial animals* defines the LOD as an amount of analyte in a specified matrix that would produce
38 a positive result at least a specified percent of the time. Prior to designing the study, the “specified percent” should be
39 determined (e.g. 50% or 95%). In most instances, a conservative estimate of the LOD is acceptable (Chapter 1.1.6, Section
40 B.1.3. *Analytical sensitivity*). When the LOD is defined as the concentration corresponding to a 95% probability of detection,
41 a dilution-to-extinction (DTE) experiment can be used and the lowest concentration in which all replicates are positive is
42 reported as a conservative estimate of the LOD (Bowden *et al.*, 2021). The DTE experiment may present unique challenges


43 for tests intended to detect antibodies (rather than antigen or nucleic acid) as it may not be possible to obtain an objective
44 measure of the concentration of antibodies (Bowden *et al.*, 2021). There are times where the reciprocal of the dilution in
45 which all replicates exceed background is reported as the relative LOD.

46 Alternatively, statistical models can be used to determine LODs. Logistic regression or probit regression can be used. Both
47 are generalised linear regression models, but the difference is in the link function. Logistic regression uses a logit link (i.e.
48 $\log(\pi/(1-\pi))$ where π is the probability of detection) and probit regression uses a probit link function (i.e. $\Phi^{-1}(\pi)$ where Φ is
49 the cumulative distribution function (CDF) of the standard normal distribution). Both models produce symmetric S-shaped
50 curves. The complimentary log-log (cloglog) with link function, $\log(-\log(\pi))$, is another type of curve but is not symmetric. It
51 was originally described in a paper by Fisher (1922) and the development in the context of a dilution assay can be found
52 in McCullagh & Nelder (1989).

53 When designing an LOD study there may be a desire to have a more exact estimate than a DTE can offer. Furthermore,
54 a DTE will not allow for a measure of uncertainty (e.g. confidence interval). In such instances, a two-stage experiment
55 would be used. The first stage would be the DTE study to provide information on the span of dilutions to test in the second
56 stage. In the second stage a smaller dilution factor would be used along with an increased number of samples tested at
57 each dilution. Figure 1 provides an example of the results of a second stage study for the validation of a real-time
58 polymerase chain reaction (PCR) along with generalised linear model fits using different link functions (logit, probit, and
59 cloglog) to estimate the LOD.

60 The model fits for the logit and probit are very close (Figure 1) and visually difficult to distinguish which might be preferred.
61 The estimates of the LOD using the probit link is 1.1 times higher than the LOD estimate using the logit link. McCullagh &
62 Nelder (1989) indicate that it is usually difficult to distinguish between the two based on goodness-of fit. Hardin & Hilbe
63 (2007) discuss various tools such as deviance, Akaike information criterion (AIC), and Bayesian information criterion (BIC),
64 that can be used to help select a link function. In this example, visually there appears to be more lack-of-fit using the model
65 with the cloglog link and this is confirmed by a dispersion estimate of 3.7. There may be scientific reasons that help one
66 select a particular link function. An example of a dilution assay is presented in McCullagh & Nelder (1989) and provides
67 the theoretical motivation for using a cloglog link.

68 Table 1 provides the estimate of the LOD along with 95% confidence intervals for each link function. The confidence interval
69 for the cloglog link function used an adjusted variance (adjusting for the dispersion). One link function should be used when
70 presenting results of such an experiment. All were included here only for illustration. In this example, the LODs estimates
71 using the clog-log link functions. If this difference is meaningful in terms of acceptability of the assay, further investigation
72 into the selection of link function may be warranted. However, there may not be a real practical difference in drawing
73 conclusions of the acceptability of the assay in terms of the differences in the LOD estimates based on the link function
74 chosen. In this particular example, a large dispersion estimate for the cloglog function suggests some lack of fit and can
75 be used to rule out the cloglog link. Ultimately, if the differences in the LOD estimates between using the probit or logit link
76 is crucial, the remaining performance characteristics will aid in determining the fitness for purpose of the assay. In this
77 example, the LOD was estimated to be 79 copies/100 μ l using the logit link and 126 copies/100 μ l using the probit link
78 which is approximately 1.5 times higher than the LOD using the logit link.



79
80

Fig. 1. LOD data plotted with different models using various link functions.

81

Table 1. LOD estimates for various link functions

Link	LOD (95% confidence interval)
Logit	1.9 (95% CI: 1.0, 2.8)
Probit	2.1 (95% CI: 1.2, 3.0)
Complementary log-log	2.3 (95% CI: 1.1, 3.5)

82 For a real-time PCR, another design consideration is whether to dilute before or after extraction which changes the
83 interpretation. More sources of variability are incorporated into the design if samples are extracted at each dilution.
84 Obviously, the extraction efficiency of the nucleic acid extraction method and amplification efficacy of a real-time PCR
85 method can separately impact the estimate of LOD.

86 It is important to keep in mind that it is not sufficient to report the LOD as number of copies without identifying the
87 concentration, including the per unit basis. The probabilities will depend on units (per ml, per aliquot, etc.). Specifically, a
88 test method will have a higher observed probability of detecting one copy per aliquot than detecting one copy per mL if the
89 size of aliquot for testing is smaller than 1 ml. It is also beneficial to report the method used for determining the concentration
90 of a sample.

91 **B. ANALYTICAL SPECIFICITY**

92 Analytical specificity includes selectivity, exclusivity, and inclusivity. The latter two measures can both be assessed through
93 a table where isolates tested are reported on a per lineage, isolate, species or genus basis, as appropriate for the target
94 analyte and the intended purpose of the test. This table would include samples that the assay should detect (inclusivity)
95 and those genetically similar that the assay was designed not to detect (exclusivity). Selectivity refers to the extent to which
96 a method can accurately quantify the targeted analyte in the presence of inhibitors or degradants. Selectivity also includes
97 assessment of nonspecific binding. A diagnostic assay that is intended to distinguish infected from vaccinated animals
98 (DIVA) should demonstrate that a positive result is only obtained from infected and not vaccinated animals. Kirkland &
99 Newberry (2021) provide a useful discussion regarding considerations of selection of negative animals when assessing
100 analytical specificity.

101 **C. REPEATABILITY**

102 Stage I of the Validation Pathway includes repeatability and preliminary reproducibility. Repeatability is defined in Chapter
103 1.1.6 as the level of agreement between results of replicates of a sample both within and between runs of the same test
104 method given a laboratory.

105 Bowden *et al.* (2021) provides a guide for assessing repeatability of antibody detection assays and nucleic acid detection
106 assays. In both instances, the recommendation is to test a panel of three to five samples covering the operating range of
107 the assay. For antibody detection assays, it is recommended that three to four replicates are tested of each sample in each
108 run as well as five replicates for the nucleic acid methods. For all assay types discussed, the panel is tested (with sample
109 replicates) on a minimum of 20 assays where two or more operators perform testing over several days. Bowden *et al.*
110 states “the within- and between-run variations are estimated determining the coefficient of variation (CV)”. A CV is the ratio
111 of the standard deviation to the mean.

112 Another approach commonly used to determine intra- and inter-assay variability involves testing at one or more analyte
113 concentrations repeatedly in each of several runs of the assay system (Reising *et al.*, 2021; Toohey-Kurth *et al.* 2020).
114 These variability estimates are expressed as standard deviations, rather than CVs. Such statistical analysis methods are
115 described in Vardeman & Jobe (1999) while details regarding study design are presented in Reising *et al.* (2014). Bowden
116 *et al.* (2021) also acknowledges the importance of assessing repeatability using the entire test procedure. Specifically,
117 there is mention of including nucleic acid extraction for real-time PCR as extraction can be a significant source of variability.

118 A common approach to assess repeatability for a method that does not produce quantitative results is Cochran’s Q
119 (Cochran, 1950). This is a hypothesis test that assumes, under the null hypothesis, that all percentages are the same when
120 the same samples are tested on different days, for example. While this is a common method, it is a hypothesis test designed
121 to detect differences, rather than conclude similarities.

D. DIAGNOSTIC SENSITIVITY AND DIAGNOSTIC SPECIFICITY

123 Diagnostic performance of an assay is commonly assessed by estimating diagnostic sensitivity (DSe) and diagnostic
124 specificity (DSp) or a combined measure of DSe and DSp such as the likelihood ratio of a positive or negative results. DSe
125 and DSp can be estimated when the reference or comparison method is infallible (perfect sensitivity and perfect specificity)
126 or when the reference method is imperfect. The methods used for estimation will depend on the type of reference method.
127 In general, most reference test methods are not infallible, especially for test methods intended to test ante-mortem samples.
128 Figure 2 provides a flow chart describing study design, nature of the data, data analysis and reporting of results for common
129 scenarios encountered when attempting to determine the diagnostic performance characteristics of a test under evaluation
130 (TUE).


131 Sample selection is an important consideration in terms of estimating DSe and DSp. Animal samples typically come from
132 one of the following: 1) reference bank with samples of known infection status, 2) outbreak or surveillance samples where
133 animal status is unknown, but population status (infected or not infected) is known, 3) population where neither animal nor
134 population status is known, or 4) experimental challenge studies. Chapter 1.1.6 provides a discussion of each source of
135 samples along with advantages and disadvantages of each approach.

136 Mathematically, DSe and DSp are conditional probabilities, namely, $P(T+|D+)$ and $P(T-|D-)$, respectively. These are read
137 as the probability of test positive given disease positive and the probability of test negative given disease negative,
138 respectively, and commonly described as the chance of a test being positive for a positive animal and the chance of a test
139 being negative for a negative animal. Within a herd of animals, the probability of disease positive, $P(D+)$, is described as
140 the herd prevalence. Something not discussed much in the literature but that perhaps warrants some thought is how to
141 define disease positive in the context of estimating sensitivity and specificity. If one is validating a test method intended to
142 detect antibodies, does 'disease positive' refer to a clinically diseased animal, an animal with active infection, or one that
143 simply has antibodies present even if the disease pathogen is no longer present or the animal has recovered from the
144 clinical presentation of the disease. A clear case definition helps to keep focus on the specific purpose of the test.

145 Questions are often presented in terms of the number of samples, but careful considerations should also be given to the
146 types of samples as well. If samples are obtained from repositories, are all samples considered strong positives (with large
147 amounts of target analyte) or do their reactivities span the operating range of the TUE? Have the samples undergone some
148 type of treatment (such as freezing for long term storage) that would not be incorporated into routine testing and how might
149 that impact the outcome? How do the samples represent the intended target population? While it is imperative to have a
150 sufficient number of samples for evaluation, it is important to understand the strengths and limitations of the sample set
151 chosen to assess the performance of the TUE.

152 When selecting samples with known status, estimating DSe and DSp is generally a simple calculation. If the TUE produces
153 ordinal or continuous responses, dichotomise the test results into positive/negative using the established cut-off prior to
154 determining DSe and DSp. Confidence intervals can be obtained using the Clopper-Pearson method (Clopper & Pearson,
155 1934) or the Wilson score method (Wilson, 1927). Newcombe (1998) compares seven different methods that could be
156 used in this scenario to obtain confidence intervals. The same statistical methods can be used when the reference method
157 is infallible.

158 Below is an example of estimating DSe and DSp using samples with known disease status or an infallible reference method
159 (direct method). The same procedure can be used to present relative DSe and DSp to a test method that is not infallible
160 (indirect method) but it should be noted that the resulting estimates would be relative to a reference test, rather than to true
161 disease status. The Clopper-Pearson method was used in obtaining the exact confidence intervals.



Abbreviations: DSe = diagnostic sensitivity; DSp = diagnostic specificity; LR = likelihood ratio
CI = confidence interval; PI = probability interval.

1

2

Fig. 2. Flow chart for suggested methods of statistical analysis when a single test under evaluation is evaluated with and without a reference standard.

1

Table 2. Contingency table

Test Result	Disease status	
	Positive	Negative
Positive	195	3
Negative	5	203

2 True positive (TP): test positive and disease positive

3 True negative (TN): test negative and disease negative

4 False positive (FP): test positive and disease negative

5 False negative (FN): test negative and disease positive

6 Disease positive: TP + FN

7 Disease negative: TN + FP

8 DSe: $TP/(TP+FN)$

9 DSp: $TN/(TN+FP)$

10 DSe estimate and exact confidence interval: $195/(195 + 5) = 0.98$ (95% CI: 0.94, 0.99)

11 DSp estimate and exact confidence interval: $203/(203+3) = 0.99$ (95% CI: 0.96, 1.00)

12 LR+: $0.98/(1-0.99) = 98$

13 LR-: $(1-0.98)/0.99 = 0.02$

14 The likelihood ratio (LR) is an inherent characteristic of the test; it depends solely on the combined diagnostic sensitivity and diagnostic specificity and therefore does not vary with prevalence (Caraguel & Colling, 2021). Likelihood ratios are extremely powerful, as they can be used to calculate the “post-test” probability of a disease. See equations above for LR+ and LR-. Below are the likelihood ratio estimates from the previous example.

18 LR+: Likelihood ratio of a positive test result = $DSe/(1 - DSp)$

19 LR-: Likelihood ratio of a negative test result = $(1 - DSe) / DSp$

20 LR+: $0.98/(1-0.99) = 98$

21 LR-: $(1-0.98)/0.99 = 0.02$

22 The LR ranges from zero to infinity. If the LR of a given test result is greater than one, this test result supports the presence of the infection, i.e., this test result is more likely to occur in infected animals than in non-infected animals. Conversely, if the LR is lower than one, the test result support the absence of the infection, i.e., this test result is less likely to occur in infected animals than in non-infected animals. An LR equal to ‘1’ means that the test result has no diagnostic power (i.e. the test result is as likely to occur an infected animal as it is in a non-infected animal) (Caraguel & Colling, 2021; Zhou *et al.*, 2011). The further the LR is away from one, towards either zero or infinity, the stronger the evidence provided by the test result. In the clinical context, test outputs with $LR > 10$ or $LR < 0.1$ are considered good diagnostic evidence of the infection being either present or absent, respectively.

30 Two additional metrics that are useful in test result interpretation are the positive and negative predictive values. The positive predictive value is the probability that an animal is indeed positive given it has tested positive. Likewise, the negative predictive value is the probability that an animal is negative given it has a negative test result. Both values are dependent upon the prevalence of the target population. Further details, including calculations, can be found in Section 4.2 of Chapter 1.1.6.

35 Statistical programs such as MedCalc or Epitools (Sergeant, 2018) can be used. They are specialised to compute most of the estimates used to assess diagnostic accuracy which are required for validation of diagnostic tests.

37

38 1. Bayesian latent class modelling for diagnostic test validation

39 A Bayesian latent class analysis (BLCA) is the WOAH-recommended approach (Cheung *et al.*, 2021), where insufficient
40 reference samples are available for such an analysis, not assuming the true disease status of the animals from which the
41 samples are derived. Sample size considerations for BLCA are similar to those for studies that estimate population
42 proportions (e.g., prevalence) and include the expected proportion(s) (e.g., the estimated true population prevalence); the
43 desired degree of precision of the parameters to be estimated (e.g., $\pm 2\%$, or 5%); the level of confidence (typically 95%
44 or 99%); and any complexities of the study design, such as clustering. Three principles are considered in designing a BLCA
45 model (BLCM): the disease prevalence is not the same among the populations studied, the diagnostic sensitivity and
46 specificity must be constant across different populations, and diagnostic tests under evaluation are independent and
47 conditional on an individual's true disease status.

48 Considering the above principles, a BLCM can be fit (Branscum *et al.*, 2005). The conditional dependencies between the
49 diagnostic tests can be modelled (Bronsvort *et al.*, 2006; Symons *et al.*, 2021) when neither test is perfect (Van Dreumel
50 *et al.*, 2015), and the true status of the samples is unknown. To design a model structure, when k tests are evaluated for
51 p populations, the data required are $2k$ tables per population (e.g., if $k = 3$ tests are evaluated, a $2 \times 2 \times 2$ table is required).
52 Considerations of model identifiability inform the choice and number of populations, the availability of appropriate prior
53 information and the feasibility of data collection (Cheung *et al.*, 2021).

54 The BLCM can be run on the BUGS statistical packages, such as WinBUGS or OpenBUGS (freeware; can be downloaded
55 via <https://www.mrc-bsu.cam.ac.uk/software/bugs/portal>). The code can be run in R Project (R core team, 2019) or JAGS
56 using suitable libraries like R2Bugs. The analysis code includes the following specifications:

- 57 1. The model form for the data is based on:
 - 58 i) Hui & Walter (1980) equations for the relationship between the latent class and the observed data (apparent
59 prevalence $k \times k$ tables for each population under consideration)
 - 60 ii) Prior probability distributions, which may incorporate further complexity, such as mixture distributions in the prior
61 specification of true prevalence for certain populations to allow for disease freedom (i.e. zero prevalence)
62 (Branscum *et al.*, 2004) or a logit function for the true prevalence, which allows for the inclusion of fixed and
63 random effects (Mathevon *et al.*, 2017; Wood *et al.*, 2021)
 - 64 iii) Any outputs calculated based on inferred distributions, such as Youden's index, likelihood and odds ratios for
65 any risk factors considered as fixed effects and predicted probabilities, such as the prevalence within a randomly
66 selected herd or the probability of disease freedom at a specified prevalence (see sample code in Wood *et al.*,
67 2021)
- 68 2. Data is in the structure readable to the BUGS program.
- 69 3. Initials: a call to execute the BUGS program with control parameters, such as the number of chains, the number of
70 Markov chain Monte Carlo (MCMC) iterations per chain, parameters to monitor, and initialising values for each
71 unobserved parameter for each MCMC chain.
- 72 4. Model diagnostics to check that the model specification, model fit, chain length, convergence, and posterior probability
73 distributions are appropriate to draw inferences from the model.

74 Illustrative examples of different BLCMs considering conditionality between diagnostic tests, population prevalences, and
75 prior estimates are available in the public domain. These models have been derived from various publications and were
76 reviewed by Cheung *et al.* (2021). Some model improvisations were constructed at the WOAH Centre for Diagnostic Test
77 Validation Science in the Asia Pacific Region, Australian Centre for Disease Preparedness, Geelong in Australia.


78 E. REPRODUCIBILITY

79 Chapter 1.1.6 defines reproducibility as “the ability of a test method to provide consistent results, as determined by
80 estimates of precision, when applied to aliquots of the same samples tested in different laboratories, preferably located in
81 distinct or different regions or countries using the identical assay (protocol, reagents and controls).”

82 Waugh & Clark (2021) discuss factors that will affect the reproducibility of a test among different laboratories. They indicate
83 that the ideal assessment would involve testing of identical samples in multiple laboratories where all the laboratories use
84 the same reagent(s) and controls, but obviously the equipment would be unique to the laboratory, and material not provided
85 in the test kit would be an additional source of variability. They also provide a discussion regarding the importance of
86 technical training and ongoing professional development.

87 A common method of assessing reproducibility is by using a panel of samples sent to multiple laboratories from a central
88 reference laboratory (Vaugh & Clark, 2021). Chapter 1.1.6 recommends three or more laboratories to perform the test on
89 the same samples. Statistically, including six or more laboratories, if possible, in the assessment of reproducibility is ideal
90 if variance components are to be estimated (Burdick *et al.*, 2005).

91 Figure 3 provides plot of Ct (cycle threshold) values of 15 positive samples from a panel of 20 samples, which included
92 five negatives, tested at six laboratories. To isolate the laboratory effect due to amplification only, all laboratories were
93 provided extracted RNA and all used the same thermocycler with the same version of software. A model was fit to the data
94 from the positive samples that included a fixed effect for sample and a random effect for laboratory. All negative samples
95 were negative (i.e. no Ct value observed at the completion of cycling, data not shown). Reproducibility of the amplification
96 process is reported as the standard deviation associated with laboratory and was estimated to be 1.2. In this example one
97 laboratory, Lab A, was consistently lower than the remaining laboratories. Lower Ct results are associated with more
98 nucleic acid present in the sample. In this example, the noted difference would not result in any misclassifications and
99 therefore was not considered problematic. In general, Labs B and D produced the highest Cts, but it was deemed to be
100 within an acceptable range of the remaining labs.



101

102 **Fig. 3.** Ct values plotted for 15 positive samples from a panel tested by six laboratories to assess and compare
103 differences in amplification of nucleic acid.

104

105 Johnson & Cabuang (2021) discuss proficiency testing and ring trials. Both are used to assess reproducibility. “Ring trials”
106 is common nomenclature for inter-laboratory comparison for a newly developed test. Proficiency tests are used for ongoing
107 or periodic assessment of inter-laboratory test performance. Vaugh & Clark (2021) describe that the choice of nucleic acid
108 extraction method and other factors such as choice of enzyme and master mix, amount of template used in PCR,
109 introduction of redundant nucleotides into primer/probe sequences and, for real-time PCR, choice of DNA dyes and probe
110 chemistries have an impact on the assay’s reproducibility. Therefore, there is a need to include these variables in general
111 assessments unless specific components need to be analysed in isolation as in Figure 3.

112

F. DISCUSSION

113 The design of a study and the nature of the data are key elements in selecting a statistical method for data analysis. Studies
114 should be well planned with a clear objective. When designing a study, the nature of the data will be known, and this
115 knowledge will allow for selection of a statistical method prior to data collection. Planning well-designed studies minimises
116 the potential for problems during the analysis stage.

117 Formal statistical methods aid in determining whether an assay is fit for its intended purpose. Data visualisation and data
118 summaries are valuable tools in the data assessment as well.

119 Latent class analysis continues to grow in popularity and offers a means of estimating diagnostic sensitivity, diagnostic
120 specificity, and prevalence of disease within populations when there is no infallible gold standard method. Data analysis
121 tools are readily available to aid in such analyses.

122

REFERENCES

- 123 BOSSUYT P.M., REITSMA J.B., BRUNS D.E., GATSONIS C.A., GLASZIOU P.P., IRWIG L.M., LIJMER J., MOHER D., RENNIE D. & DE
124 VET H.C.W. (2003A). Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative.
125 *Ann. Intern. Med.*, **138**, 40–44.
- 126 BOSSUYT P.M., REITSMA J.B., BRUNS D.E., GATSONIS C.A., GLASZIOU P.P., IRWIG L.M., MOHER D., RENNIE D., DE VET H.C.W. &
127 LIJMER J. (2003B). The STARD Statement for Reporting Studies of Diagnostic Accuracy: Explanation and Elaboration. *Ann.*
128 *Intern. Med.*, **138**, W1-W12.
- 129 BOSSUYT P.M., REITSMA J.B., BRUNS D.E., GATSONIS C.A., GLASZIOU P.P., IRWIG L., LIJMER J.G. MOHER D., RENNIE D., DE VET
130 H.C.W., KRESSEL H.Y., RIFAI N., GOLUB R.M., ALTMAN D.G., HOOFT L., KOREVAAR D.A., COHEN J.F. & STARD (STANDARDS FOR
131 REPORTING DIAGNOSTIC ACCURACY GROUP (2015). STARD 2015: an updated list of essential items for reporting diagnostic
132 accuracy studies. *BJM*, **351**:h5527. doi: 10.1136/bmj.h5527
- 133 BOWDEN T.R., CROWTHER J.R. & WANG J. (2021). Review of critical factors affecting analytical characteristics of serological
134 and molecular assays. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 53–73. doi:10.20506/rst.40.1.3208.
- 135 BRANSCUM A.J., GARDNER I.A. & JOHNSON W.O. (2004). Bayesian modeling of animal- and herd-level prevalences. *Prev.*
136 *Vet. Med.*, **66**, 101–112. doi:10.1016/j.prevetmed.2004.09.009.
- 137 BRANSCUM A.J., GARDNER I.A. & JOHNSON W.O. (2005). Estimation of diagnostic-test sensitivity and specificity through
138 Bayesian modeling. *Prev. Vet. Med.*, **68**, 145–163. doi:10.1016/j.prevetmed.2004.12.005.
- 139 BRONSVOORT B.M. DE C., ANDERSON J., CORTEYN A., HAMBLIN P., KITCHING R.P., NFOU C., TANYA V.N. & MORGAN K.L. (2006).
140 Geographical and age stratified distributions of foot-and-mouth disease virus-seropositive and probang-positive cattle
141 herds in the Adamawa province of Cameroon. *Vet. Rec.*, **159**, 299. doi:10.1136/vr.159.10.299.
- 142 BURDICK R.K., BORROR C.M. & MONTGOMERY D.C. (2005). Design and analysis of gauge R&R studies: making decisions
143 with confidence intervals in random and mixed ANOVA models. ASA–SIAM Series on Statistics and Applied Probability.
144 American Statistical Association (ASA), Alexandria, & Society for Industrial and Applied Mathematics (SIAM), Philadelphia,
145 USA. doi:10.1137/1.9780898718379.
- 146 CARAGUEL C.G.B. & COLLING A. (2021). Diagnostic likelihood ratio – the next generation of diagnostic test accuracy
147 measurement. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 299–309. doi:10.20506/rst.40.1.3226.
- 148 CHEUNG A., DUFOUR S., JONES G., KOSTOULAS P., STEVENSON M.A., SINGANALLUR N.B. & FIRESTONE S.M. (2021). Bayesian
149 latent class analysis when there is an imperfect reference test. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 271–286.
150 doi:10.20506/rst.40.1.3224.
- 151 CLOPPER C.J. & PEARSON E.S. (1934). The use of confidence or fiducial limits illustrated in the case of the binomial.
152 *Biometrika*, **26**, 404–413.
- 153 COCHRAN W.G. (1950). The comparison of percentages in matched samples. *Biometrika*, **37**, 256–266.
- 154 FISHER R.A. (1922). On the mathematical foundations of theoretical statistics. *Phil. Trans. R. Soc.*, **222**, 309–368.
- 155 GARDNER I.A., COLLING A. & GREINER M. (2019). Design, statistical analysis and reporting standards for test accuracy studies
156 for infectious diseases in animals: Progress, challenges and recommendations. *Prev. Vet. Med.*, **162**, 46–55.
157 doi:10.1016/j.prevetmed.2018.10.023.
- 158 HARDIN J.W. & HILBE J.M. (2007). Generalized Linear Models and Extensions, Second Edition. Stata Press, College Station,
159 Texas, USA.
- 160 HUI S. & WALTER S. (1980). Estimating the error rates of diagnostic tests. *Biometrics*, **36**, 167–171.
- 161 JOHNSON P. & CABUANG L. (2021). Proficiency testing and ring trials. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 189–203.
162 <https://doi.org/10.20506/rst.40.1.3217>

-
- 163 KIRKLAND P.D. & NEWBERRY K.M. (2021). Your assay has changed – is it still ‘fit for purpose’? What evaluation is required?
164 *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 205–215. <https://doi.org/10.20506/rst.40.1.3218>
- 165 KOSTOULAS P., NIELSEN S.S., BRANSCUM A., JOHNSON W.O., DENDUKURI N., DHAND N., TOFT N. & GARDNER I.A. (2017).
166 STARD–BLCM: standards for the reporting of diagnostic accuracy studies that use Bayesian latent class models. *Prev.*
167 *Vet. Med.*, **138**, 37–47. doi:10.1016/j.prevetmed.2017.01.006
- 168 MATHEVON Y., FOUCRAS G., FALGUIÈRES R. & CORBIERE F. (2017). Estimation of the sensitivity and specificity of two serum
169 ELISAs and one fecal qPCR for diagnosis of paratuberculosis in sub-clinically infected young-adult French sheep using
170 latent class Bayesian modeling. *BMC Vet. Res.*, **13**, 230. <https://doi.org/10.1186/s12917-017-1145-x>
- 171 MCCULLAGH P. & NELDER J.A. (1989). *Generalized Linear Models*, Second Edition. Chapman & Hall, New York, NY, USA.
- 172 NEWCOMBE R.G. (1998). Two-sided confidence intervals for the single proportion: comparison of seven methods. *Statistics*
173 *in Medicine*, **17**, 857–872.
- 174 R CORE TEAM (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing,
175 Vienna, Austria. doi:10.1093/aje/kwab093.
- 176 REISING M.M., SCHUMANN K.R., CROSSLEY B.M., GLAS P.S., JACOBSON R.H., TOOHEY-KURTH K.L., PEDERSEN J.C., SIEV D. &
177 MARTIN B.M. (2014). Methods comparison: an alternative approach for evaluating the impact of a modification to a validated
178 assay. *J. Vet. Diagn. Invest.*, **26**, 480–487. doi:10.1177/1040638714535402.
- 179 REISING M.M., TONG C., HARRIS B., TOOHEY-KURTH K.L., CROSSLEY B., MULROONEY D., TALLMADGE R.L., SCHUMANN K.R., LOCK,
180 A.B. & LOIACONO C.M. (2021). A review of guidelines for evaluating a minor modification to a validated assay. *Rev. Sci.*
181 *Tech. Off. Int. Epiz.*, **40**, 217–226. doi:10.20506/rst.40.1.3219.
- 182 SERGEANT E.S.G. (2018). Epitools Epidemiological Calculators. Ausvet. Available at: <http://epitools.ausvet.com.au>.
- 183 SYMONS R., BEATH K., DANGIS A., LEFEVER S., SMISMANS A., DE BRUECKER Y. & FRANS J. (2021). A statistical framework to
184 estimate diagnostic test performance for COVID-19. *Clin. Radiol.*, **76**, 75. doi:10.1016/j.crad.2020.10.004.
- 185 TOOHEY-KURTH K., REISING M.M., TALLMADGE R.L., GOODMAN L.B., BAI J., BOLIN S.R., PEDERSEN J.C., BOUNPHENG M.A.,
186 POGRANICHNIY R.M., CHRISTOPHER-HENNIGS J., KILLIAN M.L., MULROONEY D.M., MAES R., SINGH S. & CROSSLEY B.M. (2020).
187 Suggested guidelines for validation of real-time PCR assays in veterinary diagnostic laboratories. *J. Vet. Diagn. Invest.*,
188 **32**, 802–814.
- 189 VAN DREUMEL A.K., MICHALSKI W.P., MCNABB L.M., SHIELL B.J., SINGANALLUR N.B. & PECK G.R. (2015). Pan-serotype
190 diagnostic for foot-and-mouth disease using the consensus antigen of nonstructural protein 3B. *J. Clin. Microbiol.*, **53**,
191 1797. doi:10.1128/JCM.03491-14.
- 192 VARDEMAN S.B. & JOBE J.M. (1999). *Statistical quality assurance method for engineers*, First Edition. Wiley, New York, NY,
193 USA.
- 194 WAUGH C. & CLARK G. (2021). Factors affecting test reproducibility among laboratories. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**,
195 131–143. doi:10.20506/rst.40.1.3213.
- 196 WILKS C. (2001). Gold standards and fool’s gold (editorial). *Aus. Vet. J.*, **79**, 115.
- 197 WILSON E.B. (1927). Probable Inference, the Law of Succession, and Statistical Inference. *J. Am. Statistical Assoc.*, **22**,
198 209–212.
- 199 WOOD C., PERKINS N.R., TOZER S.J., JOHNSON W., BARNES T.S., MCGOWAN M., GIBSON J.S., ALAWNEH J., FIRESTONE S.M. &
200 WOLDEYOHANNES S.M. (2021). Prevalence and spatial distribution of *Coxiella burnetii* seropositivity in northern Australian
201 beef cattle adjusted for diagnostic test uncertainty. *Prev. Vet. Med.*, **189**, 105282. doi:10.1016/j.prevetmed.2021.105282.
- 202 ZHOU X.H., OBUCHOWSKI N.A. & MCCLISH D.K. (2011). *Statistical Methods in Diagnostic Medicine*, Second Edition. Wiley,
203 Hoboken, NJ.

*

* *

NB: FIRST ADOPTED IN 2014.

1 **Anexo 13. Capítulo 2.2.8. Comparabilidad entre pruebas tras aplicar cambios a un**
2 **método analítico validado**

3 (Este capítulo ha sido ampliamente revisado y actualizado con respecto a la versión anterior, adoptada en 2016. Aunque se
4 han incorporado algunas partes del texto existente, en aras de la claridad no se ha marcado el texto nuevo ni el suprimido.)

5 **REUNIÓN DE LA COMISIÓN DE NORMAS BIOLÓGICAS**
6 **París, 9–13 de septiembre de 2024**

7
8 **CHAPTER 2.2.8.**

9 **COMPARABILITY OF ASSAYS AFTER CHANGES**
10 **IN A VALIDATED TEST METHOD**

11 **INTRODUCTION**

12 *Assay validation is a process that determines the fitness of an assay for an intended purpose. There*
13 *will be instances over time when a validated assay may need to be modified or changed: see Figure*
14 *1, Chapter 1.1.6 Validation of diagnostic assays for infectious diseases of terrestrial animals, which*
15 *illustrates stages 1–4 of the validation pathways and validation status retention. Modifications may*
16 *be driven by such things as the availability of less expensive or better reagents, the need for*
17 *standardisation, access to reagents at scale in the event of an outbreak, or the availability increased*
18 *throughput of a test using robotic methods. Minor changes need to be evaluated through a*
19 *comparability process to demonstrate the test method remains fit for its intended purpose. In 2021,*
20 *the WOAHA Scientific and Technical Review published a special edition entitled Diagnostic Test*
21 *Validation Science. In that special edition, Reising et al. (2021) discuss guidelines for evaluating a*
22 *minor modification to a validated assay, including methods for data analysis. Chapter 2.2.5 Statistical*
23 *approaches to validation gives an overview of statistical methods that are relevant for validation of*
24 *diagnostic tests and Chapter 2.2.6 Selection and use of reference samples and panels describes the*
25 *use of reference samples and panels for different purposes. This chapter will include several*
26 *examples of experiments and data analyses previously discussed (Reising et al., 2021) that may be*
27 *used when evaluating the impact of a minor modification and to determine if the assay remains fit for*
28 *its intended use. The examples only apply if the assay has been validated and if the modification can*
29 *be classified as minor. Determining if a modification is minor may not always be straightforward and*
30 *controversy can exist about what constitutes a “minor” and a “major” change for a diagnostic assay.*
31 *There are some changes that are regarded as major because the biological basis of the assay is*
32 *fundamentally altered, for example, evolutionary changes or mutations in the nucleic acid make-up*
33 *of a pathogen will require adjustments to be primers and probes. Similarly, a change from an indirect*
34 *to a competitive enzyme-linked immunosorbent assay (ELISA) format using a highly specific*
35 *monoclonal antibody is considered a major change that would warrant complete re-validation of the*
36 *assay. Rigorous and well-designed comparability studies provide an objective assessment of whether*
37 *the assay, when used with a minor change, is as comparable to, and fit for the intended use, as the*
38 *validated assay. The outcome of the experimental study will determine whether or not the candidate*
39 *assay requires full re-validation and consequently whether or not it can be used with confidence.*
40 *Approving use from additional species (cattle versus buffalo) or different specimen types (blood*
41 *versus semen) is different from a minor modification to a validated assay and is discussed throughout*
42 *chapter 1.1.6 and in Kirkland & Newberry (2021). This topic will not be discussed further in this*
43 *chapter.*


44 *This chapter provides examples of experiments for different comparisons (e.g. limit of detection [LOD]*
45 *or performance on diagnostic samples) including methods for data visualisation and metrics for*
46 *quantifying the agreement. One should always visually inspect the data in a manner that is*
47 *appropriate for the nature of the data. This is an easy method to reveal any glaring problems such as*
48 *data transcription errors. Data visualisation tools are also useful to reveal patterns within the data,*
49 *expected or unexpected. Metrics for quantifying agreement offer quantitative evidence for decision*
50 *making.*

51 The examples presented are from real-time PCR tests, but it can be assumed that the concepts are
 52 generally applicable to other test methods. The examples also discuss experimental set-up as care
 53 should be taken not to include unwanted sources of variation. Masking of samples and reagents
 54 should be incorporated into all comparability study designs. When determining the experiments to
 55 evaluate the minor modification, the purpose of the assay should be used as a guide. Typically, the
 56 evaluation is limited to Stage 1 (analytical sensitivity and specificity, repeatability) and Stage 2
 57 (diagnostic sensitivity and specificity) characteristics as described in Chapter 1.1.6.

58 **A. DETERMINING EVALUATION AND CONCLUSION CRITERIA**

59 The following flowchart is intended to illustrate a thought process in determining the experiments necessary for
 60 demonstrating that the test under evaluation (TUE) is comparable to the original assay. There is no prescription
 61 that would be appropriate for all comparability evaluations. The type of change being made and the nature of the
 62 diagnostic test will help guide decisions regarding necessary studies. Care should be taken when determining
 63 whether a particular study is necessary and to provide justification for including or not including each evaluation into
 64 the comparability assessment. Decision criteria need to be included prior to study initiation when possible. The
 65 decision criteria presented here are for illustrative purposes only and not intended to be prescriptive. The way the
 66 limit of detection (LOD) is typically assessed is to make comparisons at consecutive dilutions on the log₁₀ scale. If
 67 it important to get a more precise comparison, then a second stage comparison can be done. If the answer for any
 68 required evaluation is no, the investigator can move forward with the next study. If the answer is yes, the study
 69 should be conducted and determine if the objective was met. If the objective is met, the investigator can continue
 70 to the next study. If the objective is not met, the modified method may be deemed unacceptable, and no further
 71 investigation is needed. There are times when all studies are conducted, and the final decision is based on the
 72 collection of results. An example of this may happen when a reagent is discontinued and needs replacement
 73 immediately. All studies were conducted and the only noted difference between the method was one log dilution in
 74 LODs. On closer examination the difference was due to a single negative replicate resulting in the inferior LOD.
 75 Therefore, the TUE was deemed acceptable.

76 *Fig. 1. Illustration of one possible pathway for a comparability assessment for*
 77 *two molecular tests including decision criteria.*



78

79 **B. LIMIT OF DETECTION**

80 The LOD is a measure of analytical sensitivity. The LOD is the estimated amount of analyte in a specified matrix
 81 that would produce a positive result at least a specified percent of the time. For initial validation, the study may use
 82 spiked samples. In this example, the objective was to compare the current real-time PCR chemistry/mastermix to


83 one made by a different commercial vendor. The mastermix made by the new vendor would be the TUE in this
 84 example. The motivation was to increase the availability of reagents in the event of an unexpected surge in testing.
 85 Therefore, the interest lies in the ability to directly compare the LOD between the two mastermixes. To set-up the
 86 experiment, nucleic acid extractions were performed for each of the three isolates. The extracted material was
 87 pooled for each isolate (not across all isolates) and serially diluted. Each dilution contained sufficient volume to test
 88 six aliquots (three per mastermix, current and TUE). On each of the three testing occasions, one operator tested
 89 an aliquot from each tenfold dilution using each mastermix on the same PCR plate. The experiment was designed
 90 so the variation associated with extraction and operator was not included and to avoid confounding the operator
 91 with mastermix. The data are displayed in Figure 2. The concentration of the last dilution showing 100% response
 92 was used as the conservative estimate of the LOD. As this was a direct comparison, quantifying the concentration
 93 of the analyte was not essential, as the endpoint dilution could be used as the basis for comparison. These data
 94 were also used to estimate amplification efficiency (AE), calculated as $(10^{[1/\text{slope}]} - 1)$, where the slope is obtained
 95 from the regression model. The LODs expressed as \log_{10} dilutions are provided in Table 1 and AEs in Table 2. A
 96 two-stage approach could be taken to obtaining a more accurate estimate of the LOD which would require testing
 97 samples created using a smaller dilution factor and increasing replicates at each dilution. This two-stage approach
 98 may rarely be necessary for a comparability study.

99 Prior to study initiation, a decision should be made regarding conditions in which the modification would be deemed
 100 acceptable. Several external considerations often affect the decision of determining acceptability of a minor
 101 modification such as cost, availability, ease of testing, etc. In this instance it was decided that the comparability
 102 study would continue if the LODs of the TUE were no less than one \log_{10} dilution worse than the current with similar
 103 efficiency estimates. Both conditions were met.

104

105
 106

Fig. 2. Cycle threshold (Ct) plotted against \log_{10} dilution for three viral isolates to compare a new (TUE) mastermix with the current mastermix.



107

108

109

Table 1. LOD estimates expressed as \log_{10} dilution

Mastermix	Isolate A	Isolate B	Isolate C
TUE	-5	-4	-5
Current	-5	-4	-4

110

111

Table 2. Amplification efficiency estimates

Mastermix	Isolate A	Isolate B	Isolate C
TUE	99	94	96
Current	101	95	96


112

C. REPEATABILITY

113 Repeatability is defined as the level of agreement between results of replicates of a sample both within and between
 114 runs of the same test method in a laboratory. Section 1.1 of Chapter 1.1.6 states that each replicate is run through
 115 all the steps of the assay for validation. In a comparability study, running all replicates through each step of the
 116 assay may not be necessary when attempting to isolate the impact of the minor modification. In this example where
 117 the modification is to the mastermix, the starting material was a pool of extracted nucleic acid diluted into low,
 118 medium, and high concentrations. Testing was conducted across multiple days by the same operator. The data are
 119 displayed in Figure 3. Table 3 provides estimates of within run and between run variability (expressed as standard
 120 deviations). A linear mixed effects model was used to estimate the inter- and intra-assay variability (reported as
 121 standard deviations). It is clear from Figure 3 that there is increased variance for the low concentration, which is not
 122 uncommon for a real-time PCR. Therefore, the intra-assay variance was estimated separately for each
 123 concentration. These measures are sensitive to any extreme values. There was nothing in the data to suggest that
 124 the TUE would perform worse than the current mastermix.

125 The study design here used three concentrations. Alternatively, a study could be designed to test at a single
 126 concentration near the assay's limit of detection.

127 **Fig. 3.** Cycle threshold plotted against test run. The colours correspond to concentration level and the plots
 128 correspond to which mastermix was used.



129

130

131 **Table 3.** Standard deviation estimates for inter- and intra-assay variability

Mastermix	Inter	Intra (high)	Intra (medium)	Intra (low)
TUE	0.19	0.13	0.17	1.04
Proposed	0.25	0.14	0.09	0.71

132

133 Another example in which repeatability is assessed would be when a control sample is being replaced. In this
 134 situation, testing can occur using a matched-pairs design. For instance, 30 routine PCR plates tested with both the
 135 current positive amplification control and the proposed replacement (TUE), resulting in 30 sets of paired data. These
 136 data can be visualised using a correlation scatterplot or a Bland–Altman plot (examples provided below).

137

D. DIAGNOSTIC CHARACTERISTICS

139 It is likely that estimating diagnostic sensitivity and diagnostic specificity for a minor modification to an assay is not
140 necessary. Instead testing positive and negative diagnostic samples using the original assay and the assay after
141 modification (i.e. TUE) would be sufficient to assess agreement for a comparability study.

142 Sample selection is a key factor in designing a study to evaluate the diagnostic performance or creating a panel of
143 samples to be tested (Kirkland & Newberry, 2021). While there is never a one-size-fits-all answer to the question of
144 how many samples should be tested, often 30 positive and 30 negatives is sufficient, for comparability, assuming
145 they are a diverse set (Reising *et al.*, 2021). The selection of samples to span the range of reactivity of the assay
146 is perhaps more important than the actual number. The question of sample size is perhaps one of the most common.
147 When the goal is to demonstrate that a treatment has some desired effect using a statistical hypothesis test, a
148 power analysis is used to determine an appropriate sample size. As discussed below, hypothesis testing is not
149 appropriate for a comparability study as the objective is not to demonstrate a difference, but rather to conclude
150 similarity.

151 A study was conducted to determine if a laborious and time-consuming sample processing step could be removed
152 from processing swab samples prior to extraction and testing on a real-time PCR used for screening. Sample
153 throughput would be substantially increased if the sample processing step could be removed without compromising
154 the test results. A limit of detection and repeatability study were conducted prior to testing diagnostic samples. For
155 the comparability study, 195 samples submitted for routine testing were tested (prospectively) side-by-side including
156 and excluding the processing step in question. More samples were tested than what would typically be necessary
157 for a comparability study when known positive and negative samples were selected randomly from a repository.
158 Table 4 provides a 2x2 cross-classification table of the results indicating that out of 124 samples that tested negative
159 in the original test, 15 samples tested positive in the TUE and out of 71 samples that tested positive in the original
160 test, 13 tested negative in the TUE. Table 5 provides estimates of Cohen's Kappa, the Pearson correlation
161 coefficient, the concordance correlation coefficient, and the mean difference, along with 95% confidence intervals
162 as metrics to assess agreement. Test results are displayed using a scatterplot in Figure 4 (scatterplot) and a Bland–
163 Altman/Tukey median difference plot (Bland & Altman, 1999; 2007) in Figure 5.

164 **Table 4.** Cross classification of results with (current) and without (TUE) sample processing step

	TUE	
Current	Negative	Positive
Negative	109	15
Positive	13	58

165

166

Table 5. Summary metrics to assess agreement


Metric	Estimate (95% confidence interval)
Cohens Kappa	0.69 (95% CI: 0.59, 0.80)
Correlation	0.93 (95% CI: 0.88, 0.96)
Concordance Correlation	0.92 (95% CI: 0.87, 0.95)
Mean Difference	-0.37 (95% CI: -0.80, 0.07)

167 The number of samples that disagreed with the positive/negative classification was about the same in both
168 directions (i.e. positive using the current method and negative using the TUE versus negative using the current
169 method and positive using the TUE). The closeness in values of the correlation and concordance correlation
170 suggests good agreement and this is visually confirmed in the scatterplot as well as the Bland-Altman plot. The
171 average difference (TUE – current) is a small negative value with a confidence interval that includes zero. The
172 individual data in Figure 4 appear to be scattered symmetrically around the average difference. The range of
173 observed values on the left side of the plot are smaller than on the right side of the plot indicate increasing variance
174 from left to right. However, this visual assessment may be a result of fewer samples with lower Ct values (higher
175 analyte concentrations). Most importantly, the Bland–Altman 95% limits of agreement of -3.58 and 2.85 suggest
176 that for most samples we can expect the discrepancy between including and excluding the laborious sample
177 processing step, should be no greater than about 3.5 cycle thresholds in either direction, which is just over one
178 log₁₀ (assuming perfect amplification). This statistic may be compared with a (preferably predefined) criterion for
179 practical or diagnostic relevance.

180 Whereas the estimate of Kappa seems low, it is important to remember there is no universal interpretation for Kappa
181 (Agresti, 2002). The estimate of Kappa is dependent upon the prevalence in the sample set tested.


182 The collection of test results allowed for the removal of the laborious and time-consuming processing step without
183 the fear of loss of test sensitivity.

184 **Fig. 4.** Scatterplot of Ct values from the TUE (without the sample processing step) and the current method (with
185 the sample processing step). The diagonal line represents the 45° line of agreement. The number in the top right
186 corner is the number of samples that were not detected by either method.



187

188 **Fig. 5.** Bland–Altman Plot. The solid horizontal line is drawn at the average of the paired differences
189 (TUE – current), and the dashed lines are the 95% limits of agreement.



190


191

E. COMPARISON OF ROC CURVES

192 Receiver operating characteristic (ROC) analysis is used to compare the accuracy of diagnostic test methods at
193 different cut-offs of one or more different tests when the same samples have been tested using different test
194 methods. Zhou *et al.* (2011) indicate that the AUC (area under the ROC curve) has several different interpretations:
195 1) the average sensitivity for all possible values of specificity; 2) the average value of specificity for all possible
196 values of sensitivity; and 3) the probability that a randomly selected diseased/infected individual would have a test
197 result that is more indicative of disease/infection than a randomly selected individual that is not diseased/infected.
198 They also provide examples of incorrect interpretations of AUC.

199 In this example, a methods comparison study was conducted to evaluate a new thermocycler (TUE). A panel of
200 120 samples, 60 positive and 60 negatives, were tested where the extracted material from each sample was
201 amplified on each thermocycler. ROC curves and the AUC were used to evaluate the data. The ROC curves are
202 displayed in Figure 6. The AUC for the current method (current thermocycler, Test A) was estimated to be 0.98 and
203 the AUC for the new thermocycler (TUE, Test B) was estimated to be 0.95. The difference in AUC was estimated
204 to be 0.03 (95% *CI*: -0.003, 0.05). It was determined that the thermocycler would be an appropriate alternative to
205 the current one because the difference in AUCs was very close to zero and the confidence interval included zero,
206 and was very narrow.

207 **Fig. 6.** ROC curves comparing two thermocyclers (current = test A, proposed = Test B).
208 The diagonal line would represent a ROC curve to a test with an AUC of 0.5.



209

210

F. DISCUSSION

211 There are many reasons why comparability studies are necessary including depleted reagents, more cost-effective
212 reagents, changes in instrumentation, etc. Analytical and diagnostic characteristics can be evaluated to determine
213 whether the TUE is comparable to the original format of the test. While statistical analysis and objective
214 assessments aid in the final decision, often practical considerations are used including, but not limited to, cost, ease
215 of use, throughput capacity and increasing surge capabilities in determining acceptable conclusion criteria.

216 A comparability study is intended to evaluate a minor modification to an already validated assay. The intention is to
217 thoroughly assess the impact the modification has to the assay without requiring revalidation. Scientific and clinical
218 considerations guide decisions and reliance should not be solely on the data. While there may be changes, such
219 as time or temperature during PCR cycling, that may require some optimisation work, a comparability assessment
220 is a direct comparison of the TUE to the current, validated method. It is not meant to be an evaluation of all possible
221 alternatives but as a direct comparison to a proposed alternative.

222 Validation, comparability, and verification studies are all intended to demonstrate the fitness for purpose of an assay.
223 WOH's formal validation standard for diagnostic assays for infectious diseases of terrestrial animals is chapter
224 1.1.6. This document has provided examples and considerations for a comparability study. Verification is discussed

225 in Kirkland & Newberry (2021). There are times when a verification or a comparability study may be used such as
 226 changes in batches of test reagents or a new lot of a test control. Verification would be used when introducing a
 227 test method into a different laboratory, in a different geographical region, or a new animal population and is
 228 discussed in Kirkland & Newberry (2021). Verification studies would not require the same direct comparison that a
 229 comparability study would. For both the diagnostic sample evaluation of a comparability study and the construction
 230 of the panel of test samples for a verification, a good representation of the population of interest should be used.
 231 Both recommend testing 30 positive and 30 negative samples. Both are tools used when a change is not made to
 232 the biological basis of the assay. The goal of both types of evaluation is to ensure the assay remains fit for the
 233 intended purpose.

234 Various data visualisation and statistical analysis tools commonly used in comparability studies including pros and
 235 cons are included in Table 6 (reproduced from Reising *et al.* [2021]). More extensive discussion of such tools and
 236 others may be found in a recent, comprehensive text by Choudhary & Nagaraja (2017).

237 **Table 6.** Commonly used statistical methods and data visualisation tools to assess agreement with pros and cons
 238 (from Reising *et al.* [2021])

Method	Pros	Cons
Data visualisation - scatterplot	Using a square plot with a line of agreement, agreement or specific bias can be evaluated visually	Does not provide a metric for agreement or bias. Subtle patterns may be less evident than in the mean-difference plot.
Correlation coefficient	Used with visualisation and concordance correlation, can help quantify degree of association	Often misused and misinterpreted. High correlation does not always correspond to agreement.
Linear regression	Allows quantitative assessment of systematic (intercept) or proportional (slope) bias	Measurement error in the independent variable (usually the original method) is not accounted for and estimates of the slope and intercept will be biased. (More advanced regression procedures can address these flaws)
Mean-difference plot	Easy to visualise bias when compared to a horizontal line. The expected extent of disagreement may be quantified using Bland–Altman 95% limits of agreement, which must be evaluated for practical significance	May need to be modified to quantify proportional bias or proportional error. Method is not resistant to outliers
Null hypothesis test for differences		Never appropriate when attempting to demonstrate a change has no practical impact. Do not use for method comparison
Equivalence test for differences	Careful consideration is necessary to set equivalence margins defining practically irrelevant differences	May require large sample sizes
Kappa	Popular measurement of agreement	Does not have absolute interpretation and is often misrepresented by comparing against predetermined scales of agreement. Sensitive to prevalence of positives in the sample, which is unrelated to method comparability
Area under the receiver operating-characteristic curve	Represents a trade-off between sensitivity and specificity. Can be used to compare diagnostic performance of the modified and original methods	Requires a sufficient number of diagnostic samples to be tested in a side-by-side fashion

239

G. DATA ANALYSIS

240 All data were stored in Microsoft EXCEL. Analysis (Pinheiro *et al.*, 2022; Wickham, 2011) and plotting (Wickham,
241 2016) were performed using R: A Language and Environment for Statistical Computing, Version 3.6.3 (R Core
242 Team 2020).

243 All data were stored in Microsoft EXCEL. Analysis and plotting were performed using R: A Language and
244 Environment for Statistical Computing, Version 3.6.3.

245

REFERENCES

246 AGRESTI A. (2002). Kappa measure of agreement. *In: Categorical Data Analysis, Second Edition.* Wiley, Hoboken,
247 New Jersey, USA, pp 434–435.

248 BLAND J.M. & ALTMAN D.G. (1999). Measuring agreement in methods comparison studies. *Stat. Methods Med. Res.*,
249 **8**, 135–160.

250 BLAND J.M. & ALTMAN D.G. (2007). Agreement between methods of measurement with multiple observations per
251 individual. *J. Biopharm. Stat.*, **17**, 571–582.

252 CHOUDHARY P.K. & NAGARAJA H.N. (2017). *Measuring Agreement: Models, Methods, and Applications.* Wiley,
253 Hoboken, New Jersey, USA.

254 International Organization for Standardization (ISO) (2017). ISO/IEC 17025:2017. General requirements for the
255 competence of testing and calibration laboratories. ISO, Geneva, Switzerland. Available at:
256 <https://www.iso.org/standard/66912.html> (accessed 18/09/2024)

257 KIRKLAND P.D. & NEWBERRY K.M. (2021). Your assay has changed – is it still ‘fit for purpose’? What evaluation is
258 required? *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 205–215. <https://doi.org/10.20506/rst.40.1.3218>.

259 PINHEIRO J., BATES D. & R CORE TEAM (2022). nlme: Linear and Nonlinear Mixed Effects Models. R package version
260 3.1-159. <https://svn.r-project.org/R-packages/trunk/nlme/>

261 R CORE TEAM (2020). R: A Language and Environment for Statistical Computing. R Foundation for Statical
262 Computing, Vienna, Austria. <https://www.R-project.org/>

263 REISING M.M., TONG C., HARRIS B., TOOHEY-KURTH K.L., CROSSLEY B., MULROONEY D., TALLMADGE R.L., SCHUMANN
264 K.R., LOCK, A.B. & LOIACONO C.M. (2021). A review of guidelines for evaluating a minor modification to a validated
265 assay. *Rev. Sci. Tech. Off. Int. Epiz.*, **40**, 217–226. doi:10.20506/rst.40.1.3219.

266 WICKHAM H. (2011). The Split-Apply-Combine Strategy for Data Analysis. *J. Stat. Software*, **40**, 1–29. URL
267 <https://www.jstatsoft.org/v40/i01/>.

268 WICKHAM H. (2016). *ggplot2: Elegant Graphics for Data Analysis.* Springer-Verlag, New York, USA.

269 ZHOU Z.H., OBUCHOWSKI N.A. & McCLISH D.K. (2011). *Statistical Methods in Diagnostic Medicine, Second Edition.*
270 Wiley, Hoboken, New Jersey, USA.

271

*

272

* *

273

NB: FIRST ADOPTED IN 2016.

4
5 CHAPTER 3.1.2.

6 AUJESZKY'S DISEASE
7 (INFECTION WITH AUJESZKY'S DISEASE VIRUS)

8 SUMMARY

9 **Description and importance of the disease:** Aujeszky's disease, also known as pseudorabies, is
10 caused by ~~an alphaherpesvirus~~ Varicellovirus suidalpha 1, a DNA virus belonging to the Order
11 Herpesvirales that infects the central nervous system and other organs, such as the respiratory tract,
12 in a variety of mammals, except infection of humans and the tailless apes is rare. It is associated
13 primarily with suidae (pigs or wild boar), the natural host, which remain latently infected following
14 clinical recovery (except piglets under 2 weeks of age, which die from encephalitis). The disease is
15 controlled by containment of infected herds ~~and by the use of vaccines or~~ and removal of latently
16 infected animals.

17 ~~A diagnosis of Aujeszky's disease is established.~~ Assays that detect the virus (by virus isolation or
18 polymerase chain reaction [PCR]), as well as the serological response are useful in the diagnosis of
19 Aujeszky's disease by detecting the agent (by virus isolation or polymerase chain reaction [PCR]),
20 as well as by detecting a serological response in the live animal.

21 **Identification of the agent:** Isolation of Aujeszky's disease virus can be made by inoculating a tissue
22 homogenate, for example of brain and tonsil or material collected from the nose/throat, into a
23 susceptible cell line such as porcine kidney (PK-15 or SK6), or primary or secondary kidney cells.
24 The specificity of the cytopathic effect ~~is can be~~ verified by immunofluorescence, immunoperoxidase
25 or neutralisation with specific antiserum. The viral DNA can also be identified using PCR; this can be
26 accomplished using real-time PCR techniques.

27 **Serological tests:** Aujeszky's disease antibodies are demonstrated by virus neutralisation, latex
28 agglutination or enzyme-linked immunosorbent assay (ELISA). A number of ELISA kits are
29 commercially available world-wide. A WOAH International Standard Reference Serum defines the
30 lower limit of sensitivity for routine testing by laboratories that undertake the serological diagnosis of
31 Aujeszky's disease.

32 ~~It is possible to distinguish between antibodies resulting from natural infection and those from~~
33 ~~vaccination with gene-deleted vaccines.~~

34 **Requirements for vaccines:** Vaccines should prevent or at least limit the excretion of virus from
35 infected pigs. Recombinant DNA-derived gene-deleted or naturally deleted live Aujeszky's disease
36 virus vaccines, lack a specific glycoprotein (gG, gE, or gC), which enables the use of companion
37 diagnostic tests to differentiate vaccinal antibodies from those resulting from natural infection.

38 A. INTRODUCTION

39 Aujeszky's disease, also known as pseudorabies, is caused by ~~Suid herpesvirus 1 (SHV-1)~~ Varicellovirus suidalpha
40 1 (SuAHV1, also called PRV [pseudorabies virus]), a member of the subfamily *Alphaherpesvirinae* and the family
41 *Orthoherpesviridae*. The virus should be handled with appropriate biosafety and containment procedures as
42 determined by biorisk analysis (see Chapter 1.1.4 *Biosafety and biosecurity: Standard for managing biological risk*
43 *in the veterinary laboratory and animal facilities*). The virus infects the central nervous system and other organs,

44 such as the respiratory tract, of a variety of mammals (such as dogs, cats, cattle, sheep, rabbits, foxes, minks, etc.)
 45 ~~with the exception of humans and the tailless apes.~~ Some recent reports from China (People's Rep. of) described
 46 human encephalitis associated with new variant SuAHV1 strains (Bo & Li, 2022; Liu et al., 2021) #SuAHV1 is
 47 associated primarily with pigs, the natural host, which remain latently infected following clinical recovery (except
 48 piglets under 2 weeks of age, which die from encephalitis). The pig is able to survive the productive infection and
 49 ~~In consequence, the pig is the only species able to survive a productive infection and therefore,~~ serves as the
 50 reservoir host. In pigs, the severity of clinical signs depends on the age of the pig, the route of infection, the virulence
 51 of the infecting strain and the immunological status of the animal. Young piglets are highly susceptible with mortality
 52 rates reaching 100% during the first 2 weeks of life. These animals show signs of hyperthermia and severe
 53 neurological disorders: trembling, incoordination, ataxia, nystagmus to opisthotonos and severe epileptiform-like
 54 seizures. When pigs are older than 2 months (grower-finisher pigs), the respiratory forms become predominant with
 55 hyperthermia, anorexia, and mild to severe respiratory signs: rhinitis with sneezing and nasal discharge that may
 56 progress to pneumonia. The frequency of secondary bacterial infections is high, depending on the health status of
 57 the infected herd. In this group of pigs, the morbidity can reach 100%, but in cases of the absence of complicated
 58 secondary infections, mortality ranges from 1% to 2% (Pejsak & Truszczynski, 2006-Mettenleiter et al., 2019). Sows
 59 and boars primarily develop respiratory signs, but in pregnant sows, the virus can cross the placenta, infect and kill
 60 the fetuses, inducing abortion, return to oestrus, or stillborn fetuses. Virus may be found in the semen of infected
 61 boars (Mettenleiter et al., 2019-van Rijn et al., 2004).

62 In the other susceptible species, ~~the disease is fatal,~~ the predominant sign being intense pruritus causing the animal
 63 to gnaw or scratch part of the body, usually the head or hind quarters, until great tissue destruction is caused. For
 64 that reason, the disease was named "mad-itch" in the past, replaced nowadays by "pseudorabies".

65 Focal necrotic and encephalomyelitis lesions occur in the cerebrum, cerebellum, adrenals and other viscera such
 66 as lungs, liver or spleen. In fetuses or very young piglets, white spots on the liver are highly suggestive of their
 67 infection by the virus. Intranuclear ~~lesions~~ inclusions are frequently found in several tissues (Mettenleiter et al.,
 68 2019).

69 Aujeszky's disease is endemic in many parts of the world, but several countries have successfully completed
 70 eradication programmes, e.g. the United States of America, Canada, New Zealand and many Member States of
 71 the European Union.

72 The disease is controlled by containment of infected herds ~~and~~ by the use of vaccines ~~or~~ and removal of latently
 73 infected animals (Pejsak & Truszczynski, 2006-Mettenleiter et al., 2019). Stamping out has been or is used in
 74 several countries usually when the infected farms are small or when the threat to neighbouring farms is very high
 75 in free countries.

76 Whereas isolation of the Aujeszky's disease virus or detection of the viral genome by the polymerase chain reaction
 77 (PCR) are used for diagnosis in the case of lethal forms of Aujeszky's disease or clinical disease in pigs, serological
 78 tests are required for diagnosis ~~of latent infections and~~ after the disappearance of the clinical signs. Affected animals
 79 except suids, usually do not live long enough to produce any marked serological response. Serological tests are
 80 recommended to confirm freedom from previous infection ~~are the tests to be used to detect subclinically or latently~~
 81 ~~infected pigs, especially in the case of qualification of the health status of the animals for international trade or other~~
 82 ~~purposes.~~

83 B. DIAGNOSTIC TECHNIQUES

84 Table 1. Test methods available for the diagnosis of Aujeszky's disease and their purpose

Method	Purpose					
	Population freedom from infection ^(a)	Individual animal freedom from infection prior to movement ^(b)	Contribute to eradication policies ^(c)	Confirmation of clinical cases ^(d)	Prevalence of infection – surveillance ^(e)	Immune status in individual animals or populations post-vaccination ^(f)
<u>Detection and</u> identification of the agent ^(a)						
Virus isolation	–	–	–	+++	–	–
Real-time PCR	–	+	+	+++	+	–
Detection of immune response						
Latex agglutination	+++	+++	+++	+	+++	+++ +

Method	Purpose					
	Population freedom from infection ^(a)	Individual animal freedom from infection prior to movement ^(b)	Contribute to eradication policies ^(c)	Confirmation of clinical cases ^(d)	Prevalence of infection – surveillance ^(e)	Immune status in individual animals or populations post-vaccination ^(f)
ELISA gB	+++	+++	+++	+	+++	+++
ELISA gE	±±	±±	±±±	±	±±	±±
VN	+	+	+	+	+	+++

85 Key: +++ = recommended for this purpose; ++ recommended but has limitations;
86 + = suitable in very limited circumstances; – = not appropriate for this purpose.
87 PCR = polymerase chain reaction; ELISA = enzyme-linked immunosorbent assay; VN = virus neutralisation.
88 ^(a)A combination of agent identification methods applied on the same clinical sample is recommended.
89 ^(a)See Appendix 1 of this chapter for justification table for the scores given to the tests for this purpose.
90 ^(b)See Appendix 2 of this chapter for justification table for the scores given to the tests for this purpose.
91 ^(c)See Appendix 3 of this chapter for justification table for the scores given to the tests for this purpose.
92 ^(d)See Appendix 4 of this chapter for justification table for the scores given to the tests for this purpose.
93 ^(e)See Appendix 5 of this chapter for justification table for the scores given to the tests for this purpose.
94 ^(f)See Appendix 6 of this chapter for justification table for the scores given to the tests for this purpose.

95 1. Detection and identification of the agent

96 1.1. Virus isolation

97 The diagnosis of Aujeszky's disease can be confirmed by isolating the virus from the oro-pharyngeal
98 fluid, nasal fluid (swabs) or tonsil swabs from living pigs, or from samples from dead pigs or following the
99 presentation of clinical signs such as encephalitis in herbivores or carnivores. For post-mortem isolation
100 of SuAHV1, samples of brain, tonsil, and lung are the preferred specimens. In cattle, infection is usually
101 characterised by a pruritus, in which case a sample of the corresponding section of the spinal cord may
102 be required in order to isolate the virus. ~~In latently infected pigs, the trigeminal ganglia is the most~~
103 ~~consistent site for virus isolation, although latent virus is usually non-infective unless reactivated, making~~
104 ~~it difficult to recover in culture.~~

105 Tissue samples are homogenised in normal saline or cell culture medium with antibiotics. The method
106 used should be suitable for the subsequent diagnostic test. The amount of tissue homogenised should
107 take into account a possible non-homogeneous distribution of the virus (e.g. in the brain). A tissue
108 homogenate of approximately 10% is recommended. The resulting suspension is clarified by low-speed
109 centrifugation, e.g. at 900 **g** for 10 minutes. The supernatant fluid is used to inoculate any sensitive cell
110 culture system. Numerous types of cell line or primary cell cultures are sensitive to SuAHV1, but a porcine
111 kidney cell line (PK-15 or SK6) is generally employed. The overlay medium for the cultures should contain
112 antibiotics (such as: 200 IU/ml penicillin; 100 µg/ml streptomycin; 100 µg/ml polymyxin; and 3 µg/ml
113 fungizone).

114 SuAHV1 induces a cytopathic effect (CPE) that usually appears within 24–72 hours, but cell cultures
115 may be incubated for 5–7 days. The monolayer develops accumulations of birefringent cells, followed by
116 complete detachment of the cell sheet. Syncytia also develop, the appearance and size of which are
117 variable. In the absence of any obvious CPE, it is advisable to make one blind passage into further
118 cultures after freeze-thawing the cell culture vessel. Additional evidence may be obtained by staining
119 infected cover-slip cultures with haematoxylin and eosin to demonstrate the characteristic herpesviral
120 acidophilic intranuclear inclusions with margination of the chromatin. Virus identity should be confirmed
121 by immunofluorescence, immunoperoxidase, neutralisation using specific antiserum following the
122 method described in Section B.2.1. or by PCR.

123 ~~The isolation of SHV-1 makes it possible to confirm Aujeszky's disease, but failure to isolate does not~~
124 ~~guarantee freedom from infection.~~

125 1.2. Identification of virus by the polymerase chain reaction

126 The PCR can be used to identify SuAHV1 genomes in secretions or organ samples. Many individual
127 laboratories have established effective protocols, but there is as yet no internationally agreed
128 standardised approach.

129 The PCR is based on the selective amplification of a specific part of the genome using two primers
 130 located at each end of the selected sequence. In a first step, the complete DNA may be isolated using
 131 standard procedures (e.g. proteinase K digestion and phenol-chloroform extraction) or commercially
 132 available DNA extraction kits. Using cycles of DNA denaturation to give single-stranded DNA templates,
 133 hybridisation of the primers, and synthesis of complementary sequences using a thermostable DNA
 134 polymerase, the target sequence can be amplified up to 10⁶-fold. The primers must be designed to
 135 amplify a sequence conserved among SuAHV1 strains, for example parts of the gB, gC or gD genes that
 136 code for essential glycoproteins have been used (Mengeling *et al.*, 1992; Van Rijn *et al.*, 2004; Yoon *et*
 137 *al.*, 2006). Real-time PCRs have been developed that can differentiate gE-deleted vaccine viruses from
 138 wild-type virus based on the specific detection of gB and gE genes (Ma *et al.*, 2008; Wernike *et al.*, 2014).

139 **Real-time PCR**

<u>Pathogen/ target gene</u>	<u>Primer/probe (5'–3')</u>	<u>Concentration</u>	<u>Cycling parameters^(a)</u>
<u>Method 1: Ma <i>et al.</i> (2008)</u>			
<u>gB</u>	Fwd primer: ACA-AGT-TCA-AGG-CCC-ACA-TCT- AC Rev primer: GTC-YGT-GAA-GCG-GTT-CGT-GAT Probe: ACG-TCA-TCG-TCA-CGA-CC	10 pmol/reaction 5 pmol/reaction	40 cycles of 94°C/15 sec and 62°C/60 sec Cutoff: 35Ct
<u>gE</u>	Fwd primer: CTT-CCA-CTC-GCA-GCT-CTT-CTC Rev primer: GTR-AAG-TTC-TCG-CGC-GAG-T Probe: TTC-GAC-CTG-ATG-CCG-C	10 pmol/reaction 5 pmol/reaction	40 cycles of 94°C/15 sec and 62°C/60 sec. Cutoff: 39Ct
<u>Method 2: Wernike <i>et al.</i> (2014)</u>			
<u>gB</u>	Fwd primer: ACC-AAC-GAC-ACC-TAC-ACC-AAG Rev primer: CCT-CCT-CGA-CGA-TGC-AGT-TG Probe: CGG-GCT-TCT-ACC-ACA-CGG-GCA-CCT	20 pmol/reaction 2.5 pmol/reaction	42 cycles of 95°C/1 min, 58°C/30 sec, and 72°C/30 sec
<u>gE</u>	Fwd primer: CTG-TAC-GTG-CTC-GTG-ATG-AC Rev primer: CTC-CTT-GRT-GAC-CGT-GAC-G Probe: TCG-CCA-CCT-GGG-ACT-ACA-CGC-TCG	20 pmol/reaction 2.5 pmol/reaction	42 cycles of 95°C/1 min, 58°C/30 sec, and 72°C/30 sec

140 ^(a)A denaturation step prior to cycling has not been included.

141 **Conventional PCR**

<u>Pathogen/ target gene</u>	<u>Primer (5'–3')</u>	<u>Cycling parameters^(a)</u>
<u>Method 1: Ma <i>et al.</i> (2008); amplicon size :195pb</u>		
<u>SuAHV1</u>	Fwd: ACG-GCA-CGG-GCG-TGA-TC- Rev: GGT-TCA-GGG-TCA-CCC-GC	40 cycles of 94°C/20 sec, 55°C/30 sec, and 72°C/60 sec
<u>Method 2: Müller <i>et al.</i> (2010); amplicon size :217pb</u>		
<u>gD</u>	Fwd: CAC-GGA-GGA-CGA-GCT-GGG-GCT Rev: GTC-CAC-GCC-CCG-CTT-GAA-GCT	40 cycles of 95°C/15 sec, 60°C/10 sec, and 72°C/10 sec

142 ^(a)A denaturation step prior to cycling has not been included.

143 The amplified product may be identified from its molecular weight as determined by migration in agarose
 144 gel, with further confirmation where possible by sequencing the amplified product. More recent
 145 techniques include the use of fluorescent probes linked to an exonuclease action and real-time
 146 monitoring of the evolution of product, enabling simultaneous amplification and confirmation of the
 147 template DNA thus increasing the rapidity and specificity of the PCR assays.

148 In all cases, the main advantage of PCR, when compared with conventional virus isolation techniques,
 149 is its rapidity; with the most modern equipment, the entire process of identification and confirmation can
 150 be completed within one day. However, because of the nature of the test, many precautions need to be
 151 taken to avoid contamination of samples with extraneous DNA from previous tests or from general

152 environmental contamination in the laboratory (see Chapter 1.1.9 *Tests for sterility and freedom from*
153 *contamination of biological materials intended for veterinary use*). This may limit the value of the test for
154 many laboratories unless care is taken to avoid DNA carry-over contamination. The use of an internal
155 control is recommended so as to avoid false-negative results by ensuring adequate efficiency of DNA
156 extraction and confirming the absence of PCR inhibitors in each sample. In practice, different systems
157 can be used for detection of endogenous or exogenous genes (Hoffman *et al.*, 2009). Kits for the test
158 are commercially available (Pol *et al.*, 2013).

159 2. Serological tests

160 Virus neutralisation (VN) has been recognised as the reference method for serology (Moennig *et al.*, 1982), but for
161 general diagnostic purposes it has been widely replaced by the enzyme-linked immunosorbent assay (ELISA)
162 because of its suitability for large-scale testing (Moennig *et al.*, 1982). The tests can be performed on a variety of
163 matrices (e.g. serum, whole blood, milk, muscular exudates, and filter paper), but the preferred matrix is serum.

164 A latex agglutination test has also been developed and can be used for screening for antibodies. Kits for the test
165 are commercially available (Schoenbaum *et al.*, 1990).

166 Serological tests are usually carried out only for suids, as most often other animals (herbivores and carnivores) die
167 too quickly to produce antibodies. In free areas where pigs are not vaccinated, an active epidemiological survey
168 can be carried out using ELISA gB or gE or latex agglutination kits. As antibodies can be detected between 7 and
169 10 days post-infection, these serological tools can also be used to confirm infection in pigs in the case of a suspected
170 outbreak. In areas where pigs are vaccinated with gE deleted vaccines, the ELISA gE kits permit the differentiation
171 between infected and vaccinated pigs (DIVA), but to assess the level of immunity induced by vaccination, gB ELISA,
172 latex agglutination kits or viral neutralisation should be used. Moreover, in Aujeszky's disease free areas, the ELISA
173 gE can be used to confirm or deny a positive or doubtful result obtained with ELISA gB on serum collected from
174 unvaccinated pigs.

175 Any serological technique used should be sufficiently sensitive to give a positive result with the WOAHP International
176 Standard Reference Serum or a calibrated secondary serum. Reference serum can be obtained from the WOAHP
177 Reference Laboratory for Aujeszky's disease in France¹ (see Table given in Part 4 of this *Terrestrial Manual*). For
178 international trade purposes, the test should be sensitive enough to detect the standard serum diluted 1/2. To
179 authorise pig movement from an area where deleted gE vaccines are used to a free area, serological assays should
180 be able to detect at least the dilution of 1/8 for ELISA gE of the WOAHP International Standard Reference Serum as
181 prescribed by the European Commission (2008/2020).

182 2.1. Virus neutralisation

183 VN in cell culture can be performed in several ways, which vary according to the length of incubation of
184 the virus/serum mixtures (e.g. 1 hour at 37°C or 24 hours at 4°C) and the presence or absence of
185 complement. Most laboratories use a reaction period of 1 hour at 37°C in the absence of complement,
186 because this is easy and rapid. However, the sensitivity can be improved by increasing the incubation
187 period to 24 hours at 4°C, which facilitates the detection of antibody levels 10–15 times lower than in the
188 1-hour method. For international trade purposes, the test method should be validated as being sensitive
189 enough to detect the WOAHP Standard Reference Serum diluted 1/2.

190 VN cannot be used to differentiate antibodies of vaccinal origin from those caused by natural infection.
191 It is one of the two tests available that complies with the requirement in the WOAHP *Terrestrial Animal*
192 *Health Code* chapter when it refers to "a diagnostic test to the whole virus".

193 i) Cells

194 Cells susceptible to infection with SuAHV1 are used; they may be cell lines (e.g. PK-15, SK6,
195 MDBK), or primary or secondary cell cultures (e.g. porcine kidney).

196 ii) Cell culture medium

197 The medium depends on the type of cells. For example, the medium for PK-15 cells is Eagle's
198 minimal essential medium (MEM) + 10% fetal bovine serum (FBS) and antibiotics (100 IU/ml
199 penicillin and 100 µg/ml streptomycin or, alternatively, 50 µg/ml gentamycin).

200 iii) Maintenance of the cells

201 The cells are cultured in cell culture vessels of, for example, 75 cm². They are can be trypsinised
202 once or twice per week. ~~For weekly trypsinisation, the cells are usually cultured in 50 ml of medium,~~

¹ Please consult the online list: <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/>

203 with a multiplication rate of 5. For two trypsinisations a week, the cells are cultured in 30 ml of
204 medium, with a multiplication rate of 3. For trypsinisation, the growth medium is removed once the
205 cell sheet is complete. The cell sheet is washed with about 5 ml of recently thawed trypsin/ethylene
206 diamine tetra-acetic acid (EDTA) (0.25%) in an isotonic buffer. The washing fluid is discarded and
207 the preparation is washed again, retaining only a few drops of trypsin. The container is placed in an
208 incubator at 37°C for 5–10 minutes until the cells have become detached. Once the sheet is
209 detached and the cells are well separated, for twice weekly passage they ~~are~~ can be suspended in
210 90 ml of growth medium, and this suspension is distributed into three 75 cm² cell culture vessels.
211 For weekly trypsinisation the cells ~~are~~ can be suspended in 150 ml of growth medium and the
212 suspension distributed into five 75 cm² cell culture ~~bottles~~ flasks. These dilution rates may be
213 adapted to the cell line used.

214 iv) Virus

215 A suitable strain of SuAHV1, such as the Kojnok strain or the NIA-3 strain, is stored at a temperature
216 of –65°C or below, or in freeze-dried form at 4°C.

217 v) Preparation of stock virus suspension

218 The culture fluid is removed from a cell culture vessel containing a complete cell sheet. About 1 =
219 3 ml of stock virus suspension of known titre (about 10⁷ TCID₅₀/ml [50% tissue culture infective
220 dose]) is added, depending on the surface of the cell culture flask (25 or 75 cm²). ~~and~~ The vessel
221 is then incubated at 37°C±2°C for 1 hour with a gentle shake. Remove the inoculum and add 10–
222 50 ~~30~~ ml of culture medium is added and containing 2–5% of FBS. Then the vessel is again
223 incubated at 37°C±2°C. The vessel is examined frequently until there is about 75% cell destruction
224 (after about 18–48 hours). It is then frozen at a temperature of –65°C or lower to disrupt the cells.

225 The vessel is then thawed and shaken vigorously. Medium is collected and centrifuged at 1500 **g**
226 for 15 minutes. The supernatant fluid is divided into portions (of about 0.5 ml) in small tubes that
227 are labelled (date and virus reference) before being stored at a temperature of –65°C or lower until
228 required.

229 vi) Titration of the stock virus suspension

230 Titration of the stock suspension is performed by the method of Reed & Muench or that of Kärber,
231 and the titre is expressed per 50 µl and per ml.

232 The VN test requires an internal quality control serum with a known titre of neutralising antibody to
233 SuAHV1 (it can be calibrated against an international standard serum or a secondary standard prepared
234 from that serum), and a negative control serum (from a specific antibody free pig, e.g. from an official
235 Aujeszky's disease free herd). The test sera themselves should be of good quality, clearly labelled, of
236 known provenance with clinical history, stored in refrigeration at all times, free from fungal or bacterial
237 contamination, non-haemolysed and of sufficient quantity. Serum should be separated from the
238 coagulum without delay, thereby preventing toxicity.

239 There are qualitative and quantitative procedures for VN, both of which are described below.

240 **2.1.1. Qualitative virus neutralisation technique**

241 i) Complement in the serum samples is destroyed by heating in a water bath at 56–59°C for
242 30 minutes.

243 ii) Each undiluted serum sample is placed in two to three wells, at 50 µl per well, of a 96-well
244 cell-culture grade microtitre plate. Each serum can also be diluted 1/2 in the MEM, before
245 being placed in two other wells.

246 iii) 50 µl of virus suspension containing 100 TCID₅₀ (or 2 × 10³ TCID₅₀/ml), obtained by diluting
247 stock virus suspension of known titre with MEM, is added to each well.

248 iv) The plate is gently shaken and placed in an incubator for 1 hour at 37°C (±2°C) (5% CO₂
249 optional).

250 v) 150 µl of cell suspension containing about 150,000 cells/ml is added to each well.

251 vi) The plate is covered (for incubation in CO₂), or a plastic sheet is sealed carefully around the
252 edges of the plate (for incubation in air). The plate is shaken gently to obtain an even
253 distribution of cells at the bottom of the wells, and placed in the incubator at 37°C (±2°C)
254 (CO₂ optional) for 3–5 days.

255 vii) *Controls:* Each set of plates must include the following controls:

256 a) Virus control

-
- 257 This is to verify the amount of virus actually used for the test. The virus dose used for
258 VN (target titre 100 TCID₅₀/50 µl) is diluted with MEM at 1/10, 1/100 and 1/1000. Of
259 each dilution, 50 µl is placed in at least four wells, to which 50 µl of medium is added
260 before the wells are incubated for 1 hour at 37°C (±2°C). The cell suspension is added
261 in the same way as for the sera under test.
- 262 b) Cell control
263 150 µl cell suspension and 100 µl MEM are placed in each of at least four wells.
- 264 c) Positive serum control
265 A serum of known SuAHV1 neutralising antibody titre is used. Five dilutions are
266 prepared in the same way as for the sera under test: a dilution corresponding to the
267 serum titre, two-fold and four-fold dilutions, and 1/2 and 1/4 dilutions (equivalent to 4T,
268 2T, T, T/2 and T/4, where T is the serum titre, i.e. undiluted serum for the qualitative
269 test). Add 50 µl of virus suspension containing 100 TCID₅₀/50 µl to 50 µl of positive
270 control sample dilutions. The cells are incubated and the cell suspension is added in
271 the same way as for the sera under test.
- 272 d) Serum control
273 This is to verify the absence of a toxic effect of the sera on the cells. Wells containing
274 50 µl of each serum are incubated for 1 hour at 37°C in the presence of 50 µl of
275 medium. Then, 150 µl of cell suspension is added in the same way as for the sera
276 under test.
- 277 e) Negative serum control
278 This is ~~done to verify the specificity of the test.~~ A negative control serum, collected from
279 a known negative pig, is analysed in the same way as for sera under test.
- 280 viii) *Reading the results:* An inverted-image microscope (×100) is used to examine the wells for
281 toxic effects and CPEs after 3 to 5 days. The controls must give the following results if the
282 tests are to be considered valid:
- 283 a) Virus control
284 The titre of the viral suspension should be between 10^{1.5} and 10^{2.5} ~~30 and~~
285 ~~300~~-TCID₅₀/50 µl.
- 286 b) Cell control
287 The cell sheet must be intact.
- 288 c) Positive serum control
289 The titre obtained must be equal to the predicted titre, within one dilution.
- 290 d) Serum control
291 Examination for a CPE should take into account a possible toxic effect on cells.
- 292 e) Negative serum control
293 A CPE should be present.
- 294 ix) For the sera under test if distributed in three wells, the following results may be seen:
295 a) presence of a CPE in three wells = negative result;
296 b) absence of a CPE in three wells on day 3 = positive result;
297 c) presence of a CPE in one well but not in the others = inconclusive result, test must be
298 repeated;
299 d) small plaques indicating a CPE on day 3 = inconclusive result, test must be repeated;
300 e) toxicity in serum control and test wells = unreadable result, test must be repeated. (NB
301 replacement of medium with fresh medium after 16 hours' incubation will reduce the
302 toxicity without affecting the titre of specific antibody.) Plates can be read until day 5 of
303 incubation.

- 304 f) If the serum was initially diluted 1/2 and distributed in two wells, it is considered positive
305 if CPE is absent in one of the two wells, and it is highly recommended to retest using
306 the quantitative technique. Diluting the serum to 1/2 can prevent the toxicity effect of
307 the tested sera.
- 308 x) *Interpretation of the results:* This test is capable of detecting the presence or absence
309 of neutralising antibody to SuAHV1. It is incapable of distinguishing vaccinated animals
310 from infected animals.
- 311 The technique described (VN for 1 hour at 37°C) can give false-negative and false-
312 positive results. The sensitivity can be increased (leading to fewer false negatives) by
313 adopting a method based on neutralisation involving 24 hours of contact between virus
314 and serum at 4°C, before the addition of cells.
- 315 A qualitative technique such as this one, which employs undiluted serum samples (1/2
316 final dilution), can give a false-positive result in certain cases due to nonspecific
317 neutralisation of the virus. This problem can be addressed by carrying out a
318 confirmatory test using the quantitative technique (see Section B.2.1.2 below).
- 319 Samples giving inconclusive results may be tested by an alternative technique with
320 better sensitivity such as an ELISA or the animal should be re-bled to confirm status.

321 **2.1.2. Quantitative virus neutralisation technique**

- 322 The quantitative VN technique is similar to the qualitative procedure, but each serum is used both
323 undiluted and in a series of dilutions. Depending on the desired precision, the purpose of testing
324 and the expected titre, two wells are used for each dilution of serum, and a range of dilutions
325 appropriate for the purpose. The procedure below describes the test for an initial maximum
326 dilution of 1/16. It is possible to reach higher titres using more wells (e.g. A1 to A12 for 1/256
327 dilution).
- 328 i) Complement in the serum samples is destroyed by heating in a water bath at 56–59°C for
329 30 minutes.
- 330 ii) 75 µl of MEM is added to well A2 and 50 µl of MEM is added to wells A1, and A3 to A6 of a
331 96-well cell-culture grade microtitre plate and continued for comparable wells in rows B, C,
332 etc., for additional serum samples.
- 333 iii) 75 µl of undiluted serum sample is added to well A2, and continued for wells in rows B, C,
334 etc., with other serum samples.
- 335 iv) Using a multichannel pipette, the contents of wells in column 2 are mixed, then 50 µl is
336 transferred to column 1 and 3, and so on to column 6 or further to a predetermined row,
337 using the same nozzles. The 50 µl portions remaining after the last row are discarded.
- 338 v) 50 µl of virus suspension containing 100 TCID₅₀ (or 2 × 10³ TCID₅₀/ml), obtained by diluting
339 stock virus suspension of known titre with MEM, is added to each well in columns 2 to 6. No
340 virus is added to wells in column 1, this is a control column of serum samples.
- 341 vi) The plate is shaken and placed in an incubator for 1 hour at 37°C (±2°C) (5% CO₂ optional).
- 342 vii) 150 µl of cell suspension containing about 150,000 cells/ml is added to each well.
- 343 viii) The plate is covered (for incubation in CO₂), or a plastic sheet is sealed carefully around the
344 edges of the plate (for incubation in air). The plate is shaken lightly to obtain an even
345 distribution of cells at the bottom of the wells, and placed in the incubator at 37°C (±2°C)
346 (CO₂ optional) for 3–5 days.
- 347 ix) Controls are set up as described for the qualitative technique.
- 348 x) *Reading the results:* The neutralising titre of a serum is expressed by the denominator of
349 the highest initial dilution that brings about complete neutralisation of the CPE of the virus in
350 50% of the wells. Neutralisation at any dilution (even undiluted, equivalent to a final dilution
351 of 1/2) is considered to be positive. If the serum shows neutralisation only when undiluted
352 (with growth of virus and CPE at the 1/2 and subsequent dilutions), it would be advisable to
353 apply alternative tests (ELISA or latex agglutination) to provide confirmation of the result, or
354 to request another sampling of the animal, at least 8 days after the first.

355

356

2.2. Enzyme-linked immunosorbent assay

357 The sensitivity of the ELISA is generally superior to that of the VN test using 1-hour neutralisation without
358 complement. Some weak positive sera are more readily detected by VN tests using 24-hour
359 neutralisation, while others are more readily detectable by ELISA.

360 ELISA kits, which are available commercially, use indirect or competitive techniques for detecting
361 antibodies. They differ in their mode of preparation of antigen, conjugate, or substrate, in the period of
362 incubation and in the interpretation of the results. Their general advantage is that they enable the rapid
363 processing of large numbers of samples. This can also be automated and the results analysed by
364 computer. Some of these kits make it possible to differentiate between vaccinated and naturally infected
365 animals when used with a 'matching' vaccine (Eloit *et al.*, 1989; Van Oirschot *et al.*, 1986; Freuling *et al.*,
366 2017). Alternatively, non-commercial ELISA protocols may be adopted (Toma & Eloit, 1986; Cano-
367 Terriza *et al.*, 2019) provided they are shown to detect the WOAHI International Standard Reference
368 Serum as positive at a dilution of 1/2 (the minimum sensitivity for international trade purposes). It is
369 recommended to use a kit or in-house assay that has been validated to this standard or a secondary
370 standard prepared against the International Reference Standard by external quality control tests by an
371 independent laboratory. A suitable test protocol for whole virus antibodies is presented below (Toma &
372 Eloit, 1986).

373

2.2.1. Preparation of antigen

- 374 i) A cell line sensitive to SuAHV1, such as PK-15 or fetal pig testis, is used. It must be free
375 from extraneous viruses, such as bovine viral diarrhoea virus. The cells should be split and
376 seeded into fresh 75 cm² flasks the day before inoculation. A suitable medium such as MEM,
377 without serum, is used to overlay the cultures.
- 378 ii) Virus inoculated, and control uninoculated flasks are processed in parallel throughout. A
379 suitable well characterised strain of SuAHV1 is used, e.g. Kojnock strain. When a confluent
380 cell monolayer has developed (approximately 24 hours after seeding), it is inoculated with
381 10⁸ TCID₅₀ SuAHV1 in 5 ml medium; and 5 ml medium (without virus) is placed in control
382 flasks. The cultures are left for adsorption for 30 minutes at 37°C, and then overlaid with
383 20 ml medium.
- 384 iii) When CPE is just beginning, the supernatant medium is discarded and 4 ml KCl (4 mM
385 solution) and glass beads are added. The flasks are shaken gently to detach cells.
- 386 iv) Cells are washed by centrifuging three times at 770 **g** in 4 mM KCl. The pellet is
387 resuspended in 4 mM KCl with 0.2% Triton X-100 (1 ml per flask) by applying 60 strokes
388 with a glass homogeniser
- 389 v) The cell homogenate is layered on to 0.25 mM sucrose in 4 mM KCl and centrifuged for
390 10 minutes at 770 **g**.
- 391 vi) The pellet is resuspended in antigen-diluting buffer, pH 9.6 (0.1 M Tris, 2 mM EDTA,
392 0.15 mM NaCl) at 1/50 the volume of the original culture medium. It may then be stored in
393 small aliquots at -70°C. Antigen is stable in this form for 2 years.

394

2.2.2. Coating microtitre plates

- 395 i) Virus antigen and control (no virus) antigen are diluted in diluting buffer, pH 9.6 (see above)
396 to a dilution predetermined in checkerboard titrations.
- 397 ii) 200 µl of antigen is dispensed into each well of 96-well ELISA-grade plates, coating alternate
398 rows with SuAHV1 positive and control antigen. Incubation is for 18 hours at 4°C.
- 399 iii) The plates are washed three times with washing solution (Tween 20, 0.5 ml/litre).
- 400 iv) Coated plates are stored at -20°C or -70°C. They are stable for several months.

401

2.2.3. Test procedure

- 402 i) Test serum samples are diluted 1/30 in PBS/Tween buffer, pH 7.2 (137 mM NaCl, 9.5 mM
403 phosphate buffer, 0.5 ml/litre Tween 20).
- 404 ii) Diluted samples are added to virus and control antigen coated wells, and incubated at 37°C
405 for 30 minutes.
- 406 iii) The plates are washed three times with washing solution (0.5 ml/litre Tween 20).

-
- 407 iv) Protein A/peroxidase conjugate is added to all wells at a predetermined dilution in
408 PBS/Tween buffer, pH 7.2 (see above), with added bovine serum albumen fraction V
409 (10 g/litre), and the plates are incubated at 37°C for 30 minutes.
- 410 v) The plates are washed three times with washing solution (0.5 ml/litre Tween 20).
- 411 vi) A suitable chromogen/substrate mixture, such as tetra methyl benzidine (TMB)/hydrogen
412 peroxide, is added to each plate.
- 413 vii) The reaction is stopped with 2 M sulphuric acid. The absorbance is read at 492 nm.

414 The test must be fully validated using known positive and negative sera, and calibrated against the
415 WOAH International Standard Reference Serum. It is highly recommended to carry out a batch control
416 for each batch of the test, to determine sensitivity and specificity in relation to the original validation
417 criteria (criteria to accept or refuse the batch have to be set). For routine analysis, all tests must include
418 positive and negative internal controls, including at least one weak positive sample that, when diluted at
419 the appropriate dilution for the test, has equivalent activity to a 1/2 dilution of the WOAH International
420 Standard Reference Serum. Internal controls are also used to monitor the sensitivity, specificity and
421 reproducibility of the test over time. For further details see Toma & Eloit (1986) and Chapter 1.1.6
422 *Validation of diagnostic assays for infectious diseases of terrestrial animals*. Commercial ELISA kits also
423 have to be validated in the setting in which they are going to be used.

424 As well as testing sera, the ELISA can be adapted to test pools of sera, filter paper disks that have been
425 moistened with a small quantity of blood obtained by puncturing a superficial vein (Banks, 1985; Toma
426 *et al.*, 1986), or muscle exudates ([Carella *et al.*, 2023](#); Le Potier *et al.*, 1998). These techniques make it
427 convenient to collect blood samples from large numbers of pigs (Vannier *et al.*, 2007). The disks are air-
428 dried before shipment to the laboratory. The (analytical) sensitivity may be lower than for a standard
429 ELISA due to the type of sample or unavoidable dilution of the sample. Use of an adapted ELISA is
430 therefore more appropriate for testing at the population level rather than for individual testing (e.g. prior
431 to animal movement), unless a validation study has shown a comparable (analytical) sensitivity to the
432 standard ELISA.

433 Requirements for the detection of gE antibodies by ELISA in pigs destined for slaughter that are to be
434 introduced into zones free from Aujeszky's disease have been defined by several control authorities. For
435 example, in the European Union, ELISA gE kits must be able to detect activity at least equivalent to a
436 1/8 dilution of the WOAH International Standard Reference Serum (European Commission, [2008-2020](#)).
437 The WOAH *Terrestrial Animal Health Code* specifies circumstances in which gE-specific tests may be
438 used. The gE ELISA can also be adapted to test blood on filter paper disks depending on its sensitivity.

439 C. REQUIREMENTS FOR VACCINES

440 1. Background

441 1.1. Rationale and intended use of the product

442 Aujeszky's disease may be controlled by the use of vaccines containing either modified live or inactivated
443 virus antigens. However, these conventional vaccines have been supplemented by recombinant DNA-
444 derived gene-deleted or naturally deleted live SuAHV1 vaccines. These vaccines, referred to as marker
445 or DIVA-vaccines, are made with a virus that lacks a specific glycoprotein (most commonly gE-, although
446 gG- or gC-deleted vaccines have also been described, as have vaccines with multiple deletions²). These
447 gene-deleted DIVA-vaccines have the advantage over conventional whole virus vaccines that it is
448 possible to distinguish infected animals from non-infected vaccinated animals. This is done by testing for
449 the antibodies directed against the protein coded for by the deleted gene, which will be absent in non-
450 infected DIVA-vaccinated pigs but present in field-infected pigs. Therefore, in countries with infected
451 pigs, where the eradication of Aujeszky's disease is planned, these DIVA-vaccines are the vaccines of
452 choice ([Pensaert *et al.*, 2004](#) [Vannier *et al.*, 2007](#)). Standards applicable to the manufacture of live and
453 inactivated virus vaccines are described. For DIVA-vaccines, the tests should include demonstrable
454 absence of a serological response in vaccinated pigs to the protein coded for by the deleted gene, and
455 in addition a demonstrable response to the same protein in vaccinated pigs that become infected by field
456 virus.

² The nomenclature for the genes changed several years ago, but the old designation is still in the literature. The old and the new nomenclature is: gII = gB; gIII = gC; gp50 = gD; gI = gE; gX = gG; gp63 = gI. Note that some commercial serological kits may still be named by the old nomenclature.

457 Other vaccines are inactivated and constituted of adjuvanted, viral subunit of purified and concentrated
458 immunogenic glycoproteins (except the gE) allowing differentiation of vaccinated from infected pigs.

459 Guidelines for the production of veterinary vaccines are given in Chapter 1.1.8 *Principles of veterinary*
460 *vaccine production*. The guidelines given here and in chapter 1.1.8 are intended to be general in nature
461 and may be supplemented by national and regional requirements.

462 2. Outline of production and minimum requirements for conventional vaccines

463 2.1. Characteristics of the seed

464 2.1.1. Biological characteristics

465 Vaccines are made using a seed-lot system in which a master seed virus (MSV) is prepared from
466 a suitable strain of Aujeszky's disease virus. A number of strains are used for vaccine
467 manufacture. The antigen in an inactivated vaccine can be one of a number of wild-type strains,
468 or the naturally deleted Bucharest virus. Modified live conventional vaccines use numerous
469 strains, such as Bartha or are derived from Aujeszky's original isolate or from other field isolates,
470 such as the NIA-3 strain (Marchioli *et al.*, 1987; McFerran & Dow, 1975; Van Oirschot *et al.*, 1990
471 1996; Visser & Lutticken, 1988).

472 It is recommended that for differentiating between infected and vaccinated animals, gene-deleted
473 strains should be used.

474 A virus identity test (using either a fluorescent antibody test, neutralisation test, [constant
475 serum/decreasing virus method], or any other suitable identity test as full genome sequencing)
476 must be conducted on the MSV.

477 2.1.2. Quality criteria (sterility, purity, freedom from extraneous agents)

478 Guidelines are given in Chapter 2.3.4. Minimum requirements for the production and quality
479 control of vaccines.

480 Most of the cell lines used to propagate SHV-1-SuAHV1 are continuous lines, such as the PK-15
481 line. A master cell stock (MCS) is established at a specified passage level. The MCS and the
482 highest passage level (MCS × n) intended for use in the preparation of a biological product is
483 specified in an Outline of Production. Both MCS and MCS × n are monitored by a variety of
484 procedures to characterise the cell line and to ensure freedom from adventitious agents. The
485 extraneous agents to be detected are generally defined in monographs or guidelines (e.g.
486 European Pharmacopoeia, US Code of Federal Regulations, EU guidelines, etc.). In general, the
487 type of agents to be looked for is founded on a risk analysis depending on the history of the viral
488 strain and cells on which the vaccinal strain was isolated and on which it is cultivated. The MCS
489 must be monitored for species of origin. A minimum of 50 mitotic cells should be examined at
490 both the MCS and MCS × n passage levels. The modal number in the MCS × n must not exceed
491 15% of the modal number of the MCS. Any marker chromosomes in the MCS must also be
492 present in the highest cell passage.

493 ~~If there is evidence that the cell line may induce malignancies in the species for which the product~~
494 ~~is intended, the cell line is tested for tumorigenicity and oncogenicity.~~

495 Both the MSV and the master cell stock (MCS) must be shown to be free from mycoplasma,
496 bacteria, fungi, cytopathogenic or haemadsorbing viruses, porcine parvovirus, cytopathic and
497 noncytopathic ovine and bovine pestiviruses and other extraneous agents, such as circovirus or
498 coronaviruses, as determined by culturing and by fluorescent antibody procedures or others, such
499 as PCR, or deep-sequencing.

500 2.2. Method of manufacture

501 2.2.1. Procedure

502 Only MSV that has been established as pure, safe and immunogenic may be used as seed for a
503 vaccine product. Cells from the MCS are propagated in a variety of growth media. All batches of
504 vaccine must be from the first to the twentieth passage of MCS.

505

506	2.2.2. In-process controls
507 508 509	It is necessary to carry out tests at each critical step of the manufacturing process. The control tests are also carried out on intermediate products with a view to verifying the consistency of the production process and the final product.
510	2.2.3. Final product batch tests
511 512 513 514 515 516 517	It is essential to differentiate the tests that are carried out on a routine basis to release batches of final product from those that are performed to define the biological properties of a vaccine. The trials carried out for batch release are not the same as the ones carried out once only to determine the safety and efficacy of a vaccine. The batch release controls are always short-term trials, as inexpensive as possible, and not always carried out in pigs. Their purpose is mainly to attest the reproducibility of the quality of the finished product, which has to be in compliance with the quality initially defined in the application for marketing authorisation <u>approval</u> .
518	i) Sterility and purity
519 520	Tests must be carried out for sterility and freedom from contamination (see chapter 1.1.9 and Section C.2.1.2 of this chapter).
521 522 523 524 525	Each batch of SHV-4 <u>SUAHV1</u> vaccines must be tested for freedom from extraneous viruses. Using a minimum amount of a monospecific antiserum, the live vaccinal strain is neutralised and inoculated into cell cultures known to be sensitive to viruses pathogenic for pigs. No CPE and no haemadsorbing agents should be detected. The vaccines have to be free from pestiviruses.
526	ii) Inactivation
527 528 529	For inactivated vaccines, inactivation must be checked using two passages in the same type of cell culture as used in the production of the vaccine. Tests can be carried out by vaccinating susceptible animals such as rabbits.
530	iii) Identity
531	Where necessary, a specific test for virus identification should be carried out.
532	iv) Safety
533 534 535	Safety tests in target animals are not required by many regulatory authorities for the release of each batch. Where required, standard procedures should be statistically relevant and target the smallest number of animals required for the relevant regulatory approval.
536	v) Batch potency
537 538	The potency of the vaccine must be demonstrated using a suitable method, the results of which have to be correlated with the efficacy tests described previously.
539 540	In this kind of test, the most difficult point is to determine an acceptability threshold for using or rejecting the batch according to the results that are obtained.
541 542 543 544	Virus content tests should be carried out using each of at least three containers. The virus titre of the vaccine must be determined and must normally not be higher than 1/10 of the dose at which the vaccine has been shown to be safe, and not lower than the minimum release titre.
545	vi) Preservatives
546 547	If no preservative is included in the final product, the manufacturer must demonstrate that the product remains acceptable for its recommended period of use after opening the vial.
548 549 550	The efficacy of preservatives in multidose containers must be demonstrated. The concentration of the preservative in the final filled vaccine and its persistence throughout shelf life must be checked.
551	vii) Precautions (hazards)
552 553	All information about possible adverse reactions induced by the vaccine must be indicated. Any putative risk for human health if the user is accidentally given a small quantity of the

554 product has to be indicated. The manufacturer should indicate all the conditions of use of
555 the vaccine: mixing, reconstitution, storage, asepsis, length of needle, route of
556 administration and health status of the vaccinated animals.

557 **2.2.4. Stability tests**

558 Tests have to be carried out to verify the shelf life proposed by the manufacturer. These tests
559 must always be real-time studies; they must be carried out on a sufficient number of batches (at
560 least three) produced according to the described production process and on products stored in
561 the final container, and normally include biological and physicochemical stability tests. The
562 manufacturer has to provide the results of analyses that support the proposed shelf life under all
563 proposed storage conditions. Usually, the proposed shelf life corresponds to the period for which
564 the product is considered to be stable minus 3 months.

565 **2.3. Requirements for authorisation regulatory approval**

566 **2.3.1. Safety requirements**

567 Local and general reactions must be examined. When a live vaccine is used, it is necessary to
568 differentiate the exact safety properties of the vaccinal strain from those of the finished product if
569 this includes an adjuvant.

570 Objective and quantifiable criteria to detect and measure adverse reactions should be used; these
571 would include temperature changes, weight gain, litter size, reproductive performance, etc., of
572 vaccinated and control groups. The tests must be performed by administering the vaccine to the
573 pigs in the recommended dose and by each recommended route of administration.

574 In general, safety is tested initially under experimental conditions, following the requirements of
575 the WOAH *Terrestrial Animal Health Code*, Chapter 7.8 *Use of animals in research and education*.
576 When the results of these preliminary tests are known, it is necessary to increase the number of
577 animals vaccinated in order to evaluate the safety of the vaccine under practical conditions.

578 **i) Laboratory testing**

579 All tests must be carried out on pigs that do not have antibodies against Aujeszky's disease
580 virus or against a subunit of the virus.

581 **a) General effects**

582 **1. Live vaccines**

583 Intranasal tests and vaccination of 3- to 5-day-old piglets are very useful for
584 ascertaining the degree of safety of a strain. At least five piglets should be used.

585 It is also essential to assess the vaccine's properties in the target animals under normal
586 conditions of use and at the youngest age intended for vaccination, e.g. fattening pigs,
587 which are generally vaccinated between 9 and 12 weeks of age. When the
588 manufacturer allows the use of the vaccine in pregnant sows and when such
589 vaccination is authorised, the vaccine's properties should also be assessed. No clinical
590 signs, including significant thermal reactions should be observed after vaccination:
591 data must be recorded before vaccination and on a schedule such as 6 hours, 24 hours
592 and 48 hours post-vaccination and then on a daily basis during the observation period.
593 These assessments have to be performed on at least ten vaccinated pigs, with five
594 unvaccinated pigs as controls.

595 The test carried out should be consistent with VICH GL41 (Examination of live
596 veterinary vaccines in target animals for absence of reversion to virulence, 2008³).
597 Reversion to virulence following serial passage must be examined. Primary
598 vaccination is done by the intranasal route. Series of at least four passages in piglets
599 are made. No fewer than two fully susceptible animals must be used for each passage.
600 The object of these assays is to test the genetic stability of live vaccine strains. The
601 tests appear to be less necessary when a genetically modified live strain is concerned,
602 especially if it is produced by gene deletion.

³ https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl41-target-animal-safety-examination-live-veterinary-vaccines-target-animals-absence-reversion_en.pdf.

603 It is recommended to test for possible excretion of the vaccine strain. For this purpose,
604 no fewer than 14 piglets, 3–4 weeks old each receive one dose of vaccine by the
605 recommended route and at the recommended site (except for vaccines administered
606 by the intranasal route). Four unvaccinated piglets are kept as controls. Suitably
607 sensitive tests for the virus are carried out individually on the nasal and/or oral
608 secretions of vaccinated and in-contact pigs as follows: nasal and oral swabs are
609 collected daily from 1 day before vaccination to 10 days after vaccination. Vaccine
610 strains that are isolated from the nasal/oral secretion collected from pigs in which the
611 vaccine was administered by the parenteral route are not recommended for eradication
612 purposes.

613 The ability of the Aujeszky's disease vaccine strain to spread from vaccinated pigs to
614 unvaccinated ones (lateral spread) must be tested by using the recommended route
615 of administration that presents the greatest risk of spread (except for vaccines
616 administered by the intranasal route). A repetition of the assays (four times) is
617 necessary as this phenomenon is difficult to detect. Four piglets should be used each
618 time for vaccination and placed in contact, 1 day later, with two unvaccinated piglets.
619 It may also be necessary to examine the spread of the strain to nontarget species that
620 may be susceptible to the vaccine strain.

621 Live attenuated vaccine strains are tested with regard to their general effects by
622 administering to 5- to 10-day-old piglets ten times the field dose. This administration of
623 an overdose makes it possible to detect reactions not produced under normal
624 conditions of use. Such reactions may be produced inadvertently when large numbers
625 of animals are vaccinated. If vaccines are administered by the intranasal route, the
626 manufacturer has to indicate clearly that the vaccine will spread from vaccinated pigs
627 to unvaccinated ones.

628 2. Inactivated vaccines

629 It is essential to test inactivated vaccines in the target animals under normal conditions
630 of use for fattening pigs and for sows when this use is claimed by the manufacturer
631 and ~~authorised~~ received regulatory approval (European Pharmacopoeia, ~~2008-2022~~;
632 Vannier *et al.*, 2007). As described previously, it is fundamental to use objective and
633 quantifiable criteria to detect and to measure adverse reactions, such as temperature
634 changes, weight performance, litter size, reproductive performance, etc., on
635 vaccinated and control groups. The tests must be performed by administering the
636 vaccine in the recommended dose and by each recommended route of administration
637 to the pigs for which it is intended.

638 Pigs or sows are usually observed until there is no further evidence of vaccine reaction.
639 The period of observation must not be fewer than 14 days from the day of
640 administration. This period has to be extended when, for example, the vaccine is used
641 in pregnant sows and it is necessary to assess the possible effects of the vaccine on
642 reproductive performance. In this case, the period of observation lasts the full duration
643 of the pregnancy.

644 Control authorities generally request vaccination with a double dose so that adverse
645 reactions, which may be at the limit of detection when a single dose is administered,
646 are more likely to be detected.

647 b) Local reactions

648 Local reactions are often associated with the use of inactivated vaccines, as these
649 side-effects can be induced by adjuvants, particularly oil adjuvants. However, some
650 Aujeszky's disease live vaccines are mixed with different adjuvants, which modify what
651 has been observed in the past.

652 Local reactions are mainly inflammatory and can be more or less complicated (necrotic
653 or suppurative), depending on the nature of the adjuvants used and the aseptic
654 conditions of the vaccination. Oil adjuvants can induce a variety of effects including
655 muscular degeneration, granuloma, fibrosis and abscessation. In addition to the nature
656 of the oil used (the intensity of the reaction is reduced when metabolisable oils are
657 used in the vaccine), the type of emulsion used (water/oil, oil/water, water/oil/water)
658 induces these reactions to a greater or lesser extent. In consequence, it is necessary
659 to observe the site of injection not only from the outside, but also by dissection after
660 slaughter, especially for growing and finishing pigs.

661 **ii) Field testing**
662 Field trials are necessary to assess the safety of an Aujeszky's disease vaccine in a large
663 number of pigs or sows. In Europe (European Pharmacopoeia, ~~2008-2022~~), tests must be
664 carried out in each category of animals for which the vaccine is intended (sows, fattening
665 pigs). At least three groups of no fewer than 20 animals each are used with corresponding
666 groups of no fewer than 10 controls. The rectal temperature of each animal is measured at
667 the time of vaccination, 6, 24 and 48 hours later. At slaughter, the injection site must be
668 examined for local reactions. If the vaccine is intended to be used in sows, reproductive
669 performances have to be recorded. Field trials are supplemented by laboratory studies of
670 efficacy correlated to vaccine potency.

671 **2.3.2. Efficacy requirements**

672 **i) Laboratory trials**
673 All tests must be carried out on pigs that do not have antibodies against Aujeszky's disease
674 virus or against a subunit of the virus, except that some tests may be done using maternally
675 immune animals.

676 **a) Assessment of passive immunity**
677 To test the efficacy of vaccines, it is important to mimic the natural infection conditions
678 (European Pharmacopoeia, 2008-2022). SuAHV1 infection gives rise to important losses of
679 young piglets from nonimmune sows. Thus, when vaccinating sows, the main goal is to
680 protect the young piglets through passive immunity conferred by the colostrum ingested
681 immediately after birth, with the secondary objective of preventing abortion.

682 To measure this passive immunity and the protection induced by vaccinating the sows,
683 experimental models have been established. The sows are vaccinated according to the
684 vaccinal protocol during pregnancy. When the piglets are, for example, 6–10 days old they
685 are given an intranasal challenge exposure with a virulent SuAHV1 strain. It is preferable to
686 use a strain titrated in median lethal doses (LD₅₀). Pigs should be inoculated by the nasal
687 route, 10² LD₅₀ per pig in 1 ml. The efficacy of the vaccine is assessed by comparing clinical
688 signs, but also and more importantly, mortality, or humane euthanasia, in piglets from
689 unvaccinated dams with that observed in piglets from vaccinated sows.

690 Piglets from vaccinated sows can be found to have 80% protection against mortality
691 compared with those from the control sows. In order for the results to be significant, it is
692 recommended that eight vaccinated sows and four control sows be used (subject to
693 satisfactory numbers of piglets from each sow).

694 **b) Assessment of active immunity**
695 1. Clinical protection
696 Several criteria can be considered when measuring active immunity induced by
697 vaccinating pigs. Generally, pigs are vaccinated at the beginning of the growing period,
698 i.e. when they are between 9 and 12 weeks old. Laboratory trials are performed by
699 challenging pigs at the end of the finishing period, when they weigh between 80 and
700 90 kg.

701 In general, at least three criteria, such as rectal temperature, weight loss and clinical
702 signs, along with mortality, are used to measure the clinical protection of pigs after
703 vaccination and challenge (De Leeuw & Van Oirschot, 1985). The antibody titres have
704 little predictive value for the efficacy of the vaccines. Weight loss compared between
705 the vaccinated and control groups is the most reproducible and reliable parameter
706 when the challenge conditions are well standardised. The measure of the difference in
707 weight gain or loss between the two groups of pigs and, in the interval of time between
708 challenge (day 0 and day 7), has a very good predictive value for the efficacy of the
709 vaccines (Stellmann *et al.*, 1989). Significant results can be obtained when weight
710 performances are compared between one group of at least eight vaccinated pigs and
711 another group of eight unvaccinated control pigs

712 For challenge, it is usually preferable to use a high titre of a virulent strain, as this
713 makes it possible to obtain a more marked difference between vaccinated and control
714 pigs. On the basis of previous work, a challenge dose with at least 10⁶ TCID₅₀/ml
715 virulent strain having undergone not more than three passages on primary cells can
716 be sufficient, but a higher titre (10^{7.5} TCID₅₀/ml) is recommended. The oro-nasal route

717 should be used to challenge the pigs by introducing the virulent strain in an
718 appropriately high volume (≥ 4 ml).

719 This method of evaluating the efficacy of SuAHV1 vaccines is now well tested and has
720 made it possible to establish an objective index for determining the efficacy of a
721 vaccine. This index, which compares the relative weight losses between vaccinated
722 and control pigs, can also be used for potency testing batches before release and for
723 batch efficacy testing. However, the value of the cut-off index will be different as the
724 conditions of the assay will not be identical. The influence of passively acquired,
725 maternally derived antibodies on the efficacy of a vaccine must be evaluated
726 adequately.

727 2. Virulent virus excretion

728 Additionally, it is desirable that vaccines should prevent or at least limit viral excretion
729 from infected pigs (~~Vannier et al., 1994~~). When a control programme against
730 Aujeszky's disease is based on large-scale vaccination, it is essential to choose the
731 vaccines or the vaccinal scheme that best limits the replication of virulent virus in
732 infected pigs. Several assays have been performed to compare vaccines on that basis.

733 Generally, the pigs are vaccinated and challenged at different periods. It is better, but
734 more time-consuming, to infect pigs at the end of the finishing period. To measure the
735 virus excretion, nasal swabs (taken at 10 cm depth in the nostrils) are taken daily from
736 each pig from the day before challenge to at least 12 days after challenge. The swabs
737 can be weighed before the sampling and immediately after to calculate the exact
738 weight of collected mucus. Medium is then added to each tube containing a swab. The
739 virus is titrated from the frozen and thawed medium.

740 Different indexes can be used to express the quantity of virulent virus excreted by pigs,
741 taking into consideration the duration and the level of viral excretion, and the number
742 of pigs excreting virulent virus.

743 3. Duration of immunity

744 It is recommended that any claims regarding the onset and duration of immunity should
745 be supported by data from trials. Assessment of duration of immunity can be based on
746 challenge trials or, as far as it is possible, on immunological and serological tests.

747 ii) **Field trials**

748 In general terms, it is extremely difficult to assess vaccine efficacy in animal populations. In
749 order to do this, it would be necessary to vaccinate the animals in the absence of the
750 pathogen that the vaccine protects against, then to await the moment of infection and to
751 compare the effects of infection in vaccinated animals (or the offspring of vaccinated dams)
752 with the effects in the unvaccinated animals of the same age, in the same building and in
753 the same batch as the vaccinated animals (or those protected passively). As all these
754 conditions are difficult to achieve in the field, field trials are certainly more appropriate to
755 safety testing than to efficacy testing, except for the development of DIVA-vaccines that offer
756 the opportunity to evaluate the effectiveness of vaccines under field conditions (Bouma,
757 2005).

758 **2.3.3. Stability**

759 Tests have to be carried out to verify the shelf life proposed by the manufacturer. These tests
760 must always be real-time studies; they must be carried out on a sufficient number of batches (at
761 least three) produced according to the described production process and on products stored in
762 the final container, and normally include biological and physicochemical stability tests. The
763 manufacturer has to provide the results of analyses that support the proposed shelf life under all
764 proposed storage conditions. Usually, the proposed shelf life corresponds to the period for which
765 the product is considered to be stable minus 3 months.

766 **3. Vaccines based on biotechnology**

767 **3.1. Vaccines available and their advantages**

768 Biotechnology combined with a better knowledge of the functions and characteristics of the SuAHV1
769 glycoproteins helped to develop new vaccines. For example, Quint *et al.* (1987) deleted glycoprotein E-

770 coding sequence from the NIA3 strain. This resulted in an efficient DIVA-vaccine against Aujeszky's
771 disease, allowing differentiation of vaccinated from infected animals (DIVA vaccines). Most of the
772 vaccines used at the moment are obtained from recombinant DNA-derived gene-deleted virus. The
773 deletion of the genes coding for the glycoprotein E is the most commonly used, allowing an attenuated
774 live virus vaccine to be obtained but still protecting against the clinical signs and reducing significantly
775 the level of the viral excretion by the pigs vaccinated and infected. Because of the ability of some
776 glycoproteins of SuAHV1 to induce strong immune responses, efficiencies of DNA vaccines, consisting
777 of plasmids encoding these glycoproteins, were tested. Indeed, DNA vaccination has a number of
778 advantages: ease of construction and standardised production of plasmids, no handling of infectious
779 particles, induction of humoral and cellular immune responses, bypass of the maternal derived immunity.
780 The pioneering study on DNA vaccination against Aujeszky's disease infection was published in 1997
781 (Gerdtz *et al.*, 1997). The use of a novel generation of plasmid amplifying the level of gene transcription
782 of the proteins of interest (Dory *et al.*, 2005) have been shown to be efficient strategies. These vaccines
783 are not yet commercialised.

784 3.2. Special requirements for biotechnological vaccines, if any

785 Criteria to assess quality, safety and efficacy of the vaccines derived from the biotechnology are the
786 same as the ones defined for conventional vaccines (see section C.2). Nevertheless, special attention
787 has to be paid to the stability of the recombinant DNA construction.

788 REFERENCES

789 BANKS M. (1985). Detection of antibodies to Aujeszky's disease virus in whole blood by ELISA-disc. *J. Virol.*
790 *Methods*, **12**, 41–45.

791 Bo Z. & Li X. (2022). A Review of Pseudorabies Virus Variants: Genomics, Vaccination, Transmission, and Zoonotic
792 Potential. *Viruses*, **14**, 1003.

793 BOUMA A. (2005). Determination of the effectiveness of pseudorabies marker vaccines in experiments and field
794 trials. *Biologicals*, **33**, 241–245.

795 CANO-TERRIZA D., MARTINEZ R., MORENO A., PEREZ-MARIN J.E., JIMENEZ-RUIZ S., PANIAGUA J., BORGE C. & GARCIA-
796 BOCANEGRA I. (2019). Survey of Aujeszky's Disease Virus in Hunting Dogs from Spain. *EcoHealth*, **16**, 351–355.
797 <https://doi.org/10.1007/s10393-019-01426-2>

798 CARELLA E., CARUSO C., MORENO A., DI BLASIO A., OBERTO F., VITALE N. & MASOERO L. (2023). Meat juice and oral
799 fluid as alternatives to serum for Aujeszky's disease monitoring in pigs. *Microorganisms*, **11**, 2418.

800 DE LEEUW P.W. & VAN OIRSCHOT J.T. (1985). Vaccines against Aujeszky's disease: evaluation of their efficacy under
801 standardized laboratory conditions. *Vet. Q.*, **7**, 780–786.

802 DORY D., TORCHÉ A.M., BÉVEN V., BLANCHARD P., LOIZEL C. & CARIOLET R. (2005). Effective protection of pigs against
803 lethal Pseudorabies virus infection after a single injection of low-dose Sindbis-derived plasmids encoding PrV gB,
804 gC and gD glycoproteins. *Vaccine*, **23**, 3483–3491.

805 ~~ELOIT M., FARCEAUD D., VANNIER P. & TOMA B. (1989). Development of an ELISA to differentiate between animals~~
806 ~~either vaccinated with or infected by Aujeszky's disease virus. *Vet. Rec.*, **124**, 91–94.~~

807 EUROPEAN COMMISSION (2020). Commission delegated regulation (EU) 2020/689 of 17 December 2019
808 supplementing Regulation (EU) 2016/429 as regards rules for surveillance, eradication programmes, and disease-
809 free status for certain listed and emerging diseases: official Journal of the European Union L **174**, 3.6.2020, p 211

810 ~~EUROPEAN COMMISSION (2008). Commission Decision of 21 February 2008 on additional guarantees in intra-~~
811 ~~Community trade of pigs relating to Aujeszky's disease and criteria to provide information on this disease~~
812 ~~2008/185/EC: Official Journal of the European Communities L **316**, 5–35.~~

813 EUROPEAN PHARMACOPOEIA, ~~SIXTH-ELEVENTH~~ EDITION (2008-2022). Monograph 0744: ~~inactivated~~ Aujeszky's disease
814 vaccine (~~inactivated~~) for pigs. Monograph 0745: Aujeszky's disease ~~live~~ vaccine (~~live~~) for pigs for parenteral
815 administration. European Directorate for the Quality of Medicines and HealthCare (EDQM), Council of Europe,
816 Strasbourg, France.

- 817 FREULING C.M., MULLER T.F. & METTENLEITER T.C. (2017). Vaccines against pseudorabies virus (PrV). *Vet. Microbiol.*,
818 206, 3–9. <https://doi.org/10.1016/j.vetmic.2016.11.019>
- 819 GERDTS V., JÖNS A., MAKOSCHEY B., VISSER N. & METTENLEITER T (1997). Protection of pigs against Aujeszky's
820 disease by DNA vaccination. *J. Gen. Virol.*, **78**, 2139–2146.
- 821 GOYAL S.M., JOO H.A., MOURNING J.R., MCPHERSON S.W. & GOYAL K. (1987). Comparison of three serotests for the
822 detection of pseudorabies antibodies in pigs. *Comp. Immunol. Microbiol. Infect. Dis.*, **10**, 167–171.
823 [https://doi.org/10.1016/0147-9571\(87\)90028-2](https://doi.org/10.1016/0147-9571(87)90028-2)
- 824 HOFFMAN B., BEER M., REID S.M., MERTENS P., OURA, C.A., VAN RIJN P.A., SLOMKA M.J., BANKS J., BROWN I.H.,
825 ALEXANDER D.J. & KING D.P. (2009). A review of RT-PCR technologies used in veterinary virology and disease
826 control: sensitive and specific diagnosis of five livestock diseases notifiable to the World Organisation for Animal
827 Health. *Vet. Microbiol.*, **139**, 1–23.
- 828 LE POTIER M.F., FOURNIER A., HOUDAYER C., HUTET E., AUVIGNE V., HERY D., SANAA M. & TOMA B. (1998). Use of
829 muscle exudates for the detection of anti-gE antibodies to Aujeszky's disease virus. *Vet. Rec.*, **143**, 385–387.
- 830 LIU Q., WANG X., XIE C., DING S., YANG H., GUO S., LI J., QIN L., BAN F., WANG D., WANG C., FENG L., MA H., WU B.,
831 ZHANG L., DONG C., XING L., ZHANG J., CHEN H., YAN R., WANG X. & LI W. (2021). A novel human acute encephalitis
832 caused by pseudorabies virus variant strain. *Clin. Infect. Dis.* **73**, e3690–e3700. doi: 10.1093/cid/ciaa987.
- 833 MA W., LAGER K.M., RICHT J.A., STOFFREGEN W.C., ZHOU F. & YOON K.J. (2008). Development of real-time
834 polymerase chain reaction assays for rapid detection and differentiation of wild-type pseudorabies and gene-deleted
835 vaccine viruses. *J. Vet. Diagn. Invest.*, **20**, 440–447.
- 836 MARCHIOLI C.C., YANCEY R.J., WARDLEY R.C., THOMSEN D.R. & POST L.E. (1987). A vaccine strain of pseudorabies
837 virus with deletions in the thymidine kinase and glycoprotein genes. *Am. J. Vet. Res.*, **48**, 1577–1583.
- 838 MENDELING W.L., LAGER K.M., VOLZ D.M. & BROCKMEIER S.L. (1992). Effect of various vaccination procedures on
839 shedding, latency and reactivation of attenuated and virulent pseudorabies virus in swine. *Am. J. Vet. Res.*, **53**,
840 2164–2173.
- 841 METTENLEITER T.C., ELHERS B., MÜLLER T., YOON K-J. & TEIFKE J.P. (2019). Herpesviruses. In: *Diseases of Swine,*
842 *Eleventh Edition*, Ramirez A., Schwartz K.J., Stevenson G.W., Zimmerman J.J., Zhang J. & Karriker L.A., eds.
843 *Wiley-Blackwell*.
- 844 McFERRAN J.B. & DOW C. (1975). Studies on immunisation of pigs with the Bartha strain of Aujeszky's disease virus.
845 *Res. Vet. Sci.*, **19**, 17–22.
- 846 MOENNIG V., WOLDESENBERT P., FEY H.R., LIESS B., DOPOTKA H.D. & BEHRENS F. (1982). Comparative evaluation of
847 ELISA and neutralization test for the diagnosis of Aujeszky's disease. In: *Current Topics in Veterinary Medicine and*
848 *Animal Science 17. Aujeszky's Disease*, Wittmann G. & Hall S.A., eds. Martinus Nijhoff, The Hague, The
849 Netherlands, 51.
- 850 MÜLLER T., KLUPP B.G., FREULING C., HOFFMANN B., MOJCICZ M., CAPUA I., PALFI V., TOMA B., LUTZ W., RUIZ-FON F.,
851 GORTARZAR C., HLINAK A., SCHAARSCHMIDT U., ZIMMER K., CONRATHS F.J., HAHN E.C. & METTENLEITER T.C. (2010).
852 Characterization of pseudorabies virus of wild boar origin from Europe. *Epidemiol. Infect.*, **138**, 1590–600.
853 <https://doi.org/10.1017/s0950268810000361>
- 854 MÜLLER T.F., TEUFFERT J., ZELLMER R. & CONRATHS F.J. (2001). Experimental infection of European wild boars and
855 domestic pigs with pseudorabies viruses with differing virulence. *Am. J. Vet. Res.*, **62**.
856 <https://doi.org/10.2460/ajvr.2001.62.252>
- 857 PENSAERT M., LABARQUE G., FAVOREEL H. & NAUWYNCK H. (2004). Aujeszky's disease vaccination and differentiation
858 of vaccinated from infected pigs. *Dev. Biol. (Basel)*, **119**, 243–254.
- 859 PEJSAK Z.K. & TRUSZCZYNSKI M. (2006). Aujeszky's disease (Pseudorabies). In: *Diseases of Swine, Ninth Edition,*
860 *Straw B.E., Zimmerman J.J., D'Allaire S. & Taylor D.J., eds, Blackwell Science, Oxford, UK, 419–433.*
- 861 POL F., DEBLANC C., OGER A., LE DIMNA M., SIMON G. & LE POTIER M.-F. (2013). Validation of a commercial real-time
862 PCR kit for specific and sensitive detection of Pseudorabies. *J. Virol. Methods*, **187**, 421–423.
- 863 QUINT W., GIELKENS A., VAN OIRSCHOT J., BERNS A. & CUYPERS H.T. (1987). Construction and characterization of
864 deletion mutants of pseudorabies virus: a new generation of 'live' vaccines. *J. Gen. Virol.*, **68**, 523–534.

865 RODGERS S.J., KARGES S.L. & SALIKI J.T. (1996). Evaluation of a Semiautomated Latex Agglutination Test for the
866 Detection of Pseudorabies Antibody in Swine Sera. *J. Vet. Diagn. Invest.*, **8**. <https://doi.org/10.1177/104063879600800205>

867 SCHOENBAUM M.A., BERAN G.W. & MURPHY D.P. (1990). A study comparing the immunologic responses of swine to
868 pseudorabies viral antigens based on the ELISA, serum virus neutralization, and latex agglutination tests. *J. Vet.*
869 *Diagn. Invest.*, **2**, 29–34. <https://doi.org/10.1177/104063879000200106>

870 STELLMANN C., VANNIER P., CHAPPUIS G., BRUN A., DAUVERGNE M., FARGEAUD D., BUGAUD M. & COLSON X. (1989). The
871 potency testing of pseudorabies vaccines in pigs. A proposal for a quantitative criterion and a minimum requirement.
872 *J. Biol. Stand.*, **17**, 17–27.

873 TOMA B. & ELOIT M. (1986). Pseudorabies virus antibodies (Aujeszky's disease). *In: Methods of Enzymatic Analysis*
874 *X, Antigens and Antibodies 1*, Bergmeyer V.C.H., ed. D-6940 Weinheim, Germany

875 TOMA B., ELOIT M. & TILMANT P. (1986). Sérodiagnostic de la maladie d'Aujeszky: utilisation de prélèvements de
876 sang sur papier filtre. *Rec. Med. Vet.*, **162**, 1111–1117.

877 ~~VAN OIRSCHOT J.T., RZIHA M.J., MOONEN, P.J.L.M., POL J.M. & VAN ZAANE D. (1986). Differentiation of serum~~
878 ~~antibodies from pigs vaccinated or infected with Aujeszky's disease virus by a competitive immunoassay. *J. Gen.*~~
879 ~~*Viro.*, **67**, 1179–1182.~~

880 ~~VAN OIRSCHOT J.T., TERPSTRA C., MOORMANN R.J.M., BERNIS A.J.M. & GIELKENS A.L.J. (1990). Safety of an Aujeszky's~~
881 ~~disease vaccine based on deletion mutant strain 783 which does not express thymidine kinase and glycoprotein I.~~
882 ~~*Vet. Rec.*, **127**, 443–446~~

883 VAN OIRSCHOT J.T., KAASHOEK M.J., RIJSEWIJK F.A. & STEGEMAN J.A. (1996). The use of marker vaccines in
884 eradication of herpesviruses. *J. Biotechnol.*, **44**, 75–81.

885 ~~VAN RIJN P.A., WELLENBERG G.J., HAKZE VAN DER HONING R., JACOBS L., MOONEN P.L. & FEITSMA H. (2004). Detection~~
886 ~~of economically important viruses in boar semen by quantitative Real Time PCR technology. *J. Virol. Methods*,~~
887 ~~**120**, 151–160.~~

888 VANNIER P., CAPUA I., LE POTIER M.F., MACKAY D.K., MUYLKENS B., PARIDA S., PATON D.J. & THIRY E. (2007). Marker
889 vaccines and the impact of their use on diagnosis and prophylactic measures. *Rev. Sci. Tech.*, **6**, 351–372.

890 ~~VANNIER P., HUTET E., BOURGUEIL E. & CARIOLET R. (1991). Level of virulent virus excreted by infected pigs previously~~
891 ~~vaccinated with different glycoprotein deleted Aujeszky's disease vaccines. *Vet. Microbiol.*, **29**, 213–223.~~

892 ~~VISSER N. & LUTTICKEN D. (1988). Experiences with a gI/TK-modified live pseudorabies virus vaccine: strain~~
893 ~~Begonia. *In: Vaccination and Control of Aujeszky's Disease*, Van Oirschot J.T., ed. Kluwer Academic Publishers,~~
894 ~~The Netherlands, 37–44.~~

895 WERNIKE K., BEER M., FREULING C.M., KLUPP B., METTENLEITER T.C., MÜLLER T., HOFFMANN B. (2014). Molecular
896 double-check strategy for the identification and characterization of Suid herpesvirus 1. *J. Virol. Methods.*, **209**, 110–
897 115.

898 ~~YOON H. A., EO S. K., ALEYAS A. G., CHA S. Y., LEE J. H., CHAE J. S., JANG H. K., CHO J. G. & SONG H. J. (2006).~~
899 ~~Investigation of pseudorabies virus latency in nervous tissues of seropositive pigs exposed to field strain. *J. Vet*~~
900 ~~*Med. Sci.*, **68**, 143–148.~~

901
902

*
* *

903 **NB:** There are WOA Reference Laboratories for Aujeszky's disease (please consult the WOA Web site:
904 <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>).
905 Please contact the WOA Reference Laboratories for any further information on
906 diagnostic tests, reagents and vaccines for Aujeszky's disease

907 **NB:** FIRST ADOPTED IN 1991. MOST RECENT UPDATES ADOPTED IN 2018.

Appendix 1: Aujeszky's disease
Intended purpose of test: population freedom from infection

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Virus neutralisation (VN)</u> Score: + Species: <u>Suidae</u>	<u>Serum</u>	<u>VN was the reference method for serology</u> Must detect at least the <u>WOAH Standard Reference Serum diluted 1/2</u>	<u>Historical study conducted in the 1980s</u> <u>Comparison of three serological tests for the detection of antibodies to SUAHV1 in a population of 1285 pig</u> <u>5.9% of sera positive by VNT</u> <u>NVT less sensitive than ELISA at the individual level</u>	<u>See references</u>	<u>1. High specificity</u>	<u>1. Low sensitivity</u> <u>2. Time consuming (3–5 days) and labour intensive</u> <u>so not suitable for high throughput.</u> <u>3. Requires incubators and microscope</u> <u>4. Requires highly trained technicians</u> <u>5. No DIVA properties</u>	<u>Goyal et al. (1987)</u> <u>Schoenbaum et al. (1990)</u>
<u>Latex agglutination</u> <u>Manual or semi-automatic</u> Score: +++ Species: <u>Suidae</u>	<u>Serum</u>	<u>Semi-automatic latex agglutination (LA) test was compared with manual LA, ELISA and VN</u>	<u>Study conducted in the 1990s on 1191 swine sera</u> <u>Overall, the sensitivities of the four tests were as follows:</u> <u>semiautomated LAT = manual LAT > ELISA > SNT. For 74 samples of known pseudorabies antibody status, the overall specificities were as follows: semi-automated LAT = manual LAT = SNT > ELISA</u>	<u>See references</u> <u>WOAH Expert opinion: the recommended test to be used at the herd level to assess the freedom of infection in absence of vaccination</u>	<u>1. High sensitivity</u>	<u>1. No DIVA properties</u> <u>2. Few kits commercially available</u>	<u>Rodgers et al. (1996)</u> <u>Schoenbaum et al. (1990)</u>
<u>ELISA gB</u> Score: +++ <u>ELISA gE</u> Score: ++ Species: <u>Suidae</u>	<u>Pig or wild boar: Serum</u> <u>Clotted blood on filter paper</u> <u>Muscle exudates</u>	<u>Reference test: VN</u>	<u>Comparative studies of VN, LA and ELISA were conducted in the 1990s</u> <u>ELISA kits currently commercialised are more robust, sensitive and specific</u> <u>They are able to detect:</u> <u>for ELISA gB at least the WOAHS Standard Reference Serum diluted 1/2</u> <u>For ELISA gE at least the WOAHS Standard Reference Serum diluted 1/8</u>	<u>See references</u> <u>+ WOAHS expert opinion based on ELISA kits initial and batch-to-batch controls conducted by the French national reference laboratory</u> <u>And on the inter-laboratory comparative test for serology organised every 2-years by the WOAHS Reference Laboratory</u> <u>The recommended test to be used at the individual and herd level to assess the absence of infection in presence or absence of vaccination (gE deleted vaccine)</u>	<u>1. High sensitivity, detects persistently infected animals</u> <u>2. Commercially available</u> <u>3. Easy to handle</u> <u>4. Rapid (<24 hours)</u> <u>5. Possibility of automation for high throughput</u> <u>6. ELISA gB can be used for individual serum or pool of five sera, and for individual filter paper or pool of five filter papers</u> <u>7. DIVA: combination of ELISA gB and ELISA gE when using gE deleted vaccine to check the absence of infection in a vaccinated group of pigs at the individual or herd level</u>	<u>1. ELISA gB: Low per cent of false positive results (<2%), mainly due to insufficient quality of sera</u> <u>2. ELISA gE to be used only on individual serum</u> <u>3. ELISA gE: Risk of false negative gE at the individual level because of delay of seroconversion to gE in vaccinated pigs</u> <u>4. Requires a microplate absorbance reader</u>	<u>Rodgers et al. (1996)</u> <u>Schoenbaum et al. (1990)</u>

Appendix 2: Aujeszky's disease**Intended purpose of test: individual animal freedom from infection prior to movement**

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Virus neutralisation (VN)</u> <u>Score: +</u> <u>Species: Suidae</u>	<u>Serum</u>	<u>VN was the reference method for serology</u> <u>Must detect at least the WOAH Standard Reference Serum diluted 1/2</u>	<u>Historical study conducted in the 1980s</u> <u>Comparison of three serological tests for the detection of antibodies to SUAHV1 in a population of 1285 pig</u> <u>5.9% of sera positive by VNT</u> <u>NVT less sensitive than ELISA at the individual level</u>	<u>See references</u>	<u>1. High specificity</u>	<u>1. Low sensitivity</u> <u>2. Time consuming (3–5 days) and labour intensive so not suitable for high throughput.</u> <u>3. Requires incubators and microscope</u> <u>4. Requires highly trained technicians</u> <u>5. No DIVA properties</u>	<u>Goyal et al., 1987</u> <u>Schoenbaum et al., 1990</u>
<u>Latex agglutination Manual or semi-automatic</u> <u>Score: +++</u> <u>Species: Suidae</u>	<u>Serum</u>	<u>Semi-automatic latex agglutination (LA) test was compared with manual LA, ELISA and VN</u>	<u>Study conducted in the 1990s on 1191 swine sera</u> <u>Overall, the sensitivities of the four tests were as follows:</u> <u>semiautomated LAT = manual LAT > ELISA > SNT. For 74 samples of known pseudorabies antibody status, the overall specificities were as follows: semi-automated LAT = manual LAT = SNT > ELISA</u>	<u>See references</u> <u>WOAH Expert opinion: the recommended test to be used at the herd level to assess the freedom of infection in absence of vaccination</u>	<u>1. High sensitivity</u>	<u>1. No DIVA properties</u> <u>2. Few kits commercially available</u>	<u>Rodgers et al. (1996)</u> <u>Schoenbaum et al. (1990)</u>
<u>ELISA gB</u> <u>Score: +++</u> <u>ELISA gE</u> <u>Score: ++</u> <u>Species: Suidae</u>	<u>Serum</u> <u>Clotted blood on filter paper</u> <u>Muscle exudates</u>	<u>Reference test: VN</u>	<u>Comparative studies of VN, LA and ELISA were conducted in the 1990s</u> <u>ELISA kits currently commercialised are more robust, sensitive and specific</u> <u>They are able to detect for ELISA gB at least the WOAH Standard Reference Serum diluted 1/2</u> <u>For ELISA gE at least the WOAH Standard Reference Serum diluted 1/8</u>	<u>See references</u> <u>+ WOAH expert opinion based on ELISA kits initial and batch-to-batch controls conducted by the French national reference laboratory</u> <u>And on the inter-laboratory comparative test for serology organised every 2-years by the WOAH Reference Laboratory</u> <u>The recommended test to be used at individual level to assess the absence of infection in presence or</u>	<u>1. High sensitivity, detects persistently infected animals</u> <u>2. Commercially available</u> <u>3. Easy to handle</u> <u>4. Rapid (<24 hours)</u> <u>5. Possibility of automation for high throughput</u> <u>6. ELISA gB can be used for individual serum or individual filter paper</u> <u>7. DIVA: ELISA gB/gE when using gE-deleted vaccine</u>	<u>1. ELISA gB: Low per cent of false positive results (<2%), mainly due to insufficient quality of sera</u> <u>2. ELISA gE to be used only on individual serum</u> <u>3. ELISA gE: Risk of false negative gE at the individual level because of delay of seroconversion to gE in vaccinated pigs</u> <u>4. Requires a microplate absorbance reader</u>	<u>Rodgers et al. (1996)</u> <u>Schoenbaum et al. (1990)</u>

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
				<u>absence of vaccination (gE deleted vaccine)</u>			
<u>PCR</u> <u>Score: +</u> <u>Species: <i>Suidae</i></u>	<u>On live suid: nasal or ejaculate swabs</u>	<u>Reference test: VI</u>	<u>Müller <i>et al.</i> (2001): Experimental infection of 18 European wild boars and 16 domestic pigs: three groups of four wild boars were inoculated with SuAHV1 Bartha, Kaplan, and a wild-boar isolate (BFW1) and housed with uninfected pigs. Two groups of domestic pigs (four and eight pigs/group, respectively) were inoculated with various doses of BFW1. Animals were observed daily for clinical signs, and samples were tested for SuAHV1 excretion and homologous antibodies. After reactivation of latent infection by induced immunosuppression, SuAHV1 was detected in tissues of necropsied animals, using cell culture and a PCR</u>	<u>See references + WOAH expert opinion based on PCR kits initial and batch-to-batch controls conducted by the French national reference laboratory</u> <u>And on the inter-laboratory comparative test for virology (PCR) organised every 2-years by the WOAH Reference Laboratory</u> <u>Suitable in limited circumstances: e.g.: in Insemination centres or selection herds, before movement; always in combination with serological testing</u>	<u>1. High sensitivity</u> <u>2. High specificity</u> <u>3. Commercially available</u>	<u>1. Nasal swabs: to be used only in acute disease with respiratory clinical signs</u> <u>Risk of false negatives for two main reasons:</u> <u>a) nasal excretion duration is short (2–15 days post-infection).</u> <u>b) cannot detect latent infection</u> <u>2. Requires extraction and thermal cycler equipment</u>	<u>Müller <i>et al.</i> (2001)</u> <u>Pol <i>et al.</i> (2013)</u>

Appendix 3: Aujeszky's disease
Intended purpose of test: contribute to eradication policies

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Virus neutralisation (VN)</u> Score: + Species: <i>Suidae</i>	<u>Serum</u>	<u>VN was the reference method for serology</u> <u>Must detect at least the WOAH Standard Reference Serum diluted 1/2</u>	<u>Historical study conducted in the 1980s</u> <u>Comparison of three serological tests for the detection of antibodies to SUAHV1 in a population of 1285 pig</u> <u>5.9% of sera positive by VNT</u> <u>NVT less sensitive than ELISA at the herd level</u>	<u>See references</u> <u>WOAH Expert opinion:</u> <u>VN is not useful at individual level for clinical case confirmation because of a delay of around 15 days post-infection for the detection of neutralising antibodies.</u> <u>Low level of interest at herd level</u>	<u>1. High specificity</u>	<u>1. Low sensitivity</u> <u>2. Time consuming (3–5 days) and labour intensive so not suitable for high throughput.</u> <u>3. Requires incubators and microscope</u> <u>4. Requires highly trained technicians</u> <u>5. No DIVA properties</u>	<u>Goyal <i>et al.</i> (1987)</u>
<u>Latex agglutination</u> <u>Manual or semi-automatic</u> Score: +++ Species: <i>Suidae</i>	<u>Serum</u>	<u>Semi-automatic latex agglutination (LA) test was compared with manual LA, ELISA and VN</u>	<u>Study conducted in the 1990s on 1191 swine sera</u> <u>Overall, the sensitivities of the four tests were as follows:</u> <u>semiautomated LAT = manual LAT > ELISA > SNT. For 74 samples of known pseudorabies antibody status, the overall specificities were as follows: semi-automated LAT = manual LAT = SNT > ELISA</u>	<u>See references</u> <u>WOAH Expert opinion:</u> <u>can be used at the individual or herd level to confirm the presence of infection</u>	<u>1. High sensitivity</u> <u>2. High specificity</u>	<u>1. No DIVA properties</u> <u>2. Few kits commercially available</u>	<u>Rodgers <i>et al.</i> (1996)</u> <u>Schoenbaum <i>et al.</i> (1990)</u>
<u>ELISA gB</u> Score: +++ <u>ELISA gE</u> Score: +++ Species: <i>Suidae</i>	<u>Serum</u> <u>Clotted blood on filter paper</u> <u>Muscle exudates</u>	<u>Reference test: VN</u>	<u>Comparative studies of VN, LA and ELISA were conducted in the 1990s</u> <u>ELISA kits currently commercialised are more robust, sensitive and specific</u> <u>They are able to detect:</u> <u>for ELISA gB at least the WOAH Standard Reference Serum diluted 1/2</u> <u>For ELISA gE at least the WOAH Standard Reference Serum diluted 1/8</u>	<u>See references</u> <u>+ WOAH expert opinion based on ELISA kits initial and batch-to-batch controls conducted by the French national reference laboratory</u> <u>And on the inter-laboratory comparative test for serology organised every 2-years by the WOAH Reference Laboratory</u> <u>The recommended test to be used at the herd level to assess the efficacy of</u>	<u>1. High sensitivity, detects persistently infected animals</u> <u>2. Commercially available</u> <u>3. Easy to handle</u> <u>4. Rapid (<24 hours)</u> <u>5. Possibility of automation for high throughput</u> <u>6. ELISA gB can be used for individual serum or pool of five sera, and for individual filter paper or pool of five filter papers</u> <u>7. DIVA: ELISA gB/gE when using gE-deleted vaccine</u>	<u>1. ELISA gB: Low per cent of false positive results (<2%), mainly due to insufficient quality of sera</u> <u>2. ELISA gE to be used only on individual serum</u> <u>3. ELISA gE: Risk of false negative gE at the individual level because of delay of seroconversion to gE in vaccinated pigs</u> <u>4. Requires a microplate absorbance reader</u>	<u>Rodgers <i>et al.</i> (1996)</u> <u>Schoenbaum <i>et al.</i> (1990)</u>

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
				<u>eradication policies of infection</u>			
<p>PCR Score: + Species: <i>Suidae</i></p>	<p><u>On live suid: nasal or ejaculate swabs</u> <u>On dead suid: tonsil; lung; trigeminal lymph node; sacral lymph node</u></p>	<p>Reference test: VI</p>	<p><u>Müller et al. (2001): Experimental infection of 18 European wild boars and 16 domestic pigs: three groups of four wild boars were inoculated with SuAHV1 Bartha, Kaplan, and a wild-boar isolate (BFW1) and housed with uninfected pigs. Two groups of domestic pigs (four and eight pigs/group, respectively) were inoculated with various doses of BFW1. Animals were observed daily for clinical signs, and samples were tested for SuAHV1 excretion and homologous antibodies. After reactivation of latent infection by induced immunosuppression, SuAHV1 was detected in tissues of necropsied animals, using cell culture and a PCR</u></p>	<p><u>See references + WOAH expert opinion based on PCR kits initial and batch-to-batch controls conducted by the French national reference laboratory</u> <u>And on the inter-laboratory comparative test for virology (PCR) organised every 2-years by the WOAH Reference Laboratory</u></p>	<p><u>1. High sensitivity</u> <u>2. High specificity</u> <u>3. Commercially available</u></p>	<p><u>1. Nasal swabs: to be used only in acute disease with respiratory clinical signs</u> <u>Risk of false negatives for two main reasons:</u> <u>a) nasal excretion duration is short (2–15 days post-infection).</u> <u>b) cannot detect latent infection</u> <u>2. Requires extraction and thermal cycler equipment</u></p>	<p><u>Müller et al. (2001)</u> <u>Pol et al. (2013)</u></p>

Appendix 4: Aujeszky's disease
Intended purpose of test: confirmation clinical cases

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Virus neutralisation (VN)</u> Score: + Species: <i>Suidae</i>	<u>Serum</u>	<u>VN was the reference method for serology</u> <u>Must detect at least the WOAHS Standard Reference Serum diluted 1/2</u>	<u>Historical study conducted in the 1980s</u> <u>Comparison of three serological tests for the detection of antibodies to SUAHV1 in a population of 1285 pig</u> <u>5.9% of sera positive by VNT</u> <u>NVT less sensitive than ELISA at the herd level</u>	<u>See references</u> <u>WOAH Expert opinion:</u> <u>VN is not useful at the individual level for clinical case confirmation because of a delay of around 15 days post-infection for the detection of neutralising antibodies.</u> <u>Low level of interest at herd level</u>	<u>1. High specificity</u>	<u>1. Low sensitivity</u> <u>2. Time consuming (3–5 days) and labour intensive so not suitable for high throughput.</u> <u>3. Requires incubators and microscope</u> <u>4. Requires highly trained technicians</u> <u>5. No DIVA properties</u>	<u>Goyal <i>et al.</i> (1987)</u>
<u>Latex agglutination</u> <u>Manual or semi-automatic</u> Score: + Species: <i>Suidae</i>	<u>Serum</u>	<u>Semi-automatic latex agglutination (LA) test was compared with manual LA, ELISA and VN</u>	<u>Study conducted in the 1990s on 1191 swine sera</u> <u>Overall, the sensitivities of the four tests were as follows:</u> <u>semiautomated LAT = manual LAT > ELISA > SNT. For 74 samples of known pseudorabies antibody status, the overall specificities were as follows: semi-automated LAT = manual LAT = SNT > ELISA</u>	<u>See references</u> <u>WOAH Expert opinion:</u> <u>can be used at the individual or herd level to confirm the presence of infection</u>	<u>1. High sensitivity</u> <u>2. High specificity</u>	<u>1. No DIVA properties</u> <u>2. Few kits commercially available</u>	<u>Rodgers <i>et al.</i> (1996)</u>
<u>ELISA gB</u> Score: + <u>ELISA gE</u> Score: + Species: <i>Suidae</i>	<u>Serum</u> <u>Clotted blood on filter paper</u> <u>Muscle exudates</u>	<u>Reference test: VN</u>	<u>Comparative studies of VN, LA and ELISA were conducted in the 1990s</u> <u>ELISA kits currently commercialised are more robust, sensitive and specific</u> <u>They are able to detect:</u> <u>for ELISA gB at least the WOAHS Standard Reference Serum diluted 1/2</u> <u>For ELISA gE at least the WOAHS Standard Reference Serum diluted 1/8</u>	<u>See references</u> <u>+ WOAHS expert opinion based on ELISA kits initial and batch-to-batch controls conducted by the French national reference laboratory</u> <u>And on the inter-laboratory comparative test for serology organised every 2-years by the WOAHS Reference Laboratory</u> <u>Can be used at the herd level to confirm the detection of infection</u>	<u>1. High sensitivity, detects persistently infected animals</u> <u>2. Commercially available</u> <u>3. Easy to handle</u> <u>4. Rapid (<24 hours)</u> <u>5. Possibility of automation for high throughput</u> <u>6. ELISA gB can be used for individual serum or pool of five sera, and for individual filter paper or pool of five filter papers</u> <u>7. DIVA: ELISA gB/gE when using gE-deleted vaccine</u>	<u>1. ELISA gB: Low per cent of false positive results (<2%), mainly due to insufficient quality of sera</u> <u>2. ELISA gE to be used only on individual serum</u> <u>3. ELISA gE: Risk of false negative gE at the individual level because of delay of seroconversion to gE in vaccinated pigs</u> <u>4. Requires a microplate absorbance reader</u>	<u>Rodgers <i>et al.</i> (1996)</u>

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<p>PCR Score: +++ Species: Suidae</p>	<p>On live suid: nasal swabs On dead suid: tonsil; lung; trigeminal lymph node; sacral lymph node</p>	Reference test: VI	<p>Müller <i>et al.</i> (2001): experimental infection of 18 European wild boars and 16 domestic pigs: three groups of four wild boars were inoculated with PrV Bartha, Kaplan, and a wild-boar isolate (BFW1) and housed with uninfected pigs. Two groups of domestic pigs (four and eight pigs/group, respectively) were inoculated with various doses of BFW1. Animals were observed daily for clinical signs, and samples were tested for PrV excretion and homologous antibodies. After reactivation of latent infection by induced immunosuppression, PrV was detected in tissues of necropsied animals, using cell culture and a polymerase chain reaction (PCR)</p>	<p>See references + WOAH expert opinion based on PCR kits initial and batch to batch controls conducted by the French national reference laboratory And on the ILCT for virology (PCR) organised every 2-years by the WOAH Reference Laboratory</p>	<ol style="list-style-type: none"> 1. High sensitivity 2. High specificity 3. Commercially available 4. Nasal swabs, tonsils, lung: To be used in acute disease with respiratory clinical signs, as nasal excretion duration is short (2–15 days post-infection) 5. Trigeminal and sacral lymph nodes and tonsils: useful to detect latently infected pig 6. Most recommended at individual level for clinical cases confirmation 	<ol style="list-style-type: none"> 1. Requires extraction and thermal cycler equipment 	<p>Müller <i>et al.</i> (2001) Pol <i>et al.</i> (2013)</p>
<p>VI Score: +++ Species : Suidae</p>	<p>On live suid: nasal swabs On dead suid: tonsil; lung; trigeminal lymph node; sacral lymph node</p>	Reference test: VI	<p>Müller <i>et al.</i> (2001): experimental infection of 18 European wild boars and 16 domestic pigs: three groups of four wild boars were inoculated with PrV Bartha, Kaplan, and a wild-boar isolate (BFW1) and housed with uninfected pigs. Two groups of domestic pigs (four and eight pigs/group, respectively) were inoculated with various doses of BFW1. Animals were observed daily for clinical signs, and samples were tested for PrV excretion and homologous antibodies. After reactivation of latent infection by induced immunosuppression, PrV was detected in tissues of necropsied animals, using cell culture and a polymerase chain reaction (PCR)</p>	<p>See reference Most recommended at individual level for clinical cases confirmation, permits virus isolation and identification of the virus by sequencing</p>	<ol style="list-style-type: none"> 1. Medium sensitivity 2. High specificity 3. Nasal swabs, tonsils, lung: To be used in acute disease with respiratory clinical signs, as nasal excretion duration is short (2–15 days post-infection) 4. Trigeminal and sacral lymph nodes : useful to detect latently infected pig 	<ol style="list-style-type: none"> 1. Medium sensitivity 2. Time consuming (up to three passages of 5 days) and labour intensive so not suitable for high throughput. 3. Requires incubators and microscope 4. Requires high trained technicians 	<p>Müller <i>et al.</i> (2001)</p>

Appendix 5: Aujeszky's disease
Intended purpose of test: prevalence of infection – surveillance

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Virus neutralisation (VN)</u> Score: + Species: <i>Suidae</i>	<u>Serum</u>	<u>VN was the reference method for serology</u> <u>Must detect at least the WOAH Standard Reference Serum diluted 1/2</u>	<u>Historical study conducted in the 1980s</u> <u>Comparison of three serological tests for the detection of antibodies to SUAHV1 in a population of 1285 pig</u> <u>5.9% of sera positive by VNT</u> <u>NVT less sensitive than ELISA at the herd level</u>	<u>See references</u>	<u>1. High specificity</u>	<u>1. Low sensitivity</u> <u>2. Time consuming (3–5 days) and labour intensive so not suitable for high throughput.</u> <u>3. Requires incubators and microscope</u> <u>4. Requires highly trained technicians</u> <u>5. No DIVA properties</u>	<u>Goyal <i>et al.</i> (1987)</u>
<u>Latex agglutination Manual or semi-automatic</u> Score: +++ Species: <i>Suidae</i>	<u>Serum</u>	<u>Semi-automatic latex agglutination (LA) test was compared with manual LA, ELISA and VN</u>	<u>Study conducted in the 1990s on 1191 swine sera</u> <u>Overall, the sensitivities of the four tests were as follows:</u> <u>semiautomated LAT = manual LAT > ELISA > SNT. For 74 samples of known pseudorabies antibody status, the overall specificities were as follows: semi-automated LAT = manual LAT = SNT > ELISA</u>	<u>See references</u> <u>WOAH Expert opinion: the recommended test to be used at the herd level to assess the prevalence of infection</u>	<u>1. High sensitivity</u> <u>2. High specificity</u>	<u>1. No DIVA properties</u> <u>2. Few kits commercially available</u>	<u>Rodgers <i>et al.</i> (1996)</u> <u>Schoenbaum <i>et al.</i> (1990)</u>
<u>ELISA gB</u> Score: +++ <u>ELISA gE</u> Score: ++ Species: <i>Suidae</i>	<u>Serum</u> <u>Clotted blood on filter paper</u> <u>Muscle exudates</u>	<u>Reference test: VN</u>	<u>Comparative studies of VN, LA and ELISA were conducted in the 1990s</u> <u>ELISA kits currently commercialised are more robust, sensitive and specific</u> <u>They are able to detect:</u> <u>for ELISA gB at least the WOAH Standard Reference Serum diluted 1/2</u> <u>For ELISA gE at least the WOAH Standard Reference Serum diluted 1/8</u>	<u>See references</u> <u>+ WOAH expert opinion based on ELISA kits initial and batch-to-batch controls conducted by the French national reference laboratory</u> <u>And on the inter-laboratory comparative test for serology organised every 2-years by the WOAH Reference Laboratory</u> <u>The recommended test to be used at the herd level to assess the prevalence of infection</u>	<u>1. High sensitivity, detects persistently infected animals</u> <u>2. Commercially available</u> <u>3. Easy to handle</u> <u>4. Rapid (<24 hours)</u> <u>5. Possibility of automation for high throughput</u> <u>6. ELISA gB can be used for individual serum or pool of five sera, and for individual filter paper or pool of five filter papers</u> <u>7. DIVA: ELISA gB/gE when using gE-deleted vaccine</u>	<u>1. ELISA gB: Low per cent of false positive results (<2%), mainly due to insufficient quality of sera</u> <u>2. ELISA gE to be used only on individual serum</u> <u>3. ELISA gE: Risk of false negative gE at the individual level because of delay of seroconversion to gE in vaccinated pigs</u> <u>4. Requires a microplate absorbance reader</u>	<u>Rodgers <i>et al.</i> (1996)</u> <u>Schoenbaum <i>et al.</i> (1990)</u>

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<p>PCR Score: + Species: <i>Suidae</i></p>	<p>On live suid: nasal or ejaculate swabs On dead suid: tonsil; lung, trigeminal lymph node; sacral lymph node</p>	<p>Reference test: VI</p>	<p>Müller <i>et al.</i> (2001): Experimental infection of 18 European wild boars and 16 domestic pigs: three groups of four wild boars were inoculated with SuAHV1 Bartha, Kaplan, and a wild-boar isolate (BFW1) and housed with uninfected pigs. Two groups of domestic pigs (four and eight pigs/group, respectively) were inoculated with various doses of BFW1. Animals were observed daily for clinical signs, and samples were tested for SuAHV1 excretion and homologous antibodies. After reactivation of latent infection by induced immunosuppression, SuAHV1 was detected in tissues of necropsied animals, using cell culture and a PCR</p>	<p>See references + WOAHP expert opinion based on PCR kits initial and batch-to-batch controls conducted by the French national reference laboratory And on the inter-laboratory comparative test for virology (PCR) organised every 2-years by the WOAHP Reference Laboratory Suitable in limited circumstances: e.g.: in insemination centres or selection herds, before movement; always in combination with serological testing</p>	<p>1. High sensitivity 2. High specificity 3. Commercially available</p>	<p>1. Nasal swabs: to be used only in acute disease with respiratory clinical signs Risk of false negatives for two main reasons: a) nasal excretion duration is short (2–15 days post-infection). b) cannot detect latent infection 2. Requires extraction and thermal cycler equipment</p>	<p>Müller <i>et al.</i> (2001) Pol <i>et al.</i> (2013)</p>

Appendix 6: Aujeszky's disease**Intended purpose of test: immune status in individual animals or populations post-vaccination**

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Virus neutralisation (VN)</u> <u>Score: +++</u> <u>Species: Suidae</u>	<u>Serum</u>	<u>VN was the reference method for serology</u> <u>Must detect at least the WOAAH Standard Reference Serum diluted 1/2</u>	<u>Historical study conducted in the 1980s on 56 pigs</u> <u>A study of pseudorabies virus (PRV)-vaccinated pigs comparing the immune responses detected by the latex agglutination test (LAT) with responses detected by other routine tests for pseudorabies antibodies indicated that LAT was more sensitive than either the ELISA or the serum virus neutralisation test (SVNT).</u> <u>The LAT detected antibodies sooner than ELISA and SVNT in unvaccinated pigs after challenge with virulent SUAHV1. The specificities of the 3 tests were found to be near 100%.</u>	<u>See references</u>	<u>1. Quantification of neutralising antibodies: useful for evaluation of vaccination at individual level, can be used to assess a boost effect</u> <u>2. High specificity</u>	<u>1. Low sensitivity</u> <u>2. Time consuming (3–5 days) and labour intensive so not suitable for high throughput.</u> <u>3. Requires incubators and microscope</u> <u>4. Requires highly trained technicians</u> <u>5. No DIVA properties</u>	<u>Schoenbaum et al. (1990)</u>
<u>Latex agglutination</u> <u>Manual or semi-automatic</u> <u>Score: ++</u> <u>Species: Suidae</u>	<u>Serum</u>	<u>Semi-automatic latex agglutination (LA) test was compared with manual LA, ELISA and VN</u>	<u>See above (VN)</u>	<u>See references</u>	<u>1. High sensitivity, detects persistently infected animals</u> <u>2. Commercially available</u> <u>3. Easy to handle</u> <u>4. Rapid (<24 hours)</u> <u>5. Possibility of automation for high throughput</u> <u>6. At the herd level, permits the percentage of vaccinated pigs to be assessed</u>	<u>1. No DIVA properties</u> <u>2. Few kits commercially available</u> <u>3. At the individual level does not permit quantification of antibodies, can be used to assess a boost effect at the herd level</u>	<u>Schoenbaum et al. (1990)</u>
<u>ELISA gB</u> <u>Score: ++</u> <u>ELISA gE</u> <u>Score: ++</u> <u>Species: Suidae</u>	<u>Serum</u> <u>Clotted blood on filter paper</u> <u>Muscle exudates</u>	<u>Reference test: VN</u>	<u>Comparative studies of VN, LA and ELISA were conducted in the 1980s</u> <u>ELISA kits currently commercialised are more robust, sensitive and specific</u> <u>They are able to detect for ELISA gB at least the WOAAH Standard Reference Serum diluted</u>	<u>See references</u> <u>+ WOAAH expert opinion based on ELISA kits initial and batch-to-batch controls conducted by the French national reference laboratory</u> <u>And on the inter-laboratory comparative</u>	<u>1. High sensitivity, detects persistently infected animals</u> <u>2. Commercially available</u> <u>3. Easy to handle</u> <u>4. Rapid (<24 hours)</u> <u>5. Possibility of automation for high throughput</u> <u>6. ELISA gB can be used for individual serum or pool of</u>	<u>1. ELISA gB: Low per cent of false positive results (<2%), mainly due to insufficient quality of sera</u> <u>2. ELISA gE to be used only on individual serum</u> <u>3. ELISA gE: Risk of false negative gE at the individual level because of delay of</u>	<u>Schoenbaum et al. (1990)</u>

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
			<u>1/2</u> <u>For ELISA gE at least the WOAH Standard Reference Serum diluted 1/8</u>	<u>test for serology organised every 2-years by the WOAH Reference Laboratory</u>	<u>five sera, and for individual filter paper or pool of five filter papers</u> <u>7. DIVA: ELISA gB/gE when using gE-deleted vaccine</u> <u>8. ELISA gB: at the herd level, permits the percentage of vaccinated pigs to be assessed</u>	<u>seronconversion to gE in vaccinated pigs</u> <u>4. Requires a microplate absorbance reader</u> <u>5. ELISA gB:</u> <u>a) at the individual level does not permit quantification of antibodies.</u> <u>b) can be used to assess a boost effect at the herd level</u>	

4
5 CHAPTER 3.1.8.

6 FOOT AND MOUTH DISEASE (INFECTION WITH
7 FOOT AND MOUTH DISEASE VIRUS)

8 SUMMARY

9 *Foot and mouth disease (FMD) is a highly-very contagious disease of mammals and has a great*
10 *potential for causing severe economic loss in susceptible cloven-hoofed animals. There are seven*
11 *serotypes of FMD virus (FMDV), namely, O, A, C, SAT 1, SAT 2, SAT 3 and Asia 1. Infection with*
12 *one serotype does not confer immunity against another. FMD cannot be differentiated clinically from*
13 *other vesicular diseases, such as swine vesicular disease, vesicular stomatitis, disease caused by*
14 *Senecavirus A (also known as Seneca Valley virus) and vesicular exanthema and Seneca Valley*
15 *virus infection. Laboratory diagnosis of any suspected FMD case is therefore a matter of urgency.*

16 *Typical cases of FMD are characterised by ~~a vesicular condition of~~ the appearance of vesicles on the*
17 *feet, on the buccal mucosa and, in females, on the mammary glands. Clinical signs can vary from*
18 *mild to severe, and fatalities may occur, especially in young animals. In some species the infection*
19 *may be subclinical, e.g. African buffalo (*Syncerus caffer*). The preferred tissue for diagnosis is*
20 *epithelium from unruptured or freshly ruptured vesicles or vesicular fluid. Where collecting this is not*
21 *possible, blood ~~and/or~~ oesophageal–pharyngeal fluid samples taken by probang cup in ruminants or*
22 *throat swabs from pigs provide an alternative source of virus. Myocardial tissue or blood can be*
23 *submitted from fatal cases, but vesicles are again preferable if present.*

24 *It is vital that samples from suspected cases be transported under secure conditions and according*
25 *to international regulations. They should only be dispatched to authorised laboratories.*

26 *Laboratory diagnosis of FMD is conducted by ~~virus isolation or by the demonstration~~ detection*
27 *FMD viral antigen or nucleic acid in appropriate samples of ~~tissue or fluid~~. Detection of virus-specific*
28 *antibody can also be used for diagnosis, and antibodies to viral nonstructural proteins (NSPs) can be*
29 *used as indicators of infection, irrespective of vaccination status. Confirmation of a case of FMD*
30 *should take account of all relevant clinical, epidemiological and laboratory findings.*

31 ***Detection and identification of the agent:*** *The presence of FMD virus is confirmed by*
32 *~~demonstration~~ detection of nucleic acid or specific antigen ~~or nucleic acid~~, with or without prior*
33 *amplification of the virus in cell culture through ~~(virus isolation in susceptible cells)~~. Due to the highly*
34 *very contagious nature and economic importance of FMD, the laboratory diagnosis and serotype*
35 *identification of the virus should be done in a laboratory with an appropriate level of bio-containment,*
36 *determined by risk analysis in accordance with Chapter 1.1.4 Biosafety and biosecurity: Standard for*
37 *managing biological risk in the veterinary laboratory and animal facilities.*

38 *Sample materials can be tested by reverse transcription polymerase chain reaction (RT-PCR) or virus*
39 *isolation using susceptible cells to amplify any nucleic acid or live virus that may be present. The*
40 *cultures should preferably be of primary bovine (calf) thyroid, but pig, lamb or calf kidney cells, or cell*
41 *lines of comparable sensitivity may be used. Once cytopathic effect (CPE) is complete in the cultures,*
42 *harvested fluids can be tested for FMDV using enzyme-linked immunosorbent assays (ELISA) or RT-*
43 *PCR. Enzyme-linked immunosorbent assays (ELISA) can also be directly used to detect FMD viral*

44 antigens and for serotyping. Lateral flow devices (LFD) ~~are also becoming more readily available and~~
45 ~~can also be used to detect FMD viral antigens even on-site. The ELISA has replaced complement~~
46 ~~fixation (CF) in most laboratories as it is more specific and sensitive and it is not affected by pro- or~~
47 ~~anti-complement factors. If the sample is inadequate or the diagnosis remains uncertain, sample~~
48 ~~materials can be tested by reverse transcription polymerase chain reaction (RT-PCR) and/or virus~~
49 ~~isolation using susceptible cell to amplify any nucleic acid or live virus that may be present. The~~
50 ~~cultures should preferably be of primary bovine (calf) thyroid, but pig, lamb or calf kidney cells, or cell~~
51 ~~lines of comparable sensitivity may be used. Once a cytopathic effect (CPE) is complete in the~~
52 ~~cultures, harvested fluids can be tested for FMDV using ELISA, CF or RT-PCR.~~

53 **Serological tests:** The demonstration of specific antibodies to nonstructural proteins (NSPs) or
54 structural proteins in nonvaccinated animals is indicative of prior infection with FMDV. This is
55 particularly useful in mild cases or where epithelial tissue cannot be collected. Tests for antibodies to
56 some NSPs of FMDV are useful in providing evidence of previous or current viral replication in the
57 host, irrespective of vaccination status. NSPs, unlike structural proteins, are highly conserved and
58 therefore are not serotype specific and as a consequence, the detection of these antibodies is not
59 serotype restricted.

60 Virus neutralisation tests (VNTs) and ELISAs for antibodies to structural proteins are used as
61 serotype-specific serological tests. VNTs depend on ~~issue cell~~ cultures and are therefore more prone
62 to variability than ELISAs; they are also slower and subject to contamination. ELISAs for detection of
63 antibodies have the advantage of being faster, and are not dependent on cell cultures. The ELISA
64 can be performed with inactivated or recombinant antigens, thus requiring less restrictive
65 biocontainment facilities.

66 **Requirements for vaccines:** Inactivated virus vaccines of varying composition are available
67 commercially. Typically, virus is used to infect a suspension or monolayer cell culture and the
68 resulting preparation is clarified, inactivated with ethyleneimine and concentrated. The antigen is
69 usually blended with oil or aqueous adjuvant for vaccine formulation. Many FMD vaccines are
70 multivalent to provide protection against the different serotypes, or to accommodate antigenic
71 diversity likely to be encountered in a given field situation.

72 The finished vaccine must be shown to be free from residual live virus. This is most effectively done
73 by evaluating the inactivation kinetics and by using in-vitro tests on concentrated inactivated virus
74 preparations prior to formulation of the vaccine and freedom from live virus is subsequently confirmed
75 during in-vivo and/or in-vitro tests on the finished product. Challenge tests are also conducted in
76 vaccinated cattle to establish a PD_{50} (50% protective dose) value or protection against generalised
77 foot infection (PGP), although a serological test, which can be performed to reduce the number of
78 animals being used, is considered to be satisfactory where a valid correlation between protection,
79 and specific antibody response has been established.

80 FMD vaccine production facilities should also have an appropriate level of bio-containment,
81 determined by risk analysis in accordance with Chapter 1.1.4.

82 Diagnostic and reference reagents are available from the WOAHP Reference Laboratories for FMD or
83 the FAO (Food and Agriculture Organization of the United Nations) World Reference Laboratory for
84 FMD (The Pirbright Institute, UK).

85 A. INTRODUCTION

86 Foot and mouth disease (FMD) is caused by a virus of the genus *Aphthovirus*, family *Picornaviridae*. There are
87 seven serotypes of FMD virus (FMDV), namely O, A, C, SAT 1, SAT 2, SAT 3, and Asia 1, that infect cloven-hoofed
88 animals. Infection with any one serotype does not confer immunity against another. Within serotypes, many strains
89 can be identified by biochemical-molecular and immunological tests. Serotype C has not been detected since 2004
90 and is now considered extinct (Paton et al., 2021).

91 Of the domesticated species, cattle, pigs, sheep, goats and water buffalo (*Bubalus bubalis*) are susceptible to FMD
92 (Food and Agricultural Organization of the United Nations [FAO]; 1984). Many species of cloven-hoofed wildlife
93 may become infected, and the virus has occasionally been recovered from other species as well. Amongst the
94 camelidae, Bactrian camels and new world camelids have been shown to be susceptible (Larska et al., 2009). In
95 Africa, SAT serotypes of FMD viruses are often maintained by African buffalo (*Syncerus caffer*). There is periodic
96 spillover of infection into livestock or sympatric cloven-hoofed wildlife. Elsewhere in the world, cattle are usually the

97 main reservoir for FMD viruses, although in some instances the viruses involved appear to be specifically adapted
98 to pigs (such as the pig-adapted Cathay strain of type O FMDV) and that requires cells of porcine origin for primary
99 isolation. Small ruminants can play an important role in the spread of FMDV, but it is not clear whether the virus
100 can be maintained in these species for long periods in the absence of infection of cattle. Strains of FMDV that infect
101 cattle have been isolated from wild pigs, antelope and deer. The evidence indicates that, in the past, infection of
102 deer was derived from contact, direct or indirect, with infected domestic animals, and that apart from African buffalo,
103 wildlife has not, so far, been shown to be able to maintain FMD viruses independently for more than a few months.

104 Infection of susceptible animals with FMDV can lead to the appearance of vesicles on the feet, in and around the
105 oral cavity, and on the mammary glands of females. The vesicles rupture and then heal whilst coronary band lesions
106 may give rise to growth arrest lines that grow down the side of the hoof. The age of lesions can be estimated from
107 these changes as they provide an indicator of the time since infection occurred (Ministry of Agriculture, Fisheries
108 and Food [of the UK], 1986). Mastitis is a common sequel of FMD in dairy cattle. Vesicles can also occur at other
109 sites, such as inside the nostrils and at pressure points on the limbs – especially in pigs. The severity of clinical
110 signs varies with the strain of virus, the exposure dose, the age and breed of animal, the host species and the
111 immunity of the animal. The signs can range from a mild or inapparent infection to one that is severe. Death may
112 result in some cases. Mortality from a multifocal myocarditis is most commonly seen in young animals: myositis
113 may also occur in other sites.

114 On premises with a history of sudden death in young cloven-hoofed livestock, close examination of adult animals
115 may often reveal the presence of vesicular lesions if FMD is involved. The presence of vesicles in fatal cases is
116 variable.

117 ~~In animals with a history of vesicular disease,~~ The detection of FMDV in samples of vesicular fluid, epithelial tissue,
118 oesophageal–pharyngeal (OP) sample, milk, or blood is sufficient to establish a diagnosis. Diagnosis may also be
119 established by the detection of FMDV in the blood, heart or other organs of fatal cases. A myocarditis may be seen
120 macroscopically (the so-called “tiger heart”) in a proportion of fatal cases.

121 FMD viruses may occur in all the secretions and excretions of acutely infected animals, including expired air.
122 ~~Transmission is generally effected~~ occurs by direct contact between infected and susceptible animals or, more
123 rarely, indirect exposure of susceptible animals to the excretions and secretions of acutely infected animals or by
124 consumption of uncooked (meat) products from infected animals. Following recovery from the acute stage of
125 infection, infectious virus disappears, ~~with the exception of~~ however low levels that may persist in the oropharynx
126 of some ruminants. Live virus or viral RNA may continue to be recovered from oropharyngeal fluids and cells
127 collected with a probang cup. FMD virus has also been shown to persist in a non-replicative form in lymph nodes
128 (Juleff *et al.*, 2008). Animals in which the virus persists in the oropharynx for more than 28 days after infection are
129 referred to as carriers. Pigs do not become carriers. Circumstantial evidence indicates, particularly in the African
130 buffalo, that carriers are able, on rare occasions, to transmit the infection to susceptible domestic animals with which
131 they come in close contact: and the mechanism involved is unknown. The carrier state in cattle usually does not
132 persist for more than 6 months, although in a small proportion, it may last up to 3 years. In African buffalo, individual
133 animals have been shown to harbour the virus for at least 5 years, but it is probably not a lifelong phenomenon.
134 Within a herd of buffalo, the virus may be maintained for 24 years or longer. Sheep and goats do not usually carry
135 FMD viruses for more than a few months, whilst there is little information on the duration of the carrier state in Asian
136 buffalo species and subspecies.

137 FMD is considered a negligible zoonotic risk. However, because of its ~~highly~~ very contagious nature for animals
138 and the economic importance of FMD, all laboratory manipulations with live viral cultures or potentially
139 infected/contaminated material such as tissue and blood samples must be performed at an appropriate containment
140 level determined by biorisk analysis (see Chapter 1.1.4 *Biosafety and biosecurity: Standard for managing biological*
141 *risk in the veterinary laboratory and animal facilities*). Countries lacking access to appropriate containment facilities
142 should send specimens to a WOAHP Reference Laboratory. Vaccine production facilities should also meet
143 these containment requirements.

144 Diagnostic and standard reagents are available in kit form or as individual items from WOAHP Reference
145 Laboratories for FMD. The use of inactivated antigens in the enzyme-linked immunosorbent assay (ELISA), as
146 controls in the antigen-detection test or to react with test sera in the liquid-phase blocking or solid-phase competitive
147 ELISA, reduces the disease security risk involved compared with the use of live virus. Reagents are supplied freeze-
148 dried or in glycerol or non-glycerinated but frozen and can remain stable at temperatures between +1°C and +8°C,
149 –30°C and –5°C and –90°C and –50°C, respectively, for many years. There are a number of commercially available
150 diagnostic test kits, for the detection of virus antigens or antibodies.

151

152

B. DIAGNOSTIC TECHNIQUES

153

Table 1. Test methods available for the diagnosis of FMD and their purpose

Method	Purpose					
	Population freedom from infection	Individual animal freedom from infection prior to movement	Contribute to eradication policies	Confirmation of clinical cases	Prevalence of infection – surveillance	Immune status in individual animals or populations post-vaccination
Detection and identification of the agent ^(a)						
Virus isolation	–	+	+++	+++	–	–
Antigen detection ELISA	–	–	+++	+++	–	–
GFT	–	–	+	+	–	–
LFD	–	–	+++	+++	–	–
Real-time RT-PCR	+	+	+++	+++	+	–
<u>Conventional</u> RT-PCR	+	+	+++	+++	+	–
Detection of immune response						
NSP Ab ELISA	+++	++	+++	+++	+++	–
SP Ab ELISA ^(b)	++	++	+++	+++	++	+++
VNT ^(b)	++	++	+++	+++	++	+++
AGID ^(b)	+	+	+	+	+	–

154

Key: +++ = recommended for this purpose; ++ recommended but has limitations;

155

+ = suitable in very limited circumstances; – = not appropriate for this purpose.

156

ELISA = enzyme linked immunosorbent assay; GFT = complement fixation test; LFD: lateral flow device; RT-PCR = reverse-transcriptase polymerase chain reaction; AGID = Agar gel immunodiffusion; NSP Ab ELISA = ELISA for antibodies against nonstructural proteins; SP Ab ELISA = ELISA for antibodies against structural proteins; VNT = Virus neutralisation test.

157

^(a)It is essential to confirm the presence of FMDV following virus isolation by an antigen or nucleic acid detection test.

158

^(b)The tests do not distinguish infected from vaccinated animals.

159

160

161

For laboratory diagnosis, the tissue of choice is epithelium or vesicular fluid. Ideally, at least 1 g of epithelial tissue should be collected from an unruptured or recently ruptured vesicle, usually from the tongue, buccal mucosa or feet. To avoid injury to personnel collecting the samples, as well as for animal welfare reasons, it is recommended that animals be sedated before any samples are obtained.

162

163

164

165

166

167

168

169

170

171

172

173

174

175

Epithelial samples should be placed in a transport medium composed of equal amounts of glycerol and 0.04 M phosphate buffer, pH 7.2–7.6, preferably with added antibiotics (penicillin [1000 International Units (IU)], neomycin sulphate [100 IU], polymyxin B sulphate [50 IU], mycostatin [100 IU]) transport fluid (composed of 0.08 M phosphate buffer containing 0.01% bovine serum albumin, 0.002% phenol red, antibiotics [1000 units/ml penicillin, 100 units/ml mycostatin, 100 units/ml neomycin, and 50 units/ml polymyxin], and adjusted to pH 7.2). If 0.04 M phosphate buffer transport medium is not available, tissue culture medium or phosphate-buffered saline (PBS) can be used instead, but it is important that the final pH of the glycerol/buffer mixture be in the range pH 7.2–7.6. FMDV is extremely labile in low pH and buffering of the transport media is critical for successful sample collection. Samples should be kept refrigerated or on ice until received by the laboratory. In case of a short transportation time and in circumstances where such medium is not present, transporting the samples to the laboratory refrigerated or on ice without transport medium can be considered.

176 Where epithelial tissue is not available from ruminant animals, for example in advanced or convalescent cases, or
177 where infection is suspected in the absence of clinical signs, samples of OP fluid can be collected by means of a
178 probang (sputum) cup (or in pigs by swabbing the throat) for submission to a laboratory for virus isolation or reverse-
179 transcription polymerase chain reaction (RT-PCR). Viraemia may also be detected by examining serum samples
180 by means of RT-PCR or virus isolation. For the collection of throat swabs from pigs up to 25 kg weight, the animal
181 should be held on its back in a wooden cradle with the neck extended. Holding a swab in a suitable instrument,
182 such as an artery forceps, the swab is pushed to the back of the mouth and into the pharynx. For larger pigs, it is
183 recommended that standing animals be restrained by a snare attached to the upper snout and that swab sampling
184 focus on peripheral surfaces in the mouth. Alternative sample matrices for diagnosis may consist of milk (Armson
185 et al., 2018; 2019), swine oral fluids collected with cotton ropes (Hole & Nfon, 2019; Senthilkumaran et al., 2017;
186 Vosloo et al., 2015), and swine meat exudates (Yeo et al., 2020). Samples collected on lateral flow devices (Fowler
187 et al., 2014; Romey et al., 2018) or FTA cards (Abosrer et al., 2022; Biswal et al., 2016) can also tested by RT-
188 PCR.

189 Before the collection of OP samples from cattle or large ruminants (e.g. buffalo), 2 ml transport fluid (composed of
190 0.08 M phosphate buffer containing 0.01% bovine serum albumin, 0.002% phenol red, antibiotics [1000 units/ml
191 penicillin, 100 units/ml mycostatin, 100 units/ml neomycin, and 50 units/ml polymyxin], and adjusted to pH 7.2)
192 should be added to a container of around 5 ml capacity capable of withstanding freezing above dry ice (solid carbon
193 dioxide) or liquid nitrogen (Kitching & Donaldson, 1987).

194 An OP sample is collected by inserting a probang over the tongue into the oro-pharyngeal area and then passing it
195 vigorously backwards and forwards 5–10 times between the first portion of the oesophagus and the back of the
196 pharynx. The purpose is to collect oro-pharyngeal fluid and especially superficial epithelial cells from these areas,
197 including the proximal part of the oesophagus, the walls of the pharynx, the tonsillar crypts and the surfaces of the
198 soft palate. If the sample does not contain adequate cellular debris the actions may be repeated.

199 After collection of OP fluid by probang, the contents of the cup should be poured into a wide-necked transparent
200 bottle of around 20 ml capacity. The fluid is examined and should contain some visible cellular material. Where
201 mucus and cells are mainly attached to the surface of the probang cup, for example after sample collection from
202 small ruminants, a small volume of buffered medium (pH 7.0) may be placed in a wide-necked sample container,
203 into which the head of the probang may be immersed and agitated to detach and collect the sample. Care should
204 be taken not to overdilute the sample with a large volume of medium as this may reduce the probability of virus
205 detection. This fluid is then added to an approximately equal volume of transport fluid, ensuring that cellular material
206 is transferred; the mixture is shaken gently and should have a final pH of around 7.6. Samples contaminated with
207 ruminal contents may be unsuitable for culture. Samples seen to contain blood are not entirely satisfactory. Repeat
208 sampling can be done after the mouth and throat of the animal have been rinsed with water or PBS. Where several
209 animals are to be sampled, the probang must be cleaned and disinfected between each animal. This is done by
210 washing the probang in tap water, immersing it in a suitable disinfectant (e.g. 0.5% [w/v] citric acid in tap water) and
211 then rinsing off all the disinfectant with water before sampling the next animal.

212 OP samples from small ruminants are collected by putting 2 ml of transport fluid into a wide-necked bottle of about
213 20 ml capacity and, after collection, rinsing the probang cup in this transport fluid to discharge the OP sample. This
214 is then transferred to a container of about 5 ml capacity for transport. The small container should be capable of
215 withstanding freezing ~~above~~ in dry ice or liquid nitrogen (e.g. polypropylene, not polystyrene) and be leak-proof
216 (Kitching & Donaldson, 1987).

217 Samples of OP fluid should be refrigerated or frozen immediately after collection. If they are to remain in transit for
218 more than a few hours, they should preferably be frozen by being placed ~~either above~~ in dry ice or liquid nitrogen.
219 Before freezing, the containers should be carefully sealed using airtight screw caps or with silicone film. This is
220 particularly important when using dry ice, as introduction of CO₂ into the OP sample will lower its pH, inactivating
221 any FMDV that may be in the samples. Glass containers and polystyrene vials should not be used because there
222 is a risk that they will explode or crack on defrosting in the event of liquid nitrogen leaking into them. Samples should
223 reach the laboratory in a frozen state or, if this is not feasible, maintained under reliable cold chain conditions during
224 transit.

225 Special precautions are required when sending perishable suspect FMD material both within and between
226 countries. The International Air Transport Association (IATA), Dangerous Goods Regulations (DGR) have explicit
227 requirements for packaging and shipment of diagnostic specimens by ~~all commercial means of transport air~~. These
228 are summarised in Chapter 1.1.2 *Collection, submission and storage of diagnostic specimens* and Chapter 1.1.3
229 *Transport of biological materials*. Forms and guidance on sample submission, packing dangerous goods and
230 specifications for manufacture of probang cups can be found on the website of the Pirbright WOA Reference
231 Laboratory at <https://www.wrlfmd.org/laboratory-protocols>. Procedures (in Spanish) for collection and shipment of
232 field samples for the diagnosis of vesicular diseases and its differential diagnosis can be found at the Pan-American
233 FMD WOA Reference Laboratory in the technical information that is available at
234 <https://www.paho.org/es/panaftosa/laboratorio-referencia> <http://www.panaftosa.org.br>

235 1. Detection and identification of the agent

236 A range of sample types, including vesicular fluids, epithelium, OP samples, milk, serum and heart muscle from
237 cases with myocarditis, may be examined by RT-PCR or virus isolation or RT-PCR. By contrast, ELISA, ~~CF~~ and
238 the lateral flow device (LFD) are suited to the examination of epithelial suspensions, vesicular fluids or infected cell
239 culture supernatants, but are insufficiently sensitive for the direct examination of OP samples or serum. It is essential
240 to confirm the presence of FMDV following virus isolation by an FMDV-specific antigen or nucleic acid detection
241 test. A virus isolate or an RT-PCR product can be further characterised by sequencing, but a viral isolate is needed
242 for some in-vitro serological tests and for in-vivo studies of transmission, virulence and vaccine induced protection.

243 1.1. Virus isolation

244 The epithelium sample should be ~~taken removed~~ from the PBS/glycerol transport media, may be washed
245 at least twice in cell culture medium containing 2% antibiotics to reduce bacterial contamination, blotted
246 dry on absorbent paper to reduce the glycerol content, which is toxic for cell cultures, and weighed. A
247 suspension should be prepared by grinding the sample in sterile sand in a sterile pestle and mortar with
248 a small volume of tissue culture medium (or PBS) and 2% antibiotics. Grinding can also be carried out
249 by a tissue-lyser apparatus. Further medium should be added until a final volume of nine times that of
250 the epithelial sample has been added, giving a 10% suspension. This is clarified on a bench centrifuge
251 at 2000 **g** for 10 minutes. Once clarified, ~~such~~ suspensions of field samples suspected to contain FMDV
252 are inoculated onto cell cultures. Sensitive cell culture systems include primary bovine (calf) thyroid cells
253 and primary pig, calf or lamb kidney cells, but there are challenges associated with sourcing these cells
254 from FMDV-negative animals (particularly in FMD endemic countries), and the costs and time required
255 to regularly prepare batches of cells. Established cell lines, such as BHK-21 (baby hamster kidney), ZZ-
256 R 127 (fetal goat tongue cell line), LFBK- α v β 6 (fetal porcine kidney cell line expressing the bovine integrin
257 receptor) and IB-RS-2 (porcine kidney cell line) cells, may also be used but their sensitivity to field FMD
258 viruses can be variable (Gray *et al.*, 2020) are generally less sensitive than primary cells for detecting
259 low amounts of infectivity. The sensitivity of any cells used should be tested routinely with standard
260 preparations of FMDV to confirm that cells with different passage histories maintain sensitivity to FMDV.
261 It is recommended to determine the maximum number of passages for which a batch of cells can be
262 used. The use of IB-RS-2 cells and LFBK- α v β 6 aids the differentiation of swine vesicular disease virus
263 (SVDV) and Senecavirus A (SVA) from FMDV (as SVDV will usually only grow in cells of porcine origin)
264 and is often essential for the isolation of porcophilic strains, such as FMDV O Cathay. The cell cultures
265 should be examined for cytopathic effect (CPE) for 48 hours. If no CPE is detected, the cells should be
266 frozen and thawed, used to inoculate fresh cultures and examined for CPE for another 48 hours. In the
267 case of OP fluids, pretreatment with an equal volume of chloro-fluoro-carbons may improve the rate of
268 virus detection by releasing virus from immune complexes.

269 Alternatively, FMDV may be rescued by chemical transfection or electroporation of FMD viral RNA into
270 cultured cells (Dill & Eschbaumer, 2019; Romey *et al.*, 2018).

271 1.2. Immunological methods

272 1.2.1. Enzyme-linked immunosorbent assay

273 The ~~preferred main~~ procedure for the detection of FMD viral antigen and identification of viral
274 serotype is the ELISA (Ferris & Donaldson, 1992; Roeder & Le Blanc Smith, 1987). This is an
275 indirect sandwich test in which different rows in multiwell plates are coated with 'capture' rabbit
276 antisera to each of the seven serotypes of FMDV. ~~These are the 'capture' sera.~~ Test sample
277 suspensions are added to each of the rows, and appropriate controls are also included. Guinea-
278 pig antisera to each of the serotypes of FMDV are added next, followed by rabbit anti-guinea-pig
279 serum conjugated to an enzyme. Extensive washing is carried out between each stage to remove
280 unbound reagents. A colour reaction on the addition of enzyme substrate and chromogen
281 indicates a positive reaction. With strong positive reactions, this will be evident to the naked eye,
282 but results can also be read spectrophotometrically at an appropriate wavelength. In this case,
283 an absorbance reading greater than 0.1 above background indicates a positive reaction; the
284 serotype of FMDV can also be identified. In case of cross-reactions between serotypes, (strong)
285 positive samples can be diluted 1/5 and retested. Values close to 0.1 should be confirmed by
286 retesting or by amplification of the antigen by tissue culture passage and testing the supernatant
287 once a CPE has developed. Alternatively, cut-off OD values of 0.1 above background (doubtful,
288 requires retesting or prior amplification) and 0.2 above background (positive) may be used. A
289 suitable protocol is given below. Other protocols are available with slightly different formats and
290 interpretation criteria (Alonso *et al.*, 1993). As an alternative to guinea-pig or rabbit antisera,
291 suitable monoclonal antibodies (MAbs) can be used coated to the ELISA plates as capture
292 antibody or peroxidase-conjugated as detecting antibody (Grazioli *et al.*, 2020).

293 Depending on the species affected and the geographical origin of samples, it may be appropriate
294 to simultaneously test for SVDV, Senecavirus A (SVA) or vesicular stomatitis virus (VSV). Ideally
295 a complete differential diagnosis should be undertaken in all vesicular ~~conditions-cases to obtain~~
296 a final diagnosis.

297 Rabbit antiserum to the 146S antigen of each of the seven serotypes of FMDV (plus SVDV or
298 VSV if required) is used as a trapping antibody at a predetermined optimal concentration in
299 carbonate/bicarbonate buffer, pH 9.6.

300 Control antigens are prepared from selected strains of each of the seven types of FMDV (plus
301 SVDV or VSV if appropriate) grown on monolayer cultures of BHK-21 cells (IB-RS-2 cells for
302 SVDV or VSV). The unpurified supernatants are used and pretitrated on ELISA plates. The final
303 dilution chosen is that which gives an absorbance at the top of the linear region of the titration
304 curve (optical density approximately 2.0), so that the five-fold dilutions of the control antigens
305 used in the test give two additional lower optical density readings from which the titration curve
306 can be derived. PBS containing 0.05% Tween 20 and phenol red indicator is used as a diluent
307 (PBST).

308 Guinea-pig antisera prepared by inoculating guinea-pigs with 146S antigen of one of the seven
309 serotypes of FMDV (plus SVDV or VSV if required) and preblocked with normal bovine serum
310 (NBS) is used as the detecting antibody. Predetermined optimal concentrations are prepared in
311 PBS containing 0.05% Tween 20, and 5% dried, nonfat skimmed milk (PBSTM). Rabbit (or sheep)
312 anti-guinea-pig immunoglobulin conjugated to horseradish peroxidase and preblocked with NBS
313 is used at a predetermined optimum concentration in PBSTM. ~~As an alternative to guinea-pig or~~
314 ~~rabbit antisera, suitable monoclonal antibodies (MAbs) can be used coated to the ELISA plates~~
315 ~~as capture antibody or peroxidase-conjugated as detecting antibody. A validated ready-to-use kit~~
316 ~~is available, based on pre-selected monoclonal antibodies, for detection and serotyping of six of~~
317 ~~the seven FMDV serotypes.~~

318 Validation of diagnostic assays, whether these are (commercial) (MAb-based) kits or in-house
319 methods, should be performed according to Chapter 1.1.6. *Validation of diagnostic assays for*
320 *infectious diseases of terrestrial animals* and the supporting chapters in Section 2.2. *Validation of*
321 *diagnostic tests of this Terrestrial Manual.*

322 1.2.2. Test procedure

- 323 i) ELISA plates are coated with 50 µl/well rabbit antiviral sera in 0.05 M carbonate/bicarbonate
324 buffer, pH 9.6. Rows A to H receive, respectively, antisera to serotypes O, A, C, SAT 1,
325 SAT 2, SAT 3, Asia 1 and SVDV or VSV (optional). In countries from regions where SAT
326 and Asia 1 serotypes have never circulated those serotypes are not routinely included.
- 327 ii) Leave overnight at 4°C in a stationary position or place on an orbital shaker set at 100–
328 120 revolutions per minute in a 37°C incubator for 1 hour.
- 329 iii) Prepare test sample suspension (10% original sample suspension or undiluted clarified cell
330 culture supernatant fluid).
- 331 iv) The ELISA plates are washed five times in PBS.
- 332 v) On each plate, load wells of columns 4, 8 and 12 with 50 µl PBST. Additionally, add 50 µl of
333 PBST to wells 1, 2 and 3 of rows A to H on plate 1. To well 1 of row A of plate 1 add 12.5 µl
334 of control antigen type O, to well 1 of row B add 12.5 µl of control antigen type A; continue
335 in this manner for control antigen of types C, SAT 1, SAT 2, SAT 3, Asia 1 and SVDV or
336 VSV (if appropriate) in order to well 1, rows C to H. Mix diluent in well 1 of rows A to H and
337 transfer 12.5 µl from well 1 to 2 (rows A to H), mix and transfer 12.5 µl from well 2 to 3, mix
338 and discard 12.5 µl from well 3 (rows A to H) (this gives a five-fold dilution series of each
339 control antigen). It is only necessary to change pipette tips on the micropipette between
340 antigens. The remainder of the plate can be loaded with the test sample(s). Add 50 µl of
341 sample one to wells 5, 6 and 7 of rows A to H, the second sample is placed similarly in
342 columns 9, 10 and 11, rows A to H.

343 If more than two samples are to be tested at the same time, the other ELISA plates should
344 be used as follows:

345 Dispense 50 µl of the PBST to the wells (rows A to H) of columns 4, 8 and 12 (buffer control
346 columns). Note that the control antigens are not required on these plates. These test
347 samples may be added in 50 µl volumes in rows A to H to columns 1, 2, 3; 5, 6, 7; 9, 10, 11,
348 respectively.

- 349 vi) Cover with lids and place on an orbital shaker at 37°C for 1 hour.
- 350 vii) Wash the plates by flooding with PBS – wash three times as before and empty residual
351 wash fluid. Blot the plates dry.
- 352 viii) Transfer 50 µl volumes of each guinea-pig serum dilution to each plate well in the
353 appropriate order, e.g. rows A to H receive, respectively, antisera to serotypes O, A, C,
354 SAT 1, SAT 2, SAT 3, Asia 1 and SVDV or VSV (optional).
- 355 ix) Cover the plates with lids and replace on the orbital shaker. Incubate at 37°C for 1 hour.
- 356 x) The plates are washed again three times, and 50 µl of rabbit anti-guinea-pig immunoglobulin
357 conjugated to horseradish peroxidase is added to each well. The plates are incubated at
358 37°C for 1 hour on a rotary shaker.
- 359 xi) The plates are washed again three times, and 50 µl of substrate solution, containing 0.05%
360 % H₂O₂ plus orthophenylene diamine (OPD) or a suitable ~~alternative~~ safer chromogen such
361 as 3,3',5,5' tetramethylbenzidine (TMB), is added to each well.
- 362 xii) The reaction is stopped after 15 minutes by the addition of 50 µl of 1.25 M sulphuric acid.
363 The plates are read at an appropriate wavelength on a spectrophotometer linked to a
364 computer. For example, 492 nm on a spectrophotometer linked to a computer for OPD and
365 450 nm for TMB.

366 1.2.3. Lateral flow device test

367 There are commercially available pan-serotype or serotype-specific lateral flow devices (LFD) for
368 the detection of FMDV antigens in the field (Ferris *et al.*, 2009), but the OIE has not yet received
369 a validation dossier for these tests. As soon as a dossier is received, the manufacturer could
370 apply for inclusion on the OIE test register. Currently one ready-to-use LFD kit¹, validated for the
371 detection of FMDV from East Asia of serotypes O, A and Asia-1 in epithelium samples or fluid
372 from blisters or ruptured lesions of suspected swine or cattle, has been certified by WOA as fit
373 for purpose for a period of 5 years. Validation of test kits should be performed according to
374 Chapter 1.1.6 and the supporting chapters in Section 2.2. Validation of diagnostic tests of this
375 Terrestrial Manual. The results obtained with non-certified LFDs should thus be confirmed by
376 validated laboratory assays. LFDs can be shipped to the laboratory and used for molecular
377 detection and characterisation of FMDV (Fowler *et al.*, 2014; Romey *et al.*, 2018).

378 1.2.4. Complement fixation test

379 In general, the ELISA is preferable to the complement fixation test (CFT) because it is more
380 sensitive and it is not affected by pro- or anti-complementary factors (Ferris & Dawson, 1988). If
381 ELISA reagents are not available, or if subtyping is pursued, the CFT may be performed as
382 follows:

383 The CF50% protocol in tubes used widely in South America for typing, subtyping and for
384 establishing serological relationships (r values) is performed as follows: 0.2 ml antiserum to each
385 FMDV serotype diluted at a predetermined optimal dilution in veronal buffer diluent (VBD) or
386 borate-saline solution (BSS) is placed in separate tubes. To these, 0.2 ml of test sample
387 suspension is added, followed by 0.2 ml of a complement dilution containing 4 units of
388 complement. The test system is incubated at 37°C for 30 minutes prior to the addition of 0.4 ml
389 2% standardised sheep red blood cells (SRBC) in VBD or BSS sensitised with rabbit anti-SRBC.
390 The reagents are incubated at 37°C for further 30 minutes and the tubes are subsequently
391 centrifuged and read. Samples with less than 50% haemolysis are considered positive.

392 Other protocols performed in microplates are available and are performed as follows: antisera to
393 each of the seven types of FMDV are diluted in VBD in 1.5-fold dilution steps from an initial 1/16
394 dilution to leave 25 µl of successive antiserum dilutions in U-shaped wells across a microtitre
395 plate. To these are added 50 µl of 3 units of complement, followed by 25 µl of test sample
396 suspension(s). The test system is incubated at 37°C for 1 hour prior to the addition of 25 µl of
397 1.4% SRBC in VBD sensitised with 5 units of rabbit anti-SRBC. The reagents are incubated at
398 37°C for a further 30 minutes and the plates are subsequently centrifuged and read. Appropriate
399 controls for the test suspension(s), antisera, cells and complement are included. CF titres are
400 expressed as the reciprocal of the serum dilution producing 50% haemolysis. A CF titre ≥36 is
401 considered to be a positive reaction. Titre values of 24 should be confirmed by retesting an
402 antigen that has been amplified through tissue culture passage.

¹ [vdrq-fmdv-3diff-pan-ag-rapid-kit-1.pdf \(woah.org\)](http://vdrq-fmdv-3diff-pan-ag-rapid-kit-1.pdf)

403

1.3. Nucleic acid recognition-detection methods

404 RT-PCR can be used to amplify genome fragments of FMDV in a wide range of diagnostic materials
405 including vesicular fluids, epithelium, milk, serum, whole blood and OP samples. Real-time RT-PCR ~~has~~
406 ~~a sensitivity comparable to that of virus isolation is very sensitive~~ and automated procedures enhance
407 sample throughput (Reid *et al.*, 2003). ~~Serotyping primers have also been developed (Vangrype &~~
408 ~~De Clercq, 1996)~~ Simplified RT-PCR systems for potential field-use ~~are under development have been~~
409 ~~developed (Callahan *et al.*, 2002; Goller *et al.*, 2018; Hole & Nfon, 2019; Howson *et al.*, 2018).~~

410

1.3.1. Agarose gel-based Conventional RT-PCR assay

411 A gel-based RT-PCR procedure is described (Reid *et al.*, 2000). The RT-PCR assay consists of
412 the three successive procedures of (i) extraction of template RNA from the test or control sample
413 followed by (ii) RT of the extracted RNA, (iii) PCR amplification of the RT product and (iv) detection
414 of the PCR products by agarose gel electrophoresis.

415

1.3.2. Test procedure

- 416 i) Add 200 µl of test sample to 1 ml of RNA extraction reagent in a sterile tube. Store at
417 -70°C until required for RNA extraction.
- 418 ii) Transfer 1 ml of the solution from i) into a fresh, sterile tube containing 200 µl of chloroform.
419 Vortex mix for about 10–15 seconds and leave at room temperature for 3 minutes.
- 420 iii) Centrifuge for 15 minutes at 20,000 **g**.
- 421 iv) Transfer 500 µl of the aqueous phase into a fresh, sterile tube containing 1 µl of glycogen
422 (20 mg/ml) and add 500 µl of iso-propyl-alcohol (propan-2-ol). Vortex mix for a few seconds.
- 423 v) Leave at room temperature for 10 minutes then centrifuge for 10 minutes at 20,000 **g**.
- 424 vi) Carefully discard the supernatant fluid from each tube taking care not to dislodge or lose
425 any pellet at the bottom of the tube. Add 1 ml of 70% ethanol and vortex mix for a few
426 seconds.
- 427 vii) Centrifuge for 10 minutes at 20,000 **g**.
- 428 viii) Carefully remove the supernatant fluid from each tube taking care not to dislodge or lose
429 any pellet at the bottom of the tube.
- 430 ix) Air dry each tube at room temperature for 2–3 minutes.
- 431 x) Resuspend each pellet by adding 20 µl of nuclease-free water to the tube.
- 432 xi) Keep the extracted RNA samples on ice if the RT step is about to be performed. Otherwise
433 store at -70°C.

434 NOTE: As an alternative to phenol/chloroform, RNA extraction can be performed using
435 commercially available kits based on chaotropic salt lysis and silica RNA affinity. The RNA
436 can be extracted through both manual and (semi-)automated techniques.

- 437 xii) For each sample to be assayed, add 2 µl of random hexamers (20 µg/ml) and 5 µl of
438 nuclease-free water into a sterile 0.5 ml microcentrifuge tube. It is recommended to prepare
439 the dilution in bulk for the total number of samples to be assayed but allowing for one extra
440 sample.
- 441 xiii) Add 5 µl of RNA from the extraction procedure described above to give a volume of 12 µl in
442 each tube. Mix by gently pipetting up and down.
- 443 xiv) Incubate at 70°C for 5 minutes.
- 444 xv) Cool at room temperature for 10 minutes.
- 445 xvi) During the 10-minute incubation period, prepare the RT reaction mixture described below
446 for each sample. Prepare the reaction mixture in bulk in a sterile 1.5 ml microcentrifuge tube
447 for the number of samples to be assayed plus one extra sample.
- 448 First strand buffer, 5× conc. (4 µl); bovine serum albumin (acetylated), 1 mg/ml (2 µl);
449 dNTPs, 10 mM mixture each of dATP, dCTP, dGTP, dTTP (1 µl); DTT, 1 M (0.2 µl); Moloney
450 Murine Reverse Transcriptase, 200 U/µl (1 µl).
- 451 xvii) Add 8 µl reaction mix to the 12 µl of random primer/RNA mix. Mix by gently pipetting.
- 452 xviii) Incubate at 37°C for 45 minutes.

- 453 xix) Keep the RT products on ice if the PCR amplification step is about to be performed,
454 otherwise store at -20°C .
- 455 xx) Prepare the PCR mix described below for each sample. It is recommended to prepare the
456 mix in bulk for the number of samples to be tested plus one extra sample.
- 457 Nuclease-free water (35 μl); PCR reaction buffer, 10x conc (5 μl); MgCl_2 , 50 mM (1.5 μl);
458 dNTPs, 10 mM mixture each of dATP, dCTP, dGTP, dTTP (1 μl); forward primer-4,
459 10 pmol/ μl (1 μl); reverse primer-2, 10 pmol/ μl (1 μl); *Taq* Polymerase, 5 units/ μl (0.5 μl).
- 460 xxii) Add 45 μl of PCR reaction mix to a well of a PCR plate or to a microcentrifuge tube for each
461 sample to be assayed followed by 5 μl of the RT product to give a final reaction volume of
462 50 μl .
- 463 xxiii) Spin the plate or tubes for 1 minute in a suitable centrifuge to mix the contents of each well.
- 464 xxiii) Place the plate in a thermal cycler for PCR amplification and run the following programme:
- 465 94 $^{\circ}\text{C}$ for 5 minutes: 1 cycle;
466 94 $^{\circ}\text{C}$ for 1 minute, 55 $^{\circ}\text{C}$ for 1 minute, 72 $^{\circ}\text{C}$ for 2 minutes: 30 cycles;
467 72 $^{\circ}\text{C}$ for 7 minutes: 1 cycle.
- 468 Times and temperatures may need to be optimised to the particular enzymes, reagents and
469 PCR equipment used in individual laboratories.
- 470 xxiv) Mix a 20 μl aliquot of each PCR reaction product with 4 μl of staining solution and load onto
471 a 1.5% agarose gel. After electrophoresis a positive result is indicated by the presence of a
472 328 bp band corresponding to FMDV sequence in the 5' untranslated region of the genome.

473 1.3.3. Stock solutions

- 474 i) Nuclease-free water, RNA extraction reagent, chloroform, glycogen, iso-propyl-alcohol
475 (propan-2-ol), ethanol, random hexanucleotide primers, First, strand buffer, BSA
476 (acetylated), dNTPs, DTT, Moloney Murine Reverse Transcriptase, PCR reaction buffer
477 (10x), MgCl_2 and *Taq* Polymerase are commercially available.
- 478 ii) Primers at a concentration of 10 pmol/ μl : Forward primer-4 sequence 5'-GCCTG-GTCTT-
479 TCCAG-GTCT-3' (positive strand); Reverse primer 2-sequence 5'-CCAGT-CCCCT-TCTCA-
480 GATC-3' (negative strand).

481 1.3.4. Real-time RT-PCR assay

482 Real-time RT-PCR assays employ total RNA extracted from the test or control samples followed
483 by RT and subsequent PCR amplification of the extracted RNA. The real-time RT-PCR assay can
484 use the same procedures of extraction of total RNA from the test or control sample followed by
485 RT of the extracted RNA as for the conventional agarose gel-based procedure. Automated
486 extraction of total nucleic acid from samples followed by automated pipetting programmes for the
487 RT and PCR steps (Reid *et al.*, 2003) can be used as an alternative to the manual procedures
488 described above. PCR amplification of the RT product is performed by a different procedure. A
489 These simpler one-step methods for combining that combine the RT and PCR steps has also
490 been described (Shaw *et al.*, 2007) and is are widely used by laboratories. Detection of the PCR
491 products in agarose gels is not required following real-time amplification.

- 492 i) Take the RT products from step xix (see above). Extract RNA from the sample according to
493 a locally validated method or a protocol provided by a WOA Reference Laboratory for
494 FMD. NB: Different methods for RNA extraction (manual, commercial conventional column
495 or magnetic bead-based rapid RNA extraction methods) are available and selection of an
496 appropriate method needs to consider the assay sensitivity.
- 497 ii) Prepare the RT-PCR reaction mix described below for each sample containing the one-tube
498 RT-PCR reaction master mix, real-time PCR forward primer, 10 pmol/ μl ; real-time PCR
499 reverse primer, 10 pmol/ μl ; labelled probe, 5 pmol/ μl , with the remaining volume
500 accommodated by nuclease-free water. Again It is recommended to prepare the mix in bulk
501 for the number of samples to be tested plus one extra sample: nuclease-free water (6 μl);
502 PCR reaction master mix, 2x conc. (12.5 μl); real-time PCR forward primer, 10 pmol/ μl
503 (2.25 μl); real-time PCR reverse primer, 10 pmol/ μl (2.25 μl); labelled probe, 5 pmol/ μl (1 μl).
- 504 iii) Add 24-20 μl RT-PCR reaction mix to a well of a real-time PCR plate or to a PCR tube for
505 each sample to be assayed followed by 4-5 μl of the RT product extracted RNA to give a
506 final reaction volume of 25 μl . NB: Final reaction volumes used in the test can vary according
507 to the source of the commercial one-step RT-PCR master mix.

508 iv) Spin the plate/tube for 1 minute in a suitable centrifuge to ~~mix the contents of each well~~
509 ensure that the fluids are at the bottom of the wells/tubes.

510 v) Place the plate/tube in a real-time PCR machine for RT and PCR amplification and run the
511 following programme:

512 50°C for ~~2-15~~ minutes: 1 cycle;
513 95°C for ~~40-2~~ minutes: 1 cycle;
514 95°C for 15 seconds, 60°C for 1 minute: 50 cycles.

515 Times and temperatures may need to be optimised to the particular enzymes, reagents and
516 PCR equipment used in individual laboratories.

517 vi) *Reading the results:* Assign a threshold cycle (C_T) value to each PCR reaction from the
518 amplification plots after verification of the sigmoidal shape of the plot and establishment of
519 the baseline (a plot of the fluorescence signal versus cycle number; different cut-off values
520 may be appropriate for different sample types; Parida *et al.*, 2007). The C_T values used to
521 assign samples as either FMDV positive, or negative, “borderline” or doubtful should be
522 defined by individual laboratories using appropriate reference material. ~~For example at the~~
523 ~~OIE Reference Laboratory at Pirbright, negative test samples and negative controls should~~
524 ~~have a C_T value at >50.0. Positive test samples and positive control samples should have~~
525 ~~a C_T value <40. Samples with C_T values falling within the range 40–50 are designated~~
526 ~~“borderline” and can or doubtful should be retested. Strong positive FMD samples have a~~
527 ~~C_T value below 20.0 (Reid *et al.*, 2001).~~

528 Simultaneous detection in a duplex format of an internal quality control, such as β -actin, can be
529 performed to verify PCR performance, sample quality and performance of the RNA extraction,
530 and is thus a preventative measure against false-negative results (Gorna *et al.*, 2016; Moniwa *et*
531 *al.*, 2007). A positive amplification control can be synthesised and used to detect potential false-
532 positive results due to contamination if a wild-type virus is used as positive control (Moniwa *et al.*,
533 2007).

534 1.3.5. Stock solutions for real-time PCR assay

535 i) Nuclease-free water and real-time PCR reaction master mixes are available from
536 commercial suppliers.

537 ii) ~~Either~~ Any of the ~~two~~ following primers and probe sets can be used for real-time PCR of
538 FMDV:

539 5'UTR (Reid *et al.*, 2001) Forward primer: CACYT-YAAGR-TGACA-YTGRT-ACTGG-TAC;
540 Reverse primer: CAGAT-YCCRA-GTGWG-ICITG-TTA and labelled probe: CCTCG-
541 GGGTA-CCTGA-AGGGC-ATCC.

542 3D (Callahan *et al.*, 2002) Forward primer: ACTGG-GTTTT-ACAAA-CCTGT-GA; Reverse
543 primer: GCGAG-TCCTG-CCACG-GA and labelled probe: TCCTT-TGCAC-GCCGT-
544 GGGAC.

545 3D (Moniwa *et al.*, 2007) Forward primer: ACTGG-GTTTT-AYAAA-CCTGT-GATG; Reverse
546 primer: TCAAC-TTCTC-CTGKA-TGGTC-CCA and labelled probe: ATCCT-CTCCT-
547 TTGCA-CGC.

548 Addition of nonspecific tail sequences to the 5'-terminus of these primers improves the
549 robustness and overall performance of the real-time PCR assays, in particular of the 5'UTR
550 assay (Vandenbussche *et al.*, 2016; 2017).

551 RT-PCR assays should meet the WOAHS Standards for validation (Chapter 1.1.6 and the
552 supporting chapters in Section 2.2. *Validation of diagnostic tests of this Terrestrial Manual*)
553 and should be able to detect a broad spectrum of globally circulating FMDV strains.

554 1.3.6. Molecular epidemiology

555 The molecular epidemiology of FMD is based on the comparison of genetic differences between
556 viruses. Dendrograms showing the genomic relationship between vaccine and field strains for all
557 seven serotypes based on sequences derived from the 1D gene (encoding the VP1 viral protein)
558 have been published (Knowles & Samuel, 2003; see also <https://www.wrlfmd.org/>). A list of FMDV
559 prototype strains that can form the basic reference points of a phylogenetic tree is available
560 at: <https://foot-and-mouth.org/FMDV-nomenclature-working-group/prototype-strains>. VP1
561 sequencing can also be used as an alternative method for serotyping by immunological methods.

562 In areas where the circulating lineages of FMDV are well known and where sequencing capability
563 is difficult to access, lineage-specific real-time RT-PCR assays can allow for rapid
564 characterisation at a relatively low cost (Bachanek-Bankowska *et al.*, 2016; Chestley *et al.*, 2022;
565 Saduakassova *et al.*, 2023). Comparison of whole genome sequences can provide further
566 discrimination between closely related viruses and help to recreate the transmission pathways
567 between farms within outbreaks (Cottam *et al.*, 2008). RT-PCR amplification of FMDV RNA,
568 followed by nucleotide sequencing, is the current preferred option for generating the sequence
569 data to perform these comparisons. Many laboratories have developed molecular techniques for
570 performing these studies, and WOAH Reference Laboratories hold databases containing ~~over~~
571 6000 partial several thousands of FMDV sequences.

572 The recommended method for VP1 analysis ~~Sanger sequencing~~ is to:

- 573 i) ~~Extract-Purify~~ FMDV RNA directly from epithelial suspensions or from a low passage cell
574 culture passage material.
- 575 ii) Perform an RT-PCR of the complete 1D gene (or if only part of the 1D gene, then the 3' end
576 of the gene is more useful).
- 577 iii) Determine the nucleotide sequence of the PCR product (or at least 170 nucleotides
578 [preferably 420 for the SAT types] at the 3' end of the gene).

579 A protocol complete with primer sequences, is available (Knowles *et al.*, 2016) ~~or can be~~
580 ~~downloaded from the following World Wide Web URLs at:~~ [https://www.wrlfmd.org/laboratory-](https://www.wrlfmd.org/laboratory-protocols/vp1-sequencing)
581 [protocols/vp1-sequencing](http://bvs.panaftosa.org.br/) <http://bvs.panaftosa.org.br/>

582 Other methods to obtain full or partial FMDV VP1 sequences by Sanger sequencing are described
583 by Dill *et al.* (2017) and Amaral-Doel *et al.* (1993), respectively.

584 Full genome FMDV sequences can be obtained by either Sanger sequencing (Carrillo *et al.*, 2005;
585 Cottam *et al.*, 2008; Dill *et al.*, 2017), or by high-throughput sequencing (Logan *et al.*, 2014).

586 2. Serological tests

587 Serological tests for FMD are performed in support of four main purposes namely: 1) to certify individual animals
588 prior to import or export (i.e. for trade); 2) to confirm suspected cases of FMD; 3) to substantiate absence of infection;
589 4) to demonstrate the efficacy of vaccination. For substantiating freedom from infection, different approaches are
590 required according to whether the population has been vaccinated or not and if vaccination has been used, whether
591 this has been applied as an emergency application or as part of an ongoing programme of vaccination. Different
592 tests and different interpretations of test results will be appropriate according to the above-mentioned purposes and
593 the validation of the selected procedure must take account of the purpose. For example, test cut-offs may be set at
594 a different threshold for herd-based serosurveillance than is appropriate for certifying freedom from infection for
595 individual animals for the purposes of international trade.

596 Serological tests for FMD are of two types; those that detect antibodies to viral structural proteins (SP) and those
597 that detect antibodies to viral nonstructural proteins (NSPs).

598 The SP tests are relatively serotype-specific and detect antibodies elicited by vaccination and infection; examples
599 are the virus neutralisation test (VNT) (Golding *et al.*, 1976), the solid-phase competition ELISA (SPCE; Brocchi *et al.*,
600 *et al.*, 1990; Chenard *et al.*, 2003; Mackay *et al.*, 2001; Paiba *et al.*, 2004) and the liquid-phase blocking ELISA (LPBE;
601 Hamblin *et al.*, 1986; 1987). These tests are highly sensitive, ~~providing that provided~~ the virus or antigen used in
602 the test is closely matched to the strain circulating in the field. ~~They~~ These are the tests used to certify animals prior
603 to movement, including for international trade purposes, ~~and are appropriate for~~ confirming previous or ongoing
604 infection in nonvaccinated animals ~~as well as for~~ and monitoring the immunity conferred by vaccination in the field.
605 The VNT requires cell culture facilities, the use of live virus and takes 2–3 days to provide results. The ELISAs are
606 blocking- or competition-based assays that use serotype-specific polyclonal antibodies (PABs) or MAbs, are quicker
607 to perform and are not dependent on tissue culture systems and the use of live viruses. The SP ELISAs can be
608 cross-reactive between serotypes and caution must be taken when they are used for surveillance where multiple
609 FMDV serotypes may be circulating (Ludi *et al.*, 2022). Furthermore, low titre false-positive reactions can be
610 expected in a small proportion of the sera in either ELISA formats. An approach combining screening by ELISA and
611 confirming the positives by the VNT minimises the occurrence of false-positive results. Reference sera to
612 standardise FMD SP serological tests for some serotypes and subtypes are available from the WOAHP Reference
613 Laboratory at Pirbright.

614 The detection of antibody to the NSPs of FMDV can be used to identify past or present infection with any of the
615 seven serotypes of the virus, whether or not the animal has also been vaccinated. Therefore, the tests can be used

616 to confirm suspected cases of FMD and to evaluate prevalence of infection or to substantiate freedom from infection
617 on a population basis. For certifying animals for trade, the tests have the advantage over SP methods that the
618 serotype of virus does not have to be known. However, there is experimental evidence that some cattle, vaccinated
619 and subsequently challenged with live virus and confirmed persistently infected, may ~~not be detected in some anti-~~
620 ~~NSP tests, causing give~~ false-negative results (Brocchi *et al.*, 2006). These assays measure antibody to NSPs
621 using antigens produced by recombinant techniques in a variety of *in-vitro* expression systems. Antibody to the
622 polyproteins 3AB or 3ABC are generally considered to be the most reliable indicators of infection (Mackay *et al.*,
623 1997). In animals seropositive for antibody to 3AB or 3ABC, antibody to one or more of the other NSPs can aid in
624 the final interpretation of the test (Bergmann *et al.*, 2000; Mackay *et al.*, 1997). However, lack of vaccine purity ~~may~~
625 ~~affect diagnostic specificity as the presence of NSPs in some vaccine preparations may result in the presence of~~
626 ~~antibodies to NSPs in misclassification in animals that have been repeatedly vaccinated, potentially leading to~~
627 ~~misclassification of the animals as FMDV infected.~~ Procedures for evaluating vaccine purity are covered in Section
628 D of this chapter.

629 International standard sera for testing of cattle have been developed and are among others available from the
630 WOA Reference Laboratories in Brazil and UK (Campos *et al.*, 2008). ~~In the future, Standard sera will be~~ also be
631 ~~made~~ available for sheep and pigs. Bovine serum panels have also been established to compare the sensitivity of
632 NSP tests (Parida *et al.*, 2007).

633 2.1. Virus neutralisation test

634 The quantitative VNT ~~microtest~~ for antibodies to FMDV ~~antibody~~ is performed with IB-RS-2, BHK-21,
635 lamb or pig kidney cells in flat-bottomed tissue-culture grade microtitre plates.

636 Stock virus is grown in cell monolayers and stored at -20°C after the addition of 50% glycerol- (virus has
637 been found to be stable under these conditions for at least 1 year-) or stored at -70°C or colder. To
638 decrease complement activity, the sera are ~~inactivated~~ placed in a water bath at 56°C for 30 minutes
639 before testing. The control standard serum is 24-day well-characterised convalescent or post-vaccination
640 serum. A suitable medium ~~is~~ can be Eagle's complete medium/LYH (Hank's balanced salt solution with
641 yeast lactalbumin hydrolysate) with HEPES buffer and antibiotics.

642 The test is an equal volume test in 50 μl amounts.

643 2.1.1. Test procedure

- 644 i) Starting from a 1/4 dilution, sera are diluted in a twofold, dilution series down or across the
645 plate, using at least two ~~rows of wells~~ per serum, ~~preferably four rows,~~ dilution and a volume
646 of 50 μl .
- 647 ii) ~~Previously titrated~~ Virus with a known titre is added; each 50 μl ~~unit~~ volume of virus
648 suspension should ideally contain about 100 TCID₅₀ (50% tissue culture infective dose)
649 within an accepted range (e.g. 32–320 TCID₅₀). A back titration must be carried out at the
650 time of testing to ensure that the virus dose used to neutralise the sera falls within the
651 accepted range of 32–320 ($10^{1.5}$ – $10^{2.5}$) TCID₅₀.
- 652 iii) Controls should include a standard antiserum of known titre, a cell control and a medium
653 control, ~~and a virus titration used to calculate the actual virus titre used in the test.~~
- 654 iv) Incubate at 37°C for 1 hour with the plates covered.
- 655 v) A cell suspension ~~at of~~ approximately 10^6 cells/ml is made up in medium containing 10%
656 bovine serum (specific antibody negative) for cell growth. A volume of 50 μl of cell
657 suspension is added to each well.
- 658 vi) Plates are sealed ~~with pressure sensitive tape~~ and incubated at 37°C for 2–3 days.
659 Alternatively, the plates may be covered with loosely fitting lids and incubated in an
660 atmosphere of 3–5% carbon dioxide at 37°C for 2–3 days.
- 661 vii) Microscope readings may be feasible after 48 hours. The plates ~~are finally~~ can be fixed and
662 stained ~~routinely~~ on the third day. Fixation is effected with 10% formal/saline for 30 minutes.
663 For staining, the plates are immersed in 0.05% methylene blue in 10% formalin for
664 30 minutes. An alternative fixative/stain solution is naphthalene blue black solution (0.4%
665 [w/v] naphthalene blue black, 8% [w/v] citric acid in saline). The plates are rinsed in tap water
666 if deemed non-infectious by local risk assessments.
- 667 viii) Positive wells (where the virus has been neutralised and the cells remain intact) are seen to
668 contain blue-stained cells sheets; the negative wells (where virus has not been neutralised)
669 are completely or partially empty. Titres are expressed as the final dilution of serum present
670 in the serum/virus mixture where 50% of wells are protected (Kärber, 1931). The test is

671 considered to be valid when the back-titration of the virus confirms that the amount of virus
672 used per well is in the range $\log_{10} 1.5 - 2.5$ TCID₅₀ of 32-320 ($10^{1.5} - 0^{2.5}$) TCID₅₀ and the
673 positive standard serum is within twofold of its expected titre.

674 ix) Interpretation of tests can vary between laboratories in regard to the negative/positive cut-
675 off threshold. Laboratories should establish their own criteria by reference to standard
676 reagents that can be obtained from the WOAHP Reference Laboratory at Pirbright. In general,
677 a titre of 1/45 or more of the final serum dilution in the serum/virus mixture is regarded as
678 positive. A titre of less than 1/16 is considered to be negative. For certification of individual
679 animals for the purposes of international trade, titres of 1/16 to 1/32 are considered to be
680 doubtful, and further serum samples may be requested for testing; results are considered to
681 be positive if the second sample has a titre of 1/16 or greater. For the purposes of herd-
682 based serosurveillance as part of a statistically valid serological survey, a cut-off of 1/45 may
683 be appropriate. Cut-off titres for evaluating immunological protection afforded by vaccination
684 have to be established from experience of potency test results with the relevant vaccine and
685 target species.

686 2.2. Solid-phase competition enzyme-linked immunosorbent assay

687 The method described (Paiba *et al.*, 2004) can be used for the detection of antibodies against each of
688 the seven serotypes of FMDV. As an alternative to guinea-pig or rabbit antisera, suitable monoclonal
689 antibodies (MAbs) can be used coated to the ELISA plates as capture antibody or peroxidase-conjugated
690 as detecting antibody (Brocchi *et al.*, 1990). Commercial kits based on monoclonal antibodies-MAbs are
691 available from different manufacturers for serotype O (Chenard *et al.*, 2003), serotype A, serotype Asia
692 1, serotype SAT-1 and serotype SAT-2 with a in different formats but with similar performance
693 characteristics (Ludi *et al.*, 2022). Validation of test kits should be performed according to Chapter 1.1.6
694 and the supporting chapters in Section 2.2. Validation of diagnostic tests of this Terrestrial Manual.

695 Serotype-specific rabbit antiserum to the 146S antigen of one of the seven types of-FMDV is used as the
696 trapping antibody at a predetermined optimal concentration in carbonate/bicarbonate buffer, pH 9.6.

697 Antigens are prepared by inactivating viruses propagated in cell culture with ethyleneimine using the
698 procedures described for vaccine manufacture. The final dilution chosen is that which, after addition of
699 an equal volume of diluent, gives an absorbance on the upper part of the linear region of the titration
700 curve (optical density approximately 1.5). PBS containing 0.05% Tween 20, 10% NBS and 5% normal
701 rabbit serum and phenol red indicator is used as a diluent (blocking buffer).

702 Serotype-specific guinea-pig antisera, prepared by inoculating guinea-pigs with 146S antigen of one of
703 the seven serotypes FMDV and preblocking with normal bovine serum (NBS), is used as the detecting
704 antibody. Predetermined optimal concentrations are prepared in blocking buffer (PBS containing 0.05%
705 Tween 20, and 5% dried, nonfat skimmed milk [PBSTM]).

706 Rabbit (or sheep) anti-guinea-pig immunoglobulin conjugated to horseradish peroxidase and preblocked
707 with NBS is used as conjugate at a predetermined optimum concentration in PBSTM blocking buffer.

708 Test sera are diluted in PBST blocking buffer.

709 The solid-phase competitive ELISA is more specific but as sensitive as the liquid-phase blocking ELISA
710 (Mackay *et al.*, 2001; Paiba *et al.*, 2004). Methods have been described for the development of secondary
711 and working standard sera (Goris & De Clercq, 2005a) and for charting assay performance (Goris & De
712 Clercq, 2005b).

713 2.2.1. Test procedure

714 i) ELISA plates are coated with 50 µl/well rabbit antiserum homologous to the antigen being
715 used, diluted in carbonate/bicarbonate buffer, pH 9.6, and left overnight in a humid chamber
716 at 4°C.

717 ii) The ELISA plates are washed three times with PBS.

718 iii) Then 50 µl of the FMDV antigen diluted in blocking buffer is added to each well of the ELISA
719 plates (blocking buffer: 0.05% [w/v] Tween 20, 10% [v/v] NBS, 5% [v/v] normal rabbit serum).
720 The plates are covered and placed on an orbital shaker at 37°C for 1 hour, with continuous
721 shaking.

722 iv) After washing three times with PBS, 40 µl of blocking buffer is added to each well, followed
723 by 10 µl of test sera (or control sera), giving an initial serum dilution of 1/5.

- 724 v) Immediately 50 µl of guinea-pig anti-FMDV antiserum diluted in blocking buffer is added,
725 giving a final serum dilution of 1/10.
- 726 vi) The plates are covered and incubated on an orbital shaker at 37°C for 1 hour.
- 727 vii) After washing three times with PBS, 50 µl of anti-guinea-pig Immunoglobulin conjugate
728 (preblocked by incubation for 1 hour at room temperature with an equal volume of NBS)
729 diluted in blocking buffer is added. The plates are covered and incubated for 1 hour at 37°C
730 on an orbital shaker.
- 731 viii) After washing three times with PBS, 50 µl of substrate solution, containing 0.05% H₂O₂ plus
732 orthophenylene diamine or a suitable alternative chromogen, is added to each well.
- 733 ix) The reaction is stopped after 10 minutes by the addition of 50 µl of 1 M sulphuric acid. The
734 plates are read at 492 nm on a spectrophotometer linked to a computer.
- 735 x) *Controls:* On each plate two wells are used for conjugate control (no guinea-pig serum), four
736 wells each for strong and weak positive sera, two wells for negative sera, and four wells for
737 0% competition (no test sera).
- 738 xi) *Interpretation of the results:* A percentage of inhibition is calculated for each well, either
739 manually or using a suitable computer programme (100 – [optical density of each test or
740 ~~value sera~~/mean optical density of the 0% competition] × 100%), representing the
741 competition between the test sera and the guinea-pig anti-FMDV antisera for the FMDV
742 antigen on the ELISA plate. Laboratories should validate the assay in terms of the cut-off
743 value above which sera should be considered positive in relation to (i) the particular
744 serotypes and strains of virus under investigation (ii) the purpose of testing (iii) the
745 population under test, using the methods described in Chapter 1.1.6 *Validation of diagnostic*
746 *assays for infectious diseases of terrestrial animals. This cut-off value for a positive result*
747 *can either be a fixed or dynamic value. In the latter case this cut-off value is calculated for*
748 *each individual test based on the per cent competition obtained for strong positive, weak*
749 *positive, cut-off and negative working standards (Goris & De Clercq, 2005a). Working*
750 *standards are also used for monitoring and charting cross-session assay performance*
751 *(Goris & De Clercq, 2005b). At the WOA Reference Laboratory at Pirbright, for serotype*
752 *O, for all species, for the purposes of demonstrating freedom from infection in a naïve*
753 *population, greater than 60% inhibition is considered positive (Paiba et al., 2004). For*
754 *maximum sensitivity, for example when certifying individual animals for international trade,*
755 *an inconclusive range may be set between 40 and 60%.*

756 2.3. Liquid-phase blocking enzyme-linked immunosorbent assay

757 Antigens are prepared from selected strains of FMDV grown on monolayers of BHK-21 cell cultures. The
758 unpurified supernatants are used and pre-titrated in a twofold dilution series but without serum. The final
759 dilution chosen is that which, after addition of an equal volume of diluent (see below), gives an
760 absorbance on the upper part of the linear region of the titration curve (optical density approximately
761 1.5). PBS containing 0.05% Tween 20 and phenol red indicator is used as a diluent (PBST). The other
762 reagents used in the test are the same as those in the solid-phase ~~blocking-competition~~ ELISA. An
763 example of the test procedure is described below. Temperature and incubation times can vary depending
764 on the protocol.

765 2.3.1. Test procedure

- 766 i) ELISA plates are coated with 50 µl/well rabbit antiserum homologous to the antigen being
767 used and left overnight in a humid chamber at room temperature.
- 768 ii) The ELISA plates are washed three times with PBS.
- 769 iii) In U-bottomed multiwell plates (carrier plates) 50 µl of a duplicate, twofold series of each
770 test serum is prepared, starting at 1/8. To each well, 50 µl of a constant dose of viral antigen
771 that is homologous to the rabbit antisera used to coat the plates is added and the mixtures
772 are left overnight at 4°C, or incubated at 37°C for 1 hour. The addition of the antigen
773 increases the final serum dilution to 1/16.
- 774 iv) Then 50 µl of serum/antigen mixtures is transferred from the carrier plates to the rabbit-
775 serum coated ELISA plates and the plates are incubated at 37°C for 1 hour on a rotary
776 shaker.
- 777 v) After washing, 50 µl of guinea-pig antiserum homologous to the viral antigen used in the
778 previous step (iv) (preblocked with NBS and diluted in PBST containing 5% skimmed milk
779 powder) is added to each well. The plates are then incubated at 37°C for 1 hour on a rotary
780 shaker.

- 781 vi) The plates are washed and 50 µl of rabbit anti-guinea-pig immunoglobulin conjugated to
782 horseradish peroxidase (preblocked with NBS and diluted in PBST containing 5% skimmed
783 milk powder) is added to each well. The plates are incubated at 37°C for 1 hour on a rotary
784 shaker.
- 785 vii) The plates are washed again three times and 50 µl of substrate solution, containing 0.05%
786 H₂O₂ plus orthophenylene diamine or a suitable alternative chromogen, is added to each
787 well.
- 788 viii) The reaction is stopped after 15 minutes by the addition of 50 µl of 1 M sulphuric acid. The
789 plates are read at 492 nm on a spectrophotometer linked to a computer.
- 790 ix) Controls: A minimum of four wells each of strong positive, weak positive and negative bovine
791 reference sera at a final dilution of 1/32 should be included on each plate together with an
792 equivalent number of reaction (antigen) control wells containing antigen in diluent alone
793 without serum. For end-point titration tests, duplicate twofold dilution series of positive and
794 negative homologous bovine reference sera should be included on at least one plate of
795 every run.
- 796 x) *Interpretation of the results:* Antibody titres are expressed as the 50% end-point titre, i.e. the
797 dilution at which the reaction of the test sera results in an optical density equal to 50%
798 inhibition of the median optical density of the reaction (antigen) control wells (Kärber, 1931).
799 The median is calculated as the mean of two mid-values of the reaction control wells,
800 eliminating from the calculation the highest and lowest values (alternatively, the mean value
801 can be used after setting suitable tolerance limits to control for inter-well variation). In
802 general sera with titres greater than or equal to 1/90 are considered to be positive. A titre of
803 less than 1/40 is considered to be negative. For certification of individual animals for the
804 purposes of international trade, titres of greater than 1/40, but less than 1/90 are considered
805 to be doubtful, and further serum samples may be requested for testing; results are
806 considered to be positive if the second sample has a titre of 1/40 or greater. For the purposes
807 of herd-based serosurveillance as part of a statistically valid serological survey, a cut-off of
808 1/90 may be appropriate. Cut-off titres for evaluating immunological protection afforded by
809 vaccination have to be established from experience of potency test results with the relevant
810 vaccine and target species.

811 2.4. Nonstructural protein (NSP) antibody tests

812 Antibody to expressed recombinant FMDV NSPs (e.g. 3A, 3B, 2B, 2C, 3ABC) can be measured by
813 different ELISA formats or immunoblotting. These ELISAs either use purified antigens absorbed directly
814 to microplates or use PAbs or MAbs to trap specific antigens from semi-purified preparations (Bergmann
815 *et al.*, 2000; De Diego *et al.*, 1997; Mackay *et al.*, 1997; Sorensen *et al.*, 1998). The screening method
816 used in Panaftosa is described in detail below. Other indirect and competitive ELISAs detecting bovine
817 antibodies to 3ABC have been shown to have equivalent diagnostic performance characteristics (Brocchi
818 *et al.*, 2006). This same study corroborates preliminary data from Panaftosa that suggests that the
819 diagnostic performance characteristics of these tests are similar in cattle, sheep and pigs. Commercial
820 kits validated for identification of antibodies against FMDV NSPs in cattle and other species are also
821 available. Validation should be performed accordingly Chapter 1.1.6 and the supporting chapters in
822 Section 2.2. *Validation of diagnostic tests of this Terrestrial Manual.*

823 2.4.1. Indirect enzyme-linked immunosorbent assay

- 824 a) Preparation of recombinant antigens
825 See Section B.2.4.2. *Enzyme-linked immunoelectrotransfer blot assay.*
- 826 b) Test procedure
- 827 i) Microplates are coated overnight at 4°C with 1 µg/ml of the fusion antigen 3ABC in
828 carbonate/ bicarbonate buffer, pH 9.6 (100 µl per well). Antigen 3ABC was expressed and
829 purified as indicated for the EITB (enzyme-linked immunoelectrotransfer blot) tests (Neizert
830 *et al.*, 1991).
- 831 ii) The plates are washed six times with PBS, pH 7.2, supplemented with 0.05% Tween 20
832 (PBST).
- 833 iii) Test sera (100 µl per well) are added in a 1/20 dilution in blocking buffer consisting of PBS,
834 0.05% Tween 20, 5% nonfat dry milk, 10% equine sera and 0.1% *Escherichia coli* lysate.
835 Each plate includes a set of strong and weak positive and negative controls calibrated
836 against the International Standard Sera described below.
- 837 iv) The plates are incubated for 30 minutes at 37°C and washed six times in PBST.

- 838 v) Horseradish-peroxidase-conjugated rabbit anti-species IgG is diluted optimally in the
839 blocking buffer, added at 100 µl per well and the plates are incubated for 30 minutes at 37°C.
- 840 vi) After six washings, each well is filled with 100 µl of 3'3', 5'5'-tetramethylbenzidine plus
841 0.004% (w/v) H₂O₂ in phosphate/citrate buffer, pH 5.5.
- 842 vii) The reaction is stopped after 15 minutes of incubation at room temperature by adding 100 µl
843 of 0.5 M H₂SO₄. Absorbance is read at 450 nm and at 620 nm for background correction.
- 844 viii) *Interpreting the results:* Test results are expressed as per cent positivity relative to the strong
845 positive control [(optical density of test or control wells/optical density of strong positive
846 control) × 100] or alternatively as a test to control (T/C) index relative to a cut-off (i.e.
847 threshold positive) control. Profiling the NSP antibody reactivity levels in herds along with
848 age/vaccination stratification aids interpretation of herd infection status in vaccinated
849 populations (Bergmann *et al.*, 2003). Test cut-off values, with or without suspicious zones,
850 need to be determined with consideration to the purpose of testing and the intended target
851 population. Inconclusive results may be followed up using confirmatory tests, retesting with
852 EITB or a second NSP ELISA (taking account of the conditional dependence of the two
853 tests). The overall test system sensitivity and specificity must be taken into account when
854 designing the serosurveillance programme. Although not a suitable test for certifying animals
855 prior to movement, NSP ELISAs may be a valuable adjunct in circumstances where the
856 serotype or subtype of virus in the originating country is not known.

857 2.4.2. Enzyme-linked immunoelectrotransfer blot assay (EITB)

858 The EITB assay has been widely applied in South America as a confirmatory test for the above-
859 described screening method. Further information is available from the WOAHP Reference
860 Laboratory, Panaftosa, PAHO/WHO.

- 861 a) Preparation of test strips containing the recombinant antigens
- 862 i) The five bioengineered FMDV NSPs 3A, 3B, 2C, 3D and 3ABC are expressed in *E. coli*
863 C600 by thermo-induction. The 3D polypeptide is expressed in its complete form
864 (McCullough *et al.*, 1992) whereas the rest of the proteins are obtained as fusions to the N-
865 terminal part of the MS-2 polymerase gene (Strebel *et al.*, 1986).
- 866 ii) The expressed polymerase is purified over phosphocellulose, followed by poly(U)
867 Sepharose columns. The fused proteins 3A, 3B, 2C and 3ABC are purified by sequential
868 extraction of the bacterial extracts with increasing concentrations of urea. The 7M fraction
869 containing the fusion proteins is further purified on a preparative 10% SDS-PAGE (sodium
870 dodecyl sulphate-polyacrylamide gel electrophoresis). The fusion protein band is excised
871 from the gel and electroeluted (McCullough *et al.*, 1992).
- 872 iii) A mixture containing 20 ng/ml of each one of the purified recombinant polypeptides is
873 separated on 12.5% SDS-PAGE and electrophoretically transferred to nitrocellulose
874 (McCullough *et al.*, 1992).
- 875 b) Test procedure
- 876 i) The required amount of test strips should be assessed, taking into account that for each
877 nitrocellulose sheet, which defines one transferred gel, a positive, a weakly positive, a cut-
878 off and a negative control serum should be assayed. In general, 24 nitrocellulose strips,
879 each 3 mm wide, should result from a gel.
- 880 ii) A volume of 0.8 ml of saturation buffer (50 mM Tris/HCl, pH 7.5; 150 mM NaCl; 0.2% Tween
881 20; 5% nonfat dry milk; and 0.05% bacterial *E. coli* lysate) is added to each well. The
882 antigen-coated strips are blocked by placing the trays on a rocker and agitating for
883 30 minutes at room temperature (20–22°C).
- 884 iii) A dilution of 1/200 of test sera and of each of the controls is added to the appropriate trough.
885 The strips must be completely submerged and facing upwards, and maintained in that
886 position during the whole process.
- 887 iv) Strips are incubated for 60 minutes on a rocker at room temperature.
- 888 v) Liquid is removed from the trays, and each test strip is washed three times with washing
889 solution (50 mM Tris/HCl, pH 7.5; 150 mM NaCl; and 0.2% Tween 20) by agitation for
890 5 minutes.
- 891 vi) The alkaline-phosphatase-conjugated rabbit anti-bovine solution is added to each test well,
892 and the strips are incubated with shaking for 60 minutes at room temperature.
- 893 vii) The liquid is removed from the trays and each test strip is washed three times with washing
894 solution as above.

- 895 viii) Substrate solution (0.015% bromochloroindolyolphosphate/0.03% nitroblue tetrazolium) is
896 prepared in substrate buffer (100 mM NaCl; 5 mM MgCl₂; and 100 mM Tris/HCl, pH 9.3),
897 and is added to each test well.
- 898 ix) Strips are incubated by placing the test tray on the orbital mixer and agitating until the cut-
899 off control shows five distinct, discernible bands. Strips are washed with running deionised
900 water and air-dried.
- 901 x) *Interpreting the results:* The EITB may be scanned with a densitometer but visual reading,
902 although more subjective, is considered suitable as well. Individual control sera are tested
903 that exhibit minimal but consistent staining for each of the five antigens. A test sample is
904 considered positive if antigens 3ABC, 3A, 3B and 3D ($\pm 2C$) demonstrate staining densities
905 equal to or higher than that of their appropriate controls. A sample is considered negative if
906 two or more antigens demonstrate densities below their control sera. Test samples not fitting
907 either profile are considered indeterminate.

908 C. REQUIREMENTS FOR VACCINES

909 The control of FMD is a national and regional responsibility and, in many countries, the vaccine may be used only
910 under the control of the Veterinary Authority.

911 Guidelines for the production of veterinary vaccines are given in Chapter 1.1.8 *Principles of veterinary vaccine*
912 *production*. The guidelines given here and in chapter 1.1.8 are intended to be general in nature and may be
913 supplemented by national and regional requirements. Varying requirements relating to quality, safety and efficacy
914 apply in particular countries or regions in order for manufacturers to obtain ~~an authorisation or licence~~ regulatory
915 approval for a veterinary vaccine. Where possible, manufacturers should seek to obtain such ~~a licence or~~
916 ~~authorisation~~ regulatory approval for their FMD vaccines as independent verification of the quality of their product.

917 FMD vaccine production facilities should operate under appropriate biosecurity and containment procedures and
918 practices as outlined in Chapter 1.1.4 *Biosafety and biosecurity: Standard for managing biological risk in the*
919 *veterinary laboratory and animal facilities*.

920 Routine vaccination against FMD is used in many countries or zones recognised as free from foot and mouth
921 disease with vaccination and in countries where the disease is endemic. In contrast, a number of disease-free
922 countries have never vaccinated their livestock but have preferred the use of strict movement controls and culling
923 of infected and contact animals when outbreaks have occurred. Nevertheless, many disease-free countries
924 maintain the option to vaccinate and have their own strategic reserves of highly concentrated inactivated virus
925 preparations. Such antigen reserves offer the potential of supplying formulated vaccine in an 'emergency' at short
926 notice. (See also Chapter 1.1.10 *Vaccine banks*.)

927 Traditional FMD vaccines may be defined as a fixed formulation containing defined amounts (limits) of one or more
928 chemically inactivated cell-culture-derived preparations of a seed virus strain blended with a suitable adjuvant/s and
929 excipients. See chapter 1.1.8 for biotechnology-derived vaccines such as recombinant or peptide vaccines.

930 Antigen banks may be defined as stockpiles of antigen components, registered or licensed according to the finished
931 vaccine, and which can be stored under ultra-low temperatures for a long time for subsequent formulation into
932 vaccine as and when required.

933 The vaccines are formulated for their specific purpose and in the case of vaccines destined for use in cattle, both
934 aluminium hydroxide saponin adjuvanted and oil adjuvanted vaccines may be used. For use in swine, double oil
935 emulsions are preferred due to their efficacy.

936 FMD vaccines may be classified as either 'standard' or 'higher' potency vaccines. Standard potency vaccines are
937 formulated to contain sufficient antigen and appropriate adjuvant to ensure that they meet the minimum potency
938 level required (recommended 3 PD₅₀ [50% protective dose]; 75% EPP (expected percentage of protection) or
939 12 protected out of 16 vaccinated and challenged in PGP [protection against generalised foot infection] test) for the
940 duration of the shelf life claimed by the manufacturer. This kind of vaccine is usually suitable for use in routine
941 vaccination campaigns. For vaccination in naïve populations to control FMD outbreaks, higher potency vaccines
942 (e.g. > 6 PD₅₀ for the duration of the shelf life claimed by the manufacturer) are recommended for their wider
943 spectrum of immunity as well as their rapid onset of protection.

944 Because of the presence of multiple serotypes of the virus, it is common practice to prepare vaccines from two or
945 more different virus serotypes. In certain areas, it may be advisable to include more than one virus strain per
946 serotype to ensure broad antigenic coverage against prevailing viruses.

947 1. Seed virus management

948 1.1. Characteristics of the seed virus

949 Selection of master seed viruses (MSVs) should ideally be based on their ease of growth in cell culture,
950 virus yield, antigenic stability at industrial level and broad antigenic spectrum. Isolates to prepare MSVs
951 should be characterised and distributed, preferably by the WOAHA FMD Reference laboratories; they
952 should be selected in accordance with the regional epidemiological importance of each strain.

953 The exact source of the isolate should be recorded and should include details such as the location,
954 species and the type of material from which the virus was derived. Unique nomenclature should be used
955 to identify the FMDV strain. The *in-vitro* passage history of the virus and details of the ingredients should
956 be recorded in accordance with chapter 1.1.8. The passage level of the seed virus should be kept to a
957 minimum to avoid antigenic or genetic changes.

958 1.2. Method of culture

959 Methods of culture shall comply with the chapter 1.1.8. Where no suitable established vaccine strain
960 exists, new vaccine strains are derived through the establishment of MSVs from local field isolates by
961 adapting them to growth in suspension or monolayer cells by serial passages. In order to remove the risk
962 of contaminating lipid-enveloped viruses, it is recommended that putative MSVs undergo a validated
963 organic solvent treatment prior to, or during, adaptation.

964 1.3. Validation as a vaccine strain

965 MSVs must be antigenic and genetically well characterised and proven to be pure and free from
966 extraneous agents in accordance with Chapter 1.1.9 *Tests for sterility and freedom from contamination*
967 *of biological materials intended for veterinary use* and those listed by the appropriate ~~licensing-regulatory~~
968 authorities. Homology should be established with the original candidate isolates and effectiveness
969 against the circulating strains from which they were developed should be proven. This often
970 encompasses a number of methods, the most reliable being *in-vivo* protection assays. Alternatively, *in-*
971 *vitro* tests (preferably virus neutralisation) can also be used, which require the availability of post-
972 vaccination sera against these master seeds (see Section D of this chapter).

973 Seed viruses may be stored at low temperature (e.g. -70°C) or freeze-dried. Working seed viruses may
974 be expanded in one or a few more passages from the master seed stock and used to infect the final cell
975 culture.

976 Consideration should also be given to minimising the risk of transmission of transmissible spongiform
977 encephalopathy agents (TSEs) by ensuring that TSE risk materials are not used as the source of the
978 virus or in any of the media used in virus propagation.

979 1.4. Emergency procedures for provisional acceptance of new MSV, and subsequent 980 release of formulated vaccines

981 In the case of incursion in a region of a new strain to which protection is not elicited by existing vaccine
982 strains, it may be necessary to develop a new vaccine strain from a representative field isolate. Before
983 the new MSV can be accepted, full compliance should be demonstrated with the relevant guidelines to
984 demonstrate freedom from all extraneous agents listed by the appropriate ~~licensing-regulatory~~ authorities
985 using both general and specific tests, and to establish homology to the original candidate isolates. The
986 time taken to raise the specific antisera necessary to neutralise the new strain for use in the general tests
987 for detection of extraneous agents and to conduct other specific tests that require specialised techniques
988 may be lengthy. Therefore, in emergency situations where there is insufficient time to complete full testing
989 of the MSV, provisional acceptance of the new strain should be based on a risk analysis of the possibility
990 of contamination of the antigen produced from the new MSV with extraneous agents. This risk
991 assessment should take into account that the virus is inactivated using a chemical inactivation with first
992 order kinetics. Further assurance is provided by the requirement for the kinetics of inactivation to be
993 monitored and recorded for each production batch.

994 2. Method of manufacture

995 The recommended method of virus propagation for antigen production is the growth of FMDV in large-scale
996 suspension cultures or monolayers using cell lines under sterile conditions.

-
- 997 A suitable strain of the virus is used to infect a suspension or monolayers of an established cell line, such as BHK-
998 21. Such cell cultures should be proven to be free from contaminating microorganisms.
- 999 When the virus is expected to have reached its maximum yield, the culture is clarified, often by centrifugation and/or
1000 filtration. The virus is subsequently inactivated by addition of an inactivant of first order, usually ethyleneimine (EI)
1001 in the form of binary ethyleneimine (BEI) (Bahemann, 1990). It is important that the necessary safety precautions
1002 for working with BEI/EI are fully observed. The BEI is added to a virus suspension, to give a predetermined final
1003 concentration. Inactivation must be duly validated and documented to show the inactivation kinetic and the results
1004 of the inactivation controls. The time period for BEI treatment and temperature used for inactivation must be
1005 validated for the actual conditions and equipment used. To decrease the likelihood of live virus failing to contact the
1006 inactivant, e.g. BEI/EI, it is essential to transfer the vessel contents immediately to a second sterile vessel where
1007 inactivation is allowed to go to completion according to the validated inactivation kinetic and taking into account
1008 possible regulatory requirements for additional waiting times.
- 1009 During inactivation, the virus titre is monitored by a sensitive and reproducible technique. After inactivation any
1010 residual BEI/EI in the harvest should be neutralised, for example by adding excess sodium thiosulphate solution to
1011 a final concentration of 2%.
- 1012 The inactivated virus is concentrated by ultrafiltration. Concentrated inactivated virus may be purified further by
1013 procedures such as chromatography. These concentrated and purified antigens can be formulated into vaccines or
1014 stored at low temperatures for many years, and made into vaccine when required by dilution in a suitable buffer
1015 and addition of adjuvants (Doel & Pullen, 1990).
- 1016 Conventional FMD vaccines are usually formulated as oil adjuvanted or aqueous. Oil-adjuvanted vaccines are
1017 usually formulated as water-in-oil emulsion using mineral oils. The mineral oil is usually premixed with an
1018 emulsifying agent before the addition of a proportion, or all, of the aqueous phase of the vaccine, and emulsified by
1019 use of a colloid mill or continuous mechanical or flow ultrasonic emulsifier. More complex double emulsions
1020 (water/oil/water) may be produced by emulsifying once more in an aqueous phase containing a small amount of
1021 detergent such as Tween 80. Ready-to-use oil adjuvants are now available commercially for different types of
1022 emulsion.
- 1023 Aqueous vaccine is prepared by adsorbing the virus on to aluminium hydroxide gel, one of the adjuvant constituents
1024 of the final vaccine blend. The final blend of the vaccine may include other components, such as antifoam,
1025 lactalbumin hydrolysate, tryptose phosphate broth, amino acids, vitamins, buffer salts and other substances. An
1026 adjuvant such as saponin is also usually incorporated, as well as preservatives.
- 1027 When using novel components, including adjuvants or preservatives, in any vaccine it is important to take into
1028 account that its status, with regard to residues in products derived from food-producing species, must be assessed
1029 to ensure that adequate assurance can be giving to ~~licensing-regulatory~~ authorities in relation to safety for
1030 consumers. This requirement limits considerably the choice of adjuvants and preservatives for use in food-
1031 producing species.
- 1032 **3. In-process control**
- 1033 In general, virus titres reach optimum levels between 18 and 24 hours of the cell culture being infected, depending
1034 on the serotype. The time chosen to harvest the culture may be based on a number of assays; for instance cell
1035 death. Virus concentration may be assessed by an infectivity test, sucrose or CsCl density gradient or serological
1036 techniques. It is preferable to use more than one method as they may complement one another.
- 1037 **3.1. Inactivation kinetics**
- 1038 During inactivation of the virus, timed samples should be taken at regular intervals for the purpose of
1039 monitoring the rate and linearity of the inactivation process. Virus titres in the samples are determined
1040 by inoculation of cell cultures proven to be highly susceptible to FMDV, e.g. BHK. Such cultures permit
1041 the testing of statistically meaningful samples under reproducible conditions. The log₁₀ infectivity of the
1042 timed samples are plotted against time, and the inactivation procedure is not considered to be
1043 satisfactory unless at least the latter part of the slope of the line is linear and extrapolation indicates that
1044 there would be less than one infectious particle per 10⁴ litres of liquid preparation at the end of the
1045 inactivation period.
- 1046 **3.2. Inactivation control**
- 1047 The test for innocuity is an in-process test that should be carried out for every batch of antigen. Cells
1048 used to test for absence of residual live virus should undergo a sensitivity test to prove that they are
1049 suitable for virus replication. Following inactivation, a sample of each batch of inactivated antigen

1050 representing at least 200 doses of vaccine antigen should be tested for freedom from infectious virus by
1051 inoculation of sensitive monolayer cell cultures, preferably of the same origin as those used for the
1052 production of antigen. It may be necessary to concentrate the antigen to do this, in which case it must
1053 be shown that the concentrated material does not interfere with the sensitivity or reading of the assay.
1054 The cell sheets are examined daily over a period of 2–3 days, after which the spent medium is transferred
1055 to fresh monolayers and the original monolayers are replenished with fresh medium. Using this method,
1056 traces of live virus can be amplified by the passage procedure and detected on the basis of CPE
1057 observed. Three passages of the original virus preparation are commonly used. A variant on this method
1058 is to freeze–thaw the old monolayers to release intracellular virus, which can be detected by further
1059 passage.

1060 **4. Final product batch tests**

1061 **4.1. Innocuity testing**

1062 The bulk inactivated antigen and the final formulated product should undergo innocuity test to prove
1063 absence of infectious virus. In the final product, antigen must be extracted from adjuvant following an
1064 appropriate validated method. A sample representing at least 200 doses of vaccine (including all product
1065 presentations) must be used for testing for freedom of infectious virus by inoculation of sensitive cell
1066 culture monolayers. After elution, antigen may be concentrated for inoculation in cell monolayers. Test
1067 procedure is as described in Section C.3.2 *Inactivation control*.

1068 **4.2. Sterility testing**

1069 The bulk inactivated antigen, concentrated antigen and the final formulated product should undergo
1070 sterility testing. Guidelines on techniques and culture media, which allow the detection of a wide range
1071 of organisms, are described in Chapter 1.1.9.

1072 **4.3. Identity testing**

1073 The bulk inactivated antigen, concentrated antigen and the final formulated product should undergo
1074 identity testing to demonstrate that the relevant strains are present. No other FMD virus serotype
1075 registered on the manufacturing site should be present in the vaccine, to be assured by appropriate tests
1076 such as serotype-specific RT-PCR.

1077 **4.4. Purity testing**

1078 Purity relates to the level of FMD NSPs in the final product, which should not induce antibodies that
1079 would interfere with serological tests used for sero-surveillance of virus circulation in vaccinated
1080 populations. Products claiming to be purified from NSPs have to demonstrate their level of purification.
1081 Lack of reactivity has to be demonstrated in the final product (see Section C.5. *Requirements for*
1082 *registration of vaccine*). In cases where consistency of purification is demonstrated and approved in the
1083 registration dossier, and the production process is approved for consistency in accordance with the
1084 standard requirements referred to in chapter 1.1.8, the Veterinary Authority may agree to omit the test in
1085 the final product.

1086 Confirmation of vaccine purity may be shown by testing sera from animals vaccinated at least twice with
1087 the batch for absence of antibodies to NSPs.

1088 **4.5. Safety testing**

1089 The safety of the final product should be proven batch to batch. The safety testing is conducted to detect
1090 any abnormal local or systemic adverse reactions. In cases where consistent safety of the product is
1091 demonstrated and approved in the registration dossier and the production process is approved for
1092 consistency in accordance with the standard requirements referred to in chapter 1.1.8, Veterinary
1093 Authority may agree to omit the test in the final product.

1094 Safety could be checked in animals used for the potency test. Animals are inoculated by the
1095 recommended route of administration with the recommended dose of vaccine. When potency is
1096 assessed by PGP or EPP, all animals are observed for local and systemic reactions to vaccination for
1097 the 30 days duration of the potency test. When PD₅₀ test is used, at least two healthy sero-negative
1098 target animals inoculated as above are observed for local and systemic reactions to vaccination for no
1099 fewer than 14 days. Any undue reaction attributable to the vaccine should be assessed and may prevent
1100 acceptance of the batch.

1101 **4.6. Potency testing**

1102 Potency is examined on the final formulated product, or alternatively for antigen banks on a
1103 representative batch of vaccine prepared from the same bulk inactivated antigen.

1104 The potency testing standard is the vaccination challenge test. However, indirect tests can also be used
1105 for practicability and animal welfare considerations, as long as correlation has been validated to
1106 expectancy of protection in the target animal. Frequently indirect potency tests include antibody titration
1107 after vaccination of target species. Alternative methods could be used if suitably validated.

1108 Ideally, indirect tests are carried out for each strain for one species and each formulation of vaccine to
1109 establish correlation between the indirect test results and the vaccine efficacy.

1110 **4.6.1. Expected percentage of protection (EPP) (Maradei *et al.*, 2008; Periolo *et al.*, 1993)**

1111 The EPP estimates the likelihood that cattle would be protected against a challenge of
1112 10,000 bovine infective doses after a single vaccination.

1113 i) Individual sera collected 30–60 days post-vaccination using a full dose of the vaccine are
1114 required from a group of either 16 or 30 18–24 month-old cattle.

1115 ii) This panel of sera and sera of two control cattle are tested for antibody titres to the
1116 homologous FMD vaccine strain in an LPB-ELISA or VN test (see Sections B.2.1 *Virus*
1117 *neutralisation* and B.2.3 *Liquid-phase blocking enzyme-linked immunosorbent assay*).

1118 iii) The antigens used in the ELISA may be inactivated using BEI.

1119 iv) The EPP is determined by reference to predetermined tables of correlation between
1120 serological titres and clinical protection² (Maradei *et al.*, 2008; Periolo *et al.*, 1993).

1121 v) Batches with at least 75% EPP (with 16 vaccinated cattle) or at least 70% EPP (with
1122 30 vaccinated cattle) are satisfactory for potency.

1123 The presence of more than one serotype in a vaccine does not diminish the induction of antibodies
1124 against another serotype or the correlation of antibody titre with protection.

1125 **4.6.2. Other methods for evaluating protection**

1126 Other tests were published using different ELISA methods and VNT methods to indirectly evaluate
1127 the protection given by vaccines. Their results could be accepted only if a valid correlation with
1128 protection in relation to the vaccine strain being tested and the serological method being used
1129 has been scientifically demonstrated.

1130 **5. Requirements for registration of vaccine**

1131 **5.1. Manufacturing process**

1132 For registration of vaccine, all relevant details concerning manufacture of the vaccine and quality control
1133 testing (see Sections C.1–4) should be submitted to the National Veterinary Authority. This information
1134 shall be provided from three consecutive vaccine batches with a volume not less than 1/3 of the minimum
1135 allowed industrial batch volume from the country of origin.

1136 **5.2. Safety**

1137 For the purposes of gaining regulatory approval, a trial batch of vaccine should be tested for local and
1138 systemic toxicity by each recommended route of administration in an *in-vivo* test in at least eight animals
1139 of each target species. Double dose (e.g. two injections) and repeat single dose (after 14 days) tests
1140 using vaccines formulated to contain the maximum permitted payload and number of antigens are
1141 recommended to be conducted. In total animals receive three injections. The animals are observed for
1142 local and systemic reactions to vaccination for no fewer than 14 days after each injection. Any undue
1143 reaction attributable to the vaccine should be assessed and may prevent acceptance of the vaccine by
1144 the National Veterinary Authority.

1145 **5.3. Efficacy**

² The WOA Reference Laboratory in Brazil can provide tables upon request

1146 Vaccine efficacy is estimated in vaccinated animals directly, by evaluating their resistance to live virus
1147 challenge or indirectly through *in-vitro* testing using well established correlations. The uncertainty of
1148 measurement in tests should be taken into account when interpreting its significance (Goris *et al.*, 2008).
1149 Vaccine efficacy should be established for every strain to be ~~authorised~~approved for use in the vaccine.

1150 Live reference FMD viruses corresponding to the main vaccine virus strains used in the region are
1151 available under certain conditions from WOAHA Reference Laboratories for FMD in the region and from
1152 the National Veterinary Authority. These reference viruses are stored at ultralow temperatures and are
1153 sent, in strict accordance with shipping regulations.

1154 The stock of challenge virus to be aliquoted is prepared from lesions collected from at least two cattle
1155 above 6 months of age that have been recognised as free from FMDV antibodies. These animals are
1156 tranquillised, then inoculated intradermally in the tongue with the suspension in about 20 sites of 0.1 ml
1157 each. The vesiculated tongue tissue or other body parts and vesicular fluid is harvested at the peak of
1158 the lesions, approximately 2 days later.

1159 Harvested tissue is macerated and a 2% suspension is prepared, filtered through a 0.2 µm filter, aliquoted
1160 and quickly frozen in the gas phase of liquid nitrogen; this constitutes the challenge virus stock. The
1161 infective titres of this stock are determined both in cell culture (TCID₅₀) and in two cattle (BID₅₀) (50%
1162 bovine infectious dose). Two tranquillised cattle are injected intradermally in the tongue with tenfold
1163 dilutions (1/10 through 1/10,000), using four sites per dilution. The cattle titrations are read 2 days later.
1164 Titres are usually above 10⁶ TCID₅₀ for 0.1 ml and above 10⁵ BID₅₀ for 0.1 ml, calculated using the
1165 Spearman–Kärber method. The dilution for use in the cattle challenge test is 10 000 BID₅₀ in a total
1166 volume of 2 × 0.1 ml and is injected intradermally in the upper surface of the tongue both for the PD₅₀
1167 test and PGP test.

1168 **5.3.1. PD₅₀ test**

1169 The number of protective doses in a vaccine is estimated from the resistance to infectious virus
1170 challenge of animal groups receiving different amounts of vaccine. Cattle of at least 6 months of
1171 age, obtained from areas free from FMD that have not previously been vaccinated against FMD
1172 and are free from antibodies to FMDV should be used. Three groups of no fewer than five cattle
1173 per group should be vaccinated by the route recommended by the manufacturer. The vaccine
1174 should be administered at different doses per group by injecting different volumes of the vaccine.
1175 For example, if the label states that the injection of 2 ml corresponds to the administration of
1176 1 dose of vaccine, a 1/4 dose of vaccine would be obtained by injecting 0.5 ml, and a 1/10 dose
1177 would be obtained by injecting 0.2 ml. These animals and a control group of two unvaccinated
1178 animals are challenged either 3 weeks (aqueous) or up to 4 weeks (oil) after vaccination with a
1179 suspension of bovine virus that is fully virulent and appropriate to the virus types in the vaccine.
1180 The challenge test is done by inoculating the equivalent of a total of 10,000 BID₅₀ intradermally
1181 into two sites on the upper surface of the tongue (0.1 ml per site). Animals are observed for at
1182 least 8 days. Vaccinated animals are considered unprotected if they show FMD lesions on at least
1183 1 foot within 7 days after inoculation. Unprotected animals will show lesions at sites other than
1184 the tongue. Control animals must develop lesions on at least three feet. From the number of
1185 animals protected in each group, the PD₅₀ content of the vaccine is calculated. There are a variety
1186 of methods for calculating PD₅₀ but procedures based on the Kärber (1931) method are generally
1187 preferred when interpreting PD₅₀ estimates calculated in this way. The vaccine should contain at
1188 least 3 PD₅₀ per dose for cattle.

1189 **5.3.2. PGP test (protection against generalised foot infection)**

1190 For this method, a group of 16 FMD-seronegative cattle of 18–24 months of age, with the same
1191 characteristics described for the PD₅₀ test, are vaccinated with a full bovine dose by the route and
1192 in the volume recommended by the manufacturer. These animals and a control group of two
1193 unvaccinated animals are challenged 4 weeks or more after vaccination with a suspension of
1194 bovine virus that is fully virulent and appropriate to the virus types in the vaccine. The challenge
1195 test is performed by inoculating the equivalent of a total of 10,000 BID₅₀ intradermally into two
1196 sites on the upper surface of the tongue (0.1 ml per site). Animals are observed for 7–8 days.
1197 Vaccinated animals are considered unprotected if they show FMD lesions on at least 1 foot within
1198 7 days after inoculation. Unprotected animals will show lesions on the feet within 7 days after
1199 inoculation. Control animals must develop lesions on at least three feet. For routine prophylactic
1200 use, the vaccine should protect at least 12 animals out of 16 vaccinated. This test does not
1201 provide an estimate of how many protective doses are in a single vaccine dose but comparison
1202 between tests suggested that 12 protected out of 16 vaccinated and challenged animals
1203 correlates with 3 PD₅₀ (Vianna Filho *et al.*, 1993).

1204

1205	5.3.3. Efficacy estimated by indirect tests
1206	When direct challenge tests are not available to estimate efficacy, National Veterinary Authority may decide to use indirect tests (such as VN or LPB-ELISA), provided there is a correlation determined between antibody level and protection against challenge with 10,000 BID ₅₀ .
1207	
1208	
1209	
1209	5.3.4. Efficacy in other species
1210	Efficacy tests in other target species, such as sheep, goats, pigs or buffalo are either different or not yet standardised. In general, a successful test in cattle is considered to be sufficient evidence of the quality of a vaccine to endorse its use in other species. Under circumstances where a vaccine is produced for use primarily in a species other than cattle, it may be more appropriate to potency test the vaccine in that same species. With respect to sheep, goats and African (<i>Syncerus caffer</i>) or Asiatic buffalo (<i>Bubalus bubalis</i>), due to the often inapparent nature of the disease in these species, potency results from a cattle test may be a more reliable indicator of vaccine quality than attempting a potency test reliant on the detection of clinical signs in these other species.
1211	
1212	
1213	
1214	
1215	
1216	
1217	
1218	5.4. Purity: testing for antibody against NSP
1219	Viral circulation within a defined population can be assessed by testing for presence of antibodies against NSPs. Furthermore, the WOAH <i>Terrestrial Animal Health Code</i> stipulates that a criterion for regaining FMD free status following an outbreak, if vaccine is used, is to test the vaccinated animals for antibodies against NSP. Likewise, countries wishing to be recognised as FMD free with vaccination must demonstrate the absence of virus circulation by showing that vaccinated animals are free from antibody to NSPs arising as a result of infection. Consequently, FMD antigens used to formulate vaccines that may be used in these circumstances should be purified to reduce the NSP content. In addition to providing supporting documentation on the processes involved in such purification, manufacturers should demonstrate lack of immunogenicity against NSPs as part of the licensing procedure in order to make such a claim on their product literature. When purity tests include the use of full vaccine doses, at least eight cattle should be booster vaccinated at 28–30 days after first vaccination and tested for purity 28–30 days later. Up to one reactive animal at 28–30 days post-booster vaccination could be accepted. If more than two animals are reactive at 28–30 days post-booster vaccination, the batch should be rejected. If two animals are reactive, the manufacturers have the option to ask for a batch retest. A recommended test method that can be used is to vaccinate not less than 8 naïve cattle with a full dose of the vaccine containing the maximum number of strains and amounts of antigen permitted on the authorisation. Cattle should be vaccinated at least twice at 21- to 30-day intervals and then tested before each revaccination and 30–60 days after the last vaccination for the presence of antibody to NSPs using the tests described in Section B.2.4 <i>Nonstructural protein (NSP) antibody tests</i> . Negative results in NSP assays may support claims that the vaccine does not induce antibody to NSPs for the number of injections tested. These cattle may be the same as those used for the safety test described in Section C.5.2 <i>Safety</i> .
1220	
1221	
1222	
1223	
1224	
1225	
1226	
1227	
1228	
1229	
1230	
1231	
1232	
1233	
1234	
1235	
1236	
1237	
1238	
1239	
1240	5.5. Duration of immunity
1241	The duration of immunity (D.O.I.) of an FMD vaccine will depend on the efficacy (formulation and antigen payload). As part of the authorisation <u>regulatory approval</u> procedure, the manufacturer should be required to demonstrate the D.O.I. of a given vaccine by either challenge or the use of a validated alternative test, such as serology using the same test and animals described in Section C.5.3 <i>Efficacy</i> tested at the end of the claimed period of protection, in compliance with Section C.5.3. D.O.I. studies should be conducted in each species for which the vaccine is indicated or the manufacturer should indicate that the D.O.I. for that species is not known. Likewise, the manufacturer should demonstrate the effectiveness of the recommended booster regime in line with these guidelines, usually by measuring the magnitude and kinetics of the serological response observed.
1242	
1243	
1244	
1245	
1246	
1247	
1248	
1249	
1250	5.6. Stability
1251	The stability of all vaccines, including oil emulsion vaccines, should be demonstrated as part of the shelf-life determination studies for authorisation <u>regulatory approval</u> .
1252	
1253	The shelf life of conventional FMD vaccines is usually 1–2 years at 2–8°C. Vaccines should never be frozen or stored above the target temperature.
1254	
1255	Stability should be tested using the same methods described in Section C.5.3 <i>Efficacy</i> , but vaccinating the animals at the end of the shelf life of the product.
1256	
1257	

1258	5.7. Precautions (hazards)
1259	Current FMD vaccines are innocuous and present no toxic hazard to the vaccinators. Manufacturers
1260	should provide adequate warnings that medical advice should be sought in case of self-injection of a
1261	vaccine.
1262	6. Storage and monitoring of concentrated antigens
1263	Chapter 1.1.10 provides international standards for vaccine banks.
1264	The process of storing concentrated antigens at ultra-low temperature for later formulation into FMD vaccine as
1265	described in Section C.2, is a well established procedure for building stocks of immunogenic material ready to be
1266	formulated into vaccines in case of need. It not only forms the basis for the storage of antigens in a strategic reserve
1267	for emergency purposes, but allows the manufacturer immediate access to many different antigen strains that can
1268	be rapidly formulated and dispatched to the customer (Lombard & Fussel, 2007). Such stockpiling minimises delays
1269	subsequent to an order, particularly where a multivalent vaccine is requested. Another advantage of this procedure
1270	is that much of the quality testing can be completed well in advance of shipment. It is necessary to state that the
1271	concentrated antigens have to be controlled using standards indicated in Sections C.1–4.
1272	6.1. Storage conditions
1273	6.1.1. Facilities
1274	It is important that all aspects of the storage of concentrated antigens conform fully to
1275	internationally accepted requirements such as those referred to in chapter 1.1.8. Housing,
1276	facilities and procedures should ensure the security of the stored antigen and prevent tampering,
1277	contamination or damage.
1278	6.1.2. Containment of stored antigens
1279	The dose numbers or volumes stored are an important consideration, particularly where a reserve
1280	is shared between WOAHA Member Countries and there is variation in number of doses perceived
1281	to be needed by each Member in an emergency. Where the requirement is for a large stockpile
1282	of a particular vaccine strain that can only be produced from several separate production runs,
1283	vaccine bank managers must consider the need to either formulate each lot into a representative
1284	final blend for testing purposes or mixing the individual batches, at some convenient point, for
1285	ease of formulating and/or testing.
1286	The type of container used to hold antigen concentrate is important. Under ultra-low temperature
1287	conditions it is important to use containers made from materials that do not become brittle or
1288	fragile at a temperature range allowing for heat sterilisation and cold storage.
1289	6.1.3. Labelling of stored antigens
1290	The concentrated antigens do not need to be labelled according to final or finished vaccine
1291	requirements and may be labelled as “in process” materials. Under ultra-low temperature
1292	conditions, the method of labelling must be of a durable nature. From experience, wire tagging
1293	bottles is the most preferred option using a metal/plastic tag sizeable enough to allow the
1294	necessary detail. Such detail should include the antigen/vaccine strain, batch number, date
1295	received and should also include an individual container or stock number. This information should
1296	be clear to read and marked on the tag using an indelible marker pen. Storage records and
1297	positions of containers should be carefully maintained.
1298	6.2. Monitoring of stored concentrated antigens
1299	It is vitally important that antigen concentrates are optimally maintained and routinely monitored in order
1300	to have some assurance that they will be efficacious when needed. Therefore arrangements should be
1301	made to monitor these antigen concentrates on a routine basis and to include where necessary, and at
1302	appropriate time intervals, a testing regime to ensure integrity of the antigen component or acceptable
1303	potency of the final product.
1304	146S quantification, vaccination serology or vaccination challenge studies can be used for monitoring
1305	FMD antigen banks. It is recommended to carry out these tests on receipt (year 0) and every 5 years
1306	thereafter.

1307 To support these testing requirements for depositories of antigen, concentrates should include a number
1308 of small samples that are representative of the larger stock. Small aliquots/stocks of FMD antigen have
1309 usually consisted of a volume representing approximately one milligram of antigen. These aliquots
1310 should be stored side by side with the bulk antigen,

1311 **7. Emergency release of vaccines prepared from concentrated antigens**

1312 In situations of extreme urgency and subject to agreement by the National Veterinary Authority, a batch of vaccine
1313 may be released before completion of the tests and the determination of potency if a test for sterility has been
1314 carried out on the bulk inactivated antigen and all other components of the vaccine and if the test for safety and the
1315 determination of potency have been carried out on a representative batch of vaccine prepared from the same bulk
1316 inactivated antigen. In this context, a batch is not considered to be representative unless it has been prepared with
1317 not more than the amount of antigen or antigens and with the same formulation as the batch to be released.

1318 **D. VACCINE MATCHING TESTS**

1319 **1. Introduction**

1320 Appropriate vaccine strain selection is an important element in the control of FMD and is necessary for the
1321 application of vaccination programmes in FMD-affected regions as well as for the establishment and maintenance
1322 of vaccine antigen reserves to be used in the event of new FMD incursions. The decision to change or include new
1323 strains in vaccine formulations is a multifaceted process and, among other issues, experimental, epidemiological
1324 and field observations should be considered.

1325 Vaccination against one serotype of FMDV does not cross-protect against other serotypes and may also fail to
1326 protect fully or at all against other strains of the same serotype. The most direct and reliable method to measure
1327 cross-protection is to vaccinate relevant target species and then to challenge them by exposure to the virus isolate
1328 against which protection is required. This will take account of both potency and cross-reactivity.

1329 However, such an approach requires the use of live FMDV and appropriate biosecurity procedures and practices
1330 must be used. The facility should meet the appropriate level of biocontainment, determined by risk analysis as
1331 outlined in Chapter 1.1.4 *Biosafety and biosecurity: Standard for managing biological risk in the veterinary laboratory*
1332 *and animal facilities*. In addition to the safety concerns, this procedure is slow and expensive and requires specific
1333 expertise that is best available in WOAHA Reference laboratories. The use of animals for such studies should be
1334 avoided where possible by the use of *in-vitro* alternatives.

1335 A variety of *in vitro* serological methods can be used to quantify antigenic differences between FMDV strains and
1336 thereby estimate the likely cross-protection between a vaccine strain and a field isolate. Genetic characterisation
1337 and antigenic profiling together with epidemiological observations can also reveal the emergence of new strains for
1338 which vaccine matching may be required and, conversely, may indicate that an isolate is similar to one for which
1339 vaccine matching information is already available. Such tests should be carried out in laboratories that work
1340 according to the standard specified in chapter 1.1.4 and Chapter 1.1.5 *Quality management in veterinary testing*
1341 *laboratories*, preferably WOAHA Reference Laboratories for FMD.

1342 Shipping of samples should be in accordance with Chapter 1.1.3 *Transport of biological materials*.

1343 Vaccine potency and booster doses may contribute to the range of antigenic cover provided by a vaccine. A highly
1344 potent vaccine that stimulates a strong immune response may give protection to heterologous viruses. Furthermore,
1345 booster doses of vaccine can increase efficacy and the subsequent breadth of antigenic cover provided by a given
1346 vaccine, although the onset of full protection may be delayed (Pay, 1984).

1347 **2. Selection of field viruses for vaccine matching**

1348 For vaccine matching, preferably, more than one representative isolate should be evaluated from any outbreak.

1349 Viruses should be selected based on epidemiological information, for instance isolation at different stages of an
1350 outbreak, from different geographical locations, or from different hosts (Alonso *et al.*, 1987). Field evidence for a
1351 suspected lack of vaccine quality as shown by reduced apparent protection, is an important criterion for vaccine
1352 matching, but other reasons for apparent vaccine failure (inadequate coverage, inadequate cold chain, insufficient
1353 boosting, lack of complementary control measures, etc.) should be also thoroughly explored.

1354 The serotype of the field isolate is usually determined by ELISA or ~~CFT~~ using type-specific serological reagents,
1355 although methods based on MAbs or genetic typing may also be used. If the number of viruses exceeds the capacity

1356 of the laboratory to carry out methods described in Section D.4 *Vaccine matching tests*, a pre-selection of isolates
1357 should be done.

1358 In order to minimise the risk of missing a relevant sample, the pre-selection should be carried out using all the
1359 isolates received by the laboratory. The recommended approach is to engage in serological validated antigenic
1360 profiling methods using MAb ELISA or CFT. VP1 sequencing should be used to verify the genetic homogeneity of
1361 the virus isolate population and its genetic distance with respect to the available vaccine strains.

1362 The emergence of a new virus strain may be characterised by rapid dissemination with many outbreaks, and
1363 isolates from such epidemics are a priority for vaccine matching. Furthermore, isolates showing prevalence within
1364 the outbreak are the best candidates for vaccine matching tests. Isolates showing important differences with vaccine
1365 strains and not prevalent within the outbreak should be monitored closely through active surveillance in the field.

1366 **3. Selection of vaccine strains to be matched**

1367 The serotype of the virus, the region of origin and any information on the characteristics of the field isolate and, as
1368 appropriate, the vaccine strain used in the region of origin, may give indications as to the vaccine strains to be
1369 selected for vaccine matching tests. The availability of reagents for matching to particular vaccine strains may limit
1370 the extent of testing that is possible. To avoid this problem, it is expected that vaccine manufacturers should provide,
1371 upon request of the vaccine purchaser and WOA Reference Laboratories, post-vaccination sera produced during
1372 final product batch potency testing. It is also recommended that WOA Reference Laboratories guarantee the
1373 availability of reference post-vaccination sera produced with relevant vaccine strains. Vaccine matching approaches
1374 have two purposes: first, to guide the selection of the most effective vaccine strain for use in a particular field
1375 circumstance, either routine prophylactic vaccination or emergency use, for which matching requirements are not
1376 necessarily the same; and second, to monitor, on an ongoing basis, the suitability of vaccine strains maintained in
1377 strategic antigen reserves.

1378 **4. Vaccine matching tests**

1379 The serological relationship between a field isolate and a vaccine virus (r value) can be determined by VNT, or
1380 ELISA or CFT. One way testing is recommended (r_1) with a vaccine antiserum, rather than two way testing (r_2),
1381 which also requires an antiserum against the field isolate to be matched. *In-vitro* neutralisation may be more relevant
1382 to predict *in-vivo* protection by the vaccine than other measures of virus-antibody interaction. VNT using the
1383 chequer-board titration method or other layout can be undertaken based in the laboratory experience. ELISA
1384 depends on the availability of trapping and detector antibodies suitable to the field strains, but it is more reproducible
1385 than VNT and can be carried out with inactivated virus. ~~CFT can be used as a screening method to select strains
1386 to be tested by VNT or ELISA.~~ The reproducibility of VNT results can be improved by incorporating multiple virus
1387 dilutions into the test so that the virus titre can be determined accurately by logistical regression.

1388 For either VNT or ELISA, post-vaccination sera should be derived from at least five cattle 21–30 days after primary
1389 vaccination and/or 21–30 days after booster vaccination. The titre of antibody to the vaccine strain is established
1390 for each serum. Sera are used individually or pooled, after excluding low responders (Mattion *et al.*, 2009).

1391 **4.1. Relationship between the field isolate and the vaccine strain**

1392 The recommended standard test is the VNT. The ELISA can also be used if suitable reagents are
1393 available or as a screening test. ~~The CFT is suitable as a screening test to select strains to be analysed
1394 by VNT or ELISA.~~

1395 **4.1.1. Vaccine matching by two-dimensional (chequerboard) neutralisation test**

1396 This test uses antiserum raised against a vaccine strain. The titres of this serum against
1397 100 TCID₅₀% of the homologous vaccine strain and the same dose of a field isolate are compared
1398 to estimate the immunological coverage of the vaccine strain in relation to the field virus. For the
1399 test each 100 µl of virus/serum mixture contains 100 TCID₅₀ of test virus.

1400 **4.1.1.1. Test procedure**

1401 The procedure is similar to that of the VNT (see Section B.2.1 *Virus neutralisation*).

1402 Additional biological reagents are: monovalent 21–30 day post-vaccination bovine sera
1403 (inactivated at 56°C for 45–60 minutes), the homologous vaccine strain; and the test virus,
1404 a field isolate of the same serotype as the vaccine strain.

- 1405 i) Field isolates are passaged on cell cultures until adapted to give 100% CPE in
1406 24 hours. Passages should be kept to a minimum. When adapted, determine the virus
1407 titre (\log_{10} TCID₅₀/ml) by end-point titration.
- 1408 ii) For each test and vaccine virus a chequerboard titration is performed of virus against
1409 vaccine serum along with a back-titration of virus. Cells are added and incubated at
1410 37°C for 48–72 hours after which time CPE is assessed.
- 1411 iii) Antibody titres of the vaccine serum against the vaccine strain and field isolate for each
1412 virus dose used are calculated using the Spearman–Kärber method. The titre of the
1413 vaccine serum against 100 TCID₅₀ of each virus can then be estimated by regression.
1414 The relationship between the field isolate and the vaccine strain is then expressed as
1415 an 'r' value as:

$$r_1 = \frac{\text{reciprocal arithmetic titre of reference serum against field virus}}{\text{reciprocal arithmetic titre of reference serum against vaccine virus}}$$

1416 4.1.1.2. Interpretation

1417 *Interpretation of the results of cross-reactivity tests:* It has been generally accepted that in
1418 the case of neutralisation, r_1 values greater than 0.3 indicate that the field isolate is
1419 sufficiently similar to the vaccine strain so that use of a vaccine based on this strain is likely
1420 to confer protection against challenge with the field isolate. However, protection depends on
1421 both the cross-reactivity of antibodies elicited by the vaccine and the strength of the antibody
1422 response. The latter will be influenced by the potency of the vaccine and the number of
1423 doses given.

1424 When deciding whether or not to use vaccines for which r_1 values lower than 0.3 are
1425 observed, factors to be considered include the availability of better matching vaccine strains,
1426 the potency of the vaccine and the potential for this to be increased to provide heterologous
1427 responses, the possibility of using additional booster doses, and the extent to which control
1428 of disease will be complemented by other zoonosanitary measures or will be dependent on
1429 vaccination. The combined impact of potency and match can be estimated from the
1430 serological titre of the vaccine antiserum against the field virus, although correlating this
1431 precisely to protection requires a cross-protection test.

1432 Alternatively, a suitable field isolate could be adapted to become a new vaccine strain.

1433 Tests should always be repeated more than once. The confidence with which 'r' values can
1434 be taken to indicate differences between strains is related to the number of times that the
1435 examination is repeated. In practice, a minimum of at least three repetitions is advised.

1436 4.1.2. Vaccine matching by expectancy of protection (EPP) determined by one-dimensional 1437 neutralisation test

1438 Vaccine matching based on EPP values is widely used in South America where correlation tables
1439 are available for the vaccine strains used in the Region. This test uses antiserum raised against
1440 a vaccine strain (primo and booster vaccination). The titres of sera against 100 TCID₅₀/100 μ l of
1441 sera/virus mixtures of the homologous vaccine strain and the same dose of a field isolate are
1442 compared to estimate the immunological coverage of the vaccine strain in relation to the field
1443 virus.

1444 4.1.2.1. Test procedure

1445 The procedure is similar to that of the VNT (see Section B.2.1 *Virus neutralisation*).

1446 Additional biological reagents are: monovalent 21–30 day post-vaccination, and/or 21–
1447 30 day post-booster vaccination bovine sera (inactivated at 56°C for 45–60 minutes); the
1448 homologous vaccine strain; and the test virus, a field isolate of the same serotype as the
1449 vaccine strain. For regions where multivalent vaccines are used, it is advisable to use sera
1450 panels raised against the vaccine commonly used in the vaccination programme.

1451 i) Field isolates are passaged on cell cultures until adapted to give 100% CPE in
1452 24 hours. Passages should be kept to a minimum. When adapted, determine the virus
1453 titre (\log_{10} TCID₅₀/ml) by end-point titration.

1454 ii) For each test and vaccine virus, a titration of antibodies is performed against a fixed
1455 amount of virus (100 TCID₅₀ of virus/100 μ l of mixture sera/virus), along with a back-
1456 titration of working virus. Sera/virus mixtures and virus back titration are incubated at

1457 37°C for 60 minutes and then inoculated on to microplates with preformed cell
1458 monolayers. Each serum dilution is inoculated in four wells and at least six sera
1459 dilutions are used. Microplates are incubated at 37°C for 48 hours under CO₂
1460 atmosphere after which time CPE is assessed.

1461 iii) Antibody titres of the vaccine serum against the vaccine strain and field isolate are
1462 calculated using the Spearman–Kärber method. The titre of the vaccine serum against
1463 100 TCID₅₀ of each virus can then be estimated and expressed per ml. Individual EPP
1464 values are determined for each individual neutralisation titre using predefined
1465 correlation tables, and then the mean of the EPP is calculated for each group of sera
1466 (vaccinated and booster vaccinated). The immunological coverage of the vaccine
1467 strain is expressed by the EPP value.

1468 4.1.2.2. Interpretation of the results

1469 To interpret the results it is necessary to have a correlation defined between *in-vitro* titres
1470 and *in-vivo* challenge protection against 10,000 BID₅₀ of vaccine virus. In the PANAFTOSA
1471 experience with FMDV control and eradication programmes in South America, a mean EPP
1472 value of 75% in booster vaccinated animals indicates that the vaccine strain is suitable to
1473 be used together with appropriate field measures to control outbreaks with the field strain
1474 under test (correlation tables for O1, A24 and C3 are available upon request to
1475 PANAFTOSA).

1476 4.1.3. Vaccine matching by ELISA

1477 Similarly, the liquid-phase blocking ELISA described in Section B.2.3 is recommended for vaccine
1478 matching calculating the r_1 or EPP value.

1479 4.1.3.1. Test procedure

1480 The procedure is similar to that of the LPBE (see Section B.2.3 *Liquid-phase blocking*
1481 *enzyme-linked immunosorbent assay*).

1482 Additional biological reagents are: monovalent 21–30 day post-vaccination and/or 21–
1483 30 day post-booster vaccination bovine sera (inactivated at 56°C for 45–60 minutes); the
1484 homologous vaccine strain; and the test virus, a field isolate of the same serotype as the
1485 vaccine strain. For regions where multivalent vaccines are used, it is advisable to use sera
1486 panels raised against the vaccine commonly used in the vaccination programme.

1487 4.1.3.2. Interpretation of the results

1488 *Interpretation of r_1 results:* it has been proposed that in the case of LPBE, r_1 values greater
1489 than 0.4 indicate that the field isolate is sufficiently similar to the vaccine strain so that use
1490 of a vaccine based on this strain is likely to confer protection against challenge with the field
1491 isolate. However, protection depends on both the cross-reactivity of antibodies elicited by
1492 the vaccine and the strength of the antibody response. The latter will be influenced by the
1493 potency of the vaccine and the number of doses given. When deciding whether or not to use
1494 vaccines for which r_1 values lower than 0.4 are observed, factors to be considered include
1495 the availability of better matching vaccine strains, the potency of the vaccine and the
1496 potential for heterologous responses to be increased, the possibility of using additional
1497 booster doses, and the extent to which control of disease will be complemented by other
1498 zoo sanitary measures or will be dependent on vaccination.

1499 *Interpretation of EPP results:* to interpret the results it is necessary to have a correlation
1500 defined between *in-vitro* titres and *in-vivo* challenge protection against 10,000 BID₅₀ of
1501 vaccine virus. In the PANAFTOSA experience with FMDV control and eradication
1502 programmes in South America, a mean EPP value of 75% in booster vaccinated animals
1503 indicates that the vaccine strain is suitable to be used together with appropriate field
1504 measures to control outbreaks with the field strain under test (correlation tables for O1, A24
1505 and C3 are available upon request to PANAFTOSA).

1506 4.1.4. Vaccine matching by CFT

1507 The CFT preferably performed in a tube, can be used as a screening test to select those strains
1508 to be tested by VN or ELISA. The test is performed as described in Section B.1.2.4. Additional
1509 biological reagents are guinea-pig hyper-immune sera against vaccine strains. Sera antibody titre
1510 is determined against homologous virus and field strains. The r_1 value is calculated as previously
1511 described:

$$r_1 = \frac{\text{reciprocal arithmetic titre of reference serum against field virus}}{\text{reciprocal arithmetic titre of reference serum against vaccine virus}}$$

1512 ~~Interpretation of the results: it is generally accepted that r_1 values equal or greater to 0.25 indicate~~
1513 ~~that the field isolate is sufficiently similar to the vaccine strain. Studies by VNT or ELISA need to~~
1514 ~~be performed with selected strains to confirm suggested CFT classification.~~

1515 4.2. Testing the fitness for purpose of a vaccine

1516 The “r” value should not be used in isolation to select the most appropriate vaccine strain to be used in
1517 the field. Particularly when it suggests an insufficient match of a certain vaccine strain, the suitability of
1518 a vaccine based on such a vaccine strain could be demonstrated by a heterologous cross-protection
1519 challenge test carried out as described in Section C.4.3 *Identity testing* in animals vaccinated with a
1520 known vaccine and challenged with the (heterologous) field virus. Vaccinate at least seven cattle without
1521 FMD antibodies, with a commercial dose of the current vaccine to be used in the region. Between
1522 28 and 30 days later, boost all these animals with a second commercial dose in the same conditions and
1523 vaccinate a second group of at least seven animals with the same vaccine dosage and same route.
1524 Challenge the two groups and two control animals (not vaccinated) 30 days later with the equivalent of
1525 a total of 10,000 BID 50% of the new field strain duly titrated. The results are valid if each of the two
1526 control animal shows podal lesions on at least three feet. Final results are reported either as the number
1527 of protected animals (without podal lesion) over the total number of animal per group, or by percentage
1528 of protection where 100% is the total number of animals used per group. If results in the group of once
1529 vaccinated cattle indicate a protection level under 50%, and in the group of twice vaccinated cattle,
1530 protection under 75%, the change for a more appropriate vaccine strain is recommended.

1531 The use of the EPP method is possible when correlation studies have been performed for the vaccine
1532 strain. The EPP method proved to be useful in some regions of the world applied together with
1533 epidemiological observations and active surveillance in the field. This method measures the reactivity of
1534 a panel of post-vaccination antisera using either VNT or ELISA and relates the serological titres to the
1535 probability of protection, established through correlation tables associating antibody titres with protection
1536 against challenge of 10000 BID₅₀ of the homologous vaccine strain.

1537 REFERENCES

- 1538 ABOSRER F., PEZZONI G., BROCCCHI E., CASTELLI A., BASELLI S., GRAZIOLI S., MADANI H., KRAIM E., DAYHUM A. &
1539 ELDAGHAYES I. (2022). FTA Cards as a Rapid Tool for Collection and Transport of Infective Samples: Experience
1540 with Foot-and-Mouth Disease Virus in Libya. *Animals (Basel)*, **2**, 3198. <https://doi.org/10.3390/ani12223198>
- 1541 ALONSO F.A., CASAS OLASCOAGA R.C., ASTUDILLO V.M., SONDAHL M.S., GOMES I. & VIANNA FILHO Y.L. (1987). Updating
1542 of foot-and-mouth disease virus strains of epidemiological importance in South America. *Bol. Centr. Panam. Fiebre*
1543 *Aftosa*, **53**, 11–18.
- 1544 ALONSO A., GOMES M.D., RAMALHO A.K., ALLENDE R., BARAHONA H., SONDHAL M. & OSÓRIO F. (1993). Characterization
1545 of foot-and-mouth disease virus by monoclonal antibodies. *Viral Immunol.*, **6**, 219–228.
- 1546 AMARAL-DOEL C.M., OWEN N.E., FERRIS N.P., KITCHING R.P. & DOEL T.R. (1993). Detection of foot-and-mouth disease
1547 viral sequences in clinical specimens and ethyleneimine-inactivated preparations by the polymerase chain reaction.
1548 *Vaccine*, **11**, 415–421. doi: 10.1016/0264-410x(93)90281-2.
- 1549 ARMSON B., MIOULET V., DOEL C., MADI M., PARIDA S., LEMIRE K.A., HOLDER D.J., DAS A., MCINTOSH M.T. & KING D.P.
1550 (2018). Detection of foot-and-mouth disease virus in milk samples by real-time reverse transcription polymerase
1551 chain reaction: Optimisation and evaluation of a high-throughput screening method with potential for disease
1552 surveillance. *Vet. Microbiol.*, **223**, 189–194. doi: 10.1016/j.vetmic.2018.07.024.
- 1553 ARMSON B., WADSWORTH J., KIBONA T., MSHANGA D., FOWLER V.L., KNOWLES N.J., MIOULET V., REEVE R., KING D.P.,
1554 BACHANEK-BANKOWSKA K. & LEMBO T. (2019). Opportunities for enhanced surveillance of foot-and-mouth disease in
1555 endemic settings using milk samples. *Transbound. Emerg. Dis.*, **66**, 1405–1410. doi: 10.1111/tbed.13146.
- 1556 BACHANEK-BANKOWSKA K., MERO H.R., WADSWORTH J., MIOULET V., SALLU R., BELSHAM G.J., KASANGA C.J., KNOWLES
1557 N.J. & KING D.P. (2016). Development and evaluation of tailored specific real-time RT-PCR assays for detection of
1558 foot-and-mouth disease virus serotypes circulating in East Africa. *J. Virol. Methods*, **237**, 114–120. doi:
1559 10.1016/j.jviromet.2016.08.002

- 1560 BAHNEMANN H.G. (1990). Inactivation of viral antigens for vaccine preparation with particular reference to the
1561 application of binary ethylenimine. *Vaccine*, **8**, 299–303.
- 1562 BERGMANN I.E., MALIRAT V., NEIZERT E., PANIZUTTI N., SANCHEZ C. & FALCZUK A. (2000). Improvement of
1563 serodiagnostic strategy for foot and mouth disease virus surveillance in cattle under systematic vaccination: a
1564 combined system of an indirect ELISA-3ABC with an enzyme-linked immunoelectrotransfer blot. *Arch. Virol.*, **145**,
1565 473–489.
- 1566 BERGMANN I.E., NEIZERT E., MALIRAT V., ORTIZ S., COLLING A., SANCHEZ C. & CORREA MELO E. (2003). Rapid
1567 serological profiling by enzyme-linked immunosorbent assay and its use as an epidemiological indicator of foot-
1568 and-mouth disease viral activity. *Arch. Virol.*, **148**, 891–901.
- 1569 BISWAL J.K., SUBRAMANIAM S., RANJAN R. & PATTNAIK B. (2016). Evaluation of FTA(®) card for the rescue of infectious
1570 foot-and-mouth disease virus by chemical transfection of extracted RNA in cultured cells. *Mol. Cell. Probes*, **30**,
1571 225–230. doi: 10.1016/j.mcp.2016.06.002.
- 1572 BROCCHI E., BERGMANN I.E., DEKKER A., PATON D.J., SAMMIN D.J., GREINER M., GRAZIOLI S., DE SIMONE F., YADIN H., HAAS
1573 B., BULUT N., MALIRAT V., NEIZERT E., GORIS N., PARIDA S., SORENSEN K. & DE CLERCQ K. (2006). Comparative evaluation
1574 of six ELISAs for the detection of antibodies to the non-structural proteins of foot-and-mouth disease virus. *Vaccine*,
1575 **24**, 6966–6979.
- 1576 BROCCHI E., DE SIMONE F., BUGNETTI M., GAMBA D. & CAPUCCI L. (1990). Application of a monoclonal antibody-based
1577 competition ELISA to the measurement of anti-FMDV antibodies in animal sera. Report of the European
1578 Commission for the Control of Foot-and-Mouth Disease (Session of the Research Group of the Standing Technical
1579 Committee) Lindholm, Denmark, Appendix 14; FAO, Rome, Italy.
- 1580 CALLAHAN J.D., BROWN F., CSORIO F.A., SUR J.H., KRAMER E., LONG G.W., LUBROTH J., ELLIS S.J., SHOULARS K.S.,
1581 GAFFNEY K.L., ROCK D.L. & NELSON W.M. (2002). Use of a portable real-time reverse transcriptase-polymerase chain
1582 reaction assay for rapid detection of foot-and-mouth disease virus. *J. Am. Vet. Med. Assoc.*, **220**, 1636–1642.
- 1583 CAMPOS R.M., MALIRAT V., NEIZERT E., GRAZIOLI S., BROCCHI E., SANCHEZ C., FALCZUK A.J., ORTIZ S., REBELLO M.A. &
1584 BERGMANN I.E. (2008). Development and characterization of a bovine serum evaluation panel as a standard for
1585 immunoassays based on detection of antibodies against foot-and-mouth disease viral non-capsid proteins. *J. Virol.*
1586 *Methods*, **151**, 15–23.
- 1587 CARRILLO C., TULMAN E.R., DELHON G., LU Z., CARRENO A., VAGNOZZI A., KUTISH G.F. & ROCK D.L. (2005). Comparative
1588 genomics of foot-and-mouth disease virus. *J. Virol.*, **79**, 6487–6504. doi: 10.1128/JVI.79.10.6487-6504.2005.
- 1589 CHENARD G., MIEDEMA K., MOONEN P., SCHRIJVER R.S. & DEKKER A. (2003). A solid-phase blocking ELISA for detection
1590 of type O foot-and-mouth disease virus antibodies suitable for mass serology. *J. Virol. Methods*, **107**, 89–98.
- 1591 CHESTLEY T., SROGA P., NEBROSKI M., HOLE K., ULARAMU H., LUNG O. & NFOR C. (2022). Development of reverse-
1592 transcriptase, real-time PCR assays to distinguish the Southern African Territories (SAT) serotypes 1 and 3 and
1593 topotype VII of SAT2 of Foot-and-Mouth Disease Virus. *Front. Vet. Sci.*, **9**, 977761. doi: 10.3389/fvets.2022.977761
- 1594 COTTAM E.M., WADSWORTH J., SHAW A.E., ROWLANDS R.J., GOATLEY L., MAAN S., MAAN N.S., MERTENS P.P.C., EBERT
1595 K., LI Y., RYAN E.D., JULEFF N., FERRIS N.P., WILESMITH J.W., HAYDON D.T., KING D.P., PATON D.J. & KNOWLES N.J.
1596 (2008). Transmission pathways of foot-and-mouth disease virus in the United Kingdom in 2007. *PLoS Pathog.*, **4**
1597 (4), e1000050.
- 1598 DE DIEGO M., BROCCHI E., MACKAY D. & DE SIMONE F. (1997). The use of the non-structural polyprotein 3ABC of FMD
1599 virus as a diagnostic antigen in ELISA to differentiate infected from vaccinated cattle. *Arch. Virol.*, **142**, 2021–2033.
- 1600 DILL V., BEER M. & HOFFMANN B. (2017). Simple, quick and cost-efficient: A universal RT-PCR and sequencing strategy for
1601 genomic characterisation of foot-and-mouth disease viruses. *J. Virol. Methods*, **246**, 58–64. doi:
1602 10.1016/j.jviromet.2017.04.007.
- 1603 DILL V. & ESCHBAUMER M. (2019). Reliable detection, sequencing, and transfection of foot-and-mouth disease virus
1604 RNA from badly preserved vesicular epithelium. *J. Vet. Diagn. Invest.*, **31**, 778–782. doi:
1605 10.1177/1040638719870859.
- 1606 DOEL T.R. & PULLEN L. (1990). International bank for foot-and-mouth disease vaccines: stability studies with virus
1607 concentrates and vaccines prepared from them. *Vaccine*, **8**, 473–478.

- 1608 FERRIS N.P. & DAWSON M. (1988). Routine application of enzyme linked immunosorbent assay in comparison with
1609 complement fixation for the diagnosis of foot and mouth and swine vesicular disease. *Vet. Microbiol.*, **16**, 201–209.
- 1610 FERRIS N.P. & DONALDSON A.I. (1992). The World Reference Laboratory for Foot and Mouth Disease: a review of
1611 thirty-three years of activity (1958–1991). *Rev. sci. tech. Off. int. epiz.*, **11**, 657–684.
- 1612 FERRIS N.P., NORDENGRABH A., HUTCHINGS G.H., REID S.M., KING D.P., EBERT K., PATON D.J., KRISTERSSON T., BROCCHI
1613 E., GRAZIOLI S. & MERZA M. (2009). Development and laboratory validation of a lateral flow device for the detection
1614 of foot-and-mouth disease virus in clinical samples. *J. Virol. Methods*, **155**, 10–17.
- 1615 FOOD AND AGRICULTURAL ORGANIZATION OF THE UNITED NATIONS (FAO) (1984). Emerging Diseases of Livestock. Vol. 1.
1616 The Diseases and their Diagnosis, Geering W.A., ed. FAO, Rome, Italy, 43–51.
- 1617 FOWLER V.L., BANKOWSKI B.M., ARMSON B., DI NARDO A., VALDAZO-GONZALEZ B., REID S.M., BARNETT P.V., WADSWORTH
1618 J., FERRIS N.P., MIOULET V. & KING D.P. (2014). Recovery of viral RNA and infectious foot-and-mouth disease virus
1619 from positive lateral-flow devices. *PLoS One*, **14**, 9(10):e109322. doi: 10.1371/journal.pone.0109322.
- 1620 GOLDING S.M., HEDGER R.S., TALBOT P. & WATSON J. (1976). Radial immunodiffusions and serum neutralisation
1621 techniques for the assay of antibodies to swine vesicular disease. *Res. Vet. Sci.*, **20**, 142–147.
- 1622 GOLLER K.V., DILL V., MADI M., MARTIN P., VAN DER STEDE Y., VANDENBERGE V., HAAS B., VAN BORM S., KOENEN F.,
1623 KASANGA C.J., NDUSILO N., BEER M., LIU L., MIOULET V., ARMSON B., KING D.P. & FOWLER V.L. (2018). Rapid and simple
1624 detection of foot-and-mouth disease virus: Evaluation of a cartridge-based molecular detection system for use in
1625 basic laboratories. *Transbound. Emerg. Dis.*, **65**, 578–584. doi: 10.1111/tbed.12744.
- 1626 GORIS N. & DE CLERCQ K. (2005a). Quality assurance/quality control of foot and mouth disease solid phase
1627 competition enzyme-linked immunosorbent assay – Part I. Quality assurance: development of secondary and
1628 working standards. *Rev. sci. tech. Off. int. Epiz.*, **24**, 995–1004.
- 1629 GORIS N. & DE CLERCQ K. (2005b). Quality assurance/quality control of foot and mouth disease solid phase
1630 competition enzyme-linked immunosorbent assay – Part II. Quality control: comparison of two charting methods to
1631 monitor assay performance. *Rev. sci. tech. Off. int. Epiz.*, **24**, 1005–1016.
- 1632 GORIS N., MARADEI E., D'ALOIA R., FONDEVILA N., MATTION N., PEREZ A., SMITSAART E., NAUWYNCK H.J., LA TORRE J.,
1633 PALMA E. & DE CLERCQ K. (2008). Foot-and-mouth disease vaccine potency testing in cattle using homologous and
1634 heterologous challenge strains: precision of the “Protection against Podal Generalisation” test. *Vaccine*, **26**, 3432–
1635 3437.
- 1636 GORNA K., RELMY A., ROMÉY A., ZIENTARA S., BLAISE-BOISSEAU S. & BAKKALI KASSIMI L. (2016). Establishment and
1637 validation of two duplex one-step real-time RT-PCR assays for diagnosis of foot-and-mouth disease. *J. Virol. Methods*,
1638 **235**, 168–175.
- 1639 GRAY A.R., WOOD B.A., HENRY E., AZHAR M., KING D.P. & MIOULET V. (2020). Evaluation of Cell Lines for the Isolation
1640 of Foot-and-Mouth Disease Virus and Other Viruses Causing Vesicular Disease. *Front. Vet. Sci.*, **7**, 426. doi:
1641 10.3389/fvets.2020.00426
- 1642 GRAZIOLI S., FERRIS N.P., DHO G., PEZZONI G., MORRIS A.S., MIOULET V. & BROCCHI E. (2020). Development and
1643 validation of a simplified serotyping ELISA based on monoclonal antibodies for the diagnosis of foot-and-mouth
1644 disease virus serotypes O, A, C and Asia 1. *Transbound. Emerg. Dis.*, **67**, 3005–3015. doi: 10.1111/tbed.13677
- 1645 HAMBLIN C., BARNETT I.T.R. & HEDGER R.S. (1986). A new enzyme-linked immunosorbent assay (ELISA) for the
1646 detection of antibodies against foot-and-mouth disease virus. I. Development and method of ELISA. *J. Immunol.*
1647 *Methods*, **93**, 115–121.
- 1648 HAMBLIN C., KITCHING R.P., DONALDSON A.I., CROWTHER J.R. & BARNETT I.T.R. (1987). Enzyme-linked immunosorbent
1649 assay (ELISA) for the detection of antibodies against foot-and-mouth disease virus. 3. Evaluation of antibodies after
1650 infection and vaccination. *Epidemiol. Infect.*, **99**, 733–744.
- 1651 HOLE K. & NEON C. (2019). Foot-and-mouth disease virus detection on a handheld real-time polymerase chain
1652 reaction platform. *Transbound. Emerg. Dis.*, **66**, 1789–1795. doi: 10.1111/tbed.13227.
- 1653 HOWSON E.L.A., ARMSON B., LYONS N.A., CHEPKWONY E., KASANGA C.J., KANDUSI S., NDUSILO N., YAMAZAKI W., GIZAW
1654 D., CLEAVELAND S., LEMBO T., RAUH R., NELSON W.M., WOOD B.A., MIOULET V., KING D.P. & FOWLER V.L. (2018). Direct
1655 detection and characterization of foot-and-mouth disease virus in East Africa using a field-ready real-time PCR
1656 platform. *Transbound. Emerg. Dis.*, **65**, 221–231. doi: 10.1111/tbed.12684.

-
- 1657 JULEFF N., WINDSOR M., REID E., SEAGO J., ZHANG Z., MONAGHAN P., MORRISON I.W. & CHARLESTON B. (2008). Foot-
1658 and-mouth disease virus persists in the light zone of germinal centres. *PLoS One*, **3** (10), e3434.
- 1659 KÄRBER G. (1931). Beitrag zur kollektiven behandlung pharmakologischer reihenversuche. *Archive für*
1660 *Experimentelle Pathologie Pharmakologie*, **162**, 480–483.
- 1661 KITCHING R.P. & DONALDSON A.I. (1987). Collection and transportation of specimens for vesicular virus investigation.
1662 *Rev. sci. tech. Off. int. Epiz.*, **6**, 263–272.
- 1663 KNOWLES N.J. & SAMUEL A.R. (2003). Molecular epidemiology of foot-and-mouth disease virus. *Virus Res.*, **91**, 65–
1664 80.
- 1665 KNOWLES N.J., WADSWORTH J., BACHANEK-BANKOWSKA K. & KING D.P (2016). VP1 sequencing protocol for foot and
1666 mouth disease virus molecular epidemiology. *Rev. sci. tech. Off.int. Epiz.*, **35**, 741–755.
- 1667 LARSKA M., WERNERY U., KINNE J., SCHUSTER R., ALEXANDERSEN G. & ALEXANDERSEN S. (2009). Differences in the
1668 susceptibility of dromedary and Bactrian camels to foot-and-mouth disease virus. *Epidemiol. Infect.*, **137**, 549–554.
- 1669 LUDI A.B., MORRIS A., GUBBINS S., ASFOR A., AFZAL M., BROWNING C.F., GRAZIOLI S., FOGLIA E.A., WILSDEN G., BURMAN
1670 A., BROCCHI E., PATON D.J. & KING D.P. (2022). Cross-Serotype Reactivity of ELISAs Used to Detect Antibodies to
1671 the Structural Proteins of Foot-and-Mouth Disease Virus. *Viruses*, **14**, 1495. <https://doi.org/10.3390/v14071495>
- 1672 LOGAN G., FREIMANIS G.L., KING D.J., VALDAZO-GONZÁLEZ B., BACHANEK-BANKOWSKA K., SANDERSON N.D., KNOWLES
1673 N.J., KING D.P. & COTTAM E.M. (2014). A universal protocol to generate consensus level genome sequences for foot-
1674 and-mouth disease virus and other positive-sense polyadenylated RNA viruses using the Illumina MiSeq. *BMC*
1675 *Genomics*, **15**, 828. doi: 10.1186/1471-2164-15-828.
- 1676 LOMBARD M. & FUESSEL A.E. (2007). Antigen and vaccine banks: technical requirements and the role of the
1677 European antigen bank in emergency foot and mouth disease vaccination. *Rev. sci. tech. Off.int. Epiz.*, **26**, 117–
1678 134.
- 1679 MACKAY D.K., BULUT A.N., RENDLE T., DAVIDSON F. & FERRIS N.P. (2001). A solid-phase competition ELISA for
1680 measuring antibody to foot-and-mouth disease virus. *J. Virol. Methods*, **97**, 33–48.
- 1681 MACKAY D.K.J., FORSYTH M.A., DAVIES P.R., BERLINZANI, A., BELSHAM G.J., FLINT M. & RYAN M.D. (1997). Differentiating
1682 infection from vaccination in foot-and-mouth disease using a panel of recombinant, non-structural proteins in ELISA.
1683 *Vaccine*, **16**, 446–459.
- 1684 MARADEI E., LA TORRE J., ROBILOLO B., ESTEVES J., SEKI C., PEDEMONTE A., IGLESIAS M, D'ALOIA R. & MATTION N. (2008).
1685 Updating of the correlation between IpELISA titers and protection from virus challenge for the assessment of the
1686 potency of polyvalent aphtovirus vaccines in Argentina. *Vaccine*, **26**, 6577–6586.
- 1687 MATTION N., GORIS N., WILLEMS T., ROBILOLO B., MARADEI E., BEASCOECHEA C.P., PEREZ A., SMITSAART E., FONDEVILA N.,
1688 PALMA E., DE CLERCQ K. & LA TORRE J. (2009). Some guidelines for determining foot-and-mouth disease vaccine
1689 strain matching by serology. *Vaccine*, **27**, 741–747.
- 1690 McCULLOUGH K.C., DE SIMONE F., BROCCHI E., CAPUCCI L., CROWTHER J.R. & KIHM U. (1992). Protective immune
1691 response against foot-and-mouth disease. *J. Virol.*, **66**, 1835–1840.
- 1692 MINISTRY OF AGRICULTURE, FISHERIES AND FOOD (1986). Foot-and-mouth disease. Ageing of lesions. Her Majesty's
1693 Stationery Office, London, UK.
- 1694 MONIWA M., CLAVIJO A., LI M., COLLIGNON B. & KITCHING P.R. (2007). Performance of a foot-and-mouth disease virus
1695 reverse transcription-polymerase chain reaction with amplification controls between three real-time instruments. *J.*
1696 *Vet. Diagn. Invest.*, **19**, 9–20. doi: 10.1177/104063870701900103.
- 1697 NEIZERT E., BECK E., AUGÉ DE MELLO P., GOMES I. & BERGMANN I.E. (1991). Expression of the aphtovirus RNA
1698 polymerase gene in *Escherichia coli* and its use together with other bioengineered non-structural antigens in
1699 detection of lager persistent infections. *Virology*, **184**, 799–804.
- 1700 PAIBA G.A., ANDERSON J., PATON D.J., SOLDAN A.W., ALEXANDERSEN S., CORTEYN M., WILSDEN G., HAMBLIN P., MACKAY
1701 D.K. & DONALDSON A.I. (2004). Validation of a foot-and-mouth disease antibody screening solid-phase competition
1702 ELISA (SPCE). *J. Virol. Methods*, **115**, 145–158.
-

- 1703 PARIDA S., FLEMING L., GIBSON D., HAMBLIN P.A., GRAZIOLI S., BROCCHI E. & PATON D.J. (2007). Bovine serum panel
1704 for evaluating foot-and-mouth disease virus non-structural protein antibody tests. *J. Vet. Diagn. Invest.*, **19**, 539–
1705 544.
- 1706 PATON D.J., DI NARDO A., KNOWLES N.J., WADSWORTH J., PITUCO E.M., COSIVI O., RIVERA A.M., KASSIMI L.B., BROCCHI E., DE
1707 CLERCQ K., CARRILLO C., MAREE F.F., SINGH R.K., VOSLOO W., PARK M.K., SUMPTION K.J., LUDI A.B. & KING D.P. (2021). The
1708 history of foot-and-mouth disease virus serotype C: the first known extinct serotype? *Virus Evol.*, **7**(1):veab009. doi:
1709 10.1093/ve/veab009
- 1710 PAY T.W.F. (1984). Factors influencing the performance of foot-and-mouth disease vaccines under field conditions.
1711 *In: Applied Virology*, Kurstak E. ed., Academic Press Inc., New York, USA, 73–86.
- 1712 PERIOLO O., SEKI C., GRIGERA P., ROBIOLO B., FERNANDEZ G., MARADEI E., D'ALOIA R. & LA TORRE J.L. (1993). Large-
1713 scale use of liquid-phase blocking sandwich ELISA for the evaluation of protective immunity against aphthovirus in
1714 cattle vaccinated with oil adjuvanted vaccines in Argentina. *Vaccine*, **11**, 754–776.
- 1715 REID S.M., FERRIS N.P., HUTCHINGS G.H., SAMUEL A.R. & KNOWLES N.J. (2000). Primary diagnosis of foot-and-mouth
1716 disease by reverse transcription polymerase chain reaction. *J. Virol. Methods*, **89**, 167–176.
- 1717 REID S.M., FERRIS N.P., HUTCHINGS G.H., ZHANG Z., BELSHAM G.J. & ALEXANDERSEN S. (2001). Diagnosis of foot-and-
1718 Mouth disease by real-time fluorogenic PCR assay. *Vet. Rec.*, **149**, 621–623.
- 1719 REID S. M., GRIERSON S.S., FERRIS N.P., HUTCHINGS G.H. & ALEXANDERSEN S. (2003). Evaluation of automated RT-
1720 PCR to accelerate the laboratory diagnosis of foot-and-mouth disease virus. *J. Virol. Methods*, **107**, 129–139.
- 1721 ROEDER P.L. & LE BLANC SMITH P.M. (1987). The detection and typing of foot-and-mouth disease virus by enzyme-
1722 linked immunosorbent assay: a sensitive, rapid and reliable technique for primary diagnosis. *Res. Vet. Sci.*, **43**,
1723 225–232.
- 1724 ROMEY A., RELMY A., GORNA K., LALOY E., ZIENTARA S., BLAISE-BOISSEAU S. & BAKKALI KASSIMI L. (2018). Safe and
1725 cost-effective protocol for shipment of samples from Foot-and-Mouth Disease suspected cases for laboratory
1726 diagnostic. *Transbound. Emerg. Dis.*, **65**, 197–204. doi: 10.1111/tbed.
- 1727 SADJAKASSOVA M.A., WOOD B.A., HENRY E., GRAY A.R., MIOULET V., SULTANOV A.A., WADSWORTH J., KNOWLES N.J., DI
1728 NARDO A., KING D.P. & BACHANEK-BANKOWSKA K. (2023). Establishing a molecular toolbox of lineage-specific real-
1729 time RT-PCR assays for the characterization of foot-and-mouth disease viruses circulating in Asia. *Front. Vet. Sci.*,
1730 **10**, 1271690. doi: 10.3389/fvets.2023.1271690.
- 1731 SENTHILKUMARAN C., YANG M., BITTNER H., AMBAGALA A., LUNG O., ZIMMERMAN J., GIMÉNEZ-LIROLA L.G. & NEON C.
1732 (2017). Detection of genome, antigen, and antibodies in oral fluids from pigs infected with foot-and-mouth disease
1733 virus. *Can. J. Vet. Res.*, **81**, 82–90.
- 1734 SHAW A.E., REID S.M., EBERT K., HUTCHINGS G.H., FERRIS N.P. & KING, D.P. (2007). Protocol: Implementation of a one-
1735 step real-time RT-PCR protocol for diagnosis of foot-and-mouth disease. *J. Virol. Methods*, **143**, 81–85.
- 1736 SORENSEN K.J., MADSEN K.G., MADSEN E.S., SALT J.S., NQUINDI J. & MACKAY D.K.J. (1998). Differentiation of infection
1737 from vaccination in foot-and-mouth disease by the detection of antibodies to the non-structural proteins 3D, 3AB
1738 and 3ABC in ELISA using antigens expressed in baculovirus. *Arch. Virol.*, **143**, 1461–1476.
- 1739 STREBEL K., BECK E., STROHMAIER D. & SCHALLER H. (1986). Characterisation of foot-and-mouth disease virus gene
1740 products with antisera against bacterially synthesised fusion proteins. *J. Virol.*, **57**, 983–991.
- 1741 VANDEBUSSCHE F., LEFEBVRE D.J., DE LEEUW I., VAN BORM S. & DE CLERCQ K. (2017). Laboratory validation of two
1742 real-time RT-PCR methods with 5'-tailed primers for an enhanced detection of foot-and-mouth disease virus. *J.*
1743 *Virol. Methods*, **246**, 90–94. doi: 10.1016/j.jviromet.2017.04.014.
- 1744 VANDEBUSSCHE F., MATHIJS E., LEFEBVRE D., DE CLERCQ K. & VAN BORM S. (2016). A Tale of Tails: Dissecting the
1745 Enhancing Effect of Tailed Primers in Real-Time PCR. *PLoS One*, **11**(10):e0164463. doi:
1746 10.1371/journal.pone.0164463.
- 1747 VANGRYSPERRE W. & DE CLERCQ K. (1996). Rapid and sensitive polymerase chain reaction based detection and
1748 typing of foot and mouth disease virus in clinical samples and cell culture isolates, combined with a simultaneous
1749 differentiation with other genomically and/or symptomatically related viruses. *Arch. Virol.*, **141**, 331–344.

1750 VIANNA FILHO Y.L., ASTUDILLO V., GOMES I., FERNANDEZ G., ROZAS C.E.E., RAVISON J.A. & ALONSO A. (1993). Potency
1751 control of foot-and-mouth disease vaccine in cattle. Comparison of the 50% protective dose and protection against
1752 generalisation. *Vaccine*, **11–14**, 1424–1428.

1753 VOSLOO W., MORRIS J., DAVIS A., GILES M., WANG J., NGUYEN H.T., KIM P.V., QUACH N.V., LE P.T., NGUYEN P.H., DANG
1754 H., TRAN H.X., VU P.P., HUNG V.V., LE Q.T., TRAN T.M., MAI T.M., LE Q.T. & SINGANALLUR N.B. (2015). Collection of Oral
1755 Fluids Using Cotton Ropes as a Sampling Method to Detect Foot-and-Mouth Disease Virus Infection in Pigs.
1756 *Transbound. Emerg. Dis.*, **62**(5):e71-5. doi: 10.1111/tbed.12196.

1757 YEO S., YANG M., NYACHOTI M., RAUH R., CALLAHAN J.D. & NFOR C. (2020). Detection of Foot-and-Mouth Disease
1758 Virus in Swine Meat Juice. *Pathogens*, **9**, 424. doi: 10.3390/pathogens9060424.

1759
1760

*
* *

1761 **NB:** There are WOAHP Reference Laboratories for foot and mouth disease
1762 (please consult the WOAHP web site:
1763 <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>).
1764 Please contact WOAHP Reference Laboratories for any further information on
1765 FMD diagnostic tests, reagents and vaccines.

1766 **NB:** FIRST ADOPTED IN 1990. MOST RECENT UPDATES ADOPTED IN 2022.

CHAPTER 3.1.9.

HEARTWATER

SUMMARY

Description and importance of the disease: Heartwater (also known as cowdriosis) is an acute, fatal, non-contagious, infectious, tick-borne rickettsial disease of ruminants caused by *Ehrlichia ruminantium* (formerly *Cowdria ruminantium*) and transmitted by *Amblyomma* ticks. It occurs in nearly all sub-Saharan countries of Africa, in its neighbouring islands, and also in the Caribbean. The disease can cause high mortality (up to 90%) in susceptible domestic ruminants. Goats and sheep are more susceptible than cattle, and European breeds are generally more susceptible than indigenous African breeds.

Clinically, the disease most commonly presents as an acute form characterised by a sudden high fever, depressed demeanour, nervous signs and a high mortality. Hydropericardium and hydrothorax and lung oedema are commonly associated post-mortem lesions. Acute and peracute clinical forms of the disease occur: in the former, there are high death rates without many clinical manifestations and, in the latter, there is a higher recovery rate.

Recovered animals become carriers of infection. Certain wild animals can play a role as reservoir; *Rusa* deer, white-tailed deer, and springbok are susceptible to this infection and can experience high mortality.

Identification of the agent: The specific diagnosis of heartwater is based on the specific detection of the pathogen during the febrile phase or by observation of colonies of *E. ruminantium* in capillary endothelial cells of the brain.

In the absence of a molecular diagnostic tool capability, a piece of cerebellum can easily be removed with a curette through the foramen magnum after cutting off the head, while a sample of cerebral cortex can be obtained through a hole made in the skull with a hammer and a large nail. Brain smears are prepared by crushing to a paste and spreading thinly a small piece of cerebral or cerebellar cortex between two microscope slides. The capillaries are spread out in a single cell layer by drawing one slide across the other. The smears are air-dried, fixed with methanol and stained with Giemsa. The colonies (clusters) of *E. ruminantium* are reddish-purple to blue, and very often close to the nucleus of the infected endothelial cell. They can be scanty and difficult to find, particularly in peracute cases, but they are always present in the brain of a ruminant that died from heartwater, if not treated with drugs. Colonies are not likely to be detected in animals that were treated with antibiotics. The colonies are still visible 2 days after death in a brain that has been stored at room temperature (20–25°C) and up to 34 days in a brain that has been stored in a refrigerator at 4°C.

Ehrlichia ruminantium can be isolated from the blood of an infected host using cultivation on ruminant endothelial cells. When a cytopathic effect consisting of plaques of cell lysis appears, the presence of characteristic morulae is confirmed by staining the cell monolayer with Giemsa or RAL555 or by immunofluorescence.

Molecular tools such as nested polymerase chain reaction (PCR) and real-time PCR targeting *E. ruminantium*-specific genes are currently available for the detection of the presence of

44 *E. ruminantium* in the blood of animals with clinical signs, in organs from dead animals (confirming
45 clinical cases of heartwater), and also in the tick vectors. They could not however, detect
46 *E. ruminantium* in asymptomatic carriers. Two multi-pathogen methods, including *E. ruminantium*
47 detection, have been developed allowing differential diagnosis for tick-borne diseases to be
48 undertaken. Apart from diagnosis, molecular methods are widely used for research on the
49 *E. ruminantium* genome and for epidemiological studies, including *E. ruminantium* tick prevalence.
50 No commercial molecular kits targeting *E. ruminantium* are currently available.

51 **Serological tests:** Two enzyme-linked immunosorbent assays (ELISAs) have been evaluated: an
52 indirect ELISA and a competitive ELISA targeting major antigenic protein 1 (MAP1) antibodies.

53 The current indirect ELISA uses a recombinant antigen expressed as a partial fragment of the MAP1
54 antigens – the MAP1-B ELISA – which gives improved specificity over earlier methods. However, the
55 assay still detects cross-reacting antibodies to other Ehrlichial organisms including Ehrlichia
56 chaffeensis, *E. canis* and Panola Mountain Ehrlichia. Hence, definitive proof of heartwater must rely
57 on epidemiological evidence and additional molecular testing indicating the presence of the organism.
58 This ELISA can help to monitor experimental infections and to measure the immune response of
59 immunised animals, whose pre-immunisation serological history is known or for epidemiological
60 studies. Serology has very limited diagnostic use as clinically infected animals remain sero-negative
61 during the febrile reaction and sero-convert after recovery.

62 Serology is also not an effective import test efficacious test for health certification prior to international
63 movement. Prior to importation of animals from a heartwater endemic region, it is important to study
64 the epidemiological data to try to establish that the herd and the resident ticks are not infected.
65 Repeated serology on the herds and PCR on tick samples in targeted herds can be carried out to
66 demonstrate that they are free of *E. ruminantium*.

67 **Requirements for vaccines:** Immunisation against heartwater by the 'infection and treatment'
68 method using infected blood is still in use in some countries. A first-generation vaccine consisting of
69 inactivated purified elementary bodies of *E. ruminantium* emulsified in an oil adjuvant has given
70 promising results in experimentally controlled conditions and has demonstrated significant protection
71 in the field, but only for homologous challenges. Further improvement of the method to produce the
72 inactivated vaccine using bioreactors, antigen storage conditions, and different adjuvant has
73 demonstrated good efficiency in controlled conditions. An additional isolate, Welgevonden, has been
74 attenuated and shown to confer good protection in controlled conditions, and significant protection
75 has also been obtained using DNA vaccination. However, none of these experimental vaccines has
76 been fully validated under field conditions. Field trials and studies on genetic characterisation of
77 strains have revealed the presence of a high number of *E. ruminantium* strains in restricted areas.
78 Thus, antigenic diversity is important in formulating effective vaccines, and further investigations are
79 critical for the delivery of any vaccine in the field.

80

A. INTRODUCTION

81 Heartwater (cowdriosis) is a rickettsial disease of domestic and wild ruminants caused by *Ehrlichia ruminantium*
82 (formerly *Cowdria ruminantium*) and transmitted by *Amblyomma* ticks (Marcelino *et al.*, 2016). *Ehrlichia ruminantium*
83 is classified in the order Rickettsiales and in the family Anaplasmataceae, together with the genus *Anaplasma*.
84 Although ruminants remain the primary target of the pathogen, in South Africa a possible canine *E. ruminantium*
85 infection has been reported, and *E. ruminantium* has been strongly suspected in several cases of rapidly fatal
86 encephalitis in humans. However, in all cases, evidence of *E. ruminantium* infection was based on molecular
87 detection. Isolation and characterisation of the infectious agent is necessary before *E. ruminantium* can be
88 considered an emerging pathogen in species other than ruminants and especially in humans. Since then, no other
89 clinical human case associated with heartwater has been observed.

90 Heartwater is an important tick-borne disease of livestock in Africa occurring in nearly all the sub-Saharan countries
91 where *Amblyomma* ticks are present and in the surrounding islands: Madagascar, Reunion, Mauritius, Zanzibar,
92 the Comoros Islands and Sao Tomé. The disease is also reported in three Caribbean islands (Guadeloupe, Marie-
93 Galante and Antigua) (Marcelino *et al.*, 2016). All domestic and wild ruminants can be infected, but the former
94 appear to be the most susceptible. Indigenous domestic ruminants are usually more resistant to the disease. Wild
95 animals could play a role as reservoir, but Rusa deer, white-tailed deer, springbok, chital, timor deer, which are
96 used in wildlife farming, seem to be the main wild ruminant species in which heartwater can have a significant
97 economic impact.

98 The average natural incubation period is 2–3 weeks, but can vary from 10 days to 1 month. In most cases,
 99 heartwater is an acute febrile disease, with a sudden rise in body temperature, which may exceed 41°C within 1–
 100 2 days after the onset of fever. It remains high for 4–5 weeks with small fluctuations and drops shortly before death.

101 Fever is followed by inappetence, sometimes listlessness, diarrhoea, particularly in cattle, and dyspnoea indicative
 102 of lung oedema. Nervous signs develop gradually. The animal is restless, walks in circles, makes sucking
 103 movements and stands rigidly with tremors of the superficial muscles. Cattle may push their heads against a wall
 104 or present aggressive or anxious behaviour. Finally, the animal falls to the ground, pedalling and exhibiting
 105 opisthotonos, nystagmus and chewing movements. The animal usually dies during or following such an attack.

106 Subacute heartwater with less pronounced signs, and peracute heartwater with sudden death, can also occur,
 107 according to the breed of ruminant and the strain of *E. ruminantium* involved.

108 The most common macroscopic lesions are hydropericardium, hydrothorax, pulmonary oedema, intestinal
 109 congestion, oedema of the mediastinal and bronchial lymph nodes, petechiae on the epicardium and endocardium,
 110 congestion of the brain, and moderate splenomegaly (Marcelino *et al.*, 2016).

111 A tentative diagnosis of heartwater is based on the presence of *Amblyomma* vectors, nervous signs, and presence
 112 of transudates in the pericardium and thorax on post-mortem examination. When making a diagnosis based on
 113 clinical signs, the following other diseases should be considered: bovine cerebral babesiosis and theileriosis,
 114 anaplasmosis, botulism, haemonchosis in small ruminants, rabies and poisoning.

115 B. DIAGNOSTIC TECHNIQUES

116 Table 1. Test methods available for diagnosis of heartwater and their purpose

Method	Purpose					
	Population freedom from infection ^(a)	Individual animal freedom from infection prior to movement ^(b)	Contribute to eradication policies	Confirmation of clinical cases ^(c)	Prevalence of infection – surveillance ^(a)	Immune status in individual animals or populations post-vaccination ^(b)
Identification of the agent						
<i>In-vitro</i> bacterium isolation	–	–	–	+	–	–
Real-time PCR	–*	–	–	+++	–	–
Nested PCR	–*	–	–	+++	–	–
Multi- pathogen real-time PCR	–*	–	–	+++	–	–
Detection of immune response						
ELISA	++	+	–	–	+++	++

117 Key: +++ = recommended for this purpose; ++ recommended but has limitations;

118 + = suitable in very limited circumstances; – = not appropriate for this purpose.

119 *can be used to screen tick populations, in parallel with serology on hosts.

120 PCR = polymerase chain reaction; ELISA = enzyme-linked immunosorbent assay.

121 ^(a)See Appendix 1 of this chapter for justification table for the scores giving to the tests for this purpose.

122 ^(b)See Appendix 2 of this chapter for justification table for the scores giving to the tests for this purpose.

123 ^(c)See Appendix 3 of this chapter for justification table for the scores giving to the tests for this purpose.

124 1. Identification of the agent

125 During the febrile reaction, *E. ruminantium* can be readily isolated in culture from blood or plasma; however, it is
 126 difficult to detect these organisms in a blood smear. Typical colonies of *E. ruminantium* can be observed in brain
 127 smears made after death and this represents a definitive diagnosis for heartwater.

128 Opening the cranium is not necessary. An alternative method is to cut off the head in front of the first cervical
129 vertebra. Then, introduce a curette through the foramen magnum, between the medulla and the meninges. The
130 curette is turned over towards the brain and removed with a piece of cerebellum. Another method consists of making
131 a hole in the skull with a hammer and a large nail and aspirating a sample of brain cortex with a needle attached to
132 a syringe. These methods also lessen the danger to the operator in cases where the nervous signs have been
133 caused by rabies.

134 In the live animal, a brain biopsy may be obtained aseptically after local anaesthesia, although with difficulty;
135 appropriate restraint must be used especially with large and horned animals. Colonies of *Ehrlichia* are observed
136 during the febrile period. This method is useful for experimental studies, but not suitable for routine diagnosis.

137 Colonies of *E. ruminantium* are still present 48 hours after death in a brain that has been stored at room temperature
138 (20–25°C) and for up to 34 days in a brain that has been stored in a refrigerator at 4°C.

139 A small fragment of grey matter (approximately the size of a match head) is placed on a microscope slide, crushed
140 to a paste consistency by another slide and, while maintaining pressure, the slides are drawn over each other
141 lengthwise to produce a single layer of cells. The slides are air-dried, fixed in methanol, and stained with eosin and
142 methylene blue or Giemsa. They are then examined under a microscope at a low magnification (×10 objective) to
143 locate the cerebral capillaries and with a magnification of at least ×50 to identify the colonies of rickettsiae. *Ehrlichia*
144 *ruminantium* are reddish-purple to blue coccoid organisms in the cytoplasm close to the cell nucleus which is
145 coloured in pink (Marcelino *et al.*, 2016). Experience is required as *E. ruminantium* colonies must be differentiated
146 from other haemoparasites (*Babesia bovis*), certain blood cells (thrombocytes, granulocytes), normal subcellular
147 structures (mitochondria, mast cell granules), or stain artefacts (stain precipitates).

148 *Ehrlichia ruminantium* colonies are formed from clusters of granules (0.2–0.5 µm), sometimes arranged in the shape
149 of a ring or a horseshoe (1–3 µm), that are placed close to the nucleus inside the endothelial cell. The granules can
150 be scanty, particularly in peracute cases, but they are always present in the brain of an animal that died from
151 heartwater. However, if the animal has been treated with doxycyclin or oxytetracyclin 48 hours before, the granules
152 of *Ehrlichia* tend to fuse, making the diagnosis very difficult, and sometimes impossible. Transmission electron
153 microscopy has been used to demonstrate that the *E. ruminantium* organisms develop inside a vacuole-like
154 structure, which is surrounded by a membrane in the endothelial cell's cytoplasm. Each organism is enclosed by a
155 double membrane. Within the vacuole-like structure, *E. ruminantium* electron-dense forms (elementary bodies), as
156 well as intermediate reticulate forms, are identified.

157 **1.1. Isolation of *Ehrlichia ruminantium* using *in-vitro* culture**

158 Although numerous cell lines have been shown to support the growth of *E. ruminantium*, isolation is not
159 the test of first choice for rapid diagnosis of heartwater, as it is labour intensive and time-consuming. For
160 a rapid diagnosis, molecular methods are preferred. However, *E. ruminantium* isolation should be
161 encouraged for typing the strains present in a region for the purpose of vaccination programmes.
162 *Ehrlichia ruminantium* can be isolated from the blood of reacting animals by cultivation on ruminant
163 endothelial cells. Endothelial cells from umbilical cord, aorta, or the pulmonary artery of different ruminant
164 species (cattle, goat, sheep) are used most often for isolation, although other endothelial cell types (brain
165 capillaries, circulating endothelial cells, etc.) have been described for the routine culture of the
166 microorganism. Endothelial cell lines from sable, eland, buffalo, kudu and bush pig can also be used to
167 grow *E. ruminantium*. No standard cell line has yet been designated for isolation.

168 **1.1.1. Isolation procedure**

169 i) The blood of the clinically affected animal (optimally on the second or third day of febrile
170 reaction) is collected in anticoagulant (heparin or sodium citrate, not ethylene diamine tetra-
171 acetic acid) and diluted 1/2 in the complete culture medium consisting of Glasgow-high
172 glucose (4.5 g/litre) Dubelco minimal essential medium (DMEM) supplemented with 10%
173 inactivated fetal bovine serum, 200 mM L-glutamine, and antibiotics if necessary (penicillin
174 100 U/ml, streptomycin 100 µg/ml).

175 ii) The culture medium is poured off the endothelial cell monolayer, and sampled blood
176 (approximately 2 ml for a 25 cm² flask) is added. The flask is incubated at 37°C (if possible
177 with 5% CO₂) on a rocking platform for 2 hours.

178 iii) After incubation, the blood is poured off and the monolayer is gently washed three times
179 with culture medium prewarmed at 37°C. Fresh complete culture medium (5 ml per 25 cm²
180 flask) is added and the flask is incubated at 37°C with 5% CO₂. The medium is changed
181 every 2 days.

182 (The use of plasma instead of blood is more efficient when taken from an animal with a
183 febrile reaction >41°C. In this case, steps ii and iii above may be replaced with the following:

- 184 a) Seed 4 ml of plasma (smaller inoculum can be used if there is a limited amount of
185 plasma available) on to a susceptible endothelial cell culture and incubate for 1 hour
186 at 37°C on a rocking platform.
- 187 b) Wash plasma three times with culture medium prewarmed at 37°C. and then add 5 ml
188 of complete culture medium (per 25 cm² flask) and observe for development of
189 cytopathic effect cell lysis.
- 190 iv) The monolayer is inspected regularly for the appearance of small plaques of cell lysis. The
191 first plaques generally appear after about 2 weeks. Passaging on uninfected cell monolayers
192 is performed when the lysis reaches 80% of the cell layer. The remaining cells are stained
193 with eosine and methylene blue or Giemsa and examined microscopically for the presence
194 of *E. ruminantium* morulae (Marcelino *et al.*, 2016).

195 2. Molecular methods

196 2.1. Detection of *Ehrlichia ruminantium* using nested polymerase chain reaction

197 Two nested polymerase chain reaction (PCR) assays have been developed to enhance detection of low
198 levels of rickettsemia (Martinez *et al.*, 2004; Semu *et al.*, 2001). Both use the *pCS20* region as the target
199 sequence. The Semu *et al.* assay uses two external primers: U24 (5'-TTT-CCC-TAT-GAT-ACA-GAA-
200 GGT-AAC-3') and L24 (5'-AAA-GCA-AGG-ATT-GTG-ATC-TGG-ACC-3'), and then the AB 128 (5'-ACT-
201 AGT-AGA-AAT-TGC-ACA-ATC-TAT-3') and AB 129 (5'-TGA-TAA-CTT-GGT-GCG-GGA-AAT-CCT-T-
202 3') for the nested reaction. The analytical sensitivity of detection of this assay is one organism per
203 reaction. The other nested PCR assay (Martinez *et al.*, 2004) uses a pair of external primers that
204 comprise AB128/AB130 (5'-ACT-AGC-AGC-TTT-CTG-TTC-AGC-TAG 3') followed by a second
205 amplification based on AB128/AB129 primers. The final PCR product is 278 pb long. The nested PCR
206 shows a hundred-fold improvement in sensitivity compared with the simple AB128/AB129 PCR, and an
207 average detection limit of 6 organisms per reaction.

208 Lack of amplification with conventional *pCS20* nested PCR was observed due to single nucleotide
209 polymorphisms (SNPs) on primer hybridisation areas of the *pCS20* fragment DNA. Thus, AB128/129
210 and 130 primers modified using universal nucleotides allowed the detection of a wider range of
211 *E. ruminantium* strains: AB128' (5'-ACT-AGT-AGA-AAT-TGC-ACA-ATC-YAT-3'), AB130' (5'-RCT-DGC-
212 WGC-TTT-YTG-TTC-AGC-TAK-3') and AB129' (5'-TGA-TAA-CTT-GGW-GCR-RGD-ART-CCT-T-3').
213 This *pCS20* nested PCR ~~is was~~ used ~~routinely~~ at the WOH Reference Laboratory for diagnostic
214 purposes on blood samples from clinical cases and for tick screening (Adakal *et al.*, 2009; 2010a; Cangi
215 *et al.*, 2016) just before validation of the *pCS20* real time PCR (see further). The *pCS20* nested PCRs
216 allow detection in organs (lung and brain) from infected dead animals, blood from infected animals during
217 hyperthermia, and ticks fresh, frozen or preserved in 70% ethanol. The detection of *E. ruminantium* by
218 nested PCR is possible in the blood of animals 1 or 2 days before hyperthermia and during the
219 hyperthermia period but not on asymptomatic animals.

220 A nested PCR targeting the entire *map1* polymorphic gene has been developed in parallel in order to
221 type the strains by restriction fragment length polymorphism (RFLP) or sequencing of the amplification
222 fragment directly from the pathological samples testing positive in the *pCS20* nested PCR (Martinez *et*
223 *al.*, 2004). The *map1* nested PCR performs well although with a slightly lower sensitivity than the *pCS20*
224 nested PCR with 60 copies per sample. This tool is useful for genetic characterisation of *E. ruminantium*
225 but not for diagnosis due to the polymorphic property of *map1* targeted genes.

226 The genetic characterisation and structure of the *E. ruminantium* population at the regional level is
227 essential for the selection of potential vaccinal strains. The genetic typing of strains was previously done
228 using RFLP on the *map1* polymorphic gene after PCR amplification (Adakal *et al.*, 2010b; Faburay *et al.*,
229 2007). However, multi-locus methods adapted to *E. ruminantium* have been validated such as multi-
230 locus sequence typing (Adakal *et al.*, 2009) and multi-locus variable number of tandem repeat sequence
231 analysis (Pilet *et al.*, 2012). These tools are being used on field tick samples for molecular
232 epidemiological studies to better characterise the genetic structure of *E. ruminantium* strains (Adakal
233 *et al.*, 2010a; Cangi *et al.*, 2016). However, these genetic characterisations are not associated with clusters
234 of protection.

235 2.2. Detection of *Ehrlichia ruminantium* using real-time PCR

236 Several real-time PCR tests targeting *map1*, *map1-1* and *pCS20* region genes have been developed for
237 the detection of *E. ruminantium* organisms. SYBR Green real-time PCRs targeting *map1* and *map1-1*
238 were used to detect and quantify *E. ruminantium* *in vitro* during mass antigen production in a bioreactor
239 and in experimentally infected sheep during the hyperthermia period (Marcelino *et al.*, 2005; 2007;

240 Peixoto *et al.*, 2005; Postigo *et al.*, 2002). They were tested on a limited number of strains (up to six
241 strains) and therefore they are not recommended for diagnostic purposes due to the polymorphic
242 characteristics of *map1* multigenic family.

243 A real-time PCR assay targeting the *pCS20* region using a fluorescent-labelled probe has been
244 developed to detect *E. ruminantium* in livestock blood and ticks from the field, and has a sensitivity similar
245 to the nested PCR with seven copies per sample. The sequences of primers and probes are: CowF (5'-
246 CAA-AAC-TAG-TAG-AAA-TTG-CAC-A-3'), CowR (5'-TGC-ATC-TTG-TGG-TGG-TAC-3') and Cow
247 probe (5'-FAM-TCC-TCC-ATC-AAG-ATA-TAT-AGC-ACC-TAT-TA-XT-PH-3'). Unfortunately, this assay
248 displayed cross reaction with *E. canis* and *E. chaffeensis*. It successfully detected 15 different
249 *E. ruminantium* strains (Steyn *et al.*, 2008). As shown previously for the *pCS20* nested PCR, the
250 presence of SNPs on hybridisation regions could inhibit strain detection. Testing more strains is
251 necessary to further validate the method.

252 The method of choice for detecting *E. ruminantium* in animal blood during clinical phase or directly in
253 ticks is a more recently new real-time PCR targeting another *pCS20* region that has been developed and
254 demonstrated a good reproducibility, sensitivity and specificity, with a limit of detection of 6 copies per
255 sample. It can be used with appropriate fluorescent probes. Primers and probes are: Sol1F (ACA-AAT-
256 CTG-GYC-CAG-ATC-AC), Sol1R (CAG-CTT-TCT-GTT-CAG-CTA-GT) and Sol1^{TQM} (6-FAM-ATC-AAT-
257 TCA-CAT-GAA-ACA-TTA-CAT-GCA-ACT-GG-BHQ1). It detects 16 *E. ruminantium* strains from
258 different geographical areas and there is no cross protection with *Anaplasma marginale*,
259 *A. phagocytophilum*, *A. platys*, *Babesia bovis*, *B. bigemina*, *E. canis*, *E. muris* and *Rickettsia felis* and
260 *parkeri* (Cangi *et al.*, 2017). It has been tested on 700 tick field samples from Mozambique and ~~will be it~~
261 is used routinely in the WOA Reference Laboratory for diagnostic use and tick screening.

262 Although nested and real-time PCR methods have proved highly effective in detecting infection in ticks
263 or in animal samples during the clinical phase of the disease or after death, they could not allow detection
264 of *E. ruminantium* in healthy carrier ruminants. A useful technique for confirming the status of a suspected
265 carrier animal, whose blood is PCR negative, is to feed batches of naive ticks on the animal and then
266 test the ticks by *pCS20* nested or real-time PCR. It is not known whether ticks act simply by concentrating
267 circulating organisms, or by amplifying their number or even by inducing release of micro-organisms in
268 the circulation during feeding.

269 **2.3. Detection of *E. ruminantium* using multi-pathogen real-time PCR**

270 A single FRET-real-time PCR has been developed to differentiate eight species in four distinct groups in
271 a single reaction: *E. canis*, *E. chaffeensis*, *E. ewingii*, *E. muris*, *E. ovina*, *Ehrlichia* sp. BOV2010, Panola
272 Mountain *Ehrlichia* and *E. ruminantium* (Zhang *et al.*, 2015). It is based on 16S recombinant RNA
273 amplification using two fluorescent probes; different dissociation curves are detected depending on the
274 species. *Ehrlichia ruminantium* could be clearly differentiated from other species with the lowest melting
275 temperature. The limit of detection is five copies per sample and simultaneous detection is possible with
276 a mix of 300 copies of each species. However, only four *E. ruminantium* strains were tested. Even if the
277 lack of amplification is limited due to the targeted conserved gene 16S recombinant RNA, validation on
278 more *E. ruminantium* strains is necessary.

279 On the other hand, Sayler *et al.* developed a dual-plex Taqman real-time PCR targeting the *groEL* gene
280 of Panola Mountain *Ehrlichia* and *E. ruminantium* (Sayler *et al.*, 2016). This assay allows Panola
281 Mountain *Ehrlichia*, which is endemic in the USA, to be differentiated from *E. ruminantium*, which is
282 currently not present. The limit of detection is 10 copies per sample, and 27 *E. ruminantium* strains from
283 11 countries were detected. It seems therefore to be a promising method for differential diagnosis
284 between the two species.

285 **2.4. Detection of *Ehrlichia ruminantium* using the reverse line blot technique**

286 The reverse line blot technique (RLB) has been used for the simultaneous detection and identification of
287 *Anaplasma* and *Ehrlichia* species known to occur in ruminants, on the basis of differences in the small
288 subunit rRNA gene (Bekker *et al.*, 2002). Primers 16S8FE and B-GA1B-new were designed from
289 conserved domains and used to amplify a 492–498 bp fragment of the 16S rRNA gene spanning the
290 variable V1 region. Species-specific oligonucleotide probes were designed in this V1 loop to allow
291 species-specific detection of *E. ruminantium*, *E. ovina*, *Ehrlichia* sp. strain Omatjenne, *Anaplasma*
292 *marginale*, *A. centrale*, *A. bovis*, *A. ovis* and *A. phagocytophilum*. One oligonucleotide probe cross-
293 reactive with all species (catch-all probe) was also designed to serve as a control in case a PCR product
294 does not hybridise to any of the species-specific probes. In the method, the species-specific probes are
295 covalently linked to the hybridisation membrane, which is hybridised with the PCR product obtained using
296 primers 16S8FE and B-GA1B-new. PCR products obtained from all above-mentioned microorganisms
297 were shown to bind with specific oligonucleotide probes only. No PCR product was detected and no

298 hybridisation occurred when the PCR-RLB was applied to *Theileria annulata*, *Babesia bigemina* or
299 mammalian DNA. Similarly, negative control ticks were always negative in the RLB assay whereas it was
300 possible to detect *Ehrlichia ruminantium* infection in 15–70% of ticks fed on experimentally infected or
301 long-term carrier sheep. In Mozambique, *E. ruminantium* could also be detected in the blood of 12
302 sentinel small ruminants placed in the field with the infected animals; mixed infection was detected in five
303 of the infected sentinel animals, thus demonstrating the usefulness of the method for detecting multiple
304 infections. The RLB has been used recently in several studies in Western Kenya and in Nigeria to
305 evaluate the prevalence of tick-borne diseases in cattle (Lorusso *et al.*, 2016; Njiiri *et al.*, 2015) however,
306 they obtained very low prevalence of *E. ruminantium*. It was suggested by the authors that sequences
307 of the primers and probes of RLB were not adapted to Kenya *E. ruminantium* strains.

308 2.5. Reading the results

309 As *E. ruminantium* is an obligate intracellular bacterium that cannot be cultivated in acellular media and
310 its isolation is complex and takes several weeks, molecular tools are the best methods for the diagnosis
311 of heartwater. Nested and real-time PCRs prove to be easier to perform and more sensitive than RLB.
312 With all PCRs, however, care must be taken to ensure that no cross-contamination occurs between
313 samples. Negative and positive controls must be included in each test. For each PCR assay, nested or
314 real-time, positive and negative extraction controls (from experimentally infected and uninfected blood
315 or organs, infected or uninfected ticks) should be included allowing detection of a default in the extraction
316 procedures. The absence of inhibitor products in each sample should be proven by targeting a
317 housekeeping gene from the vector or the host such as 16S or 18S ribosomal DNA (for tick screening,
318 Cangi *et al.*, 2017). As heartwater serology has several limitations (see Section B.3), the PCR could be
319 used to help confirm if seronegative animals, originating from an endemic area, are not infected, prior to
320 translocating them to a heartwater-free area that has the risk of becoming infected, because of the
321 presence of potential vectors. Screening of ticks by PCR, along with serology on targeted herds over
322 time could be used to establish the herd status before any movement of animals from this endemic area
323 to a free area. However, *E. ruminantium* cannot be detected in asymptomatic carriers by molecular
324 methods. The results obtained with nested PCRs, the RLB assay and real-time PCR, show that the direct
325 detection of *E. ruminantium* in the blood is only reliable during and around the febrile phase of the
326 disease. PCR-based methods appear to be more reliable in detecting infection in ticks, and this could
327 have epidemiological value in determining the geographical distribution of *E. ruminantium*. In addition,
328 when necessary in endemic areas, the inclusion of testing (originally naive) ticks fed on a suspect animal
329 would greatly improve the sensitivity of carrier detection when serology and PCR on blood have failed.
330 The procedure is nevertheless not suitable for routine diagnostic laboratories as it requires the
331 maintenance of tick colonies and the capacity to experimentally infect animals.

332 3. Serological tests

333 To minimise the problem of cross-reactions with *Ehrlichia* spp., two enzyme-linked immunosorbent assays (ELISAs)
334 based on a recombinant MAP1 antigen have been developed. The first is an indirect ELISA that uses an
335 immunogenic region of the MAP1 protein (called MAP1-B) and gives far fewer cross-reactions with *Ehrlichia* spp.
336 (MAP1-B ELISA) (Semu *et al.*, 2001). The second is a competitive ELISA that uses the *map1* gene cloned in a
337 baculovirus and monoclonal antibodies (MAbs) raised against the MAP1 protein (MAP1 C-ELISA) (Mondry *et al.*,
338 1998). Both tests have dramatically improved specificity, but they still show some reactivity with high titre sera
339 against *E. canis*, *E. chaffeensis* and Panola Mountain *Ehrlichia*. Cross reaction of serum from Panola Mountain
340 *Ehrlichia*-infected goats has been observed with *E. ruminantium* MAP1-B antigen and, conversely, serum from
341 heartwater-infected sheep with MAP1-B of Panola Mountain *Ehrlichia*, thus preventing their use in the detection of
342 *E. ruminantium* introduction on the American mainland (Sayler *et al.*, 2016). The MAP1-B ELISA has been the most
343 extensively used and will be described in detail. Serology as a diagnostic tool for detecting individual animals
344 exposed specifically to *E. ruminantium* is therefore unreliable. Serology should be considered at the herd level
345 taking into consideration the epidemiological environment and, if necessary, be complemented by molecular
346 techniques.

347 3.1. MAP1-B enzyme-linked immunosorbent assay (Mondry *et al.*, 1998 and Semu *et al.*, 348 2001)

349 Using the vector pQE9, the PCR fragment MAP1-F2R2, which encodes the amino acids 47–152 of the
350 MAP1 protein including the immunogenic region MAP1-B, is expressed in *Escherichia coli* M15[pREP4]
351 as a fusion protein containing six additional histidine residues. The recombinant MAP1-B is purified using
352 Ni²⁺-NTA agarose (nitrilotriacetic acid agarose) under denaturing conditions as described by the
353 manufacturer. The antigen is preserved at 4°C and each batch is titrated.

354 The antigen is diluted at 0.5 µg/ml in 0.05 M sodium carbonate buffer, pH 9.6, and immobilised onto
355 polystyrene plates by incubation for 1 hour at 37°C, and stored at 4°C until use. However, in initial trials,

356 an antigen concentration of 2 µg/ml reduced background noise and improved specificity (data not shown:
357 Semu *et al.*, 2001).

358 **3.1.1. Test procedure**

- 359 i) Plates are blocked for 30 minutes by adding 100 µl per well of 0.1 M phosphate buffered
360 saline (PBS), pH 7.2, supplemented with 0.1% Tween 20 (PBST) and 3% non-fat dry milk
361 (PBSTM).
- 362 ii) The plates are washed three times with PBS supplemented with 0.1% Tween 20 (PBST)
363 and twice with distilled water.
- 364 iii) 100 µl of test serum diluted 1/100 in PBSTM is added in duplicate to wells, which are then
365 incubated for 1 hour at 37°C.
- 366 iv) Plates are washed three times in PBST and twice in distilled water.
- 367 v) Horseradish-peroxidase-conjugated anti-species IgG optimally diluted in PBSTM is added
368 at 100 µl per well and the plate is incubated for 1 hour at 37°C.
- 369 vi) After washing as in step iv, each well is filled with 100 µl of 0.1 M citrate buffer, pH 5.5,
370 containing 0.5 mg/ml orthophenylene-diamine and 3 µl/ml of 9% H₂O₂.
- 371 vii) The reaction is stopped after 30 minutes of incubation at room temperature (20–25°C) by
372 adding 50 µl of 2 N H₂SO₄. Absorbance is read at 495 nm. Positive and negative controls
373 are included in each plate.

374 **3.2. MAP1 competitive enzyme-linked immunosorbent assay (Mondry *et al.*, 1998)**

375 *Recombinant MAP1 antigen is prepared as follows:* 8-day-old *Trichoplusia ni* insect larvae are infected
376 by a baculovirus expressing the *map1* gene and moribund larvae are homogenised (10% [w/v]) in PBS
377 supplemented with 0.001% (v/v) Triton X-100.

378 *Anti-MAP1 MAb is prepared as follows:* spleen cells of BALB/C mice previously inoculated with larval
379 homogenate are fused to SP2/0 cells. Supernatant fluids from hybridoma cell cultures are screened for
380 reactivity with MAP1 by immunoblotting and immunoperoxidase methods. A reactive cell culture is
381 subcloned, isotyped and subsequently used for MAb production.

382 After a further 1/800 (v/v) dilution in PBS, the antigen is immobilised on to polystyrene plates (Nunc-
383 Immuno Plates PolySorp) by incubation overnight at 4°C, and stored at –70°C.

384 **3.2.1. Test procedure**

- 385 i) Prior to use, the plates are blocked for 30 minutes by adding 100 µl per well of PBS, pH 7.2,
386 supplemented with 0.05% Tween 20 and 5% nonfat dry milk.
- 387 ii) Plates are washed three times with PBS/Tween, 50 µl/well of test serum diluted 1/50 in PBS
388 supplemented with 0.05% Tween 20 and 1% nonfat dry milk (PBSTM) is added in duplicate
389 and the plates are incubated for 30 minutes at 37°C.
- 390 iii) Without an intervening washing step, 75 µl/well of the MAb diluted 1/4000 (v/v) in PBSTM is
391 added and the plates are incubated for another 30 minutes at 37°C.
- 392 iv) Plates are washed three times in PBS/Tween and horseradish-peroxidase-conjugated anti-
393 mouse IgG optimally diluted in PBSTM is added at 50 µl per well. The plate is incubated for
394 1 hour at 37°C.
- 395 v) After three washings as before, 100 µl of 0.1 M citrate buffer, pH 5.5, containing 0.5 mg/ml
396 O-phenylene diamine and 3 µl/ml of 9% H₂O₂ are added to each well. After 30 minutes of
397 incubation at room temperature in the dark, the reaction is stopped by adding 50 µl of 2 N
398 H₂SO₄ and the absorbance is read at 495 nm. Positive and negative controls are included
399 in each plate.

400 **3.3. Reading the results**

401 Both the MAP1-B ELISA and the MAP1 C-ELISA have shown a high specificity after evaluation in
402 3000 ruminant sera (goat, sheep and cattle) collected from 14 *A. variegatum*-infested islands of the
403 Lesser Antilles, among which only three are known to be infected by *E. ruminantium* (Mondry *et al.*,
404 1998). Overall specificity calculated from the 11 heartwater-free islands was 98.5% and 99.4% for the
405 MAP1 C-ELISA and the MAP1-B ELISA, respectively. In another study undertaken in the Caribbean,
406 ELISA MAP1-B positive samples were found in four of six islands free of heartwater (Kelly *et al.*, 2011).

407 Moreover, high seroprevalence in vector-free areas of Zimbabwe or South Africa has also been reported
408 although not explained (it may be caused by a cross-reacting agent not transmitted by *Amblyomma*) and
409 should be kept in mind when interpreting the results (Kakono *et al.*, 2003).

410 Evaluating the sensitivity of the tests is more problematic as it would require knowledge of the exact
411 status of a high number of animals sampled in the field. As mentioned before there is currently no simple
412 technique available to confirm if an animal is infected. Experimentally, the sensitivity of the C-ELISA in
413 goats was reported to be 91.6–95.4% for the MAP1-B ELISA, and 96.3–96.9% for the MAP1 C-ELISA
414 (Mondry *et al.*, 1998). However, in another study the sensitivity averaged 95% for cut-off values set at
415 31% and 26.6% of the positive control serum for sheep and goat sera, respectively (Mbolo *et al.*, 1999).
416 Indeed, calculations are based on a limited number of experimentally inoculated animals in a period of
417 time soon after inoculation, when almost all the animals are still positive. Sensitivity in cattle is even lower
418 and several reports show that after infection most of the animals become seronegative again in less than
419 6 months and some animals never seroconvert (Mahan *et al.*, 1998b; Semu *et al.*, 2001). This
420 observation is in line with the difference in antibody prevalence observed between small ruminants and
421 cattle in epidemiological surveys that cannot be explained by a lower risk of infection of the latter. For
422 example, in Zimbabwean farms situated in endemic areas, more than 90% of goats presented antibodies
423 in their serum compared with only 33% of cattle maintained in the same conditions (Mahan *et al.*, 1998b).
424 Similar observations were made in the Caribbean.

425 Serological tests are useful for the assessment of heartwater antibody response in vaccinated animals.
426 The tests should not be used to screen animals for importation into heartwater-free areas. Antibodies
427 are maintained at detectable levels in naturally infected domestic ruminants for a few months only and
428 circulating antibodies disappear more rapidly in cattle than in small ruminants. It is thus possible that
429 serologically negative animals may be carriers of infection. Serology should therefore only be considered
430 as a diagnostic method to be applied at the herd level and not at the individual animal level (Peter *et al.*,
431 2001). When interpreting diagnostic serology results, other epidemiological parameters must be
432 considered.

433 **3.4. MAP1-B pan-species indirect ELISA**

434 More recently, the WOA Reference Laboratory has developed a pan-species ELISA validated in
435 domestic cattle, sheep and goats (Rodrigues *et al.*, data not yet published) This ELISA is also based on
436 MAP1-B antigen recognition, and therefore has the same analytical specificity as the MAP1-B ELISA
437 described in Section B.3.1. The test could also be used for other mammals (except felines) and wildlife
438 for large-scale seroprevalence studies to improve heartwater control and surveillance in the concerned
439 areas. In the case of species other than domestic cattle, sheep or goats, results should be interpreted
440 with care, possibly with the assistance of the WOA Reference Laboratory.

441 **C. REQUIREMENTS FOR VACCINES AND DIAGNOSTIC BIOLOGICALS**

442 No commercial vaccines are available at present. The only method of immunisation against heartwater remains the
443 “infection and treatment” method using infected blood followed by treatment of reacting animals with tetracycline.
444 This method is still in use in several areas, but it is likely to be replaced by preparations using attenuated or
445 inactivated organisms, which have given promising research results.

446 **1. Inactivated vaccine preparations**

447 Inactivated vaccine based on *E. ruminantium* elementary bodies chemically inactivated or lysed, emulsified in oil
448 adjuvant, conferred good protection against homologous and field challenges (Adakal *et al.*, 2010b; Mahan *et al.*,
449 1998a; Marcelino *et al.*, 2015a; Martinez *et al.*, 1996). However, it does not prevent vaccinated animals from
450 developing clinical signs, and morbidity is observed after virulent challenge.

451 The development of a large-scale production process and optimisation of storage conditions for the inactivated
452 vaccine has led to a decrease in the cost of a vaccinal dose to 0.11 euros (Marcelino *et al.*, 2007; Peixoto *et al.*,
453 2005). In 2015, Marcelino *et al.* developed a ready-to-use inactivated vaccine that could be easily used in the field.
454 It was shown that even after breaking the cold-chain of 3 days at 37°C, mimicking field conditions, the vaccine was
455 still efficient (Marcelino *et al.*, 2015a). This study showed the robustness of the vaccine under field conditions.

456 In Zimbabwe, field trials of the inactivated vaccine emulsified in oil adjuvant have also demonstrated protection of
457 sheep against natural tick challenge (Mahan *et al.*, 1998a). In larger field trials conducted in eastern and southern
458 Africa, a significant reduction in mortality has been achieved in cattle, goats and sheep using either a prototype
459 strain from Zimbabwe (Mbizi strain) or a local strain from the experimental sites (Mahan *et al.*, 2001). However, in
460 three out of four sites, the vaccine prepared from the local isolate was less effective than the prototype Mbizi

461 vaccine, strongly suggesting an inadequate coverage of the antigenic repertoire of isolates present in each site.
462 Vaccination trials in Burkina Faso showed a significant increase in the protective effect of inactivated vaccine when
463 a local strain was added to the Gardel vaccinal strain (Adakal *et al.*, 2010b).

464 Lack of cross-protection between *E. ruminantium* isolates due to genetic or antigenic diversity is well established,
465 but the complexity of the *E. ruminantium* population structure in the field has been underestimated. A large
466 *E. ruminantium* genetic diversity has been observed throughout Africa, the Caribbean islands and the Indian Ocean,
467 which raises the problem of the protective effect of the vaccinal strain against field strains (Adakal *et al.*, 2010a;
468 Cangi *et al.*, 2016; Raliniaina *et al.*, 2010). Even if genetic characterisation is defined, there is a lack of a genetic
469 marker associated with protection; moreover, it is essential to isolate *in-vitro* field strains to know their capacity for
470 protection against heterologous strains and be able to mix several strains in the inactivated vaccine in order to cover
471 widely the genetic diversity of field strains.

472 Inactivated vaccine is being developed commercially in South Africa. These inactivated vaccines do not prevent
473 infection but do prevent or reduce death of vaccinated animals when exposed to live virulent challenge. The
474 advantage however is that several field strains can be incorporated to make the vaccine more widely cross-
475 protective.

476 A major challenge remains the identification of *E. ruminantium* genetic markers associated with protection in order
477 to identify the vaccinal strains to include in the inactivated vaccine adapted to a region.

478 2. Attenuated vaccine preparations

479 Infection of ruminants with live *E. ruminantium* strains induces a strong long-lasting protection against a homologous
480 isolate. This is the basis for the “infection-and-treatment” method using virulent isolates. Isolates of attenuated
481 virulence that do not require the treatment of animals would be ideal, but a limited number of such attenuated
482 isolates are available. An attenuated Senegal isolate has been obtained and shown to confer 100% protection
483 against a homologous lethal challenge, but very poor protection against a heterologous challenge. The Gardel
484 isolate, which gives a significant level of cross-protection with several isolates (although far from complete), has
485 also been attenuated (Marcelino *et al.*, 2015b). A third isolate named Welgevonden from South Africa has been
486 attenuated and shown to confer complete protection against four heterologous isolates under experimental
487 conditions (Zweygarth *et al.*, 2005). However, it has not been tested in field conditions. More recently, an attenuated
488 Welgevonden strain vaccine inoculated by the intramuscular route has demonstrated good levels of safety and
489 protection against virulent homologous intravenous challenges and homologous infected tick challenges in
490 domestic cattle, goats and sheep. The advantage of this method is that it avoids the need for antibiotic treatment to
491 protect animals (Latif *et al.*, 2020). The main drawback of attenuated vaccines is their extreme lability, which
492 necessitates their storage in liquid nitrogen and their distribution in frozen conditions. In addition, they have to be
493 administered intravenously. Moreover, there is also a possible reversion to virulence and, as it is a live vaccine, it
494 could not be used in heartwater free areas. Despite the recent efforts to understand the mechanism of virulence
495 and attenuation (Marcelino *et al.*, 2015a), these are still largely unknown independently from the strain.

496 3. Recombinant vaccine preparations

497 Several reports show partial protection of mice using *map1* DNA vaccination and an improvement of protection by
498 vaccination following a prime (plasmid) – boost (recombinant MAP1) protocol (Nyika *et al.*, 2002). However,
499 protection of ruminants has never been demonstrated using this strategy. ~~In opposition~~ However, significant
500 protection of sheep was reported against homologous and heterologous experimental challenge following plasmid
501 vaccination using a cocktail of four ORFs (open reading frames) from the 1H12 locus in the *E. ruminantium* genome
502 (Collins *et al.*, 2003). No further results have been described since then. Recombinant vaccines will probably not
503 be available in the near future. A prime DNA/boost recombinant protein vaccine has been developed (Pretorius *et al.*,
504 2008). An efficient protective effect was obtained using a cocktail of four open reading frames (ORFs) against
505 homologous challenge, but the vaccine did not give satisfactory results during field tick challenge. Moreover, simple
506 intramuscular immunisation is not sufficient to induce protection. The use of a gene gun is necessary for prime DNA
507 injection, which is not suitable for a large vaccination campaign. A polymorphic gene was identified as an efficient
508 component of a recombinant vaccine against heartwater using the prime/boost method (Pretorius *et al.*, 2010).
509 However, as this gene is polymorphic, a recombinant vaccine should include at least three different genotypes.

- 511 ADAKAL H., GAVOTTE L., STACHURSKI F., KONKOBO M., HENRI H., ZOUNGRANA S., HUBER K., VACHIERY N., MARTINEZ D.,
512 MORAND S. & FRUTOS R. (2010a). Clonal origin of emerging populations of *Ehrlichia ruminantium* in Burkina Faso.
513 *Infect. Genet. Evol.*, **10**, 903–912.
- 514 ADAKAL H., MEYER D., CARASCO-LACOMBE C., PINARELLO V., ALLÈGRE F., HUBER K., STACHURSKI F., MORAND S.,
515 MARTINEZ D., LEFRANÇOIS T., VACHIÉRY N. & FRUTOS R. (2009). MLST scheme of *Ehrlichia ruminantium*: Genomic
516 stasis and recombination in strains from Burkina-Faso. *Infect. Genet. Evol.*, **9**, 1320–1328.
- 517 ADAKAL H., STACHURSKI F., KONKOBO M., ZOUNGRANA S., MEYER D., PINARELLO V., APRELON R., MARCELINO I., ALVES
518 P.M., MARTINEZ D., LEFRANÇOIS T. & VACHIERY N. (2010b). Efficiency of inactivated vaccines against heartwater in
519 Burkina Faso: Impact of *Ehrlichia ruminantium* genetic diversity. *Vaccine*, **28**, 4573–4580.
- 520 BEKKER C.P., DE VOS S., TAOUFIK A., SPARAGANO O.A. & JONGEJAN F. (2002). Simultaneous detection of *Anaplasma*
521 and *Ehrlichia* species in ruminants and detection of *Ehrlichia ruminantium* in *Amblyomma variegatum* ticks by
522 reverse line blot hybridization. *Vet. Microbiol.*, **89**, 223–238.
- 523 CANGI N., GORDON J.L., BOURNEZ L., PINARELLO V., APRELON R., HUBER K., LEFRANÇOIS T., NEVES L., MEYER D.F. &
524 VACHIÉRY N. (2016). Recombination is a major driving force of genetic diversity in the Anaplasmataceae *Ehrlichia*
525 *ruminantium*. *Front. Cell. Infect. Microbiol.*, **6**, 14 p. (eCollection 2016).
- 526 CANGI N., PINARELLO V., BOURNEZ L., LEFRANÇOIS T., ALBINA E., NEVES L. & VACHIERY N. (2017). Efficient high-
527 throughput method to detect *Ehrlichia ruminantium* in ticks. *Parasit. Vectors*, **10**, 566.
- 528 COLLINS E.N., PRETORIUS A., VAN KLEEF M., BRAYTON K.A., ZWEYGARTH E. & ALLSOPP B. (2003). Development of
529 improved vaccines for heartwater. *Ann. N. Y. Acad. Sci.*, **990**, 474–484.
- 530 FABURAY B., GEYSEN D., CEESAY A., MARCELINO I., ALVES P.M., TAOUFIK A., POSTIGO M., BELL-SAKYI L. & JONGEJAN F.
531 (2007). Immunisation of sheep against heartwater in The Gambia using inactivated and attenuated *Ehrlichia*
532 *ruminantium* vaccines. *Vaccine*, **25**, 7939–7947.
- 533 KAKONO O., HOVE T., GEYSEN D. & MAHAN S. (2003). Detection of antibodies to the *Ehrlichia ruminantium* MAP1-B
534 antigen in goat sera from three communal land areas of Zimbabwe by an indirect enzyme-linked immunosorbent
535 assay. *Onderstepoort J. Vet. Res.*, **70**, 243–249.
- 536 KELLY P.J., LUCAS H., YOWELL C., BEATI L., DAME J., URDAZ-RODRIGUEZ J. & MAHAN S. (2011). *Ehrlichia ruminantium*
537 in *Amblyomma variegatum* and domestic ruminants in the Caribbean. *J. Med. Entomol.*, **48**, 485–488.
- 538 LATIF A.A., STEYN H.C., JOSEMANS A.I., MARUMO R.D., PRETORIUS A., CHRISTO TROSKIE P., COMBRINK M.P., MOLEPO
539 L.C., HAW A., MBIZENI S., ZWEYGARTH E. & MANS B.J. (2020). Safety and efficacy of an attenuated heartwater
540 (*Ehrlichia ruminantium*) vaccine administered by the intramuscular route in cattle, sheep and Angora goats. *Vaccine*,
541 **38**, 7780–7788. doi: 10.1016/j.vaccine.2020.10.032. Epub 2020 Oct 24. PMID: 33109388.
- 542 LORUSSO V., WIJNVELD M., MAJEKODUNMI A.O., DONGKUM C., FAJINMI A., DOGO A.G., THRUSFIELD M., MUGENYI A.,
543 VAUMOURIN E., IGWEH A.C., JONGEJAN F., WELBURN S.C. & PICOZZI K. (2016). Tick-borne pathogens of zoonotic and
544 veterinary importance in Nigerian cattle. *Parasit. Vectors*, **9**, 217.
- 545 MAHAN S.M., KUMBULA D., BURRIDGE M.J. & BARBET A.F. (1998a). The inactivated *Cowdria ruminantium* vaccine for
546 heartwater protects against heterologous strains and against laboratory and field tick challenge. *Vaccine*, **16**, 1203–
547 1211.
- 548 MAHAN S.M., SEMU S.M., PETER T.F. & JONGEJAN F. (1998b). Evaluation of the MAP1-B ELISA for cowdriosis with
549 field sera from livestock in Zimbabwe. *Ann. N. Y. Acad. Sci.*, **849**, 259–261.
- 550 MAHAN S.M., SMITH G.E., KUMBULA D., BURRIDGE M.J. & BARBET A. (2001). Reduction in mortality from heartwater in
551 cattle, sheep and goats exposed to field challenge using an inactivated vaccine. *Vet. Parasitol.*, **97**, 295–308.
- 552 MARCELINO I., HOLZMULLER P., HOLZMULLER P., STACHURSKI F., RODRIGUES V. & VACHIÉRY N. (2016). *Ehrlichia*
553 *ruminantium*: The Causal Agent of Heartwater. In: Rickettsiales: Biology, Molecular Biology, Epidemiology, and
554 Vaccine Development, Part IV, Thomas S., ed. Springer International Publishing, Cham, Switzerland, 241–280.
- 555 MARCELINO I., LEFRANÇOIS T., MARTINEZ D., GIRAUD-GIRARD K., APRELON R., MANDONNET N., GAUCHERON J., BERTRAND
556 F. & VACHIÉRY N. (2015a). A user-friendly and scalable process to prepare a ready-to-use inactivated vaccine: the
557 example of heartwater in ruminants under tropical conditions. *Vaccine*, **33**, 678–685.

- 558 MARCELINO I., VACHIÉRY N., AMARAL A.I., ROLDAO A., LEFRANÇOIS T., CARRONDO M.J., ALVES P.M. & MARTINEZ D.
559 (2007). Effect of the purification process and the storage conditions on the efficacy of an inactivated vaccine against
560 heartwater. *Vaccine*, **25**, 4903–4913.
- 561 MARCELINO I., VENTOSA M., PIRES E., MÜLLER M., LISACEK F., LEFRANÇOIS T., VACHIERY N. & COELHO A.V. (2015b).
562 Comparative Proteomic Profiling of *Ehrlichia ruminantium* Pathogenic Strain and Its High-Passaged Attenuated
563 Strain Reveals Virulence and Attenuation-Associated Proteins. *PLoS One*, **10**, e0145328.
- 564 MARCELINO I., VERISSIMO C., SOUSA M.F., CARRONDO M.J. & ALVES P.M. (2005). Characterization of *Ehrlichia*
565 *ruminantium* replication and release kinetics in endothelial cell cultures. *Vet. Microbiol.*, **110**, 87–96.
- 566 MARTINEZ D., PEREZ J.M., SHEIKBOUDOU C., DEBUS A. & BENSALD A. (1996). Comparative efficacy of Freund's and
567 Montanide ISA50 adjuvants for the immunisation of goats against heartwater with inactivated *Cowdria ruminantium*.
568 *Vet. Parasitol.*, **67**, 175–184.
- 569 MARTINEZ D., VACHIERY N., STACHURSKI F., KANDASSAMY Y., RALINIAINA M., APRELON R. & GUEYE A. (2004). Nested-
570 PCR for detection and genotyping of *Ehrlichia ruminantium*. Use in genetic diversity analysis. *Ann. N.Y. Acad. Sci.*,
571 **1026**, 106–113.
- 572 MBOLOI M.M., BEKKER C.P.J., KRUITWAGEN C., GREINER M. & JONGEJAN F. (1999). Validation of the indirect MAP1-B
573 Enzyme-linked immunosorbent assay for diagnosis of experimental *Cowdria ruminantium* infection in small
574 ruminants. *Clin. Diagn. Lab. Immunol.*, **6**, 66–72.
- 575 MONDRY R., MARTINEZ D., CAMUS E., LIEBISCH A., KATZ J.B., DEWALD R., VAN VLIET A.H.M. & JONGEJAN F. (1998).
576 Validation and comparison of three enzyme-linked immunosorbent assays for the detection of antibodies to *Cowdria*
577 *ruminantium* infection. *Ann. N.Y. Acad. Sci.*, **849**, 262–272.
- 578 NJIIRI N.E., BRONSVOORT B.M., COLLINS N.E., STEYN H.C., TROSKIE M., VORSTER I., THUMBI S.M., SIBEKO K.P., JENNINGS
579 A., VAN WYK I.C., MBOLE-KARIUKI M., KIARA H., POOLE E.J., HANOTTE O., COETZER K., OOSTHUIZEN M.C., WOOLHOUSE
580 M. & TOYE P. (2015). The epidemiology of tick-borne haemoparasites as determined by the reverse line blot
581 hybridization assay in an intensively studied cohort of calves in western Kenya. *Vet. Parasitol.*, **210**, 69–76.
- 582 NYIKA A., BARBET A.F., BURRIDGE M.J. & MAHAN S.M. (2002). DNA vaccination with map1 gene followed by protein
583 boost augments protection against challenge with *Cowdria ruminantium*, the agent of heartwater. *Vaccine*, **20**,
584 1215–1225.
- 585 PEIXOTO C.C., MARCELINO I., VACHIERY N., BENSALD A., MARTINEZ D., CARRONDO M.J.T. & ALVES P. (2005).
586 Quantification of *Ehrlichia ruminantium* by real time PCR. *Vet. Microbiol.*, **107**, 273–278.
- 587 PETER T.F., O'CALLAGHAN C.J., MEDLEY G.F., PERRY B.D., SEMU S.M. & MAHAN S.M. (2001). Population-based
588 evaluation of the *Ehrlichia ruminantium* MAP 1B indirect ELISA. *Exp. Appl. Acarol.*, **25**, 881–897.
- 589 PILET H., VACHIÉRY N., BERRICH M., BOUCHOUICHA R., DURAND B., PRUNEAU L., PINARELLO V., SALDANA A., CARASCO-
590 LACOMBE C., LEFRANÇOIS T., MEYER D.F., MARTINEZ D., BOULOUIS H.J. & HADDAD N. (2012). [A new typing technique
591 for the Rickettsiales *Ehrlichia ruminantium*: multiple-locus variable number tandem repeat analysis.](#) *J. Microbiol.*
592 *Methods*, **88**, 205–211.
- 593 POSTIGO M., BELL-SAKYI L., PAXTON E. & SUMPTION K. (2002). Kinetics of experimental infection of sheep with
594 *Ehrlichia ruminantium* cultivated in ticks and mammalian cell lines. *Exp. Appl. Acarol.*, **28**, 187–193.
- 595 PRETORIUS A., LIEBENBERG J., LOUW E., COLLINS N.E. & ALLSOPP B.A. (2010). Studies of a polymorphic *Ehrlichia*
596 *ruminantium* gene for use as a component of a recombinant vaccine against heartwater. *Vaccine*, **28**, 3531–3539.
- 597 PRETORIUS A., VAN KLEEF M., COLLINS N.E., TSHIKUDO N., LOUW E., FABER F.E., VAN STRIJP M.F. & ALLSOPP B.A. (2008).
598 A heterologous prime/boost immunisation strategy protects against virulent *E. ruminantium* Welgevonden needle
599 challenge but not against tick challenge. *Vaccine*, **26**, 4363–4371.
- 600 RALINIAINA M., MEYER D., PINARELLO V., SHEIKBOUDOU C., EMBOULÉ L., KANDASSAMY Y., ADAKAL H., STACHURSKI F.,
601 MARTINEZ D., LEFRANÇOIS T. & VACHIÉRY N. (2010). Mining the genetic diversity of *Ehrlichia 1 ruminantium* using map
602 genes family. *Vet. Parasitol.*, **167** (2–4), 187–195.
- 603 SAYLER K.A., LOFTIS A.D., MAHAN S.M. & BARBET A.F. (2016). Development of a Quantitative PCR Assay for
604 Differentiating the Agent of Heartwater Disease, *Ehrlichia ruminantium*, from the Panola Mountain *Ehrlichia*.
605 *Transbound. Emerg. Dis.*, **63**, e260–e269.
- 606 SEMU S.M., PETER T.F., MUKWEDEYA D., BARBET A.F., JONGEJAN F. & MAHAN S.M. (2001). Antibody responses to Map
607 1B and other *Cowdria ruminantium* antigens are down regulated in cattle challenged with tick-transmitted
608 heartwater. *Clin. Diag. Immunol. Lab.*, **8**, 388–396.

609 STEYN H.C., PRETORIUS A., MCCRINDLE C.M., STEINMANN C.M. & VAN KLEEF M. (2008). A quantitative real-time PCR
610 assay for *Ehrlichia ruminantium* using pCS20. *Vet. Microbiol.*, **131**, 258–265.

611 ZHANG J., KELLY P., GUO W., XU C., WEI L., JONGEJAN F., LOFTIS A. & WANG C. (2015). Development of a generic
612 *Ehrlichia* FRET-qPCR and investigation of ehrlichioses in domestic ruminants on five Caribbean islands. *Parasit.*
613 *Vectors*, **8**, 506.

614 ZWEYGARTH E., JOSEMANS A.I., VAN STRIJP M.F., LOPEZ-REBOLLAR L., VAN KLEEF M. & ALLSOPP B.A. (2005). An
615 attenuated *Ehrlichia ruminantium* (Welgevonden stock) vaccine protects small ruminants against virulent heartwater
616 challenge. *Vaccine*, **23**, 1695–1702.

617 *
618 * *

619 **NB:** There is a WOAHP Reference Laboratory for heartwater (please consult the WOAHP Web site:
620 <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>)
621 Please contact the WOAHP Reference Laboratories for any further information on
622 diagnostic tests, reagents and vaccines for heartwater

623 **NB:** FIRST ADOPTED IN 1990. MOST RECENT UPDATES ADOPTED IN 2018.

624
625
626

Appendix 1: Heartwater
Intended purpose of test: purpose 1 – population freedom from infection, prevalence of infection/epidemiological surveillance

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>MAP-1B indirect ELISA</u> <u>Bovine, Caprine, Ovine: ++ and +++ respectively</u>	<u>Serum or plasma</u> <u>Antibodies against MAP1-B subunit of <i>Ehrlichia ruminantium</i></u>	<u>For cattle, goat and sheep:</u> <u>Specificity = 99.4%</u> <u>Sensibility = 96.5%</u>	<u>Positive control:</u> <u>Cattle: serum from a naturally infected animal</u> <u>Goat and sheep: sera from animals infected with a virulent culture supernatant</u> <u>Validation samples: 2418 negative sera from heartwater-free lesser Antilles</u> <u>37 positive sera from controlled conditions</u> <u>vaccinated animals</u>	<u>See reference</u>	<u>Easy to set up in a local laboratory</u>	<u>Present limitations for population freedom from infection because of the limited persistence of antibodies in animals</u> <u>Coating antigen not commercially available</u>	<u>Mondry <i>et al.</i> (1998)</u>
<u>Real-time PCR:</u> <u>≡</u>	<u>Ticks (<i>Amblyomma</i> species)</u>	<u>Three copies by reaction</u>	<u>26 different strains of <i>E. ruminantium</i> detected</u> <u>15 other <i>Ehrlichia</i>, <i>Babesia</i> and <i>Anaplasma</i> undetected, (even Panola Mountain <i>Ehrlichia</i>)</u> <u>nine uninfected <i>Amblyomma variegatum</i> samples</u>	<u>See reference</u>	<u>Can be performed to screen tick population collected on animals, as a complement to the serological test on hosts.</u> <u>Specific and rapid test.</u>	<u>Expensive and fragile equipment requires</u>	<u>Cangi <i>et al.</i> (2017)</u>

627
628
629

Appendix 2: Heartwater

Intended purpose of test: purpose 2 and purpose 5 – individual animal freedom from infection prior to movement; immune status of individual animals; population post-vaccination studies

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
MAP1-B indirect ELISA: + and ++, respectively	Serum or plasma Antibodies against MAP1-B subunit of <i>Ehrlichia ruminantium</i>	For cattle, goat and sheep: Specificity = 99,4% Sensibility = 96,5%	Positive control: Cattle: serum from a naturally infected animal Goat and sheep: sera from animals infected with a virulent culture supernatant Validation samples: 2418 negative sera from heartwater-free lesser Antilles 37 positive sera from controlled conditions vaccinated animals	See reference	Easy to set up in a local laboratory	Present limitations for population freedom from infection because of the limited persistence of antibodies in animals Coating antigen not commercially available	Mondry <i>et al.</i> (1998)

Appendix 3: Heartwater
Intended purpose of test: purpose 4 – confirmation of clinical cases

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Real-time PCR: +++</u>	<u>Fresh blood collected on EDTA or 2/3 blood + 1/3 ultrapure ethanol for longer conservation</u> <u><i>Ehrlichia ruminantium</i> pCS20 gene</u>	<u>See above</u>			<u>Method of choice for diagnostic during febrile phase</u>		
<u>Nested PCR: +++</u>	<u>Fresh blood collected on EDTA or 2/3 blood + 1/3 ultrapure ethanol for longer conservation</u> <u>Brain, lung</u> <u><i>Ehrlichia ruminantium</i> pCS20 gene</u>	<u>Six elementary bodies of <i>E. ruminantium</i> per reaction</u> <u>Diagnostic sensibility: 2 log₁₀ higher than Map1 PCR</u> <u>Specificity = as high as the Map1 PCR</u>	<u>Ticks and ruminant blood</u> <u>Comparison between Map1 nested PCR and pCS20 nested PCR</u>	<u>See reference</u>	<u>Need only a conventional PCR equipment</u>	<u>High risk of contamination because of two successive amplifications</u>	<u>Cangi <i>et al.</i> (2016)</u>
<u>In-vitro bacterium isolation: ±</u>	<u>Blood collected on heparin and treated within 4 hours after collection</u> <u>Isolation of live <i>E. ruminantium</i></u>	<u>Bacterial loads in blood, organs and ticks are not yet formally known.</u>	<u>Isolation could be performed on blood from animal in clinical phase, in organs up to 2 days after death and on ticks during all cycle life</u>	<u>See reference</u>	<u>Formal proof of the presence of the pathogen</u>	<u>Suitable but in very limited circumstances: Long, laborious, risky. Need a well-trained cell culture laboratory technician: risks of culture lost and false negative results</u>	<u>Marcelino <i>et al.</i> (2016)</u>

CHAPTER 3.1.21.
RINDERPEST
(INFECTION WITH RINDERPEST VIRUS)

SUMMARY

In the past, classical rinderpest was an acute, viral disease of domestic cattle, yaks, wild African buffaloes (Syncerus caffer) and Asian water buffaloes (Bubalus bubalis and B. arnee). It was characterised by high morbidity and mortality rates. ~~Sheep, goats, pigs and wild ungulates~~ Other species of domestic and wild cloven-hooved animals might also be affected, but are not considered epidemiologically significant. Between 2002 and 2011, there were no reported field cases of rinderpest. The eradication campaign concluded in 2011 with an international declaration of global freedom from rinderpest.

Existing collections of virulent and attenuated rinderpest viruses will remain under sequestration in approved research, diagnostic and vaccine manufacturing laboratories. To guard against the accidental release of virus from laboratory sources, FAO¹ and WOAHA are collaborating in ~~establishing the principle of~~ maintaining international oversight and regulation of facilities holding rinderpest virus (RPV). All diagnostic testing that uses RPV-containing material should be performed by an RPV WOAHA Reference Laboratory. Vaccine production and research activities that use live RPV or RPV-containing materials should be performed in an FAO-WOAHA approved Rinderpest Holding Facility (RHF) conditional on receiving explicit authorisation from FAO and WOAHA.

Rinderpest remains a notifiable disease and adequate surveillance systems must be maintained for the early detection of clinical cases should there be any accidental escape of the virus. WOAHA (with FAO) will ensure the permanent availability of educational materials demonstrating the range of signs associated with rinderpest cases in live animals.

Description of the disease: *Clinical recognition of classical rinderpest is based on the finding of an individual dead animal or small groups of extremely sick animals showing two or more of the following signs: pyrexia, inappetance, depression, emaciation, shallow erosions of the upper and lower lip and gum, erosions or blunting of the cheek papillae, serous or mucopurulent ocular and/or nasal discharges, diarrhoea or terminal recumbency. It is more than likely that the group will contain a number of dead animals with such lesions. The introductory section of this chapter provides a more detailed description.*

Detection and identification of the agent: *Laboratory confirmation is required, and is based on demonstrating the presence of the virus, ~~viral~~ virus-specific RNA or viral antigen in samples from the spleen, tonsils, lymph nodes, white blood cells, ocular or nasal secretions of acutely infected animals.*

Serological tests: *Antibodies to RPV can be detected in serum from animals that have been infected with field virus or received rinderpest vaccine. This ~~could~~ can be done ~~using estimation by~~ determination of neutralising antibody; ~~from the results of it could previously also be done using~~ a competition enzyme-linked immunosorbent assay (C-ELISA), but no such test is currently available. Any test used must be highly specific for RPV. Such*

¹ FAO: Food and Agriculture Organization of the United Nations

40 tests can currently only be carried out in FAO-WOAH approved ~~Rinderpest Holding Facilities-RHFs~~, as the
41 neutralisation tests require the use of live RPV (~~neutralisation tests~~) or antigen derived from live virus (C-ELISA).

42 **Requirements for vaccines:** ~~A live attenuated rinderpest cell culture vaccine is available. Currently, two~~
43 live attenuated rinderpest cell culture vaccines, described in this chapter, are available. Under the terms of
44 the Guidelines for Rinderpest Virus Sequestration, of Resolution No. 21 (adopted by the WOAH Assembly,
45 May 2017) governing the post-eradication era, it is not permitted to inoculate an animal with a rinderpest
46 vaccine without prior permission from WOAH and FAO.

47 In order to prepare for the possibility of a RPV re-emergence or release, FAO and WOAH, in collaboration
48 with member countries, have developed a Global Rinderpest Action Plan for the post-eradication era that
49 includes an international contingency plan, designation of a minimum number of Reference
50 Centres/Reference Laboratories and an operational framework for emergency vaccine repositories to
51 maintain preparedness. The retention and further manipulation of vaccine seed viruses is regulated jointly
52 by FAO and WOAH.

53 A. INTRODUCTION

54 In the past, classical rinderpest was an acute, viral disease of domestic cattle, yaks, wild African buffaloes (*Syncerus caffer*)
55 and Asian water buffaloes (*Bubalus bubalis* and *B. arnee*). It was characterised by high morbidity and mortality rates.
56 ~~Sheep, goats, pigs and wild ungulates. Other species of domestic and wild cloven-hooved animals~~ might also be affected
57 (Taylor & Barrett, 2007). Rinderpest is not a zoonotic disease, but the virus or virus-containing materials must be handled
58 in accordance with strict biocontainment procedures as described in Chapter 1.1.4 *Biosafety and biosecurity: Standard for*
59 *managing biological risk in the veterinary laboratory and animal facilities*, and in conformity with the Guidelines for
60 Rinderpest Virus Sequestration.

61 Between 2002 and 2011 there were no reported field cases of rinderpest. Further, in the period leading up to January
62 2011, the WOAH Scientific Commission for Animal Diseases scrutinised a comprehensive world-wide list of applications
63 (evidence-based and historical) for national recognition of rinderpest-freedom. This process concluded in 2011 with an
64 international declaration of global freedom from rinderpest. For the immediate future, existing collections of virulent and
65 attenuated rinderpest viruses will remain under sequestration in FAO-WOAH designated Rinderpest Holding Facilities
66 (RHF) research and approved vaccine manufacturing laboratories. To guard against the accidental release of virus from
67 laboratory sources, FAO and WOAH are collaborating in establishing the principle of international oversight and regulation
68 of facilities holding rinderpest virus (RPV) based on minimising the number of repositories. All diagnostic testing, vaccine
69 development and research activities that use live RPV or other RPV-containing materials² should be performed in an FAO-
70 WOAH approved RHF and after approval of the activity by WOAH and FAO.

71 Rinderpest remains a notifiable disease and adequate surveillance systems must be maintained for the early detection of
72 clinical cases should there be any accidental escape of the virus. WOAH and FAO will ensure the permanent availability
73 of educational materials demonstrating the range of signs associated with rinderpest cases in live animals. A recent
74 account of the history of rinderpest, its eradication and its socio-economic impact is available (Roeder & Rich, 2009).

75 ~~Rinderpest is caused by RPV~~ is a negative-strand RNA virus of the *Morbivirus* genus within the family *Paramyxoviridae*.
76 The virus has a single serotype with at least three geographically restricted clades: African Lineages 1 and 2 and Asian
77 Lineage 3, which cross-protect fully and are only differentiated by molecular characterisation. Although some strains of
78 rinderpest evolved into a mild, nonfatal, infectious disease of cattle, all strains retain two very dangerous attributes. The
79 first is an almost certain ability to undergo virulence modulations. The second is an ability to infect wild animal species and,
80 in African buffaloes, eland, giraffe, lesser kudu and warthog, to cause an acute infection associated with high mortality.

81 An illustrated description of the disease is given in the WOAH Atlas of Transboundary Animal Diseases (Fernandez &
82 White, 2010). Classical rinderpest has an incubation period of between 1 and 2 weeks. A peracute form is characterised
83 by high pyrexia and sudden death in newborn or young animals. The acute disease is characterised by an acute febrile
84 attack within which prodromal and erosive phases can be distinguished. The prodromal period lasts approximately 3 days,
85 during which affected animals develop a pyrexia of between 40 and 41.5°C together with partial anorexia, constipation,
86 congestion of visible mucosae, serous ocular and nasal discharges, depression and drying of the muzzle. However, it is
87 not until the onset of the erosive phase, and the development of necrotic mouth lesions, that a tentative clinical diagnosis
88 of rinderpest can be made. At the height of fever, flecks of necrotic epithelium appear on the lower lip and gum and in rapid
89 succession may appear on the upper gum and dental pad, on the underside of the tongue, on the cheeks and cheek
90 papillae and on the hard palate. Through the enlargement of existing lesions and the development of new foci, the extent
91 of the oral necrosis can increase dramatically over the following 2–3 days. Much of the necrotic material works loose giving

² See chapter 8.16 of the WOAH *Terrestrial Code* for definition of Rinderpest virus containing materials.

92 rise to shallow, non-haemorrhagic mucosal erosions. Necrotic lesions may also be found on the nares, vulva, vagina and
93 preputial sheet.

94 Diarrhoea is another characteristic feature that develops 1–2 days after the onset of mouth lesions. The diarrhoea is usually
95 copious and watery at first, but later on may contain mucus, blood and shreds of epithelium and it may be accompanied,
96 in severe cases, by tenesmus. Anorexia develops, the muzzle dries out completely, the animal is depressed and
97 emaciated, the breath is fetid and mucopurulent ocular and nasal discharges develop.

98 Deaths will occur but, depending on the strain involved, the breed of cattle infected and environmental conditions, the
99 mortality rate may vary from 100% (acute strains in European breeds), to 20–30% (acute strains in zebu cattle), to zero
100 (mild strains in zebu cattle). With both acute and mild strains, the mortality rate may be expected to rise as the virus gains
101 progressive access to large numbers of susceptible animals. In the terminal stages of the illness, animals may become
102 recumbent for 24–48 hours prior to death. Some animals die while showing severe necrotic lesions, high fever, emaciation
103 and diarrhoea, others after a sharp fall in body temperature, often to subnormal values. In survivors, the pyrexia may remit
104 slightly in the middle of the erosive period and then, 2–3 days later, return rapidly to normal accompanied by a quick
105 resolution of the mouth lesions, a halt to the diarrhoea and an uncomplicated convalescence.

106 In cases where rinderpest is suspected, post-mortem examinations should pay particular attention to the abomasum, which
107 may be highly engorged or show a grey discoloration; to the Peyer's patches, which may show lymphoid necrosis; and to
108 the development of linear engorgement and blackening of the crests of the folds of the caecum, colon and rectum. Typically
109 the carcass of the dead animal is dehydrated, emaciated and soiled. The nose and cheeks bear evidence of mucopurulent
110 discharges, the eyes are ~~is~~-sunken and the conjunctiva congested. In the oral cavity, there is often extensive desquamation
111 of necrotic epithelium, which always appears sharply demarcated from adjacent areas of healthy mucosa. The lesions
112 frequently extend to the soft palate and may also involve the pharynx and the upper portion of the oesophagus; the rumen,
113 reticulum and omasum are usually unaffected, although necrotic plaques are occasionally encountered on the pillars of
114 the rumen. The abomasum, especially the pyloric region, is severely affected and shows congestion, petechiation and
115 oedema of the submucosa. Epithelial necrosis gives the mucous membrane a grey colour. The small intestine is not
116 commonly involved except for striking changes to the Peyer's patches where lymphoid necrosis and sloughing leaves the
117 supporting architecture engorged or blackened. In the large intestine changes involve the ileocaecal valve, the caecal tonsil
118 and the crests of the longitudinal folds of the caecal, colonic and rectal mucosae. The folds appear highly engorged in
119 acute deaths or darkly discoloured in long-standing cases; in either event the lesions are referred to as 'zebra striping'.

120 The principal differential diagnoses in cattle are bovine viral diarrhoea/mucosal disease complex and malignant catarrhal
121 fever; differentiation of these diseases requires the use of appropriate laboratory tests. Definitive diagnosis of rinderpest
122 can currently only be undertaken in WOAH rinderpest Reference Laboratories.

123 In the mild form of rinderpest, which was associated with African lineage 2 strains of the virus that were found in endemic
124 areas of eastern Africa, the incubation period could be between 1 and 2 weeks and the ensuing clinical disease little more
125 than a subacute febrile attack in cattle. The fever was not invariable; it was short-lived (3–4 days) and low (38–40°C). The
126 depression that characterised more acute forms of rinderpest was absent from mildly affected animals and, as a result,
127 cattle often did not lose their appetite, and continued to graze, water and trek as well as unaffected animals. Diarrhoea, if
128 present, was not marked. On close examination there might be some slight congestion of the visible mucous membranes
129 and small, focal areas of raised, whitish epithelial necrosis might be found on the lower gum – sometimes no larger than a
130 pin head – along with a few eroded cheek papillae. Some animals totally escaped the development of such erosions, the
131 appearance of which was fleeting. Other animals might show a slight, serous, ocular or nasal secretion but, in contrast to
132 the more severe forms of the disease, these did not progress to become mucopurulent.

133 Even though infections with mild rinderpest could pass unnoticed in cattle, the virus remained highly infectious for wildlife
134 species, and among those generally regarded as highly susceptible (tragelaphine species such as lesser kudu and eland,
135 African buffalo, and giraffe) it caused fever, a nasal discharge, typical erosive stomatitis, gastroenteritis, and death. Kock
136 (2006) observed that, in addition, African buffaloes infected with lineage 2 showed enlarged peripheral lymph nodes,
137 plaque-like keratinised skin lesions and keratoconjunctivitis. Lesser kudus were similarly affected but, whereas blindness
138 – caused by a severe keratoconjunctivitis – was common, diarrhoea was unusual. Eland also showed necrosis and
139 erosions of the buccal mucosa together with dehydration and emaciation. Therefore, in these circumstances, a diagnosis
140 of rinderpest in any of these species points to the likelihood of the simultaneous transmission of the virus, even at a
141 subclinical level, in neighbouring cattle and possible dissemination of infection through live animal trade.

142

B. DIAGNOSTIC TECHNIQUES

143 Table 1. Test methods available for rinderpest diagnosis and their purpose

Method	Purpose					
	Population freedom from infection ^(a)	Individual animal freedom from infection prior to movement ^(b)	Contribute to eradication policies ^(c)	Confirmation of clinical cases ^(d)	Prevalence of infection – surveillance ^(e)	Immune status in individual animals or populations post-vaccination ^(f)
<u>Detection and identification of the agent^(g)</u>						
Virus isolation	–	–	+	+++	–	–
Antigen detection (AGID)	–	–	+	+	+	–
<u>Conventional RT-PCR</u>	=	+++	+++	+++	±	=
Real-time RT-PCR	–	+++	+++	+++	+	–
<u>Detection of immune response</u>						
AGID	+	+	+	–	+	+
C-ELISA	++	–	++	–	++	++
VN	+++	–	+++	–	+++	+++

Key: +++ = recommended for this purpose; ++ recommended but has limitations; + = suitable in very limited circumstances; – = not appropriate for this purpose.

AGID = agar gel immunodiffusion; RT-PCR = reverse-transcriptase polymerase chain reaction;

C-ELISA = competitive enzyme-linked immunosorbent assay; VN = virus neutralisation.

^(a) See Appendix 1 of this chapter for justification table for the scores given to the tests for this purpose.

^(b) See Appendix 2 of this chapter for justification table for the scores given to the tests for this purpose.

^(c) See Appendix 3 of this chapter for justification table for the scores given to the tests for this purpose.

^(d) See Appendix 4 of this chapter for justification table for the scores given to the tests for this purpose.

^(e) See Appendix 5 of this chapter for justification table for the scores given to the tests for this purpose.

^(f) See Appendix 6 of this chapter for justification table for the scores given to the tests for this purpose.

^(g) A combination of agent identification methods applied on the same clinical sample is recommended.

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

Special Post-Eradication Note: there are no diagnostic tests for RPV or antibodies to RPV for which there is a positive control that does not come within the FAO-WOAH definition of a Rinderpest Virus Containing Material (RVCM). Continued storage of RVCM requires approval of the laboratory through the FAO-WOAH Rinderpest secretariat as an FAO-WOAH Holding Facility RHE; use of RVCM for any purpose, including validation of diagnostic tests, requires explicit permission of FAO and WOAH.

160

161

162

163

164

165

166

167

168

Suspect cases, that is animals with clinical signs similar to those seen in the case of infection with RPV, will still arise, and need to be tested to ensure that any future re-emergence or escape of RPV is detected in a timely manner. For the initial testing of samples from suspect cases, laboratories that are not FAO-WOAH-approved Rinderpest Holding Facilities RHEs are recommended to use (gel-based or real-time) reverse-transcriptase polymerase chain reaction (RT-PCR) using the established primer sets. The test can be run without a RPV positive control; parallel tests using (vaccine or wild type) peste des petits ruminants virus (PPRV) and published primer sets for PPRV can be used as a control for most of the stages of the assay (RNA extraction, reverse transcription and PCR reagents); alternatively the bovine actin primers can be used in parallel as an internal control reaction. For definitive diagnosis, samples should be sent to one of the FAO-WOAH approved Rinderpest Holding Facilities rinderpest Reference Laboratories.

169

170

There are no circumstances where tests for anti-RPV antibodies will be required unless there is a re-emergence or escape of the virus.

171

172 1. Detection and identification of the agent

173 Any suspicion of rinderpest must be viewed as a potential threat to international biosecurity and must be rapidly confirmed
174 or differentiated. RT-PCR is the most rapid and specific test. If RPV is confirmed, back-tracing measures must be
175 immediately instigated. In addition, samples must be sent to a WOA Reference Laboratory for rinderpest for final
176 confirmation of the diagnosis, and the virus origin should be identified by sequencing and comparison with known RPV
177 genomic data. If possible, the virus should be isolated (Anderson *et al.*, 1996), though this should only be attempted in a
178 WOAH Reference Laboratory or a FAO-WOAH approved Rinderpest Holding Facility.

179 1.1. Virus isolation

180 RPV can be cultured from the leukocyte fraction of whole blood that has been collected into heparin or EDTA
181 (ethylene diamine tetra-acetic acid) at final concentrations of 10 international units (IU)/ml and 0.5 mg/ml,
182 respectively. Samples should be thoroughly mixed and transferred to the laboratory on ice, but never frozen.
183 On average, the onset of viraemia slightly precedes the onset of pyrexia, and may continue for 1–2 days after
184 pyrexia begins to wane. Consequently, animals showing a pyrexia are probably viraemic and therefore the best
185 source of blood with which to attempt virus isolation. However, as occasional febrile animals may no longer be
186 viraemic, samples from several febrile animals should be collected for submission. Virus can also be isolated
187 from samples of the tonsil, spleen, prescapular or mesenteric lymph nodes of dead animals; these samples may
188 be frozen for transportation. Transportation must be under biosecure conditions in compliance with international
189 transport regulations described in Chapter 1.1.2 *Collection, submission and storage of diagnostic specimens*,
190 Chapter 1.1.3 *Transport of biological materials* and with the Guidelines for Rinderpest Virus Sequestration.

191 To isolate the virus from blood, uncoagulated blood is centrifuged at 2500 **g** for 15 minutes to produce a buffy
192 coat layer at the boundary between the plasma and erythrocytes. This is removed as cleanly as possible, mixed
193 in 20 ml physiological saline and recentrifuged in a washing procedure designed to remove any neutralising
194 antibody present in the plasma. The resulting cell pellet is suspended in cell culture maintenance medium and
195 2 ml aliquots are distributed onto established monolayers of primary calf kidney, B95a marmoset
196 lymphoblastoid, *Theileria*-transformed bovine T lymphoblast or African green monkey kidney (Vero) cells,
197 preferably Vero cells expressing morbillivirus receptor SLAM. These cells may be cultured in roller tubes, culture
198 flasks or multiwell plates.

199 Alternatively, 20% suspensions (w/v) of post-mortem tissue may be used. These should be made by macerating
200 the solid tissues in serum-free culture maintenance medium using standard grinding or shearing techniques and
201 inoculating monolayers as before. The release of virus from solid tissue can be achieved in several ways.
202 Perhaps the easiest is with a pestle and mortar, but this technique requires the use of sterile sand as an abrasive.
203 Alternatively, tissue may be ground without an abrasive using all-glass grinders, for example, a Ten Broeck
204 grinder. Shearing techniques are equally applicable using laboratory blenders. Virus-containing suspensions
205 are clarified by low-speed centrifugation. The volume of the inoculum is not critical; a working volume is between
206 1 and 2 ml. Commonly used antibiotics are penicillin and streptomycin in combination, ~~each~~ at a concentration
207 of 100 IU/ml or 100 µg/ml, respectively. A similar broad-spectrum cover can be obtained using neomycin at
208 50 µg/ml. Amphotericin B should be included at 2.5 µg/ml.

209 The inoculum should be removed after 1–2 hours and replaced with fresh medium. Thereafter, the culture
210 maintenance medium should be decanted and replaced every 2 or 3 days and the monolayer observed
211 microscopically for the development of cytopathic effects (CPE). These are characterised by refractility, cell
212 rounding, cell retraction with elongated cytoplasmic bridges (stellate cells) and/or syncytium formation. The
213 speed with which the CPE develops varies by substrate and probably by strain of virus also. Up to 12 days
214 should be allowed in primary cells, a week in Vero and 2–5 days in B95a cells or Vero cells expressing SLAM.
215 Blind passages may be attempted before declaring an important sample negative. Isolates of virus can be
216 ~~partially identified by the demonstration of morbillivirus-specific precipitinogens in infected cell debris, or~~
217 ~~completely identified by either RT-PCR using RPV-specific primers (see below) or the demonstration of specific~~
218 ~~immunofluorescence using a RPV-specific monoclonal antibody.~~

219 1.2. Antigen detection by agar gel immunodiffusion

220 ~~The agar gel immunodiffusion (AGID) tests may be conducted in Petri dishes or on glass microscope slides~~
221 ~~(Foreman *et al.*, 1983). In either instance the surface should be covered with agar to a depth of about 4 mm~~
222 ~~using a 1% aqueous solution of any high quality agar or agarose. Wells are usually cut in a hexagonal pattern~~
223 ~~of six peripheral wells around a single central well. For slides, wells should be 3 mm in diameter and 2 mm~~
224 ~~apart. For Petri dishes, the wells can be increased to 4 mm in diameter and the distance between wells to 3 mm.~~
225 ~~The closer the wells are placed from each other, the shorter the reaction time.~~

226 Using a small volume pipette, rinderpest hyperimmune rabbit serum should be placed in the central well. In the
227 absence of a rinderpest containing positive control, PPRV (e.g. preparations of vaccine virus) can be used as
228 the control, which should be placed in alternate peripheral wells (i.e. one, three and five). Negative control
229 antigen is placed in well four. Test antigens are obtained as exudates from the cut surface of spleen or lymph
230 nodes submitted for testing; if no exudate can be obtained a small portion of the sample should be ground with
231 a minimum of saline. Ocular exudates may be squeezed directly from the swabs or, alternatively, by
232 compression in a microtip (the cotton wool should be cut off the swab and placed into the wide end of a plastic
233 50–250 µl pipette tip; the stem of the swab may then be used to compress the cotton wool and force a small
234 volume of exudate out of the narrow end of the tip). Test samples are added to wells two and six. Tests are best
235 developed at 4°C or low ambient temperatures. The reaction area should be inspected from 2 hours onwards
236 for the appearance of clean, sharp lines of precipitation between the wells forming a line of identity with the
237 controls. Tests should be discarded after 24 hours if no result has been obtained. The result is not acceptable
238 unless precipitation reactions are also obtained giving a line of identity with the control positive antigen
239 preparation.

240 Although the test is neither highly sensitive nor highly specific, it is robust and adaptable to field conditions. A
241 positive reaction from a large domestic ruminant should be treated as if it were rinderpest. From a small
242 ruminant, a positive result should be treated as having been derived from a case of peste des petits ruminants
243 (PPR) although further testing is recommended, given the lack of specificity in this test.

244 1.23. Nucleic acid detection and characterisation methods

245 RT-PCR techniques based on the amplification of parts of the N or F protein genes have been developed for
246 the specific diagnosis of RPV (Forsyth & Barrett, 1995). This technique is extremely sensitive, specific and can
247 detect RPV in cattle as early as two days post-infection with the advantage that results are obtained in 5 hours,
248 including the RNA extraction. The two most commonly used protocols are given in some detail below. The PCR
249 products are analysed on a 1.5% (w/v) agarose gel along with a suitable DNA size marker to identify the specific
250 DNA product.

251 A real-time RT-PCR assay for RPV diagnosis was described by Carrillo *et al.* (2010). This assay has been
252 shown to be sensitive, to detect isolates representative of all known phylogenetic lineages of the virus, and to
253 clearly differentiate RPV from PPRV and other clinically similar diseases (foot and mouth disease virus, bovine
254 viral diarrhoea virus, bovine herpes virus, vesicular stomatitis virus). Comparison of samples from
255 experimentally infected animals showed that white blood cells and conjunctival swabs are the sample of choice
256 for this test, allowing the preclinical detection of the disease by 2–4 days post-infection. In the event of a RPV
257 outbreak, this single-tube format real-time RT-PCR has the capability of preclinical diagnosis, thus aiding efforts
258 to prevent further transmission of disease. It should be noted, however, that the assay was developed after the
259 last RPV case, and was never used in practice for RPV diagnosis, and appropriate diagnostic controls are not
260 generally available.

261 In general, any molecular diagnostic methods, including RT-PCR, require appropriate positive and negative
262 controls during their execution. Careful consideration is essential when interpreting results in the absence of
263 proper control reactions. Laboratories, other than the WOAH Reference Laboratories, that wish to carry out their
264 own testing of suspect cases are advised to carry out gel-based RT-PCR using the available controls. For both
265 gel-based and real-time PCR methods, a positive control such as PPRV (with its specific primers) or bovine
266 actin, and an appropriate negative control using sterile distilled water instead of test RNA, must be included.
267 Positive reactions with an RPV-specific primer set should be confirmed either by using additional RPV-specific
268 primer sets or by sequence analysis of the DNA product.

269 1.3.1. Extraction of RNA from field samples

270 Viral RNA can be purified from lymph node nodes or tonsil tonsils (ideal), peripheral blood lymphocytes
271 (PBLs), swabs from eyes or mouth lesions, or from spleen (not ideal because of its high blood content).
272 Tissue samples should be extracted with acidified guanidinium thiocyanate phenol (Forsyth & Barrett,
273 1995) using one of the commercial preparations available. Solid tissues (0.5–1.0 g) are minced and
274 homogenised with 10 ml reagent, eye and mouth swabs are extracted with 1.0 ml, and purified PBLs
275 (from 5 ml whole blood) are homogenised with 1.0 ml; RNA is then purified according to the
276 manufacturer's procedure. For PBLs or swabs, RNA extraction spin columns are also suitable. The
277 resulting RNA is stored at –70°C or –20°C until required.

278 The cDNA synthesis and PCR are carried out using a one-tube combined reaction. Suitable reagents
279 are available from a number of manufacturers in addition to that given in the example protocol. The PCR
280 products are analysed on a 1.5% (w/v) agarose gel along with a suitable DNA size marker to identify the
281 specific DNA products. An internal positive control such as the beta-actin primers should be included to

282 validate the RNA extraction step and the RT-PCR reagents; if possible a parallel extraction of PPRV
 283 should be carried out and the viral RNA identified using PPRV-specific primers (Chapter 3.8.8, Section
 284 2.4). A negative control using sterile distilled water instead of RNA must be included in each set of
 285 reactions. Positive reactions with either RPV-specific primer set should be confirmed by sequence
 286 analysis of the DNA product. In addition, positive samples should be sent to the WOAH Reference
 287 Laboratory in the United Kingdom (UK) for confirmatory testing. It is important to use more than one set
 288 of primers for the PCR step when testing for the presence of RNA viruses, as their nucleotide sequences
 289 can vary significantly and a mismatch of the primer at the 3'-end or within the primer sequence may result
 290 in failure of the primers to amplify the DNA. The ~~FAO World Reference Laboratory³ in the UK, which is~~
 291 ~~also a WOAH Reference Laboratory for rinderpest, and the WOAH Reference Laboratory ies for~~
 292 rinderpest in France and the UK⁴, can advise on use of the technique for field sample analysis.

293 1.3.2. RT-PCR for the diagnosis of RPV based on the amplification of parts of the N and/or F genes

294 N and F gene amplification is based on the initial protocol described by Forsyth & Barrett (1995),
 295 reformulated as a one-step RT-PCR method. The test described requires the following materials: a
 296 commercial one-step RT-PCR kit, distilled water and primers, and a suitable PCR machine. Facilities for
 297 DNA agarose gel electrophoresis are also required.

298 i) Sequences of primers used:

Gene	Product size	Primer	Sequence (5' → 3')
RPV N	297 bp	B2A	ATC-CTT-GTC-GTT-RTA-TGC-TCT-YRG
		B12A	CAA-GGG-RRT-GAG-ACC-CAG-MAC-AR
RPV F	448bp	F3B	AGT-ATA-AGA-GGC-TGT-TGG-GGA-CAG-T
		F4D	TGG-GTC-TCT-GAG-GCT-GGG-TCC-AAA-T
β-Actin	275bp	BA1	GAG-AAG-CTG-TGC-TAC-GTC-GC
		BA2	CCA-GAC-AGC-ACT-GTG-TTG-GC

- 299 ii) Prepare each primer dilution by adding 5 µl of the primer stock solution (100 µM) to 45 µl of distilled
 300 water. A primer concentration of 10 µM is obtained with a final volume of 50 µl.
- 301 iii) For each test gene, prepare a PCR master mix ~~containing 0.6 µM so that the~~ final concentration of
 302 primers in the reaction is 0.6 µM; 45 µl of master mix are required per reaction.
- 303 iv) Add 5 µl of RNA template to 45 µl of each master mix. Distilled water (5 µl) is added in place of
 304 RNA to provide a negative control which has to be included in each set of tests.
- 305 v) The full thermal cycler program will depend on the machine and reagents used in a given laboratory
 306 and must be optimised. For the PCR step, 40 cycles with an annealing temperature of 55°C are
 307 recommended as an initial point for optimisation. Fully tested protocols can be obtained from either
 308 of the WOAH rinderpest Reference Laboratories.

309 Thermal cycler conditions are as follows:

50°C for 30 minutes	1 cycle	Reverse transcription step
95°C for 15 minutes	1 cycle	Inactivates RT and activates polymerase
<hr/>		
94°C for 30 seconds		
55°C for 30 seconds	40 cycles	PCR amplification of the cDNA
72°C for 1 minute		
<hr/>		
72°C for 5 minutes	1 cycle	Final extension
4°C (indefinite)	-	-

- 310 vi) Ten microlitres of each reaction are analysed by electrophoresis on a 1.5 % agarose gel. For all
 311 positive results, the remainder of the final product may be directly used for sequencing.

³ <http://www.fao.org/docrep/004/X2096E/X2096E09.htm>

⁴ <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>

312
313
314
315
316
317

1.3.3. Real-time RT-PCR for the diagnosis of RPV

The real-time RT-PCR assay is carried out essentially as described in Carrillo *et al.*, 2010. It is typically performed as a 20 µl reaction. Several suitable reagents for one step real-time RT-PCR are available, and the exact reaction conditions should be altered to fit with the reagents and the real-time PCR machine being used. For detailed advice on this test, including appropriate control reactions, contact the WOA Reference Laboratories.

318
319

2. Serological tests

2.1. Competitive enzyme-linked immunosorbent assay (ELISA)

320
321
322

There is currently no competitive ELISA available for the detection of rinderpest antibodies. Any old reagents retained in RHF's should be destroyed, as they will have expired and the assay will no longer be valid. A new assay is under development.

323
324
325
326
327
328

A competitive ELISA is useful for the detection of rinderpest antibodies in the serum of animals of any species previously exposed to the virus. The test is based on the ability of positive test sera to compete with a rinderpest anti-H protein MAb for binding to rinderpest antigen. The presence of such antibodies in the test sample will block binding of the MAb, producing a reduction in the expected colour reaction following the addition of enzyme-labelled anti-mouse IgG conjugate and a substrate/chromogen solution. As this is a solid-phase assay, wash steps are required to ensure the removal of unbound reagents.

329
330
331
332
333

The rinderpest antigen is prepared from Madin-Darby bovine kidney cell cultures infected with the attenuated Kabete 'O' strain of rinderpest virus and inactivated at 56°C for 2 hours. The viral antigen is extracted from the infected cells by repeated cycles of sonication and centrifugation. The MAb was obtained by fusing the splenocytes of hyperimmunised mice with the NSO myeloma cell line, and then shown to be rinderpest H protein specific; this MAb has now been designated as C1. Kits will continue to be available commercially.

334

2.1.1. Test procedure

335
336
337

i) Reconstitute the freeze-dried rinderpest antigen with 1 ml of sterile water and further dilute it to the manufacturer's recommended working dilution using 0.01 M phosphate buffered saline (PBS), pH 7.4.

338
339
340
341
342

ii) Immediately dispense 50 µl volumes of the diluted antigen into an appropriate number of wells of a flat-bottomed, high protein-binding ELISA microplate using two wells per test serum. Tap the sides of the microplate to ensure that the antigen is evenly distributed over the bottom of each well and, having sealed the plate, incubate it on an orbital shaker for 1 hour at 37°C. Wash the wells three times with 0.002 M PBS, pH 7.4.

343
344

iii) Add 40 µl of blocking buffer (0.01 M PBS, 0.1% [v/v] Tween-20 and 0.3% [v/v] normal bovine serum) to each test well followed by 10 µl volumes of all test sera.

345
346
347

iv) Follow the manufacturer's recommendations to prepare a working dilution of the MAb in blocking buffer, and add 50 µl of this to each test well. Seal the plates and re-incubate on an orbital shaker for 1 hour at 37°C.

348
349
350

v) Follow the manufacturer's recommendations to prepare a working dilution of rabbit anti-mouse immunoglobulin horseradish peroxidase conjugate in blocking buffer and add 50 µl to each test well. Seal the plates and re-incubate on an orbital shaker for 1 hour at 37°C.

351
352
353
354

vi) At the end of this period the plates are washed as before and immediately refilled with 50 µl volumes of substrate/chromogen mixture (1 part 3% H₂O₂ to 250 parts OPD), and incubate at room temperature for 10 minutes without shaking. Then add 50 µl of a stopping solution consisting of 1 M sulphuric acid.

355
356

vii) The test system must include known rinderpest positive and negative serum samples, a MAb control and a conjugate control.

357
358
359
360

viii) Measure the resulting absorbance values on an ELISA reader with a 492 nm interference filter and express the test results as percentage inhibition values compared with the value obtained using the MAb control. Inhibition values of 50% or more are considered to be positive and values below 50% are considered to be negative.

361
362
363

Lowering the positive/negative threshold to 40% or less increases the sensitivity of the test, but inevitably affects specificity by increasing the proportion of false positive test results encountered. In practice, the 50% value is recommended by GREP at which level sensitivity is at least 70% and specificity exceeds

364 99%. The sensitivity needs to be taken into account when designing sampling frames for
365 serosurveillance.

366 **2.2. Antibody detection by agar gel immunodiffusion (AGID)**

367 The AGID test can be used for screening bovine sera where there is suspected rinderpest disease and where
368 PPRV is not circulating. As noted in section 1.2, the test does not distinguish between PPRV and RPV, so
369 antibodies to either virus will give a positive reaction. Set up the AGID as described in 1.2, except that the central
370 well contains a suspension of PPRV vaccine, while the outer wells contain known anti-RPV antisera (positions
371 1, 3 & 5), negative control serum (e.g. commercial bovine serum) in position 4 and test sera in positions 2 and
372 6. Antibodies to RPV will cross-react with the PPRV antigens, giving rise to precipitin lines.

373 **2.13. Virus neutralisation**

374 The virus neutralisation test (VNT) is performed in roller-tubes or culture flask cultures of primary calf kidney
375 cells following the method of Plowright & Ferris (1961) or in 96-well microplates (Taylor & Rowe, 1984); both
376 tests have been validated in experimentally infected cattle.

377 In the roller tube procedure, sera, that have not been heat inactivated, are diluted at intervals of 1 in 10 and
378 then, starting with undiluted serum, mixed with an equal volume of $10^{3.0}$ TCID₅₀ per ml of an attenuated vaccine
379 strain virus. Mixtures are held overnight at 4°C, after which 0.2 ml volumes are inoculated into each of five roller
380 tubes, immediately followed by 1 ml of dispersed indicator cells suspended in growth medium at a rate of $2 \times$
381 10^5 cells per ml. Tubes are incubated at 37°C, sloped for the first 3 days, after which they are replenished with
382 maintenance medium and placed on a roller apparatus. They are examined regularly for virus-specific
383 cytopathology and positive tubes recorded and securely discarded; the final examination takes place on day 10.
384 For calculating end-points, the virus dose is regarded as satisfactory if the final dilution falls within the range
385 $10^{1.8}$ to $10^{2.8}$ TCID₅₀/tube. Under these circumstances, the presence of any detectable antibody in the 1/2 final
386 serum dilution is considered to indicate previous infection with RPV.

387 In the microplate method, sera are heat-inactivated for 30 minutes at 56°C before use. An initial serum dilution
388 of 1/5 is further diluted at twofold intervals. Thereafter, 50 µl volumes of serum are incubated with 50 µl volumes
389 of virus diluted to contain between $10^{1.8}$ and $10^{2.8}$ TCID₅₀ (Taylor & Rowe, 1984). Following a 45-minute to
390 overnight incubation, 50 µl RPV-susceptible cells (between 1 and 2×10^5 primary calf or lamb kidney cells, $5 \times$
391 10^3 Vero or Vero-SLAM cells, or 5×10^4 B95a cells) are added as indicators. Tests are terminated after 6 or
392 7 days. Such tests may give indications of nonspecific neutralisation at high serum concentrations. There appear
393 to be factors in some normal (with respect to prior rinderpest exposure) sera that bring about the failure of the
394 virus to penetrate and replicate in indicator cells. In the tube test, these factors were probably removed during
395 changes in maintenance medium; in the microplate method, they remain present the whole time. If the most
396 concentrated final serum dilution is limited to 1/10, the effect disappears.

397 It should be noted that, since this test requires the manipulation of live vaccine virus, the VNT can currently only
398 be undertaken in FAO-WOAH approved Rinderpest Holding Facilities RHEs with specific permission to carry out
399 the procedure.

400 **C. REQUIREMENTS FOR VACCINES**

401 **1. Background**

402 **1.1. Rationale and intended use of the product**

403 The live attenuated tissue culture rinderpest vaccine (TCRV) described in previous editions of the *Terrestrial*
404 *Manual* (Plowright, 1962) was developed in Kenya through the serial passage in primary bovine calf kidney cells
405 of RBOK (rinderpest bovine old Kabete, or "Kabete O"), a virulent bovine rinderpest field strain isolated in 1910.
406 While the modern division of rinderpest viruses into four lineages (Africa 1 and 2 and an old African one which
407 includes Kabete O, and Asian) was unknown until 1995 (Wamwayi *et al.*, 1995), the Plowright vaccine virus
408 undoubtedly cross-protects against all strains of all lineages. Since its development, the Plowright vaccine seed
409 was widely distributed and hundreds of millions of doses of it were used on the Indian subcontinent, the Middle
410 and Near East, and Africa in the control and eradication of rinderpest. A curated seed stock of this vaccine is
411 currently stored at the FAO-WOAH-approved RHF in France⁴, and can be provided for production of rinderpest
412 vaccine for emergency use, following explicit permission of FAO and WOAH.

413 Other ~~currently active~~-TCRV strains, LA (Nakamura & Miyamoto, 1953) and LA-AKO (Furutani *et al.*, 1957a),
414 were established from a previously developed lapinised vaccine strain, Nakamura III (alternatively known as L
415 strain; Nakamura *et al.*, 1938), by repeated passages in rabbits and chick embryos. The parental Nakamura III
416 was widely used to control the disease in East and South-East Asia. LA and LA-AKO are reported to be far less
417 virulent than the parental strain, especially in highly susceptible cattle in Eastern Asia such as Japanese black
418 and Korean yellow. Currently, LA-AKO is being used, at an FAO-WOAH-approved ~~Rinderpest Holding Facility~~
419 RHE, for production of rinderpest vaccine for emergency use.

420 2. Outline of production and minimum requirements for conventional vaccines

421 2.1. Characteristics of the seed

422 2.1.1. Biological characteristics

423 i) Plowright (RBOK) vaccine

424 The vaccine strain was developed by 90 passages in primary calf kidney cells, and shown to be
425 safe, effective and to resist reversion to virulence during 7 back passages in cattle (Plowright,
426 1962). The vaccine sequence has been published (Baron & Barrett, 1995) and deposited in the
427 public databases. Seed lots used in the manufacture of Plowright TCRV must produce a cell-culture
428 vaccine that is similarly safe and that confers an immunity in cattle lasting at least 5 years. The
429 immunogenicity of seed virus was demonstrated up to the 122nd BK passage level, which should
430 not be exceeded. Therefore, vaccine seed must be maintained in a seed lot system between
431 passage levels 90 and 120. Seed lot virus must be preserved in a freeze-dried state at a
432 temperature of -20°C or lower. The virus must be cultured in Vero cells or primary or serially
433 cultivated kidney cells derived from a normal bovine fetus or a very young calf. Serially cultivated
434 cells may not be more than ten passages removed from the primary cultivation.

435 ~~The seed virus produces a vaccine that is safe to use in a variety of European, African and Indian~~
436 ~~cattle breeds. Its safety and efficacy have never been assessed in Chinese or Japanese cattle~~
437 ~~breeds.~~

438 ii) LA-AKO vaccine

439 The master seed virus (LA-AKO) was established from the lapinised “Nakamura III” vaccine strain
440 (at the 897th rabbit passage level) by repeated passages in rabbits (29 passages) and chick
441 embryos (456 passages). LA-AKO does not cause any clinical signs except slight hyperthermia in
442 highly susceptible animals such as Japanese black cattle. It should be noted however that the virus
443 induces marked enlargement of the spleen in inoculated chick embryos (Furutani *et al.*, 1957b).
444 The whole genome sequence of LA-AKO, and its strain of origin, Nakamura III, have been
445 registered in the public database (Fukai *et al.*, 2011; Takamatsu *et al.*, 2015).

446 Seed lots should be lyophilised or frozen and stored at a temperature of -20°C or lower until use.

447 2.1.2. Quality criteria

448 i) Special considerations

449 Due to the fact that RPV has been eradicated worldwide, special consideration needs to be made
450 in regards to animal inoculation used to assess safety and efficacy. It is recommended to sequence
451 the full genome of a candidate vaccine virus and compare with reference strains of RPV to assess
452 similarities that would negate the need to inoculate animals.

453 Subject to the above, ~~for both Plowright and LA-AKO strains~~, seed lots should be shown to be:

454 a) Pure

455 Free from contamination with viruses, bacteria, fungi or mycoplasmas.

456 b) Safe

457 Inducing no abnormal clinical reaction on inoculation into rinderpest-susceptible cattle.

458 c) Efficacious

459 Inducing an immunity to rinderpest in rinderpest-susceptible cattle.

460 These tests have already established the safety and efficacy of the master seed stock of LA-AKO
461 and that of the Plowright vaccine held at the RHF in France.

462 2.2. Method of manufacture

463 2.2.1. Procedure

464 Individual vaccine batches are prepared by infecting cell cultures and, after an appropriate incubation
465 period, harvesting either the overlying media or the media and infected cells together. Virus should be
466 harvested from cultures not more than 7 days (LA-AKO) or 10 days (Plowright) after the date that these
467 cultures were infected. The decision to harvest should be based on the development of extensive
468 characteristic CPEs within the cell monolayer.

469 To constitute a batch, infected cultures must have been inoculated with the same seed virus and
470 incubated and harvested together.

471 To form a bulk suspension, the harvest should be clarified by low-speed centrifugation or by filtration
472 before mixing with cryoprotectant.

473 Multiple harvests are permissible from the same set of cultures and may be pooled to form a single bulk
474 suspension. For long-term storage and cold chain distribution, bulk suspensions are freeze dried.

475 Written records must accompany all stages of vaccine manufacture.

476 2.2.2. Requirements for substrates and media

477 i) Cells

478 Plowright vaccine may be grown in primary kidney cells from BVDV-free bovine embryos or calves,
479 or cells derived by up to ten serial subcultures from such primary cells either of these sources. In
480 addition preference, the vaccine ~~may should~~ be manufactured in approved validated and tested
481 continuous cell lines; Vero cells have been used for this purpose. The master seed stocks of LA-
482 AKO are normally prepared in embryonated SPF chick eggs, while Vero cells are used for the
483 production of working/production seed stocks or vaccine ~~of LA-AKO~~. In all cases, the cells should
484 be shown not to be infected with adventitious viruses including bovine viral diarrhoea virus (BVDV),
485 bovine leukaemia virus (BLV), bovine rotavirus and bluetongue virus (BTV), and should be
486 maintained in a seed lot system.

487 ii) Media

488 In all cases the bovine (fetal or new-born calf) serum used must come from countries that are FMD-
489 free and with a negligible risk of bovine spongiform encephalopathy; it must be shown to be free
490 from BVDV and any other adventitious viruses; the use of gamma-irradiated serum is
491 recommended.

492 Calf kidney cells are grown and maintained in Earle's Balanced Salts Solution or Eagle's Minimum
493 Essential Medium [MEM] supplemented with 0.5% lactalbumin hydrolysate and 0.1% yeast extract
494 together with 5% new-born calf serum ~~that must come from rinderpest susceptible animals and~~
495 ~~originate from countries with negligible risk of bovine spongiform encephalopathy.~~

496 Vero cells are grown in Eagle's MEM supplemented with 10% heat-treated fetal calf serum ~~and~~
497 0.295% tryptose phosphate broth (TPB), and with antibiotics as required. Other formulations of
498 medium have been used, e.g. Glasgow Modified Eagle's medium (GMEM) supplemented with 14%
499 (v/v) TPB and 6% (v/v) non-heat-treated ~~(rinderpest antibody free)~~ bovine serum, with antibiotics
500 as required. ~~All serum must come from rinderpest susceptible animals and originate from countries~~
501 ~~with negligible risk of bovine spongiform encephalopathy.~~

502 iii) Cryoprotectant

503 For lyophilisation, the bulk suspension of virus is mixed with an equal volume of a solution
504 containing either 5% lactalbumin hydrolysate and 10% sucrose, or 1% sodium glutamate, 0.3%
505 polyvinylpyrrolidone and 10% sucrose.

506

507

2.2.3. In-process controls

508
509
510
511
512
513

To ensure the properties of a master seed stock, a marker test should be undertaken where possible. A virus titration must be undertaken on each batch of a bulk suspension, and on the final bulk suspension itself, using tenfold virus dilutions in a microplate or roller tube system and employing four to ten replicates per dilution. Each batch of the final bulk suspension, or the final bulk suspension itself, should also be examined for adventitious viral contamination by relevant assays, including one or more of the following:

514
515
516

i) Samples are mixed with a neutralising titre of rabbit anti-rinderpest antiserum, added to continuous cultures of Vero cells, bovine kidney or testicular cells, and incubated at 37°C for 7 days. These cells must not develop any CPE within the incubation period.

517
518
519

ii) Samples are inoculated onto an African monkey-derived embryonic kidney cell line, MA-104, which is reported to be highly susceptible to Simian rotavirus (Smith *et al.*, 1979). Inoculated MA-104 cells must not develop CPE.

520
521
522
523
524

iii) A 10 ml of the sample from the batch of suspension clarified harvest or bulk suspension is mixed with a neutralising titre of rabbit anti-rinderpest antiserum and inoculated into a bovine leukemia virus (BLV)-susceptible sheep via an intramuscular route. The sera obtained from the sheep at 2 and 3 months after inoculation should be examined for the presence of BLV antibodies by an agarose gel immunodiffusion test.

525
526
527
528
529
530

The batch of a clarified harvest or bulk suspension may also be subjected to a marker test if available. LA-AKO vaccine induces a marked increase in the size of the spleen in inoculated chick embryos. 15 µl of 10- and 100-fold dilutions of a sample from a final bulk suspension are inoculated into a blood vessel of more than ten eggs each on day 11 to 12 after laying. Inoculated eggs are incubated at 38°C for 5 days. Spleens of inoculated chick embryos which are still alive after incubation are collected and weighed. These spleens become heavier than 15 mg in weight.

531
532
533
534
535
536
537
538
539

Checks for adventitious viral contamination should be undertaken on at least two uninfected control cell cultures prepared from the cell suspension used in batch production, after having been maintained using the same media and incubation conditions as the rinderpest-infected cells. They must be subjected to frequent in-process microscopic observations with negative results. After virus harvesting, the control cultures should be washed to remove bovine serum and re-incubated for 10 days in media containing bovine serum substitutes during which period they are again subject to frequent microscopic observations for evidence of cytopathic change. At the end of this period at least one culture should be examined for the presence of noncytopathic BVD virus using an immunofluorescence or immunoperoxidase test or RT-PCR.

540
541
542
543

The control cultures may also be examined for haemadsorption activity. The uninfected cultures should be washed to remove bovine serum, and divided into two groups. Each group is overlaid with 0.1% suspension of guinea-pig or goose red blood cells (RBCs) for 1 hour, then subjected to microscopic observation. The control cultures must not adsorb RBCs from either of those species.

544
545
546

Prior to lyophilisation, the batch of a clarified harvest or bulk suspension may be held for not more than 5 days at 4°C, but considerably longer storage is achievable if frozen at -20°C to -80°C.

547

2.2.4. Final product batch tests

548

i) Sterility and purity

549
550

Tests for sterility and freedom from contamination of biological materials intended for veterinary use may be found in chapter 1.1.9.

551
552
553
554
555

The final batch product consists of the freeze dried vials produced from a single bulk suspension; a batch may contain several filling lots. The contents of one container from each filling lot must be exposed to neutralisation by rabbit rinderpest antiserum, using a varying virus/constant serum method, and inoculated into primary bovine kidney or other susceptible cells. The identity of the product is established if no rinderpest-specific CPE develops.

556

ii) Safety and efficacy

557
558

~~Procedures may present slight variations depending on the country and system of production. For the established virus-vaccine seed stocks (Section 2.1.1), animal-based testing of safety and~~

559 efficacy ~~may be deemed~~ is unnecessary. For any other candidate vaccine that differs at the
560 sequence level from the reference vaccines, animal tests for assessing the safety and efficacy of
561 the vaccine will be required but may only be conducted with the prior approval of the FAO-WOAH
562 Rinderpest Secretariat.

563 Animals used in these procedures should be kept in isolation from other rinderpest-susceptible
564 animals. At the end of the procedures they must be killed and the carcasses disposed of securely.
565 Using rinderpest-susceptible cattle, the contents of one to five randomly selected vials are pooled
566 and used to inoculate each of two or three cattle with a volume equivalent to a single cattle field
567 dose (where a field dose is taken to be ≥ 1000 TCID₅₀). In addition, one bovine may be inoculated
568 with a volume equivalent to 100 cattle field doses. These animals are maintained in a biologically
569 secure animal facility for the following 2–3 weeks. During this period the animals are subjected to
570 daily temperature recording and frequent clinical inspections. At the end of this period, the cattle
571 are examined for the presence of rinderpest neutralising serum antibodies (Section B.2.2). The
572 vaccine is considered safe and efficacious if it does not induce any abnormal clinical reaction except
573 for slight hyperthermia and if all vaccinated animals show a RPV-neutralising titre of 1/10 or greater.

574 In general terms, the safety of the Plowright vaccine has been widely demonstrated in both
575 European and Indian breeds of cattle and Dwarf West African breeds. It has not been tested in
576 Japanese or Chinese breeds and its safety in such animals cannot be guaranteed. The LA-AKO
577 vaccine has been tested for the safety in a highly susceptible breed, Japanese black, as well as in
578 the Holstein breed.

579 iii) Batch potency

580 The close relationship between immunising potency and infectivity allows the latter to be used as
581 the basis for potency estimations. Infectivity titrations are undertaken using cells of an approved
582 continuous line or cells grown from each of three different bovine calf or embryonic kidneys. The
583 number of estimates of the virus titre, and the number of vials pooled for each estimate, should be
584 determined depending on the batch size and the local reproducibility of the assay. The sensitivity
585 of the cells used in each working session must be measured using a standard laboratory RPV
586 preparation of an approved facility. The final titre is the geometric mean of all estimates, each
587 undertaken using tenfold dilutions and four to ten observations per dilution. Potent vaccine should
588 contain ≥ 100 field doses per vial.

589 **2.3. Requirements for ~~authorisation~~ regulatory approval**

590 **2.3.1. Safety requirements**

591 i) Target and non-target animal safety

592 Plowright vaccine causes no clinical signs in rinderpest susceptible cattle or Asian water buffaloes.
593 LA-AKO vaccine causes no clinical signs except slight pyrexia in rinderpest-susceptible cattle.
594 Neither spread by contact transmission to rinderpest susceptible cattle housed in close proximity to
595 vaccinates.

596 ii) Reversion to virulence

597 Plowright vaccine virus retains its attenuated characteristics during at least five back passages in
598 cattle and lacks the ability to spread by contact. Any sub-strain of the Plowright or LA-AKO strains
599 used in the manufacture of rinderpest vaccine must be identifiable by written historical records that
600 trace its origins to either of these vaccine strains.

601 iii) Environmental considerations

602 There are no environmental considerations with respect to either the manufacture or application of
603 rinderpest vaccine.

604 **2.3.2. Efficacy requirements**

605 i) For animal production

606 Both vaccines protect vaccinated animals from clinical disease caused by virulent RPV infection.

607 ii) For control and eradication

608 For eradication purposes the object should be to use vaccine to immunise all susceptible animals
609 in and around the vicinity of an outbreak in as short a period of time as possible (Taylor *et al.*, 2002).

610 2.3.3. Stability

611 Both the Plowright and LA-AKO strains of TCRV are highly stable when correctly freeze-dried and will
612 keep for long periods at either +4 or –20°C provided the product retains a vacuum or is filled with nitrogen
613 gas. The rate of degradation of lyophilised TCRV can be altered by the choice of cryoprotectant and by
614 variations in the drying cycle. Good results have been obtained with the use of (a) a 5% lactalbumin
615 hydrolysate/10% sucrose stabiliser, a 72–74 hour drying cycle under reduced vacuum (≤ 13 Pa), initial
616 drying for 16 hours at –30°C, and a final shelf temperature of 35°C, or (b) a 1% sodium glutamate/0.3%
617 polyvinylpyrrolidone/10% sucrose stabiliser, a 48 hour drying cycle under reduced vacuum (≤ 10 Pa),
618 initial drying for 24 hours at –45°C, a final shelf temperature of 22°C, and filling the vial with nitrogen gas.

619 Following reconstitution in either normal saline or 1M magnesium sulphate, the virus becomes much
620 more thermolabile. The period for field distribution of reconstituted vaccine should not exceed its half-
621 life, but as this parameter is temperature dependent and varies between 8 and 24 hours over a range
622 from 4°C to 37°C, a universal period of 4 hours can be recommended.

623 3. Vaccines based on biotechnology

624 No biotechnology-based vaccines have so far been approved.

625 REFERENCES

- 626 ANDERSON J., BARRETT T. & SCOTT G.R (1996). Manual on the Diagnosis of Rinderpest, Second Edition. FAO Animal Health
627 Manual No.1. Food and Agriculture Organisation of the United Nations (FAO), Rome, Italy, 143 pp.
- 628 BARON M.D. & BARRETT T (1995). Sequencing and analysis of the nucleocapsid (N) and polymerase (L) genes and the terminal
629 extragenic domains of the vaccine strain of rinderpest virus. *J Gen. Virol.*, **76**, 593–602.
- 630 CARRILLO C., PRARAT M., VAGNOZZI A., CALAHAN J.D., SMOLIGA G., NELSON W.M. & RODRIGUEZ L.L. (2010). Specific detection
631 of Rinderpest virus by real-time reverse transcription-PCR in preclinical and clinical samples from experimentally infected
632 cattle. *J. Clin. Microbiol.*, **48**, 4094–4101.
- 633 COUACY-HYMANN E., BODJO S.C., DANHO T., KOFFI M.Y. & AKOUA-KOFFI C. (2006). Diagnosis and surveillance of rinderpest
634 using reverse transcription-PCR. *Afr. J. Biotechnol.*, **5**, 1717–1721.
- 635 FERNANDEZ P. & WHITE W. (2010). Atlas of Transboundary Animal Diseases. WOAHP, Paris.
- 636 FOREMAN A.J., ROWE L.W. & TAYLOR W.P. (1983). The detection of rinderpest antigen by agar gel diffusion and
637 counterimmunoelectrophoresis. *Trop. Anim. Health Prod.*, **15**, 83–85.
- 638 FORSYTH M.A. & BARRETT T. (1995). Evaluation of polymerase chain reaction for the detection and characterisation of
639 rinderpest and peste des petits ruminants viruses for epidemiological studies. *Virus Res.*, **39**, 151–163.
- 640 FORSYTH M.A., PARIDA S., ALEXANDERSEN S., BELSHAM G.J. & BARRETT T. (2003). Rinderpest virus lineage differentiation using
641 RT-PCR and SNAP-ELISA. *J. Virol. Methods*, **107**, 29–36.
- 642 FUKAI K., MORIOKA K., SAKAMOTO K. & YOSHIDA K. (2011). Characterization of the complete genomic sequence of the
643 rinderpest virus Fusan strain cattle type, which is the most classical isolate in Asia and comparison with its lapinized strain.
644 *Virus Genes*, **43**, 249–253.
- 645 FURUTANI T., KATAOKA T., KURATA K. & NAKAMURA H. (1957a). Studies on the AKO strain of lapinized-avianized rinderpest
646 virus. I. Avianization of lapinized rinderpest virus. *Bull. Natl. Inst. Anim. Health*, **32**, 117–135. (Abstract in English.)
- 647 FURUTANI T., ISHII S., KURATA K. & NAKAMURA H. (1957b). Studies on the AKO strain of lapinized-avianized rinderpest virus.
648 II. Features of multiplication of the virus in embryonating hen eggs. *Bull. Natl. Inst. Anim. Health*, **32**, 136–149. (Abstract
649 in English.)

-
- 650 KOCK R.A. (2006). Rinderpest and wildlife. *In: Rinderpest and Peste des Petits Ruminants, Virus Plagues of Large and*
651 *Small Ruminants*, Barrett T., Pastoret P.-P. & Taylor W.P., eds. Academic Press, Oxford, UK, 143–162.
- 652 NAKAMURA J., AGATSUMA S. & FUKUSHO K. (1938). Rinderpest virus infection in rabbits I: Basic investigation. *Jpn J. Vet. Med.*
653 *Sci.*, **17**, 185–204. (In Japanese only.)
- 654 NAKAMURA J. & MIYAMOTO T. (1953). Avianization of lapinized rinderpest virus. *Am. J. Vet. Res.*, **14**, 307–317.
- 655 PLOWRIGHT W. (1962). The application of monolayer tissue culture techniques in rinderpest research. II. The use of attenuated
656 culture virus as a vaccine for cattle. *Bull. Off. int. Epiz.*, **57**, 253–276.
- 657 PLOWRIGHT W. & FERRIS R.D. (1961). Studies with rinderpest virus in cell culture. III. The stability of cultured virus and its
658 use in neutralisation tests. *Arch. Gesamte Virusforsch.*, **11**, 516–533.
- 659 ROEDER P.L. & RICH K. (2009). Rinderpest Eradication in Millions Fed: Successes in Agriculture, Spielman D. & Pandya-
660 Lorch R., eds. International Food Policy Research Institute, Washington, DC 20006-1002 USA; Chapter 16, 109–116.
- 661 ROSSITER P.B. & JESSETT D.M. (1982). Microtitre techniques for the assay of rinderpest virus and neutralising antibody. *Res.*
662 *Vet. Sci.*, **32**, 253–256.
- 663 SMITH E.M., ESTES M.K., GRAHAM DY. & GERBA C.P. (1979). A plaque assay for the simian rotavirus SA11. *J. Gen. Virol.*,
664 **43**, 513–519.
- 665 TAKAMATSU H., TERUI K. & KOKUHO T. (2015). Complete genome sequence of Japanese vaccine strain LA-AKO of rinderpest
666 virus. *Genome Announc.*, doi: 10.1128/genomeA.00976-15.
- 667 TAYLOR W.P & BARRETT T. (2007). Peste des Petits Ruminants and Rinderpest in Diseases of Sheep, Fourth Edition, Aitken
668 I.D., ed. Blackwell Publishing Ltd, Oxford, UK.
- 669 TAYLOR W.P., ROEDER P.L., RWEYEMAMU M.M., MELEWAS J.N., MAJUVA P., KIMARO R.T., MOLLEL J.N., MTEI B.J., WAMBURA P.,
670 ANDERSON J., ROSSITER P.B., KOCK R., MELENGEYA T. & VAN DEN ENDE R. (2002). The control of rinderpest in Tanzania
671 between 1997 and 1998. *Trop. Anim. Health Prod.*, **34**, 471–487.
- 672 TAYLOR W.P. & ROWE L.W. (1984). A microneutralisation test for the detection of rinderpest virus antibodies. *Rev. Elev. Med.*
673 *Vet. Pays Trop.*, **37**, 155–159.
- 674 WAMWAYI H.M., FLEMING M. & BARRETT T. (1995). Characterisation of African isolates of rinderpest virus. *Vet. Microbiol.*, **44**,
675 151–163.
- 676 *
677 * *
- 678 **NB:** There are WOAHO Reference Laboratories for rinderpest (please consult the WOAHO Web site:
679 <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>).
680 Please contact the WOAHO Reference Laboratories for any further information on
681 diagnostic tests, reagents and vaccines for rinderpest
- 682 **NB:** FIRST ADOPTED IN 1990. MOST RECENT UPDATES ADOPTED IN 2018.

683

684

Appendix 1: Rinderpest
Intended purpose of test: population freedom from infection

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Virus neutralisation</u> <u>±±</u> <u>Any species of wild or domestic</u> <u>Artiodactyla</u>	<u>Serum</u> <u>Antibodies to RPV</u> <u>capable of preventing infection of cultured cells</u>	<u>Virus neutralisation is the reference test for other serological tests</u>	<u>See reference</u>	<u>See reference</u>	<u>Only currently available technique for determination of serum antibody that neutralises RPV</u> <u>Is the reference test that other tests for serum antibody are measured against</u>	<u>Very high titres of PPRV-neutralising antibody can cross-react (although such titres would be rare in cattle)</u> <u>Is not suitable for screening large numbers of samples, so using it for population surveillance is not recommended, although currently it is the only option</u> <u>Requires cell culture facilities and staff with specific experience in the lab doing such a test</u> <u>Requires use of live RPV, so can only be carried out in FAO/WOAH-approved RHF's with specific permission</u>	<u>Rossiter & Jessett (1982)</u>

Appendix 2: Rinderpest
Intended purpose of test: individual animal freedom from infection prior to movement

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Conventional RT-PCR</u> <u>+++</u>	<u>Anti-coagulant-treated blood (EDTA better than heparin); ocular or nasal swabs can also be used. Virus specific RNA (N or F gene)</u>	<u>This and real-time RT-PCR are the reference tests against which other tests are measured</u>	<u>Samples from infected and uninfected cattle (References 1 & 2) or cell-culture-grown virus (Reference 3)</u>	<u>See references</u>	<u>Highly sensitive</u> <u>Widely available technology</u> <u>Can use simple-to-obtain samples</u>	<u>Only indirect controls for the assay function are available</u> <u>Proper positive controls for the assays are only available in FAO/WOAH-approved RHF's which have specific permission for their use</u>	<u>1. Forsyth & Barrett (1995)</u> <u>2. Forsyth <i>et al.</i> (2003)</u> <u>3. Couacy-Hymann <i>et al.</i> (2006)</u>
<u>Real-time RT-PCR</u> <u>+++</u>	<u>Anti-coagulant-treated blood (EDTA better than heparin); ocular or nasal swabs can also be used. Virus specific RNA (N or F gene)</u>	<u>This and conventional RT-PCR are the reference tests against which other tests are measured</u>	<u>Samples from infected and uninfected cattle</u>	<u>See reference</u>	<u>Highly sensitive</u> <u>Widely available technology</u> <u>Can use simple-to-obtain samples</u> <u>Real-time assay is even more sensitive than gel-based assay</u>	<u>Proper positive controls for the assays are only available in FAO/WOAH-approved RHF's which have specific permission for their use</u> <u>There is a lack of experience of use of the real-time assay in diagnosis</u>	<u>Carrillo <i>et al.</i> (2010)</u>

687
688

Appendix 3: Rinderpest
Intended purpose of test: contribute to eradication policies

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Virus isolation</u> ±	<u>Anti-coagulant-treated blood (EDTA or heparin); ocular or nasal swabs; lymph nodes, tonsils or spleen from acutely infected animals</u> <u>Live RPV</u>	<u>No data; old technique that was rarely applied once</u> <u>RT-PCR and ELISAs became available</u>	<u>No data; old technique that was rarely applied once</u> <u>RT-PCR and ELISAs became available</u>	<u>None</u>	<u>Isolation and preservation of strain of live virus which can be used for other studies</u>	<u>Requires good cell culture facilities and experienced staff</u> <u>Takes a long time (> 1 week)</u> <u>Has to be combined with RT-PCR anyway to confirm virus is RPV</u> <u>Entirely unsuitable for anything but small numbers of samples</u>	
<u>Conventional RT-PCR</u> +++	<u>Anti-coagulant-treated blood (EDTA better than heparin); ocular or nasal swabs can also be used.</u> <u>Virus specific RNA (N or F gene)</u>	<u>This and real-time RT-PCR are the reference tests against which other tests are measured</u>	<u>Samples from infected and uninfected cattle (References 1 & 2) or cell-culture-grown virus (Reference 3)</u>	<u>See references</u>	<u>Highly sensitive</u> <u>Widely available technology</u> <u>Can use simple-to-obtain samples</u>	<u>Only indirect controls for the assay function are available</u> <u>Proper positive controls for the assays are only available in FAO/WOAH-approved RHF's which have specific permission for their use</u>	<u>1. Forsyth & Barrett (1995)</u> <u>2. Forsyth <i>et al.</i> (2003)</u> <u>3. Couacy-Hymann <i>et al.</i> (2006)</u>
<u>Real-time RT-PCR</u> +++	<u>Anti-coagulant-treated blood (EDTA better than heparin); ocular or nasal swabs can also be used.</u> <u>Virus specific RNA (N or F gene)</u>	<u>This and conventional RT-PCR are the reference tests against which other tests are measured</u>	<u>Samples from infected and uninfected cattle</u>	<u>See reference</u>	<u>Highly sensitive</u> <u>Widely available technology</u> <u>Can use simple-to-obtain samples</u> <u>Real-time assay is even more sensitive than gel-based assay</u>	<u>Proper positive controls for the assays are only available in FAO/WOAH-approved RHF's which have specific permission for their use</u> <u>There is a lack of experience of use of the real-time assay in diagnosis</u>	<u>Carrillo <i>et al.</i> (2010)</u>

689

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Virus neutralisation ++</u> <u>Any species of wild or domestic <i>Artiodactyla</i></u>	<u>Serum.</u> <u>Antibodies to RPV capable of preventing infection of cultured cells</u>	<u>Virus neutralisation is the reference test for other serological tests</u>	<u>See reference</u>	<u>See reference</u>	<u>Only currently available technique for determination of serum antibody that neutralises RPV</u> <u>Is the reference test that other tests for serum antibody are measured against</u>	<u>Very high titres of PPRV-neutralising antibody can cross-react</u> <u>Is not really suitable for screening large numbers of samples</u> <u>so using it for population surveillance is not recommended, although currently it is the only option</u> <u>Requires cell culture facilities in lab doing such a test</u> <u>Requires use of live RPV, so can only be carried out in FAO/WOAH-approved RHEs with specific permission</u>	<u>Rossiter & Jessett (1982)</u>

Appendix 4: Rinderpest
Intended purpose of test: confirmation of clinical cases

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Virus isolation</u> ±	<u>Anti-coagulant-treated blood (EDTA or heparin); ocular or nasal swabs; lymph nodes, tonsils or spleen from acutely-infected animals</u> <u>Live virus</u>	<u>No data; old technique that was rarely applied once RT-PCR and ELISAs became available</u>	<u>No data; old technique that was rarely applied once RT-PCR and ELISAs became available</u>	<u>None</u>	<u>Isolation and preservation of strain of live virus which can be used for other studies</u>	<u>Requires good cell culture facilities and experienced staff</u> <u>Takes a long time (> 1 week)</u> <u>Has to be combined with RT-PCR anyway to confirm virus is RPV</u> <u>Entirely unsuitable for anything but small numbers of samples</u>	
<u>Conventional RT-PCR</u> +++	<u>Anti-coagulant-treated blood (EDTA better than heparin); ocular or nasal swabs can also be used.</u> <u>Virus specific RNA (N or F gene)</u>	<u>This and real-time RT-PCR are the reference tests against which other tests are measured</u>	<u>Samples from infected and uninfected cattle (References 1 & 2) or cell-culture-grown virus (Reference 3)</u>	<u>See references</u>	<u>Highly sensitive</u> <u>Widely available technology</u> <u>Can use simple-to-obtain samples</u>	<u>Only indirect controls for the assay function are available</u> <u>Proper positive controls for the assays are only available in FAO/WOAH-approved RHF's which have specific permission for their use</u>	<u>1. Forsyth & Barrett (1995)</u> <u>2. Forsyth <i>et al.</i> (2003)</u> <u>3. Couacy-Hymann <i>et al.</i> (2006)</u>
<u>Real-time RT-PCR</u> +++	<u>Anti-coagulant-treated blood (EDTA better than heparin); ocular or nasal swabs can also be used.</u> <u>Virus specific RNA (N or F gene)</u>	<u>This and conventional RT-PCR are the reference tests against which other tests are measured</u>	<u>Samples from infected and uninfected cattle</u>	<u>See reference</u>	<u>Highly sensitive</u> <u>Widely available technology</u> <u>Can use simple-to-obtain samples</u> <u>Real-time assay is even more sensitive than gel-based assay</u>	<u>Proper positive controls for the assays are only available in FAO/WOAH-approved RHF's which have specific permission for their use</u> <u>There is a lack of experience of use of the real-time assay in diagnosis</u>	<u>Carrillo <i>et al.</i> (2010)</u>

Appendix 5: Rinderpest
Intended purpose of test: prevalence of infection – surveillance

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Conventional RT-PCR</u> ±	<u>Anti-coagulant-treated blood (EDTA better than heparin); ocular or nasal swabs can also be used. Virus specific RNA (N or F gene)</u>	<u>This and real-time RT-PCR are the reference tests against which other tests are measured</u>	<u>Samples from infected and uninfected cattle (References 1 & 2) or cell-culture-grown virus (Reference 3)</u>	<u>See references</u>	<u>Highly sensitive Widely available technology Can use simple-to-obtain samples</u>	<u>Only indirect controls for the assay function are available Proper positive controls for the assays are only available in FAO/WOAH-approved RHEs which have specific permission for their use</u>	<u>1. Forsyth & Barrett (1995) 2. Forsyth <i>et al.</i> (2003) 3. Couacy-Hymann <i>et al.</i> (2006)</u>
<u>Real-time RT-PCR</u> ±	<u>Anti-coagulant-treated blood (EDTA better than heparin); ocular or nasal swabs can also be used. Virus specific RNA (N or F gene)</u>	<u>This and conventional RT-PCR are the reference tests against which other tests are measured</u>	<u>Samples from infected and uninfected cattle</u>	<u>See reference</u>	<u>Highly sensitive Widely available technology Can use simple-to-obtain samples Real-time assay is even more sensitive than gel-based assay</u>	<u>Proper positive controls for the assays are only available in FAO/WOAH-approved RHEs which have specific permission for their use There is a lack of experience of use of the real-time assay in diagnosis</u>	<u>Carrillo <i>et al.</i> (2010)</u>
<u>irus neutralisation</u> ++ <u>Any species of wild or domestic <i>Artiodactyla</i></u>	<u>Serum Antibodies to RPV capable of preventing infection of cultured cells</u>	<u>Virus neutralisation is the reference test for other serological tests</u>	<u>See reference</u>	<u>See reference</u>	<u>Testing for antibody is superior to testing for virus RNA or antigen in surveillance due to the long period during which antibody can be detected after infection Only currently available technique for determination of serum antibody that neutralises RPV Is the reference test that other tests for serum antibody are measured against</u>	<u>Very high titres of PPRV-neutralising antibody can cross-react Is not suitable for screening large numbers of samples, so using it for population surveillance is not recommended, although currently it is the only option. Requires cell culture facilities in lab doing such a test Requires use of live RPV, so can only be carried out in FAO/WOAH-approved RHEs with specific permission</u>	<u>Rossiter & Jessett (1982)</u>

Appendix 6: Rinderpest**Intended purpose of test: Immune status in individual animals or populations post-vaccination**

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population used to measure accuracy</u>	<u>Validation report</u>	<u>Advantages: expert opinion</u>	<u>Disadvantages: expert opinion</u>	<u>References</u>
<u>Virus neutralisation ++</u> <u>Any species of wild or domestic Artiodactyla</u>	<u>Serum.</u> <u>Antibodies to RPV capable of preventing infection of cultured cells</u>	<u>Virus neutralisation is the reference test for other serological tests</u>	<u>See reference</u>	<u>See reference</u>	<u>Only currently available technique for determination of serum antibody that neutralises RPV</u> <u>Is the reference test that other tests for serum antibody are measured against</u>	<u>Very high titres of PPRV-neutralising antibody can cross-react</u> <u>Is not suitable for screening large numbers of samples, so using it for population surveillance is not recommended, although currently it is the only option</u> <u>Requires cell culture facilities in lab doing such a test</u> <u>Requires use of live RPV, so can only be carried out in FAO/WOAH-approved RHF with specific permission</u>	<u>Rossiter & Jessett (1982)</u>

CHAPTER 3.2.4.

INFESTATION OF HONEY BEES WITH *AETHINA TUMIDA* (SMALL HIVE BEETLE)

SUMMARY

Description and importance of the disease: *The small hive beetle, Aethina tumida* (Murray 1867) (Coleoptera: Nitidulidae), is a parasite and predator of honey bees. Adults and larvae of small hive beetles feed on honey bee brood, honey and pollen. While feeding on food stores the remaining honey is fermenting and the comb is destroyed. The beetles can promote structural collapse of the nest and cause the adult honey bees to abscond from severely infested colonies. The extent of beetle-associated damage depends on climate, colony strength and other conditions. Small hive beetles tend to be more problematic in areas with warm temperatures and high humidity. The small hive beetle can be a serious problem in honey-extracting facilities where stored comb, honey and wax cappings are potential feeding and breeding areas. Beetle development from egg to adult requires 3–12 weeks, depending on humidity, temperature and food availability. The flying adult beetles actively infest honey bee colonies of all strengths and sizes.

Detection and identification of the agent: An infestation by the small hive beetle can be recognised either indirectly via colony-wide damage associated with the beetle or directly via eggs, larvae and adults. An early diagnosis can be made after opening the colony and finding adult beetles under the colony lid, on the bottom board, or hiding in the combs (especially peripheral combs). In zones at risk of new introductions, it is recommended to install sentinel apiaries that consist of fully functional queenright honey bee colonies to attract and trap adult beetles. Different trap models can help to detect and capture *A. tumida*. Definitive diagnosis at the laboratory is based on morphological examination under a stereomicroscope. Confirmatory testing can be done by real-time polymerase chain reaction.

Serological tests: Serological tests are not applicable.

Requirements for vaccines: No vaccines are available.

A. INTRODUCTION

The small hive beetle (hereafter referred to as “beetle”), *Aethina tumida*, order Coleoptera, family Nitidulidae (Murray, 1867), is native to sub-Saharan Africa (Hopburn & Radloff, 1998) but has been found in various regions of the world over the past few decades. *Aethina tumida* was first detected in the United States of America in 1996. Since then it has spread to Canada and a number of countries in South and Central America. *Aethina tumida* has also been found in Australia, Egypt, Italy, Korea and the Philippines in several Asian countries and in the Mascarene region of the Indian Ocean (WOAH WAHIS Interface, database accessed on 20/06/2017–02/01/2024; Lee et al., 2017; Liu et al., 2021).

Aethina tumida is originally a pest of the honey bee *Apis mellifera*. However, since its introduction in Asia, several studies have shown that it can maintain and multiply in colonies of the Asian honey bee species *Apis cerana* (Cervancia et al., 2016; Liu et al., 2021). The beetle can also infest other social pollinators such as bumblebees (Hymenoptera: Apidae, Bombini) and stingless bees (Hymenoptera: Apidae, Meliponini), which are found in tropical and subtropical regions of America, Africa and Australia (Neumann et al., 2016). Finally, certain species of solitary bees, which have

42 small reserves of nectar and pollen, might constitute occasional hosts, for example in the absence of wild or domestic
43 social bees (Gonthier *et al.*, 2019).

44 **1. Life cycle**

45 The infesting small hive beetle adults mate in the honey bee colony and the female beetles oviposit several eggs in
46 typical clutches in small cracks or within capped brood cells (Cuthbertson *et al.*, 2013; Ellis, 2005; Lundie, 1940). In
47 some situations, more than 1000 adult beetles may occur within a colony (~~Elzen *et al.*, 1999~~). Adult beetles can survive
48 up to 12 months (records indicate up to 16 months in laboratories; Somerville [2003]), but females ~~die quickly usually~~
49 have shorter lives when ~~ovipositing~~ oviposition occurs on a daily basis (Neumann *et al.*, 2016). Females ~~can may~~
50 oviposit about 1000 eggs in their lifetime (Lundie, 1940), ~~though Hood (2004) suggested~~ the upper limit may be 2000
51 eggs. Successful egg emergence is correlated with relative humidity, with fewer eggs hatching at a relative humidity of
52 <50%. The larvae emerge from the eggs after 1–6 days (most within 3 days) and feed on pollen, honey and bee brood
53 (Lundie, 1940; Schmolke, 1974). Adult beetles can be fed by worker bees via trophallaxis, especially while confined in
54 bee-guarded “prisons” (Ellis, 2005). Larval development usually takes about 2 weeks (8–29 days depending on food
55 availability and temperature; de Guzman & Frake, 2007; Ellis *et al.*, 2002; Lundie, 1940; Schmolke, 1974). Following
56 this, the larvae reach the wandering phase and leave the colony to pupate in the soil surrounding the colony (Lundie,
57 1940). Pupation takes about 2–12 weeks depending on temperature and soil moisture (~~Ellis *et al.*, 2004~~). Emerging
58 adults leave the soil and can fly to search for new host colonies, thereby completing their life cycle.

59 In laboratory conditions, the small hive beetle can survive and reproduce on ripe or rotten fruits (~~Buchholz *et al.*, 2008~~).
60 Flowering plants might also constitute an alternative food resource for *A. tumida* in the absence of hosts, and thus
61 contribute to its survival during a biological invasion (Gonthier *et al.*, 2019). Wild bees and feral honey bee colonies
62 can act as a reservoir of *A. tumida*.

63 **2. Impact of the pest**

64 Small hive beetle is seldom a serious problem for beekeeping in Sub-Saharan Africa. The reasons for the apparent
65 difference in its impact on colonies within its native range and those in its new ranges are not well understood (~~Ellis &~~
66 ~~Hopburn, 2006~~). They may include quantitative behavioural differences between African and European honey bee
67 subspecies, different beekeeping techniques, climatic differences, or escape from natural enemies, among other
68 plausible hypotheses (~~Hood, 2004; Neumann & Elzen, 2004~~).

69 While bee colony damage due to adult beetles is relatively minor, the adults can cause colonies to abscond (i.e. the
70 adult bees completely abandon the nest; Ellis *et al.*, 2003). If not prevented, larval feeding behaviour is often associated
71 with fermentation of stored honey, causes severe damage to combs and often results in the full structural collapse of
72 the nest (Lundie, 1940). Economic losses also can be associated with beetle infestations in the honey-extracting facility.
73 Environmental conditions generally associated with extracting facilities, such as high temperatures and humidity,
74 provide optimal conditions for beetle development. Cryptic low-level reproduction may ~~also~~ occur either in the debris or
75 underneath hive inserts without any signs of colony damage (Spiewok & Neumann, 2006).

76 The impact of the small hive beetle on *Apis cerana* is poorly documented. In some cases, *A. cerana* apiaries can be
77 heavily infested, leading to significant colony losses (Liu *et al.*, 2021) and also absconding behaviour has been
78 observed (Cervancia, 2016).

79 Certain species of stingless bees are reared for honey production or pollination services. Knowledge regarding the
80 impact of *A. tumida* on stingless bees is still limited. Healthy colonies seem to be able to defend themselves, for example
81 by covering the adult beetles with propolis (Greco *et al.*, 2010).

82 Little is known about the effects of *A. tumida* on wild honey bees and bumblebees.

83

B. DIAGNOSTIC TECHNIQUES

85 Table 1. Test methods available for the diagnosis of infestation with *Aethina tumida* and their purpose

Method	Purpose					
	Population freedom from infestation ^(a)	Individual animal or bee nest freedom from infestation prior to movement ^(a)	Contribute to eradication policies ^(a)	Confirmation of clinical cases ^(a)	Prevalence of infestation – surveillance ^(a)	Immune status in individual animals or populations post-vaccination
<u>Detection and identification of the agent</u>						
<u>Visual inspection of colonies</u>	±±	±±	±±	+++ (adults) +++ (larvae)	+++ (sentinel colonies or apiaries)	≡
Morphology	+++	+++	+++	+++ (adults) + (larvae)	+++	–
Real-time PCR	++	++	++	++	+	–

86 Key: +++ = recommended for this purpose; ++ recommended but has limitations;
 87 + = suitable in very limited circumstances; – = not appropriate for this purpose. PCR = polymerase chain reaction.
 88 ^(a)See Appendix 1 of this chapter for justification table for the scores given to the tests for this purpose.

89

90 **1. Field detection**

91 **1.1. Adult beetles**

92





Fig. 1. Small hive beetle, *Aethina tumida*. Photographs by Lyle Buss (left) and Josephine Ratikan (right), University of Florida.

93 The first sign of an infestation by the small hive beetle is the occurrence of adult beetles (Figure 1). Adult
 94 beetles are ~5 mm long and ~3 mm wide, with females being slightly longer than males (Ellis *et al.*, 2004).
 95 The adults are dark brown to black (lighter brown shortly after eclosion-emergence). During inspections,
 96 adults avoid sunlight, try to hide, and can be observed while running for cover into corners or similarly
 97 over the combs. Adults can be confused with other Nitidulid beetles, which can also be associated with
 98 colonies (see Section 2.2.3 below for details; also Ellis *et al.* [2008], Marini *et al.* [2013] and Neumann &
 99 Ritter [2004]).

100

1.2. Beetle eggs, larvae and pupae



101

102

Fig. 2. Small hive beetle eggs. Photograph by Josephine Ratikan, University of Florida.

103

104

105

106

107

108

109

110

111

112

113

Small hive beetle eggs (Figure 2) are white, $\sim 1.4 \times 0.26$ mm (length \times width); $\sim 2/3$ of the size of a honey bee egg, and are deposited in clutches in cracks, on the bottom board, on the combs and underneath the cappings of sealed brood cells. Larvae (Figure 3) are whitish, up to ~ 1 cm long (wandering phase), have three pairs of legs, and have dorsal spikes. Larvae can be found mining in the wax combs (Lundie, 1940) or in colony debris (Spiewok & Neumann, 2006). Larval infestations are typically associated with a rotten smell due to death of honey bee brood or fermentation of the stored honey. Wandering larvae often leave smear trails (or "slime") inside and outside the colony (Figure 4). Once in the ground, the larvae excavate small pupation chambers (Figure 5) 1–20 cm deep in the soil (Pettis & Shimanuki, 2000), develop into pupae (Figure 6, whitish to dark brown depending on age, ~ 5 mm long and 3 mm wide) and then into adults. Most larvae tunnel into soil that is <180 cm from the colony (Pettis & Shimanuki, 2000).



Fig. 3. Dorsal (left) and ventral (right) view of a small hive beetle larva. Photographs by Josephine Ratikan, University of Florida.



Fig. 4. Comb damage attributed to the feeding/crawling habits of small hive beetle larvae. Notice the 'slime' on the frame (i.e. the wax comb looks 'wet' and it 'glistens'). This is caused by the fermentation of honey, which is moved around the comb by crawling larvae. Beetle larvae can be seen in cells in the centre of the comb, where brood was present originally. Photograph credit, University of Georgia.



Fig. 5. Small hive beetle larvae that has tunneled into the soil and hollowed out a chamber in which to pupate. Photograph credit, University of Georgia.



Fig. 6. Small hive beetle pupa (ventral view). Photograph by Lyle Buss, University of Florida.

114

115

116

It is difficult to find beetle eggs in a colony, especially at low levels of infestation. Cracks or crevices around the nest should be investigated or capped brood cells that have small holes in the cappings, possibly indicating that a female beetle has punctured the capping and oviposited within the cell.

117 Small hive beetle pupae can be found by sifting the soil around the colony and looking for the pupal chambers
118 or the pupae themselves.

119 1.3. Visual inspection of colonies

120 When monitoring honey bee colonies for the presence of small hive beetles, an examination of the hive may
121 provide an early indication of infestation. In countries still free of *A. tumida*, it is recommended to monitor
122 sentinel apiaries in zones at risk of an introduction, to detect an infestation at an early enough stage to
123 eradicate it (Chauzat *et al.*, 2016). Furthermore, if the intent is to eradicate *A. tumida*, sentinel colonies
124 should be placed in the location of infested apiaries that have been previously sanitised. Such sentinel
125 colonies act as a bait to attract free-flying beetles and must be in place immediately after all colonies are
126 destroyed, as adult beetles staying outside colonies might survive the eradication and spread further to other
127 hosts nearby (Schäfer *et al.*, 2019). The use of sentinel colonies can also be an effective and timesaving
128 approach to monitoring the presence and spread of small hive beetle in an infested territory (Formato *et al.*,
129 2021). Sentinel hives should be small to allow rapid visual inspection. They may consist of queenright honey
130 bee colonies composed of one hive-box with three frames of brood and two frames with honey and pollen,
131 and equipped with traps that can be quickly checked. They are inspected every 2–3 weeks (Formato *et al.*,
132 2021).

133 It is important to adapt the method of visual inspection to limit the expected spread of *A. tumida*, as colony
134 manipulation might induce disorder and robbing (where bees steal honey from other colonies) or adult small
135 hive beetles may occasionally leave the colonies during manipulation. The currently used visual inspection
136 methods in infested areas are most feasible in the field and easy to carry out for anyone trained to manipulate
137 a beehive (EFSA, 2015; Neumann *et al.*, 2016). Colony manipulation requires a certain minimum training
138 and awareness of small hive beetle biology, behaviour and morphology, to correctly inspect field-colonies
139 and to quickly detect and recognise damage caused by the different life stages of *A. tumida* (Cornelissen &
140 Neumann, 2018). A colony inspection begins right at the entrance of the hive and relies on the rapid but
141 meticulous examination of the lid, the inner cover, the frames and the bottom board. The following
142 recommendations are from the EFSA scientific opinion (EFSA, 2015).

143 1.3.1. Colony inspection method (EFSA, 2015)

- 144 i) Remove the lid and check for the presence of adult beetles running away.
145 ii) Remove the inner cover and check both sides. Check also the top of the frames for running
146 adults.
147 iii) Remove the frames from the hive one by one. Each side of the frame should be quickly observed
148 to check the presence of adult beetles, larvae, eggs and damage. The first frame can be left
149 outside the body of the hive to make it easier to handle the other frames. Subsequent frames
150 should be put back into the body or super (the part of the hive in which bees store honey) to
151 prevent robbing in the apiary during the examination.
152 iv) Beetles can hide inside the cells of combs. It is also important to examine the lid, the bottom
153 board, the side faces, corners, interstices of the hive and hive components.

154 If robbing is unlikely, the super can be examined by placing it on the inverted lid of the hive in a sunny spot.
155 Adults will escape from the sunlight and retreat down into the lid. After about 10 minutes, the presence of
156 adult beetles in the lid can be checked by lifting the super (Zawislak, 2014). If there is a risk of robbing, the
157 super should be inspected in the same way as the body of the hive, i.e. comb by comb, by replacing each
158 frame in the box after its examination. During the examination of the body, the super can be placed on a
159 reversed lid, so that no bees or beetles can escape (Spiewok *et al.*, 2007).

160 To improve the sensitivity of the visual inspection, the hive can first be removed from its original position,
161 then opened and replaced by an empty hive (Neumann & Hoffmann, 2008; Spiewok *et al.*, 2007). Each
162 frame is then removed and examined for beetles for the first time. The bees are then shaken into an empty
163 box and the comb is inspected for a second time for beetles, this time in the absence of bees, before being
164 placed into the new hive. Once all the frames have been examined, the original hive box and bottom board
165 are inspected. However, this method is more time-consuming, and requires additional beekeeping
166 equipment and therefore is not suitable for routine monitoring of small hive beetle infestation in large apiaries.
167 It is however, recommended for health certification to demonstrate the absence of *A. tumida* infestation in a
168 colony.

169 A method, originally described in Canada, uses a white 12-litre bucket fitted with a wire-mesh screen (about
170 6 mm) fitted halfway down the depth of the bucket. The bottom of the bucket is covered with a thin layer of
171 vegetable oil. The frames are shaken inside the bucket and bees are stopped unharmed by the wire-mesh

172 whereas beetles fall into the vegetable oil. Field data suggest that this method is more sensitive than simple
173 visual inspection when the infestation level is low[†].

174 Another method for colony examination is described below. The method can be used to search for beetle
175 adults and larvae, if larval infestations are moderate to high (Ellis *et al.*, 2002a; Ellis & Delaplane, 2006), but
176 should not be used if eradication is planned, as it might increase the number of free-flying beetles.



177
178 Fig. 7. Inspecting a colony for adult small hive beetles. The inspector on the right has shaken the bees onto a piece
179 of plywood. Both faces of the framed comb were then bounced onto the wood to dislodge the beetles from the cells.
180 The inspector on the left is shifting through the adult bees and using a mouth aspirator to collect the beetles.
181 Photograph by Keith Delaplane, University of Georgia.

- 182
- 183 Notes:
- 184 i) This procedure is best accomplished with two people, one to work the colony and the second to collect the beetles
185 if quantification is desired. Only one person is needed if beetle detection is the sole desired outcome.
- 186 ii) Some beetles inevitably fly away or hide from view during this procedure. The number of beetles that escapes is
187 presumed to be low (<5%).
- 188 iii) This procedure is best used for qualification of adult beetles. However, larval beetles can be found this way as
189 well.
- 190 a) Place a sheet of opaque plastic (~2 x 2 m, preferably white or light in colour) or plywood in front of the colony
191 which you want to inspect for beetles.
- 192 b) Lightly smoke the colony.
- 193 c) Remove the lid from the colony and bounce the lid on the plywood. This should be done to dislodge all adult
194 bees and beetles adhering to the lid.
- 195 d) A second individual (the beetle collector) should comb through the bees (this can be done with the hand or
196 using a small stick) and collect all adult beetles seen using an aspirator. All bees on the plywood should be
197 inspected as beetles can easily be concealed by clusters of bees (Figure 7).
- 198 e) Remove the outermost frame in the uppermost super (i.e. the uppermost "box" containing bees) and shake
199 the bees from the frame onto the plywood.
- 200 f) The beetle collector should repeat step d.
- 201 g) Once the bees have been shaken from the frame, the frame should be turned onto its face and bounced
202 against the plywood to dislodge adult beetles from the comb. This step should be repeated two-to-three
203 times for both sides of the frame.
- 204 h) The beetle collector should repeat step d.
- 205 i) The individual working the colony should repeat step g to all frames in the uppermost super and then bounce
206 the empty super on the plywood. This step should be repeated for all supers, all frames, and the bottom
207 board of the colony.
- 208 The latter two described colony inspection methods are time-consuming and there is a very high risk of
209 inducing disorder and robbing in the apiary (EFSA, 2015) and a risk of making the beetles fly away.

210 1.4. Colony examination using traps

[†] <http://www.omafr.gov.on.ca/english/food/inspection/bees/2011-shb-report.htm>

211 The use of traps for small hive beetle detection has been described in the Guidelines for the surveillance of
212 the small hive beetle (*Aethina tumida*) infestation (updated version: April 2016) developed by the European
213 Union reference laboratory for honey bee health (Chauzat *et al.*, 2016).

214 The principle of most small hive beetle traps is to offer shelter from bee aggression by providing a passage
215 that is large enough for beetles but too small for bees to enter. In their attempt to get away from the bees
216 that chase them, *A. tumida* adults will enter the trap in which oil or veterinary medicines may be used as a
217 killing agent. Sometimes this principle is combined with the use of bait that can increase trap efficacy. The
218 position of the trap inside the hive is important and has to be adjusted to the hive type and to climatic
219 conditions as beetles may hide on the bottom boards or in the periphery of the colony if climatic conditions
220 are warm but tend to stay within the clustering bees when temperatures are low. Therefore, traps are
221 available for all positions in the hive and all of them should be checked regularly during apiary visits.

222 Traps that are placed between frame top-bars consist of small containers that are covered by a grid. These
223 kinds of traps are usually filled with vegetable oil (~~diatomaceous earth was successfully tested in the~~
224 ~~laboratory; Cribb *et al.*, 2013)~~ and they were shown to be effective in North American conditions (Bernier *et al.*, 2015). The trap is placed between the top-bars of two frames, close to the brood nest or the winter cluster. When visiting the colony, traps are examined for the detection of any beetles. If the container is transparent, this observation is easy and straightforward. It was shown using these kinds of traps that bees might seal the openings with propolis thereby reducing their efficacy (Bernier *et al.*, 2015). Care must also be taken to prevent any oil spill.

230 In the warm season, traps placed on the bottom boards or modified bottom boards could be used for the
231 detection of adult small hive beetles. Modified bottom boards usually consist of an oil filled tray that is placed
232 underneath a grid or a mesh-screen. If the tray is covering the whole bottom, the hive must be levelled, but
233 some of these traps cover only parts of the bottom board. Although these traps work well, they require hive-
234 modification and therefore are mainly feasible for stationary beekeeping.

235



236
237 Fig. 8. Corrugated plastic insert used to detect adult small hive beetles. The plastic insert contains square flutes
238 (left) in which adult beetles hide when inserted onto the bottom board of a colony, through the colony entrance
239 (right). The insert must be used in conjunction with a traditional solid bottom board rather than a screened bottom
240 board. Photographs by James Ellis (left) and Stephanie Kimball (right), University of Florida.

241
242 Many traps were invented for use on the bottom board. One example without any bait and killing agent is a
243 4 mm corrugated plastic strip (Figure 8). It was shown to be effective in field trials in Australia and the USA.
244 The corrugated plastic suits the thigmotactic behaviour of *A. tumida* as it consists of square flutes, big
245 enough for the beetle to get in, but too small for the bees to enter (approx. 4 × 4 mm). The hive does not
246 need to be opened as traps are placed inside the hive through the entrance. It is important to properly place
247 the trap in contact with the solid floor of the hive. If not, beetles can seek refuge in the space located between
248 the trap and the floor. For optimum use, traps should be left in hives for a minimum of 48 hours before they
249 are checked. The trap should preferably be made of a transparent material so that beetles can quickly be
250 detected (Schäfer *et al.*, 2008). Other bottom board traps bring the beetle in contact with killing agents inside
251 the traps. Chemicals can have high efficacy but there is always a risk that resistant strains may develop,
252 residues might accumulate in honey or other hive products or that the chemicals could spread to the bees
253 leading to adverse side effects on them. An alternative to the use of chemicals is diatomaceous earth or
254 traps that just use adhesive film.

255

256 A biomechanical way of trapping small hive beetle inside the hive is the placement of ~~kitchen wipes or similar~~
257 ~~material~~ non-woven microfibre wipes (such as those commonly used in the household) on top of the frames.
258 The bees ~~shred~~ chew this material, which becomes fuzzy and fray to the point where ~~into fibres in which the~~
259 ~~beetles become entangled in this fibre.~~ This control method is very simple to use and economical ~~control~~
260 ~~method has the advantage of functioning without any lethal substance, but fibres might also end up in the~~
261 ~~honey.~~ However, Buteler *et al.* (2023) demonstrated that the fibres of these wipes contaminate the honey
262 and the bees with microplastic. Although the acute toxicity of these microfibres for bees is low, chronic effects
263 could be observed in the event of repeated exposure (for example, impact on immunity, on the diversity of
264 the microbiome, and more generally on mortality). The microplastic may also present a risk to public health,
265 in connection with the consumption of honey.

266 In low infested areas it is especially recommended to always undertake a combination of visual inspections
267 and traps to increase the sensitivity of detection. Depending on the seasonal conditions, it may be decided
268 to use either visual observation or traps, but, whenever possible, combining them both is best. In apiaries
269 where inspections are frequently undertaken (sentinel apiaries), surveillance traps may be used. For single
270 inspections, visual inspections may be best because of the higher detection sensitivity and to avoid a return
271 visit to check the trap.

272 For a more detailed description of different traps refer to EFSA (2015) and Neumann *et al.* (2016).

273 **2. Laboratory identification**

274 Rapid and reliable diagnosis is crucial for the implementation of sanitary measures and to avoid spread in non-infested
275 territories. Suspect field specimens should be sent to official laboratories for confirmation of *A. tumida* identification.
276 Morphological identification is fast and inexpensive, and does not require sophisticated equipment. Confirmatory testing
277 can be done by molecular methods (polymerase chain reaction [PCR]), and is particularly useful for larval identification
278 or when specimens are damaged.

279 **2.1. Special precautions required for sample handling**

280 The specimens to be identified are collected in or near honey bee hives (for example, in colonies, beekeeping
281 equipment or queen cages).

282 Suspect specimens should be killed before submission to the laboratory e.g. in 70% ethanol. Denatured
283 ethanol should not be used where molecular methods are to be ~~used~~ performed because of possible PCR
284 inhibition. Alternatively, specimens can be stored overnight at -20°C to kill the specimens.

285 On arrival at the laboratory packages should be opened in containment conditions. If the specimens are
286 found to be alive on arrival, the submission should be placed at -80°C for approximately 1 hour before any
287 work can be done with them. This procedure immobilises the specimens, which can subsequently be stored
288 in 70% ethanol.

289 **2.2. Morphological identification of adults and larvae**

290 The test method aims to identify *A. tumida* by examining the external appearance of adults or larvae
291 specimens in the laboratory. It consists of the visual examination of specimens noting morphological
292 characteristics specifically selected to differentiate *A. tumida* from other nitidulid beetles and wax moth
293 larvae, commonly found in honey bee colonies, queen cages or beekeeping equipment.

294 **2.2.1. Equipment and reagents**

295 Classical entomological materials are required for the morphological identification of *A. tumida*,
296 including a stereomicroscope (or a magnifier), entomological tweezers, evaporating dishes (glass,
297 plastic or porcelain) or Petri dishes, capped tubes for specimen storage, 70% ethanol (not denatured
298 ethanol).

299 **2.2.2. Test procedure**

300 A general observation of the specimens should be made by placing them in a dish and checking for
301 homogeneity (using a magnifier or stereomicroscope as necessary). If they are of uniform type, the
302 samples can be processed further. If they are not uniform (i.e. multiple species may be present) then
303 samples should be taken of each type present for further identification. When possible, select
304 undamaged samples for further analysis, using entomological tweezers.

305 Microscopic examination should be done at different magnifications to visualise the critical
306 identification criteria (see Section 2.2.3 below). Before observation, allow the ethanol to evaporate
307 so that the colour of the specimens can be properly assessed.

308 The size of the specimens should be ~~measured~~ evaluated. The length of adult beetles is measured
309 from the caudal to the cranial end of the specimens without taking into account the antennae and the
310 mouthparts, which may possibly protrude from the body of the insect. The width of the body is
311 measured at the widest part of the pronotum.

312 Samples can be compared with reference specimens if available.

313 After examination, beetles are stored in 70% ethanol.

314 **2.2.3. Guidelines for the identification of *Aethina tumida***

315 Differentiation should be made between *A. tumida* and other non-pest nitidulid beetles that can be
316 found in honey bee hives, for example: *Cychramus luteus*, found in Europe, that mainly feeds on
317 pollen (Neumann & Ritter, 2004), *Carpophilus lugubris*, found in hives in Italy (Marini *et al.*, 2013),
318 and *Glischrochilus fasciatus*, *Lobiopa insularis*, *Carpophilus dimidiatus* and *Epuraea corticina* found
319 in hives in the United States (Ellis *et al.*, 2008).

320 The larvae of *A. tumida* can also be mistaken for larvae of the lesser wax moth, *Achroia grisella*, or
321 the honeycomb (greater wax) moth, *Galleria mellonella*. These ~~lepidoptera~~ lepidopteran are generally
322 found in colonies and on beekeeping equipment.

323 **2.2.3.1. Adult form**

324 Identification of adult *A. tumida* is based on the following morphological criteria: (Figures 1 ~~and~~
325 9 and 10)

1. Body divided in three parts: head, thorax and abdomen.
2. Three pairs of legs.
3. Presence of elytra; elytra are sclerotised (i.e. thickened) forewings covering the
hind wings at rest in beetles and some other insects.
4. Elytra not covering the entire abdomen: some abdominal segments are apparent in
dorsal view.
5. Overall uniform body colour (no spots), light brown to black when beetles are fully
mature.
Note: The colour may change with environmental conditions and conservation of the
specimens.
6. Ends of antennae with compact, almost rounded clubs². The three terminal articles
of the antennae, corresponding to the "clubs", are narrowed between them. The
transversal size of the first segment of the clubs (proximal article) is slightly larger
than the other two segments (distal articles).
7. Sharp-Posterioro-lateral angles of the pronotum appear sharp (dorsal view)³.
8. Dimensions: length: ~~5–7~~ 3–8 mm; width: ~~3–4.5~~ 2–4 mm (approximately)
9. Colour: reddish brown when newly hatched, turning dark brown to black in
adulthood
~~Presence of a lighter band around thorax and abdomen (optional criterion)~~
Note: The colour may change with environmental conditions and conservation of the
specimens
- ~~10. Club-shaped antennae~~
- ~~11. Sharp posterioro-lateral angles of the pronotum~~

326

327 Notes:

328 i) The size of *A. tumida* can vary if the beetle is in a retracted (defensive) or "extended" position,
329 and according to sex (Ellis *et al.*, 2002; Menier & Jouan, 2003). Factors such as food availability,
330 climate or soil type could also influence size.

331 ii) *Aethina tumida* has a lighter border around the pronotum and elytra (row of fine yellow bristles).
332 This characteristic is not always observable on dead specimens preserved in ethanol.

² In the Nitidulidae, the terminal articles of the antennae are larger and club-shaped.

³ The pronotum corresponds to the dorsal part of the first segment of the thorax.




Fig. 9. Small hive beetle, *Aethina tumida* Murray.

333





Fig. 10. *Aethina tumida* antenna (Photograph: Lee et al., 2017; Drawing: Menier & Jouan, 2003).

334
335

For differential diagnosis, *Cychramus luteus* is shown below with the following features (Figure 40 11; Neumann & Ritter, 2004):

336
337
338
339

elytra completely covers the abdominal apex;
antennal clubs are looser with detached segments;
latero-posterior tips of the pronotum are not sharp;
colour of the body is light-brown.



Photograph by Malcolm Storey, 2003, www.bioimages.org.uk

Fig. 40-11. *Cychramus luteus* (Neumann & Ritter, 2004).

340
341
342

Carpophilus lugubris has the following characteristics: (Figure 44-12; Marini *et al.*, 2013):

343 body is brown;
344 elytra have orange regions;
345 legs and antennae are orange (antennal clubs are dark orange);
346 body length: 3.3–4.5 mm.
347 ~~However, as for *A. tumida*:~~
348 elytra do not cover the entire abdomen;
349 club-shaped antennae have compact segments, but their shape is oval rather than
350 rounded and the proximal article is narrower than the distal ones;
351 latero-posterior tips of the pronotum are sharp.




Fig. 44-12. *Carpophilus lugubris* (Marini *et al.*, 2013).

352


353

2.2.3.2. Larval form

354 Larvae of *A. tumida* have a light beige body. The cephalic capsule (head of the larva) is brown.
355 The colour may change with environmental conditions and conservation of the specimens. The
356 body length at maturity is about 1 cm (1.2 cm maximum) depending on feeding. The width is
357 about 1.6 mm.

358 Larva identification is based on the following morphological criteria: (see Figure 42-13 and 14).

- 359 1. Three pairs of legs, one on each of the anterior (thoracic) segments
- 360 2. All the posterior leg segments are bare and have no false legs (also called pseudopods)
- 361 on their ventral part. Two dorsal spines on each segment (these spines are thicker on the
- 362 last segment)
- 363 3. From the mesothorax⁴, presence on each segment, of two dorsal tubers on either side of
- 364 the midline. These tubers are finished with a short fine silk. They look like 'spines'. No false
- 365 legs (pseudopods or prolegs) on the ventral side of the posterior abdominal segments.
- 366 Note: The dorsal tubers are pigmented. They are terminated by a short fine silk and preceded
- 367 by two short spines. The last segment of the larva abdomen has two dorsal tubers and two
- 368 urogomphi⁵ (Figure 13).




Larva of *A. tumida*, dorsal view.

Light-beige body; Light brown cephalic capsule

Two rows of dorsal tubers ('spines') on each segment starting from the mesothorax (2-3)

Two thick dorsal tubers ('spines') and two urogomphs on last segment (2-3)



Larva of *A. tumida*, ventral view.

Three pairs of legs, one on each of the anterior segments (1)

No pseudopods on the ventral side of the posterior abdominal segments (2-3)

Fig. 12 — 13. Larva of *Aethina tumida*.
Photographs by Josephine Ratikan, University of Florida.

369

370

⁴ The mesothorax corresponds to the second thoracic segment of the larva. It has the second pair of legs. The prothorax corresponds to the first thoracic segment; it does not have a tuber, its dorsal part (tergum) is sclerified.

⁵ Urogomphus is an extension, fixed or mobile, attached to one of the last segments of the abdomen of certain larvae.




Fig. 14. Detail of dorsal tuber (Menier & Jouan, 2003)

372 To distinguish *A. tumida* larvae from Lepidoptera larvae (lesser wax moth, *A. grisella* and
 373 honeycomb/greater wax moth, *G. mellonella*), frequently present in honeybee hives:

374 The Lepidoptera larvae have pseudopods on the ventral side of the abdominal segments.

375 There are two bare segments between the last segment with legs and the first segment with
 376 pseudopods (Figure 13-15).

377 The Lepidoptera larvae can make a silky web, cocoons, and have dark faeces (these webs and
 378 faeces may be observed in the sample containers received by the laboratory).

379




Fig. 13—15. Differentiation of *A. tumida* from wax moth larvae. Photographs by Nicolas Cougoule. Anses, Sophia Antipolis laboratory.

380 Certain larvae of other species of Nitidulidae are morphologically very similar to *A. tumida*. If
 381 there is any doubt about identification, a confirmatory PCR analysis is recommended.

382

- 383 **2.2.4. Interpretation of results**
- 384 **2.2.4.1. Adult form**
- 385 i) If all the criteria 1 to 8 are confirmed for *A. tumida*, the result is “positive”. The identification of
- 386 *A. tumida* is confirmed. Confirmatory testing by PCR is advised.
- 387 ii) If certain fundamental morphological characteristics of *A. tumida* are not present (i.e. at least
- 388 one out of the criteria 1 to 8), the result is “negative”. The identification of *A. tumida* is not
- 389 confirmed.
- 390 iii) Where the positive or negative status of the sample cannot be assessed (for example, a
- 391 damaged sample makes it impossible to rule on the presence or absence of certain
- 392 morphological criteria), the result is ‘inconclusive’. Where definitive morphological criteria cannot
- 393 be determined (e.g. damaged sample), the result is “inconclusive”. Molecular identification is
- 394 essential for confirmation.
- 395 **2.2.4.2. Larval form**
- 396 i) If all the criteria 1 to 3 are confirmed, the result is “*A. tumida* suspected”. PCR testing is essential
- 397 for final confirmation and confidence in the diagnosis.
- 398 ii) If at least one out of the criteria 1 to 3 is not confirmed, the result is “negative”. The suspicion of
- 399 *A. tumida* is not confirmed.
- 400 iii) Where the positive or negative status of the sample cannot be assessed (for example, a
- 401 damaged sample makes it impossible to rule on the presence or absence of certain
- 402 morphological criteria), the result is ‘inconclusive’. Where definitive morphological criteria cannot
- 403 be determined (e.g. damaged sample), the result is “inconclusive”. Molecular identification is
- 404 essential for confirmation.

405 2.3. Molecular identification

406 The morphological identification of the small hive beetle is increasingly confirmed by molecular methods

407 using real-time PCR, especially for the examination of larvae where morphology is less not clear-cut. Various

408 real-time PCR-based methods have been reported in the literature (Li et al., 2018; Silacci et al., 2018; Ward

409 et al., 2007). The real-time PCR method described below was has been developed by Ward et al. (2007)

410 and is based on the amplification of a partial sequence of the mitochondrial gene of *A. tumida* that encodes

411 cytochrome oxidase I (COI). This method was validated in accordance with Chapter 1.1.6 Validation of

412 diagnostic assays for infectious diseases of terrestrial animals. The primers SHB207F and SHB315R can

413 amplify a fragment of 109 base pairs, specific to *A. tumida*. This fragment is visualised in real-time due to a

414 5'-labelled probe. To take into account the two haplotypes identified by bioinformatic analysis by Ward et al.

415 (2007), the SHB207F primer includes a degenerate base in the position 228 (A/G) (GenBank No.

416 AF227645). However, due to the emergence of genetic variations following its worldwide dispersal, the Ward

417 et al. (2007) method was adapted by adding a modified forward primer (SHB207F-M) to increase the level

418 of detection of certain specimens from countries in Asia and the Indian Ocean region (Del Cont et al., 2024;

419 Liu et al., 2020). The adapted method was also validated in accordance with Chapter 1.1.6 Validation of

420 diagnostic assays for infectious diseases of terrestrial animals.

421 2.3.1. Sample preparation, equipment and reagents method

422 The samples are typically adults or larvae kept in >90% non-denatured alcohol, or kept dry. Alcohol-

423 preserved specimens should be left on tissue paper allowing the alcohol to evaporate or rinsed three

424 times in a large volume of phosphate buffer (50 ml tube, for example). The specimen is then

425 transferred to a 1.5 ml microtube where it is ground manually using a disposable pellet pestle. The

426 volume depends on the size of the sample (for example: one adult beetle in 1 ml; one larva: in 200

427 µl). Samples can be stored at ≤ -16°C.

428 Genomic DNA from suspected specimens is extracted using a method that ensures the quality of the

429 nucleic acids extracted (example in Franco et al., 2022). There are a number of specialised methods

430 for particular types of samples and tissues, some of which are now commercially available either as

431 manual or automated systems for robotic workstations. Regardless of the DNA extraction method

432 used, it is recommended to add a positive extraction control, to ensure the effectiveness of the

433 extraction, and a negative extraction control to ensure absence of contamination.

434 A real-time PCR detection system and the associated data analysis software are required to perform
 435 the test. Several proprietary systems for real-time PCR are available. The method described below
 436 uses one such system, but the precise parameters of the method should be validated according to
 437 the system in use in a particular laboratory. Because of the high sensitivity of the method, appropriate
 438 measures are required to avoid DNA contamination. All materials and methods used for the test
 439 should comply with the standards set out in the Chapter 2.1.2 *Biotechnology advances in the*
 440 *diagnosis of infectious diseases*, including measures to prevent contamination of DNA in the
 441 specimen.

442 2.3.2. Preparation of reagents

443 The real-time PCR reaction mixture is usually provided as a ready to use 2x concentration. The
 444 manufacturer's instructions should be followed for use and storage. Working stock solutions for the
 445 primers and probe are prepared with nuclease-free TE buffer at the concentration of 20 µM and 50
 446 µM respectively. The stock solutions are stored at $\leq -16^{\circ}\text{C}$ – 20°C and the probe should be protected
 447 from light. Single-use aliquots can be prepared to reduce the number of freeze–thawing cycles and
 448 to increase the shelf life of the primers and probes.

449 2.3.3. Real-time PCR test procedure

Primer/probe name	Sequence
SHB207F	5'-TCT-AAA-TAC-TAC-TTT-CTT-CGA-CCC-ATC-(A/G)-3'
<u>SHB207F-M</u>	<u>5'-CCT-AAA-TAC-TAC-TTT-CTT-TGA-TCC-ATC-(A/G)-3'</u>
SHB315R	5'-TCC-TGG-TAG-AAT-TAA-AAT-ATA-AAC-TTC-TGG-3'
SHB245T probe	5'-(6-FAM)-ATC-CAA-TCC-TAT-ACC-AAC-ACT-TAT-TTT-GAT-TCT-TCG-GAC-(TAMRA)-3**

450 *To increase the signal, it is possible to modify the fluorochrome and the quencher. However, it is recommended
 451 to verify the PCR performance.

452 Positive and negative extraction controls, as well as reagent controls, should be included in each
 453 PCR test. To minimise the risk of contamination by the positive control, a dilution resulting in a Ct
 454 value of about 30 should be used. A suitable control would be crushed *A. tumida* beetles diluted to
 455 10 times the detection limit of the method (LD_{method}). Alternatively, a plasmid containing the target
 456 sequence may be added diluted to 10 times the detection limit of the PCR (LD_{PCR}). For the negative
 457 extraction control, it is recommended to use the buffer used for crushing the specimens. An internal
 458 positive control (IPC) is highly recommended to check the absence of PCR inhibitor in the extract
 459 analysed.

460 Appropriate thermocycler conditions should be determined and validated for the equipment and
 461 reagents in use in the particular laboratory.

462 PCR reagent mixtures are added in a clean room (no pathogens or amplification products should be
 463 handled), for example:

	Final concentration	Volume for one tube (µl)
Nuclease free H ₂ O	/	<u>4.43.7</u>
Real-time PCR reaction mixture (2x)	1x	12.5
SHB207F (20 µM)	320 nM	0.4
<u>SHB207F-M (20 µM)</u>	<u>320 nM</u>	<u>0.4</u>
SHB315R (20 µM)	320 nM	0.4
245 probe (50 µM)	100 nM	0.05
10x IPC Mix	1x	2.5
50x IPC DNA	0.1x	0.05
Mix total volume		20

464 Add 5 µl of the DNA template (unknown sample or plasmid DNA) or positive or negative control to
 465 the reagent mixture to a final volume of 25 µl. DNA samples are prepared and added to the PCR mix
 466 in a separate area.

467 The thermocycler programme will depend on the equipment used and the real-time PCR reaction
468 mixture, for example:

Step	Cycle	Temperature (°C)	Time (minutes)
Polymerase activation	1	95	3:00
PCR	40	95	0:10
		60	0:30

469 2.3.4. Interpretation of results

470 The threshold for the analysis of the amplification curves (determined by the background noise
471 associated with the detection system) is usually set according to the manufacturer's instructions for
472 the software used. It can be performed on confirmed negative specimens (e.g. larvae of wax moth
473 *Galleria melonella* or adult beetles of the genus *Meligethes*).

474 A result identifying *A. tumida* by real-time PCR is considered valid only if the positive extraction and
475 PCR controls are positive ($Ct \leq 35$) and if the negative extraction and PCR controls are negative (Ct
476 = N/A).

477 A positive result is recorded for any sample with a Ct value <35 . Negative results are for any sample
478 with a Ct value >35 or which presents no Ct value. Samples giving negative results should be checked
479 for the absence of PCR inhibitor in the extract analysed through the result of the IPC. PCR inhibitors
480 can lead to false negative results. Inhibition may be overcome by dilution of the sample for example
481 to 1/10.

482 3. Serological tests

483 Serological tests are not appropriate or relevant to bee colony infestations.

484 C. REQUIREMENTS FOR VACCINES

485 There are no vaccines available.

486 REFERENCES

487 BERNIER M., FOURNIER V., ECCLES L. & GIOVENAZZO P. (2015). Control of *Aethina tumida* (Coleoptera: Nitidulidae) using
488 in-hive traps. *Can. Entomol.*, **147**, 97–108.

489 BUCHHOLZ S., SCHÄFER M.O., SPIEWOK S., PETTIS J.S., DUNCAN M., RITTER W., SPOONER-HART R. & NEUMANN P. (2008).
490 Alternative food sources of *Aethina tumida* (Coleoptera: Nitidulidae). *J. Apic. Res.*, **47**, 202–209.

491 BUTELER M., VILLALOBOS E., ALMA A. M., SILVA L. & TOMBA J.P. (2023). Management practice for small hive beetle as a
492 source of microplastic contamination in honey and honeybee colonies. *Environ. Pollut.*, **334**, 122151.

493 CERVANCIA C.R., DE GUZMAN L.J., POLINTAN E.A., DUPO A.L.B. & LOCSIN A.A. (2016). Current status of small hive beetle
494 infestation in the Philippines. *J. Apic. Res.*, **55**, 74–77.

495 CHAUZAT M.P., LAURENT M., BROWN M., KRYGER P., MUTINELLI F., ROELANDT S., ROELS S., VAN DER STEDE Y., SCHÄFER M.,
496 FRANCO S., DUQUESNE V., RIVIÈRE M.P., RIBIÈRE-CHABERT M. & HENDRIKX P. (2016). Guidelines for the surveillance of the
497 small hive beetle (*Aethina tumida*) infestation. European Union Reference Laboratory for honeybee health (EURL),
498 Anses Sophie-Antipolis, France, pp. 21.

499 CORNELISSEN B. & NEUMANN P. (2018). How to Catch a Small Beetle: Top Tips for Visually Screening Honey Bee
500 Colonies for Small Hive Beetles. *Bee World*, **95**, 1–4.

501 CRIBB B. W., RICE S.J. & LEE MON D.M. (2013). Aiming for the management of the small hive beetle, *Aethina tumida*,
502 using relative humidity and diatomaceous earth. *Apidologie*, **44**, 241–253.

- 503 GUTHBERTSON A.G.S., WAKEFIELD M.E., POWELL M.E., MARRIS G., ANDERSON H., BUDGE G.E., MATHERS J.J., BLACKBURN
504 L.F. & BROWN M.A. (2013). The small hive beetle *Aethina tumida*: A review of its biology and control measures. *Curr.*
505 *Zool.*, **59**, 644–653.
- 506 DEL CONT A., KOUTSOVOULOS G., FRANCO S. & DUQUESNE V. (2024). Phylogenetic analysis of *Aethina tumida* Murray
507 (Coleoptera: Nitidulidae) from Reunion Island. *J. Apic. Res.*, **63**, 530–532.
- 508 DE GUZMAN L.I. & FRAKE A.M. (2007). Temperature affects *Aethina tumida* (Coleoptera: Nitidulidae) development. *J.*
509 *Apic. Res.*, **46**, 88–93.
- 510 EFSA (EUROPEAN FOOD SAFETY AUTHORITY) (2015). EFSA Panel on Animal Health and Welfare. Scientific opinion on
511 the survival, spread and establishment of the small hive beetle (*Aethina tumida*). *EFSA Journal*, **13**, 4328, 77 pp.
512 doi:10.2903/j.efsa.2015.4048
- 513 ELLIS J.D. (2005). Reviewing the confinement of small hive beetles (*Aethina tumida*) by western honey bees (*Apis*
514 *mellifera*). *Bee World*, **86**, 56–62.
- 515 ELLIS J.D. & DELAPLANE K.S. (2006). The effects of habitat type, ApilifeVAR™, and screened bottom boards on small
516 hive beetle (*Aethina tumida*) entry into honey bee (*Apis mellifera*) colonies. *Am. Bee J.*, **146**, 537–539.
- 517 ELLIS J.D., DELAPLANE K.S., CLINE A. & MCHUGH J.V. (2008). The association of multiple sap beetle species (Coleoptera:
518 Nitidulidae) with western honey bee (*Apis mellifera*) colonies in North America. *J. Apic. Res. Bee World*, **47**, 188–189.
- 519 ELLIS J.D., DELAPLANE K.S., HEPBURN H.R. & F.P.J. (2002a). Controlling small hive beetles (*Aethina tumida* Murray) in
520 honey bee (*Apis mellifera*) colonies using a modified hive entrance. *Am. Bee J.*, **142**, 288–290.
- 521 ELLIS J.D., DELAPLANE K.S. & HOOD W.M. (2001). Small hive beetle (*Aethina tumida*) weight, gross biometry, and sex
522 proportion at three locations in the southeastern United States. *Am. Bee J.*, **142**, 520–522.
- 523 ELLIS J.D. & HEPBURN H.R. (2006). An ecological digest of the small hive beetle (*Aethina tumida*), a symbiont in honey
524 bee colonies (*Apis mellifera*). *Insectes Sociaux*, **53**, 8–19.
- 525 ELLIS J.D., HEPBURN H.R., DELAPLANE K., NEUMANN P. & ELZEN P.J. (2003). The effects of adult small hive beetles, *Aethina*
526 *tumida* (Coleoptera: Nitidulidae), on nests and flight activity of Cape and European honey bees (*Apis mellifera*).
527 *Apidologie*, **34**, 399–408.
- 528 ELLIS J.D., HEPBURN H.R., LUCKMANN B. & ELZEN P.J. (2004). The effects of soil type, moisture, and density on pupation
529 success of *Aethina tumida* (Coleoptera: Nitidulidae). *Environ. Entomol.*, **33**, 794–798.
- 530 ELLIS J.D., NEUMANN P., HEPBURN H.R. & ELZEN P.J. (2002b). Longevity and reproductive success of *Aethina tumida*
531 (Coleoptera: Nitidulidae) fed different natural diets. *J. Econ. Entomol.*, **95**, 902–907.
- 532 ELZEN P.J., BAXTER J.R., WESTERVELT D., RANDALL C., DELAPLANE K.S., CUTTS L. & WILSON W.T. (1999). Field control and
533 biology studies of a new pest species, *Aethina tumida* Murray (Coleoptera, Nitidulidae) attacking European honey bees
534 in the Western hemisphere. *Apidologie*, **30**, 361–366.
- 535 FORMATO G., FEDERICO G., DI RUGGIERO C., PIETROPAOLI M., MILITO M. & MUTINELLI F. (2021). Definition of a protocol to
536 manage and officially confirm SHB presence in sentinel honeybee colonies. *Appl. Sci.*, **11**, 8260.
537 <https://doi.org/10.3390/app11178260>
- 538 FRANCO S., COUGOULE N., TISON A., DEL CONT A., GASTALDI C., ILCT CONSORTIUM & DUQUESNE V. (2022). Reliability of
539 Morphological and PCR Methods for the Official Diagnosis of *Aethina tumida* (Coleoptera: Nitidulidae): A European
540 Inter-Laboratory Comparison. *Insects*, **13**, 33. <https://doi.org/10.3390/insects13010033>
- 541 GONTHIER J., PAPACH A., STRAUB L., CAMPBELL J., WILLIAMS G. & NEUMANN P. (2019). Bees and flowers: How to feed an
542 invasive beetle species. *Ecol. Evol.*, **9**, 6422–6432. doi: 10.1002/ece3.5217
- 543 GRECO M.K., HOFFMANN D., DOLLIN A., DUNCAN M., SPOONER-HART R. & NEUMANN P. (2010). The alternative Pharaoh
544 approach: stingless bees mummify beetle parasites alive. *Naturwissenschaften*, **97**, 319–323.
- 545 HEPBURN H.R. & RADLOFF S.E. (1998). Honeybees of Africa. Springer Verlag, Berlin, Heidelberg, New York.
- 546 HOOD M.W. (2004). The small hive beetle, *Aethina tumida*: a review. *Bee World*, **85**, 51–59.

- 547 LEE S., HONG K.-J., CHO Y.S., CHOI Y.S., YOO M.-S. & LEE S. (2017). Review of the subgenus *Aethina* Erichson s. str.
548 (Coleoptera: Nitidulidae: Nitidulinae) in Korea, reporting recent invasion of small hive beetle, *Aethina tumida*. *J. Asia-*
549 *Pacific Entomol.*, **20**, 553–558.
- 550 LI D., WAITE D.W., FAN Q.-H., GEORGE S., SEMERARO L., BLACKET M.J. (2018). Molecular detection of small hive beetle
551 *Aethina tumida* Murray (Coleoptera: Nitidulidae): DNA barcoding and development of a real-time PCR assay. *Scientific*
552 *Reports*, **8**, 9623. doi:10.1038/s41598-018-27603-x.
- 553 LIU Y., HAN W., GAO J., SU S., BEAUREPAIRE A., YANEZ O. & NEUMANN P. (2021). Out of Africa: novel source of small hive
554 beetles infesting Eastern and Western honey bee colonies in China. *J. Apic. Res.*, **60**, 108–110.
- 555 LUNDIE A.E. (1940). The small hive beetle *Aethina tumida*, Science Bulletin 220, Dep. Agr. Forestry, Government
556 Printer, Pretoria, South Africa.
- 557 MARINI F., MUTINELLI F., MONTARSI F., CLINE A., GATTI E. & AUDISIO P. (2013). First report in Italy of the dusky sap beetle,
558 *Carpophilus lugubris*, a new potential pest for Europe. *J. Pest Sci.*, **86**, 157–160.
- 559 MENIER J. & JOUAN M. (2003). Biologie et description d'*Aethina tumida* Murray, 1867, espèce invasive déprédatrice de
560 l'Abeille mellifère (Coleoptera, Nitidulidae). *Bulletin de la Société entomologique de France*, **108**, 323–328.
- 561 MURRAY A. (1867). List of Coleoptera received from Old Calabar. *Ann. Magazine Nat. Hist.*, London, **19**, 167–179.
- 562 NEUMANN P. & ELZEN P.J. (2004). The biology of the small hive beetle (*Aethina tumida*, Coleoptera: Nitidulidae): Gaps
563 in our knowledge of an invasive species. *Apidologie*, **35**, 229–247.
- 564 NEUMANN P. & RITTER W. (2004). A scientific note on the association of *Cychramus luteus* (Coleoptera: Nitidulidae) with
565 honeybee (*Apis mellifera*) colonies. *Apidologie*, **35**, 665–666.
- 566 NEUMANN P. & HOFFMANN D. (2008). Small hive beetle diagnosis and control in naturally infested honey bee colonies using
567 bottom board traps and CheckMite+ strips. *J. Pest Sci.*, **81**, 43–48. <https://doi.org/10.1007/s10340-007-0183-8>
- 568 NEUMANN P., PETTIS J.S. & SCHÄFER M. O. (2016). *Quo vadis Aethina tumida?* Biology and control of small hive beetles.
569 *Apidologie*, **47**, 427–466.
- 570 PETTIS J. & SHIMANUKI H. (2000). Observations on the small hive beetle, *Aethina tumida*, Murray, in the United States.
571 *Am. Bee J.*, **140**, 152–155.
- 572 SCHMOLKE M.D. (1974). A study of *Aethina tumida*: the small hive beetle, Project Report, University of Rhodesia,
573 Zimbabwe, pp. 178.
- 574 SCHÄFER M., PETTIS J.S., RITTER W & NEUMANN P. (2008). A simple method for quantitative diagnosis of small hive
575 beetles, *Aethina tumida*, in the field. *Apidologie*, **39**, 564–565.
- 576 SCHÄFER M. O., CARDAIO I., CILIA G., CORNELISSEN B., CRAILSHEIM K., FORMATO G., LAWRENCE A. K., LE CONTE Y., MUTINELLI
577 F., NANETTI A., RIVERA-GOMIS J., TEEPE A. & NEUMANN P. (2019). How to slow the global spread of small hive beetles,
578 *Aethina tumida*. *Biol. Invasions*, **21**, 1451–1459.
- 579 SILACCI P., BIOLLEY C., JUD C., CHARRIÈRE J.-D. & DAINAT B. (2018). An improved DNA method to unambiguously detect
580 small hive beetle *Aethina tumida*, an invasive pest of honeybee colonies. *Pest Manage. Sci.*, **74**, 2667–2670.
581 doi:10.1002/ps.5141.
- 582 SOMERVILLE D. (2003). Study of the small hive beetle in the USA. In: Rural Industries Research and Development
583 Corporation (RIRDC) Publication No. 03/050, RIRDC Project No. DAN-213A. RIRDC, Barton, ACT, Australia.
- 584 SPIEWOK S. & NEUMANN P. (2006). Cryptic low-level reproduction of small hive beetles in honeybee colonies. *J. Apic.*
585 *Res.*, **45**, 47–48.
- 586 SPIEWOK S., PETTIS J., DUNCAN M., SPOONER-HART R., WESTERVELT D. & NEUMANN P. (2007). Small hive beetle, *Aethina*
587 *tumida*, populations. I: Infestation levels of honey bee colonies, apiaries and regions. *Apidologie*, **38**, 595–605.
588 <https://doi.org/10.1051/apido:2007042>
- 589 WARD L., BROWN M., NEUMANN P., WILKINS S., PETTIS J. & BOONHAM N. (2007). A DNA method for screening hive debris
590 for the presence of small hive beetle (*Aethina tumida*). *Apidologie*, **38**, 272–280.

591 ZAWISLAK J. (2014). Managing Small Hive Beetles. University of Arkansas, Cooperative Extension Service. Printing
592 Services FSA7075.

593

FURTHER READING

594 An FAO publication, *Good beekeeping practices: Practical manual on how to identify and control the main diseases of*
595 *the honeybee (Apis mellifera)*. TECA -Technologies and Practices for Small Agricultural Producers, No. 1.-FAO, Rome,
596 Italy, 70 pp. ISSN 2708-1168, is available free of charge at: <https://www.fao.org/3/ca9182en/CA9182EN.pdf>

597 An FAO publication, *Honey bee diseases and pests: a practical guide*, W. Ritter & P. Akwatanakul (eds). Agricultural
598 and Food Engineering Technical Report No. 4. FAO, Rome, Italy, 42 pp. ISSN 1814-1137 TC/D/A0849/E, is available
599 free of charge at: <http://www.fao.org/3/a-a0849e.pdf>

600

*

601

* *

602 **NB:** There are WOAHP Reference Laboratories for infestation with *Aethina tumida* (small hive beetle)
603 (please consult the WOAHP Web site:

604 <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>).

605 Please contact the WOAHP Reference Laboratories for any further information on
606 diagnostic tests and reagents for infestation with *Aethina tumida* (small hive beetle)

607

NB: FIRST ADOPTED IN 2008. MOST RECENT UPDATES ADOPTED IN 2018.

608
609
610

Appendix 1: Infestation of honey bees with *Aethina tumida* (small hive beetle)
Intended purposes of test: population freedom from infestation; individual animal freedom from infestation prior to movement; contribute to eradication policies; confirmation of clinical cases; prevalence of infestation – surveillance

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
Visual inspection of colonies: +++ for the purposes: 'confirmation of clinical cases' and 'prevalence of infestation – surveillance' ++ for the purposes: 'population freedom of infestation', 'individual animal freedom from infestation prior to movement' and 'contribute to eradication policies' <i>Apis mellifera</i>	<u>Sample type:</u> <i>Apis mellifera</i> colonies (including sentinel colonies) <u>Target analytes:</u> adult SHB beetles and beetle larva specimens	<u>Spiewok et al., 2007:</u> <u>Reference test:</u> visual inspection of six SHB-free colonies in which specific numbers (42, 88, 98, 112, 135 and 172) of SHB adults (unknown to the investigator) were introduced and given 1 hour to disperse inside the colonies before the inspection started <u>Results:</u> average of 9 (8; 10) SHB were not found during the visual inspection, corresponding to failure rate of 8.4% (6.4; 11.5) <u>Neumann & Hoffmann (2008):</u> <u>Reference test:</u> dissection after killing the bees and the pest to assess the number of adult SHB remained undetected during visual inspection <u>Results:</u> 14.06 ± 10.53% of the adult SHB remained undetected during visual inspections - No data reported on the detection limit and/or sensitivity of this diagnostic method (EFSA, 2015)	<u>Spiewok et al., 2007:</u> 42, 88, 98, 112, 135 and 172 adult SHB were introduced into six <i>A. mellifera</i> colonies in Maryland, USA in July/August 2005. <u>Neumann & Hoffmann (2008):</u> 30 <i>A. mellifera</i> colonies, naturally infested with SHB, in Langstroth hives with two boxes, arranged in three different apiaries in New South Wales, Australia. Experiments conducted in November 2005 (i.e. local springtime)	See references	<i>A. mellifera</i> colonies are very attractive to <i>A. tumida</i> . Such <i>A. mellifera</i> colonies can be used as sentinels in at-risk areas and for surveillance. The method is easy to learn for persons that can deal with honey bees. If done properly, the method is very accurate	The screenings are labour-intensive and time-consuming (depending on colony size and experience of the inspectors). The level of detail of the inspection determines its accurateness. To obtain reliable results, training is required. As beehive inspection implies its opening, it is not possible to apply it during winter or bad weather conditions (e.g. low temperatures, rain or snow). Visual inspection of colonies can be used in combination with traps to increase its sensitivity, particularly in these type of periods. Opening a colony for long time might induce robbing behaviour between colonies	<u>Spiewok et al. (2007)</u> <u>Neumann & Hoffmann (2008)</u> <u>EFSA (2015)</u>
Morphology +++ for all purposes <i>Apis</i> spp.	<u>Sample type:</u> Adult beetle and beetle larva specimens <u>Target analyte:</u> <i>Aethina tumida</i>	<u>Reference test:</u> real-time PCR and sequencing <u>Results:</u> DSp = 100% DSe = 100%	41 specimens of <i>A. tumida</i> (18 larvae and 23 adults) from different geographical areas (South Africa, United States, Canada, Mexico, Italy, France/Réunion Island, Mauritius, England/FERA experimental production).	Validation carried out by Anses Sophia Antipolis Laboratory. The robustness of the method was assessed by the	Rapid (less than 1 hour) Does not require sophisticated equipment, or reagents Inexpensive method	Requires a certain amount of experience and technical skill to handle specimens and identify morphological criteria. The differential diagnosis between <i>A. tumida</i> larvae and those of other Nitidulidae can	<u>Franco et al. (2022)</u>

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
			<u>82 negative specimens (67 adults and 15 larvae) corresponding to samples received for analysis (and collected in beehive environment) or to Nitidulidae species collected on plant crops</u>	<u>way of comparative laboratory testing organised with EU National Reference Laboratories (see Franco <i>et al.</i> [2022])</u>	<u>recommended for first intention diagnosis</u>	<u>be tricky. PCR is highly advisable if there is any doubt about identification. If <i>A. tumida</i> is detected in an area presumed to be free of the disease, it is recommended that identification be confirmed by PCR</u>	
<u>Real-time PCR ++ for all purposes except for 'prevalence of infestation – surveillance': + <i>Apis</i> spp.</u>	<u>Sample type: Adult and immature beetle specimens</u> <u>Target analyte: <i>Aethina tumida</i></u>	<u>Reference test: sequencing</u> <u>Results:</u> <u>DSp = 100%</u> <u>DSe = 100%</u>	<u>39 specimens of <i>A. tumida</i> from different geographical areas (South Africa, United States, Canada, Mexico, Italy, France/Réunion Island, Mauritius, England/FERA experimental production).</u> <u>28 negative specimens corresponding to samples received for analysis (and collected in beehive environment) or to Nitidulidae species collected on plant crops</u>	<u>Validation carried out by Anses Sophia Antipolis Laboratory (validation report submitted to WOA in 2016, completed with new data in 2023). The robustness of the method was assessed by the way of comparative laboratory testing organised with EU National Reference Laboratories (see Franco <i>et al.</i> [2022])</u>	<u>High specificity and sensitivity (generally more than morphology)</u> <u>Method recommended for second intention diagnosis</u> <u>Could be applied on immature stages as eggs and pupae</u>	<u>Requires reagents and equipment for real-time PCR detection and analysis system</u> <u>More expensive than the morphology</u> <u>Decrease in the level of detection in the case of new haplotypes</u>	<u>Franco <i>et al.</i> (2022)</u>

REUNIÓN DE LA COMISIÓN DE NORMAS BIOLÓGICAS
París, 9–13 de septiembre de 2024

CHAPTER 3.2.5.

INFESTATION OF HONEY BEES WITH *TROPILAEELAPS* SPP.

SUMMARY

Description and importance of the disease: The mites in the genus *Tropilaelaps* are parasites of honey bee brood. Feeding on bee larvae and pupae causes brood malformation, death of bees and subsequent colony decline or absconding. Development requires about 1 week, and the mites are dispersed on bees. Four species of the *Tropilaelaps* genus have been described so far. There are at least four species in the genus *Tropilaelaps*: *T. mercedesae*, *T. clareae*, *T. koenigerum* and *T. thajii*. Each species tends to be originally associated with a particular giant honey bee in Asia. Two species (*T. clareae* and *T. mercedesae*) are damaging pests of the European honey bee *Apis mellifera*. The other two species (*T. koenigerum* and *T. thajii*) appear to be harmless to *A. mellifera*.

Detection and identification of the agent: ~~Molecular and morphological methods are available for identifying each species.~~ An infestation by *Tropilaelaps* can be recognised either visually on bees and brood combs or by examining hive debris. Irregular brood pattern, dead or malformed immatures, bees with malformed wings that crawl at the hive's entrance, and especially the presence of fast-running, red-brown, elongated mites on the combs, are diagnostic for the presence of ~~*T. clareae* and/or *T. mercedesae*~~ or *T. clareae*. An early diagnosis can be made after opening brood cells and finding immature and adult mites therein. The hive (colony) may be treated with various chemicals that cause the mites to drop off combs and bees. Sticky boards on the bottom of the colony can be used to examine hive debris and mites. Alternatively, the "bump test" can be used for rapid screening. Definitive diagnosis at the laboratory is based on morphological examination under a microscope. Confirmatory testing can be done by conventional polymerase chain reaction and sequencing.

Serological tests: Serological tests are not applicable.

Requirements for vaccines: No vaccines are available.

A. INTRODUCTION

Tropilaelaps spp. Mites belong to the class *Arachnida*, subclass *Acari*, superorder *Parasitiformes*, order *Mesostigmata* and is a genus of mites from the *Laelapidae* family (Anderson & Roberts, 2013), which reproduces in bee brood. *Tropilaelaps* should not be confused with *Varroa*, another ectoparasitic mite of honey bees with similar characteristics in terms of life cycle and pathogenicity, and which share much of its range with *Tropilaelaps* (see Chapter 3.2.6 *Varroosis of honey bees [infestation of honey bees with *Varroa* spp.]*). They should not be confused with the mite *Varroa destructor*, a parasite that is well-established in Europe. *Tropilaelaps clareae* occurs in Asia where it is a parasite of the native honey bee *Apis dorsata breviligula*. It is also a parasite of the introduced honey bee species *A. mellifera* in the Philippines and the native honey bee species *A. dorsata binghami* on Sulawesi Island in Indonesia. *Tropilaelaps mercedesae*, which was formerly mistaken for *T. clareae*, together with *T. koenigerum*, are parasites of the native *A. dorsata dorsata* in mainland Asia and Indonesia (except Sulawesi Island). *Tropilaelaps mercedesae* is also a parasite of the introduced *A. mellifera* in these and surrounding regions

42 and, with another species, *T. thajii*, also parasitises *A. laboriosa* in mountainous Himalayan regions (Anderson & Morgan,
43 2007).

44 1. Nature and classification of the pathogen

45 *Tropilaelaps* spp. are mites belonging to the Class Arachnida, Subclass Acari, Superorder Parasitiformes, Order
46 Mesostigmata and Family Laelapidae (Anderson & Roberts, 2013). Based on genetic and morphological differences, four
47 species of *Tropilaelaps* have been described: *T. mercedesae*, *T. clareae*, *T. koenigerum* and *T. thajii* (Anderson & Morgan,
48 2007).

49 *Tropilaelaps* spp. are originally parasites of the Asian giant honey bees (*Apis dorsata*, *Apis laboriosa*, and *Apis breviligula*).
50 *Tropilaelaps koenigerum* is a parasite of *A. dorsata* in Sri Lanka, mainland Asia, and Indonesia apart from Sulawesi and
51 Borneo. *Tropilaelaps thajii* has only been observed infesting *A. laboriosa* in Vietnam. *Tropilaelaps clareae* parasitises *A.*
52 *dorsata* and *A. breviligula* in the Philippines and Indonesia. *Tropilaelaps mercedesae* was originally found in *A. dorsata* in
53 mainland Asia and Indonesia, and *A. laboriosa* in Himalayas (Chantawannakul *et al.*, 2018).

54 Amongst the four species of *Tropilaelaps*, *T. clareae* and *T. mercedesae* have successfully adapted to the European honey
55 bee *Apis mellifera* and can reproduce in the brood cells of this new host (de Guzman *et al.*, 2017). *Tropilaelaps mercedesae*,
56 which was formerly mistaken for *T. clareae*, has a wider geographical range. *Tropilaelaps clareae* has indeed only been
57 reported in *A. mellifera* in the Philippines (except Palawan Islands), whereas *T. mercedesae* is regionally widespread within
58 mainland Asia, Palawan Islands and extreme East of Europe (i.e. Krasnodar and Rostov regions, Russia), and found to
59 infest *A. mellifera* in both tropical and temperate zones (Brandorf *et al.*, 2024). Anthropogenic movements contribute to its
60 spread. Climate change is probably also a factor, creating favorable conditions for its establishment (Chantawannakul *et al.*,
61 2018).

62 2. Life cycle

63 The colonising *Tropilaelaps* female (or females; as many as a dozen may occur within a single cell) enters the brood cell
64 shortly before the cell is capped and lays from one to four eggs on a mature bee larva shortly before the brood cell is capped.
65 In its adapted host, *A. mellifera*, *Tropilaelaps* appears to prefer the drone brood is preferred by *Tropilaelaps* over that of
66 workers and may be almost 100% parasitised (Burgett *et al.*, 1983). The mite progeny, usually one male and several females,
67 feed on and seriously damage the bee brood. Development of the mite requires about 1 week. The adults, including the
68 foundress female, emerge with the adult bee and search for new hosts (de Guzman *et al.*, 2017) (Fig. 1).

69 The short life cycle, as well as a very brief stay on adult bees, explains why populations of *T. clareae* increase faster than
70 those of *Varroa* mites. When both *T. clareae* and *Varroa destructor* infest the same colony, the former may out-compete the
71 *Varroa* mite (Burgett *et al.*, 1983; Ritter & Schneider-Ritter, 1988). It has been reported that when both mite species are in
72 the same cell, the reproduction of both mites declines (Rath *et al.*, 1995).

73 Phoretic survival on adult bees is quite short (only 1–2 days up to 3 days) likely because of lack of morphological adaptation
74 for attachment and their apparent inability to feed on adult bees, linked to the fact that *Tropilaelaps* cannot pierce their
75 integument of adult bees (de Guzman *et al.*, 2017).

76 The short life cycle, as well as a very brief stay on adult bees and the possibility of deuterotoky (ability of virgin females to
77 lay both male and female eggs) (de Guzman *et al.*, 2018), explains why populations of *Tropilaelaps* increase faster than
78 those of *Varroa* mites. Buawangpong *et al.* (2015) showed that when both *T. mercedesae* and *Varroa destructor* infest the
79 same colony, the former may out-compete the *Varroa* mite.


80 Survival time in beehive products is up to 3 days in dry pollen, royal jelly and honey, and up to 6 days in empty honeycombs
81 thereby suggesting a sufficient time window for the potential introduction of *T. mercedesae* into mite-free countries via import
82 of these hive products (Khongphinitbunjong *et al.*, 2019; Pettis *et al.*, 2019).

83 The phoretic time for *Tropilaelaps* spp. is important in understanding the life cycle, and recent research suggests the period
84 can be as long as 5–10 days (Wilde, 2000a; 2000b). Gravid female mites will die within 2 days unless they deposit their eggs
85 (Woyke, 1987). The dispersal of *Tropilaelaps* is achieved by worker bees robbing colonies of stored and accidental drifting
86 of infested bees. The mites can also jump between host species when uninfested and infested foragers visit the same flowers
87 simultaneously. Beekeeping practices, such as colony divisions, transferring brood frames from one colony to another or
88 migratory beekeeping, can spread the parasite. The trade in queen bees and package bees also contributes to the spread
89 of *Tropilaelaps* spp. throughout the world. Accidental introductions can occur via infested swarms on ships (de Guzman *et*
90 *al.*, 2017).

91 Like *Varroa*, *Tropilaelaps* can act as a potential vector for honey bee viruses, such as deformed wing virus (DWV) (Forsgren
92 *et al.*, 2009). DWV has been reported to replicate in *T. mercedesae*, suggesting that the mite may act as a biological vector

93 of DWV (Dainat *et al.*, 2009). The impact of the mite–virus complex is not fully understood. Some data indicate that the major
94 impact of *Tropilaelaps* infestation could be caused by the mite itself, reducing bee host immune responses
95 (Khongphinitbunjong *et al.*, 2015).

96



97

98 **Fig. 1.** Life cycle of *Tropilaelaps* mite on European honey bee (Anderson & Roberts, 2013).

99 3. Description and impact of the disease

100 Infestation by *Tropilaelaps* causes the death of many bee larvae (up to 50%), resulting in an irregular brood pattern and of
101 which the cadavers that may partially protrude from the cells. Many malformed bees occur, with distorted–shortened
102 abdomens, stubby–distorted and stubby wings and deformed or missing legs, probably resulting from DWV associated
103 infection. Some of the affected bees crawl at the hive's entrance (Atwal & Goyal, 1971). In addition, perforated cappings are
104 seen, the result of sanitation activities by the worker bees, which evict the infested bee pupae or young adults. In highly
105 infested *A. mellifera* colonies, bald brood, a condition where the capping over pupal bees has been removed by workers,
106 can be observed (Pettis *et al.*, 2013). Some infested colonies abscond, carrying the mites to a new location.

107 The behavioral responses of honey bees to *T. mercedesae* depend on the *Apis* species. *A. cerana* and *A. dorsata* (the
108 natural host of *T. mercedesae*) showed a higher behavioral resistance than *A. mellifera* (Khongphinitbunjong *et al.*, 2012;
109 Shrestha, *et al.*, 2020). In *A. mellifera*, *T. mercedesae* infestation significantly reduced honey bee lifespan and emergence
110 weight, and had negative impacts on olfactory learning, flight ability and homing ability; it also promoted DWV levels and
111 associated clinical signs (Gao *et al.*, 2021; Khongphinitbunjong *et al.*, 2016) and could cause severe damage for colonies.
112 Heavy infestations can lead to reduced honey yields and colony losses.

113 Some of the clinical signs observed can be attributed to viral infection. Indeed, like *Varroa*, *Tropilaelaps* can act as a potential
114 vector for honey bee viruses, such as deformed wing virus (DWV), black queen cell virus (BQCV), acute bee paralysis virus
115 (ABPV), Israeli acute paralysis virus (IAPV) and sacbrood virus (SBV) (Chanpanitkitchote *et al.*, 2018; Forsgren *et al.*, 2009;
116 Truong *et al.*, 2023). The effect of the mite–virus complex is not fully understood. Some data indicate that the major impact
117 of *Tropilaelaps* infestation could be caused by the mite itself, reducing bee host immune responses and inflicting multiple
118 wounds on developing host bees when feeding (Khongphinitbunjong *et al.*, 2015). While in *V. destructor*, the mother mite
119 establishes one feeding site that she shares with her offspring, *T. mercedesae* uses multiple feeding sites on its host (Ling
120 *et al.*, 2023). Moreover, the puncture wound derived from mite feeding certainly allows for mechanical vectoring as it is an
121 entry point for several bee pathogens, including viruses (Chantawannaku *et al.*, 2018).

122 **4. Zoonotic potential and biosafety and biosecurity requirements**

123 Tropilaelaps infestation is not zoonotic. Being exotic in many areas, biosecurity measures must be implemented to avoid its
 124 dispersal. Suspect mites must be dead when sent to the laboratory (see Section B.2.1).

125 **5. Differential diagnosis**

126 Tropilaelaps should not be confused with other honey bee ectoparasites such as Varroa spp. (in particular with the two
 127 species V. destructor and V. jacobsoni, which are described in A. mellifera) and Braula coeca flies. A differential diagnosis
 128 must also be made with other Laelapidae mites living in debris of honey bee hives, such as Melittiphis alvearius (Cook &
 129 Bowman, 1983), the Ameroseiidae mite Neocypholaelaps apicola (Delfinado-Baker & Baker, 1983; Kontschán *et al.*, 2015)
 130 (Fig. 2).



Fig. 4-2. *Braula coeca* (above), *Varroa destructor* (right), *Tropilaelaps* spp. (below centre) and *Melittiphis alvearius* (left) (dorsal view).
 Photo supplied by APHA Bee Unit, York. UK Crown Copyright.

132 **B. DIAGNOSTIC TECHNIQUES**

133 Table 1. Test methods available for the diagnosis of
 134 infestation of honey bees with *Tropilaelaps* spp. and their purpose

Method	Purpose					
	Population freedom from infestation ^(a)	Individual animal or bee nest freedom from infestation prior to movement ^(a)	Contribute to eradication policies ^(a-b)	Confirmation of clinical cases ^(a)	Prevalence of infestation – surveillance ^(a)	Immune status in individual animals or populations post-vaccination
<u>Detection and identification of the agent</u>						
<u>Bee examination</u> ("ice sugar roll" method)	++	++	++	++	++	≡
<u>Capped brood examination</u>	+++	+++	+++	+++	+++	≡
<u>"Bump test"</u>	±	±	±	++	++	≡
<u>Debris examination</u>	++	++	++	++	++	≡
Morphology	+++	+++	+++	+++	+++	–

Method	Purpose					
	Population freedom from infestation ^(a)	Individual animal or bee nest freedom from infestation prior to movement ^(a)	Contribute to eradication policies ^(a-b)	Confirmation of clinical cases ^(a)	Prevalence of infestation – surveillance ^(a)	Immune status in individual animals or populations post-vaccination
Conventional PCR	++	++	++	++	+	–

Key: +++ = recommended for this purpose; ++ recommended but has limitations; + = suitable in very limited circumstances; – = not appropriate for this purpose. PCR = polymerase chain reaction.

^(a)See Appendix 1 of this chapter for justification table for the scores given to the tests for this purpose.

^(b)A combination of morphology and PCR applied on the same specimen is recommended in case of first detection in a free area.

135
136
137
138
139

140 1. Field detection of the mite

141 The first sign of an infestation by *Tropilaelaps* species is often the occurrence of red-brown, elongated mites on the combs
142 or on adult bees (Figs. 2-3 and 3-4).




143
144 Fig. 2-3. *Tropilaelaps* on *Apis dorsata* larvae. Photo by D. Anderson.
145

143
144
145

146 The body length depends on the species and varies between the male and the female. *Tropilaelaps koenigerum* is the
147 smallest member of the genus with a body length of < 0.7 mm for females and ~0.575 mm for males. Female *T. mercedesae*,
148 *T. clareae* and *T. thaii* are much longer at ~0.95–0.99 mm, ~0.87–0.885 mm and ~0.89 mm respectively, while the body
149 lengths of male *T. mercedesae* and *T. clareae* are slightly smaller than their respective females at 0.907–0.927 mm and
150 0.852–0.858 mm, respectively. Males of *T. thaii* have yet to be discovered (Anderson & Roberts, 2013).

151 In the brood cells, the different developmental stages of *Tropilaelaps* can be observed: larva, protonymph, deutonymph,
152 young adult (Fig. 4).

152



153
154 Fig. 3-4. *Tropilaelaps* offspring on *Apis mellifera* pupae. Photo by W. Ritter.

153
154
155
156
157

Tropilaelaps can easily be separated from the *Varroa* mite using a ×40-magnifying glass. The body of the *Varroa* mite is wider than it is long and it moves slowly, whereas the body of *Tropilaelaps* is elongated (Fig. 4-5), and it is a fast-moving mite.




Fig. 4–5. *Varroa destructor* and *Tropilaelaps* spp. (dorsal view). Photo supplied by APHA Bee Unit, York. UK Crown Copyright.

158 *Tropilaelaps* should also not be confused with other honey bee ectoparasites such as *Braula* flies, or other *Laelapidae* mites
 159 living in debris of honey bee hives such as *Mollitiphis alvearius* (Cook & Bowman, 1983) (Fig. 4) or the Ameroseiidae mite
 160 *Neocyphoelaclaps apicola* (Delfinado-Baker & Baker, 1983; Kentschán *et al.*, 2015).
 161

162 1.1. Mite collection Bee examination

163 Collecting mites from adult bees is a quick and simple method for *Tropilaelaps* detection. Mites are dislodged from
 164 bees by washing the bees in ethanol, soapy water or by treating them by the 'icing sugar roll' method (Anderson &
 165 Roberts, 2013; Gill *et al.*, 2024; Pettis *et al.*, 2013).

166 Collect approximately 400–200–200–300 bees in a wide-mouthed jar with lid. Scrape the bees into the jar or use a
 167 modified vacuum to suck them in. *Tropilaelaps* mites are usually only present in low numbers on adult bees. To
 168 increase the likelihood of collecting mites, a frame with emerging brood can be selected, allowing mites to be
 169 collected as they emerge with the bees (Anderson & Roberts, 2013).

170 Knock the bees to the bottom of the jar with a sharp blow; there should be about a 2.5–5 cm layer of bees on the
 171 bottom. Remove the lid and spray a 2-second burst with either starter fluid. Alternatively, use enough 70% alcohol
 172 ethanol or soapy water to cover the bees. Secure the lid, agitate the jar vigorously for 1 minute and then strain out
 173 the bees with a mesh strainer, a sieve or a mesh large enough for *Tropilaelaps* to pass through. Mites will be in the
 174 liquid.

175 Alternatively, ; or add around 25 g powdered icing sugar (or flour), secure the lid and roll the bees for one minute.
 176 Then leave the jar to stand out of direct sunlight for 1 minute. If using either replace the lid and agitate or roll the jar
 177 for about 10 seconds; mites should stick to walls. If using soap or alcohol, agitate and then strain out the bees with
 178 a coarse hardware cloth or mesh strainer; mites will be in the liquid. If using sugar or other powder, Put screening
 179 material (such as mesh strainer, sieve or hardware cloth) on top of the jar and shake the mites on to white paper tray
 180 to assess for the presence of mites. ; Repeat the process after 2 minutes. For a more accurate count, finish with an
 181 alcohol or soapy water wash to collect all the mites. The 'icing sugar roll' offers non-destructive, quick, inexpensive
 182 and easily deployable detection method, and appears to be more effective than 'ethanol wash' for *Tropilaelaps*
 183 detection (Gill *et al.*, 2024).

184 1.2. Colony and Capped brood examination

185 When monitoring honey bee colonies for the presence of *Tropilaelaps* (or *Varroa*), an examination of both drone
 186 and worker brood may provide an early indication of infestation.

187 Remove the wax cappings from large number of brood cells, preferably by using fine-nose forceps (instead of
 188 honey uncapping fork) to avoid damaging *Tropilaelaps* mites, which are more fragile than *Varroa* (Gill *et al.*, 2024).

189 Remove the immature honey bee (larva and pupae) from each cell and inspect them carefully for mites. Also, inspect
 190 the inside of the cells, as *Tropilaelaps* mites tend not to be present on pupae at certain stages of bee development
 191 (between larval instar/day 9 to pharate pupal stage/day 13, and after pink eyed stage/day 18) (Gill *et al.*, 2024). Mites
 192 can be observed inside capped bee brood by using a honey scratcher (with fork-like tines) to pull up capped
 193 pupae. The mites are clearly visible. The younger mite stages are whitish and may be almost motionless while
 194 feeding on their hosts' bodies, as their mouthparts and front legs are fixed to the cuticle of the bee host (Ritter &
 195 Schneider-Ritter, 1988). The use of a headlamp and a 40x magnification hand lens can aid mite discovery.

196 To collect the *Tropilaelaps* mites use a fine paintbrush wetted in honey, ethanol or water, or with a pair of fine
197 tweezers (Anderson & Roberts, 2013). Place the mites into small vials containing 70% undenatured ethanol for
198 storage.

199 The extent of ~~parasitisation~~ parasitism can be estimated by opening a predetermined number of brood cells (for
200 example 100) (Pettis, 2013); infestation rates are then calculated as per cent of capped brood containing live
201 mites (Burgott & Kitprasert, 1990; Pettis, 2013).

202 According to Gill et al. (2024), the ‘brood uncapping’ method is the most effective technique for *Tropilaelaps* field
203 detection.

204 **1.3. “Bump test”**

205 Another rapid and simple technique is the “bump test” (Pettis et al., 2013). The method consists of firmly rapping
206 a honey bee brood frame over a collecting pan. First, all adult bees are removed from one comb containing capped
207 brood by shaking the frame over the colony. Once adult bees are cleared away, frames are firmly bumped over a
208 white metal pan by hitting one end of the frame on the side of the pan, turning the frame, re-bumping the frame,
209 and repeating the process once more for a total of four bumps. This process dislodges mites on the surface of
210 the comb, which then can be counted (Pettis et al., 2013).

211 However, Gill et al. (2024) showed that this method could lead to significant brood mortality and was found to be
212 ineffective for detecting *Tropilaelaps*.

213 **1.4. Sticky board-Hive debris examination**

214 ~~A precise~~ Diagnosis of infestation can be made using a sticky board covered with a mesh, such as fly screen, that
215 prevents the bees from removing the dislodged mites. The mesh must be large enough for mites to pass through.

216 Make a sticky board with poster board, cardboard or other white, stiff paper coated with petroleum jelly or other
217 sticky substance (Koeniger et al., 2002; Ostiguy & Sammataro, 2000; ~~Sammataro et al., 2000~~), or use a sheet of
218 sticky shelf paper. Cut the paper to fit the bottom board of a hive. Cut a piece of hardware cloth or screen to fit on
219 top of the sticky board. To keep the bees from cleaning off the board, fold under the outside edges of the screen
220 to raise it off the board, and staple or tape in place.

221 Leave the board in the colony for up to 3 days, collecting and examining the debris for mites. Examination of the
222 debris should preferably be carried out indoors, in a laboratory for example. Indeed, variable light conditions and
223 the need to wear veils made examination of floor inserts in the field an unreliable method for detecting *Tropilaelaps*
224 (Gill et al., 2024). Use a headlamp and a magnifying glass to spot *Tropilaelaps* among the debris and other mites
225 that may be present.

226 Sieving hive debris and then floating mites in ethanol (as sometimes practiced for *Varroa* detection) is not
227 recommended, as it seems to be ineffective for *Tropilaelaps* (Gill et al., 2024).

228 ~~Acaricides are sometimes~~ can be used to knock mites off bees and will appear on the sticky boards.

229 **2. Laboratory identification of the mite**

230 Rapid and reliable diagnosis is crucial to enable implementation of sanitary measures and to avoid spread in non-infested
231 territories. In case of field suspicion, specimens suspected to belong to the genus *Tropilaelaps* should be sent to official
232 laboratories to confirm the diagnosis. Morphological identification should be carried out for primary diagnosis. This method
233 is fast and cheap, not requiring sophisticated equipment. Confirmatory testing may be done using polymerase chain reaction
234 (PCR) for molecular identification of *Tropilaelaps* species.

235 **2.1. Special precautions required for sampling**

236 The specimens to be identified are collected in honey bee hives, for example, in colonies, in batches of bees, or
237 on queen bees) or on bumble bees.

238 Suspect specimens should be killed before submission to the laboratory e.g. in 70% ethanol. Denatured ethanol
239 should not be used where molecular methods are to be used because of possible inhibition of the ~~polymerase~~
240 ~~chain reaction~~ (PCR). Alternatively, samples can be stored overnight at –20°C to kill the specimens.

241 On arrival at the laboratory, packages should be opened in containment conditions. If the specimens are found to
242 be alive on arrival, the submission should be placed at least at –8–70°C for approximately one hour before opening
243 fully. This procedure immobilises the specimens, which can subsequently be stored in 70% ethanol.

244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295

2.2. Morphological identification of *Tropilaelaps* spp.

The method is based on the visual examination of adult mites only, taking into account the morphological characteristics of the adult *Tropilaelaps* mite compared with those of other mite genera commonly found in bee colonies (particularly *V. destructor*). The visual examination described is not sufficient to differentiate amongst the four species of *Tropilaelaps* as they are morphologically very similar (Anderson & Morgan, 2007; Tangjingjai *et al.*, 2003). Species identification can be carried out by PCR and molecular sequencing (see Section B.2.3.).

2.2.1. Equipment and reagents

Classical entomological equipment and materials are required:

- Stereomicroscope
- Compound microscope (1000×)
- Hot plate
- Dishes: glass Petri dishes, porcelain ceramic dishes, watch glass or similar
- Micro-dissecting needle holders equipped with minutien pins and with pins made of fishing line (with the extremity crushed in order to obtain a spoon-like shape)
- Fine-tipped tweezers
- Glass microscope slides (classic and concave) and cover slips
- Hermetically sealed vials
- Lactic acid
- Mounting medium (e.g. Hoyer's medium) and clear nail polish for the long-term conservation of microscopic slides
- Ethanol 70% (avoid denatured ethanol).

2.2.2. Test procedure

All the specimens are placed in a dish and checked for homogeneity using a stereomicroscope. If the specimens are not homogeneous, then each type present is examined separately. ~~Samples for examination should be selected from undamaged mites.~~ Samples are taken using fine-tipped tweezers or needle holders and placed in a dish for further study.

Under the stereomicroscope, the mites are checked for the three primary identification criteria of *Tropilaelaps* spp. (see Table 2 below). If none of the three criteria are met, then further microscopic examination is not pursued.

Note: Evaluate the ratio of mite body length to width by measuring the specimen in dorsal view:

- Use the same magnification to measure length and width
- Measure where the body is widest/longest
- For length, do not include mouthparts and antennae
- For width, do not include legs.

For microscopic examination, the soft tissues must be cleared to reveal the morphological characteristics. Deposit a few drops of lactic acid on a microscope slide (using concave slides for larger specimens). Place the selected specimens on the slide in lactic acid with the needle holders (fishing line equipped) (or with extra-fine tweezers). Using two holders (minutien pin equipped), position the specimens so as to have a ventral view. Place a cover glass over the microscope slide without crushing the mite, avoiding the formation of air bubbles. If possible, carefully press on the cover glass with a tweezer in order to spread open the legs, which are usually curled up beneath the body. Place the slide on a heating plate at approximately 50°C and wait for the lactic acid to have effect (approximately 30 minutes). NB: the liquid should not boil on the slide as this would destroy the specimen.

Examine the slide(s) under the compound microscope at 100×, 200×, and then 400× magnification in order to observe fully the various diagnostic criteria as detailed in Table 2. Comparative observations should be carried out with reference slides or specimens if available. The depth of field viewed may need to vary according to the thickness of the mite's body.

Specimens can be stored at room temperature in a hermetically sealed vial with 70% ethanol. Slides may be kept long term by mounting the mites in Hoyer's medium, allowing to dry for 2–4 weeks at room temperature (depending to room conditions). 2 weeks at 50°C, then sealing the cover slip with clear nail varnish. Drying can be accelerated by using a hot plate (heating at 50°C for 1–2 weeks). For further information on storage and mounting of mites see Diemann *et al.* (2013).

296

2.2.3. Identification criteria for adult *Tropilaelaps* spp.

297

298

299

300

301

302

303

304

Tropilaelaps spp. are visible to the naked eye. It is approximately between 0.6 mm and 1.0 mm long and between 0.4 to 0.5 mm wide. *Tropilaelaps* is smaller than *V. destructor* (Figs. 4-2 and 4-5). If all the morphological characteristics of the adult mite are confirmed (criteria 1 to 9 in Table 2), the result is "positive" confirmation of the identification of *Tropilaelaps* genus. If one or more of the fundamental morphological characteristics (criteria 1 to 9) of *Tropilaelaps* spp. are not present the result is "negative" and the identification of *Tropilaelaps* genus is not confirmed. If the presence or absence of all nine criteria cannot be determined (e.g. due to a damaged sample), the result is "inconclusive" and molecular methods should be used for confirmation.

305

306

Table 2. Criteria for recognising *Tropilaelaps* spp. (Anderson & Roberts 2013; Delfinado & Baker 1961; Smiley 1991; University of Michigan 2014)

307

The following features should be examined:

308

a) The stigmata are tracheal openings;

309

b) The coxa is the first leg segment and connects the leg and the body;

310

c) The peritremes are tubular structures running on from stigmata. They could have a role in respiration;

311

d) The tritosternum is a bristle-like Y-shaped sensory organ located caudally to the gnathosoma (the gnathosoma is the body part of *Acari* that includes the mouthparts and oral aperture);

312

313

e) Reticulated means that it has broken eggshell or fish scale pattern.

	Stereomicroscope	Compound microscope
1. <i>Tropilaelaps</i> has four pairs of legs <u>AND</u> the first pair is vertically aligned, resembling antennae (Fig. 5-6). □ Class <i>Arachnida</i>	X	
2. The body is unsegmented, with a single visible region, due to the fusion of the prosoma (the equivalent of the cephalothorax) and the opisthosoma (or abdomen) into a single mass (Fig. 5-6). □ Subclass <i>Acari</i>	X	
3. The body is longer than wide (as opposed to <i>V. destructor</i>) (Figs. 4-2 and 4-5). The ratio of length to width is greater than 1.3.	X	
4. It has a pair of latero-ventral stigmata between coxa III and IV (Figs. 7-8). □ Order Parasitiforms		400x
5. Presence of elongated peritremes (Fig. 7-8). Presence of a tritosternum (Fig. 7) (optional criterion, difficult to observe). □ Suborder <i>Mesostigmata</i>		200x
6. Elongated epigynial plate, posteriorly rounded or sharp. Triangular-shaped ventrianal plate (Figs. 5-6 and 6-7). <u>Note: the point of the "triangle" is cranially oriented</u> □ Family <i>Laelapidae</i>		100x
7. Elongated epigynial plate, at least twice as long as the ventrianal plate (Figs. 5-6 and 6).		100x or 200x
8. Reticulated sternal plate (Fig. 7-8).		400x
9. Opisthosoma with coarse bristles, thick at the base, on the apical half of the ventral side (Figs. 5-6 and 6-7).		200x
Note: Criteria for distinguishing between males and females: the mobile digit of the male's chelicerae is filiform (spermodactyls) (Fig. 8). The epigynial plate is shorter in the male than in the female (Fig. 8-9). (Anderson & Morgan, 2007)		200x

314





Fig. 5—6. *Tropilaelaps clareae*, female (ventral view).
 Photo by S. Franco, Anses, Sophia Antipolis laboratory.

315



Magnification 100x




Magnification 400x

Fig. 6-7. *Tropilaelaps* sp. (ventral view). Opisthosoma, coarse apical bristles, thick at their base.
 Photos by S. Franco, Anses, Sophia Antipolis laboratory.


316
 317
 318



T. clareae – Magnification 100x




T. clareae, female (ventral view)



Sternal plate and epigynial plate (ventral view)

Reticulated sternal plate



T. clareae – Magnification 200x



Gnathosoma (ventral view)

Tritosternum



T. clareae – Magnification 200x

Fig. 7 — 8. *Tropilaelaps clareae*, anatomy.
Source of the figures: Delfinado & Baker, 1961. Photos by S. Franco, Anses, Sophia Antipolis laboratory.




Fig. 8—9. *Tropilaelaps clareae*, male and female (ventral view).
 Photos by S. Franco, Anses, Sophia Antipolis laboratory.

320

321

2.3. Molecular identification

322

323

324

325

326

327

328

329

330

331

332

333

The morphological identification of *Tropilaelaps* spp. is complicated because of their resemblance to other mites that may be found in hives. In addition, some samples may be difficult to identify using morphological methods due to loss of integrity, and these methods are not applicable to immature stages. As a result, various molecular methods have been developed (Anderson & Morgan, 2007; Del Cont *et al.*, 2021; Tangjingjai *et al.*, 2003) and PCR methods are increasingly used to confirm the suspicion of infestation. The conventional PCR method described below is based on the amplification of a partial sequence of the mitochondrial gene of *Tropilaelaps* spp. which encodes cytochrome oxidase I (COI) (Anderson & Morgan, 2007). The primers COI-TCF1 and COI-TCR2 amplify a fragment of 580 base pairs. The size of PCR products is determined by agarose gel electrophoresis a system separating DNA fragments in comparison with a DNA ladder (molecular weight marker). The primers are not specific could have a limited specificity to *Tropilaelaps* spp. and amplification of the COI gene from other parasites can occur, so it is necessary-recommended to sequence the DNA when a PCR product of the expected size is found.

334

2.3.1. Sample preparation, equipment and reagents

335

336

337

338

339

340

The samples tested are typically about 10 adult mites, kept in > 95% non-denatured alcohol or kept dry. If stored in alcohol they should first be rinsed three times in a large volume of phosphate buffer (50 ml/tube) or simply dry for several minutes on tissue paper before the DNA extraction step. The mites are then transferred to a 1.5 ml microtube. This step is important to avoid inhibition. The mites are ground in 200 µl phosphate buffer using a disposable pellet pestle in the 1.5 ml microtube. Ground samples can be stored frozen at ≤ -16°C.

341

342

343

344

345

346

A conventional PCR detection and analysis system is required. Any suitable methods or kits can be applied for the extraction of DNA, amplification in a thermocycler, followed by electrophoresis on agarose gel. All equipment and materials should be validated for use in the individual laboratory. The usual measures are required to avoid DNA contamination, and procedures should follow the standards set out in Chapter 2.1.2 *Biotechnology advances in the diagnosis of infectious diseases*. Positive and negative controls must be used for all stages.

347

2.3.2. PCR procedure

348

The primers developed by Anderson & Morgan (2007) are as follows:

Name	Sequence
COI-TCF1	5'-CTATCCTCAATTATTGAAATAGGAAC-3'

COI-TCR2

5'-TAGCGGCTGTGAAATAGGCTCG-3'

349 The PCR reaction mixture should follow the manufacturer's instructions for use and storage. Working stock
350 solutions for the primers are prepared with nuclease-free low ethylene diamine tetra-acetic acid (EDTA)
351 TE buffer at the concentration of 20 µM. The stock solutions are stored at -20°C.

352 The PCR reaction mixtures are prepared in a separate laboratory room. All reagents, except the DNA
353 samples, are mixed prior to distribution in each reaction tube. In each PCR test, appropriate controls must
354 be included, including at least a template control (NTC, reagents only), negative controls (i.e. 1 per 10
355 samples tested) and a positive control (plasmid DNA solution including the sequence to be amplified,
356 added to diluted 10 times the detection limit of the PCR [LD_{PCR}]). The amplifications are carried out in a
357 total volume of 20 µl.

358 PCR reagent mixtures are added in a clean room (no pathogens or amplification products should be
359 handled). The conditions above have been defined in the PCR validation steps. Other conditions could be
360 applied after an optimisation.

	Final concentration	Volume for one tube (µl)
Nuclease free H ₂ O	/	12.6
Taq DNA pol (5 U/µl)	0.5 U/µl	0.2
Taq DNA pol buffer (10x)	1x	2.0
MgCl ₂ (50 mM)	3.5 mM	1.3
dNTP mix (10 mM)	450 µM	0.9
COI-TCF1 (20 µM)	500 nM	0.5
COI-TCR2 (20 µM)	500 nM	0.5
Mix total volume		18

361 Add 2 µl of the DNA template (unknown sample or plasmid DNA) or negative control to the reagent mixture
362 to a final volume of 20 µl. DNA samples are prepared and added to the PCR mix in a separate area.

363 An example thermocycler programme is as follows:

Step	Cycle	Temperature (°C)	Time (minutes)
Initial denaturation	1	95	5:00
PCR	35	94	0:30
		58	0:30
		72	0:45
Final extension	1	72	7
Hold		10	∞

364 Optimisation of PCR should be carried out according to the Mastermix and PCR machine used, especially
365 testing with different annealing temperatures.

366 **Detection of amplified products:**

- 367 i) Prepare a 1.2% agarose gel in 1x TAE (Tris-acetate-EDTA) with the appropriate number of wells.
- 368 ii) 2 µl of 6x loading buffer are added to 10 µl of PCR products.
- 369 iii) Load 10 µl of the samples into the wells.
- 370 iv) To control the size of the amplified products, a 100 bp ladder is recommended.
- 371 v) Run the gel.
- 372 vi) Analyse by UV illumination after staining with a suitable DNA stain.

373 The interpretation of the results is based on the presence or absence of the amplified product: the size of
374 the expected PCR product is 580 bp including the two primers. However, the presence of a PCR product
375 of the right size is not sufficient to identify the *Tropilaelaps* genus and species. A sequencing step is
376 required.

377 2.3.3. Sequencing of PCR products

378 If a 580 bp band is detected the PCR product must be sequenced. ~~The method is not described here, and~~
379 ~~can be outsourced.~~ A panel of COI sequences available on NCBI Genbank (~~EF025423 to EF025468 and~~
380 ~~HQ533148 to HQ533159 [Luo et al., 2011])~~ is included in the analysis to construct the phylogenetic tree
381 and to identify the species of *Tropilaelaps*. An outgroup COI sequence from *Varroa destructor* (~~EF025469,~~
382 ~~253947435~~) is included.

383 3. Serological tests

384 Serological tests are not appropriate or relevant to bee colony infestations.

385 C. REQUIREMENTS FOR VACCINES

386 There are no vaccines available.

387 REFERENCES

388 ANDERSON D.L. & MORGAN M.J. (2007). Genetic and morphological variation of bee-parasitic *Tropilaelaps* mites (*Acari:*
389 *Laelapidae*): new and re-defined species. *Exp. Appl. Acarol.*, **43**, 1–24.

390 ANDERSON D.L. & ROBERTS J.M.K. (2013). Standard methods for *Tropilaelaps* mites research. *In:* The COLOSS BEEBOOK,
391 Volume II: Standard methods for *Apis mellifera* pest and pathogen research, Dietemann V., Ellis J.D., Neumann P., eds. *J.*
392 *Apicultural Res.*, **52**, <http://dx.doi.org/10.3896/IBRA.1.52.4.21>.

393 ATWAL A.S. & GOYAL N.P. (1971). Infestations of honeybee colonies with *Tropilaelaps*, and its control. *J. Apic. Res.*, **10**, 137–
394 142.

395 BRANDORF A., IVOILOVA M.M., YAÑEZ O., NEUMANN P. & SOROKER V. (2024). First report of established mite populations,
396 *Tropilaelaps mercedesae*, in Europe. *J. Apic. Res.*, 1–3. <https://doi.org/10.1080/00218839.2024.2343976>

397 BUAWANGPONG N., DE GUZMAN L.I., KHONGPHINITBUNJONG K., FRAKE A.M., BURGETT M. & CHANTAWANNAKUL P. (2015).
398 Prevalence and reproduction of *Tropilaelaps mercedesae* and *Varroa destructor* in concurrently infested *Apis mellifera*
399 colonies. *Apidologie*, **46**, 779–786.

400 BURGETT D.M. & KITPRASERT C. (1990). Evaluation of Apistan™ as a control for *Tropilaelaps clareae* (*Acari: Laelapidae*), an
401 Asian honey bee brood mite parasite. *Am. Bee J.*, **130**, 51–53.

402 BURGETT M., AKRATANAKUL P. & MORSE R.A. (1983). *Tropilaelaps clareae*: a parasite of honeybees in south-east Asia. *Bee*
403 *World*, **64**, 25–28.

404 CHANPANITKITCHOTE P., CHEN Y., EVANS J.D., LI W., LI J., HAMILTON M. & CHANTAWANNAKUL P. (2018). Acute bee paralysis virus
405 occurs in the Asian honey bee *Apis cerana* and parasitic mite *Tropilaelaps mercedesae*. *J. Invertebr. Pathol.*, **151**, 131–136.

406 CHANTAWANNAKUL P., RAMSEY S., ENGELSDORP D., KHONGPHINITBUNJONG K. & PHOKASEM P. (2018). *Tropilaelaps* mite: an
407 emerging threat to European honey bee. *Curr. Opin. Insect Sci.*, **26**, 69–75.

408 COOK V.A. & BOWMAN C.E. (1983). *Mellitiphis alvearius*, a little-known mite of the honeybee colony, found on New Zealand
409 bees imported into England. *Bee World*, **64**, 62–64.

410 DAINAT B., KEN T., BERTHOUD H. & NEUMANN P. (2009). The ectoparasitic mite *Tropilaelaps mercedesae* (*Acari, Laelapidae*)
411 as a vector of honeybee viruses. *Insectes Sociaux*, **56**, 40–43.

412 DE GUZMAN L.I., WILLIAMS G.R., KHONGPHINITBUNJONG K. & CHANTAWANNAKU P. (2017). Ecology, life history, and management
413 of *Tropilaelaps* mites. *J. Econ. Entomol.*, **110**, 319–332.

- 414 DE GUZMAN L.I., PHOKASEM P., KHONGPHINITBUNJONG K., FRAKE A.M. & CHANTAWANNAKUL P. (2018). Successful reproduction of
415 unmated *Tropilaelaps mercedesae* and its implication on mite population growth in *Apis mellifera* colonies. *J. Invertebr.*
416 *Pathol.*, **153**, 35–37.
- 417 DEL CONT A., DE GEORGES B., HULEUX A. & DUQUESNE V. (2021). Rapid identification of *Tropilaelaps* mite (Mesostigmata:
418 *Laelapidae*) species using a COI barcode-HRM. *J. Econ. Entomol.*, **114**, 520–529.
- 419 DELFINADO M.D. & BAKER E.W., (1961). *Tropilaelaps*, a new genus of mite from the Philippines (*Laelapidae*, *Acarina*).
420 *Fieldiana Zoology*, **44**, 53–56.
- 421 DELFINADO-BAKER M. & BAKER E., (1983). A new species of *Neocypholaelaps* (*Acari: Ameroseiidae*) from brood combs of the
422 Indian honey bee. *Apidologie*, **14**, 1–7.
- 423 DIETEMANN V., NAZZI F., MARTIN S.J., ANDERSON D.L., LOCKE B., DELAPLANE K.S., WAUQUIEZ Q., TANNAHILL C., FREY E.,
424 ZIEGELMANN B., ROSENKRANZ P. & ELLIS J.D. (2013). Standard methods for *Varroa* research. In: The COLOSS BEEBOOK,
425 Volume II: Standard methods for *Apis mellifera* pest and pathogen research, Dietemann V., Ellis J.D., Neumann P., eds. *J.*
426 *Apicultural Res.*, **52**, <http://dx.doi.org/10.3896/IBRA.1.52.1.09>.
- 427 FORSGREN E., DE MIRANDA J. R., ISAKSSON M., WEI S., & FRIES I. (2009). Deformed wing virus associated with *Tropilaelaps*
428 *mercedesae* infesting European honey bees (*Apis mellifera*). *Exp. Appl. Acarol.*, **47**, 87–97.
- 429 GAO J., MA S., WANG X., YANG Y., LUO Q., WANG X., LIU F., WANG Q., FU Z., DIAO Q. & DAI P. (2021). *Tropilaelaps mercedesae*
430 parasitism changes behavior and gene expression in honey bee workers. *PLoS Pathogens*, **17**(7).
- 431 GILL M.C., CHUTTONG B., DAVIES P., ETHERIDGE D., PANYARAKSA L., TOMKIES V., TONGE G. & BUDGE G. (2024). Assessment of
432 the efficacy of field and laboratory methods for the detection of *Tropilaelaps* spp. *BioRxiv*, 2024.03.26.586849.
- 433 KHONGPHINITBUNJONG K., DE GUZMAN L.I., BURGETT M.D., RINDERER T.E. & CHANTAWANNAKUL P. (2012). Behavioral responses
434 underpinning resistance and susceptibility of honeybees to *Tropilaelaps mercedesae*. *Apidologie*, **43**, 590–599.
- 435 KHONGPHINITBUNJONG K., DE GUZMAN, L. I., TARVER M. R., RINDERER T. E. & CHANTAWANNAKUL P. (2015). Interactions of
436 *Tropilaelaps mercedesae*, honey bee viruses and immune response in *Apis mellifera*. *J. Apic. Res.*, **54**, 40–47.
- 437 KHONGPHINITBUNJONG K., NEUMANN P., CHANTAWANNAKUL P. & WILLIAMS G.R. (2016). The ectoparasitic mite *Tropilaelaps*
438 *mercedesae* reduces western honey bee, *Apis mellifera*, longevity and emergence weight, and promotes Deformed wing
439 virus infections. *J. Invertebr. Pathol.*, **137**, 38–42.
- 440 KHONGPHINITBUNJONG K., CHANTAWANNAKUL P., YAÑEZ O. & NEUMANN P. (2019). Survival of ectoparasitic mites *Tropilaelaps*
441 *mercedesae* in association with honeybee hive products. *Insects*, **10**, 36.
- 442 KOENIGER G., KOENIGER N., ANDERSON D.L., LEKPRAYOON C. & TINGEK S. (2002). Mites from debris and sealed brood cells of
443 *Apis dorsata* colonies in Sabah, (Borneo) Malaysia, including a new haplotype of *Varroa jacobsoni*. *Apidologie*, **33**, 15–24.
- 444 KONTSCHÁN J., TÓBIÁS I., BOZSIK, G. & SZOCS G. (2015). First record of *Neocypholaelaps apicola* from beehives in Hungary
445 (ACARI: Mesostigmata: Ameroseiidae): Re-description and DNA barcoding. *Acta Zool. Acad. Sci. Hung.*, **61**, 237–245.
- 446 LING T.C., PHOKASEM P., SINPOO C., CHANTAWANNAKUL P., KHONGPHINITBUNJONG K. & DISAYATHANOOWAT T. (2023). *Tropilaelaps*
447 *mercedesae* infestation is correlated with injury numbers on the brood and the population size of honey bee *Apis mellifera*.
448 *Animals*, **13**, 1318.
- 449 LUO Q., ZHOU T., WANG Q., DAI P., WU Y. & SONG H. (2011). Identification of *Tropilaelaps* mites (*Acari, Laelapidae*) infesting
450 *Apis mellifera* in China. *Apidologie*, **42**, 485–498.
- 451 OSTIGUY N. & SAMMATARO D. (2000). A simplified technique for counting *Varroa* sticky boards. *Apidologie*, **31**, 707–716.
- 452 PETTIS J.S., ROSE R., LICHTENBERG E.M., CHANTAWANNAKUL P., BUAWANGPONG N., SOMANA W. & VANENGELSDORP D. (2013). A
453 rapid survey technique for *Tropilaelaps* mite (Mesostigmata: Laelapidae) detection. *J. Econ. Entomol.*, **106**, 1535–1544. Doi:
454 <http://dx.doi.org/10.1603/EC12339>
- 455 PETTIS J.S. & CHAIMANEE V. (2019). The survival of *Tropilaelaps mercedesae* on beehive products. *J. Apicultural Res.*, **58**,
456 413–415.

- 457 RATH W., BOECKING O. & DRESCHER W. (1995). The phenomena of simultaneous infestation of *Apis mellifera* in Asia with the
458 parasitic mites *Varroa jacobsoni* OUD, and *Tropilaelaps clareae* Delfinado and Barker. *Am. Bee J.*, **135**, 125–127.
- 459 RITTER W. & SCHNEIDER-RITTER U. (1988). Differences in biology and means of controlling *Varroa jacobsoni* and *Tropilaelaps*
460 *clareae*, two novel parasitic mites of *Apis mellifera*. In: Africanized Honey Bees and Bee Mites, Needham G.R., Page R.E.
461 Jr., Delfinado-Baker M. & Bowman C.E., eds. Ellis Horwood, Chichester, UK, 387–395.
- 462 SAMMATARO D., GERSON U. & NEEDHAM G.R. (2000). Parasitic mites of honey bees: life history, implications and impact. *Ann.*
463 *Rev. Entomol.*, **45**, 519–548.
- 464 SHRESTHA M., WEGENER J., GAUTAM I., SINGH M., SCHWEKENDIEK M. & BIENEFELD K. (2020). Individual-level comparisons of
465 honey bee (Hymenoptera: Apoidea) hygienic behavior towards brood infested with *Varroa destructor* (parasitiformes:
466 *Varroidae*) or *Tropilaelaps mercedesae* (mesostigmata: Laelapidae). *Insects*, **11**, 1–11.
- 467 SMILEY R.L. (1991). Insect and Mite Pests in Food, an Illustrated Key, Gorham J.R., ed. Food and Drug Administration, United
468 States Department of Agriculture, p. 6.
- 469 TANGJINGJAI W., VERAKALASA P., SITTIPRANEED S., KLINBUNGA S. & LEKPRAYOON C. (2003). Genetic differences between
470 *Tropilaelaps clareae* and *Tropilaelaps koenigerum* in Thailand based on ITS and RAPD analyses. *Apidologie*, **34**, 513–523.
- 471 TRUONG A.T., YOO M.S., YUN B.R., KANG J.E., NOH J., HWANG T.J., SEO S.K., YOON S.S. & CHO Y.S. (2023). Prevalence and
472 pathogen detection of *Varroa* and *Tropilaelaps* mites in *Apis mellifera* (Hymenoptera, Apidae) apiaries in South Korea. *J.*
473 *Apicultural Res.*, **62**, 804–812.
- 474 WILDE J. (2000a). How long can *Tropilaelaps clareae* survive on adult honeybee workers? In: Proceedings of the
475 Euroconference on Molecular Mechanisms of Disease Tolerance in Honeybees (MOMEDITO), held in Kralupy near Prague,
476 Czech Republic, 17–19 October 2000. Bee Research Institute, Dol, Czech Republic, 217–221.
- 477 WILDE J. (2000b). *Varroa destructor* and *Tropilaelaps clareae* in *Apis mellifera* colonies in Nepal. In: Proceedings of the
478 Euroconference on Molecular Mechanisms of Disease Tolerance in Honeybees (MOMEDITO), held in Kralupy near Prague,
479 Czech Republic, 17–19 October 2000. Bee Research Institute, Dol, Czech Republic, 223–238.
- 480 Woyke J. (1987). Length of stay of the parasitic mite *Tropilaelaps clareae* outside sealed honeybee brood cells as a basis
481 for its effective control. *J. Apic. Res.*, **26**, 104–109.
- 482 *
483 * *
- 484 **NB:** There is a WOAHO Reference Laboratory for infestation of honey bees with *Tropilaelaps* spp.
485 (please consult the WOAHO Web site:
486 <https://www.woaho.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3http://www.oie.int/>).
487 Please contact the WOAHO Reference Laboratory for any further information on
488 diagnostic tests and reagents for infestation of honey bees with *Tropilaelaps* spp.
- 489 **NB:** FIRST ADOPTED IN 2004. MOST RECENT UPDATES ADOPTED IN 2018.

490
491
492

Appendix 1: Infestation of honey bees with *Tropilaelaps* spp.

Intended purposes of test: population freedom from infestation; individual animal freedom from infestation prior to movement; contribute to eradication policies; confirmation of clinical cases; prevalence of infestation – surveillance

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<p><u>Field detection of the mite <i>Apis mellifera</i></u></p> <p><u>Bee examination ('wash method' using 'icing sugar roll'): ++ for all purposes</u></p> <p><u>Brood examination: +++ for all purposes</u></p> <p><u>"Bump test": + for 'population freedom from infestation', 'individual animal or bee nest freedom from infestation prior to movement' and 'contribute to eradication policies'; ++ for 'confirmation of clinical cases' and 'prevalence of infestation – surveillance'</u></p> <p><u>Debris</u></p>	<p><u>Sample type: <i>Apis mellifera</i> colonies</u></p> <p><u>Target analytes: <i>Tropilaelaps</i> spp.</u></p>	<p><u>Pettis <i>et al.</i> (2013) study aimed to compare the different methods commonly used in the field to detect <i>Tropilaelaps</i> infestation</u></p> <p><u>The test sensitivity was calculated with two different standards:</u></p> <p><u>i) Infestation verified (i.e. at least one sampling method detected mites);</u></p> <p><u>ii) Universal infestation assumed (i.e. it was assumed that every colony in an apiary with some mites is infested assuming universal infestation of all hives in an infested apiary)</u></p> <p><u>Bee examination (ethanol wash):</u></p> <p><u>i) DSe = 7.8% ;</u></p> <p><u>ii) DSe = 5.2%</u></p> <p><u>Worker brood examination (100 cells examined):</u></p> <p><u>i) DSe = 75.7%;</u></p> <p><u>ii) DSe = 56.7%</u></p> <p><u>Drone brood examination (20 cells examined):</u></p> <p><u>i) DSe = 32%;</u></p> <p><u>ii) DSe = 24.7%</u></p>	<p><u>Pettis <i>et al.</i> (2013) study: Ten <i>Apis mellifera</i> apiaries in Chiang Mai Thailand (236 colonies examined). Note: for debris examination ("drop method") and bee examination ("wash method"), experiments carried out in only three apiaries. Experiments conducted in September 2009</u></p> <p><u>Gill <i>et al.</i> (2024) study: 60 colonies of <i>A. mellifera</i>, sourced from six apiaries in Chiang Mai province Thailand. Each colony was assessed using all four of the field protocols (brood examination, 'bump test', hive debris examination (natural drop) and adult honey bee examination). Period of experiments unknown</u></p>	<p><u>See references</u></p>	<p><u>Debris examination ("drop method"): high sensitivity according to Pettis <i>et al.</i> (2013)</u></p> <p><u>Worker brood examination: high sensitivity (Pettis <i>et al.</i>, 2013), most effective method for <i>Tropilaelaps</i> detection according to Gill <i>et al.</i> (2024)</u></p> <p><u>Adult bee examination based on 'icing sugar roll': non-destructive method, quite efficient, rapid and easily applicable in the field (Gill <i>et al.</i>, 2024)</u></p> <p><u>"Bump test" method: least time-consuming, can be carried out in the field, appropriate for large field surveys</u></p>	<p><u>Debris method: time consuming (required at least two visits on consecutive days to each apiary and careful examination of sticky board insertion), difficult to practice for large-scale screening</u></p> <p><u>Worker brood examination (100 brood cell): time-consuming, induce brood destruction</u></p> <p><u>Adult bee examination (ethanol wash): low sensitivity (Gill <i>et al.</i>, 2024; Pettis <i>et al.</i>, 2013)</u></p> <p><u>"Bump test" method: induce brood destruction but less limited than brood examination (Pettis <i>et al.</i>, 2013), ineffective for <i>Tropilaelaps</i> detection (Gill <i>et al.</i>, 2024)</u></p>	<p><u>Pettis <i>et al.</i> (2013)</u></p> <p><u>Gill <i>et al.</i> (2024)</u></p>

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>examination (“drop method”): ++ for all purposes</u>		<p><u>“Bump test”:</u> i) <u>DSe = 50%;</u> ii) <u>DSe = 36.3%</u></p> <p><u>Debris examination (“Drop method”):</u> i) <u>DSe = 81.3%;</u> ii) <u>DSe = 54.2%</u></p> <p><u>The sensitivities were also evaluated at different infestation rates: minimal, medium, high. The “brood examination” was used to categorise the infestation level of the colonies. See detailed results in Pettis <i>et al.</i> (2013)</u></p> <p><u>Gill <i>et al.</i> (2024) assessed the efficacy of different field and laboratory methods for <i>Tropilaelaps</i> detection based on brood examination, ‘bump test’, hive debris examination (natural drop) and adult honey bee examination. Results indicated that uncapping infested brood with tweezers, catching mite drop using sticky traps and rolling adult bees in icing sugar were significantly more likely to detect <i>Tropilaelaps</i> than methods using an uncapping fork on infested brood, or the brood ‘bump’ method. Uncapping brood with tweezers appeared to be the more robust technique.</u></p>					

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Morphology: +++ for all purposes</u> <u>Apis spp.</u>	<u>Adult mite specimens</u>	<u>Reference tests were conventional PCR, sequencing and morphological analysis by acarologists from other reference laboratories.</u> <u>DSp = 100%</u> <u>DSe = 100%</u>	<u>Tropilaelaps mites from different species and localities (n = 14):</u> <u>*Three samples of <i>T. clareae</i> collected in different localities in the Philippines (Luzon island);</u> <u>*11 samples of <i>T. mercedesae</i> from Indonesia (New Guinea), Sri Lanka and Nepal</u> <u>Mites different from <i>Tropilaelaps</i> spp. detected in honeybee hives in France during apiary inspections (n = 17): <i>Varroa destructor</i>, <i>Varroa jacobsoni</i>, <i>Braula coeca</i>, <i>Neocypholaelaps apicola</i>, <i>Macrocheles</i> spp., <i>Androlaelaps casalis</i>, <i>Stratiolaelaps scimitus</i>, <i>Parasitellus</i> sp.</u> <u>Note:</u> <u>Due to the limited availability of reference material to validate the method, the data was consolidated through a literature review</u>	<u>Validation carried out by Anses Sophia Antipolis Laboratory (validation report submitted to WOA in 2016) and supplemented with additional data</u>	<u>Rapid (less than 1 hour).</u> <u>Does not require sophisticated equipment, or reagents</u> <u>Inexpensive</u> <u>Method recommended for first intention diagnosis</u>	<u>Requires a certain amount of experience and technical skill to handle specimens and identify morphological criteria</u> <u>Differential diagnosis between the four species of <i>Tropilaelaps</i> not possible</u> <u>PCR is highly advisable if there is any doubt about identification</u> <u>If <i>Tropilaelaps</i> is detected in an area presumed to be free of the disease, it is recommended that identification be confirmed by PCR</u>	<u>Data not published at present</u>
<u>Conventional PCR: ++ for all purposes except for 'prevalence of infestation –</u>	<u>Adult and immature mite specimens</u>	<u>Reference test was morphology, HRM-PCR or sequencing</u> <u>DSp = 100%</u> <u>DSe = 100%</u>	<u>Tropilaelaps mites from different species and localities (n = 22):</u> <u>*Three specimens of <i>T. clareae</i> from Philippines</u> <u>*19 specimens of</u>	<u>Validation carried out by Anses Sophia Antipolis Laboratory (validation</u>	<u>High specificity and sensitivity (generally more than morphology)</u> <u>Enables <i>Tropilaelaps</i> species to be identified after sequencing, HRM-</u>	<u>Requires reagents and equipment for conventional PCR detection and analysis system</u> <u>More expensive and</u>	<u>Data not published at present</u>

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>surveillance (+)</u> <u>Apis spp.</u>			<u>T. mercedesae from Pakistan, Indonesia, Sri Lanka, Vietnam and Nepal</u> <u>Mites and pathogens different from Tropilaelaps spp. detected in honeybee hives (n = 17) during apiary inspections (i.e. Varroa destructor, Braula coeca, Neocypholaelaps apicola, Macrocheles spp., Androlaelaps casalis)</u>	<u>report submitted to WOAHA in 2016) and supplemented with additional data</u>	<u>PCR</u> <u>Method recommended for second intention diagnosis</u>	<u>longer than the morphology (> 1 day of analysis)</u> <u>Need for sequencing to identify species (specific equipment and competence or subcontracting)</u>	

REUNIÓN DE LA COMISIÓN DE NORMAS BIOLÓGICAS
París, 9–13 de septiembre de 2024

SECTION 3.3.

AVES

CHAPTER 3.3.1.

AVIAN CHLAMYDIOSIS

SUMMARY

Description and importance of the disease: Avian chlamydiosis (AC) is caused by a Chlamydia species in birds. The taxonomy of the family Chlamydiaceae was recently revisited. The genus Chlamydia currently includes 44–15 recognised species, and among them *C. psittaci*, *C. avium*, *C. abortus*, *C. buteonis* and *C. gallinacea* have been isolated from birds. Among the avian species, *C. psittaci* is the only one with proven zoonotic potential.

Outbreaks of AC in psittacine birds and domestic poultry farms cause considerable economic damage. The infection can lead to systemic and occasionally fatal disease in birds. The clinical signs are generally nonspecific and vary greatly in severity, depending on the species and age of the bird and the virulence of the Chlamydia strain, but respiratory distress is mostly involved. Many birds, especially older psittacine birds and poultry, may show no clinical signs; nevertheless, they may often shed the agent for extended periods.

Special laboratory handling as determined by biological risk analysis (see Chapter 1.1.4 Biosafety and biosecurity: Standard for managing biological risk in the veterinary laboratory and animal facilities) is recommended and, even obligatory in many countries, mandatory for *C. psittaci* strains because avian chlamydial strains of this species can cause serious illness (pneumonia) and death in humans when left untreated.

Detection and identification of the agent: Due to the challenges associated with strain isolation (requirements for well preserved samples, cell culture, secure laboratory), the recommended diagnostic method is polymerase chain reaction (PCR), which provides rapid, sensitive and specific diagnosis. The preferred method for the identification of AC is no longer isolation of the organism. Considering the time involved, the need for high quality samples, the fact that some strains will never grow in vitro and the hazard to laboratory personnel, nucleic acid amplification tests (NAATs) are currently recommended for quick, sensitive and specific diagnosis. These methods include conventional and real-time polymerase chain reaction (PCR), DNA microarray based detection and DNA sequencing. Isolation, Cytological staining of smears of exudate or faeces, and of impression smears of tissues, immunohistochemical staining of cytological and histological preparations and antigen capture enzyme-linked immunosorbent assays (ELISA) can be used if NAATs are not available if PCR cannot be performed.

Serological tests: Serology alone is not particularly useful in diagnosing a current chlamydial infection in birds because of the high prevalence of this infection in birds and the long-term (up to several months) persistence of anti-chlamydial antibodies. In most bird species, there is a high

41 background rate of anti-chlamydial antibodies. Thus, to determine if a single bird is infected, serology
42 should always be used in conjunction with gene or antigen detection, or paired sera should be
43 examined. A positive test is evidence that the bird was infected by the bacterium but does not
44 necessarily indicate an active infection. False negative results can occur in birds with acute infections
45 that are sampled before seroconversion. Treatment with antibiotics may also delay or diminish the
46 antibody response.

47 The main serological methods that are used for detecting chlamydial antibodies are: (1) ~~various~~
48 agglutination ~~methods of elementary body agglutination (EBA)~~, (2) the complement fixation test and
49 (3) enzyme-linked immunosorbent assays (ELISA) ~~is highly sensitive and specific when using~~
50 recombinant proteins/peptides as antigen targets and #can ~~detect IgM, IgG and IgA, but host specific~~
51 conjugates have to be used.

52 **Requirements for vaccines:** ~~There are no commercial vaccines available for avian chlamydiosis~~
53 control in poultry.

54 A. INTRODUCTION

55 1. Description and impact of the disease

56 Avian chlamydiosis (AC) is caused by infection with a *Chlamydia* species in birds. *Chlamydia psittaci* is the most
57 important aetiological agents with a proven pathogenic and zoonotic potential. While it was considered to be the
58 only chlamydial agent in birds for a long time, a number of novel species have been identified in recent years, such
59 as avian *C. abortus*, *C. avium*, *C. buteonis* and *C. gallinacea*. In 2015, the taxonomy of the family *Chlamydiaceae*
60 was revisited by Sachse *et al.* (Sachse *et al.*, 2015). The genus *Chlamydia* currently includes 11 recognised
61 species, namely *C. abortus* (sheep, goats, cattle), *C. caviae* (guinea pigs), *C. felis* (cats), *C. muridarum* (mouse,
62 hamster), *C. psittaci* (birds and others), *C. pecorum* (sheep, cattle), *C. pneumonia* (human and others), *C. suis*
63 (swine), *C. trachomatis* (human) and two recently established species isolated from birds, *C. avium* and
64 *C. gallinacea* (Sachse *et al.*, 2014). While most of these organisms are highly host specific, *C. pneumonia* and
65 *C. psittaci* have a broader host range. The latter has been reported to occur not only in birds and humans, but also
66 in cattle, sheep, swine, horses and other animals. Until very recently, *C. psittaci* was considered to be the sole
67 causative agent of the disease in birds. Originally called psittacosis, the term ornithosis was introduced later to
68 differentiate the disease in domestic and wild fowl from the disease in psittacine birds. The two syndromes are
69 currently considered to be the same (Anderson & Vanrompay, 2008). Their earlier separation was based on the
70 assumption that in humans, ornithosis was a milder disease than psittacosis. However, it should be noted that the
71 disease in humans contracted from turkeys and ducks is often as severe as that contracted from psittacine birds.

72 Infection of birds with *C. psittaci* is common all over the world and has been found in about 465 avian species
73 (Kaleta & Taday, 2003). Outbreaks of AC in psittacine birds and domestic poultry farms cause considerable
74 economic damage. The infection can lead to systemic and occasionally fatal disease in birds. The clinical signs are
75 generally nonspecific and vary greatly in severity, depending on the species and age of the bird and the chlamydia
76 strain. *C. psittaci* AC can produce lethargy, hyperthermia, abnormal excretions, nasal and eye discharges, and
77 reduced egg production. Mortality rates will vary greatly. In pet birds, the most frequent clinical signs are
78 conjunctivitis, anorexia and weight loss, diarrhoea, yellowish droppings, sinusitis, biliverdinuria, nasal discharge,
79 sneezing, lachrymation and respiratory distress. Many birds, especially older psittacine birds and poultry, may show
80 no clinical signs; nevertheless, they may often shed the agent for extended periods. Necropsy of affected birds will
81 often reveal multifocal hepatic necrosis, spleen and liver enlargement, fibrinous airsacculitis, pericarditis and
82 peritonitis (Andersen & Vanrompay, 2008; Vanrompay, 2013). Histological lesions are suggestive of infection but
83 are non-pathognomonic unless there are identifiable chlamydiae present.

84 Until recently, nine different genotypes based on the ompA gene coding for the major outer membrane protein
85 (MOMP) were distinguished within *C. psittaci* strains. Seven of these genotypes are thought to occur predominantly
86 in a particular order or class of Aves and two in non-avian hosts, i.e. genotype A in psittacine birds, B in pigeons,
87 C in ducks and geese, D in turkeys, E in pigeons, ducks and others, E/B in ducks, turkeys and pigeons, F in
88 parakeets, WC in cattle, and M56 in rodents. Most of the avian genotypes have also been identified sporadically in
89 isolates from cases of zoonotic transmission to humans, particularly A, B and E/B (Heddema *et al.*, 2006;
90 Vanrompay *et al.*, 2007). Meanwhile, subgroups for three of the more heterogeneous genotypes have been
91 introduced, i.e. A-VS1, A-6BC, A8455, EB-E30, EB-859, EB-KKCP, D-NJ1, D-9N, and provisional genotypes to
92 cover the strains that were previously non-typable have been suggested (Sachse *et al.*, 2008).

93 Of the other *Chlamydia* species detected in birds, *C. gallinacea* appears to be fairly widespread in poultry, primarily
94 chickens and turkeys, although its presence in other birds is suspected and anecdotally documented. *Chlamydia*
95 *gallinacea* infections are mainly subclinical, although reduced weight gain has been observed in infected chickens

96 (Guo et al., 2016; Heijne et al., 2021). *Chlamydia avium* has been detected in psittacines and pigeons, and can
97 cause respiratory disease, enteritis, anaemia, emaciation and sudden death without prior signs (Sachse et al.,
98 2014). Co-infection with other *Chlamydia* spp. or pathogens may exacerbate the course of the infection. *Chlamydia*
99 *buteonis* has been associated with conjunctivitis, respiratory disease, and death in addition to subclinical carriage
100 in raptors (Laroucau et al., 2019). Recently, avian *C. abortus* has been detected in wild birds and poultry, in most
101 cases without overt disease, but with suspected zoonotic transmission.

102 Antibiotics are the only current treatment. *Chlamydia* is susceptible to a number of antibiotics: the drug of choice
103 varies from country to country. Chlortetracycline, doxycycline, and other tetracyclines are the most commonly used.
104 Treatment must be maintained for an extended period of time. For pet birds, 45 days is often recommended
105 (Vanrompay, 2013).

106 **2. Nature and classification of the pathogen**

107 Members of the *Chlamydiaceae* family are obligate intracellular bacteria with a biphasic life cycle that includes
108 extracellular infectious elementary bodies (EBs) and intracellular metabolically active reticulate bodies (RBs).
109 Replication takes place within a membrane-bound vacuole.

110 Classical genotyping of *C. psittaci* is based on the *ompA* gene, which encodes for the major outer membrane protein
111 (MOMP). The majority of genotypes are thought to occur predominantly in a particular Order or Class of aves and
112 two in non-avian hosts, i.e. genotype A in psittacines, B in pigeons, C in ducks and geese, D in turkeys, E in pigeons,
113 ducks and others, E/B in ducks, turkeys and pigeons, F in parakeets, WC in cattle, and M56 in rodents. Most of the
114 avian genotypes have been associated with human cases, particularly A, B, C and E/B (Heddema et al., 2006).
115 Recently, an analysis of the genomic sequences of *C. psittaci* strains has identified eight major groups that roughly
116 correspond to the *ompA*-based genotypes, and a rapid single nucleotide polymorphism (SNP)-based typing tool
117 now makes it possible to rapidly identify the genotype and therefore the likely origin of contamination (Vorimore et
118 al., 2021).

119 A multi-locus sequence typing (MLST) scheme based on the partial sequences of seven housekeeping genes is
120 available to evaluate the population genetic structure of chlamydiae and the diversity between and within these
121 species (Pannekoek et al., 2010; <https://pubmlst.org/>).

122 Evidence suggests that other chlamydial species, such as *C. abortus*, *C. pecorum*, *C. trachomatis*, *C. suis* and
123 *C. muridarum* can also be harboured by birds (Guo et al., 2016; Pantchev et al., 2009), as well as by the avian
124 species *C. avium* and *C. gallinacea* described by Sachse et al., in 2014. Their epidemiological importance is still
125 unclear, however *C. avium* and *C. gallinacea* appear to be quite widespread in pigeons and psittacines or poultry
126 birds, respectively. The pathogenicity of these two newly introduced species has yet to be systematically
127 investigated. In surveys reported to date, no clinical signs have been observed in chickens carrying *C. gallinacea*
128 (Guo et al., 2016; Laroucau et al., 2009), nor in most of the *C. avium* carriers among pigeons. However, it seems
129 likely from currently available data that *C. avium* is able to cause respiratory disease in parrots and pigeons (Sachse
130 et al., 2014). It is now recommended to do a differential diagnosis and use diagnostic methods that are capable of
131 differentiating between *C. psittaci* and the other species that can be hosted by birds. To date only molecular
132 methods can make this distinction.

133 **4.3. Zoonotic risk and biosafety requirements**

134 The *C. psittaci* strains of avian chlamydiae can infect humans and should be handled with appropriate biosafety
135 and containment procedures (see Chapter 1.1.4 *Biosafety and biosecurity: Standard for managing biological risk in*
136 *the veterinary laboratory and animal facilities*). Risk assessment and management are essential when performing
137 diagnosis of AC. Adequate information, communication, and health surveillance by an occupational physician are
138 recommended.

139 Most infections occur through inhalation of infectious aerosols. While the disease from psittacine birds is best
140 known, the infection in poultry is of particular concern as transmission to humans is common during handling and
141 slaughter of the birds (Dickx et al., 2010; Lagae et al., 2014). Post-mortem examinations of infected birds and
142 handling of cultures should be done in certified Class II laminar flow hoods biosafety cabinet whenever possible or
143 with proper protective equipment. Appropriate zoonotic agent decontamination procedures should be followed
144 because human infection can result from transient exposures. The incubation period is usually 5–14 days; however,
145 longer incubation periods are known. Human infections vary from inapparent to severe systemic disease with
146 interstitial pneumonia and encephalitis. The disease is rarely fatal in properly treated patients; ~~therefore so~~
147 ~~awareness of the danger and early diagnosis are important.~~ Infected ~~humans individuals~~ typically develop
148 headache, chills, malaise and myalgia, with or without signs of respiratory involvement. Pulmonary involvement is
149 common. ~~However, auscultatory findings, however,~~ may appear to be normal or to may underestimate the extent
150 of involvement. ~~Diagnosis can be difficult and in the past was usually established through testing paired sera for~~
151 ~~antibodies to chlamydia by the complement fixation test (CFT). However, some patients remain seronegative though~~

152 hospitalised with psittacosis; serology Serological diagnosis is now therefore being replaced by nucleic acid
 153 amplification tests (NAATs) polymerase chain reaction (PCR), which also allows the bird avian source to be traced.
 154 In humans, tetracycline, doxycycline, or azithromycin are usually the drugs of choice unless contraindicated. The
 155 length of treatment will vary varies with the drug, but should be continued for at least 14 days for tetracycline.

156 **4. Differential diagnosis**

157 The differential diagnosis can be salmonellosis (see Chapter 3.10.3 Salmonellosis) in the case of diarrhoea and
 158 mycoplasma infections (see Chapter 3.3.5 Avian mycoplasmosis [*Mycoplasma gallisepticum*, *M. synoviae*]) in the
 159 case of rhinitis. As multiple species can be involved in avian chlamydiosis, it is recommended to use diagnostic
 160 methods that are capable of differentiating between *C. psittaci* and the other species. To date only molecular
 161 methods can make this distinction.

162 **B. DIAGNOSTIC TECHNIQUES**

163 Table 1. Test methods available for the diagnosis of avian chlamydiosis and their purpose

Method	Purpose					
	Population freedom from infection ^(a)	Individual animal freedom from infection prior to movement ^(b)	Contribute to eradication policies	Confirmation of clinical cases ^(c)	Prevalence of infection – surveillance ^(d)	Immune status in individual animals or populations post-vaccination
<u>Detection and identification of the agent</u>						
Conventional PCR	–	–	–	++	+	–
Real-time PCR	–	–	–	+++	++	–
DNA microarray	–	–	–	++	+	–
Cytological staining	–	–	–	+	–	–
Isolation in cell culture or embryonated eggs	–	–	–	++	+	–
IHC on fixed tissue	–	–	–	++	–	–
<u>Detection of immune response</u>						
<u>ELISA</u>	<u>++</u>	<u>±</u>	<u>≡</u>	<u>±</u>	<u>++</u>	<u>≡</u>
CFT	+	+	–	+	+	–
ELISA	++	+	–	+	++	–

164 Key: +++ = recommended for this purpose; ++ recommended but has limitations;
 165 + = suitable in very limited circumstances; – = not appropriate for this purpose.
 166 PCR = polymerase chain reaction; IHC = immunohistochemistry; CFT = complement fixation test;
 167 ELISA = enzyme-linked immunosorbent assay.
 168 ^(a)See Appendix 1 of this chapter for justification table for the scores given to the tests for this purpose.
 169 ^(b)See Appendix 2 of this chapter for justification table for the scores given to the tests for this purpose.
 170 ^(c)See Appendix 3 of this chapter for justification table for the scores given to the tests for this purpose.
 171 ^(d)See Appendix 4 of this chapter for justification table for the scores given to the tests for this purpose.

172 **1. Detection and identification of the agent**

173 The preferred method for the identification of AC is no longer isolation of the organism. Considering the time
 174 involved, the need for high-quality samples, ~~the fact that some strains will never grow *in vitro*~~ and the hazard to
 175 laboratory personnel, NAATs molecular techniques are currently recommended for quick, sensitive and specific
 176 diagnosis. These include conventional and real-time polymerase chain reaction (PCR), DNA microarray based
 177 detection and DNA sequencing. Isolation, cytological staining of smears of exudate or faeces, and of impression
 178 smears of tissues, immunohistochemical staining of cytological and histological preparations ~~and antigen capture~~
 179 enzyme-linked immunosorbent assays (ELISA) can be used if ~~NAATs are not available~~ PCR methods cannot be
 180 performed.

181 The ~~samples-specimens~~ to be collected will depend on the disease-signs in evidence of the disease. Specimens
182 from acute cases should include inflammatory or fibrinous exudates in or around organs that display showing
183 lesions, ocular and nasal exudates, impression smears of liver, whole blood, and tissue samples from kidney, lung,
184 pericardium, spleen, and liver. In cases with of diarrhoea, colon-intestinal contents or excrement should faeces can
185 be used tested. In live birds, cloacal, the preferred samples are pharyngeal and nasal swabs are the preferred
186 samples. Intestinal excrement, cloacal swabs Faeces, conjunctival scrapings, and peritoneal exudates can also be
187 taken collected.

188 1.1. Molecular methods—detection of nucleic acids

189 PCR techniques have replaced isolation for the detection of chlamydiae from animal tissues.

190 *Chlamydia psittaci* can be identified detected and subtyped genotyped using: (1) species-specific
191 conventional PCR; (2) real-time PCR (reviewed in Sachse et al., 2009); (3) *ompA* sequencing (Sachse
192 *et al.*, 2008); (4) multi-locus sequence typing (MLST) (Pannekoek *et al.*, 2010) or (5) PCR-HRM (high
193 resolution melting) genotyping (Vorimore et al., 2021); and (5) DNA microarray (Sachse et al., 2005,
194 2008).

195 As mentioned above, *C. psittaci* is not the only chlamydial agent encountered in birds. If a
196 Chlamydiaceae-specific PCR or immunohistochemistry test is positive, but a species-specific test for
197 C. psittaci is negative, the newly described Chlamydial agents species described by Sachse et al. in
198 2014 have to be taken into consideration should be considered. Species-specific real-time PCRs are
199 available for their specific detection (Zocevic et al., 2013 [C. avium], Laroucau et al., 2015 [C. gallinacea],
200 Laroucau et al., 2019 [C. buteonis]) as well as for the detection of avian C. abortus strains (Aaziz et al.,
201 2023). when a given avian sample is positive in a general chlamydial test, e.g. *Chlamydiaceae*-specific
202 PCR or immunohistochemistry, but negative in a species-specific test for *C. psittaci*. In such a case,
203 partial or complete sequencing of the *ompA* gene and the rRNA operon or alternative species-specific
204 PCR assays or whole genome sequencing, will reveal the identity of the strain. The occurrence of
205 *Chlamydia* strains that are phylogenetically in between *C. psittaci* and *C. abortus* has also been
206 described (Pannekoek *et al.*, 2010; Van Loock *et al.*, 2003), and should likewise be considered as a
207 possible differential diagnosis.

208 Reagents designed to stabilise the DNA should be considered when a delay in processing the sample is
209 anticipated (DeGraves *et al.*, 2003). DNA samples can be prepared using inexpensive reagents or
210 commercially available kits. Risk of infection to laboratory staff is avoided by inactivating the sample prior
211 to testing or by handling under a Class II biosafety cabinet.

212 1.1.1. Conventional polymerase chain reaction

213 PCR techniques have been replacing isolation for the detection of chlamydiae from animal tissue.
214 Infection risks to laboratory staff are avoided by inactivation of the sample prior to testing. The
215 sensitivity of conventional PCR assays will usually exceed that of isolation. Current Conventional
216 PCR tests assays for the detection of C. psittaci target the 16S–23S rDNA or the ompA gene
217 (reviewed in Sachse et al., 2009), but sensitivity and specificity vary depending on sample
218 preparation and the PCR test used, but are considered inferior when compared with quantitative
219 real-time PCR assays. Sensitivity is can be increased by targeting a relatively short DNA segment
220 fragments or using a nested procedure. However, there is the risk of contamination if extreme
221 care is strict precaution are not taken when manipulating the reactions PCR products (see
222 Chapter 1.1.6 Validation of diagnostic assays for infectious diseases of terrestrial animals).

223 No conventional PCR assays have been developed to detect the newly described avian species.

224 1.1.2. Real-time PCR

225 Real-time PCR has become is the preferred method in diagnostic laboratories for because of its
226 speed, its rapidity, high throughput, potential for quantification and ease of standardisation
227 (Sachse *et al.*, 2009). This technology requires a fluorescent-labelled probe and a special
228 equipment, which increases costs. Its sensitivity can be equivalent to that of the nested system,
229 but contamination problems and labour are reduced as it is based on one a single reaction in a
230 closed system.

231 A hierarchical approach is recommended for the detection and identification of *C. psittaci* DNA.
232 Such an approach includes a *Chlamydiaceae*-specific screening PCR based on the sequences
233 of 23S-rRNA in positive cases (DeGraves *et al.*, 2003; Ehrlich *et al.*, 2006; Everett *et al.*, 1999),
234 followed by a *C. psittaci*-specific PCR assays based on sequences of the outer membrane protein
235 (OmpA) (Pantchev *et al.*, 2009) or on a C. psittaci-specific gene sequence allowing a clear

236 separation from phylogenetically close *C. abortus* strains (Angen *et al.*, 2021). This latter PCR
 237 system has been shown to have a higher specificity than the *ompA*-based system or of the *incA*
 238 gene (Ménard *et al.*, 2006). Minor groove binding (MGB) probes are used to rule out cross-
 239 reactions with *C. abortus*.

240 Commercial PCR kits for the detection of *C. psittaci* for human and veterinary samples are
 241 available.

242 Table 2. Examples of validated and published real-time PCR assays
 243 for screening and species identification of *C. psittaci*

<u>Reference</u>	<u>Ehricht <i>et al.</i> (2006)</u>	<u>Pantchev <i>et al.</i> (2009)</u>	<u>Angen <i>et al.</i> (2021)</u>
<u>Specificity</u>	<u><i>Chlamydiaceae</i></u>	<u><i>C. psittaci</i></u>	<u><i>C. psittaci</i></u>
<u>Target</u>	<u>23S rRNA</u>	<u><i>ompA</i></u>	<u>CDS CPSIT_RS03505</u>
<u>Amplicon size</u>	<u>111 bp</u>	<u>76 bp</u>	<u>91 bp</u>
<u>Primer forward 5'–3'</u>	<u>CTG-AAA-CCA-GTA-GCT-TAT-AAG-CGG-T</u>	<u>CAC-TAT-GTG-GGA-AGG-TGC-TTC-A</u>	<u>CGA-GGC-ATC-TTG-TAG-TAG-AGA-A</u>
<u>Primer reverse 5'–3'</u>	<u>ACC-TCG-CCG-TTT-AAC-TTA-ACT-CC</u>	<u>CTG-CGC-GGA-TGC-TAA-TGG</u>	<u>ATT-ATC-GGC-ACT-ACT-TCT-AAC-A</u>
<u>Probe 5'–3'</u>	<u>FAM-CTC-ATC-ATG-CAA-AAG-GCA-CGC-CG-TAMRA</u>	<u>FAM-CGCTACTTGGTGTGAC-BHQ1 (MGB)</u>	<u>FAM-AAA-CTA-CCC-TCC-TCA-GGG-ACC-ACT-TAMRA</u>
<u>Cycling conditions</u>	<u>95°C/10 minutes 45 x (95°C/15 seconds, 60°C/60 seconds)</u>	<u>95°C/10 minutes 45 x (95°C/15 seconds, 60°C/60 seconds)</u>	<u>95°C/10 minutes 45 x (95°C/15 seconds, 60°C/60 seconds)</u>

244 For greater sensitivity, real-time PCR protocols are recommended. However, a conventional PCR method,
 245 originally developed for improved detection of *C. abortus* in ruminants, has also been shown to detect *C. psittaci* strains.
 246 This method targets the *pmp* gene family, producing amplification products of approximately 300 bp. The primers used are:
 247 *CpsiA*: 5'-ATG-AAA-CAT-CCA-GTC-TAC-TGG-3', *CpsiB*: 5'-TTG-TGT-AGT-AAT-ATT-ATC-AAA-3'. The PCR cycle involves
 248 denaturation at 94°C for 30 seconds, annealing at 50°C for 1 minute, and extension at 72°C for 2 minutes. A final incubation
 249 step at 72°C for 10 minutes is then performed (Laroucau *et al.*, 2007).

250 The protocol of the *ompA*-based *C. psittaci*-specific assay (Pantchev *et al.*, 2009) is given in more
 251 detail below. The assay is conducted as a duplex amplification that includes an internal
 252 amplification control (IAC). A detection limit of 2 inclusion-forming units per reaction mix was
 253 determined.

254 i) The *C. psittaci*-specific oligonucleotides are primers CppsOMP1-F (5'-CAC-TAT-GTG-
 255 GGA-AGG-TGC-TTC-A-3') and CppsOMP1-R (5'-CTG-CGC-GGA-TGC-TAA-TGG-3'), as
 256 well as MGB[®] probe CppsOMP1-S (FAM-CGC-TAC-TTG-GTG-TGA-C-TAMRA). The IAC
 257 system includes primers EGFP1-F (GAC-CAC-TAC-CAG-CAG-AAC-AC) and EGFP10-R
 258 (CTT-GTA-CAG-CTC-GTC-CAT-GC), as well as TaqMan probe EGFP-HEX (HEX-AGC-
 259 ACC-CAG-TCC-GCC-CTG-AGC-A-BHQ1). Plasmid IC2 (available commercially) serves as
 260 the IAC template.

261 ii) The amplification is conducted in 96-well microtitre plates on an Mx3000P thermocycler or
 262 comparable equipment. Each 25- μ l reaction contains 12.5 μ l of 2 x universal real-time PCR
 263 Master Mix. The final concentration is 0.8 μ M for each *C. psittaci* primer, 0.4 μ M for each
 264 IAC primer, and 0.2 μ M for each probe.

265 iii) IAC template DNA (500 copies) is added to each reaction before the final volume is made
 266 up with water.

267 iv) The following cycling parameters are used: initial heating cycle at 95°C for 10 minutes
 268 (single denaturation step), 45 cycles of 95°C for 15 seconds and 60°C for 1 minute
 269 (annealing and extension).

270 v) The cycle threshold value (Ct = Cq quantification cycle) automatically calculated by the
 271 software should be used. Cq values of 35 or lower are considered as positive. Cq values
 272 higher than 35 should be treated with caution as they may represent cross-reaction with

273 related microorganisms. In such cases, the samples should be re-examined, preferentially
274 by alternative tests using different genomic targets (Ménard *et al.*, 2006; Opota *et al.*, 2015).
275 Samples can also be re-tested in the real-time PCR. In this case, only repeatedly positive
276 samples are judged as true positive.

277 Other *ompA*-based real-time PCR protocols were developed to differentiate between genotypes
278 of *C. psittaci* (Geens *et al.* 2005, Heddema *et al.*, 2015). The latter PCR is also validated for use
279 on human samples in case of a zoonotic infection and thus helpful to trace chains of zoonotic
280 transmission.

281 Real-time PCR protocols are available for the specific detection of *C. avium* (Zocovic *et al.*, 2013)
282 and *C. gallinacea* (Laroucau *et al.*, 2015) species.

283 **1.1.3. DNA microarray**

284 DNA microarray technology was shown to be a powerful tool in the diagnosis of chlamydial
285 infections (Sachse *et al.*, 2005). The assay for detection and identification of *Chlamydiaceae* spp.
286 is based on PCR amplification of the 23S rRNA gene and subsequent identification of *C. psittaci*
287 and the other avian agents *C. avium* and *C. gallinacea* by hybridisation with species-specific
288 probes. It has been validated and proved suitable for routine diagnosis (Borol *et al.*, 2008). This
289 methodological approach enables detection of mixed chlamydial infections and identification of
290 unexpected chlamydial species directly from clinical samples. An extended version of the DNA
291 microarray allows for *ompA*-based genotyping of *C. psittaci* strains and clinical samples (Sachse
292 *et al.*, 2008).

293 **1.2. Direct visualisation – cytological staining**

294 Chlamydiae can be detected in smears of cloacal or conjunctival swabs and in impression smears of tissues
295 (lung, liver, spleen, kidney and airsacs if enough material is available) by cytological staining such as Giemsa,
296 Giménez, modified Giménez, Ziehl–Neelsen and Macchiavello's stains (Campbell *et al.*, 2015). The modified
297 Giménez technique is most often used (Andersen & Vanrompay, 2008). However, none of the stains
298 specifically detects chlamydia. They are all less sensitive than antibody-based antigen detection methods or
299 specific NAATs molecular techniques. Therefore, use of a cytological staining is losing popularity.

300 **1.2.1. Modified Giménez staining**

- 301 i) Reagents
- 302 a) Solution 1
- 303 Distilled H₂O (450.0 ml) and phenol (5.0 ml) added to basic fuchsin (2.5 g) and 95% ethanol
304 (50.0 ml). Incubate at 37°C for 48 hours. Filter and store in the dark at room temperature.
- 305 b) Solution 2
- 306 Na₂HPO₄ (11.65 g); Na₂HPO₄.H₂O (2.47 g); distilled H₂O, pH 7.5 (to 1.0 litre).
- 307 c) Solution 3
- 308 Solution 1 (20.0 ml); and solution 2 (25.0 ml). Let stand for 10 minutes, filter and use.
- 309 d) Solution 4
- 310 0.5% citric acid.
- 311 e) Solution 5
- 312 Fast green (0.2 g); distilled H₂O (100.0 ml); and glacial acetic acid (0.2 ml).
- 313 f) Solution 6
- 314 Solution 5 (20.0 ml); and distilled H₂O (50.0 ml).
- 315 ii) Procedure for smears
- 316 a) Fix in methanol for 5 minutes.
- 317 b) Stain in solution 3 for 10 minutes and rinse in tap water.
- 318 c) Counterstain in solution 6 for 2 minutes.

-
- 319 d) Rinse in tap water and air-dry.
- 320 iii) Procedure for paraffin sections
- 321 a) Deparaffinise and hydrate with distilled H₂O.
- 322 b) Stain in solution 3 for 10 minutes and rinse in tap water.
- 323 c) Dip in solution 4 until no more red runs out of the section. Rinse in tap water.
- 324 d) Counterstain in Solution 6 for 20 dips.
- 325 e) Dip in two changes of 95% alcohol, for five dips each. Dehydrate, clear, and mount.
- 326 Note: a shorter procedure with “ready to use” carbol fuchsin (1/10 in distilled water), acetic acid
327 (0.1%) and malachite green counterstain (0.8%) is also available (Vanrompay *et al.*, 1992).
328 Chlamydiae will appear red against a green background.

329 1.3. Isolation in cell culture

330 1.3.1. Treatment of samples for isolation

331 Proper handling of clinical samples is necessary to prevent loss of infectivity of chlamydiae during
332 shipping and storage. A special medium consisting of sucrose/phosphate/glutamate (SPG) was
333 developed for rickettsiae and has proven to be satisfactory for transport of chlamydial field
334 samples. The medium as recommended for chlamydiae consists of SPG buffer: sucrose
335 (74.6 g/litre); KH₂PO₄ (0.52 g/litre); K₂HPO₄ (1.25 g/litre); L-glutamic acid (0.92 g/litre), and
336 bovine serum albumin – fraction V (1 g/litre), which can be sterilised by filtering. Added to this are
337 streptomycin, vancomycin, (25-100 µg/ml), amphotericin B and gentamicin (50 µg/ml each). The
338 addition of antibiotics reduces the effect of contamination, even when samples are shipped at
339 ambient temperatures. The organism remains viable for several days even in the absence of
340 refrigerative storage. This medium can also be used as a laboratory diluent and for freezing of
341 chlamydiae.

342 Contaminated samples must be pre-treated before being used to inoculate cell cultures. There
343 are three basic methods: treatment with antibiotics, treatment with antibiotics together with low-
344 speed centrifugation (Andersen & Vanrompay, 2008), and treatment with antibiotics with filtration
345 (Andersen & Vanrompay, 2008). A number of antibiotics that do not inhibit chlamydia can be
346 used. Samples are homogenised in phosphate buffered saline (PBS), pH 7.2, containing a
347 maximum of the following: streptomycin, vancomycin (100 µg/ml each), and gentamicin (50–
348 200 µg/ml). Amphotericin B or nystatin (50 µg/ml each) can be added to control yeast and fungal
349 growth. Penicillin, tetracycline and chloramphenicol should be avoided as these inhibit the growth
350 of chlamydiae. ~~In some cases, for example porcine faecal samples, treatment with penicillin G
351 (500 IE/ml) can be useful.~~

352 When contamination is light, samples should be homogenised in the antibiotic solution prior to
353 inoculation into tissue cultures. Samples are often left to stand in the antibiotic solution for
354 24 hours at 5°C before inoculation. Heavily contaminated samples, such as faecal samples,
355 should be homogenised in antibiotics and then centrifuged at 500 **g** for 20 minutes. The surface
356 layer and the bottom layer are discarded. The supernatant fluid is collected and recentrifuged.
357 The final supernatant fluid is used for inoculation. Samples should be passed through a filter of
358 450–800 µm average pore size if contamination persists.

359 Cell cultures are the most convenient method for the isolation of *C. psittaci*. The most common
360 cell lines are buffalo green monkey (BGM), McCoy, HeLa, African green monkey kidney (Vero),
361 and L cells (Vanrompay *et al.*, 1992). The cells are grown as monolayers using standard tissue
362 culture media containing 5–10% fetal calf serum and antibiotics that are not inhibitory to chlamydia
363 (as described previously).

364 When selecting cell culture equipment, it is important to remember that:

- 365 i) Chlamydiae can be identified by PCR, direct or indirect immunofluorescence, or some other
366 appropriate staining technique;
- 367 ii) The inoculum is usually centrifuged on to the monolayer to enhance its infectivity;
- 368 iii) The sample may need to be blind passaged at 4–5 days to increase sensitivity of isolation;
- 369 iv) The sample will need to be examined from two to three times during any one passage; and

370 v) Chlamydiae can be infectious to humans.

371 Small flat-bottomed vials, such as 1-dram (3.7 ml, 15 x 45 mm) shell vials or bottles containing
372 cover-slips that are 12 mm in diameter, will meet these requirements. A number of vials, often
373 four to six, are inoculated with each sample to permit fixing and staining at various intervals, and
374 to permit repassaging of apparently negative samples 6 days after inoculation. When testing
375 multiple samples, 24-well multiwell dishes can also be used as they have a labour-saving
376 advantage. However, it should be noted that cross-contamination between samples can be a
377 problem.

378 Chlamydiae can be isolated from cells that are replicating normally, but the use of non-replicating
379 cells is preferable as these may provide increased nutrients for the growth of chlamydiae.
380 Suppressed cells can also be observed for longer periods. Host cell division can be suppressed
381 by cytotoxic chemicals, such as cycloheximide, which can be added to the medium at the rate of
382 0.5–2.0 µg/ml at the time of inoculation of the monolayer (Andersen & Vanrompay, 2008). A
383 similar cytostatic effect that will enhance the growth of most chlamydial strains is reached by the
384 use of serum-free tissue culture medium.

385 Attachment of chlamydia to cells is increased by centrifuging the inoculum on to the monolayer
386 at 2000–3500 *g* for 30–90 minutes at 37°C. After a 2-hour incubation period at 37°C and 5% CO₂,
387 the inoculum is removed and replaced with serum-free or cycloheximide-containing tissue culture
388 medium, and cultures are incubated at 37–39°C. Cultures must be examined for chlamydiae at
389 regular intervals using an appropriate staining method. This is usually done on day 2 or 3, as well
390 as on day 4 or 5. Cultures that appear to be negative at the fifth day are harvested and
391 repassaged. When repassaging chlamydiae, cells and culture media should be passaged without
392 using freeze–thawing to disrupt cells, as this will destroy the chlamydiae.

393 Before staining the cultures, the medium is first removed, the cultures are washed with PBS and
394 fixed with acetone or methanol for 2–10 minutes. The fixation time will depend on the tissue
395 culture vessel used. As acetone will soften most plastics, the use of a mixture of 50% acetone
396 and 50% methyl alcohol may be preferable. A number of staining methods can be employed to
397 demonstrate chlamydial inclusions. The preferred method is direct immunofluorescence
398 (Andersen & Vanrompay, 2008). A chlamydial fluorescein-conjugated antiserum is applied to the
399 infected cells and incubated in a humid chamber for 30 minutes at 37°C. The cover-slips are then
400 washed three times with PBS, mounted immediately, and examined. Chlamydial inclusions
401 fluoresce in green. Commercial conjugate preparations using monoclonal antibodies (MAbs) are
402 available and are highly specific. Conjugates may also be prepared from polyclonal sera, but it is
403 important to obtain specific, high-titred antisera. Polyclonal antisera can be prepared in rabbits,
404 guinea-pigs, sheep or goats. Conjugates are then prepared using standard techniques (Andersen
405 & Vanrompay, 2008). Chlamydial inclusions can also be demonstrated by indirect fluorescent
406 antibody and immunoperoxidase techniques (Andersen & Vanrompay, 2008). Direct staining can
407 be done with Gimenez (see Section B.1.2.1), Giemsa, Ziehl–Neelsen, or Macchiavello's stains.
408 Except for immunofluorescence, all these stains have the advantage that standard light
409 microscopes can be used.

410 1.4. Isolation in embryonated eggs

411 Chicken embryos are still used for the primary isolation of chlamydiae. Samples should be handled and pre-
412 treated with antibiotics as described in Section B.1.3. The standard inoculation procedure is to inject up to
413 0.5 ml of inoculum into the yolk sac of a specific pathogen free 6- to 7-day-old embryo (Andersen &
414 Vanrompay, 2008). The eggs are then incubated in a humid atmosphere at 39°C, rather than at 37°C, as
415 multiplication of chlamydiae is greatly increased at the higher temperature. Replication of the organism usually
416 causes the death of the embryo within 3–10 days. If no deaths occur, two additional blind passages are usually
417 made before designating any sample as negative. Chlamydial infections will give rise to a typical vascular
418 congestion of the yolk sac membranes. These are harvested and homogenised as a 20% (w/v) suspension in
419 SPG buffer, and can be frozen to preserve the strain, or inoculated into eggs or on to cell cultures.

420 The organism can be identified by preparing an antigen from an infected yolk sac and testing it by PCR, direct
421 staining of smears using appropriate stains or by using the antigen in a serological test or by
422 immunofluorescence. Cell culture monolayers can be inoculated with the yolk sac suspension and examined
423 by direct immunofluorescence 48–72 hours later for the presence of chlamydial inclusions. Typical inclusions
424 are intracytoplasmic round or hat-shaped bodies. With some virulent strains, the inclusions rapidly break up
425 and the chlamydial antigen is dispersed throughout the cytoplasm.

426 **1.5. Antigen detection**

427 **1.5.1. Immunohistochemical staining**

428 Immunohistochemical staining can be used to detect chlamydiae in cytological and histological
429 preparations and is an indispensable tool to show the association of chlamydial agents and
430 pathological lesions in tissues. The technique is more sensitive and specific than histochemical
431 staining. Antigen detection can be performed using commercially available anti-*Chlamydia*
432 antibodies directed against LPS or MOMP (major outer membrane protein).

433 The selection of the primary antibody is very important. Both polyclonal and monoclonal
434 antibodies have been used. Because formalin affects chlamydial antigens, it is recommended that
435 polyclonal antibodies be made to purified formalin-inactivated chlamydiae. The chlamydial strain
436 used is not important, as the antibodies will be reactive mainly to the group-specific antigens.
437 MAbs should also be selected for reactions to formalin-fixed chlamydiae. A pool of group-reactive
438 MAbs can be used.

439 **1.5.2. Enzyme-linked immunosorbent assays**

440 ~~The ELISA has been extensively promoted in kit format for use in the diagnosis of human chlamydiosis.
441 These test kits detect the lipopolysaccharide (LPS) antigen (group reactive) and will detect all species of
442 *Chlamydiaceae*. A number of these kits have been tested for use in detecting chlamydiae in birds
443 (Vanrompay *et al.*, 1994), but none of the kits has been licensed for detection of *C. psittaci*. One problem
444 with some of these tests is that the chlamydial LPS shares some epitopes with other Gram-negative
445 bacteria, and these epitopes can cross-react, resulting in a high number of false-positive results. This
446 problem has been reduced or eliminated in more recently developed kits by careful selection of the MAbs
447 used. These kits, however, still lack sensitivity because a few hundred organisms are still needed to give
448 a positive reaction. Most diagnosticians believe that a diagnosis of AC can be made when a strong
449 positive ELISA reaction is obtained from birds with signs of psittacosis. Because of the number of false-
450 positive results, a positive in an individual bird without signs of disease is not considered to be significant,
451 but indicates the need for further testing using different methods.~~

452 **2. Serological tests**

453 Serology alone is not particularly useful in diagnosing a current chlamydial infection in birds because of the high
454 prevalence of this infection in birds and the long-term (up to several months) persistence of antichlamydial
455 antibodies. In most bird species, there is a high background rate of antichlamydial antibodies in birds. Thus, to
456 determine if a single bird is infected, serology should always be used in conjunction with antigen or gene detection,
457 or paired sera should be examined (Vanrompay, 2013). However, obligatory examination of paired sera removes
458 serology from immediate clinical relevance. A positive test is evidence that the bird was infected by the bacterium
459 but does not necessarily indicate an active infection. False negative results can occur in birds with acute infections
460 that are sampled before seroconversion. Treatment with antibiotics also may delay or diminish the antibody
461 response. The main serological methods that are being used for detecting chlamydial antibodies are: (1) ~~various~~
462 ~~methods of elementary body agglutination (EBA),~~ (2) the enzyme-linked immunosorbent assay (ELISA) ~~CFT~~ and
463 (3) enzyme-linked immunosorbent assay (ELISA) ~~CFT~~.

464 EBA-Agglutination tests detect primarily IgM antibodies and thus can detect early infections. A negative result does
465 not guarantee that a bird is free of infection because the sensitivity of the test is rather low. The direct CFT detects
466 avian IgG but not IgM, so recent infections can be 'missed'. Its disadvantages are that: (1) the test antigens are not
467 commercially available, (2) the test cannot be used for testing sera from avian species whose immunoglobulins do
468 not fix complement, (3) it is only relatively sensitive, (4) it cannot be used to differentiate between IgG and IgM
469 antibodies, and (5) it is fairly laborious when there is a large number of samples to be tested. The modified CFT is
470 more sensitive but has the same disadvantages as the CFT.

471 The CFT is ~~more and more~~ being replaced by highly sensitive and specific ELISAs based on the use of recombinant
472 proteins (Verminnen *et al.*, 2006) or peptide antigens (Sachse *et al.*, 2009). ELISAs can detect avian IgM, IgG and
473 IgA as long as the correct isotype-specific conjugate is used.

474 **2.1. Recombinant major outer membrane protein ELISA**

475 The recombinant major outer membrane protein (MOMP) ELISA (Verminnen *et al.*, 2006) can be
476 performed on chicken and turkey sera pretreated with kaolin to remove background activity. MOMP-
477 specific antibody titres are determined using a standard ELISA protocol and micro-well plates coated
478 with recombinant MOMP. Serum, diluted 1/100, is added to the coated wells. Recombinant MOMP is
479 produced in pcDNA4::MOMPHis transfected COS7 cells (Vanrompay *et al.*, 1999). Briefly, COS7 cells
480 are cultured in Dulbecco's modified Eagle's medium supplemented with 3.7 g of sodium bicarbonate/litre,

481 1 mM L-glutamine, and 10% fetal calf serum. Transfection with plasmid DNA is performed by the
482 diethylaminoethyl dextran method. Forty-eight hours post-transfection recombinant MOMP production is
483 monitored by an indirect immunofluorescence staining using serovar and genus-specific MAbs. His-tag
484 labelled recombinant MOMP is purified by affinity chromatography and the protein concentration is
485 determined by the bicinchoninic acid protein assay. For the determination of antibody titres, 1/2000 and
486 1/4000 dilutions of biotinylated anti-chicken/turkey IgG (H+L) antibody and peroxidase-conjugated
487 streptavidin are used, respectively. The results are positive if the absorbance exceeds the cut-off value
488 of the mean of the negative control sera plus three times the standard deviation.

489 No commercial ELISA kits are available for detection of antibodies against *C. psittaci* and other avian
490 chlamydiae.

491 **2.2. Modified direct complement fixation test for *Chlamydia***

492 For AC, a modified direct CFT method is used. This method differs from the direct CFT in that normal,
493 unheated chicken serum from chickens without chlamydial antibody is added to the complement dilution. The
494 normal serum increases the sensitivity of the CFT procedure so that it can be used to test sera from avian
495 species whose antibodies do not normally fix guinea-pig complement.

496 **2.2.1. Test procedure**

- 497 i) Serum to test is heat-inactivated at 60°C for 30 minutes prior to use.
- 498 ii) Serum is then diluted 1/5 in veronal (barbiturate) buffer saline (VBS)
- 499 iii) Twofold dilutions of the diluted serum are prepared in 96-well round bottom microtitre plates.
- 500 iv) Guinea-pig complement is diluted in VBS prior to the addition of the antigen and
501 2 complement haemolytic units are used.
- 502 v) Sera complemented with 5 % of fresh chicken serum, complement and antigen are reacted
503 in the plates and incubated for 1 hour at 37°C (and alternate acceptable procedure is
504 overnight incubation at 4°C).
- 505 vi) A 2–4% suspension of sensitised washed red blood cells is added.
- 506 vii) Plates are incubated for 30 minutes at 37°C, and the centrifuged for 5 minutes at 600 g.

507 When using ~~commercially available CFT antigens and ready-to-use CFT reagents~~, the
508 manufacturers' instructions should be applied.

509 Recommended controls to verify test conditions:

- 510 i) Positive control: a control serum that gives a positive reaction;
- 511 ii) Negative control serum: a control serum that gives a negative reaction;
- 512 iii) Anti-complementary control (serum control): diluent + inactivated test serum + complement
513 + haemolytic system;
- 514 iv) Antigen control: diluent + antigen + complement + haemolytic system;
- 515 v) Haemolytic system control: diluent + haemolytic system;
- 516 vi) Complement control: diluent + complement titration + antigen + haemolytic system.
- 517 vii) The absence of anti-complementary activity must be checked for each serum;
518 anticomplementary sera must be excluded from analyses.

519 A sample that produces 100%haemolysis at the 1/5 dilution is negative and a sample that
520 produces 25–100% haemolysis is positive.

521 **2.2.2. CFT antigen preparation**

522 The simplest methods start with the growth of chlamydiae in cell culture. The two methods
523 described below produce antigens that can be used in the micro-CFT. The procedures are quite
524 similar: both include the growth of chlamydiae in cell culture, the inactivation of the chlamydiae,
525 partial purification of the antigen, mechanical disruption, and dilution into the appropriate buffer.
526 The method selected will depend on the equipment available.

527 The first procedure (Grimes, 1985) starts with the chlamydiae and cell culture debris harvested
528 when cytopathic effects are noted. The culture is inactivated by the addition of phenol to a final
529 concentration of 1.0%, incubated for 24 hours at 37°C, and concentrated by centrifugation at

530 10,000 **g** for 1 hour. The sediment is reconstituted to 10% of the original volume using VBS, pH
531 7.2, containing 1.0% phenol and 1.0% glycerol.

532 The sediment is then homogenised in an omnimixer at top speed for three 1-minute periods while
533 cooled in ice water. The homogenate is centrifuged for 15 minutes at 100 **g** to remove debris.
534 Some procedures suggest heating the antigen for 30 minutes in a boiling water bath at this time.
535 The supernatant is saved and diluted to the desired concentration.

536 In the second procedure for the production of antigen for the CFT (Bracewell & Bevan, 1986),
537 antigen is prepared from L cells infected with a psittacine strain. The cell culture medium is
538 discarded, and the cells are heated for 40 minutes at 56°C. The cells are lysed in distilled water,
539 the chlamydiae are disrupted by ultrasonication, and then made isotonic in VBS. The antigen is
540 tested against a standard sheep convalescent serum and used at 2 units in the micro- CFT.

541 There are a number of procedures for preparing the antigen from infected yolk sacs, some of
542 which are quite elaborate. However, with the following procedure it is relatively easy to prepare a
543 crude infected yolk sac antigen that works well in the modified direct CFT. An egg-adapted strain
544 of *Chlamydia* is used to inoculate 6–7-day-old embryonated chicken eggs via the yolk sac. The
545 yolk sacs are harvested from embryos that die between 3 and 7 days post-inoculation. The yolk-
546 sac harvest is diluted 1/3 in PBS, Tris buffer, or cell culture medium, and then autoclaved for
547 20 minutes. The suspension is cooled and then homogenised thoroughly. The use of a high-
548 speed tissue homogeniser for 3–5 minutes is recommended. After homogenisation, phenol is
549 added to make a final concentration of 0.5% phenol (prepare a 5% phenol stock solution and add
550 1 ml for every 9 ml of antigen). The antigen preparation is prepared, held for 3 days, and then the
551 supernatant is used after centrifugation for 20 minutes at 1000 **g**. The antigen can be stored for
552 long periods of time at 4°C.

553 2.3. Other tests

554 Other tests include the agar gel immunodiffusion test, the latex agglutination (LA) test, ~~the EBA test~~
555 ~~(Grimes & Arizmendi, 1996)~~ and the micro-immunofluorescence test (MIFT). Immunodiffusion is less
556 sensitive than the CFT. The LA test will detect antibodies to *C. psittaci*, and is easy and rapid to perform
557 (Grimes *et al.*, 1993). ~~Latex beads are coated with purified chlamydial antigen, mixed thoroughly with the~~
558 ~~test serum on a glass plate, and rotated for 2 minutes to enhance agglutination. The test is read against~~
559 ~~a dark background. Sera giving positive reactions should be retested with uncoated beads to eliminate~~
560 ~~possible nonspecific agglutination. The LA and direct CFTs correlate in 72.5% of tests with paired sera.~~
561 ~~The LA test has a sensitivity of 39.1% and a specificity of 98.8% relative to the direct CFT (Grimes *et al.*,~~
562 ~~1993).~~ The test detects both IgM and IgG, but it is best at detecting IgM. It has been suggested for use
563 in detecting recent or active infections. ~~The EBA test detects only IgM, and it is indicative of a current~~
564 ~~infection.~~ The MIFT is rapid and easy to perform; however, fluorescence-conjugated anti-species sera
565 are not always available.

566 C. REQUIREMENTS FOR VACCINES

567 To date, no commercial vaccines ~~against avian chlamydiosis~~ are available for avian chlamydiosis. Several vaccine
568 candidates have been evaluated in recent decades. For example, a recombinant DNA plasmid containing the
569 *C. psittaci ompA* gene provided significant (partial) protection in experimental studies in specific pathogen-free
570 (SPF) turkeys and budgerigars (Harkinezhad & Schautteet, 2009; Verminnen *et al.*, 2010). Recent research has
571 explored the use of recombinant proteins, such as the OmpA in combination with the polymorphic membrane protein
572 G. Studies have shown that the combination of multiple proteins confers superior protection compared to single-
573 valence vaccines in experimental avian models (Li *et al.*, 2022). Another promising vaccine candidate is based on
574 the plasmid Pgp3 protein, a virulence factor of *Chlamydia*. This protein has demonstrated robust immunogenicity
575 and efficacy in conferring immunity to *C. psittaci* infection in mouse models (Wang *et al.*, 2023) although vaccination
576 with a recombinant DNA plasmid containing the *C. psittaci ompA* gene provided significant (partial) protection in
577 experimentally infected specified pathogen free (SPF) turkeys (Verminnen *et al.*, 2010) and budgerigars
578 (Harkinezhad & Schautteet, 2009). DNA vaccination has the advantage that it can be used in the presence of
579 maternal antibodies (Van Looek *et al.*, 2004) and the antigen is processed in the same way as during a natural
580 infection, resulting in humoral and cell-mediated immune responses.

- 582 AAZIZ R., VINUEZA R.L., VORIMORE F., SCHNEE C., JIMÉNEZ-UZCÁTEGUI G., ZANELLA G. & LAROUCAU K. (2023). Avian
 583 *Chlamydia abortus* Strains Detected in Galapagos Waved Albatross (*Phoebastria irrorata*). *J. Wildl. Dis.*, **59**, 143–
 584 148.
- 585 ANDERSEN A.A. & VANROMPAY D. (2008). Chapter 16, Chlamydiosis. *In: A Laboratory Manual for the Isolation,*
 586 *Identification and Characterization of Avian Pathogens, Fifth Edition, Dufour-Zavala L., ed. The American*
 587 *Association of Avian Pathologists (AAAP), Jacksonville, Florida, USA.*
- 588 ANGEN Ø., JOHANNESSEN T.B., PETERSEN R.F., ULDM S.A. & SCHNEE C. (2021). Development of a species-specific
 589 real-time PCR test for *Chlamydia psittaci* and its employment in the investigation of zoonotic transmission from
 590 racing pigeons in Denmark. *Diagn. Microbiol. Infect. Dis.*, **100**, 115341.
- 591 ~~BOREL N., KEMPF E., HOTZEL H., SCHUBERT E., TORGERSON P., SLICKERS P., EHRLICH R., TASARA T., POSPISCHIL A. &~~
 592 ~~SACHSE K. (2008). Direct identification of chlamydiae from clinical samples using a DNA microarray assay—a~~
 593 ~~validation study. *Mol. Cell. Probes*, **22**, 55–64.~~
- 594 BRACEWELL C.D. & BEVAN B.J. (1986). Chlamydiosis in birds in Great Britain. 1. Serological reactions to chlamydia
 595 in birds sampled between 1974 and 1983. *J. Hyg. (Camb.)*, **96**, 447–451.
- 596 CAMPBELL T.W. (2015). Normal avian cytology. *In: Exotic Animal Hematology and Cytology, Fourth Edition, Campbell*
 597 *T.W., ed. Wiley-Blackwell, Ames, Iowa, USA and Oxford, UK, 219–227.*
- 598 ~~DEGRAVES F.J., GAO D. & KALTENBOECK B. (2003). High-sensitivity quantitative PCR platform. *Biotechniques*, **34**,~~
 599 ~~406–415.~~
- 600 DICKX V., GEENS T., DESCHUYFFELEER T., TYBERGHEN L., HARKINEZHAD T., BEECKMAN D.S., BRAECKMAN L. &
 601 VANROMPAY D. (2010). *Chlamydophila psittaci* zoonotic risk assessment in a chicken and turkey slaughterhouse. *J.*
 602 *Clin. Microbiol.*, **48**, 3244–3250.
- 603 EHRLICH R., SLICKERS P., GOELLNER S., HOTZEL H. & SACHSE K. (2006). Optimized DNA microarray assay allows
 604 detection and genotyping of single PCR-amplifiable target copies. *Mol. Cell Probes*, **20**, 60–63.
- 605 ~~EVERETT K.D.E., HORNUNG L.J. & ANDERSEN A.A. (1999). Rapid detection of the *Chlamydiaceae* and other families~~
 606 ~~in the order *Chlamydiales*: three PCR tests. *J. Clin. Microbiol.*, **37**, 575–580.~~
- 607 ~~GEENS T., DEWITTE A., BOON N. & VANROMPAY D. (2005). Development of a *Chlamydophila psittaci* species-specific~~
 608 ~~and genotype-specific real-time PCR. *Vet. Res.*, **36**, 1–11.~~
- 609 GRIMES J.E. (1985). Direct complement fixation and isolation attempts for detecting *Chlamydia psittaci* infection of
 610 psittacine birds. *Avian Dis.*, **29**, 837–877.
- 611 ~~GRIMES J.E. & ARIZMENDI F. (1996). Usefulness and limitations of three serologic methods for diagnosing or excluding~~
 612 ~~chlamydiosis in birds. *J. Am. Vet. Med. Assoc.*, **209**, 747–750.~~
- 613 GRIMES J.E., PHALEN D.N. & ARIZMENDI F. (1993). *Chlamydia* latex agglutination antigen and protocol improvement
 614 and psittacine bird anti-chlamydial immunoglobulin reactivity. *Avian Dis.*, **37**, 817–824.
- 615 GUO W., LI J., KALTENBOECK B., GONG J., FAN W. & WANG C. (2016). *Chlamydia gallinacea*, not *C. psittaci*, is the
 616 endemic chlamydial species in chicken (*Gallus gallus*). *Sci. Rep.*, **6**, 19638.
- 617 HARKINEZHAD T. & SCHAUTTEET K. (2009). Protection of budgerigars (*Melopsittacus Undulatus*) against
 618 *Chlamydophila psittaci* challenge by DNA vaccination. *Vet. Res.*, **40**, 61.
- 619 ~~HEDDEMA E., VAN HANNEN E.J., BONCAERTS M., DIJKSTRA F., TEN HOVE R.J., DE WEVER B. & VANROMPAY D. (2015).~~
 620 ~~Typing of *Chlamydia psittaci* to monitor the epidemiology and to aid in the control of Psittacosis, The Netherlands,~~
 621 ~~2008–2013. *Eurosurveillance*, **20**, pii: 21026.~~
- 622 HEDDEMA E.R., VAN HANNEN E.J., DUIM B., VANDENBROUCKE-GRAULS C.M. & PANNEKOEK Y. (2006). Genotyping of
 623 *Chlamydophila psittaci* in human samples. *Emerg. Infect. Dis.*, **12**, 1989–1990.
- 624 HEIJNE M., VAN DER GOOT J., BUYS H., DINKLA A., ROEST H.J., VAN KEULEN L. & KOETS A. (2021). Pathogenicity of
 625 *Chlamydia gallinacea* in chickens after oral inoculation. *Vet. Microbiol.*, **259**, 109166.

- 626 KALETA E.F. & TABAY E.M. (2003). Avian host range of *Chlamydophila* spp. based on isolation, antigen detection
627 and serology. *Avian Pathol.*, **32**, 435–462.
- 628 LAGAE S., KALMAR I., LAROUCAU K., VORIMORE F. & VANROMPAY D. (2014). Emerging *Chlamydia psittaci* infections in
629 chickens and examination of transmission to humans. *J. Med.*, **63**, 399–407.
- 630 LAROUCAU K., AAZIZ R., MEURICE L., SERVAS V., CHOSSAT I., ROYER H., DE BARBEYRAC B., VAILLANT V., MOYEN J.L.,
631 MEZIANI F., SACHSE K. & ROLLAND P. (2015). Outbreak of psittacosis in a group of women exposed to *Chlamydia*
632 *psittaci*-infected chickens. *Eurosurveillance*, **20**, pii: 21155.
- 633 LAROUCAU K., TRICHEREAU A., VORIMORE F. & MAHE AM. (2007). A *pmp* genes-based PCR as a valuable tool for the
634 diagnosis of avian chlamydiosis. *Vet. Microbiol.*, **121**, 150–157.
- 635 LAROUCAU K., VORIMORE F., AAZIZ R., BERNDT A., SCHUBERT E. & SACHSE K. (2009). Isolation of a new chlamydial
636 agent from infected domestic poultry coincided with cases of atypical pneumonia among slaughterhouse workers
637 in France. *Infect. Genet. Evol.*, **9**, 1240–1247.
- 638 LAROUCAU K., VORIMORE F., AAZIZ R., SOLMONSON L., HSIA R.C., BAVOIL P.M., FACH P., HÖLZER M., WUENSCHMANN A.
639 & SACHSE K. (2019). *Chlamydia buteonis*, a new *Chlamydia* species isolated from a red-shouldered hawk. *Syst.*
640 *Appl. Microbiol.*, **42**, 125997.
- 641 LI Q., CHEN S., YAN Z., FANG H., WANG Z. & HE C. (2022). A Novel Intranasal Vaccine With PmpGs + MOMP Induces
642 Robust Protections Both in Respiratory Tract and Genital System Posting *Chlamydia psittaci* Infection. *Front. Vet.*
643 *Sci.*, **9**, 855447.
- 644 MENARD A., CLERC M., SUBTIL A., MECRAUD F., BEBEAR C. & DE BARBEYRAC B. (2006). Development of a real-time PCR
645 for the detection of *Chlamydia psittaci*. *J. Med. Microbiol.*, **55**, 471–473.
- 646 OPOTA O., JATON K., BRANLEY J., VANROMPAY D., ERARD V., BOREL N., LONGBOTTOM D. & GREUB G. (2015). Improving
647 the molecular diagnosis of *Chlamydia psittaci* and *Chlamydia abortus* infection with a species-specific duplex real-
648 time PCR. *J. Med. Microbiol.*, **64**, 1174–1185.
- 649 PANNEKOEK Y., DICKX V., BEECKMAN D.S.A., KEIJZERS W.C., VRETOU E., VANROMPAY D. & VAN DER ENDE A. (2010). Multi
650 Locus Sequence Typing of *Chlamydia* reveals host species jumps by *Chlamydia psittaci* and *Chlamydia abortus*.
651 *PLoS One*, **5**, e14179.
- 652 PANTCHEV A., STING R., BAUERFEIND R., TYCZKA J. & SACHSE K. (2009). New real-time PCR tests for species-specific
653 detection of *Chlamydophila psittaci* and *Chlamydophila abortus* from tissue samples. *Vet. J.*, **181**, 145–150.
- 654 SACHSE K., BAVOIL P.M., KALTENBOECK B., STEPHENS R.S., KUO C.C., ROSSELLÓ-MÓRA R. & HORN M. (2015).
655 Emendation of the family *Chlamydiaceae*: proposal of a single genus, *Chlamydia*, to include all currently recognized
656 species. *Syst. Appl. Microbiol.*, **38**, 99–103.
- 657 SACHSE K., HOTZEL H., SLICKERS P., ELLINGER T. & EHRLICH R. (2005). DNA microarray-based detection and
658 identification of *Chlamydia* and *Chlamydophila*. *Mol. Cell Probes*, **19**, 41–50.
- 659 SACHSE K., LAROUCAU K., HOTZEL H., SCHUBERT E., EHRLICH R. & SLICKERS P. (2008). Genotyping of *Chlamydophila*
660 *psittaci* using a new DNA microarray assay based on sequence analysis of *ompA* genes. *BMC Microbiol.*, **8**, 63.
- 661 SACHSE K., LAROUCAU K., RIEGE K., WEHNER S., DILCHER M., CREASY H.H., WEIDMANN M., MYERS G., VORIMORE F.,
662 VICARI N., MAGNINO S., LIEBLER-TENORIO E., RUETTGER A., BAVOIL P.M., HUFERT F.T., ROSSELLÓ-MÓRA R. & MARZ M.
663 (2014). Evidence for the existence of two new members of the family *Chlamydiaceae* and proposal of *Chlamydia*
664 *avium* sp and *Chlamydia gallinacea* sp. nov. *Syst. Appl. Microbiol.*, **37**, 79–88.
- 665 SACHSE K., VRETOU E., LIVINGSTONE M., BOREL N., POSPISCHIL A. & LONGBOTTOM D. (2009). Recent developments in
666 the laboratory diagnosis of chlamydial infections (review). *Vet. Microbiol.*, **135**, 2–21.
- 667 VAN LOOCK M., LAMBIN S., VOLCKAERT G., GODDEERIS B.M. & VANROMPAY D. (2004). Influence of maternal antibodies
668 on *Chlamydophila psittaci*-specific immune responses in turkeys elicited by naked DNA. *Vaccine*, **22**, 1616–1623.
- 669 VAN LOOCK M., VANROMPAY D., HERRMANN B., VANDER STAPPEN J., VOLCKAERT G., GODDEERIS B.M. & EVERETT K.D.
670 (2003). Missing links in the divergence of *Chlamydophila abortus* from *Chlamydophila psittaci*. *Int. J. Syst. Evol.*
671 *Microbiol.*, **53**, 761–770.

672 VANROMPAY D. (2013). Chapter 24, Avian Chlamydiosis. *In: Diseases of Poultry, Thirteenth Edition*, Swayne D.,
673 Glisson J.R., McDougald L.R., Nolan L.K., Suarez D.L. & Nair V.L., eds. Wiley-Blackwell Publishing, Hoboken, New
674 Jersey, USA.

675 VANROMPAY D., DUCATELLE R. & HAESBROUCK F. (1992). Diagnosis of avian chlamydiosis; specificity of the modified
676 Gimenez staining on smears and comparison of the sensitivity of isolation in eggs and three different cell cultures.
677 *J. Vet. Med. [B]*, **39**, 105–112.

678 VANROMPAY D., COX E., VOLCKAERT G. & GODDEERIS B. (1999). Turkeys are protected from infection with *Chlamydia*
679 *psittaci* by plasmid DNA vaccination against the major outer membrane protein. *Clin. Exp. Immunol.*, **118**, 49–55.

680 VANROMPAY D., HARKINEZHAD T., VAN DE WALLE M., BEECKMAN D., VAN DROOGENBROECK C., VERMINNEN K., LETEN R.,
681 MARTEL A. & CAUWERTS K. (2007). *Chlamydia psittaci* transmission from pet birds to humans. *Emerg. Infect.*
682 *Dis.*, **13**, 1108–1110.

683 VANROMPAY D., VAN NEROM A., DUCATELLE R. & HAESBROUCK F. (1994). Evaluation of five immunoassays for
684 detection of *Chlamydia psittaci* in cloacal and conjunctival specimens from turkeys. *J. Clin. Microbiol.*, **32**, 1470–
685 1474.

686 VERMINNEN K., BEECKMAN D., SANDERS N., DE SMEDT S. & VANROMPAY D. (2010). Vaccination of turkeys against
687 *Chlamydia psittaci* through optimised DNA formulations and administration. *Vaccine*, **28**, 3095–3105.

688 VERMINNEN K., VAN LOOCK M., HAFEZ H.M., DUCATELLE, R., HAESBROUCK F. & VANROMPAY D. (2006). Evaluation of a
689 recombinant enzyme-linked immunosorbent assay for detecting *Chlamydia psittaci* antibodies in turkey sera.
690 *Vet. Res.*, **37**, 623–632.

691 VORIMORE F., AAZIZ R., DE BARBEYRAC B., PEUCHANT O., SZYMAŃSKA-CZERWIŃSKA M., HERRMANN B., SCHNEE C. &
692 LAROUCAU K. (2021). New SNP-Based Genotyping Method for *C. psittaci*: Application to Field Samples for Quick
693 Identification. *Microorganisms*, **9**, 625.

694 WANG C., JIN Y., WANG J., ZHENG K., LEI A., LU C., WANG S. & WU Y. (2023). Protective Immunity against *Chlamydia*
695 *psittaci* Lung Infection Induced by a DNA Plasmid Vaccine Carrying CPSIT_p7 Gene Inhibits Dissemination in
696 BALB/c Mice. *Int. J. Mol. Sci.*, **24**, 7013.

697 ZOCEVIC A., VICARI N., GASPARINI J., JACQUIN L., SACHSE K., MAGNINO S. & LAROUCAU K. (2013). A real-time PCR assay
698 for the detection of atypical strains of *Chlamydiaceae* from pigeons. *PLoS One*, **8**, e58741.

699 *
700 * *

701 **NB:** There are WOAHO Reference Laboratories for avian chlamydiosis (please consult the WOAHO Web site:
702 <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>.
703 Please contact the WOAHO Reference Laboratories for any further information on
704 diagnostic tests and reagents for avian chlamydiosis

705 **NB:** FIRST ADOPTED IN 1990. MOST RECENT UPDATES ADOPTED IN 2018.

706

707

Appendix 1: Avian chlamydiosis
Intended purpose of test: population freedom from infection

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>ELISA</u> <u>±±</u> <u>birds</u>	<u>Serum</u> <u>Antibodies against <i>C. psittaci</i></u>	<u>N/A</u>	<u>N/A</u>	<u>See references</u>	<u>High sensitivity</u> <u>Rapid and simple</u>	<u>No commercial test</u> <u>Limited availability of avian conjugates</u>	<u>Verminnen <i>et al.</i> (2006)</u> <u>Sachse <i>et al.</i> (2009)</u>
<u>CFT</u> <u>±</u> <u>birds</u>	<u>Serum</u> <u>Antibodies against <i>C. psittaci</i></u>	<u>N/A</u>	<u>N/A</u>	<u>See references</u>	<u>Inexpensive</u>	<u>Low sensitivity and specificity</u> <u>Limited commercial availability of antigen</u>	<u>Grimes (1985)</u> <u>Bracewell & Bevan (1986)</u>

708

709

Appendix 2: Avian chlamydiosis**Intended purpose of test: individual animal freedom from infection prior to movement**

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>ELISA</u> ± <u>birds</u>	<u>Serum</u> <u>Antibodies against C. psittaci</u>	<u>N/A</u>	<u>N/A</u>	<u>See references</u>	<u>High sensitivity</u> <u>Rapid and simple</u>	<u>No commercial test</u> <u>Limited availability avian conjugates</u>	<u>Verminnen et al. (2006)</u> <u>Sachse et al. (2009)</u>
<u>CFT</u> ± <u>birds</u>	<u>Serum</u> <u>Antibodies against C. psittaci</u>	<u>N/A</u>	<u>N/A</u>	<u>See references</u>	<u>Inexpensive</u>	<u>Low sensitivity and specificity</u> <u>Limited commercial availability of antigen</u>	<u>Grimes (1985)</u> <u>Bracewell & Bevan (1986)</u>

710

711

Appendix 3: Avian chlamydiosis
Intended purpose of test: confirmation of clinical cases

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Conventional PCR</u> <u>++</u> <u>birds</u>	<u>Cloacal, pharyngeal, ocular swabs from live birds</u> <u>Spleen, liver, lungs, intestine from dead birds</u> <u>C. psittaci DNA</u>	<u>N/A</u>	<u>N/A</u>	<u>See reference</u>	<u>High specificity</u>	<u>Intermediate sensitivity</u> <u>Time consuming</u>	<u>Laroucau et al. (2007)</u>
<u>Real-time PCR</u> <u>+++</u> <u>birds</u>	<u>Cloacal, pharyngeal, ocular swabs from live birds</u> <u>Spleen, liver, lungs, intestine from dead birds</u> <u>C. psittaci DNA</u>	<u>N/A</u>	<u>N/A</u>	<u>See references</u>	<u>High sensitivity and specificity</u> <u>Rapid</u>	<u>Needs expensive laboratory equipment</u>	<u>Pantchev et al. (2009)</u> <u>Angen et al. (2021)</u>
<u>Cytological staining</u> <u>±</u> <u>birds</u>	<u>Cloacal, pharyngeal, ocular swabs from live birds</u> <u>Spleen, liver, lungs, intestine from dead birds</u> <u>C. psittaci bacteria</u>	<u>N/A</u>	<u>N/A</u>	<u>N/A</u>	<u>Simple and cheap</u>	<u>Low to intermediate sensitivity</u> <u>Depends on experienced staff</u>	
<u>Isolation in cell culture or embryonated eggs</u> <u>++</u> <u>birds</u>	<u>Cloacal, pharyngeal, ocular swabs from live birds</u> <u>Spleen, liver, lungs, intestine from dead birds</u> <u>C. psittaci isolate</u>	<u>N/A</u>	<u>N/A</u>	<u>N/A</u>	<u>Gold standard</u> <u>Obtaining isolates for further characterisation</u>	<u>Low to intermediate sensitivity</u> <u>Cumbersome and long laboratory procedures</u> <u>Depends on experienced staff</u>	
<u>Antigen detection by IHC</u> <u>++</u> <u>birds</u>	<u>Cloacal, pharyngeal, ocular swabs from live birds</u> <u>Spleen, liver, lungs, intestine from dead birds</u> <u>C. psittaci antigen</u>	<u>N/A</u>	<u>N/A</u>	<u>N/A</u>	<u>Enables association of Chlamydia presence with tissue lesions</u>	<u>Intermediate sensitivity</u>	
<u>ELISA</u> <u>±</u> <u>birds</u>	<u>Serum</u> <u>Antibodies against C. psittaci</u>	<u>N/A</u>	<u>N/A</u>	<u>See references</u>	<u>High sensitivity</u> <u>Rapid and simple</u>	<u>No commercial test</u> <u>Limited availability of avian conjugates</u>	<u>Verminnen et al. (2006)</u> <u>Sachse et al. (2009)</u>
<u>CFT</u> <u>±</u> <u>birds</u>	<u>Serum</u> <u>Antibodies against C. psittaci</u>	<u>N/A</u>	<u>N/A</u>	<u>See references</u>	<u>Inexpensive</u>	<u>Low sensitivity and specificity</u> <u>Limited commercial availability of antigen</u>	<u>Grimes (1985)</u> <u>Bracewell & Bevan (1986)</u>

712

Appendix 4: Avian chlamydiosis
Intended purpose of test: prevalence of infection – surveillance

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Conventional PCR</u> ± <u>birds</u>	<u>Cloacal, pharyngeal, ocular swabs from live birds</u> <u>Spleen, liver, lungs, intestine from dead birds</u> <u>C. psittaci DNA</u>	<u>N/A</u>	<u>N/A</u>	<u>See reference</u>	<u>High specificity</u>	<u>Intermediate sensitivity</u> <u>Time consuming</u>	<u>Laroucau et al. (2007)</u>
<u>Real-time PCR</u> ++ <u>birds</u>	<u>Cloacal, pharyngeal, ocular swabs from live birds</u> <u>Spleen, liver, lungs, intestine from dead birds</u> <u>C. psittaci DNA</u>	<u>N/A</u>	<u>N/A</u>	<u>See references</u>	<u>High sensitivity and specificity</u> <u>Rapid</u>	<u>Needs expensive lab equipment</u>	<u>Pantchev et al. (2009)</u> <u>Angen et al. (2021)</u>
<u>Isolation in cell culture or embryonated eggs</u> ± <u>birds</u>	<u>Cloacal, pharyngeal, ocular swabs from live birds</u> <u>Spleen, liver, lungs, intestine from dead birds</u> <u>C. psittaci isolate</u>	<u>N/A</u>	<u>N/A</u>	<u>N/A</u>	<u>Gold standard</u> <u>Obtaining isolates for further characterisation</u>	<u>Low to intermediate sensitivity</u> <u>Cumbersome and long laboratory procedures</u> <u>Depends on experienced staff</u>	
<u>ELISA</u> ++ <u>birds</u>	<u>Serum</u> <u>Antibodies against C. psittaci</u>	<u>N/A</u>	<u>N/A</u>	<u>See references</u>	<u>High sensitivity</u> <u>Rapid and simple</u>	<u>No commercial test</u> <u>Limited availability of avian conjugates</u>	<u>Verminnen et al. (2006)</u> <u>Sachse et al. (2009)</u>
<u>CFT</u> ± <u>birds</u>	<u>Serum</u> <u>Antibodies against C. psittaci</u>	<u>N/A</u>	<u>N/A</u>	<u>See references</u>	<u>Inexpensive</u>	<u>Low sensitivity and specificity</u> <u>Limited commercial availability of antigen</u>	<u>Grimes (1985)</u> <u>Bracewell & Bevan (1986)</u>

CHAPTER 3.3.2.

AVIAN INFECTIOUS BRONCHITIS

SUMMARY

Description and importance of the disease: Avian infectious bronchitis (IB) is caused by the Gammacoronavirus infectious bronchitis virus (IBV). It has no zoonotic relevance. The virus causes infections mainly in chickens and is a significant pathogen of commercial meat and egg type birds. IB is an acute, contagious disease characterised primarily by respiratory signs in growing chickens. In hens, decreased egg production and quality are often observed. Several strains of the virus are nephropathogenic and may produce interstitial nephritis and mortality. The severity of IBV-induced respiratory disease is enhanced by the presence of other pathogens, including bacteria, leading to chronic complicated airsacculitis. Diagnosis of IB requires detection of the virus by virus isolation, antigen staining techniques or demonstration of viral nucleic acid from diseased flocks. Demonstration of a rising serum antibody response may also be useful. The widespread use of live and inactivated vaccines may complicate both the interpretation of virus detection and serology findings. The occurrence of antigenic variant strains may overcome immunity induced by vaccination.

Detection and identification of the agent: For the common respiratory form, IBV is most successfully isolated from upper respiratory tract, tracheal mucosa and lung several days to one week following infection. For other forms of IB, or in a more chronic phase of the infection, kidney, oviduct or the caecal tonsils of the intestinal tract tissues may be better sources of virus depending on the pathogenesis of the disease. Reverse-transcriptase polymerase chain reaction (RT-PCR) is increasingly being used to identify the spike (S) glycoprotein genotype of IBV field strains. Genotyping using primers specific for the S1 subunit of the S gene or sequencing of the same gene generally provides similar but not always identical findings to serotyping by haemagglutination inhibition (HI) or virus neutralisation (VN) tests. Supplementary tests include electron microscopy, the use of monoclonal antibodies, VN, immuno-histochemical or immunofluorescence tests, and immunisation–challenge trials in chickens. Specific-Specified pathogen free chicken embryonated eggs or chicken tracheal organ cultures (TOCs) from embryos may be used for virus isolation. Following inoculation of the allantoic cavity, IBV produces embryo stunting, curling, clubbing of the down, or urate deposits in the mesonephros of the kidney, often within three serial passages. Alternatively, VN or HI tests using specific antiserum may be used to identify the serotype.

Serological tests: Commercial enzyme-linked immunosorbent assays (ELISA) kits are often used for monitoring serum antibody responses. The antigens used in the kits are broadly cross-reactive among serotypes and allow for general serological monitoring of vaccinal responses and field challenges. The HI test is used for identifying serotype-specific responses to vaccination and field challenges especially in young growing chickens-rearing hens. Because of multiple infections and vaccinations, the sera of breeders and layers contain cross-reactive antibodies and the results of HI and VN test testing cannot be used with a high degree of confidence for serotyping the infection.

Requirements for vaccines: Both live attenuated and oil emulsion inactivated vaccines are available. Live vaccines, usually attenuated by serial passage in chicken embryos, confer better local immunity of the respiratory tract than inactivated vaccines. The use of live vaccines carries a risk of residual pathogenicity associated with vaccine back-passage in flocks. However, proper mass application will generally result in safe application of live vaccines.

Inactivated vaccines are injected and a single inoculation does not confer significant protection unless preceded by one or more live IBV priming vaccinations.

A. INTRODUCTION

Avian infectious bronchitis (IB) was first described in the United States of America (USA) in the 1930s as an acute respiratory disease mainly of young chickens. A viral aetiology was established, and the agent was termed avian infectious bronchitis virus (IBV). The virus is a member of the genus *Gammacoronavirus*, subfamily *Coronavirinae* *Orthocoronavirinae*, family *Coronaviridae*, in the order *Nidovirales*. IBV and other avian coronaviruses of turkeys and pheasants are classified as gammacoronaviruses, with mammalian coronaviruses comprising *Alpha* and *Betacoronaviruses*. ~~Novel~~-Related coronaviruses have been discovered in wild birds and pigs and have been designated *Deltacoronaviruses* (Woo *et al.*, 2012), interestingly the avian *Deltacoronaviruses* have a different genomic order and show no close relationship to the *gammacoronaviruses*. Coronaviruses have a non-segmented, positive-sense, single-stranded RNA genome.

IB affects chickens of all ages (Britton & Cavanagh, 2007; Cavanagh *et al.*, 2002); IBV-like viruses have been isolated from turkeys, pheasants and guinea fowl. The disease is transmitted by the air-borne route, direct chicken-to-chicken contact, contact with infected faeces and indirectly through mechanical spread (contaminated poultry equipment or egg-packing materials, manure used as fertiliser, farm visits, etc.). IB occurs world-wide and assumes a variety of clinical forms, the principal one being respiratory disease that develops after infection of the respiratory tract tissues following inhalation or ingestion. Infection of the oviduct at a very young age can lead to permanent damage and, in hens, can lead to cessation of egg-laying or production of thin-walled and misshapen shells with loss of shell pigmentation. IB can be nephropathogenic causing acute nephritis, urolithiasis and mortality, especially in young birds. After apparent recovery, chronic nephritis can produce death at a later time. Vaccine and field strains of IBV may persist in the caecal tonsils of the intestinal tract and be excreted in faeces for weeks or longer in clinically normal chickens. For an in-depth review of IB, refer to Jackwood & de Wit, (2013–2020). A detailed discussion of IBV antigen, genome and antibody detection assays prepared by de Wit (2000) is also available.

The clinical signs induced by IBV infections are not specific and could be caused by a number of other pathogens. There is therefore a need to adopt a broad diagnostic approach to understanding the role of other pathogens. The differential diagnosis for respiratory disease includes pathogens such as avian metapneumovirus, low pathogenic avian influenza, Newcastle disease virus, infectious laryngotracheitis virus, *Mycoplasma gallisepticum* and *synoviae*, and *Avibacterium paragallinarum*. For nephrosis and nephritis, the differential diagnosis includes, amongst others, astroviruses, infectious bursal disease virus, intoxications and dehydration. For drops in egg production, alternative causes include the respiratory pathogens mentioned but also avian encephalomyelitis or egg-drop syndrome virus.

There have been no reports of human infection with IBV.

B. DIAGNOSTIC TECHNIQUES

~~Confirmation of~~ Confirmatory diagnosis of IBV is based on detection of virus RNA, virus detection, or seroconversion. Extensive use is made of live and inactivated vaccinations, which may complicate diagnosis by serological methods as antibodies to vaccination and field infections cannot always be distinguished. Persistence of live vaccines may also confuse attempts at recovering or identifying the causative field strain of IBV.

Table 1. Test methods available for the diagnosis of infectious bronchitis virus and their purpose

Method	Purpose					
	Population freedom from infection ^(a)	Individual animal freedom from infection prior to movement ^(b)	Contribute to eradication policies ^(c)	Confirmation of clinical cases ^(d)	Prevalence of infection – surveillance ^(e)	Immune status in individual animals or populations (post-vaccination) ^(f)
<u>Detection and</u> identification of the agent						
Virus isolation (embryos or TOCs)	+(g)	++ ^(h)	–	+++	+	+(i)
Staining by immunohistochemistry	–	–	–	++	+	+(i)
Gene sequencing (virus identification)	–	–	–	++	++ ⁽ⁱ⁾	–

Method	Purpose					
	Population freedom from infection ^(a)	Individual animal freedom from infection prior to movement ^(b)	Contribute to eradication policies ^(a)	Confirmation of clinical cases ^(d)	Prevalence of infection – surveillance ^(e)	Immune status in individual animals or populations (post-vaccination) ^(f)
<u>Conventional RT-PCR</u> (detection of virus-genome-derived RNA)	+ ^(g, k)	++	++	+++	+++	+ ⁽ⁱ⁾
Real-time RT-PCR (conserved gene)	++ ^(g, k)	++	++	+++	+++	+ ⁽ⁱ⁾
<u>Real-time RT-PCR</u> (lineage or genotype specific)	+++ ^(k, l)	+++	+++	+++	+++	+++ ⁽ⁱ⁾
VN (virus identification)	–	–	–	–	+	–
Detection of immune response						
VN (antibody detection)	–	– ^(l)	–	+ ^(m)	+ ⁽ⁿ⁾	++
HIT (antibody detection)	–	– ^(l)	+	+ ^(m)	+ ⁽ⁿ⁾	++
ELISA (antibody detection)	+++ ^(o)	+	++	+++ ^(m)	+++ ^(m, p)	++

Key: +++ = recommended for this purpose; ++ recommended but has limitations;

+ = suitable in very limited circumstances; – = not appropriate for this purpose.

TOC = tracheal organ culture; RT-PCR = reverse-transcription polymerase chain reaction; VN = virus neutralisation;

HIT = haemagglutination inhibition test; ELISA = enzyme-linked immunosorbent assay.

^(a)See Appendix 1 of this chapter for justification table for the scores given to the tests for this purpose.

^(b)See Appendix 2 of this chapter for justification table for the scores given to the tests for this purpose.

^(c)See Appendix 3 of this chapter for justification table for the scores given to the tests for this purpose.

^(d)See Appendix 4 of this chapter for justification table for the scores given to the tests for this purpose.

^(e)See Appendix 5 of this chapter for justification table for the scores given to the tests for this purpose.

^(f)See Appendix 6 of this chapter for justification table for the scores given to the tests for this purpose.

^(g)Suitable for ensuring lack of infection during the past 10 days;

^(h)Suitable at the individual level only during excretion periods;

⁽ⁱ⁾Sometimes used in the evaluation of vaccines to assess protection against viral excretion, but can be positive even when good clinical protection is achieved.

^(j)Especially suitable for surveillance of a given or an emerging genotype-lineage;

^(k)Detection in cloacal samples can be several weeks longer than in tracheal samples, strain depending;

^(l)Limited suitability for this purpose as it may be too specific due to the serotype used as an antigen or genotype, use of a panel of lineage-specific tests present in the region is recommended;

^(m)Suitable provided paired samples collected a few weeks apart can be analysed;

⁽ⁿ⁾Serotype-specificity drops when chicken has been in contact to multiple types of IBV.

^(o)Suitable for ensuring lack of infections dating back to more than 10 days;

^(p)Especially suitable when IB surveillance is not focused on a given serotype;

1. Detection and identification of the agent

1.1. Sampling

Samples appropriate to the form of IB observed must be obtained as soon as signs of clinical disease are evident. For acute respiratory disease, swabs from the upper respiratory tract of live birds or tracheal and lung tissues from diseased birds should be harvested. For birds with nephritis or egg-production problems, samples from the kidneys, ~~or~~ oviduct or cloaca, respectively, should be collected in addition to respiratory specimens. Although virus isolation is a well-established method, IBV identification by reverse-transcriptase polymerase chain reaction (RT-PCR) and subsequent sequencing or the use of a panel of genotype-lineage-specific RT-PCRs will be the most used methods in the field. A positive RT-

118 PCR result is not proof that IBV is present in the kidney cells and causing damage; it could also be
119 caused by viraemia or contamination of the swabs by organs other than the airsac. In situations where
120 IB-induced nephritis is suspected, kidney samples should also be ~~selected~~ collected from fresh carcasses
121 for histochemistry or immunofluorescence to demonstrate local replication. A high degree rate of virus
122 recovery has been reported from the caecal tonsil or faeces. However, isolates from the intestinal tract
123 may have no relevance to the latest infection or clinical disease. IBV isolation may be facilitated using
124 sentinel ~~specific~~ specified pathogen free (SPF) chickens placed at one or more times in contact with
125 commercial poultry. Vaccinated chickens might be used to detect IBV strains for which the vaccination
126 regimes used might not be sufficiently effective. Blood samples from acutely affected birds as well as
127 convalescent chickens can also be submitted for serological testing.

128 1.2. Culture

129 Samples must be placed in cold transport media containing penicillin (10,000 International Units [IU]/ml)
130 and streptomycin (10 mg/ml) and kept on ice and be frozen as soon as possible. Suspensions of tissues
131 (10–20% w/v) are prepared in sterile phosphate buffered saline (PBS) or nutrient broth for egg
132 inoculation, or in tissue culture medium for chicken tracheal organ culture (TOC) inoculation (Cook *et al.*,
133 1976). The suspensions are clarified by low-speed centrifugation and filtration through bacteriological
134 filters (0.2 µ) before inoculation of SPF embryonated chicken eggs or TOCs.

135 SPF embryonated chicken eggs and/or TOCs are used for primary isolation of IBV. Cell cultures are not
136 recommended for primary isolation as it is often necessary to adapt IBV isolates to growth in chicken
137 embryos before cytopathic effect (CPE) is produced in chick embryo kidney cells.

138 Embryonated eggs used for virus isolation should originate preferably from SPF chickens or from breeder
139 sources that have been neither infected nor vaccinated with IBV. Most commonly, 0.1–0.2 ml of sample
140 supernatant is inoculated into the allantoic cavity of 9–11-day-old embryos. Eggs are candled daily for
141 7 days with mortality within the first 24 hours being considered nonspecific. The initial inoculation usually
142 has limited macroscopic effects on the embryo unless the strain is derived from a vaccine and is already
143 egg adapted. Normally, the allantoic fluids of all eggs are pooled after harvesting 3–6 days after infection;
144 this pool is diluted 1/5 or 1/10 in antibiotic broth and used to infect another set of eggs for up to a total of
145 three to four passages. Typically, a field strain will induce observable embryonic changes consisting of
146 stunted and curled embryos with feather dystrophy (clubbing) and urate deposits in the mesonephros on
147 the second to fourth passage. Embryo mortality in later passages may occur as the strain becomes more
148 egg adapted. RT-PCR can be used to check whether the last passage is really negative for IBV. Other
149 viruses, notably adenoviruses that are common to the respiratory tract, also produce embryo lesions
150 indistinguishable from IBV. The IBV-laden allantoic fluid should not agglutinate red blood cells and
151 isolation of IBV must be confirmed by serotyping or genotyping. Infective allantoic fluids are kept at –
152 20°C or below for short-term storage, –60°C or below for long-term storage or at 4°C after lyophilisation.

153 TOCs prepared from 19- to 20-day-old embryos can be used to isolate IBV directly from field material
154 (Cook *et al.*, 1976). An automatic tissue-chopper is desirable for the large-scale production of suitable
155 transverse sections or rings of the trachea for this technique (Darbyshire *et al.*, 1978). The rings are
156 about 0.5–1.0 mm thick, and are maintained in a medium consisting of Eagle's N-2-
157 hydroxyethylpiperazine N'-2-ethanesulphonic acid (HEPES) in roller drums (15 rev/hour) at 37°C.
158 Infection of tracheal organ cultures usually produce results in ciliostasis within 24–48 hours. Ciliostasis
159 may be produced by other viruses and suspect IBV cases must be confirmed by serotyping or genotyping
160 methods.

161 1.3. Methods for detection and identification ~~and detection~~

162 The initial tests performed on IBV isolates are directed at eliminating other viruses from diagnostic
163 consideration. Chorioallantoic membranes from infected eggs are collected, homogenised, and tested
164 for ~~avian Avia~~adenovirus group 4 by immunodiffusion or PCR. ~~Group 4 avian Avia~~adenovirus infections of
165 commercial chickens are common, and the virus often produces stunted embryos indistinguishable from
166 IBV-infected embryos. Furthermore, harvested allantoic fluids do not hemagglutinate (HA) chick red
167 blood cells. Genetic-based tests, RT-PCR, and sequence analysis are used commonly to identify an
168 isolate as IBV. The presence of IBV in ~~infective~~ infected allantoic fluid or TOCs is usually ~~detected~~
169 confirmed by RT-PCR amplification. Other techniques may be used ~~as well~~, for example, cells present
170 in the chorioallantoic membranes or allantoic fluid of infected eggs or TOCs may be tested for IBV antigen
171 using fluorescent antibody tests, immunohistochemistry or an antigen- enzyme-linked immunosorbent
172 assays (ELISA) using a group-specific monoclonal antibody (MAb) or polyclonal antiserum.

173

174

1.4. Serotype identification

175 Antigenic variation among IBV strains is common (Jackwood & de Wit, 2013-2020), but at present there
176 is no agreed definitive classification system for serotyping. Nevertheless, antigenic relationships and
177 differences among strains are important, as vaccines based on one particular serotype may show little
178 or no protection against viruses of a different antigenic group. As a result of the regular emergence of
179 antigenic variants, the viruses, and hence the disease situation and vaccines used, may be quite different
180 in different geographical locations. Ongoing assessment of the viruses present in the field is necessary
181 to produce vaccines that will be efficacious in the face of antigenic variants that arise. Serotyping of IBV
182 isolates and strains has been done using haemagglutination inhibition (HI) and virus neutralisation (VN)
183 tests in chick embryos, TOCs and cell cultures. MABs have been described and used in antigen-ELISAs
184 or immunofluorescence tests for typing of IBV strains, but the availability number of suitable MABs is very
185 limited (de Wit, 2000). Owing to the number of variants, the requirements to raise a monospecific
186 antisera in SPF birds for each novel strain and the complexity of serotyping, means that serotyping is
187 hardly used anymore.

188

1.5. Lineage or genotype identification

189 Development of improved techniques for nucleotide sequencing, the availability of IBV sequence data,
190 especially relating to the S gene, in computer databases and the demonstration that even relatively short
191 sequence lengths can allow meaningful results in phylogenetic analyses have led to an increase in such
192 studies and have largely replaced HI and VN serotyping for determining the identity of a field strain. The
193 molecular basis of antigenic variation has been investigated, usually by nucleotide sequencing of the
194 gene coding for the spike (S) protein or, more specifically, nucleotide sequencing of the gene coding for
195 the S1 subunit of the S protein where it is believed that the epitopes to which neutralising antibodies bind
196 are found. A high correlation with HI or VN results has not been seen, while different serotypes generally
197 have large differences (20–50%) in the deduced amino acid sequences of the S1 subunit, other viruses
198 that are clearly distinguishable in neutralisation tests show only 2–3% differences in amino acid
199 sequences.

200 The primary advantages of genotyping methods are a rapid turnaround time, and the ability to detect a
201 variety of genotypes or lineages, depending on the primer sets used. Genetic diversity between IBV
202 isolates has been confirmed, but viruses sharing temporal, geographical, antigenic or epidemiological
203 parameters tend to fall into specific lineages and this has proven valuable in assessing both the global
204 epidemiology and local spread of IBV (de Wit *et al.*, 2011; Jackwood, 2012; Valastro *et al.*, 2016).
205 Sequence analysis of the S gene provides the required information for determining the level of genetic
206 homology and the relationship of an IBV S gene to other IBV isolates including vaccine strains.

207 ~~It has been~~ Work has shown that coronaviruses isolated from turkeys, pheasants and guinea fowl are
208 genetically similar to IBV, having approximately 90% nucleotide identity in the highly conserved region II
209 of the 3' untranslated region (UTR) of the IBV genome (Cavanagh *et al.*, 2001; 2002). The potential role
210 of these coronaviruses in IBV infections has not been determined. This is the same for the
211 gammacoronaviruses that have been detected in wild birds (Muradrasoli *et al.*, 2010)

212 The major uses of RT-PCR tests are virus identification at the genetic level and its application in the
213 understanding of epidemiological investigations during IBV outbreaks. The RT-PCR tests, as they now
214 exist however, do not provide information on viral pathogenicity.

215

1.5.1. Reverse-transcriptase polymerase chain reaction (RT-PCR)

216 The wider availability and increased speed of production of results obtained using commercially
217 available kits for RT-PCR and automatic sequencers now means such studies are within the
218 capabilities of many more diagnostic laboratories, providing more accurate and meaningful
219 results. Tracheal or oropharyngeal swabs are ~~often primarily~~ used as the specimens of choice
220 because they are easy to obtain and process. However, cloacal swabs are also taken in cases
221 where the infection may be a bit older, especially in layer and breeder birds. Such samples usually
222 contain little extraneous organic material that can interfere with RNA recovery and amplification
223 by PCR. The system used for RNA extraction will also affect the success of RT-PCR on clinical
224 specimens, and even with commercial kits care should be taken in selecting the most appropriate
225 system validated for the samples to be analysed. The usual target region for IBV characterisation
226 is the S1 subunit of the S glycoprotein gene.

227 Many one and two-step RT-PCR kits are commercially available from manufacturers claiming
228 superior enzyme sensitivity and fidelity. Reverse transcription is performed according to the
229 manufacturer's instructions. Most diagnostic laboratories determine the genotype or lineage of
230 IBV isolates using partial sequence analysis, usually about 700 nt long, of the S1 region of the S

231 gene (Callison et al., 2006). Given the diverse nature of the IBV S1 sequence, primer sets might
 232 need to be updated from time to time and the actual region sequenced may vary. Such analyses
 233 allow for rapid epidemiological assessment of the origins and spread of the viruses responsible
 234 for IBV outbreaks and the detection of vaccine strains within flocks. It should be noted that for
 235 more refined epidemiological studies and for more accurate studies on the evolution of IBV, the
 236 phylogenetic studies need to use complete S gene and even whole genome sequences.

237 **1.5.2. Real-time RT-PCR analysis**

<u>Pathogen/ target gene</u>	<u>Primer/probe (5'–3')</u>	<u>Concentration</u>	<u>Cycling parameters^(a)</u>
Method 1: Roh et al., 2014			
<u>IBV 5'UTR</u>	F: IBV 5' GU391: GCT-TTT-GAG-CCT-AGC-GTT R: IBV 5' GL533: GCC-ATG-TTG-TCA-CTG-TCT-ATT Probe: IBV 5' G: FAM-CAC-CAC-CAG-AAC-CTG-TCA-CCT-C-BHQ-1	10 µM 10 µM 4 µM	One cycle of 50°C/30 min and 95°C/15 min followed by 40 cycles of: 94°C/1 sec and 60°C/60 sec
<u>IBV M41/S1</u>	Mass-F': CGT-KTA-CTA-CTA-YCA-AAG-TGC Mass-R': CCA-TGA-ATA-RTA-CCA-ACA-RTA-CAC Mass-P: FAM-AGC-CTG-CAT-TAT-TAR-AT-MGBNFQ	10 µM 10 µM 4 µM	One cycle of 50°C/30 min and 95°C/15 min followed by 40 cycles of: 94°C/1 sec and 60°C/60 sec

238 ^(a)A denaturation step prior to cycling has not been included.

239 Rapid confirmation of IBV can be determined using a strategy that avoids post-amplification
 240 processing (sequence analysis). The most common method for IBV is real-time RT-PCR. The
 241 real-time RT-PCR assay uses specific probes against the target sequence, the use of fluorogenic
 242 hydrolysis probes or fluorescent dyes eliminate the requirement of any post-amplification
 243 processing step and results can be obtained in less than 3 hours.

244 A generic IBV real-time PCR that targets a conserved region in the IBV genome (e.g. the 5' UTR)
 245 can be used for the detection of IBV in a clinical sample (Callison et al., 2006). Lineage-genotype-
 246 specific real-time PCRs targeting the S1 gene for genotypes-lineages that are known to circulate
 247 in the region may be used in conjunction with this generic IBV PCR. Genotype-lineage specific
 248 primers and probes have been published for a number of genotypes such as Massachusetts
 249 (primer sets XCE3-(CAG-ATT-GCT-TAC-AAC-CAC-C) and MCE1+ (AAT-ACT-ACT-TTT-ACG-
 250 TTA-CAC), 793B primer sets XCE3-(CAG-ATT-GCT-TAC-AAC-CAC-C) and BCE1+ (AGT-AGT-
 251 TTT-GTG-TAT-AAA-CCA), Arkansas and others (Cavanagh et al., 1999; Roh et al., 2014).
 252 However, due to the high variability between and on-going evolution within genotypes (Valastro
 253 et al., 2016), continual updating of the genotype-specific and genotype-lineage-specific primers
 254 and probes is needed (Molenaar et al., 2020; 2024). When the genotype-lineage specific RT-
 255 PCRs are negative and the generic RT-PCR is positive, additional sequencing may be needed to
 256 identify the strain involved and to adapt the primers and probes used in the genotype specific
 257 PCRs accordingly. Using a genotype lineage-specific RT-PCR for every IBV vaccine strain used
 258 in the hatchery, each vaccine strain is expected to be detected around 5–7 days post-vaccination
 259 in a high percentage of the vaccinated birds confirming replication of the vaccine strain.

260 **2. Serological tests**

261 A number of tests have been described. Those considered here include VN, agar gel immunodiffusion (AGID), HI
 262 and ELISA. Each test has advantages and disadvantages in terms of practicality, specificity, sensitivity and cost. In
 263 general, ELISAs are most suitable for routine serological testing and can detect antibodies caused by vaccination
 264 and field exposure. ELISA can detect antibody responses to all serotypes, but a difference in sensitivity may exist
 265 for low antibody levels against strains of some serotypes. AGID also detects IBV antibodies against all types of IBV
 266 but lacks sensitivity and is liable to yield inconsistent results as the presence and duration of precipitating antibodies
 267 may vary with individual birds. VN and HI tests are more serotype specific, especially in young birds that have not
 268 been exposed to different types of IBV (de Wit, 2000). VN tests are too expensive and impractical for use in routine
 269 conditions. VN and HI when used on serial sera from young growing chickens such as pullets and broilers can give
 270 information on the serotype-specific antibody status of a flock. In layers and breeders, higher levels of HI or VN
 271 antibodies against the challenge virus are correlated with higher levels of protection against egg drop (Box et al.,
 272 1988; De Wit et al., 2019). Regular monitoring of sera from flocks for IB antibody titres may help to indicate the level
 273 of vaccine or field challenge responses. Because chicken sera from older birds that have been in contact with
 274 vaccines and the field strain of several serotypes contain antibodies that are highly cross-reactive against
 275 antigenically unrelated strains, serodiagnosis of suspected disease outbreaks of IB at the serotype level cannot be

276 used with a high degree of confidence as the detected antibodies against a certain serotype might be induced by
277 infections of other types of IBV.

278 **2.1. Virus neutralisation**

279 In VN tests, all sera should first be heated to 56°C for 30 minutes. Virus is mixed with serum and
280 incubated for 30–60 minutes at 37°C or room temperature. Chicken embryos are most often employed,
281 but antibodies can be measured using TOC or cell culture systems. Two methods have been used to
282 estimate neutralising antibodies. One employs a constant serum concentration reacted with varying
283 dilutions of virus (the alpha method) and the other employs a constant amount of virus and varying
284 dilutions of serum (the beta method).

285 In the alpha method, tenfold dilutions of egg-adapted virus are reacted with a fixed dilution (usually 1/5)
286 of antiserum, and the mixtures are inoculated into groups of from five to ten eggs. The virus alone is
287 titrated in parallel. End-points are calculated by the Kärber or the Reed and Muench methods. The results
288 are expressed as a neutralisation index (NI) that represents the \log_{10} difference in the titres of the virus
289 alone and that of the virus/antiserum mixtures. The NI values may reach 4.5–7.0 in the case of
290 homologous virus/serum mixtures; values of <1.5 are not specific, but a heterologous virus will give a
291 value as low as 1.5.

292 The beta method is the more widely used neutralisation test for antibody assay with chicken embryos or
293 cells. Two- or four-fold dilutions of antiserum are reacted in equal volumes with a dilution of virus, usually
294 fixed at 100 or 200 EID₅₀ (median embryo-infective doses) per 0.05 ml and 0.1 ml of each mixture
295 inoculated into the allantoic cavity of each of from five to ten embryonated eggs. A control titration of the
296 virus is performed simultaneously to confirm that the fixed virus dilution in the virus/serum mixtures was
297 between $10^{1.5}$ and $10^{2.5}$ EID₅₀. End-points of the serum titres are determined by the Kärber or Reed and
298 Muench method as before, but here are expressed as reciprocals of \log_2 dilutions. This fixed-
299 virus/varying-serum method is also employed for neutralisation tests in tracheal organ cultures using five
300 tubes per serum dilution, as is conventional with other viruses. The results are calculated according to
301 Reed and Muench, and the virus titres are expressed as median ciliostatic doses per unit volume
302 (\log_{10} CD₅₀). Serum titres are again expressed as \log_2 dilution reciprocals. This test is more sensitive
303 than others, but technical logistics hamper its more widespread adoption. For cell-adapted strains it is
304 recommended to check the S1 sequence for mutations that might affect the antigenicity.

305 **2.2. Haemagglutination inhibition**

306 A standard protocol for a HI test for IBV has been described (Alexander *et al.*, 1983), and the test
307 procedure detailed below is based on that standard. Most strains and isolates of IBV will agglutinate
308 chicken red blood cells (RBCs) after neuraminidase treatment (Schultze *et al.*, 1992). The strain selected
309 to produce antigen may be varied, depending on the requirements of diagnosis. The antigen for the HI
310 test is prepared from IBV-laden allantoic fluids.

311 For HA and HI tests, procedures are carried out at 4°C or a validated higher temperature, such as 20°C.

312 **2.2.1. Haemagglutination test**

- 313 i) Dispense 0.025 ml of PBS, pH 7.0–7.4, into each well of a plastic U-or-V-bottom microtitre
314 plate.
- 315 ii) Place 0.025 ml of virus antigen in the first well. For accurate determination of the HA content,
316 this should be done from a close range of an initial series of dilutions, i.e. 1/2, 1/3, 1/5, 1/7
317 and 1/9.
- 318 iii) Make twofold dilutions of 0.025 ml volumes of the virus antigen across the plate.
- 319 iv) Dispense a further 0.025 ml of PBS into each well.
- 320 v) Dispense 0.025 ml of 1% (v/v) chicken RBCs to each well.
- 321 vi) Mix by tapping the plate gently and allow the RBCs to settle for 40–60 minutes at 4°C, when
322 control RBCs should be settled to a distinct button.
- 323 vii) HA is ~~more easily~~ determined by tilting the plate and observing the presence or absence of
324 tear-shaped streaming of the RBCs. The titration should be read to the highest dilution giving
325 complete HA in which there is (no sedimentation or streaming); this is 100% HA and
326 represents 1 HA unit (HAU) and can be calculated accurately from the initial range of
327 dilutions.

-
- 328 **2.2.2. Haemagglutination-inhibition test**
- 329 The HI test is used in the diagnosis and routine flock monitoring of vaccine responses.
- 330 i) Dispense 0.025 ml of PBS into each well of a plastic U-or-V-bottom microtitre plate.
- 331 ii) Place 0.025 ml of serum into the first well of the plate.
- 332 iii) Make twofold dilutions of 0.025 ml volumes of the serum across the plate.
- 333 iv) Add 4 HAU of virus antigen in 0.025 ml to each well and leave for 30 minutes.
- 334 v) Add 0.025 ml of 1% (v/v) chicken RBCs to each well and, after gentle mixing, allow the RBCs
335 to settle for 40–60 minutes when control RBCs should be settled to a distinct button.
- 336 vi) The HI titre is the highest dilution of serum causing complete inhibition of 4 HAU of antigen.
337 The agglutination is assessed more exactly by tilting the plates. Only those wells in which
338 the RBCs ‘stream’ at the same rate as the control wells (containing 0.025 ml RBC and
339 0.05 ml PBS only) should be considered to show inhibition.
- 340 vii) The validity of results should be assessed against a negative control serum, which should
341 not give a titre $>2^2$, and a positive control serum, for which the titre should be within one
342 dilution of the known titre.
- 343 viii) Sera are usually regarded as positive if they have a titre of 2^4 or more. However, it should
344 be noted that even in SPF flocks, a very small proportion of birds may show a nonspecific
345 titre of 2^4 , but usually in birds over 1 year of age. Because chicken sera from older birds that
346 have been in contact with several types of IBV contain antibodies that can be highly cross-
347 reactive against antigenically unrelated strains, a cut-off of the HI test of 2^4 will be too low.

348 **2.3. Enzyme-linked immunosorbent assay**

349 Commercial kits for ELISAs are widely available and used. These ELISAs use different cut-offs and
350 mathematical formulas to convert the ELISA result into a titre. This means that every ELISA has its own
351 interpretation and the titre results of different ELISAs on the same serum will differ.

352 **C. REQUIREMENTS FOR VACCINES**

353 **1. Background**

354 Strains used in live virus vaccines generally require attenuation. At present, a minority of countries only permits the
355 use of attenuated live vaccines of the Massachusetts type, such as the H120 strain. Most countries also have
356 licensed-approved vaccines against other serotypes depending on the local situation and needs. Commonly used
357 administration routes for live vaccines are spray (course spray or aerosol) or in the drinking water (oral route).
358 Administration by eye-drop, if carefully done, is a very good method but in many cases too expensive or not possible
359 due to lack of vaccination crews.

360 The grouping of IBV strains that confer cross-protective immunity is the most important typing system from a
361 practical point of view because it provides direct information about the efficacy of a vaccine (de Wit, 2000). The
362 number of cross-protective groups that exists is unknown, but cross-challenge experiments in chicken tend to
363 identify a smaller number of groups compared with serotypes and genotypes, presumably because they are
364 measuring the complete immune response and not just a part of it. In general, there is a higher chance of a good
365 level of cross-protection between strains with a high level of genetic homology in the S-gene than between strains
366 with a low homology. However, the vaccination-challenge experiments have shown that the relationship is not very
367 strong (de Wit *et al.*, 2011). Therefore, a cross-immunisation study has to be performed to be able to determine the
368 cross-protective immunity of a strain. Many factors can influence the outcome of such studies and should be
369 accounted for (de Wit & Cook, 2014).

370 Live vaccines confer better local immunity in the respiratory tract and suitable combinations of vaccines of different
371 serotypes also may protect against a wider antigenic spectrum of field strains (Cook *et al.*, 1999; de Wit *et al.*, 2013).
372 Live vaccines carry a risk of residual pathogenicity associated with vaccine back-passage in flocks. However, proper
373 application of vaccine can achieve uniform distribution of the vaccine in the flock and avoid back-passage.
374 Furthermore, the use of vaccines at the manufacturer’s recommended dosages will also help avoid back-passage
375 reversion that may be caused by fractional dose application. For long-living birds, vaccination with live vaccines
376 only during the rearing period will often not be sufficient to induce a long-lasting protection against challenge in the
377 laying period. Boosting with inactivated vaccines of a good quality can be very efficient in increasing the level of
378 protection against challenge in the laying period. The efficacy of inactivated vaccines depends heavily on proper
379 priming with a live vaccine(s). Inactivated vaccines must be administered to birds individually, by intramuscular or

380 subcutaneous injection. Variant strains may be used to prepare inactivated autogenous vaccines for controlling IB
381 in layers and breeders, subject to local legislative requirements.

382 There are prospects for genetically engineered vaccines (Armesto *et al.*, 2011; Casais *et al.*, 2003), and *in-ovo*
383 vaccination (Tarpey *et al.*, 2006; Wakenell *et al.*, 1995), but the progress for live vaccines is slow compared with
384 other poultry diseases.

385 Guidelines for the production of veterinary vaccines are given in Chapter 1.1.8 *Principles of veterinary vaccine*
386 *production*. The guidelines given here and in chapter 1.1.8 are intended to be general in nature. National and
387 international standards that apply in the country in which IB vaccines are manufactured must be complied with. The
388 ~~licensing-regulatory~~ authority should provide information and guidance on requirements. These are now often
389 presented in general terms, as applying to all vaccines – avian and mammalian, live and inactivated, or viral and
390 bacterial vaccines. There may also be specific requirements applying to IB vaccines, live and inactivated. As
391 examples, references are given to the European and USA regulations (European Pharmacopoeia [~~2017a; 2017b~~
392 11.1, 2023; 11.4, 2024] ; USDA, ~~2017-2024~~).

393 For IB vaccines, important differences among countries may arise regarding the challenge virus to be used for
394 potency tests, and its validation. Traditionally, the virulent M41 (Mass 41) strain of the Massachusetts (Mass) type
395 has been used for challenge tests of both live and inactivated vaccines of the Mass serotype. Although this type is
396 still common, it is not the only or the dominant type in any country and many countries allow the use of vaccines
397 from other serotypes of IBV. Establishing criteria for validating the challenge virus may be more difficult for non-
398 Massachusetts types, because of their varying virulence. Inactivated vaccines are often expected to protect against
399 drops in egg production. The traditional M41 challenge should cause a drop of at least 67% in the unvaccinated
400 controls, which was considered by many IB specialists as being excessive and also too dependent on the chicken
401 genetic line and on particular challenge parameters. For other types of IBV, much lower drops in egg production
402 may be regarded as satisfactory, depending on published evidence of the effects of these strains in the field. It
403 therefore seems necessary to relax the criteria for Massachusetts type challenges, and the European
404 Pharmacopoeia now defines a satisfactory drop in egg production for Massachusetts types to be at least 35%, and
405 for non-Massachusetts types to be at least 15% in non-vaccinated birds, provided that the drop is 'commensurate
406 with the documented evidence' (European Pharmacopoeia). However, under laboratory conditions, in many cases
407 even a 35% drop in egg production by M41 or 15% for variant viruses is hard to achieve in the more modern genetic
408 chicken lines than in the past. It can be recommended that an egg drop of at least 10-15% in non-vaccinated birds
409 should be the minimal drop produced by any IB challenge virus. Appropriate statistical analyses should also be
410 included in any vaccination-challenge study. Inactivated and live vaccines may also claim protection against other
411 clinical signs such as respiratory signs, nephritis or loss of egg shell quality.

412 2. Outline of production and minimum requirements for vaccines

413 2.1. Characteristics of the seed

414 Guidelines for the production of veterinary vaccines are given in Chapter 1.1.8 *Principles of veterinary*
415 *vaccine production* and Chapter 1.1.9 *Tests for sterility and freedom from contamination of biological*
416 *materials for veterinary use*.

417 The seed-lot (master seed) system should be employed for whatever type of vaccine is produced. Each
418 virus must be designated as to strain and origin and must be free from contamination with other strains
419 of IBV and extraneous agents. The master seed virus is the backbone of the vaccine. A few samples of
420 the master seed are used to produce a working seed. This working seed is used for production batches.
421 The master seed should be of such a size that it is sufficient for the life span of a product.

422 For live virus vaccines, a minority of countries permit only strains of the Massachusetts type. Many
423 countries allow other strains as well, usually on the basis that those strains are already present in their
424 national flocks. The antigenic type incorporated in ~~both live and inactivated~~ vaccines requires justification
425 if there is doubt as to its existence in a country.

426 2.1.1. Biological characteristics of the master seed

427 i) Live vaccines

428 Currently live IBV vaccines are normally attenuated by multiple repeat passage of a virulent
429 virus in specific pathogen free (SPF) embryonated chicken eggs (Cavanagh, 2003).
430 Spontaneous mutations may arise throughout the IBV genome some of which lead to
431 attenuation of the virus, or minor populations present in the inoculum may be selected during
432 passaging, leading to attenuation. However, as a consequence of this method the
433 attenuated viruses produced by this approach have only a few mutations that are
434 responsible for loss of virulence and these will differ between vaccine strains. Two major
435 drawbacks of this method are that once the virus is used to inoculate chickens the mutations
436 within the attenuated vaccine viruses may back-mutate or be re-selected resulting in virulent

437 virus, an undesirable consequence, or that as a consequence of multiple passage the
438 immunogenicity of the attenuated virus will not result in adequate protection. Recent work
439 by Keep *et al.* (2024) has shown that the Beaudette S protein expressed from a virulent M41
440 genomic background not only attenuates the recombinant virus but provides protection
441 against challenge with virulent M41 indicating that multiple passage may not affect
442 antigenicity with respect to protection. ~~Therefore Nevertheless,~~ it is recommended that the
443 number of passages from the master seed to the working seeds is preferably not more than
444 five. Results from efficacy studies using experimental batches at the highest passage
445 claimed for production should be ~~taken into account~~ considered when setting the upper limit
446 of passage allowed for the vaccine. ~~To test the worst-case scenario, it is recommended to~~
447 ~~test the~~ It is essential that the efficacy ~~on using of~~ the working seed that is used to produce
448 the final product ~~that will be used in the field~~ must be determined. The master seed has to
449 comply satisfactorily with the required tests for extraneous agents and safety. The working
450 seeds must be grown in SPF chicken eggs to minimise the risk of introduction of potential
451 pathogens.

452 ii) Inactivated vaccines

453 The IBV strains, for inactivated vaccines, are grown in SPF eggs, non-SPF eggs from
454 healthy flocks (where allowed by the regulatory authority) or cell culture and are chemically
455 inactivated usually by an agent that binds to and destroys the genomic RNA. Batches of
456 inactivated virus suspension must be tested for residual infectivity using embryonated eggs
457 or suitable cell cultures.

458 Every seed lot must be free from bacterial, fungal, mycoplasmal and viral contamination.

459 For the detection of extraneous viruses, the seed is first treated with a high-titred monospecific
460 antiserum prepared against the strain under examination or against one of identical type. This
461 mixture is cultured in a variety of ways, designed to confirm the absence of any viruses considered
462 from past experience to be potential contaminants. The antiserum must not contain antibodies to
463 adenovirus, avian encephalomyelitis virus, avian rotavirus, chicken anaemia virus, fowlpox virus,
464 infectious laryngotracheitis virus, influenza A virus, Newcastle disease virus, infectious bursal
465 disease virus, leukosis virus, reovirus, Marek's disease virus, turkey herpesvirus, adeno-
466 associated virus, egg-drop syndrome 76 (EDS76) virus, avian nephritis virus, avian
467 metapneumovirus or reticuloendotheliosis virus. The inoculum given to each unit of the culture
468 system used should contain a quantity of the neutralised IBV component under test that had an
469 initial infectivity of at least ten times the minimum field dose. These systems include:

- 470 1. SPF chicken embryos, incubated for 9–11 days, inoculated via both allantoic sac and
471 chorioallantoic membrane (two passages);
- 472 2. Chicken embryo fibroblast cultures or other cells that are genetically susceptible for leukosis
473 virus subgroups A, B, and J but not to endogenous avian leukosis virus. The COFAL test
474 (test for avian leukosis using complement fixation), or double-antibody sandwich ELISA for
475 group-specific leukosis antigen is performed on cell extracts harvested at 14 days. An
476 immunofluorescence test for reticuloendotheliosis virus is done on cover-slip cultures after
477 two passages.
- 478 3. SPF chicken kidney cultures that are examined for CPEs, cell inclusions and haemadsorbing
479 agents passaged at intervals of no fewer than 5 days for up to 20 days' total incubation.
- 480 4. SPF chickens of minimum vaccination age inoculated intramuscularly with 100 field doses,
481 and on to the conjunctiva with ten field doses; this is repeated 2–3 weeks later ~~when the~~
482 ~~chickens are also inoculated both into the foot pad and intranasally with ten field doses.~~
483 Observations are made for 5–6 weeks overall, and serum is collected for tests for antibodies
484 against the extraneous viruses listed above—avian encephalomyelitis, infectious bursal
485 disease, Marek's disease, Newcastle disease and *Salmonella* Pullorum infection.

486 **2.1.2. Validation as a vaccine strain**

487 The vaccine virus shall be shown to be satisfactory with respect to safety and efficacy for the
488 chickens for which it is intended. Tests on vaccine virus should include a test for reversion ~~any~~
489 ~~potential ability to revert~~ to virulence. Live and inactivated vaccine seed must be tested for safety
490 as in Section C.2.2.4.

491 Efficacy should be demonstrated using a batch vaccine at the highest passage level intended to
492 be registered approved.

493 For live vaccines, a minimum of ten SPF chickens that are not older than the minimum age to be
494 recommended for vaccination are vaccinated by the route intended for field use (e.g. intranasally
495 or by eyedrop) at the recommended dose. Ten unvaccinated control birds from the same age and
496 source are retained separately. All birds of both groups are challenge inoculated either
497 intranasally or by eyedrop 3–4 weeks later or other time interval in line with the desired claim for
498 onset or duration of immunity, with $10^{3.0}$ – $10^{5.0}$ EID₅₀ of reference challenge virus, the optimal
499 challenge dose may depend on the challenge strain. A swab of the trachea is taken from each
500 bird 4–5 days after challenge and placed in 3 ml of antibiotic broth. Each fluid is tested for IBV by
501 the inoculation (0.2 ml) of five embryonated eggs, 9–11 days of age. An alternative test to that of
502 taking swabs is to kill birds at 4–6 days after challenge and examine microscopically the tracheal
503 rings for ciliary activity. Failure to resist challenge is indicated by an extensive loss of ciliary
504 motility. The live vaccine is suitable for use if at least 80% of the challenge vaccinated birds show
505 no evidence of infectious IBV in their trachea, while 80% or more of the control birds should have
506 evidence of the presence of the virus.

507 To assess an inactivated vaccine intended to protect laying birds, 30 or more SPF chickens are
508 vaccinated as recommended at the earliest permitted age. If a primary vaccination with live
509 vaccine is first undertaken, an additional group of birds is given only the primary vaccination. In
510 both cases, these primary vaccinations should be done at no later than 3 weeks of age. The
511 inactivated vaccine is given after the live priming vaccination according to the vaccination
512 schedule to be recommended. A further group of 30 control birds are left unvaccinated. All groups
513 are housed separately until 4 weeks before peak egg production, and then are housed together
514 or in similar conditions. ~~Individual~~ Egg production is monitored and once it is regular, all birds are
515 challenged, egg production being recorded for ~~a further 3–4 weeks~~ at least 4 weeks. The
516 challenge should be sufficient to ensure a significant loss of production ~~during the 3 weeks~~
517 after challenge. The loss in the non-vaccinated control group should be at least 35% where challenge
518 has been made with a Massachusetts-type strain unless justified. Where it is necessary to carry
519 out a challenge with a strain of another serotype for which there is documented evidence that the
520 strain will not cause a 35% drop in egg production, the challenge must produce a drop in egg
521 production commensurate with the documented evidence and not less than 15% unless justified.

522 ~~;~~ ~~the group that received primary live virus vaccine followed by inactivated vaccine should not~~
523 ~~significantly drop in production compared with the previous level, and the group given only a~~
524 ~~primary vaccination should show an intermediate drop in production. The vaccine complies with~~
525 ~~the test if egg production or quality is significantly better in the group having received the~~
526 ~~inactivated vaccine than in any control group. The inactivated vaccine complies with the test if~~
527 ~~egg production or egg quality is significantly better in the group vaccinated with live and~~
528 ~~inactivated vaccine than in the group only vaccinated with live vaccine, and the egg production or~~
529 ~~egg quality of the group vaccinated with the inactivated vaccine is significantly better than in the~~
530 ~~non-vaccinated group.~~

531 Sera are collected from all birds at vaccination, 4 weeks later, and at challenge; there should be
532 no response in the negative control birds.

533 To assess an inactivated vaccine intended to protect birds against respiratory disease, 20 SPF
534 chickens aged 4 weeks are vaccinated as recommended. An additional 20 control birds of the
535 same age and origin are housed with this first group. Antibody responses are determined 4 weeks
536 later; there should be no response in the control birds. All birds are then challenged with 10^3 CID₅₀
537 (50% chick infective dose) or other dose depending on the strain of virulent virus, killed 4–7 days
538 later, and tracheal sections are examined for ciliary motility, or tracheal swabs evaluated for
539 challenge virus recovery. At least 80% of the unvaccinated controls should display complete
540 ciliostasis, whereas the tracheal cilia of a similar percentage of the vaccinated birds should remain
541 unaffected. Tracheal swabs from at least 90% of the vaccinated birds should be negative for virus
542 isolation, while tracheal swabs from at least 90% of the control birds should be positive for virus
543 isolation.

544 Both live and inactivated multivalent vaccines containing other fractions such as Newcastle
545 disease, infectious bursal disease, avian metapneumo-, reo- and EDS76 viruses are available.
546 The efficacy of the different fractions of these vaccines should each be established; this should
547 also be evaluated in the combination vaccine to assess possible interference between the
548 different vaccine components.

549 **2.2. Method of manufacture**

550 **2.2.1. Procedure**

551 All virus strains destined for live attenuated vaccines are cultured in the allantoic sac of SPF
552 chicken embryos or in suitable cell cultures. For inactivated vaccines, hens' eggs from healthy
553 non-SPF flocks (where permitted by the regulatory authority) or suitable cell cultures may be used.
554 The pooled fluid is clarified and then titrated for infectivity. For live vaccines this fluid is lyophilised
555 or frozen in vials, tablets or other forms, and for inactivated vaccines, the inactivated virus is
556 blended with e.g. high-grade mineral oil or other suitable adjuvant to form an emulsion to which a
557 preservative can be added.

558 **2.2.2. Requirements for ingredients**

559 See chapter 1.1.8 with special focus on products of biological origin (POBs) originating from a
560 country with negligible risk for transmissible spongiform encephalopathies (TSEs).

561 **2.2.3. In-process controls**

562 The required antigen content is based on initial test batches of vaccine of proven efficacy in
563 laboratory and field trials. Infectivity titrations are done in chicken embryos.

564 Live vaccine should have a titre not less than the minimum dose, which has been proven to be
565 efficacious in the laboratory studies. For inactivated vaccines, which are produced on hens' eggs
566 from healthy non-SPF flocks, validated methods must be in place to exclude the presence of
567 potential contaminants in the eggs. Otherwise, the inactivating agent and inactivation procedure
568 must be shown under manufacture not only to be effective on IBV, but also on other potential
569 contaminants; with the use of beta-propiolactone or formalin, any live leukosis viruses and
570 Salmonella species must be eliminated; and with other inactivating agents, the complete range of
571 potential contaminants must be rendered ineffective. Before inactivation procedures, it is
572 important to ensure homogeneity of suspensions, and a test of inactivation should be conducted
573 on each batch of both bulk harvest after inactivation and the final product.

574 **2.2.4. Final product batch tests**

575 i) Sterility

576 Every batch of live vaccine should be tested for the absence of extraneous agents as for the
577 seed virus (see chapter 1.1.9). For vaccines administered via drinking water, spray or ~~skin~~
578 ~~scarification~~ in ovo, one non-pathogenic micro-organism per dose is acceptable.

579 ii) Safety (target animal batch safety test)

580 a) For live attenuated vaccines

581 Use no fewer than ten chickens from an SPF flock that are of the minimum age stated on
582 the label for vaccination. Administer by eyedrop to each chicken ten doses of the vaccine
583 reconstituted so as to obtain a concentration suitable for the test. Observe the chickens for
584 21 days. For vaccines intended for chickens that are 2 weeks old or more, use the chickens
585 inoculated in the 'test for extraneous agents using chickens' (see Section C.2.1.1 point 4).
586 If during the period of observation, more than two chickens die from causes not attributable
587 to the vaccine, repeat the test. The vaccine complies with the test if no chicken shows
588 serious clinical signs, in particular respiratory signs, and no chicken dies from causes
589 attributable to the vaccine.

590 b) For inactivated vaccines

591 Inject a double dose of vaccine by the recommended route into each of ten 14- to 28-day-
592 old chickens from an SPF flock. Observe the chickens for 21 days. Ascertain that no
593 abnormal local or systemic reaction occurs.

594 Safety tests in target animals are not required by many regulatory authorities for the release of
595 each batch. Where required, standard procedures are generally conducted using fewer animals
596 than are used in the safety tests required for the relevant regulatory approval.

597 iii) Batch potency

598 The potency test is developed from the results of efficacy tests on the furthest passage from
599 the master seed virus. Live vaccines are tested for potency by titration of infectivity, and

600 inactivated vaccines by measuring antibody production or alternative methods. An example
601 of a potency test for inactivated vaccine consists of vaccinating 10 SPF chickens, at least 2
602 weeks of age, and showing that their mean HI titre 4 weeks later is not significantly less than
603 those obtained for a batch that has shown satisfactory efficacy.

604 iv) Stability

605 Vaccine must be shown to have the required potency to achieve the claimed duration of
606 immunity at the end of the claimed shelf life.

607 At least three batches should be tested for stability and must give satisfactory results for
608 3 months beyond the claimed shelf life. The stability of a live vaccine must be measured by
609 maintenance of an adequate infectivity titre. The stability of an inactivated vaccine is
610 measured at intervals by batch potency tests. The concentration of preservative and
611 persistence through the shelf life should be assessed. There should be no physical change
612 in the vaccine and it should regain its former emulsion state after one quick shake.

613 There are maximum level requirements for the use of antibiotics, preservatives and residual
614 inactivating agents.

615 **2.3. Requirements for ~~authorisation/registration/licensing~~ regulatory approval**

616 **2.3.1. Manufacturing process**

617 For ~~registration approval~~ of vaccine, all relevant details concerning manufacture of the vaccine
618 and quality control testing (see Section C.2.1 and 2) should be submitted to the authorities.
619 Information shall be provided from three consecutive vaccine batches to demonstrate consistency
620 of production.

621 **2.3.2. Safety requirements**

622 Additional testing required for live IB vaccines and precautions:

623 i) The reversion-to-virulence test carried out should be consistent with VICH GL41
624 (Examination of live veterinary vaccines in target animals for absence of reversion to
625 virulence, 2008¹). Reversion-to-virulence for attenuated/live vaccines and environmental
626 considerations (dissemination and spread of live vaccines and their potential to cause
627 problems for non-vaccinated animals and non-target animals in case of genetically modified
628 vaccines). The vaccine complies when there is no indication of an increase in virulence of
629 virus recovered from the final bird passage compared with the original vaccine that was used
630 for the first passage. It is recommended to use at least five sequential passages over birds
631 by natural spreading or eye-drop application of a suspension of fresh mucosal tissue.
632 Validated alternative methods may be used as well.

633 ii) Precautions (hazards)

634 IBV itself is not known to present any danger to staff employed in vaccine manufacture or
635 testing. Extraneous agents may be harmful, however, and the initial stages of handling a
636 new seed virus should be carried out in a safety cabinet. It is a wise precaution with all
637 vaccine production to take steps to minimise exposure of staff to aerosols of foreign proteins.
638 Persons allergic to egg materials must never be employed in this work. Manufacturers
639 should provide adequate warnings that medical advice should be sought in the case of self-
640 injection (including for adjuvants, oil-emulsion vaccine, preservatives, etc.) with warnings
641 included on the product label/leaflet so that the vaccinator is aware of any danger.

642 **2.3.3. Efficacy requirements**

643 To ~~register~~ achieve regulatory approval, a commercial vaccine, a batch or batches produced
644 according to the standard method and containing the minimum amount of antigen or potency
645 value shall prove its efficacy (protection). Efficacy should be demonstrated using a batch vaccine
646 at the highest passage level intended to be ~~registered~~ approved. Each batch of live vaccine should
647 contain sufficient live virus per dose per bird to last until the expiry date, indicated as the minimum
648 dose that has been proven to be efficacious in laboratory studies.

¹ https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl41-target-animal-safety-examination-live-veterinary-vaccines-target-animals-absence-reversion_en.pdf

649 Vaccine efficacy (protection) is estimated in vaccinated animals directly by evaluating their
650 resistance to challenge. Vaccine efficacy should be established for each serotype of IBV against
651 which protection is claimed.

652 The challenge models for determining efficacy are as outlined in Section C.2.2.2.1.2.

653 **REFERENCES**

654 ALEXANDER D.J., ALLAN W.H., BIGGS P.M., BRACEWELL C.D., DARBYSHIRE J.H., DAWSON P.S., HARRIS A.H., JORDAN
655 F.T., MACPHERSON I., MCFERRAN J.B., RANDALL C.J., STUART J.C., SWARBRICK O. & WILDING G.P. (1983). A standard
656 technique for haemagglutination inhibition tests for antibodies to avian infectious bronchitis virus. *Vet. Rec.*, **113**,
657 64.

658 ARMESTO M., EVANS S., CAVANAGH D., ABU-MEDIAN A.B., KEEP S. & BRITTON P. (2011). A recombinant avian
659 infectious bronchitis virus expressing a heterologous spike gene belonging to the 4/91 serotype. *PLoS ONE*, **6**,
660 e24352.

661 BOX P.G., HOLMES H.C., FINNEY P.M. & FROYMANN R. (1988). Infectious bronchitis in laying hens: the relationship
662 between haemagglutination inhibition antibody levels and resistance to experimental challenge. *Avian Pathol.*, **17**,
663 349–361.

664 BRITTON P. & CAVANAGH D. (2007). Avian coronavirus diseases and infectious bronchitis vaccine development. *In*:
665 *Coronaviruses: Molecular and Cellular Biology*. Thiel V., ed. Caister Academic Press, Norfolk, UK, 161–181.

666 CALLISON S.A., HILT D.A., BOYNTON T.O., SAMPLE B.F., ROBISON R., SWAYNE D.E. & JACKWOOD M.W. (2006).
667 Development and evaluation of a real-time Taqman RT-PCR assay for the detection of infectious bronchitis virus
668 from infected chickens. *J. Virol. Methods*, **138**, 60–65.

669 CASAIS R., DOVE B., CAVANAGH D. & BRITTON P. (2003). A recombinant avian infectious bronchitis virus expressing a
670 heterologous spike gene demonstrates that the spike protein is a determinant of cell tropism. *J. Virol.*, **77**, 9084–
671 9089.

672 CAVANAGH D. (2003). Severe acute respiratory syndrome vaccine development: experiences of vaccination against
673 avian infectious bronchitis coronavirus. *Avian Pathol.*, **32**, 567–582.

674 CAVANAGH D., MAWDITT K., BRITTON P. & NAYLOR C.J. (1999). Longitudinal field studies of infectious bronchitis virus
675 and avian pneumovirus in broilers using type-specific polymerase chain reactions. *Avian Pathol.*, **28**, 593–605.

676 CAVANAGH D., MAWDITT K., SHARMA M., DRURY S.E., AINSWORTH H.L., BRITTON P. & GOUGH R.E. (2001). Detection of
677 a coronavirus from turkey poult in Europe genetically related to infectious bronchitis virus of chickens. *Avian*
678 *Pathol.*, **30**, 355–368.

679 CAVANAGH D., MAWDITT K., WELCHMAN D. DE B., BRITTON P. & GOUGH R.E. (2002). Coronaviruses from pheasants
680 (*Phasianus colchicus*) are genetically closely related to coronaviruses of domestic fowl (infectious bronchitis virus)
681 and turkeys. *Avian Pathol.*, **31**, 81–93.

682 COOK J.K.A., DARBYSHIRE J.H. & PETERS R.W. (1976). The use of chicken tracheal organ cultures for the isolation
683 and assay of avian infectious bronchitis virus. *Arch. Virol.*, **50**, 109–118.

684 COOK J.K.A., ORBELL S.J., WOODS M.A. & HUGGINS M.B. (1999). Breadth of protection of the respiratory tract provided
685 by different live-attenuated infectious bronchitis vaccines against challenge with infectious bronchitis viruses of
686 heterologous serotypes. *Avian Pathol.*, **28**, 477–485.

687 DARBYSHIRE J.H., COOK J.K.A. & PETERS R.W. (1978). Growth comparisons of avian infectious bronchitis virus strains
688 in organ cultures of chicken tissues. *Arch. Virol.*, **56**, 317–325.

689 DE WIT J.J. (2000). Technical review. Detection of infectious bronchitis virus. *Avian Pathol.*, **29**, 71–93.

690 DE WIT J.J., BOELM G.J., VAN GERWE T.J. & SWART W.A. (2013). The required sample size in vaccination-challenge
691 experiments with infectious bronchitis virus, a meta-analysis. *Avian Pathol.*, **42**, 9–16.

692 DE WIT J.J. & COOK J.K. (2014). Factors influencing the outcome of infectious bronchitis vaccination and challenge
693 experiments. *Avian Pathol.*, **43**, 485–497.

- 694 DE WIT J.J., COOK J.K. & VAN DER HEIJDEN H.M. (2011). Infectious bronchitis virus variants: a review of the history,
695 current situation and control measures. *Avian Pathol.*, 40, 223–235.
- 696 DE WIT J.J., MALO A. & COOK J.K.A. (2019). Induction of IBV strain-specific neutralizing antibodies and broad
697 spectrum protection in layer pullets primed with IBV Massachusetts (Mass) and 793B vaccines prior to injection of
698 inactivated vaccine containing Mass antigen. *Avian Pathol.*, 48, 135–147.
- 699 EUROPEAN PHARMACOPOEIA 9th (2017a). Avian infectious bronchitis vaccine (live). European Directorate for the
700 Quality of Medicines and HealthCare (EDQM), Council of Europe, Strasbourg, France, 1008–1010.
- 701 EUROPEAN PHARMACOPOEIA 9th (2017b). Avian infectious bronchitis vaccine (inactivated). European Directorate for
702 the Quality of Medicines and HealthCare (EDQM), Council of Europe, Strasbourg, France, 1007–1008.
- 703 EUROPEAN PHARMACOPOEIA 11.1 (2023). Avian bronchitis virus vaccine (live). European Directorate for the Quality of
704 Medicines and HealthCare (EDQM), Council of Europe, Strasbourg, France, 4597–4598.
- 705 EUROPEAN PHARMACOPOEIA 11.4 (2024). Avian bronchitis virus vaccine (inactivated). European Directorate for the
706 Quality of Medicines and HealthCare (EDQM), Council of Europe, Strasbourg, France, 5542–5543.
- 707 JACKWOOD M.W. (2012). Review of infectious bronchitis virus around the world. *Avian Dis.*, 56, 634–641.
- 708 JACKWOOD M.W. & DE WIT J.J. (2013). Infectious Bronchitis. *In: Diseases of Poultry*, Thirteenth edition, Swayne D.E.,
709 Glisson J.R., McDougald L.R., Nolan L.K., Suarez D.L. & Nair V., Eds. Blackwell Publishing Professional Ames,
710 Iowa, USA, 117–135.
- 711 JACKWOOD M.W. & DE WIT J.J. (2020). Infectious Bronchitis. *In: Diseases of Poultry*, Fourteenth edition, Swayne
712 D.E., Boulianne M., McDougald L.R., Nair V. & Suarez D.L., eds. Wiley-Blackwell, Hoboken, New Jersey, USA,
713 167–188.
- 714 KEEP S., STEVENSON-LEGGETT P., WEBB I., FONES A., KIRK J., BRITTON P. & BICKERTON E. (2024). The spike protein of
715 the apathogenic Beaudette strain of avian coronavirus can elicit a protective immune response against a virulent
716 M41 challenge. *PLoS One*, 19(1): e0297516. <https://doi.org/10.1371/journal.pone.0297516>.
- 717 MOLENAAR R.J., DIJKMAN R. & DE WIT J.J. (2020). Characterization of infectious bronchitis virus D181, a new serotype
718 (GII-2). *Avian Pathol.*, 49, 243–250.
- 719 MOLENAAR R.J., DIJKMAN R., JORNA I. & DE WIT J.J. (2024). Extensive genetic and biological characterization of
720 infectious bronchitis virus strain D2860 of genotype GVIII. *Avian Pathol.*, 53 (accepted).
- 721 MURADRASOLI S., BALINT A., WAHLGREN J., WALDENSTROM J., BELAK S., BLOMBERG J. & OLSEN B. (2010). Prevalence
722 and phylogeny of coronaviruses in wild birds from the Bering Strait area (Beringia). *PLoS One*, 5, e13640.
- 723 ROH H.J., JORDAN B.J., HILT D.A. & JACKWOOD M.W. (2014). Detection of infectious bronchitis virus with the use of
724 real-time quantitative reverse transcriptase-PCR and correlation with detection in embryonated eggs. *Avian Dis.*,
725 58, 398–403.
- 726 SCHULTZE B., CAVANAGH D. & HERRLER G. (1992). Neuraminidase treatment of avian infectious bronchitis coronavirus
727 reveals a haemagglutinating activity that is dependent on sialic acid-containing receptors on erythrocytes. *Virology*,
728 189, 792–794.
- 729 TARPEY I., ORBELL S.J., BRITTON P., CASAIS R., HODGSON T., LIN F., HOGAN E. & CAVANAGH D. (2006). Safety and
730 efficacy of an infectious bronchitis virus used for chicken embryo vaccination. *Vaccine*, 24, 6830–6838.
- 731 UNITED STATES DEPARTMENT OF AGRICULTURE (USDA), Animal and Plant Health Inspection Service (APHIS)
732 (4 January, 2017–13 March 2024). Code of Federal Regulations. 9 CFR § 113.327 Bronchitis Vaccine. US
733 Government Printing Office, Washington, D.C., USA. [https://www.gpo.gov/fdsys/granule/CFR-2011-title9-](https://www.gpo.gov/fdsys/granule/CFR-2011-title9-vol1/CFR-2011-title9-vol1-sec113-327)
734 [vol1/CFR-2011-title9-vol1-sec113-327](https://www.gpo.gov/fdsys/granule/CFR-2011-title9-vol1-sec113-327)
- 735 VALASTRO V., HOLMES E. C., BRITTON P., FUSARO A., JACKWOOD M.W., CATTOLI G. & MONNE I. (2016). S1 gene-based
736 phylogeny of infectious bronchitis virus: An attempt to harmonize virus classification. *Infect. Genet. Evol.*, 39, 349–
737 364.

738 WAKENELL P.S., SHARMA J.M. & SLOCOMBE R.F. (1995). Embryo vaccination of chickens with infectious bronchitis
739 virus: histologic and ultrastructural lesion response and immunologic response to vaccination. *Avian Dis.*, **39**, 752–
740 765.

741 WOO P.C.Y., LAU S.K.P., LAM C.S.F., LAU C.C.Y., TSANG A.K.L., LAU J.H.N., BAI R., TENG J.L.L., TSANG C.C.C.,
742 WANG M., ZENG B.-J., CHAN K.-H. & YUEN K.-Y. (2012). Discovery of seven novel mammalian and avian
743 coronaviruses in the genus *Deltacoronavirus* supports Bat coronaviruses as the gene source of *Alphacoronavirus*
744 and *Betacoronavirus* and avian coronaviruses as the gene source of *Gammacoronavirus* and *Deltacoronavirus*. *J.*
745 *Viro.*, **86**, 3995–4008.

746 *
747 * *

748 **NB:** At the time of publication (~~2018-2024~~) there were no WOA Reference Laboratories
749 for avian infectious bronchitis (~~adenomatosis~~) (please consult the WOA Web site:
750 <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>).

751 **NB:** FIRST ADOPTED IN 1989. MOST RECENT UPDATES ADOPTED IN 2018.

Appendix 1: Avian infectious bronchitis
Intended purpose of test: population freedom from infection

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Virus isolation</u> ± <u>avian</u>	<u>Organ samples, swabs</u>	<u>High in acute phase of infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Detects infectious virus, basis for strains for experiments and antigens</u>	<u>Low availability</u>	<u>De Wit (2000)</u>
<u>Conventional RT-PCR</u> ++ <u>avian</u>	<u>RNA</u>	<u>High in acute phase of infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Basis for sequencing</u>		<u>De Wit (2000)</u>
<u>Real-time RT-PCR conserved gene</u> ++ <u>avian</u>	<u>RNA</u>	<u>High in acute and subacute phase of the infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Ct value provides information about quantity</u>	<u>No difference between vaccines and field strains of same genotype-lineage</u>	<u>De Wit (2000)</u>
<u>Real-time RT-PCR lineage or genotype specific</u> ++ <u>avian</u>	<u>RNA</u>	<u>High in acute and subacute phase of the infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Ct value provides information about quantity</u>	<u>No difference between vaccines and field strains of same genotype-lineage, panel must be appropriate for the region</u>	<u>De Wit (2000)</u>
<u>ELISA</u> ++ <u>avian</u>	<u>Serum antibodies</u>	<u>Positive in 2 weeks post-infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Group-specific, commercial ELISAs for chicken sera are widely available</u>	<u>Group-specific can remain negative in well protected young birds</u>	<u>De Wit (2000)</u>

Appendix 2: Avian infectious bronchitis
Intended purpose of test: individual animal freedom from infection prior to movement

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Virus isolation</u> ++ <u>avian</u>	<u>Organ samples, swabs</u>	<u>High in acute phase of infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Detects infectious virus, basis for strains for experiments and antigens</u>	<u>Low availability</u>	<u>De Wit (2000)</u>
<u>Conventional RT-PCR</u> ++ <u>avian</u>	<u>RNA</u>	<u>High in acute phase of infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Basis for sequencing</u>		<u>De Wit (2000)</u>
<u>Real-time RT-PCR</u> ++ <u>avian</u>	<u>RNA</u>	<u>High in acute and subacute phase of the infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Ct value provides information about quantity</u>	<u>No difference between vaccines and field strains of same genotype-lineage</u>	<u>De Wit (2000)</u>
<u>ELISA</u> ± <u>avian</u>	<u>Serum antibodies</u>	<u>Positive in 2 weeks post-infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Group-specific, commercial ELISAs for chicken sera are widely available</u>		<u>De Wit (2000)</u>

Appendix 3: Avian infectious bronchitis
Intended purpose of test: contribute to eradication policies

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Conventional RT-PCR</u> <u>++</u> <u>avian</u>	<u>RNA</u>	<u>High in acute phase of infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Basis for sequencing</u>		<u>De Wit (2000)</u>
<u>Real-time RT-PCR conserved gene</u> <u>++</u> <u>avian</u>	<u>RNA</u>	<u>High in acute and subacute phase of the infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Ct value provides information about quantity</u>	<u>No difference between vaccines and field strains of same genotype-lineage</u>	<u>De Wit (2000)</u>
<u>Real-time RT-PCR lineage or genotype specific</u> <u>++</u> <u>avian</u>	<u>RNA</u>	<u>High in acute and subacute phase of the infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Ct value provides information about quantity</u>	<u>No difference between vaccines and field strains of same genotype-lineage, panel must be appropriate for the region</u>	<u>De Wit (2000)</u>
<u>HIT</u> <u>±</u> <u>avian</u>	<u>Serum HI antibodies</u>	<u>Seroconversion usually within 2 weeks</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Serotype specificity, correlation with level of protection in layers and breeders</u>	<u>Serotype specificity drops in case of contact with multiple types of IBV, difference between laboratories can be significant</u>	<u>De Wit (2000)</u>
<u>ELISA</u> <u>++</u> <u>avian</u>	<u>Serum antibodies</u>	<u>Seroconversion usually within 2 weeks</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Group specific, commercial ELISAs for chicken sera are widely available</u>	<u>Group specific can remain negative in well protected young birds</u>	<u>De Wit (2000)</u>

Appendix 4: Avian infectious bronchitis
Intended purpose of test: confirmation of clinical cases

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Virus isolation</u> +++ <u>avian</u>	<u>Organ samples, swabs</u>	<u>High in acute phase of infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Detects infectious virus, basis for strains for experiments and antigens</u>	<u>Low availability</u>	<u>De Wit (2000)</u>
<u>Staining by immunohistochemistry</u> ∇ ++ <u>avian</u>	<u>Organs</u>		<u>Multiple studies</u>	<u>See reference</u>	<u>Shows infection of cells</u>	<u>Low availability</u>	<u>De Wit (2000)</u>
<u>Gene sequencing</u> ++ <u>avian</u>	<u>RNA</u>	<u>High</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Epidemiology, vaccines and field strains of same genotype lineage can be discriminated</u>	<u>Relevance of mutations hard to predict</u>	<u>De Wit (2000)</u>
<u>Conventional RT-PCR</u> +++ <u>avian</u>	<u>RNA</u>	<u>High in acute phase of infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Basis for sequencing</u>		<u>De Wit (2000)</u>
<u>Real-time RT-PCR conserved gene</u> +++ <u>avian</u>	<u>RNA</u>	<u>High in acute and subacute phase of the infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Ct value provides information about quantity</u>	<u>No difference between vaccines and field strains of same genotype lineage</u>	<u>De Wit (2000)</u>
<u>Real-time RT-PCR Lineage or genotype specific</u> ++ <u>avian</u>	<u>RNA</u>	<u>High in acute and subacute phase of the infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Ct value provides information about quantity</u>	<u>No difference between vaccines and field strains of same genotype lineage, panel must be appropriate for the region</u>	<u>De Wit (2000)</u>
<u>VNT</u> + <u>avian</u>	<u>Serum neutralising antibodies</u>	<u>Seroconversion usually within 3 weeks</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Serotype specificity, correlation with level of protection in layers and breeders</u>	<u>Serotype specificity drops in case of contact with multiple types of IBV</u>	<u>De Wit (2000)</u>

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>HIT</u> <u>±</u> <u>avian</u>	<u>Serum</u> <u>HI antibodies</u>	<u>Seroconversion usually</u> <u>within 2 weeks</u>	<u>Multiple</u> <u>studies</u>	<u>See</u> <u>reference</u>	<u>Serotype specificity,</u> <u>correlation with level of</u> <u>protection in layers and</u> <u>breeders</u>	<u>Serotype specificity drops in</u> <u>case of contact with multiple</u> <u>types of IBV,</u> <u>difference between</u> <u>laboratories can be significant</u>	<u>De Wit (2000)</u>
<u>ELISA</u> <u>±±</u> <u>avian</u>	<u>Serum</u> <u>antibodies</u>		<u>Multiple</u> <u>studies</u>	<u>See</u> <u>reference</u>	<u>Group specific, commercial</u> <u>ELISAs for chicken sera</u> <u>are widely available</u>	<u>Group specific can remain</u> <u>negative in well protected</u> <u>young birds</u>	<u>De Wit (2000)</u>

Appendix 5: Avian infectious bronchitis
Intended purpose of test: prevalence of infection – surveillance

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Virus isolation</u> ++ avian	<u>Organ samples, swabs</u>	<u>High in acute phase of infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Detects infectious virus, basis for strains for experiments and antigens</u>	<u>Low availability</u>	<u>De Wit (2000)</u>
<u>Staining by immunohistochemistry</u> √ ± avian	<u>Organs</u>		<u>Multiple studies</u>	<u>See reference</u>	<u>Shows infection of cells</u>	<u>Low availability</u>	<u>De Wit (2000)</u>
<u>Gene sequencing</u> ± avian	<u>RNA</u>	<u>High</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Epidemiology, vaccines and field strains of same genotype-lineage can be discriminated</u>	<u>Relevance of mutations hard to predict</u>	<u>De Wit (2000)</u>
<u>Conventional RT-PCR</u> +++ avian	<u>RNA</u>	<u>High in acute phase of infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Basis for sequencing</u>		<u>De Wit (2000)</u>
<u>Real-time RT-PCR conserved gene</u> +++ avian	<u>RNA</u>	<u>High in acute and subacute phase of the infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Ct value provides information about quantity</u>	<u>No difference between vaccines and field strains of same genotype lineage</u>	<u>De Wit (2000)</u>
<u>Real-time RT-PCR Lineage or genotype specific</u> ++ avian	<u>RNA</u>	<u>High in acute and subacute phase of the infection</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Ct value provides information about quantity</u>	<u>No difference between vaccines and field strains of same genotype lineage, panel must be appropriate for the region</u>	<u>De Wit (2000)</u>
<u>VNT</u> ± avian	<u>Serum neutralising antibodies</u>	<u>Seroconversion usually within 3 weeks</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Serotype specificity, correlation with level of protection in layers and breeders</u>	<u>Serotype specificity drops in case of contact with multiple types of IBV</u>	<u>De Wit (2000)</u>

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>HIT</u> <u>±</u> <u>avian</u>	<u>Serum</u> <u>HI antibodies</u>	<u>Seroconversion</u> <u>usually within</u> <u>2 weeks</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Serotype specificity,</u> <u>correlation with level of</u> <u>protection in layers and</u> <u>breeders</u>	<u>Serotype specificity drops in</u> <u>case of contact with multiple</u> <u>types of IBV,</u> <u>Difference between</u> <u>laboratories can be</u> <u>significant</u>	<u>De Wit (2000)</u>
<u>ELISA</u> <u>±±</u> <u>Avian</u>	<u>Serum antibodies</u>		<u>Multiple studies</u>	<u>See reference</u>	<u>Group specific, commercial</u> <u>ELISAs for chicken sera are</u> <u>widely available</u>	<u>Group specific can remain</u> <u>negative in well protected</u> <u>young birds</u>	<u>De Wit (2000)</u>

762

763

Appendix 6: Avian infectious bronchitis**Intended purpose of test: Immune status in individual animals or populations post-vaccination**

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population used to measure accuracy</u>	<u>Validation report</u>	<u>Advantages: expert opinion</u>	<u>Disadvantages: expert opinion</u>	<u>References</u>
<u>VNT</u> <u>++</u> <u>avian</u>	<u>Serum neutralising antibodies</u>	<u>Seroconversion usually within 3 weeks</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Serotype specificity, correlation with level of protection in layers and breeders</u>	<u>Serotype specificity drops in case of contact with multiple types of IBV</u>	<u>De Wit (2000)</u>
<u>HIT</u> <u>++</u> <u>avian</u>	<u>Serum HI antibodies</u>	<u>Seroconversion usually within 2 weeks</u>	<u>Multiple studies</u>	<u>See reference</u>	<u>Serotype specificity, correlation with level of protection in layers and breeders</u>	<u>Serotype specificity drops in case of contact with multiple types of IBV. Difference between laboratories can be significant</u>	<u>De Wit (2000)</u>
<u>ELISA</u> <u>++</u> <u>avian</u>	<u>Serum antibodies</u>		<u>Multiple studies</u>	<u>See reference</u>	<u>Group specific, commercial ELISAs for chicken sera are widely available</u>	<u>Group specific can remain negative in well protected young birds</u>	<u>De Wit (2000)</u>

CHAPTER 3.3.4.

AVIAN INFLUENZA
(INCLUDING INFECTION WITH HIGH PATHOGENICITY
AVIAN INFLUENZA VIRUSES)

SUMMARY

Influenza A-Avian influenza (AI) is a viral disease caused by specified viruses that are members of belong to the family Orthomyxoviridae, and placed in the genus Alphainfluenzavirus (Influenzavirus A or influenza A virus). There are seven influenza-four influenzavirus genera (Alphainfluenzavirus, Betainfluenzavirus, Gammainfluenzavirus, Deltainfluenzavirus), but only influenza A viruses are known to infect birds. Diagnosis is by detection and characterisation of fragments of their genome or by isolation of the virus or by detection and further characterisation of fragments of its genome. This is because Infections in birds can give rise to a wide variety of clinical signs that may vary according to the host (e.g. species, age, immune status, opportunistic co-infections), strain of virus, the host's immune status, presence of any secondary exacerbating organisms and environmental conditions. Certain strains of avian influenza virus (AIV) can infect mammals and spillover events have sporadically been observed in humans.

Detection and identification of the agent: *Suspensions in antibiotic solution of oropharyngeal and cloacal swabs (or faeces) taken from live birds, or of faeces and pooled samples of organs from dead birds, are inoculated into the allantoic cavity of 9 to 11 day old embryonated chicken eggs. The eggs are incubated at 37°C (range 35–39°C) for 2–7 days. The allantoic fluid of any eggs containing dead or dying embryos during the incubation and all eggs at the end of the incubation period are tested for the presence of haemagglutinating activity. The presence of influenza A virus can be determined by application of reverse-transcription polymerase chain reaction (RT-PCR) on oropharyngeal, tracheal or cloacal swabs taken from live or dead birds, fresh faeces and pooled samples of organs and tissues from dead birds. Swabs and organs can be taken also from species other than birds susceptible to influenza A infection. The approach to diagnosis using RT-PCR is based on initial generic detection of AIV RNA in clinical specimens, primarily by targeting fragments of one or more segments of the influenza A genome, which are highly conserved for all influenza A viruses. Virus isolation (VI) can be achieved using embryonated chicken eggs and allows the detection of infectious (replication-competent) virus and its characterisation. Compared with VI, molecular diagnostics are more rapid, sensitive and cost-effective laboratory tests that are adaptable to high throughputs. The presence of influenza A virus can be confirmed by an immunodiffusion test between concentrated virus and an antiserum to the nucleoprotein and/or matrix antigens, both of which are common to all influenza A viruses, or by real time reverse transcription polymerase chain reaction (real time RT-PCR) on the allantoic fluids. For these reasons, isolation in embryos has largely been replaced with a rapid initial diagnosis of AIV by direct detection in samples, of one or more segments of the influenza A genome using real time RT-PCR or other validated molecular techniques.*

For serological virus subtyping of the virus, the genome of specific H and N subtypes can be identified using molecular protocols with subtype-specific primers and probes (e.g. conventional or real-time RT-PCR) or sequencing analysis. For serological subtyping, a Reference Laboratory laboratories should conduct

44 haemagglutination and neuraminidase inhibition tests against a battery of polyclonal or monospecific antisera
45 to each of the 16 haemagglutinin (H1–16) and 9 neuraminidase (N1–9) subtypes of influenza A virus-avian
46 influenza. ~~Alternatively, the genome of specific H and N subtypes is identified using RNA detection~~
47 ~~technologies with subtype specific primers and probes (e.g. real-time RT-PCR) or sequencing and~~
48 ~~phylogenetic analysis.~~

49 As the general term 'highly pathogenicity avian influenza' and the historical term 'fowl plague' refer to infection
50 with high pathogenicity (HP) strains of influenza A virus, it is necessary to assess the pathogenicity of influenza
51 A virus isolates at least for primary disease events for domestic poultry. All naturally occurring high
52 pathogenicity avian influenza (HPAI) strains isolated to date have been either of the H5 or H7 subtype, with a
53 subset of H5 or H7 isolates being of low pathogenicity (LP). Verification of high or low pathogenicity of a virus
54 isolate is achieved by obtaining an intravenous pathogenicity index (IVPI) following inoculation of a minimum
55 of eight susceptible 4- to 8-week-old chickens with infectious virus; strains are considered to be of high
56 pathogenicity if they cause more than 75% mortality within 10 days, or when the inoculation of 10 susceptible
57 4- to 8-week-old chickens resulting results in an IVPI greater than 1.2. Characterisation of suspected high
58 pathogenicity strains of the virus should be conducted in a secure biocontainment laboratory facility capable
59 of housing such pathogens according to local and international legislation. The methods used for the
60 determination of strain virulence for birds have evolved over recent years with a greater understanding of the
61 molecular basis of pathogenicity. ~~Regardless of their pathogenicity for chickens, H5 or H7 viruses with a~~
62 ~~polybasic HA0 cleavage site amino acid sequence similar to any of those that have been observed in high~~
63 ~~pathogenicity/HP viruses are considered to be influenza A viruses with high pathogenicity. H5 and H7 isolates~~
64 ~~that are not of highly pathogenicity for chickens and do not have a HA0 cleavage site amino acid sequence~~
65 ~~similar to any of those that have been observed in highly pathogenic viruses are considered to have be of low~~
66 ~~pathogenicity. However, in some circumstances it is necessary to verify high or low pathogenicity of a virus~~
67 ~~isolate using the intravenous inoculation of a minimum of eight susceptible 4- to 8-week-old chickens with~~
68 ~~infectious virus; strains are considered to be of high pathogenicity if they cause more than 75% mortality within~~
69 ~~10 days, or inoculation of 10 susceptible 4- to 8-week-old chickens resulting in an intravenous pathogenicity~~
70 ~~index (IVPI) of greater than 1.2. Characterisation of suspected highly pathogenic strains of the virus should~~
71 ~~be conducted in a virus-secure biocontainment laboratory. Defining pathogenicity by the molecular route aids~~
72 ~~in reducing animal experiments. Although classified as LPAI according to official definitions using IVPI or~~
73 ~~molecular criteria, certain Low pathogenicity avian influenza (LPAI) in poultry-LPAI viruses (e.g H9 subtype)~~
74 ~~may be accompanied by a sudden and unexpected increase in virulence (emerging disease) in poultry or have~~
75 ~~proven natural transmission to humans associated with severe consequences. In these disease scenarios~~
76 ~~there should be formal monitoring in relevant poultry populations by national authorities. The occurrence of~~
77 ~~H5 and H7 low pathogenicity avian influenza viruses-LPAIVs should be monitored as some have the potential~~
78 ~~to mutate into high pathogenicity avian influenza viruses-HPAIVs.~~

79 **Serological tests:** As all influenza A viruses have antigenically similar-conserved nucleoprotein and matrix
80 antigens-proteins, these antigens are preferred targets of influenza A group serological screening methods.
81 Enzyme-linked immunosorbent assays (ELISAs) are widely used to detect antibodies to these antigens in
82 either host species-dependent (indirect) or species-independent (competitive) test formats. Haemagglutination
83 inhibition (HI) tests ~~have~~ are also ~~been~~ employed in routine diagnostic serology, generally for subtyping
84 activities, but it is possible that this technique may miss some particular infections because antibodies directed
85 against the haemagglutinin (HA) are highly subtype- and even strain-specific within certain subtypes and thus
86 HI can vary in specificity is subtype specific. Therefore, depending on the testing purpose, the choice of HA
87 antigen to be used in the HI test is critical to the performance of this test.

88 **Requirements for vaccines:** ~~The first use of Traditionally, vaccination in an avian influenza eradication~~
89 ~~programme was against LPAI. The programmes used inactivated oil-emulsion vaccines with the same~~
90 ~~haemagglutinin and neuraminidase subtypes as the circulating field virus, and infected flocks were identified~~
91 ~~by detection of virus or antibodies against the virus in non-vaccinated sentinel birds. During the 1990s the~~
92 ~~prophylactic use of inactivated oil-emulsion vaccines was employed in Mexico and Pakistan to control~~
93 ~~widespread outbreaks of HPAI and H5/H7 LPAI. During the 1999–2001 outbreak of H7 LPAI in Italy, an~~
94 ~~inactivated vaccine was used with the same (i.e. homologous) haemagglutinin subtype to the field virus, but~~
95 ~~with a different (i.e. heterologous) neuraminidase. This allowed the serological differentiation of non-infected~~
96 ~~vaccinated birds from vaccinated birds infected with the field virus and ultimately aided resulted in eradication~~
97 ~~of the field virus. Prophylactic use of H5 and H7 vaccines has been practised in parts of Italy, aimed at~~
98 ~~preventing H5/H7 LPAI infections, and several Multiple countries in Asia, Africa, and the Middle East, Europe,~~

99 Central and South America have already been using or have started to use vaccination as a supplementary
100 aid in controlling or preventing H5/H7 HPAI in China (People's Rep. of) for H7N9, and in Mexico for H7N3 HPAI
101 virus infections. Native HPAI viruses should not be used as the seed virus for production of vaccine.

102 If LPAI and HPAI viruses are used in challenge studies, an appropriate level of containment should be used
103 as determined by risk assessment.

104 A. INTRODUCTION

105 Influenza in birds is caused by infection with viruses of the family *Orthomyxoviridae* placed in the genus *Alphainfluenzavirus*
106 (*influenzavirus A* or influenza A virus) (International Committee on Taxonomy of Viruses [ICTV], 2019). Influenza A viruses
107 are the only orthomyxoviruses known to naturally affect birds (Swayne & Sims, 2020). Among the four genera of
108 influenzaviruses (Alphainfluenzavirus, Betainfluenzavirus, Gammainfluenzavirus, Deltainfluenzavirus) that infect
109 vertebrates, only influenza A viruses are known to infect birds. Many species of birds have been shown to be susceptible to
110 infection with influenza A viruses; aquatic birds form a major reservoir of these viruses, and the overwhelming majority of
111 isolates have been of low pathogenicity (low virulence) for chickens and turkeys. Influenza A viruses have antigenically
112 closely related nucleoprotein and matrix proteins, but are classified into subtypes on the basis of their haemagglutinin (H)
113 and neuraminidase (N) antigens (World Health Organization Expert Committee, 1980). At present, 16 H subtypes (H1–H16)
114 and 9 N subtypes (N1–N9) are recognised in birds, with a new H19 subtype recently proposed. In addition, further influenza
115 A subtypes (H17N10, H18N11) for influenza A viruses have been identified in bats in Central and South America from bats
116 in Guatemala (ICTV 2019; Swayne *et al.*, 2020; Tong *et al.*, 2013). Further to this, some avian influenza virus strains
117 principally of H3, H5, H7, H9 and H10 subtypes, have caused sporadic zoonotic infections and some strains of these
118 subtypes have been highlighted as potential pandemic risks should additional mutations occur that support sustained human-
119 to-human transmission.

120 To date, naturally occurring high pathogenicity influenza A viruses (HPAIV) that produce acute clinical disease in chickens,
121 turkeys and other birds of economic importance have been associated only with the H5 and H7 subtypes. There is the risk
122 of a H5 or H7 virus of low pathogenicity (H5/H7 low pathogenicity avian influenza [LPAI]) becoming highly pathogenic by
123 mutation at the H protein cleavage site. Low pathogenicity H5 and H7 occur widely in poultry and aquatic wild birds alongside
124 a vast range of non-H5/H7 subtypes. , although intercontinental spread of HPAI has received greater attention in recent
125 years. There is the risk of a H5 or H7 virus of low pathogenicity (H5/H7 low pathogenicity avian influenza [LPAI]) becoming
126 highly pathogenic by mutation. Some avian influenza virus strains have caused sporadic zoonotic infections principally of
127 H5, H7 and H9 subtypes and these three subtypes have been highlighted as potential pandemic risks should additional
128 mutations occur that support sustained human-to-human transmission (Cox *et al.*, 2017). Recently, HPAIV have caused a
129 pandemic of unprecedented magnitude among avian species accompanied by severe losses to the poultry industry and wild
130 bird species. This pandemic event is due to HPAI H5 viruses of the goose/Guangdong lineage (Gs/GD), clade 2.3.4.4b
131 (clade based upon H only), which have established enzootic status in several wild bird population worldwide. These HPAI
132 H5 viruses have also caused infections in a remarkable number of terrestrial and marine mammals mainly following close
133 contact with infected poultry, wild birds, captive birds or contaminated equipment, environment or feed.

134 Throughout this chapter of the *Terrestrial Manual*, the following terms will be used: 1) HPAI as an infection by an avian
135 influenza virus that meets the definition of high pathogenicity, 2) LPAI as an infection with any H1–H16 avian influenza virus
136 that is not of high pathogenicity, and 3) influenza A as an infection with any HPAI or LPAI virus.

137 Depending on the species, age and type of bird, specific characteristics of the viral strain involved, and on environmental
138 factors, the highly pathogenic disease, HPAI infection outcome in fully susceptible birds, may vary from one of range from
139 sudden death with no preceding overt clinical signs, to a more characteristic disease with variable clinical presentations
140 including respiratory and nervous signs, such as ocular and nasal discharges, coughing, sneezing and dyspnoea, swelling of
141 the sinuses and/or head, apathy, reduced vocalisation, marked reduction in feed and water intake, cyanosis of the
142 unfeathered skin, wattles and comb, incoordination, and nervous signs and diarrhoea (Swayne *et al.*, 2020). In laying birds,
143 additional clinical features include a marked drop in egg production, usually accompanied by an increase in numbers of poor
144 quality eggs. Typically, high morbidity is accompanied by high and rapidly escalating unexplained mortality (see Section
145 B.1.4 Assessment of pathogenicity for details on clinical signs). However, none of these signs can be considered
146 pathognomonic for infection with AIV. In certain host species such as Pekin ducks (*Anas platyrhynchos domesticus*) and its
147 wildlife sister species, mallards and mandarin ducks, some HPAI viruses do not necessarily produce significant clinical
148 disease. In addition, LPAI viruses which normally cause only a mild or no clinical disease, may in certain circumstances
149 produce a spectrum of clinical signs, the severity of which may approach that of resemble that expected with HPAI infection,
150 particularly if exacerbating infections and/or adverse environmental conditions are present where bird health may be
151 impacted by other factors (e.g. other infectious agents or environmental factors that may affect disease severity).
152 Confirmatory diagnosis of the disease, therefore, depends on the isolation or detection of the causal virus cause of infection
153 and the demonstration that it fulfils one of the defined criteria described in Section B.1.4 Assessment of pathogenicity.

154 Testing sera from suspect birds using antibody detection methods may supplement diagnosis, but these methods are not
 155 suitable for a definitive identification ~~either subtyping or pathotyping of infection~~. Diagnosis for official control purposes is
 156 established on the basis of agreed official criteria for pathogenicity according to *in-vivo* tests or ~~to the haemagglutinin~~
 157 subtyping and characterisation of molecular determinants (i.e. the presence of a cleavage site of the haemagglutinin
 158 precursor protein HA0 consistent with HPAI virus) ~~and haemagglutinin subtyping~~. These definitions evolve as scientific
 159 knowledge of the disease increases.

160 Occasionally, where the infection pressure is high (e.g. following outbreaks in wild birds), spillover events into non-avian
 161 species have been described (Runstadler & Puryear, 2024). Infection of terrestrial and marine mammals with HPAI H5 viruses
 162 of clade 2.3.4.4b can result in a highly variable clinical picture. Signs described so far in the order Carnivora primarily include
 163 neurological signs such as circling, lack of coordination, ataxia, tremors and lethargy. Loss of appetite, apathy,
 164 hypersalivation, fever, dyspnea (shallow and accelerated breathing), nasal discharge, and abortion have been also reported.
 165 Both for domestic and wild mammals of the order Carnivora, subclinical or clinically mild infections have been also
 166 documented. Furthermore, HPAI H5N1 clade 2.3.4.4b virus has also been identified as the cause of udder infections leading
 167 to mastitis in dairy cattle in the USA. Clinical signs in infected cattle may include reduced feed intake with decreased
 168 rumination and rumen motility, respiratory signs such as clear nasal discharge, dehydration, fever and a sudden decrease
 169 in milk production. Affected cows may produce thicker, concentrated milk similar to colostrum or may stop producing milk.
 170 Other clinical signs may include abnormal faecal consistency, lethargy and abortion. Subclinical infection has been also
 171 reported¹.

172 Regardless of the species infected, HPAI should be subject to official control by national authorities. In addition, LPAI,
 173 particularly H5 and H7 subtypes, may be subject to national or state/provincial control. The viruses that cause ~~influenza A~~
 174 avian influenza have the potential to spread from the laboratory if adequate levels of biosecurity and biosafety are not in
 175 place. Avian influenza viruses should be handled with appropriate measures as described in Chapter 1.1.4 *Biosafety and*
 176 *biosecurity: Standard for managing biological risk in the veterinary laboratory and animal facilities*. Biocontainment measures
 177 should be determined by risk analysis as described in Chapter 1.1.4. The measures required may vary ~~among~~ depending
 178 on the genetics of the subtypes and pathotypes of influenza A viruses manipulated, with higher level containment being
 179 indicated for some LPAI and HPAI viruses. ~~Such viruses and~~ Such viruses may require additional procedural, equipment and facility
 180 enhancements under specific conditions such as high virus concentrations, housing infected animals or conducting
 181 procedures ~~with aerosol-generating activities that may result in the generation of aerosols~~. The occupational risk of operators
 182 working with zoonotic viruses should be carefully assessed to ensure safe working practises commensurate with the
 183 pathogens being handled. Countries lacking access to such a specialised national or regional laboratory facilities should
 184 send specimens to a WOAHP Reference Laboratory depending on the purposes of handling the viruses.

185 B. DIAGNOSTIC TECHNIQUES

186 Table 1. Test methods available for the diagnosis of avian influenza and their purpose

Method	Purpose					
	Population freedom from infection ^(a)	Individual animal freedom from infection prior to movement ^(a)	Contribute to eradication policies ^(a)	Confirmation of clinical cases ^(a)	Prevalence of infection – surveillance (including vaccinated flocks) ^(e)	Immune status in individual animals or populations post-vaccination ^(a)
<u>Detection and identification of the agent^(g)</u>						
Virus isolation	+	+++	+	+++	+	–
Antigen detection	+	+	+	+	+	–
Real-time RT-PCR	+++	+++	+++	+++	+++	–
<u>Conventional RT-PCR</u>	±	±	±	±±	±	≡

¹ <https://www.aphis.usda.gov/sites/default/files/hpai-livestock-case-definition.pdf>

Method	Purpose					
	Population freedom from infection ^(a)	Individual animal freedom from infection prior to movement ^(b)	Contribute to eradication policies ^(c)	Confirmation of clinical cases ^(d)	Prevalence of infection – surveillance (including vaccinated flocks) ^(e)	Immune status in individual animals or populations post-vaccination ^(f)
Detection of immune response						
AGID	+ (Influenza A)	+ (Influenza A)	++ (Influenza A)	+ (convalescent)	++ (Influenza A)	++ (Influenza A)
HI	+++ (H5 or H7)	++ (H5 or H7)	+++ (H5 or H7)	++ (convalescent)	+++ (H5 or H7)	+++ (H5 or H7)
ELISA	+++	+	++	+ (convalescent)	+++	++

Key: +++ = recommended for this purpose; ++ recommended but has limitations; + = suitable in very limited circumstances; – = not appropriate for this purpose.

RT-PCR = reverse-transcription polymerase chain reaction; AGID = agar gel immunodiffusion;

HI = haemagglutination inhibition test; ELISA = enzyme-linked immunosorbent assay.

^(a)See Appendix 2 of this chapter for justification table for the scores given to the tests for this purpose.

^(b)See Appendix 3 of this chapter for justification table for the scores given to the tests for this purpose.

^(c)See Appendix 4 of this chapter for justification table for the scores given to the tests for this purpose.

^(d)See Appendix 5 of this chapter for justification table for the scores given to the tests for this purpose.

^(e)See Appendix 6 of this chapter for justification table for the scores given to the tests for this purpose.

^(f)See Appendix 7 of this chapter for justification table for the scores given to the tests for this purpose.

^(g)A combination of agent identification methods applied on the same clinical sample is recommended.

187
188
189
190
191
192
193
194
195
196
197

198 1. Detection and identification of the agent

199 Detection and identification of influenza A viruses as the cause of infections and disease in poultry and other birds requires
200 a thorough diagnostic investigation to differentiate from similar diseases caused by other viral agents especially
201 *Orthoavulavirus javaense*, commonly known as avian paramyxovirus type 1 virus (APMV-1) (Family *Paramyxoviridae*,
202 subfamily *Avulavirinae*, genus *Orthoavulavirus* (APMV-1, used hereafter). Individual influenza A and APMV-1 virus isolates
203 vary greatly in virulence, causing various disease outcomes syndromes evident as subclinical infections, drops in egg
204 production, respiratory disease, and severe and disease with high mortality disease. The latter clinical outcome syndrome
205 can be caused by either HPAI or virulent APMV (Newcastle disease viruses). Therefore, as no disease manifestation is
206 defined as being pathognomonic for influenza A or APMV-1 infection it is judicious to have a single sampling procedure is
207 recommended. This sampling approach, coupled with and simultaneously conduct specific differentiating differential
208 diagnostic tests evaluation using assays specific for either both influenza A and or APMV-1 viruses on field samples, allows
209 to obtain an accurate aetiological diagnosis of a single agent or, on occasion, confirmation of dual infection.

210 1.1. Samples for virus detection isolation

211 When handling or sampling suspect cases of avian influenza, it is imperative to use appropriate biosafety
212 measures as described in Chapter 1.1.4 *Biosafety and biosecurity: Standard for managing biological risk in the*
213 *veterinary laboratory and animal facilities*.

214 Virus isolation is the reference method but is laborious and time intensive, used primarily for diagnosis of a first
215 clinical case in an outbreak and to obtain virus isolates for further laboratory analysis.

216 For both molecular and virological investigations of severe the disease and high mortality in poultry flocks, it is
217 usual to attempt virus isolation-detection from samples collected from recently dead birds or moribund birds that
218 have been humanely killed humanely. Samples taken from dead birds should include intestinal contents (faeces)
219 or cloacal swabs and oropharyngeal or tracheal swabs. Samples from trachea, lungs, air sacs, brain, intestine,
220 spleen, caecal tonsils, kidneys, brain, liver and heart should also be collected and processed either separately or
221 as a pool. When pooling samples, the brain should be collected and processed first (to avoid cross contamination
222 with other tissue types) and kept separate as presence of virus in the brain may be an indicator of HPAI or NDV
223 virulent APMV-1. Further pools of tissues or organs should be made consistent with known virus tropisms between
224 HPAI and LPAI, i.e. grouped at the level of respiratory or, systemic and gastrointestinal tracts.

225 Samples from live birds should include both oropharyngeal or tracheal and cloacal swabs, the latter should be
226 visibly coated with faecal material. To avoid harming them, swabbing of small delicate birds should be done with
227 the use of especially small swabs that are usually commercially available and intended for use in human
228 paediatrics or the collection of fresh faeces may serve as an adequate alternative (caution that some influenza A
229 viruses and APMV-1 type 1 avian paramyxoviruses in birds can have a strong respiratory tropism). ~~Similar~~ Swab
230 samples can be pooled from the same anatomical site (i.e. cloacal swabs with cloacal swabs, oropharyngeal
231 swabs with oropharyngeal swabs), from the same species and the same premises. Most commonly pooling of
232 five is used or occasionally more, if validation of this approach has been undertaken to ensure no significant loss
233 of sensitivity, if appropriately validated not to reduce sensitivity of detection, but specific swab types should be
234 used (Spackman *et al.*, 2013). Furthermore, the type of swabs used may affect test sensitivity or validity with thin
235 wire or plastic shafted swabs preferred. Swabs should be collected and tested individually from wild or captive
236 waterfowl. These birds may carry multiple subtypes of AI virus, and pooling the swabs in a single tube may
237 compromise the detection and the correct characterisation of one or more virus subtypes.

238 In addition to testing sick and dead birds, in active surveillance scenarios of populations appearing healthy,
239 environmental samples collected from water, drinker biofilms, feeder troughs, floors, walls, nests, cages, or fans
240 as well as air, have been proposed as a less invasive and more economical surveillance strategy (Harder *et al.*,
241 2023). Although progress has been made in exploiting environmental sample matrices for the detection of AIV,
242 protocols harmonisation and proper validation of such techniques in comparison with routine methodology is
243 mostly lacking and further investigations are needed to ascertain their suitability for surveillance of AIV.

244 As described above, the HPAI H5N1 clade 2.3.4.4b virus has demonstrated the capacity to infect a broad range
245 of mammals, most likely as a consequence of exposure to infected poultry, wild birds, and captive birds or even
246 to contaminated environment, materials or feed. In the majority of HPAI H5 clade 2.3.4.4b positive live
247 domestic/farmed carnivores (e.g. cats, minks, arctic foxes, raccoon dog) and wild mammals (e.g. foxes, sea lions),
248 the virus has been detected in nasal or tracheal/oropharyngeal swabs and, to a lesser extent, in rectal swabs. In
249 the post-mortem examination of dead or severely ill or deceased animals, the highest viral loads of HPAI H5 virus
250 has mainly been found at the level of the central nervous system and in the lower respiratory tract; hence, both
251 these anatomical sites should be examined. Of note, neurological disease induced by HPAI H5 viruses in
252 mammals can manifest without clinical respiratory disease. In this case, respiratory samples can test negative
253 despite efficient virus replication in the central nervous system. In infected lactating dairy cattle, milk samples
254 have been shown to yield the highest virus concentration. Milk from each of the four quarters (3–10 ml per animal)
255 are the preferred sample from lactating animals. Deep nasal swabs should be used for non-lactating animals (see
256 OFFLU website²).

257 The clinical samples should be placed in virus transport media (isotonic phosphate-buffered saline (PBS) pH 7.0–
258 7.4 or normal saline (0.9% (w/v) NaCl) or protein based media such as brain-heart-infusion or tris-buffered tryptose
259 broth isotonic phosphate-buffered saline (PBS), pH 7.0–7.4 with antibiotics or a solution containing protein and
260 antibiotics. The antibiotics to be used and their concentration can be varied according to local conditions, but
261 could be, for example, penicillin (2000 units/ml), streptomycin (2 mg/ml), gentamycin (50 µg/ml) and mycostatin
262 (1000 units/ml) for tissues and oropharyngeal or tracheal swabs, but at five-fold higher concentrations for faeces
263 and cloacal swabs. It is important to re-adjust the pH of the solution to pH 7.0–7.4 following the addition of the
264 antibiotics. It is ~~recommended~~ advisable that a solution for transport of the swabs should contain protein to
265 stabilise the virus (e.g. brain–heart infusion, up to 5% [v/v] cattle serum, 0.5% [w/v] bovine albumen or similar
266 commercially available transport media). Indeed, brain-heart-infusion (BHI) broth has been demonstrated to give
267 added stability than PBS for virus recovery. If control of *Chlamydomphila* is desired, 0.05–0.1 mg/ml oxytetracycline
268 should be included. Faeces and finely minced tissues should be prepared as 10–20% (w/v) suspensions in the
269 antibiotic solution. Suspensions should be processed as soon as possible after incubation for 1–2 hours at room
270 temperature. In case the use of transport media is prevented by logistic or economical issues, swabs must be
271 returned to their casing and submitted dry to the laboratory as quickly as possible (<24 hours), assuring they are
272 immediately chilled on ice or with frozen gel packs. When immediate processing is impractical, samples may be
273 stored at 4°C for up to 4 days. For a prolonged storage, diagnostic samples and isolates should be kept at –80°C
274 but for transport, ~~on~~ dry ice (≤–50°C) is widely used. Repeated freezing and thawing should be avoided.

275 Preserving the quality and integrity of biological samples during transportation may be challenging in remote areas
276 where laboratory facilities are limited and cold chain maintenance is difficult. For these reasons, the use of
277 technologies and reagents (Rattanamas *et al.*, 2022) that increase the capacity to detect and diagnose viral
278 infections in these scenarios are becoming increasingly common for the transport of samples to laboratories for
279 the direct detection of AIV via nucleic acid assays. However, whilst these methods may enable molecular
280 detection, the processes involved will inactivate virus infectivity, thus preventing virus characterisation by isolation.

² https://www.offlu.org/wp-content/uploads/2024/05/2024_05_10_HPAI_Dairy-cattle.pdf

281 As such, it is advisable to limit their use to contexts where proper conditions for sample preservation are difficult
282 to achieve.

283 1.2. Virus isolation

284 The preferred method of growing influenza A viruses is by the inoculation of specific pathogen free (SPF)
285 embryonated chicken eggs, or specific antibody negative (SAN) eggs. The supernatant fluids of faeces, swabs or
286 tissue suspensions can be obtained through clarification by centrifugation at 1000 **g** for approximately 10 minutes
287 at a temperature not exceeding 25°C. Clarified preparations can be inoculated into three to five embryonated SPF
288 or SAN chicken eggs of 9–11 days' incubation using a number of routes including the amniotic sac, chorioallantoic
289 sac or membrane (at least one of which should be used for primary isolation) and allantoic sacs. The inoculated
290 eggs are typically incubated at 37°C (range 35–39°C) for 2–7 days. Recent studies have generated validation
291 data to support a shortening of this time period to a 4-day time period by adopting a 'rapid-passage approach'.
292 Eggs containing dead or dying embryos as they arise detected by candling, and all eggs remaining at the end of
293 the incubation period, should first be chilled to 4°C for 4 hours or overnight (the latter is the preferred option). After
294 checking that the embryos have died, the amnio-allantoic fluids should be recovered and tested with a screening
295 test (such as haemagglutination [HA] test), influenza A type-specific test (such as agar gel immunodiffusion test
296 [AGID] or solid-phase antigen-capture enzyme-linked immunosorbent assays [ELISA] or lateral-flow
297 immunochromatography) or influenza A subtype-specific test (such as haemagglutination inhibition [HI] and
298 neuraminidase [N] inhibition [NI] tests) or a molecular test to detect influenza A specific nucleic acid signatures
299 (such as real-time reverse transcription polymerase chain reaction [RT-PCR]) as described later (see Section
300 B.1.5.2 Direct RNA detection 1.2.2). Detection of HA activity, in bacteria-free amnio-allantoic fluids verified by
301 microbiological assay, indicates a high probability of the presence of an influenza A virus or of an APMV-1-avian
302 orthaavulavirus (formerly avian paramyxovirus). Fluids that give a negative reaction should be passaged into at
303 least one further batch of eggs, and up to three passages.

304 Routine checks for bacterial contamination should be conducted by streaking samples in Luria-Broth-Bertani agar
305 plates and reading these at 24 and 48 hours of incubation against a light source. BHI agar and blood agar plates
306 may also be used. For larger numbers of samples, initial cultures could be in tryptose phosphate broth.
307 Contaminated samples can be treated by incubation with increased antibiotic concentrations for 2–4 hours
308 (gentamicin, penicillin g, and amphotericin b solutions at final concentrations to a maximum of 1 mg/ml, 10,000
309 U/ml, and 20 µg/ml, respectively). Samples heavily contaminated by bacteria that cannot be removed by
310 centrifugation or controlled by antibiotics can be filtrated through 0.45 and 0.2 micron sterile filters. Filtration
311 should be used only when other methods fail because aggregation it may significantly reduce virus titre.

312 1.3. Virus identification

313 The presence of influenza A virus can be confirmed in AGID tests by demonstrating the presence of the
314 nucleoprotein or matrix antigens, both of which are common to all influenza A viruses (see Section B.2.2 *Agar gel*
315 *immunodiffusion*). The antigens may be prepared by concentrating the virus from infective allantoic fluid or
316 extracting the infected chorioallantoic membranes; these are tested against known positive antisera. Virus may
317 be concentrated from infective allantoic fluid by ultracentrifugation, or by precipitation under acid conditions. The
318 latter method consists of the addition of 1.0 M HCl to infective allantoic fluid until it is approximately pH 4.0. The
319 mixture is placed in an ice bath for 1 hour and then clarified by centrifugation at 1000 **g** at 4°C. The supernatant
320 fluid is discarded. The virus concentrates are resuspended in glycine/sarcosyl buffer consisting of 1% (w/v)
321 sodium lauroyl sarcosinate buffered to pH 9.0 with and 0.5 M glycine. These concentrates contain both
322 nucleoprotein and matrix polypeptides and infectivity is destroyed.

323 Preparations of nucleoprotein-rich antigen can also be obtained from chorioallantoic membranes for use in the
324 AGID test (Beard, 1970). This method involves removal of the chorioallantoic membranes from infected eggs that
325 have allantoic fluids with HA activity. The membranes are then homogenised or ground to a paste. This is
326 subjected to three freeze–thaw cycles, followed by centrifugation at 1000 **g** for 10 minutes. The pellet is discarded
327 and the supernatant is used as an antigen following treatment with 0.1% formalin or 1% betapropiolactone.

328 Use of the AGID test to demonstrate nucleoprotein or matrix antigens is a satisfactory way to indicate the presence
329 of influenza A virus in amnioallantoic fluid, but lacks sensitivity compared to other methods including molecular
330 assays (see Section 1.2.2), but various experimental and commercial rapid, solid-phase antigen-capture ELISAs
331 (AC-ELISAs) are an effective and easy to use alternative (Swayne et al., 2020). Most AC-ELISAs have been
332 approved and marketed to detect human influenza A virus in clinical specimens. Some have demonstrated
333 effectiveness for detection of influenza A, but many of these commercial tests have had low sensitivity (Slomka
334 et al., 2012). Those validated for veterinary use are preferred (see Section B.1.5.1 Antigen detection).

335 Any HA activity of sterile fluids harvested from the inoculated eggs is most likely to be caused by an influenza A
336 virus or APMV-1 virus an avian paramyxovirus, but However, a few strains of avian reovirus, as well as nonsterile

337 fluid containing HA of bacterial origin (e.g. mycoplasmas) can cause the agglutination of red blood cells (RBCs) so
338 multiple approaches to define the cause of HA activity may be required. Most laboratories will have antiserum
339 specific to Newcastle disease virus (avian paramyxovirus type 1 virulent, APMV1), and in view of its widespread
340 occurrence and almost universal use as a live vaccine in poultry, it is best to evaluate its presence by
341 haemagglutination inhibition (HI) tests (see Chapter 3.3.14 *Newcastle disease*).

342 Alternatively, the presence of influenza virus can be confirmed by the use of conventional RT-PCR or real-time
343 RT-PCR targeting conserved viral genome segments, e.g. the matrix gene using nucleoprotein-specific or matrix-
344 specific conserved primers (Hassan *et al.*, 2022; Nagy *et al.*, 2020-2021; Spackman *et al.*, 2002; 2020). The
345 presence of subtype H5 or H7 influenza virus can also be confirmed by using H5- or H7-specific primers (Hassan
346 *et al.*, 2022; Slomka *et al.*, 2007b; Spackman *et al.*, 2002). See Section B.1.5.2 Direct RNA detection for details
347 on molecular procedures.

348 Antigenic subtyping can be accomplished by monospecific antisera prepared against purified or recombinant H
349 and N subtype-specific proteins, used in HI and NI tests, or polyclonal antisera raised against a range of intact
350 influenza viruses and used in HI and NI tests. For laboratories conducting the HI test to H subtype it is strongly
351 recommended that two sera for each H subtype is used but with a heterologous N and should ideally use antisera
352 to contemporary viruses relevant to the region in which the virus is detected. Subtyping can also be accomplished
353 using H and N subtype specific primers in RT-PCR and real-time RT-PCR tests; or using sequence analysis of H
354 and N genes (Section B.1.5.2 *Direct RNA detection*). Subtype identification by these techniques is becoming
355 increasingly common but is beyond the scope of many diagnostic laboratories not specialising-specialised in
356 influenza viruses. Assistance is available from the can be assisted by WOAH Reference Laboratories and
357 Collaborating Centres (see WOAH website for up-to-date list).

358 1.4. Assessment of pathogenicity

359 The term HPAI relates to the assessment of pathogenicity in chickens and implies the involvement of high
360 pathogenicity strains of virus. It is used to describe a disease of fully susceptible chickens with clinical signs that
361 may include one or more of the following: ocular and nasal discharges, coughing, snicking and dyspnoea, swelling
362 of the sinuses and/or head, listlessness, reduced vocalisation, marked reduction in feed and water intake,
363 cyanosis of the unfeathered skin, wattles and comb, incoordination, nervous signs and diarrhoea. In laying birds,
364 additional clinical features include a marked drop in egg production usually accompanied by an increase in
365 numbers of poor-quality eggs. Typically, high morbidity is accompanied by high and rapidly escalating unexplained
366 mortality. However, none of these signs can be considered pathognomonic and high mortality may occur in their
367 absence. In addition, LPAI viruses that normally cause only mild or no clinical disease, may cause a much more
368 severe disease if predisposing infections or adverse environmental factors are present and, in certain
369 circumstances, the spectrum of clinical signs may mimic HPAI.

370 The historical term 'fowl plague' has been abandoned in favour of the more accurate term HPAI. Because all
371 naturally occurring HPAI viruses to date have been H5 and H7 subtypes and genomic studies have determined
372 HPAI viruses arise by mutation of H5/H7 LPAI viruses, all H5/H7 LPAI viruses may potentially become HPAI but
373 predicting which LPAI strains will mutate to HPAI is not possible. Pathogenicity shifts have been associated with
374 changes to the proteolytic cleavage site of the haemagglutinin including: 1) substitutions of non-basic with basic
375 amino acids (arginine or lysine); 2) insertions of multiple basic amino acids from codons duplicated from the
376 haemagglutinin cleavage site; 3) short insertions of basic and non-basic amino acids from unknown source; 4)
377 recombination with inserts from other influenza A virus gene segments or avian host cellular genome (e.g. 28S
378 rRNA) that lengthen the proteolytic cleavage site; and 5) loss of the shielding glycosylation site at residue 13 in
379 combination with multiple basic amino acids at the cleavage site³. Nucleotide sequencing and amino acid
380 deduction sequencing of the cleavage sites of H5 and H7 subtype influenza A isolates of low pathogenicity for
381 birds may identify viruses that have the capacity, following simple mutation, to have high pathogenicity for poultry.

382 The following methods and criteria have been adopted by the WOAH for determining pathogenicity of an influenza
383 A virus:

- 384 a) *Molecular assessment*: For all H5 and H7 viruses in chickens, the amino acid sequence of the proteolytic
385 cleavage site must be determined. The presence of multiple basic amino acids in the HA0 cleavage site is
386 the genotypic standard for HPAI strains; therefore, if the isolate being tested has an HA0 cleavage site
387 motif identical to previous HPAI viruses, it should be designated as HPAI irrespective of a low or high
388 pathogenicity outcome following pathotyping in chickens (see the table that lists all the reported
389 haemagglutinin proteolytic cleavage sites of HA0 protein for H5 and H7 LPAI and HPAI viruses based on
390 deduced amino acid sequence, which can be found on the OFFLU site (see footnote 2-1). Furthermore, any

³ <http://www.offlu.org/wp-content/uploads/2021/01/Influenza-A-Cleavage-Sites.pdf> <https://www.offlu.org/wp-content/uploads/2022/01/Influenza-A-Cleavage-Sites-Final-04-01-2022.pdf>

391 isolate with a new motif must be tested *in vivo* by IVPI. In case of difficulties in the interpretation of the
392 cleavage site motif, WOAHA or FAO reference laboratories should be consulted.

393 b) *In-vivo* assessment: One of the two following *in-vivo* tests methods to determine pathogenicity in chickens
394 is used. A high pathogenicity influenza A virus is:

395 i) any influenza A virus that is lethal⁴ for six, seven or eight of eight 4- to 8-week-old susceptible
396 chickens within 10 days following intravenous inoculation with 0.2 ml of a 1/10 dilution of a bacteria-
397 free, infective allantoic fluid

398 or

399 ii) any influenza A virus that has an intravenous pathogenicity index (IVPI) greater than 1.2- when using
400 the following is the IVPI procedure:

401 □ Fresh infective allantoic fluid, confirmed free at least from APMV-1 and ~~other extraneous agents~~
402 bacteria, with a HA titre >1/16 (>24 or >log₂ 4 when expressed as the reciprocal) is diluted 1/10 in
403 sterile isotonic saline.

404 □ 0.1 ml of the diluted virus is injected intravenously into each of ten 4- to 8-week-old SAN susceptible
405 chickens; if possible, SPF chickens should be used.

406 □ Birds are examined at ~~24-hour intervals~~ agreed according to local ethical guidance for 10 days. At
407 each observation, each bird is scored 0 if normal, 1 if sick, 2 if severely sick, 3 if dead. (The judgement
408 of sick and severely sick birds is a subjective clinical assessment. Normally, 'sick' birds would show
409 one of the following signs and 'severely sick' more than one of the following signs: respiratory
410 involvement, depression, diarrhoea, cyanosis of the exposed skin or wattles, oedema of the face
411 and/or head, nervous signs. Dead individuals must be scored as 3 at each of the remaining daily
412 observations after death⁵).

413 □ The IVPI is the mean score per bird per observation over the 10-day period. An index of 3.00 means
414 that all birds died within 24 hours, and an index of 0.00 means that no bird showed any clinical signs
415 during the 10-day observation period.

416 ~~b) For all H5 and H7 viruses of low pathogenicity in chickens, the amino acid sequence of the connecting
417 peptide of the haemagglutinin molecule (HA0) (i.e. the cleavage site) must be determined. The presence
418 of several multiple basic amino acids, inserts of cellular or viral nucleic acids or loss of specific glycosylation sites
419 in the HA0 cleavage site is the genotypic standard for HPAI strains; therefore, if the isolate being tested has
420 an HA0 cleavage site motif identical to previous HPAI viruses, it should be designated as HPAI irrespective
421 of a low or high pathogenicity determined by pathotyping in chickens (see the table that lists all the reported
422 haemagglutinin proteolytic cleavage sites of HA0 protein for H5 and H7 LPAI and HPAI viruses based on
423 deduced amino acid sequence, which can be found on the OFFLU site (see footnote 2 1). Furthermore, any
424 isolate with a new motif must be tested *in vivo* by IVPI. In case of difficulties in the interpretation of the
425 cleavage site motif, WOAHA and/or FAO reference laboratories should be consulted.~~

426 The WOAHA classification system to identify influenza A viruses for which disease notification and control
427 measures should be taken is defined in the *Terrestrial Code in Chapter 10.4 Infection with high*
428 *pathogenicity avian influenza viruses* and Chapter 1.1 *Notification of diseases and provision of*
429 *epidemiological information*.

430 A variety of strategies and techniques, including commercial kits and automated sequencers, have
431 successfully been used successfully to define the nucleotide sequence of the nucleotides at that portion
432 of the HA gene coding for the cleavage site region of the haemagglutinin of H5 and H7 subtypes of avian
433 influenza virus, enabling the amino acids there to be deduced. This can be done by RNA extraction from
434 the sample and direct sequencing of the haemagglutinin proteolytic cleavage site. Various stages in the
435 procedure can be facilitated using commercially available kits and automated sequencers.

436 Furthermore, real-time RT-PCR techniques have become critical in rapidly defining viral pathotype (James
437 et al., 2022) often significantly reducing turnaround times in diagnostic laboratories. These assays can be
438 used to pathotype viruses in the following scenarios: in case of an overt and widespread circulation of a
439 definite genotype in wild birds in a specific area; in the event of documented secondary outbreaks linked

⁴ To minimise pain and distress, when birds are too sick to eat or drink reach well defined ethically accepted humane endpoints, they should be killed humanely ethanased.

⁵ To minimise pain and distress, when birds reach humane endpoints are too sick to eat or drink, they should be ethanased killed humanely and scored as dead at the next observation.

440 to H5/H7 confirmed cases for which the cleavage site sequence has been determined; to quickly confirm
441 a strong clinical suspicion.

442 Determination of the cleavage site by sequencing or real-time RT-PCR ~~other methods~~ has become the
443 method of choice for initial assessment of the pathogenicity of these viruses and has been incorporated
444 into agreed definitions. This has reduced the number of *in-vivo* tests, although the initial ~~Sanger~~
445 sequencing result of a HA cleavage site for an H5 or H7 LPAI virus should be confirmed by either
446 inoculation of birds or deep sequencing using high throughput sequencing technologies assuring a high
447 depth of coverage with a minimum of 1000 reads to exclude the presence of any HPAI virus in the
448 background of an LPAI virus infection of the same H5 or H7 subtype.

449 Although all the truly HPAI viruses isolated to date have been of H5 or H7 subtypes, at least three isolates,
450 all of H10 subtype (H10N1, H10N4 and H10N5), have been reported that would have fulfilled ~~both~~ the
451 WOAH and EU *in-vivo* definitions for HPAI viruses (~~Bonfante *et al.*, 2014; Wood *et al.*, 1996~~) as they killed
452 6/10, 7/10 and 8/10 chickens with IVPI values >1.2 when the birds were inoculated intravenously. However,
453 these viruses did not induce death or signs of disease when inoculated intranasally and did not have a
454 haemagglutinin cleavage site sequence compatible with HPAI virus. Similarly, other intravenously
455 inoculated influenza A viruses are nephrotropic and birds that die have high titres of virus in their kidneys
456 indicating a renal pathogenic mechanism (~~Stemons & Swayne, 1990~~), but such laboratory-induced
457 pathobiology is not comparable to multi-organ infection and systemic disease caused by HPAI viruses. An
458 H4N2 virus isolated from quail had a multibasic cleavage site sequence (PEKRRTR/GLF) but with an IVPI
459 value of 0.0 (~~Wong *et al.*, 2014~~) suggesting the multibasic cleavage site in viruses other than H5 and H7
460 alone may not be sufficient for declaration of HPAI virus and the *in-vivo* test should be carried out.
461 Conversely, four viruses (A/chicken/Pennsylvania/1/83 [H5N2] and A/goose/Guangdong/2/96 [H5N1],
462 A/turkey/England/87-92BFC/91 [H5N1] or A/chicken/Texas/298313/04 [H5N2]) have been described that
463 have HA0 cleavage sites containing multiple basic amino acids, but which show low pathogenicity (IVPI
464 <1.2) when inoculated intravenously into 6-week-old chickens (~~Londt *et al.*, 2007~~). No single explanation
465 including the presence of a glycosylation site masking the HA0 cleavage site was reported emphasising
466 both intra-haemagglutinin and multigenic influences in rare circumstances upon phenotypic expression of
467 high pathogenicity. The presence of high pathogenicity haemagglutinin cleavage site in H5 and H7
468 influenza A viruses necessitates declaration of high pathogenicity to facilitate immediate control of the
469 disease, otherwise a delay to complete *in-vivo* testing may result in continued onward transmission and
470 spread between premises with severe consequence for future eradication once confirmed as a HPAI virus.

471 ~~A table is available on the OFFLU website that lists all the reported haemagglutinin proteolytic cleavage site~~
472 ~~of HA0 protein for H5 and H7 LPAI and HPAI viruses based on deduced amino acid sequence. This table will~~
473 ~~be updated as new viruses are characterised; it can be found on the OFFLU site (see footnote 2 1).~~

474 1.5. Antigen capture and molecular techniques

475 At present, conventional virus isolation and characterisation techniques for the diagnosis of influenza A viruses
476 remain ~~a key methods~~ for initial diagnosis of influenza A infection in a primary disease event and to provide virus
477 for more detailed analyses including *in-vivo* testing and gene sequencing. Furthermore, they may be invaluable
478 in confirming or disproving the presence of infectious virus when other test results including conventional and
479 real-time RT-PCR are ~~inconclusive all weakly positive~~. However, ~~conventional classical~~ methods tend to be costly,
480 labour intensive and slow and the delays associated with these approaches are often not compatible with the
481 implementation of control measures. There have been enormous developments and improvements in molecular
482 and other diagnostic techniques, many of which are now routinely applied as a first choice for the diagnosis of
483 influenza A infections (Figure 1).




Fig. 1. Schematic overview of screening tests, subtyping assays, and characterisation methods for AIV. As rapid and sensitive diagnosis of AIV is of paramount importance in its early control and eradication, molecular-based tests are recommended as the first choice for the diagnosis of the pathogen. Tests in italics and brackets in the table may be used as alternative diagnostic methods, depending on the primary objective of the investigation and the virus being targeted.

1.5.1. Antigen detection

There are several commercially available AC-ELISA kits that can detect the presence of influenza A viruses in poultry (Swayne *et al.*, 2020). Most of the kits are enzyme immunoassays or are based on immunochromatography (lateral flow devices, LFD) and use a monoclonal antibody against the nucleoprotein; they should be able to detect any influenza A virus. The main advantages of LFDs are these tests is that they can demonstrate the presence of influenza A virus within 15 minutes, they are very easy to use and may be used "pen-side". The disadvantages are that they may lack sensitivity, they may not have been validated for different species of birds, H and N subtype identification is not achieved and the kits are expensive. The tests should only be interpreted on a flock basis and not as an individual bird test. Oropharyngeal or tracheal samples from clinically affected or dead birds provide the best sensitivity. Nevertheless, the lack of sensitivity is a major drawback to the use of available antigen detection tests. Test sensitivities may vary between cloacal and tracheal swabs, whilst the tests can perform less well with samples from waterfowl or wild birds compared with chickens. Improved but moderate sensitivity of LFDs in so named lateral flow devices was reported when using samples of feather follicles from birds infected with HPAI (Slomka *et al.*, 2012). Because of low sensitivity, antigen detection is mainly used for initial field screening of high mortality clinical cases for suspected influenza A virus infections followed by confirmation of results using a more sensitive laboratory-based test. Negative LFD test results do not necessarily rule out an influenza A infection and other laboratory-based testing pipelines should be used for confirmatory diagnosis where suspicion is raised.

509

1.5.2. Direct RNA detection

510

Table 2. Molecular assay for the detection of type A avian influenza virus*

<u>Primer/probe</u>	<u>Primer/probe sequence (5'–3')</u>	<u>Target</u>
<u>Heine et al. (2015)</u> https://www.izsvenezie.com/reference-laboratories/avian-influenza-newcastle-disease/diagnostic-protocols/		
<u>Forward</u>	<u>AGA-TGA-GYC-TTC-TAA-CCG-AGG-TCG</u>	<u>AI M gene</u>
<u>Reverse</u>	<u>TGC-AAA-AAC-ATC-YTC-AAG-TCT-CTG</u>	
<u>Reverse</u>	<u>TGC-AAA-CAC-ATC-YTC-AAG-TCT-CTG</u>	
<u>Reverse</u>	<u>TGC-AAA-GAC-ATC-YTC-AAG-TCT-CTG</u>	
<u>Reverse</u>	<u>TGC-AAA-TAC-ATC-YTC-AAG-TCT-CTG</u>	
<u>Probe</u>	<u>FAM-TCA-GGC-CCC-CTC-AAA-GCC-GA-TAMRA/BHQ1</u>	
<u>Nagy et al. (2021)</u> https://science.vla.gov.uk/flu-lab-net/protocols.html		<u>Nagy et al., 2021.</u> https://www.izsvenezie.com/reference-laboratories/avian-influenza-newcastle-disease/diagnostic-protocols/
<u>Forward</u>	<u>GGC-CCC-CTC-AAA-GCC-GA</u>	<u>AI M gene</u>
<u>Reverse</u>	<u>CGT-CTA-CGY-TGC-AGT-CC</u>	
<u>Probe</u>	<u>FAM-TCA-CTK-GGC-ACG-GTG-AGC-GT-MGB</u>	
<u>Hassan et al. (2022)</u>		
<u>Forward</u>	<u>AGA-TGA-GYC-TTC-TAA-CCG-AGG-TCG</u>	<u>AI M gene</u>
<u>Reverse</u>	<u>TGC-AAA-AAC-ATC-TTC-AAG-TYT-CTG</u>	
<u>Reverse</u>	<u>TGC-AAA-GAC-ACT-TTC-CAG-TCT-CTG</u>	
<u>Reverse</u>	<u>TGC-AAA-I(Inosine)AC-ATC-YTC-AAG-TYT-CTG</u>	
<u>Probe</u>	<u>FAM-TCA-GGC-CCC-CTC-AAA-GCC-GA-BHQ1</u>	

511

512

*Not all the molecular methods described in Section B.1.5.2 *Direct RNA detection* are included in this table and only some of the methods used for influenza A screening are reported as examples

513

514

515

516

517

518

519

520

521

522

523

As demonstrated by the current definitions of HPAI, molecular techniques are used preferentially for diagnosis for some time now including. Furthermore, there have recently been developments towards their application to the detection and characterisation of influenza A viruses directly from clinical specimens of infected birds. It is imperative that when using highly sensitive molecular detection methods that allow rapid direct detection of viral RNA for confirmatory laboratory diagnosis of influenza A infections, stringent protocols are in place to prevent the risk of cross-contamination between clinical samples. In addition, RNA detection test methodologies should be validated to the WOH standard (see Chapter 1.1.6 *Validation of diagnostic assays for infectious diseases of terrestrial animals*) using clinical material and virus isolates to demonstrate the tests as being 'fit for purpose' for application in a field diagnostic setting, which may should include the use of internal test standards. The control reactions enable greater confidence in the integrity of the molecular reactions, clinical samples and results.

524 Furthermore, these evaluations enable the appropriate setting of test thresholds for interpretation between
525 positive and negative samples. The increased sensitivity of real-time RT-PCR may leads to the detection
526 of viral RNA in samples in the absence of actively infectious viruses ~~and care should be taken when~~
527 ~~interpreting outputs with small detection limits that may not be indicative of active infection.~~ This problem
528 can be overcome through the serial testing of multiple samples from the same cohort of infected birds, and
529 is especially relevant when testing samples from domestic poultry for disease investigation.

530 In settings with more limited facilities, conventional RT-PCR techniques on clinical samples can, with the
531 correctly defined primers, result in rapid detection and subtype identification (at least of H5 and H7 ~~and~~ H9
532 subtypes, ~~and more recently developed assays are also available for other subtypes~~), including a cDNA
533 product that can be used for nucleotide sequencing (Slomka et al., 2007a). However, these approaches
534 have now been largely replaced by the preferred molecular detection tests for influenza A virus by real-
535 time RT-PCR, a modification to the RT-PCR that reduces the time and cross contamination risks, and
536 increases sensitivity and specificity for both virus identification ~~of virus subtype and sequencing and~~
537 subtyping. These are ideal qualities for influenza A outbreak management, where the period of time in
538 which an unequivocal diagnosis can be obtained is crucial for decision making by the relevant Veterinary
539 Authority. In addition, RT-PCR systems can be designed to operate in a 96-well format and combined with
540 high-throughput robotic RNA extraction from specimens.

541 For example, Spackman et al. (2002) used a single-step real-time RT-PCR primer/fluorogenic hydrolysis
542 probe system to allow detection of influenza A viruses and determination of subtype H5 or H7. The test
543 performed well relative to virus isolation and offered a cheaper and much more rapid alternative, with
544 diagnosis on clinical samples in less than 3 hours. In additional studies, the real-time RT-PCR was shown
545 to have sensitivity and specificity equivalent to virus isolation in numerous settings but updates to
546 primer/probe design can be beneficial over time to accommodate genetic evolution in gene regions
547 targeted by assays (Laconi et al., 2020). These Properly designed molecular tests can provide high
548 sensitivity and specificity similar to those of virus isolation when used on tracheal and oropharyngeal swabs
549 of chickens and turkeys, but may lack sensitivity for detection of influenza A virus in faecal swabs, faeces
550 and tissues in some bird species, because of the presence of PCR inhibitors resulting in false-negative
551 results (Das et al., 2006). Incorporation of a positive internal control during RNA extraction into the test will
552 verify a proper test run. In addition, improvements in RNA extraction and RNA treatment kits have been
553 made available in the market developed to eliminate most PCR inhibitors from test samples.

554 Real-time RT-PCR, usually based around the hydrolysis probe method for generation of the target-specific
555 fluorescence signal, has become the method of choice in many laboratories for at least partial diagnosis
556 directly from clinical specimens. The method offers rapid results, with sensitivity and specificity comparable
557 to virus isolation. These are ideal qualities for influenza A outbreak management, where the period of time
558 in which an unequivocal diagnosis can be obtained is crucial for decision making by the relevant Veterinary
559 Authority. In addition, real-time RT-PCR systems can be designed to operate in a 96-well format and
560 combined with high-throughput robotic RNA extraction from specimens (Aguero et al., 2007).

561 The approach to diagnosis using real-time RT-PCR adopted in most laboratories has been is based on the
562 initial generic detection of screening for influenza A virus in clinical samples, primarily by initially targeting
563 the matrix (M) gene, which is highly conserved for all influenza A viruses (Table 2), although further generic
564 PCR targets have been identified in the NP and PB1 gene segments, followed by Specific real-time RT-
565 PCR testing for H5 and H7 subtype viruses are then used to follow up on M gene positive results.
566 Numerous assays have been reported for a highly sensitive detection of M (or NP)-gene fulfilling the criteria
567 for a suitable screening test. For example, Spackman et al. (2002) used a single-step real-time RT-PCR
568 primer/fluorogenic hydrolysis probe system to allow detection of influenza A viruses. The test performed
569 well relative to virus isolation and offered an inexpensive and much more rapid alternative, with diagnosis
570 on clinical samples in less than 3 hours. In-silico monitoring of influenza A screening tools should be
571 conducted and updates applied as available; this is the case of the Spackman et al. (2002) protocol, which
572 has been updated via the introduction of degenerated bases in the primer sequences targeting the M gene
573 (Hassan et al., 2022; Laconi et al., 2020; Spackman et al., 2020). These updates also allow the inclusion
574 of an internal process control to prevent false negative results arising from PCR inhibition or failure in
575 nucleic acids extraction. With improvements in assay design and using novel biochemical approaches,
576 screening assays relevant to all influenza A viruses from all hosts (animal and human) have been
577 developed (Nagy et al., 2021) with high relevance to an avian-'other' host interface.

578 In cases where laboratories do not have access to a real-time RT-PCR platform for screening samples for
579 the M gene, an alternative solution could be to use the primer set described in the real-time RT-PCR
580 protocols from Spackman et al. (2022) or Heine et al. (2015) or Hassan et al. (2022). However, it should
581 be noted that validation data for this type of use is not currently available and, in addition, due to the small

582 size of the amplicon (less than 100 bp), the RT-PCR results should be visualised on silver-stained SDS-
583 PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) gels or 2–3% agarose gel.

584 Subtyping by PCR represents a greater challenge due to the diversity within subtypes. Maintaining
585 sensitive and specific tools for subtyping requires constant *in-silico* monitoring and routine updates to
586 primer/probe design to accommodate genetic evolution in gene regions targeted by molecular assays. For
587 subtype identification, oligonucleotides primers used in real-time RT-PCR are often targeted at the HA2
588 region, as this is relatively well conserved within the haemagglutinin genes of the H5 and H7 subtypes
589 (Spackman *et al.*, 2008; Spackman & Suarez, 2008). ~~It has therefore served as the target region for these~~
590 ~~subtypes.~~ Spackman *et al.* (2002) demonstrated specific detection of these subtypes, but cautioned that
591 ~~their these~~ H5 and H7 primer/probe sequences ~~had been were~~ designed for the detection of North
592 American H5 and H7 ~~isolates viruses~~ and might not be suitable for all H5 and H7 ~~isolates viruses~~. This
593 proved to be the case. Slomka *et al.* (2007b) described modification of the H5 oligonucleotide sequences
594 used by Spackman *et al.* (2002) to enable the detection of the Eurasian ‘Goose/Guangdong lineage’
595 (Gs/GD) H5N1 subtype and other Eurasian H5 subtypes ~~that have been isolated within the past 15 years~~
596 in both poultry and wild birds. As the group of ‘Gs/GD’ viruses diversified and spread across several
597 continents, it has become important that diagnostics in all settings have proven fit for purpose detection of
598 this H5 lineage of viruses divided into multiple clades (World Health Organization/World Organisation for
599 Animal Health/Food and Agriculture Organization [WHO/WOAH/FAO] & H5N1 Evolution Working Group,
600 2014). Eastern and western hemisphere H7 AIVs are known to be phylogenetically distinguishable from
601 each other; hence, real-time RT-PCRs for the detection of Eurasian H7 AIVs in biological samples have
602 been developed and tested on a variety of H7 viruses collected from geographically and temporally distinct
603 H7 outbreaks (Hassan *et al.*, 2022; Liu *et al.*, 2018; Slomka *et al.*, 2009).

604 When the presence of H5/H7 subtypes is ruled out in clinical samples testing positive for influenza A, the
605 diagnostic investigations should continue until subtype identification. Because of the economic implications
606 to the poultry sector and the zoonotic risk in endemic areas, detection of H9 is generally prioritised over
607 other subtypes, and new diagnostic tools have recently been made available to improve detection of any
608 H9 lineage (Panzarin *et al.*, 2022). Due to challenges with maintaining sensitive and specific subtyping
609 PCR tools, protocols that leverage influenza A detection followed by subtype attempts are best placed for
610 highest success. Newer rapid methods for HA and NA subtyping have been developed ~~that to~~ enable the
611 simultaneous detection and subtyping speeding the time to achieve rapid identification of an influenza A
612 virus using arrays (Hassan *et al.*, 2022; Hoffmann *et al.*, 2016; James *et al.*, 2018) or microchip (Kwon *et*
613 *al.*, 2019) technologies. The validated Eurasian real-time RT-PCR have proven valuable in the
614 investigation of many H5Nx HPAI clinical samples and other subtypes submitted to International Reference
615 Laboratories from Europe, Africa, Asia and North America since 2005 (Liu *et al.*, 2018; Slomka *et al.*,
616 2007). Each set of primers and probes needs to be validated against a diverse set of viruses to make the
617 test applicable in a diverse range of avian species, and in viruses from broad geographic areas and time
618 periods. In addition, real-time RT-PCR methods are now widely used for the rapid and accurate
619 determination of the neuraminidase subtype (James *et al.*, 2018).

620 One of the problems with rapidly emerging new tests is that methods and protocols may be developed and
621 reported without the test being properly validated. ~~This has been addressed for some of the real-time RT-~~
622 ~~PCR protocols. In the European Union, National Reference Laboratories have collaborated to define and~~
623 ~~validate protocols that can be recommended for use within Europe (Hoffmann *et al.*, 2016; Nagy *et al.*,~~
624 ~~2020; Slomka *et al.* 2007). Importantly this should include routine analysis of detected viruses (coordinated~~
625 ~~through WOAH Reference Laboratories) in standard assays to ensure reliable specific detection of~~
626 ~~contemporary viruses affecting poultry and other populations. In addition, given the high variability in the~~
627 ~~influenza A genome it is imperative that assays used in routine diagnosis and surveillance have ongoing~~
628 ~~demonstration of their fitness for detection of contemporary viruses validated for use in the region where~~
629 ~~they are applied. There should be an appropriate match for local strains taking account of significant~~
630 ~~regional and intercontinental variability amongst particular endemic viruses. Laconi *et al.* (2020) in~~
631 ~~reviewing five validated well used real-time RT-PCR methods concluded that continuous monitoring of~~
632 ~~assay performance using both *in silico* and *in vitro* methodology was important as the emergence of new~~
633 ~~strains containing mutations within primer and probe binding areas might significantly affect the positive~~
634 ~~outcome of a test. Increasingly with improvements in assay design and using novel biochemical~~
635 ~~approaches screening assays relevant to all influenza A viruses from all hosts (animal and human) have~~
636 ~~been developed (Nagy *et al.*, 2020) with high relevance to an avian–other host interface.~~

637 As stated before (see Section B.1.4 Assessment of pathogenicity), the molecular pathotyping of H5/H7 is
638 largely based on the determination of the cleavage site sequence of the HA0 precursor of these subtypes.
639 This can be achieved by RT-PCR followed by Sanger sequencing of the amplification product. Real-time
640 RT-PCR protocols that amplify regions across the cleavage site of the HA0 gene have also been described
641 developed that amplify regions across the cleavage site of the HA0 gene to determine the viral pathotype.
642 This may result in useful tests for specific viruses. For example, Hoffman *et al.* (2007) have described a

643 real-time RT-PCR test specific to the Eurasian HPAI H5N1-Qinghai-like clade 2.2 viruses that represents
644 a rapid means of determining the pathotype for this subgroup of H5N1 HPAI viruses without sequencing.
645 In situations where large numbers of positive samples/cases are detected during disease events the same
646 outbreak, these specific targeted real-time RT-PCR assays ~~have been developed for~~ allow the
647 simultaneous sensitive detection and pathotyping of viruses. This can prove to be very useful, particularly
648 when applying to early warning systems such as surveillance of wild bird populations for local presence of
649 HPAI (Graaf *et al.*, 2017; Hassan *et al.*, 2022; James *et al.*, 2022; Naguib *et al.*, 2017).

650 In low-resource setting laboratories, the detection of AIV can be hampered by the need to maintain a cold
651 chain for wet reagents along with the adequate provision of reagents. In such circumstances, the use of
652 lyophilised molecular reagents for increased thermal stability should be considered to maximise
653 surveillance capacities. The interchangeability of the wet and lyophilised reagents may be different between
654 distinct molecular protocols and thus validation is required before their routine use.

655 Modifications to the straightforward RT-PCR method of detection of viral RNA have been designed to
656 reduce the effect of inhibitory substances in the sample taken, the possibility of contaminating nucleic acids
657 and the time taken to produce a result. The loop-mediated isothermal amplification (LAMP) system for H5
658 and H7 detection appears to show high sensitivity and reliable specificity (Ahn *et al.*, 2019; Bao *et al.*,
659 2014), but may have limited application because of susceptibility to viral mutations affecting the target
660 regions, reducing virus detection (Postel *et al.*, 2010).

661 ~~Increasing innovation and technological improvements have made it possible that molecular based and~~
662 ~~improved antigen detection technologies have developed sufficiently to permit rapid flock side tests for the~~
663 ~~detection of presence of influenza A virus specific subtypes and pathogenicity markers (Inui *et al.*, 2019).~~
664 ~~Furthermore, innovations in test design have enabled for example the development of point of care chip~~
665 ~~based ultrafast PCR approaches tests such as chip-based PCR and recombinase polymerase~~
666 ~~amplification (RPA) (Kwon *et al.*, 2018) with increasing application anticipated in the future.~~

667 1.5.3. Gene sequencing

668 Currently real-time RT-PCR is the preferred method of virus surveillance because the test provides rapid
669 sensitive diagnostics for influenza A, as well as subtypes H5, H7 and H9 and is available in high
670 throughputs. However, greater use of sequencing technologies, particularly as unit costs reduce with
671 improvement in technology, offers powerful opportunities to simultaneously detect and sequence viruses
672 directly from clinical samples in a laboratory or field setting, for example applying nanopore technology (Ip
673 *et al.*, 2023 King *et al.*, 2020).

674 Increasingly gene sequencing is being applied not only to detailed characterisation of viruses for use in
675 molecular epidemiology but also in virus subtyping, and defining host range markers, for host range
676 including the ones with zoonotic risk implications, and detecting the emergence of new genotypes through
677 reassortment. Sanger sequencing methodology has been widely used for decades and enables the rapid
678 determination of typically a single (H) target gene in 24-36 hours to define virus pathogenicity (see Section
679 B.1.4.b B.1.4.1.4) and still has widespread utility. However, as genomic data can be rapidly determined using
680 next generation sequencing technology, it enables a broader a more resolved analysis using a range of
681 bioinformatics tools is possible (Zhang *et al.*, 2017). For example, with the advent of greater access to
682 sequencing methodology either through specialised laboratories or commercial providers it is now possible
683 to determine the genomic sequences of influenza A viruses from birds to provide a level of characterisation
684 important in rapid pathogen identification and outbreak intervention. Conventionally, nucleotide sequences
685 have been used in outbreak epidemiology to infer virus origin and precise-~~clear~~ relationships between
686 different viruses associated within the same event (by phylogeny) to support outbreak management. Virus
687 gene Either whole genome or partial haemagglutinin and neuraminidase sequences of haemagglutinin and
688 neuraminidase can rapidly be compared to known sequences of all subtypes in gene databases and used
689 to reveal closest match thereby identifying the virus subtype and phylogenetic relationships. This often
690 avoids the need to culture the virus for rapid identification although reliability and quality of data reduces
691 with increasing cycle threshold values in samples from real-time RT-PCR testing.

692 1.5.4. Molecular epidemiology and phylogenetics

693 Phylogenetic techniques ~~Increasingly such analyses~~ are now being applied at the whole genome level to
694 reveal virus genotypes and provide greater analytical specificity resolution to the ~~analyses~~ outbreak
695 investigations. Such approaches are especially valuable to track ~~since~~ virus evolution which can be more
696 precisely mapped and also determine new genotypes that might arise as a result of including change
697 through genetic reassortment, a key mechanism associated with virus diversity and fitness for birds. This
698 approach is especially valuable for early or first incursions in a new event as it enables greater precision
699 in determining virus origin and the mechanisms leading to the emergence of a virus. However, it also

700 represents a tool to track movements of the virus between infected premises (IPs) and follow its
701 evolutionary trajectories. This Whole genome sequencing has become increasingly important in
702 characterising the rapid evolution and wide diversity of Gs/GD lineage viruses associated with
703 transcontinental spread. The WHO/WOAH/FAO H5N1 Evolution Working Group (2014) developed criteria
704 to distinguish genetic groups specific to the H5 hemagglutinin (HA) gene of the Gs/GD lineage, including
705 a dynamic nomenclature system to define subclades within that lineage. The continuing circulation of HPAI
706 H5N1 viruses in poultry or wild birds has resulted in the ongoing evolution of the H5 HA with the emergence
707 of multiple HA subclades. Since 2005, there have been five intercontinental movements of multiple clades
708 of the H5Nx Gs/GD HPAI lineage viruses: in 2005 clade 2.2; in 2008–2010 clade 2.3.2.1; in 2014–2015
709 clades 2.3.4.4c and 2.3.2.1; in 2016–2017 clade 2.3.4.4b; and in 2020–2023 clade 2.3.4.4b.

710 Translation of nucleotide sequences of all genomic segments into amino acid sequences enables data
711 mining for other virus characteristics or traits such as tropism, host range markers including zoonotic and
712 predicted antiviral drug susceptibility which are invaluable for informing outbreak management.

713 Full access to comprehensive genetic sequences and related metadata from AI outbreaks is crucial not
714 only to identify the determinants of its transmissibility and pathogenicity but also to reconstruct the
715 dissemination dynamics of AIV and to follow the evolution of the virus. Multiple public databases for
716 influenza virus sequence data exist and allow rapid and complete information sharing (e.g. GISAID,
717 GenBank) with the international scientific community. As there is an urgent need to make genomic data
718 publicly available during ongoing epidemics, in case of difficulties in generating and analysing whole
719 genome sequence data, WOA or FAO Reference Laboratories should be consulted.

720 2. Serological tests

721 2.1. Enzyme-linked immunosorbent assay (ELISA)

722 Commercial ELISA kits that detect antibodies against the influenza A nucleoprotein are available. Kits with an
723 indirect and competitive/blocking format have been developed and validated and are now being used to detect
724 influenza A virus-specific antibodies in different animal species. Several avian influenza competitive ELISA (AIV
725 C-ELISA) or blocking ELISA (AIV B-ELISA) have been developed and validated as a more sensitive alternative
726 to the AGID test (see Section B.2.2 Agar gel immunodiffusion) for the detection of influenza A group reactive
727 antibodies in sera from chickens and other bird species (SCAHLs, 2009). This AIV ELISA platform, as in either a
728 “competitive” or “blocking” format, detects antibodies to influenza A viruses by allowing these antibodies to
729 compete for antigen binding sites with a monoclonal antibody against an epitope on the nucleoprotein that is
730 conserved in all influenza A viruses.

731 The kits should be validated for the specific species of interest and for the specific purpose(s) for which they are
732 to be used. Several different test and antigen preparation methods are used. Such tests have usually been
733 evaluated and validated by the manufacturer, and it is therefore important to carefully follow ~~that~~ the instructions
734 specified for their intended use ~~be followed carefully~~. Please see the WOA Register for kits certified by the
735 WOA⁶. ELISA kits are of moderate cost and are amenable to high throughput screening for influenza A virus
736 infections and have strong utility for application to large-scale serosurveillance programmes and compare
737 favourably to HI (Arnold *et al.*, 2018). However, all positive results must be followed by ~~undergo~~ HI test for
738 subtyping to H5 and H7. Some subtype-specific ELISA kits are available, e.g. for antibodies to H5, H7, H9 and
739 some N subtypes (i.e. N1) but generally are of lower sensitivity than influenza A ELISA. Recently, employing
740 bead-based immunoassay technology and recombinantly expressed influenza virus proteins, multiplex serological
741 assays have been developed that offer options for improved diagnostic bandwidth (combining several HA and NA
742 subtypes or further targets of notifiable poultry diseases) and an economising testing schedule. Further validation
743 is required to prove them fit for purpose in routine laboratory settings.

744 To test serum samples obtained from mammals for exposure to avian influenza viruses, a preliminary screening
745 can be performed with a commercially available multispecies competitive ELISA kit targeting antibodies specific
746 for nucleoprotein (NP) of type A influenza viruses. Prior to routine testing, it is recommended to carefully evaluate
747 the validity of ELISAs in the species under examination due to the unknown diagnostic performance of these
748 commercial assays with mammalian sera other than the ones declared by the kit manufacturer. Additional
749 confirmatory serological tests (e.g. HI) are required.

750

⁶ <https://www.woah.org/en/what-we-offer/veterinary-products/#ui-id-5/>

751

2.2. Agar gel immunodiffusion

752 Whilst the AGID is relatively inexpensive and suitable for resource limited settings, it is advisable to use more
753 sensitive platforms such as ELISA for flock level serological investigations including pre-export/import screening
754 of birds for historical exposure to influenza A.

755 All influenza A viruses have antigenically similar a degree of conservation across protein structures for the
756 nucleoprotein and antigenically similar matrix antigens proteins. As such, Owing to this fact AGID tests are able
757 to detect the presence or absence of antibodies to any influenza A virus, based on reactivity to these conserved
758 proteins as concentrated virus preparations, as described above, will contain an abundance of both matrix and
759 nucleoprotein antigens; the matrix antigen diffuses more rapidly than the nucleoprotein antigen proteins. AGID
760 tests have been widely and routinely used to detect specific antibodies in chicken and turkey flocks as an
761 indication of infection, but AGID tests are less reliable at detecting antibodies following infection with influenza A
762 viruses in other avian species. These have generally employed nucleoprotein-enriched preparations made from
763 the chorioallantoic membranes of embryonated chicken eggs (Beard, 1970) that have been infected at 10 days
764 of age, homogenised, freeze-thawed three times, and centrifuged at 1000 g. The supernatant fluids are
765 inactivated by the addition of 0.1% formalin or 1% betapropiolactone, recentrifuged and used as antigen. Not all
766 avian species may produce precipitating antibodies following infection with influenza viruses, for example ducks.
767 The AGID is a low-cost serological screening test of reduced sensitivity for detection of generic influenza A
768 infections, but must be followed by HI tests for subtyping influenza A positives ~~as to H5 and H7 sera.~~

769 Tests are usually carried out using gels of 1% (w/v) agarose or purified type II agar and 8% (w/v) NaCl in 0.01 M
770 phosphate buffer, pH 7.2, poured to a thickness of 2–3 mm in Petri dishes or on microscope slides, and incubated
771 in a humidified chamber. Using a template and cutter, wells of approximately 5 mm in diameter are cut into the
772 agar at a distance of about 3 mm from each other. A pattern of wells must place each suspect serum adjacent to
773 a known positive serum and antigen. Each well should have reagent added to fill the well, corresponding to the
774 top of the meniscus with the top of the gel, but do not over fill. Approximately 25–30 µl of each reagent should be
775 required per well, but this depends on thickness of the gel, with thicker gels requiring an additional volume of
776 reagent.

777 Wells should be examined for precipitin lines at 24 hours, and weak positive samples or samples for which specific
778 lines have not formed should be incubated longer and examined again at 48 hours. The time to formation of visible
779 precipitin line is dependent on the concentrations of the antibody and the antigen. The precipitin lines are best
780 observed against a dark background that is illuminated from behind. A specific, positive result is recorded when
781 the precipitin line between the known positive control wells is continuous with the line between the antigen and
782 the test well. Crossed lines are interpreted to be caused by the test serum lacking identity with the antibodies in
783 the positive control well.

784 Whilst the AGID is relatively inexpensive and suitable for resource limited settings it is being increasingly replaced
785 by other platforms such as ELISA for flock level serological investigations including pre-export/import screening
786 of birds for historical exposure to influenza A.

787 2.3. Haemagglutination and haemagglutination inhibition tests

788 Variations in the procedures for HA and HI tests are practised in different laboratories. The following
789 recommended examples apply to the use of V-bottomed microwell plastic plates in which the final volume for both
790 types of test is 0.075 ml. U-bottomed plates can be used but care in reading is required as the clarity is less
791 defined. The reagents required for these tests are isotonic PBS (0.01 M), pH 7.0–7.4, and RBCs taken from a
792 minimum of three SPF or SAN chickens and pooled into an equal volume of Alsever's solution. Cells should be
793 washed three times in PBS before use as a 1% (packed cell v/v) suspension. Positive and negative control
794 antigens and antisera should be run with each test, as appropriate.

795 2.3.1. Haemagglutination test

- 796 i) Dispense 0.025 ml of PBS into each well of a plastic V-bottomed microtitre plate.
- 797 ii) Place 0.025 ml of virus suspension (i.e. infective allantoic fluid) in the first well. For accurate
798 determination of the HA content, this should be done from a close range of an initial series of dilutions,
799 i.e. 1/3, 1/4, 1/5, 1/6, etc.
- 800 iii) Make twofold dilutions of 0.025 ml volumes of the virus suspension across the plate.
- 801 iv) Dispense a further 0.025 ml of PBS to each well.
- 802 v) Dispense 0.025 ml of 1% (v/v) chicken RBCs to each well.

-
- 803 vi) Mix by tapping the plate gently and then allow the RBCs to settle for about 40 minutes at room
804 temperature, i.e. about 20°C, or for 60 minutes at 4°C, if ambient temperatures are high, by which
805 time control RBCs should have formed a distinct button.
- 806 vii) HA is determined by tilting the plate and observing the presence or absence of tear-shaped streaming
807 of the RBCs. The titration should be read to the highest dilution giving complete HA (no streaming);
808 this represents 1 HA unit (HAU) and can be calculated accurately from the initial range of dilutions.

809 2.3.2. Haemagglutination inhibition test

- 810 i) Dispense 0.025 ml of PBS into each well of a plastic V-bottomed microtitre plate.
- 811 ii) Place 0.025 ml of serum into the first well of the plate.
- 812 iii) Make twofold dilutions of 0.025 ml volumes of the serum across the plate.
- 813 iv) Add 4 HAU of virus/antigen in 0.025 ml to each well and leave for a minimum of 30 minutes at room
814 temperature (i.e. about 20°C) or 60 minutes at 4°C.
- 815 v) Add 0.025 ml of 1% (v/v) chicken RBCs to each well and mix gently, allow the RBCs to settle for
816 about 40 minutes at room temperature, i.e. about 20°C, or for 60 minutes at 4°C if ambient
817 temperatures are high, by which time control RBCs should have formed a distinct button.
- 818 vi) The HI titre is the highest dilution of serum causing complete inhibition of 4 HAU of antigen. The
819 agglutination is assessed by tilting the plates. Only those wells in which the RBCs stream at the same
820 rate as the control wells (containing 0.025 ml RBCs and 0.05 ml PBS only) should be considered to
821 show inhibition.
- 822 vii) The validity of results should be assessed against a negative control serum, which should not give a
823 titre $>1/4$ ($>2^2$ or $>\log_2 2$ when expressed as the reciprocal), and a positive control serum for which
824 the titre should be within one dilution of the known titre.

825 The HI test is primarily used to determine if antibodies indicating influenza A virus infections are subtyped as H5
826 and H7 or other H subtypes (H1-4, H6, H8-16). HI titres may be regarded as being positive if there is inhibition at
827 a serum dilution of 1/16 (2^4 or $\log_2 4$ when expressed as the reciprocal) or more against 4 HAU of antigen. Some
828 laboratories prefer to use 8 HAU in HI tests. While this is permissible, it affects the interpretation of results so that
829 a positive titre is 1/8 (2^3 or $\log_2 3$) or more. The meaning of a minimum positive titre should not be misinterpreted;
830 it does not imply, for example, that immunised birds with that titre will be protected against challenge or that birds
831 with lower titres will be susceptible to challenge. Appropriate virus/antigen control, positive control serum and
832 RBC control well should be included with each batch of HI tests.

833 Chicken sera rarely give nonspecific positive agglutination reactions in this test and any pretreatment of the sera
834 is unnecessary. Sera from species other than chickens may sometimes cause agglutination of chicken RBCs
835 resulting in nonspecific agglutination. Therefore, each serum should first be tested for this idiosyncrasy and, if
836 present, it should be inhibited by adsorption of the serum with chicken RBCs. This is done by adding 0.025 ml of
837 packed chicken RBCs to each 0.5 ml of antiserum, mixing gently and leaving for at least 30 minutes; the RBCs are
838 then pelleted by centrifugation at 800 **g** for 2–5 minutes and the adsorbed sera are decanted. Alternatively, RBCs
839 of the avian species under investigation could be used. Nonspecific inhibition of agglutination can be caused by
840 steric inhibition when the tested serum contains antibodies against the same N subtype as the H antigen used in
841 the HI test. The steric inhibition reaction can result in RBC buttoning in the bottom of the plate or streaming at
842 the same rate as the control. If using whole virus antigen in HI test for subtyping, it is important to ensure that two
843 antigens for each haemagglutinin subtype are used with heterologous neuraminidase i.e. H5N1 and H5N6 to
844 eliminate the possibility of interference in the assay with anti-N antibodies that can lead to false typing results.
845 Alternatively, the H antigen used can be recombinant or purified H protein that lacks N protein. The HI test is
846 based on antigenic binding between the H antigen and antiserum and thus other factors may cause nonspecific
847 binding of the H antigen and sera leading to a nonspecific inhibition reaction. At this time there are no documented
848 cross reactions or nonspecific inhibition reactions between the different haemagglutinin subtypes of influenza A.

849 Where influenza A viruses of avian origin emerge in non-avian species, the detection of antibodies against avian
850 influenza in mammals may be required. For this a pretreatment of the sera is necessary. Three volumes of
851 appropriately diluted receptor-destroying enzyme (RDE) are added to one volume of serum. The mixture is
852 incubated overnight at 37°C, and subsequently inactivated at 56°C for 30 minutes and brought to a final dilution
853 of 1/10 by adding six volumes of PBS. To remove nonspecific haemagglutinating factors, if present, one volume
854 of packed chicken erythrocytes can be added to 20 volumes of serum and incubated at 4°C under gentle shaking
855 for 1 hour before removing erythrocytes by centrifugation at 300 **g** for 5 minutes. HI tests are performed using
856 four haemagglutinating units of virus with 0.5% chicken erythrocytes according to standard procedures described
857 above.

858 **2.4. Neuraminidase antibody detection inhibition tests**

859 The neuraminidase-inhibition test has been used to identify the influenza A neuraminidase type of isolates as well
860 as to characterise the presence of anti-N antibodies antibody in infected birds. The procedure requires specialised
861 expertise and reagents; consequently, this testing is usually done in a WOA Reference Laboratory. ~~The A DIVA~~
862 (differentiating infected from vaccinated animals) strategy ~~used previously in Italy also relies on a serological test~~
863 ~~to detect specific anti-N antibodies; the test procedure has also~~ been described (Capua *et al.*, 2003). Recent
864 developments favoured an enzyme-linked lectin assay (ELLA) to measure NA-specific antibodies which allows
865 for improved test harmonisation.

866 **C. REQUIREMENTS FOR VACCINES**

867 **1. Background**

868 The past two decades have been marked by a significant change in the epidemiological and ecological dynamics of HPAI
869 viruses. An increasing number of HPAI lineages have emerged in poultry and one of them, the H5Nx Gs/GD Eurasian lineage
870 with its descendant clades, has demonstrated the ability of HPAI viruses to expand their host range well beyond domestic
871 birds. As detailed in Section A. Introduction, the Gs/GD clade 2.3.4.4b virus extensively circulates in wild bird populations
872 and since 2022, it has reached a global spread. As such, and due to the impact on both wild bird and poultry populations,
873 vaccination has been considered in areas that have previously relied on conventional control measures of biosecurity, early
874 detection, stamping-out and movement restrictions. Vaccination using appropriately matched vaccines is an important
875 complementary tool to be taken into account for the control of HPAI. When properly implemented, vaccination can reduce
876 virus circulation, limit economic losses, improve animal welfare and minimise environmental impact, thus reducing the risk
877 of spillover to wild animals and humans (Harder *et al.*, 2023).

878 However, for multiple reasons, vaccination alone is not a universal panacea for the solution to the control of HPAI if
879 eradication is the desired result. Without the application of monitoring systems, strict biosecurity and depopulation in the face
880 of infection, HPAI will ~~might~~ become endemic in vaccinated poultry populations. Furthermore, Long-term circulation of the
881 wildtype virus in a-vaccinated populations may result in both antigenic and genetic changes as has occurred with H5Nx
882 (Gs/GD lineage), H7N3, H7N9 and H9N2 influenza A viruses in Mexico, and various Middle Eastern and Asian countries
883 (Swayne & Sims, 2020). The currently used vaccines and the use of vaccination have been reviewed and both challenges
884 and opportunities of application considered (EFSA Panel on Animal Health and Animal Welfare [AHAW] *et al.*, 2023; FAO,
885 2016; Swayne & Sims, 2020).

886 The haemagglutinin is the primary influenza A viral protein that elicits a protective humoral immune response used in officially
887 approved poultry vaccines and such immunity is haemagglutinin subtype specific. ~~To date~~ Historically, the majority of
888 influenza A vaccines used in poultry have been inactivated whole virus vaccines prepared from infective allantoic fluid of
889 embryonated chicken eggs, inactivated by beta-propiolactone or formalin and emulsified with mineral oil adjuvants. Because
890 of the potential for reassortment leading to increased virulence, live-attenuated conventional influenza vaccines against any
891 subtype are not recommended. However, biotechnology holds great potential to generate live avian influenza virus vaccines
892 with altered gene segments which reduce the risk of reassortment, limit replication and abrogate negative aspects of live
893 influenza A virus vaccines (Song *et al.*, 2007). The existence of a large number of haemagglutinin subtypes (i.e. H1–16),
894 together with the known variation-antigenic diversity seen across of different strains within a single subtype pose serious
895 problems when selecting strains to produce inactivated influenza A vaccines. In addition, some isolates do not grow to a
896 sufficiently high titre to produce adequately potent vaccines without costly pre-concentration. While some vaccination
897 strategies use autogenous vaccines, i.e. vaccines prepared from isolates specifically involved in an epizootic, others rely on
898 vaccines prepared from biologically characterised, fully approved seed strain viruses possessing the same haemagglutinin
899 subtype as the field virus and capable of yielding high concentrations of antigen. Historically, inactivated vaccines for LPAI
900 and HPAI control have used LPAI viruses with a matching haemagglutinin subtype from outbreaks as seed strains, but with
901 development of resistance in the field associated with prolonged vaccine use, the majority of inactivated vaccine seed strains
902 are now reverse genetic derived virus with antigenically close matching haemagglutinin, and sometimes neuraminidase, to
903 circulating field viruses. Use of native HPAI viruses as inactivated vaccine seed strains is strongly discouraged because of
904 biosafety concerns during production and when in use.

905 Since the 1970s in the USA, inactivated influenza A vaccines have been used primarily in turkeys against LPAI viruses under
906 emergency vaccination programmes, but since the 2000s, most vaccines have been against H1 and H3 swine influenza A
907 viruses used under a routine preventative vaccination programme in breeder turkeys (Swayne *et al.*, 2020). Since the early
908 1990s, vaccination of chickens against H9N2 LPAI virus has been used extensively in Asia and the Middle East using billions
909 of inactivated vaccine doses (Swayne & Sims, 2020). Vaccination was used to control multiple incursions of avian influenza
910 viruses of the H5 and H7 subtypes between 2000 and 2006 in Italy (EFSA Panel on AHAW *et al.*, 2023). Vaccination against
911 HPAI was first used in Mexico during the H5N2 outbreaks of 1994–1995 (Villarreal, 2007), and in Pakistan (Naeem, 1998)
912 during the H7N3 outbreaks of 1995. Beginning with H5N1 ~~goose/Guangdong~~ (Gs/GD) lineage HPAI outbreaks in Hong Kong

913 in 2002 (Sims, 2003), a vaccination policy was adopted using H5N2 LPAI vaccine seed strains and subsequently replaced
914 with H5Nx reverse genetic vaccine seed strains in China (People's Rep. of), as the field virus spread throughout and outside
915 of China. Between 2002 and 2010, 113 billion doses of vaccine was used to control HPAI with 95% being inactivated and 5%
916 recombinant vaccines, and a similar usage rate continues (Swayne *et al.*, 2011; Swayne & Sims, 2020). As the H5Nx Gs/GD
917 lineage HPAI spread across the globe, additional countries have implemented emergency and/or preventative vaccination
918 programmes for HPAI control. Similarly, preventive and emergency vaccination against H5N1 HPAI has been permitted
919 implemented for outdoor poultry and zoo birds in several European Union countries ~~in the 2000s~~.

920 Live recombinant virus-vectored vaccines with H5 influenza A virus haemagglutinin gene inserts have been approved and
921 used ~~in a few countries~~ increasingly since 1997, mostly in chickens, and include recombinant fowl poxvirus (rFPV),
922 recombinant Newcastle disease virus (rNDV) and recombinant herpesvirus turkey vaccines (rHVT). Since 2015, non-
923 replicating, haemagglutinin based H5 RNA particle, H5 expressed baculovirus and H5 DNA vaccines have also been
924 approved for vaccination of poultry ~~but have had limited use~~ (EFSA Panel on AHAW *et al.*, 2023; Swayne & Sims, 2020).

925 1.1. Rationale and intended use of the product vaccines

926 Experimental work has shown, for HPAI and LPAI, that potent and properly administered vaccines increase
927 resistance to ~~or prevent~~ infection, ~~protect against~~ reduce clinical signs and mortality, prevent ~~drops~~ reduction in
928 egg production, reduce virus shedding from respiratory and intestinal tracts, protect from diverse field viruses
929 within the same haemagglutinin subtype, protect from low and high challenge exposure, and reduce excretion
930 and thus prevent contact transmission of challenge virus (Capua *et al.*, 2004; EFSA Panel on AHAW *et al.*, 2023;
931 Swayne & Sims, 2020). Although, in experimental vaccination studies, a challenge virus is still able to infect and
932 replicate in clinically healthy vaccinated SPF birds when exposed to high doses, ~~the vaccination should reduce~~
933 virus shedding to quantities shed may be that are insufficient for onward transmission of the virus (Van der Goot
934 *et al.*, 2005). Vaccinated herds in which the reproduction factor of infection is suppressed to below 1 ($R_0 < 1$) are
935 unlikely to pose a risk of further spread of field viruses (EFSA Panel on AHAW *et al.*, 2024). Most of the work
936 evaluating vaccines has been done in chickens and ~~to a lesser extent in turkeys and ducks~~, so turkeys and some
937 care must be taken in extrapolating the results obtained to other species. It is recommended to first evaluate each
938 specific vaccine in the species in which it is to be used. Most national HPAI and LPAI control regulations reserve
939 the right to use vaccines ~~in emergencies as 1) preventive tool, based on the outcome of risk assessments for~~
940 disease introduction or spread, when other preventive measures are considered insufficient, or 2) in emergency
941 scenarios as an immediate response to an outbreak to create barriers to further spread of the disease. In all
942 cases, an adequate surveillance plan to guarantee the absence of circulation of the virus in the face of vaccination
943 must be developed (EFSA Panel on AHAW *et al.*, 2024; WOA *Terrestrial Code*, Chapter 10.4 *Infection with high*
944 *pathogenicity avian influenza viruses*).

945 The conditions that determine risk assessments on the implementation of vaccination against HPAI in poultry
946 depend on multiple variables, such as i) the epidemiological situation (e.g. high number of poultry outbreaks,
947 infected wild bird populations, high risk of virus introduction from neighbouring areas); ii) the characteristics of the
948 susceptible poultry population (e.g. high density of poultry farms, presence of species with high genetic value,
949 presence of species that may not show clinical signs of infection); iii) environmental considerations (e.g. farms
950 near wetlands, areas with a high density of migratory wild birds), iv) social and trade considerations (i.e. traditions
951 of live poultry marketing, transboundary trade) (EFSA Panel on AHAW *et al.*, 2023).

952 There may be regional specific rules on the use of vaccination as a further layer of protection against HPAI (e.g.
953 European Commission [EC], 2023).

954 2. Outline of production and minimum requirements for conventional vaccines

955 The information below is based primarily on the experiences in the USA and the guidance and policy for regulatory approval
956 of influenza A vaccines in that country (United States Department of Agriculture, 1995 [updated 2006]). The basic principles
957 for producing vaccines, particularly inactivated vaccines, are common to several viruses e.g. Newcastle disease (chapter
958 3.3.14).

959 Guidelines for the production of veterinary vaccines are given in Chapter 1.1.8 *Principles of veterinary vaccine production*.
960 The guidelines given here and in chapter 1.1.8 are intended to be general in nature and may be supplemented by national
961 and regional requirements.

962 The vaccine production facility should operate under the appropriate biosecurity procedures and practices. If HPAI virus is
963 to be used in challenge studies, the facility used for such studies should meet the competent veterinary authority within the
964 country minimum requirements for Containment Group 3 pathogens as outlined in chapter 1.1.4.

965 2.1. Characteristics of the seed

966	2.1.1. Biological characteristics
967 968 969 970 971	For any subtype, only well characterised influenza A virus of proven low pathogenicity, preferably obtained from an international or national repository, should be used to establish a master seed for inactivated vaccines. HPAI viruses should not be used as seed virus for vaccine. For HPAI, reverse genetics produced vaccine seed strains based on haemagglutinin gene of the HPAI virus are preferred, but should have the cleavage site sequence altered <u>de-engineered</u> to <u>contain</u> that of a H5/H7 LPAI virus.
972 973 974 975	A master seed is established from which a working seed is obtained. The master seed and working seed are produced in SPF or SAN embryonated eggs. The establishment of a master culture may only involve producing a large volume of infective allantoic fluid (minimum 100 ml), which can be stored as lyophilised aliquots (0.5 ml).
976	2.1.2. Quality criteria (sterility, purity, freedom from extraneous agents)
977 978	The established master seed should be controlled/examined for sterility, safety, potency and absence of specified extraneous agents (<u>Chapter 1.1.8</u>).
979	2.2. Method of manufacture
980	2.2.1. Procedure
981 982 983 984	For vaccine production, a working seed, from which batches of vaccine are produced, is first established in SPF or SAN embryonated eggs by expansion of an aliquot of master seed to a sufficient volume to allow vaccine production for 12–18 months. It is best to store the working seed in liquid form at below –60°C as lyophilised virus does not always multiply to high titre on subsequent first passage.
985 986 987 988 989	The routine procedure is to dilute the working seed in sterile isotonic buffer (e.g. PBS, pH 7.2), so that about 10^3 – 10^4 EID ₅₀ in 0.1 ml are inoculated into each allantoic cavity of 9- to 11-day-old embryonated SPF or SAN chicken eggs. These are then incubated at 37°C. Eggs containing embryos that die within 24 hours should be discarded. The incubation time will depend on the virus strain being used and will be predetermined to ensure maximum yield with the minimum number of embryo deaths.
990 991 992	The infected eggs should be chilled at 4°C before being harvested. The tops of the eggs are <u>disinfected</u> , removed and the allantoic fluids collected by suction. The inclusion of any yolk material and albumin should be avoided. All fluids should be stored immediately at 4°C and tested for bacterial contamination.
993 994 995 996 997 998 999 1000	In the manufacture of inactivated vaccines, the harvested allantoic fluid is treated with either formaldehyde (a typical final concentration is 1/1000, i.e. 0.1% formalin) or beta-propiolactone (BPL) (a typical final concentration is 1/1000–1/4000, i.e. 0.1–0.025% of 99% pure BPL) <u>or other approved inactivation methods</u> . The <u>exposure</u> time required must be sufficient to ensure freedom from <u>live virus any infectious virus</u> . Most inactivated vaccines are formulated with non-concentrated inactivated allantoic fluid (active ingredient). However, active ingredients may be concentrated for easier storage of antigen. The active ingredient is usually emulsified with mineral or vegetable oil and surfactants <u>in the final product formulation</u> . The exact <u>content of</u> formulations are generally commercially <u>sensitive and are not released secrets</u> .
1001	2.2.2. Requirements for substrates and media
1002 1003 1004 1005	The inactivated influenza A vaccines prepared from conventional <u>or reverse genetics generated viruses</u> are produced in 9- to 11-day-old embryonated SPF or SAN chicken eggs. The method of production is basically the same as for propagating the virus aseptically (<u>see Section B.1.2 Virus isolation</u>); all procedures are performed under <u>sterile aseptic</u> conditions.
1006	2.2.3. In-process controls
1007 1008 1009	For inactivated vaccines, completion of the inactivation process should be tested in embryonated eggs, taking at least 10 aliquots of 0.2 ml from each batch and passaging each aliquot at least twice through SPF or SAN embryos. Viral infectivity must not remain.
1010	2.2.4. Final product batch tests
1011 1012	Most countries have published specifications for the control of production and testing of vaccines, which include the definition of the obligatory tests on vaccines during and after manufacture.
1013	i) Sterility and purity

1014 Tests for sterility and freedom from contamination of biological materials intended for veterinary use
1015 may be found in chapter 1.1.9.

1016 ii) Safety

1017 For inactivated vaccines, a double dose is administered by the recommended route to ten 3-week-
1018 old birds, and these are observed for 2 weeks for absence of clinical signs of disease or local lesions.

1019 iii) Batch potency

1020 Potency of influenza A vaccine is generally evaluated by testing the ability of the vaccine to induce a
1021 significant HI titre in SPF or SAN birds. Indeed, because of their ability to block virus attachment and
1022 entry into host cells of influenza type A viruses, the antibodies against the HA protein measured by
1023 such a test are recognised to be the most powerful mediators of resistance to influenza infection and
1024 are considered the primary immune correlate of protection. Conventional potency testing involving
1025 the use of three diluted doses and challenge with HPAI virus may also be used for vaccines prepared
1026 to give protection against LPAI subtypes. For inactivated vaccines against HPAI or LPAI virus,
1027 potency tests may rely on the measurement of immune response or challenge and assessment of
1028 morbidity, mortality (HPAI only) and quantitative reduction in challenge virus replication in respiratory
1029 (oropharyngeal or tracheal) and intestinal (cloaca) tracts (the latter parameter assessed by collection
1030 of oropharyngeal/tracheal and cloacal swabs). Assessment of haemagglutinin antigen content could
1031 allow for *in-vitro* extrapolation to potency for subsequent vaccine batches.

1032 iv) Preservatives

1033 A preservative may be used for vaccine in multidose containers.

1034 **2.3. Requirements for regulatory approval**

1035 **2.3.1. Safety requirements**

1036 i) Target and non-target animal safety

1037 Most inactivated influenza A vaccines are approved for use in chickens and turkeys. Field trials in the
1038 target species should be conducted to determine tolerance and safety of the vaccine at full dose.
1039 Recently the use of inactivated influenza A vaccines has been expanded to ducks, geese, other
1040 poultry and zoo birds. Any ~~extra~~-off-label use of the vaccines should be done cautiously and under
1041 the supervision of a veterinarian experienced in disease control through vaccination in the test
1042 species. Care must be taken to avoid self-injection with oil emulsion vaccines.

1043 ii) Reversion-to-virulence for attenuated/live vaccines

1044 Only inactivated influenza A virus vaccines are recommended. Live conventional influenza vaccines
1045 against any subtype are not ~~recommended~~ acceptable because of the risk for reassortment of gene
1046 segments of vaccine virus with field virus, potentially creating more pathogenic field viruses.

1047 iii) Environmental consideration

1048 None

1049 **2.3.2. Efficacy requirements**

1050 i) For animal production

1051 For regulatory purposes, influenza A vaccines should pass an efficacy challenge test using a
1052 statistically relevant number of SPF or SAN chickens per group. The challenge should occur at a
1053 minimum of three weeks post-vaccination, using a challenge HPAI virus dose that causes 90% or
1054 greater mortality in the sham population. A standardised challenge dose of 10⁶ mean chicken embryo
1055 infectious doses is most widely used. Protection from mortality in the vaccine group should be a
1056 minimum of ~~80-90%~~ 90%. For LPAI, mortality is not a feature of challenge models, therefore a statistically
1057 significant reduction in virus shedding titre and/or the number of birds shedding virus from oropharynx
1058 or cloaca should be observed between sham and test vaccine groups. Other metrics of protection
1059 can be used to determine efficacy such as prevention of drops in egg production.

1060 In establishing minimum antigen requirements, 50 PD₅₀ or 3 µg of haemagglutinin per dose have
1061 been recommended (~~Swayne & Sims, 2020~~). Minimum HI serological titres in field birds should be

1062 1/32 to protect from mortality or greater than 1/128 to provide reduction in challenge virus replication
1063 and shedding for antigenically close related vaccine and challenge viruses.

1064 Use of appropriate antigens (i.e. antigenically matched to circulating strains) is critical for the
1065 achievement of adequate vaccine efficacy (clinical protection and significant reduction of shedding)
1066 against field viruses and to minimise vaccine failures regardless of the vaccine platform. Antigen
1067 selection should be based on the molecular and antigenic relatedness of the candidate vaccine strain
1068 and of the field isolates in the HA1 protein. Several studies have demonstrated that HI titres correlate
1069 with protection when the vaccine and field strains are antigenically closely related, in particular for
1070 inactivated vaccines. For novel vaccine platforms (e.g. HVT-vectored or replicon particles) a less
1071 clear association between HI titres and protection has been demonstrated, putatively as the result of
1072 a major stimulation of cell-mediated immunity.

1073 ii) For control and eradication
1074 Efficacy should be the same as for animal production.

1075 2.3.3. Stability

1076 When stored under the recommended conditions, the final vaccine product should maintain its potency for
1077 at least 1 year. Inactivated vaccines must not be frozen.

1078 3. Vaccines based on biotechnology

1079 3.1. Vaccines available and their advantages

1080 Recombinant live vaccines for influenza A viruses have been produced by inserting the gene coding for the
1081 influenza A virus haemagglutinin into a non-influenza live virus vector and using this recombinant virus to
1082 immunise poultry against influenza A (Swayne & Sims, 2020). Recombinant live vector vaccines have several
1083 advantages over inactivated influenza A vaccines: 1) they induce mucosal, humoral and cellular immunity; 2) they
1084 can be mass administered *in ovo* or to 1-day-old birds in the biosecure hatchery to induce early protection; and
1085 3) they enable easy serological differentiation of infected from non-infected vaccinated birds because they do not
1086 induce the production of antibodies against the nucleoprotein or matrix antigens that are common to all influenza
1087 A viruses: i.e. differentiation of infected from vaccinated animals (DIVA). Therefore, only field-infected birds will
1088 exhibit antibodies in the AGID test or ELISAs directed towards the detection of influenza group A (nucleoprotein
1089 and/or matrix) antibodies. However, recombinant live vaccines have limitations in that they may have reduced
1090 replication and thus induce no or only partial protective immunity in birds that have had field exposure to or vaccine
1091 induced immunity against the vector virus or the H gene insert (Bertran *et al.*, 2018; Swayne & Sims, 2020). If
1092 used in day-old or young birds, the effect of maternal antibodies to the vector virus on vaccine efficacy may vary
1093 with the vector type; i.e. most severe inhibition in decreasing order for Newcastle disease virus, fowl poxvirus and
1094 HVT vectors. In addition, because the vectors are live viruses that may have a restricted host range, the use of
1095 such vaccines must be restricted to species in which efficacy has been demonstrated. These limitations may
1096 prevent the choice of these vaccine candidates under emergency vaccination campaigns, which require the
1097 simultaneous administration of birds of different ages and species (EFSA Panel on AHAW *et al.*, 2023).

1098 A rFPV-H5 vaccine, with H gene insert for A/turkey/Ireland/1378/1983 (H5N8), was developed in the early 1980s
1099 and ~~authorised~~ approved beginning in 1998 for use against H5N2 LPAI of Mexico (Swayne & Sims, 2020). This
1100 vaccine has principally been used in Mexico with expansion into several other countries within Central America
1101 and Vietnam with over 9 billion doses used between 1998 and 2016. This rFPV-H5 has had the H gene insert
1102 updated to A/chicken/Mexico/P-14/2016 (H5N2) (Bertran *et al.*, 2020). An rFPV-H7 with haemagglutinin insert
1103 from A/chicken/Guanajuato/07437-15/2015 (H7N3) has been developed and approved with deployment to Mexico
1104 in 2018 against H7N3 HPAI, and a rFPV-H5 with H and N gene inserts from A/goose/Guangdong/1996 (H5N1,
1105 clade 0) was used in China against the H5N1 HPAI during 2005 (Chen & Bu, 2009; Criado *et al.*, 2019; Swayne
1106 & Sims, 2020). rFPV can be effective when given to 1-day-old chicks with varying levels of maternal immunity
1107 (Arriola *et al.*, 1999). However, when very high levels of inhibitory immunity is anticipated because of previous
1108 infection or vaccination, the efficacy of the recombinant live vaccine in such day-old chicks should be confirmed
1109 and may require a prime-boost application of recombinant vaccine followed at a minimum 10 days later by
1110 inactivated influenza A vaccine boost to give optimal immunity (EFSA Panel on AHAW *et al.*, 2023; Richard-Mazet
1111 *et al.*, 2014; Swayne & Sims, 2020).

1112 Newcastle disease virus can also be used as a vector for expressing influenza haemagglutinin genes. A
1113 recombinant Newcastle disease vaccine virus (rNDV) expressing a H5 HA gene (rNDV-H5) was shown to protect
1114 SPF chickens against challenge with both virulent Newcastle disease virus and a HPAI H5N2 virus (Voits *et al.*,
1115 2006). A similar recombinant virus based on Newcastle disease virus vaccine strain La Sota and expressing H

1116 gene of A/goose/Guangdong/1996 (clade 0) (H5N1) was produced in China (the People's Rep. of) (~~Ge et al.,~~
1117 2007) and reported to be efficacious in protection studies with either virus. This rNDV-H5 (clade 0) vaccine has
1118 been used widely with subsequent updating of HA insert twice with clade 2.3.4 and 2.3.2 clade haemagglutinin
1119 inserts (~~Swayne & Sims, 2020~~). An rNDV-H5 with H gene insert from A/chicken/Mexico/435/2005 (H5N2) has
1120 been developed, approved and deployed in Mexico against H5N2 LPAI (~~Swayne & Sims, 2020~~). An rNDV-H5
1121 vaccine with H gene insert from A/chicken/Iowa/04-20/2015 (H5N2) (Gs/GD lineage, clade 2.3.4.4) insert was
1122 effective in protecting chickens against challenge with homologous H5N2 HPAI virus in chickens lacking immunity
1123 to the Newcastle disease virus vector or the H gene insert, but rNDV-H5 vaccine was ineffective as a primary or
1124 booster vaccine in poultry with maternal immunity or well-immunised against Newcastle disease or the H5
1125 haemagglutinin protein (~~Bertran et al., 2018~~). rNDV-H5 vaccines are effective as a primary vaccine if used in
1126 Newcastle disease or H5 antibody negative chickens, or as a priming vaccine followed by a boost with an
1127 inactivated influenza A vaccine in Newcastle disease or H5 antibody positive chickens. The major advantage of
1128 rNDV-H5 is the ability for low cost mass application by spray in the hatchery or field (~~Swayne & Sims, 2020~~).

1129 Since 2010, a rHVT-H5 with haemagglutinin insert of A/swan/Hungary/4999/2006 (Gs/GD lineage, clade 2.2) has
1130 been approved and used in several countries such as Bangladesh, Egypt, Iraq, Pakistan and Vietnam ~~Egypt and~~
1131 ~~Bangladesh~~ against H5Nx Gs/GD lineage HPAI and in Mexico against H5N2 LPAI (EFSA Panel on AHAW *et al.*,
1132 2023; ~~Rauw et al., 2011; Swayne & Sims, 2020~~). This rHVT-H5 vaccine has produced broad protection across
1133 diverse H5 HPAI viruses (~~Rauw et al., 2014~~). Vaccine trials using HVT-H5 vaccines in combination with a DNA or
1134 a subunit vaccine have also been conducted in Europe providing protection against clade 2.3.4.4b in layers in the
1135 Netherlands and in fattening turkeys in Italy reaching 100% survival after challenge at 50 days with HPAI 2.3.4.4b
1136 isolate (EFSA Panel on AHAW et al., 2023). Furthermore, maternally derived antibodies to rHVT vector or H5
1137 haemagglutinin protein have had minimal negative impact on the effectiveness of the vaccine in broiler chickens
1138 after a single vaccination at 1 day of age (~~Bertran et al., 2018~~). The rHVT-H5 is limited to application only *in ovo*
1139 or at 1 day of age to chickens in the hatchery, as application later on the farm is not feasible because of the
1140 ubiquitous infection by Marek's disease viruses or use of Marek's disease vaccines. Furthermore, rHVT-H5
1141 vaccines are in the later stages of development. Some of these products have been used in strategies for HA
1142 insert optimisation by computational models in an effort to increase the breadth of protection offered against
1143 viruses belonging to different H5 clades. In addition, rHVT-H9 vaccines have also been tested in some Asian
1144 countries.

1145 Because of the induction of broader immunity across mucosal, humoral and cellular areas, recombinant live
1146 vectored vaccines have had a longer use life in the field before appearance of field viruses that are resistant to
1147 the vaccine strains as compared to inactivated whole virus vaccines which produce primarily a strong humoral
1148 immunity and require more frequent updates to maintain efficacy in the field. Several A-recombinant duck enteritis
1149 viruses in domestic ducks for the prevention of H5 and/or H7 HPAI has have been developed and shown efficacy
1150 but is pending regulatory approval and deployment in domestic ducks under experimental conditions in China
1151 (People's Rep. of) (~~Liu et al., 2014~~).

1152 Non-replicating haemagglutinin-based RNA particle and DNA vaccines with the H gene from
1153 A/Gyrfalcon/Washington/40188-6/2014 (H5N8) (Gs/GD lineage, clade 2.3.4.4) have been approved for poultry
1154 use in the USA (~~Swayne & Sims, 2020~~). The H5 RNA particle vaccine is part of the USA emergency vaccine bank,
1155 along with rHVT-H5 and an inactivated H5N2 vaccines. The H5 RNA particle vaccine has been demonstrated to
1156 be an effective booster vaccine to replace ~~reverse genetics generated~~ inactivated H5Nx vaccine (~~Bertran et al.,~~
1157 2017). A baculovirus with the H gene insert from A/duck/China/E319-2/2003 (Gs/GD lineage, clade 2.3.32) has
1158 been approved for poultry use in several countries such as Iran, Iraq, Egypt, Jordan ~~Bangladesh, Egypt and~~
1159 ~~Mexico~~ (EFSA Panel on AHAW *et al.*, 2023; ~~Swayne & Sims, 2020~~). This vaccine technology induced a statistically
1160 significant reduction of HPAI clade 2.3.4.4b shedding after challenge at 7 weeks of age on conventional mule
1161 ducks and, since autumn 2023, it has been used in the preventive vaccination campaign in ducks in France (EFSA
1162 Panel on AHAW et al., 2023). Since this category-type of vaccine only contains the specific influenza A
1163 haemagglutinin protein, ~~they it are is~~ easily amenable to serological DIVA testing using assays designed for
1164 identifying antibodies to the nucleoprotein/matrix protein. However, field reports of protection with vectored and
1165 conventional influenza A vaccines suggest that protection by single dose of the vectored vaccines for long lived
1166 poultry is not feasible, with long-term field protection requiring a booster with inactivated influenza A vaccine or
1167 non-replicating, haemagglutinin-based vaccine (~~Swayne & Sims, 2020~~). Other baculovirus-related recombinant
1168 protein-based vaccine candidates have been designed also against other HA subtypes.

1169 More recently, a vaccine based on RNA replicon technology has become available. Recombinant RNA replicons
1170 are able to provide single-cycle replication *in vivo*, which restricts the spread of the vaccine replicon between
1171 vaccinated birds, prevents the replicon from causing disease and, at the same time, allows the stimulation of both
1172 humoral and cell-mediated immunity. Vaccine trials have been conducted in France in mule ducks, which turned
1173 out to be effective in reducing virus shedding following the challenge with clade 2.3.4.4b. The vaccine has also
1174 undergone a field trial in geese in Hungary (EFSA Panel on AHAW et al., 2023).

1175 The use of engineered and packaged mRNA is being considered for future developments and applications in
1176 poultry. These approaches can overcome the obstacles of the species-specificity of some viral vectors and
1177 therefore allow vaccination of multiple poultry species. Pure mRNA vaccines can also prevent the induction of
1178 immunity against replicon components that could interfere with booster applications. Although veterinary
1179 applications of such technology are currently limited in particular for AIV, vaccines for use in humans are in later
1180 stages of development.

1181 ~~In addition to these approved vaccines,~~ various experimental haemagglutinin-based H5 and H7 influenza A
1182 vaccines have been described using *in-vivo* or *in-vitro* expression systems including recombinant adenoviruses,
1183 salmonella, *Lactobacillae*, vaccinia, avian leucosis virus, various eukaryotic systems (plants or cell cultures) and
1184 infectious laryngotracheitis virus (Swayne & Sims, 2020). Even the use of virus-like particles (VLPs) for vaccine
1185 production in veterinary vaccinology has increased in the past few years thanks to the favourable characteristics
1186 intrinsic to VLPs, such as high immunogenicity, safety and versatility. VLPs are self-assembled viral protein
1187 complexes the structure of which closely mimic those of their parent viruses in conformation and organisation.
1188 Prototypes of AI vaccines based on VLPs have shown promising results in experimental trials.

1189 **3.2. Special requirements for biotechnological vaccines, if any**

1190 Live recombinant vectored vaccines with influenza A haemagglutinin gene inserts should have an environmental
1191 impact assessment completed to determine the risk of the vaccine to be virulent in non-target avian species and
1192 will not increase in virulence in the target avian species.

1193 **4. ~~Surveillance methods for detecting~~ Detection of infection in vaccinated flocks and** 1194 **vaccinated birds**

1195 A strategy that allows differentiation of infected from vaccinated animals (DIVA), has been put forward as a possible solution
1196 to the eventual eradication of HPAI and H5/H7 LPAI without involving mass culling of birds and the resulting economic
1197 damage, especially in developing countries (FAO, 2004). This strategy has the benefits of vaccination (less virus in the
1198 environment), but the ability to identify infected flocks would still allow the implementation of additional control measures,
1199 including stamping out of infected flocks. DIVA strategies use one of two broad detection schemes within the vaccinated
1200 population: 1) detection of influenza A virus ('virus DIVA'), or 2) detection of antibodies against influenza A field virus infection
1201 ('serological DIVA'). At the flock level, a simple method consists of regularly monitoring sentinel birds left unvaccinated in
1202 each vaccinated flock, but this approach does have some management problems, particularly with regards to identifying the
1203 sentinels in large flocks. As an alternative or adjunct system, testing for field exposure may be performed on the vaccinated
1204 birds either by detection of field virus or antibodies against the virus. To detect the field virus, oropharyngeal or cloacal swabs
1205 from baseline daily mortality ("bucket sampling") or sick birds can be tested, individually or as pools, by molecular methods,
1206 such as real-time RT-PCR or AC-ELISA of the vaccinated populations (Swayne & Kapczynski, 2008). Molecular methods
1207 are the most sensitive tools to be used to monitor vaccinated poultry flocks for circulating AI viruses. They enable a direct
1208 and rapid insight into virus circulation within the flock at the time point of sampling and can be used to provide information
1209 on the subtype and pathotype of the virus. The efficacy of this approach mainly depends on the number of samples taken
1210 and the frequency of sampling (Harder et al., 2023). Surveillance strategies to be implemented following the vaccination of
1211 poultry holdings against HPAI were assessed in an EFSA Scientific Opinion (EFSA Panel on AHAW et al., 2024). One of
1212 the most effective surveillance strategies, identified by simulations and models described in the Opinion, includes sampling
1213 all dead birds (up to a number of 5, 10, 15 and 20, according to the target species or the desired sensitivity) collected within
1214 48 hours before sample submission at defined sampling intervals. Reducing the sampling intervals, but not increasing the
1215 number of sampled birds, optimizes the early detection surveillance sensitivity. To demonstrate disease freedom and for
1216 early detection of HPAI virus following preventive vaccination, monthly virological testing of all dead birds up to 15 per flock
1217 is recommended, combined with passive surveillance in both vaccinated and unvaccinated flocks. It remains to be proven in
1218 well-controlled validation studies whether environmental sampling, in the form of swabs or boot socks taken from floors,
1219 walls, feeder troughs, nests, cages, or fans as well as air, water and drinker biofilms, may represent a future option for less
1220 invasive and economical virological surveillance in scenarios of subclinical infection usually observed in vaccinated poultry
1221 (EFSA Panel on AHAW et al., 2024; Harder et al., 2023).

1222 To use serological DIVA schemes, vaccination systems that enable the detection of field exposure in vaccinated populations
1223 should be used. Several systems have been used. First, use of a vaccine containing a virus of the same haemagglutinin
1224 subtype but a different neuraminidase (N) from the field virus. Antibodies to the N of the field virus act as natural markers of
1225 infection. This system was used in Italy following the re-emergence of a H7N1 LPAI virus in 2000, ~~and used where~~ an H7N3
1226 inactivated vaccine was used with the detection of N3-specific antibodies indicating a vaccinated flock, N1 antibodies
1227 indicating infection, and both N1 and N3 antibodies indicating an infected, vaccinated flock (Capua et al., 2003). However,
1228 this method is labour intensive and time consuming and these inherent problems have prevented its wider use. In addition,
1229 problems with this system or with recently developed NA subtype-specific ELISAs would arise if a field virus emerges that
1230 has a different N antigen to the existing field virus or if subtypes with different N antigens are already circulating in the field
1231 as is present in many low and middle income countries with H5Nx (Gs/GD lineage), H9N2 and other NA subtypes in live
1232 poultry markets (Swayne & Sims, 2020). A second serological DIVA option is the use of vaccines that contain only HA, e.g.

1233 replicating or non-replicating recombinant vaccines or subunit vaccines, which allows validated, classical AGID and
1234 nucleoprotein (NP)- or matrix protein-based ELISAs to be used to detect antibodies indicative of infection in vaccinated birds.
1235 Finally, for inactivated vaccines, a test that detects antibodies to the nonstructural viral or M2e proteins have been described
1236 (Avellaneda *et al.*, 2010; Lambrecht *et al.*, 2007). These systems are yet to be validated in the field.

1237 DIVA serological surveillance in long-lived poultry is useful to retrospectively demonstrate freedom from infection in a region,
1238 zone or compartment as it demonstrates the absence of infection in the preceding period. However, one problem with DIVA
1239 serological testing is the challenge of interpreting results in a scenario of endemic co-circulation of LPAI viruses in poultry
1240 (e.g. H9N2 in Asia, Africa and the Middle East). This is because most of the DIVA serological tests available rely on the
1241 detection of antibody to NP, which is common to all influenza A viruses. For vaccinated flocks in areas with endemic LPAIV,
1242 therefore, routine screening by subtype-specific PCR for the subtype of concern is the most appropriate method.

1243 Implementation of any vaccination plan should go hand in hand with a system of enhanced surveillance, which needs to be
1244 developed according to the epidemiological scenario, the socioeconomic context and the aim of the vaccination. Delegated
1245 regulation (EU) 2023/361⁷ allows the possibility of vaccination against HPAI in the European Union and provides specific
1246 requirements for surveillance in the context of emergency and preventive vaccination programmes.

1247 **5. Continued evaluation and updating of vaccine seed strains to protect against emergent** 1248 **variant field virus strains**

1249 Historically, H5 LPAI inactivated vaccine seed strains and recombinant fowl poxviruses with H5 gene inserts have shown
1250 broad cross protection in chickens against challenge by diverse H5 HPAI viruses from Eurasia and North America (Swayne
1251 & Kapczynski, 2008). In 1995, Mexico implemented influenza A vaccine use for poultry as one tool in the HPAI control
1252 strategy, with eradication of HPAI strain by June 1995, but as H5N2 LPAI viruses continued to circulate, H5N2 vaccination
1253 was maintained (Villarreal, 2007). Within a few years, multiple lineages of antigenically variant divergent H5N2 LPAI field
1254 viruses emerged that escaped from immunity induced by the original 1994 inactivated vaccine seed strain (Lee *et al.*, 2004).
1255 Similarly, emergent H5Nx HPAI Gs/GD lineage field viruses have arisen in China (the People's Rep. of), Indonesia, Egypt
1256 and various other Asian and Middle Eastern countries since 2005 that escaped from immunity induced by classical H5
1257 inactivated LPAI vaccine seed strains and even reverse genetics generated H5 vaccine seed strains used in commercial
1258 vaccines (Grund *et al.*, 2011; Liu *et al.*, 2020; Swayne & Sims, 2020). Similarly, H9N2 LPAI field viruses resistant to
1259 inactivated vaccine seed strains have arisen in multiple countries in Asian and Middle East after prolonged usage of a single
1260 inactivated vaccine seed strain. It is not clear whether the emergence of these antigenic variants is related to use of vaccines
1261 or improper use of vaccines, but the emergence of resistance-escape mutants necessitated the change in vaccine seed
1262 strains to antigenically match the circulating field strains (Cattoli *et al.*, 2011; Lee *et al.*, 2016). China ~~as is~~ the largest user
1263 of avian influenza vaccines. To ensure a complete protection against the different clades of viruses, China has updated its
1264 inactivated H5Nx (Gs/GD lineage) and H7N9 seed strains ten eight times and four times once, respectively, with the life
1265 span of a seed strain ranging from 3 to 7 years (Liu *et al.*, 2020; Swayne & Sims, 2020). Mexico has updated its H5N2
1266 inactivated seed strains twice and its rFPV-H5 once over a 20-year period of H5 vaccine use (Swayne & Sims, 2020). Initially
1267 H9N2 inactivated vaccine usage in South Korea, was associated with decreased field virus diversity, as vaccinal immunity
1268 completely inhibited antigenically closely related field virus replication (Lee *et al.*, 2016). However, over time, field virus
1269 diversity increases as antigenic variants arise in the field and expand their populations. ~~The live recombinant vectored~~
1270 ~~vaccines have been updated less frequently, suggesting a broader immunity, requiring less frequent insert updates as~~
1271 ~~compared inactivated vaccine seed strains.~~

1272 All influenza A vaccination programmes should have an epidemiologically relevant surveillance programme that includes all
1273 relevant geographical regions and production sectors (Harder *et al.*, 2023). The resulting isolates, along with viruses obtained
1274 from outbreaks, should be assessed for genetic and antigenic variation as part of an ongoing programme for assessing
1275 vaccine effectiveness in the field. Initially, the viruses should be sequenced and analysed for critical amino acid changes
1276 within the five major antigenic epitopes of the HA. A representative subset of antigenic variants should be tested for cross-
1277 reactivity in a HI test using a panel of standard antisera produced against diverse influenza A viruses from the same HA
1278 subtype and the data analysed for quantitative changes by antigenic cartography (Fouchier & Smith, 2010). Based on this
1279 cartographic data, a few of the predominant circulating influenza A viruses and selected antigenic variants should be used
1280 in challenge efficacy studies (Swayne *et al.*, 2015). Vaccines that are not protective should be discontinued and replaced
1281 with vaccines containing updated inactivated vaccine seed strains or HA inserts within other vaccine platforms. Based on
1282 the timeline for emergence of antigenic variants for H5N1 viruses in China (People's Rep. of), vaccines should be assessed
1283 at a minimum every 2–3 years for efficacy against predominant circulating field viruses of the country or region. Alternatively,
1284 vaccine seed strains should be updated when a vaccine-escape mutant accounts for more than 30% of the relevant AIV
1285 subtype (Liu *et al.*, 2020). Based on this scientific information, the competent Veterinary Authority within the country should
1286 establish, in consultation with leading veterinary vaccine scientists and international organisations, naturally isolated or
1287 reverse genetics derived LPAI vaccine seed strains for conventional inactivated vaccines, ~~and or~~ H5 and H7 haemagglutinin
1288 gene insert cassettes for recombinant vaccines optimised to ensure relevance to the emergent wildtype viral populations. In
1289 some situations, more than one seed strain or vaccines type may be necessary to cover all production sectors within a
1290 country. Only high quality and potent vaccines should be approved for use in control programmes. Proper administration of

⁷ http://data.europa.eu/eli/reg_del/2023/361/oj

1291 high quality, potent vaccines is and optimal management of the farms are critical in inducing protective immunity in poultry
1292 populations.

1293 In 2022, an OFFLU initiative (OFFLU Avian Influenza Matching – AIM) was established to provide improved information on
1294 the antigenic characteristics of AIVs to support vaccination programmes particularly with vaccine strain selection. Global
1295 updates will be regularly posted on the OFFLU website to provide information on antigenic characteristics of circulating AIVs,
1296 including vaccine challenge trials, that can support decisions when designing or modifying vaccination programmes. As the
1297 efficacy of OFFLU AIM activity depends on information and samples from countries experiencing outbreaks of avian influenza
1298 especially outbreaks that occur in vaccinated flocks, laboratories/national authorities are encouraged to share these data
1299 with OFFLU (see OFFLU website for up-to-date information⁸).

1300

REFERENCES

1301 AGUERO M., SAN MICUEL E., SÁNCHEZ A., GÓMEZ-TEJEDOR C. & JIMÉNEZ-CLAVERO M.A. (2007). A fully automated procedure for
1302 the high-throughput detection of avian influenza virus by real-time reverse transcription–polymerase chain reaction. *Avian*
1303 *Dis.*, **51**, 235–241. doi: 10.1637/7634-042806R1.1.

1304 AHN S.J., BAEK Y.H., LLOREN K.K.S., CHOI W.S., JEONG J.H., ANTIGUA K.J.C., KWON H.I., PARK S.J., KIM E.H., KIM Y.I., SI Y.J.,
1305 HONG S.B., SHIN K.S., CHUN S., CHOI Y.K. & SONG M.S. (2019). Rapid and simple colorimetric detection of multiple influenza
1306 viruses infecting humans using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic
1307 platform. *BMC Infect. Dis.*, **19**, 676. doi.org/10.1186/s12879-019-4277-8

1308 ARNOLD M.E., SLOMKA M.J., BREED A.C., HJULSAGER C.K., PRITZ-VERSCHUREN S., VENEMA-KEMPER S., BOUWSTRA R.J.,
1309 TREBBIEN R., ZOHARI S., CEERAZ V., LARSEN L.E. & BROWN I.H. (2018). Evaluation of ELISA and haemagglutination inhibition
1310 as screening tests in serosurveillance for H5/H7 avian influenza in commercial chicken flocks. *Epidemiol. Infect.*, **146**, 1–8.
1311 <https://doi.org/10.1017/S0950268817002898>

1312 ARRIOLA J.M., FARR W., URIBE G. & ZURITA J. (1999). Experiencias de campo en el uso de vacunos contra influenza aviar. *In:*
1313 *Proceedings Curso de Enfermedades Respiratorias de las Aves, Asociacion Nacional de Especialistas en Cienvias*
1314 *Avicolase*, 3–13.

1315 AVELLANEDA G., MUNDT E., LEE C.W., JADHAO S. & SUAREZ D.L. (2010). Differentiation of infected and Vaccinated animals
1316 (DIVA) using the NS1 protein of avian influenza virus. *Avian Dis.*, **54** (Suppl. 1), 278–286. doi: 10.1637/8644-020409-Reg.1.

1317 BAO H., ZHAO Y., WANG Y., XU X., SHI J., ZENG X., WANG X. & CHEN H. (2014). Development of a reverse transcription loop-
1318 mediated isothermal amplification method for the rapid detection of subtype H7N9 avian influenza virus (2014). *BioMed Res.*
1319 *Int.*, Art. no. 525064. doi: 10.1155/2014/525064

1320 BEARD C.W. (1970). Demonstration of type specific influenza antibody in mammalian and avian sera by immunodiffusion.
1321 *Bull. WHO*, **42**, 779–785.

1322 BERTRAN K., BALZLI C., LEE D.H., CRIADO M., KILLMASTER L., KAPCZYNSKI D.H. & SWAYNE D.E. (2018). Maternal antibody
1323 inhibition of recombinant Newcastle disease virus vectored vaccine in a primary or booster avian influenza vaccination
1324 program of broiler chickens. *Vaccine*, **36**, 6361–6372, 2018. doi: 10.1016/j.vaccine.2018.09.045.

1325 BERTRAN K., BALZLI C., LEE D.H., SUAREZ D.L., KAPCZYNSKI D.R. & SWAYNE D.E. (2017). Protection of White Leghorn chickens
1326 by U.S. emergency H5 vaccines against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus. *Vaccine*, **35**, 6336–
1327 6344. doi: 10.1016/j.vaccine.2017.05.051.

1328 BERTRAN K., CRIADO M.F., LEE D.H., KILLMASTER L., SÁ E SILVA M., WIDENER J., PRITCHARD N. & SWAYNE D.E. (2020). Protection
1329 of White Leghorn chickens by recombinant fowlpox vector vaccine with updated H5 insert against Mexican H5N2 high and
1330 low pathogenicity avian influenza viruses. *Vaccine*, **39**, 1526–1534. doi:10.1016/j.vaccine.2019.11.072

1331 BONFANTE F., FUSARO A., ZANARDELLO C., PATRONO L.V., DE NARDI R., MANIERO S. & TERRECINO C. (2014). Lethal
1332 Nephrotropism of an H10N1 Avian Influenza Virus Stands Out as an Atypical Pathotype *Vet. Microbiol.*, **173**, 189–200.

1333 Brown J.D., Stallknecht D.E., Berghaus R.D., Page Luttrell M., Velek K., Kistler W., T. Costa, Yabsley M.J. & Swayne D.
1334 (2009). Evaluation of a Commercial Blocking Enzyme-Linked Immunosorbent Assay To Detect Avian Influenza Virus

⁸ <https://www.offlu.org/wp-content/uploads/2023/11/OFFLU-AIM-REPORT-2023.pdf>

- 1335 Antibodies in Multiple Experimentally Infected Avian Species. *Clin. Vaccine Immunol.*, **16**, [https://doi.org/10.1128/CVI.00084-](https://doi.org/10.1128/CVI.00084-09)
1336 09
- 1337 CAPUA I., TERREGINO C., CATTOLI G., MUTINELLI F. & RODRIGUEZ J.F. (2003). Development of a DIVA (Differentiating Infected
1338 from Vaccinated Animals) strategy using a vaccine containing a heterologous neuraminidase for the control of avian
1339 influenza. *Avian Pathol.*, **32**, 47–55. doi:10.1080/0307945021000070714
- 1340 CAPUA I., TERREGINO C., CATTOLI G. & TOFFAN A. (2004). Increased resistance of vaccinated turkeys to experimental infection
1341 with an H7N3 low pathogenicity avian influenza virus. *Avian Pathol.*, **33**, 47–55. doi: 10.1080/03079450310001652077
- 1342 CATTOLI G., FUSARO A., MONNE I., COVEN F., JOANNIS T., EL-HAMID H.S., HUSSEIN A.A., CORNELIUS C., AMARIN N.M., MANCINI M.,
1343 HOLMES E.C. & CAPUA I. (2011). Evidence for differing evolutionary dynamics of A/H5N1 viruses among countries applying or
1344 not applying avian influenza vaccination in poultry. *Vaccine*, **29**, 9368–9375. doi: 10.1016/j.vaccine.2011.09.127
- 1345 CHEN H. & BU Z. (2009). Development and application of avian influenza vaccines in China. *Curr. Top. Microbiol. Immunol.*,
1346 **333**, 153–162. doi: 10.1007/978-3-540-92465-3_7
- 1347 COMIN A., TOFT N., STEGEMAN A., KLINCKENBERG D. & MARANGON S. (2013). Serological diagnosis of avian influenza in poultry:
1348 is the haemagglutination inhibition test really the 'gold standard'? *Influenza Other Respir. Viruses*, **7**, 257–264. doi:
1349 [10.1111/j.1750-2659.2012.00391.x](https://doi.org/10.1111/j.1750-2659.2012.00391.x).
- 1350 COX N.J., TROCK S.C. & UYEKI T.M. (2017). Public health implications of animal influenza viruses. In: Animal Influenza, Second
1351 Edition, Swayne D.E., Ed. Wiley-Blackwell, Ames, Iowa, USA, pp 92–132.
- 1352 CRIADO M.F., BERTRAN K., LEE D.H., KILLMASTER L., STEPHENS C.B., SPACKMAN E., ATKINS E., SA E SILVA M., MEBATSION T., SMITH
1353 R., HUGHES T., WIDENER J., PRITCHARD N. & SWAYNE D.E. (2019). Addition of N-glycosylation sites on the globular head of the
1354 hemagglutinin induced escape of a 2015 Mexican H7N3 highly pathogenic avian influenza virus from vaccine-induced
1355 immunity. *Vaccine*, **37**, 2232–2243. doi: 10.1016/j.vaccine.2019.03.009
- 1356 DAS A., SPACKMAN E., SENNE D., PEDERSEN J. & SUAREZ D.L. (2006). Development of an internal positive control for rapid
1357 diagnosis of avian influenza virus infections by real-time reverse transcription-PCR with lyophilized reagents. *J. Clin.*
1358 *Microbiol.*, **44**, 3065–3073.
- 1359 EUROPEAN FOOD SAFETY AUTHORITY (EFSA) PANEL ON ANIMAL HEALTH AND ANIMAL WELFARE (EFSA AHAW PANEL), EUROPEAN
1360 UNION REFERENCE LABORATORY FOR AVIAN INFLUENZA (EURL), NIELSEN S.S., ALVAREZ J., BICOUT D.J., CALISTRI P., CANALI E.,
1361 DREWE JA., GARIN-BASTUJI B., GONZALES ROJAS J.L., GORTÁZAR C., HERSKIN M., MICHEL V., MIRANDA CHUECA M.Á., PADALINO
1362 B., ROBERTS HC., SPOOLDER H., STAHL K., VELARDE A., WINCKLER C., BASTINO E., BORTOLAMI A., GUINAT C., HARDER T.,
1363 STEGEMAN A., TERREGINO C., AZNAR ASENSIO I., MUR L., BROGLIA A., BALDINELLI F. & VILTROP A. (2023). Vaccination of poultry
1364 against highly pathogenic avian influenza – part 1. Available vaccines and vaccination strategies. *EFSA Journal*, **21**, 1–87.
1365 <https://doi.org/10.2903/j.efsa.2023.8271>. Supplementary information on ToR 1 data [Data set]. *Zenodo*.
1366 <https://doi.org/10.5281/zenodo.8354898>
- 1367 EUROPEAN FOOD SAFETY AUTHORITY (EFSA) PANEL ON ANIMAL HEALTH AND ANIMAL WELFARE (AHAW); EUROPEAN UNION
1368 REFERENCE LABORATORY FOR AVIAN INFLUENZA; NIELSEN SS, ALVAREZ J, BICOUT DJ, CALISTRI P, CANALI E, DREWE JA, GARIN-
1369 BASTUJI B, GORTÁZAR C, HERSKIN MS, MICHEL V, MIRANDA CHUECA M.Á, PADALINO B, ROBERTS HC, SPOOLDER H, STAHL K,
1370 VELARDE A, VILTROP A, WINCKLER C, BORTOLAMI A, GUINAT C, HARDER T, STEGEMAN A, TERREGINO C, LANFRANCHI B, PREITE L,
1371 AZNAR I, BROGLIA A, BALDINELLI F & GONZALES ROJAS JL (2024). Vaccination of poultry against highly pathogenic avian
1372 influenza - Part 2. Surveillance and mitigation measures. *EFSA J.*; **22**(4):e8755. doi: [10.2903/j.efsa.2024.8755](https://doi.org/10.2903/j.efsa.2024.8755).
- 1373 FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS (FAO) (2004). FAO, OIE & WHO Technical consultation on the
1374 Control of Avian Influenza. Animal health special report. FAO, Rome, Italy. Available online
1375 <https://www.fao.org/3/y5537e/y5537e0a.htm>
- 1376 FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS (2016). Rational use of vaccination for prevention and control
1377 of H5 highly pathogenic avian influenza. *Focus on*, **10**, 1–12. FAO, Rome, Italy.
- 1378 FOUCHIER R.A.M. & SMITH D.J. (2010). Use of antigenic cartography in vaccine seed strain selection. *Avian Dis.*, **54**, 220–
1379 223.
- 1380 GE J., DENG G., WEN Z., TIAN G., WANG Y., SHI J., WANG X., LI Y., HU S., JIANG Y., YANG C., YU K., BU Z. & CHEN H. (2007).
1381 Newcastle disease virus based live attenuated vaccine completely protects chickens and mice from lethal challenge of
1382 homologous and heterologous H5N1 avian influenza viruses. *J. Virol.*, **81**, 150–158.

- 1383 GRAAF A., BEER M. & HARDER T. (2017). Real-time reverse transcription PCR-based sequencing-independent pathotyping of
1384 Eurasian avian influenza A viruses of subtype H7. *Virology*, **14**, 137. doi: 10.1186/s12985-017-0808-3
- 1385 GRUND C., ABDELWHAB E.S., ARAFA A.S., ZILLER M., HASSAN M.K., ALY M.M., HAFEZ H.M., HARDER T.C. & BEER M. (2011). Highly
1386 pathogenic avian influenza virus H5N1 from Egypt escapes vaccine-induced immunity but confers clinical protection against
1387 a heterologous clade 2.2.1 Egyptian isolate. *Vaccine*, **29**, 5567–5573. doi: 10.1016/j.vaccine.2011.04.006.
- 1388 HARDER T., DE WIT S., GONZALES J.L., HO J.H.P., MULATTI P., PRAJITNO T.Y. & STEGEMAN A. (2023). Epidemiology-driven
1389 approaches to surveillance in HPAI-vaccinated poultry flocks aiming to demonstrate freedom from circulating HPAIV.
1390 *Biologicals*, **83**, 101694. doi: 10.1016/j.biologicals.2023.101694
- 1391 HASSAN K.E., AHRENS A.K., ALI A., EL-KADY M.F., HAFEZ H.M., METTENLEITER T.C., BEER M. & HARDER T. (2022). Improved
1392 Subtyping of Avian Influenza Viruses Using an RT-qPCR-Based Low Density Array: 'Riems Influenza a Typing Array',
1393 Version 2 (RITA-2). *Viruses*, **14**, 415. <https://doi.org/10.3390/v14020415>.
- 1394 HEINE H.G., FOORD A.J., WANG J., VALDETER S., WALKER S., MORRISSY C., WONG F.Y.K. & MEEHAN B. (2015). Detection of highly
1395 pathogenic zoonotic influenza virus H5N6 by reverse-transcriptase quantitative polymerase chain reaction. *Virology*, **12**, 18
1396 <https://doi.org/10.1186/s12985-015-0250-3>
- 1397 HOFFMANN B., HOFFMANN D., HENRITZ D., BEER M. & HARDER T.C. (2016). Riems influenza a typing array (RITA): An RT-qPCR-
1398 based low density array for subtyping avian and mammalian influenza a viruses. *Sci. Rep.*, **6**, 27211.
- 1399 INUI K., NGUYEN T., TSENG H.J., TSAI C.M., TSAI Y.L., CHUNG S., PADUNGTOD P., ZHU H., GUAN Y., KALPRAVIDH W. & CLAES F.
1400 (2019). A field-deployable insulated isothermal RT-PCR assay for identification of influenza A (H7N9) shows good
1401 performance in the laboratory. *Influenza Other Respir. Viruses*, **13**, 610–617.
- 1402 INTERNATIONAL COMMITTEE ON TAXONOMY OF VIRUSES. (2019). Orthomyxoviridae. Virus Taxonomy: 2019 Release.
1403 [https://talk.ictvonline.org/ictv-reports/ictv_9th_report/negative-sense-rna-viruses-](https://talk.ictvonline.org/ictv-reports/ictv_9th_report/negative-sense-rna-viruses-2011/w/negrna_viruses/209/orthomyxoviridae)
1404 [2011/w/negrna_viruses/209/orthomyxoviridae](https://talk.ictvonline.org/ictv-reports/ictv_9th_report/negative-sense-rna-viruses-2011/w/negrna_viruses/209/orthomyxoviridae). Accessed 9 June 2020.
- 1405 IP H.S., UHM S., KILLIAN M.L. & TORCHETTI M.K. (2023). An Evaluation of Avian Influenza Virus Whole-Genome Sequencing
1406 Approaches Using Nanopore Technology. *Microorganisms*, **11**, 529. doi: 10.3390/microorganisms11020529
- 1407 JAMES J., SEEKINGS A.H., SKINNE P., PURCHASE K., MAHMOOD S., BROWN I.H., HANSEN R.D.E., BANYARD A. C. & REID S. M.
1408 (2022). Rapid and sensitive detection of high pathogenicity Eurasian clade 2.3.4.4b avian influenza viruses in wild birds and
1409 poultry. *J. Virol. Methods*, **301**, 114454. <https://doi.org/10.1016/j.jviromet.2022.114454>
- 1410 JAMES J., SLOMKA M., REID S., THOMAS S., MAHMOOD S., BYRNE A., COOPER J., RUSSELL C., MOLLETT B., AGYEMAN-DUA E., ESSEN
1411 S., BROWN I. & BROOKES S. (2018). Development and application of real-time PCR assays for specific detection of
1412 contemporary avian influenza virus subtypes N5, N6, N7, N8 and N9; *Avian Dis.*, **63**, 209–218. [https://doi.org/10.1637/11900-](https://doi.org/10.1637/11900-051518-Reg.1)
1413 [051518-Reg.1](https://doi.org/10.1637/11900-051518-Reg.1)
- 1414 KING J., SCHULZE C., ENGELHARDT A., HLINAK A., LENNERMANN S.L., RIGBERS K., SKUBALLA J., STAUBACH C., METTENLEITER T.C.,
1415 HARDER T., BEER M. & POHLMANN A. (2020). Novel HPAIV H5N8 reassortant (Clade 2.3.4.4b) detected in Germany. *Viruses*,
1416 **12**, Art. no. 281, [https://www.scopus.com/inward/record.uri?eid=2-s2.0-](https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081231134&doi=10.3390%2fv12030281&partnerID=40&md5=4e8bd3edb9a711a33c6ec7abc68a5f49)
1417 [85081231134&doi=10.3390%2fv12030281&partnerID=40&md5=4e8bd3edb9a711a33c6ec7abc68a5f49](https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081231134&doi=10.3390%2fv12030281&partnerID=40&md5=4e8bd3edb9a711a33c6ec7abc68a5f49) doi:
1418 10.3390/v12030281
- 1419 KWON S.H., LEE S., JANG J., SEO Y. & LIM H.Y. (2018). A point-of-care diagnostic system to influenza viruses using chip-based
1420 ultra-fast PCR. *J. Med. Virol.*, **90**, 1019–1026.
- 1421 KWON N.Y., AHN J.J., KIM J.H., KIM S., LEE J.H., KWON J.H., SONG C.S. & HWANG S.Y. (2019). Rapid Subtyping and Pathotyping
1422 of Avian Influenza Virus using Chip-based RT-PCR. *Biochip J.*, **13**, 333–340. <https://doi.org/10.1007/s13206-019-3405-2>
- 1423 LACONI A., FORTIN A., BEDENDO G., SHIBATA A., SAKODA Y., AWUNI J.A., GO-MARO E., ARAFA A., MAKEN ALI A.S., TERREGINO C.
1424 & MONNE I. (2020). Detection of avian influenza virus: a comparative study of the in silico and in vitro performances of current
1425 RT-qPCR assays. *Sci. Rep.*, **10**, Art. No. 8441. doi: 10.1038/s41598-020-64003-6.
- 1426 LAMBRECHT B., STEENSELS M., VAN BORM S., MEULEMANS G. & VAN DEN BERG T. (2007). Development of an M2e-specific
1427 enzyme-linked immunosorbent assay for differentiating infected from vaccinated animals. *Avian Dis.*, **51** (Suppl. 1), 221–
1428 226. doi: 10.1637/7589-040206R.1.

- 1429 LEE C.W., SENNE D.A. & SUAREZ D.L. (2004). Effect of vaccine use in the evolution of Mexican lineage H5N2 avian influenza
1430 virus. *J. Virol.*, **78**, 8372–8381. doi: 10.1128/JVI.78.15.8372-8381.2004.
- 1431 LEE D.H., FUSARO A., SONG C.S., SUAREZ D.L. & SWAYNE D.E. (2016). Poultry vaccination directed evolution of H9N2 low
1432 pathogenicity avian influenza viruses in Korea. *Virology*, **488**, 225–231. Doi: 10.1016/j.virol.2015.11.023.
- 1433 LIU J., CHEN P., JIANG Y., WU L., ZENG X., TIAN G., GE J., KAWAOKA Y., BU Z. & CHEN H. (2011). A duck enteritis virus-vectored
1434 bivalent live vaccine provides fast and complete protection against H5N1 avian influenza virus infection in ducks. *J. Virol.*,
1435 **85**, 10989–10998. doi: 10.1128/JVI.05420-11
- 1436 LIU J., YAO L., ZHAI F., CHEN Y., LEI J., BI Z., HU J., XIAO Q., SONG S., YAN L. & ZHOU J. (2018). Development and application of
1437 a triplex real-time PCR assay for the simultaneous detection of avian influenza virus subtype H5, H7 and H9. *J. Virol.*
1438 *Methods*, **252**, 49–56.
- 1439 LIU S., ZHUANG Q., WANG S., JIANG W., JIN J., PENG C., LOU G., LI J., YU J., YU X., LI H., SUN S., YUAN L. & CHEN J. (2020). Control
1440 of avian influenza in China: Strategies and lessons. *Transbound. Emerg. Dis.*, **67**, 1–9. doi: 10.1111/tbed.13515.
- 1441 LONDT B.Z., BANKS J. & ALEXANDER D.J. (2007). Highly pathogenic avian influenza viruses with low virulence for chickens in
1442 *in vivo* tests. *Avian Pathol.*, **36**, 347–350.
- 1443 MONNE I., ORMELLI S., SALVIATO A., DE BATTISTI C., BETTINI F., SALOMONI A., DRAGO A., ZECCHIN B., CAPUA I. & CATTOLI G. (2008).
1444 Development and Validation of a One-Step Real-Time PCR Assay for Simultaneous Detection of Subtype H5, H7, and H9
1445 Avian Influenza Viruses. *J. Clin. Microbiol.*, **46**, <https://doi.org/10.1128/jcm.02204-07>
- 1446 NAEEM K. (1998). The avian influenza H7N3 outbreak in South Central Asia. Proceedings of the Fourth International
1447 Symposium on Avian Influenza, Athens, Georgia, USA. Swayne D.E. & Slemmons R.D., eds. U.S. Animal Health Association,
1448 31–35.
- 1449 NAGUIB M.M., GRAAF A., FORTIN A., LUTTERMANN C., WERNERY U., AMARIN N., HUSSEIN H.A., SULTAN H., AL ADHADH B., HASSAN
1450 M.K., BEER M., MONNE I. & HARDER T.C. (2017). Novel real-time PCR-based patho- and phylotyping of potentially zoonotic
1451 avian influenza a subtype H5 viruses at risk of incursion into Europe in 2017. *Euro Surveill.*, **22**, 30435. doi: 10.2807/1560-
1452 7917.ES.2017.22.1.30435.
- 1453 NAGY A., ČERNÍKOVÁ L., KUNTEOVÁ K., DIRBÁKOVÁ Z., THOMAS S.S., SLOMKA M.J., DÁN Á., VARGA T., MÁTÉ M., JIRINCOVÁ H. &
1454 BROWN I.H. (2020–2021). A universal RT-qPCR assay for “One Health” detection of influenza A viruses. *PLoS One*, **16** (1),
1455 e0244669. <https://doi.org/10.1371/journal.pone.0244669>
- 1456 PANZARIN V., MARCIANO S., FORTIN A., BRIAN I., D’AMICO V., GOBBO F., BONFANTE F., PALUMBO E., SAKODA Y., LE K.T., CHU D.H.,
1457 SHITTU I., MESEKO C., HAIDO A.M., ODOOM T., DIOUF M.N., DJEGUI F., STEENSELS M., TERREGINO C. & MONNE I. (2022). Redesign
1458 and Validation of a Real-Time RT-PCR to Improve Surveillance for Avian Influenza Viruses of the H9 Subtype. *Viruses*, **14**,
1459 1263. <https://doi.org/10.3390/v14061263>
- 1460 POSTEL A., LETZEL T., FRISCHMANN S., GRUND C., BEER M. & HARDER T. (2010). Evaluation of two commercial loop-mediated
1461 isothermal amplification assays for detection of avian influenza H5 and H7 hemagglutinin genes. *J. Vet. Diagn. Invest.*, **22**,
1462 61–66.
- 1463 RATTANAMAS K., TAESUJI M., KULTHONGGATE U., JANTAFONG T., MAMOM T. & RUENPHET S. (2022). Sensitivity of RNA viral nucleic
1464 acid-based detection of avian influenza virus, Newcastle disease virus, and African horse sickness virus on flinders
1465 technology associates card using conventional reverse-transcription polymerase chain reaction. *Vet. World*, **15**, 2754–2759.
1466 doi: 10.14202/vetworld.2022.2754-2759
- 1467 RAUW F., PALYA V., VAN B.S., WELBY S., TATAR-KIS T., GARDIN Y., DORSEY K.M., ALY M.M., HASSAN M.K., SOLIMAN M.A.,
1468 LAMBRECHT B. & VAN DEN BERG T. (2011). Further evidence of antigenic drift and protective efficacy afforded by a recombinant
1469 HVT-H5 vaccine against challenge with two antigenically divergent Egyptian clade 2.2.1 HPAI H5N1 strains. *Vaccine*, **29**,
1470 2590–2600. doi: 10.1016/j.vaccine.2011.04.048
- 1471 RICHARD MAZET A., GOUTEBROZE S., LE GROS F.X., SWAYNE D.E. & BUBLOT M. (2014). Immunogenicity and efficacy of fowlpox-
1472 vectored and inactivated avian influenza vaccines alone or in a prime-boost schedule in chickens with maternal antibodies.
1473 *Vet. Res.*, **45**:e107. doi: [10.1186/s13567-014-0107-6](https://doi.org/10.1186/s13567-014-0107-6).

- 1474 RUNSTADLER J.A. & PURYEAR W.B. (2024). The virus is out of the barn: the emergence of HPAI as a pathogen of avian and
1475 mammalian wildlife around the globe. *Am. J. Vet. Res.*, **85**(5):ajvr.24.01.0018. doi: 10.2460/ajvr.24.01.0018.
- 1476 SCAHL'S (SUB-COMMITTEE ON ANIMAL HEALTH LABORATORY STANDARDS [AUSTRALIA/NEW ZEALAND]) (2009). SCAHLS Approved
1477 Tests. Avian Influenza b-ELISA. http://www.scahls.org.au/new_tests/scahls_approved_tests
- 1478 SEEKINGS A.H., SLOMKA M.J., RUSSELL C., HOWARD W.A., CHOUDHURY B., NUÑEZ A., LÖNDT B.Z., W. COX A, CEERAZ V., THORÉN
1479 P., IRVINE R.M., MANVELL R.J., BANKS J. & BROWN I.H. (2018). Direct evidence of H7N7 avian influenza virus mutation from
1480 low to high virulence on a single poultry premises during an outbreak in free range chickens in the UK, 2008. *Infect., Genet.*
1481 *Evol.*, **64**, 13–31. <https://doi.org/10.1016/j.meegid.2018.06.005>
- 1482 SIMS L.D. (2003). Avian influenza in Hong Kong 1997–2002. *Avian Dis.*, **47**, 832–838. doi:10.1637/0005-2086-47.s3.832
- 1483 SLEMONS R.D. & D.E. SWAYNE (1990). Replication of a waterfowl origin influenza virus in the kidney and intestine of chickens.
1484 *Avian Dis.*, **34**, 277–284.
- 1485 SLOMKA M.J., COWARD V.J., BANKS J., LÖNDT B.Z., BROWN I.H., VOERMANS J., KOCH G., HANDBERG K.J., JØRGENSEN P.H.,
1486 CHERBONNEL-PANSART M., JESTIN V., CATTOLI G., CAPUA I., EJDERSUND A., THORÉN P. & CZIFRA G. (2007a). Identification of
1487 sensitive and specific avian influenza polymerase chain reaction methods through blind ring trials organized in the European
1488 Union. *Avian Dis.*, **51** (1 Suppl), 227–234. doi: 10.1637/7674-063006R1.1.
- 1489 SLOMKA M.J., PAVLIDIS T., BANKS J., SHELL W., McNALLY A., ESSEN S. & BROWN I.H. (2007b). Validated H5 Eurasian real-time
1490 reverse transcriptase–polymerase chain reaction and its application in H5N1 outbreaks in 2005–2006. *Avian Dis.*, **51**, 373–
1491 377.
- 1492 SLOMKA M.J., PAVLIDIS T., COWARD V., VOERMANS J., KOCH G., HANNA A., BANKS J. & BROWN I.H. (2009). Validated realtime
1493 reverse transcriptase PCR methods for the diagnosis and pathotyping of Eurasian H7 avian influenza viruses. *Influenza*
1494 *Other Respir. Viruses*, **3**, 151–164. <https://doi.org/10.1111/j.1750-2659.2009.00083.x>
- 1495 SLOMKA M.J., REID S.M., BYRNE A.M.P., COWARD V.J., SEEKINGS J., COOPER J.L., PEERS-DENT J., AGYEMAN-DUA E., DE SILVA D.,
1496 HANSEN R.D.E., BANYARD A.C. & BROWN I.H. (2023). Efficient and Informative Laboratory Testing for Rapid Confirmation of
1497 H5N1 (Clade 2.3.4.4) High-Pathogenicity Avian Influenza Outbreaks in the United Kingdom. *Viruses*, **15**, 1344
1498 <https://doi.org/10.3390/v15061344>
- 1499 SLOMKA M.J., TO T., TONG H., COWARD V., MAWHINNEY I., BANKS J. & BROWN I.H. (2012). Evaluation of lateral flow devices for
1500 identification of infected poultry by testing swab and feather specimens during H5N1 highly pathogenic avian influenza
1501 outbreaks in Vietnam. *Influenza Other Respir. Viruses*, **6**, 318–327.
- 1502 SONG H., NIETO G.R. & PEREZ D.R. (2007). A New Generation of Modified Live Attenuated Avian Influenza Viruses Using a
1503 Two-Strategy Combination as Potential Vaccine Candidates. *J. Virol.*, **17**, 9238–9248. doi: 10.1128/JVI.00893-07.
- 1504 SPACKMAN E. (2020). Avian Influenza Virus Detection and Quantitation by Real-Time RT-PCR. *Methods Mol. Biol.*, **2123**,
1505 137–148. doi: 10.1007/978-1-0716-0346-8_11.
- 1506 SPACKMAN E., IP H.S, SUAREZ D.L., SLEMONS R.D. & STALLKNECHT D.E. (2008). Analytical validation of a real-time reverse
1507 transcription polymerase chain reaction test for Pan-American lineage H7 subtype Avian influenza viruses. *J. Vet. Diagn.*
1508 *Invest.*, **20**, 612–616.
- 1509 SPACKMAN E., PEDERSEN J.C., MCKINLEY E.T. & GELB J. (2013). Optimal specimen collection and transport methods for the
1510 detection of avian influenza virus and Newcastle disease virus. *BMC Vet. Res.*, **9**, 35.
- 1511 SPACKMAN E., SENNE D.A., MYERS T.J., BULAGA L.L., GARBER L.P., PERDUE M.L., LOHMAN K., DAUM L.T. & SUAREZ D.L. (2002).
1512 Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian H5 and H7
1513 hemagglutinin subtypes. *J. Clin. Microbiol.*, **40**, 3256–3260.
- 1514 SPACKMAN E. & SUAREZ D.L. (2008). Detection and identification of the H5 hemagglutinin subtype by real-time RT-PCR.
1515 *Methods Mol. Biol.*, **436**, 27–33.
- 1516 SWAYNE D.E. & KAPCZYNSKI D. (2008). Vaccines, vaccination, and immunology for avian influenza viruses in poultry. *In: Avian*
1517 *Influenza*. Swayne D.E. ed., Wiley-Blackwell, Ames, Iowa, USA, 407–451.

- 1518 SWAYNE D.E., PAVADE G., HAMILTON K., VALLAT B. & MIYAGISHIMA K. (2011). Assessment of national strategies for control of
 1519 high pathogenicity avian influenza and low pathogenicity notifiable avian influenza in poultry, with emphasis on vaccines and
 1520 vaccination. *Rev. sci. tech. Off. Int. Epiz.*, **30**, 839–870. doi: 10.20506/rst.30.3.2081
- 1521 SWAYNE D.E. & SIMS L. (2020). Avian influenza. *In: Veterinary Vaccines: Principles and Applications*, Metwally S, El-Idrissi
 1522 M., Viljoen G., eds. Wiley, Chichester, United Kingdom, 229–251.
- 1523 SWAYNE D.E., SUAREZ D.L. & SIMS L.D. (2020). Influenza. *In: Diseases of Poultry, Fourteenth Edition*. Swayne D.E., Boulianne,
 1524 M., Logue, C., McDougald L.R., Nair, V., & Suarez D.L., eds. Wiley Publishing, Ames, Iowa, USA, 210–256.
- 1525 SWAYNE D.E., SUAREZ D.L., SPACKMAN E., JADHAO S., DAUPHIN G., KIM M., MCGRANE J., WEAVER J., DANIELS P., WONG F.,
 1526 SELLECK P., WIYONO A., INDRIANI R., YUPIANA Y., SIREGAR E.S., PRAJITNO T., FOUCHIER R. & SMITH D. (2015). Antibody titer has
 1527 positive predictive value for vaccine protection against challenge with natural antigenic drift variants of H5N1 high
 1528 pathogenicity avian influenza viruses from Indonesia. *J. Virol.*, **89**, 3746–3762. doi: 10.1128/JVI.00025-15.
- 1529 TONG S., ZHU X., LI Y., SHI M., ZHANG J., BOURGEOIS M., YANG H., CHEN X., REGUENCO S., GOMEZ J., CHEN L.M., JOHNSON A.,
 1530 TAO Y., DREYFUS C., YU W., MCBRIDE R., CARNEY P.J., GILBERT A.T., CHANG J., GUO Z., DAVIS C.T., PAULSON J.C., STEVENS J.,
 1531 RUPPRECHT C.E., HOLMES E.C., WILSON I.A. & DONIS R.O. (2013). New world bats harbor diverse influenza A viruses. *PLoS*
 1532 *Pathog.*, **9**, e1003657. doi: [10.1371/journal.ppat.1003657](https://doi.org/10.1371/journal.ppat.1003657)
- 1533 VAN DER GOOT J.A., KOCH G., DE JONG M.C. & VAN BOVEN M. (2005). Quantification of the effect of vaccination on transmission
 1534 of avian influenza (H7N7) in chickens. *Proc. Natl Acad. Sci. USA*, **102**, 18141–18146. doi:10.1073/pnas.0505098102.
- 1535 VEITS J., WIESNER D., FUCHS W., HOFFMANN B., GRNZOW H., STARICK E., MUNDT E., SCHIRRMIEIER H., MEBATSION, T.,
 1536 METTENLEITER T.C. & ROMER-OBENDORFER A. (2006). Newcastle disease virus expressing H5 hemagglutinin gene protects
 1537 chickens against Newcastle disease and avian influenza. *Proc. Natl Acad. Sci. USA*, **103**, 8197–8202. doi:
 1538 [10.1016/j.vaccine.2007.09.048](https://doi.org/10.1016/j.vaccine.2007.09.048)
- 1539 VILLARREAL C. (2007). Experiences in control of avian influenza in the Americas. *Dev. Biol.*, **130**, 53–60.
- 1540 WONG S.S., YOON S.W., ZANIN M., SONG M.S., OSHANSKY C., ZARAKET H., SONNBERG S., RUBRUM A., SEILER P., FERGUSON A.,
 1541 KRAUSS S., CARDONA C., WEBBY R.J. & CROSSLEY B. (2014). Characterization of an H4N2 influenza virus from quails with a
 1542 multibasic motif in the hemagglutinin cleavage site. *Virology*, **468–470**, 72–80. doi: 10.1016/j.viro.2014.07.048
- 1543 WOOD G.W., BANKS J., STRONG I., PARSONS G. & ALEXANDER D.J. (1996). An avian influenza virus of H10 subtype that is highly
 1544 pathogenic for chickens but lacks multiple basic amino acids at the haemagglutinin cleavage site. *Avian Pathol.*, **25**, 799–
 1545 806.
- 1546 WORLD HEALTH ORGANIZATION/WORLD ORGANISATION FOR ANIMAL HEALTH/FOOD AND AGRICULTURE ORGANIZATION
 1547 (WHO/OIE/FAO) H5N1 EVOLUTION WORKING GROUP (2014). Revised and updated nomenclature for highly pathogenic avian
 1548 influenza A (H5N1) viruses. *Influenza Other Respir. Viruses*, **8**, 384–388. <https://doi.org/10.1111/irv.12230>
- 1549 WORLD HEALTH ORGANIZATION EXPERT COMMITTEE (1980). A revision of the system of nomenclature for influenza viruses: a
 1550 WHO Memorandum. *Bull. WHO*, **58**, 585–591.
- 1551 ZHANG Y., AEVERMANN B.D., ANDERSON T.K., BURKE D.F., DAUPHIN G., GU Z., HE S., KUMAR S., LARSEN C.N., LEE A.J., LI X.,
 1552 MACKEN C., MAHAFFEY C., PICKETT B.E., REARDON B., SMITH T., STEWART L., SULOWAY C., SUN G., TONG L., VINCENT A.L.,
 1553 WALTERS B., ZAREMBA S., ZHAO H., ZHOU L., ZMASEK C., KLEM E.B. & SCHEUERMANN R.H. (2017). Influenza Research Database:
 1554 An integrated bioinformatics resource for influenza virus research. *Nucleic Acids Res.*, **45** (D1), D466–D474.

*
* *

1557 **NB:** There are WOA Reference Laboratories for avian influenza (please consult the WOA Web site:
 1558 <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>).
 1559 Please contact the WOA Reference Laboratories for any further information on
 1560 diagnostic tests, reagents and vaccines for avian influenza

1561 **NB:** FIRST ADOPTED IN 1989 AS AVIAN INFLUENZA (FOWL PLAGUE). MOST RECENT UPDATES ADOPTED IN 2021.

APPENDIX 3.3.4.1.

BIOSAFETY GUIDELINES FOR HANDLING HIGH PATHOGENICITY AVIAN INFLUENZA VIRUSES IN VETERINARY DIAGNOSTIC LABORATORIES

INTRODUCTION

The spread of high pathogenicity H5Nx avian influenza throughout Asia, Africa and Europe has led to an increase in the number of laboratories performing diagnostics for this pathogen. High pathogenicity avian influenza (HPAI) viruses, in general, are a serious threat to birds and mortality is often 100% in susceptible chickens. In addition, the agents can also pose a serious zoonotic threat, with approximately 60% mortality reported in humans infected with H5N1 HPAI virus. In recognition of the need for guidance on how to handle these viruses safely, the WOAHA has established the following biocontainment guidelines for handling specimens that may contain HPAI virus. They are based on Chapter 1.1.4 *Biosafety and biosecurity: Standard for managing biological risk in the veterinary laboratory and animal facilities*, the World Health Organization⁹, and Centers for Disease Control and Prevention¹⁰.

BIOCONTAINMENT LEVELS

Samples for diagnostic testing for HPAI virus using the following techniques do not require high-level containment but should be carried out at an appropriate biosafety and containment level determined by risk analysis (see Chapter 1.1.4. *Biosafety and biosecurity: Standard for managing biological risk in the veterinary laboratory and animal facilities*):

- Conventional and real-time reverse transcriptase polymerase chain reaction (RT-PCR)
- Antigen-capture assays
- Serology

Virus isolation and identification procedures for handling specimens that may contain high-titred replication-competent HPAI virus should as a minimum, include the following:

- Personnel protective equipment should be worn, including solid-front laboratory coats, gloves, safety glasses and respirators with greater than or equal to 95% efficiency.
- Specimens from potentially infected birds or animals should only be processed in type II or type III biological safety cabinets (BSC).
- Necropsies of birds should be performed in a Type II BSC while wearing respiratory protection, such as a N95 respirator, or in a Type III biological safety cabinet, or other primary containment devices with 95% efficient air filtration.
- Centrifugation should be performed in sealed centrifuge cups.
- Centrifugation rotors should be opened and unloaded in a BSC.
- Work surfaces and equipment should be decontaminated after specimen processing.
- Contaminated materials should be decontaminated by autoclaving or disinfection before disposal or should be incinerated.

If chickens or other birds or mammals are inoculated with HPAI viruses, inoculation should be done in appropriate containment including:

⁹ WHO laboratory biosafety guidelines for handling specimens suspected of containing avian influenza A virus, 12 January 2005.

¹⁰ Biosafety in Microbiological and Biomedical Laboratories, 5th edition. HHS Publication No. (CDC) 21-1112. <https://www.cdc.gov/labs/pdf/CDC-BiosafetyMicrobiologicalBiomedicalLaboratories-2009-P.PDF> 1 December 2009.

-
- 1598 • Inoculated chickens should be held in animal isolation cabinets or other primary containment devices, or non-isolation
1599 cages/floor pens in specially designed containment rooms
- 1600 • Animal isolation cabinets should be in a separate facility that is equipped to handle the appropriate biocontainment for
1601 HPAI.
- 1602 • The room should be under negative pressure to the outside and the animal isolation cabinets should be under negative
1603 pressure to the room.
- 1604 • Animal isolation cabinets should have HEPA-filtered inlet and exhaust air.
- 1605 • Biosafety cabinet or other primary containment devices should be available in the animal facility to perform post-mortem
1606 examinations and to collect specimens.

1607
1608
1609

*
* *

1610

1611

NOTE ON APPENDICES 2 TO 7

1612
1613
1614
1615
1616

In 2023, a new section was added to WOAHP Terrestrial Manual chapters to describe the rationale behind the selection of tests for different purposes given in Table 1 Test methods available and their purpose and an explanation of their score. It was felt that this information would help the reader to find relevant information for the selection of tests while making sure that the selection process is science-based and transparent. The information will also address queries received from Members and provide justification for different tests.

1617
1618

Appendix 2: Avian influenza
Intended purpose of test: population freedom from infection

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
Detection and identification of the agent							
Real-time RT-PCR M gene (Nagy <i>et al.</i> [2021]) +++	Extracted RNA from clinical (swabs and tissues) and environmental specimens	Originally validated as for Nagy <i>et al.</i> (2021). Stringently assessed further, in context of H5N1 clade 2.3.4.4b HPAIV outbreaks. Slomka <i>et al.</i> (2023) defined a highly stringent criterion adapted to this validation of 514 poultry swabs: For a given swab, if it registered a positive result (Ct<36) by any of the three AIV real-time RT-PCRs (M-gene Nagy <i>et al.</i> [2021], H5[HA2] [Slomka <i>et al.</i> (2007b)] and H5[HP] [James <i>et al.</i> (2022)]), then by consensus it is considered as an H5Nx positive swab. If all three tests are negative (Ct>36), then by consensus it is considered as AIV negative. Se and Sp for the three AIVRT-PCRs were calculated for this assay relative to consensus swab status (positive/negative) DSe: 90.6% DSp: 100% (affirmed 100% Sp originally demonstrated by Nagy <i>et al.</i> [2021])	Additional validation based on H5N1 (clade 2.3.4.4b) HPAIV testing at 12 UK poultry outbreak premises (514 swabs, equal numbers of oro-pharyngeal and cloacal) during autumn 2021, which featured in Slomka <i>et al.</i> (2023) Chickens: eight premises, 350 swabs Turkeys: three premises, 124 swabs Ducks: One premise: 40 swabs	See references Validated by WOAH Reference Laboratory in UK – report available on request^	-Use of 99,353 M-gene sequences to ensure that as far as possible, the primer and probe designs match a vast range of animal and human influenza A viruses -Assessed in several independent European National Reference Laboratories, featuring an extensive range of human and animal influenza A viruses (laboratory isolates and 1455 clinical specimens) -Sensitively detect many contemporary swine, equine and human influenza A virus strains -Can be used to detect infection in vaccinated birds (DIVA approach) for monitoring freedom from infection in vaccinated or unvaccinated poultry flocks. -Viable virus is not requested -Adaptable to high throughput -Rapid	-Despite the thorough bioinformatics input to the primer/probe design (see left), no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered, as accepted by Nagy <i>et al.</i> (2021). Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]). -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	Nagy <i>et al.</i> (2021). Slomka <i>et al.</i> (2023)
Real-time RT-PCR M gene (Heine <i>et al.</i> [2015]; Laconi <i>et al.</i> [2020], protocol 3) +++	Extracted RNA from clinical specimens (swabs and tissues)	Reference test was genetic sequencing DSe = 100% DSp = 100%	92 avian samples and 117 mammalian samples of known infectious status (121 true positive and 88 true negative samples)	See references Validated by WOAH Reference Laboratory in Italy – report available on request^	- <i>In silico</i> evaluation of primers/probe match using 4088 AIV M-gene sequences (Laconi <i>et al.</i> [2020]) -Assessed on extensive range of avian influenza A viruses belonging to different subtypes and genotypes -Tested on multiple sample matrixes from mammalian and avian species -Assessed in several independent European National Reference Laboratories	-Despite being tested on a variety of AIV subtypes, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]).	Heine <i>et al.</i> (2015). Laconi <i>et al.</i> (2020)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
					<ul style="list-style-type: none"> -Can be used to detect infection in vaccinated birds (DIVA approach) for monitoring freedom from infection in vaccinated or unvaccinated poultry flocks -Viable virus is not requested -Adaptable to high throughput -Rapid 	<ul style="list-style-type: none"> -<i>In silico</i> evaluation demonstrated that the test may have decreased sensitivity in the detection of a cluster of H5N1 viruses related to the A/chicken/East_Java/Av1955/2022 (EPI_ISL_13690275), belonging to the 2.3.2.1c clade, due to primers mismatches -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment 	
Real-time RT-PCR M gene (Hassan <i>et al.</i> [2022]) +++	Extracted RNA from clinical specimens (swabs and tissues) and egg-grown isolates	Reference test was genome sequencing DSe = 100% DSp=100%	122 clinical samples 428 virus isolates	See reference	<ul style="list-style-type: none"> -<i>In silico</i> evaluation of primers/probe match using >3000 AIV M-gene sequences -Assessed on extensive range of avian and porcine influenza A viruses belonging to different subtypes and genotypes -Assessed also on a minor selection of human IAV isolates (<20) -Can be used to detect infection in vaccinated birds (DIVA approach) for monitoring freedom from infection in vaccinated or unvaccinated poultry flocks. -Viable virus is not requested -Adaptable to high throughput -Rapid 	<ul style="list-style-type: none"> -Despite tested on a variety of AIV subtypes, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]) -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment 	Hassan <i>et al.</i> (2022)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
Real-time RT-PCR H5 (Hassan <i>et al.</i> [2022]) +++	Extracted RNA from clinical specimens (swabs and tissues) and egg-grown isolates	Reference test was genome sequencing DSe = 100% DSp=100%	122 clinical samples 428 virus isolates	See reference	- <i>In silico</i> evaluation of primers/probe match using >700 AIV H5-gene sequences -Specificity assessed on extensive range of avian, porcine and human influenza A viruses belonging to different subtypes and genotypes -Assessed also on a minor selection of human IAV isolates (<20) - Combines two distinct target regions along the H5 HA gene -Viable virus is not requested -Adaptable to high throughput -Rapid	-Despite tested on a variety of AIVs, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]) -Failed to detect an individual Eurasian wild bird LP H5 isolate (EU-RL ring trial) -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	Hassan <i>et al.</i> (2022)
Real-time RT-PCR H5 (Slomka <i>et al.</i> [2007b]) +++	Extracted RNA from clinical (swabs and tissues) and environmental specimens	Originally validated as for Slomka <i>et al.</i> (2007b). Stringently assessed further, in context of H5N1 clade 2.3.4.4b HPAIV outbreaks. Slomka <i>et al.</i> (2023) defined a highly stringent criterion adapted to this validation of 514 poultry swabs: For a given swab, if it registered a positive result (Ct<36) by any of the three AIV real-time RT-PCRs (M-gene Nagy <i>et al.</i> [2021], H5[HA2] and H5[HP]), then by consensus it is considered as an H5N1 positive swab. If all three tests are negative (Ct>36), then by consensus it is considered as AIV negative. Se and Sp for the three AIVRT-PCRs were calculated for this assay relative to	514 poultry swabs, see above entry for Nagy <i>et al.</i> (2021) M-gene real-time RT-PCR: Chickens: Eight premises, 350 swabs Turkeys: Three premises, 124 swabs Ducks: One premises, 40 swabs	See references Validated by WOAHP Reference Laboratory in UK – report available on request	-The real-time RT-PCR H5(HA2) has been proven to successfully and sensitively detect Eurasian-origin H5 AIVs, through careful targeting of the relatively conserved HA2 region of the H5 gene. Detected H5 AIVs include not only the H5Nx clade 2.3.4.4b HPAIVs, but earlier clades of the “goose/Guangdong” lineage (GsGd), as well as non-GsGd H5 LPAIVs (references cited by Slomka <i>et al.</i> (2023)). -Viable virus is not requested -Adaptable to high throughput -Rapid	-The real-time RT-PCR H5(HA2) is optimised for detection of Eurasian H5 AIVs and may be notably less sensitive for detection of American lineage H5 AIVs (acknowledged by Slomka <i>et al.</i> [2007b]), due to divergence in the HA2 portion of the H5 gene -Despite tested on a variety of AIVs, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more	Slomka <i>et al.</i> (2007b) Slomka <i>et al.</i> (2023)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
		consensus swab status (positive/negative): DSe: 96.2% DSp: 100%				than one assay (Slomka <i>et al.</i> [2023]) -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	
Real-time RT-PCR H5 (Spackman <i>et al.</i> [2002]) +++	Extracted RNA from clinical specimens (swabs)	Reference test was HI Results for 100% of the samples were in agreement between real-time RT-PCR H5 and VI	Eight swab samples from live-bird markets (test population composed by 202 samples but only eight samples were tested by real-time RT-PCR H5 as the remaining 194 samples were typed as H7 positive samples by real-time RT-PCR H7 and VI)	See Reference	-The real-time RT-PCR H5(HA2) has been proven to successfully and sensitively detect American-origin H5 AIVs, through careful targeting of the relatively conserved HA2 region of the H5 gene -Viable virus is not requested -Adaptable to high throughput -Rapid	-The real-time RT-PCR H5(HA2) is optimised for detection of American H5 AIVs due to divergence in the HA2 portion of the H5 gene -Despite tested on a variety of AIVs, no AIV real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]) -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	Spackman <i>et al.</i> (2002)
Real-time RT-PCR H5(HP) (James <i>et al.</i> [2022]) +++	Extracted RNA from clinical (swabs and tissues) and	Originally validated as from James <i>et al.</i> (2022). Stringently assessed further, in context of H5N1 clade 2.3.4.4b HPAIV outbreaks, relative to consensus (see above entry for	514 poultry swabs, see above entry for Nagy <i>et al.</i> (2021) M-gene real-time RT-PCR:	Validated by WOAHL Reference Laboratory in UK – report	-In addition to its description by James <i>et al.</i> (2022), the real-time RT-PCR H5(HP) has been shown to be highly sensitive in the detection of H5N1 HPAIV in swabs obtained	-There remains the possibility that future H5 HPAIV incursions (due to GsGd or non-GsGd lineage viruses) may include H5 gene sequence variants that may not be	James <i>et al.</i> (2022). Slomka <i>et al.</i> (2023)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
	environmental specimens	Nagy <i>et al.</i> [2021] M-gene real-time RT-PCR and Slomka <i>et al.</i> [2007b] H5 real-time RT-PCR): DSe: 98.3% DSp: 100%	Chickens: eight premises, 350 swabs Turkeys: three premises, 124 swabs Ducks: One premises: 40 swabs	available on request	from UK poultry outbreaks caused by the H5N1 clade 2.3.4.4b HPAIV during 2021–2022 (Slomka <i>et al.</i> [2023]) -This assay can be used once a sample has been confirmed as positive by the generic influenza A virus screening or H5 HA2 RRT-PCR assays to detect the presence of a multi-basic cleavage site (MBCS) sequence indicative of H5 HPAIV -Viable virus is not requested -Adaptable to high throughput -Rapid	detected as sensitively as the current H5N1 clade 2.3.4.4b HPAIV strains circulating since autumn 2021. Clearly this concern applies to any AIV real-time RT-PCR, underlining the importance of ongoing validation, to ensure fitness-for-purpose for the sensitive detection of newly emerging viral strains -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	
Real-time RT-PCR H7 (Hassan <i>et al.</i> [2022]) +++	Extracted RNA from clinical specimens (swabs and tissues) and egg-grown isolates	Reference test was genome sequencing DSe = 100% DSp=100%	122 clinical samples 428 virus isolates	See Reference	- <i>In silico</i> evaluation of primers/probe match using >300 AIV H7-gene sequences -Specificity assessed on extensive range of avian influenza A viruses belonging to different subtypes and genotypes -Combines two distinct target regions along the H7 HA gene -Viable virus is not requested -Adaptable to high throughput -Rapid	Despite tested on a variety of AIVs, no influenza A virus-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	Hassan <i>et al.</i> (2022)
Real-time RT-PCR H7(HA2) (Slomka <i>et al.</i> [2009]) +++	Extracted RNA from clinical (swabs and tissues) and	Slomka <i>et al.</i> (2009) described and validated the H7(HA2) real-time RT-PCR relative to M-gene real-time RT-PCR of Spackman <i>et</i>	AIV laboratory isolates included: H7 AIVs: n=65; non-H7 AIVs: n=57. Clinical specimens	See references	-The real-time RT-PCR H7(HA2) has been proven to successfully and sensitively detect Eurasian-origin H7 AIVs, through careful targeting of the relatively conserved HA2 region of	-The real-time RT-PCR H7(HA2) is optimised for detection of Eurasian H7 AIVs is less sensitive for detection of American lineage H7 AIVs (noted by Slomka <i>et al.</i>	Slomka <i>et al.</i> (2009). Seekings <i>et al.</i> (2018).

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
	environmental specimens	<i>al.</i> (2002); see separate entry) DSe: 95.4% DSp: 97.9%	from H7N7 (LP and HPAIV inoculations): n=117 swabs; plus 180 AIV negative swabs		the H7 gene. The real-time RT-PCR H7(HA2) demonstrated its value during H7 chicken outbreaks, both LP and HPAIV (Seekings <i>et al.</i> [2018], Reid <i>et al.</i> [2019]). -Viable virus is not requested -Adaptable to high throughput -Rapid	[2009]), due to divergence in the HA2 portion of the H7 gene. -Despite tested on a variety of AIVs, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay; -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus; -Risk of cross contamination; -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA; -Needs specialised equipment	Reid <i>et al.</i> (2019)
Real-time RT-PCR H7 (Spackman <i>et al.</i> [2002]) +++		Reference test was HI Results for 98% of the samples were in agreement between real-time RT-PCR H7 and VI	202 swab samples from live-bird markets	See Reference	-The real-time RT-PCR H7(HA2) has been proven to successfully and sensitively detect American-origin H7 AIVs, through careful targeting of the relatively conserved HA2 region of the H7 gene -Viable virus is not requested -Adaptable to high throughput -Rapid	-The real-time RT-PCR H7(HA2) is optimised for detection of American H7 AIVs due to divergence in the HA2 portion of the H7 gene. -Despite tested on a variety of AIV subtypes, no H7 real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed H7 testing strategy that may feature more than one assay. -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus; -Risk of cross contamination;	Spackman <i>et al.</i> (2002)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
						-Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA; -Needs specialised equipment	
H5 conventional RT-PCR (Slomka <i>et al.</i> [2007a]) +++		Reference test was genome sequencing DSe = 99.36% DSp=100%	426 avian and 43 mammalian samples of known infectious status (472 known positive samples and 63 known negative samples)	Validated by WOAHP Reference Laboratory in Italy – report available on request^	-The RT-PCR H5(HA2) has been proven to successfully and sensitively detect Eurasian-origin H5 AIVs -Can be used once a sample has been confirmed as positive by the generic influenza A virus screening or H5 HA2 RRT-PCR assays to detect the presence of a multi-basic cleavage site (MBCS) sequence indicative of H5 HPAIV by Sanger sequencing -Viable virus is not requested	-The RT-PCR H5(HA2) is optimised for detection of Eurasian H5 AIVs. Despite tested on a variety of AIVs, no H5RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV testing strategy that may feature more than one assay. -Does not give information on the pathotype of the virus (HPAI or LPAI virus); -Risk of cross contamination; -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA; -Needs specialised equipment	Slomka <i>et al.</i> (2007a)
H7 conventional RT-PCR (Slomka <i>et al.</i> [2007a]) +++		Reference test was genome sequencing DSe = 100% DSp=100%	89 avian samples of known infectious status (59 known positive samples and 30 known negative samples)	Validated by WOAHP Reference Laboratory in Italy – report available on request^	-The RT-PCR H7(HA2) has been proven to successfully and sensitively detect Eurasian-origin H7 AIVs. -Can be used once a sample has been confirmed as positive by the generic influenza A virus screening or H7 HA2 RRT-PCR assays to detect the presence of a multi-basic cleavage site (MBCS) sequence indicative of H7 HPAIV by Sanger sequencing -Viable virus is not requested	The RT-PCR H7(HA2) is optimised for detection of Eurasian H7 AIVs. Despite tested on a variety of AIVs, no H7RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV testing strategy that may feature more than one assay	Slomka <i>et al.</i> (2007a)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
Virus isolation +	Tracheal swabs, cloacal swabs, and organ samples Target: Infectious virus	Reference tests were real-time RT-PCR for H5 subtype and sequencing DSe=76% Negative results by VI for H5 could be explained by considering the condition of the clinical samples at the time of their arrival (cold chain was not constantly maintained during shipping, compromising the viability of the viruses) DSp=100%	725 avian samples	See reference	-Demonstrates the presence of infectious (replication-competent) virus (essential to assess the efficacy of inactivation processes and for AIV phenotypic characterisation) -High specificity -Detects all AIV subtypes	-Time consuming -Relies on proper care to protect the virus in the samples from environmental damage, and use of an adequate transport system to maintain infectivity and replication competence -Difficult to manage for high throughput -Require high-level containment	Monne <i>et al.</i> (2008)
	Swabs Target: Infectious virus	Reference test was real-time RT-PCR for type A influenza Overall the results of the two assays agreed on 1385 samples (89%) and disagreed on 165 samples (11%)	1550 clinical swab samples from live-bird markets	See reference	As in the above line	As in the above line	Spackman <i>et al.</i> (2002)
Antigen-capture immunoassays +	Tracheal and cloacal swabs Feather pulp Target: influenza virus internal proteins	DSe and DSp differ based on the antigen-capture immunoassay used. The accuracy data presented here are the ones from Slomka <i>et al.</i> (2012). Reference test was real-time RT-PCR DSe = between 31.6% and 36.8% for tracheal and cloacal swabs and between 33.3% and 84.0% for feathers depending on which device was assessed	282 avian samples	See reference	-Fast (about 15 minutes after addition of the sample) -Specific -May be used "pen-side"	-Poor sensitivity	Slomka <i>et al.</i> (2012)
Detection of immune response							
Haemagglutination inhibition test +++	Serum samples Antibodies against the hemagglutinin (HA) antigen	A Bayesian version of latent class analysis was used to compare the results of multiple serological tests from different study settings reported in the literature DSe = 98.8% DSp= 99.5%	114 serum sample	See reference	-Identify AIV subtype-specific antibodies such as H5 and H7 -Relatively inexpensive on a per sample basis -No special equipment is needed -Results can be obtained in about 2 hours -Not species-specific	-Serum and antigen must be antigenically matched -The HI assay as an antibody screening assay is not practical unless one is targeting specific subtypes or lineages -The accuracy can be affected by steric inhibition from the NA	Comin <i>et al.</i> (2013)
ELISA +++	Serum samples	DSe and DSp differ based on the ELISA used and the antibodies	281 serum sample	See reference	-Rapid results	-Indirect ELISA is species-specific	Brown <i>et al.</i> (2009)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
	Antibodies against the Influenza virus internal proteins	tested The values reported here are estimated applying AGID and blocking ELISA on sera from AI virus experimental-infection trials (Brown <i>et al.</i> [2009]) DSe = 82% DSp= 100%	(178 positive and 103 negative)		-Ability to screen large numbers of samples in a semiautomated manner -NP-ELISA assays can be used to demonstrate freedom from infection in vaccinated birds (DIVA approach) if compatible vaccines are applied (i.e. vaccines that do not contain the AI-NP in the formulation)	-Requires some specialised equipment -Sensitivity and specificity may vary between ELISA assays used	
AGID +	Serum samples Antibodies against the Influenza virus internal proteins	Estimated applying AGID and blocking ELISA on sera from AI virus experimental-infection trials. DSe = 67,4% DSp= 100%	281 serum sample (178 positive and 103 negative)	See reference	-Simple and economical test -Does not require specialised laboratory equipment	-Electrolyte concentration, buffer, pH, and incubation temperatures can affect precipitate formation -Sera from waterfowl should not be tested by this method (lack of sensitivity as these birds do not produce precipitating antibodies) -Time consuming	Brown <i>et al.</i> (2009)

Appendix 3: Avian Influenza*

Intended purpose of test: individual animal freedom from infection prior to movement

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
Detection and identification of the agent							
Real-time RT-PCR M gene (Nagy <i>et al.</i> , [2021]) +++	Extracted RNA from clinical (swabs and tissues) and environmental specimens	Originally validated as for Nagy <i>et al.</i> (2021). Stringently assessed further, in context of H5N1 clade 2.3.4.4b HPAIV outbreaks. Slomka <i>et al.</i> (2023) defined a highly stringent criterion adapted to this validation of 514 poultry swabs: For a given swab, if it registered a positive result (Ct<36) by any of the three AIV real-time RT-PCRs (M-gene Nagy <i>et al.</i> [2021], H5[HA2] [Slomka <i>et al.</i> (2007b)] and H5[HP] [James <i>et al.</i> (2022)]), then by consensus it is considered as an H5Nx positive swab. If all three tests are negative (Ct>36), then by consensus it is considered as AIV negative. Se and Sp for the three AIVRT-PCRs were calculated for this assay relative to consensus swab status (positive/negative): DSe: 90.6% DSp: 100% (affirmed 100% Sp originally demonstrated by Nagy <i>et al.</i> [2021])	Additional validation based on H5N1 (clade 2.3.4.4b) HPAIV testing at 12 UK poultry outbreak premises (514 swabs, equal numbers of oropharyngeal and cloacal) during autumn 2021, which featured in Slomka <i>et al.</i> (2023) Chickens: eight premises, 350 swabs Turkeys: three premises, 124 swabs Ducks: One premise: 40 swabs	See references Validated by WOAH Reference Laboratory in UK – report available on request	-Use of 99,353 M-gene sequences to ensure that as far as possible, the primer and probe designs match a vast range of animal and human influenza A viruses -Assessed in several independent European National Reference Laboratories, featuring an extensive range of human and animal influenza A viruses (laboratory isolates and 1455 clinical specimens) -Sensitively detect many contemporary swine, equine and human influenza A virus strains -Viable virus is not requested -Adaptable to high throughput -Rapid -Can be used to detect infection in vaccinated birds (DIVA approach) for monitoring freedom from infection in vaccinated or unvaccinated poultry flocks	-Despite the thorough bioinformatics input to the primer/probe design (see left), no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered, as accepted by Nagy <i>et al.</i> (2021). Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]) -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	Nagy <i>et al.</i> (2021) Slomka <i>et al.</i> (2023)
Real-time RT-PCR M gene (Heine <i>et al.</i> [2015]; Laconi <i>et al.</i> [2020], protocol 3) +++	Extracted RNA from clinical specimens (swabs and tissues)	Reference test was genetic sequencing DSe = 100% DSp = 100%	92 avian samples and 117 mammalian samples of known infectious status (121 true positive and 88 true negative samples)	See references Validated by WOAH Reference Laboratory in Italy – report available on request^	- <i>In silico</i> evaluation of primers/probe match using 4088 AIV M-gene sequences (Laconi <i>et al.</i> [2020]) -Assessed on extensive range of avian influenza A viruses belonging to different subtypes and genotypes -Tested on multiple sample matrixes from mammalian and avian species -Assessed in several independent European National Reference Laboratories	-Despite tested on a variety of AIV subtypes, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more	Heine <i>et al.</i> (2015) Laconi <i>et al.</i> (2020)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
					<ul style="list-style-type: none"> -Can be used to detect infection in vaccinated birds (DIVA approach) for monitoring freedom from infection in vaccinated or unvaccinated poultry flocks. -Viable virus is not requested -Adaptable to high throughput -Rapid 	<p>than one assay (Slomka <i>et al.</i> [2023]).</p> <ul style="list-style-type: none"> -<i>In silico</i> evaluation demonstrated that the test may have decreased sensitivity in the detection of a cluster of H5N1 viruses related to the A/chicken/East_Java/Av1955/2022 (EPI_ISL_13690275), belonging to the 2.3.2.1c clade, due to primers mismatches. -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment 	
Real-time RT-PCR M gene (Hassan <i>et al.</i> [2022]) +++	Extracted RNA from clinical specimens (swabs and tissues) and egg-grown isolates	Reference test was genome sequencing DSe = 100% DSp=100%	122 clinical samples 428 virus isolates	See reference	<ul style="list-style-type: none"> - In silico evaluation of primers/probe match using >3000 AIV M-gene sequences -Assessed on extensive range of avian and porcine influenza A viruses belonging to different subtypes and genotypes - Assessed also on a minor selection of human IAV isolates (<20) -Can be used to detect infection in vaccinated birds (DIVA approach) for monitoring freedom from infection in vaccinated or unvaccinated poultry flocks. -Viable virus is not requested -Adaptable to high throughput -Rapid 	<p>-Despite tested on a variety of AIV subtypes, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023])</p> <ul style="list-style-type: none"> -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA 	Hassan <i>et al.</i> (2022)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
Real-time RT-PCR H5 (Hassan <i>et al.</i> [2022]) +++	Extracted RNA from clinical specimens (swabs and tissues) and egg-grown isolates	Reference test was genome sequencing DSe = 100% DSp=100%	122 clinical samples 428 virus isolates	See reference	<ul style="list-style-type: none"> - <i>In silico</i> evaluation of primers/probe match using >700 AIV H5-gene sequences - Specificity assessed on extensive range of avian, porcine and human influenza A viruses belonging to different subtypes and genotypes - Assessed also on a minor selection of human IAV isolates (<20) - Combines two distinct target regions along the H5 HA gene - Viable virus is not requested - Adaptable to high throughput - Rapid 	<ul style="list-style-type: none"> - Needs specialised equipment - Despite tested on a variety of AIVs, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]) - Failed to detect an individual Eurasian wild bird LP H5 isolate (EU-RL ring trial) - Does not give information on the pathotype of the virus (HPAI or LPAI virus) - Does not give information on whether live or inactivated virus - Risk of cross contamination - Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA - Needs specialised equipment 	Hassan <i>et al.</i> (2022)
Real-time RT-PCR H5 (Slomka <i>et al.</i> [2007b]) +++	Extracted RNA from clinical (swabs and tissues) and environmental specimens	Originally validated as for Slomka <i>et al.</i> (2007b). Stringently assessed further, in context of H5N1 clade 2.3.4.4b HPAIV outbreaks. Slomka <i>et al.</i> (2023) defined a highly stringent criterion adapted to this validation of 514 poultry swabs: For a given swab, if it registered a positive result (Ct<36) by any of the three AIV real-time RT-PCRs (M-gene Nagy <i>et al.</i> [2021], H5[HA2] and H5[HP]), then by consensus it is considered as an H5N1 positive swab. If all three tests are negative (Ct>36), then by consensus it is considered as AIV negative. See	514 poultry swabs, see above entry for Nagy <i>et al.</i> (2021) M-gene real-time RT-PCR: Chickens: eight premises, 350 swabs Turkeys: three premises, 124 swabs Ducks: one premises: 40 swabs	See references Validated by WOAHA Reference Laboratory in UK – report available on request*.	<ul style="list-style-type: none"> - The real-time RT-PCR H5(HA2) has been proven to successfully and sensitively detect Eurasian-origin H5 AIVs, through careful targeting of the relatively conserved HA2 region of the H5 gene. Detected H5 AIVs include not only the H5Nx clade 2.3.4.4b HPAIVs, but earlier clades of the “goose/Guangdong” lineage (GsGd), as well as non-GsGd H5 LPAIVs (references cited by Slomka <i>et al.</i> (2023)) - Viable virus is not requested - Adaptable to high throughput - Rapid 	<ul style="list-style-type: none"> - The real-time RT-PCR H5(HA2) is optimised for detection of Eurasian H5 AIVs and may be notably less sensitive for detection of American lineage H5 AIVs (acknowledged by Slomka <i>et al.</i> [2007b]), due to divergence in the HA2 portion of the H5 gene - Despite tested on a variety of AIVs, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing 	Slomka <i>et al.</i> (2007b). Slomka <i>et al.</i> (2023)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
		and Sp for the three AIVRT-PCRs were calculated for this assay relative to consensus swab status (positive/negative) DSe: 96.2% DSp: 100%				strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]) -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	
Real-time RT-PCR H5 (Spackman <i>et al.</i> [2002]) +++	Extracted RNA from clinical specimens (swabs)	Reference test was HI Results for 100% of the samples were in agreement between real-time RT-PCR H5 and VI	Eight swab samples from live-bird markets (test population composed by 202 samples but only eight samples were tested by real-time RT-PCR H5 as the remaining 194 samples were typed as H7 positive samples by real-time RT-PCR H7 and VI)	See Reference	-The real-time RT-PCR H5(HA2) has been proven to successfully and sensitively detect American-origin H5 AIVs, through careful targeting of the relatively conserved HA2 region of the H5 gene. -Viable virus is not requested -Adaptable to high throughput -Rapid	-The real-time RT-PCR H5(HA2) is optimised for detection of American H5 AIVs due to divergence in the HA2 portion of the H5 gene. -Despite tested on a variety of AIVs, no AIV real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]). -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	Spackman <i>et al.</i> (2002)
Real-time RT-PCR H5(HP) (James <i>et al.</i> [2022])	Extracted RNA from clinical (swabs and	Originally validated as from James <i>et al.</i> (2022). Stringently assessed further, in context of H5N1 clade	514 poultry swabs, see above entry for Nagy <i>et al.</i> (2021)	Validated by WOAHP Reference	-In addition to its description by James <i>et al.</i> (2022), the real-time RT-PCR H5(HP) has been shown to	-There remains the possibility that future H5 HPAIV incursions (due to GsGd or non-GsGd lineage	James <i>et al.</i> (2022)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
+++	tissues) and environmental specimens	2.3.4.4b HPAIV outbreaks, relative to consensus (see above entry for Nagy <i>et al.</i> (2021) M-gene real-time RT-PCR and Slomka <i>et al.</i> (2007b) H5 real-time RT-PCR: DSe: 98.3% DSp: 100%	M-gene real-time RT-PCR: Chickens: eight premises, 350 swabs Turkeys: three premises, 124 swabs Ducks: one premises: 40 swabs	Laboratory in UK – report available on request	be highly sensitive in the detection of H5N1 HPAIV in swabs obtained from UK poultry outbreaks caused by the H5N1 clade 2.3.4.4b HPAIV during 2021–2022 (Slomka <i>et al.</i> [2023]). -This assay can be used once a sample has been confirmed as positive by the generic influenza A virus screening or H5 HA2 RRT-PCR assays to detect the presence of a multi-basic cleavage site (MBCS) sequence indicative of H5 HPAIV -Viable virus is not requested -Adaptable to high throughput -Rapid	viruses) may include H5 gene sequence variants which may not be detected as sensitively as the current H5N1 clade 2.3.4.4b HPAIV strains circulating since autumn 2021. Clearly this concern applies to any AIV real-time RT-PCR, underlining the importance of ongoing validation, to ensure fitness-for-purpose for the sensitive detection of newly emerging viral strains. -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	Slomka <i>et al.</i> (2023)
Real-time RT-PCR H7 (Hassan <i>et al.</i> [2022]) +++	Extracted RNA from clinical specimens (swabs and tissues) and egg-grown isolates	Reference test was genome sequencing DSe = 100% DSp=100%	122 clinical samples 428 virus isolates	See Reference	- <i>In silico</i> evaluation of primers/probe match using >300 AIV H7-gene sequences -Specificity assessed on extensive range of avian influenza A viruses belonging to different subtypes and genotypes - Combines two distinct target regions along the H7 HA gene -Viable virus is not requested -Adaptable to high throughput -Rapid	-Despite tested on a variety of AIVs, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay-Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	Hassan <i>et al.</i> (2022)
Real-time RT-PCR H7(HA2) (Slomka <i>et al.</i> [2009])	Extracted RNA from clinical (swabs and	Slomka <i>et al.</i> (2009) described and validated the H7(HA2) real-time RT-PCR relative to M-gene	AIV laboratory isolates included:	See references	-The real-time RT-PCR H7(HA2) has been proven to successfully and sensitively detect Eurasian-origin H7	-The real-time RT-PCR H7(HA2) is optimised for detection of Eurasian H7 AIVs is less sensitive for	Slomka <i>et al.</i> (2009)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
+++	tissues) and environmental specimens	real-time RT-PCR of Spackman <i>et al.</i> (2002; see separate entry): DSe: 95.4% DSp: 97.9%	H7 AIVs: n=65; non-H7 AIVs: n=57. Clinical specimens from H7N7 (LP and HPAIV inoculations): n=117 swabs; plus 180 AIV negative swabs		AIVs, through careful targeting of the relatively conserved HA2 region of the H7 gene. The real-time RT-PCR H7(HA2) demonstrated its value during H7 chicken outbreaks, both LP and HPAIV (Seekings <i>et al.</i> [2018], Reid <i>et al.</i> [2019]). -Viable virus is not requested -Adaptable to high throughput -Rapid	detection of American lineage H7 AIVs (noted by Slomka <i>et al.</i> [2009]), due to divergence in the HA2 portion of the H7 gene. -Despite tested on a variety of AIVs, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay; -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus; -Risk of cross contamination; -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA; -Needs specialised equipment	Seekings <i>et al.</i> (2018) Reid <i>et al.</i> (2019)
Real-time RT-PCR H7 (Spackman <i>et al.</i> [2002]) +++		Reference test was HI Results for 98% of the samples were in agreement between real-time RT-PCR H7 and VI	202 swab samples from live-bird markets	See Reference	-The real-time RT-PCR H7(HA2) has been proven to successfully and sensitively detect American-origin H7 AIVs, through careful targeting of the relatively conserved HA2 region of the H7 gene -Viable virus is not requested -Adaptable to high throughput -Rapid	-The real-time RT-PCR H7(HA2) is optimised for detection of American H7 AIVs due to divergence in the HA2 portion of the H7 gene. -Despite tested on a variety of AIV subtypes, no H7 real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed H7 testing strategy that may feature more than one assay. -Does not give information on the pathotype of the virus (HPAI or LPAI virus)	Spackman <i>et al.</i> (2002)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
						<ul style="list-style-type: none"> -Does not give information on whether live or inactivated virus; -Risk of cross contamination; -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA; -Needs specialised equipment 	
H5 conventional RT-PCRs (Slomka <i>et al.</i> [2007a]) +++		Reference test was genome sequencing DSe = 99.36% DSp=100%	426 avian and 43 mammalian samples of known infectious status (472 know positive samples and 63 known negative samples)	Validated by WOAHP Reference Laboratory in Italy – report available on request^	<ul style="list-style-type: none"> -The RT-PCR H5(HA2) has been proven to successfully and sensitively detect Eurasian-origin H5 AIVs -Can be used once a sample has been confirmed as positive by the generic influenza A virus screening or H5 HA2 RRT-PCR assays to detect the presence of a multi-basic cleavage site (MBCS) sequence indicative of H5 HPAIV by Sanger sequencing -Viable virus is not requested 	<ul style="list-style-type: none"> -The RT-PCR H5(HA2) is optimised for detection of Eurasian H5 AIVs Despite tested on a variety of AIVs, no H5RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV testing strategy that may feature more than one assay -Does not give information on whether live or inactivated virus; -Risk of cross contamination; -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA; -Needs specialised equipment 	Slomka <i>et al.</i> (2007)
H7 conventional RT-PCRs (Slomka <i>et al.</i> [2007a]) +++		Reference test was genome sequencing DSe = 100% DSp=100%	89 avian samples of known infectious status (59 know positive samples and 30 known negative samples)	Validated by WOAHP Reference Laboratory in Italy – report available on request^	<ul style="list-style-type: none"> The RT-PCR H7(HA2) has been proven to successfully and sensitively detect Eurasian-origin H7 AIVs -Can be used once a sample has been confirmed as positive by the generic influenza A virus screening or H7 HA2 RRT-PCR assays to detect the presence of a multi-basic cleavage site (MBCS) sequence indicative of H7 HPAIV by Sanger sequencing -Viable virus is not requested 	<ul style="list-style-type: none"> The RT-PCR H7(HA2) is optimised for detection of Eurasian H7 AIVs. Despite tested on a variety of AIVs, no H7RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV testing strategy that may feature more than one assay 	Slomka <i>et al.</i> (2007)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
Virus isolation +++	Tracheal swabs, cloacal swabs, and organ samples Target: infectious virus	Reference tests were real-time RT-PCR for H5 subtype and sequencing DSe=76% Negative results by VI for H5 could be explained by considering the condition of the clinical samples at the time of their arrival (cold chain was not constantly maintained during shipping, compromising the viability of the viruses) DSp=100%	725 avian samples	See reference	-Demonstrates the presence of infectious (replication-competent) virus (essential to assess the efficacy of inactivation processes and for AIV phenotypic characterisation) -High specificity -Detects all AIV subtypes	-Time consuming -Relies on proper care to protect the virus in the samples from environmental damage, and use of an adequate transport system to maintain infectivity and replication competence. -Difficult to manage for high throughput -Require high-level containment	Monne <i>et al.</i> (2008)
	Swabs Target: Infectious virus	Reference test was real-time RT-PCR for type A influenza Overall the results of the two assays agreed on 1,385 samples (89%) and disagreed on 165 samples (11%)	1550 clinical swab samples from live-bird markets	See reference	As in the above line	As in the above line	Spackman <i>et al.</i> (2002)
Antigen-capture immunoassays +	Tracheal and cloacal swabs Feather pulp Target: Influenza virus internal proteins	DSe and DSp differ based on the antigen-capture immunoassay used The accuracy data presented here are the ones from Slomka <i>et al.</i> [2012] Reference test was real-time RT-PCR DSe = between 31.6% and 36.8% for tracheal and cloacal swabs and between 33.3% and 84.0% for feathers depending on which device was assessed	282 avian samples	See reference	-Fast (about 15 minutes after addition of the sample) -Specific -May be used "pen-side"	-Poor sensitivity	Slomka <i>et al.</i> (2012)
Detection of immune response							
Haemagglutination inhibition test ++	Serum samples Antibodies against the hemagglutinin (HA) antigen	A Bayesian version of latent class analysis was used to compare the results of multiple serological tests from different study settings reported in the literature DSe = 98.8% DSp= 99.5%	114 serum sample	See reference	-Identify AIV subtype-specific antibodies such as H5 and H7 -Relatively inexpensive on a per sample basis -No special equipment is needed -Results can be obtained in about 2 hours -Not species-specific	-Serum and antigen must be antigenically matched -The HI assay as an antibody screening assay is not practical unless one is targeting specific subtypes or lineages -The accuracy can be affected by steric inhibition from the NA	Comin <i>et al.</i> (2013)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
ELISA +	Serum samples Antibodies against the Influenza virus internal proteins	DSe and DSp differ based on the ELISA used and the antibodies tested The values reported here are estimated applying AGID and blocking ELISA on sera from AI virus experimental-infection trials (Brown <i>et al.</i> [2009]) DSe = 82% DSp= 100%	281 serum sample (178 positive and 103 negative)	See reference	-Rapid results -Ability to screen large numbers of samples in a semiautomated manner	-Indirect ELISA is species-specific -Requires some specialised equipment -Sensitivity and specificity may vary between ELISA assays used	Brown <i>et al.</i> (2009)
AGID +	Serum samples Antibodies against the Influenza virus internal proteins	Estimated applying AGID and blocking ELISA on sera from AI virus experimental-infection trials. DSe = 67,4% DSp= 100%	281 serum sample (178 positive and 103 negative)	See reference	-Simple and economical test -Does not require specialised laboratory equipment	-Electrolyte concentration, buffer, pH, and incubation temperatures can affect precipitate formation -Sera from waterfowl should not be tested by this method (lack of sensitivity as these birds do not produce precipitating antibodies) -Time consuming	Brown <i>et al.</i> (2009)

1621

1622

Appendix 4: Avian Influenza*
Intended purpose of test: contribute to eradication policies

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
Detection and identification of the agent							
Real-time RT-PCR M gene (Nagy <i>et al.</i> [2021]) +++	Extracted RNA from clinical (swabs and tissues) and environmental specimens	Originally validated as for Nagy <i>et al.</i> (2021). Stringently assessed further, in context of H5N1 clade 2.3.4.4b HPAIV outbreaks. Slomka <i>et al.</i> (2023) defined a highly stringent criterion adapted to this validation of 514 poultry swabs: For a given swab, if it registered a positive result (Ct<36) by any of the three AIV real-time RT-PCRs (M-gene Nagy <i>et al.</i> [2021], H5[HA2] [Slomka <i>et al.</i> (2007b)] and H5[HP] [James <i>et al.</i> [2022]], then by consensus it is considered as an H5Nx positive swab. If all three tests are negative (Ct>36), then by consensus it is considered as AIV negative. Se and Sp for the three AIVRT-PCRs were calculated for this assay relative to consensus swab status (positive/negative): DSe: 90.6% DSp: 100% (affirmed 100% Sp originally demonstrated by Nagy <i>et al.</i> [2021])	Additional validation based on H5N1 (clade 2.3.4.4b) HPAIV testing at 12 UK poultry outbreak premises (514 swabs, equal numbers of oropharyngeal and cloacal) during autumn 2021, which featured in Slomka <i>et al.</i> (2023) Chickens: eight premises, 350 swabs Turkeys: three premises, 124 swabs Ducks: one premise: 40 swabs	See references Validated by WOAHP Reference Laboratory in UK – report available on request ^o .	-Use of 99,353 M-gene sequences to ensure that as far as possible, the primer and probe designs match a vast range of animal and human influenza A viruses -Assessed in several independent European National Reference Laboratories, featuring an extensive range of human and animal influenza A viruses (laboratory isolates and 1455 clinical specimens) -Sensitively detect many contemporary swine, equine and human influenza A virus strains -Can be used to detect infection in vaccinated birds (DIVA approach) for monitoring freedom from infection in vaccinated or unvaccinated poultry flocks. -Viable virus is not requested -Adaptable to high throughput -Rapid	-Despite the thorough bioinformatics input to the primer/probe design (see left), no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered, as accepted by Nagy <i>et al.</i> (2021). Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]) -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	Nagy <i>et al.</i> (2021). Slomka <i>et al.</i> (2023)
Real-time RT-PCR M gene (Heine <i>et al.</i> [2015]; Laconi <i>et al.</i> [2020], protocol 3) +++	Extracted RNA from clinical specimens (swabs and tissues)	Reference test was genetic sequencing DSe = 100% DSp = 100%	92 avian samples and 117 mammalian samples of known infectious status (121 true positive and 88 true negative samples)	See references Validated by WOAHP Reference Laboratory in Italy – report available on request [^]	- <i>In silico</i> evaluation of primers/probe match using 4088 AIV M-gene sequences (Laconi <i>et al.</i> [2020]) -Assessed on extensive range of avian influenza A viruses belonging to different subtypes and genotypes -Tested on multiple sample matrixes from mammalian and avian species -Assessed in several independent European National Reference Laboratories	-Despite tested on a variety of AIV subtypes, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more	Heine <i>et al.</i> (2015). Laconi <i>et al.</i> (2020)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
					<ul style="list-style-type: none"> -Can be used to detect infection in vaccinated birds (DIVA approach) for monitoring freedom from infection in vaccinated or unvaccinated poultry flocks. -Viable virus is not requested -Adaptable to high throughput -Rapid 	<p>than one assay (Slomka <i>et al.</i> [2023]).</p> <ul style="list-style-type: none"> -<i>In silico</i> evaluation demonstrated that the test may have decreased sensitivity in the detection of a cluster of H5N1 viruses related to the A/chicken/East_Java/Av1955/2022 (EPI_ISL_13690275), belonging to the 2.3.2.1c clade, due to primers mismatches. -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment 	
Real-time RT-PCR M gene (Hassan <i>et al.</i> [2022]) +++	Extracted RNA from clinical specimens (swabs and tissues) and egg-grown isolates	Reference test was genome sequencing DSe = 100% DSp=100%	122 clinical samples 428 virus isolates	See reference	<ul style="list-style-type: none"> - In silico evaluation of primers/probe match using >3000 AIV M-gene sequences -Assessed on extensive range of avian and porcine influenza A viruses belonging to different subtypes and genotypes - Assessed also on a minor selection of human IAV isolates (<20) -Can be used to detect infection in vaccinated birds (DIVA approach) for monitoring freedom from infection in vaccinated or unvaccinated poultry flocks. -Viable virus is not requested -Adaptable to high throughput -Rapid 	<ul style="list-style-type: none"> -Despite tested on a variety of AIV subtypes, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]) -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA 	Hassan <i>et al.</i> (2022)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
Real-time RT-PCR H5 (Hassan <i>et al.</i> [2022]) +++	Extracted RNA from clinical specimens (swabs and tissues) and egg-grown isolates	Reference test was genome sequencing DSe = 100% DSp=100%	122 clinical samples 428 virus isolates	See reference	<ul style="list-style-type: none"> - <i>In silico</i> evaluation of primers/probe match using >700 AIV H5-gene sequences - Specificity assessed on extensive range of avian, porcine and human influenza A viruses belonging to different subtypes and genotypes - Assessed also on a minor selection of human IAV isolates (<20) - Combines two distinct target regions along the H5 HA gene - Viable virus is not requested - Adaptable to high throughput - Rapid 	<ul style="list-style-type: none"> - Needs specialised equipment - Despite tested on a variety of AIVs, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]) - Failed to detect an individual Eurasian wild bird LP H5 isolate (EU-RL ring trial) - Does not give information on the pathotype of the virus (HPAI or LPAI virus) - Does not give information on whether live or inactivated virus - Risk of cross contamination - Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA - Needs specialised equipment 	Hassan <i>et al.</i> (2022)
Real-time RT-PCR H5 (Slomka <i>et al.</i> [2007b]) +++	Extracted RNA from clinical (swabs and tissues) and environmental specimens	Originally validated as for Slomka <i>et al.</i> (2007b) Stringently assessed further, in context of H5N1 clade 2.3.4.4b HPAIV outbreaks. Slomka <i>et al.</i> (2023) defined a highly stringent criterion adapted to this validation of 514 poultry swabs: For a given swab, if it registered a positive result (Ct<36) by any of the three AIV real-time RT-PCRs (M-gene Nagy <i>et al.</i> [2021], H5[HA2] and H5[HP]), then by consensus it is considered as an H5N1 positive swab. If all three tests are negative (Ct>36), then by consensus it is considered as AIV negative. Se and Sp for the three	514 poultry swabs, see above entry for Nagy <i>et al.</i> (2021) M-gene real-time RT-PCR: Chickens: eight premises, 350 swabs Turkeys: three premises, 124 swabs Ducks: one premises: 40 swabs	See references Validated by WOAHA Reference Laboratory in UK – report available on request	<ul style="list-style-type: none"> - The real-time RT-PCR H5(HA2) has been proven to successfully and sensitively detect Eurasian-origin H5 AIVs, through careful targeting of the relatively conserved HA2 region of the H5 gene. Detected H5 AIVs include not only the H5Nx clade 2.3.4.4b HPAIVs, but earlier clades of the “goose/Guangdong” lineage (GsGd), as well as non-GsGd H5 LPAIVs (references cited by Slomka <i>et al.</i> [2023]). - Viable virus is not requested - Adaptable to high throughput - Rapid 	<ul style="list-style-type: none"> - The real-time RT-PCR H5(HA2) is optimised for detection of Eurasian H5 AIVs and may be notably less sensitive for detection of American lineage H5 AIVs (acknowledged by Slomka <i>et al.</i> [2007b]), due to divergence in the HA2 portion of the H5 gene - Despite tested on a variety of AIVs, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing 	Slomka <i>et al.</i> (2007b) Slomka <i>et al.</i> (2023)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
		AIVRT-PCRs were calculated for this assay relative to consensus swab status (positive/negative) DSe: 96.2% DSp: 100%				strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]) -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	
Real-time RT-PCR H5 (Spackman <i>et al.</i> [2002]) +++	Extracted RNA from clinical specimens (swabs)	Reference test was HI Results for 100% of the samples were in agreement between real-time RT-PCR H5 and VI	Eight swab samples from live-bird markets (test population composed by 202 samples but only eight samples were tested by real-time RT-PCR H5 as the remaining 194 samples were typed as H7 positive samples by real-time RT-PCR H7 and VI)	See Reference	-The real-time RT-PCR H5(HA2) has been proven to successfully and sensitively detect American-origin H5 AIVs, through careful targeting of the relatively conserved HA2 region of the H5 gene. -Viable virus is not requested -Adaptable to high throughput -Rapid	-The real-time RT-PCR H5(HA2) is optimised for detection of American H5 AIVs due to divergence in the HA2 portion of the H5 gene. -Despite tested on a variety of AIVs, no AIV real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]). -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	Spackman <i>et al.</i> (2002)
Real-time RT-PCR H5(HP) (James <i>et al.</i> [2022])	Extracted RNA from clinical (swabs and	Originally validated as from James <i>et al.</i> (2022) Stringently assessed further, in context of H5N1 clade	514 poultry swabs, see above entry for Nagy <i>et al.</i> (2021)	Validated by WOAHP Reference	-In addition to its description by James <i>et al.</i> (2022), the real-time RT-PCR H5(HP) has been shown to	-There remains the possibility that future H5 HPAIV incursions (due to GsGd or non-GsGd lineage	James <i>et al.</i> (2022)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
+++	tissues) and environmental specimens	2.3.4.4b HPAIV outbreaks, relative to consensus (see above entry for Nagy <i>et al.</i> (2021) M-gene real-time RT-PCR and Slomka <i>et al.</i> (2007b) H5 real-time RT-PCR: DSe: 98.3% DSp: 100%	M-gene real-time RT-PCR: Chickens: eight premises, 350 swabs Turkeys: three premises, 124 swabs Ducks: one premises: 40 swabs	Laboratory in UK – report available on request	be highly sensitive in the detection of H5N1 HPAIV in swabs obtained from UK poultry outbreaks caused by the H5N1 clade 2.3.4.4b HPAIV during 2021-2022 (Slomka <i>et al.</i> [2023]). -This assay can be used once a sample has been confirmed as positive by the generic influenza A virus screening or H5 HA2 RRT-PCR assays to detect the presence of a multi-basic cleavage site (MBCS) sequence indicative of H5 HPAIV -Viable virus is not requested -Adaptable to high throughput -Rapid	viruses) may include H5 gene sequence variants which may not be detected as sensitively as the current H5N1 clade 2.3.4.4b HPAIV strains circulating since autumn 2021. Clearly this concern applies to any AIV real-time RT-PCR, underlining the importance of ongoing validation, to ensure fitness-for-purpose for the sensitive detection of newly emerging viral strains. -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	Slomka <i>et al.</i> (2023)
Real-time RT-PCR H7 (Hassan <i>et al.</i> [2022]) +++	Extracted RNA from clinical specimens (swabs and tissues) and egg-grown isolates	Reference test was genome sequencing DSe = 100% DSp=100%	122 clinical samples 428 virus isolates	See Reference	- In silico evaluation of primers/probe match using >300 AIV H7-gene sequences -Specificity assessed on extensive range of avian influenza A viruses belonging to different subtypes and genotypes - Combines two distinct target regions along the H7 HA gene -Viable virus is not requested -Adaptable to high throughput -Rapid	Despite tested on a variety of AIVs, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	Hassan <i>et al.</i> (2022)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
Real-time RT-PCR H7(HA2) (Slomka <i>et al.</i> [2009]) +++	Extracted RNA from clinical (swabs and tissues) and environmental specimens	Slomka <i>et al.</i> (2009) described and validated the H7(HA2) real-time RT-PCR relative to M-gene real-time RT-PCR of Spackman <i>et al.</i> (2002; see separate entry): DSe: 95.4% DSp: 97.9%	AIV laboratory isolates included: H7 AIVs: n=65; non-H7 AIVs: n=57. Clinical specimens from H7N7 (LP and HPAIV inoculations): n=117 swabs; plus 180 AIV negative swabs.	See references	-The real-time RT-PCR H7(HA2) has been proven to successfully and sensitively detect Eurasian-origin H7 AIVs, through careful targeting of the relatively conserved HA2 region of the H7 gene. The real-time RT-PCR H7(HA2) demonstrated its value during H7 chicken outbreaks, both LP and HPAIV (Seekings <i>et al.</i> , 2018, Reid <i>et al.</i> , 2019). -Viable virus is not requested -Adaptable to high throughput -Rapid	-The real-time RT-PCR H7(HA2) is optimised for detection of Eurasian H7 AIVs is less sensitive for detection of American lineage H7 AIVs (noted by Slomka <i>et al.</i> [2009]), due to divergence in the HA2 portion of the H7 gene. -Despite tested on a variety of AIVs, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay; -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus; -Risk of cross contamination; -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA; -Needs specialised equipment	Slomka <i>et al.</i> (2009). Seekings <i>et al.</i> (2018). Reid <i>et al.</i> (2019)
Real-time RT-PCR H7 (Spackman <i>et al.</i> [2002]) +++		Reference test was HI Results for 98% of the samples were in agreement between real-time RT-PCR H7 and VI	202 swab samples from live-bird markets	See Reference	-The real-time RT-PCR H7(HA2) has been proven to successfully and sensitively detect American-origin H7 AIVs, through careful targeting of the relatively conserved HA2 region of the H7 gene. -Viable virus is not requested -Adaptable to high throughput -Rapid	-The real-time RT-PCR H7(HA2) is optimised for detection of American H7 AIVs due to divergence in the HA2 portion of the H7 gene. -Despite tested on a variety of AIV subtypes, no H7 real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed H7 testing strategy that may feature more than one assay.	Spackman <i>et al.</i> (2002)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
						<ul style="list-style-type: none"> -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus; -Risk of cross contamination; -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA; -Needs specialised equipment 	
H5 conventional RT-PCRs (Slomka <i>et al.</i> [2007a]) +++		Reference test was genome sequencing DSe = 99.36% DSp=100%	426 avian and 43 mammalian samples of known infectious status (472 know positive samples and 63 known negative samples)	Validated by WOAHP Reference Laboratory in Italy – report available on request [^] .	<ul style="list-style-type: none"> -The RT-PCR H5(HA2) has been proven to successfully and sensitively detect Eurasian-origin H5 AIVs. -Can be used once a sample has been confirmed as positive by the generic influenza A virus screening or H5 HA2 RRT-PCR assays to detect the presence of a multi-basic cleavage site (MBCS) sequence indicative of H5 HPAIV by Sanger sequencing -Viable virus is not requested 	<p>The RT-PCR H5(HA2) is optimised for detection of Eurasian H5 AIVs.</p> <p>Despite tested on a variety of AIVs, no H5RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV testing strategy that may feature more than one assay.</p> <ul style="list-style-type: none"> -Does not give information on whether live or inactivated virus; -Risk of cross contamination; -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA; -Needs specialised equipment 	Slomka <i>et al.</i> (2007a)
H7 conventional RT-PCRs (Slomka <i>et al.</i> [2007a]) +++		Reference test was genome sequencing DSe = 100% DSp=100%	89 avian samples of known infectious status (59 know positive samples and 30 known negative samples)	Validated by WOAHP Reference Laboratory in Italy – report available on request [^] .	<ul style="list-style-type: none"> The RT-PCR H7(HA2) has been proven to successfully and sensitively detect Eurasian-origin H7 AIVs. -Can be used once a sample has been confirmed as positive by the generic influenza A virus screening or H7 HA2 RRT-PCR assays to detect the presence of a multi-basic cleavage site (MBCS) sequence indicative of H7 HPAIV by Sanger sequencing -Viable virus is not requested 	<p>The RT-PCR H7(HA2) is optimised for detection of Eurasian H7 AIVs.</p> <p>Despite tested on a variety of AIVs, no H7RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV testing strategy that may feature more than one assay</p>	Slomka <i>et al.</i> (2007a)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
Virus isolation +	Tracheal swabs, cloacal swabs, and organ samples Target: Infectious virus	Reference tests were real-time RT-PCR for H5 subtype and sequencing DSe=76% Negative results by VI for H5 could be explained by considering the condition of the clinical samples at the time of their arrival (cold chain was not constantly maintained during shipping, compromising the viability of the viruses) DSp=100%	725 avian samples	See reference	-Demonstrates the presence of infectious (replication-competent) virus (essential to assess the efficacy of inactivation processes and for AIV phenotypic characterisation) -High specificity -Detects all AIV subtypes	-Time consuming -Relies on proper care to protect the virus in the samples from environmental damage, and use of an adequate transport system to maintain infectivity and replication competence. -Difficult to manage for high throughput -Require high-level containment	Monne <i>et al.</i> (2008)
	Swabs Target: Infectious virus	Reference test was real-time RT-PCR for type A influenza Overall the results of the two assays agreed on 1,385 samples (89%) and disagreed on 165 samples (11%)	1,550 clinical swab samples from live-bird markets	See reference	As in the above line	As in the above line	Spackman <i>et al.</i> (2002)
Antigen-capture immunoassays +	Tracheal and cloacal swabs Feather pulp Target: Influenza virus internal proteins	DSe and DSp differ based on the antigen-capture immunoassay used. The accuracy data presented here are the ones from Slomka <i>et al.</i> (2012). Reference test was real-time RT-PCR DSe = between 31.6% and 36.8% for tracheal and cloacal swabs and between 33.3% and 84.0% for feathers depending on which device was assessed	282 avian samples	See reference	-Fast (about 15 min after addition of the sample) -Specific -May be used "pen-side"	-Poor sensitivity	Slomka <i>et al.</i> (2012)
Detection of immune response							
Haemagglutination inhibition test +++	Serum samples Antibodies against the hemagglutinin (HA) antigen	A Bayesian version of latent class analysis was used to compare the results of multiple serological tests from different study settings reported in the literature DSe = 98.8%	114 serum sample	See reference	-Identify AIV subtype-specific antibodies such as H5 and H7 -Relatively inexpensive on a per sample basis -No special equipment is needed	-Serum and antigen must be antigenically matched -The HI assay as an antibody screening assay is not practical unless one is targeting specific subtypes or lineages	Comin <i>et al.</i> (2013)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
		DSp= 99.5%			-Results can be obtained in about 2 hours -Not species-specific	-The accuracy can be affected by steric inhibition from the NA	
ELISA ++	Serum samples Antibodies against the Influenza virus internal proteins	DSe and DSp differ based on the ELISA used and the antibodies tested. The values reported here are estimated applying AGID and blocking ELISA on sera from AI virus experimental-infection trials (Brown <i>et al.</i> [2009]) DSe = 82% DSp= 100%	281 serum sample (178 positive and 103 negative)	See reference	-Rapid results -Ability to screen large numbers of samples in a semiautomated manner	-Indirect ELISA is species-specific -Requires some specialised equipment -Sensitivity and specificity may vary between ELISA assays used.	Brown <i>et al.</i> (2009)
AGID ++	Serum samples Antibodies against the Influenza virus internal proteins	Estimated applying AGID and blocking ELISA on sera from AI virus experimental-infection trials. DSe = 67,4% DSp= 100%	281 serum sample (178 positive and 103 negative)	See reference	-Simple and economical test -Does not require specialised laboratory equipment	-Electrolyte concentration, buffer, pH, and incubation temperatures can affect precipitate formation -Sera from waterfowl should not be tested by this method (lack of sensitivity as these birds do not produce precipitating antibodies) -Time consuming	Brown <i>et al.</i> (2009)

Appendix 5: Avian Influenza*
Intended purpose of test: confirmation of clinical cases

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
Detection and identification of the agent							
Real-time RT-PCR M gene (Nagy <i>et al.</i> [2021]) +++	Extracted RNA from clinical (swabs and tissues) and environmental specimens	Originally validated as for Nagy <i>et al.</i> (2021) Stringently assessed further, in context of H5N1 clade 2.3.4.4b HPAIV outbreaks. Slomka <i>et al.</i> (2023) defined a highly stringent criterion adapted to this validation of 514 poultry swabs: For a given swab, if it registered a positive result (Ct<36) by any of the three AIV real-time RT-PCRs (M-gene Nagy <i>et al.</i> [2021], H5[HA2] [Slomka <i>et al.</i> (2007b)] and H5[HP] [James <i>et al.</i> (2022)]), then by consensus it is considered as an H5Nx positive swab. If all three tests are negative (Ct>36), then by consensus it is considered as AIV negative. Se and Sp for the three AIVRT-PCRs were calculated for this assay relative to consensus swab status (positive/negative): DSe: 90.6% DSp: 100% (affirmed 100% Sp originally demonstrated by Nagy <i>et al.</i> (2021))	Additional validation based on H5N1 (clade 2.3.4.4b) HPAIV testing at 12 UK poultry outbreak premises (514 swabs, equal numbers of oropharyngeal and cloacal) during autumn 2021, which featured in Slomka <i>et al.</i> (2023) Chickens: eight premises, 350 swabs Turkeys: three premises, 124 swabs Ducks: one premise: 40 swabs	See references Validated by WOAH Reference Laboratory in UK – report available on request	-Use of 99,353 M-gene sequences to ensure that as far as possible, the primer and probe designs match a vast range of animal and human influenza A viruses -Assessed in several independent European National Reference Laboratories, featuring an extensive range of human and animal influenza A viruses (laboratory isolates and 1455 clinical specimens) -Sensitively detect many contemporary swine, equine and human influenza A virus strains -Can be used to detect infection in vaccinated birds (DIVA approach) for monitoring freedom from infection in vaccinated or unvaccinated poultry flocks. -Viable virus is not requested -Adaptable to high throughput -Rapid	-Despite the thorough bioinformatics input to the primer / probe design (see left), no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered, as accepted by Nagy <i>et al.</i> (2021). Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]) -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	Nagy <i>et al.</i> (2021) Slomka <i>et al.</i> (2023)
Real-time RT-PCR M gene (Heine <i>et al.</i> [2015]; Laconi <i>et al.</i> [2020], protocol 3) +++	Extracted RNA from clinical specimens (swabs and tissues)	Reference test was genetic sequencing DSe = 100% DSp = 100%	92 avian samples and 117 mammalian samples of known infectious status (121 true positive and 88 true negative samples)	See references Validated by WOAH Reference Laboratory in Italy – report available on request [^]	-Is silico evaluation of primers/probe match using 4088 AIV M-gene sequences (Laconi <i>et al.</i> [2020]) -Assessed on extensive range of avian influenza A viruses belonging to different subtypes and genotypes -Tested on multiple sample matrixes from mammalian and avian species -Assessed in several independent European National Reference Laboratories	-Despite tested on a variety of AIV subtypes, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature	Heine <i>et al.</i> (2015) Laconi <i>et al.</i> (2020)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
					<ul style="list-style-type: none"> -Can be used to detect infection in vaccinated birds (DIVA approach) for monitoring freedom from infection in vaccinated or unvaccinated poultry flocks. -Viable virus is not requested -Adaptable to high throughput -Rapid 	<ul style="list-style-type: none"> more than one assay (Slomka <i>et al.</i> [2023]) -In silico evaluation demonstrated that the test may have decreased sensitivity in the detection of a cluster of H5N1 viruses related to the A/chicken/East_Java/Av1955/2022 (EPI_ISL_13690275), belonging to the 2.3.2.1c clade, due to primers mismatches. -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment 	
Real-time RT-PCR M gene (Hassan <i>et al.</i> [2022]) +++	Extracted RNA from clinical specimens (swabs and tissues) and egg-grown isolates	Reference test was genome sequencing DSe = 100% DSp=100%	122 clinical samples 428 virus isolates	See reference	<ul style="list-style-type: none"> - In silico evaluation of primers/probe match using >3000 AIV M-gene sequences -Assessed on extensive range of avian and porcine influenza A viruses belonging to different subtypes and genotypes - Assessed also on a minor selection of human IAV isolates (<20) -Can be used to detect infection in vaccinated birds (DIVA approach) for monitoring freedom from infection in vaccinated or unvaccinated poultry flocks. -Viable virus is not requested -Adaptable to high throughput -Rapid 	<ul style="list-style-type: none"> -Despite tested on a variety of AIV subtypes, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]) -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction 	Hassan <i>et al.</i> (2022)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
						inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	
Real-time RT-PCR H5 (Hassan <i>et al.</i> [2022]) +++	Extracted RNA from clinical specimens (swabs and tissues) and egg-grown isolates	Reference test was genome sequencing DSe = 100% DSp=100%	122 clinical samples 428 virus isolates	See reference	- In silico evaluation of primers/probe match using >700 AIV H5-gene sequences -Specificity assessed on extensive range of avian, porcine and human influenza A viruses belonging to different subtypes and genotypes - Assessed also on a minor selection of human IAV isolates (<20) - Combines two distinct target regions along the H5 HA gene -Viable virus is not requested -Adaptable to high throughput -Rapid	-Despite tested on a variety of AIVs, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]) -Failed to detect an individual Eurasian wild bird LP H5 isolate (EU-RL ringtrial) -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	Hassan <i>et al.</i> (2022)
Real-time RT-PCR H5 (Slomka <i>et al.</i> [2007b]) +++	Extracted RNA from clinical (swabs and tissues) and environmental specimens	Originally validated as for Slomka <i>et al.</i> , (2007b). Stringently assessed further, in context of H5N1 clade 2.3.4.4b HPAIV outbreaks. Slomka <i>et al.</i> (2023) defined a highly stringent criterion adapted to this validation of 514 poultry swabs: For a given swab, if it registered a positive result (Ct<36) by any of the three AIV real-time RT-PCRs (M-gene Nagy <i>et al.</i> [2021], H5[HA2] and H5[HP]), then by consensus it is considered as an H5N1 positive swab. If all three tests are negative	514 poultry swabs, see above entry for Nagy <i>et al.</i> (2021) M-gene real-time RT-PCR: Chickens: eight premises, 350 swabs Turkeys: three premises, 124 swabs Ducks: one premises: 40 swabs	See references Validated by WOAHP Reference Laboratory in UK – report available on request	-The real-time RT-PCR H5(HA2) has been proven to successfully and sensitively detect Eurasian-origin H5 AIVs, through careful targeting of the relatively conserved HA2 region of the H5 gene. Detected H5 AIVs include not only the H5Nx clade 2.3.4.4b HPAIVs, but earlier clades of the “goose/Guangdong” lineage (GsGd), as well as non-GsGd H5 LPAIVs (references cited by Slomka <i>et al.</i> (2023)). -Viable virus is not requested -Adaptable to high throughput -Rapid	-The real-time RT-PCR H5(HA2) is optimised for detection of Eurasian H5 AIVs and may be notably less sensitive for detection of American lineage H5 AIVs (acknowledged by Slomka <i>et al.</i> 2007b), due to divergence in the HA2 portion of the H5 gene -Despite tested on a variety of AIVs, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to	Slomka <i>et al.</i> (2007b) Slomka <i>et al.</i> (2023)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
		(Ct>36), then by consensus it is considered as AIV negative. Se and Sp for the three AIVRT-PCRs were calculated for this assay relative to consensus swab status (positive/negative): DSe: 96.2% DSp: 100%				<p>apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023])</p> <ul style="list-style-type: none"> -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment 	
Real-time RT-PCR H5 (Spackman <i>et al.</i> [2002]) +++	Extracted RNA from clinical specimens (swabs)	Reference test was HI Results for 100% of the samples were in agreement between real-time RT-PCR H5 and VI	Eight swab samples from live-bird markets (test population composed by 202 samples but only eight samples were tested by real-time RT-PCR H5 as the remaining 194 samples were typed as H7 positive samples by real-time RT-PCR H7 and VI)	See Reference	<ul style="list-style-type: none"> -The real-time RT-PCR H5(HA2) has been proven to successfully and sensitively detect American-origin H5 AIVs, through careful targeting of the relatively conserved HA2 region of the H5 gene -Viable virus is not requested -Adaptable to high throughput -Rapid 	<ul style="list-style-type: none"> -The real-time RT-PCR H5(HA2) is optimised for detection of American H5 AIVs due to divergence in the HA2 portion of the H5 gene. -Despite tested on a variety of AIVs, no AIV real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]) -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment 	Spackman <i>et al.</i> (2002)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
Real-time RT-PCR H5(HP) (James <i>et al.</i> [2022]) +++	Extracted RNA from clinical (swabs and tissues) and environmental specimens	Originally validated as from James <i>et al.</i> (2022). Stringently assessed further, in context of H5N1 clade 2.3.4.4b HPAIV outbreaks, relative to consensus (see above entry for Nagy <i>et al.</i> (2021) M-gene real-time RT-PCR and Slomka <i>et al.</i> (2007b) H5 real-time RT-PCR: DSe: 98.3% DSp: 100%	514 poultry swabs, see above entry for Nagy <i>et al.</i> (2021) M-gene real-time RT-PCR: Chickens: eight premises, 350 swabs Turkeys: three premises, 124 swabs Ducks: one premises: 40 swabs	Validated by WOAHA Reference Laboratory in UK – report available on request	-In addition to its description by James <i>et al.</i> (2022), the real-time RT-PCR H5(HP) has been shown to be highly sensitive in the detection of H5N1 HPAIV in swabs obtained from UK poultry outbreaks caused by the H5N1 clade 2.3.4.4b HPAIV during 2021-2022 (Slomka <i>et al.</i> , 2023). -This assay can be used once a sample has been confirmed as positive by the generic influenza A virus screening or H5 HA2 RRT-PCR assays to detect the presence of a multi-basic cleavage site (MBCS) sequence indicative of H5 HPAIV -Viable virus is not requested -Adaptable to high throughput -Rapid	-There remains the possibility that future H5 HPAIV incursions (due to GsGd or non-GsGd lineage viruses) may include H5 gene sequence variants which may not be detected as sensitively as the current H5N1 clade 2.3.4.4b HPAIV strains circulating since autumn 2021. Clearly this concern applies to any AIV real-time RT-PCR, underlining the importance of ongoing validation, to ensure fitness-for-purpose for the sensitive detection of newly emerging viral strains. -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	James <i>et al.</i> (2022) Slomka <i>et al.</i> (2023)
Real-time RT-PCR H7 (Hassan <i>et al.</i> [2022]) +++	Extracted RNA from clinical specimens (swabs and tissues) and egg-grown isolates	Reference test was genome sequencing DSe = 100% DSp=100%	122 clinical samples 428 virus isolates	See Reference	- <i>In silico</i> evaluation of primers/probe match using >300 AIV H7-gene sequences -Specificity assessed on extensive range of avian influenza A viruses belonging to different subtypes and genotypes - Combines two distinct target regions along the H7 HA gene -Viable virus is not requested -Adaptable to high throughput -Rapid	Despite tested on a variety of AIVs, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay-Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	Hassan <i>et al.</i> (2022)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
Real-time RT-PCR H7(HA2) (Slomka <i>et al.</i> [2009]) +++	Extracted RNA from clinical (swabs and tissues) and environmental specimens	Slomka <i>et al.</i> (2009) described and validated the H7(HA2) real-time RT-PCR relative to M-gene real-time RT-PCR of Spackman <i>et al.</i> (2002; see separate entry): DSe: 95.4% DSp: 97.9%	AIV laboratory isolates included: H7 AIVs: n=65; non-H7 AIVs: n=57. Clinical specimens from H7N7 (LP and HPAIV inoculations): n=117 swabs; plus 180 AIV negative swabs	See references	-The real-time RT-PCR H7(HA2) has been proven to successfully and sensitively detect Eurasian-origin H7 AIVs, through careful targeting of the relatively conserved HA2 region of the H7 gene. The real-time RT-PCR H7(HA2) demonstrated its value during H7 chicken outbreaks, both LP and HPAIV (Seekings <i>et al.</i> [2018], Reid <i>et al.</i> [2019]) -Viable virus is not requested -Adaptable to high throughput -Rapid	-The real-time RT-PCR H7(HA2) is optimised for detection of Eurasian H7 AIVs is less sensitive for detection of American lineage H7 AIVs (noted by Slomka <i>et al.</i> [2009]), due to divergence in the HA2 portion of the H7 gene. -Despite tested on a variety of AIVs, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay; -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus; -Risk of cross contamination; -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA; -Needs specialised equipment	Slomka <i>et al.</i> (2009) Seekings <i>et al.</i> (2018) Reid <i>et al.</i> (2019)
Real-time RT-PCR H7 (Spackman <i>et al.</i> [2002]) +++		Reference test was HI Results for 98% of the samples were in agreement between real-time RT-PCR H7 and VI	202 swab samples from live-bird markets	See Reference	-The real-time RT-PCR H7(HA2) has been proven to successfully and sensitively detect American-origin H7 AIVs, through careful targeting of the relatively conserved HA2 region of the H7 gene -Viable virus is not requested -Adaptable to high throughput -Rapid	-The real-time RT-PCR H7(HA2) is optimised for detection of American H7 AIVs due to divergence in the HA2 portion of the H7 gene. -Despite tested on a variety of AIV subtypes, no H7 real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed H7 testing strategy that may feature more than one assay.	Spackman <i>et al.</i> (2002)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
						<ul style="list-style-type: none"> -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus; -Risk of cross contamination; -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA; -Needs specialised equipment 	
H5 conventional RT-PCR (Slomka <i>et al.</i> [2007a]) +++		Reference test was genome sequencing DSe = 99.36% DSp=100%	426 avian and 43 mammalian samples of known infectious status (472 know positive samples and 63 known negative samples)	Validated by WOAHP Reference Laboratory in Italy – report available on request^	<ul style="list-style-type: none"> -The RT-PCR H5(HA2) has been proven to successfully and sensitively detect Eurasian-origin H5 AIVs. -Can be used once a sample has been confirmed as positive by the generic influenza A virus screening or H5 HA2 RRT-PCR assays to detect the presence of a multi-basic cleavage site (MBCS) sequence indicative of H5 HPAIV by Sanger sequencing -Viable virus is not requested 	<p>The RT-PCR H5(HA2) is optimised for detection of Eurasian H5 AIVs.</p> <p>Despite tested on a variety of AIVs, no H5RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV testing strategy that may feature more than one assay</p> <ul style="list-style-type: none"> -Does not give information on whether live or inactivated virus; -Risk of cross contamination; -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA; -Needs specialised equipment 	Slomka <i>et al.</i> (2007a)
H7 conventional RT-PCR (Slomka <i>et al.</i> [2007a]) +++		Reference test was genome sequencing DSe = 100% DSp=100%	89 avian samples of known infectious status (59 know positive samples and 30 known negative samples)	Validated by WOAHP Reference Laboratory in Italy – report available on request^	<ul style="list-style-type: none"> The RT-PCR H7(HA2) has been proven to successfully and sensitively detect Eurasian-origin H7 AIVs. -Can be used once a sample has been confirmed as positive by the generic influenza A virus screening or H7 HA2 RRT-PCR assays to detect the presence of a multi-basic cleavage site (MBCS) sequence indicative of H7 HPAIV by Sanger sequencing -Viable virus is not requested 	<p>The RT-PCR H7(HA2) is optimised for detection of Eurasian H7 AIVs.</p> <p>Despite tested on a variety of AIVs, no H7RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV testing strategy that may feature more than one assay</p>	Slomka <i>et al.</i> (2007a)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
Virus isolation +++	Tracheal swabs, cloacal swabs, and organ samples Target: Infectious virus	Reference tests were real-time RT-PCR for H5 subtype and sequencing DSe=76% Negative results by VI for H5 could be explained by considering the condition of the clinical samples at the time of their arrival (cold chain was not constantly maintained during shipping, compromising the viability of the viruses) DSp=100%	725 avian samples	See reference	-Demonstrates the presence of infectious (replication-competent) virus (essential to assess the efficacy of inactivation processes and for AIV phenotypic characterisation) -High specificity -Detects all AIV subtypes	-Time consuming -Relies on proper care to protect the virus in the samples from environmental damage, and use of an adequate transport system to maintain infectivity and replication competence. -Difficult to manage for high throughput -Require high-level containment	Monne <i>et al.</i> (2008)
	Swabs Target: Infectious virus	Reference test was real-time RT-PCR for type A influenza Overall, the results of the two assays agreed on 1,385 samples (89%) and disagreed on 165 samples (11%)	1550 clinical swab samples from live-bird markets	See reference	As in the above line	As in the above line	Spackman <i>et al.</i> (2002)
Antigen-capture immunoassays +	Tracheal and cloacal swabs Feather pulp Target: Influenza virus internal proteins	DSe and DSp differ based on the antigen-capture immunoassay used. The accuracy data presented here are the ones from Slomka <i>et al.</i> (2012) Reference test was real-time RT-PCR DSe = between 31.6% and 36.8% for tracheal and cloacal swabs and between 33.3% and 84.0% for feathers depending on which device was assessed	282 avian samples	See reference	-Fast (about 15 minutes after addition of the sample) -Specific -May be used "pen-side"	-Poor sensitivity	Slomka <i>et al.</i> (2012)
Detection of immune response							
Haemagglutination inhibition test ++	Serum samples Antibodies against the hemagglutinin (HA) antigen	A Bayesian version of latent class analysis was used to compare the results of multiple serological tests from different study settings reported in the literature DSe = 98.8% DSp= 99.5%	114 serum sample	See reference	-Identify AIV subtype-specific antibodies such as H5 and H7 -Relatively inexpensive on a per sample basis -No special equipment is needed, -Results can be obtained in about 2 hours -Not species-specific	-Provide information on historical exposure to IAV -No genetic data or phenotypic data -Cross-reactions can occur between different lineages within one subtype, or even among different subtypes	Comin <i>et al.</i> (2013)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
						<ul style="list-style-type: none"> -Serum and antigen must be antigenically matched -The HI assay as an antibody screening assay is not practical unless one is targeting specific subtypes or lineages -The accuracy can be affected by steric inhibition from the NA 	
ELISA +	Serum samples Antibodies against the Influenza virus internal proteins	DSe and DSp differ based on the ELISA used and the antibodies tested The values reported here are estimated applying AGID and blocking ELISA on sera from AI virus experimental-infection trials (Brown <i>et al.</i> [2009]) DSe = 82% DSp= 100%	281 serum sample (178 positive and 103 negative)	See reference	<ul style="list-style-type: none"> -Rapid results -Ability to screen large numbers of samples in a semiautomated manner 	<ul style="list-style-type: none"> -Provide information on historical exposure to IAV -Indirect ELISA is species-specific -Requires some specialised equipment -Sensitivity and specificity may vary between ELISA assays used 	Brown <i>et al.</i> (2009)
AGID +	Serum samples Antibodies against the Influenza virus internal proteins	Estimated applying AGID and blocking ELISA on sera from AI virus experimental-infection trials. DSe = 67,4% DSp= 100%	281 serum sample (178 positive and 103 negative)	See reference	<ul style="list-style-type: none"> -Simple and economical test -Does not require specialised laboratory equipment 	<ul style="list-style-type: none"> -Provide information on historical exposure to IAV -Electrolyte concentration, buffer, pH, and incubation temperatures can affect precipitate formation -Sera from waterfowl should not be tested by this method (lack of sensitivity as these birds do not produce precipitating antibodies) -Time consuming 	Brown <i>et al.</i> (2009)

1625

1626

Appendix 6: Avian Influenza*

Intended purpose of test: prevalence of infection – surveillance (including vaccinated flocks)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
Detection and identification of the agent							
Real-time RT-PCR M gene (Nagy <i>et al.</i> [2021]) +++	Extracted RNA from clinical (swabs and tissues) and environmental specimens	Originally validated as for Nagy <i>et al.</i> (2021). Stringently assessed further, in context of H5N1 clade 2.3.4.4b HPAIV outbreaks. Slomka <i>et al.</i> (2023) defined a highly stringent criterion adapted to this validation of 514 poultry swabs: For a given swab, if it registered a positive result (Ct<36) by any of the three AIV real-time RT-PCRs (M-gene Nagy <i>et al.</i> [2021], H5[HA2] [Slomka <i>et al.</i> (2007b)] and H5[HP] [James <i>et al.</i> (2022)]), then by consensus it is considered as an H5Nx positive swab. If all three tests are negative (Ct>36), then by consensus it is considered as AIV negative. Se and Sp for the three AIVRT-PCRs were calculated for this assay relative to consensus swab status (positive/negative): DSe: 90.6% DSp: 100% (affirmed 100% Sp originally demonstrated by Nagy <i>et al.</i> [2021])	Additional validation based on H5N1 (clade 2.3.4.4b) HPAIV testing at 12 UK poultry outbreak premises (514 swabs, equal numbers of oro-pharyngeal and cloacal) during autumn 2021, which featured in Slomka <i>et al.</i> (2023) Chickens: eight premises, 350 swabs Turkeys: three premises, 124 swabs Ducks: one premise: 40 swabs	See references Validated by WOAHA Reference Laboratory in UK – report available on request	-Use of 99,353 M-gene sequences to ensure that as far as possible, the primer and probe designs match a vast range of animal and human influenza A viruses -Assessed in several independent European National Reference Laboratories, featuring an extensive range of human and animal influenza A viruses (laboratory isolates and 1455 clinical specimens) -Sensitively detect many contemporary swine, equine and human influenza A virus strains -Can be used to detect infection in vaccinated birds (DIVA approach) for early detection or monitoring freedom from infection in vaccinated or unvaccinated poultry flocks. -Viable virus is not requested -Adaptable to high throughput -Rapid	-Despite the thorough bioinformatics input to the primer/probe design (see left), no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered, as accepted by Nagy <i>et al.</i> (2021). Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]) -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	Nagy <i>et al.</i> (2021) Slomka <i>et al.</i> (2023)
Real-time RT-PCR M gene (Heine <i>et al.</i> [2015]; Laconi <i>et al.</i> [2020], protocol 3) +++	Extracted RNA from clinical specimens (swabs and tissues)	Reference test was genetic sequencing DSe = 100% DSp = 100%	92 avian samples and 117 mammalian samples of known infectious status (121 true positive and 88 true negative samples)	See references Validated by WOAHA Reference Laboratory in Italy – report available on request^.	-Is silico evaluation of primers/probe match using 4088 AIV M-gene sequences (Laconi <i>et al.</i> [2020]) -Assessed on extensive range of avian influenza A viruses belonging to different subtypes and genotypes -Tested on multiple sample matrixes from mammalian and avian species	-Despite tested on a variety of AIV subtypes, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more	Heine <i>et al.</i> (2015) Laconi <i>et al.</i> (2020)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
					<ul style="list-style-type: none"> -Assessed in several independent European National Reference Laboratories -Can be used to detect infection in vaccinated birds (DIVA approach) for early detection or monitoring freedom from infection in vaccinated or unvaccinated poultry flocks. -Viable virus is not requested -Adaptable to high throughput -Rapid 	<p>than one assay (Slomka <i>et al.</i> [2023])</p> <ul style="list-style-type: none"> -<i>In silico</i> evaluation demonstrated that the test may have decreased sensitivity in the detection of a cluster of H5N1 viruses related to the A/chicken/East_Java/Av1955/2022 (EPI_ISL_13690275), belonging to the 2.3.2.1c clade, due to primers mismatches. -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment 	
Real-time RT-PCR M gene (Hassan <i>et al.</i> [2022]) +++	Extracted RNA from clinical specimens (swabs and tissues) and egg-grown isolates	Reference test was genome sequencing DSe = 100% DSp=100%	122 clinical samples 428 virus isolates	See reference	<ul style="list-style-type: none"> - <i>In silico</i> evaluation of primers/probe match using >3000 AIV M-gene sequences -Assessed on extensive range of avian and porcine influenza A viruses belonging to different subtypes and genotypes - Assessed also on a minor selection of human IAV isolates (<20) -Can be used to detect infection in vaccinated birds (DIVA approach) for early detection or monitoring freedom from infection in vaccinated or unvaccinated poultry flocks. -Viable virus is not requested -Adaptable to high throughput -Rapid 	<ul style="list-style-type: none"> -Despite tested on a variety of AIV subtypes, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]) -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA 	Hassan <i>et al.</i> (2022)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
Real-time RT-PCR H5 (Hassan <i>et al.</i> [2022]) +++	Extracted RNA from clinical specimens (swabs and tissues) and egg-grown isolates	Reference test was genome sequencing DSe = 100% DSp=100%	122 clinical samples 428 virus isolates	See reference	<ul style="list-style-type: none"> - <i>In silico</i> evaluation of primers/probe match using >700 AIV H5-gene sequences - Specificity assessed on extensive range of avian, porcine and human influenza A viruses belonging to different subtypes and genotypes - Assessed also on a minor selection of human IAV isolates (<20) - Combines two distinct target regions along the H5 HA gene - Viable virus is not requested - Adaptable to high throughput - Rapid 	<ul style="list-style-type: none"> - Needs specialised equipment - Despite tested on a variety of AIVs, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]) - Failed to detect an individual Eurasian wild bird LP H5 isolate (EU-RL ring trial) - The interpretation of subtype-specific RT-qPCRs in flocks vaccinated with live vectored H5 vaccines could be affected (i.e. Organs where active replication of the vaccine is taking place would yield positive results to such assay even in the absence of field virus) - Does not give information on the pathotype of the virus (HPAI or LPAI virus) - Does not give information on whether live or inactivated virus - Risk of cross contamination - Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA - Needs specialised equipment 	Hassan <i>et al.</i> (2022)
Real-time RT-PCR H5 (Slomka <i>et al.</i> [2007b]) +++	Extracted RNA from clinical (swabs and tissues) and environmental specimens	Originally validated as for Slomka <i>et al.</i> (2007b). Stringently assessed further, in context of H5N1 clade 2.3.4.4b HPAIV outbreaks. Slomka <i>et al.</i> (2023) defined a highly stringent criterion adapted to this validation of 514 poultry swabs: For a given swab, if it registered a positive	514 poultry swabs, see above entry for Nagy <i>et al.</i> (2021) M-gene real-time RT-PCR: Chickens: eight premises, 350 swabs	See references Validated by WOAHP Reference Laboratory in UK – report available on request	- The real-time RT-PCR H5(HA2) has been proven to successfully and sensitively detect Eurasian-origin H5 AIVs, through careful targeting of the relatively conserved HA2 region of the H5 gene. Detected H5 AIVs include not only the H5Nx clade 2.3.4.4b HPAIVs, but earlier clades of the	- The real-time RT-PCR H5(HA2) is optimised for detection of Eurasian H5 AIVs and may be notably less sensitive for detection of American lineage H5 AIVs (acknowledged by Slomka <i>et al.</i> [2007b]), due to divergence in the HA2 portion of the H5 gene	Slomka <i>et al.</i> (2007b). Slomka <i>et al.</i> (2023)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
		result (Ct<36) by any of the three AIV real-time RT-PCRs (M-gene Nagy <i>et al.</i> [2021], H5[HA2] H5[HP]), then by consensus it is considered as an H5N1 positive swab. If all three tests are negative (Ct>36), then by consensus it is considered as AIV negative. Se and Sp for the three AIVRT-PCRs were calculated for this assay relative to consensus swab status (positive/negative): DSe: 96.2% DSp: 100%	Turkeys: three premises, 124 swabs Ducks: one premises: 40 swabs		“goose/Guangdong” lineage (GsGd), as well as non-GsGd H5 LPAIVs (references cited by Slomka <i>et al.</i> , 2023). -Viable virus is not requested -Adaptable to high throughput -Rapid	-Despite tested on a variety of AIVs, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay (Slomka <i>et al.</i> [2023]) -The interpretation of subtype-specific RT-qPCRs in flocks vaccinated with live vectored H5 vaccines could be affected (i.e. Organs where active replication of the vaccine is taking place would yield positive results to such assay even in the absence of field virus) -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	
Real-time RT-PCR H5 (Spackman <i>et al.</i> [2002]) +++	Extracted RNA from clinical specimens (swabs)	Reference test was HI Results for 100% of the samples were in agreement between real-time RT-PCR H5 and VI	Eight swab samples from live-bird markets (test population composed by 202 samples but only eight samples were tested by real-time RT-PCR H5 as the remaining 194 samples were typed as H7 positive	See Reference	-The real-time RT-PCR H5(HA2) has been proven to successfully and sensitively detect American-origin H5 AIVs, through careful targeting of the relatively conserved HA2 region of the H5 gene -Viable virus is not requested -Adaptable to high throughput -Rapid	-The real-time RT-PCR H5(HA2) is optimised for detection of American H5 AIVs due to divergence in the HA2 portion of the H5 gene -Despite tested on a variety of AIVs, no AIV real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV testing	Spackman <i>et al.</i> (2002)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
			samples by real-time RT-PCR H7 and VI)			<p>strategy that may feature more than one assay (Slomka <i>et al.</i> [2023])</p> <ul style="list-style-type: none"> -The interpretation of subtype-specific RT-qPCRs in flocks vaccinated with live vectored H5 vaccines could be affected (i.e. Organs where active replication of the vaccine is taking place would yield positive results to such assay even in the absence of field virus) -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment 	
Real-time RT-PCR H5(HP) (James <i>et al.</i> [2022]) +++	Extracted RNA from clinical (swabs and tissues) and environmental specimens	Originally validated as for James <i>et al.</i> (2022). Stringently assessed further, in context of H5N1 clade 2.3.4.4b HPAIV outbreaks, relative to consensus (see above entry for Nagy <i>et al.</i> (2021) M-gene real-time RT-PCR and Slomka <i>et al.</i> (2007b) H5 real-time RT-PCR: DSe: 98.3% DSp: 100%	514 poultry swabs, see above entry for Nagy <i>et al.</i> (2021) M-gene real-time RT-PCR: Chickens: eight premises, 350 swabs Turkeys: three premises, 124 swabs Ducks: one premises: 40 swabs	Validated by WOAHP Reference Laboratory in UK – report available on request	<ul style="list-style-type: none"> -In addition to its description by James <i>et al.</i> (2022), the real-time RT-PCR H5(HP) has been shown to be highly sensitive in the detection of H5N1 HPAIV in swabs obtained from UK poultry outbreaks caused by the H5N1 clade 2.3.4.4b HPAIV during 2021-2022 (Slomka <i>et al.</i> [2023]) -Can be used once a sample has been confirmed as positive by the generic influenza A virus screening or H5 HA2 RRT-PCR assays to detect the presence of a multi-basic cleavage site (MBCS) sequence indicative of H5 HPAIV -Viable virus is not requested -Adaptable to high throughput -Rapid 	<ul style="list-style-type: none"> -There remains the possibility that future H5 HPAIV incursions (due to GsGd or non-GsGd lineage viruses) may include H5 gene sequence variants which may not be detected as sensitively as the current H5N1 clade 2.3.4.4b HPAIV strains circulating since autumn 2021. Clearly this concern applies to any AIV real-time RT-PCR, underlining the importance of ongoing validation, to ensure fitness-for-purpose for the sensitive detection of newly emerging viral strains. -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction 	James <i>et al.</i> (2022)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
						inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	
Real-time RT-PCR H7 (Hassan <i>et al.</i> [2022]) +++	Extracted RNA from clinical specimens (swabs and tissues) and egg-grown isolates	Reference test was genome sequencing DSe = 100% DSp=100%	122 clinical samples 428 virus isolates	See Reference	- In silico evaluation of primers/probe match using >300 AIV H7-gene sequences -Specificity assessed on extensive range of avian influenza A viruses belonging to different subtypes and genotypes - Combines two distinct target regions along the H7 HA gene -Viable virus is not requested -Adaptable to high throughput -Rapid	Despite tested on a variety of AIVs, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay. -The interpretation of subtype-specific RT-qPCRs in flocks vaccinated with live vectored H7 vaccines could be affected (i.e. Organs where active replication of the vaccine is taking place would yield positive results to such assay even in the absence of field virus) -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on whether live or inactivated virus -Risk of cross contamination -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment	Hassan <i>et al.</i> (2022)
Real-time RT-PCR H7(HA2) (Slomka <i>et al.</i> [2009]) +++	Extracted RNA from clinical (swabs and tissues) and environmental specimens	Slomka <i>et al.</i> (2009) described and validated the H7(HA2) real-time RT-PCR relative to M-gene real-time RT-PCR of Spackman <i>et al.</i> (2002; see separate entry): DSe: 95.4% DSp: 97.9%	AIV laboratory isolates included: H7 AIVs: n=65; non-H7 AIVs: n=57. Clinical specimens from H7N7 (LP and HPAIV inoculations): n=117 swabs; plus 180 AIV negative swabs.	See references	-The real-time RT-PCR H7(HA2) has been proven to successfully and sensitively detect Eurasian-origin H7 AIVs, through careful targeting of the relatively conserved HA2 region of the H7 gene. The real-time RT-PCR H7(HA2) demonstrated its value during H7 chicken outbreaks, both LP and HPAIV (Seekings <i>et al.</i> , 2018, Reid <i>et al.</i> , 2019).	-The real-time RT-PCR H7(HA2) is optimised for detection of Eurasian H7 AIVs is less sensitive for detection of American lineage H7 AIVs (noted by Slomka <i>et al.</i> [2009]), due to divergence in the HA2 portion of the H7 gene -Despite tested on a variety of AIVs, no influenza A virus real-time RT-PCR can guarantee sensitive detection of all strains	Slomka <i>et al.</i> (2009). Seekings <i>et al.</i> (2018) Reid <i>et al.</i> (2019)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
					<ul style="list-style-type: none"> -Viable virus is not requested -Adaptable to high throughput -Rapid 	<p>that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed AIV real-time RT-PCR testing strategy that may feature more than one assay;</p> <ul style="list-style-type: none"> -The interpretation of subtype-specific RT-qPCRs in flocks vaccinated with live vectored H7 vaccines could be affected (i.e. Organs where active replication of the vaccine is taking place would yield positive results to such assay even in the absence of field virus) -Does not give information on the pathotype of the virus (HPAI or LPAI virus) -Does not give information on the pathotype of the virus (HPAI or LPAI virus); -Risk of cross contamination; -Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA -Needs specialised equipment 	
real-time RT-PCR H7 (Spackman <i>et al.</i> [2002]) +++		Reference test was HI Results for 98% of the samples were in agreement between real-time RT-PCR H7 and VI	202 swab samples from live-bird markets	See Reference	<ul style="list-style-type: none"> -The real-time RT-PCR H5(HA2) has been proven to successfully and sensitively detect American-origin H7 AIVs, through careful targeting of the relatively conserved HA2 region of the H7 gene. -Viable virus is not requested -Adaptable to high throughput -Rapid 	<ul style="list-style-type: none"> -The real-time RT-PCR H7(HA2) is optimised for detection of American H7 AIVs due to divergence in the HA2 portion of the H7 gene. -Despite tested on a variety of AIV subtypes, no H7 real-time RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak/epizootic threat context, it is prudent to apply an appropriately informed H7 testing strategy that may feature more than one assay. -The interpretation of subtype-specific RT-qPCRs in flocks 	Spackman <i>et al.</i> (2002)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
						<p>vaccinated with live vectored H7 vaccines could be affected (i.e. Organs where active replication of the vaccine is taking place would yield positive results to such assay even in the absence of field virus)</p> <p>-Does not give information on the pathotype of the virus (HPAI or LPAI virus)</p> <p>-Does not give information on whether live or inactivated virus;</p> <p>-Risk of cross contamination;</p> <p>-Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA;</p> <p>-Needs specialised equipment</p>	
H5 conventional RT-PCR (Slomka <i>et al.</i> [2007a]) +++		Reference test was genome sequencing DSe = 99.36% DSp=100%	426 avian and 43 mammalian samples of known infectious status (472 know positive samples and 63 known negative samples)	Validated by WOAHA Reference Laboratory in Italy – report available on request [^]	<p>-The RT-PCR H5(HA2) has been proven to successfully and sensitively detect Eurasian-origin H5 AIVs.</p> <p>-Can be used once a sample has been confirmed as positive by the generic influenza A virus screening or H5 HA2 RRT-PCR assays to detect the presence of a multi-basic cleavage site (MBCS) sequence indicative of H5 HPAIV by Sanger sequencing</p> <p>-Viable virus is not requested</p>	<p>The RT-PCR H5(HA2) is optimised for detection of Eurasian H5 AIVs.</p> <p>Despite tested on a variety of AIVs, no H5RT-PCR can guarantee sensitive detection of all strains that may be encountered. Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV testing strategy that may feature more than one assay.</p> <p>-Does not give information on whether live or inactivated virus;</p> <p>-Risk of cross contamination;</p> <p>-Risk of false negative results in case of PCR inhibitors, extraction inefficiency, genetic diversity of viruses, instability of RNA;</p> <p>-Needs specialised equipment</p>	Slomka <i>et al.</i> (2007a)
H7 conventional RT-PCR (Slomka <i>et al.</i> [2007a]) +++		Reference test was genome sequencing DSe = 100% DSp=100%	89 avian samples of known infectious status (59 know positive samples and 30 known negative samples)	Validated by WOAHA Reference Laboratory in Italy – report available on request [^] .	<p>The RT-PCR H7(HA2) has been proven to successfully and sensitively detect Eurasian-origin H7 AIVs.</p> <p>-Can be used once a sample has been confirmed as positive</p>	<p>The RT-PCR H7(HA2) is optimised for detection of Eurasian H7 AIVs.</p> <p>Despite tested on a variety of AIVs, no H7RT-PCR can guarantee sensitive detection of all strains that may be encountered.</p>	Slomka <i>et al.</i> (2007a)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
					by the generic influenza A virus screening or H7 HA2 RRT-PCR assays to detect the presence of a multi-basic cleavage site (MBCS) sequence indicative of H7 HPAIV by Sanger sequencing -Viable virus is not requested	Therefore, in an outbreak / epizootic threat context, it is prudent to apply an appropriately informed AIV testing strategy that may feature more than one assay	
Virus isolation +	Tracheal swabs, cloacal swabs, and organ samples Target: Infectious virus	Reference tests were real-time RT-PCR for H5 subtype and sequencing DSe=76% Negative results by VI for H5 could be explained by considering the condition of the clinical samples at the time of their arrival (cold chain was not constantly maintained during shipping, compromising the viability of the viruses) DSp=100%	725 avian samples	See reference	-Demonstrates the presence of infectious (replication-competent) virus (essential to assess the efficacy of inactivation processes and for AIV phenotypic characterisation) -High specificity -Detects all AIV subtypes	-Time consuming -Relies on proper care to protect the virus in the samples from environmental damage, and use of an adequate transport system to maintain infectivity and replication competence. -Difficult to manage for high throughput -Require high-level containment	Monne <i>et al.</i> (2008)
	Swabs Target: Infectious virus	Reference test was real-time RT-PCR for type A influenza Overall, the results of the two assays agreed on 1,385 samples (89%) and disagreed on 165 samples (11%)	1550 clinical swab samples from live-bird markets	See reference	As in the above line	As in the above line	Spackman <i>et al.</i> (2002)
Antigen-capture immunoassays +	Tracheal and cloacal swabs Feather pulp Target: Influenza virus internal proteins	DSe and DSp differ based on the antigen-capture immunoassay used. The accuracy data presented here are the ones from assays described in Slomka <i>et al.</i> (2012). Reference test was real-time RT-PCR DSe = between 31.6% and 36.8% for tracheal and cloacal swabs and between 33.3% and 84.0% for feathers depending on which device was assessed	282 avian samples	See reference	-Fast (about 15 minutes after addition of the sample) -Specific -May be used "pen-side"	-Poor sensitivity	Slomka <i>et al.</i> (2012)
Detection of immune response							

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
Haemagglutination inhibition test +++	Serum samples Antibodies against the hemagglutinin (HA) antigen	A Bayesian version of latent class analysis was used to compare the results of multiple serological tests from different study settings reported in the literature DSe = 98.8% DSp= 99.5%	114 serum sample	See reference	-Identify AIV subtype-specific antibodies such as H5 and H7 -Relatively inexpensive on a per sample basis -No special equipment is needed, -Results can be obtained in about 2 hours -Not species-specific	-Serum and antigen must be antigenically matched -The HI assay as an antibody screening assay is not practical unless one is targeting specific subtypes or lineages -The accuracy can be affected by steric inhibition from the NA	Comin <i>et al.</i> (2013)
ELISA +++	Serum samples Antibodies against the Influenza virus internal proteins	DSe and DSp differ based on the ELISA used The values reported here are estimated applying AGID and blocking ELISA on sera from AI virus experimental-infection trials (Brown <i>et al.</i> [2009]) DSe = 82% DSp= 100%	281 serum sample (178 positive and 103 negative)	See reference	-Rapid results, -Ability to screen large numbers of samples in a semiautomated manner -NP-ELISA assays can be used to demonstrate freedom from infection in vaccinated birds (DIVA approach) if compatible vaccines are applied (i.e. vaccines that do not contain the AI-NP in the formulation)	-Indirect ELISA is species-specific -Requires some specialised equipment -Sensitivity and specificity may vary between ELISA assays used	Brown <i>et al.</i> (2009)
AGID ++	Serum samples Antibodies against the Influenza virus internal proteins	Estimated applying AGID and blocking ELISA on sera from AI virus experimental-infection trials. DSe = 67,4% DSp= 100%	281 serum sample (178 positive and 103 negative)	See reference	-Simple and economical test -Does not require specialised laboratory equipment -Can be used for surveillance in flocks vaccinated with DIVA vaccines with NP as a negative marker (i.e. vaccines that do not contain the AI-NP in the formulation)	-Electrolyte concentration, buffer, pH, and incubation temperatures can affect precipitate formation -Sera from waterfowl should not be tested by this method (lack of sensitivity as these birds do not produce precipitating antibodies) -Qualitative only -Time consuming	Brown <i>et al.</i> (2009)

Appendix 7: Avian Influenza*
Immune status in individual animals or populations post-vaccination

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
Detection of immune response							
Haemagglutination inhibition test +++	Serum samples Antibodies against the hemagglutinin (HA) antigen	A Bayesian version of latent class analysis was used to compare the results of multiple serological tests from different study settings reported in the literature DSe = 98.8% DSp= 99.5%	114 serum sample	See reference	-Allow to assess the immune status in individual animals or populations post-vaccination (vaccine coverage) using antigens antigenically close to the vaccine; -Identify AIV subtype-specific antibodies such as H5 and H7 -Relatively inexpensive on a per sample basis -No special equipment is needed -Results can be obtained in about 2 hours -Not species-specific	-Serum and antigen must be antigenically matched -The HI assay as an antibody screening assay is not practical unless one is targeting specific subtypes or lineages -The accuracy can be affected by steric inhibition from the NA -To assess vaccine coverage, it should be considered that it can perform poorly in flocks that have received only replicating-vectored vaccines as these predominantly induce T-cell over humoral immune responses	Comin <i>et al.</i> (2013)
AGID ++	Serum samples Antibodies against the Influenza virus internal proteins	Estimated applying AGID and blocking ELISA on sera from AI virus experimental-infection trials DSe = 67,4% DSp= 100%	281 serum sample (178 positive and 103 negative)	See reference	-Simple and economical test -Does not require specialised laboratory equipment -Can be used to detect past infection in vaccinated birds (DIVA approach) if compatible vaccines are applied (i.e. vaccines that do not contain the AI-NP in the formulation)	-Electrolyte concentration, buffer, pH, and incubation temperatures can affect precipitate formation -Sera from waterfowl should not be tested by this method (lack of sensitivity as these birds do not produce precipitating antibodies) -Qualitative only -Targets virus proteins not involved in mounting protective immunity (not suitable to assess vaccine coverage) -Time consuming	Brown <i>et al.</i> (2009)
ELISA ++	Serum samples Antibodies against the Influenza virus internal proteins	DSe and DSp differ based on the ELISA used and the antibodies tested. The values reported here are estimated applying AGID and blocking ELISA on sera from AI virus experimental-infection trials (Brown <i>et al.</i> [2009]) DSe = 82% DSp= 100%	281 serum sample (178 positive and 103 negative)	See reference	-Rapid results -Ability to screen large numbers of samples in a semiautomated manner -NP-ELISA assays can be used to detect past infection in vaccinated birds (DIVA approach) if compatible vaccines are applied (i.e. vaccines that do not contain the AI-NP in the formulation)	-Indirect ELISA is species-specific -Requires some specialised equipment -Sensitivity and specificity may vary between ELISA assays used. -NP-ELISA targets virus internal proteins not involved in mounting protective immunity (not suitable to assess vaccine coverage)	Brown <i>et al.</i> (2009)

Test with score and species	Sample type and target analytes	Accuracy	Test population	Validation report	Advantages: expert opinion	Disadvantages: expert opinion	References
					- NP-ELISA assays can be used to monitor the vaccination uptake if inactivated whole virus vaccines are used and endemic LPAIV infections are excluded from flocks		

1629 ^contact: eurl.ai.nd.secretariat@izsvenezie.it;

1630 °contact: AIWRL@APHA.gov.uk

1631 *IMPORTANT NOTES:

1632 It is important to clarify that the accuracy data reported here refer to the results of specific investigations carried out according to the criteria described in the scientific literature
 1633 or in the validation dossiers as shown in the table. The results of DSe and DSp must therefore be interpreted with caution considering the characteristics of the virus used and
 1634 the conditions under which the test was applied (e.g. sample type, reference test used, purpose of the investigation, commercial kit used, etc.). The choice of one test rather
 1635 than another must not be attributed solely to the accuracy of the specific test. The most appropriate diagnostic approach to be used will be dependent on the primary objective
 1636 of the investigation and the virus that is being targeted. The table provides an explanation of the utility of different assays for different purposes and can be used by laboratory
 1637 scientists to guide them in deciding how to approach a specific diagnostic need.

1638 Not all the molecular methods described in Chapter 3.3.4 are included in this table and only some of the methods used for influenza A screening and H5 and H7 subtyping
 1639 are reported as examples. Importantly, AIV exhibits rapid evolutionary dynamics and therefore, there is the possibility that future AIV incursions may be caused by viral strains
 1640 which may not be detected as sensitively as expected by the molecular tests described here. This underlines the importance of ongoing validation, to ensure fitness-for-
 1641 purpose for the sensitive detection of newly emerging viral strains.

CHAPTER 3.4.9.

ENZOOTIC BOVINE LEUKOSIS

SUMMARY

Description and importance of the disease: *Enzootic bovine leukosis (EBL) is a disease of cattle caused by the bovine leukaemia virus (BLV), a member of the family Retroviridae. Cattle may be infected at any age, including the embryonic stage. Infection is lifelong and results in a persistent antibody response. Most infections are subclinical, but a proportion of cattle (~30%) over 3 years old develop persistent lymphocytosis, and a smaller proportion develop lymphosarcomas (tumours) in various internal organs. Natural infection has also been recorded in water buffaloes and capybaras. Clinical signs, if present, depend on the organs affected. Cattle with lymphosarcomas may die suddenly, or weeks or months after the onset of clinical signs dependent on the location and number of tumours and the tumour's growth characteristics.*

Detection and identification of the agent: *Virus can be detected in the culture supernatant following in-vitro culture of peripheral blood mononuclear cells (PBMC) from infected animals, by BLV antigen detection, by polymerase chain reaction (PCR) or by electron microscopy. Proviral DNA can also be detected in PBMC or tumours of infected animals by PCR.*

Serological tests: *The antibody detection methods widely used are the agar gel immunodiffusion (AGID) assay using serum and the enzyme-linked immunosorbent assay (ELISA) using serum or milk. These tests have formed the basis for successful eradication policies in many countries. ~~Other tests, such as radio-immunoassay, can also be used.~~ There are a number of AGID and ELISA kits ~~are commercially available~~ AGID and ELISA kits.*

Requirements for vaccines: *No vaccine against BLV is available.*

A. INTRODUCTION

~~There may be several causes of lymphosarcomas in cattle, but the only definitely known cause is the retrovirus, bovine leukaemia virus (BLV), which causes enzootic bovine leukosis (EBL).~~

1. Description and impact of the disease

~~Enzootic bovine leukosis (EBL) is a disease of cattle caused by the bovine leukaemia virus (BLV), a member of the family Retroviridae. The term sporadic bovine leukosis (SBL) is usually reserved for young animals (calves) as well as cutaneous and thymic types of lymphoma, which is defined by the age of the animal affected and the distribution of the tumours. The cause of SBL is not known. There may also be lymphosarcomatous conditions that do not fall into either the SBL or EBL categories, i.e. adult multicentric lymphoma with sporadic occurrence of unknown aetiology. Only lymphomas caused by BLV infection should be termed leukosis or enzootic bovine leukosis (Gillot *et al.*, 2007).~~

~~Although animals can become infected with BLV at any age, tumours (lymphosarcomas) are seen typically in animals over 3 years of age. Infections are usually subclinical; only 30–70% of infected cattle develop persistent~~

41 lymphocytosis, and 0.1–10% of the infected animals develop tumours (lymphosarcomas). Although animals can
42 become infected at any age, tumours are seen typically in animals over 4 years of age. Clinical signs will depend
43 on the site of the tumours and may include digestive disturbances, inappetence, weight loss, weakness or general
44 debility and sometimes neurological manifestations. Superficial lymph nodes may be obviously enlarged and may
45 be palpable under the skin and by rectal examination. At necropsy, lymph nodes and a wide range of tissues are
46 found to be infiltrated by neoplastic cells. Organs most frequently involved are the abomasum, right auricle of the
47 heart, spleen, intestine, liver, kidney, omasum, lung, and uterus. The susceptibility of cattle to persistent
48 lymphocytosis, and perhaps also to tumour development, is genetically determined.

49 There is ~~growing~~ evidence of the role of the virus in immunological dysfunctions and in increased culling rates. Two
50 large-scale investigations estimated the mean decline in milk production per cow among test-positive BLV herds
51 compared with test-negative herds as very similar at 2.5% and 2.7%, respectively (Emanuelsson *et al.*, 1992; Ott
52 *et al.*, 2003). Such findings have been again confirmed in recent studies (Nekouei *et al.*, 2016; Norby *et al.*, 2016).
53 In addition, a 7% lower conception rate in BLV test-positive cows compared with test-negative cows has been
54 reported. Increased culling rates and a greater susceptibility to other diseases with infectious aetiology, e.g. mastitis,
55 diarrhoea and pneumonia were also demonstrated among test-positive BLV herds (Emanuelsson *et al.*, 1992).
56 Reduced protective immunity following vaccination in BLV infected cattle has also been reported (Frie *et al.*, 2016;
57 Puentes *et al.*, 2016). Therefore, despite no obvious clinical signs during the long subclinical infection period,
58 economic losses caused by persistent BLV infections are relevant.

59 Virus can be detected by *in-vitro* cultivation of peripheral blood mononuclear cells (PBMC). The virus is present in
60 PBMC and in tumour cells as provirus integrates into the DNA of infected cells. Virus is also found in the cellular
61 fraction of various body fluids (nasal and bronchial fluids, saliva, milk). Natural transmission depends on the transfer
62 of infected cells, for example during parturition. Artificial transmission occurs, e.g. by blood-contaminated needles,
63 surgical equipment, gloves used for rectal examinations. Lateral transmission in the absence of these contributory
64 factors is usually slow (Monti *et al.*, 2005). In regions where blood-sucking insects occur in large numbers, especially
65 tabanids, these may transmit the virus mechanically. Viral antigens and proviral DNA can be identified in semen,
66 milk and colostrum of infected animals (Dus Santos *et al.*, 2007; Romero *et al.*, 1983). Natural transmission through
67 these secretions, however, has not clearly been demonstrated.

68 ~~Although several species can be infected by inoculation of the virus, natural infection occurs only in cattle (*Bos*~~
69 ~~*taurus* and *Bos indicus*), water buffaloes, and capybaras. Sheep are very susceptible to experimental inoculation~~
70 ~~and develop tumours more often at a younger age than cattle. A persistent antibody response can also be detected~~
71 ~~after experimental infection in deer, rabbits, rats, guinea-pigs, cats, dogs, sheep, rhesus monkeys, chimpanzees,~~
72 ~~antelopes, pigs, goats and buffaloes.~~

73 BLV was probably present in Europe during the 19th century, from where it spread to the American continent in the
74 first half of the 20th century. It may then have spread back into Europe and been introduced into other countries for
75 the first time by the import of cattle from North America (Johnson & Kaneene, 1992). Despite the global BLV
76 presence, a number of countries, particularly in Western Europe, are recognised as officially free from BLV infection
77 due to continued surveillance programmes.

78 **2. Nature and classification of the pathogen**

79 BLV, a delta retrovirus, is the causative agent of EBL. As with all retroviruses, BLV integrates into the host's cell
80 genome (provirus) thereby leading to a lifelong infection. Although several species can be infected by inoculation
81 of the virus, natural infection occurs only in cattle (*Bos taurus* and *Bos indicus*), water buffaloes, and capybaras.
82 Sheep are very susceptible to experimental inoculation and develop tumours more often at a younger age than
83 cattle. A persistent antibody response can also be detected after experimental infection in deer, rabbits, rats, guinea-
84 pigs, cats, dogs, sheep, rhesus monkeys, chimpanzees, antelopes, pigs, goats and buffaloes.

85 **3. Zoonotic potential and biosafety and biosecurity requirements**

86 Several studies have been carried out in an attempt to determine whether BLV causes disease in humans,
87 especially through the consumption of milk from infected cows (Burmeister *et al.*, 2007; Perzova *et al.*, 2000). There
88 was speculation about the involvement in BLV in human breast cancers (Buehring *et al.*, 2015), however such
89 findings were not confirmed by other researchers (Gillet & Willems, 2016; Zhang *et al.*, 2016). Hence with no
90 conclusive evidence of zoonotic transmission, it is ~~now~~ generally thought that BLV is not a hazard to humans. BLV
91 is present in peripheral blood mononuclear cells (PBMC) and in tumour cells. Virus is also found in the cellular
92 fraction of various body fluids (nasal and bronchial fluids, saliva, milk). Natural transmission depends on the transfer
93 of infected cells, for example during parturition. Artificial transmission occurs, e.g. by blood-contaminated needles,
94 surgical equipment, gloves used for rectal examinations. Lateral transmission in the absence of these contributory
95 factors is usually slow (Monti *et al.*, 2005). In regions where blood-sucking insects occur in large numbers, especially
96 tabanids, these may transmit the virus mechanically. Viral antigens and proviral DNA can be identified in semen,

97 milk and colostrum of infected animals (Dus Santos *et al.*, 2007; Romero *et al.*, 1983). Natural transmission through
 98 these secretions, however, has not clearly been demonstrated.

99 **4. Differential diagnosis**

100 There may be several causes of lymphosarcomas in cattle, but the only definitely known cause is BLV.
 101 The term sporadic bovine leukosis (SBL) is usually reserved for young animals (calves) as well as
 102 cutaneous and thymic types of lymphoma, which is defined by the age of the animal affected and the
 103 distribution of the tumours. The cause of SBL is not known. There may also be lymphosarcomatous
 104 conditions that do not fall into either the SBL or EBL categories, i.e. adult multicentric lymphoma with
 105 sporadic occurrence of unknown aetiology. Only lymphomas caused by BLV infection should be termed
 106 leukosis or enzootic bovine leukosis (Gillet *et al.*, 2007).
 107

108 **B. DIAGNOSTIC TECHNIQUES**

109 Table 1. Test methods available for the diagnosis of enzootic bovine leukosis and their purpose

Method	Purpose					
	Population freedom from infection ^(a)	Individual animal freedom from infection prior to movement ^{(a),(b)}	Contribute to eradication policies ^(a)	Confirmation of clinical cases ^{(a),(b)}	Prevalence of infection – surveillance ^(a)	Immune status in individual animals or populations post-vaccination
<u>Detection and</u> identification of the agent ^(c)						
Virus isolation ^(a)	–	+	–	+	–	–
PCR	+	++	+	++	+	–
Detection of immune response						
AGID	+++	+++	+++	+++	+++	–
ELISA	+++	+++	+++	+++	+++	–

110 Key: +++ = recommended for this purpose; ++ recommended but has limitations;
 111 + = suitable in very limited circumstances; – = not appropriate for this purpose.
 112 PCR = polymerase chain reaction; AGID = agar gel immunodiffusion; ELISA = enzyme-linked immunosorbent assay.
 113 ^(a)See Appendix 1 of this chapter for justification table for the scores given to the tests for this purpose.
 114 ^(b)See Appendix 2 of this chapter for justification table for the scores given to the tests for this purpose.
 115 ^(c)A combination of agent identification methods applied on the same clinical sample is recommended.

116 **1. Detection and identification of the agent**

117 BLV is an exogenous retrovirus and belongs to the genus *Deltaretrovirus* within the subfamily *Orthoretrovirinae* and
 118 the family *Retroviridae*. It is structurally and functionally related to the primate T-lymphotropic viruses 1, 2 and 3
 119 (STLV-1, -2, -3) and human T-lymphotropic virus[es] 1 and 2 (HTLV-1 and -2). The major target cells of BLV are B
 120 lymphocytes (Beyer *ET AL.*, 2002; Gillet *et al.*, 2007). The virus particle consists of two positive sense single-stranded
 121 RNA that encode for the nucleoprotein p12, capsid (core) protein p24, transmembrane glycoprotein gp30, envelope
 122 glycoprotein gp51, and several enzymes, including the reverse transcriptase. Proviral DNA, which is generated after
 123 reverse transcription of the viral genome, integrates randomly into the DNA of the host cell where it persists without
 124 constant production of viral progeny. When infected cells are cultured *in-vitro*, usually by co-cultivation of PBMC
 125 with indicator cells, infectious virus is produced, most readily through stimulation with mitogens.

126 **1.1. Virus isolation**

127 PBMC from 1.5 ml of peripheral blood in ethylene diamine tetra-acetic acid (EDTA) are separated on a
 128 ficoll/sodium metrizoate density gradient, cultured with 2×10^6 fetal bovine lung (FBL) cells, and
 129 subsequently grown for 3–4 days in 40 ml of minimal essential medium (MEM) containing 20% fetal calf
 130 serum. Virus causes syncytia to develop in the cell monolayer of the FBL cells. Short-term cultures can
 131 be prepared by culturing PBMC in the absence of FBL cells in 24-well plates for 3 days (Miller *et al.*,
 132 1985). The p24 and gp51 antigens can subsequently be detected in the supernatant of the cultures by

133 radio-immunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), immunoblot or agar gel
134 immunodiffusion (AGID), and the presence of the BLV particles or BLV-provirus can be demonstrated
135 by electron microscopy and by PCR, respectively.

136 1.2. Nucleic acid detection by polymerase chain reaction (PCR)

137 The use of the polymerase chain reaction (PCR) to detect BLV provirus has been described by various
138 workers (Fechner *et al.*, 1996; Rola-Luszczak *et al.*, 2013). Primers constructed to match the *gag*, *pol*
139 and *env* regions of the genome have all been used with variable success. So far, real-time PCR is the
140 most rapid and sensitive method. The methods described are conventional PCRs based on primer
141 sequences from the *env* gene, coding for gp51 and a real-time method based on detection of the *pol*
142 gene. ~~The technique is restricted to those laboratories that have the facilities for molecular virology, and~~
143 ~~the usual precautions and control procedures must be in place to ensure validity of the test results (see~~
144 ~~Chapter 1.1.6 *Validation of diagnostic assays for infectious diseases of terrestrial animals*).~~

145 PCR is mainly used as an adjunct to serology for confirmatory testing. The detection of BLV infection in
146 individual animals by PCR can be useful in the following circumstances:

- 147 i) Young calves with colostral antibodies;
- 148 ii) Tumour cases, for differentiation between sporadic and infectious lymphoma;
- 149 iii) Tumour tissue from suspected cases collected at slaughterhouses;
- 150 iv) New infections, before development of antibodies to BLV;
- 151 v) Cases of weak positive or uncertain results in ELISA;
- 152 vi) The systematic screening of cattle in progeny-testing stations (before introduction into artificial
153 insemination centres);
- 154 vii) Cattle used for production of vaccines, ensuring that they are BLV free.

155 1.2.1. Sensitivity and reliability of the method

156 i) *Analytical sensitivity*

157 Although the PCR assay has a theoretical sensitivity of one target molecule, in practice the
158 analytical sensitivity may be approximately five to ten target molecules of proviral DNA.

159 ii) *False-positive results*

160 The high sensitivity of the nested PCR may cause problems of false-positive results due to
161 contamination between samples (Belak & Ballagi-Pordany, 1993). To minimise this, several
162 special procedures are adopted throughout the protocol, such as the use of laminar air-flow
163 hoods, separate rooms for different steps of the procedure, new gloves or the use of special
164 tube openers for each individual assay and negative controls (e.g. water blanks).

165 iii) *False-negative results*

166 It should be noted that only a small proportion of the PBMC can be infected, thus limiting
167 the sensitivity of the assay. The presence of inhibitory substances in some samples may
168 cause false-negative results. To ~~detect-confirm~~ this, at least one ~~positive-internal~~
169 amplification control is used on each sample every test run. In addition, assays can use
170 internal controls (mimics) that are added to each sample. ~~The mimic is a modified target~~
171 ~~molecule that is amplified with the same primers as the real target, but that generates a PCR~~
172 ~~product with different size, which can be visualised by agarose gel electrophoresis. The~~
173 ~~mimic is added at a low concentration that favours the amplification of the real target (&~~
174 ~~Belak, 1996). However, it is possible for the mimic to compete with the true target. It may~~
175 ~~therefore be necessary to analyse each sample with or without the mimic.~~

176 1.2.2. Sample preparation

177 PBMC are separated from EDTA blood samples by using a density separation centrifugation
178 method. Alternatively buffy coat may be used, or even whole blood, e.g. where samples have
179 been frozen.

180 Tumours or other tissues should be homogenised to a 10% suspension.

181 **1.2.3. DNA extraction**

182 Purification of total DNA is a prerequisite for achieving optimal sensitivity. Various purification
183 methods are commercially available and suitable for the assay.

184 Special precautions should be taken during all steps to minimise the risk of contamination (Belak
185 & Ballagi-Pordany, 1993).

186 **1.2.4. Nested PCR procedure**

187 Several PCR protocols for the detection of BLV provirus sequences have been published; as an
188 example, an assay developed by Fechner *et al.* (1996) is described in detail. The BLV region
189 used as target is the env gene, encoding for gp51 protein. The sequence used for designing the
190 primers is available from GenBank, accession No. K02120.

191 **1.2.4.1. Method developed by Fechner *et al.* (1996)**

192 i) Primer design and sequences

Oligo	Env-Sequence (5'–3')	Position
BLV-env-1	TCT-GTG-CCA-AGT-CTC-CCA-GAT-A	5032–5053
BLV-env-2	AAC-AAC-AAC-CTC-TGG-GAA-GGG	5629–5608
BLV-env-3	CCC-ACA-AGG-GCG-GCG-CCG-GTT-T	5099–5121
BLV-env-4	GCG-AGG-CCG-GGT-CCA-GAG-CTG-G	5542–5521

193 The BLV-env-1/BLV-env-2 PCR-product size is 598 bp. The BLV-env-3/BLV-env-4 PCR-
194 product size is 444 bp

195 ii) Reaction mixtures

196 Reaction solutions are mixed (except DNA sample) before adding to the separate reaction
197 tubes. One negative control (double distilled H₂O) per five samples, and one positive control
198 should be added. Total volumes of mixtures are calculated by multiplying the indicated
199 volumes by the total number of samples, including controls, plus one.

200 The first PCR can be performed using a 50 µl reaction volume. For one reaction, the assay
201 is optimised to 5 µl (10×) PCR buffer, 20 µl DNA (~1 µg of DNA), 1.25 µl each of the env-
202 specific primers BLV-env-1 and BLV-env-2 (20 pmol/µl), 0.15 dNTP (each 25 mM), 3 µl
203 MgCl₂ (25 mM), 0.25 µl Taq polymerase (1.25U), and 19.1 µl of distilled H₂O. The reaction
204 follows the temperature profile: 2 minutes denaturation at 94°C; 30 cycles of 30 seconds at
205 95°C, 30 seconds at 58°C and 60 seconds at 72°C; followed by 4 minutes at 72°C.

206 The nested PCR can be performed using a 50 µl reaction volume. For one reaction, the
207 assay is optimised to 3 µl PCR product of the first PCR, 5 µl (10×) PCR buffer, 1.25 µl each
208 of the env-specific primers BLV-env-3 and BLV-env-4 (20 pmol/µl), 0.15 dNTP (each 25
209 mM), 0.25 µl Taq polymerase (1.25U), and 36.1 µl of distilled H₂O. The reaction follows the
210 temperature profile: 2 minutes denaturation at 94°C; 30 cycles of 30 seconds at 95°C,
211 30 seconds at 58°C and 60 seconds at 72°C; followed by 4 minutes at 72°C.

212 iii) Laboratory procedure

213 Mix PCR-reagents for the first or nested PCR and use separate gloves or tube openers for
214 each individual tube when adding the DNA samples. Put the samples on ice. Heat the
215 thermoblock to 94°C. Place samples in the thermoblock and start the PCR-programmes
216 accordingly.

217 iv) Agarose gel electrophoresis

218 Load approximately 10 µl of the nested PCR products with 20 µl loading buffer on a 2%
219 agarose gel containing 0.01% ethidiumbromide (or alternative, safer stains for visualising
220 PCR products). Using 0.5 × Tris/borate/EDTA (TBE) buffer, electrophoresis is performed
221 with 90 mA for 2 hours. To control the size of the amplification products, a 100 bp ladder is
222 recommended. Analysis of PCR products is done by UV illumination.

- 223 v) Interpretation of the results
- 224 a) Positive samples should have PCR products of the expected size (444 bp), similar to the
- 225 positive control.
- 226 b) Negative samples should have no PCR products of the expected size (444 bp).
- 227 c) The assay must be repeated if the positive control remained negative, or if the negative
- 228 water controls are positive.
- 229 vi) Confirmatory testing
- 230 For confirmatory identification, the PCR products can be sequenced, hybridised to a probe,
- 231 or analysed by restriction fragment length polymorphism (RFLP) analysis (Fechner *et al.*,
- 232 1997).

233 1.2.5. Real-time PCR procedure

234 Several real-time PCR protocols for the detection of BLV provirus sequences have been

235 published ([Jaworski *et al.*, 2018](#); [Pluta *et al.*, 2024](#)). The Rola-Łuszczak *et al.* (2013) method is

236 described in detail here as an example. The BLV region used as target is the pol gene. The

237 sequence used for designing the primers is available from GenBank, accession No. K02120.

238 1.2.5.1. Method developed by Rola-Łuszczak *et al.* (2013)

- 239 i) Primer design and sequences

Oligo	Pol-Sequence (5'–3')	Position
MRBLVL	CCT-CAA-TTC-CCT-TTA-AAC-TA	2321-2340
MRBLVR	GTA-CCG-GGA-AGA-CTG-GAT-TA	2421-2440
MRBLV probe	6FAM GAA-CGC-CTC-CAG-GCC-CTT-CA BHQ1	2341-2360

240 PCR-product size: 120 bp

- 241 ii) Reaction mixtures

242 Reaction solutions are mixed (except DNA sample) before adding to the separate reaction

243 tubes. One negative control (double-distilled H₂O) per five samples and one positive control

244 should be added. Total volumes of mixtures are calculated by multiplying the indicated

245 volumes by the total number of samples, including controls, plus one.

246 The reaction mixture for each PCR test contains 12.5 µl of 2 × PCR master mix, 0.4 µM of

247 each of the primers and 0.2 µM of the specific BLV probe and 500 ng of extracted genomic

248 DNA, using a final reaction volume of 25 µl. Amplification was performed according to the

249 following conditions: initial incubation and polymerase activation at 95°C for 15 minutes,

250 denaturation at 94°C for 60 seconds, annealing at 60°C for 60 seconds through 50 cycles.

- 251 iii) Laboratory procedure

252 Mix PCR-reagents and use separate gloves or tube openers for each individual tube when

253 adding the DNA samples. Put the samples on ice. Place samples in the thermoblock and

254 run at appropriate parameters.

- 255 iv) Interpretation of the results

256 a) Test controls: all controls should give the expected results with positive control falling within

257 the designated range and both the negative control (NC) and no template control (NTC)

258 should have no Ct (threshold cycle) values.

- 259 b) Test samples

260 1) ~~Positive samples are those with Ct result: any sample that has a cycle threshold (Ct)~~

261 ~~value less than or equal to 40.95 is regarded as positive.~~

262 b2) ~~Negative samples are those without a result: any sample that shows no Ct value or~~

263 ~~those with a value greater than 40.96 is regarded as negative.~~

264 c) The assay must be repeated if the positive control ~~remained~~ displays as negative, or if the
265 negative ~~water~~ no template controls ~~are positive~~ have Ct values. Samples on the borderline
266 of cut-off (i.e. Ct of 40) should be retested and confirmed.

267 vd) Confirmatory testing ~~For confirmatory identification; if required,~~ the PCR products can be
268 sequenced.

269 2. Serological tests

270 Infection with the virus in cattle is lifelong and gives rise to a persistent antibody response. Antibodies can first be
271 detected 3–16 weeks after infection. Maternally derived antibodies may take up to 6 or 7 months to disappear.
272 There is no way of distinguishing passively transferred antibodies from those resulting from active infection. Active
273 infection, however, can be confirmed by the detection of BLV provirus by the PCR. Passive antibody tends to protect
274 calves against infection. During the periparturient period, cows may have serum antibody that is undetectable by
275 AGID because of an antibody shift from the dam's circulation to her colostrum. Therefore, when using the AGID
276 test, a negative test result on serum taken at this time (2–6 weeks pre- and 1–2 weeks post-partum) is not conclusive
277 and the test should be repeated. However, the AGID can be performed at this stage with first-phase colostrum.

278 The antibodies most readily detected are those directed towards the gp51 and p24 of the virus. Most AGID tests
279 and ELISAs in routine use detect antibodies to the glycoprotein gp51, as these appear earlier. Methods of
280 performing these tests have been published (Dimmock *et al.*, 1987; European Commission, 2009). ELISAs are
281 usually more sensitive than the AGID tests.

282 ~~Weak positive and negative~~ WOAHP reference sera for use in ELISA ~~are is~~ available in freeze-dried irradiated form,
283 from the WOAHP national reference laboratory in Germany (FLI Reims)¹. ~~The calibration of these sera is based on~~
284 ~~the accredited~~ WOAHP reference serum, named E05, ~~which~~ has been validated against the former reference serum
285 E4 by different AGID and ELISAs.

286 2.1. Enzyme-linked immunosorbent assay

287 Either an indirect or blocking ELISA may be used. Assays based on both of these are available
288 commercially; different kits may be required for serum or milk samples. Some ELISAs are sufficiently
289 sensitive to be used with pooled samples. ELISAs are carried out in solid-phase microplates. BLV antigen
290 is used to coat the plates either directly or by the use of a capture polyclonal or monoclonal antibody
291 (MAb). The antigen is prepared from the cell culture supernatant of persistently BLV-infected cell lines.
292 Fetal lamb kidney (FLK) cells are most commonly used for commercial tests (Van der Maaten & Miller,
293 1976). Since 2004, a new BLV-producing cell line, PO714, which is free from other viral infections and
294 contains a provirus of the Belgian subgroup, has been made available (Beier *et al.*, 2004). The antigen
295 is used at a predetermined dilution (e.g. 1/10) in phosphate buffered saline. In kit form, the plates are
296 sometimes purchased precoated. Some preservatives may be added to milk samples to prevent souring.
297 Preserved samples will not usually deteriorate significantly if stored for up to 6 weeks at 4°C.

298 2.1.1. Blocking enzyme-linked immunosorbent assay – serum ELISA

299 The following method is suitable for antibody detection in single or pooled serum samples.

300 2.1.1.1. Test procedure

301 i) Coating the plate

302 All wells are coated with BLV antibody, prediluted in coating buffer (100 µl/well), the plate is
303 sealed and incubated for 18 hours at 4°C. A wash cycle (standard wash) is performed, which
304 is three washes filling wells to the top, with a 3-minute soak in between each wash, and then
305 the plate is blotted. BLV antigen is added, prediluted in wash buffer (100 µl/well), the plate
306 is sealed and incubated for 2 hours at 37°C. A standard wash cycle is performed.

307 ii) Preparation and addition of samples and controls

308 The positive and negative control sera are prediluted (1/2) in wash buffer and the solution is
309 added to four wells per control (100 µl/well). For testing pooled samples, 80 sera may be
310 bulked then diluted (1/2) using wash buffer and the solution is added to two wells
311 (100 µl/well) per sample. Single samples should be diluted 1/100 using wash buffer and the
312 solution added to two wells (100 µl/well) per sample. After plating out the samples, the plate

¹ <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>

313 is sealed and incubated for 18 hours at 4°C. A brief wash is performed by filling the wells
314 and immediately emptying them.

315 iii) Preparation and addition of conjugates and substrate

316 Prediluted biotinylated antibody is added (100 µl/well) to all wells – predilute using wash
317 buffer + 10% fetal calf serum – the plate is sealed and incubated on a rocking table for 1 hour
318 at 37°C. A standard wash is performed as described earlier. The peroxidase-conjugated
319 avidin is prediluted in wash buffer and the solution is added to all wells (100 µl/well). The
320 plate is sealed and incubated on a rocking table for 30 minutes at 37°C. A standard wash is
321 performed. 100 µl orthophenylamine diamine substrate is added to all wells, the plate is
322 covered and left in the dark for 9 minutes. The reaction is stopped with 100 µl of 0.5 M
323 sulphuric acid per well.

324 2.1.1.2. Reading and interpretation of results

325 The plate reader is blanked on air and the absorbance is read at 490 nm. For dual wave-
326 length readers a reference filter between 620 nm and 650 nm is used. Results are read
327 within 60 minutes after the addition of stop solution.

328 The absorbance of the negative control should be about 1.1 ± 0.4 ; if the absorbance is below
329 0.7, the colour development time in step iii above (preparation and addition of conjugates
330 and substrate) should be increased. Conversely, the time should be shortened if the
331 absorbance is above 1.5. The absorbance of the positive control should be less than the
332 absorbance of the negative control $\times 0.25$.

333 A sample is positive when the absorbance of each of the two test wells is identical with or
334 less than the mean absorbance of the four negative wells $\times 0.5$.

335 A sample is negative when the absorbance of each of the two test wells is identical with or
336 higher than the mean absorbance of the four negative control wells $\times 0.65$.

337 For samples giving values between the absorbance of the negative control $\times 0.5$ and $\times 0.65$,
338 it is recommended to retest the animal, using a sample taken 1 month later.

339 2.1.1.3. Sensitivity of the enzyme-linked immunosorbent assay

340 The sensitivity of pooled milk ELISAs can be evaluated using the WOA ~~H weak positive and~~
341 ~~reference sera, E05~~. Assays should give a positive result on ~~WOAH reference sera~~ E05
342 diluted in negative milk 250 times more than the number of individual milks in the pool (EU
343 Directive 88/406). For example, for pools of 60 milks, E05 should be diluted $1/250 \times 60 =$
344 $1/15,000$. For individual milk samples the positive WOA ~~H reference sera~~ E05 diluted $1/250$
345 in negative milk must be positive.

346 Where pooled serum samples are tested, the WOA ~~H reference serum~~ E05 must test positive
347 at a dilution 10 times higher than the number of individual animals in the pool. For example,
348 for a pool of 50 individual samples, the WOA ~~H reference serum~~ diluted $1/500$ in negative
349 serum should give a positive result. In assays where serum samples are tested individually,
350 WOA ~~H reference serum~~ E05 diluted $1/10$ must be positive.

351 For some ELISA kits, a positive result is not recommended as the sole determinant of
352 individual animal disease status; verification by a secondary method is recommended.

353 2.1.2. Indirect enzyme-linked immunosorbent assay – Milk ELISA

354 The following method is suitable for antibody detection in pooled milk samples.

355 2.1.2.1. Controls

356 Strong positive, weak positive, negative milk and diluent controls should be included in each
357 assay. A strong positive control should be prepared by diluting the WOA ~~H reference serum~~
358 E05 $1/25$ in negative milk. A weak positive control should be prepared by diluting, in negative
359 milk, the WOA ~~H reference serum~~ E05 25 times the number of individual milk samples in the
360 pool under test. The milk used for diluting the WOA ~~H reference serum~~ controls should be
361 unpasteurised, cream free and preserved.

362

363

2.1.2.2. Example test procedure

364 i) Milk samples must be stored, undisturbed in a refrigerator until a definite cream layer has
365 formed (24–48 hours), or alternatively, centrifuged at 2000 rpm for 10 minutes, the cream
366 layer should be removed prior to testing.

367 ii) A BLV antigen and a control negative antigen are precoated in alternate columns in the
368 plate. 100 µl of test sample is added to 100 µl wash buffer in the plate to make a 1/2 dilution,
369 adding to two control antigen wells and two BLV antigen wells.

370 iii) The plate is sealed and mixed on a shaker.

371 iv) The plate is incubated between 14 and 18 hours at 2–8°C.

372 v) 300 µl per well of wash diluent is added and discarded, and then 200 µl per well wash diluent
373 is added, shaken for 10 seconds and discarded. Finally, 300 µl of wash diluent is added and
374 soaked for 3 minutes and discarded.

375 vi) 200 µl per well of anti-bovine IgG-horseradish peroxidase affinity-purified conjugate diluted
376 in wash diluent is added and the plate is incubated for 90 minutes at room temperature.

377 vii) The plate is washed by adding 300 µl of wash diluent per well; this is then discarded and a
378 further 300 µl of wash diluent is added. This is left to soak for 3 minutes and discarded.
379 Steps vi and vii are repeated.

380 viii) 200 µl of ABTS (2,2'-azino-bis-[3-ethylbenzothiazoline-6-sulphonic acid]) substrate
381 (prewarmed to 25°C) is added and the plate is incubated for 20 minutes at room temperature
382 in the dark. The reaction may be stopped by adding 50 µl of stopping solution.

2.1.2.3. Reading and interpreting the results

384 The plate reader is blanked on air and the absorbance is read at 405 nm. All microplate
385 wells must be read within 2 hours of addition of stopper. The absorbance readings of the
386 wells containing negative antigen are subtracted from the readings of wells containing the
387 positive antigen. The two net absorbance values for each test sample should be averaged.
388 The same applies for the replicate weak positive controls. Replicates should be within
389 0.1 absorbance units of each other.

390 For the test to be considered valid, the averaged net absorbance of the weak positive (WP)
391 controls should be 0.2–0.6 absorbance units. The net absorbance of the strong positive
392 control should be >1.0 absorbance units. The net absorbance of the negative and diluent
393 controls should be less than the lower limit of the inconclusive range.

394 Assuming that the above criteria are met:

395 i) Test samples are positive if their net absorbance value is greater than or equal to that of the
396 WP control.

397 ii) Test samples are inconclusive if their net absorbance value is 75% or less of the net
398 absorbance value of the WP control:

399 i.e. if the WP control net absorbance = 0.40

400 then the lower limit of the inconclusive range = $0.40 \times 0.750 = 0.30$

401 the inconclusive range in this example would be 0.30–0.39

402 and samples of ≥ 0.40 are considered positive.

403 iii) Test samples are negative if their net absorbance value is less than the lower limit of the
404 'inconclusive' range (< 0.30 in the example).

2.2. Agar gel immunodiffusion

405 The AGID test is a specific, but not very sensitive, test for detecting antibody in serum samples from
406 individual animals. It is, however, unsuitable for milk samples (except first colostrums) because of lack
407 of specificity and sensitivity. The AGID is simple and easy to perform and has proven to be highly useful
408 and efficient as a basis for eradication schemes. Reference sera are included with commercial AGID test
409 kits.
410

-
- 411 **2.2.1. Agar gel**
- 412 A 0.8–1.2% solution of agar or agarose is prepared in 0.2 M Tris buffer, pH 7.2, with 8.5% NaCl.
413 One method of preparing the agar is to dissolve 24.23 g of Tris methylamine in 1 litre of distilled
414 water and adjust to pH 7.2 with 2.5 M HCl. Sodium chloride (85 g) is dissolved in 250 ml Tris/HCl
415 and made up to 1 litre. Agarose (8 g) is added and the mixture is heated in a pressure cooker or
416 autoclave at 4.55 kg/sq. cm for 10 minutes. The mixture is dispensed in 15 ml aliquots, which can
417 be stored at 4°C for up to approximately 6 weeks.
- 418 **2.2.2. Antigen**
- 419 The antigen must contain specific glycoprotein gp51 of BLV. Antigen is prepared in a suitable cell
420 culture system, such as permanently infected FLK cell monolayers. The cells used to produce the
421 BLV antigen should be free from noncytopathic bovine viral diarrhoea virus and of bovine
422 retroviruses, bovine immunodeficiency-like virus (lentivirus), and bovine syncytial virus
423 (spumavirus). After 3–4 days' culture at 37°C, the growth medium is replaced with maintenance
424 medium. The cells are harvested after 7 days using standard trypsin/versene solution. The cell
425 suspension is centrifuged at 500 **g** for 10 minutes. Cells are resuspended in growth medium; 30%
426 of the cells are returned to the culture vessel and the remainder is discarded. All culture
427 supernatants are collected. The supernatants are concentrated 50–100-fold by available
428 methods. This can be done by concentration in Visking tubing immersed in polyethylene glycol,
429 or by precipitation with ammonium sulphate followed by ultrafiltration, or by precipitation in
430 polyethylene glycol followed by desalting and size separation on a polyacrylamide bead column.
431 The antigen contains gp51 predominantly, but may also contain p24.
- 432 The antigen may be standardised for glycoprotein gp51 by titration against the WOA reference
433 serum E05 as follows: a twofold dilution of the antigen preparation is made. The highest dilution
434 that, when tested against undiluted WOA reference serum E05, gives a precipitation line
435 equidistant between the antigen and the serum will contain one unit. Two units of antigen are
436 used in the test.
- 437 **2.2.3. Known positive control serum**
- 438 The positive control serum comes from a naturally or experimentally infected animal (cattle or
439 sheep). The precipitation line formed should be a sharp distinct line midway between the antigen
440 and the control serum wells. A dilution of the control positive serum that gives a weak positive
441 result should be included in the test as an indicator of the test's sensitivity.
- 442 **2.2.4. Known negative control serum**
- 443 Serum from uninfected animals (cattle, sheep) is used.
- 444 **2.2.5. Test sera**
- 445 Sera from any species of animal are suitable.
- 446 **2.2.6. Test procedure**
- 447 i) The agar is melted by heating in a water bath and poured into Petri dishes (15 ml per Petri
448 dish of diameter 8.5 cm). The poured plates are allowed to cool at 4°C for about 1 hour
449 before holes are cut in the agar. A punch is used that cuts a hexagonal arrangement of six
450 wells round a central well. Various dimensions of wells can be used; one satisfactory pattern
451 has been produced using wells of 6.5 mm in diameter with 3 mm between wells. For best
452 results, agar plates are used the same day that they are poured and cut.
- 453 ii) Antigen is placed in the central wells of the hexagonally arranged patterns. Test sera are
454 placed alternately with positive control serum in the outer wells. There should be one control
455 pattern per plate with positive control serum, weak positive control serum and negative
456 control serum in the place of test sera.
- 457 iii) The test plates are kept at room temperature (20–27°C) in a closed humid chamber, and
458 read at 24, 48 and 72 hours.
- 459 iv) *Interpretation of the results:* A test serum is positive if it forms a specific precipitation line
460 with the antigen and forms a line of identity with the control serum. A test serum is negative
461 if it does not form a specific line with the antigen and if it does not bend the line of the control
462 serum. Nonspecific lines may occur; these do not merge with or deflect the lines formed by
463 the positive control. A test serum is a weak positive if it bends the line of the control serum
464 towards the antigen well without forming a visible precipitation line with the antigen; the
465 reaction is inconclusive if it cannot be read either as negative or positive. A test is invalid if
-

466 the controls do not give the expected results. Sera giving inconclusive or weak positive
467 results can be concentrated and retested.

468 **C. REQUIREMENTS FOR VACCINES**

469 Despite advances in research on experimental vaccines there is, as yet, no commercially available vaccine for the
470 control of EBL.

471 **REFERENCES**

472 ~~BALLAGI-PORDANY A. & BELAK S. (1996). The use of mimics as internal standards to avoid false negatives in~~
473 ~~diagnostic PCR. *Mol. Cell. Probes*, **10**, 159–164.~~

474 BEIER D., RIEBE R., BLANKENSTEIN P., STARICK E., BONDZIO A. & MARQUARDT O. (2004). Establishment of a new bovine
475 leucosis virus producing cell line. *J. Virol. Methods*, **121**, 239–246.

476 BELAK S. & BALLAGI-PORDANY A. (1993). Experiences on the application of the polymerase chain reaction in a
477 diagnostic laboratory. *Mol. Cell. Probes*, **7**, 241–248.

478 BEYER J., KÖLLNER B., TEIFKE J.P., STARICK E., BEIER D., REIMANN I., GRUNWALD U. & ZILLER M. (2002). Cattle infected
479 with bovine leukaemia virus may not only develop persistent B-cell lymphocytosis but also persistent B-cell
480 lymphopenia. *J. Vet. Med. [B]*, **49**, 270–277.

481 BUEHRING G.C., SHEN H.M., JENSEN H.M., JIN D.L., HUDES M. & BLOCK G. (2015). Exposure to bovine leukemia virus
482 is associated with breast cancer: a case-control study. *PLoS One*, **10**, e0134304.

483 BURMEISTER T., SCHWARTZ S., HUMMEL M., HOELZER D. & THIEL E. (2007). No genetic evidence for involvement of
484 Deltaretroviruses I adult patients with precursor and mature T-cell neoplasms. *Retrovirology*, **4**, 11.

485 DIMMOCK C.K., RODWELL B.J. & CHUNG Y.S. (1987). Enzootic bovine leucosis. Pathology, Virology and Serology.
486 Australian standard diagnostic techniques for animal disease. No. 49. Australian Agricultural Council.

487 DUS SANTOS M.J., TRONO K., LAGER I. & WIGDOROVITZ A. (2007). Development of a PCR to diagnose BLV genome in
488 frozen semen samples. *Vet. Microbiol.*, **119**, 10–18.

489 EMANUELSSON U., SCHERLING K. & PETTERSSON H. (1992). Relationships between herd bovine leukemia virus
490 infection status and reproduction, disease incidence, and productivity in Swedish dairy herds. *Prev. Vet. Med.*, **12**,
491 121–131.

492 EUROPEAN COMMISSION (2009). Commission Decision of 15 December 2009 amending Annex D to Council Directive
493 64/432/EEC as regards the diagnostic tests for enzootic bovine leucosis (2009/976/EU): *Official Journal of the*
494 *European Union* L **336**, 36-41.

495 FECHNER H., BLANKENSTEIN P., LOOMAN A.C., ELWERT J., GEUE L., ALBRECHT C., KURG A., BEIER D., MARQUARDT O. &
496 EBNER D. (1997). Provirus variants of the bovine leukemia virus and their relation to the serological status of naturally
497 infected cattle. *Virology*, **237**, 261–269.

498 FECHNER H., KURG A., GEUE L., BLANKENSTEIN P., MEWES G., EBNER D. & BEIER D. (1996). Evaluation of polymerase
499 chain reaction (PCR) application in diagnosis of bovine leukaemia virus (BLV) infection in naturally infected cattle.
500 *Zentralbl. Veterinarmed. B*, **43**, 621–630.

501 FRIE M.C., SPORER K.R., WALLACE J.C., MAES R.K., SORDILLO L.M., BARTLETT P.C. & COUSSENS P.M. (2016). Reduced
502 humoral immunity and atypical cell-mediated immunity in response to vaccination in cows naturally infected with
503 bovine leukemia virus. *Vet. Immunol. Immunopathol.*, **182**, 125–135.

504 GILLET N., FLORINS A., BOXUS M., BURTEAU C., NIGRO A., VANDERMEERS F., BALON H., BOUZAR A.-B., DEFOICHE J.,
505 BURNY A., REICHERT M., KETTMANN R. & WILLEMS L. (2007). Mechanisms of leukemogenesis induced by bovine
506 leukemia virus: prospects for novel anti-retroviral therapies in human. *Retrovirology*, **4**, 18.

507 GILLET N.A. & WILLEMS L. (2016). Whole genome sequencing of 51 breast cancers reveals that tumors are devoid
508 of bovine leukemia virus DNA. *Retrovirology*, **13**, 75.

- 509 JAWORSKI J.P., PLUTA A., ROLA ŁUSZCZAK M., MCGOWAN S.L., FINNEGAN C., HEENEMANN K., CARIGNANO H.A., ALAVAREZ
510 I. MURAKAMI K., WILLEMS L., VAHLENKAMP T.W., TRONO K.G. CHOUDHURY B. & KUZMAK J. (2018). Interlaboratory
511 Comparison of Six Real-Time PCR Assays for Detection of Bovine Leukemia Virus Proviral DNA. *J. Clin. Microbiol.*
512 **56**, 10.
- 513 JOHNSON R. & KANEENE J.B. (1992). Bovine leukaemia virus and enzootic bovine leukosis. *Vet. Bull.*, **62**, 287–312.
- 514 KHUDHAIR Y.I., AL-SHAMMARI A.M., HASSO S.A. & YASEEN N. (2021). Isolation of Bovine leukemia virus from cows with
515 persistent lymphocytosis in Iraq. *Veterinary and Animal Science*, **14**.
- 516 KUCZEWSKI A., ORSEL K., BARKEMA H.W., KELTON D.F., HUTCHINS W.A. & VAN DER MEER F.J.U.M. (2018). Short
517 communication: Evaluation of 5 different ELISA for the detection of bovine leukemia virus antibodies. *J. Dairy Sci.*
518 **101**, 2433–2437.
- 519 MILLER L.D., MILLER J.M., VAN DER MAATEN M.J. & SCHMERR M.J.F. (1985). Blood from bovine leukaemia virus-
520 infected cattle: antigen production correlated with infectivity. *Am. J. Vet. Res.*, **46**, 808–810.
- 521 MONTI G.E., SCHRIJVER R. & BEIER D. (2005). Genetic diversity and spread of bovine leukaemia virus isolates in
522 Argentine dairy cattle. *Arch. Virol.*, **150**, 443–458.
- 523 NEKOU EI O., VAN LEEUWEN J., STRYHN H., KELTON D. & KEEFE G. (2016). Lifetime effects of infection with bovine
524 leukemia virus on longevity and milk production of dairy cows. *Prev. Vet. Med.*, **133**, 1–9.
- 525 NORBY B., BARTLETT P.C., BYREM T.M. & ERSKINE R.J. (2016). Effect of infection with bovine leukemia virus on milk
526 production in Michigan dairy cows. *J. Dairy Sci.*, **99**, 2043–2052.
- 527 OTT S.L., JOHNSON R. & WELLS S.J. (2003). Association between bovine-leukosis virus seroprevalence and herd-
528 level productivity on US dairy farms. *Prev. Vet. Med.*, **61**, 249–262.
- 529 PERZOVA R.N., LOGHRAN T.P., DUBE S., FERRER J., ESTEBAN E. & POIESZ B.J. (2000). Lack of BLV and PTLV DNA
530 sequences in the majority of patients with large granular lymphocyte leukaemia. *Br. J. Haematol.*, **109**, 64–70.
- 531 PUENTES R., DE BRUN L., ALGORTA A., DA SILVA V., MANSILLA F., SACCO G., LLAMBI S. & CAPOZZO A.V. (2016).
532 Evaluation of serological response to foot-and-mouth disease vaccination in BLV infected cows. *BMC Vet. Res.*,
533 **12**, 119.
- 534 REICHEL M.P., THAM K.M., BARNES S. & KITTELBERGER R. (1998). Evaluation of alternative methods for the detection
535 of bovine leukaemia virus in cattle. *NZ Vet. J.*, **46**, 140–146.
- 536 ROLA-ŁUSZCZAK M., FINNEGAN C., OLECH M., CHOUDHURY B. & KUŹMAK J. (2013). Development of an improved real
537 time PCR for the detection of bovine leukaemia provirus nucleic acid and its use in the clarification of inconclusive
538 serological test results. *J. Virol. Methods*, **189**, 258–264.
- 539 ROMERO C.H., CRUZ G.B. & ROWE C.A. (1983). Transmission of bovine leukaemia virus in milk. *Trop. Anim. Health*
540 *Prod.*, **15**, 215–218.
- 541 TRONO K.G., PEREZ-FILGUEIRA D.M., DUFFY S., BORCA M.V. & CARRILLO C. (2001). Seroprevalence of bovine leukemia
542 virus in dairy cattle in Argentina: comparison of sensitivity and specificity of different detection methods. *Vet.*
543 *Microbiol.*, **83**, 235–248.
- 544 VAN DER MAATEN M.J. & MILLER J.M. (1976). Replication of bovine leukaemia virus in monolayer cell cultures. *Bibl.*
545 *Haematol.*, **43**, 360–362.
- 546 YONEYAMA S., KOBAYASHI S., MATSUNAGA T., TONOSAKI K., LENG D., SAKAI Y., YAMADA S., KIMURA A., ICHIJO T., HIKONO
547 H. & MURAKAMI K. (2022). Comparative Evaluation of Three Commercial Quantitative Real-Time PCRs Used in
548 Japan for Bovine Leukemia Virus. *Viruses*, **14**, 1182.
- 549 ZHANG R., JIANG J., SUN W., ZHANG J., HUANG K., GU X., YANG Y., XU X., SHI Y. & WANG C. (2016). Lack of association
550 between bovine leukemia virus and breast cancer in Chinese patients. *Breast Cancer Res.*, **18**, 101. ~~No abstract~~
551 ~~available.~~
- 552 *
- 553 * *

554 **NB:** There are WOA Reference Laboratories for enzootic bovine leukosis (please consult the WOA Web site:
555 <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>).
556 Please contact the WOA Reference Laboratory for any further information on
557 diagnostic tests and reagents for enzootic bovine leukosis

558 **NB:** FIRST ADOPTED IN 1991. MOST RECENT UPDATES ADOPTED IN 2018.

559
560

Appendix 1: Enzootic bovine leukosis

Intended purpose of test: individual animal freedom from infection prior to movement; confirmation of clinical cases

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Virus isolation</u> ± <u>Bovine</u>	<u>PBMC</u> <u>Cell cultures</u> <u>inoculated with</u> <u>PBMC</u>	<u>Reference tests were</u> <u>nested PCR and</u> <u>ELISA</u> <u>Two out of six cell</u> <u>cultures were positive</u> <u>by CPE (DSe=33%)</u>	<u>N/A: this test is not</u> <u>recommended for routine</u> <u>diagnosis but in instances</u> <u>where the virus isolate is</u> <u>desirable for downstream</u> <u>applications e.g. <i>in vivo</i></u>	<u>See reference</u>	<u>The isolated virus may be</u> <u>used for additional <i>in-vitro</i> or</u> <u><i>in-vivo</i> characterisation or</u> <u>applications</u>	<u>1) Slow, time-consuming,</u> <u>can be difficult and</u> <u>expensive</u> <u>2) Selection of different</u> <u>susceptible cell type may be</u> <u>critical</u> <u>3) May only be suitable for</u> <u>certain cases e.g. animals</u> <u>with persistent lymphocytosis</u>	<u>Khudhair <i>et al.</i></u> <u>(2021)</u>

561
562
563

Appendix 2: Enzootic bovine leukosis

Intended purpose of test: population freedom from infection; individual animal freedom from infection prior to movement; contribute to eradication policies; confirmation of clinical cases and prevalence of infection – surveillance

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>PCR</u> <u>Nested PCR</u> <u>Real time PCR</u> ± <u>Bovine</u>	<u>Genomic DNA from PBMC, whole blood, tumour or tissue sample as lymph node and spleen</u>	<u>Nested PCR: reference tests were ELISA and AGID. Nested PCR showed 100% DSe, while ELISA and AGID showed DSe 82.7% and 71.2%, respectively</u>	<u>52 BLV infected, nested PCR positive cattle</u>	<u>See references</u>	<u>1. Direct, sensitive and rapid detection of infection before development of antibodies to BLV</u> <u>2. Detects BLV during early phase of infection or in the presence of colostrum antibodies</u>	<u>1. In most cases requires DNA preparation</u> <u>2. False-negative in case of low proviral load and the presence of PCR inhibitors</u> <u>3. Possibilities of carry-over cross contamination</u>	<u>Fechner et al. (1996)</u>
		<u>Real-time PCR: reference test was ELISA. DSe varied from 56% to 98%, depending on the technique used</u>	<u>56 serologically positive cattle, selected from infected herds from seven countries</u>		<u>1) As with nested PCR</u> <u>2) Possibility to quantify the proviral load</u> <u>3) Suitable for high throughput testing</u> <u>4) Less risk of cross contamination</u>	<u>1) As with points 1 and 2 for nested PCR</u> <u>2) Expensive equipment and reagents e.g. probes may be difficult to source in LMICs</u>	<u>Jaworski et al. (2018)</u>
		<u>DSe varied from 98.4% to 99.4%, depending on the technique used</u>	<u>317 serologically positive cattle</u>				<u>Yoneyama et al. (2021)</u>
<u>AGID</u> ++ <u>Bovine</u>	<u>Serum, antibodies, p24, gp51</u>	<u>Reference test was western blot. DSe for AGID was 95.9% while DSp was 95.7%</u>	<u>399 cattle from 19 herds tested by tested by AGID and western blot</u>	<u>See reference</u>	<u>1) Excellent specificity</u> <u>2) Technically simple.</u> <u>3) Not expensive</u>	<u>1) Low sensitivity (Ab detected after 4–8 weeks a.i.)</u> <u>2) Time consuming i.e. results typically read after 3 days</u> <u>3) Interpretation may be subjective – two readers suggested</u>	<u>Reichel et al. (1998)</u>

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
ELISA +++ Bovine	Serum, milk, antibodies p24, gp51	<u>When reference test was PCR relative DSe was 91.0 (CI: 87.8–94.3) and DSp was 83.9 (CI: 77.3–90.5) when Bayesian model was employed</u>	<u>524 cattle from six herds including: 1) herd with no serological evidence of BLV infection 2) herd with more than 50% of cattle seropositive 3) herd with less than 5% of adult cattle seropositive 4) three farms were of unknown BLV status</u>	See references	1) High sensitivity (Abs detected after 2–4 weeks a.i.), good specificity 2) Quantitative readout 3) Test is performed in a few hours 4) Technically simple 5) Suitable for high-throughput screening	1) Lower specificity in comparison to the AGID, false positive can occur	<u>Monti et al. (2005)</u>
		<u>Reference test was PCR. Relative DSe was 97.2% and DSp was 97.5%</u>	<u>339 dairy cattle tested by PCR. 178 were positive and 161 were negative</u>				<u>Trono et al. (2001)</u>
		<u>Relative DSe was 100% (CI: 87–100) and DSp varied from 95% (CI :83–99) to 100% (CI :87–100)</u>	<u>116 dairy cattle from five herds including 54 BLV positive and 62 negative. Serological status was estimated based on five ELISAs</u>				<u>Kuczewski et al. (2018)</u>

5
6 CHAPTER 3.4.13.

7 THEILERIOSIS IN CATTLE
8 (INFECTION WITH *THEILERIA ANNULATA*,
9 *T. ORIENTALIS* AND *T. PARVA*)

10 SUMMARY

11 **Description and importance of the disease:** Tick-transmitted *Theileria* parasites of cattle are a
12 major constraint to the improvement of the livestock industry in large parts of Europe, Africa and Asia.
13 *Theileria annulata*, *T. orientalis* and *T. parva*, the most economically important species, are
14 responsible for mortality and losses in production. Bovine theileriosis is generally controlled by the
15 use of acaricides to kill ticks, but this method is not sustainable. Acaricides are expensive, they cause
16 environmental damage, and over time ticks develop resistance to them requiring newer acaricides to
17 be developed. More sustainable and reliable methods for the control of theileriosis that deploy a
18 combination of strategic tick control and vaccination are desirable. However, these are yet to be
19 successfully applied on a large scale in endemic areas.

20 **Detection and identification of the agent:** Diagnosis of a variety of disease syndromes caused by
21 the parasites is principally based on clinical signs, knowledge of disease and vector distribution, and
22 identification of parasites in Giemsa-stained blood and lymph node smears. The presence of
23 multinucleate intra-cytoplasmic and free schizonts, in lymph node biopsy smears, is a characteristic
24 diagnostic feature of acute infections with *T. parva* and *T. annulata*. Animals infected with *T. parva*
25 show enlarged lymph nodes, starting with the parotid lymph node, fever, a gradually increasing
26 respiratory rate, dyspnoea and occasional diarrhoea. Post-mortem lesions observed are pulmonary
27 oedema with froth in the trachea, enlargement of lymph nodes and spleen, haemorrhages in internal
28 organs, abomasal erosions, the presence of parasitised lymphocytes and lympho-proliferative
29 infiltrations in visceral tissues. The gross pathology caused by schizonts of *T. annulata* resembles
30 that of *T. parva*, while the piroplasm stages may also be pathogenic, causing anaemia and jaundice.
31 For *T. annulata*, the first lymph nodes involved are the pre-crural ones as a result of the predilection
32 sites of the vector ticks. Conversely, *T. orientalis* is not a lymphoproliferative disease but affects
33 animals mainly via the intra-erythrocytic phase. This results in clinical signs of abortion, anaemia,
34 fever, jaundice and lethargy.

35 **Molecular-based tests:** In addition, molecular diagnostic tests, particularly those based on the
36 polymerase chain reaction and reverse line blot hybridisation are proving to be powerful tools for
37 detecting theileria parasites in the vertebrate and invertebrate hosts, characterising species and
38 parasite polymorphisms, defining population genetics and generating epidemiological data.

39 **Serological tests:** The most widely used diagnostic test for *Theileria* species has been the indirect
40 fluorescent antibody (IFA) test. For the IFA test, both schizont and piroplasm antigens may be
41 prepared on slides or in suspension and preserved by freezing at $\leq -20^{\circ}\text{C}$, except in the case of the
42 piroplasm suspension, which is stored at 4°C . Test sera are diluted with phosphate-buffered saline
43 and incubated with the antigen in suspension, and anti-bovine immunoglobulin conjugate is then

44 added. Using the test as described, the fluorescence is specific to the causative agent. The IFA test
45 is sensitive, fairly specific, and usually easy to perform. However, because of the problems of cross-
46 reactivity among some *Theileria* species, the test has limitations for large-scale surveys in areas
47 where species distribution overlaps. The IFA test for *T. parva* does not distinguish among the different
48 immunogenic stocks. An indirect enzyme-linked immunosorbent assay for *T. parva* and *T. mutans*,
49 based on recombinant parasite-specific antigens, has demonstrated higher sensitivity and specificity.
50 The IFA test for *T. orientalis* does not differentiate between pathogenic and non-pathogenic strains.

51 **Requirements for vaccines:** Reliable vaccines of known efficacy have been developed for *T. parva*
52 and *T. annulata*. For *T. annulata*, the vaccine is prepared from schizont-infected cell lines that have
53 been isolated from cattle and attenuated during in vitro culture. The vaccine must remain frozen until
54 shortly before administration. Vaccination against *T. parva* is based on a method of infection and
55 treatment in which cattle are given a subcutaneous dose of tick-derived sporozoites and a
56 simultaneous treatment with a long-acting tetracycline formulation. This treatment results in a mild or
57 inapparent East Coast fever reaction followed by recovery. Recovered animals demonstrate a robust
58 immunity to homologous and, to varying degrees, heterologous challenge, which usually lasts for the
59 lifetime of an animal. In endemic areas characterised by high transmission intensities, immunisation
60 of animals with a stock(s) engendering a broad-spectrum immunity is desirable to cover a range of
61 immunologically distinct *T. parva* strains that exist in the field. Immunised animals may become
62 carriers of the immunising parasite stock. Safety precautions must be taken in the preparation and
63 handling of *T. parva* vaccines to protect the workers and to avoid contamination of the stabilates.
64 Consideration should also be given to the risk of introducing new isolates into an area where they
65 may then become established through a carrier state.

66 A. INTRODUCTION

67 Theileriae are obligate intracellular protozoan parasites that infect both wild and domestic *Bovidae* throughout much
68 of the world. They are transmitted by ixodid ticks, and have complex life cycles in both vertebrate and invertebrate
69 hosts. There are a number of species of *Theileria* spp. that infect cattle; the ~~two~~ three most pathogenic and
70 economically important are *T. parva*, ~~and~~ *T. annulata* and pathogenic strains of *Theileria orientalis*. *Theileria parva*
71 occurs in 13 countries in sub-Saharan Africa causing three disease syndromes namely East Coast fever (ECF),
72 Corridor disease (CD) and Zimbabwean theileriosis (January disease, JD). These syndromes differ in the origin of
73 the parasite, ECF and JD being tick transmitted from cattle to cattle (cattle-derived) and CD from buffalo to cattle
74 (buffalo-derived), whilst *Theileria annulata* (tropical/Mediterranean theileriosis) occurs in southern Europe as well
75 as North Africa and Asia. Endemic regions of *T. annulata* and *T. parva* do not overlap extensively. *Theileria annulata*
76 can occur in cattle, yaks, water buffalo and camels and is transmitted by ticks of the genus *Hyalomma*. Tropical
77 theileriosis is more severe in European breeds, with a mortality rate of 40–90%, while the mortality rate in indigenous
78 breeds of cattle from endemic areas can be as low as 3%. In Spain, *T. annulata* infections are mainly restricted to
79 the southern and Mediterranean areas such as Menorca island, where the tick vector (*Hyalomma* sp.) is present.
80 In northern Spain, reports of the presence of *Hyalomma* ticks are sporadic, as are associated *T. annulata* infections.
81 However, tick distribution might change because of changes in climatic conditions.

82 ~~*Theileria orientalis/buffeli* complex is now thought to consist of two species~~ has at least two strains of economic
83 importance, namely Chitose and Ikeda – *T. orientalis*, occurring in the far east, and *T. buffeli* having a global
84 distribution (Gubbels et al., 2000; Jeong et al., 2010). Infection is generally subclinical; however, disease can occur
85 in cattle depending on a number of epidemiological factors (including previous exposure to theileriae, stress or
86 health status, and variations in the species-strain pathogenicity, as reported recently in Australia and New Zealand
87 Australasia (Gebrekidan et al., 2015; McFadden et al., 2014). The main tick vector, *Haemaphysalis longicornis*
88 accompanied by the Ikeda strain has spread from to North the America (Hutcheson et al., 2019).

89 *Theileria taurotragi* and *T. mutans* generally cause no disease or mild disease, and *T. velifera* is nonpathogenic.
90 These last three parasites are found mainly in Africa, and overlap in their distributions, complicating the
91 epidemiology of theileriosis in cattle. This has been further complicated by the finding of multiple related genotypes
92 in cattle and buffalo, suggesting a genetically diverse population of *Theileria* circulating in bovids.

93 ~~*Theileria lestoquardi*, also transmitted by *Hyalomma* ticks, is the only species of economic significance infecting~~
94 ~~small ruminants and it also occurs in north Africa, the Mediterranean basin and Asia. In sheep and goats, the~~
95 ~~morbidity rate from *T. lestoquardi* can approach 100% with a mortality rate of 46–100% in the most susceptible~~
96 ~~breeds. *Theileria uilenbergi* and *T. luwenshuni* are pathogenic ovine piroplasmids described in north-western China~~
97 ~~(People's Rep. of), though *Theileria* parasites with similar sequences have been found in sheep in northern Spain~~
98 ~~and Turkey, but apparently with a low pathogenicity. *Theileria luwenshuni* has also been detected in sheep in the~~
99 ~~United Kingdom associated with clinical signs (Phipps et al., 2016).~~

100 Some *T. parva* stocks produce a carrier state in recovered cattle, and studies using DNA markers for parasite
 101 strains have shown that *T. parva* carrier animals are a source of infection that can be transmitted naturally by ticks
 102 in the field (Bishop *et al.*, 1992; Kariuki *et al.*, 1995; Marcotty *et al.*, 2002; Maritim *et al.*, 1989). The severity of ECF
 103 may vary depending on factors such as the virulence of the parasite strain, sporozoite infection rates in ticks and
 104 genetic background of infected animals. Indigenous cattle in ECF-endemic areas are often observed to experience
 105 mild disease or subclinical infection, while introduced indigenous or exotic cattle usually develop severe disease.

106 The most practical and widely used method for the control of theileriosis is the chemical control of ticks with
 107 acaricides. However, tick control practices are not always fully effective for a number of reasons, including
 108 development of acaricide resistance, the high cost of acaricides, poor management of tick control, and illegal cattle
 109 movement in many countries. Vaccination using attenuated schizont-infected cell lines has been widely used for
 110 *T. annulata*, while for *T. parva* control, infection and treatment using tick-derived sporozoites and tetracycline is
 111 being implemented in a number of countries in eastern, central and southern Africa.

112 Chemotherapeutic agents such as parvaquone, buparvaquone and halofuginone are available to treat *T. parva* and
 113 *T. annulata* infections. Treatments with these agents rely on early detection of clinically affected animals and do not
 114 completely bring about eradication of theilerial infections, leading to the development of carrier states in their hosts.

115 ~~The immune response to theileriae parasites is complicated. Cell-mediated immunity is thought to be the most
 116 important protective response in *T. parva* and *T. annulata*. In *T. parva*, the principal protective responses are
 117 mediated through killing of infected cells by bovine major histocompatibility complex (MHC) class I-restricted
 118 cytotoxic T lymphocytes. *Theileria annulata* schizonts inhabit macrophages and B cells. Innate and adaptive
 119 immune responses cooperate to protect cattle against *T. annulata* theileriosis. Intracellular parasites are mostly
 120 affected by cell-mediated immunity. Infection of leukocytes with *T. annulata* activates the release of cytokines,
 121 initiating an immune response and helping to present parasite antigen to CD4⁺ T cells. These cells produce
 122 interferon- γ (IFN- γ), which activates non-infected macrophages to synthesise tumour necrosis factor α (TNF- α) and
 123 nitric oxide (NO), which destroy schizont- and piroplasm-infected cells. CD8⁺ T cells have recently been shown to
 124 recognise parasite antigens presented by the MHC and to kill infected leukocytes. B cells produce antibody that
 125 along with NO kill extracellular merozoites and intracellular piroplasms. On the other hand, overproduction of
 126 cytokines, in particular TNF- α , by macrophages generates many of the clinical signs and pathological lesions that
 127 characterise *T. annulata* theileriosis and the outcome of the infection depends upon the fine balance between
 128 protective and pathological properties of the immune system.~~

129 B. DIAGNOSTIC TECHNIQUES

130 Diagnosis of acute theileriosis is based on clinical signs, knowledge of disease, and vector distribution as well as
 131 examination of Giemsa-stained blood, lymph node and tissue impression smears. *Theileria parva* and *T. annulata*
 132 are diagnosed by the detection of schizonts in white blood cells or piroplasms in erythrocytes. The piroplasmic stage
 133 follows the schizont stage and, in both *T. parva* and *T. annulata*, it is usually less pathogenic and is thus often found
 134 in recovering or less acute cases. Infection with other *Theileria* parasites that also produce schizonts or piroplasms
 135 complicate the use of microscopy as diagnostic technique. It is hoped that A combination of serological enzyme-
 136 linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) will greatly enhance our present
 137 capacity to identify infected animals, thus making possible accurate surveys of *Theileria* species. Eventually, the
 138 aim would be to develop these technologies for the diagnosis of all the vector-borne diseases.

139 Table 1. Test methods available for the diagnosis of theileriosis and their purpose

Method	Purpose					
	Population freedom from infection ^(a)	Individual animal freedom from infection prior to movement ^(a)	Contribute to eradication policies	Confirmation of clinical cases ^(a)	Prevalence of infection – surveillance ^(a)	Immune status in individual animals or populations post-vaccination
<u>Detection and identification of the agent^(b)</u>						
Microscopic examination	–	+++	–	+++	–	–
PCR	<u>±±</u>	<u>±±±</u>	++	+++	<u>±±</u>	–
<u>Detection of immune response</u>						
IFAT	+	+++	++	–	+++	–

Method	Purpose					
	Population freedom from infection ^(a)	Individual animal freedom from infection prior to movement ^(a)	Contribute to eradication policies	Confirmation of clinical cases ^(a)	Prevalence of infection – surveillance ^(a)	Immune status in individual animals or populations post-vaccination
ELISA	+	+	++	–	+++	–

Key: +++ = recommended for this purpose; ++ recommended but has limitations; + = suitable in very limited circumstances; – = not appropriate for this purpose.

PCR = polymerase chain reaction; IFAT = indirect fluorescent antibody test; ELISA = enzyme-linked immunosorbent assay.

^(a)See Appendix 1 of this chapter for justification table for the scores giving to the tests for this purpose.

^(b)A combination of agent identification methods applied on the same clinical sample is recommended. This is because parasitaemia may fluctuate below agent detection limits in carrier animals, while antibodies may still be detected using serology. Conversely, in early infection, or in cases where a carrier is not exposed to vector and parasite challenge, the antibody titre may fall below the detection limit, while still testing positive for the agent.

1. Detection and identification of the agent

1.1. Microscopic examination

Multinucleate intralymphocytic and extracellular schizonts can be found in Giemsa-stained biopsy smears of lymph nodes, and are a characteristic diagnostic feature of acute infections with *T. parva* and *T. annulata*. Both intracellular and free-lying schizonts may be detected, the latter having been released from parasitised cells during preparation of the smears. Schizonts are transitory in *T. mutans* and the *T. orientalis/buffeli* group, in which the piroplasm stage may be pathogenic. *Theileria taurotragi* schizonts are not readily detected in Giemsa-stained blood smears. A veil to the side of the piroplasm may distinguish *T. velifera*. The schizonts of *T. mutans*, if detected, are distinct from *T. parva*, having larger, flattened, and irregular nuclear particles. The piroplasms (intra-erythrocytic stage) of *T. parva*, *T. annulata* and *T. mutans* are similar, but those of *T. annulata* and *T. mutans* are generally larger and may be seen to divide. However, for practical purposes schizonts and piroplasms of different theilerias are very difficult to discriminate in Giemsa-stained smears.

The schizont is the pathogenic stage of *T. parva* and *T. annulata*. It initially causes a lymphoproliferative, and later a lymphodestructive disease. The infected animal shows enlargement of the lymph nodes, fever, a gradually increasing respiratory rate, dyspnoea and/or diarrhoea. The most common post-mortem lesions are enlarged lymph nodes, a markedly enlarged spleen, pulmonary oedema, froth in the trachea, erosions and ulceration of the abomasum, and enteritis with necrosis of Peyer's patches. Lymphoid tissues become enlarged in the initial stages of the disease, but then atrophy if the animal survives into the chronic stages of the disease. When examined histologically, infiltrations of immature lymphocytes are present in lung, kidney, brain, liver, spleen, and lymph nodes. Schizont-parasitised cells may be found in impression smears from all tissues: lung, spleen, kidney and lymph node smears are particularly useful for demonstrating schizonts. In longer standing cases, foci of lymphocytic infiltrations in kidneys appear as white infarcts. In animals that recover, occasional relapses may occur. A nervous syndrome called 'turning sickness' is sometimes observed in *T. parva*-endemic areas, and is considered to be associated with the presence of intravascular and extravascular aggregations of schizont-infected lymphocytes, causing thrombosis and ischaemic necrosis throughout the brain.

In *T. annulata*, both the schizont and piroplasm stages may be pathogenic. Schizonts are scarce in the peripheral blood of acutely sick animals and their presence in blood smears indicates a poor prognosis. However, schizonts can be easily detected in smears from lymph nodes, spleen and liver tissues obtained by needle biopsy of these organs. The gross pathology caused by schizonts of *T. annulata* resembles that of *T. parva*, while anaemia and jaundice are features of both schizont and piroplasm pathology. Pathogenic strains of *T. mutans* also cause anaemia, as can strains from Japan and Korea referred to as *T. sergenti*, as well as the pathogenic *T. orientalis* strains.

Piroplasms of most species of *Theileria* may persist for months or years in recovered animals, and may be detected intermittently in subsequent examinations. However, negative results of microscopic examination of blood films do not exclude latent infection. Relapse parasitaemia can be induced with some *Theileria* species by splenectomy. Piroplasms are also seen in impression smears prepared at post-mortem, but the parasites appear shrunken and their cytoplasm is barely visible.

1.2. Molecular methods

The early DNA-based molecular methods to detect *Theileria* species were based on Southern blotting using a range of probes, derived from ribosomal RNA gene sequences, to detect all the *Theileria* species that are known to infect cattle (Allsopp *et al.*, 1993; Bishop *et al.*, 1995). DNA probes specific for *T. parva* (Allsopp & Allsopp, 1988; Conrad *et al.*, 1987; Morzaria *et al.*, 1999a) and *T. mutans* (Morzaria *et al.*, 1989) were also developed. The Southern blotting methods have largely been supplanted by species-specific conventional PCR protocols designed to detect *T. annulata* or *T. parva* carrier cattle using PCR followed by agarose electrophoresis-based detection (Bishop *et al.*, 1992; D'Oliveira *et al.*, 1995; Odongo *et al.*, 2010; Skilton *et al.*, 2002). Several PCR assays have also been developed using specific genes or satellite sequences for characterisation of different isolates/strains/clones of *T. parva* (Geyson *et al.*, 1999; Oura *et al.*, 2003; Patel *et al.*, 2011). Whole genome sequencing may become a method to differentiate between disease syndrome strains.

A reverse line blot (RLB) assay based on hybridisation of PCR products to specific oligonucleotide probes immobilised on a membrane for simultaneous detection of different *Theileria* species has been introduced (Gubbels *et al.*, 1999), and fluorescence resonance energy transfer (FRET)-based real-time assays have been developed and largely replace conventional PCR assays in diagnostic laboratories because of their ease of use and to prevent contamination developed for specific diagnosis of *T. parva* (Pienaar *et al.*, 2011; Ros-Garcia *et al.*, 2012; Sibeko *et al.*, 2008).

The primer and probe sequences for several of these assays are presented in Table 2, together with the cycling conditions for the commonly used p104 nested PCR for *T. parva*.

PCR amplification of the p33/34 genes of the *T. orientalis/buffeli* complex followed by restriction enzyme analysis can be used to characterise the various types (Kawazu *et al.*, 1992; Kubota *et al.*, 1995). A multiplex real-time PCR has been developed that can detect and differentiate the buffeli, Ikeda, chitose and type 5 strains (Perera *et al.*, 2015). The multiplexed tandem PCR amplifies the 23-kDa piroplasm membrane protein, nuclear internal transcribed spacer I and the major piroplasm surface protein. The test is sold as a kit and details on the primers are proprietary. A quantitative real-time PCR able to detect *T. orientalis* Ikeda and Chitose strains has also been developed based on the major piroplasm surface protein (Bogema *et al.*, 2015).

Table 2. PCR primers and probes for the detection of *Theileria annulata* or *T. parva*

Target gene	Primer sequences (5'-3')	Probe sequences/cycling conditions	Reference
<i>Theileria annulata</i>			
30 kDa protein	GTA-ACC-TTT-AAA-AAC-GT GTT-ACG-AAC-ATG-GGT-TT	n/a	D'Oliveira <i>et al.</i> (1995)
<u>18S rRNA</u> (hydrolysis probe)	<u>AGA-CCT-TAA-CCT-GCT-AAA-TAG-G</u> <u>CAT-CAC-AGA-CCT-GTT-ATT-GC</u>	<u>FAM-AAG- [+] TTT- [+ C] TA- [+ C] TG- [+ T] CC-CGT-T-</u> <u>BHQ1 ([+ N] indicate a LNA base)</u>	<u>Ros-Garcia</u> <u><i>et al.</i> (2012)</u>
<i>Theileria parva</i>			
p104	ATT-TAA-GGA-ACC-TGA-CGT-GAC-TGC TAA-GAT-GCC-GAC-TAT-TAA-TGA-CAC-C	n/a	Skilton <i>et al.</i> (2002)
p104 (nested)	Primary PCR: ATT-TAA-GGA-ACC-TGA-CGT-GAC-TGC TAA-GAT-GCC-GAC-TAT-TAA-TGA-CAC-C Secondary PCR: GGC-CAA-GGT-CTC-CTT-CAG-ATT-ACG TGG-GTG-TGT-TTC-CTC-GTC-ATC-TGC Cycling conditions: Primary: ● 94°C for 1 minute ● 40 cycles of 94°C/1 minute, 60°C/1 minute, 72°C/1 minute	<u>Cycling conditions:</u> <u>Primary:</u> ● 94°C/1 minute ● 40 cycles of 94°C/1 minute, 60°C/1 minute, 72°C/1 minute ● 72°C for 9 minutes after the last cycle. <u>Secondary: use 1 µl primary product</u> ● 94°C/1 minute ● 30 cycles of 94°C/1 minute, 55°C/1 minute, 72°C/1 minute	Odongo <i>et al.</i> (2010)

Target gene	Primer sequences (5'–3')	Probe sequences/cycling conditions	Reference
	<ul style="list-style-type: none"> 72°C for 9 minutes after the last cycle. Secondary: <ul style="list-style-type: none"> 94°C for 1 minute <ul style="list-style-type: none"> 30 cycles of 94°C/1 minute, 55°C/1 minute, 72°C/1 minute 72°C for 9 minute after the last cycle 	<ul style="list-style-type: none"> 72°C for 9 minutes after the last cycle n/a	
18S RNA (RLB)	GAG-GTA-GTG-ACA-AGA-AAT-AAC-AAT-A TCT-TCG-ATC-CCC-TAA-CTT-TC	TTC-GGG-GTC-TCT-GCA-TGT	Gubbels <i>et al.</i> , (1999)
18S RNA (FRET)	CTG-CAT-CGC-TGT-GTC-CCT-T ACC-AAC-AAA-ATA-GAA-CCA-AAG-TC	GGG-TCT-CTG-CAT-GTG-GCT TAT-FL LCRed640-TCG-GAC-GGA-G TTC-GCT-PH	Sibeko <i>et al.</i> (2008)
<u>18S rRNA (FRET)</u>	<u>GGT-AAT-TCC-AGC-TCC-AAT-AG</u> <u>AAA-GTA-AAC-ATC-CAG-ACA-AAG-CG</u>	<u>GGG-TCT-CTG-CAT-GTG-GCT-TAT-FL</u> <u>LCRed640-TCG-GAC-GGA-GTT-CGC-T-PH</u>	<u>Pienaar <i>et al.</i> (2011)</u>
<u><i>Theileria orientalis</i></u>			
<u>Major piroplasm surface protein</u>	<u>GCA-AAC-AAG-GAT-TTG-CAC-GC</u> <u>TGT-GAG-ACT-CAA-TGC-GCC-TAG-A</u>	<u>VIC-CAT-GAA-CAG-TGC-TTG-GC-MGB (Ikeda)</u> <u>NED-TCC-TCA-GCG-CTG-TTC-T-MGB (Chitose)</u>	<u>Bogema <i>et al.</i> (2015)</u>

218 2. Serological tests

219 2.1. The indirect fluorescent antibody test

220 The indirect fluorescent antibody (IFA) test is the most widely used diagnostic test for *Theileria* spp. The
 221 IFA test is robust, easy to perform and provides adequate sensitivity and specificity for use in the field
 222 for detection of prior infection with *T. parva* and *T. annulata* under experimental situations and in a
 223 defined epidemiological environment where only one theilerial species is present. The IFA test has
 224 limitations for large-scale serological surveys due to its reduced specificity in field situations where
 225 several *Theileria* species co-exist. There is a need for tests that are more specific, easy to interpret, and
 226 robust enough to be used in field conditions. No serological tests exist yet for *T. orientalis* Chitose or
 227 Ikeda strains.

228 2.1.1. Preparation of schizont antigen

229 i) Schizont antigen slides

230 The antigens used for the IFA test are intracytoplasmic schizonts derived from infected
 231 lymphoblastoid cell lines for *T. parva* and from infected macrophage cell lines for
 232 *T. annulata*.

233 Cultures of 200 ml to 1 litre of either *T. parva* or *T. annulata* schizont-infected cells
 234 containing 10⁶ cells/ml, of which at least 90% of the cells are infected, are centrifuged at
 235 200 **g** for 20 minutes at 4°C. The supernatant fluid is removed and the cell pellet is
 236 resuspended in 100 ml of cold (4°C) phosphate-buffered saline (PBS), pH 7.2–7.4, and
 237 centrifuged as before. This washing procedure is repeated three times, and after the final
 238 wash the cell pellet is resuspended in PBS (approximately 20–100 ml) to give a final
 239 concentration of 10⁷ cells/ml.

240 Using a template or pipette tip, thin layers of the cell suspension are placed on Teflon-coated
 241 multispot slides, or on ordinary slides using nail varnish for separation. The smears should
 242 give between 50 and 80 intact cells per field view when examined under a ×40 objective
 243 lens. The antigens are distributed on to the slides using multichannel or a 100 µl pipette. By
 244 dispensing and immediately sucking up the schizont suspension, a monolayer of schizonts
 245 remains in each well. This is performed for each enclosure until the volume is exhausted.
 246 With this method, approximately 600 good quality slides containing a total of 6000 individual
 247 antigen spots can be obtained. The slides are air-dried, fixed in acetone for 10 minutes,
 248 individually wrapped in tissue paper and then in groups of five in aluminium foil, and

249 stored in airtight, waterproof plastic containers at either -20°C or -70°C . The antigens
250 keep for at least 1 year at -20°C and longer at -70°C .

251 ii) Schizont antigen in suspension

252 First, 500 ml of *T. parva*- or *T. annulata*-infected cells containing 10^6 cells/ml are centrifuged
253 at 200 **g** for 10 minutes at 4°C , and the cell pellet obtained is washed twice in 100 ml of cold
254 PBS. The viability of the cells is determined by eosin or trypan blue exclusion (it should be
255 greater than 90%). The cells are resuspended at 10^7 /ml in cold PBS. To this volume, two
256 volumes of a cold fixative solution containing 80% acetone and 0.1% formaldehyde (0.25%
257 formalin) in PBS are added drop by drop while the cell suspension is stirred gently and
258 continuously in an ice bath. The cell suspension is kept at -20°C and allowed to fix for
259 24 hours. Siphon about 2/3 of the volume off, centrifuge and decant. The fixed cells are then
260 washed three times in cold saline and centrifuged at 200–400 **g** for 20 minutes at 4°C . After
261 the last wash, the cells are resuspended into 5 ml PBS + 0.2% BSA (bovine serum albumin)
262 at 10^7 /ml. The fixed cells are distributed in aliquots of 0.5 ml. The antigen is stable at 4°C
263 with 0.2% sodium azide as preservative for 2 weeks, and keeps indefinitely at -20°C . This
264 method can also be used to prepare schizont antigen for *T. taurotragi*.

265 2.1.2. Preparation of piroplasm antigen

266 The piroplasm stage of *Theileria* spp. cannot be maintained in culture, therefore the piroplasm
267 antigen must be prepared from the blood of infected animals. Due regard should be paid to the
268 principle of 'The Three Rs' as set out in the WOAH *Terrestrial Code*, Chapter 7.8 *Use of animals*
269 *in research and education*.

270 i) Piroplasm antigen slides

271 Experimental infections are induced by infecting cattle subcutaneously with sporozoites, or
272 applying ticks infected with *T. parva*, *T. annulata* or *T. taurotragi*. Infection with *T. annulata*
273 is invariably produced by inoculation of blood drawn from cattle with acute theileriosis.
274 Splenectomy of the recipient cattle prior to the infection considerably increases the
275 piroplasm parasitaemia in red blood cells (RBC). Peak parasitaemias are of short duration
276 and if animals survive the disease the percentage of infected RBC decreases considerably
277 in a few days. Infections with the parasite group referred to as *T. orientalis/buffeli*, *T. mutans*
278 or *T. velifera* are usually induced by inoculating splenectomised cattle intravenously with
279 blood from a carrier animal, or with a blood stabilate, or by application of infected ticks. When
280 the piroplasm parasitaemia is 10% or higher, 100 ml of the infected blood is collected from
281 the jugular vein in a heparinised or ethylene diamine tetra-acetic acid (EDTA) vacutainer,
282 and gently mixed with 2 litres of PBS. The mixture is centrifuged at 500 **g** for 10 minutes at
283 4°C ; the plasma and buffy coat are removed, the RBC are again resuspended in 2 litres of
284 PBS, and the centrifugation step is repeated. It is important to remove the buffy coat after
285 each wash. This washing procedure is repeated four times. After the final wash, an aliquot
286 of the packed RBC is used to make doubling dilutions in PBS, and a 5 μl drop of each dilution
287 is placed on slides. The dried spots are fixed in methanol and stained with Giemsa's stain,
288 and the concentration of RBC is examined using a light microscope. The dilution that gives
289 a single layer of RBC spread uniformly on the spot is then selected for large-scale
290 preparation of piroplasm antigen slides. Approximately 10,000 antigen slides
291 (100,000 antigen spots) can be prepared from 100 ml of infected blood. The antigen smears
292 are allowed to dry at room temperature before fixing in cold (4°C) acetone for 10 minutes.
293 The fixed smears can be stored as for the schizont antigen slides, and kept for similar
294 periods.

295 ii) Piroplasm antigen suspension

296 An alternative method of preparing antigens to that described above is available, and has
297 been tested for *T. parva*. In this procedure, 100 ml of blood are taken from an animal with a
298 high piroplasm parasitaemia and prepared as described previously, and the packed cell
299 volume is adjusted to 5% in PBS.

300 One volume of the RBC suspension is added to two volumes of the fixative (see Section
301 B.2.1.1.ii above) while stirring. The cells are allowed to fix at -20°C for 24 hours. The fixed
302 cells are then washed three times with PBS and centrifuged at 1000 **g** for 30 minutes. The
303 deposit is resuspended to the original volume of blood with PBS containing 0.2% sodium
304 azide, and distributed in aliquots of 0.5 ml.

305 The piroplasm antigen is stable at 4°C when preserved with 0.2% sodium azide for a period
306 of at least 3 years.

307

2.1.3. Standardisation of antigen

308 Schizont or piroplasm antigen suspensions are mixed on a rotor mixer and titrated in PBS by
309 doubling dilution starting from undiluted through to 1/16. The dilution giving a cell distribution of
310 approximately 50–80 schizont-infected cells or 150–200 infected RBC per field view when
311 examined under a $\times 40$ objective lens is recommended for use for that batch of antigen. Using this
312 dilution, test antigen smears are prepared on slides. These antigen smears plus the antigen slides
313 previously frozen (and thawed before use) are tested against a range of dilutions of a panel of
314 known strong, intermediate and weak positive and negative control sera. If the positive control
315 sera titrate to their known titres and the negative control sera give no fluorescence, the antigen is
316 used in the routine IFA test.

317 Both types of antigen preparations, acetone-fixed smears stored at either -20°C or -70°C , and
318 antigens fixed in suspension and stored at either 4°C or -20°C , are used routinely in many
319 laboratories. The sensitivity of both types of antigen is comparable. In laboratories where
320 adequate low temperature storage facilities and a reliable supply of electricity are available, the
321 antigen slides can be used. However, such antigens can only be transported on dry ice or in liquid
322 nitrogen. Antigens fixed in suspension have the advantage over antigen slides in that the initial
323 method of preparation is simpler and quicker. A large batch of this antigen can be stored in one
324 container, and aliquots may be taken out as necessary from which fresh smears are prepared for
325 the IFA test. The need for a large storage facility is thereby avoided. The antigens fixed in
326 suspension can also be stored at 4°C and can be safely transported at room temperature without
327 loss of antigenicity.

328

2.1.3.1. Preparation of bovine lymphocyte lysate

329 A lymphocyte lysate is prepared according to the method described by Goddeeris *et al.*
330 (1982), for use in tests with antigens of *T. parva* in suspension. Briefly, a 3-month-old calf is
331 splenectomised and maintained in a tick-free environment. To exclude the possibility of
332 latent theilerial infections, Giemsa-stained blood smears are examined daily for a period of
333 4 weeks for parasites. The parasite-free animal is killed and the thymus and all the
334 accessible lymph nodes are removed. These tissues are sliced into small pieces in cold PBS
335 containing 0.45% EDTA as anticoagulant. Cells are teased out of the tissue, separated from
336 the debris by passing through a muslin cloth, and washed three times with PBS/EDTA by
337 centrifugation at 200 *g* for 20 minutes at 4°C . The washed lymphocytes are resuspended in
338 PBS without EDTA, to give a final concentration of 5×10^7 cells/ml. The cells are disrupted
339 by sonication in 100-ml aliquots on ice for 5 minutes using the 3/8 probe. The sonicated
340 material is centrifuged at 1000 *g* for 30 minutes at 4°C , and the supernatant, adjusted to
341 10 mg protein/ml, is stored at -20°C in 4-ml aliquots.

342

2.1.3.2. Test procedure

- 343 i) With schizont or piroplasm slide antigen
- 344 a) Remove antigen slides from freezer and allow to thaw for 30 minutes at 4°C and then for
345 30 minutes at room temperature.
- 346 b) Inactivate the sera to be tested for 30 minutes in a water bath at 56°C .
- 347 c) Unpack the slides and label the numbers of the sera tested.
- 348 d) Prepare 1/40 and 1/80 dilutions of sera to be tested. Validated positive and negative sera
349 are included with each test as controls. Further doubling dilutions can be made if end-point
350 antibody titres are desired.
- 351 e) Transfer 25 μl of each serum dilution to a spot of antigen.
- 352 f) Incubate in a humid chamber for 30 minutes at room temperature.
- 353 g) Remove the serum samples from the antigen wells by washing with PBS and rinse by
354 immersing in two consecutive staining jars containing PBS for 10 minutes each time.
- 355 h) Distribute to each well 20 μl of diluted anti-bovine immunoglobulin fluorescein isothiocyanate
356 conjugate at appropriate dilution (generally, dilutions recommended by manufacturers are
357 suitable; however, minor adjustments may be necessary for optimal results). Incorporate
358 Evans blue into the conjugate at a final dilution of 1/10,000 as a counterstain and incubate
359 in a humid chamber for 30 minutes at room temperature.
- 360 i) Repeat step g and mount with a cover-slip in a drop of PBS/glycerol (50% volumes of each).
- 361 j) Read the slides under a fluorescent microscope equipped with epi-Koem illumination (100 W
362 mercury lamp), UV filter block, $\times 6.3$ eyepieces and Phaco FL 40/1.3 oil objective lens.

- 363 ii) With schizont antigen stored in suspension
 364 a) Thaw frozen antigen at room temperature.
 365 b) Distribute the antigen suspension on the spots of multispot slides, using multichannel or a
 366 100- μ l pipette. By dispensing and immediately sucking up the suspension a monolayer of
 367 schizont-infected cells remains on each well.
 368 c) Allow slides to dry at room temperature or 37°C.
 369 d) Dilute test and control sera 1/40 in lymphocyte lysate (195 μ l lymphocyte lysate + 5 μ l
 370 serum).
 371 e) Proceed as described in steps e to j (Section B.2.1.3.2.i).
- 372 iii) With piroplasm antigen stored in suspension
 373 a) Resuspend piroplasm antigen (stored at 4°C) by agitation and disperse RBC by passing the
 374 suspension through a 25-gauge needle to break the clumps.
 375 b) Dilute the antigen to previously standardised dilutions (see preparation of piroplasm
 376 antigen).
 377 c) Allow slides to dry at room temperature or 37°C.
 378 d) Proceed as described in steps d and e (Section B.2.1.3.2.ii).

379 2.1.4. Characteristics of the indirect fluorescent test

380 The incorporation of Evans blue provides a good contrast, enabling good differentiation of non-
 381 infected cells from the infected ones under the fluorescent microscope. Mounting the slides in
 382 50% glycerol, at pH 8.0, reduces the rapid fading of fluorescein isothiocyanate and makes
 383 photography of the preparation possible. Once prepared, slides are stable and can be read for up
 384 to 72 hours after preparation when kept at 4°C in the dark.

385 The sensitivity of the IFA test depends on the period of time that has elapsed since the onset of
 386 infection. Following infection with sporozoites, antibodies to *T. parva* and *T. annulata* are first
 387 detected between days 10 and 14 using the schizont antigen. Using the piroplasma antigen,
 388 antibodies are first detected between days 15 and 21. Antibodies last for a variable period of time
 389 after recovery, depending on such factors as the establishment of a carrier state,
 390 chemotherapeutic intervention, and presence or absence of a rechallenge. Following recovery
 391 from infection with *T. parva* or *T. annulata*, high levels of antibody are generally detected for 30–
 392 60 days. The antibody levels gradually decline and low antibody titres are still detectable 4–
 393 6 months after recovery. Later, antibody may become undetectable at a serum dilution of 1/40,
 394 but may persist for more than 1 year following a single challenge. In ECF endemic regions, the
 395 seroprevalence in cattle population fluctuates considerably depending on the level and regularity
 396 of challenge. In an endemic area where a seasonal transmission cycle of ECF occurs, IFA has
 397 been shown to lack sensitivity. The overall diagnostic sensitivity of the IFA test has been evaluated
 398 as 55% at a cut off titre 1/40 and 28% at cut off 1/160. The specificity of the test for the two cut
 399 off points was 86% and 95% respectively (Billiouw *et al.*, 2005).

400 The IFA test is useful for identifying herds that contain carriers of *T. annulata*, but is not always
 401 sufficiently sensitive to detect all infected individuals. Both schizont and merozoite (piroplasm) IFA
 402 antigens have failed to detect antibody in some animals despite carrying patent infection with
 403 piroplasms (Darghouth *et al.*, 1996).

404 In *T. mutans* infections induced by sporozoite inoculation, antibodies are first detected between
 405 days 10 and 15 after the appearance of piroplasms. Low titres are detectable for at least 12–
 406 24 months.

407 The *T. parva* IFA test is highly sensitive for detection of antibodies in an epidemiological situation
 408 where only one species of *Theileria* exists. However, if the test is used to detect antibodies where
 409 mixed infections of *Theileria* occur, the specificity of the test needs to be carefully evaluated. For
 410 example, *T. annulata* and *T. parva* cross-react, although these cross-reactions are four- to six-
 411 fold lower than with the homologous sera. The cross-reactivity between the two species has little
 412 practical significance as the geographical distribution of these two parasites does not overlap. In
 413 the IFA test such cross-reactivity does not occur between *T. parva* and *T. mutans* or between
 414 *T. annulata* and *T. mutans*. There is a low level of cross-reactivity between *T. parva* and
 415 *T. taurotragi*, reducing the specificity of these two tests in many parts of sub-Saharan Africa where

416 their distribution overlaps. In areas where African buffalo and cattle come into frequent contact,
417 cross-reactivity between *T. parva* and *Theileria* sp. (buffalo) may occur in cattle.

418 A panel of monoclonal antibodies (MAbs) detecting various epitopes on the polymorphic
419 immunodominant antigen of the *T. parva* schizont stage has been generated. This panel can be
420 used in the IFA test using the schizont-infected lymphoblastoid cells to detect differences between
421 certain stocks of *T. parva* and between *T. parva* and other theilerial species. This test has been
422 deployed as one of the several characterisation tools to differentiate various stocks of *T. parva*,
423 and for quality control during sporozoite stabilate preparation (Bishop *et al.*, 1994).

424 2.2. Enzyme-linked immunosorbent assays

425 Serological tests based on the enzyme-linked immunosorbent assay (ELISA) have been developed for
426 the detection of antibodies to *T. annulata* (Gray *et al.*, 1980). Tests used for *T. parva* and *T. mutans* are
427 indirect ELISAs based on parasite-specific antigens, PIM and p32, respectively (Katende *et al.*, 1998;
428 Morzaria *et al.*, 1999a). These ELISAs provide higher (over 95%) sensitivity than the IFA tests. The
429 ELISA reagents are available from the International Livestock Research Institute, Nairobi, Kenya. The
430 PIM antigen shows cross-reactivity between *T. parva* and *T. sp.* (buffalo) and should be considered as
431 a confounding factor where African buffalo and cattle come into contact.

432 C. REQUIREMENTS FOR VACCINES

433 C1. Cell culture live vaccines for *Theileria annulata*

434 1. Background

435 Vaccination against *T. parva* and *T. annulata* has been attempted since the causal organisms were first recognised
436 early in the last century. However, reliable live vaccines of known potency are a more recent development. The
437 most widely used are attenuated schizont cell culture vaccines against *T. annulata*. The procedures for production
438 and safety testing have been described (Food and Agriculture Organization of the United Nations [FAO], 1984;
439 Hashemi-Fesharki, 1988; Pipano, 1989b), and the vaccine is used in Israel, Iran, Turkey, Spain, India, northern
440 Africa, central Asia and the People's Republic of China.

441 Despite the fact that vaccination with the cell culture vaccine against *T. annulata* has been available for more than
442 three decades and has shown to be effective under field conditions, the use of this vaccine has been limited. The
443 concern about the introduction of vaccine-derived parasites into the field tick population has led to individual
444 countries developing vaccines from local isolates (Morisson & Mc Keever, 2006). Some attenuated cell lines have
445 lost the ability to differentiate to erythrocytic merozoites (piroplasms) when inoculated to cattle and in one instance,
446 *Hyalomma* nymphs fed on vaccinated cattle did not become infected (Kachani *et al.*, 2004a). However, in most
447 cases the loss of differentiation is based on macroscopic examination of blood films from vaccine inoculated cattle.
448 This drawback, the difficulties in standardisation of the antigenic composition of the cultured parasites and the need
449 of a cold chain for distribution of the vaccine to the field are limiting factors in commercialisation of this vaccine
450 (Morisson & Mc Keever, 2006).

451 2. Outline of production and minimum requirements for vaccines

452 2.1. Characteristics of the seed

453 2.1.1. Biological characteristics of the master seed

454 Primary cultures of *T. annulata*-infected cells may be established from trypsinised lymph nodes,
455 liver, or spleen taken aseptically from an infected animal after death, or from the buffy coat of
456 heparinised peripheral blood separated on a density gradient (Ficoll Hypaque), or by lymphocytes
457 harvested from lymph node biopsy material using a plastic syringe method (Brown, 1979; FAO,
458 1984).

459 Seed cultures are prepared from cryopreserved cell lines that have been isolated from cattle and
460 attenuated as described below. Vaccines should be produced from a seed culture (master seed)
461 that has been passed less than 30 times, because there is some uncertainty about the
462 immunogenic stability of these cultures in long-term passage.

463

2.1.2. Quality criteria (sterility, purity, freedom from extraneous agents)

464
465
466
467
468

Tests for sterility and freedom from contamination of biological materials intended for veterinary use may be found in chapter 1.1.9. As cell culture material is derived from field animals, their cells might be potential sources of contamination of the vaccine with extraneous pathogens. Potential contaminants include bovine leukosis, mycoplasma, bovine viral diarrhoea virus, bovine spongiform encephalopathy (BSE) and other bacteria and viruses.

469
470
471

Cell cross-contamination in cell cultures is a common problem during cell culturing and use. The problem can be solved by increasing the awareness and by introducing regular quality control of cell cross-contamination.

472

2.1.3. Validation as a vaccine strain

473
474
475
476
477
478
479
480
481
482

Attenuation of *T. annulata* schizonts is achieved by prolonged growth and passage in culture (Pipano, 1989b). The loss of parasite virulence appears to be due to a change in parasite gene expression. Attenuation is assessed by the inoculation of the culture into susceptible calves every 20–30 passages. A sample of culture should be cryopreserved every ten passages in case of accidental loss or contamination. Complete attenuation is achieved when cultures do not cause fever or detectable schizonts and piroplasms in susceptible cattle but could take up to 300 passages. An attenuated culture will reliably infect cattle at 10^5 cells and induce a serological reaction, and will not produce disease at 10^9 cells. Cultures may be cryopreserved using either dimethyl sulphoxide (DMSO) or glycerol. Two methods of storing and delivering the vaccine are described below.

483

2.2. Method of manufacture

484

2.2.1. Procedure

485
486
487
488
489
490
491
492
493
494
495
496

The infected cells are cultured initially in Eagle's minimal essential medium (MEM) or Leibovitz L15 medium supplemented with 20% calf serum and containing penicillin (100 units/ml), streptomycin (50 µg/ml), and mycostatin (75 units/ml) in ~~25-ml~~ 25-cm² plastic screw-cap tissue-culture flasks. An alternative medium is RPMI 1640 with 10% fetal calf serum, 2 mM glutamine, penicillin and streptomycin, and is usually used with established cultures. Medium is replenished every 3–4 days. The presence of bright refractile cells free in the medium (on examination using a phase-contrast or inverted microscope) is indicative of infected cell growth. The cultures may establish as a monolayer or in suspension. Passage is ~~effected~~ performed by decanting the medium, adding 0.025% EDTA (versene) for 15 minutes to monolayer cultures, dispersing the cells, then counting and dispensing according to flask size. Approximately 10^6 cells are introduced into a 25 cm² flask, and the same seed rate in 100–200 ml is used in larger flasks. The general culture technique is as described by Brown (1979).

497
498
499

Serum is essential for maintenance of these cultures, and is obtained either from calves up to the age of 6 months, or from commercial sources, and is tested for toxicity through three passages in an established cell line before use.

500

2.2.2. Requirements for ingredients

501
502

Before starting to produce vaccine, seed material with known characteristics is required (~~Pipano, 1997~~). Three types of seed material are distinguished:

503

i) Master seed

504
505
506
507
508
509
510
511
512
513

Schizont-infected cells from a specific passage that have been selected and permanently stored and from which all other passages are derived. The master seed should consist of a single uniform batch of seed that has been mixed and filled into containers as one batch. As *T. annulata* schizont-infected cells are used for the manufacturing process, the master seed also represents the master cell stock (see Chapter 1.1.8 *Principles of veterinary vaccine production*). To prepare a master seed, schizont-infected cells that have proved to be safe for cattle are propagated to obtain in a single culture passage approximately 5×10^8 cells. The cells are cryopreserved in about 100 cryotubes each containing 5×10^6 cells. A viability check of the master seed should be performed once the master seed has been cryopreserved for at least 24 hours by reviving one of the cryotubes.

514

ii) Working seed

515
516

Schizont-infected cells at a passage level between the master seed and the production seed. To prepare a working seed, the contents of a single cryotube of master seed are

517 transferred to a 10 ml centrifuge tube containing 8 ml complete medium. The tube is
518 centrifuged at 600 **g** for 15 minutes at 4°C and the pellet is transferred into a 75 cm² culture
519 flask containing 15–20 ml medium. The medium is replaced the next day, and 4 days later
520 the cells are dispersed and subcultured in larger vessels. After 5–6 subcultivations, a
521 sufficient number of infected cells is available to start the production run.

522 iii) Production seed

523 Schizont-infected cells from a specific passage level are used without further propagation
524 for the preparation of a batch of vaccine. The production seed is obtained by propagating
525 large numbers of cells in monolayer or suspension cultures. Monolayer cultures are grown
526 in flasks, 150 cm² to 175 cm², which usually provide an average of from 7 × 10⁷ to 8 ×
527 10⁷ cells per vessel. About 80 ml of complete medium per flask is required. In a roller bottle
528 culture system, 1.2–1.5 × 10⁸ cells can be obtained in a conventional roller bottle (700 cm²)
529 containing 100–120 ml of medium. To obtain optimal yield of cells, stationary cultures or
530 roller bottles cultures are incubated for 6–7 days with culture media as described previously,
531 see Section C1.2.2.1.

532 The schizont-infected cells from all vessels are harvested and pooled together and the total
533 number is computed. Alternatively, about 20% of the cells may be seeded again to prepare
534 another batch of vaccine. Several batches of vaccine can be produced using a portion of the
535 production seed as working seed. As prolonged cultivation may generate alteration in the futures
536 of the schizonts, such as immunogenic capacity, after several batches, subsequent vaccine is
537 produced by making a fresh production seed from the master seed.

538 Schizont-infected cells are mixed with DMSO at a final concentration of 7% or glycerol at a final
539 concentration of 10%, and dispensed in 1.8-ml aliquots into 2-ml plastic vials, each vial containing
540 ten doses of concentrated vaccine. As DMSO immediately penetrates the cell membranes, the
541 time spent in dispensing the vaccine into the vials should be as short as possible. When glycerol
542 is used, an equilibration time of 30–40 minutes is required before freezing the vaccine. There is
543 no consensus on how many schizont-infected cells should constitute one dose of the vaccine. A
544 recommended practical approach is to prepare doses of 10⁶–10⁷ infected cells in order to
545 counteract variable environmental conditions in the field. However, considerable protection
546 against sporozoite-induced infection has been achieved by vaccination with 10⁵ infected cells
547 (Kachani *et al.*, 2004b).

548 The vaccine is frozen by introducing the vials in an ultracold deep freezer (–70°C) and transferring
549 them 24 hours later to liquid nitrogen containers. Alternatively, vials can be introduced in gas
550 phase liquid nitrogen for 3 hours and then immersed in the liquid nitrogen for storage (Pipano,
551 1989b). Vaccine is transported to the field in liquid nitrogen, and diluted 1/10 in isotonic buffered
552 saline in a screw-cap bottle with a rubber or silicone septum for aseptic withdrawal. For dilution
553 of vaccine frozen with glycerol, isotonic buffered saline should also contain 10% glycerol in order
554 to avoid osmotic damage to the schizonts. The vaccine is administered subcutaneously within
555 30 minutes of thawing (Pipano, 1977).

556 The vaccination regimen in Iran up to 1990 was to inoculate two different mild strains 1 month
557 apart. But, in order to reduce cost and save time, a new method was implemented involving only
558 a single dose of a local live attenuated vaccine strain (Hashemi-Fesharki, 1998). A fresh culture
559 vaccine is used in Morocco, usually at a tenfold lower dose (10⁴ schizont-infected cells) (Kachani
560 *et al.*, 2004b). However, there are problems with quality control of vaccines with short shelf life.

561 **2.2.3. In-process controls**

562 Records of the source and passages of the working seed material should be maintained. Seeds
563 should be free of infective agents such as enzootic bovine leukosis, bovine immunodeficiency
564 virus, bovine pestivirus, bovine syncytial virus, Rift Valley fever, etc. Test procedures will depend
565 on availability preferably using DNA analysis.

566 pH, temperature and coloration of the solutions should be checked during the process and must
567 have been shown to be free from contaminants. Numbers and contamination in growing cell
568 cultures should be checked on a daily basis by examination using an inverted microscope.

569 **2.2.4. Final product batch tests**

570 i) Sterility

571 572	Tests for sterility and freedom from contamination of biological materials intended for veterinary use may be found in chapter 1.1.9.
573	ii) Safety precautions
574 575 576	Safety tests in target animals are not required by many regulatory authorities for the release of each batch. Where required, standard procedures are generally conducted using fewer animals than are used in the safety tests required for the relevant regulatory approval.
577 578 579	<i>Theileria annulata</i> schizonts are not hazardous for humans or contagious for animals, therefore the main purpose in designing a vaccine production facility is to prevent contamination of the product by extraneous organisms.
580	a) Freedom from properties causing undue local or systemic reactions
581 582 583 584 585 586 587	For testing the safety of the master seed, two to four susceptible calves, of the most sensitive stock available, are inoculated with a tenfold greater dose than is recommended for immunisation. This dose should not produce clinical signs beyond a transient rise in temperature. With completely attenuated master seed, no schizonts or piroplasms will be seen in lymph node and liver smears or in blood films. However, different breeds of cattle may show different sensitivities to the vaccine. This should be borne in mind when vaccine from a partially attenuated master seed is to be administered to high-grade cattle stocks.
588 589 590 591 592	Following a successful test for safety of a sample, all subsequent batches produced from the same master seed can be released without further testing for safety. However, if parasites are detected in the blood or tissues of vaccinated field animals, or if clinical signs develop following the inoculation of the vaccine, the batch or a parallel batch, from the same master seed, should be retested for safety.
593	iii) Batch potency
594 595	In Israel the schizont vaccines are tested using a documented procedure (Pipano, 1989a) before release.
596 597 598 599 600 601 602 603 604	Usually, the schizont vaccine is produced in small individual batches (3–5 thousand doses), which makes the full testing of each batch impractical for economic reasons. It is recommended therefore that the first batch of vaccine produced from a master seed be tested for safety, efficacy, potency and sterility, while each subsequent batch be tested for sterility and potency only. This recommendation is based on the fact that once the cultured schizonts become attenuated, no reversion to virulence has ever been observed during further cultivation. As far as efficacy is concerned, no obvious alteration of the immunogenic properties has been observed during the limited number (20–30) of passages involved in producing the actual vaccine.
605	a) Viability of schizont-infected cells
606 607 608 609 610 611 612 613 614 615	The potency test is conducted by quantitative <i>in-vitro</i> methods. Frozen vaccine remains stable during the storage period, even for long periods, but some loss of viability occurs during the freezing and thawing processes. Viability should be tested under conditions as similar as possible to those obtained when the vaccine is used in the field. For this reason, vaccine should be thawed and the diluted suspension of schizont-infected cells should be left at ambient temperature for 60 minutes before performing the viability tests. A simple test for evaluating viability of the infected cells is nigrosin dye exclusion counting (Wathanga et al., 1986) . Vaccine that, after being thawed and diluted and left at room temperature for 1 hour, still contains 50% or more live cells can be released for use although in most cases 80–90% of live cells are found.
616 617 618 619 620 621 622 623 624 625 626	Viability of the schizonts is also reflected by the plating efficiency of the schizont-infected cells (Wathanga et al., 1986) , as only cells containing viable schizonts multiply in culture. For this purpose, the thawed, diluted vaccine is transferred from the bottle to a centrifuge tube. A sample for counting is taken and the suspension is centrifuged for 15 minutes at 600 g . Meanwhile, the total number of cells (live and dead) is determined in order to ascertain that the frozen vaccine had the necessary initial concentration of cells. After centrifugation, the supernatant is discarded and the cells are resuspended to the original volume using complete culture medium. Serial tenfold dilutions of cells in complete medium are performed in sterile 10 ml tubes so that the last two dilutions contain 50, and 5 cells per ml, respectively. Twelve replicates of 200 µl from each of the last two dilutions are introduced into a 96-well culture plate. The plates are incubated at 37°C in a 5% CO ₂ atmosphere and

627 cultures are checked with an inverted microscope 6 and 9 days after seeding. The number
628 of wells theoretically containing 1 cell each in which growth is observed is counted. Vaccine
629 showing a plating efficiency <2 (cells) are adequate for field use.

630 **2.3. Requirements for ~~authorisation/registration/licensing~~ regulatory approval**

631 **2.3.1. Manufacturing process**

632 For ~~registration~~ regulatory approval of vaccine, all relevant details concerning manufacture of the
633 vaccine and quality control testing (see Sections C2.2.1 and C2.2.2) should be submitted to the
634 regulatory authorities. This information shall be provided from three consecutive vaccine batches
635 with a volume not less than 1/3 of the typical industrial batch volume.

636 **2.3.2. Safety requirements**

637 i) Target and non-target animal safety

638 *Theileria annulata* schizonts are not contagious for animals. These vaccines produce no
639 adverse effects in healthy cattle. However, animals with existing infections, particularly viral
640 infections, may not tolerate vaccination well. The administration of a viral vaccine, such as
641 for foot and mouth disease, during the immunisation period (reaction period) is not
642 recommended as the immune response may be compromised (Hashemi-Fesharki, 1988).
643 In Iran, it is not recommended to vaccinate cows that are over 5 months pregnant, although
644 studies in pregnant cattle with the vaccine stocks used in Israel found no effect on pregnancy
645 (Pipano, 1989a). The immunity engendered is long lasting.

646 In general, cattle should be immunised in the first few months of life, and tick challenge
647 under natural conditions reinforces the immunity. Although antigenically different strains of
648 *T. annulata* have been identified (Pipano, 1977), it is generally considered that there is
649 sufficient cross-protection among strains to provide adequate protection against field
650 challenge as observed in Israel. In the vast infected areas of central Asia, a single stock has
651 proved immunologically effective in 1.5 million cattle (Dolan, 1989; Wathanga et al., 1986).
652 However, as described previously, two stocks are used routinely in Iran (Hashemi-Fesharki,
653 1988).

654 ii) Reversion-to-virulence for attenuated/live vaccines and environmental considerations

655 Once the cultured schizonts become attenuated, no reversion-to-virulence has ever been
656 observed during further cultivation.

657 iii) Precautions (hazards)

658 Different breeds of cattle may show different sensitivities to the vaccine. This should be
659 borne in mind when vaccine from a partially attenuated master seed is to be administered
660 to high-grade cattle stocks.

661 **2.3.3. Efficacy requirements**

662 i) Capacity to protect against naturally transmitted theileriosis

663 The batch of experimental vaccine used for the safety test can also be used for testing
664 efficacy of the culture-derived anti-theilerial vaccine. Three or four calves are vaccinated
665 with a conventional dose of vaccine and 6 weeks later, the vaccinated calves and the same
666 number of unvaccinated calves are infected with sporozoites of *T. annulata*. Infection can
667 be induced by live adult ticks issued from *T. annulata*-infected pre-imaginal stages or by
668 inoculation of stabilate prepared from macerated infected ticks (for techniques see Section
669 C2.2) Experience shows that inoculation of stabilate (macerated ticks) generally induces a
670 more severe response than an equivalent number of live, infected ticks allowed to feed on
671 the cattle. However in the long run, the results obtained by challenge with stabilate appear
672 to be more reproducible than those obtained with different batches of live ticks.

673 There are no internationally agreed standards for the size of a challenge dose used in testing
674 the efficacy of *T. annulata* culture-derived vaccine. Five to ten female and the same number
675 of infected, unfed male *Hyalomma* ticks have been used for infection of cattle. Alternatively,
676 stabilate equivalent to 2–4 macerated ticks inoculated subcutaneously in the neck area will
677 invariably produce acute theileriosis. The responses to the challenge infection of the
678 vaccinated and unvaccinated control calves are monitored using the following parameters:
679 duration and severity of pyrexia, rate of schizont-infected cells in lymph node or liver biopsy
680 smears, rate of piroplasm infected erythrocytes in the blood films, decrease in white and red

681 blood cell counts, and severity of clinical manifestations such as anorexia, depression and
682 recumbency.

683 The results of the efficacy test depend on factors such as immunological characteristics of
684 the *T. annulata* isolate grown and attenuated in culture, the virulence and dose of the field
685 isolate used for challenge, the species of infected ticks used to produce sporozoites.
686 Research studies (Pipano, 1989b) shows that calves vaccinated with schizont vaccine may
687 exhibit an apparently near total protection or show a low level parasitaemia, accompanied
688 by mild fever and insignificant alteration of the remaining parameters from their pre-
689 vaccination values following a potentially lethal homologous challenge. A lesser degree of
690 protection has been exhibited when cattle vaccinated with schizont vaccine were challenged
691 with tick-derived parasites from a geographically remote area. In contrast, in most of the
692 trials the non-vaccinated control calves have exhibited a high level of parasitaemia and
693 pancytopenia accompanied by severe clinical manifestations. In the absence of specific
694 medication, the majority of the control animals have succumbed to the infection (Pipano,
695 1989b).

696 Field observations have also been used for evaluation of the efficacy of anti-theilerial
697 vaccines (Pipano, 1989a; Stepanova & Zablotskii, 1989). Susceptible indigenous cattle as
698 well as high-grade exotic breeds were protected against clinical theileriosis and death in
699 pastures on which nonvaccinated cattle succumbed to theileriosis. As completely attenuated
700 schizont vaccine does not yield piroplasms, the presence of this theilerial stage in vaccinated
701 cattle showing no clinical signs is considered to be the result of unapparent tick-induced
702 infection.

703 The frozen vaccine is viably preserved in large liquid nitrogen refrigerators at production
704 facility and transported to farms in smaller liquid nitrogen containers. Field centres for
705 storage and supply of vaccine can be set up in theileriosis-enzootic areas. The basic
706 equipment required for field application of frozen vaccine includes a wide mouthed jar for
707 preparing a 40°C water bath, a thermometer for measuring the temperature of water, long
708 forceps, face shield and temperature-resistant gloves. Application of the frozen vaccine to
709 field cattle begins by donning the face shield and temperature-resistant gloves. The required
710 numbers of vials are withdrawn with the forceps from the canister of the liquid nitrogen
711 refrigerator. When withdrawing the vials, the canister should be kept as deep as possible in
712 the neck of the refrigerator to avoid quick warming of the remaining vials. Each withdrawn
713 vial should be checked in order to ascertain that liquid nitrogen has not leaked inside. The
714 liquid nitrogen does not alter the vaccine, but may cause the vial to explode when introduced
715 in the water bath. Such a vial should be held at ambient temperature for 1–2 minutes to allow
716 the nitrogen to escape and then processed in the usual way. Leaking of liquid nitrogen into
717 a vial containing frozen vaccine has raised questions to about the sterility of the frozen
718 vaccine. However the system has been used for decades with no significant problem
719 observed. The vaccine is administered subcutaneously within 30 minutes of thawing
720 (Pipano, 1977).

721 2.3.4. Duration of immunity

722 Controversial results about the length of immunity engendered by vaccination with the cell culture
723 vaccine have been obtained. Periods of from more than 48 months (Stepanova & Zablotskii, 1989)
724 to less than 13 months (Oueli et al., 2004) have been reported.

725 2.3.5. Stability

726 The frozen vaccine has a practically unlimited shelf life.

727 C2. Immunisation of cattle against *Theileria parva* by the infection and treatment 728 method (live vaccine)

729 1. Background

730 Vaccination against *T. parva* is based on a method of infection and treatment in which an aliquot of viable
731 sporozoites is inoculated subcutaneously, and the animals are simultaneously treated with a formulation of a long-
732 acting tetracycline, the so-called infection and treatment method (ITM) (Radley, 1981). Tetracyclines reduce the
733 severity of the infection, and the resulting mild infection is usually controlled by the host's immune response, so that
734 a carrier state is achieved. There are always risks associated with the use of live parasites for immunisation,
735 however, with appropriate quality control and careful determination of a safe and effective immunising dose, the

736 method can and is being used successfully in the field. Some *T. parva* stocks have been shown to infect cattle
737 reliably without inducing disease, and these can be used without tetracycline treatment. One such stabilate is being
738 applied in the field and offers considerable advantages over potentially lethal stabilate infections and savings in the
739 cost of vaccination. However, different stabilates of these stocks can produce severe disease in cattle, emphasising
740 the importance of a carefully controlled immunising dose.

741 2. Outline of production and minimum requirements for vaccines

742 2.1. Characteristics of the seed

743 2.1.1. Biological characteristics of the master seed

744 *Theileria parva* infected ticks can be produced by feeding nymphal *Rhipicephalus appendiculatus*
745 ticks on the ears of an animal undergoing an active ECF infection. After moulting, these ticks,
746 when prefed for 4 days on rabbits will have infective sporozoites in their salivary glands. By
747 grinding these prefed ticks in a specific medium, sporozoites will be released in the supernatants
748 and a stabilate can be produced (FAO, 1984) that can be cryopreserved and when in sufficient
749 quantity be earmarked as a master seed.

750 If needed, working seed stabilates are prepared by injecting cryopreserved sporozoites from a
751 master seed into experimental cattle and producing a working seed stabilate as described below.
752 Vaccines should be produced from a seed (working seed) that has not undergone further tick
753 passages after its immunological characterisation because this might change after passage.

754 2.1.2. Quality criteria (sterility, purity, freedom from extraneous agents)

755 i) Field collection of ticks

756 It is important that well characterised laboratory strains of *R. appendiculatus* be used during
757 preparation of immunising stabilates.

758 If field ticks are collected for experimental purposes, then consideration should be given to
759 the possible hazard to humans from pathogens present in these ticks. The most important
760 pathogen that has been recognised is Crimean–Congo haemorrhagic fever virus, usually
761 associated with ticks of the genus *Hyalomma* and widely prevalent within the geographical
762 distribution of *R. appendiculatus*. Those handling field tick collections should, therefore, be
763 made aware of potential hazards. Ticks of *Hyalomma* species generally should not be
764 removed from hosts; engorged or partially engorged ticks should not be crushed between
765 the fingers. If removed, ticks should be handled with a forceps.

766 ii) Tick-handling facilities

767 The handling of field-collected ticks in the laboratory must be controlled so as to avoid
768 accidental attachment to personnel. Field-collected ticks should be fed on rabbits and cattle
769 in isolation facilities. Animals on which laboratory-infected or field-collected ticks have fed
770 should be destroyed. Following engorgement of field-collected ticks on laboratory animals,
771 aliquots should be homogenised and tested for extraneous human pathogens by inoculation
772 in baby hamster kidney (BHK) and Vero cells. The effects of these inoculations should be
773 studied through three passages. Any unused ticks should be destroyed by chemical means
774 or by incineration.

775 Tests for sterility and freedom from contamination of biological materials intended for
776 veterinary use may be found in chapter 1.1.9. As stabilate material is derived from field
777 animals and rabbits, their cells might be potential sources of contamination of the vaccine
778 with extraneous pathogens. Potential contaminants include bovine leukosis, mycoplasma,
779 bovine viral diarrhoea virus, BSE or other *Theileria* species transmitted by *R. appendiculatus*
780 and alongside other bacteria and viruses.

781 In the case of different stocks being used on the same premises, problems with labels could
782 be minimised by using appropriate pencils and clear codes. Preparation of different
783 stabilates should be done sequentially to avoid cross-contamination and mislabelling.
784 Regular quality control should be introduced to ensure the right stock(s) are used.

785 2.1.3. Validation as a vaccine strain

786 A vaccine strain should be identified in cross-immunity trials. These are set up between a vaccine
787 strain and stabilates from *T. parva* field isolates from the area where the protection of the vaccine

788 strain is required. Ideally, five animals and two controls should be used per test, taking into
789 account that these should be set up in two ways. First using the vaccine as a challenge in animals
790 immunised with the local isolates and confirmed by subsequent homologous challenge. Secondly,
791 using the local strain(s) as challenge in animals immunised with the vaccine and confirmed by
792 subsequent homologous challenge. This will give information as to what extent a vaccine strain
793 will give protection. On the other hand, results will indicate if a breakthrough might occur from the
794 local *T. parva* population, present in carrier animals in the region where the vaccine will be
795 deployed. A second test consists in testing whether infection with the vaccine strain can be
796 controlled by the intended tetracycline treatment during the vaccination process.

797 2.2. Method of manufacture

798 2.2.1. Procedure

799 Vaccine batches are produced in several institutes in eastern Africa, using different strains,
800 possibly requiring different parameters than the ones described here. For consistency in
801 immunisation in field, it is essential that tick-derived sporozoite stabilates of an immunising stock
802 are prepared from a fully characterised 'working seed stabilate'. The 'working seed stabilate'
803 should be derived directly from the reference 'master seed stabilate', which is available in suitable
804 quantity for future preparation of immunising stabilates. Immunising stabilates can be prepared
805 according to a proposed set of standards (Morzaria *et al.*, 1999b).

806 2.2.2. Requirements for ingredients

807 Before starting to produce vaccine, seed material with known characteristics is required. Three
808 types of seed material are distinguished:

809 i) Master seed

810 The master seed is a cryopreserved sporozoite stabilate from a specific stock that has been
811 selected and permanently stored and from which all other seeds are derived. The master
812 seed should consist of a single uniform batch of seed that has been mixed and filled into
813 containers as one batch. As *T. parva*-infective sporozoites are used for the manufacturing
814 process, the master seed also represents the master stock (see Chapter 1.1.8). To prepare
815 a master seed, *T. parva*-infected adult *R. appendiculatus* ticks are used that have fed as
816 nymphs on the ears of an animal going through an active ECF infection. After moulting,
817 these ticks, when prefed during 4 days on rabbits will have infective sporozoites in their
818 salivary glands. These can be quantified by dissecting prefed ticks and determining infection
819 rates in the dissected salivary glands by coloration (Walker *et al.*, 1981). By grinding these
820 prefed ticks in a specific medium, sporozoites will be released in the supernatants and a
821 stabilate can be produced (FAO, 1984) that can be cryopreserved in minimum
822 100 cryotubes each containing preferably a set of infected acinus equivalent per vial or in
823 case of a new stock an equivalent of 10 infected ticks per vial. A viability check of the master
824 seed should be performed once the master seed has been cryopreserved for at least
825 24 hours by reviving one of the cryotubes.

826 ii) Working seed

827 The working seed is derived from infective sporozoites at a passage level between the
828 master seed and the production seed. To prepare a working seed, the contents of a single
829 cryotube of master seed are injected into a naive healthy experimental animal to produce
830 an acute ECF infection.

831 iii) Production seed

832 To prepare a vaccine batch, the contents of sufficient cryotubes of working seed is mixed
833 and the appropriate dose is injected into the required number of naive experimental cattle
834 to produce an acute ECF infection.

835 Infection is established, with the working seed stabilate of *T. parva*, by inoculation of healthy cattle
836 serologically and, ideally, PCR-negative for tick-borne diseases. During the parasitaemic phase
837 of the ensuing disease reaction, clean laboratory-raised nymphs of *R. appendiculatus* are fed on
838 the animals, and the engorged infected ticks are collected. The resultant adult ticks, within
839 3 weeks to 4 months after moulting, are applied in ear-bags to healthy rabbits. About 600 ticks
840 are applied to each ear and unattached ticks are removed after 24 hours. After 4 days, the ticks
841 are removed and samples (usually 60 ticks) taken to determine infection rates in dissected
842 salivary glands. The remaining ticks are counted into batches of approximately 1000. An estimate
843 of the total number of ticks can be obtained by counting and weighing a given number of ticks

844 and then weighing the total number of ticks. The ticks are washed in a sieve under fast flowing
845 tap water and may be surface disinfected in 1% benzalkonium chloride, or in 70% alcohol, and
846 then rinsed again in distilled water.

847 The ticks are placed (~1000) in heavy glass specimen jars or plastic beakers, and 50 ml MEM
848 with Hank's or Earle's salts and 3.5% bovine plasma albumin (BPA) is added. The jars are kept
849 on ice, and the ticks are ground using a tissue homogeniser (for instance Silverson LR2) for
850 2 minutes using a large aperture disintegrating head, and for 3 minutes using a small aperture
851 head (emulsor screen). For smaller batches, an alternative method may consist of grinding the
852 ticks, in batches of 1000 ticks using a mortar and pestle. Ticks are then crushed continuously by
853 teams of two people for 15–30 minutes in a mortar; 30–35 ml cooled MEM/3.5% BSA medium,
854 without glycerine with 50–100 g crushed glass is initially used. The difference (from 50 ml)
855 MEM/BSA without glycerine is used to rinse the mortar and pestle and glass material used in
856 crushing the ticks. Note that most of the crushing is done at the sidewalks of the mortar. Check
857 for good crushing under a stereoscopic microscope and otherwise add glass. ALWAYS KEEP
858 MEDIA AT 4°C.

859 The ground-up tick material is made up to 50 ml for every 1000 ticks, then centrifuged at 50 **g** for
860 5 minutes, and the supernatant is harvested. An equal volume of cold 15% glycerol in MEM/BSA
861 is added dropwise while the tick material is maintained chilled on ice and stirred by a magnetic
862 stirrer. The final volume will contain sporozoites from the equivalent of ten ticks/ml. The number
863 of tick-equivalents/ml can be adjusted if parasite infection rates in a particular tick batch were
864 either very high or very low. The final concentration of glycerol in the sporozoite stabilate is 7.5%.

865 The bottle containing the ground up tick material (gut) is fitted with a dispenser. Cryotubes of 1 ml
866 are filled with the stabilate (1 ml per vial) while constantly stirring on an ice bath. Aliquots are kept
867 at 4°C. Alternatively, artificial insemination equipment, as used to dispense semen, has been
868 used with pre-labelled plastic straws. This latter system is ideal for large volume stabilates, and
869 colour coding and labelling provide additional check on the identity of the immunising stabilate.
870 An equilibration time of 30–45 minutes should be allowed.

871 The aliquots are then stored in insulation trays and moved to a –80°C deep-freezer as soon as
872 possible. They are kept there for 24 hours, to allow a gradual cooling down (step-freezing) of the
873 stabilate. On the second day, the aliquots are transferred into liquid nitrogen until use.
874 Alternatively vials can be introduced in gas-phase liquid nitrogen for 3 hours and then immersed
875 in the liquid nitrogen for storage (~~Pipano, 1989b~~). Vaccine is transported to the field in liquid
876 nitrogen. Vials are taken out at the place of vaccination, by immersing the liquid nitrogen vials in
877 lukewarm water (38°C) for 30 minutes to allow for good regeneration. It should be administered
878 within 60 minutes after withdrawal from the liquid nitrogen container. Once unfrozen it can be kept
879 alive on ice (+4°C) for another 6 hours (~~Marcotty et al., 2001; Mbao et al., 2007~~). The infection
880 and treatment method is usually applied using long-acting tetracycline intramuscularly, and it is
881 recommended that the tetracycline be administered first, in case an animal escapes having
882 received stabilate only. Thereafter the stabilate is inoculated subcutaneously over the parotid
883 lymph node at the base of the ear.

884 The procedure for the preparation and testing of a multi-valent ITM vaccine (the Muguga cocktail)
885 has been described in detail (Patel *et al.*, 2016). It is important to note that each of the component
886 stabilates is produced before combining the infected and fed ticks immediately before
887 homogenisation. The number of ticks from each component is calculated to produce a final
888 vaccine stabilate containing equal numbers of infected acini from each component.

889 **2.2.3. In-process controls**

890 Records of the source and passages of the working seed material should be maintained. Seeds
891 should be free of infective agents like enzootic bovine leukosis, bovine immunodeficiency virus,
892 bovine pestivirus, bovine syncytial virus, Rift Valley fever, etc. Test procedures will depend on
893 availability preferably using DNA analysis.

894 **2.2.4. Final product batch tests**

895 i) Sterility

896 Tests for sterility and freedom from contamination of biological materials for veterinary use
897 may be found in chapter 1.1.9.

898 ii) Safety

899 Both ticks and experimental mammals are potential sources of contamination of stabilates
900 with extraneous pathogens. In both cases, potential contaminants include *Ehrlichia bovis*,
901 bovine *Borrelia* sp., orbiviruses, bunyaviruses, and others. Field-collected ticks should
902 therefore not be used for the preparation of stabilates to be used for immunisation. Well
903 characterised and pathogen-free laboratory colonies of ticks should be used for this
904 purpose. Only healthy cattle and rabbits, free from tick-borne parasites, should be used for
905 tick feeding. Stabilates should be prepared under aseptic conditions. In some
906 circumstances, the use of antibiotics at concentrations appropriate for tissue culture may be
907 indicated. Prepared stabilates should be subjected to routine tests for any viral infections in
908 BHK and Vero cells (as above). Stabilates should be subjected to routine characterisation
909 *in vivo*, which should involve infectivity testing in intact susceptible cattle, sensitivity to
910 tetracyclines and other anti-theilerial drugs, and cross-immunity studies. A characterised
911 'working seed stabilate' should be prepared to ensure the purity of the *T. parva* stocks in the
912 daughter immunising stabilate.

913 During stabilate preparation care must also be taken to avoid extraneous contamination of
914 the stock being used with other *T. parva* stocks. Quality assurance procedures must be
915 enforced, for example for the handling of infected ticks, and the rules should be adhered to
916 rigidly. Tick unit facilities should allow for strict separation of infected and uninfected ticks.
917 Tick unit personnel should use separate overalls for each batch of ticks used in stabilate
918 preparation, and the overalls should be sterilised daily. Simultaneous work on many different
919 stocks should be avoided. Stabilate storage systems should incorporate clear labelling of
920 each stabilate tube or straw also mentioning the preferred number of doses per vial or straw.
921 This will vary according to use in small holder dairy or pastoral herds etc.

922 Quality control checks on the stabilate should determine the similarity to the parent seed
923 stock and also detect any extraneous *T. parva* contamination.

924 iii) Batch potency

925 The evaluation of the number of acini infected with *T. parva* in dissected tick salivary glands,
926 before grinding, is a useful indicator of the level of infection but does not take into account
927 the variable loss of viability during stabilate preparation caused by the intensity of grinding
928 and the freeze-thaw processes. Furthermore, the state of maturation of the sporozoites is
929 difficult to estimate by histological examination of the tick salivary glands. Therefore, the
930 infectivity of the stabilate is determined by inoculation of a standard dose of 1.0 ml into
931 susceptible cattle. The contents of 2–4 randomly selected tubes are mixed and then titrated
932 in cattle, and its infectivity and lethality at different dilutions are established for use in
933 immunisation. As the response of cattle to the infection and treatment method is dependent
934 upon their susceptibility to the infection, it is important to titrate stabilates in cattle of the
935 same type as those to be immunised. Titration of vaccine stabilates remains a highly
936 controversial matter. Ideally, a median infectious dose (ID₅₀) and median lethal dose (LD₅₀)
937 should be determined by titration of the stabilate using a tenfold dilution range (Duchateau
938 *et al.*, 1998; 1999 Speybroeck *et al.*, 2008). The ID₉₉₊ (corresponding to close to 100%
939 infectivity and having minimal lethality) should then be quantified by means of a finer titration,
940 using dilutions around the LD₅₀. With respect to compound vaccines, quantification of the
941 vaccine dose is complex as different strains need to be put together, changing the total
942 lethality of the vaccine (Speybroeck *et al.*, 2008). The sensitivity to tetracyclines is also
943 determined, essentially to provide a dose of stabilate that is controlled, preferably by a single
944 dose of long-acting tetracycline administered at the same time as inoculation. The
945 immunising dose should induce a very mild or inapparent infection, and the animal should
946 develop a serological titre and be immune to lethal homologous challenge. Should a single
947 treatment with tetracycline fail to suppress the infection in all cattle, then either a lower dose
948 of the immunising stabilate or two treatments of tetracycline (on days 0 and 4) may be used.
949 A single dose of 30 mg/kg long-acting oxytetracycline has been found to be effective in field
950 immunisations, when used with an appropriate stabilate dilution. An alternative method that
951 has been used involves stabilate infection and treatment with parvaquone at 20 mg/kg on
952 day 8 (depending on the stabilate). This method can be applied where tetracyclines are not
953 reliable, but it requires that the animal be handled more than once. A single treatment with
954 buparvaquone at 2.5 mg/kg at the time of infection has also been shown to be effective with
955 stabilate infections that were not controlled with a single treatment at 20 mg/kg of a long-
956 acting formulation of tetracycline.

957 Once the procedure that results in a safe and effective immunising dose is established, it
958 must be adhered to strictly in the field, or breakdown of immunisation may occur. It is also
959 important that the stabilate dilution and drug/dose regimen be determined in the most
960 susceptible cattle in which it is likely to be used.

961	2.3. Requirements for authorisation/registration/licensing <u>regulatory approval</u>
962	2.3.1. Manufacturing process
963	For registration <u>regulatory approval</u> of vaccine, all relevant details concerning manufacture of the
964	vaccine and quality control testing (see Sections C2.2.2.1 and C2.2.2) should be submitted to the
965	<u>regulatory</u> authorities. This information shall be provided from three consecutive vaccine batches
966	with a volume not less than 1/3 of the typical industrial batch volume.
967	2.3.2. Safety requirements
968	i) Target and non-target animal safety
969	<i>Theileria parva</i> sporozoites are not hazardous to humans, but they are infectious to bovines,
970	and infection of naive animals for production of vaccine batches, as well as the titration
971	experiments for dose quantification should be done in tick-free facilities. Tests for sterility
972	and freedom from contamination of biological materials intended for veterinary use may be
973	found in chapter 1.1.9. At a meeting in Malawi in 1988, the following recommendations on
974	safety in the preparation, handling and delivery of <i>T. parva</i> infection and treatment vaccines
975	were adopted (Anon, 1989).
976	ii) Reversion-to-virulence for attenuated/live vaccines and environmental considerations
977	The introduction of an immunising stock into an area/country from which it does not originate
978	may result in that parasite, or a component parasite(s) of that stock, becoming established
979	through a carrier state in cattle and transmission by ticks. The long-term effect of the
980	introduction of new (and potentially lethal) parasites on the disease epidemiology should be
981	considered before introduction, and should be monitored carefully following immunisation.
982	The characterisation of parasites in target populations should be carried out before
983	immunisation, and at intervals following immunisation. At present the characterisation of
984	parasite stocks with reference to vaccination relies primarily on immunisation and cross-
985	challenge experiments in cattle. However, a number of methods for characterising parasite
986	stocks <i>in vitro</i> have been attempted in laboratories possessing a high degree of expertise.
987	Early studies have shown that parasite stocks that differ in MAb profile may not cross-
988	protect, whereas stocks showing similar profiles give cross-protection (Irvin & Morrison,
989	1987). However, in more recent experiments using other <i>T. parva</i> stocks, this observation
990	has been proven to be wrong. Another method to detect antigenic differences used T cell
991	clones specific for parasitised cell lines, as T cell responses are believed to be important in
992	mediating immunity against <i>T. parva</i> and the strain specificity observed in <i>in-vitro</i> killing
993	assays reflects the <i>in-vivo</i> challenge results (Irvin & Morrison, 1987 ; Taracha <i>et al.</i> , 1995).
994	Apart from this, there are no other, simpler <i>in vitro</i> assays that correlate with protection <i>in</i>
995	<i>vivo</i> . Statistically derived disease reaction index, based on parasitological, clinical and
996	haematological measurements, was proposed for characterising levels of infectivity and
997	virulence of different parasite stocks and assessing the impact of control intervention against
998	theileriosis (Rowlands <i>et al.</i> , 2000; Schetters <i>et al.</i> , 2010). Recently, DNA typing for
999	characterisation of vaccine stabilates has been used and could be based on multi-locus
1000	genotyping using polymorphic antigen genes or satellite markers or a combination of both
1001	(Hemmink <i>et al.</i> , 2016; Patel <i>et al.</i> , 2011).
1002	iii) Precautions (hazards)
1003	Care should be taken during the preparation of sporozoite stabilates to avoid aerosol
1004	infection of personnel with extraneous pathogens when ticks are being ground. Those
1005	grinding ticks should be educated in the potential hazards involved; access to areas where
1006	ticks are homogenised should be restricted to specified and informed personnel; personnel
1007	should wear protective clothing, including gloves and masks; and tick grinding should be
1008	carried out in a microbiological safety cabinet (see Chapter 1.1.4 <i>Biosafety and biosecurity:</i>
1009	<i>Standard for managing biological risk in the veterinary laboratory and animal facilities</i>).
1010	2.3.3. Efficacy requirements
1011	i) Capacity to protect against naturally transmitted theileriosis
1012	Although successful final product batch testing (see Section C.2.2.4.iii) indicates that a
1013	vaccine batch is immunogenic, it is important to note that protection against homologous
1014	challenge does not necessarily indicate that the vaccine will protect against all <i>T. parva</i>
1015	strains encountered in the field, and that the 'needle' challenge used in pen trials does not
1016	necessarily reflect a challenge delivered by ticks. This can only be assessed by controlled

1017 field trials, which are expensive, complicated and lengthy. The need for and extent of field
1018 trials for each vaccine batch is the subject of debate and there is no agreed protocol. The
1019 least intensive approach, if veterinary authorities allow, is to closely monitor the initial 'roll-
1020 out' of the vaccine after successful final product batch testing as described above, with
1021 particular attention being given to the incidence of 'reactors' soon after vaccination and the
1022 occurrence of any 'breakthrough' cases following field exposure.

1023 ii) Use in the field

1024 The frozen vaccine is viably preserved in large liquid nitrogen repositories at the production
1025 facility and transported to farms in smaller liquid nitrogen containers. Field centres for
1026 storage and supply of vaccine can be set up in theileriosis-enzootic areas. The basic
1027 equipment required for field application of frozen vaccine includes a wide-mouthed jar for
1028 preparing a 38°C water bath, a thermometer for measuring the temperature of water, long
1029 forceps, face shield and temperature-resistant gloves. Application of the frozen vaccine to
1030 field cattle begins by putting on a face shield and temperature-resistant gloves. The required
1031 numbers of vials are withdrawn with the forceps from the canister of the liquid nitrogen
1032 refrigerator. When withdrawing the vials, the canister should be kept as deep as possible in
1033 the neck of the refrigerator to avoid quick warming of the remaining vials. Each withdrawn
1034 vial should be checked to ascertain that liquid nitrogen has not leaked inside. The liquid
1035 nitrogen does not alter the vaccine, but may cause the vial to explode when introduced in
1036 the water bath. Such a vial should be held at ambient temperature for 1–2 minutes to allow
1037 the nitrogen to escape and then processed in the usual way. The reported leaking of liquid
1038 nitrogen into a vial containing frozen vaccine has raised questions about the sterility of the
1039 frozen vaccine. However the system has been used for decades with no significant problem
1040 observed.

1041 **2.3.4. Breadth of immunity**

1042 Unlike *T. annulata*, where considerable cross-protection is observed among different strains in
1043 the field, a more complex situation exists for *T. parva*. Two strategies are used to try to overcome
1044 this antigenic complexity. A combination of three stocks, which provides a broad spectrum of
1045 protection, has been tested in a number of countries. Two large batches of a trivalent stabilate
1046 have been prepared by the International Livestock Research Institute (ILRI, Nairobi), the first in
1047 1996 for the FAO and another one in 2008. These stabilates were prepared to the latest proposed
1048 standards and have been used safely and effectively in Tanzania. Further batches are being
1049 prepared at the African Union Centre for Ticks and Tick-Borne Diseases, Lilongwe, Malawi with
1050 increasing demand for the infection and treatment method of immunisation in *T. parva*-endemic
1051 areas in sub-Saharan Africa. If an immunising stabilate fails to protect against a 'breakthrough
1052 stock', this should be isolated, characterised, tested and considered for use, either alone, or as
1053 an addition to the current immunising stabilate. Another strategy is to prepare stabilates of
1054 national or local stocks for use within defined areas. This latter strategy is more costly in time and
1055 resources, but it avoids, to some extent, the introduction of new stocks into an area. With
1056 movement of cattle, there is a risk of the introduction of different stocks into an area, which may
1057 breakthrough the immunity provided by the local stock. Therefore, the use of local or introduced
1058 stocks for immunisation needs to be carefully evaluated (Goyson, 2008; McKeever, 2007).

1059 The infection and treatment method of immunisation is effective provided the appropriate quality
1060 assurance measures are enforced. In the longer term, the attendant delivery problems and the
1061 risk of induction of carrier states and disease transmission, emphasise the need for the
1062 identification of protective antigens for development of subunit vaccines.

1063 **2.3.5. Duration of immunity**

1064 There have been few reports of controlled experiments to determine the duration of immunity
1065 induced by infection and treatment, in either the presence or absence of field challenge. However,
1066 Burridge *et al.* (1972) established that cattle that had survived an experimental infection (without
1067 treatment) and were subsequently maintained in an ECF-free environment, survived a lethal
1068 homologous challenge up to 43 months later.

1069 **2.3.6 Stability**

1070 If kept in liquid nitrogen, the frozen vaccine has a practically unlimited shelf life.

1071

- 1073 ALLSOPP B.A. & ALLSOPP M.T.E.P. (1988). *Theileria parva*: genomic DNA studies reveal non-specific diversity. *Mol. Biochem. Parasitol.*, **28**, 77–84.
- 1074
- 1075 ALLSOPP B.A., BAYLIS H.A., ALLSOPP M.T.E.P., CAVALIER SMITH T., BISHOP R.P., CARRINGTON D.M., SOHANPAL B. & SPOONER P. (1993). Discrimination between six species of *Theileria* using oligonucleotide probes which detect small subunit ribosomal RNA sequences. *Parasitology*, **107**, 157–165.
- 1076
- 1077
- 1078 ANON (1989). Theileriasis in Eastern, Central and Southern Africa, Dolan T.T., ed. Proceedings of a meeting on East Coast fever immunization held in Malawi, 18–20 September 1988. International Laboratory for Research on Animal Diseases, Nairobi, Kenya, 174–176.
- 1079
- 1080
- 1081 BILLIOUW M., BRANDT J., VERCRUYSE J., SPEYBROECK N., MARCOTTY T., MULUMBA M. & BERKVENNS D. (2005). Evaluation of the indirect fluorescent antibody test as a diagnostic tool for East Coast fever in eastern Zambia. *Vet. Parasitol.*, **127**, 189–198.
- 1082
- 1083
- 1084 BISHOP R., SOHANPAL B., KARIUKI D.P., YOUNG A.S., NENE V., BAYLIS H., ALLSOPP B.A., SPOONER P.R., DOLAN T.T. & MORZARIA S.P. (1992). Detection of a carrier state in *Theileria parva* infected cattle by the polymerase chain reaction. *Parasitology*, **104**, 215–232.
- 1085
- 1086
- 1087 BISHOP R.P., ALLSOPP B.A., SPOONER P.R., SOHANPAL B.K., MORZARIA S.P. & GOBRIGHT E.I. (1995). *Theileria*: improved species discrimination using oligonucleotides derived from large subunit ribosomal RNA sequences. *Exp. Parasitol.*, **80**, 107–115.
- 1088
- 1089
- 1090 BISHOP R.P., SPOONER P.R., KANHAI G.K., KIARIE J., LATIF A.A., HOVE T., MASAKA S. & DOLAN T.T. (1994). Molecular characterization of *Theileria* parasites: application to the epidemiology of theileriosis in Zimbabwe. *Parasitology*, **109**, 573–581.
- 1091
- 1092
- 1093 BISHOP R.P., HEMMINCK J.D., MORRISON W.L., WEIR W., TOYE P.G., SITT T., SPOONER P.R., MUSOKE A.J., SKILTON R.A. & ODONGO D.O. (2015). The African buffalo parasite *Theileria* sp. (buffalo) can infect and immortalize cattle leukocytes and encodes divergent orthologues of *Theileria parva* antigen genes. *Int. J. Parasitol. Parasites Wildl.*, **4**, 333–342.
- 1094
- 1095
- 1096
- 1097 BOGEMA D.R., DEUTSCHER A.T., FELL S., COLLINS D., EAMENS G.J. & JENKINS C. (2015) Development and validation of a quantitative PCR assay using multiplexed hydrolysis probes for detection and quantification of *Theileria orientalis* isolates and differentiation of clinically relevant subtypes. *J. Clin. Microbiol.* **53**, 941–950.
- 1098
- 1099
- 1100 BROWN C.G.D. (1979). Propagation of *Theileria*. In: Practical Tissue Culture Application, Maramorosch K. & Hirumi H., eds. Academic Press, New York, USA, 223–254.
- 1101
- 1102 BURRIDGE M., MORZARIA S., CUNNINGHAM M. & BROWN C. (1972). Duration of immunity to East Coast fever (*Theileria parva* infection of cattle). *Parasitology*, **64**, 511–515.
- 1103
- 1104 ~~CONRAD P.A., IAMS K., BROWN W.C., SOHANPAL B. & OLE-MOIYI O.K. (1987). DNA probes detect genomic diversity in *Theileria parva* stocks. *Mol. Biochem. Parasitol.*, **25**, 213–226.~~
- 1105
- 1106 DARGHOUTH M.E.A., BOUATTOR A., BEN-MILED L. & SASSI L. (1996). Diagnosis of *Theileria annulata* – infection of cattle in Tunisia: comparison of serology and blood smears. *Vet. Res.*, **27**, 613–627.
- 1107
- 1108 DOLAN T.T. (1989). Theileriasis: A comprehensive review. *Rev. sci. tech. Off. int. Epiz.*, **8**, 11–36.
- 1109
- 1110 D'OLIVEIRA C., VANDERMERVE M., HABELA M., JACQUIET P. & JONGEJAN F. (1995). Detection of *Theileria annulata* in blood samples of carrier cattle by PCR. *J. Clin. Microbiol.*, **33**, 2665–2669.
- 1111
- 1112 ~~DUCHATEAU L., BERKVENNS D.L. & ROWLANDS G.J. (1999). Decision rules for small vaccine experiments with binary outcomes based on conditional an expected power and size of the Fisher exact test. *J. Appl. Statistics*, **26**, 689–700.~~
- 1113
- 1114 ~~DUCHATEAU L., McDERMOTT B. & ROWLANDS G.J. (1998). Power evaluation of small drug and vaccine experiments with binary outcomes. *Stat. Med.*, **17**, 111–120.~~
- 1115
- 1116 EL DAMATY H.M., YOUSEF S.G., MAHMMOD Y.S., EL-BALKEMY F.A. & MWEU M.M. (2021). Sensitivity and specificity of piroplasm indirect fluorescent antibody test and PCR for *Theileria annulata* infection in clinically asymptomatic large ruminants using Bayesian latent class analysis. *Vet. Parasitol. Reg. Stud. Reports*, **24**, 100563.
- 1117

-
- 1118 FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS (FAO) (1984). Tick and Tick-borne Disease Control:
1119 A Practical Field Manual. FAO, Rome, Italy.
- 1120 GEBREKIDAN H., GASSER R.B., PERERA P.K., McGRATH S., McGRATH S., STEVENSON M.A. & JABBAR A. (2015).
1121 Investigating the first outbreak of oriental theileriosis in cattle in South Australia using multiplexed tandem PCR
1122 (MT-PCR). *Ticks Tick Borne Dis.*, **6**, 574–578.
- 1123 GEYSEN D. (2008). Live immunisation against *Theileria parva*: spreading the disease? *Trends Parasitol.*, **24**, 245–246.
- 1124 GEYSEN D., BISHOP R., SKILTON R., DOLAN T.T. & MORZARIA S. (1999). Molecular epidemiology of *Theileria parva* in
1125 the field. *Trop. Med. Int. Health*, **4**, A21–27.
- 1126 GODDEERIS B.M., KATENDE J.M., IRVIN A.D. & CHUMO R.S.C. (1982). Indirect fluorescent antibody test for experimental
1127 and epidemiological studies on East Coast fever (*Theileria parva* infection of cattle). Evaluation of a cell culture
1128 schizont antigen fixed and stored in suspension. *Res. Vet. Sci.*, **33**, 360–365.
- 1129 GRAY M.A., LUCKINS A.G., RAE P.F. & BROWN C.G.D. (1980). Evaluation of an enzyme immunoassay for
1130 serodiagnosis of infections with *Theileria parva* and *Theileria annulata*. *Res. Vet. Sci.*, **29**, 360–366.
- 1131 GUBBELS G., DE VOS A., VAN DER WEILDE M., VISERAS J., SCHOULS L., DEVRIES E. & JONGEJAN F. (1999). Simultaneous
1132 detection of bovine *Theileria* and *Babesia* species by reverse line blot hybridisation. *J. Clin. Microb.*, **37**, 1782–1789.
- 1133 GUBBELS M.J., HONG Y., VAN DER WEIDE M., QI B., NIJMAN I.J. & GUANGYUAN L. (2000). Molecular characterisation of
1134 the *Theileria buffeli/orientalis* group. *Int. J. Parasitol.*, **30**, 943–952.
- 1135 HASHEMI-FESHARKI R. (1988). Control of *Theileria annulata* in Iran. *Parasitol. Today*, **4**, 36–40.
- 1136 HASHEMI-FESHARKI R. (1998). Recent development in control of *Theileria annulata* in Iran. *Parasite*, **5**, 193–196.
- 1137 HEMMINK J.D., WEIR W., MACHUGH N.D., GRAHAM S.P., PATEL E., PAXTON E., SHIELS B., TOYE P.G., MORRISON W.I. &
1138 PELLE R. (2016). Limited genetic and antigenic diversity within parasite isolates used in a live vaccine against
1139 *Theileria parva*. *Int. J. Parasitol.*, **46**, 495–506.
- 1140 HUTCHESON J.H., LINDSAY R.L. & DERGOSOUFF S.J. (2019) *Haemaphysalis longicornis*: a tick of considerable
1141 importance, now established in North America. *Can. J. Public Health*, **110**, 118–119.
- 1142 IRVIN A.D. & MORRISON W.I. (1987). Immunopathology, immunology and immunoprophylaxis of *Theileria* infections.
1143 In: Immune Response in Parasitic Infections: Immunology, Immunopathology, and Immunoprophylaxis, Soulsby
1144 E.J.L. ed. CRC Press, Boca Raton, Florida, USA, 223–274.
- 1145 JEONG W., YOON S.H., AN D.J., CHO S.H., LEE K.K. & KIM J.Y. (2010) A molecular phylogeny of the benign *Theileria*
1146 parasites based on major piroplasm surface protein (MPSP) gene sequences. *Parasitology*, **137**, 241–249.
- 1147 KACHANI M., EL-HAJ N., KAHOUACHE & OUHELLI H. (2004a). Vaccin vivant contre la theileriose bovine constitué par
1148 des macroschizonte de *Theileria annulata*: innocuité, durée de l'immunité et absence de portage. *Revue Méd. Vet.*,
1149 **155**, 624–631.
- 1150 KACHANI M., EL-HAJ N. & OUHELLI H. (2004b). Condition de stockage d'un vaccin vivant contre *Theileria annulata*.
1151 *Revue Méd. Vet.*, **155**, 467–471.
- 1152 KARIUKI D.P., YOUNG A.S., MORZARIA S.P., LESAN A.C., MINING S.K., OMWOYO P., WAFULA J.L. & MOLYNEUX D.H. (1995).
1153 *Theileria parva* carrier state in naturally infected and artificially immunised cattle. *Trop. Anim. Health Prod.*, **27**, 15–25.
- 1154 KATENDE J., MORZARIA S., TOYE P., SKILTON R., NENE V., NKONGE C. & MUSOKE A. (1998). An enzyme-linked
1155 immunosorbent assay for the detection of *Theileria parva* antibodies in cattle using a recombinant polymorphic
1156 immunodominant molecule. *Parasitol. Res.*, **84**, 408–416.
- 1157 KAWAZU S., SUGIMOTO C., KAMIO T. & FUJISAKE K. (1992). Analysis of the genes encoding immunodominant piroplasm
1158 surface proteins of *Theileria sargentii* and *Theileria buffeli* by nucleotide sequencing and polymerase chain reaction.
1159 *Mol. Biochem. Parasitol.*, **56**, 169–176.
- 1160 KUBOTA S., SUGIMOTO C. & ONUMA M. (1995). A genetic analysis of mixed population in *Theileria sargentii* stocks and
1161 isolates using allele-specific polymerase chain reaction. *J. Vet. Med. Sci.*, **57**, 279–282.
-

- 1162 MARGOTTY T, BILLIOUW M., CHAKA G., BERKVEN D., LOSSON B. & BRANDT J. (2001). Immunisation against East Coast
1163 fever by the infection and treatment method: evaluation of the use of ice baths for field delivery and appraisal of an
1164 acid formulation of long-acting tetracycline. *Vet. Parasitol.*, **99**, 175–187.
- 1165 MARGOTTY T.B.J., BILLIOUW M., CHAKA G., LOSSON B. & BERKVEN D. (2002). Immunisation against *Theileria parva* in
1166 eastern Zambia: influence of maternal antibodies and demonstration of the carrier status. *Vet. Parasitol.*, **110**, 45–56.
- 1167 MARITIM A.C., YOUNG A.S., LESAN A.C., NDUNGU S.G., MUTUGI J.J. & STACE D.A. (1989). Theilerial parasites isolated
1168 from carrier cattle after immunization with *Theileria parva* by the infection and treatment method. *Parasitology*, **99**,
1169 139–147.
- 1170 MBAO V., BERKVEN D., DORNY P., VAN DEN BOSSCHE P. & MARGOTTY T. (2007) Comparison of the survival on ice of
1171 thawed *Theileria parva* sporozoites of different stocks cryoprotected by glycerol or sucrose. *Onderstepoort J. Vet.*
1172 *Res.*, **74**, 9–15.
- 1173 MCFADDEN A.M., RAWDON T.G., MEYER J., MAKIN J., CLOUGH R.R., THAM K., MULLNER P. & GEYSEN D. (2011). An outbreak
1174 of haemolytic anaemia associated with infection of *Theileria orientalis* in naive cattle. *N.Z. Vet. J.*, **59**, 79–85.
- 1175 MCKEEVER D.J. (2007). Live immunisation against *Theileria parva*: containing or spreading the disease? *Trends*
1176 *Parasitol.*, **23**, 565–568.
- 1177 MORISSON W.I & Mc KEEVER D.J. (2006). Current status of vaccine development against *Theileria* parasites.
1178 *Parasitology*, **133**, S169–S187.
- 1179 MORZARIA S.P., KATENDE J., MUSOKE A., NENE V., SKILTON R. & BISHOP R. (1999a). Development of sero-diagnostic
1180 and molecular tools for the control of important tick-borne pathogens of cattle in Africa. *Parasitologia*, **41** (Suppl. 1),
1181 73–80.
- 1182 MORZARIA S.P., MUSOKE A.J., DOLAN T.T., NENE V., NORVAL R.A.I. & BISHOP R. (1989). Studies on pathogenic
1183 *Theileria mutans*. Annual Scientific Report, International Laboratory for Research on Animal Diseases, Nairobi,
1184 Kenya, 7–8.
- 1185 MORZARIA S., SPOONER P., BISHOP R. & MWAURA S. (1999b). The preparation of a composite stabilate for
1186 immunisation against East Coast fever. In: Live Vaccines for *Theileria parva*: Deployment in Eastern, Central and
1187 Southern Africa. Proceedings of a Joint OAU, FAO and ILRI Workshop held at ILRI, Nairobi, Kenya 10–12 March
1188 1997. ILRI, Kenya, 56–61.
- 1189 ODONGO D.O., SUNTER J.D., KIARA H.K., SKILTON R.A. & BISHOP R.P. (2010). A nested PCR assay exhibits enhanced
1190 sensitivity for detection of *Theileria parva* infections in bovine blood samples from carrier animals. *Parasitol. Res.*,
1191 **106**, 357–365.
- 1192 OUELLI H., KACHANI M., EL-HAJ N. & RAÏSS S. (2004). Vaccin vivant contre *Theileria annulata* et durée de l'immunité.
1193 *Revue Méd. Vet.* **155**, 472–475.
- 1194 OURA C.A., ODONGO D.O., LUBEGA G.W., SPOONER P.R., TAIT A. & BISHOP R.P. (2003). A panel of microsatellite and
1195 minisatellite markers for the characterisation of field isolates of *Theileria parva*. *Int. J. Parasitol.*, **33**, 1641–1653.
- 1196 PATEL E.H., LUBEMBE D.M., GACHANJA J., MWAURA S., SPOONER P. & TOYE P. (2011). Molecular characterization of
1197 live *Theileria parva* sporozoite vaccine stabilates reveals extensive genotypic diversity. *Vet. Parasitol.*, **179**, 62–68.
- 1198 PATEL E., MWAURA S., KIARA H., MORZARIA S., PETERS A. & TOYE P. (2016). Production and dose determination of
1199 Infection and Treatment Method Vaccine used to control East Coast fever in cattle. *Ticks Tick Borne Dis.*, **7**, 306–314.
- 1200 PERERA P.K., GASSER R.B., PULFORD D.J., STEVENSON M.A., FIRESTONE S.M., MCFADDEN A.M. & JABBAR A. (2015).
1201 Comparison of the performance of three PCR assays for the detection and differentiation of *Theileria orientalis*
1202 genotypes. *Parasit. Vectors*, **8**, 192.
- 1203 PHIPPS L.P., HERNÁNDEZ-TRIANA L.M., GOHARRIZ H., WELCHMAN D. & JOHNSON N. (2016). Detection of *Theileria*
1204 *luwenshuni* in sheep from Great Britain. *Parasites Vectors*, **9**, 203.
- 1205 PIENAAR R., POTGIETER F.T., LATIF A.A., THEKISOE O.M. & MANS B.J. (2011). The Hybrid II assay: a sensitive and
1206 specific real-time hybridization assay for the diagnosis of *Theileria parva* infection in Cape buffalo (*Syncerus caffer*)
1207 and cattle. *Parasitology*, **138**, 1935–1944.

- 1208 PIPANO E. (1977). Basic principles of *Theileria annulata* control. In: Theileriosis, Henson J.B. & Campbell M., eds.
1209 International Development Research Centre, Ottawa, Canada, 55–66.
- 1210 PIPANO E. (1989a). Bovine theileriosis in Israel. *Rev. sci. tech. Off. int. Epiz.*, **8**, 79–87.
- 1211 PIPANO E. (1989b). Vaccination against *Theileria annulata* theileriosis. In: Veterinary Protozoan and Hemoparasitic
1212 Vaccines, Wright I.G., ed. CRC Press, Boca Raton, Florida, USA, 203–234.
- 1213 PIPANO E. (1997). Vaccines against hemoparasitic diseases in Israel with special reference to quality assurance.
1214 *Trop. Anim. Health Prod.*, **29**, 86S–90S.
- 1215 RADLEY D.E. (1981). Infection and treatment immunization against theileriosis. In: Advances in the Control of
1216 Theileriosis, Irvin A.D., Cunningham M.P. & Young A.S., eds. Martinus Nijhoff Publishers, The Hague, The
1217 Netherlands, 227–237.
- 1218 ROS-GARCIA A., NICOLÁS A., GARCÍA-PÉREZ A.L., JUSTE R.A. & HURTADO A. (2012). Development and evaluation of a
1219 real-time PCR assay for the quantitative detection of *Theileria annulata* in cattle. *Parasit. Vectors*, **5**, 171.
- 1220 ROWLANDS G.J., MUSOKE A.J., MORZARIA S.P., NAGDA S.M., BALLINGAL K.T. & MCKEEVER D.J. (2000). A statistically
1221 derived index for classifying East Coast fever reactions in cattle challenged with *Theileria parva* under experimental
1222 conditions. *Parasitology*, **120**, 371–381.
- 1223 SCHETTERS T.P., ARTS G., NIESSEN R. & SCHAAP D. (2010). Development of a new score to estimate clinical East
1224 Coast fever in experimentally infected cattle. *Vet. Parasitol.*, **167**, 255–259.
- 1225 SIBEKO K.P., OOSTHUIZEN M.C., COLLINS N.E., GEYSEN D., RAMBRITCH N.E., LATIF A.A., GROENEVELD H.T., POTGIETER
1226 F.T. & COETZER J.A. (2008). Development and evaluation of a real-time polymerase chain reaction test for the
1227 detection of *Theileria parva* infections in Cape buffalo (*Syncerus caffer*) and cattle. *Vet. Parasitol.*, **155**, 37–48.
- 1228 SKILTON R.A., BISHOP, R.P.; KATENDE, J.M.; MWAURA, S. & MORZARIA S.P. (2002). The persistence of *Theileria parva*
1229 infection in cattle immunized using two stocks which differ in their ability to induce a carrier state: analysis using a
1230 novel blood spot PCR assay. *Parasitology*, **124**, 265–276.
- 1231 SPEYBROECK N., MARCOTTY T., AERTS M., DOLAN T., WILLIAMS B., LAUER J., MOLENBERGHS G., BURZYKOWSKI T.,
1232 MULUMBA M. & BERKVEN D. (2008). Titrating *Theileria parva*: Single stocks against combination of stocks. *Exp.*
1233 *Parasitol.*, **118**, 522–530.
- 1234 STEPANOVA N.I. & ZABLOTSKII V.T. (1989). Bovine theileriosis in the USSR. *Rev. sci. tech. Off. int. Epiz.*, **8**, 89–92.
- 1235 TARACHA E.L.N., GODDEERIS B.M., MORZARIA S.P. & MORRISON W.I. (1995). Parasite strain specificity of precursor
1236 cytotoxic t cells in individual animals correlates with cross-protection in cattle challenged with *Theileria parva*. *Infect.*
1237 *Immun.*, **63**, 1258–1262.
- 1238 WALKER A.R., YOUNG A.S. & LEITCH B.L. (1981) Assessment of *Theileria* infections in *Rhipicephalus appendiculatus*
1239 ticks collected from the field. *Z. Parasitenkd.*, **65**, 63–69.
- 1240 WATHANGA J.M., JONES T.W. & BROWN C.G.D. (1986). Cryopreservation of *Theileria* infected lymphoblastoid cells
1241 with functional assessment of viability. *Trop. Anim. Health Prod.*, **18**, 191–197.
- 1242 *
- 1243 * *
- 1244 **NB:** There is a WOAHO Reference Laboratory for theileriosis (see the WOAHO Web site for the most up-to-date list:
1245 <http://www.woaho.org/en/scientific-expertise/reference-laboratories/list-of-laboratories/>).
1246 Please contact the WOAHO Reference Laboratory for any further information on
1247 diagnostic tests, reagents and vaccines for theileriosis
- 1248 **NB:** FIRST ADOPTED IN 1991. MOST RECENT UPDATES ADOPTED IN 2018.

1249

1250

1251

Appendix 1: Theileriosis in cattle

Intended purpose of test: population freedom from infection, individual animal freedom from infection prior to movement, confirmation of clinical cases, prevalence of infection – surveillance

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
IFAT for <i>T. parva</i> Bovine Population: + Movement: + Clinical disease: - Surveillance: +++	Serum Glass slides with schizont whole body antigen	Reference test: No Dsp = 86% @1:40 Dsp = 95% @ 1:160 Dse = 55% @ 1:40 Dse = 28% @ 1:160	1. Herd of 105 sentinel cattle that tested negative at start and 63 calves born over surveillance period (1995–2000). 2. No true negative sample set used	See reference	1. Easy workflow 2. Sensitivity 3. Low cost 4. Low cost, sensitivity and ease of workflow allows surveillance of large populations	1. May show cross-reactivity with antibodies against <i>T. taurotragi</i> , <i>T. mutans</i> and <i>T. sp.</i> (buffalo). 2. Cell culture facilities required to produce antigen 3. Antigen is cold sensitive 4. Requires a fluorescent microscope. 5. High per cent of false negative results under endemic vs epidemic conditions. 6. Highly operator dependent 7. Low diagnostic sensitivity may not detect positive animals in small populations 8. Infected individuals from non-endemic regions not constantly challenged may test negative 9. Positive animals that present clinical disease may have prior exposure to parasites in endemic regions	Billiouw <i>et al.</i> (2005)
ELISA for <i>T. parva</i> Bovines Population: + Movement: + Clinical disease: - Surveillance: +	Serum P1M antigen	Reference test: IFAT DSe = >99% Dsp = 98%%	1. 12 experimentally infected cattle served as positive set 2. 712 serum samples from various non-endemic regions were used as negative set	See reference	1. More sensitive than IFAT 2. Antigen highly variable and may impact different geographical regions.	1. Not commercially available 2. P1M antigen may show cross-reactivity to <i>T. sp.</i> (buffalo) 3. Need spectrophotometer 4. Use monoclonal anti-bovine secondary conjugate that preclude use for buffalo 5. Antigen variability may limit testing of population freedom 6. Antigen variability may limit testing for individual movement 7. Positive animals that present clinical disease may have prior exposure to parasites in endemic regions 8. Cross-reactivity may limit surveillance capacity	Bishop <i>et al.</i> (2015) Katende <i>et al.</i> (1998)
P104 Nested-PCR for <i>T. parva</i> Bovines Buffalo Population: +++ Movement: ++ Clinical disease: ++ Surveillance: +++	EDTA-blood P104 gene	Reference test: No Dsp = nd Dse = nd	1. Two Experimentally infected animals 2. 151 field samples in endemic regions in Kenya (42.3% positive) 3. 169 field samples in endemic region in southern Sudan (36% positive)	See reference	1. More sensitive than IFAT 2. Direct detection of parasite 3. Highly specific since p104 is unique 4. High specificity and sensitivity would allow testing of populations from freedom	1. Two-step PCR with potential for contamination 2. False negative values due to variation in primer regions 3. Variation in primer sequences may miss a low percentage of positive animals	Odongo <i>et al.</i> (2010)

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
					<p>10. <u>Positive testing of animals with clinical signs may allow confirmation of clinical cases using Ct values as estimate of parasitaemia</u></p> <p>11. <u>High specificity and sensitivity allow accurate surveillance of disease</u></p>		
<p><u>IFAT for <i>T. annulata</i></u> <u>Bovine</u> <u>Population: +</u> <u>Movement: +</u> <u>Clinical disease: -</u> <u>Surveillance: +++</u></p>	<p><u>Serum</u> <u>Glass slides with piroplasm antigen</u></p>	<p><u>Reference test: No</u> <u>Dsp = 82%</u> <u>Dse = 72%</u></p>	<p><u>1. 70 bovines in endemic region monitored for 1 year</u></p>	<p><u>See references</u></p>	<p><u>1. Easy workflow</u> <u>2. Specific</u> <u>3. Relatively sensitive for surveillance purposes</u></p>	<p><u>1. Requires a fluorescent microscope</u> <u>2. Operator dependent</u> <u>3. Low diagnostic sensitivity may not detect positive animals in small populations</u> <u>4. Infected individuals from non-endemic regions not constantly challenged may test negative</u> <u>5. Positive animals that present clinical disease may have prior exposure to parasites in endemic regions</u></p>	<p><u>El Damaty et al. (2021)</u></p>
<p><u>Conventional PCR for <i>T. annulata</i></u> <u>Population: ++</u> <u>Movement: ++</u> <u>Clinical disease: ++</u> <u>Surveillance: +++</u></p>	<p><u>EDTA-blood</u> <u>18S ribosomal RNA gene</u></p>	<p><u>Reference test: No</u> <u>Dsp = 95%</u> <u>Dse = 83%</u></p>	<p><u>1. 70 bovines in endemic region monitored for 1 year</u></p>	<p><u>See references</u></p>	<p><u>1. More sensitive than IFAT</u> <u>2. Direct detection of parasite</u> <u>3. Lower cost than real-time PCR</u> <u>4. High specificity</u> <u>5. Relative high sensitivity, high specificity and low cost allow surveillance of large populations</u></p>	<p><u>1. Time consuming</u> <u>2. Relative low sensitivity would not allow for declaration of freedom in small populations</u> <u>3. Relative low sensitivity would impact on declaration of freedom for individual freedom for movement</u> <u>4. Positive testing of animals with clinical signs may allow confirmation of clinical cases if PCR amplicon is quantified to estimate parasitaemia</u></p>	<p><u>El Damaty et al. (2021)</u></p>
<p><u>Real-time PCR for <i>T. annulata</i></u> <u>Population: ++</u> <u>Movement: ++</u> <u>Clinical disease: ++</u> <u>Surveillance: +++</u></p>	<p><u>EDTA-blood</u> <u>18S ribosomal RNA gene</u></p>	<p><u>Reference test: No</u> <u>Dsp = 100%</u> <u>Dse = nd</u></p>	<p><u>1. 102 cattle samples from endemic region</u> <u>2. 39 cattle samples from non-endemic region</u></p>	<p><u>See references</u></p>	<p><u>1. More sensitive than IFAT</u> <u>2. Direct detection of parasite</u> <u>3. Single step PCR that prevents contamination</u> <u>4.</u></p>	<p><u>1. Need a real-time PCR system</u> <u>2. Unknown diagnostic sensitivity impact on assessment for testing population freedom of infection, individual freedom of infection for movement and ability to be used for surveillance</u> <u>3. Positive testing of animals with clinical signs may allow confirmation of clinical cases if PCR amplicon is quantified to estimate parasitaemia</u></p>	<p><u>Ros-Garcia et al. (2012)</u></p>
<p><u>Multiplex real-time PCR for <i>T. orientalis</i></u> <u>genotypes buffeli, chitose, ikeda, type 5</u> <u>Population: +++</u> <u>Movement: +++</u></p>	<p><u>EDTA-blood</u> <u>p23 gene: buffeli</u> <u>MPSP gene: chitose</u> <u>ITS-1 gene: ikeda</u> <u>MPSP gene: type 5</u></p>	<p><u>Reference test: No</u> <u>Dsp = 98.9%</u> <u>Dse = 98%</u></p>	<p><u>1. 154 cattle from an outbreak region</u></p>	<p><u>See references</u></p>	<p><u>1. One test to differentiate four genotypes both non-pathogenic and pathogenic</u> <u>2. Sensitive and specific</u> <u>3. High sensitivity, specificity and screening of wide array of strains</u></p>	<p><u>1. Need a high resolution melt real-time PCR system</u> <u>2. Mixed infections may complicate result interpretation</u> <u>3. Contamination would be difficult to detect due to the multiplex design</u></p>	<p><u>Perera et al. (2015)</u></p>

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Clinical disease: ++</u> <u>Surveillance: +++</u>					<u>allow for declaration of freedom in populations</u> <u>4. High sensitivity and specificity allow declaration of freedom for individual freedom for movement</u> <u>5. Positive testing of animals with clinical signs may allow confirmation of clinical cases if PCR amplicon is quantified to estimate parasitaemia</u> <u>6. High sensitivity and specificity allow surveillance of populations for a variety of strains or genotypes</u>		
<u>Quantitative real-time PCR for <i>T. orientalis</i></u> <u>Chitose and Ikeda strains</u> <u>Population: ++</u> <u>Movement: ++</u> <u>Clinical disease: ++</u> <u>Surveillance: +++</u>	<u>EDTA-blood</u> <u>MPSP gene</u>	<u>Reference test: No</u> <u>Chitose/Ikeda:</u> <u>Dsp = 92.6%;</u> <u>96.4% Dse =</u> <u>89.6%; 99.4%</u>	<u>1. 318 cattle samples from endemic region</u> <u>2. 237 samples that tested positive with different tests used for sensitivity</u> <u>3. 81 samples that tested negative using prior PCR tests</u>	<u>See references</u>	<u>1. Direct detection of parasite</u> <u>2. Differentiate pathogenic strains</u> <u>3. High specificity</u> <u>4. High sensitivity</u> <u>5. Single step PCR that prevents contamination</u> <u>6. Relative high sensitivity, high specificity and low cost allow surveillance of large populations</u>	<u>1. Need a real-time PCR system</u> <u>2. Test not validated against non-pathogenic strains</u> <u>3. Relative low sensitivity would not allow for declaration of freedom in small populations</u> <u>4. Relative low sensitivity would impact on declaration of freedom for individual freedom for movement</u> <u>5. Positive testing of animals with clinical signs may allow confirmation of clinical cases if PCR amplicon is quantified to estimate parasitaemia</u>	<u>Bogema <i>et al.</i> (2015)</u>

CHAPTER 3.4.14. TRICHOMONOSIS

SUMMARY

Description and importance of the disease: *Trichomonosis is a venereal disease of cattle caused by Trichomonas foetus, a flagellate protozoan parasite.*

Trichomonosis is ~~asymptomatic-subclinical~~ in bulls, however in cows the disease is characterised by infertility, abortion, embryonic and early fetal death, fetal maceration, pyometra and vaginal discharge. The disease has a world-wide distribution and, at one time, was of major economic importance as a cause of abortion and infertility, especially in dairy cattle. The widespread use of artificial insemination in many areas of the world has contributed to reduced prevalence. Nevertheless, trichomonosis is still of importance in countries with extensive farming practices where artificial insemination is not used.

Transmission of the disease is primarily by coitus, but mechanical transmission by insemination instruments or by gynaecological examination can occur. The organism can survive in whole or diluted semen at 5°C. Bulls over 3–4 years old are the main reservoir of the parasite as they tend to be long-term carriers, whereas most cows and young bulls (less than 3 years old) may clear the infection spontaneously. For these reasons samples from bulls are usually preferred for diagnosing and controlling the disease in herds.

Identification of the agent by in-vitro culture and microscopy: *Trichomonas foetus is a flagellate, pyriform protozoan parasite, approximately 8–18 µm long and 4–9 µm wide, with three anterior and one posterior flagellae and an undulating membrane. The organisms move with a jerky, rolling motion and are seen in culture tests of preputial samples of infected bulls and vaginal washings or cervico-vaginal mucus of infected cows, or sometimes in aborted fetuses. Trichomonas foetus can be cultured in vitro and may be ~~viewed~~ detected by microscopy using wet mounts or stained slides. The standard diagnostic method for bulls involves the appropriate collection, examination and culture of smegma from the prepuce and penis, while in cows the preferred sample is vaginal mucus. Smegma can be collected by a variety of means including preputial lavage, brushing or scraping the preputial cavity and glans penis at the level of the fornix with a dry insemination pipette. A number of in-vitro culture media exist, including a commercially available field culture test kit, which supports trichomonad growth and allows direct microscopic examination.*

Identification of the agent by molecular methods: *Bovine trichomonosis ~~may can~~ also be detected by polymerase chain reaction (PCR) amplification. Both conventional and quantitative real-time PCR have been used successfully in the identification of T. foetus and the diagnosis of trichomonosis. Both methods have been used either in combination with culture or alone. ~~The conventional PCR has increased sensitivity when combined with culture, while the quantitative PCR has been successfully used on clinical samples. The quantitative real-time PCR has been validated both in the USA and Canada and it is now available as a commercial kit. This assay is also used routinely in Australia. Various commercial kits are also available for the detection of parasite DNA directly in clinical samples.~~*

Serological tests: *~~Attempts have been made at developing~~ Immunological tests, including an agglutination test using mucus collected from the cervix and an antigen made from cultured organisms, ~~and these were~~ have been used as herd tests, ~~–however, these tests lack sensitivity and are not used~~ suitable for the individual diagnosis of trichomonosis. ELISAs developed to target whole IgG, IgG1 and IgG2 in serum and IgA in vaginal mucus are most commonly applied to confirm immune status in individual animals or populations post-vaccination. There is one report demonstrating the use of these ELISAs to confirm clinical infection in heifers.*

51 Requirements for vaccines: A partially efficacious, killed whole-cell vaccine is commercially
52 available as either a monovalent, or part of a polyvalent vaccine containing Campylobacter and
53 Leptospira. The efficacy of several experimental whole cell vaccines and purified T. foetus membrane
54 extracts demonstrate that T. foetus clearance rates are shorter compared with unvaccinated heifers.
55 Subunit vaccines are less effective and recombinant vaccines have not been developed.

56 A. INTRODUCTION

57 1. Description and importance of the disease

58 Trichomonosis is a bovine venereal disease caused by the flagellate protozoan parasite, *Trichomonas foetus*.
59 The habitual hosts of T. foetus are cattle (Bos taurus, B. indicus). This parasite can be present in the genital tract
60 of infected bulls, more precisely, the preputial cavity. It localises on the surface of the epithelium of the penis and
61 on the proximal foreskin in the fornix area (BonDurant, 1997), a suitable microenvironment for facultative or
62 microaerophilic microorganisms. In bulls trichomoniasis is subclinical, and infection can persist for the life of the bull
63 (Collantes-Fernández et al., 2018). However, shortly after infection, preputial discharge associated with small
64 nodules on penile membranes may be detected (Dąbrowska et al., 2019). For bulls older than 3–4 years,
65 spontaneous recovery rarely occurs, resulting in a permanent source of infection in herds. In bulls under 3–4 years
66 of age, infection may be transient. One of the proposed measures for controlling T. foetus infection in a herd is the
67 use of bulls under 3–4 years of age rather than bulls older than 3–4 years (Yao, 2013).

68 In the infected cow, the initial lesion is a vaginitis, which, in pregnant animals, results in invasion of the cervix and
69 uterus. Various sequelae can result, including a placentitis leading to early abortion (1–16 weeks), uterine
70 discharge, and pyometra. In some cases, despite infection, pregnancy is not terminated by abortion and a normal,
71 full-term calf is born. On a herd basis, cows may, following infection, exhibit irregular oestrous cycles, uterine
72 discharge, pyometra, or early abortion (BonDurant, 1997; Skirrow & BonDurrant, 1988). Cows usually clear their
73 infection within 90 days and acquire a short-lived immune protection to T. foetus for a period of at least a year and
74 in some cases up to three years (BonDurant, 1997).

75 In some cases, despite infection, pregnancy is not terminated by abortion and a normal, full-term calf is born. On a
76 herd basis, cows may, following infection, exhibit irregular oestrous cycles, uterine discharge, pyometra, or early
77 abortion (BonDurant, 1997; Skirrow & BonDurrant, 1988). Cows usually clear their infection within 90 days and
78 acquire a short-lived immune protection to T. foetus for a period of at least a year and in some cases up to three
79 years (BonDurant, 1997). Transmission of infection occurs by coitus, or by gynaecological examination of cows
80 using contaminated instruments. It may also occur via artificial insemination (AI) as semen from infected bulls may
81 be passively contaminated by T. foetus present in the preputial cavity. Therefore, all bulls must be routinely checked
82 for the absence of T. foetus infection. Where AI along with diagnostic monitoring and culling of infected bulls is
83 used, trichomonosis has been controlled; however, it is still prevalent in the Americas, Australia, South Africa and
84 Eastern European countries where extensive farming and natural mating is practised.

85 2. Causal-Taxonomical classification of the pathogen

86 *Trichomonas foetus* belongs to the genus *Trichomonas* in the family Trichomonadidae, Order
87 Trichomonadorida. Trichomonas foetus is pyriform, 8–18 µm long and 4–9 µm wide, with three anterior and one
88 posterior flagellae, and an undulating membrane. Live organisms move with a jerky, rolling motion, and can be
89 detected by light microscopy. Phase-contrast dark-field microscopy or other methods must be used to observe the
90 details needed for identification when growing in medium cultures, are usually observed in a trophozoite stage,
91 appearing with a pyriform or ovoid shape (Collantes-Fernández et al., 2018; Dąbrowska et al., 2019). Under
92 unfavourable environmental conditions, cells adopt a “defensive mechanism” and change into pseudocysts, having
93 a spherical shape without flagellates or undulating membranes. This can be observed in post-exponential phases
94 in laboratory cultures, but also in fresh preputial and swab samples (Dąbrowska et al., 2019). Detailed morphological
95 descriptions, including electron microscopy studies, have been published (Benchimol et al., 2021; Warton &
96 Honigberg, 1979). Trichomonas foetus has only the trophozoite stage and multiplies by longitudinal binary fission;
97 sexual reproduction is not known to occur. Three serotypes are recognised based on agglutination (Skirrow &
98 BonDurrant, 1988): the ‘belfast’ strain, reported predominantly in Europe, Africa and the USA (Gregory et al., 1990);
99 the ‘brisbane’ strain described in Australia (Elder, 1964) and the ‘manley’ strain, which has been reported in only a
100 few outbreaks (Skirrow & BonDurrant, 1988)

101 The habitual hosts of T. foetus are cattle (Bos taurus, B. indicus). The bovine gastrointestinal tract hosts a number
102 of other, commensal trichomonads e.g. Pentatrichomonas hominis, Tetratrichomonas buttreyi, Tetratrichomonas
103 pavlova, Trichomonas enteris and Pseudotrichomonas species, which often contaminate preputial samples
104 (Taylor et al., 1994). The number of flagellae, observed under phase-contrast illumination or after staining, is an
105 important morphological characteristic that can help differentiate T. foetus from other bovine flagellated parasites.

106 However, non-*T. foetus* trichomonads are often difficult to distinguish from *T. foetus* based on culture and
107 morphology (Taylor *et al.*, 1994).

108 *Tritrichomonas suis*, a commensal of pigs, and bovine *T. foetus* are indistinguishable morphologically, serologically
109 and antigenically. The use of modern molecular techniques such as restriction fragment length polymorphism
110 (RFLP), randomly amplified polymorphic DNA analysis (RAPD), variable length repeats (VLR), and internal
111 transcribed spacers 1 and 2 (ITS1 and 2) polymerase chain reaction methods (PCR), supports the view that these
112 two species are identical (Tachezy *et al.*, 2002). More recently, *T. foetus* and *T. suis* were found to be identical at
113 9/10 loci and the use of the *T. suis* senior synonym has been suppressed in favour of *T. foetus* (Šlapeta *et al.*, 2012).

114 *Tritrichomonas foetus* has been reported in domestic cats, horses and roe deer. Other species, such as goats, pigs,
115 dogs, rabbits and guinea-pigs, have been experimentally infected (Levine, 1973). *Tritrichomonas foetus* has also
116 been isolated from cats with diarrhoea and is now commonly known as the 'cat genotype' *T. foetus* (Šlapeta *et al.*,
117 2012). *Tritrichomonas foetus* has also been reported to cause infections in humans including meningoencephalitis
118 and peritonitis in immunocompromised and immunosuppressed individuals (Yao, 2012). In humans, only three
119 cases have been reported (to 2016) of infection by *Tritrichomonas foetus* and these were related with rare
120 opportunistic infections in immunocompromised and immunosuppressed individuals (Suzuki *et al.*, 2016)."

121 Transmission of infection occurs by coitus, or by gynaecological examination of cows using contaminated
122 instruments. It may also occur via artificial insemination (AI) as semen from infected bulls may be passively
123 contaminated by *T. foetus* present in the preputial cavity. Therefore, all bulls must be routinely checked for absence
124 of *T. foetus* infection. Where AI along with diagnostic monitoring and culling of infected bulls is used, trichomonosis
125 has been controlled; however, it is still prevalent in the Americas, Australia, South Africa and Eastern European
126 countries where extensive farming is still practised, and natural mating is allowed.

127 The site of infection in bulls is primarily the preputial cavity (BonDurant, 1997), and little or no clinical manifestation
128 occurs. For bulls older than 3–4 years, spontaneous recovery rarely occurs, resulting in a permanent source of
129 infection in herds. In bulls under 3–4 years of age, infection may be transient. One of the proposed measures for
130 controlling *T. foetus* infection in a herd is the use of bulls under 3–4 years of age rather than bulls older than 3–4
131 years (Yao, 2013).

132 *Tritrichomonas foetus* is present in small numbers in the preputial cavity of infected bulls, with some concentration
133 in the fornix and around the glans penis (BonDurant, 1997). Chronically infected bulls show no gross lesions. In the
134 infected cow, the initial lesion is a vaginitis, which, in pregnant animals, results in invasion of the cervix and uterus.
135 Various sequelae can result, including a placentitis leading to early abortion (1–16 weeks), uterine discharge, and
136 pyometra. In some cases, despite infection, pregnancy is not terminated by abortion and a normal, full-term calf is
137 born. On a herd basis, cows may, following infection, exhibit irregular oestrous cycles, uterine discharge, pyometra,
138 or early abortion (BonDurant, 1997; Skirrow & BonDurrant, 1988). Cows usually clear their infection within 90 days
139 and acquire a short lived immune protection to *T. foetus* for a period of at least a year and in some cases up to
140 three years (BonDurant, 1997).

141 **3. Zoonotic potential and biosafety and biosecurity requirements**

142 *Tritrichomonas foetus* is not identified as a zoonotic agent. Laboratory manipulations should be performed with
143 appropriate biosafety and containment procedures as determined by biological risk analysis (see Chapter 1.1.4
144 *Biosafety and biosecurity: Standard for managing biological risk in the veterinary laboratory and animal facilities*).

145 **4. Differential diagnosis**

146 Diseases such as campylobacteriosis, leptospirosis, brucellosis, neosporosis, chlamydiosis, bovine viral diarrhoea,
147 infectious bovine rhinotracheitis and anaplasmosis, that may cause clinical signs including infertility, vaginitis,
148 pyometra, abortions and vaginal discharge, should be excluded.

149 **B. DIAGNOSTIC TECHNIQUES**

150 A tentative diagnosis of trichomonosis as a cause of reproductive failure in a herd is based on the clinical history,
151 signs of early abortion, repeated returns to service, or irregular oestrous cycles. Confirmation of infection depends
152 on the demonstration of *T. foetus* in placental fluid, stomach contents of the aborted fetus, uterine washings,
153 pyometra discharge, vaginal mucus or preputial smegma. In infected herds, the most reliable material for diagnosis
154 is either preputial or vaginal washings or scrapings (Buller & Corney, 2013; Yao, 2013). The quantity of organisms
155 may differ depending on the sample. There are numerous *T. foetus* cells in the aborted fetuses, in the uterus several
156 days after abortion, and, in the vaginal mucus of recently infected cows for 12–20 days after infection. Samples
157 collected from bulls, cows and aborted fetuses are tested by conventional methods (direct examination and culture)

158 or by molecular methods. The sampling techniques are the same in both cases; however, samples for culture are
 159 inoculated into transport medium or culture medium, whereas those for molecular biology can be collected either in
 160 medium or in phosphate-buffered saline (PBS) or normal saline.

161 Table 1. Test methods available for the diagnosis of trichomonosis and their purpose

Method	Purpose					
	Population freedom from infection ^(a)	Individual animal freedom from infection prior to movement ^(a)	Contribute to eradication policies ^(a)	Confirmation of clinical cases ^(a)	Prevalence of infection – surveillance ^(a)	Immune status in individual animals or populations post-vaccination
<u>Detection and identification of the agent^(f)</u>						
Microscopy for morphological identification	+++	++	+++	+++	++	–
Conventional PCR on clinical samples	+	++	–	++	–	–
Conventional PCR in combination with culture	++	+++	–	+++	+	–
Real-time PCR	+++	+++	+++	+++	++	–
<u>ELISA</u>	≡	≡	≡	+++	≡	+++
<u>Detection of an immune response</u>						
<u>IgG ELISA (serum), IgA ELISA (vaginal mucus)</u>	≡	≡	≡	++	≡	+++

162 Key: +++ = recommended for this purpose; ++ recommended but has limitations;
 163 + = suitable in very limited circumstances; – = not appropriate for this purpose.
 164 PCR = polymerase chain reaction.

165 ^(a)See Appendix 1 of this chapter for justification table for the scores given to the tests for this purpose.
 166 ^(b)See Appendix 2 of this chapter for justification table for the scores given to the tests for this purpose.
 167 ^(c)See Appendix 3 of this chapter for justification table for the scores given to the tests for this purpose.
 168 ^(d)See Appendix 4 of this chapter for justification table for the scores given to the tests for this purpose.
 169 ^(e)See Appendix 5 of this chapter for justification table for the scores given to the tests for this purpose.
 170 ^(f)A combination of agent identification methods applied on the same clinical sample is recommended.

171 1. Identification Detection and identification of the agent

172 A tentative diagnosis of trichomonosis as a cause of reproductive failure in a herd is based on the clinical history,
 173 signs of early abortion, repeated returns to service, or irregular oestrous cycles. Confirmation of infection depends
 174 on the demonstration of *T. foetus* in placental fluid, stomach contents of the aborted fetus, uterine washings,
 175 pyometra discharge, vaginal mucus or preputial smegma. In infected herds, the most reliable material for diagnosis
 176 is either preputial or vaginal washings or scrapings (Buller & Corney, 2013; Yao, 2013).

177 The number of organisms varies in different situations. They are numerous in the aborted fetus, in the uterus several
 178 days after abortion and, in recently infected cows, they are plentiful in the vaginal mucus 12–20 days after infection.
 179 In the infected bull, *T. foetus* organisms are present on the mucosa of the prepuce and penis, apparently not
 180 invading the submucosal tissues. It is recommended to allow at least 1 week after the last service before taking a
 181 preputial sample.

182 1.1. Sampling techniques and transport conditions Collection of samples

183 A number of Several techniques for collecting preputial samples from bulls or vaginal samples from cows
 184 have been described. It is important to avoid faecal contamination, as this may introduce intestinal
 185 protozoa that may be confused with *T. foetus* (Taylor *et al.*, 1994). Also, the presence of urine may

186 interfere with DNA detection (Clothier *et al.*, 2019). Contamination of samples should be minimised by
187 removal of extraneous material and soiled hair from around the preputial orifice or vulva; however,
188 cleansing of the area, particularly with disinfectants, is to be avoided, as this may reduce diagnostic
189 sensitivity.

190 ~~Samples collected from bulls, cows and aborted fetuses are tested by conventional methods (direct~~
191 ~~examination and culture) or by molecular methods. The sampling techniques are the same in both cases;~~
192 ~~however, samples for culture are inoculated into transport medium or culture medium, whereas those for~~
193 ~~molecular biology can be collected either in medium or in phosphate buffered saline (PBS) or normal~~
194 ~~saline.~~

195 **1.1.1. Collection of samples: Bulls**

196 Samples can be collected from bulls by three methods: ~~namely~~ scraping, brushing or washing
197 (Buller & Corney, 2013; Yao, 2013). When using the same sampling method, a sample can be
198 used for the detection of bovine genital campylobacteriosis (see Chapter 3.4.4 *Bovine genital*
199 *campylobacteriosis*). All three methods provide similar analytical sensitivity, independently of the
200 diagnostic method implemented afterwards, i.e. culture or polymerase chain reaction (PCR)
201 methods. The sampling techniques should be chosen based on the context and local conditions.
202 For optimal sensitivity (95% or more) the first sampling should be done after a 1-week sexual rest
203 and bulls should be sampled and tested three times at weekly intervals (Yao, 2013).

- 204 i) Scraping the preputial and penile mucosa with an artificial insemination pipette connected
205 to a syringe or a bulb via a silicone rubber tube, is a common technique.
- 206 ii) Special brushes made of metal or plastic, may be used to collect smegma from the penis
207 and prepuce (Yao, 2013). Plastic disposable brushes, with a hole in the tip (hollow 'brush'
208 or 'rasper') are commercialised for this purpose. They are easy to use and fast. The tool is
209 gently scraped along the surface of the penis and internal prepuce near the fornix. The
210 collected smegma is rinsed into ~5 ml PBS or normal saline, or medium.
- 211 iii) Preputial lavage is still a common technique. A strong plastic tubing attached to a rubber
212 bulb is inserted into the full length of the preputial cavity and the latter is washed with 20–30
213 ml PBS pH 7.2 or normal saline. Collecting washes from the artificial vagina after semen
214 collection is not recommended due to low diagnostic sensitivity (Gregory *et al.*, 1990).

215 ~~Sampling techniques for bulls have been compared by several laboratories (reviewed in Yao,~~
216 ~~2013). The results indicate that all three methods, i.e. brushing, scraping and lavage, provide~~
217 ~~similar analytical sensitivity, irrespective of the diagnostic method implemented afterwards, i.e.~~
218 ~~culture or PCR. Thus the sampling techniques should be chosen based on the context and local~~
219 ~~conditions.~~

220 ~~Several laboratories have examined the effect on diagnostic sensitivity of repeated sampling~~
221 ~~(reviewed in Yao [2013]). For optimal sensitivity (95% or more) the first sampling should be done~~
222 ~~after a 1-week sexual rest and bulls should be sampled and tested three times at weekly intervals.~~

223 **1.1.2. Collection of samples: Cows**

224 Samples from cows are collected by washing the vagina, or by scraping the cervix with an artificial
225 insemination pipette or a brush. The collected mucus is rinsed into ~ 5 ml PBS or normal saline
226 (if PCR is intended) or in medium.

227 **1.1.3. Samples from Aborted fetus**

228 Abortions due to *T. foetus* may occur at any time during gestation from 2 months onwards, but
229 most frequently at 3–5 months (Buller & Corney, 2013). When abortions in that period occur and
230 *T. foetus* infection is suspected, the placenta and fetal fluids should be sampled, together with the
231 lungs of the aborted foetus (Buller & Corney, 2013). The abomasal content is also reported to
232 contain high numbers of *T. foetus* (Rhyan *et al.*, 1988).

233 **1.2. Transport**

234 The choice of sampling and diagnostic techniques should take into account several factors including the
235 transport conditions and possibilities, and the expected duration of transport. PBS or normal saline is not
236 a good transport medium if the samples are to be cultured (Bryan *et al.*, 1999). The use of a transportation
237 media with nutrients and antibiotics is essential for the survival of the parasite. Therefore, there are
238 different media used today as transportation and culture media, e.g. a thioglycolate broth media with
239 antibiotics, Diamond's medium, or a commercial plastic pouch (Bryan *et al.*, 1999; Collantes-Fernández

240 et al., 2018). Under certain transport conditions, extended transport of cultures from remote areas to
241 diagnostic laboratories, i.e. northern Australia, leads to heavily contaminated field isolates thus higher
242 concentrations of antibiotics and fungicides are applied to isolate pure *T. foetus*. Yeast and fungi are
243 viewed using microscopy and bacteria screened using blood agar plates (Tabor et al., 2023). Note: if
244 *T. foetus* can be visualised in heavily contaminated cultures using microscopy and if storage of pure
245 cultures is not needed, the high doses of antibiotics are not required.

246 Samples for diagnosis should arrive at the laboratory, ideally within 48 hours after sample collection.
247 Where samples must be submitted to a laboratory and cannot be delivered within 24 hours, a transport
248 medium containing antibiotics should be used (e.g. a thioglycolate broth media with antibiotics (Bryan et
249 al., 1999)) or a commercial plastic pouch. PBS or normal saline is not a good transport medium if the
250 samples are to be cultured (Bryan et al., 1999). During transportation, the organisms samples should be
251 protected from light and extremes of temperature, especially if cultures are to be undertaken in the
252 laboratory. The temperature should remain above 5°C and below 37°C during transport (Bryan et al.,
253 1999). Transport at 25°C followed by culture at 37°C is considered optimal for the survival and growth of
254 *T. foetus* (Buller & Corney, 2013). Freezing samples can result in negative cultures (Bryan et al., 1999;
255 Loy et al., 2023), however it has been demonstrated that cooling or freezing samples for PCR analysis
256 do not affect detection limits (Loy et al., 2023).

257 In conclusion, the choice of sampling and diagnostic techniques should take into account several factors
258 including the transport conditions and possibilities, and the expected duration of transport.

259 The use of lyophilised modified Diamond's medium in areas where cold chain storage of this medium
260 prior to use is difficult, has been proved efficient (Rush et al., 2019).

261 **1.3. Identification of *T. foetus* by direct examination or in culture**

262 **1.3.1. Direct detection of parasites**

263 Direct detection of parasites by microscopy immediately after sample collection, or on reception
264 of the sample in transport medium, can be attempted (see below for examination and identification
265 criteria). However, the organisms are often too few to allow for direct detection from the original
266 samples. Thus, cultures should be prepared to allow multiplication of the parasites above the
267 detection limit (around 10⁴/ml; Bryan et al., 1999).

268 **1.3.2. Culture media**

269 Samples should be inoculated into culture media as soon as possible after collection and
270 thereafter incubated at 30°C–37°C, for 48–72 hours or longer, depending on the culture medium
271 used, before being examined (see Section B.1.2.2.1). Inoculated media should not be chilled or
272 refrigerated as this would affect survival of *T. foetus*.

273 **1.2.2.1. Culture media**

274 Several culture media can be used. Diamond's trichomonad medium has been widely used for
275 decades with some modifications over time (Bryan et al., 1999). Today there are many variations
276 from the original Diamond's medium that can be bought ready to use or prepared in a laboratory
277 (Bryan et al., 1999; Clothier et al., 2019; Paradiso & Oyhenart, 2023; Rush et al., 2019). However,
278 other culture media can be used for example such as the liver infusion broth medium (Lun et al.
279 2000) also named TFM medium, Clausen's and Oxoid's media. Commercial culture kits are also
280 available in various countries. It is important to ensure that the culture media are used before their
281 established expiry date as many media do not have a long shelf life. In-house made media should
282 normally be kept for no longer than 1 month at 5°C ± 3°C.

283 The quality of the water used is important and an antifungal can be added to the media to control
284 yeast growth. Quality control checks including sterility checks should be carried out on all batches
285 of media.

286 When liquid cultures will be further used for DNA extraction, agar can be omitted from the media
287 due to the difficulty of harvesting pure *T. foetus* cells in the presence of the agar; a two per cent
288 agar plug can be layered on top of the liquid medium to provide the anaerobic conditions for
289 growth without the agar interfering with harvesting (Tabor et al., 2023).

290 It is important to make sure that the culture media are used before their established expiry date,
291 as many media are not stable. In-house made media should normally be kept for no longer than
292 1 month at 5°C ± 3°C.

- 293 **a) — Composition of three commonly used culture media**
- 294 i) Modified Diamond's Medium (Bryan *et al.*, 1999; Lun *et al.*, 2000)
- 295 Modified Diamond's Medium can be prepared as follows:
- 296 The modified Diamond's medium consists of: 2-g% trypticase peptone, 1-g% yeast extract,
297 0.5-g% maltose, 0.1-g% L-cysteine hydrochloride, and 0.02-g% L-ascorbic acid, and is made
298 up with 90 ml distilled water containing 0.08-g% each of K₂HPO₄ and 0.08% KH₂PO₄ are
299 dissolved in distilled water. The pH of this solution is adjusted to 7.2 using NaOH or HCl,
300 and adjusted to pH 7.2–7.4 with sodium hydroxide or hydrochloric acid. Following the
301 addition of 0.05-g% agar, the medium is autoclaved for 10–15 minutes at 121°C, allowed to
302 cool to 49°C, and then 10 ml inactivated bovine serum (inactivated by heating to 56°C for
303 30 minutes), 100,000 units crystalline penicillin-C and 0.1 g streptomycin sulphate are added
304 aseptically.
- 305 After cooling the medium (room temperature or at least 48°C), 10% inactivated serum (56°C
306 for 30 minutes) and antibiotics are added aseptically. Different types of inactivated serum
307 can be used: bovine serum, fetal bovine serum (FBS), horse serum, sheep serum, are some
308 examples (Diamond, 1957; Paradiso & Oyhenart, 2023; Rush *et al.*, 2019). Their availability
309 and accessibility may depend on the country and laboratory. Antibiotics such as penicillin G
310 (1000 U/ml) streptomycin sulphate (1000 µg/ml) and amphotericin B (10–25 µg/ml) are
311 recommended for samples to be analysed. For purified cultures, the use of antibiotics can
312 be omitted (Diamond, 1957).
- 313 The medium is aseptically dispensed in 3–10 ml aliquots into sterile vials and kept 46 ×
314 125 mm screw top vials and refrigerated at 4°C until use. Before use, aliquots should be
315 pre-warmed to room temperature, or ideally, 37°C. The incorporation of agar into the
316 medium confines contaminating organisms largely to the upper portion of the culture
317 medium, while helping to maintain microaerophilic conditions at the bottom where the
318 trichomonads occur in largest numbers.
- 319 ii) *Tritrichomonas foetus* medium (TFM) (based on modified Plastringe's medium)
- 320 TFM medium can be prepared as follows: 2.5% neutralised liver digest, 1% tryptose are
321 dissolved in distilled water. The pH of this solution is adjusted to 7.4 using NaOH or HCl.
322 Following the addition of 0.3% of Bacto agar, this medium is autoclaved for 15 minutes at
323 121°C. The TFM consists of: 12.5 g neutralised liver digest, 5 g tryptose dissolved in 500 ml
324 distilled water. The pH is adjusted to 7.4 with sodium hydroxide or hydrochloric acid.
325 Following addition of 1.5 g Bacto agar, the medium is autoclaved for 15 minutes at 121°C.
326 An antibiotic solution containing 0.75 g penicillin and 0.082 g streptomycin is prepared in
327 400 ml distilled water. To prepare 1 litre of TFM, 500 ml basal medium is combined with 500
328 ml sterile inactivated (at 56°C for 30 minutes) bovine serum and 10 ml of an antibiotic
329 solution. The antibiotics penicillin G and streptomycin sulphate are used at a final
330 concentration of 75 µg/ml and 8.2 µg/ml respectively. This medium can be stored at –20°C.
- 331 iii) Media in a pouch
- 332 Where a combination of convenience and sensitivity is required, a combined specimen
333 transport and culture kit may be used (BonDurant, 1997; Borchartt *et al.*, 1992). The kit
334 consists of a clear flexible plastic pouch with two chambers. The upper chamber contains
335 special medium into which the sample is introduced. Field samples for direct inoculation into
336 the culture pouch would normally be collected by the preputial scraping technique
337 (BonDurant, 1997). Samples collected by preputial washing require centrifugation before
338 introduction of the sediment into the upper chamber. Following mixing, the medium is forced
339 into the lower chamber, and the pouch is then sealed and incubated at 37°C. Microscopic
340 examination for trichomonads can be done directly through the plastic pouch (Borchartt *et*
341 *al.*, 1992).
- 342 The quality of the water used is important and an antifungal can be added to the media to
343 control yeast growth.
- 344 Quality control checks including sterility checks should be carried out on all batches of
345 media.
- 346 It is important to make sure that the culture media are used before their established expiry
347 date, as many media are not stable. In-house made media should normally be kept for no
348 longer than 1 month at 5°C ± 3°C.
- 349 **b) — Growth characteristics in the different media**

350 Lun et al. (2000) tested the three media described above, i.e. Diamond's, liver infusion broth
351 medium and a commercial culture kit. They found that the three media supported the growth
352 of *T. foetus* at 37°C, sixteen isolates from various geographical origins were tested. The
353 growth characteristics of these isolates were different in the three media. For isolates grown
354 in Diamond's the growth kinetics appeared less variable among isolates, the peak
355 concentration tended to be reached earlier (by day 2–4 post inoculation) and was generally
356 higher (above 107 organisms per ml) than with the other two media. However, the parasites
357 died faster after reaching the peak concentration in Diamond's medium. This has
358 implications for monitoring of cultures (see Section B.1.2.3).

359 1.3.3. Culture inoculation

360 It is desirable to process samples collected by preputial wash or vaginal wash by centrifugation.
361 If the sampling conditions in the field do not permit the use of a centrifuge, the samples should be
362 decanted for 15–20 minutes on the bench. A volume of approximately 1 ml or less of the sediment
363 or the pellet from the centrifugation step is then inoculated into culture media.

364 When using commercial sampling devices with a disposable brush, the latter is aseptically cut off
365 directly into culture medium after sampling.

366 1.3.3.1. Culture conditions

367 Samples should be inoculated into culture media as soon as possible after collection and
368 thereafter incubated between 30°C–37°C. A laboratory isolate of *T. foetus* should be
369 cultured in parallel with the test samples, as a media positive control.

370 The optimal incubation period to reach peak concentration is between 2 days up to 7 days
371 for modified Plastridge's medium and commercial kit media. As for modified Diamond's
372 medium, incubation can be done between 2 days up to 5 days, however it is from day 2 up
373 to day 4 that they reach their peak, and from day 5 (included) onwards unviable parasites
374 start to appear in cultures (Lun et al., 2000).

375 Cultures should be maintained at a temperature within the range 30°C–37°C. In no case
376 should the incubation temperature rise above 37°C.

377 A known isolate of *T. foetus* should be cultured in parallel with the test samples, as a control.

378 It is advisable to start examining culture media microscopically at day 2–4 following
379 inoculation, which in most media will correspond to the peak concentration. If Diamond's
380 medium is being used, a single examination at day 2, 3 or 4 may be performed as the
381 parasites are rapidly dying out in this medium from day 5 onwards (BonDurant et al., 1996;
382 Lun et al., 2000). With other media supporting slower growth, such as liver broth infusion
383 and even more so with commercial medium, it is recommended to examine the cultures at
384 intervals until day 7 post-inoculation (Bryan et al., 1999; Lun et al., 2000). A single
385 examination at day 7 is an alternative option with those media that support slower growth of
386 *T. foetus* than Diamond's (Section B.1.2.3).

387 In conclusion, it should be emphasised that the different culture media described above are
388 equally successful provided the culture procedures follow the general requirements and are
389 adapted to the type of medium. Laboratories should evaluate what is most suitable for them
390 in their own context, given their facilities and expertise, and considering the climatic,
391 logistical, and economic considerations.

392 1.3.3.2. Culture cryopreservation

393 One method of conserving *T. foetus* cultures consists of using a freezing solution containing
394 10% inactivated calf serum, 80% RPMI (Roswell Park Memorial Institute) 1640 medium
395 (without L-glutamine) and 10% dimethyl sulfoxide.

396 Cultures are grown for 2–3 days in media and centrifuged at 1500 g for 10 minutes. Five
397 hundred µl of the lower layer is then added to 1 ml of freezing solution. Vials are paced in a
398 freezing apparatus at –80°C for approximately 24 hours to cool the vials at around
399 –1°C/minute. After this period, vials are transferred into storage boxes at –80°C or liquid
400 nitrogen.

401 To recover *T. foetus* from cryopreservation, vials are placed at 30°C until the solution has
 402 just thawed, then quickly transferred into prewarmed medium. Subculture is made every 2–
 403 3 days, checking under the microscope for growth and motility; full recovery is reached in
 404 about 3–4 subcultures.

405 **1.2.3. Summary of times for optimal growth and survival for different media**

406 ~~The optimal growth for modified Plastridge's medium, *Trichomonas* medium and commercial kit~~
 407 ~~media is after 2–7 days, and the survival time in culture is 1–7 days; for modified Diamond's~~
 408 ~~medium optimal growth is after 2–4 days and survival time in culture is 1–4/5 days (Buller &~~
 409 ~~Corney, 2013).~~

410 **1.3.4. *Tritrichomonas foetus* detection and identification by microscope ~~microscopic~~**
 411 **examination**

412 Initial detection of organisms can be done by light microscopy, on a wet mount slide prepared
 413 directly from a drop of the sample or culture, or through the wall of a plastic pouch. When a drop
 414 of culture medium is examined, it should be carefully taken from the bottom of the tube, where
 415 the trichomonads are likely to concentrate due to the microaerophilic conditions.

416 The organisms may be seen under a standard compound microscope using a magnification of
 417 x40 or x80 initially, then x100 or x400. *Tritrichomonas foetus* is motile and normally exhibits jerky
 418 movements in wet preparations. Sufficient time, i.e. 2–5 minutes, should be devoted to
 419 examination of each slide, to allow the detection of parasites in low numbers and observation of
 420 the morphological features.

421 The pear-shaped organisms have three anterior and one posterior flagellae and an undulating
 422 membrane that extends nearly to the posterior end of the cell. They also have an axostyle that
 423 usually extends beyond the posterior end of the cell (Table 2). There are several other
 424 microorganisms similar to *T. foetus* that can also be found in cattle and that are very difficult to
 425 distinguish from *T. foetus*. It must therefore be considered that routine examination by microscopy
 426 can render false positive results (Dąbrowska *et al.*, 2019). Molecular detection in combination
 427 with culture is recommended when possible.

428 When relatively high numbers of organisms are present, phase-contrast microscopy is ~~may be~~
 429 very valuable in revealing ~~these *T. foetus* features and/or~~ a rapid, Giemsa-based staining
 430 procedure ~~may can~~ also be used (Buller & Corney 2013; Lun & Gajadhar, 1999). ~~Both these~~
 431 techniques ~~work best when relatively high numbers of organisms are present, especially the~~
 432 staining technique.

433 The staining of trichomonads is best performed using Lugol's iodine, which enhances the
 434 morphological features of the flagellae and the membrane (Lun & Gajadhar, 1999). Briefly, 1 ml
 435 of the culture containing the parasites is concentrated at high speed e.g. 16,000 **g** for 10 seconds.
 436 The supernatant is removed and the pellet is resuspended homogenously in the culture medium
 437 containing 10% bovine serum. A thin smear is prepared on a microscope slide using 10 µl of the
 438 suspension. The slide is air-dried and fixed for 1 minute in methyl alcohol and then stained in
 439 Lugol's iodine for 1 minute. The slide is subsequently stained with the rapid Giemsa method
 440 following the manufacturer's instructions. The slide is then washed thoroughly to remove any
 441 remaining stain and air dried before being examined at x 100 under oil-immersion (Buller &
 442 Corney, 2013). The Staining ~~allows~~ may help in the differentiation of *T. foetus* from other
 443 trichomonads as shown (see in Table 2).

444 Table 2. Morphological features of trichomonads (Buller & Corney, 2013)

Organism	Anterior flagella	Posterior flagella	Undulating membrane	Host
Tritrichomonas				
<i>T. foetus</i>	3	1	2–5	Cattle
<i>T. enteris</i>	3	1	3	Cattle
<i>T. vaginalis</i>	4	0	4	Human
Tetratrichomonas				

Organism	Anterior flagella	Posterior flagella	Undulating membrane	Host
<i>T. buttreayi</i>	3 or 4 variable length	3–5	1	Pigs, cattle
<i>T. pavlovi</i>	4	1	2–4	Calves
Pentatrichomonas				
<i>P. hominis</i>	4	1	3 waves	Human, primates, cats, dogs, cattle

445

1.3.5. Overall sensitivity and specificity of culture and identification

446

Any estimate of the diagnostic sensitivity and specificity of the culture and identification test will be dependent on the efficacy of sample collection, handling and processing, as well as the composition and quality of the culture medium.

447

448

449

In bulls, a commercial pouch kit has a sensitivity of 92% (95% confidence interval, 84–96%), while the same device used in experimentally infected young cows had an apparent sensitivity of 88% through a 10-week period after infection (Kittel *et al.*, 1998).

450

451

452

Estimates for Diamond's and related media have been variable, possibly due to variation in composition and preparation, but range from 78% to 99% (Skirrow & BonDurrant, 1988). Until recently, it has been assumed that the specificity of the culture test was 100%, but this is likely to be an overestimation.

453

454

455

456

Diagnostic results with samples from bulls using either Diamond's medium or a field kit have shown that the two methods give comparable results (Borchardt *et al.*, 1992; Bryan *et al.*, 1999; Kittel *et al.*, 1998; Lun *et al.*, 2000). It should be emphasised that not every sample taken from a particular bull known to be infected, will necessarily give a positive culture result. Even when conditions of sampling, transport, culture and identification are optimal, more than one negative sample should be obtained before there is reasonable assurance that the animal is not infected. This is the basis for most breeding regulations to specify that bulls above 6 months of age should be tested three times at weekly intervals before concluding on the absence of *T. foetus* infection. For bulls ~~below under~~ 6 months, ~~or that~~ and those that have been kept with negative bulls only and never mated, one negative test is considered sufficient.

457

458

459

460

461

462

463

464

465

466

In females, as the infection is usually cleared within 90–95 days, it may be difficult to isolate organisms from individuals in the late stages of their infection.

467

468

The diagnosis of abortion induced by *T. foetus* may be relatively easy where an aborted foetus is recovered, because of the large number of organisms demonstrable in the fetal abomasal contents or placental fluids (Rhyan *et al.*, 1988). In addition, immunohistochemical techniques and molecular methods can be used to demonstrate ~~*Trichomonas*~~ *T. foetus* organisms in tissues of aborted fetuses.

469

470

471

472

473

1.3.6. Immunohistochemical techniques

474

Immunohistochemical techniques using monoclonal antibodies have been described for revealing *T. foetus* organisms in formalin-fixed tissues (Rhyan *et al.*, 1995). These techniques can be used to identify *T. foetus* in tissues from aborted fetuses (e.g. placenta and lungs).

475

476

477

1.4. Molecular methods – detection of nucleic acids

478

PCR diagnostic frameworks are best determined for a particular region and country taking into account transport time to the laboratory, temperature of the sample, and optimised DNA extraction and PCR methods used at the laboratory. Currently, the best option is to use published protocols (adapted to the particular laboratory) or commercial *T. foetus* real-time PCR kits applied to transport medium or PBS, which guarantees fast preliminary results especially when using boiled lysates.

479

480

481

482

483

Several molecular methods have been described for the detection of *T. foetus* DNA prepared from cultures or directly from clinical samples. These include conventional and real-time PCR methods targeting conserved regions of the 5.8S ribosomal RNA gene and the flanking internal transcribed spacer regions (ITS). A PCR diagnostic test offers a number of potential advantages, including increased analytical sensitivity, faster diagnostic turnaround time, and the fact that the organisms in the collected

484

485

486

487

488 sample are not required to be intact and viable. However, attention to inhibitors must be considered when
 489 sampling (Clothier *et al.*, 2019; Collántes-Fernández *et al.*, 2018).

490 **1.4.1. DNA Extraction**

491 The preferred samples for DNA extraction are smegma and vaginal mucus in PBS or normal
 492 saline, transport medium and cultures.

493 **1.4.1.1. Heat lysis**

494 One ml of sample (vaginal mucus or smegma) is centrifuged for 5 minutes at 12,000 **g**. The
 495 supernatant is removed and the pellet is resuspended in 500 µl RNase/DNase-free water.
 496 The suspension is heated at 95°C for 10 minutes. The lysate is centrifuged at 2000 **g** for
 497 3 minutes and 5 µl of the supernatant is tested.

498 **1.4.1.2. Magnetic beads-based extraction**

499 Magnetic beads extraction is an automated method in which DNA can be isolated from crude
 500 samples by adding magnetic beads and without much processing. This methodology uses
 501 a robotic system and therefore, specific equipment for magnetic separation. It is sensitive
 502 and suitable for high throughput set up, where numerous samples are submitted for *T. foetus*
 503 testing. There is a variety of magnetic beads kits commercially available on the market. This
 504 methodology uses a robotic system; it is sensitive and suitable for high throughput set up,
 505 where numerous samples are submitted for *T. foetus* testing.

506 **1.4.1.3. Spin column method**

507 This method uses spin columns and is more suitable for manual extraction of a small number
 508 of samples. There are a number of spin column kits available on the market and they all
 509 perform similarly.

510 ~~The sensitivity of conventional PCRs is enhanced when using purified DNA extracts~~
 511 ~~obtained by the use of commercial kits, e.g. magnetic beads or spin column methods. The~~
 512 ~~real-time PCR can be used for all three extraction methods. Increased sensitivity has been~~
 513 ~~observed by McMillen & Lew (2006) when using the heat lysis method, which was not~~
 514 ~~suitable for conventional PCR. For conventional PCR, it is best to use commercial DNA~~
 515 ~~extraction kits, as the heat lysis method is not suitable. For real-time PCR, the three~~
 516 ~~extraction methods can be used, but there is evidence that the heat lysis method has optimal~~
 517 ~~sensitivity (McMillen & Lew, 2006).~~

518 **1.4.2. Conventional PCR**

<u>Pathogen/ target gene</u>	<u>Primer (5'–3')</u>	<u>Concentration</u>	<u>Cycling parameters^(a)</u>
<u>Method 1: Felleisen <i>et al.</i> (1998); GenBank Accession No.: M81842; amplicon size: 347 bp</u>			
<u>TFR3</u> <u>TFR4</u>	<u>TFR3: 5'-CGG-GTC-TTC-CTA-TAT-GAG-ACA-GAA-CC-3'</u> <u>TFR4: 5'-CCT-GCC-GTT-GGA-TCA-GTT-TCG-TTA-A-3'</u>	<u>1 µM</u> <u>(final concentration)</u>	<u>40 cycles of: 94°C/30 sec</u> <u>and 67°C/30 sec</u> <u>Extension 72°C/90 sec</u>
<u>Method 2: Campero <i>et al.</i> (2003); GenBank Accession No.: M81842; amplicon size: 372 bp (TFR1+TFR2) and 347 bp (TFR3+TFR4)</u>			
<u>TFR1</u> <u>TFR2</u> <u>TFR3</u> <u>TFR4</u>	<u>TFR1: 5'-TGCTTCAGTTCAGCGGGTCTTCC-3'</u> <u>TFR2: 5'-CGGTAGGTGAACCTGCCGTTGG-3'</u> <u>TFR3: 5'-CGG-GTC-TTC-CTA-TAT-GAG-ACA-GAA-CC-3'</u> <u>TFR4: 5'-CCT-GCC-GTT-GGA-TCA-GTT-TCG-TTA-A-3'</u>	<u>(not mentioned)</u>	<u>30 cycles of: 94°C/30 sec</u> <u>and 58°C/20 sec</u> <u>Extension 72°C/30 sec</u> <u>Final extension 72°C/20min</u>

519 ^(a)A denaturation step prior to cycling has not been included.

520 Felleisen *et al.* (1998) described a conventional PCR that uses primers TFR3 and TFR4 to
 521 differentiate *T. foetus* from other commensal trichomonads, which are faecal contaminants of
 522 clinical samples submitted for the diagnosis of bovine trichomonosis.

523 ~~The primers used are TFR3 and TFR4, which target a 347bp region and have the following~~
 524 ~~sequences:~~

525 TFR3 5'-CGG-GTC-TTC-CTA-TAT-GAG-ACA-GAA-CC-3'
 526 TFR4 5'-CCT-GCC-GTT-GGA-TCA-GTT-TCG-TTA-A-3'

527 The PCR is usually conducted for 40 cycles with a 30 second denaturation at 94°C, 30 seconds
 528 annealing at 67°C and 90 seconds extension at 72°C for 90 seconds. The final extension is
 529 performed at 72°C for 15 minutes (Folleisen *et al.*, 1998).

530 The use of two sets of primers together, one set amplifying DNA from the trichomonad group
 531 (TFR1 and TFR2) and the *T. foetus*-specific set of primers TFR3 and TFR4 (Folleisen *et al.*, 1998)
 532 allowed the differentiation of *T. foetus* from other commensal trichomonads of the gastrointestinal
 533 tract that are often faecal contaminants of the bovine reproductive system (Campero *et al.*, 2003).
 534 *Tritrichomonas foetus* DNA is amplified by both sets of primers, while the DNA of commensal
 535 trichomonads is only amplified by the TFR1 and TFR2 primers.

536 Using pan-trichomonal primers and *T. foetus*-specific primers in a PCR assay, amplification
 537 products of 372 bp were detected in all virgin bull isolates, but only with the pan-trichomonal
 538 primers. Positive control isolates of *T. foetus* yielded amplification products of the expected size
 539 (372 and 347 bp) with the two sets of primers, respectively (Campero *et al.*, 2003).

540 The sequences of the generic primers TFR1 and TFR2, which amplify a 372 bp region of the
 541 internal transcribed spacer (ITS)1 and ITS2 region of the trichomonad group, are as follows:

542 TFR1 5'-GTA-GGT-GAA-CCT-GCC-GTT-G-3'
 543 TFR2 5'-ATG-CAA-CGT-TCT-TCA-TCG-TG-3'

544 The PCR is conducted for 30 cycles with a 30 second denaturation at 94°C, followed by
 545 20 seconds annealing at 58°C and a 30 second extension at 72°C. The final extension was
 546 performed at 72°C for 20 minutes.

547 Hayes *et al.* (2003) have also used RFLP of the amplicon generated by primers TFR1 and TFR2
 548 to differentiate various trichomonads including *T. foetus*. The TFR3 and TFR4 primers have also
 549 been used in conjunction with DNA chelating fluorescent dyes under real-time PCR conditions for
 550 research purposes rather than diagnostic screening for trichomonosis (Casteriano *et al.*, 2016) or
 551 in comparison with other PCR methods (Polo *et al.*, 2022). Grahn *et al.* (2005) have also used
 552 the TFR1 and TFR2 primers in combination with a fluorophore, whereas the forward primer
 553 (TFR1) is labelled with a 6FAM fluorophore, resulting in increased sensitivity of the conventional
 554 PCR.

555 Hayes *et al.* (2003) have also used RFLP of the amplicon generated by primers TFR1 and TFR2
 556 to differentiate various trichomonads including *T. foetus*.

557 A loop mediated isothermal amplification assay (LAMP) targeting *T. foetus* 5.8S rDNA has been
 558 reported with slightly higher sensitivity than the TFR3/TFR4 PCR and demonstrated increased
 559 specificity (Oyhenart *et al.*, 2013). Due to the simplicity of the assay over PCR or real time PCR,
 560 the LAMP assay may be a cheaper alternative for low skill operators, however the assay has not
 561 been field tested at this stage.

562 1.4.3. Real-time PCR or quantitative PCR

563 Real-time PCR methods are a more advantageous detection method as it combines the high
 564 specificity of end-point PCR with higher sensitivity. However, it is more expensive and requires
 565 highly trained personnel, which can be a limitation for some laboratories (Oyhenart, 2018).

<u>Pathogen/ target gene</u>	<u>Primer/probe (5'–3')</u>	<u>Concentration</u>	<u>Cycling parameters^(a)</u>
<u>Method 1: McMillen & Lew (2006); GenBank Accession No.: AF339736</u>			
<u>TFR2</u>	<u>TFR2: 5'-GCG-GCT-GGA-TTA-GCT-TTC-TTT-3'</u> <u>TFR2: 5'-GGC-GCG-CAA-TGT-GCA-T-3'</u>	<u>900 nM</u>	<u>50°C/2min to activate UDG (if used) 40 cycles of: 95°C/20 sec and 60°C/45 sec</u>
	<u>TrichP2: 6FAM-ACA-AGT-TCG-ATC-TTT-G-MGB</u>	<u>80 nM</u>	
<u>Method 2: Polo <i>et al.</i> (2022); GenBank Accession No.: AF466749.1</u>			

EF1A1	Ftf_EF1A1: 5'-AGTCCGCCGCCAAATCAA-3' Rtf_EF1A1: 5' CTC TTCAACTTCGGCTGTGA-3'	0.5 µM	45 cycles of: 95°C/20 sec and 61°C/35 sec
	Ptf_EF1A1: 6-FAM-ATCATCAAGTACGGCTCAGT-MGBNFQ	0.4 µM	

566 A Minor Groove Binder (MGB) probe real-time PCR method described by McMillen & Lew (2006),
567 based on the ITS-1 region within the same rDNA regions as the TFR3-TFR4 PCR primers, was
568 shown to be highly specific and sensitive compared with culture/microscopy and the previously
569 described PCR methods (McMillen & Lew, 2006).

570 Assay sensitivity was evaluated with 10-fold dilutions of known numbers of *T. foetus* cells, and
571 compared with that for microscopy following culture and the TFR3-TFR4 PCR assay. The probe-
572 based real-time PCR assay detected a single cell per assay directly from non-cultured smegma
573 or vaginal mucus and was 2500-fold and 250-fold more sensitive than microscopy following
574 selective culture respectively and 500-fold more sensitive than culture followed by the TFR3-
575 TFR4 PCR assay. When compared with TFR3-TFR4 amplification of *T. foetus* DNA from cultures,
576 the real-time PCR was consistently 10-fold more sensitive for smegma samples at 0, 2 and 5
577 days post culture. For vaginal mucus, both PCRs demonstrated equivalent sensitivities at days 0
578 and 2 with 10-fold increase in sensitivity for real-time PCR at day 5 post culture. The sensitivity
579 of the TFR3-TFR4 PCR assay was 10-fold lower compared with the real-time PCR assay when
580 testing purified DNA extracted from clinical specimens. Furthermore, the sensitivity of the real-
581 time PCR assay improved 500-fold when using crude cell lysates, which were not suitable as
582 template for the conventional PCR assay (McMillen & Lew, 2006). Initial evaluations of this real-
583 time PCR method showed that from 159 Australian diagnostic specimens, 14 bulls were positive
584 by real-time PCR (directly from clinical specimens: smegma and vaginal mucus) with only three
585 confirmed by selective culture/microscopy detection (Fisher's exact test $p < 0.001$) (McMillen &
586 Lew 2006). The real-time PCR was designed with a MGB probe. The substitution of the MGB
587 probe with other probes e.g. black hole quenchers or TAMRA will result in false positive results.
588 The real-time PCR uses the following primers and probe:

589 TFF2 (20µM) — 5'-GCG-GCT-GGA-TTA-GCT-TTC-TTT-3'
590 TFR2 (20µM) — 5'-GGC-GCG-CAA-TGT-GCA-T-3'
591 TrichP2 (5µM) — 5'-6FAM-ACA-AGT-TCG-ATC-TTT-G-MGB-3'

592 The real-time PCR is performed using a 25 µl reaction containing commercially available
593 mastermix, 900 nM of TFF2 and TFR2 primers and 80 nM of TichP2 probe. When using a uracyl
594 DNA glycosylase (UDG) containing mastermix, the real-time PCR is conducted at 50°C for
595 2 minutes to activate the UDG and prevent any carryover contamination, followed by incubation
596 at 95°C for 2 minutes, and then 40 cycles of denaturation at 95°C for 20 seconds and
597 annealing/extension at 60°C for 45 seconds. The fluorescence is acquired in the green channel
598 at the end of each annealing/extension step.

599 *Trichomonas mobilensis*, present to date only in squirrel monkeys, can potentially pose a
600 problem in analysis of field samples when using PCR protocols based on rDNA-ITS. This region
601 has been identified *in silico* to be highly similar with the *T. foetus* and therefore, potentially render
602 false positive results (Polo *et al.*, 2022).

603 For confirmation of clinical cases, a real-time PCR assay based on the EF1-alpha-Tf1 gene has
604 been shown to have an analytical sensitivity of approximately 5.75 *T. foetus* genome copies (Polo
605 *et al.*, 2022).

606 Robust evaluation of the commercial version of this real-time PCR assay has been undertaken
607 as described by Effinger *et al.* (2014) using real-time PCR post-culture. This evaluation used
608 833 cultured smegma samples, which were tested by five laboratories in the USA using the
609 commercial real-time PCR kit different DNA processing methods, PCR equipment and PCR
610 cycling conditions. Pools consisting of one *T. foetus* positive and four negative smegma samples
611 were also processed and 96% of the positive samples were detected in these pools. For individual
612 sample testing an overall agreement of 95.89% was attained between the five participating
613 laboratories. A recent study undertaken in Canada showed that real-time PCR detection of *T.*
614 *foetus* in pooled preputial samples in PBS was more sensitive than culture methods. The study
615 also demonstrated that there was no difference in the detection of *T. foetus* from known infected
616 bulls between direct real-time PCR (from PBS), culture/microscopy or culture/real-time PCR.

617 Another real-time PCR method, which targets the gene encoding beta-tubulin 1 from *T. foetus*,
618 has been developed. It is available on the market as commercial kits. Despite the high degree of

619 conservation of beta tubulin genes in trichomonads, the test is claimed to be specific and it has
620 broad range detection of *T. foetus* isolates. However, there is only limited and unpublished data
621 on the evaluation of these kits.

622 ~~PCR diagnostic frameworks are best determined for a particular region and country taking into~~
623 ~~account transport time to the diagnostic laboratory, temperature of the sample, and optimised~~
624 ~~DNA extraction and PCR methods used at the diagnostic laboratory. Currently, the best option is~~
625 ~~to use published protocols (adapted to the particular laboratory) or commercial *T. foetus* real-time~~
626 ~~PCR kits applied to transport medium or PBS, which guarantees fast preliminary results especially~~
627 ~~when using boiled lysates.~~

628 **1.4.4. Loop-mediated isothermal amplification (LAMP)**

629 A loop mediated isothermal amplification assay (LAMP) targeting *T. foetus* 5.8S rDNA has been
630 reported with slightly higher sensitivity than the TFR3/TFR4 PCR and demonstrated increased
631 specificity (Oyhenart *et al.*, 2013). Due to the simplicity of the assay over PCR or real-time PCR,
632 the LAMP assay may be a less expensive alternative for low skill operators. However, the assay
633 has not yet been field tested.

634 Another LAMP assay targeting the *T. foetus* elongation factor 1 alfa (tf-ef1a1) showed even higher
635 sensitivity. With this assay, it was possible to amplify *T. foetus* DNA without DNA purification from
636 infected cervical vaginal mucus. This was possible by embedding a fragment of paper strip in
637 cervical vaginal samples and then cutting and transferring into a tube containing the LAMP mix
638 (Oyhenart, 2018). This paper strip is a chemically treated filter paper for the collection of biological
639 samples for DNA analysis and may not be commercially available in every country. This assay
640 has not yet been tested in positive samples from naturally infected cattle.

641 ~~PCR diagnostic frameworks are best determined for a particular region and country taking into~~
642 ~~account transport time to the diagnostic laboratory, temperature of the sample, and optimised~~
643 ~~DNA extraction and PCR methods used at the diagnostic laboratory. Currently, the best option is~~
644 ~~to use published protocols (adapted to the particular laboratory) or commercial *T. foetus* real-time~~
645 ~~PCR kits applied to transport medium or PBS, which guarantees fast preliminary results especially~~
646 ~~when using boiled lysates.~~

647 **1.5. Combination of culture and PCR on 5-day cultures**

648 Combining PCR methods and culture has been reported to yield higher sensitivity or improved specificity
649 and has been suggested as the most cost-effective and practical approach to assess bulls before
650 breeding (Michi *et al.*, 2016). However, it has also been reported that testing clinical samples from bulls
651 directly by PCR is more sensitive than culture followed by PCR (McMillen & Lew, 2006), even though
652 most laboratories process cultures as a priority.

653 The culture and PCR combination should be implemented in some specific situations where specificity
654 is a problem, due to occurrence of other trichomonads that may result in false positives in culture. In view
655 of the difficulty of distinguishing *T. foetus* from other trichomonads based on morphology, it is
656 recommended that, whenever the facilities exist for DNA-based methods, cultures with trichomonads be
657 systematically tested by PCR to confirm the presence of *T. foetus*.

658 **2. Serological tests**

659 ~~Bulls do not develop prominent immune responses to *T. foetus*. Some immunological tests have been developed~~
660 ~~for the diagnosis of bovine trichomonosis, such as mucus agglutination test and intradermal test (Rhyan *et al.*, 1999)~~
661 ~~and an antigen-capture enzyme-linked immunosorbent was described more recently (BonDurant, 1997). However,~~
662 ~~these tests appear very limited in use due to low sensitivity or specificity, and thus they are not recommended for~~
663 ~~the detection of *T. foetus* in individual animals. ELISAs based on whole *T. foetus* cells rather than specific antigens~~
664 ~~are the most reliable and these serological tests are useful in vaccination studies to ensure IgG and IgA responses~~
665 ~~post-vaccination in serum and vaginal mucus, respectively. There is some evidence that these ELISAs can also be~~
666 ~~used for the confirmation of clinical cases in heifers. Serum whole IgG ELISA, and IgG1 and IgG2 indirect ELISAs,~~
667 ~~have demonstrated post-vaccination responses in vaccinated bulls.~~

668 ~~Infected cows develop specific IgG1 and IgG2 antibodies that are present in the vaginal mucus and in serum, but~~
669 ~~these are not exploited for diagnostic purposes.~~

670

671

C. REQUIREMENTS FOR VACCINES

672 1. Background

673 There are currently no globally registered drugs for the treatment of *T. foetus* infections with the culling of positive
674 animals the only control tool. Prevention using vaccination has been the most widely adopted method to control
675 trichomonosis and to manage cow infertility. Whole cell vaccines for cows have been shown to offer protection and
676 are available commercially (Corbeil, 1994) as either a monovalent vaccine or part of a polyvalent vaccine also
677 containing *Campylobacter* and *Leptospira* spp. (BonDurant, 1997; Cobo *et al.*, 2004). These products have shown
678 efficacy in the female but not in the bull.

679 One example of a method of whole cell vaccine production is by growing *T. foetus* (culture VMC-84) in modified
680 Diamond's medium (Corbeil, 1994) and freezing the culture at -20°C for 60 minutes. After thawing, a suspension
681 of 5×10^7 organisms/ml in PBS is added to the CL vaccine.

682 Several types of non-commercial vaccine approaches have been described including inactivated whole cell
683 vaccines, subunit vaccines and fractionated cell extracts.

684 Inactivated whole cell vaccines have been the most studied and commercialised for the control of bovine
685 trichomonosis. No *T. foetus* vaccine prevents *T. foetus* infection but rather they shorten the time to clear *T. foetus*
686 infection compared with unvaccinated cattle. Several different adjuvants have been used with the most common
687 being mineral oil followed by aluminium hydroxide in studies undertaken before 2002. More recently, a comparison
688 of four adjuvants used with the inactivated whole *T. foetus* vaccine demonstrated that Quil A mixed with aluminium
689 hydroxide led to the fastest clearance of *T. foetus* infection (27 days) followed by Montanide ISA 206 VG or Quil A
690 (41 days) with aluminium hydroxide clearing at 55 days (Fuchs *et al.*, 2017). Two or three doses of inactivated
691 vaccines every 3 to 4 weeks are the most common vaccination regimes used.

692 Two subunit vaccines have been described (Tf190 adhesin and TF1.17 surface antigen) with only one
693 demonstrating efficacy following challenge. TF1.17 surface antigen (immunoaffinity purified) was adjuvanted using
694 incomplete Freund's (IFA) and, following three doses of 100 µg 3 weeks apart, heifers were challenged 2 weeks
695 later. Seventy-five per cent of the vaccinated heifers had cleared by week 6 in contrast to at least 10 weeks for
696 unvaccinated controls (BonDurant *et al.*, 1993). This trial was repeated by the same group, which also compared
697 IFA with IFA + dextran sulfate as adjuvants giving similar results (Anderson *et al.*, 1996). Subunit vaccines have
698 not been directly compared with inactivated vaccines, but would appear to have longer parasite clearance rates
699 and will not be discussed further here.

700 Although a few different versions of fractionated cell extracts have been described, *T. foetus* purified membrane
701 extracts have demonstrated slightly better *T. foetus* clearance rates and calving rates compared with inactivated
702 whole cell vaccines (Cobo *et al.*, 2002; Clark *et al.*, 1984). Anecdotally, early studies suggested that vaccines
703 produced from inactivated *T. foetus* cells or fractionated proteins could be used to treat *T. foetus* positive bulls,
704 particularly if younger than 5.5 years of age (Clark *et al.*, 1983; 1984). Subsequent studies have suggested that this
705 is not a reliable treatment regime and is not a recommended practise (Alling *et al.*, 2018; Herr *et al.*, 1991; Tabor *et*
706 *al.*, 2023).

707 Characteristics of a target product profile:

- 708 i) For whole cell inactivated *T. foetus* vaccines, studies have used local strains for vaccine development.
- 709 ii) Membrane fractions as *T. foetus* vaccines have limited application to date, and the use of local strains should
- 710 also apply but has not been demonstrated to date.

711 Guidelines for the production of veterinary vaccines are given in Chapter 1.1.8 *Principles of veterinary vaccine*
712 *production*. The guidelines given below and in chapter 1.1.8 are intended to be general in nature and may be
713 supplemented by national and regional requirements.

714 2. Outline of production and minimum requirements for vaccines

715 2.1. Characteristics of the seed

716 2.1.1. Biological characteristics of the master seed

717 *Inactivated vaccines*

718 There are considerable variations in the nomenclature of *T. foetus* strains used in inactivated
719 vaccine experiments, however the most common are abbreviated letters and numbers associated
720 with the geographical origin of the isolate and number, respectively. Examples include BP-4 from

721 Beltsville, USA, isolated in 1954 (ATCC isolate 30003) and MT85-330.1 from Montana, USA,
722 isolated in 1985. Most commonly the isolate is from a persistently infected bull. There are no
723 published data reporting the maximum time for *T. foetus* culture and passages for vaccine
724 production. Nonetheless, seed cultures are cryopreserved and thawed to produce vaccine
725 production batches to minimise long-term culture of seeds.

726 Membrane fraction vaccines

727 *Tritrichomonas foetus* strains used for inactivated vaccines have also been developed as
728 membrane fraction vaccines.

729 See chapter 1.1.8 for guidelines on master seeds.

730 **2.1.2. Quality criteria (sterility, purity, freedom from extraneous agents)**

731 *Tritrichomonas foetus* seeds must be pure culture and free from extraneous bacteria, yeast, and
732 fungi. Culture media inoculated using bovine clinical samples (mucus from vagina or preputial
733 reproductive tracts) may require high doses of antimicrobials and anti-fungals, prior to several
734 subculture passages to obtain pure *T. foetus* cell lines for vaccine development. Negative aerobic
735 blood agar cultures and *T. foetus* microscopy are tools used to confirm culture purity (see Chapter
736 1.1.9 *Tests for sterility and freedom from contamination of biological materials intended for*
737 *veterinary use*).

738 **2.1.3. Validation as a vaccine strain**

739 Suitability as a vaccine strain in cattle is demonstrated in efficacy and safety trials.

740 **2.2. Method of manufacture**

741 **2.2.1. Procedure**

742 Inactivated vaccines

743 *Tritrichomonas foetus* cultures are grown in suitable broth media omitting the agar from the
744 medium and either using an agar plug or suitable gas microaerophilic conditions e.g. nitrogen.
745 Cultures are subcultured until the desired volume and cell density is achieved, confirmed by
746 microscopy cell counts. Cells are inactivated by formaldehyde or formalin or heating to 65°C or
747 lyophilisation or irradiation. Cells in solution are subsequently harvested by centrifugation,
748 washed, and resuspended at the desired cell count (vaccine dose) in PBS. The culture is then
749 blended with adjuvant prior to filling sterile vials.

750 Membrane fraction vaccines

751 *Tritrichomonas foetus* cells are collected from a 24- to 48-hour culture, washed (3x) with PBS pH
752 7.2 by centrifugation at 7500 *g* for 15 minutes and suspended in homogenising buffer: PBS
753 containing 1 mM MgCl₂·6H₂O (PBS-CIMg) and 1% phenyl-methylsulphonyl fluoride (88 mg/ml
754 methanol). The suspension is sonicated for five rounds of 5 minutes on ice in an ultrasonicator
755 (Sonifier 250 Branson Sonic Power, USA). The sonicate is centrifuged at 1100 *g* for 10 minutes
756 and the supernatant is layered onto 10 ml of 41% (v/v) sucrose in homogenising buffer before
757 centrifuging at 30,000 *g* for 150 minutes at 6°C. The membranes are collected from the interface
758 between the buffer and the sucrose solution.

759 **2.2.2. Requirements for ingredients**

760 See Chapter 1.1.8 and culture methods described above.

761 **2.2.3. In-process controls**

762 The purity of the culture is determined at each stage of production prior to inactivation. Microscopy
763 and bacterial agar plates are used to confirm *T. foetus* cells and absence of contaminants
764 respectively. Inactivated cells are cultured and examined microscopically to confirm the complete
765 inactivation. Analytical assays to determine levels of chemical inactivators are done on bulk
766 vaccine and must be within specified limits. Production parameters must be managed to ensure
767 that manufacturing processes are consistent between batches.

768

-
- 769 **2.2.4. Final product batch tests**
- 770 i) Sterility
- 771 Sterility tests are done on each batch. For the USA, these are detailed in the 9 CFR Part
772 113.26 (CFR USDA, 2013). Depending on the jurisdiction, the requirements may vary and
773 need to be checked by Regulatory body of the given country or region. See also Chapter
774 1.1.9.
- 775 ii) Identity
- 776 The identity of the inactivated product is ensured through the master seed concept and good
777 manufacturing controls.
- 778 iii) Safety
- 779 Batch testing would occur by inoculating cattle to confirm safety of vaccination. No
780 withholding periods for milk or meat are necessary following vaccination, unless specified
781 by local legislation.
- 782 iv) Batch potency
- 783 Inactivated vaccines should be tested for batch potency in a vaccination challenge trial.

784 **2.3. Requirements for regulatory approval**

785 **2.3.1. Manufacturing process**

- 786 For regulatory approval of vaccine, all relevant details concerning manufacture of the vaccine and
787 quality control testing (see Section C.2.1 Characteristics of the seed and Section C.2.2 Method
788 of manufacture) should be submitted to the authorities. This information shall be provided from
789 three consecutive vaccine batches with a volume not less than 1/3 of the typical industrial batch
790 volume.
- 791 In-process controls are part of the manufacturing process.

792 **2.3.2. Safety requirements**

- 793 Each commercial product requires a 'Safety Data Sheet' (SDS), which should include information
794 in regard to: hazard identification, first aid measures, accidental release measures, handling and
795 storage, exposure controls and personal protection, physical and chemical properties, stability
796 and reactivity, toxicological information, ecological information, disposal considerations, transport
797 information, regulatory information, and any other information pertinent to the region or country.
- 798 i) Target and non-target animal safety
- 799 Inactivated vaccines do not pose a hazard to non-target species. Generally inactivated
800 vaccines are safe as currently there are many inactivated veterinary vaccines on the market.
801 It is favourable to vaccinate young bulls and heifers for protection from trichomonosis
802 preferably before breeding.
- 803 Safety needs to be evaluated in the field setting prior to regulatory approval. This evaluation
804 typically involves approximately three different geographical locations or husbandry
805 conditions and many cattle. The number of cattle recommended varies on the jurisdiction
806 and regional regulations for product approval.
- 807 ii) Reversion-to-virulence for attenuated/live vaccines and environmental considerations
- 808 Not applicable for inactivated vaccines.
- 809 iii) Precautions (hazards)
- 810 Vaccines prepared with aluminium hydroxide adjuvants may cause temporary nodules at
811 the site of injection. Operator self-injection poses no immediate issues. Vaccines prepared
812 with oil-based adjuvants may cause larger nodules. To avoid lasting lumps, it is important
813 that correct vaccination procedures are followed to ensure vaccine is deposited under the
814 skin and not into the muscle. Operator self-injection requires immediate medical attention.
815 Safety precautions should be clearly outlined on the commercial product including the SDS,
816 and it is recommended that experienced personnel administer vaccines to cattle.

817

2.3.3. Efficacy requirements

818 Vaccine doses usually contain 10⁷ to 10⁸ cells per dose with a minimum of two doses required for
819 protection from live challenge. Vaccine challenge is either achieved by artificial challenge with live
820 *T. foetus* cells (typically doses of 10⁵–10⁶ cells) originating from a strain that is different to the
821 vaccine strain or by natural service with infected cattle. When natural service is used for
822 vaccinated heifers, calf output is a good measure of vaccine efficacy. Trichomonosis vaccine
823 efficacy is often measured by the time taken to clear *T. foetus* from the reproductive tract, which
824 is measured using culture and direct real-time PCR. Note these vaccines do not eliminate
825 *T. foetus* infection following challenge, but vaccination decreases the time taken to clear *T. foetus*
826 compared to unvaccinated cattle.

827 The number of cattle needed to confirm efficacy for product registration varies between different
828 jurisdictions and regions.

2.3.4. Vaccines permitting a DIVA strategy (detection of infection in vaccinated animals)

830 Not applicable to this disease.

2.3.5. Duration of immunity

832 Efficacy for 1 year is usually demonstrated by repeating challenge at 6–9 months post-
833 vaccination. Annual boosts of the vaccine are subsequently recommended prior to breeding
834 seasons.

2.3.6. Stability

836 Inactivated vaccines are stored at 2–8°C (refrigerated) and should not be frozen. The shelf life of
837 the product needs to be determined by the manufacturer and clearly stated on the product.

3. Vaccines based on biotechnology

839 There are no biotechnology-based vaccines for bovine trichomonosis.

840

REFERENCES

841 ALLING C., RAE D.O., MA X., NEUMANN L., LOLLIS L.G., STEELE E., YELVINGTON, J., NAIKARE, H.K., WALDEN H.S., CREWS
842 J. & BOUGHTON R. (2018). Systemic humoral immunity in beef bulls following therapeutic vaccination against
843 *Tritrichomonas foetus*. *Vet. Parasitol.*, **255**, 69–73.

844 ANDERSON M.L., BONDURANT R.H., CORBEIL R.R. & CORBEIL L.B. (1996). Immune and inflammatory responses to
845 reproductive tract infection with *Tritrichomonas foetus* in immunized and control heifers. *J. Parasitol.*, **82**, 594–600.

846 BENCHIMOL M., MIRANDA-MAGALHÃES A., PEREIRA-NEVES A. & DE SOUZA W. (2001). *Tritrichomonas foetus*: New
847 structures by high-resolution scanning helium ion microscopy. *Biocell*, **45**, 259–266.

848 BONDURANT R.H. (1997). Pathogenesis, diagnosis and management of trichomoniasis in cattle. *Vet. Clin. North Am.*
849 *Food Anim. Pract.*, **13**, 345–361.

850 BONDURANT R.H., CORBEIL R.R. & CORBEIL L.B. (1993). Immunization of virgin cows with surface antigen TF1.17 of
851 *Tritrichomonas foetus*. *Infect. Immun.*, **61**, 1385–1394.

852 BONDURANT R.H., VAN HOOSEAR K.A., CORBIEL L.B. & BERNOCO D. (1996). Serological response to in vitro-shed
853 antigen(s) of *Tritrichomonas foetus* in cattle. *Clin. Diagn. Lab. Immunol.*, **3**, 432–437.

854 BORCHARDT K.A., NORMAN B.B., THOMAS M.W. & HARMON W.M. (1992). Evaluation of a new culture method for
855 diagnosing *Tritrichomonas foetus*. *Vet. Med.*, **87**, 104–112.

856 BRYAN L.A., CABBELL J.R. & GAJADHAR A.A. (1999). Effects of temperature on the survival of *Tritrichomonas foetus*
857 in transport, Diamond's and InPouch™ TF media. *Vet. Rec.*, **144**, 227–232.

858 BULLER N. & CORNEY B. (2013). Bovine Trichomonosis. Australian New Zealand Standard Diagnostic Procedure.
859 <https://www.agriculture.gov.au/agriculture-land/animal/health/laboratories/procedures/asdt/bovine-trichomoniasis>
860 (2024) — <http://www.agriculture.gov.au/SiteCollectionDocuments/animal/ah/ANZSDP-Bovine-trichomoniasis.pdf>
861 (assessed 1 August 2017).

- 862 CASTERIANO A., MOLINI U., KANDJUMBWA K., KHAISEB S., FREY C.F. & ŠLAPETA J. (2016). Novel genotype of
863 *Tritrichomonas foetus* from cattle in Southern Africa. *Parasitology*, **143**, 1954–1959.
- 864 CAMPERO C.M., HIRST R.G., LADDS P.W., VAUGHAN J.A., EMERY D.L., WATSON D.L. (1990). Measurement of antibody
865 in serum and genital fluids of bulls by ELISA after vaccination and challenge with *Tritrichomonas foetus*. *Aust. Vet.*
866 *J.*, **67** (5), 175-178.
- 867 CAMPERO C.M., RODRIGUEZ DUBRA C., BOLONDI A., CACCIATO C., COBO E., PEREZ S., ODEON A., CIPOLLA A. &
868 BONDURANT R.H. (2003). Two-step (culture and PCR) diagnostic approach for differentiation of non-*T.foetus*
869 trichomonads from genitalia of virgin bulls in Argentina. *Vet. Parasitol.* **112**, 167–175.
- 870 CLARK B., DUFTY J. & PARSONSON I. (1983). Immunisation of bulls against trichomoniasis. *Aust. Vet. J.*, **60**, 178–179.
- 871 CLARK B., EMERY D. & DUFTY J. (1984). Therapeutic immunisation of bulls with the membranes and glycoproteins of
872 *Tritrichomonas foetus* var. brisbane. *Aust. Vet. J.*, **61**, 65–66.
- 873 CLOTHIER K.A., NABB B.M., TORAIN A., REINL S. & ONDRAK J. (2019). Effects of Biological Materials and Collection
874 Media on PCR Detection of *Tritrichomonas foetus*. *Open J. Anim. Sci.*, **9**, 121–128.
- 875 COBO E. R., CANO D., ROSSETTI O. & CAMPERO C. M. (2002). Heifers immunized with whole-cell and membrane
876 vaccines against *Tritrichomonas foetus* and naturally challenged with an infected bull. *Vet. Parasitol.*, **109**, 169–
877 184.
- 878 COBO E.R., FAVETTO P.H., LANE V.M., FRIEND A., VANHOOSER K., MITCHELL J., BONDURANT R.H. (2007). Sensitivity and
879 specificity of culture and PCR of smegma samples of bulls experimentally infected with *Tritrichomonas foetus*.
880 *Theriogenology*, **68**, 853-860.
- 881 COBO E.R., MORSELLA C., CANO D., CIPOLLA A. & CAMPERO C. M. (2004). Immunization in heifers with dual vaccines
882 containing *Tritrichomonas foetus* and *Campylobacter fetus* antigens using systemic and mucosal routes.
883 *Theriogenology*, **62**, 1367–1382.
- 884 CODE OF FEDERAL REGULATIONS, US DEPARTMENT OF AGRICULTURE (2013). Animals and Animal Products – Code of
885 Federal Regulations. Title 9, Chapter 1, Subchapter E, Part 113, Applicability. [eCFR :: 9 CFR 113.6 -- Animal and](#)
886 [Plant Health Inspection Service testing.](#)
- 887 COLLANTES-FERNÁNDEZ E., FORT M.C., ORTEGA-MORA L.M. & SCHARES G. (2018). *Trichomonas*. In: Parasitic Protozoa
888 of Farm Animals and Pets, Florin-Christensen M. & Schnittger L., eds. Springer, USA.
- 889 CORBEIL L.B. (1994). Vaccination strategies against *Tritrichomonas foetus*. *Parasitol. Today*, **10**, 103–106.
- 890 CORBEIL L.B., CAMPERO C.M., RYAN J.C., ANDERSON M.L., GERSHWIN L.J., AGNEW D.W., MUNSON L., BONDURANT R.H.
891 (2005). Uterine mast cells and Immunoglobulin-E antibody responses during clearance of *Tritrichomonas foetus*.
892 *Vet. Pathol.*, **42**, 282-290.
- 893 DĄBROWSKA J., KARAMON J., KOCHANOWSKI M., SROKA J., ZDYBEL J. & CENCEK T. (2019). *Tritrichomonas foetus* as a
894 causative agent of tritrichomonosis in different animal hosts. *J. Vet. Res.*, **63**, 533–541.
- 895 DIAMOND L.S. (1957). The establishment of various Trichomonads of animals and man in axenic cultures. *J. Parasit.*,
896 **43**, 488–490.
- 897 EFFINGER L., PEDDIREDDI L., SIMUNICH M., OBERST R., O'CONNELL C. & LEYVA-BACA I. (2014). Pooling of cultured
898 samples and comparison of multistate laboratory workflows with the MagMAX sample preparation system and
899 VetMAX quantitative polymerase chain reaction reagents for detection of *Tritrichomonas foetus* colonized bulls. *J.*
900 *Vet. Diagn. Invest.*, **26**, 72–87.
- 901 ELDER J.K. (1964). Examination of twelve strains of *Trichomonas foetus* (Reidmuller) isolated in Queensland and
902 the description of a new serotype, *T. foetus* var. brisbane. *Queensl. J. Agric. Sci.*, **21**, 193–203.
- 903 FELLEISEN R.S.J., LAMBELET N., BACHMANN P., NICOLET J., MULLER N. & GOTTSTEIN B. (1998). Detection of
904 *Tritrichomonas foetus* by PCR and DNA enzyme immunoassay based on rRNA gene unit sequences. *J. Clin.*
905 *Microbiol.*, **36**, 513–519.
- 906 FUCHS L.I., FORT M.C., CANO D., BONETTI C.M., GIMÉNEZ H.D., VÁZQUEZ P.M. BACIGALUPE D., BRECCIA J.A., CAMPERO
907 C.M. & OYHENART J.A. (2017). Clearance of *Tritrichomonas foetus* in experimentally infected heifers protected with
908 vaccines based on killed-*T. foetus* with different adjuvants. *Vaccine*, **35**, 1341–1346.

- 909 GAULT R.A., KVASNICKA W.G., HANKS D., HANKS M. & HALL M.R. (1995). Specific antibodies in serum and vaginal
910 mucus of heifers inoculated with a vaccine containing *Trichomonas foetus*. *Am. J. Vet. Res.*, **56**, 454–459.
- 911 GRAHN R.A., BONDURANT R.H., HOSEAR K.A., WALKER R.L. & LYON L.A. (2005). An improved molecular assay for
912 *Trichomonas foetus*. *Vet. Parasitol.*, **127**, 33–41.
- 913 GREGORY M.W., ELLIS B. & REDWOOD D.W. (1990). Comparison of sampling methods for the detection of
914 *Trichomonas foetus*. *Vet. Rec.*, **127**, 16.
- 915 HAYES D.C., ANDERSON R.R. & WALKER R.L. (2003). Identification of trichomonadid protozoa from the bovine
916 preputial cavity by polymerase chain reaction and restriction fragment length polymorphism typing. *J. Vet. Diagn.*
917 *Invest.*, **15**, 390–394.
- 918 HERR S., RIBEIRO L., CLAASSEN E. & MYBURGH J.G. (1991). A reduction in the duration of infection with *Trichomonas*
919 *foetus* following vaccination in heifers and the failure to demonstrate a curative effect in infected bulls.
920 *Onderstepoort Vet. Res.*, **58**, 41–45.
- 921 KITTEL D.R., CAMPERO C., VAN HOSEAR K.A., RHYAN J.C. & BONDURANT R.H. (1998). Comparison of diagnostic
922 methods for detection of active infection with *Trichomonas foetus* in beef heifers. *J. Am. Vet. Med. Assoc.*, **213**,
923 519–522.
- 924 LEVINE N.D. (1973). The Trichomonads. In: Protozoan Parasites of Domestic Animals and of Man, Levine N.D., ed.
925 Burgess Publishing Company, Minnesota, USA, 88–110.
- 926 LOY D.S., GOMES R.S., DUTTA E., BRODERSEN B.W. & LOY J.D. (2023). Time and temperature stability of
927 *Trichomonas foetus* in phosphate-buffered saline as evaluated by a reverse transcription real-time PCR assay
928 and field analysis. *Front. Vet. Sci.*, **10**, 1101502.
- 929 LUN Z.-R. & GAJADHAR A.A. (1999). A simple and rapid method for staining *Trichomonas foetus* and *Trichomonas*
930 *vaginalis*. *J. Vet. Diagn. Invest.*, **11**, 471–474.
- 931 LUN Z.-R., PARKER S. & GAJADHAR A.A. (2000). Comparison of growth rates in *Trichomonas foetus* isolates from
932 various geographic regions using three different culture media. *Vet. Parasitol.*, **89**, 199–208.
- 933 McMILLEN L. & LEW A.E. (2006). Improved detection of *Trichomonas foetus* in bovine diagnostic specimens using
934 a novel probe-based real time PCR assay. *Vet. Parasitol.*, **141**, 204–215.
- 935 MICH I.A.N., FAVETTO P.H., KASTELIC J. & COBO E.R. (2016). A review of sexually transmitted bovine trichomoniasis
936 and campylobacteriosis affecting cattle reproductive health. *Theriogenology*, **85**, 781–791.
- 937 OYHENART J. (2018). Direct detection of *Trichomonas foetus* in cattle genital fluid through loop mediated isothermal
938 amplification of elongation factor 1 alpha 1. *Vet. Parasitol.*, **261**, 67–72.
- 939 OYHENART J., MARTÍNEZ F., RAMÍREZ R., FORT M., & BRECCIA J.D. (2013). Loop mediated isothermal amplification of
940 5.8S rDNA for specific detection of *Trichomonas foetus*. *Vet. Parasitol.*, **193**, 59–65.
- 941 PALOMARES R.A., HURLEY D.J., CRUM L.T., ROLLIN E., COLLOP T., WILLIARD A., FELTON J., PARRISH J. & CORBEIL L.B.
942 (2017). Serum, uterine, and vaginal mucosal IgG antibody responses against *Trichomonas foetus* after
943 administration of a commercial killed whole *T foetus* vaccine in beef cows. *Theriogenology*, **87**, 235–241.
- 944 PARADISO F. & OYHENART J. (2023). In vitro culture of *Trichomonas foetus* in bovine cervico-vaginal fluid. *Exp.*
945 *Parasitol.*, **249**, 108532.
- 946 PÉREZ A., COBO E., MARTÍNEZ A., CAMPERO C. & SPÄTH E. (2006). Bayesian estimation of *Trichomonas foetus*
947 diagnostic test sensitivity and specificity in range beef bulls. *Vet. Parasitol.*, **142**, 159–162.
- 948 POLO C., GARCÍA-SECO T., FERNÁNDEZ V., HERNÁNDEZ M., BRIONES V., DIEZ-GUERRIER A., DOMÍNGUEZ L. & PÉREZ-
949 SANCHO M. (2022). Molecular detection of *Trichomonas foetus* in bovine samples: a novel real-time polymerase
950 chain reaction (PCR) assay targeting EF1-alpha-Tf1 and a comparative study of published PCR techniques.
951 *Parasitol. Res.*, **121**, 1725–1733.
- 952 RHYAN J.C., STACKHOUSE L.L. & QUINN W.J. (1988). Fetal and placental lesions in bovine abortion due to
953 *Trichomonas foetus*. *Vet. Pathol.*, **25**, 350–355.
- 954 RHYAN J.C., WILSON K.L., BENGESE D.E., STACKHOUSE L.L. & QUINN W.J. (1995). The immunohistochemical detection
955 of *Trichomonas foetus* in formalin-fixed paraffin-embedded sections of bovine placenta and fetal lung. *J. Vet.*
956 *Diagn. Invest.*, **7**, 98–101.

- 957 RHYAN J.C., WILSON K.L., WAGNER B., ANDERSON M.L., BONDURANT R.H., BURGESS D.E., MUTWIRI G.K. & CORBEIL L.B.
 958 (1999). Demonstration of *Tritrichomonas foetus* in the external genitalia and of specific antibodies in preputial
 959 secretions of naturally infected bulls. *Vet. Pathol.*, **36**, 406–411.
- 960 RUSH G., REYNOLDS M.W., CALVANI N.E.D & ŠLAPETA J. (2019). Addressing the constraints of *Tritrichomonas foetus*
 961 sample collection in remote areas: lyophilized modified Diamond's media as a substitute for liquid medium.
 962 *Parasitology*, **146**, 1184–1187.
- 963 SKIRROW S.Z. & BONDURANT R.H. (1988). Bovine trichomoniasis. *Vet. Bull.*, **58**, 591–603.
- 964 SKIRROW S.Z. & BONDURANT R.H. (1990). Immunoglobulin isotype of specific antibodies in reproductive tract
 965 secretions and sera in *Tritrichomonas foetus*-infected heifers. *Am. J. Vet. Res.*, **51**, 645–653.
- 966 ŠLAPETA J., MÜLLER N., STACK C.M., WALKER G., LEW-TABOR A. & TACHEZY J. (2012). Comparative analysis of
 967 *Tritrichomonas foetus* (Riedmüller, 1928) cattle genotype and *Tritrichomonas suis* (Davaine, 1875) at 10 DNA loci.
 968 *Int. J. Parasitol.*, **42**, 1143–1149.
- 969 SUMMARELL C.C.G., HAIRGROVE T.B., SCHROEDER M.E., CONLEY R. & BOUNOHENG M.A. (2018). Improvements in
 970 *Tritrichomonas foetus* molecular testing. *J. Vet. Diagn. Invest.*, **30**, 603–608.
- 971 SUZUKI J., KOBAYASHI S., OSUKA H., KAWAHATA D., OISHI T., SEKIGUCHI K., HAMADA A. & IWATA S. (2016).
 972 Characterization of a human isolate of *Tritrichomonas foetus* (cattle/swine genotype) infected by a zoonotic
 973 opportunistic infection. *J. Vet. Med. Sci.*, **78**, 633–640. doi: 10.1292/jvms.15-0644.
- 974 TABOR A.E., BOE-HANSEN G., MCGOWAN M. & MCCOSKER K. (2023). Product development of an Australian
 975 trichomoniasis vaccine: Meat & Livestock Australia Donor Company Final Report P.PSH.1368. MLA Ltd, P.O. Box
 976 1961, North Sydney NSW 2059, Australia.
- 977 TACHEZY J., TACHEZY R., HAMPL V., SEDINOVA M., VANAGOVA S., VRLIK M., VAN RANST M., FLEGR J. & KULDAJ J. (2002).
 978 Cattle pathogen *Tritrichomonas foetus* (Riedmüller, 1928) and pig commensal *Tritrichomonas suis* (Gruby &
 979 Delafond, 1843) belong to the same species. *J. Eukaryot. Microbiol.*, **49**, 154–163.
- 980 TAYLOR M.A., MARSHALL R.N. & STACK M. (1994). Morphological differentiation of *Tritrichomonas foetus* from other
 981 protozoa of the bovine reproductive tract. *Br. Vet. J.*, **150**, 73–80.
- 982 WARTON A. & HONIGBERG B.M (1979). Structure of trichomonads as revealed by scanning electron microscopy. *J.*
 983 *Protozoot.*, **26**, 56–62.
- 984 YAO C. (2012). Opportunistic human infections caused by *Tritrichomonas* species: a mini-review. *Clin. Microbiol.*
 985 *News*, **34**, 127–131
- 986 YAO C. (2013). Diagnosis of *Tritrichomonas foetus*-infected bulls, an ultimate approach to eradicate bovine
 987 trichomoniasis in US cattle? *J. Med. Microbiol.*, **62**, 1–9.
- 988 *
 989 * *
- 990 **NB:** At the time of publication (2024) there were no WOAHP Reference Laboratories for trichomoniasis
 991 (please consult the WOAHP Web site:
 992 <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>).
- 993 **NB:** FIRST ADOPTED IN 1991 AS TRICHOMONIASIS. MOST RECENT UPDATES ADOPTED IN 2018.

Appendix 1: Trichomonosis
Intended purpose of test: population freedom from infection

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Culture followed by microscopy for morphological identification</u> +++ Bovine	<u>Preputial smegma inoculated into pouch media</u>	<u>1 week after infection:</u> Se = 72.43% Sp = 95.4% <u>3 consecutive weeks post-infection:</u> Se = 80.0% Sp = 98.1%	<u>Mature dairy bulls:</u> 30 infected <u>intrapreputially inoculated with <i>T. foetus</i></u> 49 not infected		<u>-Basic microbiology laboratory equipment required</u> <u>-Findings are consistent with the recommendation of three consecutive negative results at weekly intervals before concluding on absence of <i>T. foetus</i> infection</u>	<u>-Does not differentiate between <i>T. foetus</i> and other trichomonads</u>	<u>Cobo et al. (2007)</u>
<u>PCR in combination with culture</u> ++ Bovine	<u>Smegma samples cultured in a pouch 37°C</u> <u>5.8S rRNA</u> <u>Preputial scraping samples cultured in a pouch 37°C</u> <u>5' Taq nuclease real-time PCR assay with MGB probe (McMillen & Lew, 2006)</u>	<u>Se = 95%</u> <u>Sp = 100%</u> <u>Agreement between culture PCR and analysis by microscope = 98% (kappa = 0.96; McNemar test p = 0.2)</u> <u>Culture: Sp = 98.8 (95 CI, 97.0–99.5%)</u> <u>PCR: Sp = 100% (95% CI, 98.9–100%)</u>	<u>Field bulls:</u> 56 positives 110 negatives 180 bulls 150 steers		<u>-Confirmation of positive cases after identification of trichomonads by microscopy;</u>	<u>-Cost of the analysis increases as it is culture + PCR</u>	<u>Summarell et al. (2018)</u> <u>Guerra et al. (2014)</u>
<u>PCR</u> +++ Bovine	<u>Preputial smegma inoculated into PBS</u> <u>PCR specific primers (TFR1, TFR2, TFR3 and TFR4) for the 5.8S rRNA gene and the flanking internal transcribed spacer regions ITS1 and ITS2</u>	<u>3 consecutive weeks (post-infection):</u> Se = 85.0% Sp = 95.4%	<u>Mature dairy bulls:</u> 30 infected <u>intrapreputially - inoculated with <i>T. foetus</i></u> 49 not infected		<u>-It is possible to differentiate between <i>T. foetus</i> and other trichomonads</u>	<u>-False negative results can occur due to degradation of DNA/ presence of inhibitors</u> <u>-Requires highly trained personnel and specific molecular biology equipment</u>	<u>Cobo et al. (2007)</u>

Appendix 2: Trichomonosis
Intended purpose of test: individual animal freedom from infection prior to movement

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Culture followed by microscopy for morphological identification</u> ±± Bovine	<u>Preputial fluid samples inoculated in Plastridge's medium</u>	<u>Se = 72.43%</u> <u>(95%probability interval: 58.79–87.25%)</u> <u>Sp = 95.24%</u> <u>(95%probability interval: 94–96.39%)</u>	<u>2832 mature (>4 years old) from 124 beef herds – suspected to be <i>T. foetus</i> infected</u>		<u>-Basic microbiology laboratory equipment required</u>	<u>-False negative results may be obtained if animals are tested only once</u> <u>-Sampling technique, conditions of storage/transport of culture media and samples may affect test sensitivity</u> <u>- PCR in addition to culture is recommended as a confirmatory test for positive cultures</u>	<u>Perez <i>et al.</i> (2006)</u>
<u>PCR in combination with culture</u> ±± Bovine	<u>Smegma samples cultured in a pouch 37°C</u> <u>5.8S rRNA</u> <u>Preputial scraping samples cultured in a pouch 37°C</u> <u>5' Taq nuclease real-time PCR assay with MGB probe (McMillen & Lew, 2006)</u>	<u>Se = 95%</u> <u>Sp = 100%</u> <u>Agreement between culture PCR and analysis by microscope = 98%</u> <u>(kappa = 0.96; McNemar test $p = 0.2$)</u> <u>Culture: Sp = 98.8 (95 CI, 97.0–99.5%)</u> <u>PCR: Sp = 100% (95% CI, 98.9–100%)</u>	<u>Field bulls:</u> <u>56 positives</u> <u>110 negatives</u> <u>180 bulls</u> <u>150 steers</u>		<u>-Confirmation of positive cases after identification of trichomonads by microscopy</u>	<u>-Cost of the analysis increases as it is culture + PCR</u>	<u>Summarell <i>et al.</i> (2018)</u> <u>Guerra <i>et al.</i> (2014)</u>
<u>PCR</u> +++ Bovine	<u>Preputial wash fluids, vaginal mucus or vaginal washing fluids</u> <u>Primers TFR3 and TFR4 directed to the rRNA gene units</u>	<u>Se = 50 parasites/ml</u>	<u>7 bulls with suspected <i>T. foetus</i> infection (positive by microscopy)</u> <u>71 cows with abortion problems</u> <u>123 healthy bulls</u> <u>20 healthy cows</u>		<u>-Better sensitivity</u> <u>-This method overcomes possible problems with sensitivity when performing culture + microscopy</u>	<u>-False negative results can occur due to degradation of DNA</u> <u>-The use of these specific primers does not differentiate <i>T. foetus</i> from <i>T. suis</i> (swine) or <i>T. mobilensis</i> (squirrel monkey)</u> <u>-Requires highly trained personnel and specific molecular biology equipment</u>	<u>Felleisen <i>et al.</i> (1998)</u>

998

999

Appendix 3: Trichomonosis
Intended purpose of test: contribute to eradication policies

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Culture followed by microscopy for morphological identification</u> +++ <u>Bovine</u>	<u>Preputial smegma inoculated into pouch media</u>	<u>1 week after infection:</u> <u>Se = 72.43%</u> <u>Sp = 95.4%</u> <u>3 consecutive weeks post-infection:</u> <u>Se = 80.0%</u> <u>Sp = 98.1%</u>	<u>Mature dairy bulls:</u> <u>30 infected</u> <u>intrapreputially -</u> <u>inoculated with <i>T. foetus</i></u> <u>49 not infected</u>		<u>-Basic microbiology laboratory equipment required</u> <u>-Findings are consistent with the recommendation of three consecutive negative results at weekly intervals before concluding on absence of <i>T. foetus</i> infection</u>	<u>-Does not differentiate between <i>T. foetus</i> and other trichomonads</u> <u>-If only one test is made, the sensibility of this test is lower than other methods</u>	<u>Cobo et al. (2007)</u>
<u>Real-time PCR</u> +++ <u>Bovine</u>	<u>Preputial smegma inoculated into PBS</u> <u>PCR specific primers (TFR1, TFR2, TFR3 and TFR4) for the 5.8S rRNA gene and the flanking internal transcribed spacer regions ITS1 and ITS2</u>	<u>3 consecutive weeks (post-infection):</u> <u>Se = 85.0%</u> <u>Sp = 95.4%</u>	<u>Mature dairy bulls:</u> <u>30 infected</u> <u>intrapreputially inoculated with <i>T. foetus</i></u> <u>49 not infected</u>		<u>-It is possible to differentiate between <i>T. foetus</i> and other trichomonads</u>	<u>-False negative results can occur due to degradation of DNA/ presence of inhibitors</u> <u>-Requires highly trained personnel and specific molecular biology equipment</u>	<u>Cobo et al. (2007)</u>

1000

1001

Appendix 4: Trichomonosis
Intended purpose of test: confirmation of clinical cases

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Culture followed by microscopy for morphological identification</u> +++ Bovine	<u>Preputial fluid samples inoculated in Plastringe's medium</u>	<u>Se = 72.43% (95%probability interval: 58.79–87.25%)</u> <u>Sp = 95.24% (95%probability interval: 94–96.39%)</u>	<u>2832 mature (>4 years old) from 124 beef herds – suspected to be <i>T. foetus</i> infected</u>		<u>-Basic microbiology laboratory equipment required</u>	<u>-False negative results may be obtained if animals are tested only once</u> <u>-Sampling technique, conditions of storage/transport of culture media and samples may affect test sensitivity</u> <u>- PCR in addition to culture is recommended as a confirmatory test for positive cultures</u>	<u>Perez <i>et al.</i> (2006)</u>
<u>PCR in combination with culture</u> ++ Bovine	<u>Smegma samples cultured in a pouch 37°C</u> <u>5.8S rRNA</u> <u>Preputial scraping samples cultured in a pouch 37°C</u> <u>5' Taq nuclease real-time PCR assay with MGB probe (McMillen & Lew, 2006)</u>	<u>Se = 95%</u> <u>Sp = 100%</u> <u>Agreement between culture PCR and analysis by microscope = 98% (kappa = 0.96; McNemar test $p = 0.2$)</u> <u>Culture: Sp = 98.8 (95 CI, 97.0–99.5%)</u> <u>PCR: Sp = 100% (95% CI, 98.9–100%)</u>	<u>Field bulls:</u> <u>56 positives</u> <u>110 negatives</u> <u>180 bulls</u> <u>150 steers</u>		<u>-Confirmation of positive cases after identification of trichomonads by microscopy</u>	<u>-Cost of the analysis increases as it is culture + PCR</u>	<u>Summarell <i>et al.</i> (2018)</u> <u>Guerra <i>et al.</i> (2014)</u>
<u>PCR</u> +++ Bovine	<u>Preputial wash fluids, vaginal mucus or vaginal washing fluids</u> <u>Primers TFR3 and TFR4 directed to the rRNA gene units</u>	<u>Se = 50 parasites/ml</u>	<u>7 bulls with suspected <i>T. foetus</i> infection (positive by microscopy)</u> <u>71 cows with abortion problems</u> <u>123 healthy bulls</u> <u>20 healthy cows</u>		<u>-Better sensitivity</u> <u>-This method overcomes possible problems with sensitivity when performing culture + microscopy</u>	<u>-False negative results can occur due to degradation of DNA</u> <u>-The use of these specific primers does not differentiate <i>T. foetus</i> from <i>T. suis</i> (swine) or <i>T. mobilensis</i> (squirrel monkey)</u> <u>-Requires highly trained personnel and specific molecular biology equipment</u>	<u>Felleisen <i>et al.</i> (1998)</u>
<u>ELISA IgA ++</u> <u>ELISA IgG1 ++</u> <u>ELISA IgG2 +</u> <u>ELISA IgM –</u>	<u>Vaginal, cervical and uterine secretions, serum using whole <i>T. foetus</i> cell antigen</u>	<u>Reference test was culture: trichomonads disappeared from the vagina of infected heifers after 13–28 weeks, from the uterus after 12–26 weeks. Two</u>	<u>Four <i>T. foetus</i> vaginally inoculated heifers and two control heifers</u>		<u>-Vaginal samples most reliable for IgA ELISA</u> <u>-IgA ELISA most reliable over IgG1, IgG2 and IgM when</u>	<u>-Low number of heifers used in this validation</u>	<u>Skirrow & BonDurant (1990)</u>

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Whole IgG ++ Bovine</u>		<u>control heifers were negative for the duration of the trial</u> <u>Specificity and Sensitivity of IgA ELISA comparable to culture</u> <u>Vaginal IgA and IgG1 increased significantly at weeks 7–9 and remained high for at least 24 weeks. Vaginal IgG2 and IgM responses inconsistent</u> <u>Cervical IgA and IgG1 increased at weeks 7–9 and IgG2 increased in ¾ heifers by 10–12 weeks. IgM inconsistent</u> <u>Uterine IgA in 2/4 heifers by 7–9 weeks but did not last as long as for vaginal and cervical IgA. IgG1 at 10–12 weeks. IgG2 and IgM inconsistent.</u>			<u>testing reproductive tract secretions</u> <u>-IgG1 and IgG2 responses from serum and not reproductive tract samples</u>		
<u>ELISA IgG1 ++ ELISA IgG2 + ELISA IgM ++ ELISA IgA ++ Bovine</u>	<u>Preputial samples (smegma) against <i>T. foetus</i> TF1.17 surface antigen</u>	<u>Reference test was <i>T. foetus</i> whole cell ELISA antigen</u> <u>IgG1 responses were greatest. IgA and IgM responses were approximately equal, and IgG2 responses were very low. In each case, the response in infected bulls was significantly greater than that in the controls</u> <u>IgG1, $p = 0.01$; IgG2, $p = 0.04$; IgM, $p = 0.04$; IgA, $p = 0.03$</u>	<u>32 bulls: 16 <i>T. foetus</i>-infected bulls; 16 <i>T. foetus</i> culture negative bulls</u>		<u>-The bull immune response may enhance immunologic protection at the local level.</u> <u>-Specific antibody detection in smegma using IgG1, IgM and IgA better than previous studies using total immunoglobulins</u>	<u>-Access to <i>T. foetus</i> TF1.17 antigen may be limited.</u> <u>-ELISAs using whole <i>T. foetus</i> antigen were not compared</u>	<u>Rhyan <i>et al.</i> (1999)</u>

1002

1003

Appendix 5: Trichomonosis
Intended purpose of test: prevalence of infection – surveillance

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Culture followed by microscopy for morphological identification</u> +++ Bovine	<u>Preputial smegma inoculated into pouch media</u>	<u>1 week after infection:</u> Se = 72.43% Sp = 95.4% <u>3 consecutive weeks post-infection:</u> Se = 80.0% Sp = 98.1%	<u>Mature dairy bulls:</u> 30 infected <u>intrapreputially - inoculated with <i>T. foetus</i></u> 49 not infected		<u>-Findings are consistent with the recommendation of three consecutive negative results at weekly intervals before concluding on absence of <i>T. foetus</i> infection</u> <u>-Basic microbiology laboratory equipment required</u>	<u>-Does not differentiate between <i>T. foetus</i> and other trichomonads</u> <u>-If only one test is made, the sensibility of this test is lower than other methods</u>	<u>Cobo et al. (2007)</u>
<u>PCR in combination with culture</u> ++ Bovine	<u>Smegma samples cultured in a pouch 37°C</u> <u>5.8S rRNA</u> <u>Preputial scraping samples cultured in a pouch 37°C</u> <u>5' Taq nuclease real-time PCR assay with MGB probe (McMillen & Lew, 2006)</u>	<u>Se = 95%</u> <u>Sp = 100%</u> <u>Agreement between culture PCR and analysis by microscope = 98%</u> <u>(kappa = 0.96; McNemar test p = 0.2)</u> <u>Culture: Sp = 98.8 (95 CI, 97.0–99.5%)</u> <u>PCR: Sp = 100% (95% CI, 98.9–100%)</u>	<u>Field bulls:</u> 56 positives 110 negatives <u>180 bulls</u> <u>150 steers</u>		<u>-Confirmation of positive cases after identification of trichomonads by microscopy</u>	<u>-Cost of the analysis increases as it is culture + PCR</u>	<u>Summarell et al. (2018)</u> <u>Guerra et al. (2014)</u>
<u>Real-time PCR</u> +++ Bovine	<u>Preputial smegma inoculated into PBS</u> <u>PCR specific primers (TFR1, TFR2, TFR3 and TFR4) for the 5.8S rRNA gene and the flanking internal transcribed spacer regions ITS1 and ITS2</u>	<u>3 consecutive weeks (post-infection):</u> Se = 85.0% Sp = 95.4%	<u>Mature dairy bulls:</u> 30 infected <u>intrapreputially inoculated with <i>T. foetus</i></u> 49 not infected		<u>-It is possible to differentiate between <i>T. foetus</i> and other trichomonads</u>	<u>-False negative results can occur due to degradation of DNA/ presence of inhibitors</u> <u>-Requires highly trained personnel and specific molecular biology equipment</u>	<u>Cobo et al. (2007)</u>

1004

1005

Appendix 6: Trichomonosis**Intended purpose of test: immune status in individual animals or populations post-vaccination**

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>IgG ELISA +++</u> <u>Bovine</u>	<u>Serum/Preputial washings/Seminal plasma using whole <i>T. foetus</i> cell antigen and membrane protein antigen used in ELISAs</u>	<u>Reference test was microagglutination test – serum titres less sensitive than IgG ELISA</u> <u>Seminal plasma: IgG detected in vaccinated bulls with variable individual responses</u> <u>Preputial washings: low IgG responses in 4/7 vaccinated bulls only</u> <u>Serum: Good IgG titres in all vaccinated bulls</u>	<u>11 bulls: seven vaccinated (three doses <i>T. foetus</i> membranes) and four unvaccinated controls naïve to <i>T. foetus</i> – all challenged with live <i>T. foetus</i></u>		<u>-ELISA more sensitive than microagglutination test</u> <u>-Seminal plasma not recommended when comparing challenged vaccinated and unvaccinated bulls</u> <u>-Serum is the most reliable sample for whole IgG ELISA</u>	<u>ELISA descriptions used in the publication did not always define which Immunoglobulin thus compromising interpretations</u>	<u>Campero <i>et al.</i> (1990)</u>
<u>IgG1 ELISA +++</u> <u>IgG2 ELISA ++</u> <u>IgA ELISA +++</u> <u>IgM ELISA +</u> <u>Bovine</u>	<u>Serum/cervicovaginal mucus</u>	<u>Reference test was culture. 80% of unvaccinated heifers remained infected 8 weeks after challenge with a mean duration of 10.2 weeks compared to 3.2 weeks for 60% of the naturally challenged and 3.5 weeks for 85% of the artificially challenged vaccinated heifers, respectively</u> <u>Serum: IgG1 and IgA isotypes detected in vaccinated heifers</u> <u>Cervicovaginal mucus: IgA and IgG1 isotypes detected in vaccinated heifers</u>	<u>35 Heifers: 10 unvaccinated challenged with infected bulls; 10 vaccinated challenged with infected bulls; 15 vaccinated challenged with intravaginal inoculation</u>		<u>-In serum, IgG1 predominant isotype</u> <u>-In cervicovaginal mucus, IgA predominant response</u> <u>-Culture confirmed clearance of <i>T. foetus</i> in response to vaccination</u>	<u>-Results in contrast to Skirrow & BonDurant (1990) who reported no detectable IgA and IgM in serum</u>	<u>Gault <i>et al.</i> (1995)</u>
<u>Whole ELISA</u> <u>IgG+++</u>	<u>Serum</u>	<u>Reference test was haemolytic test and <i>T. foetus</i> culture</u> <u>ELISA was more sensitive and reliable than the haemolytic test.</u>	<u>40 heifers: 12 heifers vaccinated with whole cells, 12 vaccinated with cellular membrane vaccine, and 16 unvaccinated; challenged by service using <i>T. foetus</i> infected bull</u>		<u>-Whole IgG ELISA reliable and demonstrated a stronger response to the cell membrane extract vaccine over the whole cell vaccine</u>		<u>Cobo <i>et al.</i> (2002)</u>
<u>IgG ELISA using TF1.17 antigen +++</u> <u>IgG ELISA using</u>	<u>Serum, uterine and vaginal mucosal IgG to</u>	<u>Reference to <i>T. foetus</i> culture and real-time PCR</u> <u>All animals were <i>T. foetus</i></u>	<u>20 postpartum beef cows: 10 vaccinated with</u>		<u>-IgG responses to TF1.17 reliably detected in response to vaccination in serum,</u>	<u>-Control unvaccinated cattle had IgG serum responses to whole <i>T.</i></u>	<u>Palomares <i>et al.</i> (2017)</u>

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>whole <i>T. foetus</i> antigen -/+ Bovine</u>	<u>whole <i>T. foetus</i> and surface antigen TF1.17</u>	<u>negative by real-time PCR and culture prior to vaccination</u> <u>Serum IgG to whole <i>T. foetus</i> antigen positive in vaccinated and unvaccinated cows. No difference in IgG uterine responses to whole cell antigen</u> <u>Serum, vaginal and uterine IgG responses to TF1.17 higher in vaccinated cows compared with controls</u>	<u>commercial vaccine and 10 unvaccinated</u>		<u>uterine and vaginal mucosa</u> <u>-Serum, uterine and vaginal mucosal IgG responses were not differentiated in vaccinated and unvaccinated control cows</u>	<u><i>foetus</i> antigen suggesting pre-exposure to <i>T. foetus</i> however real-time PCR and culture negative</u> <u>-IgG serum results following inactivated <i>T. foetus</i> whole cell vaccination using whole <i>T. foetus</i> ELISA antigen reported here is inconsistent with other reports</u>	
<u>Indirect ELISA IgG1 +++</u> <u>Indirect ELISA IgG2 +++</u> <u>Bovine</u>	<u>Serum</u>	<u>Reference tests were culture and real-time PCR</u> <u>No significant decrease in infection measured by real-time PCR and culture in the vaccine treated group</u> <u>IgG1 and IgG2 responses increased from weeks 2-18 in response to vaccination compared to controls.</u>	<u>20 <i>T. foetus</i> infected bulls: 10 treated with commercial vaccine, 10 controls</u>		<u>-IgG1 and IgG2 indirect ELISAs provide a good indication of vaccination responses in vaccinated <i>T. foetus</i> positive bulls</u>	<u>-<i>T. foetus</i> whole vaccines cannot be used as therapeutic in <i>T. foetus</i> infected bulls</u>	<u>Alling <i>et al.</i> (2018)</u>

1006

SECTION 3.6.

EQUIDAE

CHAPTER 3.6.1.

AFRICAN HORSE SICKNESS (INFECTION WITH
AFRICAN HORSE SICKNESS VIRUS)

SUMMARY

Description of the disease: African horse sickness (AHS) is an infectious but noncontagious viral disease especially affecting horses, although all species of the family equidae are susceptible to infection. It is caused by an orbivirus of the family Sedoreoviridae and characterised by alterations in the respiratory and circulatory functions. Disease, when present, varies from severe breakdown of the respiratory and circulatory systems resulting in death, to mild fever, depending on the levels of immunity and the equid species involved. AHS is transmitted by at least two species of Culicoides. Nine different serotypes have been described.

All serotypes of AHS occur in eastern and southern Africa. AHS serotypes 9, 4 and 2 have been found in North and West Africa, from where they occasionally spread into countries surrounding the Mediterranean. Examples of outbreaks that have occurred outside Africa are: in the Middle East (1959–1963), in Asia (Thailand 2020), in Spain (serotype 9, 1966, serotype 4, 1987–1990), and in Portugal (serotype 4, 1989).

Laboratory diagnosis of AHS is essential. Although the clinical signs and lesions are characteristic of the severe forms of the disease, such signs, they can still be confused with those of other equine diseases.

As a viral disease, the laboratory diagnosis of AHS can be based on the identification of infectious virus, virus nucleic acid, viral antigens or specific antibodies. A wide variety of laboratory tests have been adapted for the detection of both AHS virus (AHSV) and specific antibodies.

Detection and identification of the agent: a rapid and highly sensitive diagnosis is usually achieved by nucleic acid viral detection using reverse-transcription polymerase chain reaction (PCR). Nevertheless, it is particularly important to perform virus isolation and serotyping whenever AHS outbreaks occur outside the enzootic regions in order to choose a homologous serotype for the vaccine.

AHSV can be isolated from blood collected during the early febrile stage. For virus isolation, the other tissues of choice for diagnosis are spleen, lung, and lymph nodes, collected at necropsy. Sample preparations can be inoculated in cell cultures, such as baby hamster kidney-21 (BHK-21), monkey stable (MS), African green monkey kidney (Vero) or insect cells (KC) or —intravenously into embryonated eggs. Virus isolates can be serotyped by a type-specific serological test such as virus

39 neutralisation (VN), by type-specific reverse-transcription PCR or by sequencing. Molecular typing
40 assays can also be carried out on clinical samples.

41 ~~Several~~ Other methods such as enzyme-linked immunosorbent assays (ELISAs) for the rapid
42 detection of AHSV antigen in ~~blood, spleen tissues and supernatant from infected cells have been~~
43 developed although they are currently out of use due to their limited sensitivity. Identification of AHSV
44 RNA has also been achieved using a reverse-transcription polymerase chain reaction (PCR) method.
45 ~~Virus isolates can be serotyped by a type-specific serological test such as virus neutralisation (VN),~~
46 ~~by type-specific reverse-transcription PCR or by sequencing.~~

47 **Serological tests:** ~~Horses that survive natural infection develop antibodies against the infecting~~
48 ~~serotype of AHSV within 8–12 days post-infection. This may be demonstrated by several serological~~
49 ~~methods, such as complement fixation test, ELISA, immunoblotting and VN. The latter test is~~ can be
50 used for serotyping.

51 **Requirements for vaccines:** ~~Attenuated (monovalent and polyvalent) live vaccines for use in~~
52 ~~horses, mules and donkeys, are currently commercially available. Subunit vaccines~~ Inactivated
53 vaccines were used in the past and recombinant approaches have been evaluated experimentally.

54 A. INTRODUCTION

55 1. Description and impact of the disease

56 African horse sickness (AHS) (Peste equina africana, Peste equine) is an infectious, non-contagious arthropod-
57 borne disease ~~of especially of horses, although all equids are susceptible to infection, which is caused by a double-~~
58 stranded RNA orbivirus belonging to the family Sedoreoviridae. ~~equidae, caused by a double-stranded RNA~~
59 ~~orbivirus belonging to the family SedorReoviridae.~~ The genus *Orbivirus* also includes bluetongue virus and epizootic
60 haemorrhagic disease virus, which have similar morphological and biochemical properties with distinctive
61 pathological and antigenic properties as well as host ranges. Nine antigenically distinct serotypes of AHSV have
62 been identified by virus neutralisation; some cross-reaction has been observed between 1 and 2, 3 and 7, 5 and 8,
63 and 6 and 9, but no cross-reactions with other known orbiviruses occur. The virus can be inactivated at 72°C for
64 120 minutes (confirmed by three blind passages in the Vero cell line).

65 The virion is an unenveloped particle of a size around 70 nm. The genome of AHS virus (AHSV) is composed of
66 ten double-stranded RNA segments, encoding seven structural proteins (VP1-7), most of which have been
67 completely sequenced for AHSV serotypes 4, 6 and 9 (Roy *et al.*, 1991; Venter *et al.*, 2000; Williams *et al.*, 1998),
68 and four nonstructural proteins (NS1, NS2, NS3, NS3A) (Grubman & Lewis, 1992; Laviada *et al.*, 1993). Proteins
69 VP2 and VP5 form the outer capsid of the virion, and proteins VP3 and VP7 are the major inner capsid proteins.
70 Proteins VP1, VP4 and VP6 constitute minor inner capsid proteins. The NS3 proteins are the second most variable
71 AHSV proteins (Van Niekerk *et al.*, 2001), the most variable being the major outer capsid protein, VP2. This protein,
72 VP2, is the determinant of AHSV serotypes and, together with VP5, the target for virus neutralisation activity
73 (Martinez-Torrecuadrada *et al.*, 2004). At least two field vectors are involved in the transmission of the virus:
74 *Culicoides imicola* and *C. bolitinos*.

75 AHS is enzootic in sub-Saharan Africa, although occasional outbreaks have occurred in northern Africa (1965,
76 1989–1990, 2007–2010), the Middle East (1959–1961), Asia (Thailand 2020), and in Europe (Spain: 1966, 1987–
77 1990, and Portugal: 1989) (Lu *et al.*, 2020; Sanchez-Vizcaino, 2004).

78 There are four classical clinical forms of AHS: pulmonary, cardiac, mixed, and horse sickness fever. The peracute,
79 pulmonary form occurs in fully susceptible animals and has a short course, often only a few hours, and a high
80 mortality rate. The animal exhibits respiratory distress, an extended head and neck, and profuse sweating.
81 Terminally, froth exudes from the nostrils. The cardiac, oedematous form has a more subacute course with mortality
82 reaching 50%. The head and neck may show severe swelling that can extend down to the chest. Swelling of the
83 supraorbital fossae is characteristic and may include conjunctival swelling with petechiae. Paralysis of the
84 oesophagus may result in aspiration pneumonia and sublingual haemorrhages are always a poor prognostic sign.
85 The mixed, acute form is most commonly seen and has features of both the cardiac and pulmonary forms. Mortality
86 can reach 70%. Horse sickness fever is an often overlooked, mild form of the disease and is seen in partially
87 immune horses and more resistant ~~equidae~~ equids such as ~~zebra and donkeys, as well as in zebra post-~~
88 experimental infection (Coetzer & Guthrie, 2005).

89 Clinical cases have also been described in dogs, with acute respiratory distress syndrome or sudden death. The
90 mortality in dogs is high, and they may play a role in spread of the disease (Oura, 2018). Historically, infection was
91 attributable to the consumption of infected horse meat, however more recent evidence includes the suspicion of
92 vector-transmission (O'Dell *et al.*, 2018).

93 The disease has both a seasonal (late summer/autumn) and a cyclical incidence with major epizootics in southern
94 Africa during warm-phase events, such as occurrences of El Niño (Baylis *et al.*, 1999). Mortality due to AHS is
95 related to the equid species of equidae affected and to the strain or serotype of the virus. Among equidae, horses
96 are the most susceptible to AHS with a mortality rate of 50–95%, followed by mules with mortality around 50%. In
97 enzootic regions of Africa, donkeys are very resistant to AHS and experience only subclinical infections. In
98 European and Asian countries, however, donkeys are moderately susceptible and have a mortality rate of 10%.
99 Zebras are also markedly resistant with no clinical signs, except for fever, although this has only been observed
100 after experimental inoculation, and they may also have an extended viraemia (up to 40 days).

101 ~~A laboratory diagnosis is essential to establish a correct and confirmatory diagnosis. Although some clinical signs~~
102 ~~and lesions are characteristic, AHS can be confused with other diseases. For example, the supraorbital swelling,~~
103 ~~which is often present in horses with subacute AHS, is, in combination with an appropriate history, sufficient for a~~
104 ~~tentative diagnosis. Other signs and lesions are less specific for AHS, and other diseases such as equine~~
105 ~~encephalosis, equine infectious anaemia, Hendra virus, equine viral arteritis, piroplasmosis and purpura~~
106 ~~haemorrhagica should be excluded (WOAH, 2010).~~

107 Attenuated (monovalent and polyvalent) live vaccines for use in horses, mules and donkeys, are currently
108 commercially available.

109 ~~There is no evidence that humans can become infected with any field strain of AHSV, either through contact with~~
110 ~~naturally or experimentally infected animals or by virus manipulation in laboratories. Laboratory manipulations~~
111 ~~should be performed with appropriate containment determined by biorisk analysis (see Chapter 1.1.4 Biosafety and~~
112 ~~biosecurity: Standard for managing biological risk in the veterinary laboratory and animal facilities).~~

113 **2. Nature and classification of the pathogen**

114 AHS is caused by African horse sickness virus (AHSV), a double-stranded RNA orbivirus belonging to the family
115 Sedoreoviridae. The genus *Orbivirus* also includes bluetongue virus and epizootic haemorrhagic disease virus,
116 which have similar morphological and biochemical properties with distinctive pathological and antigenic properties
117 as well as host ranges. Nine antigenically distinct serotypes of AHSV have been identified by virus neutralisation;
118 some cross-reaction has been observed between 1 and 2, 3 and 7, 5 and 8, and 6 and 9, but no cross-reactions
119 with other known orbiviruses occur. The virus can be inactivated at 72°C for 120 minutes (confirmed by three blind
120 passages in the Vero cell line).

121 The virion is an unenveloped particle of a size around 70 nm. The genome of AHSV is composed of ten double-
122 stranded RNA segments, encoding seven structural proteins (VP1-7), and four nonstructural proteins (NS1, NS2,
123 NS3, NS3A). Proteins VP2 and VP5 form the outer capsid of the virion, and proteins VP3 and VP7 are the major
124 inner capsid proteins. Proteins VP1, VP4 and VP6 constitute minor inner capsid proteins (Roy *et al.*, 1994). The
125 NS3 proteins are the second most variable AHSV proteins, the most variable being the major outer capsid protein,
126 VP2. This protein, VP2, is the determinant of AHSV serotypes and, together with VP5, the target for virus
127 neutralisation activity.

128 **3. Zoonotic potential and biosafety and biosecurity requirements**

129 There is no evidence that humans can become infected with any field strain of AHSV, either through contact with
130 naturally or experimentally infected animals or by virus manipulation in laboratories. However, infection by vaccine
131 strains of AHSV has been described in four laboratory workers of a vaccine-packing facility, but it must be stressed
132 that the infections described occurred under particular circumstances with known encephalitogenic strains and there
133 is no evidence to suggest that AHS virus should ordinarily be considered a human pathogen (van der Meyden *et*
134 *al.*, 1992). Laboratory manipulations should be performed with appropriate containment determined by biorisk
135 analysis (see Chapter 1.1.4 Biosafety and biosecurity: Standard for managing biological risk in the veterinary
136 laboratory and animal facilities).

137 **4. Differential diagnosis**

138 A laboratory diagnosis is essential to establish a correct and confirmatory diagnosis. Although some clinical signs
139 and lesions are characteristic, AHS can be confused with other diseases. For example, the supraorbital swelling,
140 which is often present in horses with subacute AHS, is, in combination with an appropriate history, sufficient for a
141 tentative diagnosis. Other signs and lesions are less specific for AHS, and other diseases such as equine
142 encephalosis, equine infectious anaemia, Hendra virus, equine viral arteritis, piroplasmosis and purpura
143 haemorrhagica should be excluded (WOAH, 2010).

B. DIAGNOSTIC TECHNIQUES

145 Table 1. Test methods available for the diagnosis of African horse sickness and their purpose

Method	Purpose					
	Population freedom from infection ^(a)	Individual animal freedom from infection prior to movement ^{(b)(c)}	Contribute to eradication policies ^(d)	Confirmation of clinical cases ^(e)	Prevalence of infection – surveillance ^(f)	Immune status in individual animals or populations post-vaccination ^(g)
Detection and identification of the agent^(h)						
Real-time RT-PCR	+	+++	+++	+++	++	-
Agarose gel-based RT-PCR	±	±	±	++	+	-
Virus isolation	-	+	-	+++	-	-
Detection of immune response						
ELISA (serogroup specific based on VP7)	+++	+++	++	+	+++	++
CFT	+	+	+	+	+	+
VN	+	+	-	+	+	+++

146
147
148
149
150
151
152
153
154
155
156
157
158

Key: +++ = recommended for this purpose; ++ recommended but has limitations; + = suitable in very limited circumstances; - = not appropriate for this purpose.
RT-PCR = reverse-transcription polymerase chain reaction; ELISA = enzyme-linked immunosorbent assay; VN = virus neutralisation; CFT = complement fixation test.

^(a) See Appendix 1 of this chapter for justification table for the scores given to the tests for this purpose.

^(b) See Appendix 2 of this chapter for justification table for the scores given to the tests for this purpose.

^(c) For serological tests, paired samples may be required as recommended in the *Terrestrial Code Chapter 12.1. 'Infection with African horse sickness virus'*, Article 12.1.7 'Recommendations for importation from AHS infected countries or zones'

^(d) See Appendix 3 of this chapter for justification table for the scores given to the tests for this purpose.

^(e) See Appendix 4 of this chapter for justification table for the scores given to the tests for this purpose.

^(f) See Appendix 5 of this chapter for justification table for the scores given to the tests for this purpose.

^(g) See Appendix 6 of this chapter for justification table for the scores given to the tests for this purpose.

^(h) A combination of agent identification methods applied on the same clinical sample is recommended.

159
160
161
162
163
164
165
166
167
168
169
170

Several techniques are already available for AHS viral identification ranging from the rapid capture (indirect sandwich) enzyme-linked immunosorbent assay (ELISA) (Rubio *et al.*, 1998), using either polyclonal antibodies (PAbs) or monoclonal antibodies (MAbs), to the polymerase chain reaction (PCR) test, including reverse-transcription (RT) PCR for discrimination of the nine AHSV serotypes or virus isolation in cell culture. If possible, more than one test should be performed to diagnose an outbreak of AHS, especially the index case. The initial test can be a polymerase chain reaction (PCR) quick test such as enzyme-linked immunosorbent assay (ELISA) or polymerase chain reaction (PCR), followed by virus isolation in tissue culture. Serological techniques for serogroup specific detection enzyme-linked immunosorbent assay (ELISA) can also be used as a complementary method to detect infection by the detection of seroconversion, for which paired samples should be analysed. Virus neutralisation (VN) for serotype identification, type-specific reverse-transcription (RT)-PCR or sequencing should be performed as early in the outbreak as possible so that the serotype can be identified and the correct vaccine selected.

171
172
173
174
175
176
177

At present, there are no international standards for viruses or diagnostic reagents, and there is no standard methodology for the identification of AHSV. However, a viral and antibody panel has been evaluated, and comparative studies between different ELISAs for AHSV antigen and antibody determination have been carried out in different laboratories, including in the European Union (EU) Reference Laboratory for AHS. The results have demonstrated a high level of correlation for both antigen and antibody determination with an in-house test and commercial kits. Similar studies have been conducted with several RT-PCR assays also providing a high level of correlation. Further information on comparative studies of different test methods and kits is available from the

178 WOAH Reference Laboratories for AHS. A very important aspect of the diagnosis is the selection of samples and
179 their safe transportation to the laboratory.

180 At present, international standards, both viral and antibody panels, for the identification of AHSV and specific
181 antibodies, are available at the European Union (EU) Reference Laboratory (RL) for AHS. Inactivated virus of
182 serotypes 1–9 reference strains can be obtained from the WOAH Reference Laboratory in Spain to set up the RT-
183 PCR detection method and establish its analytical sensitivity in comparison with real-time RT-PCR procedure
184 (Aguero *et al.*, 2008). These materials have been distributed worldwide.

185 Since 2007, proficiency tests have been organised annually by the EU-RL for AHSV antibody determination and
186 viral genome detection. Laboratories involved in AHS official control around the world have participated. A
187 commercial blocking ELISA for AHSV antibodies detection has been widely used by participants and the results
188 have demonstrated a good performance. Regarding viral genome detection, real-time RT-PCR methods have been
189 widely used and similar results have been obtained with different RT-PCR assays.

190 A key aspect of the diagnosis is the selection of samples and their correct storing and safe transporting. Orbiviruses
191 remain viable at 4°C in ethylene diamine tetra-acetic acid (EDTA) blood samples for weeks or at –80°C for long-
192 term storage. Organ samples should be frozen at –80°C for 48–72 hours. Serum samples for antibody detection
193 should be kept at –20°C if storage is required for >1 week. Both the International Air Transport Association (IATA)
194 and the European Agreement concerning the International Carriage of Dangerous Goods by Road (ADR) categorise
195 clinical samples and culture containing AHSV as B UN 3373 (see Chapter 1.1.3 *Transport of biological materials*).

196 **1. Identification of the agent**

197 **1.1. Virus isolation**

198 Unclotted whole blood collected during the early febrile stage of the disease from sick animals, as well
199 as small pieces (2–4 g) of spleen, lung and lymph nodes from animals that have died, are the samples
200 of choice for diagnosis. Samples should be kept at 4°C during transportation and short-term storage prior
201 to processing.

202 **1.1.1. Cell culture**

203 Successful direct isolation of AHSV has been performed on baby hamster kidney (BHK-21),
204 monkey stable (MS) and African green monkey kidney (Vero) mammalian cell lines and on
205 *Culicoides* and mosquito insect cell lines. Blood samples collected in an appropriate anticoagulant
206 can be used undiluted as the inoculum. After 15–60 minutes of adsorption at ambient temperature
207 or at 37°C, the cell cultures are washed and maintenance medium is added. Alternatively and
208 more commonly, the blood is washed, lysed and diluted 1/10. This procedure removes unwanted
209 antibody, which could neutralise free virus, and promotes release of virus associated with the red
210 blood cell membranes. When tissue samples, such as spleen, lung, etc., are used, a 10% tissue
211 suspension is prepared in phosphate buffered saline (PBS) or cell culture medium, containing
212 antibiotics.

213 A cytopathic effect (CPE) may appear between 2 and 10 days post-infection with mammalian
214 cells. Three blind passages should be performed before considering the samples to be negative.
215 No CPE is observed in insect cells but the presence of the virus can be detected in the
216 supernatant after 5–7 days by real-time RT-PCR. Supernatant from infected insect cells can then
217 be passed onto mammalian cells, which will show CPE after one or two passages. Positive CPE
218 must be confirmed by real time RT-PCR or VNT. Real-time RT-PCR results should be carefully
219 interpreted as positive results do not necessarily indicate the presence of infectious virus.

220 **1.2. Nucleic acid methods**

221 **1.2.1. Reverse-transcription polymerase chain reaction**

222 RT-PCR is a highly sensitive technique that provides a rapid identification of AHS viral nucleic
223 acid in blood and other tissues of infected animals. ~~This technique has greatly improved the~~
224 ~~laboratory diagnosis of AHS by increasing the sensitivity of detection and shortening the time~~
225 ~~required for the diagnosis.~~ The RT-PCR procedure will detect virus-specific nucleic acid after the
226 virus is no longer viable and capable of establishing a new infection in either insects or
227 mammalian cells. ~~Therefore, positive results do not necessarily indicate the presence of infectious~~
228 ~~virus.~~

229 Several agarose gel-based RT-PCR assays for the specific detection of AHSV RNA have been
230 described targeted at viral segments 3, 7 or 8 (Aradaib, 2009; Bremer *et al.* & Viljoen, 1998;

231 ~~Laviada *et al.*, 1997; Sakamoto *et al.*, 1994; Stone-Marschat *et al.*, 1994; Zientara *et al.*, 1994).~~
232 The most widely used method employs primers corresponding to the 5' end (nucleotides 1–21)
233 and 3' end (nucleotides 1160–1179) of RNA segment 7 (coding for VP7) amplifying the complete
234 viral segment (Zientara *et al.*, 1994).

235 Real-time RT-PCR methods for the highly sensitive and specific detection of AHSV RNA have
236 been developed based on the use of a pair of primers and a labelled probe from conserved
237 sequences of viral segments 3, 5 or 7 (Agüero *et al.*, 2008; Bachanek-Bankowska *et al.*, 2014;
238 ~~Fernández-Pinero *et al.*, 2009; Rodríguez-Sánchez *et al.*, 2008~~). A duplex real-time RT-PCR has
239 also been described that targets segments 7 and 8 of the genome (coding for NS4-VP7 and NS2
240 respectively) (Quan *et al.*, 2010).

241 Although both gel-based and real-time RT-PCR procedures can detect reference strains from the
242 nine virus serotypes, real-time RT-PCR provides advantages over agarose gel-based RT-PCR
243 methods, with its faster analysis time, higher sensitivity, and suitability for high-throughput
244 automation. Nevertheless, gel-based RT-PCR methods, particularly those amplifying long RNA
245 fragments (~~Laviada *et al.*, 1997; Zientara *et al.*, 1994~~), can be very useful in the further genetic
246 characterisation of the virus by sequencing of the amplicons. In addition, it may be beneficial in
247 laboratories without the capacity to perform real-time RT-PCR.

248 In 2015 the WOA Reference Laboratories for AHS carried out an international ring trial to gather
249 information on the performance of the different methods used in the main AHSV diagnostic
250 laboratories. Ten different RT-PCR protocols were evaluated. Although in this trial some methods
251 could only be tested in one or two laboratories, they produced very good results and therefore
252 are suitable for further evaluation and validation. The study identified that the real-time RT-PCR
253 methods of Agüero *et al.* (2008) and Guthrie *et al.* (2013) correctly detected all the representative
254 strains included in the international ring trial with a high sensitivity in the analysis of field samples.
255 These methods are validated for certification of individual animals prior to movement and are
256 described below.

257 Details of AHSV gel-based RT-PCR and real-time RT-PCR methods are given below.

258 To assure a good reaction it is necessary to extract from the sample an AHSV RNA of high quality.
259 The extraction of nucleic acids from clinical samples can be performed by a variety of in-house
260 and commercially available methods.

261 **1.2.2. Agarose gel-based RT-PCR procedure (Zientara *et al.*, 1994)**

262 Denaturation of extracted RNA has to be performed prior to the RT-PCR procedure as the AHSV
263 genome consists of double-stranded RNA. The sequences of the PCR primers used are 5'-GTT-
264 AAA-ATT-CGG-TTA-GGA-TG-3', which corresponds to the messenger RNA polarity, and 5'-
265 GTA-AGT-GTA-TTC-GGT-ATT-GA-3', which is complementary to the messenger RNA polarity.

266 All the components required for the reverse transcription and PCR are included in the reaction
267 tube containing the denatured RNA. A one-step RT-PCR is carried out by incubating in a
268 thermocycler as follows: 45 minutes to 1 hour at 37–55°C, 5–10 minutes at 95°C, then 40 cycles
269 of: 94–95°C for 1 minute, 55°C for 1–1.5 minutes, 70–72°C for 2–2.5 minutes, followed by a final
270 extension step of 7–8 minutes at 70–72°C. Analysis of the PCR products is carried out by agarose
271 gel electrophoresis. AHS-positive samples will resolve in a 1179 base-pair band that can
272 additionally be used as template in the sequencing reaction, using the PCR primers independently
273 to obtain the nucleotide sequence of viral segment 7..

274 **1.2.3. Real-time RT-PCR procedure (Agüero *et al.*, 2008)**

275 This group-specific real-time RT-PCR has been employed with very good results by the
276 participating national reference laboratories of the EU Member States in annual proficiency tests
277 for the period 2009–~~2015~~ 2023. Moreover, in an international ring trial organised in 2015 under
278 the auspices of the WOA Reference Laboratory network, it was found to be one among other
279 top-ranking protocols.

280 **a) Protocol**

281 The assay targets AHSV segment 7 (VP7) and is described in Agüero *et al.* (2008). ~~It is able to~~
282 ~~detect all known AHSV types and strains currently circulating. It is highly recommended to include~~
283 an internal control in the PCR to detect inhibitors in the sample that may produce a false negative
284 result. The method, which has been optimised for both VP7 and VP7 plus β -actin, is able to detect
285 all known AHSV types and strains currently circulating.

-
- 286 i) RNA extraction from blood and tissue samples
287 Commercial kits are widely available; the RNA extraction step can be performed according
288 to the procedures specified in each kit.
- 289 ii) Several one-step real-time RT-PCR kits are commercially available that can be used
290 depending on local or case-specific requirements, kits used and equipment available. Some
291 basic steps as described by Agüero *et al.* (2008) are given below. (For primers and probe
292 sequences see Table 2).
- 293 iii) Primer stock concentration is diluted to a working concentration of 8 μM whereas probe is
294 diluted to a working concentration 50 μM .
- 295 iv) 2.5 μl of each 8 μM primer working stock ~~8 μM~~ (final concentration 1 μM) is added to each
296 well of the PCR plate (or tube or strip) that will contain RNA samples, positive or negative
297 controls. The plate is held on ice.
- 298 v) 2 μl of RNA samples, including test and positive and negative controls, is added to each
299 well.
- 300 vi) Samples are subjected to heat denaturation at 95°C for 5 minutes, followed by rapid cooling
301 on ice for further 5 minutes.
- 302 vii) An appropriate volume of real-time one-step RT-PCR master mix for the number of samples
303 to be tested is prepared following the manufacturer's instructions. Probe should be included
304 in a final concentration of 0.25 μM (0.1 μl of 50 μM probe working stock, ~~50 μM~~ per sample).
305 β -actin primers/probe should be included in a final concentration of 0.05 μM (0.1 μl of
306 working stock 10 μM of each primer and probe per sample).
- 307 viii) 13 μl of master mix is distributed in each well on the PCR plate containing the denatured
308 primers and RNA.
- 309 ix) The plate is placed in a real-time thermal cycler programmed with the following profile:
310 48°C x 25 minutes
311 95°C x 10 minutes
312 40 cycles: 95°C x 15 seconds, 55°C x 35 seconds, 72°C x 30 seconds
- 313 If reagents and thermal cycler allowing fast reactions are employed then the following
314 program can be used:
315 48°C x ~~25-10~~ minutes
316 95°C x 10 minutes
317 40 cycles: 97°C x 2 seconds, 55°C x 30 seconds
318 Fluorescence data are acquired at the end of the 55°C step.
- 319 Note: times and temperatures may vary and should be optimised for the reagents or kit used.
- 320 **b) Interpretation of the results**
- 321 The assay is considered not valid if atypical amplification curves are obtained. If this is the case,
322 the assay must be repeated.
- 323 The assay is considered positive when a typical amplification curve is obtained and the Ct value
324 (the number of polymerase chain reaction (PCR) cycles required for fluorescent signal to exceed
325 the background) is lower or equal to the defined Ct threshold (35) within 40 PCR cycles (Ct \leq 35).
- 326 The assay is considered inconclusive when a typical amplification curve is obtained and the Ct
327 value is higher ~~to than~~ the defined Ct threshold (35) within 40 PCR cycles (Ct \geq 35).
- 328 The assay is considered negative when a horizontal amplification curve is obtained and does not
329 cross the threshold line within 40 PCR cycles and the Ct for the internal control (β -actin) is lower
330 or equal to 32.
- 331 **~~c) Diagnostic characteristics~~**
- 332 i) ~~Cut-off determination~~
- 333 ~~The positive cut-off for the test method is less than 35 PCR cycles (Ct \leq 35).~~
- 334 ~~The negative cut-off for the test method is 40 PCR cycles.~~

335 Test results between the positive and negative cut-offs (35 and 40 PCR cycles) are
336 considered inconclusive ($35 \leq Ct \leq 40$).

337 ii) ~~Diagnostic sensitivity and specificity~~

338 The diagnostic specificity (DSp) and diagnostic sensitivity (DSe) were calculated according
339 to the procedure detailed in Chapter 1.1.6 *Validation of diagnostic assays for infectious*
340 *diseases of terrestrial animals*.

341 In total 186 known negatives and 132 known positive samples were analysed to estimate
342 DSe and DSp of the Agüero AHS real-time RT-PCR method, which is higher than the
343 minimum number required (73) for an estimated DSe and DSp of 95% allowing a 5% error.
344 DSe and DSp were 97% and 100%, respectively. It can thus be concluded that the number
345 of known status samples used to calculate these diagnostic parameters was sufficient to
346 comply with WOAHP requirements.

347 **d) Reproducibility**

348 Reproducibility of the Agüero real-time RT-PCR method in the international ring trial cited above
349 was at least 93.55%, correctly identifying all positive and negative samples included in the panel.
350 All laboratories detected dilutions of positive samples to at least 10^{-5} . Similar results have been
351 reported in other proficiency test programmes.

352 ~~Inactivated virus of serotypes 1–9 reference strains can be obtained from the WOAHP Reference~~
353 ~~Laboratory in Spain to set up the RT-PCR detection method.~~

354 **1.2.4. Real-time RT-PCR procedure (Guthrie *et al.*, 2013)**

355 **a) Protocol**

356 The test method presented here is adapted from Guthrie *et al.* (2013) and is capable of detecting
357 all known AHSV types and strains currently circulating. The assay targets AHSV segment 7 (VP7).
358 The procedure given may require modification to accommodate individual laboratory or different
359 RT-PCR kit requirements.

360 i) RNA extraction from blood and tissue samples

361 Commercial kits are widely available; the RNA extraction step can be performed according
362 to the procedures specified in each kit.

363 ii) Kits for the one-step real-time RT-PCR are available commercially. Below are some basic
364 steps as described by Guthrie *et al.* (2013), which can be modified depending on local or
365 case-specific requirements, kits used and equipment available.

366 iii) Primer and probe mix stock solutions are made up in a 25x concentration at 5 μ M for the
367 forward and reverse primers and 3 μ M for the probe.

368 iv) 5 μ l of RNA samples, including test and positive and negative controls, are added to
369 appropriate wells of the PCR plate (or tube or strip).

370 v) Samples are subjected to heat denaturation at 95°C for 2 minutes, and held on ice for at
371 least 3 minutes.

372 vi) An appropriate volume of real-time one-step RT-PCR master mix for the number of samples
373 to be tested is prepared, following the manufacturer's instructions. 1 μ l of 25x primer probe
374 mix stock solution (from step iii above) is included in the master mix to give a final
375 concentration in each well of 200 nM for each primer and 120 nM of the probe.

376 vii) 20 μ l of master mix is distributed in each well on the PCR plate containing the denatured
377 RNA.

378 viii) The plate is placed in a real-time thermal cycler programmed for reverse transcription and
379 cDNA amplification or fluorescence detection as suggested by the manufacturers.

380 The following thermal profile is an example:

381 48°C x 10 minutes

382 95°C x 10 minutes

383 40 cycles: 95°C x 15 seconds, 60°C x 45 seconds

384 Note: times and temperatures may vary and should be optimised for the reagents or kit used.

385 **b) Interpretation of the results**

386 **Note:** the positive/inconclusive/negative cut-off values shown should be validated or adjusted in
387 individual laboratories according to the reagents and equipment in use.

388 Samples are classified as “AHSV positive” if the normalised fluorescence for the AHSV real-time
389 RT-PCR assay exceeds a 0.1 threshold within 36 PCR cycles in all replicates of a sample.

390 Samples are classified as “AHSV Inconclusive” if the normalised fluorescence for the AHSV real-
391 time RT-PCR assay exceeds a 0.1 threshold between 36 and 40 PCR cycles in any replicate of
392 a sample.

393 Samples are classified as “AHSV negative” if the normalised fluorescence for the AHSV assay
394 did not exceed a 0.1 threshold within 40 PCR cycles in all replicates of a sample and if the
395 normalised fluorescence for the internal positive control assay exceeded a 0.1 threshold within
396 33 PCR cycles.

397 ~~e) Diagnostic characteristics~~

398 ~~i) Cut-off determination~~

399 ~~The positive cut-off for the test method is less than 36 PCR cycles.~~

400 ~~The negative cut off for the test method is 40 PCR cycles.~~

401 ~~Test results between the positive and negative cut-offs (36 and 40 PCR cycles) are~~
402 ~~considered inconclusive.~~

403 ~~ii) Diagnostic sensitivity and specificity~~

404 ~~The DSe and DSp of the AHSV real-time RT-PCR for detection of AHSV nucleic acid in~~
405 ~~whole blood samples were estimated by comparison with virus isolation using a two test~~
406 ~~two-population Bayesian latent class model that allowed for conditional dependence~~
407 ~~(correlation) among test results. A total of 503 equine blood samples collected from~~
408 ~~individual horses with pyrexia and one or more clinical signs typical of AHS were used to~~
409 ~~represent AHS suspect cases. Blood samples were also collected from two separate healthy~~
410 ~~populations of horses (503 and 98 horses each, respectively) that were not vaccinated~~
411 ~~against AHS and that were highly unlikely to have been exposed to natural infection with~~
412 ~~AHSV; these samples were used to represent AHS negative cases.~~

413 ~~The median diagnostic specificity of the test method exceeded 99.9%.~~

414 ~~The median diagnostic sensitivity of the test method exceeded 97.8%.~~

415 **c) Reproducibility**

416 In the international ring trial cited above the Guthrie FRET probe real-time RT-PCR method
417 demonstrated sensitivity in excess of 88.1%, a specificity of 100%, correctly identifying all positive
418 and negative samples included in the panel. All laboratories detected dilutions of positive samples
419 to at least 10⁻⁵.

420 Table 2. Comparison of the real-time RT-PCR methods of Agüero et al. (2008) and Guthrie et al. (2013)

	Agüero et al. (2008)	Guthrie et al. (2013)
Target	Group specific (VP7)	Group specific (VP7)
Primers (5'-3')	CCA-GTA-GGC-CAG-ATC-AAC-AG	AGA-GCT-CTT-GTG-CTA-GCA-GCC-T
	CTA-ATG-AAA-GCG-GTG-ACC-GT	GAA-CCG-ACG-CGA-CAC-TAA-TGA
Probe (5'-3')	FAM-GCT-AGC-AGC-CTA-CCA-CTA-MGB	FAM-TGC-ACG-GTC-ACC-GCT-MGB
Annealing temperature	55°C	60°C
Number of amplification cycles	40	40

	Agüero <i>et al.</i> (2008)	Guthrie <i>et al.</i> (2013)
Analytical sensitivity (LOD)	Dilution 10^{-5} of a viral suspension of AHSV-4 reference strain with a titre of $10^{6.3}$ TCID ₅₀ /ml, which corresponded to a Ct of 34.3 ± 0.5 ($10^{1.3}$ TCID ₅₀ /ml)	Dilution of 3.02×10^{-6} of a AHSV positive blood samples, with corresponding Ct of 35.71
Diagnostic specificity	100%	99.9%.
Diagnostic sensitivity	97%	97.8%.

421 **1.3. AHSV typing**

422 Until recently, the VN test has been the method of choice for typing as well as the ‘gold’ standard test for
 423 identifying AHSV isolated from the field using type-specific antisera (Verwoerd, 1979). This technique
 424 takes 5 or more days before results are obtained. The development of type-specific gel-based RT-PCR
 425 (Maan *et al.*, 2011; ~~Salleau *et al.*, 2000; Van Schalkwyk *et al.*, 2019~~), and real-time RT-PCR using
 426 hybridisation probes (Koekemoer, 2008) targeting AHSV Seg-2 for identification and differentiation of
 427 AHSV genotypes, as well as the more recently described type-specific real-time RT-PCR assays based
 428 on the use of labelled DNA probes–MGB probes (Bachanek-Bankowska *et al.*, 2014; Villalba *et al.*, 2024;
 429 Weyer *et al.*, 2015) provides a rapid typing method for AHSV in tissue samples and blood. In comparison
 430 to VN tests, these methods can be used to ~~very~~ significantly increase the speed and reliability of detection
 431 and identification ~~(compared with VN tests)~~ of the nine serotypes of AHSV. ~~Type-specific real-time RT-~~
 432 ~~PCR assays based on the use of labelled DNA probes–MGB probes have been developed recently by~~
 433 ~~Bachanek-Bankowska *et al.*, 2014, Weyer *et al.*, 2015).~~

434 However, the genetic variation that may appear over time in the AHSV genome, ~~in particular specifically~~
 435 in the VP2 coding region, where specific primers/probes for typing assays have to be designed, makes
 436 the detection of all genetic variants within each serotype by this type of technique difficult. Therefore,
 437 although molecular methods ~~are able to can~~ rapidly type AHSV in many positive field samples, VN should
 438 be kept as the gold standard for serotyping AHSV isolates.

439 **2. Serological tests**

440 Indirect and competitive blocking ELISAs using either soluble AHSV antigen or a recombinant protein VP7 (~~Hamblin~~
 441 ~~*et al.*, 1990; Laviada *et al.*, 1992; Maree & Paweska, 2005; Wade-Evans *et al.*, 1993~~) have proved to be good
 442 methods for the detection of anti-AHSV group-reactive antibodies, especially for large-scale investigations (~~Rubio~~
 443 ~~*et al.*, 1998~~). ~~Both of these tests have been recognised by the European Commission (2002).~~ The competitive
 444 blocking ELISA can also be used for testing wildlife as species-specific anti-globulin is not required with this method.
 445 An immunoblotting test has also been adapted for anti-AHS antibody determination (Laviada *et al.*, 1992), which is
 446 especially suitable for small numbers of sera. The complement fixation (CF) test has been widely used, but some
 447 sera are anti-complementary, particularly donkey and zebra sera.

448 **2.1. Blocking enzyme-linked immunosorbent assay**

449 The competitive blocking ELISA technique detects specific antibodies against AHSV, present in any
 450 equine species. VP7 is the main antigenic protein within the molecular structure of AHSV and it is
 451 conserved across the nine AHSV serotypes. An MAb directed against VP7 is used in this test, allowing
 452 high sensitivity and specificity. Moreover, other species of the family Equidae (e.g. donkeys, zebra, etc.)
 453 can be tested thus preventing the problem of specificity experienced occasionally using the indirect
 454 ELISAs. VP7 recombinant antigen is non-infectious, which provides a high level of security ~~(European~~
 455 ~~Commission, 2002).~~

456 The principle of this test is to block the specific reaction between the recombinant VP7 protein absorbed
 457 on an ELISA plate and a conjugated MAb against VP7. AHSV antibodies present in a suspect serum
 458 sample will block this reaction. A decrease in the amount of colour is evidence of the presence of AHSV
 459 antibodies in the serum sample.

460 The competitive blocking ELISA is commercially available. The reproducibility of the test was assessed
 461 in an international ring trial (Durán-Ferrer *et al.*, 2019).

462 **2.1.1. Test procedure**

463 The test described here is an example of a blocking ELISA.

- 464 i) *Solid phase*: coat 96-well ELISA plates with 50–100 ng of recombinant AHSV-4 VP7 diluted
465 in carbonate/bicarbonate buffer, pH 9.6. Incubate overnight at 4°C.
- 466 ii) Wash the plates three times with PBS 0.1× containing 0.135 M NaCl and 0.05% (v/v)
467 Tween 20 (washing solution). Gently tap the plates onto absorbent material to remove any
468 residual wash.
- 469 iii) *Test samples*: serum samples to be tested, and positive and negative control sera (if not
470 ready to use by kit manufacturer), are diluted 1/5 in diluent containing 0.35 M NaCl, 0.05%
471 Tween 20; and 0.1% Kathon, 100 µl per well. Incubate for 1 hour at 37°C.
- 472 iv) Wash the plates five times with PBS 0.1× containing 0.135 M NaCl and 0.05% (v/v)
473 Tween 20 (washing solution). Gently tap the plates onto absorbent material to remove any
474 residual wash.
- 475 v) *Conjugate*: dispense 100 µl/well of horseradish peroxidase-conjugated MAb anti-VP7 at
476 optimal dilution in a suitable diluent. The MAb and diluent may be included in commercial
477 kits. Incubate for 30 minutes at 37°C.
- 478 vi) Wash the plates as described in step iv.
- 479 vii) *Substrate/chromogen*: add 100 µl/well substrate/chromogen solution, e.g. ABTS (2,2'-azino-
480 di-[3-ethyl-benzothiazoline]-6-sulphonic acid) 5 mg/ml diluted 1/10 in 0.1 M phosphate/
481 citrate buffer, pH 4, containing 0.03% H₂O₂, and incubate for 10 minutes at room
482 temperature.
- 483 Colour development is stopped by adding 100 µl/well of 2% (w/v) of SDS. Alternative
484 chromogen systems may be used (e.g. tetramethyl benzidine).
- 485 viii) Read the plates at 405 nm.
- 486 ix) *Validation of the assay*: positive control lower than 0.2 and negative control higher than 1.0.
- 487 x) *Interpretation of results*: determine the blocking percentage (BP) of each sample by applying
488 the following formula:

$$BP = \frac{\text{Abs (Control Neg)} - \text{Abs (sample)}}{\text{Abs (Control Neg)} - \text{Abs (Control Pos)}} \times 100$$

489 Samples showing BP value lower than 45% are considered negative for antibodies to AHSV.
490 Samples showing BP value higher than 50% are considered positive for antibodies to AHSV.
491 Samples with BP value between 45% and 50% are considered doubtful and must be retested. If
492 the result is the same, resample and test 2 weeks later.

493 2.2. Indirect enzyme-linked immunosorbent assay

494 The recombinant VP7 protein has been used as antigen⁴ for AHSV antibody determination with a high
495 degree of sensitivity and specificity (Laviada *et al.*, 1992; Maree & Paweska, 2005). Other advantages
496 of this antigen are its stability and its lack of infectivity. The conjugate used in this method is a horseradish
497 peroxidase anti-horse gamma-globulin reacting with horse, mules and donkeys. The method described
498 by Maree & Paweska (2005) uses protein G as conjugate that also reacts with zebra serum. The indirect
499 ELISA is recently also commercially available.

500 2.2.1. Test procedure

501 There are several test procedures described; this is an example of one AHS indirect ELISA
502 procedure.

- 503 i) *Solid phase*: Coat 96-well ELISA plates with recombinant AHSV-4 VP7 diluted in
504 carbonate/bicarbonate buffer, pH 9.6. Incubate overnight at 4°C.
- 505 ii) Wash the plates five times with distilled water containing 0.01% (v/v) Tween 20 (washing
506 solution). Gently tap the plates on to absorbent material to remove any residual wash.
- 507 iii) Block the plates with PBS, pH 7.2 + 5% (w/v) skimmed milk, 200 µl/well, for 1 hour at 37°C.
- 508 iv) Remove the blocking solution and gently tap the plates on to absorbent material.

⁴—The antigen can be provided on request by the Centro de Investigación en Sanidad Animal (CISA), Spain. The delivery time is 4–6 months.

- 509 v) *Test samples:* Serum samples to be tested, and positive and negative control sera, are
510 diluted 1/25 in PBS + 5% (w/v) skimmed milk + 0.05% (v/v) Tween 20, 100 µl per well.
511 Incubate for 1 hour at 37°C. For titration, add twofold dilution series from 1/25 (100 µl/well),
512 one serum per plate column, in duplicate columns, and do the same with positive and
513 negative controls. Incubate for 1 hour at 37°C.
- 514 vi) Wash the plates as described in step ii.
- 515 vii) *Conjugate:* Dispense 100 µl/well of horseradish peroxidase conjugated anti-horse gamma-
516 globulin diluted in PBS + 5% milk + 0.05% Tween 20, pH 7.2. Incubate for 1 hour at 37°C.
- 517 viii) Wash the plates as described in step ii.
- 518 ix) *Chromogen/Substrate:* Add 200 µl/well of chromogen/substrate solution (10 ml 80.6 mM
519 DMAB [3-(dimethylamino) benzoic acid] + 10 ml 1.56 mM MBTH [3-methyl-2-
520 benzothiazolinone hydrazone] + 5 µl H₂O₂). Colour development is stopped by adding 50 µl
521 of 3 N H₂SO₄ after approximately 5–10 minutes (before the negative control begins to be
522 coloured). Other chromogens such as ABTS, tetramethyl benzidine or orthophenyldiamine
523 can also be used.
- 524 x) Read the plates at 600 nm, ~~or~~ 620 nm, or 450nm, depending on the chromogen used.
- 525 xi) *Interpretation of results:* Calculate the cut-off value by adding 0.06 to the value of the
526 negative control. (0.06 is the standard deviation derived with a group of 30 negative sera)
527 Test samples giving absorbance values lower than the cut-off are regarded as negative.
528 Test samples giving absorbance values greater than the cut-off + 0.15 are regarded as
529 positive. Test samples giving intermediate absorbance values are doubtful and a second
530 technique must be employed to confirm the result.

531 2.3. Complement fixation

532 The CF test has been used extensively in the past, but currently its use is decreasing and has been
533 replaced in many laboratories by ELISA as a screening technique. This progressive replacement is
534 because of the higher sensitivity and degree of standardisation of ELISA as well as a significant number
535 of sera with anti-complementary activity. Nevertheless, the CF test is a useful tool in endemic areas for
536 the demonstration and titration of group-specific IgM antibodies against AHSV notably following a recent
537 infection or vaccination.

538 2.3.1. Reagents

- 539 Veronal buffered saline containing 1% gelatin (VBSG).
- 540 ii) Serum samples, free from erythrocytes, must be heat inactivated: horse serum at 56°C,
541 zebra serum at 60°C and donkey serum at 62°C, for 30 minutes.
- 542 iii) The antigen is a sucrose/acetone extract of AHSV-infected mouse brain. The control antigen
543 is uninfected mouse brain, extracted in the same way. In the absence of an international
544 standard serum, the antigen should be titrated against a locally prepared positive control
545 serum. In the test, four to eight units are used. The antigen may also be obtained by
546 inoculation of the virus in suitable cell culture (see Section B.1 above).
- 547 iv) The complement is a normal guinea-pig serum.
- 548 v) The haemolysin is a hyperimmune rabbit serum against sheep red blood cells (SRBCs).
- 549 vi) The SRBCs are obtained by aseptic puncture of the jugular vein and preserved in Alsever's
550 solution² or sodium citrate.
- 551 vii) The haemolytic system (HS) is prepared by diluting the haemolysin to contain two
552 haemolytic doses and using this to sensitise washed SRBCs. The SRBCs are standardised
553 to a 3% concentration.
- 554 viii) *Control sera:* A positive control serum is obtained locally and validated. Serum from a
555 healthy antibody-negative horse is used as the negative control serum.

556

² 20.5 g dextrose (114 mM), 7.9 g sodium citrate 2H₂O (27 mM), 4.2 g NaCl (71 mM), H₂O to 1 litre. Adjust to pH with 1 M citric acid.

557

2.3.2. Test procedure

- 558 i) The reaction is performed in 96-well round-bottom microtitre plates in a final volume of
559 100 µl/well or in tubes if the macro-technique is used, at 4°C for 18 hours.
- 560 ii) All the sera, samples and controls are diluted 1/5 in VBSG and 25 µl of each serum is added
561 in duplicate. A twofold dilution series of each serum is done from 1/5 to 1/160.
- 562 iii) Add 25 µl of the antigen diluted according to the previous titration.
- 563 iv) Add 25 µl of the complement diluted according to a previous titration.
- 564 v) Incubate at 4°C for 18 hours.
- 565 vi) 25 µl of HS is added to all wells on the microtitre plate.
- 566 vii) The plate is incubated for 30 minutes at 37°C.
- 567 viii) Plates are then centrifuged at 200 **g**, and the wells are scored for the presence of
568 haemolysis. Control of sera, complement, antigen and HS are used
- 569 ix) Results are read using 50% haemolysis as the end point. The inverse of the highest dilution
570 of serum specifically fixing complement with the CF antigen is called the titre.
- 571 x) A titre of 1/10 or more is positive, under 1/10 is negative.

572

2.4. Virus neutralisation serology (VN)

573 Serotype-specific antibody can be detected using the VN serology test (House *et al.*, 1990). The VN ~~test~~
574 serology may have additional value in epidemiological surveillance and transmission studies, mainly in
575 endemic areas where multiple serotypes are likely to be present.

576

2.4.1. VN serology test procedure

- 577 i) From a starting dilution of 1/5, serial twofold dilutions of the test sera are made in a cell-
578 culture grade flat-bottomed 96-well microtitre plate, using cell culture medium as diluent. For
579 each sample two wells are used at each dilution. Control positive and negative sera should
580 also be included in each batch of tests. An equal volume (e.g. 25 µl) of a stock of AHSV
581 containing 100 TCID₅₀ (50% tissue culture infective dose) is added to each well.
- 582 ii) Serum/virus mixtures are incubated for 60 minutes at 37°C 5% CO₂ and 95% humidity prior
583 to the addition of 0.1 ml of Vero cell suspension (200,000 cells/ml) to each test well.
- 584 iii) A back titration of virus stock is prepared for each test using four wells per tenfold dilution,
585 25 µl per well. Test plates are incubated at 37°C, 5% CO₂, 95% humidity for 4–5 days, until
586 the back titration indicates that the stock virus contains 30–300 TCID₅₀.
- 587 iv) After incubation for 4–5 days, the test is read using an inverted microscope. Wells are scored
588 for the presence or absence of CPE. The presence of CPE in the wells containing the serum
589 sample indicates that the tested serum does not contain specific neutralising antibodies
590 against the virus ~~in the assay that cannot neutralise the virus~~, therefore producing cell lysis
591 with the consequent destruction of the cell layer.
- 592 By contrast, the absence of CPE in the wells containing the serum sample indicates that the
593 tested serum does contain specific neutralising antibodies against the virus ~~in the assay that~~
594 ~~can neutralise the virus~~, therefore maintaining intact the cell layer.
- 595 v) Alternatively, the plates are then fixed and stained in a solution of 0.15% (w/v) crystal violet
596 in 2% (v/v) glutaraldehyde and rinsed or they may be fixed with 70% ethanol and stained
597 with 1% basic fuchsin.
- 598 vi) The 50% end-point titre of the serum is calculated by the Spearman–Kärber method and
599 expressed as the negative log₁₀.

600

601

602 C. REQUIREMENTS FOR VACCINES

603 1. Background

604 1.1. Rationale and intended use of the product

605 Polyvalent or monovalent live attenuated AHS vaccines, based on the selection in Vero cell culture of
606 genetically stable macroplaques, have been used for the control of AHSV in and out of Africa (~~Erasmus,~~
607 ~~1976;~~ ~~Sanchez-Vizcaino, 2004~~). Polyvalent vaccines are commercially available.

608 It must be noted that detection of viral genome in animals vaccinated with live attenuated AHS vaccines
609 has been described up to 16 weeks after vaccination (Weyer et al., 2017).

610 An inactivated monovalent (serotype 4) AHSV vaccine based on virus purification and inactivation with
611 formalin was produced commercially in the early 1990s (House et al., 1992), but is not commercially
612 available at the present time. More recently, inactivated vaccines have been produced and successfully
613 used against all serotypes (Rodríguez et al., 2020). Subunit AHSV vaccines based on serotype 4 outer
614 capsid protein VP2 and VP5 plus inner capsid protein VP7, derived from single and dual recombinant
615 baculovirus expression vectors have been used experimentally in different combinations to immunise
616 horses (Martinez et al., 1996). The protective efficacy of VP2 in a subunit vaccine was also evaluated
617 (Scanlen et al., 2002). However, these vaccines are not commercially available. Other examples of
618 experimental new generation vaccines described but currently not commercially available, include virus-
619 vectored vaccines (e.g. modified vaccinia Ankara virus: Alberca et al., 2014), plant-derived virus-like
620 particles (O’Kennedy et al., 2024) as well as entry-competent replicative-abortive (ECRA) and disabled
621 infection single animal (DISA) reverse genetics vaccine platforms (Van Rijn et al., 2018).

622 2. Outline of production and minimum requirements for conventional vaccines

623 At present only the live attenuated AHS vaccines (polyvalent or monovalent) are commercially available. Guidelines
624 for the production of veterinary vaccines are given in Chapter 1.1.8 *Principles of veterinary vaccine production*. The
625 guidelines given here and in chapter 1.1.8 are intended to be general in nature and may be supplemented by
626 national and regional requirements.

627 3. Live attenuated African horse sickness vaccine

628 3.1. Characteristics of the seed

629 3.1.1. Biological characteristics

630 The seed virus is prepared by selection in Vero cells of genetically stable large plaques from low
631 passage levels of AHSV. The plaque mutants are then further multiplied by three passages in
632 Vero cells. A large quantity of this antigen is lyophilised and stored at -20°C as seed stock
633 antigen.

634 3.1.2. Quality criteria

635 The seed virus must be shown to be free of contaminating viruses, bacteria and mycoplasmas by
636 the appropriate techniques. The serotype identity of the seed virus is confirmed.

637 3.2. Method of manufacture

638 3.2.1. Procedure

639 At the onset of a production run, working antigens are produced from the seed stock antigen in
640 either BHK-21 or Vero cell cultures. The working antigens are tested for sterility, purity and identity
641 and should contain at least 1×10^6 plaque-forming units (PFU)/ml of infectious virus.

642 3.2.2. Requirements for substrates and media

643 Roller bottle cultures of Vero or BHK-21 cells are grown using gamma-irradiated bovine serum in
644 the growth medium. Once the cultures are confluent, the medium is poured off and the cells are
645 seeded with the working antigens. After 1 hour, maintenance medium is added to the cultures.
646 Incubation is continued at 37°C for 2–3 days. When the CPE is advanced, both cells and
647 supernatant medium are harvested. The products from the same serotype are pooled and stored
648 at 4°C..

649 **3.2.3. In-process control**

650 The pooled harvests of the individual serotypes are tested for sterility and assayed for infectivity
651 by plaque titration on Vero cell cultures. The minimum acceptable titre is 1×10^6 PFU/ml.

652 Finally, two multivalent vaccines are constituted by mixing equal volumes of serotypes 1, 3, 4 and
653 2, 6, 7, 8 respectively. Serotypes 5 and 9 are not included in vaccine formulations. A monovalent
654 type can also be prepared. After addition of suitable stabiliser, the vaccine is distributed in 1.0 ml
655 volumes into glass vials and freeze-dried.

656 **3.2.4. Final product batch test**

657 i) Sterility

658 Following lyophilisation, five bottles of vaccine are selected at random and tested for sterility
659 by internationally accepted methods. Tests for sterility and freedom from contamination of
660 biological materials intended for veterinary use are given in chapter 1.1.9.

661 ii) Safety

662 Innocuity of a vaccine is determined by the inoculation of reconstituted vaccine into mice
663 (0.25 ml intraperitoneally), guinea-pig (1.0 ml intraperitoneally), and a horse (5.0 ml
664 subcutaneously). All the animals are observed daily for 14 days. The rectal temperature of
665 the horse is taken twice daily for 14 days and should never exceed 39°C.

666 iii) Batch potency

667 Potency is largely based on virus concentration in the vaccine.

668 The minimum immunising dose for each serotype is about 1×10^3 PFU/dose. The infectivity
669 titre of the final product is assayed by plaque titration in Vero cell cultures and should contain
670 at least 1×10^5 PFU/dose. The horse used for safety testing is also used for determining the
671 immunogenicity of a vaccine.

672 Serum samples are collected on the day of vaccination and 21 days later, and are tested for
673 neutralising antibodies against each serotype by the plaque-reduction test using twofold
674 serum dilutions and about 100 PFU of virus. The horse should develop a neutralising
675 antibody titre of at least 20 against at least three of the four serotypes in the quadrivalent
676 vaccine.

677 **3.3. Requirements for regulatory approval ~~authorisation~~**

678 No specific guideline is described for AHS vaccine. However, a guideline is described in the EU for
679 Bluetongue virus under exceptional circumstances that could probably be used for AHS virus. This
680 guideline includes the minimum date requirements for the ~~authorisation~~ regulatory approval under
681 exceptional circumstances for vaccine production for emergency use against bluetongue virus
682 (Regulation EC N°726/2004, in particular Articles 38, 39 and 43 thereof and Article 26 of Direction
683 2001/82/EC), including guidance measures to facilitate the rapid inclusion of new or different virus
684 serotypes.

685 **4. Vaccines based on biotechnology**

686 **4.1. Vaccines available and their advantages**

687 None is available commercially. Experimental ~~subunit~~ vaccines developed by different approaches have
688 been described (Section C.1.1 *Rationale and intended use of the product*).

689 **4.2. Special requirements for biotechnological vaccines, if any**

690 None.

691

- 693 AGÜERO M., GÓMEZ-TEJEDOR C., ANGELES CUBILLO M., RUBIO C., ROMERO E. & JIMÉNEZ-CLAVERO A. (2008). Real-time
694 fluorogenic reverse transcription polymerase chain reaction assay for detection of African horse sickness virus. *J.*
695 *Vet. Diagn. Invest.*, **20**, 325–328.
- 696 ALBERCA B., BACHANEK-BANKOWSKA K., CABANA M., CALVO-PINILLA E., VIAPLANA E., FROST L., GUBBINS S., URNIZA A.,
697 MERTENS P. & CASTILLO-OLIVARES J. (2014). Vaccination of horses with a recombinant modified vaccinia Ankara
698 virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical
699 protection against challenge. *Vaccine*, **32**, 3670–3674.
- 700 ARADAIB I.E. (2009). PCR detection of African horse sickness virus serogroup based on genome segment three
701 sequence analysis. *J. Virol. Methods*, **159**, 1–5.
- 702 BACHANEK-BANKOWSKA K., MAAN S., CASTILLO-OLIVARES J., MANNING N.M., MAAN N.S., POTGIETER A.C., DI NARDO A.,
703 SUTTON G., BATTEN C. & MERTENS P.P. (2014). Real-time RT-PCR assays for detection and typing of African horse
704 sickness virus. *PLoS One*, **9** (4), e93758.
- 705 ~~BAYLIS M., MELLOR P.S. & MEISWINKEL R. (1999). Horse sickness and ENSO in South Africa. *Nature*, **397**, 574.~~
- 706 ~~BREMER C.W., DUNCU-KIMBENGA B. & VILJOEN G.J. (1998). Detection of African horsesickness virus in Zebra by RT-~~
707 ~~PCR and the development of different methods for confirming AHSV specificity of RT-PCR products. Proceedings~~
708 ~~of the Eighth International Conference on Equine Infectious Diseases, Dubai, 23–26 March 1998. R & W~~
709 ~~Publications (Newmarket) Ltd, Newmarket, UK.~~
- 710 BREMER C.W. & VILJOEN G.J. (1998) Detection of African horsesickness virus and discrimination between two equine
711 orbivirus serogroups by reverse transcription polymerase chain reaction. *Onderstepoort J. Vet. Res.*, **65**, 1–8.
- 712 COETZER J.A.W. & GUTHRIE A.J. (2005). African horsesickness. *In: Infectious Diseases of Livestock*, Second Edition.
713 Coetzer J.A.W. & Tustin R.C., eds. Oxford University Press, Cape Town, 1231–1246.
- 714 DURÁN-FERRER M., AGÜERO M., ZIENTARA S., SMITH S., POTGIETER C., RUEDA P., SASTRE P., MONACO F., VILLALBA R.,
715 TENA-TOMÁS C., BATTEN C., FROST L., FLANNERY J., GUBBINS S., LUBISI B.A., SÁNCHEZ-VIZCAÍNO J.M., EMERY M.,
716 STURGILL T., OSTLUND E. & CASTILLO-OLIVARES J. (2019). Assessment of reproducibility of a VP7 Blocking ELISA
717 diagnostic test for African horse sickness. *Transbound. Emerg. Dis.*, doi: 10.1111/tbed.12968.
- 718 ~~ERASMUS B.J. (1976). A new approach to polyvalent immunisation against African horse sickness. *In: Proceedings*
719 ~~of the Fourth International Conference on Equine Infectious Diseases, Lyon, France, September 1976. Princeton,~~
720 ~~N.J. Veterinary Publications, USA, 401–403.~~~~
- 721 ~~EUROPEAN COMMISSION (2002). Commission decision of 21 February 2002 amending Annex D to Council Directive~~
722 ~~90/426/EEC with regard to the diagnostic tests for African horse sickness. *Off. J. European Communities*, **L53**, 37–~~
723 ~~42.~~
- 724 ~~FERNÁNDEZ-PINERO J., FERNÁNDEZ-PACHECO P., RODRÍGUEZ B., SOTELO E., ROBLES A., ARIAS M. & SÁNCHEZ-VIZCAÍNO~~
725 ~~J.M. (2009). Rapid and sensitive detection of African horse sickness virus by real-time PCR. *Res. Vet. Sci.*, **86**,~~
726 ~~353–358.~~
- 727 ~~GRUBMAN M. & LEWIS S. (1992). Identification and characterisation of the structural and non-structural proteins of~~
728 ~~African horse sickness virus and determination of the genome coding assignments. *Virology*, **186**, 444–451.~~
- 729 GUTHRIE A.J., MACLACHLAN N.J., JOONE C., LOURENS C.W., WEYER C.T., QUAN M., MONYAI M.S. & GARDNER I.A. (2013).
730 Diagnostic accuracy of a duplex real-time reverse transcription quantitative PCR assay for detection of African
731 horsesickness virus. *J. Virol. Methods*, **189**, 30–35.
- 732 ~~HAMBLIN C., GRAHAM S.D., ANDERSON E.C. & CROWTHER J.R. (1990) A competitive ELISA for the detection of group-~~
733 ~~specific antibodies to African horse sickness virus. *Epidemiol. Infect.*, **104**, 303–312.~~
- 734 HOUSE C., MIKICIUK P.E. & BERNINGER M.L. (1990). Laboratory diagnosis of African horse sickness: comparison of
735 serological techniques and evaluation of storage methods of samples for virus isolation. *J. Vet. Diagn. Invest.*, **2**,
736 44–50.
- 737 HOUSE J., LOMBARD M., HOUSE C., DUBOURGET P. & MEBUS C. (1992). Efficacy of an inactivated vaccine for African
738 horse sickness serotype 4. *In: Bluetongue, African Horse Sickness and Related Orbiviruses: Proceedings of the*

- 739 Second International Symposium, Walton T.E. & Osburn B.I., eds. CRC Press, Boca Raton, Florida, USA, 891–
740 895.
- 741 KOEKEMOER J.J. (2008). Serotype-specific detection of African horsesickness virus by real-time PCR and the
742 influence of genetic variations. *J. Virol. Methods*, **154**, 104–110.
- 743 ~~LAVIADA M.D., ARIAS M. & SANCHEZ-VIZCAINO J.M. (1993). Characterization of African horse sickness virus serotype
744 4-induced polypeptides in Vero cells and their reactivity in Western immunoblotting. *J. Gen. Virol.*, **74**, 81–87.~~
- 745 LAVIADA M.D., ROY P. & SANCHEZ-VIZCAINO J.M. (1992). Adaptation and evaluation of an indirect ELISA and
746 immunoblotting test for African horse sickness antibody detection. *In: Bluetongue, African Horse Sickness and
747 Related Orbiviruses: Proceedings of the Second International Symposium.* Walton T.E. & Osburn B.I., Eds. CRC
748 Press, Boca Raton, Florida, USA, 646–650.
- 749 ~~LAVIADA M.D., SANCHEZ-VIZCAINO J.M., ROY P. & SOBRINO F. (1997). Detection of African horsesickness virus by the
750 polymerase chain reaction. *Invest. Agr. SA.*, **12**, 97–102.~~
- 751 LU G., PAN J., OU J., SHAO R., HU X., WANG C. & LI S. (2020). African horse sickness: Its emergence in Thailand and
752 potential threat to other Asian countries. *Transbound. Emerg. Dis.*, **67**, 1751–1753. doi: 10.1111/tbed.13625.
- 753 MAAN N.S., MAAN S., NOMIKOU K., BELAGANAHALLI M.N., BACHANEK-BANKOWSKA K. & MERTENS P.P.C. (2011).
754 Serotype-specific primers and gel-based RT-PCR assays for 'typing' African horse sickness virus: identification of
755 strains from Africa. *PLoS One*, **6** (10), e25686.
- 756 MAREE S. & PAWESKA J.T. (2005). Preparation of recombinant African horse sickness virus VP7 antigen via a simple
757 method and validation of a VP7-based indirect ELISA for the detection of group-specific IgG antibodies in horse
758 sera. *J. Virol. Methods*, **125**, 55–65.
- 759 MARTINEZ J., DIAZ-LAVIADA M., ROY P., SANCHEZ C., VELA C., SANCHEZ-VIZCAINO J.M. & CASAL I. (1996). Full protection
760 against AHSV in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7. *J. Gen. Virol.*, **77**,
761 1211–1221.
- 762 ~~MARTINEZ-TORRECUADRADA J., LANGEVELD J., MELOEN R. & CASAL I. (2001). Definition of neutralizing sites on African horse
763 sickness virus serotype 4 VP2 at the level of peptides. *J. Gen. Virol.*, **82**, 2415–2424.~~
- 764 O'DELL N., ARNOT L., JANISCH C.E. & STEYL J.C.A. (2018). Clinical presentation and pathology of suspected vector-
765 transmitted African horse sickness in South African domestic dogs from 2006 to 2017. *Vet. Rec.* **182**, 715.
766 doi:10.1136/vr.104611
- 767 O'KENNEDY M.M., ROTH R., EBERSOHN K., DU PLESSIS L.H., MAMPUTHA S., RUTKOWSKA D.A., DU PREEZ I., VERSCHOOR
768 J.A. & LEMMER Y. (2024). Immunogenic profile of a plant-produced nonavalent African horse sickness viral protein
769 2 (VP2) vaccine in IFNAR^{-/-} mice. *PLoS One*, **19**, e0301340.
- 770 ~~OURA C. (2018). A possible role for domestic dogs in the spread of African horse sickness virus. *Vet. Rec.*, **182**, 713–
771 714). <https://www.ncbi.nlm.nih.gov/pubmed/29934455>~~
- 772 QUAN M., LOURENS C.W., MACLACHLAN N.J., GARDNER I.A. & GUTHRIE A.J. (2010). Development and optimisation of
773 a duplex real-time reverse transcription quantitative PCR assay targeting the VP7 and NS2 genes of African horse
774 sickness virus. *J. Virol. Methods*, **167**, 45–52.
- 775 RODRÍGUEZ M., JOSEPH S., PFEFFER M., RAGHAVAN R. & WERNERY U. (2020). Immune response of horses to inactivated
776 African horse sickness vaccines. *BMC Vet. Res.*, **6**, 322. doi: 10.1186/s12917-020-02540-y.
- 777 ~~RODRIGUEZ-SANCHEZ B., FERNANDEZ-PINERO J., SAILLEAU C., ZIENTARA S., BELAK S., ARIAS M. & SANCHEZ-VIZCAINO J.M.
778 (2008). Novel gel-based and real-time PCR assays for the improved detection of African horse sickness virus. *J. Virol.
779 Methods*, **151**, 87–94.~~
- 780 ~~ROY P., HIRASAWA T., FERNANDEZ M., BLINOV V.M. & SANCHEZ-VIZCAINO RODRIGUEZ J.M. (1991). The complete sequence
781 of the group-specific relationship to bluetongue virus. *J. Gen. Virol.*, **72**, 1237–1241.~~
- 782 ROY P., MERTENS P.C. & CASAL I. (1994). African Horse Sickness Structure. *Comp. Immunol. Microb. And Infec. Dis.*,
783 **17**, 243–273.

- 784 RUBIO C., CUBILLO M.A., HOOGHUIS H., SANCHEZ-VIZCAINO J.M., DIAZ-LAVIADA M., PLATEAU E., ZIENTARA S., CRUCIERE C. &
785 HAMBLIN C. (1998). Validation of ELISA for the detection of African horse sickness virus antigens and antibodies. *Arch.*
786 *Virool.* (Suppl.), **14**, 311–315.
- 787 SAILLEAU C., HAMBLIN C., PAWESKA J. & ZIENTARA S. (2000). Identification and differentiation of nine African horse sickness
788 virus serotypes by RT-PCR amplification of the serotype-specific genome segment 2. *J. Gen. Virol.*, **81**, 831–837.
- 789 SAKAMOTO K., PUNYAHOTRA R., MIZUKOSHI N., UEDA S., IMAGAWA H., SUCIURA T., KAMADA M. & FUKUSHO A. (1994).
790 Rapid detection of African horsesickness virus by the reverse transcriptase polymerase chain reaction (RT-PCR)
791 using the amplicon for segment 3 (VP3 gene). *Arch. Virol.*, **36** (1–2), 87–97.
- 792 SANCHEZ-VIZCAINO J.M. (2004). Control and eradication of African horse sickness with vaccine. *In: Control of*
793 *Infectious Diseases by Vaccination*, Schudel A. & Lombard M., eds. *Developments in Biologicals*, **119**, 255–258. S.
794 Karger AG, Basel, Switzerland.
- 795 SCANLEN M., PAWESKA J., VERSCHOOR J. & DIJK A. (2002). The protective efficacy of a recombinant VP2-based African
796 horsesickness subunit vaccine candidate is determined by adjuvant. *Vaccine*, **20**, 1079–1088.
- 797 STONE-MARSCHAT M., CARVILLE A., SKOWRONEK A. & LAEGREID W.W. (1994). Detection of African horse sickness virus
798 by reverse transcription PCR. *J. Clin. Microbiol.*, **32**, 697–700.
- 799 VAN NIEKERK M., VAN STADEN V., VAN DIJK A.A. & HUISMANS H. (2001). Variation of African horsesickness virus
800 nonstructural protein NS3 in southern Africa. *J. Gen. Virol.*, **82**, 149–158.
- 801 VAN DER MEYDEN C.H., ERASMUS B.J., SWANEPOEL R. & PROZESKY O.W. (1992) Encephalitis and chorioretinitis associated
802 with neurotropic African horsesickness virus infection in laboratory workers. Part I. Clinical and neurological
803 observations. S. Afr. Med. J., **81**, 451–454.
- 804 VAN RIJN P.A., MARIS-VELDHUIS M.A., POTGIETER C.A. & VAN GENNIP R.G.P. (2018). African horse sickness virus
805 (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled
806 Infectious Single Animal (DISA) vaccine platform. Vaccine, **36**, 1925–1933.
- 807 VAN SCHALKWYK A., FERREIRA M.L. & ROMITO M. (2019). Using a new serotype-specific polymerase chain reaction
808 (PCR) and sequencing to differentiate between field and vaccine-derived African horse sickness viruses. J. Virol.
809 Methods, **266**, 89–94.
- 810 VENTER M., NAPIER G. & HUISMANS H. (2000). Cloning, sequencing and expression of the gene that encodes the
811 major neutralisation-specific antigen of Africa horsesickness virus serotype 9. *J. Virol. Methods*, **86**, 41–53.
- 812 VERWOERD D.W., HUISMANS H., ERASMUS B.J. (1979). Orbiviruses. *In: Comprehensive Virology*, Fraenkel-Conrat H.,
813 Wagner R.R., eds. Plenum Press, London, UK, Vol. **14**, 285–345.
- 814 VILLALBA R., TENA-TOMÁS C., RUANO M. J., VALERO-LORENZO M., LÓPEZ-HERRANZ A. & AGÜERO M. (2024).
815 Development and validation of three triplex Real-Time RT-PCR assays for typing African Horse Sickness virus:
816 utility for disease control and other laboratory applications. Viruses, **16**, 470.
- 817 WADE-EVANS A., WOOLHOUSE T., O'HARA R. & HAMBLIN C. (1993). The use of African horse sickness virus VP7
818 antigen, synthesised in bacteria, and anti-VP7 monoclonal antibodies in a competitive ELISA. *J. Virol. Methods*, **45**,
819 179–188.
- 820 WEYER C.T., GREWAR J.D., BURGER P., JOONE C., LOURENS C., MACLACHLAN N.J. & GUTHRIE A.J. (2017). Dynamics of
821 African horse sickness virus nucleic acid and antibody in horses following immunization with a commercial
822 polyvalent live attenuated vaccine. Vaccine, **35**, 2504–2510.
- 823 WEYER C.T., JOONE C., LOURENS C.W., MONYAI M.S., KOEKEMOER O., GREWAR J.D., VAN SCHALKWYK A., MAJIWA P.O.,
824 MACLACHLAN N.J. & GUTHRIE A.J. (2015). Development of three triplex real-time reverse transcription PCR assays
825 for the qualitative molecular typing of the nine serotypes of African horse sickness virus. *J. Virol. Methods*, **223**, 69–
826 74.
- 827 WILLIAMS C.F., INOUE T., LUCAS A.M., ZANOTTO P.M. & ROY Y.P. (1998). The complete sequence of four major
828 structural proteins of African horse sickness virus serotype 6: evolutionary relationship within and between the
829 orbivirus. *Virus Res.*, **53**, 53–73.

830 WORLD ORGANISATION FOR ANIMAL HEALTH (WOAH) (2010). African horse sickness. *In: Atlas of Transboundary Animal*
831 *Diseases*, Fernandez P.J. & White W.R., eds. WOA, Paris, France, 12–18.

832 ZIENTARA S., SAILLEAU C., MOULAY S. & CRUCIERE C. (1994). Diagnosis of the African horse sickness virus serotype
833 4 by a one-tube, one manipulation RT-PCR reaction from infected organs. *J. Virol. Methods*, **46**, 179–188.

834 *

* *

836 **NB:** There are WOA Reference Laboratories for African horse sickness (please consult the WOA Web site:
837 <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>).
838 Please contact the WOA Reference Laboratories for any further information on
839 diagnostic tests, reagents and vaccines for African horse sickness

840 **NB:** FIRST ADOPTED IN 1991. MOST RECENT UPDATES ADOPTED IN 2019.

841
842

Appendix 1: African horse sickness
Intended purpose of test: population freedom from infection

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Identification of the agent</u>							
<u>Real-time RT-PCR + Equids</u>	<u>EDTA blood/tissue (VP7)</u>	(1) <u>Dse 97% DSp 100%</u> (2) <u>Dse > 99.9% DSp > 97.8%</u>	(1) <u>186 known negatives and 132 known positive samples</u> (2) <u>503 equine blood samples collected from suspect cases; two separate healthy populations of horses (503 and 98 horses) were used as negative cases</u>	(1) <u>Validation report done at LCV (EURL), sent to WOAAH and published in WOAAH Bulletin n° 2016-1</u> (2) <u>Validation report done at CVR (WOAH-RL), sent to WOAAH and published in Guthrie <i>et al.</i> (2013)</u>	- <u>High sensitivity, specificity and reproducibility</u> - <u>High throughput</u> - <u>Minimal risk of cross contamination</u> - <u>Applicable to uninfected samples allowing viral genome to be detected even after the viraemic window as well as in poor condition or inactivated samples</u>	- <u>Expensive equipment</u> - <u>Expensive reagents</u> - <u>Surviving animals present shorter periods of viraemia in comparison with antibodies</u> - <u>Detection of viral genome in animals vaccinated with live attenuated AHS vaccines has been described up to 16 weeks after vaccination</u>	(1) <u>Agüero <i>et al.</i> (2008)</u> (2) <u>Guthrie <i>et al.</i> (2013)</u> <u>Quan <i>et al.</i> (2010)</u>
<u>Agarose gel-based RT-PCR +</u>	<u>EDTA blood/tissue (VP7)</u>	<u>Not available</u>	<u>Not available</u>		- <u>Less expensive instruments than those used in real-time RT-PCR</u> - <u>High sensitivity, specificity and reproducibility</u> - <u>Applicable to uninfected samples</u>	- <u>Longer analysis time than real-time RT-PCR</u> - <u>Not suitable for high throughput analysis</u> - <u>Risk of cross contamination</u> - <u>Surviving animals present shorter periods of viraemia in comparison with antibodies</u>	<u>Zientara <i>et al.</i> (1994)</u>
<u>Virus isolation –</u>	<u>EDTA blood/tissue</u>	<u>DSe ≥ 50% DSp > 99%</u>	- <u>91 BTV positive blood samples collected from naturally infected animals during BTV outbreaks in Spain in 2007–2018 (validation done jointly for all Orbiviruses)</u> - <u>12 tissue samples from horses experimentally infected with AHSV-9</u>	<u>Dossier for Verification of the Orbivirus isolation carried out at LCV (EURL)</u>	- <u>Detection of infectious virus</u> - <u>Getting available isolates for further studies</u>	- <u>Time consuming</u> - <u>Laborious</u> - <u>Requirement for samples from viraemic period</u> - <u>Requirement for well conserved samples</u> - <u>Biosafety laboratory consideration BLS3</u>	

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
						- Requirement for cell cultures - Low sensitivity	
<u>Detection of immune response</u>							
<u>ELISA (serogroup specific based on VP7) +++ Equids</u>	<u>Serum (antibodies against VP7)</u>	(1) DSe ≥ 95% DSp > 99% (2) DSe > 99% Dsp > 99%	(1, 2) <u>Goat, sheep and guinea-pig sera from animals inoculated with AHS1-AHS9</u> (1) <u>Nine sera from horse naturally infected and positive by VN</u> (1) <u>152 sera from horses vaccinated and serotyped by VN</u> (1, 2) <u>Sera from horses from free areas (512, 1015)</u> (1) <u>24 bovine pos to BTV, 20 horse sera pos to EA and nine deer sera pos to EHDV</u> (1) <u>Seven sera from the WOAHA reference collection, from different equidae species and in different levels of positivity</u> (1) <u>Seven sera from two experimentally infected horses with AHS9</u> (1) <u>70 samples from the EU-RL proficiency tests organised from 2014 to 2020</u> (1) <u>129 pos sera from vaccinated or experimentally or naturally infected Equidae, and 57 neg sera from naïve equidae</u>	(1, 2) <u>Manufacturer's validated method certificates</u> (1) <u>Dossier for Verification of blocking ELISA for detection of antibodies against African horse sickness virus carried out at LCV (EU-RL). Stage 3 of validation (PT) published in Durán-Ferrer <i>et al.</i> (2019)</u>	- <u>High sensitivity and specificity</u> - <u>Commercially available (both B-ELISA and I-ELISA)</u> - <u>Cost-effective</u> - <u>VP7 is highly conserved among serotypes</u> - <u>Long lasting of presence of antibodies in affected animals</u>	- <u>Unable to differentiate vaccinated from infected animals</u> - <u>Unable to differentiate serotype specificity of the antibodies</u>	(1) <u>B-ELISA INGEZIM AHSV Compac Plus 2.0 (Gold Standard Diagnostics); Durán-Ferrer <i>et al.</i> (2019)</u> (2) <u>I-ELISA IDScreen African horse sickness indirect (IDVET)</u>
<u>VN + Equids</u>	<u>Serum (neutralising serotype-specific antibodies against VP2)</u>	<u>DSe: > 95% (infected animals)</u> <u>DSp > 99%</u>	(1) <u>18 sera from sheep experimentally inoculated with AHS1-AHS9</u> (2) <u>Seven sera from two experimentally infected horses with AHS9</u>	<u>Dossier for Verification of the Orbivirus Seroneutralisation Test carried out at LCV (EU-RL)</u>	- <u>Allows serotyping from serum samples</u>	- <u>Unable to differentiate vaccinated from infected animals</u> - <u>Depends on the availability of live virus strains of all serotypes and susceptible cultured cells</u> - <u>Cross-reactions may appear between serotypes</u> - <u>Time consuming</u> - <u>Laborious</u> - <u>Biosafety laboratory consideration BLS3</u>	

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
CFT + Equids	Serum	Not available	Not available	Not available	- Useful in recent infections or vaccination	- High number of sera presenting anticomplementary activity - Less sensitivity than ELISA - Less degree of standardisation than ELISA	

Appendix 2: African horse sickness
Intended purpose of test: individual animal freedom from infection prior to movement*

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Identification of the agent</u>							
<u>Real-time RT-PCR +++ Equids</u>	<u>EDTA blood/tissue (VP7)</u>	(1) <u>Dse 97% Dsp 100%</u> (2) <u>Dse > 99.9% Dsp > 97.8%</u>	(1) <u>186 known negatives and 132 known positive samples</u> (2) <u>503 equine blood samples collected from suspect cases; two separate healthy populations of horses (503 and 98 horses) were used as negative cases</u>	(1) <u>Validation report done at LCV (EURL), sent to WOAAH and published in WOAAH Bulletin n° 2016-1</u> (2) <u>Validation report done at CVR (WOAH-RL), sent to WOAAH and published in Guthrie et al. (2013)</u>	- <u>High sensitivity, specificity and reproducibility</u> - <u>Rapid technique</u> - <u>Minimal risk of cross contamination</u> - <u>Applicable to uninfected samples allowing viral genome to be detected even after the viraemic window as well as in poor condition or inactivated samples</u>	- <u>Expensive equipment</u> - <u>Expensive reagents</u> - <u>Surviving animals present shorter periods of viraemia in comparison with antibodies</u> - <u>Detection of viral genome in animals vaccinated with live attenuated AHS vaccines has been described up to 16 weeks after vaccination</u> - <u>Discordant results are possible in the case of weak positive samples</u>	(1) <u>Agüero et al. (2008)</u> (2) <u>Guthrie et al. (2013)</u> <u>Quan et al., (2010)</u>
<u>Agarose gel-based RT-PCR ++</u>	<u>EDTA blood/tissue (VP7)</u>	<u>Not available</u>	<u>Not available</u>		- <u>Less expensive instruments than those used in real-time RT-PCR</u> - <u>High sensitivity, specificity and reproducibility</u> - <u>Rapid technique</u> - <u>Applicable to uninfected samples</u>	- <u>Longer analysis time than real-time RT-PCR</u> - <u>Risk of cross contamination</u> - <u>Surviving animals present shorter periods of viraemia in comparison with antibodies</u>	<u>Zientara et al. (1994)</u>
<u>Virus isolation –+</u>	<u>EDTA blood/tissue</u>	<u>DSe ≥ 50% Dsp > 99%</u>	- <u>91 BTV positive blood samples collected from naturally infected animals during BTV outbreaks in Spain in 2007–2018 (validation done jointly for all Orbiviruses)</u> - <u>12 tissue samples from horses experimentally infected with AHSV-9</u>	<u>Dossier for Verification of the Orbivirus isolation carried out at LCV (EURL)</u>	- <u>Detection of infectious virus</u>	- <u>Time consuming</u> - <u>Laborious</u> - <u>Requirement for well conserved samples</u> - <u>Biosafety laboratory consideration BLS3</u> - <u>Requirement for cell cultures</u> - <u>Low sensitivity</u>	

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>*Detection of immune response</u>							
<u>ELISA (serogroup specific based on VP7) +++ Equids</u>	<u>Serum (antibodies against VP7)</u>	(1) <u>DSe ≥ 95%</u> <u>DSp > 99%</u> (2) <u>DSe > 99%</u> <u>Dsp > 99%</u>	(1, 2) <u>Goat, sheep and guinea-pig sera from animals inoculated with AHS1-AHS9</u> (1) <u>Nine sera from horse naturally infected and positive by VN</u> (1) <u>152 sera from horses vaccinated and serotyped by VN</u> (1, 2) <u>Sera from horses from free areas (512, 1015)</u> (1) <u>24 bovine pos to BTV, 20 horse sera pos to FA and nine deer sera pos to EHDV</u> (1) <u>Seven sera from the WOA reference collection, from different equidae species and in different levels of positivity</u> (1) <u>Seven sera from two experimentally infected horses with AHS9</u> (1) <u>70 samples from the EU-RL proficiency tests organised from 2014 to 2020</u> (1) <u>129 pos sera from vaccinated or experimentally or naturally infected equidae, and 57 neg sera from naïve equidae</u>	(1, 2) <u>Manufacturer's validated method certificates</u> (1) <u>Dossier for Verification of blocking ELISA for detection of antibodies against African horse sickness virus carried out at LCV (EU-RL). Stage 3 of validation (PT) published in Durán-Ferrer et al. (2019)</u>	- <u>High sensitivity and specificity</u> - <u>Commercially available (both B-ELISA and I-ELISA)</u> - <u>Cost-effective</u> - <u>VP7 is highly conserved among serotypes</u> - <u>Long lasting of presence of antibodies in affected animals</u>	- <u>Unable to differentiate vaccinated from infected animals</u> - <u>Seroconversion takes place after at least 8–12 d.p.i.</u>	(1) <u>B-ELISA INGEZIM AHSV Compac Plus 2.0 (Gold Standard Diagnostics); Durán-Ferrer et al. (2019)</u> (2) <u>I-ELISA IDScreen African horse sickness indirect (IDVET)</u>
<u>VN + Equids</u>	<u>Serum (neutralising serotype-specific antibodies against VP2)</u>	<u>DSe: > 95%</u> <u>(infected animals)</u> <u>DSp > 99%</u>	(1) <u>18 sera from sheep experimentally inoculated with AHS1–AHS9</u> (2) <u>Seven sera from two experimentally infected horses with AHS9</u>	<u>Dossier for Verification of the Orbivirus Seroneutralisation Test carried out at LCV (EU-RL)</u>	- <u>Allows serotyping from serum samples</u>	- <u>Unable to differentiate vaccinated from infected animals</u> - <u>Depends on the availability of live virus strains of all serotypes and susceptible cultured cells</u> - <u>Cross-reactions may appear between serotypes</u> - <u>Time consuming</u> - <u>Laborious</u> - <u>Biosafety laboratory consideration BLS3</u>	

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
CFT + Equids	Serum	Not available	Not available	Not available	- Useful in recent infections or vaccination	- High number of sera presenting anticomplementary activity - Less sensitivity than ELISA - Less degree of standardisation than ELISA	

845 *For serological tests, paired samples may be required as recommended in the *Terrestrial Code* Chapter 12.1. 'Infection with African horse sickness virus', Article 12.1.7 'Recommendations for
846 importation from AHS infected countries or zones'

847
848

Appendix 3: African horse sickness
Intended purpose of test: contribute to eradication policies

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Identification of the agent</u>							
<u>Real-time RT-PCR +++ Equids</u>	<u>EDTA blood/tissue (VP7)</u>	<u>(1) Dse 97% DSp 100%</u> <u>(2) Dse > 99.9% DSp > 97.8%</u>	<u>(1) 186 known negatives and 132 known positive samples</u> <u>(2) 503 equine blood samples collected from suspect cases; two separate healthy populations of horses (503 and 98 horses) were used as negative cases</u>	<u>(1) Validation report done at LCV (EURL), sent to WOAAH and published in WOAAH Bulletin n° 2016-1</u> <u>(2) Validation report done at CVR (WOAH-RL), sent to WOAAH and published in Guthrie et al. (2013)</u>	<u>- High sensitivity, specificity and reproducibility</u> <u>- High throughput</u> <u>- Rapid technique</u> <u>- Minimal risk of cross contamination</u> <u>- Applicable to uninfected samples allowing viral genome to be detected even after the viraemic window as well as in poor condition or inactivated samples</u>	<u>- Expensive equipment</u> <u>- Expensive reagents</u> <u>- Surviving animals present shorter periods of viraemia in comparison with antibodies</u> <u>- Detection of viral genome in animals vaccinated with live attenuated AHS vaccines has been described up to 16 weeks after vaccination</u>	<u>(1) Agüero et al. (2008)</u> <u>(2) Guthrie et al. (2013)</u> <u>Quan et al., (2010)</u>
<u>Agarose gel-based RT-PCR ++</u>	<u>EDTA blood/tissue (VP7)</u>	<u>Not available</u>	<u>Not available</u>		<u>- Less expensive instruments than those used in real-time RT-PCR</u> <u>- High sensitivity, specificity and reproducibility</u> <u>- Rapid technique</u> <u>- Applicable to uninfected samples</u>	<u>- Longer analysis time than real-time RT-PCR</u> <u>- Not suitable for high throughput analysis</u> <u>- Risk of cross contamination</u> <u>- Surviving animals present shorter periods of viraemia in comparison with antibodies</u>	<u>Zientara et al. (1994)</u>
<u>Virus isolation –</u>	<u>EDTA blood/tissue</u>	<u>DSe ≥ 50% DSp > 99%</u>	<u>- 91 BTV positive blood samples collected from naturally infected animals during BTV outbreaks in Spain in 2007–2018 (validation done jointly for all Orbiviruses)</u> <u>- 12 tissue samples from horses experimentally infected with AHSV-9</u>	<u>Dossier for Verification of the Orbivirus isolation carried out at LCV (EURL)</u>	<u>- Detection of infectious virus</u> <u>- Getting available isolates for further studies</u>	<u>- Time consuming</u> <u>- Laborious</u> <u>- Requirement for samples from viraemic period</u> <u>- Requirement for well conserved samples</u> <u>- Biosafety laboratory consideration BLS3</u> <u>- Requirement for cell</u>	

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
						<u>cultures</u> - <u>Low sensitivity</u>	
<u>Detection of immune response</u>							
<u>ELISA (serogroup specific based on VP7) ++</u> <u>Equids</u>	<u>Serum (antibodies against VP7)</u>	<u>(1) DSe ≥ 95%</u> <u>DSp > 99%</u> <u>(2) DSe > 99%</u> <u>Dsp > 99%</u>	<u>(1, 2) Goat, sheep and guinea-pig sera from animals inoculated with AHS1-AHS9</u> <u>(1) Nine sera from horse naturally infected and positive by VN</u> <u>(1) 152 sera from horses vaccinated and serotyped by VN</u> <u>(1, 2) Sera from horses from free areas (512, 1015)</u> <u>(1) 24 bovine pos to BTV, 20 horse sera pos to EA and nine deer sera pos to EHDV</u> <u>(1) Seven sera from the WOA reference collection, from different equidae species and in different levels of positivity</u> <u>(1) Seven sera from two experimentally infected horses with AHS9</u> <u>(1) 70 samples from the EU-RL proficiency tests organised from 2014 to 2020</u> <u>(1) 129 pos sera from vaccinated or experimentally or naturally infected equidae, and 57 neg sera from naive equidae</u>	<u>(1, 2) Manufacturer's validated method certificates</u> <u>(1) Dossier for Verification of blocking ELISA for detection of antibodies against African horse sickness virus carried out at LCV (EU-RL). Stage 3 of validation (PT) published in Durán-Ferrer <i>et al.</i> (2019)</u>	- <u>High sensitivity and specificity</u> - <u>Commercially available (both B-ELISA and I-ELISA)</u> - <u>Cost-effective</u> - <u>VP7 is highly conserved among serotypes</u> - <u>Long lasting of presence of antibodies in affected animals</u>	- <u>Unable to differentiate vaccinated from infected animals</u> - <u>Unable to differentiate serotype specificity of the antibodies</u> - <u>Seroconversion takes place after at least 8–12 d.p.i.</u>	<u>(1) B-ELISA INGEZIM AHSV Compac Plus 2.0 (Gold Standard Diagnostics); Durán-Ferrer <i>et al.</i> (2019)</u> <u>(2) I-ELISA IDScreen African horse sickness indirect (IDVET)</u>
<u>VN –</u> <u>Equids</u>	<u>Serum (neutralising serotype-specific antibodies against VP2)</u>	<u>DSe: > 95%</u> <u>(infected animals)</u> <u>DSp > 99%</u>	<u>(1) 18 sera from sheep experimentally inoculated with AHS1–AHS9</u> <u>(2) Seven sera from two experimentally infected horses with AHS9</u>	<u>Dossier for Verification of the Orbivirus Seroneutralisation Test carried out at LCV (EU-RL)</u>	- <u>Allows serotyping from serum samples</u>	- <u>Unable to differentiate vaccinated from infected animals</u> - <u>Depends on the availability of live virus strains of all serotypes and susceptible cultured cells</u> - <u>Cross-reactions may appear between serotypes</u> - <u>Time consuming</u> - <u>Laborious</u>	

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
						- Biosafety laboratory consideration BLS3	
<u>CFT + Equids</u>	<u>Serum</u>	<u>Not available</u>	<u>Not available</u>	<u>Not available</u>	- Useful in recent infections or vaccination	- High number of sera presenting anticomplementary activity - Less sensitivity than ELISA - Less degree of standardisation than ELISA	

Appendix 4: African horse sickness
Intended purpose of test: confirmation of clinical cases

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Identification of the agent</u>							
<u>Real-time RT-PCR +++</u> Equids	<u>EDTA blood/tissue (VP7)</u>	(1) <u>Dse 97%</u> <u>DSp 100%</u> (2) <u>Dse > 99.9%</u> <u>DSp > 97.8%</u>	(1) <u>186 known negatives and 132 known positive samples</u> (2) <u>503 equine blood samples collected from suspect cases; two separate healthy populations of horses (503 and 98 horses) were used as negative cases</u>	(1) <u>Validation report done at LCV (EURL), sent to WOAAH and published in WOAAH Bulletin n° 2016-1</u> (2) <u>Validation report done at CVR (WOAH-RL), sent to WOAAH and published in Guthrie et al. (2013)</u>	- <u>High sensitivity, specificity and reproducibility</u> - <u>High throughput</u> - <u>Rapid technique</u> - <u>Minimal risk of cross contamination</u> - <u>Applicable to uninfected samples allowing viral genome to be detected even after the viraemic window as well as in poor condition or inactivated samples</u>	- <u>Expensive equipment</u> - <u>Expensive reagents</u> - <u>Surviving animals present shorter periods of viraemia in comparison with antibodies</u> - <u>Detection of viral genome in animals vaccinated with live attenuated AHS vaccines has been described up to 16 weeks after vaccination</u>	(1) <u>Agüero et al. (2008)</u> (2) <u>Guthrie et al. (2013)</u> <u>Quan et al., (2010)</u>
<u>Agarose gel-based RT-PCR ++</u>	<u>EDTA blood/tissue (VP7)</u>	<u>Not available</u>	<u>Not available</u>		- <u>Less expensive instruments than those used in real-time RT-PCR</u> - <u>High sensitivity, specificity and reproducibility</u> - <u>Rapid technique</u> - <u>Applicable to uninfected samples</u>	- <u>Longer analysis time than real-time RT-PCR</u> - <u>Not suitable for high throughput analysis</u> - <u>Risk of cross contamination</u> - <u>Surviving animals present shorter periods of viraemia in comparison with antibodies</u>	<u>Zientara et al. (1994)</u>
<u>Virus isolation +++</u>	<u>EDTA blood/tissue</u>	<u>DSe ≥ 50%</u> <u>DSp > 99%</u>	- <u>91 BTV positive blood samples collected from naturally infected animals during BTV outbreaks in Spain in 2007–2018 (validation done jointly for all Orbiviruses)</u> - <u>12 tissue samples from horses experimentally infected with AHSV-9</u>	<u>Dossier for Verification of the Orbivirus isolation carried out at LCV (EURL)</u>	- <u>Detection of infectious virus</u> - <u>Getting available isolates for further studies</u>	- <u>Time consuming</u> - <u>Laborious</u> - <u>Requirement for samples from viraemic period</u> - <u>Requirement for well conserved samples</u> - <u>Biosafety laboratory consideration BLS3</u> - <u>Requirement for cell cultures</u> - <u>Low sensitivity</u>	

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Detection of immune response</u>							
<u>ELISA (serogroup specific based on VP7) + Equids</u>	<u>Serum (antibodies against VP7)</u>	(1) <u>DSe ≥ 95%</u> <u>DSp > 99%</u> (2) <u>DSe > 99%</u> <u>Dsp > 99%</u>	(1, 2) <u>Goat, sheep and guinea-pig sera from animals inoculated with AHS1-AHS9</u> (1) <u>Nine sera from horse naturally infected and positive by VN</u> (1) <u>152 sera from horses vaccinated and serotyped by VN</u> (1, 2) <u>Sera from horses from free areas (512, 1015)</u> (1) <u>24 bovine pos to BTV, 20 horse sera pos to FA and nine deer sera pos to EHDV</u> (1) <u>Seven sera from the WOAHS reference collection, from different equidae species and in different levels of positivity</u> (1) <u>Seven sera from two experimentally infected horses with AHS9</u> (1) <u>70 samples from the EU-RL proficiency tests organised from 2014 to 2020</u> (1) <u>129 pos sera from vaccinated or experimentally or naturally infected equidae, and 57 neg sera from naïve equidae</u>	(1, 2) <u>Manufacturer's validated method certificates</u> (1) <u>Dossier for Verification of blocking ELISA for detection of antibodies against African horse sickness virus carried out at LCV (EU-RL). Stage 3 of validation (PT) published in Durán-Ferrer et al. (2019)</u>	- <u>High sensitivity and specificity</u> - <u>Commercially available (both B-ELISA and I-ELISA)</u> - <u>Cost-effective</u> - <u>VP7 is highly conserved among serotypes</u>	- <u>Unable to differentiate vaccinated from infected animals</u> - <u>Unable to differentiate serotype specificity of the antibodies</u> - <u>Seroconversion takes place after at least 8–12 d.p.i.</u>	(1) <u>B-ELISA INGEZIM AHSV Compac Plus 2.0 (Gold Standard Diagnostics); Durán-Ferrer et al. (2019)</u> (2) <u>I-ELISA IDScreen African horse sickness indirect (IDVET)</u>
<u>VN + Equids</u>	<u>Serum (neutralising serotype-specific antibodies against VP2)</u>	<u>DSe: > 95%</u> <u>(infected animals)</u> <u>DSp > 99%</u>	(1) <u>18 sera from sheep experimentally inoculated with AHS1–AHS9</u> (2) <u>Seven sera from two experimentally infected horses with AHS9</u>	<u>Dossier for Verification of the Orbivirus Seroneutralisation Test carried out at LCV (EU-RL)</u>	- <u>Allows serotyping from serum samples</u>	- <u>Unable to differentiate vaccinated from infected animals</u> - <u>Depends on the availability of live virus strains of all serotypes and susceptible cultured cells</u> - <u>Cross-reactions may appear between serotypes</u> - <u>Time consuming</u> - <u>Laborious</u> - <u>Biosafety laboratory consideration BLS3</u>	

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
CFT + Equids	Serum	Not available	Not available	Not available	- Useful in recent infections or vaccination	- High number of sera presenting anticomplementary activity -Less sensitivity than ELISA -Less degree of standardisation than ELISA	

851

852

Appendix 5: African horse sickness
Intended purpose of test: prevalence of infection – surveillance

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Identification of the agent</u>							
<u>Real-time RT-PCR ++ Equids</u>	<u>EDTA blood/tissue (VP7)</u>	(1) <u>Dse 97% DSp 100%</u> (2) <u>Dse > 99.9% DSp > 97.8%</u>	(1) <u>186 known negatives and 132 known positive samples</u> (2) <u>503 equine blood samples collected from suspect cases; two separate healthy populations of horses (503 and 98 horses) were used as negative cases</u>	(1) <u>Validation report done at LCV (EURL), sent to WOAAH and published in WOAAH Bulletin n° 2016-1</u> (2) <u>Validation report done at CVR (WOAH-RL), sent to WOAAH and published in Guthrie et al. (2013)</u>	- <u>High sensitivity, specificity and reproducibility</u> - <u>High throughput</u> - <u>Rapid technique</u> - <u>Minimal risk of cross contamination</u> - <u>Applicable to uninfected samples allowing viral genome to be detected even after the viraemic window as well as in poor condition or inactivated samples</u>	- <u>Expensive equipment</u> - <u>Expensive reagents</u> - <u>Surviving animals present shorter periods of viraemia in comparison with antibodies</u> - <u>Detection of viral genome in animals vaccinated with live attenuated AHS vaccines has been described up to 16 weeks after vaccination</u>	(1) <u>Agüero et al. (2008)</u> (2) <u>Guthrie et al. (2013)</u> <u>Quan et al., (2010)</u>
<u>Agarose gel-based RT-PCR +</u>	<u>EDTA blood/tissue (VP7)</u>	<u>Not available</u>	<u>Not available</u>		- <u>Less expensive instruments than those used in real-time RT-PCR</u> - <u>High sensitivity, specificity and reproducibility</u> - <u>Rapid technique</u> - <u>Applicable to uninfected samples</u>	- <u>Longer analysis time than real-time RT-PCR</u> - <u>Not suitable for high throughput analysis</u> - <u>Risk of cross contamination</u> - <u>Surviving animals present shorter periods of viraemia in comparison with antibodies</u>	<u>Zientara et al. (1994)</u>
<u>Virus isolation –</u>	<u>EDTA blood/tissue</u>	<u>DSe ≥ 50% DSp > 99%</u>	- <u>91 BTV positive blood samples collected from naturally infected animals during BTV outbreaks in Spain in 2007–2018 (validation done jointly for all Orbiviruses)</u> - <u>12 tissue samples from horses experimentally infected with AHSV-9</u>	<u>Dossier for Verification of the Orbivirus isolation carried out at LCV (EURL)</u>	- <u>Detection of infectious virus</u> - <u>Getting available isolates for further studies</u>	- <u>Time consuming</u> - <u>Laborious</u> - <u>Requirement for samples from viraemic period</u> - <u>Requirement for well conserved samples</u> - <u>Biosafety laboratory consideration BLS3</u> - <u>Requirement for cell cultures</u> - <u>Low sensitivity</u>	

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Detection of immune response</u>							
<u>ELISA (serogroup specific based on VP7) +++ Equids</u>	<u>Serum (antibodies against VP7)</u>	<u>(1) DSe ≥ 95% DSp > 99%</u> <u>(2) DSe > 99% Dsp > 99%</u>	<u>(1, 2) Goat, sheep and guinea-pig sera from animals inoculated with AHS1-AHS9</u> <u>(1) Nine sera from horse naturally infected and positive by VN</u> <u>(1) 152 sera from horses vaccinated and serotyped by VN</u> <u>(1, 2) Sera from horses from free areas (512, 1015)</u> <u>(1) 24 bovine pos to BTV, 20 horse sera pos to EA and nine deer sera pos to EHDV</u> <u>(1) Seven sera from the WOA reference collection, from different equidae species and in different levels of positivity</u> <u>(1) Seven sera from two experimentally infected horses with AHS9</u> <u>(1) 70 samples from the EU-RL proficiency tests organised from 2014 to 2020</u> <u>(1) 129 pos sera from vaccinated or experimentally or naturally infected equidae, and 57 neg sera from naïve equidae</u>	<u>(1, 2) Manufacturer's validated method certificates</u> <u>(1) Dossier for Verification of blocking ELISA for detection of antibodies against African horse sickness virus carried out at LCV (EU-RL). Stage 3 of validation (PT) published in Durán-Ferrer et al. (2019)</u>	<u>- High sensitivity and specificity</u> <u>- Commercially available (both B-ELISA and I-ELISA)</u> <u>- Cost-effective</u> <u>- VP7 is highly conserved among serotypes</u>	<u>- Unable to differentiate vaccinated from infected animals</u> <u>- Unable to differentiate serotype specificity of the antibodies</u> <u>- Seroconversion takes place after at least 8–12 d.p.i.</u>	<u>(1) B-ELISA INGEZIM AHSV Compac Plus 2.0 (Gold Standard Diagnostics); Durán-Ferrer et al. (2019)</u> <u>(2) I-ELISA IDScreen African horse sickness indirect (IDVET)</u>
<u>VN ± Equids</u>	<u>Serum (neutralising serotype-specific antibodies against VP2)</u>	<u>DSe: > 95% (infected animals)</u> <u>DSp > 99%</u>	<u>(1) 18 sera from sheep experimentally inoculated with AHS1-AHS9</u> <u>(2) Seven sera from two experimentally infected horses with AHS9</u>	<u>Dossier for Verification of the Orbivirus Seroneutralisation Test carried out at LCV (EU-RL)</u>	<u>- Allows serotyping from serum samples</u>	<u>- Unable to differentiate vaccinated from infected animals</u> <u>- Depends on the availability of live virus strains of all serotypes and susceptible cultured cells</u> <u>- Cross-reactions may appear between serotypes</u> <u>- Time consuming</u> <u>- Laborious</u> <u>- Biosafety laboratory consideration BLS3</u>	

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>CFT + Equids</u>	<u>Serum</u>	<u>Not available</u>	<u>Not available</u>	<u>Not available</u>	<u>- Useful in recent infections or vaccination</u>	<u>- High number of sera presenting anticomplementary activity</u> <u>- Less sensitivity than ELISA</u> <u>- Less degree of standardisation than ELISA</u>	

Appendix 6: African horse sickness**Intended purpose of test: immune status in individual animals or populations post-vaccination**

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Identification of the agent</u>							
<u>Real-time RT-PCR</u> = Equids	<u>EDTA blood/tissue (VP7)</u>	(1) <u>Dse 97%</u> <u>DSp 100%</u> (2) <u>Dse > 99.9%</u> <u>DSp > 97.8%</u>	(1) <u>186 known negatives and 132 known positive samples</u> (2) <u>503 equine blood samples collected from suspect cases; two separate healthy populations of horses (503 and 98 horses) were used as negative cases</u>	(1) <u>Validation report done at LCV (EURL), sent to WOAAH and published in WOAAH <i>Bulletin</i> n° 2016-1</u> (2) <u>Validation report done at CVR (WOAH-RL), sent to WOAAH and published in Guthrie <i>et al.</i> (2013)</u>	- None for this purpose	- Not suitable for this purpose	(1) <u>Agüero <i>et al.</i> (2008)</u> (2) <u>Guthrie <i>et al.</i> (2013)</u> <u>Quan <i>et al.</i>, (2010)</u>
<u>Agarose gel-based RT-PCR –</u>	<u>EDTA blood/tissue (VP7)</u>	<u>Not available</u>	<u>Not available</u>		- None for this purpose	- Not suitable for this purpose	<u>Zientara <i>et al.</i> (1994)</u>
<u>Virus isolation –</u>	<u>EDTA blood/tissue</u>	<u>DSe ≥ 50%</u> <u>DSp > 99%</u>	- <u>91 BTV positive blood samples collected from naturally infected animals during BTV outbreaks in Spain in 2007–2018 (validation done jointly for all Orbiviruses)</u> - <u>12 tissue samples from horses experimentally infected with AHSV-9</u>	<u>Dossier for Verification of the Orbivirus isolation carried out at LCV (EURL)</u>	- None for this purpose	- Not suitable for this purpose	
<u>Detection of immune response</u>							
<u>ELISA (serogroup specific based on VP7) ++</u> Equids	<u>Serum (antibodies against VP7)</u>	(1) <u>DSe ≥ 95%</u> <u>DSp > 99%</u> (2) <u>DSe > 99%</u> <u>Dsp > 99%</u>	(1, 2) <u>Goat, sheep and guinea-pig sera from animals inoculated with AHS1-AHS9</u> (1) <u>Nine sera from horse naturally infected and positive by VN</u> (1) <u>152 sera from horses vaccinated and serotyped by VN</u> (1, 2) <u>Sera from horses from free areas (512, 1015)</u> (1) <u>24 bovine pos to BTV,</u> <u>20 horse sera pos to EA and nine deer sera pos to EHDV</u> (1) <u>Seven sera from the WOAAH</u>	(1, 2) <u>Manufacturer's validated method certificates</u> (1) <u>Dossier for Verification of blocking ELISA for detection of antibodies against African horse sickness virus carried out at LCV (EU-RL), Stage 3 of validation (PT) published in Durán-Ferrer <i>et al.</i> (2019)</u>	- <u>High sensitivity and specificity</u> - <u>Commercially available (both B-ELISA and I-ELISA)</u> - <u>Cost-effective</u> - <u>VP7 is highly conserved among serotypes</u> - <u>Long lasting of presence of</u>	- <u>Unable to differentiate serotype specificity of the antibodies</u> - <u>Seroconversion takes place after at least 8–12 d.p.i.</u>	(1) <u>B-ELISA INGEZIM AHSV Compac Plus 2.0 (Gold Standard Diagnostics); Durán-Ferrer <i>et al.</i> (2019)</u> (2) <u>I-ELISA IDScreen African horse sickness indirect (IDVET)</u>

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
			reference collection, from different Equidae species and in different levels of positivity (1) Seven sera from two experimentally infected horses with AHS9 (1) 70 samples from the EU-RL proficiency tests organised from 2014 to 2020 (1) 129 pos sera from vaccinated or experimentally or naturally infected Equidae, and 57 neg sera from naïve, equidae		antibodies in affected animals		
<u>VN +++ Equids</u>	<u>Serum (neutralising serotype-specific antibodies against VP2)</u>	<u>DSe: > 95% (infected animals)</u> <u>DSp > 99%</u>	(1) 18 sera from sheep experimentally inoculated with AHS1–AHS9 (2) Seven sera from two experimentally infected horses with AHS9	<u>Dossier for Verification of the Orbivirus Seroneutralisation Test carried out at LCV (EU-RL)</u>	- Allows serotyping from serum samples	- Depends on the availability of live virus strains of all serotypes and susceptible cultured cells - Cross-reactions may appear between serotypes - Time consuming - Laborious - Biosafety laboratory consideration BLS3	
<u>CFT + Equids</u>	<u>Serum</u>	<u>Not available</u>	<u>Not available</u>	<u>Not available</u>	- Useful in recent infections or vaccination	- High number of sera presenting anticomplementary activity - Less sensitivity than ELISA - Less degree of standardisation than ELISA	

CHAPTER 3.6.5.

EQUINE INFECTIOUS ANAEMIA

SUMMARY

Equine infectious anaemia (EIA) is a persistent viral infection of equids. The causative agent, EIA virus (EIAV) is a lentivirus in the family Retroviridae, subfamily Orthoretrovirinae. Other members of the genus Lentivirus include: bovine immunodeficiency virus; caprine arthritis encephalitis virus; feline immunodeficiency virus; human immunodeficiency virus 1; human immunodeficiency virus 2; simian immunodeficiency virus; and maedi/visna virus, Jembrana disease virus, and Puma lentivirus. Although EIA may be suspected on the basis of clinical signs and pathological lesions, confirmation of infection requires further serological and molecular-based testing is usually by serology. Infected horses remain viraemic carriers for life and, with very rare exceptions, yield a positive serological test result. Although antibody levels fluctuate, EIAV infection generates a persistent antibody response. All equids older than 12 months that test seropositive are identified as virus carriers. In young equids less than 12 months of age, positive serological reactions can be due to maternal antibodies; therefore, the EIA status may have to rely solely on molecular techniques. As virus reservoirs, infected equids represent a transmission risk to other equids. The virus is primarily blood-borne. Biting flies are mechanical vectors for the virus in nature and infection is often spread via iatrogenic routes.

Identification of the agent: EIAV cannot be differentiated clinically from a number of other aetiological agents of haemolytic anaemic fever syndromes and systemic equine diseases. Diagnosis of EIAV infection is laboratory dependent and based on the demonstration of a specific antibody response, virus isolation, or detection of viral nucleic acid.

Virus can be isolated by inoculating suspect blood into a susceptible horse or onto leukocyte cultures prepared from susceptible horses. Recognition of infection in experimentally challenged horses may be made based on the basis of clinical signs, haematological changes, positive serological reactions and/or detection of the virus by molecular techniques. Successful virus isolation in horse leukocyte cultures equine monocyte-derived macrophages (eMDMs), derived from peripheral blood mononuclear cells (PBMCs), need to be confirmed by the detection of specific EIA antigen, by immunofluorescence assay, polymerase chain reaction-based techniques, or by the inoculation of culture fluids into susceptible horses. Virus isolation is rarely attempted due to the time, difficulty and expense involved.

Serological tests: Agar gel immunodiffusion (AGID) tests and enzyme-linked immunosorbent assays (ELISAs), are simple, reliable serological tests for the demonstration of EIAV infection. The AGID tests should be used to confirm positive ELISA results. An immunoblot may be used in case of discrepancy in the results. Antibody levels are highly variable, and fluctuate due to the changing nature of the virus and the immune status of the infected subject. EIA antigens can be prepared from infected tissue-cell cultures or by using recombinant DNA technology. A variety of licensed and validated commercial test kits is available.

Colloidal gold immunochromatographic strip (CGICG) test has demonstrated potential for the diagnostic of EIA.

41 **Requirements for vaccines:** An attenuated live vaccine was developed in the early 1970s and used
42 extensively in China (People's Rep. of) between 1975 and 1990. Numerous other methods of vaccine
43 production have since been attempted with ~~variable results~~ limited success. The strategy for EIA control has
44 shifted from vaccination to quarantine to avoid the interference of vaccinal antibodies with diagnostic tests.
45 There are no vaccines currently available.

46 A. INTRODUCTION

47 1. Description of disease and aetiology

48 Equine infectious anaemia (EIA) occurs worldwide and causes significant losses to the equine industry (Li *et al.*, 2023). EIA
49 is a WOAHA notifiable disease. The infection, formerly known as swamp fever, is limited to equids including horses, donkeys,
50 mules and hinny (Wang *et al.*, 2023), though studies on the presence of the infection in zebras are scarce. Many cases
51 remain clinically ~~unapparent~~ inapparent. The disease is characterised by recurrent febrile episodes, thrombocytopenia,
52 anaemia, rapid loss of weight, cachexia, jaundice, and oedema of the lower parts of the body (Li *et al.*, 2023). If death does
53 not result from one of the acute clinical attacks, a chronic stage develops, and the infection tends to become inapparent.
54 The incubation period is normally 1–3 weeks, but may be as long as 3 months or more. Some horses remain subclinical until
55 they experience some form of stress (Harrold *et al.*, 2020) or may never show outward clinical signs. In acute cases, lymph
56 nodes, spleen and liver are hyperaemic and enlarged. Histologically, these organs are infiltrated with nests of immature
57 lymphocytes and plasma cells. Kupffer cells in the liver often contain haemosiderin or erythrocytes. The enlarged spleen
58 may be felt on rectal examination. Differential diagnoses include equine viral arteritis (Chapter 3.6.9), *Anaplasma*
59 *phagocytophilum*, *Piroplasmosis*, *leptospirosis*, *severe strongylosis* and other causes of oedema, fever, anaemia, or
60 thrombocytopaenia/ ecchymoses.

61 EIA virus (EIAV) is in the genus *Lentivirus* in the family *Retroviridae*, subfamily *Orthoretrovirinae*. Other members of the
62 genus include: bovine immunodeficiency virus; caprine arthritis encephalitis virus; feline immunodeficiency virus; human
63 immunodeficiency virus 1; human immunodeficiency virus 2; simian immunodeficiency virus; ~~and~~ maedi/visna virus;
64 Jembrana disease virus and Puma lentivirus.

65 Once a horse is infected with EIAV, its blood remains infectious for the remainder of its life and the horse can potentially
66 transmit the infection to other horses (Cheevers & McGuire, 1985). Transmission occurs by transfer of blood or contaminated
67 secretions from an infected horse. In nature, spread of the virus is most likely via interrupted feeding of bloodsucking
68 horseflies (*Tabanidae*) and stable flies (Dantas Malossi *et al.*, 2020) on an clinically ill infected horse and then on susceptible
69 horses. Transmission by haematophagous flies is mechanical as it does not involve EIAV replication in their tissues (Fideles
70 Resende *et al.*, 2022). Transmission can also occur by the iatrogenic transfer of blood ~~through the use of~~ using contaminated
71 blood products, needles, syringes, IV administration sets or other equipment. Infection can also be transmitted through the
72 congenital route or body secretions, e.g. semen, sweat, urine (Romo-Sáenz *et al.*, 2021). No effective treatment or vaccine
73 is currently available (Dantas Malossi *et al.*, 2020). In utero infection of the fetus may occur (Kemen & Coggins, 1972). The
74 virus titre-viral load is higher in the plasma of horses with clinical signs and the risk of transmission is higher from these
75 animals than the carrier animals with a lower ~~v-virus titre-viral load~~. However, studies in mules indicate infected animals
76 have demonstrated a lack of correlation between viral load and serological reactivity. Naturally infected asymptomatic mules
77 with positive enzyme-linked immunosorbent assay (ELISA) and indeterminate but negative or equivocal agar gel
78 immunodiffusion (AGID) test results can may have high viral-virus nucleic acid loads at the same level as animals with strong
79 antibody responses, and are therefore equally likely as a potential source of transmission (Sciicluna *et al.*, 2013) in the plasma
80 and could potentially contribute to the maintenance and spread of infection.

81 EIAV is not considered a risk for human health. Laboratory manipulations should be carried out at an appropriate biosafety
82 and containment level determined by biorisk analysis (see Chapter 1.1.4 *Biosafety and biosecurity: Standard for managing*
83 *biological risk in the veterinary laboratory and animal facilities*).

84 B. DIAGNOSTIC TECHNIQUES

85 AGID tests (Coggins *et al.*, 1972) and ELISAs (Suzuki *et al.*, 1982) are accurate, reliable tests for the detection of EIA in
86 horses, except for animals in the early stages of infection and foals of infected dams (McCannico *et al.*, 2000; United States
87 Department of Agriculture [USDA], 2007). In other rare circumstances, misleading results may occur when the level of virus
88 circulating in the blood during an acute episode of the disease is sufficient to bind available antibody, and if initial antibody
89 levels never rise high enough to be detectable (Toma, 1980). Although the ELISA will detect antibodies somewhat earlier
90 and at lower concentrations than the AGID test, positive ELISAs are confirmed using the AGID test. This is due to false-
91 positive results that have been noted with indirect ELISAs. The AGID test is specific, thus has the advantage of distinguishing

92 between EIA and non-EIA antigen–antibody reactions. Nonspecific reactions in AGID may occur with antigen derived from
 93 the spleen of infected animals or equine dermal cell cultures that might contain other cellular or host-derived proteins with
 94 consequent nonspecific precipitation lines with antibodies present in the tested serum against non-EIAV antigens.
 95 Recombinant technology for the production of EIAV antigens can obviate AGID nonspecific reactions (Alvarez *et al.*, 2007).
 96 Competitive ELISA developed using specific monoclonal antibodies against a common epitope on viral P26 protein showed
 97 high specificity and sensitivity (Hu *et al.*, 2023). A colloidal gold immunochromatographic (CGICG) fast test strip was
 98 developed with good specificity, sensitivity, stability, and repeatability, which provides a tool for point-of-care testing for the
 99 primary screening of EIAV antibodies (Zhang *et al.*, 2024). Discrepancies between testing methods or tests with questionable
 100 results can be further evaluated by immunoblot testing (Issel *et al.*, 1999–2013; Rusvai *et al.*, 2009).

101 Table 1. Test methods available for the diagnosis of equine infectious anaemia and their purpose

Method	Purpose					
	Population freedom from infection ^(a)	Individual animal freedom from infection prior to movement ^(b)	Contribute to eradication policies ^(c)	Confirmation of clinical cases ^(d)	Prevalence of infection – surveillance ^(e)	Immune status in individual animals or populations (post-vaccination)
Identification of the agent ^(f)						
PCR	–	+/-	–	+/-	–	–
Virus isolation	–	–	–	+	–	–
Detection of immune response						
AGID	++	++	++	+++	++	–
ELISA	+++	+++	+++	+++	+++	–
Immunoblot	–	++	++	++	–	–

102 Key: +++ = recommended for this purpose; ++ recommended but has limitations;
 103 + = suitable in very limited circumstances; – = not appropriate for this purpose.

104 PCR = polymerase chain reaction; AGID = agar gel immunodiffusion; ELISA = enzyme-linked immunosorbent assay.

105 ^(a)See Appendix 1 of this chapter for justification table for the scores given to the tests for this purpose.

106 ^(b)See Appendix 2 of this chapter for justification table for the scores given to the tests for this purpose.

107 ^(c)See Appendix 3 of this chapter for justification table for the scores given to the tests for this purpose.

108 ^(d)See Appendix 4 of this chapter for justification table for the scores given to the tests for this purpose.

109 ^(e)See Appendix 5 of this chapter for justification table for the scores given to the tests for this purpose.

110 ^(f)A combination of agent identification methods applied on the same clinical sample is recommended.

111 1. Identification of the agent

112 1.1. Virus isolation and identification

113 **Virus isolation is usually not necessary to make a diagnosis.**

114 Isolation of the virus from suspect horses may be made by inoculating their blood (plasma, serum, leukocytes) or
 115 spleen homogenates onto leukocyte–equine monocyte-derived macrophages (eMDMs) derived from peripheral
 116 blood mononuclear cells (PBMCs) cultures prepared from horses free of infection (Fidalgo-Carvalho *et al.*, 2009).
 117 Virus production in cultures can be confirmed by detection of specific EIA antigen by ELISA (Shane *et al.*, 1984),
 118 by immunofluorescence assay (Weiland *et al.*, 1982), or by molecular tests (Cook *et al.*, 2002; Dong *et al.*, 2012).
 119 Virus isolation is rarely attempted because of the difficulty of growing horse leukocyte cultures and poor
 120 adaptability of some strains to cell culture (Ma *et al.*, 2014).

121 1.2. Polymerase chain reaction

122 A nested polymerase chain reaction (PCR) assay to detect EIA proviral DNA from the peripheral blood of horses
 123 has been described (Nagarajan & Simard, 2001–2007). The nested PCR method is based on primer sequences

124 from the gag region of the proviral genome. It has proven to be a sensitive technique to detect field strains of EIAV
125 in white blood cells of EIA infected horses; the lower limit of detection is typically around 10 genomic copies of
126 the target DNA (Nagarajan & Simard, 2004; 2007). A real-time reverse-transcriptase PCR assay has also been
127 described (Cook *et al.*, 2002). Other real-time PCR methods are based on primer sequences from the exon 1 tat
128 genomic portion (118 bp) that has a limit of detection of the EIAV tat RNA transcript of 1 genomic copy (Sciicluna
129 *et al.*, 2013). Another real-time PCR amplifies a fragment between the tat and the gag genes (Li *et al.*, 2023). To
130 increase the diagnostic sensitivity, PCR methods for detecting viral RNA and proviral DNA should be used. To
131 confirm the results of these very sensitive assays, it is recommended that duplicate samples of each diagnostic
132 specimen be processed. Because of the risk of cross contamination, it is also important that proper procedures
133 are followed (see Chapter 1.1.5 *Quality management in veterinary testing laboratories* and Chapter 1.1.6
134 *Validation of diagnostic assays for infectious diseases of terrestrial animals*). It should be noted that primer
135 mismatches with circulating virus, possibly caused by the high rate of mutation in the virus, may cause a failure
136 of PCR to detect virus (Cappelli *et al.*, 2014; Li *et al.*, 2023; Quinlivan *et al.*, 2007; Sciicluna *et al.*, 2013).

137 The following are some of the circumstances where the PCR assay maybe used for the detection of EIAV infection
138 in horses:

- 139 i) Conflicting results on serologic tests;
- 140 ii) Suspected infection but negative or questionable serologic results;
- 141 iii) Complementary test to serology for the confirmation of positive results;
- 142 iv) Confirmation of early infection, ~~before when the~~ serum antibodies to EIAV ~~develop are not detectable~~;
- 143 v) ~~Ensuring~~ In addition to serology, to ensure that horses that are ~~to be~~ used for antiserum or vaccine production
144 or as blood donors are free of EIAV;
- 145 vi) Confirmation of the status of a foal from an infected mare.

146 2. Serological tests

147 Due to the persistence of EIAV in infected equids, detection of serum antibody to EIAV confirms the diagnosis of EIAV
148 infection. An efficient diagnostic algorithm in terms of sensitivity and specificity can be adopted, such as the one based on a
149 three-tiered diagnostic system (Issel *et al.*, 2013; Sciicluna *et al.*, 2013). This procedure involves initial screening by ELISA
150 (Tier 1) with test-positive samples confirmed by the AGID (Tier 2) and, in the case of ELISA positive/AGID negative results,
151 final verification by Immunoblotting (IB) (Tier 3).

152 2.1. Agar gel immunodiffusion test

153 The AGID test detects precipitating antibody produced in response to EIAV infection. Specific reactions are
154 indicated by precipitation lines between the EIA antigen and the test serum and confirmed by their identity with
155 the reaction between the antigen and the positive standard serum.

156 Reagents for AGID are available commercially from several companies. Alternatively, AGID antigen and reference
157 serum may be prepared as described below.

158 2.1.1. Preparation of antigen

159 Specific EIA antigen may be prepared from the spleen of acutely infected horses (Coggins *et al.*, 1973),
160 from infected equine tissue culture (Malmquist *et al.*, 1973), from a persistently infected canine thymus cell
161 line (Bouillant *et al.*, 1986), or from proteins expressed in bacteria or baculovirus using the recombinant
162 DNA technique (Archambault *et al.*, 1989; Keng *et al.*, 1997). Preparation from infected cultures or from
163 recombinant DNA techniques gives a more uniform result than the use of spleen cells and allows for better
164 standardisation of reagents.

~~To obtain a satisfactory antigen from spleen, a horse must be infected with a highly virulent strain of EIAV. The resulting incubation period should be 5–7 days, and the spleen should be collected 9 days after inoculation, when the virus titre is at its peak and before any detectable amount of precipitating antibody is produced. Undiluted spleen pulp is used in the immunodiffusion test as antigen (Coggins *et al.*, 1973). Extraction of antigen from the spleen with a saline solution and concentration with ammonium sulphate does not give as satisfactory an antigen as selection of a spleen with a very high titre of EIA antigen.~~

~~Alternatively,~~ Equine fetal kidney or dermal cells or canine thymus cells are infected with a strain of EIAV
172 adapted to grow in tissue culture (American Type Culture Collection, or Chinese strain adapted to equine
173 fetal dermal cells). Virus is collected from cultures by precipitation with 8% polyethylene glycol or by

174 pelleting by ultracentrifugation. The diagnostic antigen, p26, is released from the virus by treatment with
175 detergent or ether (~~Malmquist et al., 1973~~). EIAV core proteins, expressed in bacteria, i.e. *E. coli* or
176 baculovirus (~~Alvarez et al., 2007; Scicluna et al., 2019~~), are commercially available and find practical use
177 as high quality antigens for serological diagnosis (~~Bannai et al. 2023~~).

178 The p26 is an internal structural protein of the virus that is coded for by the *gag* gene. The p26 is more
179 antigenically stable among EIAV strains than the virion glycoproteins gp45 and gp90 (~~Montelaro et al.,
180 1984~~). There is evidence of strain variation in the p26 amino acid sequence; however, there is no evidence
181 to indicate that this variation influences any of the serological diagnostic tests (~~Zhang et al., 1999~~).


182 2.1.2. Preparation of standard antiserum

183 A known positive antiserum may be collected from a horse previously experimentally or naturally infected
184 with EIAV. This serum should yield a single dense precipitation line that is specific for EIA, as demonstrated
185 by a reaction of identity in comparison with a known standard positive reference serum. It is essential to
186 balance the antigen and antibody concentrations ~~in order to~~ ensure the optimal sensitivity of the test.
187 Reagent concentrations should be adjusted ~~to form by cross-testing serial dilutions of antigen and serum~~
188 to obtain a narrow precipitation line approximately equidistant between the two wells containing ~~antigen~~
189 ~~and serum~~ the antigen and the standard positive reference serum (Chapter 2.2.6 Selection and use of
190 reference samples and panels). A list of WOAH-approved International Standard Reagents is also
191 available¹.

192 2.1.3. Test procedure (Association Française de Normalisation [AFNOR], 2000; Coggins et al., 1973; 193 Pearson & Coggins, 1979)

- 194 i) Immunodiffusion reactions are carried out in a layer of agar in plastic Petri dishes as glass dishes
195 can result in slippage. For Petri dishes that are 100 mm in diameter, 15–17 ml of 1% Noble agar in
196 0.145 M borate buffer (9 g H₃BO₃, plus 2 g NaOH per litre), pH 8.6 (± 0.2) is used. A metal punch is
197 used to create several “rosettes,” each of six wells surrounding a centre well of the same diameter.
198 The wells are 5.3 mm in diameter and 2.4 mm apart. Each well must contain the same volume of
199 reagent and should be completely but not over-filled.
- 200 ii) The antigen is placed in the central well and the standard antiserum is placed in alternate exterior
201 wells. Serum samples for testing are placed in the remaining three wells.
- 202 iii) The dishes are maintained at room temperature in a humid environment (18°C–26°C recommended).
- 203 iv) After 24 ~~—and~~ 48 hours the precipitation reactions are examined over a narrow beam of intense,
204 oblique light and against a black background, with also the help of a magnification. The reference
205 lines should be clearly visible at 24 hours, and at that time, any test sera that are strongly positive
206 may also have formed lines of identity with those between the standard reagents. A weakly positive
207 reaction may take 48 hours to form and is indicated by a slight bending of the standard serum
208 precipitation line between the antigen well and the test serum well. For EIA AGID, the bending caused
209 by a weak positive reaction looks like a very small hook or rounding into the sample well. Sera with
210 high precipitating antibody titres will form a complete line of identity or may form broader precipitin
211 bands that break into the sample well or tend to be diffuse (see Figure 1). Such reactions can be
212 confirmed as specific for EIA by dilution at 1/2 ~~or 1/4~~ and subsequent serial dilutions prior to retesting;
213 these then give a more distinct line of identity. Sera devoid of EIA antibody will not form precipitation
214 lines and will have no effect on the reaction lines of the standard reagents. Nonspecific precipitation
215 lines may occur. These nonspecific lines can cross the control lines, typically showing no line of
216 identity with the control lines.
- 217 v) Interpretation of the results: Horses that are in the early stages of an infection may not give a positive
218 serological reaction in an AGID test. Such animals should be bled again after 3–4 weeks, or, in case
219 of clinical signs at least a week after their appearance. To make a diagnosis in a young foal, it may
220 be necessary to determine the antibody status of the dam. If the mare passes EIA antibody to the
221 foal through colostrum, then a period of 6 months or longer after birth must be allowed for the
222 maternally-derived antibody to wane. Sequential testing of the foal at monthly intervals may be useful
223 to observe the decline in maternal antibody. To conclude that the foal is not infected, a negative result
224 must be obtained (following an initial positive result) at least 2–3 months after separating the foal from
225 contact with the EIA positive mare or any other positive horse. It should be noted that maternal
226 antibodies can often be detected for up to 12 months of age, therefore alternative diagnostic methods
227 should be considered, for example PCR could be used to determine the presence/absence of EIA
228 virus in the blood of the foal.

¹ <https://www.woah.org/en/what-we-offer/veterinary-products/reference-reagents/>



229 Fig. 1. Reactions in AGID test for EIAV. From: Issel et al. (2013).

230 **2.2. Enzyme-linked immunosorbent assay**

231 Several diagnostic test kits for EIA, including AGID and ELISA, are licensed in various countries for the diagnosis
 232 of equine infectious anaemia and are available internationally (Hu *et al.*, 2023; Nardini *et al.*, 2017). The ELISAs
 233 generally target antibody produced against the p26 core protein antigen but may also have a second target
 234 antibody produced against the gp45 antigen. These antigens may also be synthetic fusion proteins or recombinant
 235 antigens. Typical ELISA protocols are used. Both indirect and competitive ELISAs are used for disease
 236 surveillance. If commercial ELISA materials are not available, a non-competitive ELISA using p26 antigen purified
 237 from cell culture material may be employed (Shane *et al.*, 1984).

238 A positive test result by ELISA should be confirmed using the AGID test because false-positive results have been
 239 noted with the ELISA. The results can also be confirmed by the immunoblotting technique. A standard antiserum
 240 for immunodiffusion, which contains detectable antibody, is available from the WOAH Reference Laboratories².
 241 This standard should not be used as the reference for minimum detection limits for the ELISA reaction. Uniform
 242 methods for EIA control have been published (USDA, 2007).

243 **2.3. Immunoblotting test**

244 Immunoblotting (IB) is characterised by both high sensitivity and specificity and is the alternative confirmatory
 245 assay for ELISA/AGID discordant results. In the IB, the immunological reactivity to EIAV antigens, as in the case
 246 of using the whole virus, p26, gp45 and gp90 adsorbed on the IB membrane, can be used to define the serological
 247 status of the animal for EIA: a p26 positive band together with at least one of the other antigen defines a subject
 248 as serologically positive for EIAV (Issel *et al.*, 2013; Scicluna *et al.* 2019). This test is not commercially available
 249 and has not been the subjected to an international proficiency test; this test is only available at WOAH Reference
 250 Laboratory in Italy.

251 **2.4. Colloidal gold immunochromatographic test**

252 Colloidal gold immunochromatographic test (CGICG) is a method that has been widely used for disease screening
 253 and surveillance, especially in human diseases such as COVID-19. In the CGICG methods, the P26 and gp45
 254 are major antigens used to detect EIAV antibodies. The CGICG test for EIAV antibody detection showed high
 255 sensitivity and specificity, and can be concluded within 15 minutes in on-site detection (Alvarez *et al.*, 2010; Zhang
 256 *et al.*, 2024), thereby providing an alternative method for disease surveillance.

257 **C. REQUIREMENTS FOR VACCINES**

258 Inactivated and subunit EIAV vaccines were tested in different laboratories and proved to protect infections of homologous
 259 prototype strains only. An attenuated live vaccine, developed in the early 1970s, was extensively used in China (People's
 260 Rep. of) between 1975 and 1990 and was effective in controlling the prevalence of EIA. With low prevalence since 1990, the
 261 strategy for EIA control has shifted from vaccination to quarantine to avoid the interference of vaccine antibodies with
 262 diagnostic tests that are not yet capable to differentiate vaccinated and infected subjects.

² <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>

263 Although no safety concerns arose with the use of attenuated EIAV vaccine in China, it should be noted that, like other
264 lentiviruses, EIAV is highly mutable and can integrate into host genomes ([Lin et al., 2020](#); [Liu et al., 2017](#)). The use of a live
265 EIAV vaccine should be considered only after a thorough risk assessment.

266

REFERENCES

267 [ALVAREZ I., GUTIERREZ G., BARRANDEGUY M. & TRONO K. \(2010\). Immunochromatographic lateral flow test for detection of](#)
268 [antibodies to Equine infectious anemia virus. *J. Virol. Methods*, **167**, 152–157. doi: 10.1016/j.jviromet.2010.03.026](#)

269 [ALVAREZ I., GUTIERREZ G., VISSANI A., RODRIGUEZ S., BARRANDEGUY M. & TRONO K. \(2007\). Standardization and validation of](#)
270 [an agar gel immunodiffusion test for the diagnosis of equine infectious anemia using a recombinant p26 antigen. *Vet.*](#)
271 [Microbiol., **121**, 344–351.](#)

272 ASSOCIATION FRANÇAISE DE NORMALISATION (AFNOR) (2000). Animal Health Analysis Methods. Detection of Antibodies
273 against Equine Infectious Anaemia by the Agar Gel Immunodiffusion Test. NF U 47-002. AFNOR, 11 avenue Francis de
274 Pressensé, 93571 Saint-Denis La Plaine Cedex, France.

275 [ARCHAMBAULT D., WANG Z., LACAL J.C., GAZIT A., YANIV A., DAHLBERG J.E. & TRONICK S.R. \(1989\). Development of an enzyme-](#)
276 [linked immunosorbent assay for equine infectious anaemia virus detection using recombinant Pr55gag. *J. Clin. Microbiol.*,](#)
277 [27, 1167–1173.](#)

278 [BANNAL H., KAMBAYASHI Y., NEMOTO M., YAMANAKA T. & TSUJIMURA K. \(2023\). Comparison of 4 agars gel immunodiffusion kits](#)
279 [for serologic detection of equine infectious anemia virus antibodies. *J. Vet. Diagn. Invest.*, **35**, 431–433.](#)
280 [doi:10.1177/10406387231171567](#)

281 [BOUILLANT A.M.P., NELSON K., RUCKERBAUER C.M., SAMAGH B.S. & HARE W.C.D. \(1986\). The persistent infection of a canine](#)
282 [thymus cell line by equine infectious anaemia virus and preliminary data on the production of viral antigens. *J. Virol. Methods*,](#)
283 [13, 309–321.](#)

284 [CAPPELLI K., CAPOMACCIO S., COOK F.R., FELICETTI M., MARENZONI M.L., COPPOLA G., VERINI-SUPPLIZI A., COLETTI M. &](#)
285 [PASSAMONTI F. \(2014\). Molecular detection, epidemiology, and genetic characterization of novel European field isolates of](#)
286 [equine infectious anemia virus. *J. Clin. Microbiol.*, **49**, 27–33.](#)

287 [CHEEVERS W.M. & MCGUIRE T.C. \(1985\). Equine infectious anaemia virus; immunopathogenesis and persistence. *Rev. Infect.*](#)
288 [Dis., **7**, 83–88.](#)

289 [COGGINS L., NORCROSS N.L. & KEMEN M.J. \(1973\). The technique and application of the immunodiffusion test for equine](#)
290 [infectious anaemia. *Equine Infect. Dis.*, **III**, 177–186.](#)

291 [COGGINS L., NORCROSS N.L. & NUSBAUM S.R. \(1972\). Diagnosis of equine infectious anaemia by immunodiffusion test. *Am. J.*](#)
292 [Vet. Res., **33**, 11–18.](#)

293 [COOK R.F., COOK S.J., LI F.L., MONTEJARO R.C. & ISSEL C.J. \(2002\). Development of a multiplex real-time reverse](#)
294 [transcriptase-polymerase chain reaction for equine infectious anemia virus \(EIAV\). *Virol. Methods*, **105**, 171–179.](#)

295 [DANTAS MALOSSI C., FIORATTI E.G., CARDOSO J.F., MAGRO A.J., KROON E.G., MOURA DE AGUIAR D., BORGES A.M.C.M., NOGUEIRA](#)
296 [M.F., ULLMANN L.S. & PESSOA ARAUJO J.JR \(2020\). High Genomic Variability in Equine Infectious Anemia Virus Obtained from](#)
297 [Naturally Infected Horses in Pantanal, Brazil: An Endemic Region Case. *Viruses*, **12**, 207.](#)

298 [DONG J.B., ZHU W., COOK F.R., GOTO Y., HORII Y. & HAGA T. \(2012\). Development of a nested PCR assay to detect equine](#)
299 [infectious anemia proviral DNA from peripheral blood of naturally infected horses. *Arch. Virol.*, **157**, 2015–2111.](#)

300 [FIDELES RESENDE C., SANTOS A.M., COOK R.F., VICTOR R.M., FALCÃO CÂMARA R.J., PEREIRA GONÇALVES G., GONÇALVES LIMA J.,](#)
301 [MACIEL E SILVA A.G., CERQUEIRA LEITE R. & DOS REIS J.K.P. \(2022\). Low transmission rates of Equine infectious anemia virus](#)
302 [\(EIAV\) in foals born to seropositive feral mares inhabiting the Amazon delta region despite climatic conditions supporting](#)
303 [high insect vector populations. *BMC Vet. Res.*, **18**, 286.](#)

304 [FIDALGO-CARVALHO I., CRAIGO J.K., BARNES S., COSTA-RAMOS C. & MONTEJARO R.C. \(2009\). Characterization of an equine](#)
305 [macrophage cell line: application to studies of EIAV infection. *Vet. Microbiol.*, **136**, 8–19.](#)

- 306 HARROLD S.M., COOK S.J., COOK R.F., RUSHLOW K.E., ISSEL C.J. & MONTELARO R.C. (2000). Tissue sites of persistent infection
307 and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally
308 infected equids. *J. Virol.*, **74**, 3112–3121.
- 309 HU Z., GUO K., DU C., SUN J., NALETOSKI I., CHU X., LIN Y., WANG X.F., BARRANDEGUY M., SAMUEL M., WANG W., LAU P.I., WERNERY
310 U., RAGHAVAN U. & WANG X. (2023). Development and evaluation of a blocking ELISA for serological diagnosis of equine
311 infectious anemia. *Appl. Microbiol. Biotechnol.*, **107**, 3305–3317. <https://doi.org/10.1007/s00253-023-12504-5>
- 312 ISSEL C. J., COOK S. J., COOK R. F. & CORDES T.R. (1999) Optimal paradigms for the serological diagnosis of equine infectious
313 anemia. *J. Eq. Vet. Sci.* **19**, 720–724.
- 314 ISSEL C.J., SCICLUNA M.T., COOK S.J., COOK R.F., CAPRIOLI A., RICCI I., ROSONE F., CRAIGO J.K., MONTELARO R.C. & AUTORINO
315 G.L. (2013) Challenges and proposed solutions for more accurate serological diagnosis of equine infectious anaemia. *Vet*
316 *Rec.*, **172**, 210.
- 317 KEMEN M.J. & COGGINS L. (1972). Equine infectious anaemia: transmission from infected mares to foals. *J. Am. Vet. Med.*
318 *Assoc.*, **161**, 496–499.
- 319 KONG X. K., PANG H., SUGIURA T., SENTSUI H., ONODERA T., MATSUMOTO Y. & AKASHI H. (1997). Application of equine infectious
320 anaemia virus core proteins produced in a Baculovirus expression system, to serological diagnosis. *Microbiol. Immunol.*, **41**,
321 975–980.
- 322 LI S., GUO K., WANG X.F., LIN Y., WANG J., WANG Y., DU C., HU Z. & WANG X. (2023). Development and evaluation of a real-
323 time quantitative PCR for the detection of equine infectious anemia virus. *Microbiol. Spectr.*, **11**: e02599-23.
324 <https://doi.org/10.1128/spectrum.02599-23>
- 325 LIN Y., WANG X.F., WANG Y., DU C., REN H., LIU C., ZHU D., CHEN J., NA L., LIU D., YANG Z. & WANG X. (2020). *Env* diversity-
326 dependent protection of the attenuated equine infectious anaemia virus vaccine. *Emerg. Microbes Infect.*, **9**, 1309–1320.
- 327 LIU Q., WANG X.F., DU C., LIN Y.Z., MA J., WANG Y.H., ZHOU J.H. & WANG X. (2017). The integration of a macrophage-adapted
328 live vaccine strain of equine infectious anaemia virus (EIAV) in the horse genome. *J. Gen. Virol.*, **98**, 2596–2606.
- 329 MA J., WANG S.S., LIN Y.Z., LIU H.F., LIU Q., WEI H.M., WANG X.F., WANG Y.H., DU C., KONG X.G., ZHOU J.H. & WANG X. (2014)
330 Infection of equine Monocyte-Derived Macrophages with an attenuated Equine Infectious Anemia Virus (EIAV) strain. *Vet*
331 *Res.*, **45**, 82.
- 332 MALMQUIST W.A., BARNETT D. & BECVAR C.S. (1973). Production of equine infectious anaemia antigen in a persistently infected
333 cell line. *Arch. Gesamte Virusforsch.*, **42**, 361–370.
- 334 McCONNICO R.S., ISSEL C.J., COOK S.J., COOK R.F., FLOYD C. & BISSON H. (2000). Predictive methods to define infection with
335 equine infectious anemia virus in foals out of reactor mares. *J. Eq. Vet. Sci.*, **20**, 387–392.
- 336 MONTELARO R.C., PAREKH B., ORREGO A. & ISSEL C.J. (1984). Antigenic variation during persistent infection by equine
337 infectious anaemia, a retrovirus. *J. Biol. Chem.*, **16**, 10539–10544.
- 338 NAGARAJAN M.M. & SIMARD C. (2001). Detection of horses infected naturally with equine infectious anemia virus by nested
339 polymerase chain reaction. *J. Virol. Methods*, **94**, 97–109.
- 340 NAGARAJAN M.M. & SIMARD C. (2007). Gag genomic heterogeneity of equine infectious anemia virus (EIAV) in naturally
341 infected horses in Canada: implication on EIA diagnosis and peptide-based vaccine development. *Virus Res.*, **129**, 228–
342 235.
- 343 NARDINI R., AUTORINO G.L., ISSEL C.J., COOK R.F., RICCI I., FRONTOSO R., ROSONE F. & SCICLUNA M.T. (2017) Evaluation of six
344 serological ELISA kits available in Italy as screening tests for equine infectious anaemia surveillance. *BMC Vet. Res.*, **13**,
345 105.
- 346 PEARSON J.E. & COGGINS L. (1979). Protocol for the immunodiffusion (Coggins) test for equine infectious anaemia. *Proc. Am.*
347 *Assoc. Vet. Lab. Diagnosticians*, **22**, 449–462.
- 348 QUINLIVAN M., COOK F.R. & CULLINANE A. (2007). Real-time quantitative RT-PCR and PCR assays for a novel European field
349 isolate of equine infectious anaemia virus based on sequence determination of the gag gene. *Vet. Rec.*, **160**, 611–618.

350 ROMO-SÁENZ C.I., TAMEZ-GUERRA P., OLIVAS-HOLGUIN A., RAMOS-ZAYAS Y., OBREGÓN-MACÍAS N., GONZÁLEZ-OCHOA G., ZAVALA
351 F. J., DE LA SERNA D., RODRÍGUEZ-PADILLA C., TAMEZ-GUERRA R. & GÓMEZ-FLORES R. (2021). Molecular detection of equine
352 infectious anaemia virus in clinically normal, seronegative horses in an endemic area of Mexico. *J. Vet. Diagn. Invest.*, **33**,
353 758–761.

354 RUSVAI M., BAKONYI T., HORNYÁK A., BALKÁ G., HANS A. & NOWOTNY N. (2009). RT-PCR detection and phylogenetic analysis
355 of Hungarian equine infectious anaemia virus strains. *In: Proceedings of the 8th International Congress of Veterinary*
356 *Virology*, 23–26 August 2009, Budapest, Hungary. Veterinary Medical Research Institute, Hungarian Academy of Sciences
357 Budapest Hungary.

358 SCICLUNA M.T., ISSEL C.J., COOK F.R., MANNA G., CERSINI A., ROSONE F., FRONTOSO R, CAPRIOLI A., ANTONETTI V. & AUTORINO
359 G.L. (2013). Is a diagnostic system based exclusively on agar gel immunodiffusion adequate for controlling the spread of
360 equine infectious anaemia? *Vet. Microbiol.*, **165**, 123–134.

361 SCICLUNA M.T., AUTORINO G.L., COOK S.J., ISSEL C.J., COOK R.F. & NARDINI R. (2019). Validation of an immunoblot assay
362 employing an objective reading system and used as a confirmatory test in equine infectious anaemia surveillance programs.
363 *J. Virol. Methods*, **266**, 77–88.

364 SHANE B.S., ISSEL C.J. & MONTELARO R.C. (1984). Enzyme linked immunosorbent assay for detection of equine infectious
365 anemia virus p26 antigen and antibody. *J. Clin. Microbiol.*, **19**, 351–355.

366 SUZUKI T., UEDA S. & SAMEJIMA T. (1982). Enzyme-linked immunosorbent assay for diagnosis of equine infectious anaemia.
367 *Vet. Microbiol.*, **7**, 307–316.

368 TOMA B. (1980). Réponse sérologique négative persistante chez une jument infectée. *Rec. Med. Vet.*, **156**, 55–63.

369 UNITED STATES DEPARTMENT OF AGRICULTURE (USDA) (2007). Equine Infectious Anemia Uniform Methods and Rules. Animal
370 and Plant Health Inspection Service, USDA:
371 https://www.aphis.usda.gov/vs/nahss/equine/eia/eia_umr_jan_10_2007.pdf

372 ~~WEILAND F., MATHEKA H.D. & BOHM H.O. (1982). Equine infectious anaemia: detection of antibodies using an~~
373 ~~immunofluorescence test. *Res. Vet. Sci.*, **33**, 347–350.~~

374 WANG X.F., ZHANG, X.M., MA W., LI J. & WANG X. (2023). Host cell restriction factors of equine infectious anemia virus. *Virol.*
375 *Sin.*, **38**, 485–496.

376 WORLD ORGANISATION FOR ANIMAL HEALTH (WOAH) (1998). Guidelines of the Office International des Epizooties for laboratory
377 quality evaluation, for international reference standards for antibody assays and for laboratory proficiency testing. *Rev. Sci.*
378 *Tech. Off. Int. Epiz.*, **17**, 600–631. English, French, Spanish. <http://dx.doi.org/10.20506/rst.17.2.1120>

379 ZHANG W., AUYONG D.B., OAKS J.L. & MCGUIRE T.C. (1999). Natural variation of equine infectious anemia virus Gag protein
380 cytotoxic T lymphocyte epitopes. *Virology*, **261**, 242–252.

381 ZHANG Z., GUO K., CHU X., LIU M., DU C., HU Z. & WANG X. (2024). Development and evaluation of a test strip for the rapid
382 detection of antibody against equine infectious anemia virus. *Appl. Microbiol. Biotechnol.*, **108**, 85.
383 <https://doi.org/10.1007/s00253-023-12980-9>

384 *
385 * *

386 **NB:** There are WOAH Reference Laboratories for equine infectious anaemia:
387 (please consult the WOAH Web site:
388 <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>)
389 Please contact the WOAH Reference Laboratories for any further information on
390 diagnostic tests and reagents for equine infectious anaemia

391 **NB:** FIRST ADOPTED IN 1989. MOST RECENT UPDATES ADOPTED IN 2019.

Appendix 1: Equine infectious anaemia
Intended purpose of test: population freedom from infection

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
PCR =	Blood Plasma Organs (spleen, liver) Exon 1 tat Blood samples LTR-tat	For Exon 1 tat: <u>Analytical sensitivity (LOD) = 1 copy target/µl</u> <u>Analytical specificity = 44 exon 1 tata amplicons sequenced</u> For LTR-tat: <u>Analytical sensitivity (LOD) = 10 copy target/µl</u> <u>Analytical specificity = 40 LTR-tat amplicons sequenced</u>	For Exon 1 tat: <u>5 Mules plasma (all positive)</u> <u>37 positive equine bloods</u> <u>16 positive equine plasma</u> For LTR-tat: <u>53 blood samples (40 positive sequenced and 13 negative)</u> <u>See reference</u>	See reference	For Exon 1 tat and LTR tat <u>1. High analytical sensitivity</u> <u>2. High analytical specificity</u>	For Exon 1 tat and LTR tat <u>1. Relatively low turnover</u> <u>2. High costs</u> <u>3. Requires specific laboratory equipment</u> <u>4. Requires skilled laboratory personnel</u> <u>5. Potential low diagnostic specificity due to the high genetic variability of the virus</u>	Scicluna <i>et al.</i> (2013)
AGID ++	Serum recombinant p26	Reference test: IB <u>Specificity 100%</u> <u>Sensitivity 59.4%</u>	<u>548 samples positive in a screening ELISA subsequently analysed by AGID and IB at the WOAHR, Italy</u>	To be published	<u>1. High specificity</u> <u>2. High sensitivity in case of populations not previously tested</u> <u>3. Low cost</u> <u>4. Minimal laboratory equipment required</u>	<u>1. Low sensitivity in case of early infection or low antibody levels</u> <u>2. Low turnover</u> <u>3. Results are not readily available</u> <u>4. In case of low levels of reactivity, interpretation of results depends on technical expertise</u>	
ELISA +++	Serum, recombinant p26, chimeric recombinant p26/gp45	Reference test were: AGID, IB Recombinant p26: <u>Dsp: 73.2% (CI: 67.6–78.1%)</u> <u>Dse: 100% (CI: 91.6–100%)</u> <u>50% inhibition as determined by ROC analysis.</u> Recombinant p26/gp45: <u>Dsp: 99.3% (CI: 96.8–99.8%)</u> <u>Dse: 100% (CI: 100–100%)</u> <u>50% inhibition as determined by ROC analysis.</u> bELISA: Reference tests were AGID <u>Dsp = 100%</u> <u>Dse = 97.0%</u> <u>Accuracy 98.3%</u>	Recombinant p26: <u>324 Field sera analysed by immunoblot (52 positive, 272 negative).</u> <u>96 Sera of horses experimentally vaccinated</u> <u>1,102 field sera analysed by AGID test (857 positive and 245 negative)</u> <u>Intralaboratory test with nine laboratories</u> Recombinant p26/gp45: <u>96 Sera of horses experimentally vaccinated</u> <u>615 field sera analysed by AGID test</u> bELISA: <u>1129 negative samples were taken from different farms in</u>	See reference	<u>1. High sensitivity</u> <u>2. Serological ELISAs are commercially available in many countries, together with in house ELISAs (see references)</u> <u>3. A comparative analysis of some commercial and in house ELISAs reported that their diagnostic performances are comparable (see reference)</u> <u>4. Rapid to carry out with an immediate result output</u>	<u>1. Specific laboratory equipment required</u> <u>2. Considering the diagnostic specificity, positive samples should be confirmed using AGID and, in case of discordant results, in IB</u> <u>3. Generally, low sensitivity during early stages of infection</u> <u>4. The bELISA will of course only test positive from the onset of antibodies in the sera, and will miss sera without antibodies, which can occur when sera are collected from early-stage infections in horses</u> <u>5. False-positive results have been noted with some ELISAs</u>	Nardini <i>et al.</i> (2016) Nardini <i>et al.</i> (2017) Scicluna <i>et al.</i> (2018) Naves <i>et al.</i> (2019) Dominguez <i>et al.</i> (2021) Hu <i>et al.</i> (2023) Russi <i>et al.</i> (2023)

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
			<p><u>China which were free from EIA</u> <u>18 positive sera, 45 negative sera, and 353 test serum samples from Argentina</u> <u>3 standard positive sera</u> <u>15,900 serum samples of either horses or donkeys collected from different provinces of China</u></p>		<p><u>5. Low cost</u> <u>6. Target antigen used is usually highly conserved</u> <u>7. High turnover</u> <u>8. No cross reactivity with other known viruses</u> <u>9. Detection sensitivity and specificity of the bELISA were higher than those of either AGID or cELISA</u> <u>10. bELISA detects the disease much earlier than does AGID</u> <u>11. bELISA has not produced a single false-positive result</u></p>		

Appendix 2: Equine infectious anaemia
Intended purpose of test: individual animal freedom from infection prior to movement

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>PCR</u> +/-	<u>Blood</u> <u>Plasma</u> <u>Organs (spleen, liver)</u> <u>Exon 1 tat</u> <u>Blood samples</u> <u>LTR-tat</u>	For Exon 1 tat: <u>Analytical sensitivity (LOD) = 1 copy target/ul</u> <u>Analytical specificity = 44 exon 1 tata amplicons sequenced</u> For LTR-tat: <u>Analytical sensitivity (LOD) = 10 copy target/ul</u> <u>Analytical specificity = 40 LTR-tat amplicons sequenced</u>	For Exon 1 tat: <u>5 Mules plasma (all positive)</u> <u>37 positive equine bloods</u> <u>16 positive equine plasma</u> For LTR-tat: <u>53 blood samples (40 positive sequenced and 13 negative)</u> <u>See reference</u>	<u>See reference</u>	For Exon 1 tat and LTR tat <u>1. High analytical sensitivity</u> <u>2. High analytical specificity</u>	For Exon 1 tat and LTR tat <u>1. Requires specific laboratory equipment</u> <u>2. Skilled personnel required</u> <u>3. Potential low diagnostic specificity due to the high genetic variability of the virus</u>	<u>Scicluna et al. (2013)</u>
<u>AGID</u> ++	<u>Serum</u> <u>recombinant p26</u>	<u>Reference test: IB</u> <u>Specificity 100%</u> <u>Sensitivity 59.4%</u>	<u>548 samples positive in a screening ELISA subsequently analysed by AGID and IB at the WOAHL, Italy</u>	<u>To be published</u>	<u>1. High specificity</u> <u>2. Low cost</u> <u>3. Minimal laboratory equipment required</u>	<u>1. Low sensitivity in case of early infection or low antibodies levels</u> <u>2. Results are not readily available</u> <u>3. In case of low levels of reactivity, interpretation of results depends on technical expertise</u>	
<u>ELISA</u> +++	<u>Serum</u> <u>recombinant p26</u> <u>chimeric recombinant p26/gp45</u>	<u>Reference test were: AGID, IB</u> <u>Recombinant p26:</u> <u>Dsp: 73.2% (CI: 67.6–78.1%)</u> <u>Dse: 100% (CI: 91.6–100%)</u> <u>50% inhibition as determined by ROC analysis.</u> <u>Recombinant p26/gp45:</u> <u>Dsp: 99.3% (CI: 96.8-99.8%)</u> <u>Dse: 100% (CI: 100-100%)</u> <u>50% inhibition as determined by ROC analysis.</u> <u>bELISA:</u> <u>Reference tests were AGID</u> <u>Dsp = 100%</u> <u>Dse = 97.0%</u> <u>Accuracy 98.3%</u>	<u>Recombinant p26:</u> <u>1. 324 Field sera analysed by immunoblot (52 positive, 272 negative).</u> <u>2. 96 Sera of horses experimentally vaccinated</u> <u>3. 1,102 field sera analysed by AGID test (857 positive and 245 negative)</u> <u>4. Intralaboratory test with nine laboratories</u> <u>Recombinant p26/gp45:</u> <u>1. 96 Sera of horses experimentally vaccinated</u> <u>3. 615 field sera analysed by AGID test</u> <u>bELISA:</u> <u>1129 negative samples were taken from different farms in</u>	<u>See reference</u>	<u>1. High sensitivity</u> <u>2. Serological ELISAs are commercially available in many countries, together with in house ELISAs (see references)</u> <u>3. A comparative analysis of some commercial and in house ELISAs reported that their diagnostic performances are comparable (see reference)</u> <u>4. Rapid to carry out with an immediate result output</u>	<u>1. Specific laboratory equipment required</u> <u>2. Considering the diagnostic specificity, positive samples should be confirmed using AGID and, in case of discordant results, in IB</u> <u>3. Generally, low sensitivity during early stages of infection</u> <u>4. The bELISA will of course only test positive from the onset of antibodies in the sera, and will miss sera without antibodies, which can occur when sera are collected from early-stage infections in horses</u> <u>5. False-positive results have been noted with some ELISAs</u>	<u>Nardini et al. (2016)</u> <u>Nardini et al. (2017)</u> <u>Scicluna et al. (2018)</u> <u>Naves et al. (2019)</u> <u>Dominguez et al. (2021)</u> <u>Hu et al. (2023)</u> <u>Russi et al. (2023)</u>

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
			<p><u>China which were free from EIA</u> <u>18 positive sera, 45 negative sera, and 353 test serum samples from Argentina</u> <u>3 standard positive sera</u> <u>15,900 serum samples of either horses or donkeys collected from different provinces of China (People's Rep. of)</u></p>		<p><u>5. Low cost</u> <u>6. Target antigen used is usually highly conserved</u> <u>7. High turnover</u> <u>8. No cross reactivity with other known viruses</u> <u>9. Detection sensitivity and specificity of the bELISA were higher than those of either AGID or cELISA</u> <u>10. bELISA detects the disease much earlier than does AGID</u> <u>11. bELISA has not produced a single false-positive res</u></p>		

Appendix 3: Equine infectious anaemia
Intended purpose of test: contribute to eradication policies

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
PCR =	Blood Plasma Organs (spleen, liver) Exon 1 tat Blood samples LTR-tat	For Exon 1 tat: <u>Analytical sensitivity (LOD) = 1 copy target/µl</u> <u>Analytical specificity = 44 exon 1 tata amplicons sequenced</u> For LTR-tat: <u>Analytical sensitivity (LOD) = 10 copy target/µl</u> <u>Analytical specificity = 40 LTR-tat amplicons sequenced</u>	For Exon 1 tat: <u>5 Mules plasma (all positive)</u> <u>37 positive equine bloods</u> <u>16 positive equine plasma</u> For LTR-tat: <u>53 blood samples (40 positive sequenced and 13 negative)</u> <u>See reference</u>	<u>See reference</u>	For Exon 1 tat and LTR tat <u>1. High analytical sensitivity</u> <u>2. High analytical specificity</u> <u>3. Historical experimental infection studies in susceptible equids indicated that positive results correlated with infectivity</u>	For Exon 1 tat and LTR tat <u>1. Relatively low turnover</u> <u>2. High costs</u> <u>3. Requires specific laboratory equipment</u> <u>4. Requires skilled laboratory personnel</u> <u>5. Potential low diagnostic specificity due to the high genetic variability of the virus</u>	<u>Scicluna et al. (2013)</u>
AGID ++	Serum recombinant p26	Reference test: IB <u>Specificity 100%</u> <u>Sensitivity 59.4%</u>	<u>548 samples positive in a screening ELISA subsequently analysed by AGID and IB at the WOAHL, Italy</u>	<u>To be published</u>	<u>1. High specificity</u> <u>2. High sensitivity in the initial stages of the intended purpose</u> <u>3. Low cost</u> <u>4. Minimal laboratory equipment required</u>	<u>1. Low sensitivity in case of early infection or low antibody levels</u> <u>2. Low turnover</u> <u>3. Results not readily available</u> <u>4. In case of low levels of reactivity, interpretation of results depends on technical expertise</u>	
ELISA +++	Serum recombinant p26 chimeric recombinant p26/gp45	Reference test were: AGID, IB Recombinant p26: <u>Dsp: 73.2% (CI: 67.6–78.1%)</u> <u>Dse: 100% (CI: 91.6–100%)</u> <u>50% inhibition as determined by ROC analysis.</u> Recombinant p26/gp45: <u>Dsp: 99.3% (CI: 96.8–99.8%)</u> <u>Dse: 100% (CI: 100–100%)</u> <u>50% inhibition as determined by ROC analysis.</u> bELISA: <u>Reference tests were AGID</u> <u>Dsp = 100%</u>	Recombinant p26: <u>1. 324 Field sera analysed by immunoblot (52 positive, 272 negative).</u> <u>2. 96 Sera of horses experimentally vaccinated</u> <u>3. 1,102 field sera analysed by AGID test (857 positive and 245 negative)</u> <u>4. Intralaboratory test with 9 laboratories</u> Recombinant p26/gp45: <u>1. 96 Sera of horses experimentally vaccinated</u> <u>3. 615 field sera analysed by AGID test</u>	<u>See reference</u>	<u>1. High sensitivity</u> <u>2. Serological ELISAs are commercially available in many countries, together with in house ELISAs (see references)</u> <u>3. A comparative analysis of some commercial and in house ELISAs reported that their diagnostic performances are comparable (see reference)</u> <u>4. Rapid to carry out with an immediate result output</u> <u>5. Low cost</u> <u>6. Target antigen used is</u>	<u>1. Specific laboratory equipment required</u> <u>2. Considering the diagnostic specificity, positive samples should be confirmed using AGID and, in case of discordant results, in IB</u> <u>3. Generally, low sensitivity during early stages of infection</u> <u>4. The bELISA will of course only test positive from the onset of antibodies in the sera, and will miss sera without antibodies, which</u>	<u>Nardini et al. (2016)</u> <u>Nardini et al. (2017)</u> <u>Scicluna et al. (2018)</u> <u>Naves et al. (2019)</u> <u>Dominguez et al. (2021)</u> <u>Hu et al. (2023)</u> <u>Russi et al. (2023)</u>

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
		Dse = 97.0% Accuracy 98.3%	<u>bELISA:</u> 1129 negative samples were taken from different farms in China which were free from EIA 18 positive sera, 45 negative sera, and 353 test serum samples from Argentina 3 standard positive sera 15,900 serum samples of either horses or donkeys collected from different provinces of China (People's Rep. of)		usually highly conserved 7. High turnover 8. No cross reactivity with other known viruses 9. Detection sensitivity and specificity of the bELISA were higher than those of either AGID or cELISA 10. bELISA detects the disease much earlier than does AGID 11. bELISA has not produced a single false-positive res	can occur when sera are collected from early-stage infections in horses 5. False-positive results have been noted with some ELISAs	

Appendix 4: Equine infectious anaemia
Intended purpose of test: confirmation of clinical cases

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
PCR ±	Blood Plasma Organs (spleen, liver) Exon 1 tat Blood samples LTR-tat	For Exon 1 tat: <u>Analytical sensitivity (LOD) = 1 copy target/µl</u> <u>Analytical specificity = 44 exon 1 tata amplicons sequenced</u> For LTR-tat: <u>Analytical sensitivity (LOD) = 10 copy target/µl</u> <u>Analytical specificity = 40 LTR-tat amplicons sequenced</u>	For Exon 1 tat: <u>5 Mules plasma (all positive)</u> <u>37 positive equine bloods</u> <u>16 positive equine plasma</u> For LTR-tat: <u>53 blood samples (40 positive sequenced and 13 negative)</u> See reference	See reference	For Exon 1 tat and LTR tat <u>1. High analytical sensitivity</u> <u>2. High analytical specificity</u>	For Exon 1 tat and LTR tat <u>1. Relatively low turnover</u> <u>2. High costs</u> <u>3. Requires specific laboratory equipment</u> <u>4. Requires skilled laboratory personnel</u> <u>5. Potential low diagnostic specificity due to the high genetic variability of the virus</u>	Scicluna <i>et al.</i> (2013)
Virus isolation ±	Plasma, serum, leukocytes or spleen homogenates, EIA virus	Data not available	Data not available	Data not available	Useful for the study of field strains	<u>1. Low sensitivity</u> <u>2. Skilled personnel required</u> <u>3. Time consuming, not suitable for high turnover</u>	Fidalgo-Carvalho <i>et al.</i> (2009) Ma <i>et al.</i> (2014)
AGID ++	Serum recombinant p26	Reference test: IB <u>Specificity 100%</u> <u>Sensitivity 59.4%</u>	<u>548 samples positive in a screening ELISA subsequently analysed by AGID and IB at the WOAHL, Italy</u>	To be published	<u>1. High specificity</u> <u>2. High sensitivity in the initial stages of the intended purpose</u> <u>3. Low cost</u> <u>4. Minimal laboratory equipment required</u>	<u>1. Low sensitivity in case of early infection or low antibody levels</u> <u>2. Low turnover</u> <u>3. Results not readily available</u> <u>4. In case of low levels of reactivity, interpretation of results depends on technical expertise</u>	
ELISA +++	Serum recombinant p26 chimeric recombinant p26/gp45	Reference test were: AGID, IB Recombinant p26: <u>Dsp: 73.2% (CI: 67.6–78.1%)</u> <u>Dse: 100% (CI: 91.6–100%)</u> <u>50% inhibition as determined by ROC analysis.</u> Recombinant p26/gp45:	Recombinant p26: <u>1. 324 Field sera analysed by immunoblot (52 positive, 272 negative).</u> <u>2. 96 Sera of horses experimentally vaccinated</u> <u>3. 1,102 field sera analysed by AGID test (857 positive and 245 negative)</u> <u>4. Intralaboratory test with 9</u>	See reference	<u>1. High sensitivity</u> <u>2. Serological ELISAs are commercially available in many countries, together with in house ELISAs (see references)</u> <u>3. A comparative analysis of some commercial and in</u>	<u>1. Specific laboratory equipment required</u> <u>2. Considering the diagnostic specificity, positive samples should be confirmed using AGID and, in case of discordant results, in IB</u> <u>3. Generally, low sensitivity during early stages of infection</u> <u>4. The bELISA will of course</u>	Nardini <i>et al.</i> (2016) Nardini <i>et al.</i> (2017) Scicluna <i>et al.</i> (2018) Naves <i>et al.</i> (2019) Dominguez <i>et al.</i> (2021)

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
		<p>Dsp: 99.3% (CI: 96.8-99.8%) Dse: 100% (CI: 100-100%) 50% inhibition as determined by ROC analysis. bELISA: Reference tests were AGID Dsp = 100% Dse = 97.0% Accuracy 98.3%</p>	<p>laboratories Recombinant p26/gp45: 1. 96 Sera of horses experimentally vaccinated 3. 615 field sera analysed by AGID test bELISA: 1129 negative samples were taken from different farms in China which were free from EIA 18 positive sera, 45 negative sera, and 353 test serum samples from Argentina 3 standard positive sera 15,900 serum samples of either horses or donkeys collected from different provinces of China (People's Rep. of)</p>		<p>house ELISAs reported that their diagnostic performances are comparable (see reference) 4. Rapid to carry out with an immediate result output 5. Low cost 6. Target antigen used is usually highly conserved 7. High turnover 8. No cross reactivity with other known viruses 9. Detection sensitivity and specificity of the bELISA were higher than those of either AGID or cELISA 10. bELISA detects the disease much earlier than does AGID 11. bELISA has not produced a single false-positive res</p>	<p>only test positive from the onset of antibodies in the sera, and will miss sera without antibodies, which can occur when sera are collected from early-stage infections in horses 5. False-positive results have been noted with some ELISAs</p>	<p>Hu <i>et al.</i> (2023) Russi <i>et al.</i> (2023)</p>

Appendix 5: Equine infectious anaemia
Intended purpose of test: prevalence of infection – surveillance

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
PCR ±	Blood Plasma Organs (spleen, liver) Exon 1 tat Blood samples LTR-tat	For Exon 1 tat: <u>Analytical sensitivity (LOD) = 1 copy target/µl</u> <u>Analytical specificity = 44 exon 1 tata amplicons sequenced</u> For LTR-tat: <u>Analytical sensitivity (LOD) = 10 copy target/µl</u> <u>Analytical specificity = 40 LTR-tat amplicons sequenced</u>	For Exon 1 tat: <u>5 Mules plasma (all positive)</u> <u>37 positive equine bloods</u> <u>16 positive equine plasma</u> For LTR-tat: <u>53 blood samples (40 positive sequenced and 13 negative)</u> <u>See reference</u>	<u>See reference</u>	For Exon 1 tat and LTR tat <u>1. High analytical sensitivity</u> <u>2. High analytical specificity</u>	For Exon 1 tat and LTR tat <u>1. Relatively low turnover</u> <u>2. High costs</u> <u>3. Requires specific laboratory equipment</u> <u>4. Requires skilled laboratory personnel</u> <u>5. Potential low diagnostic specificity due to the high genetic variability of the virus</u>	<u>Scicluna et al. (2013)</u>
AGID ++	Serum <u>recombinant p26</u>	Reference test: IB <u>Specificity 100%</u> <u>Sensitivity 59.4%</u>	<u>548 samples positive in a screening ELISA subsequently analysed by AGID and IB at the WOAHL, Italy</u>	<u>To be published</u>	<u>1. High specificity</u> <u>2. High sensitivity in the initial stages of the intended purpose</u> <u>3. Low cost</u> <u>4. Minimal laboratory equipment required</u>	<u>1. Low sensitivity in case of early infection or low antibody levels</u> <u>2. Low turnover</u> <u>3. Results not readily available</u> <u>4. In case of low levels of reactivity, interpretation of results depends on technical expertise</u>	

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
ELISA +++	Serum recombinant p26 chimeric recombinant p26/gp45	Reference test were: AGID, IB Recombinant p26: Dsp: 73.2% (CI: 67.6–78.1%) Dse: 100% (CI: 91.6–100%) 50% inhibition as determined by ROC analysis. Recombinant p26/gp45: Dsp: 99.3% (CI: 96.8-99.8%) Dse: 100% (CI: 100-100%) 50% inhibition as determined by ROC analysis. bELISA: Reference tests were AGID Dsp = 100% Dse = 97.0% Accuracy 98.3%	Recombinant p26: 1. 324 Field sera analysed by immunoblot (52 positive, 272 negative). 2. 96 Sera of horses experimentally vaccinated 3. 1,102 field sera analysed by AGID test (857 positive and 245 negative) 4. Intralaboratory test with 9 laboratories Recombinant p26/gp45: 1. 96 Sera of horses experimentally vaccinated 3. 615 field sera analysed by AGID test bELISA: 1129 negative samples were taken from different farms in China which were free from EIA 18 positive sera, 45 negative sera, and 353 test serum samples from Argentina 3 standard positive sera 15,900 serum samples of either horses or donkeys collected from different provinces of China (People's Rep. of)	See reference	1. High sensitivity 2. Serological ELISAs are commercially available in many countries, together with in house ELISAs (see references) 3. A comparative analysis of some commercial and in house ELISAs reported that their diagnostic performances are comparable (see reference) 4. Rapid to carry out with an immediate result output 5. Low cost 6. Target antigen used is usually highly conserved 7. High turnover 8. No cross reactivity with other known viruses 9. Detection sensitivity and specificity of the bELISA were higher than those of either AGID or cELISA 10. bELISA detects the disease much earlier than does AGID 11. bELISA has not produced a single false-positive res	1. Specific laboratory equipment required 2. Considering the diagnostic specificity, positive samples should be confirmed using AGID and, in case of discordant results, in IB 3. Generally, low sensitivity during early stages of infection 4. The bELISA will of course only test positive from the onset of antibodies in the sera, and will miss sera without antibodies, which can occur when sera are collected from early-stage infections in horses 5. False-positive results have been noted with some ELISAs	Nardini <i>et al.</i> (2016) Nardini <i>et al.</i> (2017) Scicluna <i>et al.</i> (2018) Naves <i>et al.</i> (2019) Dominguez <i>et al.</i> (2021) Hu <i>et al.</i> (2023) Russi <i>et al.</i> (2023)

4
5 CHAPTER 3.8.2.

6 **SMALL RUMINANT LENTIVIRUSES (CAPRINE**
7 **ARTHRITIS/ENCEPHALITIS**
8 **& MAEDI-VISNA)**

9 SUMMARY

10 *Caprine arthritis/encephalitis (CAE) and maedi-visna (MV) are persistent lentivirus infections of goats*
11 *and sheep. They are often grouped together as the small ruminant lentiviruses (SRLVs). Maedi-visna*
12 *is also known as ovine progressive pneumonia (OPP). Phylogenetic analyses comparing nucleotide*
13 *sequences of MV virus (MVV) and CAE virus (CAEV) have demonstrated that these are closely*
14 *related lentiviruses. One source of CAEV and MVV transmission is colostrum and milk. The source*
15 *of horizontal transmission in the absence of lactation remains unknown; however, faeces and lung*
16 *fluids are known to harbour infectious virus. Ovine lentiviruses have been identified in most of the*
17 *sheep-rearing countries of the world, with the notable exceptions of Australia and New Zealand. The*
18 *distribution of CAEV is highest in industrialised countries, and seems to have coincided with the*
19 *international movement of European breeds of dairy goats. Clinical and subclinical MV and CAE are*
20 *associated with progressive, mononuclear cell inflammatory lesions in the lungs, joints, udder and*
21 *central nervous system. Indurative mastitis is common in both host species, and its economic*
22 *significance may be underestimated. Laboured breathing associated with emaciation caused by*
23 *progressive pneumonitis is the predominant feature in clinically affected sheep, whereas polyarthritis*
24 *is the main clinical sign in goats. However, most lentivirus-infected sheep and goats are largely*
25 *subclinical, but remain persistent carriers of virus and are capable of transmitting infection via*
26 *colostrum or milk and respiratory secretions. The most practical and reliable approach to confirming*
27 *a diagnosis of MV or CAE is a combination of serology and clinical evaluation. Although serology*
28 *represents the most cost-effective method of diagnosing infection in persistently infected, clinically*
29 *normal animals, it should be understood that testing errors can occur. The frequency of error depends*
30 *on several factors including but not limited to: 1) the assay format, 2) the homology between the strain*
31 *of virus used in the assay and the strains of virus present in the tested populations, and 3) the viral*
32 *antigen used in the assay.*

33 **Detection and identification of the agent:** *Virus isolation can be attempted from live clinical or*
34 *subclinical cases by co-cultivating peripheral blood or milk leukocytes with appropriate ovine or*
35 *caprine cell cultures, such as choroid plexus (MVV) or synovial membrane (CAEV) cells. Virus*
36 *isolation is very specific but has variable sensitivities. Following necropsy, virus isolation is most*
37 *readily accomplished by establishing explant cultures of affected tissues, e.g. lung, choroid plexus,*
38 *synovial membrane, spleen or udder. Also, alveolar macrophages may be obtained from the lung at*
39 *post-mortem and co-cultivated with susceptible cells. The cytopathic effects are characteristic,*
40 *consisting of the appearance of refractile stellate cells and syncytia. The presence of MVV or CAEV*
41 *can be confirmed by immunolabelling methods, reverse transcription activity and electron microscopy.*

42 **Nucleic acid recognition-detection methods:** *Many standard and a few quantitative polymerase*
43 *chain reaction (PCR) assays for detecting MV and CAE provirus have been described and are used*
44 *routinely in many laboratories for the rapid detection, quantitation, and identification of the small*

45 ruminant lentivirus strains. Cloning and/or sequencing of PCR products is the most direct method to
46 confirm the specificity of PCR results.

47 **Serological tests:** Most infected sheep and goats possess detectable specific antibodies that can
48 be assayed by a number of different serological tests. The two most commonly used are the agar gel
49 immunodiffusion test and the enzyme-linked immunosorbent assay (ELISA). Western blot analysis
50 and radio-immunoprecipitation are also performed, but only in specialised laboratories. A milk
51 antibody assay may be appropriate in dairy goat herds. The time required for seroconversion
52 following infection can be relatively prolonged and unpredictable, being measured in months rather
53 than in weeks. However, after seroconversion, the antibody response usually persists and antibody-
54 positive sheep and goats are regarded as virus carriers.

55 **Requirements for vaccines:** There are no vaccines available.

56 A. INTRODUCTION

57 Caprine arthritis/encephalitis (CAE) of goats and maedi-visna (MV) of sheep are persistent virus infections caused
58 by closely related lentiviruses (Minguijón *et al.*, 2015; Peterhans *et al.*, 2004). Maedi-visna is also known as ovine
59 progressive pneumonia (OPP). Sheep can be experimentally infected with CAE and goats can be experimentally
60 infected with MV. In addition, phylogenetic analyses comparing nucleotide sequences of MV virus (MVV) and CAE
61 virus (CAEV) show clear indications of the existence and epidemiological importance of cross-species transmission
62 between sheep and goats without demonstrating clearly that one virus has emerged from the other (Shah *et al.*,
63 2004a; 2004b). Despite the fact that MVV and CAEV are still classified as two different viral species, there is an
64 increasing consensus among the scientific community to consider them as two different genotypes (A and B,
65 respectively) of a larger group of viruses, named small ruminant lentiviruses (SRLV), displaying different genetic,
66 antigenic and biological properties.

67 MV and CAE are characterised by lifelong persistence of the causal agent in host monocytes and macrophages,
68 and a variable length of time between infection and induction of a serologically detectable antiviral antibody
69 response. Most infected sheep and goats do not exhibit clinical disease, but remain persistently infected and are
70 capable of transmitting virus (Adams *et al.*, 1983; Crawford *et al.*, 1980).

71 Maedi-visna is an Icelandic name that describes two of the clinical syndromes recognised in MV virus (MVV)-
72 infected sheep. 'Maedi' means 'laboured breathing' and describes the disease associated with a progressive
73 interstitial pneumonitis, and 'visna' means 'shrinkage' or 'wasting', the signs associated with a paralysing
74 meningoencephalitis. Whereas progressive lung disease is the primary finding with MVV infection, chronic
75 polyarthritis, with synovitis and bursitis is the primary clinical outcome of CAEV infection. Encephalitis occurs
76 primarily in kids aged between 2 and 6 months following CAEV infection, though more rare compared with when
77 first recognised in the early 1980s. Thus but careful differential diagnoses need to be conducted to rule out other
78 syndromes or infections in kids. Indurative mastitis occurs in both syndromes. The lungs of sheep affected by MV
79 do not collapse when removed from the thorax and often retain the impression of the ribs. The lungs and lymph
80 nodes increase in weight (up to 2–3 times the normal weight). The lesions are uniformly distributed throughout the
81 lungs, which are uniformly discoloured or mottled grey-brown in colour and of a firm texture. Diagnosis of CAEV
82 and MVV induced respiratory disease was reviewed by Chakraborty *et al.* (2014). Udders affected by MV are
83 diffusely indurated and associated lymph nodes may be enlarged.

84 When MV or CAE is the suspected cause of clinical disease, confirmation of the diagnosis can be achieved by a
85 combination of clinical evaluation, detection and identification of the viruses, or by serology and, when necessary,
86 histological examination of appropriate tissues collected at necropsy. Important tissues to examine include lung for
87 progressive interstitial pneumonitis, brain and spinal cord for meningoencephalitis, udder for indurative mastitis,
88 affected joints and synovium for arthritis, and kidney for vasculitis (Crawford & Adams, 1984). The nature of the
89 inflammatory reaction in each site is similar, consisting of an interstitial, mononuclear cell reaction, sometimes with
90 large aggregates of lymphoid cells and follicle formation.

91

B. DIAGNOSTIC TECHNIQUES

Table 1. Test methods available for the diagnosis of caprine arthritis/encephalitis and maedi-visna and their purpose

Method	Purpose					
	Population freedom from infection ^(a)	Individual animal freedom from infection prior to movement ^(b,c)	Contribute to eradication policies ^(d)	Confirmation of clinical cases ^(e)	Prevalence of infection – surveillance ^(f)	Immune status in individual animals or populations post-vaccination ^(g)
<u>Detection and identification of the agent</u>						
Virus isolation	–	–	–	+	–	–
Antigen detection	–	–	–	+	–	–
PCR	+	+	++	+++ _±	++	–
<u>Detection of immune response</u>						
AGID	+	++ ^(h) +	++ ^(h)	++ +	+++	+ _±
GFT	–	–	–	–	–	–
ELISA	+++	+++ ^(h)	+++ ^(h)	+ _±	+++	+ _±
VN	–	–	–	–	–	+++ _±
IFAT	–	–	–	–	–	–

Key: +++ = recommended for this purpose; ++ recommended but has limitations;

+ = suitable in very limited circumstances; – = not appropriate for this purpose.

PCR = polymerase chain reaction; AGID = agar gel immunodiffusion; GFT = complement fixation test;

ELISA = enzyme-linked immunosorbent assay; VN = virus neutralisation; IFAT = indirect fluorescent antibody test.

^(a)See Appendix 1 of this chapter for justification table for the scores given to the tests for this purpose.

^(b)See Appendix 2 of this chapter for justification table for the scores given to the tests for this purpose.

^(c)A combination of agent identification method and detection of immune response is recommended.

^(d)See Appendix 3 of this chapter for justification table for the scores given to the tests for this purpose.

^(e)See Appendix 4 of this chapter for justification table for the scores given to the tests for this purpose.

^(f)See Appendix 5 of this chapter for justification table for the scores given to the tests for this purpose.

^(g)No vaccines available for small ruminant lentiviruses.

^(h)Samples from animals under 6 months of age are not recommended for testing due to maternal antibody interference, especially if heat-treated colostrum is used for eradication purposes.

1. Detection and identification of the agent

Isolation and characterisation of MVV or CAEV would not normally be attempted for routine diagnostic purposes.

Due to the persistent nature of these infections, the establishment of a positive antibody status is sufficient for the

~~identification~~ detection of virus carriers. However, due to a late seroconversion after infection, negative serology

may occur in recently infected animals.

There are two approaches to the isolation of MVV and CAEV: one for use with the live animal, and the second for

use with necropsy tissues.

1.1. Isolation from the live animal

1.1.1. Maedi-visna virus

The MV provirus DNA is carried in circulating monocytes and tissue macrophages. Virus isolation

from the live animal therefore requires the establishment of leukocyte preparations, with aseptic

precautions, from peripheral blood or milk during lactation, culturing them together with indicator

cells. Sheep choroid plexus (SCP) cells are commonly used for this purpose. These indicator cells

can be prepared as primary explant cultures from fetal or new-born virus-free lambs, and their

number can be multiplied over three to four passages for storage in liquid nitrogen. The recovered

122 SCP cells are suitable for co-cultivation for up to 10 or 15 passages. Although the cells continue
123 to grow well thereafter, their susceptibility to MVV may become reduced.

124 Leukocyte preparations can be made from peripheral blood as buffy coats by the centrifugation
125 at 1000 **g** of heparinised, ethylenediamine tetra-acetic acid (EDTA) or citrated samples for
126 15 minutes. The cells are aspirated, suspended in Hanks' balanced salt solution (HBSS), and
127 further purified by centrifugation at 400 **g** on to a suitable cushion of density medium for
128 40 minutes. The interface cells are spin-washed once or twice in HBSS at 100 **g** for 10 minutes,
129 and the final cell pellet is resuspended in medium to a concentration of approximately 10⁶ cells/ml;
130 cells are generally cultured for 10–12 days in Teflon bags and are then added to a washed
131 monolayer of slightly subconfluent SCP cells in a flask with an area of 25 cm².

132 Leukocytes can be similarly deposited from milk by centrifugation, when they are spin-washed,
133 resuspended and finally added to SCP monolayer cultures.

134 These cultures are maintained at 37°C in a 5% CO₂ atmosphere, changing the medium and
135 passaging as necessary. They are examined for evidence of a cytopathic effect (CPE), which is
136 characterised by the appearance of refractile stellate cells with dendritic processes accompanied
137 by the formation of syncytia. The cultures should be maintained for several weeks before being
138 discarded as uninfected. Once a CPE is suspected, cover-slip cultures should be prepared. These
139 are fixed, and evidence of viral antigen is sought by immunolabelling, usually by means of indirect
140 fluorescent antibody or by the use of indirect immunoperoxidase methods. In addition, the cells
141 of any suspect monolayers are deposited by centrifugation, and preparations are made for the
142 identification of any characteristic lentivirus particles by transmission electron microscopy.
143 Reverse transcriptase in the supernatant of the cell culture is indicative of the presence of
144 retroviruses.

145 1.1.2. Caprine arthritis/encephalitis virus

146 The same principles that apply to the isolation of MVV also apply to the isolation of CAEV. CAEV
147 was originally isolated by explantation of synovial membrane from an arthritic goat (Crawford &
148 Adams, 1984). With live CAEV-infected goats, peripheral blood, milk, and possibly joint fluid
149 aspirate represent the most suitable specimens from which leukocyte preparations can be
150 established. Goat synovial membrane (GSM) cells are suitable indicator cells. If a CPE is
151 suspected, tests for detection of viral antigen should be carried out, as described above.

152 1.2. Isolation from necropsy tissues

153 1.2.1. Caprine arthritis/encephalitis virus and maedi-visna virus

154 Samples of suspect tissues, collected as fresh as possible, such as lung, synovial membranes,
155 udder, ~~etc. spleen~~, are collected aseptically into sterile HBSS or cell culture medium and minced
156 finely (the smaller the better) in a Petri dish using scalpel blades. Approximately 10–20 fragments
157 are resuspended with 10 ml of medium (i.e. Dulbecco's modified Eagle's medium) supplemented
158 with 2x antibiotic/antimycotic solution, transferred into a 14 ml tube and incubated for 3 hours at
159 37°C in a humid 5% CO₂ atmosphere. Sedimented fragments are then resuspended into 10 ml
160 of medium with 1x antibiotic/antimycotic solution and 10% FBS and individual fragments are
161 collected by Pasteur pipette and transferred to 25 cm² flasks approximately 20–30 fragments per
162 flask, and a drop of growth medium is placed carefully on each. The flasks are then incubated at
163 37°C in a humid 5% CO₂ atmosphere, and left undisturbed for a few 3–5 days to allow the
164 individual explants to adhere to the plastic. Partial fresh medium changes can be added with care
165 made every 3 days until a confluent monolayer is obtained (usually 10–15 days), after which rafts
166 of cells will gradually grow out from the fragments. When there is sufficient cell out-growth, the
167 cultures are trypsin dispersed to allow the development of cell monolayers and propagated at
168 weekly intervals. Paired culture wells (i.e. 24 wells microplate) can be fixed and Giemsa stained
169 to facilitate These can be examined examination for CPE at each passage, and any suspected
170 virus growth is confirmed in the same way as for the co-cultivations.

171 Adherent macrophage cultures are easy to establish from lung-rinse material (post-mortem
172 broncho-alveolar lavage) and can be tested for virus production by serology, electron microscopy,
173 or reverse transcriptase assay within 1–2 weeks. Virus isolations can be done by co-cultivation
174 of macrophages and SCP or GSM cells as described for leukocytes above.

175

176 **1.3. Nucleic acid recognition-detection methods**

177 **Real-time PCR**

<u>Pathogen/ target gene</u>	<u>Primer/probe (5'-3')</u>	<u>Concentration</u>	<u>Cycling parameters^(a)</u>
<u>Method^{(b)(c)}: Schaer <i>et al.</i> (2022); GenBank Accession No.: M33677</u>			
<u>Geno A LTR-gag</u>	<u>RTMVVLRgag-F: GGG-GAC-GCC-TGA-AGT-RAG-GTA-A</u> <u>RTMVVLRgag-R: YTT-GAG-CTC-RGG-GTA-YCC-CTT</u> <u>RTMVVLRgag-P: FAM-CTT-TGA-GCC-TTG-CKT-CGC-CAT-GTC-T-TAMRA</u>	<u>900 nM</u> <u>900 nM</u> <u>200nM</u>	<u>40 cycles of:</u> <u>95°C/15_sec and</u> <u>60°C/60_sec</u>
<u>Geno B LTR-gag</u>	<u>RTCAELTRgag-F: CTG-RAG-GAG-TAM-GGT-AAG-TRA-CTC-TGC</u> <u>RTCAELTRgag-R: TTG-ATR-CAT-TTK-TCS-AKC-TCA-GGA-TAA</u> <u>RTCAELTRgag-P: FAM-CCG-GAG-ACT-TGC-CTC-GCC-ATG-TC-TAMRA</u>	<u>900 nM</u> <u>900 nM</u> <u>200nM</u>	<u>40 cycles of:</u> <u>95°C/15_sec and</u> <u>60°C/60_sec</u>

178 ^(a)A denaturation step prior to cycling has not been included.
 179 ^(b)IUPAC (International Union of Pure and Applied Chemistry) codes were used to indicate degenerated primers. ^(c)This method
 180 has been proposed as a second nested amplification step after a first conventional PCR, see reference for details.

181 **Conventional PCR**

<u>Pathogen/ target gene</u>	<u>Primer (5'-3')</u>	<u>Concentration</u>	<u>Cycling parameters^(a)</u>
<u>Method 1: Extramiana <i>et al.</i> (2002); GenBank Accession No.: M10608, amplicon size: 291[bp]</u>			
<u>SRLV-LTR</u>	<u>LTRs: TGA-CAC-AGC-AAA-TGT-AAC-CGC-AAG</u>	<u>0.5 µM</u>	<u>SRLV-LTR</u>

182 ^(a)A denaturation step prior to cycling has not been included.

183 Nucleic acid recognition-detection methods may be used for the detection, quantitation, and identification
 184 of MV and CAE proviral DNA using the standard polymerase chain reaction (PCR) followed by Southern
 185 blotting, *in situ* hybridisation, or cloning and/or sequencing of the PCR product (Alvarez *et al.*, 2006;
 186 Extramiana *et al.*, 2002; Herrmann-Hoesing *et al.*, 2007; Johnson *et al.*, 1992). Standard PCR techniques
 187 for the detection of MV and CAE proviral DNA in cells and tissues are routinely used in many laboratories
 188 and are generally used as supplemental tests for determining infection status of those animals that
 189 cannot be definitively diagnosed by serology (Deandros *et al.*, 2005). Real-time or quantitative PCR
 190 techniques are used in some laboratories and these tests, in addition to determining infection status,
 191 also quantify the amount of MV or CAE provirus in an animal (Alvarez *et al.*, 2006; De Regge & Cay,
 192 2013; Herrmann-Hoesing *et al.*, 2007). Furthermore, molecular techniques such as PCR, cloning and
 193 sequencing also provide knowledge on a country's or region's specific MV and CAE strains, which may
 194 influence which serological assay and corresponding MV or CAE antigen to use. Phylogenetic analyses
 195 of MV and CAE proviral DNAs from SRLV strains throughout the world have suggested that in some
 196 areas, MV may have naturally infected goats, and CAE may have naturally infected sheep (Shah *et al.*,
 197 2004a; 2004b). Recently, loop-mediated isothermal amplification (LAMP) was applied to the detection of
 198 CAE provirus (Balbin *et al.*, 2014). LAMP uses 4-6 primers that amplify 6-8 regions of the target gene
 199 (Notomi *et al.*, 2000). In the future, molecular diagnostic tests along with phylogenetic analyses of MV
 200 and CAE provirus may be used to track transmission. Sensitivity of PCR methods may be influenced by
 201 the high genetic heterogeneity of SRLV and some primer sets have been developed for detection of
 202 specific viral genotype/subtypes (De Regge & Cay, 2013; Schaer *et al.*, 2022).

203 An important issue in the use of PCR is specificity. Because of the possibility of amplifying unrelated
 204 sequences from the host's genomic DNA (false positives), the amplified product should be checked by
 205 either hybridisation, restriction endonuclease digestion patterns, or sequencing. Sequencing provides
 206 the best proof of specificity in the validation of PCR-based tests and is recommended by the WOAH (see
 207 Chapter 2.1.2 *Biotechnology advances in the diagnosis of infectious diseases*). Sensitivity of PCR-based
 208 tests can be improved by the use of nested PCR, but specificity of the nested PCR test should be checked
 209 using hybridisation, restriction endonuclease digestion patterns, or sequencing methods. A high
 210 throughput sequencing approach is becoming a useful tool in specialised laboratories to characterise
 211 viral isolates at the full genome level (Colitti *et al.*, 2019).

212

213 2. Serological tests

214 Ovine and caprine lentivirus infections are frequently persistent, so antibody detection is a valuable serological
215 tool for identifying virus carriers. The close antigenic relationship between MVV and CAEV does not extend
216 to detection of heterologous antibody in some serological assays (Knowles *et al.*, 1994).

217 The assays most commonly used to serologically diagnose the presence of a small ruminant lentivirus
218 infection are agar gel immunodiffusion (AGID) and the enzyme-linked immunosorbent assay (ELISA). AGID
219 was first developed and reported in 1973 (Terpstra & De Boer, 1973), and the ELISA was first developed and
220 reported in 1982 (Houwens *et al.*, 1982). The AGID is specific, reproducible and simple to perform, but
221 experience is required for reading the results. The ELISA is economical, quantitative and can be automated,
222 thus making it useful for screening large numbers of sera. The sensitivity and specificity of both the AGID
223 assay and ELISA depend upon the virus strain used in the assay, viral antigen preparation, and the standard
224 of comparison assay. Western blot analysis and/or radio-immunoprecipitation are the standards of
225 comparison used to assess sensitivity and specificity of new AGID tests and ELISAs.

226 2.1. Agar gel immunodiffusion

227 There are two MV and CAE viral antigens of major importance in routine serology, a viral surface
228 envelope glycoprotein commonly referred to as SU or gp135, and a nucleocapsid protein referred to as
229 CA or p28. These are both conserved in an antigen preparation consisting of medium harvested from
230 infected cell cultures and concentrated approximately 50-fold by dialysis against polyethylene glycol. As
231 an example the WLC-1 strain of MV virus is commonly used in the AGID assay in the United States
232 (Cutlip *et al.*, 1977)⁴ and a Canadian MV field strain is used for AGID tests in Canada (Simard & Briscoe,
233 1990b).

234 It is important to recognise that the sensitivity of the AGID test for detecting anti-CAEV antibody is
235 dependent on both the virus strain and the viral antigen used (Adams & Gorham, 1986; Knowles *et al.*,
236 1994). It was demonstrated that an AGID test with CAEV gp135 afforded greater sensitivity than an AGID
237 test with CAEV p28 (Adams & Gorham, 1986). Also, it was shown that when compared with radio-
238 immunoprecipitation, the sensitivity of the AGID test for anti-CAEV antibody was 35% greater using CAE
239 virus antigen over using MV virus antigen (Knowles *et al.*, 1994). The most likely explanation for this
240 difference in sensitivity between the CAE and MV virus antigen for the detection of anti-CAEV antibody
241 is that although the radio-immunoprecipitation assay requires only the binding of a single epitope by
242 antibody to obtain a positive result, precipitation in an agar gel requires multiple epitope-antibody
243 interactions. Although the MV and CAE viruses have 73–74.4% nucleotide sequence identity in the
244 envelope gene, this amount of identity may not be sufficient to produce sufficient antibody to CAE and
245 MV mutually common epitopes resulting in undetectable antibody/antigen precipitin lines using MV virus
246 antigen. When the appropriate antigen is used, the AGID test performance is high. When compared with
247 immunoprecipitation, the AGID for the detection of anti-CAEV antibody, if CAEV antigen was used, had
248 92% sensitivity and 100% specificity (Knowles *et al.*, 1994). In addition, the AGID for detection of anti-
249 MVV antibody, if MVV antigen was used, had 99.3 and 99.4% sensitivity and specificity, respectively.

250 In adult persistently MVV-infected sheep and CAEV-infected goats, the predominant
251 immunoprecipitating antibody response is directed against gp135 antigen. An anti-p28 response is
252 usually present at a lower titre than the anti-gp135 response in persistently infected adult small ruminants
253 using immunoprecipitation. In some CAEV-infected goats there is evidence to suggest that an anti-gp135
254 antibody response is produced, in the absence of an anti-p28 response and vice versa, in a proportion
255 of individuals (Rimstad *et al.*, 1994). Hence, for validation of a test, standard sera producing both anti-
256 gp135 and anti-p28 precipitin lines are required.

257 The gel medium is 0.7–1% agarose in 0.05 M Tris buffer, pH 7.2, with 8.0% NaCl. The test is conveniently
258 performed in plastic Petri dishes, or in 10 cm² plastic trays. The pattern and size of the wells will
259 determine the number of sera tested per plate. Various well patterns can be adopted, but a hexagonal
260 arrangement with a central well is usual: for example, a pattern with alternating large (5 mm in diameter)
261 and small (3 mm in diameter) peripheral wells, 2 mm apart and 2 mm from a central antigen well that is
262 3 mm in diameter. The large peripheral wells are used for test sera and the small ones for standard sera.
263 A weak positive control must be included in each test. The plates are incubated overnight at 20–25°C in
264 a humid chamber, and then examined for precipitin lines. Plates may be incubated at 2–8°C for another
265 24 hours to enhance the precipitin lines.

⁴—This virus has been distributed by Dr Howard Lehmkuhl, National Animal Disease Center, United States Department of Agriculture, P.O. Box 70, Ames, Iowa, USA.

266 An important consideration is the need for experienced personnel to interpret the AGID. Interpretation of
267 AGID results is dependent on the antigen used. Examples of AGIDs with different antigen preparations
268 and a guide for interpretation of the results can be found in Adams *et al.* (1983).

269 2.2. Enzyme-linked immunosorbent assay

270 Currently, there are over 30 different ELISAs reported for the detection of anti-MVV or anti-CAEV
271 antibodies in the sera of sheep or goats, respectively (~~Deandres *et al.*, 2005~~). Most of these ELISAs are
272 indirect ELISAs (I-ELISA) although there are three reported competitive ELISAs (C-ELISA) using
273 monoclonal antibodies (MAbs) (Herrmann *et al.*, 2003; ~~Houwens & Schaake, 1987~~). Half of I-ELISAs use
274 purified whole virus preparations for antigen whereas the other half use recombinant protein and/or
275 synthetic peptide antigens. Some I-ELISAs use a combination of both CAEV-like and MVV-like antigens.
276 A few of the I-ELISAs have shown high sensitivity and specificity against a standard of comparison,
277 western blot analysis or radio-immunoprecipitation (Rosati *et al.*, 1994; Saman *et al.*, 1999). When
278 compared with radio-immunoprecipitation, one C-ELISA has shown high sensitivity and specificity both
279 in sheep and goats in the USA suggesting that this one test can be used for both MVV and CAEV US
280 surveillance (Herrmann *et al.*, 2003). ELISAs have been used for several years in some European
281 countries in control and eradication schemes for MVV in sheep and CAEV in goats (~~Motha & Ralston,~~
282 ~~1994~~; Pépin *et al.*, 1998), AGID is useful to confirm positive ELISA results due to its high specificity. A
283 number of both I-ELISAs and C-ELISAs are commercially available.

284 Whole-virus antigen preparations are produced by differential centrifugation of supernatants from
285 infected cell cultures and detergent treatment of purified virus, and are coated on microplates (~~Dawson~~
286 ~~*et al.*, 1982~~; Simard & Briscoe, 1990a; Zanoni *et al.*, 1994). Whole-virus preparations should contain both
287 gp135 and p28. Recombinant antigens or synthetic peptides are usually produced from whole or partial
288 segments of the gag or envelope genes and may be used in combination (~~Power *et al.*, 1995~~; Rosati *et*
289 *al.*, 1994; Saman *et al.*, 1999). Thus, recombinant gag or envelope gene products fused with glutathione
290 S-transferase fusion protein antigen that have been produced in *Escherichia coli* provide a consistent
291 source of antigen for international distribution and standardisation.

292 The ELISA technique is also applicable to colostrum or milk, and some studies have evaluated paired
293 serum and milk samples. Because colostrum and milk are sources of CAEV transmission, the testing of
294 milk samples for anti-CAEV or anti-MVV antibody would not provide timely information for the prevention
295 of transmission, especially to offspring from the immediate gestation. An I-ELISA based on a variable
296 and immunodominant epitope of the capsid antigen has been proposed as a serotyping method for
297 discrimination between SRLV genotypes (Nogarol *et al.*, 2019).

298 The ELISA is performed at room temperature (~25°C) and is easy to perform in laboratories that have
299 the necessary equipment (microplate reader) and reagents. It is convenient for large-scale screening, as
300 it is a reliable and quantitative technique for demonstrating small ruminant lentiviruses (SRLVs)
301 antibodies in sheep and goats. It requires relatively pure antigen. One disadvantage of several ELISAs
302 is that many have not been validated against a standard of comparison such as western blot analysis or
303 radio-immunoprecipitation. The test method should be validated in accordance with Chapter 1.1.6
304 *Validation of diagnostic assays for infectious diseases of terrestrial animals* using a standard of
305 comparison such as western blot analysis or radio-immunoprecipitation. To date, only one ELISA has
306 met these testing standards (Zanoni *et al.*, 1994).

307 For I-ELISA, wells of the microplate are coated with antigen. Diluted serum samples are added to the
308 wells and react to antigens bound to the solid support. Unbound material is removed by washing after a
309 suitable incubation period. Conjugate (e.g. horseradish-peroxidase-labelled anti-ruminant Ig) reacts with
310 specific antibodies bound to the antigen. Unreacted conjugate is removed by washing after a suitable
311 incubation period. Enzyme substrate is added. The rate of conversion of substrate is proportional to the
312 amount of bound antibodies. The reaction is terminated after a suitable time and the amount of colour
313 development is measured spectrophotometrically. A disadvantage of the I-ELISA is that test sera
314 typically need to be diluted 1/50 or greater in order to lower the number of false positives. Some I-ELISAs
315 require a biphasic test format, including a negative antigen well, to minimise false positive reactions.

316 Specific MAbs have been used in a C-ELISA for SRLVs to capture gp135 or p28 as antigen (Frevereiro
317 *et al.*, 1999; Herrmann *et al.*, 2003; ~~Houwens & Schaake, 1987~~; ~~Ozyoruk *et al.*, 2004~~). C-ELISA
318 overcomes the problem of antigen purity, as the specificity of this test depends on the MAb epitope. For
319 C-ELISA, sample sera containing anti-SRLV antibodies inhibit binding of enzyme-labelled MAb to SRLV
320 antigen coated on the plastic wells. Binding of the enzyme-labelled MAb conjugate is detected by the
321 addition of enzyme substrate and quantified by subsequent colour product development. Strong colour
322 development indicates little or no blockage of enzyme-labelled MAb binding and therefore the absence
323 of SRLV antibodies in sample sera. In contrast, weak colour development due to the inhibition of the
324 enzyme-labelled MAb binding to the antigen on the solid phase indicates the presence of SRLV

325 antibodies in sample sera. The format of the C-ELISA requires that serum antibodies must bind to or
326 bind in close proximity to the specific MAb epitope. C-ELISA is less suitable than I-ELISA for antibody
327 detection in milk, due to lower IgG concentration.

328 **2.2.1. Materials and reagents**

329 Microtitre plates with 96 flat-bottomed wells, freshly coated or previously coated with SRLV
330 antigen; microplate reader (equipped with 405, 450, 490 and 620 nm filters); 37°C humidified
331 incubator; 1-, 8- and 12-channel pipettes with disposable plastic tips; microplate shaker (optional);
332 fridge; freezer.

333 Positive and negative control sera; conjugate (e.g. ruminant anti-immunoglobulin labelled with
334 peroxidase); tenfold concentration of diluent (e.g. phosphate buffered saline/Tween); distilled
335 water; 10× wash solution; substrate or chromogen (e.g. ABTS [2,2'-azino-bis-(3-ethylbenzo-
336 thiazoline-6-sulphonic acid)] or TMB [3,3',5,5'-tetramethylbenzidine]); stop solution (e.g.
337 detergent, sulfuric acid).

338 **2.2.2. Indirect ELISA: test procedure**

- 339 i) Dilute the serum samples, including control sera, to the appropriate dilution (e.g. 1/20) and
340 distribute 0.1–0.2 ml per well (in duplicate if biphasic ELISA). Control sera are positive and
341 negative sera provided by the manufacturer and an internal positive reference serum from
342 the laboratory in order to compare the titres between different tests.
- 343 ii) Cover the plate with a lid and incubate at room temperature or 37°C for 30–90 minutes.
344 Empty the contents and wash three times in washing solution at room temperature.
- 345 iii) Add the appropriate dilution of freshly prepared conjugate to the wells (0.1 ml per well).
346 Cover each plate and incubate as in step ii. Wash again three times.
- 347 iv) Add 0.1 ml of freshly prepared or ready-to-use chromogen substrate solution to each well
348 (e.g. ABTS in citrate phosphate buffer, pH 5.0, and 30% H₂O₂ solution [0.1 µl/ml]).
- 349 v) Shake the plate; after incubation, stop the reaction by adding stopping solution to each well
350 (e.g. 0.1 ml sulphuric acid).
- 351 vi) Read the absorbance of each well with the microplate reader at 405 nm (ABTS) or 450–
352 620 nm (TMB). The absorbance values will be used to calculate the results.
- 353 vii) Interpretation of the results
- 354 For commercial kits, interpretations and validation criteria are provided with the kit.

355 Interpretation criteria should be developed and validated for the individual procedures and
356 reagents used in the laboratory. The following is given as an example:

357 Calculate the mean absorbance (Ab) of the sample serum and of the positive (Ab_{pos}) and
358 negative (Ab_{neg}) control sera, and for each serum, calculate the percentage:

359
$$\frac{Ab - Ab_{neg}}{Ab_{pos} - Ab_{neg}} \times 100$$

360 if a test sample has mean absorbance of <30% it is classed as negative, 30-40% is classed
361 as doubtful, and >40% as positive.

362 **2.2.3. Competitive ELISA: test procedure**

- 363 i) Add 0.05 ml of undiluted serum and positive/negative controls to antigen-coated plate.
- 364 ii) Incubate for 1 hour at room temperature.
- 365 iii) Empty the plate and wash the plate three with diluted wash solution.
- 366 iv) Add 0.05 ml of diluted ~~MAb antibody~~ peroxidase conjugate to each well. Mix well and
367 incubate for 30 minutes at room temperature.
- 368 v) After the 30-minute incubation, empty the plate and repeat the washing procedure described
369 in step iii.
- 370 vi) Add 0.05 ml of substrate solution (ex: TMB) to each well. Mix and cover plate with aluminium
371 foil. Incubate for 20 minutes at room temperature. Do not empty wells.

- 372 vii) Add 0.05 ml of stop solution to each well. Mix. Do not empty wells.
- 373 viii) Immediately after adding the stop solution, the plate should be read on a plate reader (620,
374 630 or 650 nm).
- 375 ix) Interpretation of results
- 376 Interpretation criteria should be developed and validated for the individual procedures and
377 reagents used in the laboratory. The following is given as an example:
- 378 Calculation: $100 - [(Sample\ Ab \times 100)/(Mean\ negative\ control\ Ab)] = \% inhibition.$
- 379 For goats, if a test sample causes >33.2% inhibition, it is positive; if a test sample causes
380 <33.2% inhibition, it is negative. For sheep, if a test sample causes >20.9% inhibition, it is
381 positive; if a test sample causes <20.9% inhibition, it is negative.

382 C. REQUIREMENTS FOR VACCINES

383 There are no vaccines available.

384 REFERENCES

- 385 ADAMS D.S. & GORHAM J.R. (1986). The gp135 of caprine arthritis encephalitis virus affords greater sensitivity than
386 the p28 in immunodiffusion serology. *Res. Vet. Sci.*, **40**, 157–160.
- 387 ADAMS D.S., KLEVJER-ANDERSON P., CARLSON J.L., MCGUIRE T.C. & GORHAM J.R. (1983). Transmission and control
388 of caprine arthritis-encephalitis virus. *Am. J. Vet. Res.*, **44**, 1670–1675.
- 389 ADJADJ N.R., VICCA J., MICHIELS R. & DE REGGE N. (2019). (Non-)Sense of Milk Testing in Small Ruminant Lentivirus
390 Control Programs in Goats. Comparative Analysis of Antibody Detection and Molecular Diagnosis in Blood and
391 Milk. *Viruses*, **12**, 3.
- 392 ALVAREZ V., ARRANZ J., DALTABUIT M., LEGINAGOIKOA I., JUSTE R.A., AMORENA B., DE ANDRES D., LUJAN L.L., BADIOLA
393 J.J. & BARRIATUA E. (2006). PCR detection of colostrum-associated Maedi-Visna virus (MVV) infection and
394 relationship with ELISA-antibody status in lambs. *Res. Vet. Sci.*, **80**, 226–234.
- 395 BALBIN M.M., BELOTINDOS L.P., ABES N.S. & MINGALA C.N. (2014). Caprine arthritis encephalitis virus detection in
396 blood by loop-mediated isothermal amplification (LAMP) assay targeting the proviral gag region. *Diagn. Microbiol.*
397 *Infect. Dis.*, **79**, 37–42.
- 398 BERTONI G., ZAHNO M.L., ZANONI R., VOGT H.R., PETERHANS E., RUFF G., CHEEVERS W.P., SONIGO P. & PANCINO G.
399 (1994). Antibody reactivity to the immunodominant epitopes of the Caprine Arthritis-Encephalitis Virus gp38
400 transmembrane protein associates with the development of arthritis. *J. Virol.*, **68**, 7139–7147.
- 401 BRINKHOF J.M., HOUWERS D.J., MOLL L., DERCKSEN D. & VAN MAANEN C. (2010). Diagnostic performance of ELISA and
402 PCR in identifying SRLV-infected sheep and goats using serum, plasma and milk samples and in early detection of
403 infection in dairy flocks through bulk milk testing. *Vet. Microbiol.*, **142**, 193–198.
- 404 CHAKRABORTY S., KUMAR A., TIWARI R., RAHAL A., MALIK Y., DHAMA K., PAL A. & PRASAD M. (2014). Advances in
405 diagnosis of respiratory diseases of small ruminants. *Vet. Med. Int.*, Article ID 508304, 16 pp.
- 406 COLITTI B., CORADDUZZA E., PUGGIONI G., CAPUCCHIO M.T., REINA R., BERLOTTI L. & ROSATI S. (2019). A new
407 approach for Small Ruminant Lentivirus full genome characterization revealed the circulation of divergent strains.
408 *PLoS ONE* **14**(2): e0212585.
- 409 CRAWFORD T.B. & ADAMS D.S. (1981). Caprine arthritis encephalitis: clinical features and presence of antibody in
410 selected goat populations. *J. Am. Vet. Med. Assoc.*, **178**, 713–719.
- 411 CRAWFORD T.B., ADAMS D.S., CHEEVERS W.P. & CORK L. C. (1980). Chronic arthritis in goats caused by a retrovirus.
412 *Science*, **207**, 997–999.

- 413 CUTLIP R.C., JACKSON T.A. & LAIRD O.A. (1977). Immunodiffusion test for ovine progressive pneumonia. *Am. J. Vet. Res.*, **38**, 1081–1084.
414
- 415 DAWSON M., BIRONT P. & HOUWERS D.J. (1982). Comparison of serological tests used in three state veterinary laboratories to identify maedi-visna virus infection. *Vet. Rec.*, **111**, 432–434.
416
- 417 DEANDRES D., KLEIN D., WATT N.J., BERRIATUA E., TORSTEINSDOTTIR S., BLACKLAWS B.A. & HARKISS G.D. (2005). Diagnostic tests for small ruminant lentiviruses. *Vet. Microbiol.*, **107**, 49–62.
418
- 419 DE REGGE N. & CAY B. (2013). Development, validation and evaluation of added diagnostic value of a q(RT)-PCR for the detection of genotype A strains of small ruminant lentiviruses. *J. Virol. Methods*, **194**, 250–257.
420
- 421 EXTRAMIANA A.B., GONZALEZ L., CORTABARRIA N., GARCIA M. & JUSTE R.A. (2002). Evaluation of a PCR technique for the detection of Maedi-Visna proviral DNA in blood, milk and tissue samples of naturally infected sheep. *Small Rum. Res.*, **44**, 109–118.
422
423
- 424 FREVEREIRO M., BARROS S. & FUGULHA T. (1999). Development of a monoclonal antibody blocking-ELISA for detection of antibodies against Maedi-Visna virus. *J. Virol. Methods*, **81**, 101–108.
425
- 426 GREGO E., PROFITI M., GIAMMARIOLI M., GIANNINO L., RUTILI D., WOODALL C. & ROSATI S. (2002). Genetic heterogeneity of small ruminant lentiviruses involves immunodominant epitope of capsid antigen and affects sensitivity of single-strain-based immunoassay. *Clin. Diagn. Lab. Immunol.*, **9**, 828–832.
427
428
- 429 HERRMANN L.M., CHEEVERS W.P., MCGUIRE T.C., ADAMS D.S., HUTTON M.M., GAVIN W.G. & KNOWLES D.P.A. (2003). Competitive-inhibition enzyme-linked immunosorbent assay for detection of serum antibodies to caprine arthritis-encephalitis virus: diagnostic tool for successful eradication. *Clin. Diagn. Lab. Immunol.*, **10**, 267–271.
430
431
- 432 HERRMANN-HOESING L.M., WHITE S.N., LEWIS G.S., MOUSEL M.R. & KNOWLES D.P. (2007). Development and validation of an ovine progressive pneumonia virus quantitative PCR. *Clin. Vacc. Immunol.*, **14**, 1274–1278.
433
- 434 HOUWERS D.J., GIELKENS A.L.J. & SCHAAKE J. (1982). An indirect enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to maedi-visna virus. *Vet. Microbiol.*, **7**, 209.
435
- 436 HOUWERS D.J. & SCHAAKE J. (1987). An improved ELISA for the detection of antibodies to ovine and caprine lentiviruses, employing monoclonal antibodies in a one-step assay. *J. Immunol. Methods*, **98**, 151–154.
437
- 438 JOHNSON L.K., MEYER A.L. & ZINK M.C. (1992). Detection of ovine lentivirus in seronegative sheep by *in situ* hybridization, PCR and cocultivation with susceptible cells. *Clin. Immunol. Immunopathol.*, **65**, 254–260.
439
- 440 KNOWLES D.P., EVERMANN J.F., SCHROPSHIRE C., VANDER SCHALIE J., BRADWAY D., GEZON H.M. & CHEEVER W.P. (1994). Evaluation of agar gel immunodiffusion serology using caprine and ovine lentiviral antigens for detection of antibody to caprine-arthritis encephalitis virus. *J. Clin. Microbiol.* **32**, 243–245.
441
442
- 443 MICHELIS R., VAN MAEL E., QUINET C., ADJADJ N.R., CAY A.B. & DE REGGE N. (2018). Comparative analysis of different serological and molecular tests for the detection of small ruminant lentiviruses (srlvs) in Belgian sheep and goats. *Viruses*, **10**, 696.
444
445
- 446 MINGUIJÓN E., REINA R., PÉREZ M., POLLEDO L., VILLORIA M., RAMÍREZ H., LEGINAGOIKOA I., BADIOLA J.J., GARCÍA-MARÍN J.F., DE ANDRÉS D., LUJÁN L., AMORENA B. & JUSTE R.A. (2015). Small ruminant lentivirus infections and diseases. *Vet. Microbiol.*, **181**, 75–89.
447
448
- 449 MOTH A.M.J. & RALSTON J.C. (1994). Evaluation of ELISA for detection of antibodies to CAE in milk. *Vet. Microbiol.*, **38**, 359–367.
450
- 451 NOGAROL C., BERTOLOTTI L., KLEVAR S., PROFITI M., GJERSET B. & ROSATI S. (2019). Serological characterization of small ruminant lentiviruses: A complete tool for serotyping lentivirus infection in goat. *Small Rum. Res.*, **176**, 42–46.
452
453
- 454 NOTOMI T., OKAYAMA H., MASUBUCHI, H., YONEKAWA, T., WATANABE, K., AMINO N. & HASE T. (2000). Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res.*, **28** (12): E63.
455

456 OZYORUK F., CHEEVERS W.P., HULLINGER G.A., MCGUIRE T.C., HUTTON M. & KNOWLES D.P. (2001). Monoclonal
457 antibodies to conformational epitopes of the surface glycoprotein of caprine arthritis-encephalitis virus: potential
458 application to competitive inhibition enzyme-linked immunosorbent assay for detecting antibodies in goat sera. *Clin.
459 Diagn. Lab. Immunol.*, **8**, 44–51.

460 PÉPIN M., VITU C., RUSSO P., MORNEX J.F. & PETERHANS E. (1998). Maedi-visna virus infection in sheep: a review.
461 *Vet. Res.*, **29**, 341–367.

462 PETERHANS E., GREENLAND T., BADIOLA J., HARKISS G., BERTONI G., AMORENA B., ELIASZEWICZ M., JUSTE R., KRASSNIG
463 R., LAFONT J.P., LENIHAN P., PETURSSON G., PRITCHARD G., THORLEY G., VITU C., MORNEX J.F. & PÉPIN M. (2004).
464 Routes of transmission and consequences of small ruminant lentiviruses (SRLVs) infection and eradication
465 schemes. *Vet. Res.*, **35**, 257–274.

466 ~~POWER C., RICHARDSON S., BRISCOE M. & PASICK J. (1995). Evaluation of two recombinant Maedi-Visna virus proteins
467 for use in an enzyme-linked immunosorbent assay for the detection of serum antibodies to ovine lentiviruses. *Clin.
468 Diagn. Lab. Immunol.*, **2**, 631–633.~~

469 RIMSTAD E., EAST N., DEROCK E., HIGGINS J. & PEDERSEN N.C. (1994). Detection of antibodies to caprine
470 arthritis/encephalitis virus using recombinant gag proteins. *Arch. Virol.*, **134**, 345–356.

471 ROSATI S., KWANG J., TOLARI F. & KEEN J.E. (1994). A comparison of whole virus and recombinant transmembrane
472 ELISA and immunodiffusion for detection of ovine lentivirus antibodies in Italian sheep flocks. *Vet. Res. Commun.*,
473 **18**, 73–80.

474 SAMAN E., VAN EYNDE G., LUJAN L., EXTRAMANIA B., HARKISS G., TOLARI F., GONZALEZ L., AMORENA B., WATT N.J. &
475 BADIOLA J.J. (1999). A new sensitive serological assay for detection of lentivirus infections in small ruminants, *Clin.
476 Diagn. Lab. Immunol.*, **6**, 734–740.

477 SCHAER J., CVETNIC Z., SUKALIC T., DÖRIG S., GRISIGER M., ISCARO C., FELIZIANI F., PFEIFER F., ORIGGI F., ZANONI R.G.
478 & ABRIL C.E. (2022). Evaluation of Serological Methods and a New Real-Time Nested PCR for Small Ruminant
479 Lentiviruses. *Pathogens*, **11**, 129.

480 SHAH C., BÖNI J., HUDER J.B., VOGT H.R., MÜLHERR J., ZANONI R., MISEREZ R., LUTZ H. & SCHÜPBACH J. (2004a).
481 Phylogenetic analysis and reclassification of caprine and ovine lentiviruses based on 104 new isolates: evidence
482 for regular sheep-to-goat transmission and worldwide propagation through livestock trade. *Virology*, **319**, 12–26.

483 SHAH C., HUDER J.B., BÖNI J., SCHÖNMANN M., MÜLHERR J., LUTZ H. & SCHÜPBACH J. (2004b). Direct evidence for
484 natural transmission of small ruminant lentiviruses of subtype A4 from goats to sheep and vice versa. *J. Virol.*, **78**,
485 7518–7522.

486 SIMARD C.L. & BRISCOE M.R. (1990a). An enzyme-linked immunosorbent assay for detection of antibodies to maedi-
487 visna virus in sheep. A simple technique for production of antigen using sodium dodecyl sulfate treatment. *Can. J.
488 Vet. Res.*, **54**, 446–450.

489 SIMARD C.L. & BRISCOE M.R. (1990b). An enzyme-linked immunosorbent assay for detection of antibodies to Maedi-
490 visna virus in sheep. Comparison to conventional agar gel immunodiffusion test. *Can. J. Vet. Res.*, **54**, 451–456.

491 TERPSTRA C. & DE BOER G.F. (1973). Precipitating antibodies against maedi-visna virus in experimentally infected
492 sheep. *Archiv für die gesamte Virusforschung*, **43**, 53–62.

493 ZANONI R.G., VOGT H.R., POHL B., BOTTCHER J., BOMMELI W. & PETERHANS E. (1994). An ELISA based on whole virus
494 for the detection of antibodies to small-ruminant lentiviruses. *J. Vet. Med. B*, **41**, 662–669.

495
496

*
* *

497 **NB:** At the time of publication (2025) there were no WOAHP Reference Laboratories
498 for caprine arthritis/encephalitis & maedi-visna (please consult the WOAHP Web site for the current list:
499 <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>.)

500 **NB:** CAPRINE ARTHRITIS/ENCEPHALITIS FIRST ADOPTED IN 1990; MAEDI-VISNA FIRST ADOPTED 1989.
501 MOST RECENT UPDATES ADOPTED IN 2017.

Appendix 1: Caprine arthritis/encephalitis & maedi-visna
Intended purpose of test: population freedom from infection

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>PCR +</u>	<u>Blood (PBMC)</u>	Reference was agreement of AGID or ELISA DSe 84% (Blood samples), DS _p 100% (<u>Extramiana et al., 2002</u>) Reference was agreement of two serological tests and western blot DSe 75,52%, DS _p 100% (<u>Schaer et al., 2022</u>)	<u>115 sheep (Spain): blood, milk cells, target tissues</u> <u>Different European countries 221 sheep and 69 goats</u> <u>396 sheep</u>	<u>See references</u>	<u>High specificity</u> <u>Moderate sensitivity</u>	<u>Expensive</u> <u>Require equipped laboratory</u> <u>Some protocols were developed for a specific genotype (i.e. MVV-like)</u>	<u>Extramiana et al. (2002)</u> <u>Schaer et al. (2022)</u>
<u>AGID +</u>	<u>Serum p28 and/or gp135</u>	Reference test was immunoprecipitation DSe 91%, DS _p 100% (<u>Knowles et al., 1994</u>) Reference test was agreement of four of six serological tests and real-time PCR <u>Sheep</u> DSe 35-100%, DS _p 100% <u>Goat</u> DSe 75-87%, DS _p 100% (<u>Michiels et al., 2018</u>)	<u>218 goat serum (111 negative and 117 positive)</u> <u>51 positive and 502 negative sheep sera</u> <u>24 positive and 370 negative goat sera</u>	<u>See references</u>	<u>Easy to perform</u> <u>Does not require equipped laboratory</u> <u>High specificity</u> <u>Low-cost reagents</u> <u>Commercially available</u>	<u>Time consuming</u> <u>Low sensitivity</u> <u>Not suitable for pooled sera or milk testing</u> <u>Commercially available antigens are derived from few, well culture adapted, strains</u>	<u>Knowles et al. (1994)</u> <u>Michiels et al. (2018)</u>
<u>ELISA +++</u>	<u>Serum, plasma, milk</u> <u>Gag and Env antigen</u> <u>One or more genotype-derived antigen</u> <u>Indirect or competitive</u>	Reference test was immunoprecipitation DSe 100%, DS _p 96,4% (<u>Herrmann et al., 2003</u>) Reference test was agreement of four of six serological tests and real-time PCR <u>Sheep</u> DSe up to 100%, DS _p up to 99,6% <u>Goat</u> DSe up to 100%, DS _p up to 100% (<u>Michiels et al., 2018</u>) Reference test was AGID and western blot DSe 99,4%, DS _p 99,3% (<u>Saman et al., 1999</u>) Reference was agreement of two serological tests, western blot and nested PCR DSe 92,2%, DS _p 98,9% (<u>Schaer et al., 2022</u>)	<u>US 200 goat sera (140 negative and 60 positive)</u> <u>Belgium</u> <u>51 positive and 502 negative sheep sera</u> <u>24 positive and 370 negative goat sera</u> <u>Different European countries</u> <u>2336 sheep</u> <u>different European countries 221 sheep and 69 goats</u>	<u>See references</u>	<u>Easy to perform</u> <u>High sensitivity</u> <u>Commercially available</u> <u>Indirect ELISA</u> <u>suitable for pooled sera or milk</u>	<u>Moderate specificity</u> <u>C-ELISA not suitable for pooled sera or milk testing</u> <u>Genotype specific ELISA</u> <u>less sensitive to detect heterologous infection (especially genotype B antigen for genotype A infection)</u>	<u>Herrmann et al. (2003)</u> <u>Michiels et al. (2018)</u> <u>Saman et al. (1999)</u> <u>Schaer et al. (2022)</u>

Appendix 2: Caprine arthritis/encephalitis & maedi-visna
Intended purpose of test: individual animal freedom from infection prior to movement

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>PCR +</u>	<u>Blood (PBMC)</u>	<u>Reference was agreement of two serological tests and western blot</u> <u>DSe 75,52%, DSp 100%</u> <u>(Schaer et al., 2022)</u>	<u>Different European countries 221 sheep and 69 goats</u>	<u>See reference</u>	<u>High specificity</u> <u>Moderate sensitivity</u> <u>May detect very early stage of infection</u>	<u>Expensive</u> <u>Require equipped laboratory</u> <u>Less sensitive than antibody response detection</u>	<u>Schaer et al. (2022)</u>
<u>AGID ++</u>	<u>Serum</u> <u>p28 and gp135</u>	<u>Reference test was immunoprecipitation</u> <u>DSe 91%, DSp 100%</u> <u>(Knowles et al., 1994)</u>	<u>218 goat serum</u> <u>(111 negative and 117 positive)</u>	<u>See reference</u>	<u>Easy to perform</u> <u>Does not require equipped laboratory</u> <u>High specificity</u> <u>Low-cost reagents</u> <u>Commercially available</u>	<u>Time consuming</u> <u>Low sensitivity especially for heterologous genotype antibody detection.</u> <u>Commercially available antigens are derived from few, well culture adapted, strains</u>	<u>Knowles et al. (1994)</u>
<u>ELISA +++</u>	<u>Serum, plasma, milk</u> <u>Gag and Env antigen</u> <u>One or more genotype-derived antigen</u> <u>Indirect or competitive</u>	<u>Reference test was immunoprecipitation</u> <u>DSe 100%, DSp 96,4%</u> <u>(Herrmann et al., 2003)</u> <u>Reference test was agreement of four out of six serological tests and real-time PCR</u> <u>Sheep</u> <u>DSe up to 100%, DSp up to 99,6%</u> <u>Goat</u> <u>DSe up to 100%, DSp up to 100%</u> <u>(Michiels et al., 2018)</u> <u>Reference test was AGID and western blot</u> <u>DSe 99,4%, DSp 99,3%</u> <u>(Saman et al., 1999)</u> <u>Reference was agreement of two serological tests, western blot and nested PCR</u> <u>DSe 92,2%, DSp 98,9%</u> <u>(Schaer et al., 2022)</u>	<u>US 200 goat sera</u> <u>(140 negative and 60 positive)</u> <u>Belgium</u> <u>51 positive and 502 negative sheep sera</u> <u>24 positive and 370 negative goat sera</u> <u>Different European countries</u> <u>2336 sheep</u> <u>Different European countries 221 sheep and 69 goats</u>	<u>See references</u>	<u>Easy to perform</u> <u>High sensitivity</u> <u>Commercially available</u>	<u>Moderate specificity</u> <u>Genotype specific ELISA</u> <u>less sensitive to detect heterologous infection (especially genotype B antigen for genotype A infection)</u>	<u>Herrmann et al. (2003)</u> <u>Michiels et al. (2018)</u> <u>Saman et al. (1999)</u> <u>Schaer et al. (2022)</u>

Appendix 3: Caprine arthritis/encephalitis & maedi-visna
Intended purpose of test: contribute to eradication policies

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>PCR ++</u>	<u>Blood (PBMC)</u> <u>Useful targets:</u> <u>LTR, gag, pol</u>	<u>Reference was agreement of AGID or ELISA</u> <u>DSe 84% (PBMC), DSp 100%</u> <u>(Extramiana <i>et al.</i>, 2002)</u> <u>Reference was agreement of two serological tests and western blot</u> <u>DSe 75,52%, DSp 100%</u> <u>(Schaer <i>et al.</i>, 2022)</u>	<u>115 sheep (Spain): blood,</u> <u>milk cells, target tissues</u> <u>Different European</u> <u>countries 221 sheep and</u> <u>69 goats</u> <u>396 sheep</u>	<u>See</u> <u>references</u>	<u>High specificity</u> <u>Moderate sensitivity</u> <u>Sequence analysis of</u> <u>PCR targeting gag gene</u> <u>offers useful information</u> <u>to select appropriate</u> <u>serological test based</u> <u>on SRLV genotype/s in</u> <u>the population</u>	<u>Expensive</u> <u>Require equipped</u> <u>laboratory</u> <u>Some protocols were</u> <u>developed for a specific</u> <u>genotype (i.e. MVV-like)</u>	<u>Extramiana <i>et al.</i></u> <u>(2002)</u> <u>Schaer <i>et al.</i> (2022)</u> <u>Shah <i>et al.</i> (2004a)</u>
<u>AGID ++</u>	<u>Serum</u> <u>p28 and/or gp135</u>	<u>Reference test was immunoprecipitation</u> <u>DSe 91%, DSp 100%</u> <u>(Knowles <i>et al.</i>, 1994)</u> <u>Reference test was agreement of four of six</u> <u>serological tests and real-time PCR</u> <u>Sheep</u> <u>DSe 35-100%, DSp 100%</u> <u>Goat</u> <u>DSe 75-87%, DSp 100%</u> <u>(Michiels <i>et al.</i>, 2018)</u>	<u>218 goat serum</u> <u>(111 negative and</u> <u>117 positive)</u> <u>51 positive and</u> <u>502 negative sheep sera</u> <u>24 positive and</u> <u>370 negative goat sera</u>	<u>See</u> <u>references</u>	<u>Easy to perform</u> <u>Does not require</u> <u>equipped laboratory</u> <u>High specificity</u> <u>Low-cost reagents</u> <u>Commercially available</u>	<u>Time consuming</u> <u>Low sensitivity</u> <u>Not suitable for pooled</u> <u>sera or milk testing</u> <u>Commercially available</u> <u>antigens are derived</u> <u>from few, well culture</u> <u>adapted, strains</u> <u>Not practical for large</u> <u>number of samples</u>	<u>Knowles <i>et al.</i> (1994)</u> <u>Michiels <i>et al.</i> (2018)</u>
<u>ELISA +++</u>	<u>Serum, plasma,</u> <u>milk</u> <u>Gag and Env</u> <u>antigen</u> <u>One or more</u> <u>genotype-derived</u> <u>antigen</u> <u>Indirect or</u> <u>competitive</u>	<u>Reference test was immunoprecipitation</u> <u>DSe 100%, DSp 96,4%</u> <u>(Herrmann <i>et al.</i>, 2003)</u> <u>Reference test was agreement of four out of</u> <u>six serological tests and real-time PCR</u> <u>Sheep</u> <u>DSe up to 100%, DSp up to 99,6%</u> <u>Goat</u> <u>DSe up to 100%, DSp up to 100%</u> <u>(Michiels <i>et al.</i>, 2018)</u> <u>Reference test was AGID and western blot</u> <u>DSe 99,4%, DSp 99,3%</u> <u>(Saman <i>et al.</i>, 1999)</u> <u>Reference was agreement of two serological</u> <u>tests, western blot and nested PCR</u> <u>DSe 92,2%, DSp 98,9%</u> <u>(Schaer <i>et al.</i>, 2022)</u>	<u>US 200 goat sera</u> <u>(140 negative and</u> <u>60 positive)</u> <u>Belgium</u> <u>51 positive and</u> <u>502 negative sheep sera</u> <u>24 positive and</u> <u>370 negative goat sera</u> <u>Different European</u> <u>countries</u> <u>2336 sheep</u> <u>Different European</u> <u>countries 221 sheep and</u> <u>69 goats</u>	<u>See</u> <u>references</u>	<u>Easy to perform</u> <u>High sensitivity</u> <u>Commercially available</u> <u>Suitable for high</u> <u>throughput screening</u> <u>Indirect ELISA suitable</u> <u>for pooled sera or milk</u>	<u>Moderate specificity</u> <u>C-ELISA not suitable for</u> <u>pooled sera or milk</u> <u>testing</u> <u>Genotype specific</u> <u>ELISA less sensitive to</u> <u>detect heterologous</u> <u>infection (especially</u> <u>genotype B antigen for</u> <u>genotype A infection)</u>	<u>Herrmann <i>et al.</i> (2003)</u> <u>Michiels <i>et al.</i> (2018)</u> <u>Saman <i>et al.</i> (1999)</u> <u>Schaer <i>et al.</i> (2022)</u>

Appendix 4: Caprine arthritis/encephalitis & maedi-visna
Intended purpose of test: confirmation of clinical cases

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Virus isolation +</u>	<u>Tissues (spleen, mammary gland, lymph nodes, lung, choroid plexus, synovial membrane, skin)</u> <u>Peripheral blood mononuclear cells, milk epithelial cells.</u>	<u>Reference was gross and histopathological lesions and RT activity on tissue culture supernatant.</u>	<u>16 sheep 26 goats</u>	<u>See reference</u>	<u>Allows downstream characterisation (antigenic and genetic)</u> <u>High specificity</u> <u>High sensitivity</u>	<u>Requires fresh tissues or cells</u> <u>Time consuming</u> <u>Requires equipped laboratory and tissue culture skills</u> <u>Expensive</u>	<u>Colitti et al. (2019)</u>
<u>Antigen detection ±</u>	<u>Tissues (lung, udder, synovial membrane)</u> <u>Immunohistochemistry</u>	<u>Reference was virus isolation and PCR</u>	<u>Six sheep and six goats</u>	<u>No robust diagnostic validation studies have been published for this purpose</u>	<u>No particular advantage over other direct methods</u>	<u>Requires equipped laboratory and histopathological skills</u> <u>Requires broad reactive Mabs</u>	<u>Grego et al. (2002)</u>
<u>PCR +++</u>	<u>Blood (PBMC), tissues</u>	<u>Reference was agreement of AGID or ELISA</u> <u>DSe 94% (combined tissue + PBMC), DSp 100%</u> <u>(Extramiana et al., 2002)</u> <u>Reference was gross and histopathological lesions and virus isolation (Colitti et al., 2019).</u>	<u>115 sheep (Spain): blood, milk cells, target tissues</u> <u>16 sheep 26 goats</u>	<u>Many validation studies have been carried out using field samples, viral field isolates or strains and a subset of samples from clinically affected sheep or goats.</u> <u>Although from the latter set no robust data are available in each study, there is a consensus to consider the usefulness of PCR-based methods for confirmation of clinical cases (necropsy tissues)</u>	<u>High specificity (especially if combined with amplicon sequencing)</u> <u>Moderate sensitivity</u>	<u>Expensive</u> <u>Require equipped laboratory</u> <u>Some protocols were developed for a specific genotype (i.e. MVV-like)</u>	<u>Extramiana et al. (2002)</u> <u>Colitti et al. (2019)</u> <u>Alvarez et al. (2006)</u> <u>De Regge & Cay (2013)</u> <u>Shah et al. (2004a)</u>
<u>AGID ++</u>	<u>Serum</u> <u>p28 and gp135</u>	<u>Reference test was immunoprecipitation</u> <u>DSe 91%, DSp 100%</u> <u>(Knowles et al., 1994)</u> <u>Reference test was agreement</u>	<u>218 goat serum (111 negative and 117 positive) no data available for clinically affected goats</u>	<u>No robust diagnostic validation studies have been published for this purpose</u>	<u>Easy to perform</u> <u>Does not require equipped laboratory</u> <u>High specificity</u> <u>Good sensitivity (clinical stage of infection)</u>	<u>Time consuming</u> <u>Commercially available antigens are derived from few, well culture adapted, strains</u>	<u>Knowles et al. (1994)</u>

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
		<u>of four of six serological tests and real-time PCR</u>	<u>51 positive and 502 negative sheep sera</u> <u>24 positive and 370 negative goat sera</u>		<u>Low-cost reagents</u> <u>Commercially available</u>		
<u>ELISA ++</u>	<u>Serum</u> <u>Gag and Env antigen (TM antigen)</u>	<u>Reference test was arthritic index, RIPA, WB (Bertoni et al., 1994)</u> <u>Reference was virus isolation</u>	<u>190 Swiss goat (108 clinically affected)</u> <u>17 goats and three sheep (Italy)</u>	<u>See references</u>	<u>Easy to perform</u> <u>High sensitivity</u> <u>Commercially available</u> <u>Anti-TM antibodies have been specifically associated to clinical stage of infection in arthritic goats</u>	<u>Moderate specificity</u> <u>Genotype specific ELISA less sensitive to detect heterologous infection (especially genotype B antigen for genotype A infection)</u>	<u>Bertoni et al. (1994)</u> <u>Colitti et al. (2019)</u>

Appendix 5: Caprine arthritis/encephalitis & maedi-visna
Intended purpose of test: prevalence of infection – surveillance

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>PCR ++</u>	<u>Blood (PBMC)</u> <u>Milk (MEC)</u>	<u>Reference was agreement of two serological tests and western blot</u> <u>DSe 75.52%, DSp 100%</u> <u>(Schaer <i>et al.</i>, 2022)</u> <u>Reference was agreement with antibody detection on paired samples (Adjadj <i>et al.</i>, 2019)</u>	<u>Different European countries 221 sheep and 69 goats</u> <u>396 sheep</u> <u>231 goat blood and milk samples (Belgium)</u>	<u>See references</u>	<u>High specificity</u> <u>Moderate sensitivity</u>	<u>Expensive</u> <u>Require equipped laboratory</u> <u>Some protocols were developed for a specific genotype (i.e. MVV-like)</u> <u>Milk PCR less sensitive than blood PCR; Blood PCR less sensitive than antibody detection</u>	<u>Schaer <i>et al.</i> (2022)</u> <u>Adjadj <i>et al.</i> (2019)</u>
<u>AGID +++</u>	<u>Serum</u> <u>p28 and/or gp135</u>	<u>Reference test was immunoprecipitation</u> <u>DSe 91%, DSp 100%</u> <u>(Knowles <i>et al.</i>, 1994)</u> <u>Reference test was agreement of four of six serological tests and real-time PCR</u> <u>Sheep</u> <u>DSe 35-100%, DSp 100%</u> <u>Goat</u> <u>DSe 75-87%, DSp 100%</u> <u>(Michiels <i>et al.</i>, 2018)</u>	<u>218 goat serum (111 negative and 117 positive)</u> <u>51 positive and 502 negative sheep sera</u> <u>24 positive and 370 negative goat sera</u>	<u>See reference</u>	<u>Easy to perform</u> <u>Does not require equipped laboratory</u> <u>High specificity</u> <u>Low-cost reagents</u> <u>Commercially available</u>	<u>Time consuming</u> <u>Low sensitivity</u> <u>Not suitable for pooled sera or milk testing</u> <u>Commercially available antigens are derived from few, well culture adapted, strains</u>	<u>Knowles <i>et al.</i> (1994)</u> <u>Michiels <i>et al.</i> (2018)</u>
<u>ELISA +++</u>	<u>Serum, plasma, milk</u> <u>Gag and Env antigen</u> <u>One or more genotype-derived antigen</u> <u>Indirect or competitive</u>	<u>Reference test was immunoprecipitation</u> <u>DSe 100%, DSp 96.4%</u> <u>(Herrmann <i>et al.</i>, 2003)</u> <u>Reference test was agreement of four of six serological tests and real-time PCR</u> <u>Sheep</u> <u>DSe up to 100%, DSp up to 99.6%</u> <u>Goat</u> <u>DSe up to 100%, DSp up to 100%</u> <u>(Michiels <i>et al.</i>, 2018)</u> <u>Reference test was AGID</u>	<u>US 200 goat sera (140 negative and 60 positive)</u> <u>Belgium</u> <u>51 positive and 502 negative sheep sera</u> <u>24 positive and 370 negative goat sera</u> <u>Different European countries</u> <u>2336 sheep</u> <u>196 goat milk samples</u> <u>188 sheep milk samples</u> <u>Different European</u>	<u>See references</u>	<u>Easy to perform</u> <u>High sensitivity</u> <u>Commercially available</u> <u>Indirect ELISA suitable for pooled sera or milk</u>	<u>Moderate specificity</u> <u>C-ELISA not suitable for pooled sera or milk testing</u> <u>Genotype specific ELISA less sensitive to detect heterologous infection (especially genotype B antigen for genotype A infection)</u>	<u>Herrmann <i>et al.</i> (2003)</u> <u>Michiels <i>et al.</i> (2018)</u> <u>Saman <i>et al.</i> (1999)</u> <u>Brinkhof <i>et al.</i> (2010)</u> <u>Schaer <i>et al.</i> (2022)</u>

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
		<u>and western blot</u> <u>DSe 99,4%, DSp 99,3%</u> <u>(Saman <i>et al.</i>, 1999)</u> <u>Reference was antibody</u> <u>detection on paired blood</u> <u>serum samples</u> <u>Goat</u> <u>RSe 98%, RSp 100%</u> <u>(K=0,98)</u> <u>Sheep</u> <u>RSe 97%, RSp 98%</u> <u>(K=0,95</u> <u>(Brinkhof <i>et al.</i>, 2010)</u> <u>Reference was agreement</u> <u>of two serological tests,</u> <u>western blot and nested</u> <u>PCR</u> <u>DSe 92,2%, DSp 98,9%</u> <u>(Schaer <i>et al.</i>, 2022)</u>	<u>countries 221 sheep and</u> <u>69 goats</u>				

2 REUNIÓN DE LA COMISIÓN DE NORMAS BIOLÓGICAS
3 París, 9–13 de septiembre de 2024

4
5 CHAPTER 3.8.5.

6 ENZOOTIC ABORTION OF EWES
7 (OVINE CHLAMYDIOSIS)
8 (INFECTION WITH *CHLAMYDIA ABORTUS*)

9 SUMMARY

10 **Description and importance of the disease:** *Ovine chlamydiosis, also known as enzootic abortion of ewes*
11 *(EAE) or ovine enzootic abortion (OEA), is caused by the bacterium Chlamydia abortus. Chlamydial abortion*
12 *typically occurs in the last 2–3 weeks of pregnancy with the appearance of stillborn lambs and inflamed*
13 *placentas. However, infection can also result in the delivery of full-term stillborn lambs or weak lambs that do*
14 *not survive longer than 48 hours. Infected ewes can also give birth to healthy lambs. There are rarely any*
15 *predictive signs that abortion is going to occur, although behavioural changes and a vulval discharge can be*
16 *observed in the last 48 hours of pregnancy.*

17 *Diagnosis of enzootic abortion depends on the detection of antigen or nucleic acid of the causative agent in*
18 *the products of abortion or vaginal excretions of freshly aborted females. A humoral antibody response may*
19 *be detected following abortion. Goats as well as sheep and, less commonly, cattle, pigs, horses and wild*
20 *ruminants, can be affected. Chlamydiosis of small ruminants caused by C. abortus is zoonotic and the*
21 *organism must be handled with appropriate biosafety precautions. Pregnant women are particularly at risk.*

22 **Detection and identification of the agent:** *The basis for a positive diagnosis of infection with C. abortus*
23 *depends on a history of abortion in sheep or goats (often in late pregnancy), evidence of purulent to necrotising*
24 *placentitis with vasculitis, and the demonstration of ~~large numbers of the organism in affected placenta~~*
25 *(usually present in large numbers) by ~~quantitative~~-polymerase chain reaction (PCR) or antigen tests or in*
26 *stained smears. The still moist fleece of fetuses or their abomasal content or vaginal swabs of females that*
27 *have freshly aborted are also useful. It is important to distinguish cotyledonary damage caused by Toxoplasma*
28 *gondii and, in stained smears, to be aware of the morphological similarities between C. abortus and Coxiella*
29 *burnetii, the agent of Q fever.*

30 *Chlamydial organisms in tissues and smears can be detected by staining, or antigen-detection methods*
31 *(immunohistochemistry or immunofluorescence), whereas chlamydial DNA can be detected by PCR-based*
32 *methods ~~including real-time PCR and DNA microarray~~. Some of these methods are available in commercial*
33 *kit form.*

34 *Chlamydia abortus can be isolated only in living cells; thus facilities for growth in cell cultures or chicken*
35 *embryos, with appropriate biohazard containment, are required.*

36 **Serological tests:** *A rise in antibody titre to C. abortus, which can be detected by enzyme-linked*
37 *immunosorbent assay (ELISA), is common after abortion or stillbirth, but this does not occur in every case.*
38 *Chlamydia abortus shares common antigens with other Chlamydia species and some Gram-negative bacteria,*
39 *so that the complement fixation (CF) test or crude-ELISAs are not specific and no longer recommended.*
40 *Serological screening during the period after parturition helps to identify infected flocks, to which control*
41 *measures can then be applied. Serological tests to differentiate between vaccinated and naturally infected*
42 *sheep or goats (DIVA tests) are not currently available.*

43 **Requirements for vaccines:** *Inactivated and live vaccines are available that have been reported to prevent*
44 *abortion and to reduce excretion. They assist in control of the disease but will not eradicate it.*

45 A. INTRODUCTION

46 1. Description and impact of the disease

47 Ovine chlamydiosis (enzootic abortion of ewes [EAE] or ovine enzootic abortion [OEA]) is caused by the bacterium
48 *Chlamydia abortus*. Chlamydial abortion in late pregnancy causes serious economic loss in many sheep-rearing areas of
49 the world, except Australia and New Zealand, particularly where flocks are closely congregated during the parturient period
50 (Aitken & Longbottom, 2007; Longbottom & Coulter, 2003). Abortion typically occurs in the last 2–3 weeks of pregnancy with
51 the appearance of stillborn lambs and grossly inflamed placentas. Infection can also result in the delivery of full-term stillborn
52 lambs and weak lambs that generally fail to survive beyond 48 hours. It is also not uncommon in multiple births for an infected
53 ewe to produce one dead lamb and one or more weak or healthy lambs. Infection is generally established in a 'clean'
54 (immunologically naïve) flock through the introduction of infected replacements and results in a small number of abortions in
55 the first year, followed by an 'abortion storm' in the second year that can affect around 30% of ewes.

56 Infected animals show no clinical illness prior to abortion, although behavioural changes and a vulval discharge may be
57 observed in ewes within the last 48 hours of pregnancy. Pathogenesis commences around day 90 of gestation coincident
58 with a phase of rapid fetal growth when chlamydial invasion of placentomes produces a progressively diffuse inflammatory
59 response, thrombotic vasculitis and tissue necrosis. Milder changes occur in the fetal liver and lung and, in cases with severe
60 placental damage, there may be evidence of hypoxic brain damage (Buxton *et al.*, 2002; Longbottom *et al.*, 2013). Abortion
61 probably results from a combination of impairment of materno-fetal nutrient and gaseous exchange, disruption of hormonal
62 regulation of pregnancy and induced cytokine aggression (Entrican, 2002). Infected ewes shed vast numbers of infective
63 *C. abortus* at the time of abortion or parturition, particularly in the placenta and uterine discharges, thus providing an infection
64 source. Ewes having aborted do not usually abort again from *C. abortus* infection.

65 Chlamydial abortion also occurs to a similar extent in goats and, less frequently, cattle, pigs, horses and wild ruminants may
66 be affected. In sheep, abortion in late pregnancy with expulsion of necrotic fetal membranes are diagnostic indicators.

67 2. Nature and classification of the pathogen

68 As a member of the *Chlamydiaceae* family, *Chlamydia abortus* has a biphasic developmental life cycle with two
69 morphoforms: extracellular infectious elementary bodies (EBs) and intracellular metabolically active reticulate bodies (RBs).
70 Replication takes place within a membrane-bound vacuole. The bacteria obtain essential nutrients by hijacking intracellular
71 organelles and redirecting transport vesicles.

72 The closest phylogenetically related species of *C. abortus* is the primarily avian pathogen *C. psittaci*, while *C. pecorum* also
73 resides in ruminant hosts. Both should be considered for a differential diagnosis. Recently, the *C. abortus* species has been
74 expanded to include not only genotypes from ruminants but also avian genotypes with unknown pathogenicity that were
75 detected in poultry and wild birds (Zareba-Marchewka *et al.*, 2021).

76 Taxonomically, the family *Chlamydiaceae* comprises a group of Gram-negative, obligate intracellular bacteria within the
77 single genus *Chlamydia*, which includes eleven species: *C. trachomatis* (humans), *C. suis* (swine), *C. muridarum* (mouse
78 and hamster), *C. psittaci* (avian), *C. felis* (cat), *C. abortus* (sheep, goat and cattle), *C. caviae* (guinea-pig), *C. pecorum*
79 (sheep, cattle and, koala), *C. pneumoniae* (humans), *C. avium* and *C. gallinaceae* (both in birds) (Sachse *et al.*, 2015) as
80 well as two candidate species named *Candidatus Chlamydia ibidis* and *Candidatus Chlamydia sanzina* (Taylor-Brown *et*
81 *al.*, 2016; Vorimore *et al.*, 2013).

82 Infected ewes shed vast numbers of infective *C. abortus* at the time of abortion or parturition, particularly in the placenta and
83 uterine discharges, thus providing an infection source. Ewes having aborted do not usually abort again from *C. abortus*
84 infection. Recent evidence suggests that the proportion of infected ewes is reduced at the subsequent breeding season and
85 only low levels of chlamydial DNA are detected during the periovulation period and at lambing, so that this would not have
86 significant impact on the epidemiology (Gutiérrez *et al.*, 2011; Livingstone *et al.*, 2009).

87 3. Zoonotic risk and biosafety requirements

88 Human infection may be acquired from infected products of abortion or parturition or from carelessly handled laboratory
89 cultures of the organism, with manifestations ranging from subclinical infection to acute influenza-like illness. Cultures and
90 potentially infected tissues should be handled with appropriate biosafety and containment procedures as determined by
91 biorisk analysis (see Chapter 1.1.4 *Biosafety and biosecurity: Standard for managing biological risk in the veterinary*
92 *laboratory and animal facilities*). Authenticated cases of human placentitis and abortion caused by *C. abortus* of

93 ovine/caprine origin indicate that pregnant women are at special risk and should not be exposed to sources of infection
 94 ([Borel & Sachse, 2022](#); [Longbottom & Coulter, 2003](#); [Sillis & Longbottom, 2011](#); [Turin et al., 2022](#)).

95 4. Differential diagnosis

96 Specific experience is needed to distinguish the diffuse pattern of necrosis and inflammation caused by *C. abortus* infection
 97 from necrosis caused by *Toxoplasma gondii*, which is limited to the cotyledons. Differentiation from other infectious causes
 98 of abortion, such as brucellosis (see Chapter 3.1.4), ~~coxiellosis~~ Q fever (see Chapter 3.1.18) or other bacterial pathogens
 99 (*Campylobacter* [[see Chapter 3.10.4](#)], *Listeria* [[see Chapter 3.10.5](#)], *Salmonella* [[see Chapter 3.10.7-3](#)]), can be achieved by
 100 conducting further agent-specific diagnostic tests. ~~Recently,~~ Other chlamydial species, such as *C. pecorum* and *C. psittaci*,
 101 have been implicated as abortigenic agents in ruminants ([Berri et al., 2009](#); ~~Lenzke et al., 2011~~).

102 B. DIAGNOSTIC TECHNIQUES

103 Table 1. Test methods available for the diagnosis of enzootic abortion of ewes and their purpose

Method	Purpose					
	Population freedom from infection ^(a)	Individual animal freedom from infection prior to movement ^(b)	Contribute to eradication policies ^(c)	Confirmation of clinical cases ^(d)	Prevalence of infection – surveillance ^(e)	Immune status in individual animals or populations (post-vaccination) ^(f)
<u>Detection and</u> identification of the agent ^(g)						
Stained smears	–	–	–	+	–	–
Bacterial isolation	–	–	–	++	–	–
Antigen detection by IHC	–	–	–	++	+	–
Conventional PCR	–	–	–	+++	++	–
Real-time PCR	–	–	–	+++	++	–
Detection of immune response						
CFT	+	+	+	+	+	+
ELISA	+++	++	+++	++	+++	+++
<u>CFT</u>	±	±	±	±	±	±

104 Key: +++ = recommended for this purpose; ++ recommended but has limitations;

105 + = suitable in very limited circumstances; – = not appropriate for this purpose.

106 IHC = immunohistochemistry; PCR = polymerase chain reaction; CFT = complement fixation test;

107 ELISA = enzyme-linked immunosorbent assay.

108 ^(a)See Appendix 1 of this chapter for justification table for the scores given to the tests for this purpose.

109 ^(b)See Appendix 2 of this chapter for justification table for the scores given to the tests for this purpose.

110 ^(c)See Appendix 3 of this chapter for justification table for the scores given to the tests for this purpose.

111 ^(d)See Appendix 4 of this chapter for justification table for the scores given to the tests for this purpose.

112 ^(e)See Appendix 5 of this chapter for justification table for the scores given to the tests for this purpose.

113 ^(f)See Appendix 6 of this chapter for justification table for the scores given to the tests for this purpose.

114 ^(g)A combination of agent identification methods applied on the same clinical sample is recommended.

115 1. Identification of the agent

116 1.1. Smears

117 Where the clinical history of the flock and the character of lesions in aborted placentae suggest enzootic abortion,
 118 a diagnosis can be attempted by microscopic examination of smears made from affected chorionic villi or adjacent

119 chorion. Smears are stained according to modified Machiavello, Giemsa, *Brucella* differential, or modified Ziehl–
120 Neelsen (Stamp *et al.*, 1950). In positive cases stained by the latter method and examined under a high-power
121 microscope, large numbers of small (300 nm) coccoid elementary bodies are seen individually or in clumps
122 stained red against the blue background of cellular debris. Under dark-ground illumination, the elementary bodies
123 appear pale green. Fluorescent antibody tests (FATs) using a specific antiserum or monoclonal antibody may be
124 used for identification of *C. abortus* in smears. However, polymerase chain reaction (PCR)-based tests are
125 superior to stained or FAT smears regarding sensitivity and specificity and should therefore be applied if available.
126 Stained smears might be useful as an initial screening test, but confirmation by molecular methods is highly
127 recommended ~~due to inferior sensitivity of staining and lack of species specificity.~~

128 If placental material is not available, smears may be prepared from vaginal swabs of ewes that have aborted
129 within the previous 24 hours, or from the moist fleece of a freshly aborted or stillborn lamb that has not been
130 cleaned by its mother, or from the abomasal content of the aborted or stillborn lamb. In general, such preparations
131 contain fewer organisms than placental smears.

132 In terms of morphology and staining characteristics, *C. abortus* resembles *Coxiella burnetii* (see chapter 3.1.17 Q
133 fever), which, in some circumstances, may provoke abortion and which causes Q fever in humans. Care must be
134 taken to differentiate between these two organisms in cases lacking a good history or evidence of chlamydia-
135 induced placental pathology.

136 1.2. Isolation of the agent – cell culture

137 Cell culture is the method of choice for isolation of the organism. The causative agent of ovine chlamydiosis is
138 zoonotic and thus isolation and identification procedures must be carried out with appropriate biosafety and
139 containment procedures as determined by biorisk analysis (see chapter 1.1.4).

140 Tissue samples, such as cotyledons, placental membranes, fetal lung or liver, or vaginal swabs, that may be
141 subject to delay before laboratory isolation, should be maintained in a suitable transport medium in the interim
142 period. For optimal recovery, such samples should be stored frozen, preferably at –80°C. The most satisfactory
143 medium is sucrose/phosphate/glutamate or SPG medium (sucrose [74.6 g/litre], KH₂PO₄ [0.52 g/litre], K₂HPO₄
144 [1.25 g/litre], L-glutamic acid [0.92 g/litre]) supplemented with bovine serum albumin – fraction V (1 g/litre),
145 antibiotics (streptomycin and gentamycin are suitable, but not penicillin), and a fungal inhibitor. A tissue-to-
146 medium ratio of 1:10 is commonly employed. Alternatively, approximately 1 g of tissue can be ground with sterile
147 sand in 8 ml of transport medium.

148 *Chlamydia abortus* of ovine origin can be isolated in a variety of cell types. McCoy, Buffalo Green Monkey (BGM)
149 or baby hamster kidney (BHK) cells are most commonly used. For confirmatory diagnosis, cultured cell
150 monolayers are suspended in growth medium at a concentration of 2 × 10⁵ cells/ml. Aliquots of 2 ml of the
151 suspension are dispensed into flat-bottomed vials or 24-well plates, each containing a single 12 mm coverslip.
152 Confluent coverslip monolayers are achieved after incubation at 37°C for 24 hours. The growth medium is
153 removed and replaced with 2 ml of test inoculum, which is then centrifuged at 2500–3500 g for 30–60 minutes
154 onto the coverslip monolayer and incubated at 37°C and 5% CO₂ for 2 hours. The inoculum is removed and
155 replaced with serum-free or cycloheximide (0.5 µg/ml) containing tissue culture medium, and then incubated at
156 37°C for 2–3 days. The coverslip monolayers are fixed in methanol and stained using Giemsa or Gimenez
157 procedures (Arens & Weingarten, 1981; Gimenez, 1964), or are detected by immunofluorescence using species-
158 or genus-specific antibodies (Sachse *et al.*, 2009). After methanol fixation, infected cultures contain basophilic
159 (Giemsa) or eosinophilic (Gimenez) fluorescent intracytoplasmic inclusions. Similar procedures are used in
160 culturing *C. abortus* for antigen preparation.

161 1.3. Isolation of the agent – chicken embryos

162 Test samples are prepared as 10% suspensions in nutrient broth containing streptomycin (not penicillin)
163 (200 µg/ml); 0.2 ml of suspension is inoculated into the yolk sac of 6- to 8-day old embryos, which are then further
164 incubated at 37°C. Infected embryos die between 4 and 13 days after inoculation. Smears prepared from their
165 vascularised yolk sac membranes reveal large numbers of elementary bodies.

166 1.4. Antigen detection in tissue sections

167 In histopathological sections, antigen detection can be performed using commercially available anti-
168 *Chlamydiaceae* antibodies directed against lipopolysaccharide (LPS) or MOMP (major outer membrane protein)
169 (Borel *et al.*, 2006). Immunohistochemistry is an indispensable tool to show the association of chlamydial agent
170 and pathological lesions in tissues. Genus- or species-specific antibodies in combination with streptavidin–biotin
171 are used to detect the chlamydial antigen within histological lesions of the placenta or inner organs (mostly lung
172 and liver) of aborted fetuses (Sachse *et al.*, 2009).

173 Intracellular chlamydial inclusions can be demonstrated by Giemsa staining of thin ($\leq 4 \mu\text{m}$) sections taken from
 174 target tissues that have been suitably fixed in fluids such as Bouin or Carnoy. However, unambiguous
 175 immunological staining procedures as described above are more suitable.

176 1.5. Detection of DNA by conventional PCR, and real-time PCR and DNA microarray

177 Amplification of chlamydial DNA by PCR for verifying the presence of chlamydiae in biological samples is the
 178 method of choice because of high sensitivity and specificity of PCR. Conventional PCR protocols for *C. abortus*
 179 DNA detection target the 16S–23S rRNA region (Everett & Andersen, 1999) or *pmp* genes (Laroucau *et al.*, 2001)
 180 and can be combined with restriction fragment length polymorphism (RFLP) analysis for discriminating between
 181 amplified DNA sequences originating from *C. abortus*, *C. psittaci* and *C. pecorum*.

182 Real-time PCR ~~has become~~ is now the preferred method in diagnostic laboratories due to its high specificity,
 183 rapidity, high throughput and ease of standardisation (Sachse *et al.*, 2009). ~~A hierarchical approach is~~
 184 ~~recommended including~~ Different methods are available either with a *Chlamydiaceae*-specific screening PCR
 185 based on the sequences of 23S rRNA (Ehrlich *et al.*, 2006), and, in positive cases, followed by a *C. abortus*-
 186 specific PCR assay based on sequences of the outer membrane protein (*ompA*) (Livingstone *et al.*, 2009;
 187 Pantchev *et al.*, 2009) or other *C. abortus*-specific target genes for species identification, or with direct detection
 188 of *C. abortus*. Commercial tests for the detection of *C. abortus* are available or DNA microarray hybridisation
 189 assays (Sachse *et al.*, 2005). Both real-time PCR and DNA microarray have been validated for the direct detection
 190 and identification of organisms from clinical samples (Borol *et al.*, 2008; Pantchev *et al.*, 2010).

191 PCR assays in combination with RFLP analysis or HRM (high resolution melting) analysis have been developed
 192 with the aim of differentiating naturally infected ~~from vaccinated~~ animals from animals vaccinated ~~from vaccinated~~
 193 with the commercial live attenuated vaccine (DIVA) (Laroucau *et al.*, 2010; Vorimore *et al.*, 2012; Wheelhouse *et*
 194 *al.*, 2010).

195 Table 2. Examples of validated published real-time PCR assays
 196 for screening and ~~specification~~ species identification of *C. abortus*

Reference	Ehrlich <i>et al.</i> (2006)	Livingstone <i>et al.</i> (2009)	Pantchev <i>et al.</i> (2009)
Specificity	<i>Chlamydiaceae</i>	<i>C. abortus</i>	<i>C. abortus</i>
Target	23S rRNA	<i>ompA</i>	<i>ompA</i>
Amplicon size	111 bp	86 bp	82 bp
Primer forward 5'–3'	CTG-AAA-CCA-GTA-GCT-TAT-AAG-CGG-T	GCG-GCA-TTC-AAC-CTC-GTT	GCA-ACT-GAC-ACT-AAG-TCG-GCT-ACA
Primer reverse 5'–3'	ACC-TCG-CCG-TTT-AAC-TTA-ACT-CC	CCT-TGA-GTG-ATG-CCT-ACA-TTG-G	ACA-AGC-ATG-TTC-AAT-CGA-TAA-GAG-A
Probe 5'–3'	FAM-CTC-ATC-ATG-CAA-AAG-GCA-CGC-CG-TAMRA	FAM-TGT-TAA-AGG-ATC-CTC-CAT-AGC-AGC-TGA-TCA-G-TAMRA	FAM-TAA-ATA-CCA-CGA-ATG-GCA-AGT-TGG-TTT-AGC-G-TAMRA
Cycling conditions	95°C/10 minutes 45 x (95°C/15 seconds, 60°C/60 seconds)	95°C/10 minutes 45 x (95°C/15 seconds, 60°C/60 seconds)	95°C/10 minutes 45 x (95°C/15 seconds, 60°C/60 seconds)

197 2. Serological tests

198 Sheep and goats are generally tested serologically within 3 months of abortion or parturition. Infection is evident through *C.*
 199 *abortus*-specific antibody response principally during active placental invasion by the pathogen in the last month of gestation
 200 and following the bacteraemia that often accompanies abortion. Consequently, serum collected after abortion will reveal an
 201 elevated antibody titre resulting from current or previous infection. None of the serological tests available to date can
 202 differentiate vaccination titres from those acquired as a result of natural infection (DIVA tests).

203 2.1. ELISA

204 Several ELISAs are commercially available for *Chlamydia* diagnosis in ewes (~~overview in~~ O'Neill *et al.*, 2018;
 205 Sachse *et al.*, 2009). Care must be taken to select an appropriate ELISA for each diagnostic problem considering
 206 different specificities and sensitivities. ~~LPS or EB (elementary body) Crude~~ antigen-based ELISAs cannot
 207 differentiate between animals infected with *C. pecorum* and *C. abortus*, but were proven to be more sensitive

208 primary screening tools for EAE compared with the complement fixation (CFT) (Bommana *et al.*, 2019). Specific
209 detection of anti-*C. abortus* antibodies can be accomplished by the use of ELISAs based on synthetic peptides of
210 MOMP, recombinant MOMP (Salti-Montesanto *et al.*, 1997), or POMP90 (polymorphic outer membrane protein)
211 (Longbottom *et al.*, 2002; Wilson *et al.*, 2009). Most recently, a new indirect ELISA based on POMP90 has been
212 commercialised and shown to be both sensitive and specific for *C. abortus*, in particular in differentiating animals
213 infected with *C. pecorum* (Anon, 2015; Essig & Longbottom, 2015). Specific *C. abortus* ELISAs based on
214 recombinant proteins are commercialised and allow differentiation of animals infected with *C. pecorum* (Wilson *et*
215 *al.*, 2009).

216 2.2. Complement fixation test

217 Complement fixation (CFT) has traditionally been the most widely used procedure for detecting EAE. However,
218 antigenic cross-reactivity between *C. abortus* and *C. pecorum*, which is endemic in small ruminants—many
219 countries, as well as with some Gram-negative bacteria (e.g. *Acinetobacter*), can give rise to false-positive CFT
220 results. This is because chlamydial antigen contains LPS as an immunodominant component, which is common
221 to all *Chlamydiaceae* species. Furthermore, the CFT has been shown to be less sensitive than alternative tests.
222 Therefore, CFT is no longer recommended as the method of choice for serological diagnosis of EAE, but might
223 be used for herd diagnosis when no alternative tools are available and the limitations mentioned above are taken
224 into consideration.

225 Antigen is prepared from heavily infected yolk sac membranes obtained from chicken embryos that have been
226 inoculated in the same manner as for isolation of the organism from field material. The preparation of the antigen
227 should be carried out in a biosafety cabinet with the appropriate biosecurity precautions to prevent human infection
228 (see chapter 1.1.4). Chopped and ground membranes are suspended in phosphate buffer, pH 7.6, at the rate of
229 2 ml per g membrane. After removal of crude debris, the supernatant fluid is centrifuged at 10,000 **g** for 1 hour at
230 4°C, the deposit is resuspended in a small volume of saline, and a smear of this is examined to ensure a high
231 yield of chlamydiae. The suspension is held in a boiling water bath for 20 minutes, or is autoclaved, and sodium
232 azide (0.3%) is added as a preservative. Antigen may also be prepared from cell cultures infected with *C. abortus*.
233 Infected monolayers are suspended in phosphate buffer, pH 7.6, and the cells are disrupted by homogenisation
234 or ultrasonication. Gross debris is removed and subsequent procedures are as for the preparation of antigen from
235 infected yolk sacs. In either case, CFTs with standardised complement and antisera will establish the optimal
236 working dilution for each batch of antigen. Antigen for CF testing of ruminant sera is commercially available.

237 Samples are tested at twofold dilutions from 1/32 to 1/512. CF titres are expressed as the highest serum dilution
238 giving 50% or less haemolysis: 50% haemolysis is graded 2+, and 0% haemolysis is graded 4+. A titre of 4+ at a
239 dilution of 1/32 or greater is assumed to be positive, whereas a titre of 2+ at a dilution of 1/32 is assumed to be
240 equivocal (Stamp *et al.*, 1950).

241 C. REQUIREMENTS FOR VACCINES

242 1. Background

243 1.1. Rationale and intended use of the product

244 Currently, two types of vaccine (inactivated and attenuated live vaccines) are available commercially, to be
245 administered intramuscularly or subcutaneously at least 4 weeks before breeding to aid in the prevention of
246 abortion. A multi-component recombinant vaccine against *C. abortus* remains a future goal of chlamydial vaccine
247 research (Longbottom & Livingstone, 2006).

248 Inactivated vaccines can be prepared from infected yolk sacs or cell cultures (Jones *et al.*, 1995) and incorporate
249 whole organisms or fractions of them (Tan *et al.*, 1990) using the appropriate biosecurity precautions to prevent
250 human infection (see chapter 1.1.4). Operator care should be observed in handling commercial inactivated
251 vaccines that incorporate mineral oil-based adjuvants, as self-injection can result in severe local inflammation and
252 tissue necrosis. The commercial live attenuated vaccine is based on a chemically induced temperature-sensitive
253 mutant strain (strain 1B) of the organism that grows at 35°C but not at 39.5°C, the body temperature of sheep
254 (Rodolakis, 1986). This vaccine is supplied lyophilised and must be reconstituted in diluent immediately before
255 administration. Operator care should be observed in handling and administering this live vaccine, particularly by
256 immunocompromised individuals and pregnant women. Importantly, the live vaccine must not be given to animals
257 being treated with antibiotics, particularly tetracyclines. Inactivated vaccines are safe for administration during
258 pregnancy, whereas live vaccines cannot be used in pregnant animals.

259 Both types of vaccine have a role to play in controlling disease, but neither confers absolute protection against
260 challenge or completely reduces the shedding of infective organisms. However, vaccinates exposed to infection

261 do experience significantly lower abortion rates and reduced excretion of chlamydiae for at least two to three
262 lambings after vaccination. It has been claimed that the live vaccine could be an aid to eradication of disease
263 (Nietfeld, 2001). In addition, the live vaccine strain 1B has been detected in the placentas of vaccinated animals
264 that have aborted as a result of OEA, suggesting a possible role for the vaccine in causing disease, and genomic
265 studies proved the lack of attenuation (Longbottom *et al.*, 2018; Wheelhouse *et al.*, 2010). However, but despite
266 this the use of the live vaccine remains the most effective method of protecting from the disease (Essig &
267 Longbottom, 2015; ~~Stuen & Longbottom, 2014~~).

268 Vaccine stored under refrigeration (5±3°C) should remain stable for at least 1 year. No firm data are available,
269 but revaccination is recommended every 1–3 years, according to the exposure risk.

270 **2. Outline of production and minimum requirements for conventional inactivated vaccines**

271 **2.1. Characteristics of the seed**

272 **2.1.1. Biological characteristics**

273 One or more ovine abortion isolates that consistently grow productively in the chosen substrate are
274 suitable, and an early passage of the seed stock can be established. Alternatively, an isolate that has been
275 adapted to the chicken embryo by multiple passage (>100) can be used. Although adaptation to the embryo
276 may diminish the isolate's virulence for sheep, there is no evidence that such change reduces its protective
277 efficacy as an inactivated vaccine.

278 **2.1.2. Quality criteria (sterility, purity, freedom from extraneous agents)**

279 Before inoculation of ~~large numbers of~~ embryos or cell cultures, the viability and freedom from
280 contamination (e.g. other pathogens, fungi, mycoplasma, toxins, etc.) of seed stock should be verified. It
281 may be convenient to collect the total harvest in separate manageable lots. In this case, the infectivity of
282 an aliquot of each lot should be separately titrated to ensure that each matches the requirements (see
283 below). Store under refrigeration.

284 **2.2. Method of manufacture**

285 **2.2.1. Procedure**

286 For production, cell monolayers or chicken embryos are infected with *C. abortus*. Once the final harvest
287 suspension is obtained, an aliquot is removed for titration of its infectivity. The bulk is treated with formalin
288 to a final concentration of 4%, and stored until sterility tests confirm complete inactivation.

289 **2.2.2. Requirements for substrates and media**

290 The inactivated harvest is centrifuged and resuspended in phosphate buffered saline containing 0.2%
291 formalin to a volume representing a preinactivation infectivity titre of approximately 10⁸ infectious units/ml.
292 Usually, the aqueous suspension is blended with an oil adjuvant, either directly or after precipitation by
293 potassium alum (AlK[SO₄]₂·12 H₂O). A preservative, such as 0.01% thiomersal, may also be added.

294 **2.2.3. In-process controls**

295 The main requirements are to ensure adequate growth of *C. abortus*, avoidance of extraneous infection of
296 the culture substrate, completeness of inactivation and biohazard awareness by process workers.

297 **2.2.4. Final product batch tests**

298 Each separate batch of manufactured vaccine should be tested for sterility, safety and potency.

299 i) Sterility and purity

300 Tests for sterility and freedom from contamination of biological materials intended for veterinary use
301 may be found in chapter 1.1.9.

302 ii) Safety

303 Subcutaneous inoculation into two or more seronegative sheep of twice the standard dose of
304 manufactured vaccine should elicit no systemic reaction, but oil-adjuvant vaccines can cause a
305 nonharmful swelling at the inoculation site.

306

307 iii) Batch potency
308 At present, potency is judged by the occurrence of a serological response in previously unvaccinated
309 sheep given 1 ml of vaccine subcutaneously. Blood samples taken before and 28 days after
310 vaccination are compared. Ultimately, potency has to be determined by a controlled vaccination-
311 challenge study or field performance. No *in-vitro* correlation of protective efficacy has yet been
312 established.

313 2.3. Requirements for authorisation

314 2.3.1. Safety requirements

315 See Chapter 1.1.8 *Principles of veterinary vaccine production*.

316 2.3.2. Efficacy requirements

317 See chapter 1.1.8.

318 2.3.3. Stability

319 See chapter 1.1.8.

320 3. Vaccines based on biotechnology

321 3.1. Vaccines available and their advantages

322 No biotechnology-based vaccines are currently in use for this disease.

323 REFERENCES

324 AITKEN I.D. & LONGBOTTOM D. (2007). Chlamydial abortion. *In: Diseases of Sheep Fourth Edition*, Aitken I.D., ed. Blackwell
325 Scientific Ltd., Oxford, UK, 105-112.

326 ANON (2015). Diagnostic test for ovine chlamydiosis. *Vet. Rec.*, **176**, 393.

327 ARENS M. & WEINGARTEN M. (1981). Vergleichende Untersuchungen an Buffalo Green monkey (BGM) Zellen und Mäusen
328 zur Isolierung von *Chlamydia psittaci* aus Kot und Organproben von Vögeln. *Zentralbl. Veterinarmed. [B]*, **28**, 301–309.

329 BERRI M., REKIKI A., BOUMEDINE K.S. & RODOLAKIS A. (2009). Simultaneous differential detection of *Chlamydophila abortus*,
330 *Chlamydophila pecorum*, and *Coxiella burnetii* from aborted ruminant's clinical samples using multiplex PCR. *BMC*.
331 *Microbiol.*, **9**, 130.

332 BOMMANA S., JELOCNIK M., BOREL N., MARSH I., CARVER S. & POLKINGHORNE A. (2019). The limitations of commercial serological
333 assays for detection of chlamydial infections in Australian livestock. *J. Med. Microbiol.* **68**, 627–632.

334 BOREL N., KEMPF E., HOTZEL H., SCHUBERT E., TORGERSON P., SLICKERS P., EHRLICH R., TASARA T., POSPISCHIL A. & SACHSE K.
335 (2008). Direct identification of chlamydiae from clinical samples using a DNA microarray assay – a validation study. *Mol.*
336 *Cell. Probes*, **22**, 55–64.

337 BOREL N., THOMA R., SPAENI P., WEILENMANN R., TEANKUM K., BRUGNERA E., ZIMMERMANN D.R., VAUGHAN L. & POSPISCHIL A.
338 (2006). *Chlamydia*-related abortions in cattle from Graubünden, Switzerland. *Vet. Pathol.*, **43**, 702–708.

339 BOREL N. & SACHSE K. (2022). Zoonotic Transmission of *Chlamydia* spp.: Known for 140 Years, but still Underestimated. *In:*
340 *Zoonoses: Infections Affecting Humans and Animals*, Second Edition, Sing A. ed. Springer Nature, Switzerland, 793–819.

341 BUXTON D., ANDERSON I.E., LONGBOTTOM D., LIVINGSTONE M., WATTEGADERA S. & ENTRICAN G. (2002). Ovine chlamydial
342 abortion: characterization of the inflammatory immune response in placental tissues. *J. Comp. Pathol.*, **127**, 133–141.

343 EHRLICH R., SLICKERS P., GOELLNER S., HOTZEL H. & SACHSE K. (2006). Optimized DNA microarray assay allows detection and
344 genotyping of single PCR-amplifiable target copies. *Mol. Cell. Probes.*, **20**, 60–63.

345 ENTRICAN G. (2002). Immune regulation during pregnancy and host-pathogen interactions in infectious abortion. *J. Comp.*
346 *Pathol.*, **126**, 79–94.

-
- 347 ESSIG A. & LONGBOTTOM D. (2015). *Chlamydia abortus*: New aspects of infectious abortion in sheep and potential risk for
348 pregnant women. *Curr. Clin. Microbiol. Reports*, **2**, 22–34.
- 349 EVERETT K.D. & ANDERSEN A.A. (1999). Identification of nine species of the Chlamydiaceae using PCR RFLP. *Int. J. Syst.*
350 *Bacteriol.*, **49**, 803–813.
- 351 GIMENEZ D.F. (1964). Staining rickettsiae in yolk-sac cultures. *Stain Technol.*, **39**, 135–140.
- 352 GUTIERREZ J., WILLIAMS E.J., O'DONOVAN J., BRADY C., PROCTOR A.F., MARQUES P.X., WORRALL S., NALLY J.E., MCELROY M.,
353 BASSETT H.F., SAMMIN D.J. & MARKEY B.K. (2011). Monitoring clinical outcomes, pathological changes and shedding of
354 *Chlamydophila abortus* following experimental challenge of periparturient ewes utilizing the natural route of infection. *Vet.*
355 *Microbiol.*, **147**, 119–126.
- 356 JONES G.E., JONES K.A., MACHELL J., BREBNER J., ANDERSON I.E. & HOW S. (1995). Efficacy trials with tissue-culture grown,
357 inactivated vaccines against chlamydial abortion in sheep. *Vaccine*, **13**, 715–723.
- 358 LAROUCAU K., SOURIAU A. & RODOLAKIS A. (2001). Improved sensitivity of PCR for *Chlamydophila* using *pmp* genes. *Vet.*
359 *Microbiol.*, **82**, 155–164.
- 360 LAROUCAU K., VORIMORE F., SACHSE K., VRETOU E., SIARKOU V.I., WILLEMS H., MAGNINO S., RODOLAKIS A. & BAVOIL P.M. (2010).
361 Differential identification of *Chlamydophila abortus* live vaccine strain 1B and *C. abortus* field isolates by PCR-RFLP.
362 *Vaccine*, **28**, 5653–5656.
- 363 LENZKO H., MOOG U., HENNING K., LEDERBACH R., DILLER R., MENGE C., SACHSE K., SPRAGUE L.D. (2011). High frequency of
364 chlamydial co-infections in clinically healthy sheep flocks. *BMC Vet. Res.*, **7**, 29.
- 365 LIVINGSTONE M., WHEELHOUSE N., MALEY S.W. & LONGBOTTOM D. (2009). Molecular detection of *Chlamydophila abortus* in
366 post-abortion sheep at oestrus and subsequent lambing. *Vet. Microbiol.*, **135**, 134–141.
- 367 LONGBOTTOM D. & COULTER L.J. (2003). Animal chlamydioses and zoonotic implications. *J. Comp. Pathol.*, **128**, 217–244.
- 368 LONGBOTTOM D., FAIRLEY S., CHAPMAN S., PSARROU E., VRETOU E. & LIVINGSTONE M. (2002). Serological diagnosis of ovine
369 enzootic abortion by enzyme-linked immunosorbent assay with a recombinant protein fragment of the polymorphic outer
370 membrane protein PCOMP90 of *Chlamydophila abortus*. *J. Clin. Microbiol.*, **40**, 4235–4243.
- 371 LONGBOTTOM D. & LIVINGSTONE M. (2006). Vaccination against chlamydial infections of man and animals. *Vet. J.*, **171**, 263–
372 275.
- 373 LONGBOTTOM D., LIVINGSTONE M., MALEY S., VAN DER ZON A., ROCCHI M., WILSON K., WHEELHOUSE N., DAGLEISH M., AITCHISON
374 K., WATTEGEDERA S., NATH M., ENTRICAN G. & BUXTON D. (2013). Intranasal infection with *Chlamydia abortus* induces dose-
375 dependent latency and abortion in sheep. *PLoS One*, **8**, e57950.
- 376 LONGBOTTOM D., SAIT M., LIVINGSTONE M., LAROUCAU K., SACHSE K., HARRIS S.R., THOMSON N.R. & SETH-SMITH H.M.B. (2018).
377 Genomic evidence that the live *Chlamydia abortus* vaccine strain 1B is not attenuated and has the potential to cause disease.
378 *Vaccine*, **36**, 3593–3598.
- 379 NIETFELD J.C. (2001). Chlamydial infections in small ruminants. USA. *Vet. Clin. North Am. Food Anim. Pract.*, **17**, 301–314.
- 380 O'NEILL L.M., O'DRISCOLL Á. & MARKEY B. (2018). Comparison of three commercial serological tests for the detection of
381 *Chlamydia abortus* infection in ewes. *Ir. Vet. J.*, **71**, 13. doi: 10.1186/s13620-018-0124-2.
- 382 PANTCHEV A., STING R., BAUERFEIND R., TYCZKA J. & SACHSE K. (2009). New real-time PCR tests for species-specific detection of
383 *Chlamydophila psittaci* and *Chlamydophila abortus* from tissue samples. *Vet. J.*, **181**, 145–150.
- 384 PANTCHEV A., STING R., BAUERFEIND R., TYCZKA J. & SACHSE K. (2010). Detection of all *Chlamydophila* and *Chlamydia* spp. of
385 veterinary interest using species-specific real-time PCR assays. *Comp. Immunol. Microbiol. Infect. Dis.*, **33**, 473–484.
- 386 RODOLAKIS A. (1986). Use of a live temperature-sensitive vaccine in experimental and natural infections. In: Chlamydial
387 Diseases of Ruminants, Aitken I.D., ed. Commission of the European Communities, Luxembourg, 71–77.
- 388 SACHSE K., HOTZEL H., SLICKERS P., ELLINGER T. & EHRLICH R. (2005). DNA microarray-based detection and identification of
389 *Chlamydia* and *Chlamydophila* spp. *Mol. Cell. Probes*, **19**, 41–50.
- 390 SACHSE K., VRETOU E., LIVINGSTONE M., BOREL N., POSPISCHIL A. & LONGBOTTOM D. (2009). Recent developments in the
391 laboratory diagnosis of chlamydial infections (Review). *Vet. Microbiol.*, **135**, 2–21.
-

- 392 SACHSE K., BAVOIL P.M., KALTENBOECK B., STEPHENS R.S., KUO C.C., ROSSELLO-MORA R. & HORN M. (2015). Emendation of
393 the family *Chlamydiaceae*: proposal of a single genus, *Chlamydia*, to include all currently recognized species. *Syst. Appl.*
394 *Microbiol.*, **38**, 99–103.
- 395 SALTI-MONTESANTO V., TSOI E., PAPAVALASSIOU P., PSARROU E., MARKEY B.M., JONES G.E. & VRETOU E. (1997). Diagnosis of
396 ovine enzootic abortion, using a competitive ELISA based on monoclonal antibodies against variable segments 1 and 2 of
397 the major outer membrane protein of *Chlamydia psittaci* serotype 1. *Am. J. Vet. Res.*, **58**, 228–235.
- 398 SILLIS M. & LONGBOTTOM D. (2011). Chlamydiosis. In: Oxford Textbook of Zoonoses, Biology, Clinical Practice and Public
399 Health Control, Palmer S.R., Lord Soulsby, Torgerson P.R. & Brown D.W.G., eds. Oxford University Press, Oxford, UK, 146–
400 157.
- 401 STAMP J.T., MCEWEN A.D., WATT J.A.A. & NISBET D.I. (1950). Enzootic abortion in ewes. I. Transmission of the disease. *Vet.*
402 *Rec.*, **62**, 251–254.
- 403 STUEN S. & LONGBOTTOM D. (2011). Treatment and control of *Chlamydial* and *Rickettsial* infections in sheep and goats. *Vet.*
404 *Clin. Food Anim.*, **27**, 213–233.
- 405 TAN T.W., HERRING A.J., ANDERSON I.E. & JONES G.E. (1990). Protection of sheep against *Chlamydia psittaci* infection with a
406 subcellular vaccine containing the major outer membrane protein. *Infect. Immun.*, **58**, 3101–3108.
- 407 TAYLOR-BROWN A., BACHMANN N.L., BOREL N. & POLKINGHORNE A. (2016). Culture-independent genomic characterisation of
408 *Candidatus Chlamydia sanzinia*, a novel uncultivated bacterium infecting snakes. *BMC Genomics*, **17**, 710.
- 409 TURIN L., SURINI S., WHEELHOUSE N. & ROCCHI M.S. (2022). Recent advances and public health implications for environmental
410 exposure to *Chlamydia abortus*: from enzootic to zoonotic disease. *Vet Res.*, **53**, 37. doi: 10.1186/s13567-022-01052-x.
- 411 VORIMORE F., CAVANNA N., VICARI N., MAGNINO S., WILLEMS H., RODOLAKIS A., SIARKOU V.I. & LAROUCAU K. (2012). High-
412 resolution melt PCR analysis for rapid identification of *Chlamydia abortus* live vaccine strain 1B among *C. abortus* strains
413 and field isolates. *J. Microbiol. Methods*, **90**, 241–244.
- 414 VORIMORE F., HSIA R.C., HUOT-CREASY H., BASTIAN S., DERUYTER L., PASSET A., BAVOIL P., MYERS G. & LAROUCAU K. (2013).
415 Isolation of a New *Chlamydia* species from the Feral Sacred Ibis (*Threskiornis aethiopicus*): *Chlamydia ibidis*. *Plos One*, **8**,
416 e74823.
- 417 VRETOU E., RADOUANI F., PSARROU E., KRITIKOS I., XYLOURI E. & MANGANA O. (2007). Evaluation of two commercial assays for
418 the detection of *Chlamydia abortus* antibodies. *Vet Microbiol.*, **123**, 153–161.
- 419 WHEELHOUSE N., AITCHISON K., LAROUCAU K., THOMSON J. & LONGBOTTOM D. (2010). Evidence of *Chlamydia abortus*
420 vaccine strain 1B as a possible cause of ovine enzootic abortion. *Vaccine*, **28**, 5657–5663.
- 421 WILSON K., LIVINGSTONE M. & LONGBOTTOM D. (2009). Comparative evaluation of eight serological assays for diagnosing
422 *Chlamydia abortus* infection in sheep. *Vet. Microbiol.*, **135**, 38–45.
- 423 ZAREBA-MARCHEWKA K., SZYMAŃSKA-CZERWIŃSKA M., LIVINGSTONE M., LONGBOTTOM D. & NIEMCZUK K. (2021). Whole Genome
424 Sequencing and Comparative Genome Analyses of *Chlamydia abortus* Strains of Avian Origin Suggests That *Chlamydia*
425 *abortus* Species Should Be Expanded to Include Avian and Mammalian Subgroups. *Pathogens*, **10**, 1405. doi:
426 10.3390/pathogens10111405.

*
* *

NB: There are WOA Reference Laboratories for enzootic abortion of ewes
(please consult the WOA Web site:

<https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>).

Please contact the WOA Reference Laboratories for any further information on
diagnostic tests, reagents and vaccines for enzootic abortion of ewes

NB: FIRST ADOPTED IN 1990. MOST RECENT UPDATES ADOPTED IN 2018.

435

436

Appendix 1: Enzootic abortion of ewes
Intended purpose of test: population freedom from infection

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>CFT</u> <u>±</u> <u>Ruminant</u>	<u>Serum</u> <u>antibodies against</u> <u><i>C. abortus</i></u>	<u>N/A</u>	<u>N/A</u>	<u>See reference</u>	<u>Inexpensive</u>	<u>Low sensitivity and specificity</u> <u>Limited commercial availability of antigen</u>	<u>Vretou et al. (2007);</u> <u>Bommana et al. (2019)</u>
<u>ELISA</u> <u>+++</u> <u>Ruminant</u>	<u>Serum</u> <u>antibodies against</u> <u><i>C. abortus</i></u>	<u>N/A</u>	<u>N/A</u>	<u>See reference</u>	<u>Commercially available</u> <u>High sensitivity</u> <u>Rapid and simple</u>	<u>Different specificities</u>	<u>Vretou et al. (2007);</u> <u>Wilson et al. (2009);</u> <u>O'Neill et al. (2018);</u> <u>Bommana et al. (2019)</u>

437

438

Appendix 2: Enzootic abortion of ewes
Intended purpose of test: individual animal freedom from infection prior to movement

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>CFT</u> <u>±</u> <u>Ruminant</u>	<u>Serum</u> <u>antibodies against</u> <u><i>C. abortus</i></u>	<u>N/A</u>	<u>N/A</u>	<u>See reference</u>	<u>Inexpensive</u>	<u>Low sensitivity and specificity</u> <u>Limited commercial availability of antigen</u>	<u>Vretou et al. (2007);</u> <u>Bommana et al. (2019)</u>
<u>ELISA</u> <u>±±</u> <u>Ruminant</u>	<u>Serum</u> <u>antibodies against</u> <u><i>C. abortus</i></u>	<u>N/A</u>	<u>N/A</u>	<u>See reference</u>	<u>Commercially available</u> <u>High sensitivity</u> <u>Rapid and simple</u>	<u>Different specificities</u>	<u>Vretou et al. (2007); Wilson et al. (2009); O'Neill et al. (2018); Bommana et al. (2019)</u>

439

440

Appendix 3: Enzootic abortion of ewes
Intended purpose of test: contribute to eradication policies

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>CFT</u> <u>±</u> <u>Ruminant</u>	<u>Serum</u> <u>antibodies against</u> <u><i>C. abortus</i></u>	<u>N/A</u>	<u>N/A</u>	<u>See reference</u>	<u>Inexpensive</u>	<u>Low sensitivity and specificity</u> <u>Limited commercial availability</u> <u>of antigen</u>	<u>Vretou <i>et al.</i> (2007);</u> <u>Bommana <i>et al.</i> (2019)</u>
<u>ELISA</u> <u>+++</u> <u>Ruminant</u>	<u>Serum</u> <u>antibodies against</u> <u><i>C. abortus</i></u>	<u>N/A</u>	<u>N/A</u>	<u>See reference</u>	<u>Commercially available</u> <u>High sensitivity</u> <u>Rapid and simple</u>	<u>Different specificities</u>	<u>Vretou <i>et al.</i> (2007);</u> <u>Wilson <i>et al.</i> (2009);</u> <u>O'Neill <i>et al.</i> (2018);</u> <u>Bommana <i>et al.</i> (2019)</u>

441

442

Appendix 4: Enzootic abortion of ewes
Intended purpose of test: confirmation of clinical cases

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Stained smears</u> ± <u>Ruminant</u>	<u>Placenta and fetal tissue</u> <u>C. abortus bacteria</u>	<u>N/A</u>	<u>N/A</u>	<u>N/A</u>	<u>Simple and inexpensive</u>	<u>Low to intermediate sensitivity</u> <u>Depends on experienced staff</u>	
<u>Bacterial isolation</u> ±± <u>Ruminant</u>	<u>Placenta and fetal tissue, vaginal swabs</u> <u>C. abortus isolate</u>	<u>N/A</u>	<u>N/A</u>	<u>N/A</u>	<u>Gold standard</u> <u>Obtaining isolates for further characterisation</u>	<u>Low to intermediate sensitivity</u> <u>Cumbersome and long lab procedures</u> <u>Depends on experienced staff</u>	
<u>Antigen detection by IHC</u> ±± <u>Ruminant</u>	<u>Placenta and fetal tissue</u> <u>C. abortus antigen</u>	<u>N/A</u>	<u>N/A</u>	<u>N/A</u>	<u>Enables association of Chlamydia presence with tissue lesions</u>	<u>Intermediate sensitivity</u>	
<u>Conventional PCR</u> ±± <u>Ruminant</u>	<u>Placenta and fetal tissue, vaginal swabs</u> <u>C. abortus DNA</u>	<u>N/A</u>	<u>N/A</u>	<u>See reference</u>	<u>High specificity</u>	<u>Intermediate sensitivity</u> <u>Time consuming</u>	<u>Laroucau et al. (2001)</u>
<u>Real-time PCR</u> +++ <u>Ruminant</u>	<u>Placenta and fetal tissue, vaginal swabs</u> <u>C. abortus DNA</u>	<u>N/A</u>	<u>N/A</u>	<u>See reference</u>	<u>High sensitivity and specificity</u> <u>Rapid</u>	<u>Needs expensive lab equipment</u>	<u>Pantchev et al. (2009);</u> <u>Livingstone et al. (2009)</u>
<u>CFT</u> ± <u>Ruminant</u>	<u>Serum</u> <u>Antibodies against C. abortus</u>	<u>N/A</u>	<u>N/A</u>	<u>See reference</u>	<u>Inexpensive</u>	<u>Low sensitivity and specificity</u> <u>Limited commercial availability of antigen</u>	<u>Vretou et al. (2007);</u> <u>Bommana et al. (2019)</u>
<u>ELISA</u> ±± <u>Ruminant</u>	<u>Serum</u> <u>Antibodies against C. abortus</u>	<u>N/A</u>	<u>N/A</u>	<u>See reference</u>	<u>Commercially available</u> <u>High sensitivity</u> <u>Rapid and simple</u>	<u>Different specificities</u>	<u>Vretou et al. (2007);</u> <u>Wilson et al. (2009);</u> <u>O'Neill et al. (2018);</u> <u>Bommana et al. (2019)</u>

Appendix 5: Enzootic abortion of ewes
Intended purpose of test: prevalence of infection – surveillance

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Antigen detection by IHC</u> ± <u>Ruminant</u>	<u>Placenta and fetal tissue</u> <u>C. abortus antigen</u>	<u>N/A</u>	<u>N/A</u>	<u>N/A</u>	<u>Enables association of Chlamydia presence with tissue lesions</u>	<u>Intermediate sensitivity</u>	
<u>Conventional PCR</u> ± <u>Ruminant</u>	<u>Placenta and fetal tissue,</u> <u>vaginal swabs</u> <u>C. abortus DNA</u>	<u>N/A</u>	<u>N/A</u>	<u>See reference</u>	<u>High specificity</u>	<u>Intermediate sensitivity</u> <u>Time consuming</u>	<u>Laroucau et al. (2001)</u>
<u>Real-time PCR</u> ++ <u>Ruminant</u>	<u>Placenta and fetal tissue,</u> <u>vaginal swabs</u> <u>C. abortus DNA</u>	<u>N/A</u>	<u>N/A</u>	<u>See reference</u>	<u>High sensitivity and specificity</u> <u>Rapid</u>	<u>Needs expensive laboratory equipment</u>	<u>Pantchev et al. (2009);</u> <u>Livingstone et al. (2009)</u>
<u>CFT</u> ± <u>Ruminant</u>	<u>Serum</u> <u>Antibodies against C.</u> <u>abortus</u>	<u>N/A</u>	<u>N/A</u>	<u>See reference</u>	<u>Inexpensive</u>	<u>Low sensitivity and specificity</u> <u>Limited commercial availability of antigen</u>	<u>Vretou et al. (2007);</u> <u>Bommana et al. (2019)</u>
<u>ELISA</u> +++ <u>Ruminant</u>	<u>Serum</u> <u>Antibodies against C.</u> <u>abortus</u>	<u>N/A</u>	<u>N/A</u>	<u>See reference</u>	<u>Commercially available</u> <u>High sensitivity</u> <u>Rapid and simple</u>	<u>Different specificities</u>	<u>Vretou et al. (2007);</u> <u>Wilson et al. (2009);</u> <u>O'Neill et al. (2018);</u> <u>Bommana et al. (2019)</u>

445

446

Appendix 6: Enzootic abortion of ewes**Intended purpose of test: Immune status in individual animals or populations post-vaccination**

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population used to measure accuracy</u>	<u>Validation report</u>	<u>Advantages: expert opinion</u>	<u>Disadvantages: expert opinion</u>	<u>References</u>
<u>CFT</u> ± <u>Ruminant</u>	<u>Serum</u> <u>antibodies against</u> <u><i>C. abortus</i></u>	<u>N/A</u>	<u>N/A</u>	<u>See reference</u>	<u>Inexpensive</u>	<u>Low sensitivity and specificity</u> <u>Limited commercial availability of antigen</u>	<u>Vretou et al. (2007); Bommana et al. (2019)</u>
<u>ELISA</u> +++ <u>Ruminant</u>	<u>Serum</u> <u>antibodies against</u> <u><i>C. abortus</i></u>	<u>N/A</u>	<u>N/A</u>	<u>See reference</u>	<u>Commercially available</u> <u>High sensitivity</u> <u>Rapid and simple</u>	<u>Different specificities</u>	<u>Vretou et al. (2007); Wilson et al. (2009); O'Neill et al. (2018); Bommana et al. (2019)</u>

CHAPTER 3.8.12.

SHEEP POX AND GOAT POX

* * *

C. REQUIREMENTS FOR VACCINES

1. Background

1.1. Rationale and intended use of the product

Vaccines are an important tool for controlling sheep pox and goat pox (SPP and GTP) spread in endemic regions and they can be helpful for controlling accidental outbreaks in free regions, although such outbreaks can be controlled without the use of vaccines when other control measures such as stamping out, movement restriction, cleaning and disinfection, etc., are strictly implemented and followed.

A variety of live attenuated and inactivated capripoxvirus vaccines has been used to provide protection against SPP and GTP and these were often derived by attenuating or inactivating local pathogenic strains (Davies & Mbugwa, 1985; Ramyar & Hessami, 1967). Nowadays most commercially available vaccines are based on live attenuated SPP and GTP virus strains. Live attenuated vaccines based on different SPPV strains (e.g. RM65, Romania, Băkirkoj) and GTPV strains (e.g. Mysore, Gorgan, Uttharkashi) have shown to provide good protection in experimental and field conditions when used as homologous vaccines in sheep and goats, respectively (Bhanuprakash *et al.*, 2022; Hamdi *et al.*, 2021; Oreiby *et al.*, 2022; Tuppurainen *et al.*, 2017; Yogisharadhya *et al.*, 2011). These vaccines have a good safety profile with fever and local swelling at the vaccination site as the most often reported side effects. Live attenuated SPPV-based vaccines provide a protection of at least 12 months (Kitching, 2003) and a GTP vaccine based on the Uttharkashi strain was recently reported to provide protection against challenge for up to 52 months (Bhanuprakash *et al.*, 2022).

Also some heterologous live attenuated vaccines based on lumpy skin disease virus (LSDV) strains have been described. The best known example is the Kenyan sheep and goat pox vaccine virus (KSGP) O240 which A variety of attenuated live and inactivated capripoxvirus vaccines has been used to provide protection against sheeppox and goatpox. All strains of capripoxvirus of ovine, caprine or bovine origin examined so far share a major neutralising site, so that animals recovered from infection with one strain are resistant to infection with any other strain (Capstick, 1961). Consequently, it is possible to use a single strain of capripoxvirus to protect both sheep and goats against all field strains of virus, regardless of whether their origin was in Asia or Africa (Kitching *et al.*, 1986; Kitching & Taylor, 1985). However, field evidence suggests some strains are quite host specific and are used only in sheep against SPPV and only in goat against GTPV. A number of strains of capripoxvirus have had widespread use as live vaccines (Davies & Mbugwa, 1985), for example the Romanian and RM-65 strains used mainly in sheep and the Mysore and Gorgan strains used in goats. The real identity of the commonly used Kenyan sheep and goat pox vaccine virus (KSGP) O240 was recently shown to actually be LSDV (Tuppurainen *et al.*, 2014). Vaccines based on this strain should be used carefully as this strain has shown to have residual virulence due to insufficient attenuation (Hamdi *et al.*, 2021). The limited information available furthermore indicates that heterologous vaccines provide less protection than homologous vaccines (Hamdi *et al.*, 2020).

44 None of the vaccines currently available have DIVA¹ capacity. When vaccination is envisioned, it is
45 important to select vaccines with proven safety and efficacy and perform an independent batch control
46 whereby the identity, purity and potency of the vaccine are evaluated. Virus strain identity and attenuation
47 properties must be ascertained and taken into consideration when selecting vaccine strains for use in
48 cattle, sheep and goats. The protective dose depends on the vaccine strain used. Immunity in sheep and
49 goats against capripox following vaccination with the 0240 strain lasts over a year and the Romanian
50 strain gave protection for at least 30 months.

51 Killed vaccines produced from tissue culture contain only the intracellular mature virion form of the virus,
52 and lack the less robust but biologically crucial extracellular enveloped virion form. As a result, the
53 vaccine does not stimulate immunity against the extracellular enveloped virion, resulting in poor
54 protection. Killed capripox vaccines provide, at best, only temporary protection.

55 **2. Outline of production and minimum requirements for conventional vaccines**

56 General requirements set for the facilities used for the production of vaccines and for the documentation and record
57 keeping throughout the whole manufacturing process are described in Chapter 1.1.8 *Principles of veterinary vaccine*
58 *production*. The documentation should include the standard operating procedures (SOP) for the method of
59 manufacture and each step for the testing of cells and reagents used in the process, each batches and the final
60 product.

61 **2.1. Characteristics of the seed**

62 **2.1.1. Biological characteristics**

63 A strain of capripoxvirus used for vaccine production must be accompanied by a history describing
64 its origin and tissue culture or animal passage. It must be safe to use in all breeds of sheep and
65 goats for which it is intended, including pregnant and young animals. It must be non-transmissible,
66 remain attenuated after further tissue culture passage, and provide complete protection against
67 challenge with virulent field strains for a minimum of 1 year. A quantity of master seed vaccine
68 virus should be prepared and stored in order to provide a consistent working seed for regular
69 vaccine production.

70 **2.1.2. Quality criteria (sterility, purity, freedom from extraneous agents)**

71 Each master seed must be tested to ensure its identity and shown to be free from adventitious
72 viruses, in particular pestiviruses, such as border disease and bovine viral diarrhoea virus, and
73 free from contamination with bacteria, fungi and/or mycoplasmas. The general procedures for
74 sterility or purity tests are described in chapter 1.1.9. The master seed must also be safe and
75 produce no clinical reaction in all breeds of sheep or goats when given by the recommended route
76 and stimulate complete immunity to capripox in all breeds of sheep and goats for at least 1 year.
77 The necessary safety and potency tests are described in Section C.2.2.4 *Final product batch*
78 *tests*.

79 The production of vaccines, including SPP/GTP vaccines, starts within research and development (R&D) facilities
80 where vaccine candidates are produced and tested in preclinical studies to demonstrate the quality, safety and
81 efficacy of the product.

82 Minimum requirements for different production stages of veterinary vaccines are available in different chapters of
83 the *Terrestrial Manual*. These are intended to be used in combination with country-specific regulatory requirements
84 for vaccine production and release. Here we outline the most important requirements for the production of live and
85 inactivated homologous SPP/GTP vaccines. Full requirements are available in Chapter 1.1.8 *Principles of*
86 *veterinary vaccine production*, Chapter 2.3.3 *Minimum requirements for the organisation and management of a*
87 *vaccine manufacturing facility* and Chapter 2.3.4 *Minimum requirements for the production and quality control of*
88 *vaccine*, and other regulatory documentation.

89 **2.1. Quality assurance**

90 Facilities for manufacturing SPP/GTP vaccines should operate in line with the concepts of good
91 laboratory practice (GLP) and good manufacturing practice (GMP) to produce high-quality products.
92 Quality risk management and quality control with adequate documentation management, as an integral

¹ DIVA: [detection of infection in vaccinated animals](#)

93 part of the production process, have to be in place. In case some activities of the production process are
94 outsourced, those should also be appropriately defined, recorded and controlled.

95 The vaccine production process (Outline of Production) should be documented in a series of standard
96 operating procedures (SOPs), or other documents describing the manufacturing of each batch and the
97 final product (including starting materials to be used, manufacturing steps, in-process controls and
98 controls on the final product). Detailed requirements for documentation management in the process of
99 vaccine production are available in Chapter 2.3.3.

100 A completed Outline of Production is to be enclosed in a vaccine candidate dossier and used for the
101 evaluation of the production process and product by regulatory bodies.

102 **2.2. Process validation**

103 The dossier with the enclosed Outline of Production for the vaccine candidate has to be submitted for
104 regulatory approval, so it can be assessed and approved by the Competent Authority to ensure
105 compliance with local regulatory requirements. Among others, data on quality, safety, and efficacy will
106 be assessed. The procedures necessary to obtain these data are described in the subsequent sections.

107 National regulatory authorities might also require official control authority re-testing (check testing) of
108 final products and batches in government laboratories or an independent batch quality control by a third
109 party.

110 **3. Requirements for SPP/GTP vaccine candidates and batch production**

111 **3.1. Requirements for starting materials**

112 Live attenuated vaccines (LAV) and inactivated vaccines (IV) for SPP/GTP are produced using the
113 system of limited and controlled passages of master seed and working seed virus and cell banks with a
114 specified maximum. This approach aims to prevent possible changes of properties of seed virus and
115 cells that might arise from repeated passaging.

116 **3.1.1. Master seed virus**

117 Master seed virus is a quantity of virus of uniform composition derived from an original isolate,
118 passaged for a documented number of times and distributed into containers at one time and
119 stored adequately to ensure stability (via freezing or lyophilisation). Selection of master seed
120 viruses (MSVs) should ideally be based on their ease of growth in cell culture, virus yield, and in
121 accordance with the regional epidemiological importance. Also, measures to minimise
122 transmissible spongiform encephalopathies (TSE) contamination should be taken into account
123 (see Section C.3.5.1 Purity tests).

124 For each seed strain selected for SPP/GTP vaccine production, the following information should
125 be provided:

126 - Historical record: geographical origin, animal species from which the virus was recovered,
127 isolation procedure, tissue culture or animal passage history

128 - Identity: species and strain identification using DNA sequencing

129 - Purity: the absence of bacteria, fungi, mycoplasma, and other viruses (see Chapter 1.1.9
130 Tests for sterility and freedom from contamination of biological materials intended for
131 veterinary use)

132 - Safety (overdose, one/repeated dose tests, and reversion to virulence tests) (see Section
133 C.3.3 Vaccine safety)

134 - Efficacy data, linked to a specified (protective) dose (see Section C.3.4 Vaccine efficacy)

135 - Stability

136 Each master seed strain selected for production of live attenuated vaccines must remain
137 attenuated after further passage in animals (see Section C.3.3. Vaccine safety), produce minimal
138 clinical reaction when given via the recommended route, provide complete protection against
139 challenge with virulent field strains, and is preferably not transmissible.

140 A quantity of master seed virus should be prepared and stored to be further used for the
141 preparation of working seeds and production seeds. Working seed viruses may be expanded in

142 one or more (but, limited) cell culture passages from the master seed stock and used to produce
143 vaccine batches. This approach and limitation of seed virus passaging will assist in maintaining
144 uniformity and consistency in production.

145 **3.1.2. Master cell stocks**

146 The production process of SPP/GTP vaccines preferably employs an established master cell
147 stock (MCS) system with defined lowest and highest cell passage to be used to grow the vaccine
148 virus. Primary cells derived from normal tissues can be used in the production process, but the
149 use of primary cells has an inherently higher risk of introducing extraneous agents compared with
150 the use of established (well characterised) cell lines and should be avoided where alternative
151 methods of producing effective vaccines exist. For each MCS, manufacturers should
152 demonstrate:

- 153 - MCS identity
- 154 - genetic stability by subculturing from the lowest to the highest passage used for production
- 155 - stable MCS karyotype with a low level of polyploidy
- 156 - freedom from oncogenicity or tumorigenicity by using *in-vivo* studies using the highest cell
157 passage that may be used for production
- 158 - purity of MCSs from extraneous bacteria, fungi, mycoplasma, and viruses
- 159 - implemented measures to lower TSE contamination risk (see Section C.3.5.1 *Purity tests*).

160 **23.2. Method of vaccine manufacturing**

161 The method of manufacture should be documented as the Outline of Production.

162 **2.2.1. Procedure**

163 **3.2.1. SPP/GTP vaccine batch production**

164 As already mentioned in the first paragraphs of Section C, all steps undertaken in the production
165 of vaccine batches should be described and documented in the Outline of Production. The
166 production of LAV and IV against SPP/GTP starts with the inoculation of the required number of
167 working vials of seed virus reconstituted in an appropriate medium onto a suitable primary cell
168 line grown in suspension or monolayer in the exponential growth phase. At the time highest viral
169 loads are present sonication or repeated freeze-thawing are used to release the intracellular virus
170 from the cytoplasm. The lysate may then be clarified using centrifugation to remove cellular debris
171 with the retention of supernatant.

172 An aliquot of the virus suspension is titrated to check the virus titre. For LAV, the virus-containing
173 suspension is diluted to attain the dose at which the vaccine candidate will be evaluated or to at
174 least the determined protective dose for approved vaccines and is then mixed with a suitable
175 protectant and transferred to individually labelled bottles or bags for storage at low temperatures
176 such as -80°C, or for freeze-drying. Commercially available vaccines mostly contain a minimum
177 dose of 10^{2.5} TCID₅₀ (median tissue culture infective dose)/animal. A written record of all the
178 procedures followed must be kept for all vaccine batches.

179 Vaccine seed should be lyophilised and stored in 2 ml vials at -20°C. It may be stored wet at
180 -20°C, but when wet, is more stable at -70°C or lower. The virus should be cultured in primary
181 or secondary LT or LK cells of wool sheep origin for maximum yield. Vero cells may also be used
182 with suitably adapted strains.

183 Vaccine batches are produced on fresh monolayers of secondary LT or primary LK cells. A vial
184 of seed virus is reconstituted with GMEM or another appropriate medium and inoculated on to an
185 LT or LK monolayer that has been previously washed with warm PBS, and allowed to adsorb for
186 15 minutes at 37°C before being overlaid with additional GMEM. After 4-6 days, there will be
187 extensive (80-90%) CPE. The culture should be examined for any evidence of nonspecific CPE,
188 medium cloudiness or change in medium pH. The culture is freeze-thawed three times, the
189 suspension removed and centrifuged at 600 g for 20 minutes. A second passage may be required
190 to produce sufficient virus for a production batch. Live vaccine may be produced on roller bottles.

191 The procedure is repeated and the harvests from individually numbered flasks are each mixed
192 separately with an equal volume of sterile and chilled 5% lactalbumin hydrolysate and 10%
193 sucrose, and transferred to individually numbered bottles for storage at -20°C. Prior to storage,
194 0.2 ml is removed from each bottle for sterility control. An additional 0.2 ml is removed for virus

195 titration; 2 ml pools composed of 0.2 ml samples taken from ten bottles are used. A written record
196 of all the procedures must be kept for all vaccine batches.

197 Inactivated vaccines are produced, usually from unattenuated field strains of capripoxvirus, grown
198 in tissue culture as described above, inactivated with 0.03% formaldehyde, and mixed with an
199 equal volume of alhydrogel as adjuvant. Formaldehyde is no longer considered to be a suitable
200 inactivant for certain viral vaccines because its mode of action cannot be guaranteed to be totally
201 effective in inactivating all the live virus. This has not been fully investigated for capripoxvirus.

202 **3.2.2. Inactivation process for inactivated SPP/GTP vaccines**

203 Unlike LAV, inactivated vaccines contain inactivated antigens in combination with adjuvants to
204 strengthen the induced immune response after administration. The titres of the virus in
205 preparations intended for inactivation can vary between different manufacturers and production
206 processes, but should ensure the induction of an efficient immune response that provides
207 complete clinical protection.

208 To monitor the inactivation process and the level of antigen inactivation, samples are taken at
209 regular intervals during inactivation and titrated. Inactivation conditions and the length of initial
210 and repeated exposure should be documented in detail as one or more factors during the process
211 could influence the outcome. The inactivation kinetics should reach a predefined target e.g. one
212 remaining infectious unit per million doses (1×10^{-6} infectious units/dose) as suggested by APHIS
213 (2013). The confirmatory testing of inactivation is performed on each vaccine lot and represents
214 an important part of the inactivation process monitoring. In addition to all the procedures
215 mentioned above, the inactivation procedure and tests demonstrating that antigen inactivation is
216 complete and consistent must additionally be documented in the Outline of Production.

217 **3.3. Vaccine safety**

218 During the vaccine development process, vaccine safety must be evaluated in the target animal (target
219 animal batch safety test – TABST) to demonstrate the safety of the dose intended for regulatory approval.
220 The animals used in the safety testing should be representative (species, age and category [lambs,
221 ewes, ram; kid, does, buck]) for all the animals for which the vaccine is intended. Vaccinated and control
222 groups are appropriately acclimatised, housed and managed in line with animal welfare standards.
223 Animal suffering has to be eliminated or reduced and euthanasia is recommended in moribund animals.

224 Essential parameters to be evaluated in safety studies are local and systemic reactions to vaccination,
225 including local reactions at the site of administration, fever, and effect on milk production. The effect of
226 the vaccine on reproduction needs to be evaluated where applicable.

227 A part of the safety evaluation of LAV and IV can be performed during the efficacy trials (see Section
228 C.3.4 Vaccine efficacy) by measuring local and systemic responses following vaccination and before
229 challenge.

230 Guidelines for safety evaluation are provided by the European Medicine Agency (EMA) in VICH GL44:
231 TABST for LAV and IV (EMA, 2009). Safety aspects of LAV and IV against SPP/GTP to be evaluated
232 are:

233 **3.3.1. Overdose test for LAV**

234 Local and systemic responses should be measured following an overdose test whereby 10x the
235 maximum vaccine titre is administered. If the maximum vaccine titre is not specified, 10x the
236 minimum vaccine titre can be applied in multiple injection sites. Ideally, the 10x dose is dissolved
237 in the 1x dose volume of the adjuvants or diluent. Generally, eight animals per group should be
238 used (EMA, 2009).

239 **3.3.2. One dose and repeat dose test**

240 This aims to test the safety of the vaccine dose applied in the vaccination regime intended for
241 regulatory approval. LAV require one dose per year, while inactivated vaccines require a booster
242 dose in addition to the primary dose. The minimal recommended interval between administrations
243 is 14 days.

244 Generally, eight animals per group should be used unless otherwise justified (EMA, 2009). For
245 each target species, the most sensitive breed, age and sex proposed on the label should be used.
246 Seronegative animals should be used. In cases where seronegative animals are not reasonably
247 available, alternatives should be justified.

248 **3.3.3. Reversion to virulence tests**

249 The test carried out should be consistent with VICH GL41 (Examination of live veterinary vaccines
250 in target animals for absence of reversion to virulence, 2008²). Live attenuated vaccines inherently
251 carry the risk of vaccine virus reverting to virulence when repeated passages in a host species
252 could occur due to shedding and transmission from vaccinated animals to contact animals. LAV
253 vaccines should therefore be tested for non-reversion to virulence by means of passage studies.
254 Vaccine virus (MSV, not the finished vaccine) is inoculated in a group of target animals of
255 susceptible age via the natural route of infection or the route that is most likely to result in infection.
256 The vaccine virus is subsequently recovered from tissues or excretions and is used directly to
257 inoculate a further group of animals. After not less than four passages (see chapter 1.1.8), i.e.
258 use of a total of five groups of animals, the re-isolate must be fully characterised, using the same
259 procedures used to characterise the master seed virus.

260 **3.3.4. Environmental consideration**

261 This includes the evaluation of the ability of LAV vaccines to be shed, to spread and to infect
262 contact target and non-target animals, and to persist in the environment.

263 **3.4. Vaccine efficacy**

264 Data enclosed in the vaccine candidate dossier should support the efficacy of the vaccine in each animal
265 species for each vaccination regimen that is described in the product label recommendation. This
266 includes studies regarding the onset of protection when claims for onset are made and for the duration
267 of immunity. Efficacy studies should be conducted with the vaccine candidate that has been produced at
268 the highest passage level permitted for vaccine production as specified in the Outline of Production.

269 Efficacy (and safety) should be demonstrated in vaccination–challenge studies using representative (by
270 species, age and category) seronegative healthy animals for which the vaccine is intended and which
271 are tested negative for standard viral pathogens.

272 An example of a vaccination-challenge test set-up is outlined here. The group numbers mentioned can
273 be varied if statistically justified. Thirteen animals are placed in a high containment large animal unit and
274 are divided into two groups:

275 - single/repeated dose test group (n=8) – animals inoculated with the vaccine dose and route
276 intended for regulatory approval (in case of an IV, a booster dose should follow primary vaccination
277 after minimum 14 days).

278 - control group (n=5) – non-vaccinated animals

279 Throughout the *in-vivo* study, all animals are clinically examined and rectal temperatures recorded.
280 Blood, serum and swab samples are regularly collected and subjected to laboratory testing. On day 21
281 after the vaccination with a LAV or after the booster vaccination for an IV, the animals in both groups are
282 challenged with a known virulent SPP/GTP strain. The challenge virus solution should be of known titre
283 and tested free from extraneous viruses. Both intradermal or intranasal challenge models have been
284 used (Philips *et al.*, 2024 [in prep]; Wolf *et al.*, 2022). The intranasal challenge model mimics the natural
285 infection route most closely. Depending on the model, doses of challenge virus ranging from 10³
286 TCID₅₀/animal (intradermal) to 10⁶ TCID₅₀/animal (intranasal) have been applied.

287 The clinical response following challenge is recorded over a period of 14 days. No clinical signs should
288 occur in the vaccinates, other than a local reaction at the site of inoculation. At least one animal in the
289 unvaccinated control group should develop the typical clinical signs of disease. Based on experiences
290 from previous experiments, most animals show clinical signs which can be different in intensity,
291 depending on the challenge strain and dose. Subclinical infections are not typically seen.

292 Clinical and laboratory results will enable assessment of the safety and efficacy of the vaccine candidate
293 and the induced immune responses. Serum samples collected at different time points during the trial can
294 be examined to study seroconversion against selected viral diseases that could have contaminated the
295 vaccine.

296

² https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl41-target-animal-safety-examination-live-veterinary-vaccines-target-animals-absence-reversion_en.pdf.

297

3.5. Batch/serial tests before release for distribution

298 Quality tests on MSV and safety and efficacy tests on vaccine candidates are performed during the
299 evaluation process for new vaccines. Once vaccines are approved to be used in the field, it remains
300 important to verify the quality of each vaccine batch produced. An independent batch quality control
301 assessment may be warranted or requested by national or international regulatory authorities.

302

3.5.1. Purity test

303 Purity is defined by the absence of different contaminants (bacteria, fungi, mycoplasma, and other
304 viruses; see full details in chapter 1.1.9) in the vaccine and its associated diluent/adjuvants. Virus
305 isolation and bacterial culture tests can be used to show freedom from live competent replicating
306 microorganisms, but molecular methods are more rapid and sensitive, but positives can be
307 caused by genome fragments and non-infectious microorganisms.

308 Besides the contaminants mentioned above, manufacturers should demonstrate implemented
309 measures to minimise the risk of TSE contamination in ingredients of animal origin such as:

310 - all ingredients of animal origin in production facilities are from countries recognised as
311 having the lowest possible risk of bovine spongiform encephalopathy

312 - tissues or other substances used are themselves recognised as being of low or nil risk of
313 containing TSE agents.

314

3.5.2. Identity tests

315 In addition to identity tests performed on the MSV, the identity tests on final batches aim to
316 demonstrate the presence of only the selected capripoxvirus species and strain in the vaccine as
317 indicated in the Outline of Production and the absence of other strains or members of the genus
318 and any other viral contaminant that might arise during the production process. Identity testing
319 could be assured by using appropriate tests (e.g. PCRs, sanger sequencing, NGS).

320

3.5.3. Potency tests

321 Standard requirements for potency tests can be found in CFR Title 9 part 113 (2024), in the
322 European Pharmacopoeia (2012), and in this *Terrestrial Manual*.

323

3.5.3.1. Live vaccines

324 The potency of LAV against SPP/GTP can be measured by means of virus titration. The
325 virus titre must, as a rule, be sufficiently greater than that shown to be protective in the
326 efficacy test for the vaccine candidate. This will ensure that at any time prior to the expiry
327 date, the titre will be at least equal to the evaluated protective titre. The titres of currently
328 available commercial live attenuated vaccines range between 10^{2.5} and 10³ infectious
329 units/dose (Tuppurainen *et al.*, 2021).

330

3.5.3.2. Inactivated vaccines

331 For inactivated SPP/GTP vaccines, potency tests are performed using vaccination–
332 challenge efficacy studies in animal hosts (see Section C.3.4. *Vaccine efficacy*).

333

3.5.4. Safety/efficacy

334 Safety and efficacy testing is undertaken during the evaluation process of the vaccine candidate,
335 and also needs to be performed on a number of vaccine batches until robust data are generated
336 in line with international and national regulations. Afterwards, when using a seed lot system in
337 combination with strict implementation of GMP standards and depending on local regulations,
338 TABST could be waived as described in VICH50 and VICH55, providing the titer has been
339 ascertained using potency testing. Batches or serials are considered satisfactory if local and
340 systemic reactions to vaccination are in line with those described in the dossier of the vaccine
341 candidate and product literature.

342

3.5.4.1. Field safety/efficacy tests

343 Field testing of two or more batches should be performed on all animal categories for which
344 the product is indicated before release of the product for general use (see chapter 1.1.8).
345 The aim of these studies is to demonstrate the safety and efficacy of the product under
346 normal field conditions of animal care and use in different geographical locations where
347 different factors may influence product performance. A protocol for safety/efficacy testing in

348 the field has to be developed with defined observation and recording procedures. However,
349 it is generally more difficult to obtain statistically significant data to demonstrate efficacy
350 under field conditions. Even when properly designed, field efficacy studies may be
351 inconclusive due to uncontrollable outside influences.

352 **3.5.4.2. Duration of Immunity**

353 The duration of immunity (DOI) following vaccination should be demonstrated via challenge
354 or the use of a validated serology test. Efficacy testing at the end of the claimed period of
355 protection should be conducted in each species for which the vaccine is indicated or the
356 manufacturer should indicate that the DOI for that species is not known. Likewise, the
357 manufacturer should demonstrate the effectiveness of the recommended booster regime in
358 line with these guidelines, usually by measuring the magnitude and kinetics of the observed
359 serological response.

360 **4. Post-market studies**

361 **4.1. Stability**

362 Stability testing shall be carried out as specified in Annex II of Regulation (EU) 2019/6 and in the Ph.
363 Eur. 0062: Vaccines for veterinary use, on not less than three representative batches providing this
364 mimics the full-scale production described in the application. At the end of shelf-life, sterility has to be
365 re-evaluated using sterility testing or by showing container closure integrity. Multiple batches of the vaccine
366 should be re-titrated periodically throughout the shelf-life period to determine the vaccine stability.

367 **4.2. Post-marketing surveillance**

368 After release of a vaccine, its performance under field conditions should continue to be monitored by
369 competent authorities and by the manufacturer itself. Not all listed adverse effects may show up in the
370 clinical trials performed to assess safety and efficacy of the vaccine candidate due to the limited number
371 of animals used. Post-marketing surveillance studies can also provide information on vaccine efficacy
372 when used in normal practice and husbandry conditions, on duration of induced immunity, on ecotoxicity,
373 etc.

374 First, a reliable reporting system should be in place to collect consumer complaints and notifications of
375 adverse reactions. Secondly, post-marketing surveillance should be established to investigate whether
376 the reported observations are related to the use of the product and to identify, at the earliest stage, any
377 serious problem that may be encountered from its use and that may affect its future uptake.
378 Vaccinovigilance should be an on-going and integral part of all regulatory programmes for SPPV/GTPV
379 vaccines, especially for live vaccines.

380 **2.2.2. Requirements for substrate and media**

381 The specification and source of all ingredients used in the manufacturing procedure should be
382 documented and the freedom from extraneous agents: bacteria, fungi, mycoplasma and any other
383 viruses should be tested. The detailed testing procedure is described in the chapter 1.1.9. The
384 use of antibiotics must meet the requirements of the licensing authority.

385 **2.2.3. In-process controls**

386 i) Cells

387 Cells should be obtained from the testis or kidney of a healthy young lamb from a scrapie-
388 free flock of a wool sheep breed. During cultivation, cells must be observed for any evidence
389 of CPE, and for normal morphology (predominantly fibroblastic). They can usually be
390 passaged successfully up to ten times. When used for vaccine production, uninfected control
391 cultures should be grown in parallel and maintained for at least three additional passages
392 for further observation. They should be checked for the presence of noncytopathic strains
393 of bovine virus diarrhoea or border disease viruses by immunofluorescence or
394 immunoperoxidase techniques. If possible, cells should be prepared and screened prior to
395 vaccine production and stocked in 1–2 ml aliquots containing 2×10^7 cells/ml in sterile 10%
396 DMSO (dimethyl sulphoxide) and 90% FBS (fetal bovine serum) solution stored in liquid
397 nitrogen.

398

399 ii) — Serum
400 Bovine serum used in the growth or maintenance medium must be free from transmissible
401 spongiform encephalopathies (TSEs) and antibody to capripoxvirus, and tested for
402 contamination with pestivirus or any other viruses, extraneous bacteria, mycoplasma or
403 fungi.

404 iii) — Medium
405 Medium must be tested free from contamination with pestivirus or any other viruses,
406 extraneous bacteria, mycoplasma or fungi.

407 iv) — Virus
408 Seed virus and final vaccine must be titrated in tissue culture tubes or microtitre plates.
409 Vaccine samples must be examined for the presence of adventitious viruses including
410 cytopathic and noncytopathic strains of pestivirus, and should be mixed with a high-titre
411 capripoxvirus immune serum that has tested negative for antibody to pestivirus to prevent
412 the vaccine virus itself interfering with the test. The vaccine bulk can be held at -20°C or
413 below until all sterility tests and titrations have been completed, at which time it should be
414 freeze dried in 1 ml aliquots in vials sufficient for 100 doses. The vaccine harvest diluted
415 with lactalbumin hydrolysate and sucrose should have a minimum titre \log_{10} 4.5 TCID₅₀ per
416 ml after freeze drying, equivalent to a field dose of \log_{10} 2.5 TCID₅₀. A further titration is
417 carried out on five randomly chosen vials of the freeze-dried preparation to confirm the titre.

418 **2.2.4. Final product batch tests**

419 i) — Sterility/purity
420 Tests for sterility and freedom from contamination of biological materials intended for
421 veterinary use may be found in chapter 1.1.9.

422 ii) — Safety
423 The safety studies should be demonstrated by statistically valid vaccination studies using
424 seronegative young sheep and goats of known susceptibility to capripox virus. The
425 procedure described is suitable for vaccine strains such as 0240 that are equally
426 immunogenic in both sheep and goats. The choice of target animal should be adapted for
427 strains with a more restricted host preference.

428 iii) — Potency
429 Potency tests must be undertaken if the minimum immunising dose of the virus strain is not
430 known. This is usually carried out by comparing the titre of a virulent challenge virus on the
431 flanks of vaccinated and control animals. Following vaccination, the flanks of at least three
432 animals and three controls are shaved of wool or hair. \log_{10} dilutions of the challenge virus
433 are prepared in sterile PBS and six dilutions are inoculated intradermally (0.1 ml per
434 inoculum) along the length of the flank; four replicates of each dilution are inoculated down
435 the flank. An oedematous swelling will develop at possibly all 24 inoculation sites on the
436 control animals, although preferably there will be little or no reaction at the four sites of the
437 most dilute inocula. The vaccinated animals should develop an initial hypersensitivity
438 reaction at sites of inoculation within 24 hours, which should quickly subside. Small areas of
439 necrosis may develop at the inoculation site of the most concentrated challenge virus. The
440 macule/papule is measured at between 8 and 10 days post-challenge. The titre of the
441 challenge virus is calculated for the vaccinated and control animals; a difference of \log_{10} titre
442 > 2.5 is taken as evidence of protection.

443 **2.3. Requirements for authorisation**

444 **2.3.1. Safety requirements**

445 i) — Target and non-target animal safety
446 The vaccine must be safe to use in all breeds of sheep and goats for which it is intended,
447 including young and pregnant animals. It must also be non-transmissible, remain attenuated
448 after further tissue culture passage.

449 Safety tests should be carried out on the final product of each batch as described in Section
450 C.2.2.4.

451 The safety of the vaccine in non-target animals must have been demonstrated using mice
452 and guinea-pigs as described in Section C.2.2.4. There should be no evidence of pathology
453 caused by the vaccine.

454 ii) — Reversion to virulence for attenuated/live vaccines

455 The selected final vaccine should not revert to virulence during a further passages in target
456 animals.

457 iii) — Environmental consideration

458 Attenuated vaccine should not be able to perpetuate autonomously in cattle, sheep or goat
459 populations. Vaccines using the 0240 strain should not be used in *Bos taurus* breeds.
460 Strains of capripoxvirus are not a hazard to human health. There are no precautions other
461 than those described above for sterility and freedom from adventitious agents.

462 **2.3.2. Efficacy requirements**

463 i) — For animal production

464 The efficacy of the vaccine must be demonstrated in vaccination challenge experiment
465 under laboratory conditions. As described in Section C.2.2.4.

466 Once the potency of the particular strain being used for vaccine production has been
467 determined in terms of minimum dose required to provide immunity, it is not necessary to
468 repeat this on the final product of each batch, provided the titre of virus present has been
469 ascertained.

470 ii) — For control and eradication

471 Vaccination is the only effective way to control the sheep pox and goat pox outbreaks in
472 endemic countries. Unfortunately, currently no marker vaccines allowing the differentiation
473 of infected from vaccinated animals are available.

474 Immunity to virulent field virus following vaccination of sheep or goats with the 0240 strain
475 lasts over 1 year, and protection against generalised infection following intradermal
476 challenge lasts at least 3 years and is effective lifelong. The duration of immunity produced
477 by other vaccine strains should be ascertained in both sheep and goats by undertaking
478 controlled trials in an environment in which there is no possibility of field strains of
479 capripoxvirus confusing the results. The inactivated vaccines provide immunity for less than
480 1 year, and for the reasons given at the beginning of this section, may not give immunity to
481 the form of capripoxvirus usually associated with natural transmission.

482 **2.3.3. Stability**

483 All vaccines are initially given a shelf-life of 24 months before expiry. Real-time stability studies
484 are then conducted to confirm the appropriateness of the expiry date. Multiple batches of the
485 vaccine should be re-titrated periodically throughout the shelf life to determine the vaccine
486 variability.

487 Properly freeze-dried preparations of capripox vaccine, particularly those that include a
488 protectant, such as sucrose and lactalbumin hydrolysate, are stable for over 25 years when stored
489 at -20°C and for 2-4 years when stored at 4°C. There is evidence that they are stable at higher
490 temperatures, but no long-term controlled experiments have been reported. The inactivated
491 vaccines must be stored at 4°C, and their shelf-life is usually given as 1 year.

492 No preservatives other than a protectant, such as sucrose and lactalbumin hydrolysate, are
493 required for the freeze-dried preparation.

494 **3. Vaccines based on biotechnology**

495 **3.1. Vaccines available and their advantages**

496 Currently, no recombinant vaccines for capripoxviruses are commercially available. However, a new
497 generation of capripox vaccines is being developed that uses the capripoxvirus genome as a vector for
498 the genes of other ruminant pathogens such as peste des petits ruminants (PPR) virus (Berhe *et al.*,
499 2003; Tuppurainen *et al.*, 2014).

500 **3.2. Special requirements for biotechnological vaccines, if any**

501 Not applicable.

502 **REFERENCES**

503 BERHE G., MINET C., LE GOFF C., BARRETT T., NGANGNOU A., GRILLET C., LIBEAU G., FLEMING M., BLACK D.N. & DIALLO
504 A. (2003). Development of a dual recombinant vaccine to protect small ruminants against peste des petits-
505 ruminants virus and capripoxvirus infections. *J. Virol.*, **77**, 1571–1577.

506 BHANUPRAKASH V., HOSAMANI M., VENKATESAN G. & SINGH R.K. (2022). Long-term protective immunity to goatpox in
507 goats after a single immunization with a live attenuated goatpox vaccine. *Arch Virol.*, **167**, 2035–2040. doi:
508 10.1007/s00705-022-05505-8.

509 CAPSTICK P.B. (1961). Annual Report. Kenya Veterinary Department, Kenya, 45–47.

510 CODE OF FEDERAL REGULATIONS (OF THE UNITED STATES OF AMERICA) (CFR) (2024). Title 9, Parts 1–199. US
511 Government Printing Office, Washington DC, USA. [https://www.ecfr.gov/current/title-9/chapter-I/subchapter-E/part-](https://www.ecfr.gov/current/title-9/chapter-I/subchapter-E/part-113)
512 113

513 DAVIES F.G. & MBUGWA G. (1985). The alterations in pathogenicity and immunogenicity of a Kenya sheep and goat
514 pox virus on serial passage in bovine foetal muscle cell cultures. *J. Comp. Pathol.*, **95**, 565–576.

515 EUROPEAN PHARMACOPOEIA 7.0. (2012). EUROPEAN DIRECTORATE FOR THE QUALITY OF MEDICINES AND HEALTH CARE
516 (EDQM), COUNCIL OF EUROPE, STRASBOURG, FRANCE.

517 HAMDI J., BAMOUH Z., JAZOULI M., BOUMART Z., TADLAOUI K.O., FIHRI O.F. & EL HARRAK M. (2020). Experimental
518 evaluation of the cross-protection between Sheeppox and bovine Lumpy skin vaccines. *Sci. Rep.*, **10**, 8888.
519 [https://doi.org/10.1038/s41598-020-65856-7.](https://doi.org/10.1038/s41598-020-65856-7)

520 HAMDI J., MUNYANDUKI H., OMARI TADLAOUI K., EL HARRAK M. & FASSI FIHRI O. (2021). Capripoxvirus Infections in
521 Ruminants: A Review. *Microorganisms*, **9**, 902. [https://doi.org/10.3390/microorganisms9050902.](https://doi.org/10.3390/microorganisms9050902)

522 KITCHING R.P. (2003). Vaccines for lumpy skin disease, sheep pox and goat pox. *Dev. Biol.*, **114**, 161–167.

523 KITCHING R.P., HAMMOND J.M. & TAYLOR W.P. (1986). A single vaccine for the control of capripox infection in sheep
524 and goats. *Res. Vet. Sci.*, **42**, 53–60.

525 KITCHING R.P. & TAYLOR W.P. (1985). Clinical and antigenic relationship between isolates of sheep and goat pox
526 viruses. *Trop. Anim. Health Prod.*, **17**, 64–74.

527 OREIBY A., SEADA A.S., ABOU ELAZAB M.F., ABDO W., KASSAB M., HEGAZY Y., KHALIFA H.O. & MATSUMOTO T. (2022).
528 Emergency Vaccination as a Control Strategy against Sheeppox Outbreak in a Highly Susceptible Population.
529 *Animals (Basel)*, **12**, 2084. doi: 10.3390/ani12162084.

530 PHILIPS W., HAEGEMAN A., MOSTIN L., DE CLERCQ K. & DE REGGE N. (2024). Experimental evaluation of the safety and
531 efficacy of commercial sheeppox virus vaccines. [In preparation].

532 RAMYAR H. & HESSAMI M. (1967). Development of a live attenuated virus vaccine against sheep pox. *Zentralblatt fur*
533 *Veterinarmedizin*, **B. 14**, 516–519.

534 TUPPURAINEN E., DIETZE K., WOLFF J., BERGMANN H., BELTRAN-ALCRUDO D., FAHRION A., LAMIEN C.E., BUSCH F.,
535 SAUTER-LOUIS C., CONRATHS F.J., DE CLERCQ K., HOFFMANN B. & KNAUF S. (2021). Review: Vaccines and Vaccination
536 against Lumpy Skin Disease. *Vaccines (Basel)*, **9**, 1136. doi: 10.3390/vaccines9101136.

537 TUPPURAINEN E.S.M., PEARSON C.R., BACHANEK-BANKOWSKA K., KNOWLES N.J., AMAREEN S., FROST L., HENSTOCK
538 M.R., LAMIEN C.E., DIALLO A. & MERTENS P.P.C. (2014). Characterization of sheep pox virus vaccine for cattle against
539 lumpy skin disease virus. *Antiviral Res.*, **109**, 1–6.

540 WOLFF J., KING J., MORITZ T., POHLMANN A., HOFFMANN D., BEER M. & HOFFMANN B. (2020). Experimental Infection
541 and Genetic Characterization of Two Different Capripox Virus Isolates in Small Ruminants. *Viruses*, **12**, 1098. doi:
542 10.3390/v12101098.

543 YOGISHARADHYA R., BHANUPRAKASH V., HOSAMANI M., VENKATESAN G., BALAMURUGAN V., BORA D.P., BHANOT V.,
544 PRABHU M. & SINGH R.K. (2011). Comparative efficacy of live replicating sheeppox vaccine strains in Ovines.
545 *Biologicals*, **39**, 417–423. doi: 10.1016/j.biologicals.2011.09.010.

546 *
547 * *

548 **NB:** There are WOA Reference Laboratories for sheep pox and goat pox (please consult the WOA Web site:
549 <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>).
550 Please contact the WOA Reference Laboratories for any further information on
551 diagnostic tests, reagents and vaccines for sheep pox and goat pox

552 **NB:** FIRST ADOPTED IN 1989. MOST RECENT UPDATES ADOPTED IN 2024.

4
5 CHAPTER 3.9.2.

6 CLASSICAL SWINE FEVER
7 (INFECTION WITH
8 CLASSICAL SWINE FEVER VIRUS)

9 * * *

10 B. DIAGNOSTIC TECHNIQUES

11 Table 1. Test methods available for the diagnosis of classical swine fever and their purpose

Method	Purpose					
	Population freedom from infection ^{(b),(c),(e),(f)}	Individual animal freedom from infection prior to movement ^{(a),(b),(c),(e),(f)}	Contribute to eradication policies ^{(c),(d),(e),(f)}	Confirmation of clinical cases ^{(a),(b),(c),(d),(f)}	Prevalence of infection – surveillance ^{(b),(e),(f)}	Immune status in individual animals or populations post-vaccination ^{(e),(f)}
Detection of the agent ^(a)						
Virus isolation	–	+	–	+++	–	–
RT-PCR	+	+++	++	+++	++	–
ELISA (antigen)	++	+	+	+	–	–
FAT	–	–	+	+	–	–
Detection of immune response						
ELISA (antibody)	+++	+++	+++	–	+++	+++
VN (FAVN or NPLA)	+	+++ ^(h)	++	++	+++	+++

12 Key: +++ = recommended for this purpose; ++ recommended but has limitations;
13 + = suitable in very limited circumstances; – = not appropriate for this purpose.

14 RT-PCR = reverse-transcriptase polymerase chain reaction;

15 ELISA = enzyme-linked immunosorbent assay; FAT = fluorescent antibody test;

16 VN = virus neutralisation; FAVN = fluorescent antibody virus neutralisation; NPLA = neutralising peroxidase-linked assay.

17 ^(a)See Appendix 1 of this chapter for justification table for the scores given to the tests for this purpose.

18 ^(b)See Appendix 2 of this chapter for justification table for the scores given to the tests for this purpose.

19 ^(c)See Appendix 3 of this chapter for justification table for the scores given to the tests for this purpose.

20 ^(d)See Appendix 4 of this chapter for justification table for the scores given to the tests for this purpose.

21 ^(e)See Appendix 5 of this chapter for justification table for the scores given to the tests for this purpose.

22 ^(f)See Appendix 6 of this chapter for justification table for the scores given to the tests for this purpose.

23 ^(g)A combination of agent detection methods applied on the same clinical sample is recommended.

24 ^(h)Specifically for confirmation of antibody ELISA positive cases.

C. REQUIREMENTS FOR VACCINES

27 1. Background

28 CSF has severe clinical and socio-economic consequences for pig production worldwide. The control of the disease
29 is usually a national responsibility, ~~and~~. While in many countries vaccination is carried out as part of a national
30 control programme under the auspices of the veterinary authority, in other countries prophylactic vaccination has
31 been banned for several decades (e.g. USA, Canada, countries of the European Union) or compulsory vaccination
32 against CSF has been stopped more recently. It is generally accepted that the goal of CSF eradication is to be free
33 of CSF without vaccination. Nevertheless, the availability of safe and efficacious vaccines remains an important tool
34 for the control and early steps of eradication of CSF.

35 Guidelines for the production of veterinary vaccines are given in Chapter 1.1.8 *Principles of veterinary vaccine*
36 *production*. The guidelines given here and in chapter 1.1.8 are intended to be general in nature and may be
37 supplemented by national and regional requirements. Varying additional requirements relating to quality, safety and
38 efficacy will apply in particular countries or regions for manufacturers to obtain regulatory approval ~~an authorisation~~
39 ~~or licence~~ for a veterinary vaccine.

40 Wherever live CSFV is handled, the appropriate biosecurity procedures and practices should be used. The CSF
41 vaccine production facility should meet the requirements for containment outlined in Chapter 1.1.4 *Biosafety and*
42 *biosecurity: Standard for managing biological risk in the veterinary laboratory and animal facilities*.

43 The optimal CSF vaccine should have the following general characteristics: short- and long-term safety for target
44 and non-target species (especially for oral vaccines), stability, rapid induction of a stable, preferably life-long
45 immunity, efficacy against all strains and genotypes of field viruses, full clinical protection and protection against
46 carrier states, prevention of horizontal and vertical transmission. Furthermore, marker vaccines will have to be
47 accompanied by reliable discriminatory tests. Manufacture should provide for consistency of production and
48 validation.

49 Modified live vaccines (MLVs) based on several attenuated virus strains (e.g. C-strain, Thiverval, PAV-250, GPE-,
50 K-strain) are most widely used, and many of them have proven to be both safe and efficacious. In addition, E2
51 subunit vaccines produced in baculovirus or other systems are available. Inactivated whole virus vaccines are
52 presently not available.

53 Information regarding these vaccines can be found in review publications (~~Blome et al., 2017b~~; Ganges et al., 2020;
54 Postel et al., 2018).

55 Early CSF marker vaccines were based on recombinant CSFV glycoprotein E2 expressed in insect cells. Pigs
56 vaccinated with these subunit vaccines do not produce antibodies against other CSFV proteins (e.g. E^{ns}), allowing
57 reliable differentiation between vaccinated and infected animals (DIVA). These vaccines are safe and have the
58 advantage of greater thermal stability. However, compared with animals vaccinated with live vaccines, two major
59 disadvantages of these subunit vaccines were a significantly delayed onset of immunity and two inoculations were
60 required a requirement for an additional inoculation were major drawbacks compared with live vaccines. While a
61 single administration of the E2 subunit vaccine was able to prevent clinical signs and mortality, along with reduced
62 transmission following challenge infection, it did not prevent transplacental transmission. Some novel vaccine
63 candidates have shown promising improvements compared with early generation E2 subunit vaccines, including
64 clinical and virological protection as early as 7 days after a single dose vaccination. A comprehensive immunisation
65 policy based on commercial E2 vaccine, implemented in China (People's Rep. of) since 2018, includes vaccination
66 of breeding farms for the purpose of eradication and fattening pigs (Gong et al., 2019; Zhou et al., 2021).
67 Nevertheless, to provide solid protection against transplacental transmission, two doses of vaccine are required
68 (Ganges et al., 2020).

69 New generations of marker vaccines ~~are also being~~ have been developed and a chimeric pestivirus encompassing
70 the E2 from CSFV in a ruminant pestivirus backbone has been granted regulatory approval for use in domestic pigs
71 by the European Medicines Agency (EMA) and has also been authorised for use in a USA vaccine bank.

72 This vaccine, CP7_E2alf, possesses many characteristics of an optimal vaccine including: genetic stability;
73 ~~innocuousness~~ safety for target and relevant non-target species; absence of vaccine virus transmission to in-contact
74 animals or shedding through urine, faeces or semen; rapid onset of protection following a single intramuscular
75 injection; duration of immunity for at least 6 months; and protection against different CSFV genotypes (Blome et al.,
76 2017a). The CP7_E2alf vaccine capacity to prevent transplacental transmission after a single vaccine dose has
77 been proven in pregnant sows against a moderately virulent CSFV strain (Henke et al., 2018). The protection from
78 transplacental transmission against ~~CSFV~~ highly virulent strains remains to be evaluated.

79 Different DIVA strategies are available by using serological methods (e.g. ELISA) or genome detection methods
80 (e.g. RT-PCR). An opinion published by the European Food Safety Authority (EFSA, 2008) ~~demonstrated~~ proposed
81 that the combination of a vaccine that uses the C-strain with RT-PCR to detect viral genome in slaughtered animals
82 can be successfully used in a vaccination-to-live strategy (Zhao *et al.*, 2008). See also Section B.1.1.4 of this chapter.

83 For the approved chimeric vaccine CP7_E2alf, the use of a ruminant pestivirus backbone may provides serological
84 differentiation by the use of CSFV E^{ms}-ELISAs (Meyer *et al.*, 2017; Pannhorst *et al.*, 2015) or by a recently published
85 system for detecting CSFV E^{ms} IgG antibody in swine serum and oral fluid (Panyasing *et al.*, 2023). However,
86 evaluation of two such assays for DIVA capability revealed that test specificity may be compromised by infection
87 with ruminant pestiviruses, resulting in an induction of cross-reactive antibodies (Meyer *et al.*, 2017; 2018;
88 ~~Pannhorst *et al.*, 2015~~). There is therefore still room for improvement with respect to marker vaccines and their
89 companion diagnostic tests. Information regarding the current state-of-the-art with respect to CSFV vaccine
90 candidates was reviewed by ~~Blome *et al.*, 2017~~ Coronado *et al.* (2021) and Ganges *et al.* (2020).

91 CSF vaccines are used in different epidemiological settings and situations. Most countries free of the disease have
92 adopted a control strategy without prophylactic vaccination but established legal provisions for emergency
93 vaccination scenarios. In endemic situations, vaccination is mainly used to lower the impact of the disease or as a
94 first step in an eradication programme. During epidemic incidents in previously free areas, emergency vaccination
95 can be an additional tool to control and eradicate the disease and DIVA vaccines promise a valuable additional tool
96 in this context.

97 Moreover, oral vaccination of affected wild boar populations may be considered. These different scenarios and the
98 different systems of pig production may require different vaccine characteristics or may influence the focus of
99 requirements.

100 **2. Outline of production and minimum requirements for conventional live vaccines** 101 **and modified live marker vaccines**

102 Conventional live vaccines based on attenuated CSFV strains have a high level of safety and efficacy. However,
103 they do not provide a possibility to differentiate infected from vaccinated animals. In contrast, live marker vaccines
104 based on genetic technologies follow the DIVA strategy based on specific accompanying differential diagnostic
105 tests. Several studies reviewed in detail by Coronado *et al.* (2021) and Ganges *et al.* (2020) proposed live marker
106 vaccine candidates. The most frequently explored strategy is based on chimeric pestiviruses, in which one or more
107 glycoprotein-encoding regions are exchanged between a CSFV strain and a heterologous pestivirus. Another
108 strategy is the introduction of genetic marker(s) into CSFV strains.

109 This chapter provides the minimum requirements for live vaccines, both conventional and modified live marker
110 vaccines, with special requirements for all live marker vaccines added where necessary. A detailed description of
111 each production stage should be recorded in the manufacturing process documentation (see Chapter 1.1.8, Section
112 Documentation of the manufacturing process and record keeping and Chapter 2.3.3 Minimum requirements for the
113 organisation and management of a vaccine manufacturing facility, Section 3. Rules governing documentation).

114 **2.1. Characteristics of the seed**

115 ~~CSF vaccines prepared in live animals do not follow WOAHA animal welfare principles. Their production~~
116 ~~and use should be discontinued.~~

117 **2.1.1. Biological characteristics of the master seed**

118 **i) Conventional MLVs**

119 Conventional MLVs are produced from CSFV strains that have been attenuated by serial
120 passages either in cell cultures or in a suitable host species not belonging to the family *Suidae*.
121 Production is carried out in cell cultures, based on a seed-lot system. CSF vaccines prepared in
122 live animals do not follow WOAHA animal welfare principles. Their production and use is no longer
123 recommended. Master seed viruses (MSVs) for MLVs should be selected and produced, based
124 on their ease of growth in cell culture, virus yield and stability.

125 The exact source of the underlying CSFV isolate, ~~its sequence,~~ and the passage history must be
126 recorded. Including the full genome sequence in the manufacturing process documentation is
127 encouraged.

128 **ii) Live marker vaccines**

129 The origin and characteristics of the starting materials, including the parental recipient and donor
130 virus strains and added or deleted sequences, should be recorded.

131 For vaccines containing live genetically modified viruses, the final construct is considered a
132 master seed virus (MSV). The data on genetic modifications, and characteristics of the MSV, as
133 well as details of the construction procedure, should be recorded in the manufacturing process
134 documentation. Biological properties as well as genetic stability of the final construct should be
135 demonstrated. Additionally, the risk of changing the tropism or virulence due to the genetic
136 alterations shall be addressed.

137 For vaccines designed to allow DIVA, sufficient data on the accompanying diagnostic test should
138 be provided to allow adequate assessment of the DIVA properties.

139 **2.1.2. Quality criteria**

140 Only MSVs that have been established as sterile, pure (free of extraneous agents as described
141 in Chapter 1.1.9 Tests for sterility and freedom from contamination of biological materials intended
142 for veterinary use and those listed by the appropriate ~~licensing~~ regulatory approval authorities)
143 and immunogenic, should be used for vaccine virus (working seed viruses and vaccine batches)
144 production. Live vaccines must be shown not to cause disease or other adverse effects in target
145 animals injected in accordance with chapter 1.1.8 (section on *Safety tests* [for live attenuated
146 MSVs]).

147 Identity of the MSV has to be confirmed using appropriate methods ensuring unequivocal
148 identification of the strain (e.g. through the use of specific MAbs or vaccine strain-specific genome
149 detection methods).

150 **2.1.3. Validation as vaccine strain**

151 The vaccine derived from the MSV must be shown to be satisfactory with respect to safety and
152 efficacy.

153 Even if pigs are not known for susceptibility to transmissible spongiform encephalopathy (TSE)
154 agents, consideration should also be given to minimising the risk of transmission by ensuring that
155 TSE risk materials are not used as the source of the virus or in any of the media used in virus
156 propagation.

157 The vaccine virus in the final product should generally not differ by more than five passages from
158 the master seed lot. The commercial vaccine should be produced in batches in lyophilised form
159 as a homogeneous product.

160 **2.2. Method of manufacture**

161 **2.2.1. Procedure**

162 The virus is used to infect an established cell line. Such cell culture should be proven to be free
163 from contaminating microorganisms and shall comply with the requirements in chapter 1.1.8.

164 Regardless of the production method, the substrate should be harvested under aseptic conditions
165 and may be subjected to appropriate methods to release cell-associated virus (e.g. freeze-thaw
166 cycles). The harvest can be further processed by filtration and other methods. A stabiliser may
167 be added as appropriate. The vaccine is homogenised before lyophilisation to ensure a uniform
168 batch/serial.

169 **2.2.2. Requirements for ingredients**

170 All ingredients used for vaccine production should be in line with requirements in chapter 1.1.8.

171 **2.2.3. In-process controls**

172 In-process controls will depend on the protocol of production: they include virus titration of bulk
173 antigen and sterility tests.

174 **2.2.4. Final product batch/serial test**

175 **i) Sterility**

176 Tests for sterility and freedom from contamination of biological materials intended for
177 veterinary use may be found in chapter 1.1.9.

178

179	ii) Identity
180	Appropriate methods (specific antibodies or specific genome detection methods) should be
181	used for confirmation of the identity of the vaccine virus.
182	iii) Residual moisture
183	The level of moisture contained in desiccated products should be measured as described in
184	chapter 1.1.8.
185	iv) Safety
186	Batch safety testing is to be performed unless consistent safety of the product is
187	demonstrated and approved in the registration <u>regulatory approval</u> dossier and the
188	production process is approved for consistency in accordance with the standard
189	requirements referred to in chapter 1.1.8.
190	This final product batch safety test is conducted to detect any abnormal local or systemic
191	adverse reactions.
192	For batch/serial safety testing, use two healthy piglets, 6–10 weeks old, that do not have
193	antibodies against pestiviruses. Administer to each piglet by a recommended route a tenfold
194	dose of the vaccine. Observe the piglets daily for at least 14 days. The vaccine complies
195	with the test if no piglet shows notable signs of disease or dies from causes attributable to
196	the vaccine.
197	v) Batch/serial potency
198	Virus titration is a reliable indicator of vaccine potency once a relationship has been
199	established between the level of protection conferred by the vaccine in pigs and titre of the
200	modified live vaccine <i>in vitro</i> . <u>Batch/serial potency tests are required for each batch of the</u>
201	<u>product prior to release. Appropriate release titre should correlate with the results of</u>
202	<u>challenge efficacy studies, and as a rule it should be sufficiently greater to ensure efficiency</u>
203	<u>of the vaccine throughout its shelf-life.</u>
204	In the absence of a demonstrated correlation between the virus titre and protection, an
205	efficacy test will be necessary (see Section C.2.3.3).
206	2.3. Requirements for <u>regulatory approval</u> authorisation/registration/licensing
207	2.3.1. Manufacturing process
208	For regulatory approval of a vaccine, all relevant details concerning preparation of MSV,
209	manufacture of the vaccine and quality control testing (see Sections C.2.1 and C.2.2) should be
210	submitted to the authorities. This information shall be provided from three consecutive vaccine
211	batches originating from the same MSV, with a volume not less than 1/3 of the typical industrial
212	batch volume.
213	The in-process controls are part of the manufacturing process.
214	2.3.2. Safety requirements
215	For the purpose of gaining regulatory approval, the following safety tests should be performed
216	satisfactorily.
217	Vaccines should be tested for any pathogenic effects on healthy pigs, and in sows to evaluate the
218	safety in pregnant animals and their offspring.
219	i) Safety in young animals
220	Carry out the test for each recommended route of application using in each case piglets not
221	older than the minimum age recommended for vaccination. Use vaccine virus at the least
222	attenuated passage level that will be present in a batch of the vaccine.
223	Use no fewer than eight piglets of 6–8 weeks of age that do not have antibodies against
224	pestiviruses. Administer to each piglet a quantity of the vaccine virus equivalent to not less
225	than ten times the maximum virus titre likely to be contained in 1 dose of the vaccine.
226	Observe the piglets daily for at least 14 days. The body temperature of each vaccinated
227	piglet is measured on at least the 3 days preceding administration of the vaccine, at the time

228 of administration, 4 hours after and then daily for at least 14 days. The vaccine complies
229 with the test if the average body temperature increase for all piglets does not exceed 1.50°C,
230 no piglet shows a temperature rise greater than 1.50°C for a period exceeding 3 consecutive
231 days, and no piglet shows notable signs of disease or dies from causes attributable to the
232 vaccine.

233 Blood samples are taken at 7 days after vaccination and tested for leukopenia. The average
234 white blood cell (WBC) count should exceed 7×10^6 cells/ml.

235 In addition, the vaccines in their commercial presentation should be tested for safety in the
236 field (see chapter 1.1.8, section on *Field tests [safety and efficacy]*).

237 **ii) Safety test in pregnant sows and test for transplacental transmission**

238 Carry out the test with vaccination by a recommended route using no fewer than eight
239 healthy sows or gilts of the same age and origin, between the 55th and 70th days of
240 gestation, that do not have antibodies against pestiviruses. Use vaccine virus at the least
241 attenuated passage level that will be present in a batch of the vaccine.

242 Administer to each sow a quantity of the vaccine virus equivalent to not less than the
243 maximum virus titre likely to be contained in 1 dose of the vaccine. Clinical observation of
244 animals is carried out daily until farrowing. Blood samples should be taken from newborn
245 piglets before ingestion of colostrum.

246 The test is invalid if the vaccinated sows do not seroconvert before farrowing. The vaccine
247 virus complies with the test if no abnormalities in the gestation or in the piglets are noted.
248 No sow or gilt shows notable signs of disease or dies from causes attributable to the vaccine.

249 Vaccine virus or antibodies against CSFV must not be present in blood samples from
250 newborn piglets.

251 **iii) Non-transmissibility**

252 Keep together for the test no fewer than 12 healthy piglets, 6–10 weeks old and of the same
253 origin, that do not have antibodies against pestiviruses. When using the MSV to produce
254 vaccines, the number of passages should be minimised. Use vaccine virus at the least
255 attenuated passage level that will be present between the master seed lot and a batch of
256 the vaccine. Administer by a recommended route to no fewer than six piglets a quantity of
257 the vaccine virus equivalent to not less than the maximum virus titre likely to be contained
258 in 1 dose of the vaccine.

259 Maintain no fewer than six piglets as contact controls. The mixing of vaccinated piglets and
260 contact piglets is done 24 hours after vaccination.

261 After 45 days, kill all piglets humanely. Carry out appropriate tests on the piglets to detect
262 antibodies against CSFV and on the control piglets to detect CSFV in the tonsils. The
263 vaccine complies with the test if antibodies are found in all vaccinated piglets and if no
264 antibodies and no virus are found in the control piglets.

265 **iv) Reversion to virulence**

266 The test carried out should be consistent with VICH GL41 (Examination of live veterinary
267 vaccines in target animals for absence of reversion to virulence, 2008¹).

268 The test for increase in virulence consists of the administration of the vaccine virus from the
269 master seed lot or one or two passages above to piglets that do not have antibodies against
270 pestiviruses.

271 This protocol is repeated five times with at least two healthy 6–10 weeks old piglets of the
272 same age and origin per each passage.

273 Administer tested virus to each of two healthy piglets free of antibodies to pestiviruses, 6–
274 10 weeks old, by a recommended route, a quantity of the vaccine virus equivalent to not
275 less than the maximum virus titre likely to be contained in 1 dose of the vaccine. Collect an
276 appropriate quantity of blood from each piglet daily between day 2 and day 7 after
277 administration of the vaccine virus, and pool the samples taken on the same day. Then kill

¹ https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl41-target-animal-safety-examination-live-veterinary-vaccines-target-animals-absence-reversion_en.pdf

278 the piglets and take the tonsils of both of them, pool the tonsils and prepare a 10%
279 suspension in PBS, pH 7.2 kept at 4°C or at -70°C for longer storage. The euthanasia may
280 be performed earlier than 7 days post-vaccination if the existing data on the dynamics of
281 infection and virus distribution support this approach. If the optimal euthanasia time point
282 needs to be determined, it is suggested to include more piglets into the first passage and kill
283 them at different time points (between 4 and 7 days post-inoculation). Based on the maximal
284 level of the virus in tonsils, an optimal time point for euthanasia is determined and adjusted
285 accordingly for further passages.

286 ~~At the same time, the presence of CSF antigens is confirmed at each passage. Blood and~~
287 ~~pooled tonsillar tissue are used to inoculate two further pigs of the same age and origin by~~
288 ~~the same route as before.~~

289 ~~Administer 2 ml of the pooled material (blood and tonsillar tissue) with the highest virus titre~~
290 ~~by a recommended route. The presence of CSFV antigen is quantified in daily blood pools~~
291 ~~and pooled tonsils from each passage. Then, 2 ml of the sample consisting of tonsils and~~
292 ~~pooled blood from the day with the highest virus level is administered to each of two other~~
293 ~~piglets of the same age and origin by a recommended route. If no virus is found, repeat the~~
294 ~~administration once again with the same material and another two batch of piglets. If no~~
295 ~~virus is found at this point, end the process here. If, however, virus is found, carry out a~~
296 ~~second series of passages by administering 2 ml of positive material by a recommended~~
297 ~~route to each of two other piglets of the same age and origin.~~

298 Carry out this passage operation no fewer than four times (in total five groups from the start
299 of the test should be vaccinated), verifying the presence of the virus at each passage in
300 blood and tonsils. Care must be taken to avoid contamination by the virus from previous
301 passages.

302 The vaccine virus complies with the test if no indication of increasing virulence (monitored
303 by clinical observations) of the maximally passaged virus compared with the unpassaged
304 virus is observed.

305 If virus is not recovered at any passage level in the first and second series of passages, the
306 vaccine virus also complies with the test.

307 **v) Special requirements for live marker vaccines**

308 Before the release of veterinary products based on genetically modified microorganisms it
309 is necessary to perform a risk assessment to evaluate the impact on the human and animal
310 environment. Special attention of the risk assessment should be paid to potential
311 environmental consequences, the characteristics of the vaccine organism and its tissue
312 tropism, human health risk, animal health risk for both target and non-target animals,
313 persistence in the environment and increase in virulence (see Chapter 1.1.8 Sections 7.1.2
314 Increase in virulence tests and 7.1.3 Assessing risk to the environment).

315 **2.3.3. Efficacy requirements**

316 **i) Protective dose**

317 Vaccine efficacy is estimated in vaccinated animals directly, by evaluating their resistance
318 to live virus challenge and is expressed by the number of 50% protective doses (PD₅₀) for
319 pigs contained in the vaccine dose.

320 The test consists of a vaccination/challenge trial in piglets aged 6–10 weeks using different
321 dilutions of the vaccine in question and five piglets per dilution. An additional group of two
322 piglets of the same age and origin are used as controls. All animals have to be free from
323 antibodies against pestiviruses prior to the trial. Each group of piglets, except the control
324 group, is vaccinated with an appropriate dilution of the reconstituted vaccine (e.g. 1/40 and
325 1/160 using a suitable buffer solution.

326 Fourteen days after the single injection of vaccine, challenge the piglets by a suitable route
327 with a dose of a virulent strain of CSFV that kills at least 50% of the non-vaccinated piglets
328 in less than 21 days. Observe the piglets for 21 days and record the body temperature
329 3 days before challenge and daily after challenge for 21 days. The PD₅₀ content of the
330 vaccine is calculated from the number of animals protected in each group using the
331 Spearman-Kärber method.

332 The test is invalid if less than 50% of the control piglets display typical signs of serious
333 infection with CSFV, and die, and if less than 100% of the control piglets show clinical signs
334 of disease within the 21 days following challenge.

335 The vaccine complies with the test if the minimum dose corresponds to not less than
336 100 PD₅₀.

337 In addition, protection from virus replication conferred by the vaccine should be evaluated in
338 the blood and tissues from vaccinated animals using the protocols previously described in
339 Sections B.1.1.3 and B.1.1.4.

340 **ii) Protection against transplacental infection**

341 Use eight sows that do not have antibodies against pestiviruses, randomly allocated to either
342 the vaccine group ($n = 6$) or the control group ($n = 2$).

343 Between the 34th and 49th day of gestation, all sows allocated to the vaccine group are
344 vaccinated once with 1 dose of vaccine containing not more than the minimum titre stated
345 on the label. Three weeks after vaccination, all eight sows are challenged by a suitable route
346 with a dose of virulent strain of CSFV that would be sufficient to kill at least 50% of non-
347 vaccinated piglets in less than 21 days.

348 Just before farrowing, the sows are killed humanely and their fetuses are examined for
349 CSFV. Serum samples from sows and fetuses are tested for the presence of antibodies
350 against CSFV. Isolation of CSFV is carried out from blood of the sows (collected 7 and
351 9 days after challenge and at euthanasia), and from homogenised organ material (tonsils,
352 spleen, kidneys, lymph nodes) of the fetuses.

353 The real-time RT-PCR assay can be performed following the methodology described in
354 Section B.1.1.4., although always in correlation with the virus isolation test. The test is valid
355 if virus is found in at least 50% of the fetuses from the control sows (excluding mummified
356 fetuses).

357 The vaccine complies with the test if no virus is found in the blood of vaccinated sows and
358 in fetuses from the vaccinated sows, and antibodies against CSFV should not be found in
359 the serum of the fetuses from the vaccinated sows.

360 In addition, where appropriate, the vaccines should be tested for efficacy in the field (see
361 chapter 1.1.8, section on *Field tests [safety and efficacy]*).

362 **2.3.4. Duration of immunity**

363 As part of the ~~authorisation~~ regulatory approval procedure the manufacturer should demonstrate
364 the duration of immunity of a given vaccine by either challenge or the use of a validated alternative
365 test, at the end of the claimed period of protection.

366 At least ten vaccinated pigs are each inoculated with an amount of virus corresponding to
367 10⁵ PID₅₀ (median pig infectious dose) of a virulent strain of CSFV and observed for 3 weeks. The
368 vaccinated animals have to remain healthy, only the controls should die.

369 The duration of immunity after vaccination against CSF shall not be less than 6 months.

370 **2.3.5. Stability**

371 The stability of all vaccines should be demonstrated as part of the shelf-life determination studies
372 for ~~authorisation~~ regulatory approval.

373 The period of validity of lyophilised CSF vaccine should be shown to be at least 1 year.

374

375 **3. Requirements for other vaccines**

376 **3.1. Oral vaccine**

377 **2.4. Special requirement for oral vaccines**

378 **3.1.2.4.1. Background**

379 The most widely applied concept of oral bait vaccination of wild boar against CSF, including bait
380 design and immunisation scheme was developed, evaluated, and optimised by Kaden *et al.*
381 (2010). Currently used oral ~~The respective~~ vaccines are conventional MLVs, but live marker
382 vaccines also have the potential to be used as oral vaccines. Immunisation occurs by uptake of
383 the oral vaccine through the lymphoid tissues of the oral mucosa and tonsils, where expression
384 of virus stimulates the immune system (Kaden *et al.*, 2000; 2010).

385 Safety is of paramount consideration for oral vaccine use, not only for the target animals, but for
386 the environment (see chapter 1.1.8) and other species that may come in contact with the vaccine.

387 **3.1.2.4.2. Outline of production and minimum requirements for vaccines**

388 In addition to the outline of production described for injectable vaccines above, the following
389 specific requirements must be met:

390 **i) Method of manufacture**

391 **a) Final product batch/serial test**

392 After combining all of the ingredients, the final blend contains the definitive formulation that
393 is usually used in liquid form. The last step in production of a batch/serial is filling the final
394 blend into blisters/capsules to be included in baits or filling directly into the bait. This final
395 batch/serial is tested as described for the injectable vaccines, with the following differences:

396 Residual moisture test

397 The residual moisture test does not apply if the oral vaccine is presented in liquid form.

398 Safety

399 Administer orally by syringe to each piglet a volume corresponding to ten oral doses
400 as indicated by the manufacturer.

401 **ii) Requirements for regulatory approval ~~authorisation/registration/licensing~~**

402 In addition to the requirements described for injectable vaccines, the following specific
403 requirements must be met.

404 **a) The bait**

405 The bait is an integral part of the product and should ideally meet the following criteria:

406 Designed for and attractive to the target species and adapted to the mode of
407 distribution.

408 Keep its form and shape under a wide range of temperature and weather conditions.

409 Ingredients are non-harmful, comply with animal feed standards and should not
410 interfere with vaccine activity.

411 Feature a labelling system with a public warning and identification of the product.

412 **b) Safety requirements**

413 For all the tests the liquid vaccine is administered orally with a syringe (not in the final bait
414 formulation) to ensure that each animal receives the full dose.

415 Precaution hazards

416 The release of oral vaccines in the environment shall comply with the requirements in
417 chapter 1.1.8.

-
- 418 c) Efficacy requirements
419 Efficacy should be proven using the liquid vaccine administered by syringe to ensure that
420 each animal receives the full dose. Proof-of-concept studies for the final formulation (vaccine
421 integrated into bait) should be provided.

422 3.2. Recombinant E2 glycoprotein-based vaccines

423 3.2.1. Background

424 ~~As described in Guideline 3.3 Section E,~~ Conventional, live attenuated CSF vaccines have a rapid onset
425 of immunity and are effective at preventing transmission of infection (Ganges *et al.*, 2020; Postel *et al.*,
426 2018), but have the disadvantage that it is not possible using serological methods (e.g. ELISA) to
427 differentiate infected pigs from those that have merely been vaccinated. Commercial E2 subunit vaccines
428 (Marker vaccine) have a slower onset of immunity and reduce, but may not completely prevent, viral
429 shedding and transplacental infection. However, these vaccines enable a DIVA strategy to be followed
430 thereby facilitating a 'vaccination to live' strategy.

431 The vaccine only elicits antibodies against the E2 glycoprotein and therefore antibodies against other
432 CSFV antigens, such as the E^{RNS} antigen, can be used as markers of infection. New E2-based
433 formulations, with improved efficacy and/or produced in non-baculovirus based expression systems have
434 been (Suarez *et al.*, 2017), or are being developed (Blome *et al.*, 2017b; Coronado *et al.*, 2021; Ganges
435 *et al.*, 2020; Gong *et al.*, 2019).

436 3.2.2. Outline of production

437 A detailed description of each production stage should be recorded in the manufacturing process
438 documentation (see Chapter 1.1.8, Section on *Documentation of the manufacturing process and record*
439 *keeping* and Chapter 2.3.3, Section 3. *Rules governing documentation*).

440 ~~i)3.2.1.~~ Characteristics of the seed

441 E2 subunit marker vaccine is prepared by the use of Baculovirus or other expression system
442 expressing the E2 antigen of CSFV. The vaccine therefore does not contain any CSFV while the
443 baculo (vector) virus is chemically inactivated.

444 a) Biological characteristic of the master seed

445 Production is carried out in insect cell cultures, based on a seed-lot system.

446 Selection of MSVs should ideally be based on their ease of growth in cell culture, virus yield
447 and stability.

448 The exact source of the isolate including its sequence and passage history should be
449 recorded.

450 b) Quality criteria

451 Only MSVs that have been established as sterile and pure (free of extraneous agents as
452 described in chapter 1.1.9 and those listed by the appropriate licensing regulatory approval
453 authorities), and immunogenic, shall be used for preparing the vaccine virus production.

454 Appropriate methods (specific antibodies or specific genome detection methods) should be
455 used for confirmation of the identity of the MSV.

456 c) Validation as a vaccine strain

457 The vaccine prepared from the MSV is shown to be satisfactory with respect to safety and
458 efficacy for the swine for which it is intended.

459 In accordance with chapter 1.1.8, consideration should also be given to minimising the risk
460 of transmission of TSE agents by ensuring that TSE risk materials are not used as the source
461 of the virus or in any of the media used in virus propagation.

462 The vaccine virus/expression system used to produce the final product should not differ by
463 more than five passages from the material used for validating the seed lot. The commercial
464 vaccine is inactivated for residual baculovirus and adjuvanted.

465 **ii) 3.2.2. Method of manufacture**

466 **ai) Procedure**

467 The baculovirus is used to infect an established insect cell line or alternative expression cell
468 lines are established. Such cell culture should be proven to be free from contaminating
469 microorganisms and shall comply with requirements in chapter 1.1.8.

470 Regardless of the production method, the substrate should be harvested under aseptic
471 conditions and may be subjected to appropriate methods to release cell-associated virus.
472 The harvest can be further processed by filtration and other methods. Inactivation of residual
473 baculovirus is performed, preferably using a first order inactivant. The antigen is
474 homogenised before formulation with adjuvant.

475 **bii) Requirements for ingredients**

476 All ingredients used for vaccine production should be in line with requirements in chapter
477 1.1.8.

478 **eiij) In-process controls**

479 Infectivity, sterility and antigenic mass are monitored. After inactivation a test for innocuity
480 is carried out on every batch of antigen. The cells used to test for absence of residual live
481 baculovirus are the same cell line used for production or potentially equally or more sensitive
482 cells.

483 **diiv) Final product batch/serial test**

484 **a) Sterility**

485 Must comply with chapter 1.1.8.

486 **b) Identity**

487 The identity test is performed by a specific MAb-based virus neutralisation against
488 CSFV or an appropriate molecular identification. Sera prepared to be used for identity
489 testing should not be prepared using the homologous vaccine virus or baculovirus
490 expressed subunit antigen but from another source. This test may be combined with
491 the potency test (see below).

492 **c) Safety and prove of marker concept**

493 Batch safety testing is to be performed unless consistent safety of the product is
494 demonstrated and approved in the ~~registration~~ regulatory approval dossier and the
495 production process is approved for consistency in accordance with the standard
496 requirements referred to in chapter 1.1.8.

497 This final product batch safety test is conducted to detect any abnormal local or
498 systemic adverse reactions.

499 For batch/serial safety testing, use two healthy piglets, 6–10 weeks old, that do not
500 have antibodies against pestiviruses. Administer to each piglet by a recommended
501 route a double dose of the formulated vaccine. Observe the piglets daily for at least
502 14 days for local and systems reactions to vaccination. After 14 days they are each
503 injected with a second single dose of vaccine.

504 Any adverse reaction attributable to the vaccine should be assessed and may prevent
505 acceptance of the batch. The vaccine should elicit antibodies against CSFV E2 but not
506 against CSFV-E^{RNS} antigen.

507 **d) Batch/serial potency**

508 Induction of specific anti-E2 antibodies in vaccinated pigs can be used to confirm the
509 potency of each batch once the titre has been correlated with the results of the efficacy
510 test.

-
- 511 **iii)3.2.3. Requirements for regulatory approval authorisation /registration/ licensing**
- 512 a) Manufacturing process
- 513 See Section C.2.3.1.
- 514 b) Identity
- 515 The identity test is performed by virus neutralisation using immune sera against CSFV. Sera
- 516 prepared to be used for identity testing should not be prepared using the homologous
- 517 vaccine virus or baculovirus expressed subunit antigen but from another source.
- 518 c) Safety requirements
- 519 **a) Safety in young animals**
- 520 For the purposes of gaining regulatory approval, a trial batch of vaccine should be
- 521 tested for local and systemic toxicity by each recommended route of administration in
- 522 eight piglets of 6–8 weeks of age. Single-dose and repeat-dose tests using vaccines
- 523 formulated to contain the maximum permitted payload should be conducted. The
- 524 repeat dose test should correspond to the primary vaccination schedule (e.g. two
- 525 injections) plus the first revaccination (i.e. a total of three injections). The animals are
- 526 observed for local and systemic reaction to vaccination for no fewer than 14 days after
- 527 each injection. Any undue reaction attributable to the vaccine should be assessed and
- 528 may prevent acceptance of the vaccine. It has to be proven that the vaccine does not
- 529 elicit antibodies against CSFV-E^{RNS} antigen.
- 530 **b) Safety in pregnant sows**
- 531 For the purpose of gaining regulatory approval a trial batch of vaccine should be tested
- 532 for local and systemic toxicity by each recommended route of administration
- 533 corresponding to the primary vaccination schedule (e.g. two injections) in eight
- 534 pregnant sows. The sows are observed for local and systemic reactions to vaccination.
- 535 The observation period must last until parturition to examine any harmful effects during
- 536 gestation or on progeny. Any undue reaction attributable to the vaccine should be
- 537 assessed and may prevent acceptance of the vaccine. It has to be proven that the
- 538 vaccine does not elicit antibodies against CSFV-E^{RNS} antigen.
- 539 d) Efficacy requirements
- 540 **a) Protective dose**
- 541 Vaccine efficacy is estimated in animals vaccinated according to the manufacturer's
- 542 recommendation, following the methods described in Section C.2.3.3.
- 543 **b) Protection against transplacental infection**
- 544 The trial vaccine should comply with the test described in Section C.2.3.3.
- 545 e) Duration of immunity
- 546 As part of the ~~authorisation~~ regulatory approval procedure the manufacturer should
- 547 demonstrate the duration of immunity (see Section C.2.3.4).
- 548 f) Stability
- 549 The stability of all vaccines should be demonstrated as part of the shelf-life determination
- 550 studies for ~~authorisation~~ regulatory approval. The period of validity of a batch of
- 551 biotechnology-based CSF vaccine should be shown to be at least 1 year (see Section
- 552 C.2.3.5).

553 **4. Other biotechnology-based vaccines**

554 In search of an ideal vaccine, multiple studies were undertaken and several other approaches were proposed,

555 including viral vector and replicon vaccines, immunogenic CSFV peptides or DNA vaccines (reviewed by Coronado

556 et al., 2021; Ganges et al., 2020; Postel et al., 2018). The regulatory approval of such candidates should take into

557 account categorisation and special requirements provided in chapters 1.1.8 and 2.3.4, including thorough risk

558 analysis for their environmental release.

- 560 BLOME S., MOSS C., REIMANN I., KONIG P. & BEER M. (2017b). Classical swine fever vaccines — State-of-the-art. *Vet. Microbiol.*, **206**, 10–20.
- 562 BLOME S., STAUBACH C., HENKE J., CARLSON J. & BEER M. (2017e b). Classical Swine Fever – An Updated Review. *Viruses*, **9**, 86.
- 564 BLOME S., WERNIKE K., REIMANN I., KONIG P., MOSS C. & BEER M. (2017a). A decade of research into classical swine fever marker vaccine CP7_E2alf (Suvaxyn® CSF Marker): a review of vaccine properties. *Vet. Res.*, **48**, 51.
- 566 BOUMA A., STEGEMAN J.A., ENGEL B., DE KLUIJVER E.P., ELBERS A.R. & DE JONG M.C. (2001). Evaluation of diagnostic tests for the detection of classical swine fever in the field without a gold standard. *J. Vet. Diagn. Invest.*, **13**, 383–388. doi: [10.1177/104063870101300503](https://doi.org/10.1177/104063870101300503)
- 569 CORONADO L., PERERA L.C., RIOS L., FRÍAS M.T. & PÉREZ L.J. (2021). A Critical Review about Different Vaccines against Classical Swine Fever Virus and Their Repercussions in Endemic Regions. *Vaccines*, **9**, 154.
- 571 DEPNER K., BUNZENTHAL C., HEUN-MÜNCH B., STREBELOW G., HOFFMANN B. & BEER M. (2006). Diagnostic evaluation of a real-time RT-PCR assay for routine diagnosis of classical swine fever in wild boar. *J. Vet. Med. B. Infect. Dis. Vet. Public Health*, **53**, 317–320. doi: [10.1111/j.1439-0450.2006.00972.x](https://doi.org/10.1111/j.1439-0450.2006.00972.x)
- 574 DEWULF J., KOENEN F., MINTIENS K., DENIS P., RIBBENS S. & DE KRUIF A. (2004). Analytical performance of several classical swine fever laboratory diagnostic techniques on live animals for detection of infection. *J. Virol. Methods*, **119**, 137–143. doi: [10.1016/j.jviromet.2004.03.010](https://doi.org/10.1016/j.jviromet.2004.03.010)
- 577 EUROPEAN FOOD SAFETY AUTHORITY (EFSA) (2008). Annex to *The EFSA Journal*, **932**, 1–18 and **933**, 1–16, page 31.
- 579 GANGES L., CROOKE, H.R., BOHÓRQUEZ J.A., POSTEL A., SAKODA Y., BECHER P. & RUGGLI N. (2020). Classical swine fever virus: the past, present and future. *Virus Res.*, **289**, 198151.
- 581 GONG W., LI J., WANG Z., SUN J., MI S., XU J., CAO J., HOU Y., WANG D., HUO X., SUN Y., WANG P., YUAN K., GAO Y., ZHOU X., HE S. & TU C. (2019). Commercial E2 subunit vaccine provides full protection to pigs against lethal challenge with 4 strains of classical swine fever virus genotype 2. *Vet. Microbiol.*, **237**, 108403.
- 584 HANDEL K., KEHLER H., HILLS K. & PASICK J. (2004). Comparison of reverse transcriptase-polymerase chain reaction, virus isolation, and immunoperoxidase assays for detecting pigs infected with low, moderate, and high virulent strains of classical swine fever virus. *J. Vet. Diagn. Invest.*, **16**, 132–183. DOI: [10.1177/104063870401600207](https://doi.org/10.1177/104063870401600207)
- 587 HAINES F.J., HOFMANN M.A., KING D.P., DREW T.W. & CROOKE H.R. (2013). Development and validation of a multiplex, real-time RT PCR assay for the simultaneous detection of classical and African swine fever viruses. *PLoS One*, **8**(7):e71019. doi: [10.1371/journal.pone.0071019](https://doi.org/10.1371/journal.pone.0071019)
- 590 HENKE J., CARLSON J., ZANI L., LEIDENBERGER S., SCHWAIGER T., SCHLOTTAU K., TEIFKE J.P., SCHRÖDER C., BEER M. & BLOME S. (2018). Protection against transplacental transmission of moderately virulent classical swine fever virus using live marker vaccine “CP7_E2alf”. *Vaccine*, **36**, 4181–4187.
- 593 HOFFMANN B., BEER M., SCHELP C., SCHIRRMIEIER H. & DEPNER K. (2005). Validation of a real-time RT-PCR assay for sensitive and specific detection of classical swine fever. *J. Virol. Methods*, **130** (1-2), 36–44. doi: [10.1016/j.jviromet.2005.05.030](https://doi.org/10.1016/j.jviromet.2005.05.030)
- 596 KADEN V., LANGE E., FISCHER U. & STREBELOW G (2000). Oral immunisation of wild boar against classical swine fever: valuation of the first field study in Germany. *Vet. Microbiol.*, **73**, 239–252.
- 598 KADEN V., LANGE E., KÜSTER H., MÜLLER T. & LANGE B. (2010). An update on safety studies on the attenuated “RIEMSER Schweinepestoralvakzine” for vaccination of wild boar against classical swine fever. *Vet. Microbiol.*, **143**, 133–138.
- 601 LEIFER I., BLOME S., BEER M. & HOFFMANN B. (2011). Development of a highly sensitive real-time RT-PCR protocol for the detection of Classical swine fever virus independent of the 5' untranslated region. *J. Virol. Methods*, **171**, 314–317. doi: [10.1016/j.jviromet.2010.11.014](https://doi.org/10.1016/j.jviromet.2010.11.014)

604 MEYER D., FRITSCHÉ S., LUO Y., ENGEMANN C., BLOME S., BEYERBACH M., CHANG C.Y., QIU H.J., BECHER P. & POSTEL
605 A. (2017). The double-antigen ELISA concept for early detection of E^{ms}-specific classical swine fever virus
606 antibodies and application as an accompanying test for differentiation of infected from marker vaccinated animals.
607 *Transbound. Emerg. Dis.*, **64**, 2013–2022.

608 MEYER D., LOEFFEN W., POSTEL A., FRITSCHÉ S. & BECHER P. (2018). Reduced specificity of E^{ms} antibody ELISAs for
609 samples from piglets with maternally derived antibodies induced by vaccination of sows with classical swine fever
610 marker vaccine CP7_E2alf. *Transbound. Emerg. Dis.*, **65**, e505–e508.

611 PANNHORST K., FROHLICH A., STAUBACH C., MEYER D., BLOME S. & BECHER P. (2015). Evaluation of an Erns-based
612 enzyme-linked immunosorbent assay to distinguish classical swine fever virus-infected pigs from pigs vaccinated
613 with CP7_E2alf. *J. Vet. Diagn. Invest.*, **27**, 449–460.

614 PANYASING Y., GIMENEZ-LIROLA L., THANAWONGNUWECH R., PRAKOBUSUK P., KAWILAPHAN., KITTAWORNAT A., CHENG T.
615 & ZIMMERMAN J. (2023). Performance of a differentiation and infected from Vaccinated animals (DIVA) classical
616 swine fever virus (CSFV) serum and oral fluid Erns Antibody AlphaLISA assay. *Animals*, **13**, 3802.

617 PETROV A., SCHOTTE U., PIETSCHMANN J., DRÄGER C., BEER M., ANHEYER-BEHMENBURG H., GOLLER K.V. & BLOME S.
618 (2014). Alternative sampling strategies for passive classical and African swine fever surveillance in wild boar. *Vet.*
619 *Microbiol.*, **173**, 360–365. doi: [10.1016/j.vetmic.2014.07.030](https://doi.org/10.1016/j.vetmic.2014.07.030).

620 POSTEL A., AUSTERMANN-BUSCH S., PETROV A., MOENNIG V. & BECHER P. (2018). Epidemiology, diagnosis and control
621 of classical swine fever: Recent development and future challenges. *Transbound. Emerg. Dis.*, **65** Suppl. 1, 248–
622 261.

623 RISATTI G., HOLINKA L., LU Z., KUTISH G., CALLAHAN J.D., NELSON W.M., BREA TIÓ E. & BORCA M.V. (2005). Diagnostic
624 evaluation of a real-time reverse transcriptase PCR assay for detection of classical swine fever virus. *J. Clin.*
625 *Microbiol.*, **43**, 468–471. doi: [10.1128/JCM.43.1.468-471.2005](https://doi.org/10.1128/JCM.43.1.468-471.2005)

626 SUAREZ M., SORDO Y., PRIETO Y., RODRÍGUEZ M.P., MÉNDEZ L., RODRÍGUEZ E.M., RODRÍGUEZ-MALLON A., LORENZO E.,
627 SANTANA E., GONZÁLEZ N., NARANJO P., FRÍAS M.T., CARPIO Y. & ESTRADA M.P. (2017). A single dose of the novel
628 chimeric subunit vaccine E2-CD154 confers early full protection against classical swine fever virus. *Vaccine*, **34**,
629 4437–4443.

630 TERPSTRA C., BLOEMRAAD M. & GIELKENS A.L. (1984). The neutralizing peroxidase-linked assay for detection of
631 antibody against swine fever virus. *Vet. Microbiol.*, **9**, 113–120. doi: [10.1016/0378-1135\(84\)90026-9](https://doi.org/10.1016/0378-1135(84)90026-9)

632 UTTENTHAL A., STORGAARD T., OLEKSIWICZ M.B. & DE STRICKER K. (2003). Experimental infection with the Paderborn
633 isolate of classical swine fever virus in 10-week-old pigs: determination of viral replication kinetics by quantitative
634 RT-PCR, virus isolation and antigen ELISA. *Vet. Microbiol.*, **92**, 197–212. doi: [10.1016/s0378-1135\(02\)00364-4](https://doi.org/10.1016/s0378-1135(02)00364-4)

635 ZHAO J.J., CHENG D., LI N., SUN Y., SHI Z., ZHU Q.H., TU C., TONG G.Z. & QIU H.J. (2008). Evaluation of a multiplex
636 real-time RT-PCR for quantitative and differential detection of wild-type viruses and C-strain vaccine of Classical
637 swine fever virus. *Vet. Microbiol.*, **126**, 1–10.

638 ZHOU P., HUANG J., LI Y., CHEN H., WU Y., FU X., HAO X., LI Q., ZENG R. & ZHANG G. (2021). Efficiency Comparison of
639 a Novel E2 Subunit Vaccine and a Classic C-Strain Vaccine against Classical Swine Fever. *Vet. Sci.*, **8**, 148.

640
641

*
* *

642 **NB:** There are WOAHP Reference Laboratories for classical swine fever
643 (please consult the WOAHP web site for the most up-to-date list:
644 <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>).
645 Please contact WOAHP Reference Laboratories for any further information on
646 diagnostic tests, reagents and vaccines for classical swine fever

647 **NB:** FIRST ADOPTED IN 1990. MOST RECENT UPDATES ADOPTED IN 2022.

Intended purpose of test: detection of the agent – individual animal freedom from infection prior to movement; confirmation of clinical cases

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>Additional comments regarding application/utility</u>	<u>References</u>
<u>Virus isolation</u> <u>Confirmation of clinical cases:</u> +++ <u>Individual animal freedom from infection prior to movement:</u> ±	<u>Organ suspensions, anticoagulated, whole blood, leukocytes, sera, plasma, swab samples and semen</u>			<u>See references</u>	<u>High sensitivity</u> <u>High specificity after immunostaining or detection of viral genome</u> <u>Direct method for detection of infectious virus</u> <u>Further characterisation of the virus isolate (e.g. virulence, antigenic relatedness) possible</u>	<u>Slow and labour-intensive method</u> <u>Specificity requires specific detection of viral antigen or viral genome</u> <u>Not suitable for large-scale diagnostics and screening</u> <u>Good sample quality is needed to reduce cytotoxic effects as well as bacterial contamination</u> <u>Requires expertise</u> <u>High biosafety level needed</u>	<u>Time consuming and laborious method, not fit for surveillance or other population-based use</u> <u>Important for collecting virus strains for further characterisation</u>	<u>Ganges <i>et al.</i> (2020);</u> <u>Handel <i>et al.</i> (2004);</u> <u>Dewulf <i>et al.</i> (2004);</u> <u>Uttenenthal <i>et al.</i> (2003)</u>

650

651

652

Appendix 2: Classical swine fever

Intended purpose of test: detection of the agent – population freedom from infection; individual animal freedom from infection prior to movement; contribute to eradication policies; confirmation of clinical cases; prevalence of infection – surveillance

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>Additional comments regarding application/utility</u>	<u>References</u>
<p><u>RT-PCR</u></p> <p><u>Individual animal freedom from infection prior to movement and Confirmation of clinical cases: +++</u></p> <p><u>Contribute to eradication policies and Prevalence of infection – surveillance: ++</u></p> <p><u>Population freedom from infection: ±</u></p>	<p><u>Blood, serum, tissue (kidney, spleen, tonsil, lymph nodes, thymus, intestine, lung, bone marrow), swab samples, faeces, semen, cells or supernatant of infected cell culture</u></p>			<p><u>See references</u></p>	<p><u>Highest sensitivity and specificity compared with other methods</u></p> <p><u>Fast results</u></p> <p><u>Low sample amount</u></p> <p><u>High throughput possible</u></p> <p><u>Genetic DIVA possible</u></p> <p><u>Larger PCR products can be used for molecular analysis and genetic typing</u></p> <p><u>Detection of RNA genome at early and late time points after infection possible, even in absence of detectable infectious virus</u></p> <p><u>less affected by sample quality</u></p>	<p><u>Expensive equipment and consumables needed</u></p> <p><u>Well-trained laboratory staff needed</u></p> <p><u>Cool chain for some reagents</u></p> <p><u>Risk of cross-contamination due to high sensitivity</u></p> <p><u>Conventional PCR: lower sensitivity compared with real-time PCR</u></p> <p><u>Conventional and SYBR-green based PCR: lower specificity compared to probe-based real-time PCR</u></p>	<p><u>Not suitable to identify previously infected animals after clearing the virus</u></p>	<p><u>Hoffmann <i>et al.</i> (2005); Leifer <i>et al.</i> (2011); Depner <i>et al.</i> (2006); Risatti <i>et al.</i> (2005); Haines <i>et al.</i> (2013); Petrov <i>et al.</i> (2014)</u></p>

653

654

655

Appendix 3: Classical swine fever

Intended purpose of test: detection of the agent – population freedom from infection; individual animal freedom from infection prior to movement; contribute to eradication policies; confirmation of clinical cases

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>Additional comments regarding application/utility</u>	<u>References</u>
<u>ELISA (antigen detection)</u> <u>Population freedom from infection:</u> <u>±±</u> <u>Individual animal freedom from infection prior to movement,</u> <u>Contribute to eradication policies and Confirmation of clinical cases:</u> <u>±</u>	<u>Samples from animals with clinical signs or pathological lesions of disease:</u> <u>leukocytes, serum, plasma, non-coagulated blood as well as organ suspensions</u>			<u>See references</u>	<u>Screening of large sample numbers in a short time</u> <u>Method easy to handle</u> <u>Automated processing</u> <u>Commercially available</u>	<u>Less sensitive than other antigen detection methods</u> <u>Sensitivity is significantly better on blood samples from piglets than from adult pigs</u> <u>Low specificity</u> <u>Additional devices necessary</u>	<u>Not suitable to identify previously infected animals after clearing the virus</u>	<u>Ganges <i>et al.</i> (2020);</u> <u>Dewulf <i>et al.</i> (2004);</u> <u>Utenthal <i>et al.</i> (2003)</u>

656

657

Appendix 4: Classical swine fever**Intended purpose of test: detection of the agent – contribute to eradication policies; confirmation of clinical cases**

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>Additional comments regarding application/utility</u>	<u>References</u>
<u>FAT</u> <u>Contribute to eradication policies and Confirmation of clinical cases:</u> <u>±</u>	<u>Cryostat sections of tonsils, spleen, kidney, lymph nodes or distal portions of the ileum</u>			<u>See references</u>	<u>Quick and direct visualisation of antigens in tissue</u> <u>Good sensitivity and specificity</u>	<u>Relatively high risk of false (positive and negative) results, requires specialised equipment and expertise</u> <u>Highly dependent on antibodies conjugate quality</u> <u>Often very high background, inconclusive interpretation</u>	<u>Requires post-mortem collection of samples (possible to use tonsils in living animals)</u>	<u>Bouma <i>et al.</i> (2001)</u>

658
659
660
661

Appendix 5: Classical swine fever

Intended purpose of test: detection of immune response – population freedom from infection; individual animal freedom from infection prior to movement; contribute to eradication policies; prevalence of infection – surveillance; immune status in individual animals or populations post-vaccination

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>Additional comments regarding application/utility</u>	<u>References</u>
<u>ELISA (antibody detection)</u> <u>Population freedom from infection.</u> <u>Contribute to eradication policies.</u> <u>Prevalence of infection – surveillance. and</u> <u>Immune status in individual animals or populations post-vaccination:</u> +++ <u>Individual animal freedom from infection prior to movement:</u> ++	<u>Serum or plasma samples</u>			<u>See references</u>	<u>Screening of large sample numbers in a short time</u> <u>Method easy to handle and automate</u> <u>Commercially available</u>	<u>Possible cross-reactions with other pestiviruses so confirmation with comparative assay such as NPLA required</u> <u>Additional devices necessary</u>	<u>Detects animals with previous contact with CSFV after clearing the virus</u> <u>Negative results in early stages of disease, until detectable level of antibodies is produced</u> <u>Some options for DIVA application alongside DIVA vaccines available</u>	<u>Ganges <i>et al.</i> (2020)</u>

662
663
664
665

Appendix 6: Classical swine fever

Intended purpose of test: detection of immune response – population freedom from infection; individual animal freedom from infection prior to movement; contribute to eradication policies; confirmation of clinical cases; prevalence of infection – surveillance; immune status in individual animals or populations post-vaccination

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>Additional comments regarding application/utility</u>	<u>References</u>
<p><u>VN (FAVN or NPLA)</u> <u>Individual animal freedom from infection prior to movement (specifically for confirmation of antibody ELISA positive cases),</u> <u>Prevalence of infection – surveillance, and</u> <u>Immune status in individual animals or populations post-vaccination:</u> <u>+++:</u> <u>Confirmation of clinical cases and</u> <u>Contribute to eradication policies:</u> <u>++</u> <u>Population freedom from infection:</u> <u>±</u></p>	<p><u>Serum or plasma samples</u> <u>(alternative sample material: meat juice, exudates of body cavities).</u></p>			<p><u>See references</u></p>	<p><u>Discrimination of CSFV-specific antibodies from antibodies resulting from infections with BVDV, BDV and other ruminant pestiviruses</u> <u>Highly sensitive and specific method</u> <u>Detection of low antibody titres possible</u> <u>Method can always be quickly adapted to the circulating CSFV isolate or closely related isolates, as well as vaccine strains that were applied</u> <u>Allows quantification of immune response</u></p>	<p><u>Early time points of infection are not safely detected</u> <u>Slow and labour-intensive method</u> <u>High biosecurity level needed</u> <u>Potential cytotoxic effects have a negative impact on the evaluation of samples containing a low antibody titre.</u> <u>This is to be expected in animals, which are at an early stage of infection/onset of clinical signs</u> <u>Not suitable for large-scale diagnostics</u> <u>Requires expertise</u> <u>Knowledge on CSFV or other pestiviruses circulating in region important for appropriate strain selection</u></p>	<p><u>Time consuming and laborious method, not fit for surveillance or other population-based use</u> <u>Used as a confirmatory method to resolve potential false positive or cross-reactions in antibody ELISA</u></p>	<p><u>Ganges <i>et al.</i> (2020);</u> <u>Terpstra <i>et al.</i> (1984)</u></p>

666

CHAPTER 3.9.8.

SWINE VESICULAR DISEASE

SUMMARY

Description and importance of the disease: Swine vesicular disease (SVD) is a contagious disease of pigs, caused by an enterovirus and characterised by vesicles on the coronary bands, heels of the feet and occasionally on the lips, tongue, snout and teats. Strains of SVD virus (SVDV) vary in virulence, and the disease may be subclinical, mild or severe, the latter usually only being seen when pigs are housed on abrasive floors in damp conditions. The main importance of SVD is that it can be clinically indistinguishable from foot and mouth disease (FMD), and any outbreaks of vesicular disease in pigs must be assumed to be FMD until investigated by laboratory tests and proven otherwise. However, subclinical infection has been the most frequent condition observed during recent years.

Detection and identification of the agent: ~~Where a vesicular condition is seen in pigs, the demonstration by enzyme-linked immunosorbent assay (ELISA) of SVD viral antigen or detection of SVDV RNA by reverse transcription polymerase chain reaction (RT-PCR) in a sample of lesion material or vesicular fluid is sufficient for a positive diagnosis strongly supports a positive diagnosis. Other tests such as antigen-detection enzyme-linked immunosorbent assay (ELISA). If the quantity of lesion material submitted is not sufficient (less than 0.5 g), or if the test results are negative or inconclusive, a more sensitive test, such as the reverse transcriptase polymerase chain reaction (RT-PCR) or virus isolation (VI) in porcine cell cultures, may be used. If any inoculated cultures subsequently develop a cytopathic effect, the demonstration of SVD viral antigen in the cultures by ELISA or viral RNA by RT-PCR will suffice to be required to make a positive diagnosis. Subclinical infection may be detected by random sampling of pen-floor faeces tested for identification of SVD virus using RT-PCR or VI tests.~~

Serological tests: Serological tests can be used to help confirm clinical cases as well as to identify subclinical infections. Specific antibody to SVDV can be identified using ELISA for screening and the microneutralisation test for confirmation. A small proportion (up to 0.1%) of normal, uninfected pigs will react positively in serological tests for SVD. The reactivity of these singleton reactors is transient ~~so that they can be differentiated from infected pigs by resampling of the positive animal and its cohorts requiring resampling of the non-negative animal and its cohorts to eliminate the possibility that these pigs are infected with SVDV.~~

Diagnostic and standard reagents are available from reference laboratories.

Requirements for vaccines: There are currently no commercial vaccines available against SVD.

A. INTRODUCTION

Swine vesicular disease (SVD) can be a subclinical, mild or severe vesicular condition depending on the strain of virus involved, the route and dose of infection, and the husbandry conditions under which the pigs are kept. When it occurs clinically, SVD can be indistinguishable from foot and mouth disease (FMD) and therefore a differential diagnosis and laboratory investigation is an urgent requirement. However, ~~during the present century, the most recent~~ outbreaks of SVD have been less severe or with no clinical signs and infection has been detected when samples are tested for serosurveillance programmes or for export certification.

42 After its first detection in 1966, the disease occurred with epidemics in eastern and western Europe (during the 1970s and
 43 1980s), and was also detected in East Asia. Since then, SVD has only been sporadically reported, mainly from Italy where
 44 its circulation is investigated and has been controlled through a virological and serological surveillance plan. The most recent
 45 detection of SVDV in Italy was in 2015, and no serologically positive pigs have been identified since 2017. No further SVD
 46 outbreaks have been reported elsewhere in Europe or in any other country globally.

47 The incubation period for SVD is between 2 and 7 days, after which a transient fever of up to 41°C may occur. Vesicles then
 48 develop on the coronary band, typically at the junction with the heel. These may affect the whole coronary band resulting in loss
 49 of the hoof. More rarely, vesicles may also appear on the snout, particularly on the dorsal surface, on the lips, tongue and teats,
 50 and shallow erosions may be seen on the knees. Affected pigs may be lame and off their feed for a few days. Abortion is not a
 51 typical feature of SVD. Recovery is usually complete in 2–3 weeks (Loxam & Hedger, 1983). Affected pigs may excrete virus
 52 from the nose and mouth and in the faeces up to 48 hours before the onset of clinical signs. Most virus is produced in the first
 53 7 days after infection, and virus excretion from the nose and mouth normally stops within 2 weeks. Virus may continue to be
 54 shed for up to 3 months in the faeces, though under usual circumstances virus is detectable in faeces only up to 1 month.
 55 The SVD virus (SVDV) is extremely resistant to inactivation in the environment, and is stable in the pH range 2.5–12.0
 56 (Mann, 1981). This is in contrast to the FMD virus, which is very labile outside the pH range 6.0–8.0.

57 Because SVD may be mild or subclinical, it is essential when submitting samples from suspect clinical cases that serum
 58 samples from both the suspect pigs and other apparently unaffected animals in the group be included. It is possible for SVD
 59 to circulate unnoticed until it affects a particularly susceptible group. Therefore, in order to ascertain how long infection has
 60 been present, it is necessary to look for seroconversion to SVDV in apparently healthy animals. The identification of the
 61 isotype of the immunoglobulins (M or G) to SVDV may also help to ascertain the time of exposure to infection.

62 SVDV has been classified as a porcine variant of a human coxsackievirus B5 (*Enterovirus B*), in the family *Picornaviridae*.
 63 All isolates are classified in a single serotype, with four distinguishable antigenic/genomic variants (Brocchi *et al.*, 1997),
 64 which evolved sequentially in different time-periods, except for the third and fourth variants that were co-circulating in Italy
 65 during 1992–1993. All SVDVs occurring since then diverge from a common origin and cluster in a unique antigenic/genomic
 66 lineage corresponding to the fourth and most recent group; however, two genomic sub-lineages are distinguishable within it
 67 (Knowles *et al.*, 2007). Antigenically and genetically, SVDV is closely related to the human virus coxsackievirus B5 and it
 68 has been suggested that it arose through recombination with another human enterovirus, coxsackievirus A9 (Bruhn *et al.*,
 69 2015). A second adaptation of a human enterovirus to cause vesicular disease in pigs was reported in Russia in 1975
 70 involving coxsackievirus B4, which is serologically distinct from SVDV/CV-B5 (Lomakina *et al.*, 2016).

71 There are reports of seroconversion to SVDV in laboratory workers handling the agent. However, clinical disease in humans
 72 is reported to be mild, with the exception of a single case of meningitis associated with SVDV infection, and there have been
 73 no reported cases of seroconversion or disease in farmers or veterinarians working with infected pigs. Under experimental
 74 conditions, it has not been possible to show transmission of coxsackievirus B5 between pigs. Laboratory manipulations
 75 should be carried out at an appropriate biosafety and containment level determined by biorisk analysis (see Chapter 1.1.4
 76 *Biosafety and biosecurity: Standard for managing biological risk in the veterinary laboratory and animal facilities*).

77 B. DIAGNOSTIC TECHNIQUES

78 Table 1. Test methods available for the diagnosis of swine vesicular disease and their purpose

Method	Purpose					
	Population freedom from infection	Individual animal freedom from infection prior to movement ^{(a),(b)}	Contribute to eradication policies ^{(a),(b)}	Confirmation of clinical cases ^{(a),(b)}	Prevalence of infection – surveillance	Immune status in individual animals or populations post-vaccination
<u>Detection and identification of the agent</u>						
Virus isolation	–	+	+	+++	–	–
RT-PCR	–	+++	+++	+++	–	–
ELISA for antigen detection	–	–	–	+++	–	–

Method	Purpose					
	Population freedom from infection	Individual animal freedom from infection prior to movement ^{(a),(b)}	Contribute to eradication policies ^{(a),(b)}	Confirmation of clinical cases ^{(a),(b)}	Prevalence of infection – surveillance	Immune status in individual animals or populations post-vaccination
Detection of immune response						
Virus neutralisation	+	+++	+	+	+	–
Competitive ELISA for Ab screening	+++	+++	+++	+	+++	–
ELISA for IgG and IgM identification	+	+++	+++	+	+	–

Key: +++ = recommended for this purpose; ++ recommended but has limitations;

+ = suitable in very limited circumstances; – = not appropriate for this purpose.

RT-PCR = reverse-transcriptase polymerase chain reaction; ELISA = enzyme-linked immunosorbent assay.

NOTE: Selection of assays suited for different purposes should take into account the different kinetics of the diagnostic targets (agent and antibodies) during infection.

^(a)See Appendix 1 of this chapter for justification table for the scores given to the tests for this purpose.

^(b)See Appendix 2 of this chapter for justification table for the scores given to the tests for this purpose.

79
80
81
82
83
84
85

86 1. Detection and identification of the agent

87 Any vesicular condition in pigs could represent an FMD infection and differential diagnosis between FMD and other vesicular
88 conditions, including SVD, is necessary. The diagnosis of SVD requires the facilities of a specialised laboratory. Countries
89 that lack such a facility should send samples for investigation to a WOAH Reference Laboratory for SVD¹.

90 For clinical cases, the detection of SVDV antigens or genome of SVDV by means of enzyme-linked immunosorbent assay
91 (ELISA), and reverse-transcription polymerase chain reaction (RT-PCR) ~~has the same diagnostic value as or~~ virus isolation
92 can be used. Due to their speed, ELISA and RT-PCR make suitable screening tests. However, virus isolation is the reference
93 method and should be used if a positive ELISA or RT-PCR result is not associated with the detection of clinical signs of
94 disease, the detection of seropositive pigs, or a direct epidemiological connection with a confirmed outbreak. Any cytopathic
95 effect (CPE) observed in the inoculated cultures needs to be tested by ELISA or RT-PCR to demonstrate that SVDV is
96 present.

97 If there are clinical signs, investigation should start with the examination of a 10% suspension of lesion material in phosphate
98 buffered saline (PBS) or tissue culture medium and antibiotics. Faecal samples are the specimen of choice for the detection
99 of virus where subclinical SVD is suspected. Faecal samples can be collected from individual pigs or from the floor of
100 premises suspected to contain, or to have contained, pigs infected with SVD. The level of virus in faeces is usually insufficient
101 for detection by ELISA and the use of RT-PCR and/or virus isolation is required. A significant proportion of faecal samples
102 inoculated into cell cultures will give rise to the growth of other enteroviruses. These can be differentiated from SVDV by
103 ELISA or RT-PCR, but they may also outgrow SVDV that is present, and give rise to false negative results. Therefore, RT-
104 PCR is more sensitive than virus isolation when applied to faecal samples.

105 1.1. Preparation of samples

106 1.1.1. Lesion material

107 Samples should be transported in phosphate-buffered saline (PBS) with antibiotics, mixed with glycerol
108 (1/1), pH 7.2–7.6. A suspension is prepared by grinding the sample in sterile sand in a sterile pestle and
109 mortar with a small volume of PBS or tissue culture medium and antibiotics. Further medium should be
110 added to obtain approximately a 10% suspension. This is clarified by centrifugation at 2000 **g** for ~~20-10-~~
111 30 minutes and the supernatant is harvested.

112

¹ Please consult the WOAH web site for the most up-to-date list: <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>

113

1.1.2. Faecal samples

114
115
116
117

Faecal material (approximately 20 g) is resuspended in a minimal amount of tissue culture medium or phosphate buffer (0.04 M phosphate buffer or PBS). The suspension is homogenised by vortexing and clarified by centrifugation at 2000 **g** for ~~20-10~~ 30 minutes; the supernatant is harvested and filtered through a 0.45 µm filter.

118

1.2. Virus isolation

119
120
121
122
123
124
125

A portion of the clarified epithelial or faecal suspension is inoculated on to monolayers of the porcine kidney cell line IB-RS-2 cells or other susceptible porcine cell line, grown in appropriate containers (25 cm² flasks, rolling tubes, 24-, 12-, 6-well plates). Generally, SVDV will grow in cells of porcine origin only. For differential diagnosis (e.g. FMD) in case of clinical lesions, bovine other validated cell culture systems ~~should~~ may also be employed in parallel. Generally, SVDV will grow in cells of porcine origin only. Tissue culture medium containing antibiotic is supplemented with 10% bovine serum for cell growth, and with 1–3% bovine serum ~~for maintenance, and with antibiotics when test samples are inoculated to the cultures.~~

126
127
128
129
130

Cultures are examined daily. If a cytopathic effect (CPE) is observed, the supernatant fluid is harvested and virus identification is performed by ELISA and SVDV-specific ~~(or other appropriate test, e.g. RT-PCR).~~ Negative cultures ~~are~~ may be blind-passaged after 48 or 72 hours, and observed for a further 2–3 days. If no CPE is evident after the second passage, the sample is recorded “NVD” (no virus detected). When isolating virus from faeces in which the amount of virus present may be low, a third tissue culture passage may be required.

131

1.3. Immunological methods

132

1.3.1. Enzyme-linked immunosorbent assay

133
134
135
136
137
138
139
140
141
142
143
144
145
146

The detection of SVD viral antigen by an indirect sandwich ELISA has replaced the complement fixation test as the method of choice. The test has the same format as that used for FMD diagnosis. Wells of ELISA plates are coated with rabbit antiserum to SVDV. This is the capture serum. Test sample suspensions are added and incubated. Appropriate controls are also included. Guinea-pig anti-SVD detection serum is added at the next stage followed by rabbit anti-guinea-pig serum conjugated to horseradish peroxidase. Extensive washing is carried out between each stage to remove unbound reagents. A positive reaction is indicated if there is a colour reaction on the addition of chromogen (for example orthophenylenediamine) and substrate (H₂O₂). With strong positive reactions this will be evident to the naked eye, but results can also be read spectrophotometrically at the appropriate wavelength, in which case an absorbance reading ≥0.1 above background indicates a positive reaction. As an alternative to guinea-pig and rabbit antisera, suitable monoclonal antibodies (MAbs) can be used, coated to the ELISA plate as the capture antibody and peroxidase conjugated as detector antibody. For example, a simple sandwich ELISA performed with MAb 5B7 as both catching and conjugated/detector antibody, that represents also the reference method for the serological competitive ELISA, is suited for the detection of SVD viral antigen.

147
148
149
150
151

A MAb-based ELISA can also be used to study antigenic variation among strains of SVDV. Tissue-culture grown viral strains are trapped by a rabbit hyperimmune antiserum to SVDV adsorbed to the solid phase. Appropriate panels of MAbs are then reacted and the binding of MAbs to field strains is compared with the binding of MAbs to the parental strains. Strong binding indicates the presence of epitopes shared between the parental and the field strains (Brocchi *et al.*, 1997).

152

1.4. Nucleic acid recognition methods

153

1.4.1. Reverse-transcriptase-polymerase chain reaction

154
155
156
157
158
159
160
161
162
163
164

Reverse-transcriptase followed by the PCR (RT-PCR) is a useful method to detect SVD viral genome in a variety of samples from clinical and subclinical cases. Several methods have been described (~~Benedetti *et al.*, 2010; Callens & De Clercq, 1999; Fallacara *et al.*, 2000; Hakhverdyan *et al.*, 2006; Lin *et al.*, 1997; McMenamy *et al.*, 2011; Nunez *et al.*, 1998; Reid *et al.*, 2004a; 2004b; Vangrype & De Clercq, 1996~~), employing different techniques for RNA extraction, targeting different parts of the SVDV genome and using different approaches to detect the DNA products of amplification. However, in a comparative study on positive faecal samples from many different SVD outbreaks, the one-step RT-PCR incorporating a real-time format with a DNA-binding fluorescent dye ~~Benedetti *et al.*, 2010; Pezzoni *et al.*, 2020~~) had the best diagnostic performance, with the capability to reveal all the circulating genomic sub-lineages, compared with two real-time RT-PCR assays targeting the 5'-untranslated region (Reid *et al.*, 2004a; 2004b), and an RT-loop-mediated isothermal amplification (LAMP) assay (Blomström *et al.*, 2008).

165
166
167

The method reported below describes an RNA immune-extraction protocol and a one-step real-time RT-PCR protocol targeting SVDV 3D region, which codes for the RNA-polymerase. NOTE: The set of primers described below can also be used for conventional RT-PCR.

168 To isolate RNA, the immunocapture technique using a SVDV-specific MAb has been shown to be
169 particularly effective in the case of faecal samples (Fallacara *et al.*, 2000): it enables enrichment and
170 purification of the SVDV, usually present in low concentration in faeces, with efficient removal of potential
171 reaction inhibitors. NOTE: As an alternative to immunocapture, RNA extraction can be performed using
172 suitable commercially available kits based on chaotropic salt lysis and silica RNA affinity.

173 ~~This method is suitable for laboratories without equipment for real-time detection of DNA amplification~~
174 ~~products, but where such facilities are available an approach such as that described by Reid *et al.* (2004a;~~
175 ~~2004b) offers advantages in terms of ease of use and reduced risk of laboratory contamination by PCR~~
176 ~~products.~~

177 1.4.2. RNA immune-extraction

- 178 i) RNA Immune-extraction: Coat wells of an ELISA plate with a saturating solution of MAb 5B7
179 (200 µl/well, diluted in carbonate-bicarbonate buffer) by overnight incubation at 4°C. Wash plates
180 three times with PBS. Use plates immediately or store at -20°C for up to 2–3 weeks, or more if
181 stabilised.
- 182 ii) Distribute each sample (faeces suspension) into three wells of the 5B7-coated plate (200 µl/well,
183 600 µl of sample in total).
- 184 iii) After incubation for 1 hour at 37°C with very slow shaking, wash wells three times with PBS. Washing
185 is performed manually, in order to avoid cross-contamination between wells.
- 186 iv) RNA is extracted from each sample by adding approximately 100 µl/well of lysis buffer (4 M guanidine
187 thiocyanate, 25 mM sodium citrate, pH 7, 0.5% Sarkosyl). Incubate wells for 3–5 minutes and recover
188 the sample from the three wells (300–350 µl total), and transfer into a single tube.
- 189 v) RNA is then precipitated by adding a mixture of 750 µl of absolute ethanol and 35 µl of 3 M sodium
190 acetate (pH 5.2); vials are vortexed and incubated at -20°C for a minimum of 1 hour (prolonged
191 overnight precipitation at -20°C may also be suitable).
- 192 vi) Centrifuge the sample at 15,500–16,000 **g** for 30 minutes at 4°C, after which a pellet should be visible
193 which should be washed with 500 µl of 70% cold ethanol (centrifuged at 15,500–16,000 **g** for 10
194 minutes at 4°C) and dried.
- 195 vii) Resuspend the RNA pellet in 20 µl of DEPC water, or commercially available RNase-free water.

196 NOTE: As an alternative to immunocapture, RNA extraction can be performed using suitable commercially
197 available kits based on chaotropic salt lysis and silica RNA affinity.

198 1.4.2.1. One step real-time RT-PCR (with a double-stranded DNA-binding fluorescent dye)

199 The following protocol (and volumes of each of the specific reagents) for the ~~conventional~~ real-time
200 RT-PCR may need to be adjusted to suit particular reagents used.

- 201 i) Assemble the reaction mix (20 µl is the final volume for each test sample)

202	5x RT-PCR buffer	5 µl
203	2x Master Mix buffer including a DNA-binding fluorescent dye	
204	dNTPs and DNA polymerase	12.5 µl
205	dNTP mix (10 mM each dNTP)	1 µl
206	pSVDV-SS4 Forward Primer 10 pmol/ul*	1.25 µl
207	pSVDV-SA2 Reverse Primer 10 pmol/ul*	1.25 µl
208	RNase inhibitor	0.25 µl (equivalent to 5 U)
209	RT-Mix	0.25 µl
210	Rnase free water	40.75 <u>4.75 µl</u>

211 *Primer sequences: pSVDV-SS4 5'-TTC-AGA-ATG-ATT-GCA-TAT-GGG-G-3' and
212 pSVDV-SA2 5'-TCA-CGT-TTG-TCC-AGG-TTA-CY-3'

- 213 ii) Add 5 µl of each template RNA to 20 µl reaction mix.
- 214 iii) Run the following program in a thermal cycler:
- 215 i) 1 cycle at 50°C for 30 minutes (reverse transcription step)
- 216 ii) 1 cycle at 95°C for 15 minutes (initial activation step)
- 217 iii) 40 cycles, each composed of 94°C for 20-15 seconds (denaturation), 60-58°C for 20-30 seconds
218 (annealing), 72°C for 45-30 seconds (extension), 77°C for 15 seconds (detection).

- 219 ~~One cycle at 72°C for 10 minutes (final extension).~~
- 220 For the melting cycle:
- 221 ~~iv) 1 cycle at 72°C for 10 1 minute and increasing temperature from 72°C to 95°C, by incremental~~
222 ~~steps of 0.5°C for 5 seconds each. Specific amplification products for SVDV generate melting~~
223 ~~curves with a peak within the temperature range 79.5–82.5°C.~~
- 224 ~~iv) Mix a 20 µl aliquot of each sample with 4 µl of loading dye and load onto a 2% agarose gel~~
225 ~~containing an appropriate DNA intercalating dye. After electrophoresis, a positive result is~~
226 ~~indicated by the presence of a 154 bp fragment of the SVDV RNA polymerase (3D) encoding~~
227 ~~region in the gel. Alternatively, gel can be stained after electrophoresis to reduce contamination~~
228 ~~of equipment by soaking in a staining solution~~

229 **1.4.2.2. Real-time RT-PCR**

230 This test can also be adapted to the format of real-time RT-PCR with dedicated reagents/kits, in the
231 presence of a suitable DNA stain, using the following adjusted programme in a real-time PCR cycler:

- 232 ~~i) 1 cycle at 50°C for 30 minutes (reverse transcription step)~~
- 233 ~~ii) 1 cycle at 95°C for 15 minutes (initial activation step)~~
- 234 ~~iii) 40 cycles, each composed of 94°C for 15 seconds (denaturation), 58°C for 30 seconds (annealing),~~
235 ~~72°C for 30 seconds (extension), 77°C for 15 seconds (detection).~~

236 For the melting cycle:

- 237 ~~iv) 1 cycle at 72°C for 1 minute and increasing temperature from 72°C to 95°C, by incremental steps of~~
238 ~~0.5°C for 5 seconds each. Specific amplification products for SVDV generate melting curves with a~~
239 ~~peak within the temperature range 79.5–82.5°C.~~

240 **1.4.3. Sequence analyses**

241 Comparative analysis of sequences of the viral genome is useful to establish relationships between
242 isolates of SVDV. By sequencing the 1D region, which codes for the major structural protein VP1, ~~or the~~
243 ~~3D region~~ or whole genome sequence (Pezzoni *et al.*, 2021), it has been possible to group strains of SVDV
244 according to their sequence homology, and epidemiologically to relate strains causing disease in different
245 locations or at different times (Brocchi *et al.*, 1997). Databases of 1D and 3D gene sequences of SVDVs
246 are held at the WOAHP Reference Laboratory, Pirbright, UK and the WOAHP Reference Laboratory, Brescia,
247 Italy, respectively. Further sequences (including those for complete SVDV genomes) are available via the
248 International Nucleotide Sequence Database Collaboration (including GenBank, ENA, and DDBJ).

249 **2. Serological tests**

250 Serological assays are used in the laboratory confirmation of outbreaks, for serological surveillance and for export
251 certification of pigs. SVD is often diagnosed solely on the evidence of serological tests. Because of the subclinical or mild
252 nature of the disease, it is often first suspected following routine serology for disease surveillance or export certification. The
253 virus neutralisation (VN) test, the double immunodiffusion test, the radial immunodiffusion test, the counter
254 immunoelectrophoresis test and the ELISA have all been described for the detection of antibodies to SVDV (Brocchi *et al.*,
255 1995; Donaldson *et al.*, 1983; Golding *et al.*, 1976; Yang *et al.*, 2020). However, the VN test and the ELISA are the only
256 techniques commonly used. The VN test is the accepted confirmatory test, but has the disadvantage that it takes 2–3 days
257 to complete and requires tissue culture facilities and handling of live virus in appropriate biosafety and containment facilities
258 as determined by biorisk analysis (see chapter 1.1.4). The ELISA is quicker and simpler. A small proportion of sera from
259 animals with no previous exposure to SVDV may react positively in serological tests for antibody to SVDV. The 5B7 MAb
260 competitive ELISA (MAC-ELISA) is a reliable technique for detecting SVD antibody (Brocchi *et al.*, 1995; Heckert *et al.*,
261 1998) and similar results have been obtained with other ELISAs (Chenard *et al.*, 1998; Ko *et al.*, 2005). Results from a small
262 proportion, 0.2%–0.4%, of sera from normal pigs are borderline or positive by the MAC-ELISA and should be retested by
263 the VN test. Up to approximately 50% of these sera will also be positive by the VN test (i.e. 0.1–0.2% of the original
264 population). Animals that test positive by ELISA but negative by VN test can be regarded as uninfected. Repeat samples
265 should be collected from animals positive in both tests and from cohorts. A constant or declining titre in the positive animal
266 and the absence of antibody to SVDV in cohorts confirms the status of the positive animal as a 'singleton reactor'. The
267 factors responsible for 'singleton reactors' are unknown. Serological cross-reactivity with SVDV might arise due to infection
268 with another, as yet unidentified, picornavirus or may be due to other non-specific factors present in the serum. Identification
269 of the isotype of antibody present in positive sera (Brocchi *et al.*, 1995) can be helpful as sera from 'singleton' reactors
270 usually contain exclusively IgM and do not convert to IgG (De Clercq, 1998). IgM/IgG isotype-specific ELISAs are also helpful
271 in assessing the time of infection in the pig or on the infected premises. The presence of IgM, alone or together with IgG, is

272 evidence of recent infection and indicative of virus shedding, while detection of IgG alone suggests an older exposure to
273 infection (Brocchi *et al.*, 1995).

274 2.1. Virus neutralisation

275 The quantitative VN microtest for antibody to SVDV is performed using IB-RS-2 cells (or suitable susceptible
276 porcine cells) in flat-bottomed tissue-culture grade microtitre plates.

277 Virus is grown on IB-RS-2 cell monolayers and stored at -20°C after the addition of an equal volume of glycerol.
278 SVDV has been found to be stable under these conditions for at least 1 year. The sera are inactivated at 56°C for
279 30 minutes before testing. A suitable medium is Eagle's complete medium/LYH with antibiotics.

280 The test is an equal volume test in 50 μl volumes:

- 281 i) Starting from a 1/4 dilution, sera are diluted in a twofold dilution series across the plate, two rows of wells
282 per serum and a volume of 50 μl .
- 283 ii) Previously titrated virus is added; each 50 μl unit volume of virus suspension contains about 100 TCID₅₀
284 (50% tissue culture infective dose).
- 285 iii) Controls include at least ~~a weak positive serum and a negative serum~~, a cell control, a medium control and
286 a virus titration used to calculate the actual virus titre used in the test. Inclusion of a weak positive serum
287 and a negative serum can also help to interpret the results.
- 288 iv) Incubate at 37°C for 1 hour with the plates covered.
- 289 v) A cell suspension at 10^6 cells/ml is prepared in medium containing 10% bovine serum for cell growth. 50 μl
290 of cell suspension is added to each well.
- 291 vi) Plates are sealed with pressure-sensitive tape and incubated at 37°C for ~~2~~1–3 days. Alternatively, the plates
292 may be covered with loosely fitting lids and incubated in an atmosphere of 5% carbon dioxide at 37°C for 2–
293 3 days.
- 294 vii) Microscopic readings are feasible after ~~48–72~~24–72 hours; the plates may be finally fixed and stained on the
295 third day. Fixation is ~~effected~~carried out with 10% formalin/saline for 30 minutes; staining is done by
296 immersion in 0.05% methylene blue in 10% formalin for 30 minutes. The plates are rinsed in tap water.
297 Positive readings are blue-stained cell sheets (where the virus has been neutralised and the cells remain
298 intact), whilst empty wells (where virus has not been neutralised) are read as negative.
- 299 viii) Interpretation of the results

300 The test is considered to be valid when the amount of virus ~~actually~~ used per well (virus dose) is between
301 $10^{1.5}$ and $10^{2.5}$ TCID₅₀, and the positive standard sera are within twofold of their expected titre. Titres are
302 expressed as the final dilution of serum present in the serum/virus mixture where 50% of wells are protected.
303 Laboratories should establish their own cut-off titres by reference to both results from a negative population
304 and standard reagents available from the WOAHA Reference Laboratories, in particular the low-positive
305 serum defining the lowest level of antibodies that Laboratories should consistently score positive.

306 2.2. Enzyme-linked immunosorbent assay

307 Commercial kits are available for antibody detection in pig ~~specimens sera~~. In the ELISA developed by Brocchi *et al.*
308 *et al.* (1995), the SVD viral antigen is trapped to the solid phase using the MAb 5B7. The ability of test sera to inhibit
309 the binding of peroxidase-conjugated MAb 5B7 to the trapped antigen is then evaluated. Finally, the amount of
310 conjugated MAb bound is detected by the addition of substrate and chromogen.

- 311 i) ELISA plates are coated with 50 μl /well of MAb 5B7 at a saturating dilution in carbonate/bicarbonate buffer,
312 pH 9.6, by overnight incubation at 4°C .
- 313 ii) The plates are washed three times with PBS containing 0.05% Tween 20, and 50 μl of SVD antigen (SVDV
314 grown in IB-RS-2 cells, clarified, filtered and BEI-inactivated) at a predetermined optimal dilution, is added
315 to each well. The optimal dilution of antigen is determined by checkerboard titrations of antigen and
316 conjugated MAb that define the working dilution giving an absorbance on the upper part of the linear region
317 of the antigen titration curve (between 1.5 and 2.0 optical density units). Plates are then incubated for 1 hour
318 at 37°C .
- 319 iii) After three additional washes, 50 μl of diluted test sera (inactivation is irrelevant) and control sera are
320 incubated with the trapped antigen for 1 hour at 37°C . Sera can be tested at a single dilution (1/7.5) or
321 titrated. In the latter case, three-fold dilutions of sera are obtained directly in ELISA wells by adding 10 μl of
322 serum to 65 μl of buffer (1/7.5 dilution) then transferring 25 μl to sequential wells containing 50 μl of buffer,

- 323 mixing, and finally discarding 25 µl. For spot-test, the screening dilution 1/7.5 is obtained by adding 7µl of
324 each test serum (and control sera) to 45 µl of buffer previously distributed into wells.
- 325 iv) After incubation for 1 hour, 25 µl of an optimal dilution of peroxidase-conjugated MAb 5B7 (see step ii above)
326 is added to each well and the plates are incubated at 37°C for a further 1 hour.
- 327 v) After a final series of washes, the colorimetric reaction is developed by distributing 50 µl per well of the
328 substrate solution (for example 0.5 mg/ml orthophenylene-diamine in phosphate/citrate buffer, pH 5,
329 containing 0.02% H₂O₂).
- 330 vi) The reaction is stopped after 10 minutes by adding 50 µl of 2N H₂SO₄. The absorbance is read at the
331 appropriate wavelength using a microplate reader.
- 332 Antigen, sera and conjugate are diluted in PBS, pH 7.4, containing 0.05% Tween 20 and 1% yeast extract;
333 the dilution buffer for sera contains, in addition, 1.0% mouse serum (or ~~alternatively~~ another source of murine
334 immunoglobulins) to prevent nonspecific binding of pig serum to MAb 5B7 either coated to the plate or
335 conjugated to peroxidase.
- 336 vii) *Controls*: Four wells on each plate containing all reactants except test serum confirm the maximum
337 absorbance reading for the antigen; negative pig serum; a low positive standard pig serum; optionally, a
338 strong positive pig serum at four dilutions, previously calibrated in order to give ≥50% inhibition (see step vii
339 below) at the highest dilution.
- 340 viii) Interpretation of the results: Reactions are expressed as the percentage inhibition by each test serum of the
341 MAb reaction with the SVD antigen. Sera are considered to be positive when producing an inhibition ≥80%
342 at the 1/7.5 dilution; negative when producing an inhibition <70% at the 1/7.5 dilution; doubtful when
343 producing an inhibition ≥70% and <80% at the 1/7.5 dilution. The second dilution (1/22.5) ~~provides an~~
344 ~~indication of~~ indicates the level of antibodies: strongly positive sera show >80% inhibition at both 1/7.5 and
345 1/22.5 dilutions, while sera registering >80% inhibition at the 1/7.5 dilution but <50% inhibition at the 1/22.5
346 dilution are considered to be low positive or borderline. All positive, borderline and doubtful sera should be
347 confirmed using the VN test.

348 STANDARD REFERENCE SERA FOR SVD SEROLOGY

349 The WOA Reference Laboratory, Pirbright, UK maintains a panel of reference sera that have been extensively validated
350 by the National SVD Reference Laboratories of the Member States of the European Union. This panel includes the low-
351 positive serum defining the lowest level of antibodies that should consistently provide a positive result by ELISA and Virus
352 Neutralisation (RS01-04-94 or equivalent). Positive sera equivalent to these reference standards and Mab 5B7 are available
353 at the WOA Reference Laboratory, Brescia, Italy.

354 C. REQUIREMENTS FOR VACCINES

355 No commercial SVD vaccines are currently available.

356 REFERENCES

- 357 ~~BENEDETTI D., PEZZONI G., GRAZIOLI S., BARBIERI I. & BROCCHI E. (2010). Comparative performance of three genome~~
358 ~~amplification assays for detection of swine vesicular disease virus in experimental and field samples. In: Proceedings of the~~
359 ~~First Congress of the European Association of Veterinary Laboratory Diagnosticians (EAVLD), Lelystad, The Netherlands,~~
360 ~~15–17 September 2010, O-2-09.~~
- 361 BLOMSTRÖM A., HAKVERD M., REID S.M., DUKES J.P., KING D.P., BELÁK S. & BERG M. (2008). A one step reverse transcriptase
362 loop-mediated isothermal amplification assay for simple and rapid detection of swine vesicular disease virus. *J. Virol.*
363 *Methods*, **147**, 188–193.
- 364 BROCCHI E., BERLINZANI A., GAMBA D. & DE SIMONE F. (1995). Development of two novel monoclonal antibody-based ELISAs
365 for the detection of antibodies and the identification of swine isotypes against swine vesicular disease virus. *J. Virol. Methods*,
366 **52**, 155–167.
- 367 BROCCHI E., ZHANG G., KNOWLES N.J., WILSDEN G., MCCAWLEY J.W., MARQUARDT O., OHLINGER V.F. & DE SIMONE F. (1997).
368 Molecular epidemiology of recent outbreaks of swine vesicular disease: two genetically and antigenically distinct variants in
369 Europe, 1987–1994. *Epidemiol. Infect.*, **118**, 51–61.

- 370 BRUHN C.A., NIELSEN S.C., SAMANIEGO J.A., WADSWORTH J., KNOWLES N.J. & GILBERT M.T. (2015). Viral meningitis epidemics
371 and a single, recent, recombinant and anthroponotic origin of swine vesicular disease virus. *Evol. Med. Public Health*, **2015**,
372 289–303.
- 373 CALLENS M. & DE CLERCQ K. (1999). Highly sensitive detection of swine vesicular disease virus based on a single tube RT-
374 PCR system and DIG-ELISA detection. *J. Virol. Methods*, **77**, 87–99.
- 375 CHENARD G., BLOEMRAAD M., KRAMPS J.A., TERPSTRA C. & DEKKER A. (1998). Validation of a monoclonal antibody-based ELISA
376 to detect antibodies directed against swine vesicular disease virus. *J. Virol. Methods*, **75**, 105–112.
- 377 DONALDSON A.I., FERRIS N.P., KNOWLES N.J. & BARNETT I.T.R. (1983). Comparative studies of United Kingdom isolates of
378 swine vesicular disease virus. *Res. Vet. Sci.*, **35**, 295–300.
- 379 DE CLERCQ K. (1998). Reduction of singleton reactors against swine vesicular disease virus by a combination of virus
380 neutralisation test, monoclonal antibody-based competitive ELISA and isotype specific ELISA. *J. Virol. Methods*, **70**, 7–18.
- 381 FALLACARA F., PACCARINI M., BUGNETTI M., BERLINZANI A. & BROCCHI E. (2000). Detection of swine vesicular disease virus in
382 faeces samples by immune-PCR assay. *In: Veterinary Virology in the New Millennium, Proceedings of the 5th International
383 Congress of the European Society for Veterinary Virology, Brescia, Italy, 27–30 August 2000*, pp 173–174.
- 384 GOLDING S.M., HEDGER R.S., TALBOT P. & WATSON J. (1976). Radial immunodiffusion and serum neutralisation techniques for
385 the assay of antibodies to swine vesicular disease. *Res. Vet. Sci.*, **20**, 142–147.
- 386 HAKHVERDYAN M., RASMUSSEN T.B., THOREN P., UTTENTHAL A. & BELAK S. (2006). Development of a real-time PCR assay
387 based on primer-probe energy transfer for the detection of swine vesicular disease virus. *Arch. Virol.*, **151**, 2365–2376.
- 388 HECKERT A., BROCCHI E., BERLINZANI A. & MACKAY D. (1998). An international comparative analysis of a competitive ELISA for
389 the detection of antibodies to swine vesicular disease virus. *J. Vet. Diagn. Invest.*, **10**, 295–297.
- 390 KNOWLES N.J., WILSDEN G., REID S.M., FERRIS N.P., KING D.P., PATON D.J., FEVEREIRO M. & BROCCHI E. (2007). Reappearance
391 of swine vesicular disease virus in Portugal. *Vet. Rec.*, **161**, 71.
- 392 KO Y.-J., CHOI K.-S., NAH J.-J., PATON D.J., OEM J.-K., WILSDEN G., KANG S.-Y., JO N.-I., KIM J.-H., LEE H.-W. & PARK J.-M.
393 (2005). Noninfectious virus-like particle antigen for detection of swine vesicular disease virus antibodies in pigs by enzyme
394 linked immunosorbent assay. *Clin. Diagn. Lab. Immunol.*, **12**, 922–929.
- 395 LIN F., MACKAY D.K.J. & KNOWLES N.J. (1997). Detection of swine vesicular disease virus RNA by reverse transcription-
396 polymerase chain reaction. *J. Virol. Methods*, **65**, 111–121.
- 397 LOXAM J.R. & HEDGER R.S. (1983). Swine vesicular disease: clinical signs, diagnosis, epidemiology and control. *Rec. sci.
398 tech. Off. int. Epiz.*, **2**, 11–24.
- 399 LOMAKINA N.F., YU SHUSTOVA E., STRIZHAKOVA O.M., FELIX DREXLER J. & LUKASHEV A.N. (2016). Epizootic of vesicular disease
400 in pigs caused by coxsackievirus B4 in the Soviet Union in 1975. *J. Gen. Virol.*, **97**, 49–52.
- 401 MANN J.A. (1981). Swine vesicular disease. *In: Virus Diseases of Farm Animals, Vol. 2*, Gibbs E.P.J., ed. Academic Press,
402 London, UK, 365–381.
- 403 McMENAMY M.J., MCKILLEN J., REID S.M., HJERTNER B., KING D.P., ADAIR B. & ALLAN G. (2011). Development of a minor groove
404 binder assay for real-time one-step RT-PCR detection of swine vesicular disease virus. *J. Virol. Methods*, **171**, 219–224.
- 405 NUNEZ J.I., BLANCO E., HERNANDEZ T., GOMEX-TEJEDOR C., MARTIN M.I., DOPAZO J. & SOBRINO F. (1998). A RT-PCR assay for
406 the differential diagnosis of vesicular viral diseases of swine. *J. Virol. Methods*, **72**, 227–235.
- 407 PEZZONI G., BENEDETTI D., BREGOLI A., BARBIERI L., FOGLIA E.A., GRAZIOLI S. & BROCCHI E. (2020). Diagnostic Performances of
408 Different Genome Amplification Assays for the Detection of Swine Vesicular Disease Virus in Relation to Genomic Lineages
409 That Circulated in Italy. *Viruses*, **12**, 1336. doi: 10.3390/v12111336. PMID: 33233870; PMCID: PMC7699968.
- 410 PEZZONI G., BREGOLI A., CHIAPPONI C., GRAZIOLI S., DI NARDO A. & BROCCHI E. (2021). Retrospective Characterization of the
411 2006-2007 Swine Vesicular Disease Epidemic in Northern Italy by Whole Genome Sequence Analysis. *Viruses*, **13**, 1186.
412 doi: 10.3390/v13071186. PMID: 34206208; PMCID: PMC8310173
- 413 REID S.M., FERRIS N.P., HUTCHINGS G.H., KING D.P. & ALEXANDERSEN S. (2004a). Evaluation of real-time reverse transcription
414 polymerase chain reaction assays for the detection of swine vesicular disease virus. *J. Virol. Methods*, **116**, 169–176.

415 REID S.M., PATON D.J., WILSDEN G., HUTCHINGS G.H., KING D.P., FERRIS N.P. & ALEXANDERSEN S. (2004b). Use of automated
416 real-time RT-PCR to monitor experimental swine vesicular disease virus infection in pigs. *J Comp. Pathol.*, 131, 308–317.

417 VANGRYSPERRE W. & DE CLERCQ K. (1996). Rapid and sensitive polymerase chain reaction based on detection and typing of
418 foot-and-mouth disease virus in clinical samples and cell culture isolates, combined with a simultaneous differentiation with
419 other genomically and/or symptomatically related viruses. *Arch. Virol.*, **141**, 331–344.

420 YANG M., GAGLIARDI K., MCINTYRE L., XU W., GOOLIA M., AMBAGALA T., BROCCHI E., GRAZIOLI S., HOOPER-MCGREYVY K., NEON C.
421 & CLAVIJO A. (2020). Development and evaluation of swine vesicular disease isotype-specific antibody ELISAs based on
422 recombinant virus-like particles. *Transbound. Emerg. Dis.*, **67**, 406–416. doi: 10.1111/tbed.13363. Epub 2019 Oct 9. PMID:
423 31538404.

424

*

425

* *

426 **NB:** There are WOAHA Reference Laboratories for swine vesicular disease (please consult the WOAHA Web site:

427 <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>).

428 Please contact the WOAHA Reference Laboratories for any further information on
429 diagnostic tests and reagents for swine vesicular disease

430

NB: FIRST ADOPTED IN 1989. MOST RECENT UPDATES ADOPTED IN 2018.

431
432
433

Appendix 1: Swine vesicular disease

Intended purpose of test: Identification of the agent – individual animal freedom from infection prior to movement; contribute to eradication policies; confirmation of clinical cases

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>RT-PCR swine</u>	<u>Epithelial lesions, faeces</u> <u>Analyte: virus genomic target (3D)</u>	<u>Reference tests were isolation of SVDV in cell cultures or a positive result in RT-PCR combined with other evidence of infection (serology or epidemiological correlation)</u> <u>Dsp=100%</u> <u>Dse= 100%</u>	<u>78 faecal samples, collected from 78 different SVD outbreaks that occurred in Italy during 1997–2014.</u> <u>300 field faecal samples originating from SVDV-free regions plus many thousands of faecal samples tested over several years as part of the successful eradication plan in Italy</u>	<u>See reference</u>	<u>High analytical and diagnostic sensitivity</u> <u>Faster results than virus isolation</u>		<u>Pezzoni <i>et al.</i> (2021)</u>
<u>Virus Isolation swine</u>	<u>Epithelial lesions, faeces</u> <u>Analyte: live virus</u>	<u>Historically considered the reference method.</u>			<u>Enables recovery of live virus, potentially useful for subsequent studies for virus characterization</u>	<u>A significant proportion of faecal samples inoculated into cell cultures will give rise to the growth of other enteroviruses.</u> <u>Inoculation of cells with faecal samples may result in bacterial contamination, despite the use of antibiotics in the cell culture media</u> <u>Requires biocontainment conditions</u> <u>Time-consuming</u>	
<u>ELISA for antigen detection swine</u>	<u>Epithelial lesions</u> <u>Analyte: virus antigen</u>	<u>The MAb-based test was evaluated for the ability of selected monoclonal/polyclonal antibodies to recognise and capture SVDV in ELISA</u>	<u>77 European SVDV isolates collected up to 1994 and representative of the four antigenic variants of the virus were recognised by the 5B7 MAb selected for the antigen-ELISA (Brocchi <i>et al.</i>, 1997), as well as all SVD viruses isolated later on</u>	<u>See reference</u>	<u>Since based on specific SVD poly/monoclonal antibodies, the test is highly specific</u> <u>Easy to perform especially in poorly equipped laboratories</u> <u>Faster results than virus isolation</u> <u>Useful to complement virus isolation for the identification of SVDV in case of cytopathic effect</u>	<u>Lower analytical sensitivity than RT-PCR and virus isolation</u> <u>Applicable only on epithelial lesions</u>	<u>Brocchi <i>et al.</i> (1997)</u>

434

Appendix 2: Swine vesicular disease

435

Intended purpose of test: Detection of immune response – population freedom from infection; individual animal freedom from infection prior to movement; contribute to eradication policies; confirmation of clinical cases; prevalence of infection –surveillance

436

<u>Test with score and species</u>	<u>Sample type and target analytes</u>	<u>Accuracy</u>	<u>Test population</u>	<u>Validation report</u>	<u>Advantages</u>	<u>Disadvantages</u>	<u>References</u>
<u>Competitive ELISA for Ab screening swine</u>	<u>Sera</u>	<u>Dsp and Dse were calculated using field samples of known origin. Dsp=99.55% Dse= 100% The reference test used in the study was VNT Correlation between VNT and competitive ELISA in positive sera titration r=0.81, p<0.001</u>	<u>Field sera: 1) 5371 pig sera collected from 1060 SVDV-free herds 2) Positive field sera (n = 300) collected in Italy from different herds notified as SVDV outbreaks Experimental sera: 148 sera were collected from 12 pigs experimentally infected with SVDV UKG27/72 or SVDV Italy R1076/1992 and sequentially collected up to 1 or 2 months after infection</u>	<u>See reference</u>	<u>Easy to perform, suitable for large-scale application or automation Ideal for surveillance, control, and eradication</u>	<u>Singleton reactors occurrence need to be checked with VNT, IgG and IgM ELISA (and resampling)</u>	<u>Brocchi <i>et al.</i> (1995)</u>
<u>Virus neutralisation swine</u>	<u>Sera</u>	<u>It is accepted as the confirmatory test for the detection of antibodies to SVDV</u>	<u>See the sera description below</u>	<u>See reference</u>	<u>It detects neutralising antibodies</u>	<u>It requires 1–3 days for execution Maintenance and use of live virus and tissue culture cells, thus biocontainment restriction procedures are required A small proportion of sera remains false-positive in VNT when used as a confirmatory test (singleton reactors, 0.1-0.2% of a naive population)</u>	<u>Brocchi <i>et al.</i> (1995) DeClercq (1998)</u>
<u>ELISA for IgG and IgM identification swine</u>	<u>Sera</u>	<u>The methods have provided evidence of the different chronology of IgM and IgG production VNT and competitive ELISA were used as reference tests</u>	<u>See the experimental sera description for competitive ELISA</u>	<u>See reference</u>	<u>Can differentiate between IgG and IgM Can identify different stages of infection Can confirm the results of the competitive ELISA and VNT Can be helpful to confirm singleton reactors</u>	<u>For positivity confirmation, both IgG and IgM tests have to be carried out simultaneously.</u>	<u>Brocchi <i>et al.</i> (1995)</u>

SECTION 3.9.

SUIDAE

CHAPTER 3.9.1.

AFRICAN SWINE FEVER
(INFECTION WITH AFRICAN SWINE FEVER VIRUS)

SUMMARY

African swine fever (ASF) is an infectious disease of domestic and wild pigs of all breeds and ages, caused by ASF virus (ASFV). The clinical syndromes vary from peracute, acute, subacute to chronic, depending on the virulence of the virus. Acute disease is characterised by high fever, haemorrhages in the reticuloendothelial system, and a high mortality rate. Soft ticks of the Ornithodoros genus, especially O. moubata and O. erraticus, have been shown to be both reservoirs and transmission vectors of ASFV. The virus is present in tick salivary glands and passed to new hosts (domestic or wild suids) when feeding. It can be transmitted sexually between ticks, transovarially to the eggs, or transtadially throughout the tick's life.

ASFV is the only member of the Asfarviridae family, genus Asfivirus.

Laboratory diagnostic procedures for ASF fall into two groups: detection of the virus and serology. The selection of the tests to be carried out depends on the disease situation and laboratory diagnostic capacity in the area or country.

Identification of the agent: *Laboratory diagnosis must be directed towards isolation of the virus by inoculation of pig leukocyte or bone marrow cultures, the detection of antigen in smears or cryostat sections of tissues by fluorescent antibody test and/or the detection of genomic DNA by the polymerase chain reaction (PCR) or real-time PCR. The PCRs are excellent, highly sensitive, specific and rapid techniques for ASFV detection and are very useful under a wide range of circumstances. They are especially useful if the tissues are unsuitable for virus isolation and antigen detection. In doubtful cases, the material is passaged in leukocyte cell cultures and the procedures described above are repeated.*

Serological tests: *Pigs that survive natural infection usually develop antibodies against ASFV from 7–10 days post-infection and these antibodies persist for long periods of time. Where the disease is endemic, or where a primary outbreak is caused by a strain of low or moderate virulence, the investigation of new outbreaks should include the detection of specific antibodies in serum or extracts of the tissues submitted. A variety of methods such as the enzyme-linked immunosorbent assay (ELISA), the indirect fluorescent antibody test (IFAT), the indirect immunoperoxidase test (IPT), and the immunoblotting test (IBT) is available for antibody detection.*

Requirements for vaccines: *At present, there is no vaccine for ASF. Commercially produced modified live virus vaccines are available and licenced under field evaluation being evaluated and have received regulatory approval for field use in some countries.*

A. INTRODUCTION

39

40 The current distribution of African swine fever (ASF) extends across more than 50 countries in three continents (Africa, Asia
41 and Europe). Several incursions of ASF out of Africa were reported between the 1960s and 1970s. In 2007, ASF was
42 introduced into Georgia, from where it spread to neighbouring countries including the Russian Federation. From there ASF
43 spread to eastern European countries extending westwards and reaching the European Union in 2014. Further westward
44 and southern spread in Europe has occurred since that time. In all these countries, both hosts – domestic pig and wild boar
45 – were affected by the disease. In August 2018, the People's Republic of China reported its first outbreak of ASF and further
46 spread in Asia has occurred. ASF was identified on the island of Hispaniola (Haiti and the Dominican Republic) in 2021. See
47 WAHIS (<https://wahis.woah.org/#/home>) for recent information on distribution at the country level.

48 ASF virus (ASFV) is a complex large, enveloped DNA virus with icosahedral morphology. It is currently classified as the only
49 member of the *Asfviridae* family, genus *Asfivirus* (Dixon *et al.*, 2005). More than 60 structural proteins have been identified
50 in intracellular virus particles (200 nm) (Alejo *et al.*, 2018). More than a hundred infection-associated proteins have been
51 identified in infected porcine macrophages, and at least 50 of them react with sera from infected or recovered pigs (Sánchez-
52 Vizcaíno & Arias, 2012). The ASFV double-stranded linear DNA genome comprises between 170 and 193 kilobases (kb)
53 and contains between 150 and 167 open reading frames with a conserved central region of about 125 kb and variable ends.
54 These variable regions encode five multigene families that contribute to the variability of the virus genome. The complete
55 genomes of several ASFV strains have been sequenced (Bishop *et al.*, 2015; Chapman *et al.*, 2011; de Villiers *et al.*, 2010;
56 Portugal *et al.*, 2015). Different strains of ASFV vary in their ability to cause disease, but at present there is only one
57 recognised serotype of the virus detectable by antibody tests.

58 The molecular epidemiology of the disease is investigated by sequencing of the 3' terminal end of the B646L open reading
59 frame encoding the p72 protein major capsid protein, which differentiates up to 24 distinct genotypes (Achenbach *et al.*,
60 2017; Boshoff *et al.*, 2007; Quembo *et al.* 2018). To distinguish subgroups among closely related ASFV, sequence analysis
61 of the tandem repeat sequences (TRS), located in the central variable region (CVR) within the B602L gene (Gallardo *et al.*,
62 2009; Lubisi *et al.*, 2005; Nix *et al.*, 2006) and in the intergenic region between the I73R and I329L genes, at the right end of
63 the genome (Gallardo *et al.*, 2014), is undertaken. Several other gene regions such as the E183L encoding p54 protein, the
64 CP204L encoding p30 protein, and the protein encoded by the EP402R gene (CD2v), have been proved as useful tools to
65 analyse ASFVs from different locations and hence track virus spread.

66 ASF viruses produce a range of syndromes varying from peracute, acute to chronic disease and subclinical infections. Pigs
67 are the only domestic animal species that is naturally infected by ASFV. European wild boar and feral pigs are also
68 susceptible to the disease, exhibiting clinical signs and mortality rates similar to those observed in domestic pigs. In contrast
69 African wild pigs such as warthogs (*Phacochoerus aethiopicus*), bush pigs (*Potamochoerus porcus*) and giant forest hogs
70 (*Hylochoerus meinertzhageni*) are resistant to the disease and show few or no clinical signs. These species of wild pig act
71 as reservoir hosts of ASFV in Africa (Costard *et al.*, 2013; Sánchez-Vizcaíno *et al.*, 2015).

72 The incubation period is usually 4–19 days. The more virulent strains produce peracute or acute haemorrhagic disease
73 characterised by high fever, loss of appetite, haemorrhages in the skin and internal organs, and death in 4–10 days,
74 sometimes even before the first clinical signs are observed. Case fatality rates may be as high as 100%. Less virulent strains
75 produce mild clinical signs – slight fever, reduced appetite and depression – which can be readily confused with many other
76 conditions in pigs and may not lead to suspicion of ASF. Moderately virulent strains are recognised that induce variable
77 disease forms, ranging from acute to subacute. Low virulence, non-haemadsorbing strains can produce subclinical non-
78 haemorrhagic infection and seroconversion, but some animals may develop discrete lesions in the lungs or on the skin in
79 areas over bony protrusions and other areas subject to trauma. Animals that have recovered from either acute, subacute or
80 chronic infections may potentially become persistently infected, acting as virus carriers. The biological basis for the
81 persistence of ASFV is still not well understood, nor it is clear what role persistence plays in the epidemiology of the disease.

82 ASF cannot be differentiated from classical swine fever (CSF) by either clinical or post-mortem examination, and both
83 diseases should be considered in the differential diagnosis of any acute febrile haemorrhagic syndrome of pigs. Bacterial
84 septicæmias may also be confused with ASF and CSF. Laboratory tests are essential to distinguish between these diseases.

85 In countries free from ASF but suspecting its presence, the laboratory diagnosis must be directed towards isolation of the
86 virus by the inoculation of pig leukocyte or bone marrow cultures, the detection of genomic DNA by polymerase chain reaction
87 (PCR) or the detection of antigen in smears or cryostat sections of tissues by direct fluorescent antibody test (FAT). Currently
88 the PCR is the most sensitive technique and can detect ASFV DNA from a very early stage of infection in tissues, ethylene
89 diamine tetra-acetic acid (EDTA)-blood and serum samples. The PCR is particularly useful if samples submitted are
90 unsuitable for virus isolation and antigen detection because they have undergone putrefaction. Pigs that have recovered
91 from acute, subacute or chronic infections usually exhibit a viraemia for several weeks making the PCR test a very useful
92 tool for the detection of ASFV DNA in pigs infected with low or moderately virulent strains. Virus isolation by the inoculation
93 of pig leukocyte or bone marrow cultures and identification by haemadsorption tests (HAD) are recommended as a
94 confirmatory test when ASF is positive by other methods, particularly in the event of a primary outbreak or a case of ASF.

95 As no vaccine is available, the presence of ASFV antibodies is indicative of previous infection and, as antibodies are
96 produced from the first week of infection and persist for long periods, they are a good marker for the diagnosis of the disease,
97 particularly in subacute and chronic forms.

98 Vaccines should be prepared in accordance with Chapter 1.1.8 *Principles of veterinary vaccine production*. Current ASF
99 modified live virus (MLVs) vaccines are based on the live virus that have been naturally attenuated or attenuated by targeted
100 genetic recombination through cell cultures (Gladue & Borca, 2022). MLV production is based on a seed-lot system
101 consistent with the *European Pharmacopoeia* (11th edition) and that has been validated with respect to virus identity, sterility,
102 purity, stability, potency, stability, safety and immunogenicity (including spread), non-transmissibility, stability and
103 immunogenicity. ASF MLV first generation vaccines – defined as those for which peer-reviewed publications are in the public
104 domain – should meet or exceed the minimum standards as described below. Paramount Demonstration of acceptable
105 safety and efficacy against the epidemiologically relevant ASFV field strain(s) circulating in areas where the vaccine is
106 intended for use are is required. At the present time, a variety of mutants (Forth *et al.*, 2023) and recombinants (Zhao *et al.*,
107 2023) have emerged globally, and the prevalence of these strains is increasing. In addition, there is a risk that vaccine strains
108 will might revert to virulence and/or recombine with circulating strains. These conditions should be taken into account in
109 vaccine development. acceptable efficacy should be shown against the B646L (p72) genotype II pandemic virus lineage
110 currently circulating widely in domestic pigs and wild boar.

111 ASF MLV first generation vaccines allowing the differentiation of infected animals from vaccinated animals (DIVA) by suitable
112 methods (e.g. serology-based tests) are preferred. Minimum standards set out in this chapter include safety and efficacy
113 testing in young pigs (4–10 weeks old) and safety testing in pregnant sows. Demonstration of MLV safety and efficacy in
114 pigs at different growth stages, including (suckling piglets, nursery pigs, fattening pigs), the safety in breeding-age boars,
115 and gilts and pregnant sows, and onset and duration of protective immunity, are also preferred but are not required to meet
116 the minimum standard. Additional data will likely be required by Regulatory Authorities if these specific categories are
117 included in the indications for the vaccine. Details of the onset of immunity (the interval of time elapsed between vaccination
118 and challenge if protection is confirmed) and the duration of immunity (last time-point at which vaccine-induced immunity
119 has been demonstrated) (the time point at which vaccine-induced immunity begins to decline and provides less protection)
120 are also required to meet minimum standards.

121 ASF epidemiology is complex with different epidemiological patterns of infection occurring in Africa and Europe. ASF occurs
122 through transmission cycles involving domestic pigs, wild boar, wild African suids, and soft ticks (Sánchez-Vizcaíno *et al.*,
123 2015). In regions where *Ornithodoros* soft-bodied ticks are present, the detection of ASFV in these reservoirs of infection
124 contributes to a better understanding of the epidemiology of the disease. This is of major importance in establishing effective
125 control and eradication programmes (Costard *et al.*, 2013).

126 ASF is not a zoonotic disease and does not affect public health (Sánchez-Vizcaíno *et al.*, 2009).

127 ASFV should be handled with an appropriate level of bio-containment, determined by risk analysis in accordance with
128 Chapter 1.1.4 *Biosafety and biosecurity: Standard for managing biological risk in the veterinary laboratory and animal*
129 *facilities*.

130 . . .

131 **C. REQUIREMENTS FOR VACCINES [UNDER REVIEW]**

132 At present there is no commercially available vaccine for ASF. Commercially produced modified live virus vaccines are being
133 evaluated and have licensed received regulatory approval for field use in some countries.

134 **1. Background**

135 The ASF p72 genotype II strains (ASFV Georgia 2007/1 lineage) (NCBI, 2020) are recognised to be the current highest
136 global threat for domestic pig production worldwide (Penrith *et al.*, 2022). However, genotype I attenuated-low virulent strains
137 and genotype I/II recombinant strains have been reported to be circulating. In Africa, multiple genotypes are circulating.

138 Guidelines for the production of veterinary vaccines are given in Chapter 1.1.8 *Principles of Veterinary Vaccine Production*.
139 Varying additional requirements relating to quality (including purity and potency), safety, and efficacy will apply in particular
140 countries or regions for manufacturers to comply with local regulatory requirements.

141 Wherever live, virulent ASFV or ASF MLVs are stored, handled and disposed, the appropriate biosecurity level, procedures
142 and practices should be used. The ASF MLV vaccine production facility should meet the requirements for containment

143 outlined in Chapter 1.1.4 Biosafety and biosecurity: Standard for managing biological risk in the veterinary laboratory and
144 animal facilities.

145 An optimal ASF MLV first generation vaccine for the target host should have the following general characteristics (minimum
146 standards):

147 • Safe: demonstrate absence of persistent fever as defined below (see Section 2.3.2) and clinical signs of acute or
148 chronic ASF in vaccinated and in-contact animals, minimal and ideally no vaccine virus transmission, and absence of
149 an increase in virulence (genetic and phenotypic stability);

150 • Efficacious: protects against mortality, reduces acute and other forms of disease (fever accompanied by the
151 appearance of clinical signs caused by ASF) and reduces vertical (bear semen and placental) and levels of challenge
152 virus viraemia and shedding horizontal disease transmission;

153 • Quality – purity: free from wild-type ASFV and extraneous microorganisms that could adversely affect the safety,
154 potency or efficacy of the product;

155 • Quality – potent stability: the log₁₀-virus titre maintained throughout the vaccine shelf life that guarantees the efficacy
156 demonstrated by the established minimum immunising (protective) dose;

157 • Identity-Vaccine matching: based on the capacity to protect against the ASFV B646L (p72) genotype II pandemic strain
158 or other p72 genotypes of recognised epidemiological importance.

159 Vaccine production should be carried out using a validated, controlled and consistent manufacturing process.

160 ASF MLV first generation vaccines must be safe (i.e. an acceptable safety profile) for non-target species and the environment
161 in general.

162 Ideally, ASF MLV first generation vaccines that meet the minimum standards should also fulfil the following additional general
163 characteristics: i) prevents acute and persistent (carrier state) disease; ii) prevents horizontal and vertical disease
164 transmission; iii) induces rapid protective immunity (e.g. < 2-4 weeks); and iv) confers stable, life-long immunity.

165 Furthermore, ASF MLV second and future generation vaccines should meet the minimum safety and efficacy standards as
166 ASF MLV first generation vaccines, and ideally provide additional product profile benefits, including but not limited to: i)
167 contain a negative marker allowing the differentiation of infected from vaccinated animals (DIVA) by reliable discriminatory
168 tests such as serology-based tests; and ii) confer cross protection against circulating related strains and some broad range
169 of protection against other p72 genotype field strains of varying virulence (low, moderate, and high).

170 The majority of ASF global vaccine research groups and companies are currently focused on ASF MLV first generation
171 vaccine candidates that are safe and efficacious against ASF viruses belonging to the ASFV p72 genotype II pandemic strain
172 (ASFV Georgia 2007/1 lineage) (NCBI, 2020). More research is needed to determine whether these genotype II-specific
173 MLVs can effectively protect against newly circulating variants of genotype II and recombinant strains.

174 Currently, two recombinant gene deleted MLV recombinant vaccines (ASFV-G-ΔI177L and ASFV-G-ΔMGF) have been
175 licensed/received regulatory approval for field use in Vietnam for use in domestic pigs following supervised field testing to
176 evaluate the safety and effectiveness of several vaccine batches.

177 There are numerous, promising ASF MLV vaccine candidates targeting the p72 genotype II pandemic strain under
178 development, including:

179 • A naturally attenuated field strain (Lv17/WB/Rei1) (Barasona *et al.*, 2019) being developed as an oral bait vaccine for
180 wild boars;

181 • A laboratory thermo-attenuated field strain (ASFV-989) (Bourry *et al.*, 2022);

182 • Single gene-deleted, recombinant viruses (e.g. SY18ΔI226R, ASFV-G-ΔA137R) (Gladue *et al.*, 2021; Zhang *et al.*,
183 2021);

184 • Double gene-deleted, recombinant viruses (e.g. ASFV-G-Δ9GL/ΔUK; ASFV-SY18-ΔCD2v/UK; Arm-ΔCD2v-ΔA238L)
185 (O'Donnell *et al.*, 2016; Pérez-Núñez *et al.*, 2022; Teklue *et al.*, 2020);

186 • Multiple gene-deleted, recombinant viruses (ASFV-G-ΔI177L/ΔLVR; ASFV-G-ΔMGF; BA71ΔCD2; HLJ/18-7GD;
187 ASFVGΔI177LΔCD2vΔMGF, Arm07ΔMGF) (Borca *et al.*, 2021; Chen *et al.*, 2020; Kitamura *et al.*, 2023; Liu *et al.*,
188 2023; Monteagudo *et al.*, 2017; O'Donnell *et al.*, 2015).

189 Information regarding many of these MLV vaccine candidates can be found in a recent review publication (Brake, 2022).

190 Different DIVA strategies using serological methods (e.g. ELISA) or genome detection methods (e.g. differential real-time
191 PCR) have been published for some of the are not widely available for these ASF MLV first generation vaccine candidates
192 (Borca *et al.*, 2024; Velazquez-Salinas *et al.*, 2021). Therefore However, there is still room for improvement with respect to
193 marker vaccines and their companion diagnostic tests. The field use of genetically modified ASFV strains with marker genes
194 should be compliant with the Cartagena Protocol's regulations for conserving biodiversity as set out in Chapter 1.1.8
195 Principles of Veterinary Vaccine Production, Section 7.2.3.2 Additional requirements for live rDNA products.

196 Inactivated (non-replicating) whole virus vaccines are not presently available and may be difficult to develop to meet minimum
197 efficacy standards. Recombinant vectored, subunit vaccine candidates that can be produced in scalable vaccine platform
198 expression systems and mRNA-based ASF vaccines are being evaluated in ongoing laboratory research, testing and
199 evaluation in experimental challenge models. The publicly available *Center of Excellence for African Swine Fever Genomics*
200 (ASFV Genomics, 2022¹) that provides the structural protein predictions for all 193 ASFV proteins may help accelerate ASF
201 first and second generation vaccine research and development.

202 Any future use of vaccine candidates should be based on a thorough risk–benefit assessment considering all safety and
203 efficacy features, as well as the potential vaccination scenario. Fit-for-purpose vaccine use scenarios matched to the
204 intended use in a domestic pig-specific type of production system may require different vaccine product profiles or may
205 influence the focus of essential versus ideal vaccine requirements. Prudent use of ASF MLVs as part of strict, controlled
206 vaccination programmes, especially in the areas where ASF is not prevalent, should be implemented. **Transmission of**
207 **vaccine virus to non-vaccinates (domestic or wildlife) could be particularly problematic in areas where ASF is not known to**
208 **be present.**

209 It is important to know what genotypes of ASFV are circulating in a population before vaccination is introduced. Due to the
210 potential risk of recombination events between circulating low and high virulent field strains with future ~~licensed~~ vaccine
211 strains **with regulatory approval**, and the possibility of reversion to virulence of vaccine strains, strict pharmacovigilance post-
212 vaccination **using stringent reporting criteria (e.g. any fever is reportable – in contrast to the safety testing criteria below of 2**
213 **days of fever)** is essential. Field pharmacovigilance data should be collected and analysed during vaccination campaigns
214 using ASF MLV first generation vaccines post-~~licensing~~ **regulatory approval**. Active post-vaccination surveillance
215 programmes for the detection of new ASF viruses that may arise from MLV vaccine strains and naturally circulating wild-
216 type virus recombination, as well as revertant vaccine strains, should be implemented. It is also recommended that vaccine
217 manufacturers carry out laboratory experiments to further evaluate the risk of vaccine virus recombination with field and
218 vaccine strains.

219 As with any MLV vaccine, all ASF MLV vaccines should be used according to the label instructions, under the strict control
220 of the country's Regulatory Authority.

221 The minimum standards given here and in chapter 1.1.8 are intended to be general in nature and may be supplemented by
222 national, regional, and veterinary international medicinal product harmonised requirements. Minimum data requirements for
223 ~~an authorisation~~ **regulatory approval** in exceptional circumstances (e.g. unexpected introduction of the virus, sudden
224 outbreaks of the disease) should be considered where applicable.

225 **2. Outline of production and minimum requirements for vaccines**

226 **2.1. Characteristics of the seed virus**

227 **2.1.1. Biological characteristics of the master seed virus**

228 ASF MLVs are generally produced from ASFV field strains derived from naturally attenuated field isolates
229 or using DNA homologous (genetically targeted) recombination techniques in cell cultures to delete one or
230 more ASFV genes or gene families. These molecular techniques typically involve replacement of the
231 targeted ASFV gene(s) with one or more positive, marker fluorescent (e.g. BFP, eGFP, mCherry) or
232 enzyme-based (e.g. β -glucuronidase) ASFV promoter-reporter gene systems that allow the use of imaging
233 microscopy or flow cytometry to visualise, select, and clone gene-deleted, recombinant, ASF MLVs. MLV
234 production is carried out in cell cultures based on a seed-lot system.

235 Master seed viruses (MSVs) for MLVs should be selected and produced based on their ease of growth in
236 cell culture, virus yield (\log_{10} infectious titre) and genetic stability over multiple cell passages. Preferably,
237 a continuous well-characterised cell line (e.g. ZMAC-4; PIPEC; IPKM) (Borca *et al.*, 2021; Masujin *et al.*,
238 2021; Portugal *et al.*, 2020) is used to produce a master cell bank (MCB) on which the MSV and MSV-
239 derived working seed virus (WSV) can be produced. The exact source of the underlying ASFV isolate, the
240 whole genome sequence, and the passage history must be recorded.

¹ <http://asfvgenomics.com>, Accessed 4/4/2023.

241
242
243
244
245
246
247
248
249

2.1.2. Quality criteria (sterility, purity, freedom from extraneous agents)

Only MSVs that have been established as sterile, pure (free of wild-type parental virus and free of extraneous agents as described in Chapter 1.1.9 *Tests for sterility and freedom from contamination of biological materials intended for veterinary use*, and those listed by the appropriate **licensing regulatory approval** authorities) and immunogenic, should be used as the vaccine virus (WSV and vaccine batch production). Live vaccines must be shown not to cause disease or other adverse effects in target animals in accordance with chapter 1.1.8, Section 7.1 *Safety tests (for live attenuated MSVs)*, that includes target animal safety tests, increase in virulence tests, assessing the risk to the environment) and if possible, no transmission to other animals.

250
251

Identity of the MSV must be confirmed using appropriate methods (e.g. through the use of vaccine strain-specific whole genome detection methods such as next generation sequencing).

252
253
254
255
256
257
258
259
260
261
262
263
264

Demonstration of MSV stability over several cell passages is necessary, typically through at least five passages (e.g. MSV+5). For those MLV vaccines for which attenuation is linked to specific characteristics (gene deletion, gene mutations, etc.), genetic stability of attenuation throughout the production process should be confirmed by full genome sequencing and confirmation of the vaccine phenotype, for example, by confirming the virus titre obtained by growth in the cell line used for production using suitable methods. Suitable techniques to demonstrate genetic stability may include but are not limited to: genome sequencing, biochemical, proteomic, genotypic (e.g. detection of genetic markers) and phenotypic strain characterisation. If final product yields (infectious titres) are relatively low, as is typically the case with ASFV, demonstration of stability is required for the maximum passage for use in the final product manufacturing as defined by the producer. Genetic stability at a minimum of MSV+10 should be demonstrated to allow more flexibility in the outline of production. For example, if MSV+8 is the maximum passage for use in final product manufacturing, demonstration of genetic stability to at least MSV+10 is warranted.

265

2.1.3. Validation as a vaccine strain

266
267
268
269
270

The vaccine derived from the MSV must be shown to be satisfactory with respect to safety and efficacy. Live vaccines must be shown to not cause disease or other adverse effects in target animals in accordance with chapter 1.1.8, Section 7.1 *Safety tests (for live attenuated MSVs)*, that includes target animal safety tests, increase in virulence tests, assessing the risk to the environment) and if possible, no transmission to other animals.

271
272
273
274

Even if pigs are not known for susceptibility to transmissible spongiform encephalopathy (TSE) agents, consideration should also be given to minimising the risk of TSE transmission by ensuring that animal origin materials from TSE-relevant species, if no alternatives exist for vaccine virus propagation, comply with the measures on minimising the risk of transmission of TSE.

275
276

Ideally, the vaccine virus in the final product should generally not differ by more than five passages from the master seed lot.

277

ASF vaccines should be presented in a suitable pharmaceutical form (e.g. lyophilisate or liquid form).

278

2.2. Method of manufacture

279

2.2.1. Procedure

280
281
282
283
284
285
286
287
288
289

The MLV virus is used to infect swine primary cell cultures obtained from specific-pathogen free pigs, the requirements for which are defined in specific monographs (Chapter 2.3.3 *Minimum requirements for the organisation and management of a vaccine manufacturing facility*, Section 2.4.2). It should be noted that each donor pig should be considered a different "master cell stock" and be tested for purity and extraneous agents to account for the risk of contamination during cell collection and processing. Similar considerations should apply to collections over time, and the herd health of the donor pigs should be closely monitored. Compared with primary cell cultures, use of a continuous cell line generally allows for more consistency, higher serial volumes in manufacturing and aligns better with a seed lot system. Thus, preferably a master cell bank based on an established, continuous cell line shown to support genetically stable ASFV replication and acceptable titres over several passages should be used.

290
291
292
293

Cell cultures shall comply with the requirements for cell cultures for production of veterinary vaccines in chapter 1.1.8. Regardless of the production method, the substrate should be harvested under aseptic conditions and may be subjected to appropriate methods to release cell-associated virus (e.g. freeze-thaw cycles, detergent lysis). The harvest can be further processed by filtration and other purification methods.

294 A stabiliser or other excipients may be added as appropriate. The vaccine is homogenised to ensure a
295 uniform batch/serial.

296 **2.2.2. Requirements for ingredients**

297 All ingredients used for vaccine production should be in line with requirements in chapter 1.1.8.

298 **2.2.3. In-process controls**

299 In-process controls will depend on the protocol of production: they include virus titration of bulk antigen
300 and sterility tests. Biosafety precautions should align with the outcomes of a biosafety risk assessment
301 and conform to local and national guidelines.

302 **2.2.4. Final product batch tests**

303 **i) Sterility**

304 Tests for sterility and freedom from contamination of biological materials intended for veterinary use
305 may be found in chapter 1.1.9.

306 **ii) Identity**

307 Appropriate methods such as specific genome detection methods (e.g. specific differential real-time
308 PCR and/or full genome sequencing) should be used for confirmation of the identity of the vaccine
309 virus and differentiation from the parent strain of the virus as a potential contaminant.

310 **iii) Purity**

311 Appropriate methods should be used to ensure that the final product batch does not contain any
312 residual wild-type ASFV.

313 **iv) Safety**

314 Batch safety testing is to be carried out unless consistent safety of the product is demonstrated and
315 approved in the registration dossier and the production process is approved for consistency in
316 accordance with the standard requirements referred to in chapter 1.1.8.

317 **v) Batch/serial potency**

318 Virus titration is a reliable indicator of vaccine potency once a relationship has been established
319 between the vaccine minimum immunising dose (MID) (minimum protective dose) and titre of the
320 modified live vaccine in vitro. In the absence of a demonstrated correlation between the virus titre
321 and protection, an efficacy test will be necessary (Section C.2.3.3 Efficacy requirements, below).

322 **vi) Residual humidity/residual moisture**

323 The test should be carried out consistent with VICH² GL26 (*Biologicals: Testing of Residual Moisture,*
324 2003³). Required for MLV vaccines presented as lyophilisates for suspension for injection.

325 **2.3. Requirements for authorisation/registration/licensing regulatory approval**

326 **2.3.1. Manufacturing process**

327 For regulatory approval of a vaccine, All relevant details concerning history of the pre-MSV, preparation of
328 MSV, manufacture of the vaccine and quality control testing (Sections C.2.1 *Characteristics of the seed*
329 and C.2.2 *Method of manufacture*) should be submitted to the regulatory approval authorities.

330 Information shall be provided from preferably three or more preferably consecutive vaccine batches
331 originating from the same MSV and representative of routine production, with a volume not less than 1/10,
332 and more preferably with a volume not less than 1/3 of the typical industrial batch volume. The in-process
333 controls are part of the manufacturing process.

² VICH: International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medical Products

³ https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl26-biologicals-testing-residual-moisture-step-7_en.pdf

334 Genetic stability of attenuation throughout the production process (i.e. to the maximum passage level to
335 be used for vaccine production) should be confirmed by full genome sequencing and confirmation of virus
336 phenotype (e.g. virus yield in cell line used for production).

337 **2.3.2. Safety requirements**

338 For the purpose of gaining regulatory approval, the following safety tests should be performed
339 satisfactorily.

340 As a minimum standard, vaccines should be tested for any pathogenic effects on healthy domestic pigs of
341 the target age intended for use. In addition, due to risks from horizontal spread of the vaccine virus, vaccine
342 safety testing should be carried out in pregnant sows as the population that is likely to be the most sensitive
343 indicator of any adverse effects. Additional demonstration of MLV safety in pigs at different growth stages,
344 including breeding-age boars and gilts in breeding-age gilts and pregnant sows is preferred but not required
345 as a minimum standard. When the vaccine is recommended for use or may be used if in the future a
346 vaccine intended for use in breeding animals is developed, an evaluation of the impact of the vaccine on
347 reproductive performance will be a standard safety requirement.

348 **i) Safety in young animals**

349 Carry out the test by each recommended route of administration using, in each case, piglets a
350 minimum of 6-4-weeks old and not older than 10-weeks old.

351 The test is conducted using no fewer than eight healthy piglets, and preferably no fewer than ten
352 healthy piglets.

353 To obtain individual mean baseline temperatures, the body temperature of each piglet should be
354 measured on at least the 3 consecutive days preceding administration of the vaccine. Use vaccine
355 virus at the least attenuated passage level that will be present in a batch of the vaccine.

356 Administer to each piglet a quantity of the vaccine virus equivalent to not less than ten times the
357 maximum virus titre (e.g. 50% haemadsorption dose [HAD₅₀], 50% tissue culture infective dose
358 [TCID₅₀], quantitative PCR, etc.) (maximum release dose) likely to be contained in one dose of the
359 vaccine.

360 To obtain individual and group mean baseline temperatures, the body temperature of each
361 vaccinated piglet is measured on at least the 3 consecutive days preceding administration of the
362 vaccine.

363 To confirm the presence or absence of fever accompanied by acute and chronic disease, observe
364 measure body temperature and clinical signs in the piglets 4 hours after vaccination and then at least
365 once daily for at least 45 days, preferably 60 days post-vaccination. On each day during the
366 observation period the maximum increase in body temperature above the baseline observed for each
367 pig will be recorded. Carry out the daily observations for signs of acute and chronic disease using a
368 quantitative clinical scoring system adding the values for multiple clinical signs (e.g. Gallardo *et al.*,
369 2015a). These clinical signs should include fever, anorexia, recumbency, skin haemorrhage or
370 cyanosis, joint swelling and necrotic lesions around the joints, respiratory distress and digestive
371 findings).

372 At a minimum of 45 days post-vaccination, humanely euthanise all vaccinated piglets. Conduct gross
373 pathology on spleen, lung, tonsil, and kidney tissue samples and at least three different lymph nodes
374 (which should include lymph node closest to site of inoculation, gastrohepatic and submandibular
375 nodes).

376 The vaccine is compliant-complies with the test if:

377

- No piglet shows abnormal (local or systemic) reactions or notable signs of disease, or reaches
378 the pre-determined humane endpoint defined in the clinical scoring system or dies from causes
379 attributable to the vaccine;

380

- The average body temperature increase for all vaccinated piglets (group mean) for the
381 observation period does not exceed 1.5°C above baseline; and no individual piglet shows a
382 temperature rise above baseline greater than 2.5°C for a period exceeding 3 days.

383 • On each day during the observation period, the maximum increase in body temperature above
384 the baseline observed for each pig will be used to calculate the daily group mean temperature
385 rise. This mean value should not exceed 1.5°C and No individual pig should show a rise in
386 temperature above baseline greater than 1.5°C for a period exceeding 3-2 consecutive days
387 that is attributable to ASFV infection. In cases where pigs exceed the temperature standard but
388 show no behavioural changes or other clinical signs, regulators may determine vaccine safety
389 without solely relying on temperature for non-compliance.

390 • No vaccinated pigs show notable signs of disease by gross pathology.

391 **ii) Safety test in pregnant sows and test for transplacental transmission**

392 There is limited currently an absence of published information on ASFV pathogenesis in breeding
393 age gilts and in pregnant sows associated with ASFV transplacental infection and fetus
394 abortion/stillbirth. If a label claim is pursued for use in breeding age gilts and sows, then Due to risks
395 from horizontal spread and contact transmission of the vaccine virus, a safety study in line with VICH
396 GL44 (Guidelines on Target Animal Safety for Veterinary Live and Inactivated Vaccines, Section 2.2.
397 Reproductive Safety Test, 2009⁴) should be completed.

398 Carry out the test with vaccination by a recommended route using no fewer than eight healthy sows
399 of similar age, between the 55th and 70th day of gestation, that do not have antibodies against ASFV
400 and blood samples are negative on PCR. Use vaccine virus at the least attenuated passage level
401 that will be present in a batch of the vaccine.

402 Administer to each sow a quantity of the vaccine virus equivalent to not less than the maximum virus
403 titre likely to be contained in 1 dose of the vaccine. Clinical observation of animals is carried out daily
404 until farrowing. Blood samples should be taken from newborn piglets before ingestion of colostrum.

405 The test is invalid if the vaccinated sows do not seroconvert before farrowing.

406 The vaccine is compliant if:

- 407 • No pregnant sows show abnormalities in their gestation or in their piglets;
- 408 • No pregnant sows show notable signs of disease or dies from causes attributable to the vaccine;
- 409 • No vaccine virus or antibodies against ASFV are present in blood samples from newborn piglets.

410 **iii) Horizontal transmission**

411 The test is conducted using no fewer than 12 healthy piglets; a minimum of 6-4-weeks old and not
412 older than 10-weeks old, and of the same origin, that Piglets do not have antibodies against ASFV,
413 and blood samples are negative on real-time PCR. All piglets are housed together from day 0 and
414 the number of vaccinated animals is the same as the number of naïve, contact animals.

415 Co-mingle the piglets in the same pen or room so that equal numbers (at least six) can be of
416 vaccinated and the same number can remain unvaccinated (naïve contact piglets) and naïve, contact
417 piglets from day 0 in the same pen or room.

418 To obtain individual mean baseline temperatures, the body temperature of each naïve contact piglet
419 should be measured on at least the 3 consecutive days preceding administration of the vaccine. Use
420 vaccine virus at the least attenuated passage level that will be present between the master seed lot
421 and a batch of the vaccine. Administer by each the recommended route of administration to no fewer
422 than six piglets a quantity of the vaccine virus equivalent to not less than the maximum virus titre
423 (maximum release dose) likely to be contained in 1 dose of the vaccine.

424 To obtain individual and group mean baseline temperatures, the body temperature of each naïve,
425 contact piglet is measured on at least the 3 consecutive days preceding co-mingling with vaccinated
426 piglets. The body temperature of each naïve, contact piglet is then measured daily for at least 45
427 days, preferably 60 days. To confirm the presence or absence of fever accompanied by disease,
428 observe the naïve, contact piglets daily for at least 45 days, preferably 60 days. On each day during
429 the observation period the maximum increase in body temperature above the baseline observed for

⁴ https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl44-target-animal-safety-veterinary-live-inactivated-vaccines-step-7_en.pdf

430 each pig will be recorded, used to calculate the daily group mean temperature rise. This mean value
431 should not exceed 1.5°C and no individual pig should show a rise in temperature above baseline
432 greater than 1.5°C for a period exceeding 3 consecutive days. Carry out the daily observations for
433 signs of acute and chronic clinical disease using a quantitative clinical scoring system adding the
434 values for multiple clinical signs (e.g. Gallardo *et al.*, 2015a). These clinical signs should include
435 fever, anorexia, recumbency, skin haemorrhage or cyanosis, joint swelling and necrotic lesions
436 around the joints, respiratory distress and digestive findings.

437 In addition, Blood should be taken from the naïve contact piglets at least twice a week for the first 21
438 days post-vaccination and then on a weekly basis. From the blood samples, determine vaccine virus
439 titres by quantitative virus isolation (HAD₅₀/ml, TCID₅₀/ml or other methods, e.g. titration using IPT or
440 FAT detection). Real-time PCR may be used to detect positive samples, but results should be
441 confirmed by infectious virus titration as described above infectious virus titres by quantitative virus
442 isolation (e.g. HAD₅₀/ml or TCID₅₀/ml) and using a real-time PCR test.

443 If the vaccine virus is non-haemadsorbing or does not cause cytopathic effects, a real-time PCR test
444 only may be used.

445 Collect blood (serum) samples from the naïve contact pigs at least at day 21 and day 28 days and
446 carry out an appropriate test to detect vaccine virus induced antibodies.

447 At a minimum of 45 days, humanely euthanise all naïve, contact piglets. Conduct gross pathology on
448 spleen, lung, tonsil, and kidney tissue samples and at least three different lymph nodes. Determine
449 virus titres in all collected samples as described above, by quantitative virus isolation (HAD₅₀/mg or
450 TCID₅₀/mg) or other appropriate methods (e.g. IPT or FAT detection). Quantitative PCR may be used
451 to detect positive samples, but results should be confirmed by infectious virus titration as described
452 above and real-time(RT)-PCR (see Section B.1. Identification of the agent). If the vaccine virus is
453 non-haemadsorbing or does not cause cytopathic effects, a real-time PCR test or other appropriate
454 method (e.g. titration using IPT or FAT detection) may be used.

455 The vaccine complies with the test is compliant if:

- 456 • No vaccinated or naïve contact piglet shows abnormal (local or systemic) reactions or notable
457 signs of disease, reaches the predetermined humane endpoint defined in the clinical scoring
458 system or dies from causes attributable to the vaccine;
- 459 • On each day during the observation period the maximum increase in body temperature above
460 the baseline observed for each pig will be used to calculate the daily group mean temperature
461 rise. This mean value should not exceed 1.5°C and No individual naïve contact pig should
462 shows a rise in temperature above baseline greater than 1.5°C for a period exceeding 3-2
463 consecutive days that is attributable to ASFV infection. In cases where pigs exceed the
464 temperature standard but show no behavioural changes or other clinical signs, regulators may
465 determine vaccine safety without solely relying on temperature for non-compliance.

466 The average body temperature increase for all naïve, contact piglets (group mean) for the observation
467 period does not exceed 1.5°C above baseline; and no individual piglet shows a temperature rise
468 above baseline greater than 2.5°C for a period exceeding 3 days;

- 469 • No naïve, contact piglet shows notable signs of disease by gross pathology and no virus is
470 detected in their blood or tissue samples;
- 471 • No or a low percentage of contact piglets test both real-time PCR positive and seropositive No
472 naïve contact pigs test positive for antibodies to the vaccine virus. No or a low percentage of
473 naïve, contact pigs test positive to the vaccine virus and/or to antibodies against the vaccine
474 virus.

475 **iv) Post-vaccination kinetics – Dissemination of viral replication of the vaccine strain in the**
476 **vaccinated animals (MLV blood and tissue dissemination) study**

477 Prior to the reversion to virulence study (Section C2.3.2.v. below), a minimum of one study should be
478 performed to determine the dissemination of the vaccine strain the post-vaccination kinetics of virus
479 replication in the blood (viremia), tissues and viral shedding.

480 The test consists of the administration of the vaccine virus from the master seed lot to no fewer than
481 eight healthy piglets, and preferably ten healthy piglets-pigs. Pigs should be a minimum of 6-4-weeks
482 old and not older than 10-weeks. They should test negative for old and of the same origin, that do
483 not have antibodies against ASFV, and blood samples are negative on real-time by PCR.

484 Administer to each piglet, using the recommended route of administration most likely to result in
485 spread (such as the intramuscular route or intranasal route), a quantity of the master seed vaccine
486 virus equivalent to not less than the maximum virus titre (maximum release dose) likely to be
487 contained in 1 dose of the final product of the vaccine.

488 Record daily body temperatures and observe inoculated animals daily for clinical disease for at least
489 45 days, preferably 60 days.

490 Carry out the daily observations for signs of acute and chronic clinical disease using a quantitative
491 clinical scoring system adding the values for multiple clinical signs (e.g. Gallardo *et al.* (2015a). These
492 clinical signs should include fever, anorexia, recumbency, skin haemorrhage or cyanosis, joint
493 swelling and necrotic lesions around the joints, respiratory distress and digestive findings.

494 Collect blood samples from all the piglets at least two times per week from 3 days post-vaccination
495 for the first 2 weeks, then weekly for the duration of the test. Determine vaccine virus titres **in the**
496 **samples** by quantitative virus isolation (HAD₅₀/ml or TCID₅₀/ml) or other appropriate methods (e.g.
497 titration using IPT or FAT detection). Real-time PCR may be used to detect positive samples but
498 results should be confirmed by infectious virus titration as described above and using a real-time
499 PCR test. If the vaccine virus is non-haemadsorbing or does not cause cytopathic effects, a real-time
500 PCR test only may be used.

501 Determine which blood timepoint(s) should be used in the design of the reversion to virulence study
502 (Section C2.3.2.v. below), for example, specific blood sample(s) at specific timepoints that show the
503 highest titres should be considered for selection and use in the reversion to virulence study.

504 Collect oral, nasal and faecal swab samples (preferably devoid of blood to minimise assay
505 interference) at least two times per week from 3-days post-vaccination for the first 2 weeks, then
506 weekly for the duration of the test. **Test the swabs for the presence of vaccine virus.** Determine virus
507 titres in all collected samples by quantitative virus isolation (HAD₅₀/ml or TCID₅₀/ml) or other
508 appropriate methods (e.g. titration using IPT or FAT detection). Quantitative PCR may be used to
509 detect positive samples, but results should be confirmed by infectious virus titration as described
510 above and using a real-time PCR test. If the vaccine virus is non-haemadsorbing or does not cause
511 cytopathic effects, a real-time PCR test or other appropriate method (e.g. titration using IPT or FAT
512 detection) may be used.

513 Euthanise at least two piglets on days 5, 7, 14, 21, and preferably on day 28 (±2 days at each
514 timepoint) and collect spleen, lung, tonsil, kidney tissue samples and at least three different lymph
515 nodes (which should include lymph node closest to site of inoculation, gastrohepatic and
516 submandibular nodes). Determine virus titres in all collected samples by quantitative virus isolation
517 (HAD₅₀/mg or TCID₅₀/mg) or other appropriate methods (e.g. titration using IPT or FAT detection).
518 Quantitative PCR may be used to detect positive samples, but results should be confirmed by
519 infectious virus titration as described above and using real-time PCR test. If the vaccine virus is non-
520 haemadsorbing or does not cause cytopathic effects, a real-time PCR test or other appropriate
521 method (e.g. titration using IPT or FAT detection) may be used.

522 Determine which tissue(s) and timepoint(s) should be used to aid in the design of the reversion to
523 virulence study (Section C.2.3.2.v), for example, specific tissues at specific timepoints which show
524 the highest titres should be considered for selection and use in the reversion to virulence study.

525 **v) Reversion to virulence**

526 The test carried out should be consistent with VICH GL41 (Examination of live veterinary vaccines in
527 target animals for absence of reversion to virulence, 2008⁵).

528 The test for increase in virulence consists of the administration of the vaccine master seed virus to
529 healthy piglets of an age (e.g. between 6-4 weeks and 10 weeks old) suitable for recovery of the
530 strain, and of the same origin, that do not have **Piglets should test negative for antibodies against**
531 **ASFV, and blood samples that are negative on real-time by PCR.** This protocol is typically repeated
532 five times.

⁵ https://www.ema.europa.eu/en/documents/scientific-guideline/vich-gl41-target-animal-safety-examination-live-veterinary-vaccines-target-animals-absence-reversion_en.pdf

533 To obtain individual mean baseline temperatures, the body temperature of each piglet should be
534 measured on at least the 3 consecutive days preceding administration of the vaccine or passaged
535 material.

536 First passage (p1)

537 Administer to no fewer than two piglets, and preferably no fewer than four piglets using the intended
538 route of administration for the final product, a quantity of the master seed vaccine virus equivalent to
539 not less than the maximum virus titre (maximum release dose) likely to be contained in 1 dose of the
540 final product of the vaccine. Observe inoculated animals daily for the appearance of at least two and
541 preferably at least three clinical signs and record daily body temperatures using a quantitative clinical
542 scoring system adding the values for multiple clinical signs (e.g. Gallardo *et al.*, 2015a) and record
543 daily body temperatures.

544 Based on results from at least one completed post-vaccination kinetics of viral replication (MLV
545 vaccine shed and spread (virus blood and tissue dissemination study (Section C.2.3.2.iv above),
546 collect an appropriate quantity of blood from each piglet on the predetermined single timepoint(s) (i.e.
547 day 5–3–13). Determine virus titres in individual blood-samples by quantitative virus isolation
548 (HAD₅₀/ml or TCID₅₀/ml) or other appropriate methods (e.g. titration using IPT or FAT detection).
549 Real-time PCR may be used to detect positive samples, but results should be confirmed by infectious
550 virus titration as described above and by real-time PCR. If the vaccine virus is non-haemadsorbing
551 or does not cause cytopathic effects, a real-time PCR test or other appropriate method (e.g. titration
552 using IPT or FAT detection) may be used. Identify the individual blood sample(s) with the highest
553 infectious titre and reserve for the subsequent *in-vivo* passage (second pass, p2). If appropriate,
554 blood samples with the highest infectious titres from different pigs should be pooled to prepare
555 inoculum for further passages.

556 Based on results from at least one completed vaccine virus MLV blood and tissue distribution
557 dissemination study (Section C.2.3.2.iv above), euthanise piglets on the predetermined timepoint (i.e.
558 day 5, 7, 14, 21, or 28). Determine infectious virus titres in individual tissue samples by quantitative
559 virus isolation (HAD₅₀/ml or TCID₅₀/ml) or other appropriate methods (e.g. titration using IPT or FAT
560 detection). Quantitative PCR may be used to detect positive samples, but results should be confirmed
561 by infectious virus titration as described above. If the vaccine virus is non-haemadsorbing or does
562 not cause cytopathic effects, a real-time PCR test or other appropriate method (e.g. titration using
563 IPT or FAT detection) may be used. Identify individual tissue-sample type(s) with the highest
564 infectious titre. Pool the Use tissues with the highest titres from different organs from all each animals
565 with the highest titres and prepare at least a 10% virus suspension to obtain a virus titre within the
566 range used for inoculation in PBS, pH 7.2 kept at 4°C or at -70°C for longer storage. Identify the
567 individual tissue samples with the highest infectious titres from each animal and reserve for
568 subsequent *in-vivo* passage (second pass, p2). If appropriate, tissue samples with the highest
569 infectious titres from different pigs should be pooled to prepare inoculum for further passages.

570 Test each blood and tissue sample pool used for inoculation by PCR to confirm the absence of
571 potential viral agent contaminants (i.e. CSFV, FMDV, PRRSV, PCV2). Blood and pooled tissue (p1)
572 are used to inoculate 2 ml of positive material diluted to the maximum release dose likely to be
573 contained in 1 dose of the vaccine using the intended route of administration for the final product to
574 each of at least two and ideally at least four further pigs of the same age and origin.

575 Second pass (p2)

576 If no virus is found at passage 1 (p1), repeat the administration by the intended route once again with
577 the same master seed vaccine virus used in p1 (see above) pooled material (blood and pooled tissue,
578 p1) in another ten healthy piglets of the same age and origin. If no virus is found at this point during
579 this second passage (p2) at this point, end the process here.

580 Second passage (p2)

581 If however virus is found in at p1, carry out a second series of passages by administering an
582 appropriate volume (e.g. 2 ml) of positive material from p1 diluted to the maximum release dose likely
583 to be contained in 1 dose of the vaccine using the intended route of administration for the final product
584 to each of no fewer than two piglets, and preferably no fewer than four piglets of the same age and
585 origin. Observe inoculated animals daily for the appearance of at least two and preferably at least
586 three clinical signs using a quantitative clinical scoring system adding the values for multiple clinical
587 signs (e.g. Gallardo *et al.*, 2015a), and record daily body temperatures, collect blood and tissue
588 samples at the predetermined time points in the blood and tissue dissemination study (above) and
589 determine infectious virus titres in individual blood and tissue samples as described for p1 above.

590 *Third and fourth pass (p3 and p4)*
591 If no virus is found at in (p2), repeat the intramuscular administration by the intended route once again
592 with the same pooled material (blood and/or pooled tissue) from p2-1) in another eight healthy piglets
593 of the same age and origin. If no virus is found at this point, end the process here.

594 *Third and fourth passage (p3 and p4)*

595 If, however, virus is found on p2, carry out further this passages operation no fewer than two
596 additional times (p3 and p4) (to each of no fewer than two piglets, and preferably no fewer than four
597 piglets of the same age and origin). Record clinical signs and body temperature daily, collect blood
598 and tissue samples at the predetermined time points (see above) and determine infectious virus titres
599 verifying the presence of the virus at each passage in individual blood and tissue samples as
600 described for p1 above. Observe inoculated animals daily for the appearance of at least two and
601 preferably at least three clinical signs using a quantitative clinical scoring system adding the values
602 for multiple clinical signs (e.g. Gallardo et al., 2015a) and record daily body temperatures.

603 *Fifth passage (p5)*

604 Administer an appropriate volume (e.g. 2 ml) of the blood and pooled tissue (p4) to each of at least
605 eight healthy piglets of the same age and origin. Observe inoculated animals daily for at least 28 days
606 post-inoculation for the appearance of at least two and preferably at least three clinical signs using a
607 quantitative clinical scoring system adding the values for multiple clinical signs (e.g. Gallardo et al.,
608 2015a), and record daily body temperature and determine infectious virus titres in individual blood
609 and tissue samples as described above.

610 If the fifth group of animals shows no evidence of an increase in virulence indicative of reversion to
611 virulence during the observation period, further testing is not required. Otherwise, materials used for
612 the first passage and the final passage should be used in a separate experiment using at least 8
613 animals per group to directly compare the clinical signs and other relevant parameters. This study
614 should be done by the route of administration that was used for previous passages.

615 The vaccine is compliant-complies with the test if:

- 616 • No piglet shows abnormal (local or systemic) reactions, or notable signs of disease, or reaches
617 the pre-determined humane endpoint defined in the clinical scoring system or dies from causes
618 attributable to the vaccine; and
- 619 • There is no indication of increasing virulence (as monitored by daily body temperature increases
620 above the baseline accompanied by clinical sign observations) of the maximally passaged virus
621 compared with the master seed virus.

622 At a minimum, a safe MLV vaccine shall demonstrate ALL the following features (minimal standards):

- 623 • Absence of fever (on each day during the observation period, the maximum increase in body
624 temperature above the baseline observed for each pig will be used to will be recorded calculate
625 the daily group mean temperature rise. This mean value should not exceed 1.5°C and no
626 individual pig should show a rise in temperature above baseline greater than 1.5°C (defined as
627 average body temperature increase for all vaccinated piglets (group mean) for the observation
628 period does not exceed 1.5°C above baseline; and no individual piglet shows a temperature rise
629 above baseline greater than 2.5°C for a period exceeding 3-2 days that is attributable to ASFV
630 infection). In cases where pigs exceed the temperature standard but show no behavioural
631 changes or other clinical signs, regulators may determine vaccine safety without solely relying
632 on temperature for non-compliance.
- 633 • Absence of chronic and acute clinical signs and gross pathology over the entire test period or
634 minimal chronic mild clinical signs (defined as e.g. mild swollen joints with a low clinical score
635 that resolve within 1 week);
- 636 • Absence of abnormal (local or systemic) reactions;
- 637 • Minimal (defined as no naïve, contact piglet shows notable signs of disease by clinical signs and
638 gross pathology and no or a low percentage of contact piglets test both real-time PCR positive
639 and seropositive) or no vaccine virus transmission (defined as no naïve, contact piglet shows
640 notable signs of disease by clinical signs and gross pathology and no contact piglets test both
641 real-time PCR positive and seropositive) over the entire test period No or a low percentage of
642 naïve, contact pigs test positive to the vaccine virus and/or to antibodies against the vaccine
643 virus;

644 • Absence of an increase in virulence (genetic and phenotypic stability) (complies with the
645 reversion to virulence test).

646 In addition, for regulatory approval, ASF MLV the vaccines in their commercial presentation before
647 being authorised for general use should be tested for safety in the under field conditions (see chapter
648 1.1.8 Section 7.2.3). Additional Field safety studies generally evaluation studies may include
649 measurement of body temperatures, observation of local or systemic reactions and, where
650 appropriate, performance measurements such as but are not limited to: environmental persistence
651 (e.g. determination of virus recovery from bedding or other surfaces), assessment of
652 immunosuppression, and negative impacts on performance.

653 **2.3.3. Efficacy requirements**

654 **i) Protective dose**

655 Vaccine efficacy is estimated in immunised animals directly, by evaluating protection against their
656 resistance to live virus challenge. The test consists of a vaccination/challenge trial in piglets a
657 minimum of 6-4-weeks old and not more than 10-weeks old, free of antibodies to ASFV, and negative
658 blood samples by real-time PCR. The test is conducted using no fewer than 15 and preferably no
659 fewer than 24 vaccinated pigs, and no fewer than five non-vaccinated control piglets.

660 The test is conducted to determine the minimal immunising dose (MID) (also referred to as the
661 minimal protective dose [MPD] or protective fraction); using at least three groups of no fewer than
662 five and preferably not fewer than eight vaccinated piglets per group, and one additional group of no
663 fewer than five non-vaccinated piglets of the same age and origin as controls. Use vaccine containing
664 virus at the highest passage level that will be present in a batch of vaccine. Each group of piglets,
665 except the control group, is immunised with a different vaccine virus content in the same vaccine
666 volume. In at least one vaccinated group, piglets are immunised with a vaccine dose containing not
667 more than the minimum virus titre (minimum release dose) likely to be contained in one dose of the
668 vaccine as stated on the label.

669 The MID of the vaccine is calculated from the number of animals protected in each group using an
670 appropriate statistical test, such as the Spearman-Kärber method.

671 A suitable challenge model should be developed based on anticipated field usage of the vaccine. As
672 a baseline protocol, Twenty-eight 28 days (+2 days) after the single injection dose of vaccine (or if
673 using two injections doses of the vaccine then 28 days [+2 days] following the second injection dose),
674 challenge all the piglets by the intramuscular route. If previous studies have demonstrated acceptable
675 efficacy using IM challenge, then a different challenge route (e.g. direct contact, oral or oronasal)
676 may be used. Challenged, vaccinated piglets may be housed in one or more separate pens in the
677 same room or in different rooms. Challenged, naïve controls can be housed in one or more rooms
678 that are separate from challenged, vaccinated piglets.

679 Carry out the test using an ASFV representative strain of the epidemiologically relevant field strain(s)
680 where the vaccine is intended for use (e.g. ASFV B646L [p72] genotype II pandemic strain and other
681 p72 virulent genotype of recognised epidemiologic importance). For gene deleted, recombinant MLV
682 viruses, if neither challenge virus type is available, then carry out the test with the parental, virulent
683 virus used to generate the MLV recombinant virus. Use a 10e3–10e4 HAD₅₀ (or TCID₅₀ for non-HAD
684 viruses) challenge dose sufficient to cause death or meet the humane endpoint in 100% of the
685 nonvaccinated piglets in less than 21 days. Higher or lower challenge doses can be considered if
686 appropriately justified.

687 To obtain individual mean baseline temperatures, the body rectal temperature of each vaccinated
688 piglet is measured on at least the 3 days preceding administration of the challenge virus. Body
689 temperature is then measured, at the time of challenge, 4 hours after challenge, and then daily for
690 the observation period of at least 28-45 days, preferably 35-60 days. Observe the piglets at least daily
691 for at least 28 days, preferably 35 days. Carry out the daily observations for signs of acute and chronic
692 clinical disease using a quantitative clinical scoring system adding the values for multiple clinical
693 signs (e.g. Gallardo *et al.*, 2015). These clinical signs should include fever, anorexia, recumbency,
694 skin haemorrhage or cyanosis, joint swelling and necrotic lesions around the joints, respiratory
695 distress and digestive findings.

696 Collect oral, nasal, faecal swabs anal and blood samples from the vaccinated challenged piglets at
697 least two times once per week from 3 days post-challenge for at least 28-14 days, then weekly up to
698 35 days post-challenge and then every 14 days up to the end of the observation period preferably 35
699 days. From the blood samples, determine infectious virus titres by quantitative virus isolation
700 (HAD₅₀/ml or TCID₅₀/ml) or other appropriate methods (e.g. titration using IPT or FAT detection).

701 Real-time PCR may be used to detect positive samples, but results should be confirmed by infectious
702 virus titration as described above and using a real-time PCR test. If the vaccine virus is non-
703 haemadsorbing or does not cause cytopathic effects, a real-time PCR test only may be used.

704 At the end of the test period, humanely euthanise all vaccinated challenged piglets. Conduct gross
705 pathology (and histopathology if considered necessary) on spleen, lung, tonsil, and kidney tissue
706 samples and at least three different lymph nodes (which should include lymph node closest to site of
707 inoculation, gastrohepatic and submandibular nodes). Determine virus titres in all collected samples
708 by quantitative virus isolation (HAD₅₀/mg or TCID₅₀/mg) or other appropriate methods (e.g. titration
709 using IPT or FAT detection). Quantitative PCR may be used to detect positive samples, but results
710 should be confirmed by infectious virus titration as described above and real-time PCR (see Section
711 B.1. Identification of the agent). If the vaccine virus is non-haemadsorbing or does not cause
712 cytopathic effects, a real-time PCR test or other appropriate method (e.g. titration using IPT or FAT
713 detection) may be used.

714 If using a highly virulent challenge virus, as described above, the test is invalid if fewer than 100%
715 the difference between in the number of unvaccinated control piglets infected with the live challenge
716 virus and the number of vaccinated / challenged piglets vaccinated with the minimum release dose
717 that die or reach a humane endpoint is not statistically significant.

718 The vaccine (or a specific vaccine virus dose if conducting a vaccine dose titration study) is compliant
719 complies with the test if:

- 720 • No vaccinated challenged piglet dies or shows abnormal (local or systemic) reactions, or
721 reaches the humane endpoint or dies from causes attributable to ASF;
- 722 • On each day during the observation period the maximum increase in body temperature above
723 the baseline observed for each pig will be used to calculate the daily group mean. This mean
724 value should not exceed 1.5°C and no individual pig should show a rise in temperature above
725 baseline greater than 2.0°C for a period exceeding 2 consecutive days. The average body
726 temperature increase for all vaccinated challenged piglets (group mean) for the observation
727 period does not exceed 2.0°C above baseline; and no individual piglet shows a temperature
728 rise above baseline greater than 2.0°C;
- 729 • The vaccinated challenged piglets display a reduction or absence of pyrexia, typical acute
730 clinical signs or other forms of disease and gross pathology, and a reduction or absence of
731 challenge virus levels in blood, swabs and tissues.

732 **ii) Assessment for horizontal transmission (challenge virus shed and spread study)**

733 The ASF basic reproduction number, R₀, can be defined as the average number of secondary ASF
734 disease cases caused by a single ASFV infectious pig during its entire infectious period in a fully
735 susceptible population (Hayes *et al.*, 2021). In general, if the ASFV effective reproduction number
736 Re=R₀ × (S/N) (S= susceptible pigs; N= total number of pigs in a given population) is greater than
737 1.0, disease is predicted to spread. Ideally, ASF vaccination should reduce Re to less than 1.0 by
738 reducing the number of susceptible, naïve, contact pigs exposed to vaccinated, infected pigs.

739 To evaluate ASF vaccine impact on ASF disease transmission, the test consists of a
740 vaccination/challenge trial in piglets a minimum of 6-4 weeks old and not older than 10 weeks old,
741 free of antibodies to ASFV, and negative blood samples by real-time PCR.

742 The test is conducted using no fewer than 15 healthy piglets at a ratio comprising twice the number
743 of vaccinated piglets to naïve piglets (e.g. ten vaccinated and five naïve). Use vaccine containing
744 virus at the highest passage level that will be present in a batch of the vaccine.

745 The quantity of vaccine virus administered to each pig is equivalent to be not less than the minimum
746 virus titre (minimum dose) likely to be contained in one dose of the vaccine as stated on the label.
747 Following immunisation, vaccinated and naïve piglets should continue to be co-mingled.

748 Twenty-eight days (±2 days) after the single injection dose of vaccine (or if using two injections doses
749 of the vaccine then 28 days [±2 days] following the second injection dose), temporarily separate [into
750 different pen(s) or room(s)] all vaccinated piglets from naïve piglets. Challenge all vaccinated piglets
751 by the intramuscular or other previously verified route. Carry out the challenge using an ASFV
752 representative strain of the epidemiologically relevant field strain(s) where the vaccine is intended for
753 use (e.g. ASFV B646L [p72] genotype II pandemic strain and other p72 virulent genotype of
754 recognised epidemiological importance). For gene deleted, recombinant MLV viruses, if neither
755 challenge virus type is available, then carry out the test with the parental, virulent virus used to

756 generate the MLV recombinant virus. Use a 10e3–10e4 HAD₅₀ (or TCID₅₀ for non-HAD viruses
757 challenge dose sufficient to cause death or met the humane endpoint in 100% of the nonvaccinated
758 piglets in less than 21 days. Higher or lower challenge doses can be considered if appropriately
759 justified.

760 Approximately 18–24 hours later, re-introduce naïve piglets to vaccinated, challenged piglets and
761 allow for direct nose to nose contact exposure with vaccinated, challenged piglets. Allow for
762 continuous contact exposure by co-mingling both groups through the end of the study. If more than
763 one pen or room is used for co-housing, following reintroduction initially maintain a ratio of 2:1 of
764 challenged, vaccinated piglets to contact exposed, naïve piglets.

765 The rectal temperature of each contact piglet is measured on at least the 3 days preceding
766 administration of the challenge virus to vaccinated pigs, immediately prior to direct contact exposure,
767 4 hours post-contact exposure, and then daily for at least 28, preferably 35 days and twice a week
768 for at least 60 days. Observe all contact exposed piglets at least daily for at least 28 days, and then
769 twice a week for at least 60 days preferably for at least 35 days.

770 Carry out the daily observations in each contact piglet for signs of acute and chronic clinical disease
771 using a quantitative clinical scoring system adding the values for multiple clinical signs (e.g. Gallarde
772 *et al.*, 2015a). These clinical signs should include fever, anorexia, recumbency, skin haemorrhage or
773 cyanosis, joint swelling and necrotic lesions around the joints, respiratory distress and digestive
774 findings.

775 In addition, blood should be taken from the naïve contact piglets at least twice a week from 3 days
776 post-contact exposure for the duration collect blood samples from the contact piglets at least two
777 times per week from 3 days post-contact for at least 14 days, then weekly up to 35 days post-contact
778 exposure and then every 14 days up to the end of the test period. Determine virus titres in all collected
779 samples by quantitative virus isolation (HAD₅₀/mg or TCID₅₀/mg) or other appropriate methods (e.g.
780 titration using IPT or FAT detection). Quantitative PCR may be used to detect positive samples, but
781 results should be confirmed by infectious virus titration as described above. From the blood samples,
782 determine infectious challenge virus titres by quantitative virus isolation (HAD₅₀/ml or TCID₅₀/ml) and
783 using a real-time PCR test. If the vaccine virus is non-haemadsorbing or does not cause cytopathic
784 effects, a real-time PCR test only may be used.

785 Collect blood (serum) samples from the naïve contact pigs at least at day 21 and day 28 (±2 days),
786 and at the end of the test period, and carry out an appropriate test to detect vaccine virus antibodies.

787 Collect oral, nasal and faecal swab samples (preferably devoid of blood to minimise assay
788 interference) from all contact-exposed naïve piglets at least two times per week from 3-days post-
789 contact exposure for the first 2 weeks, then weekly for the duration of the test and test swabs for the
790 presence of challenge virus. Determine virus titres in all collected samples by quantitative virus
791 isolation (HAD₅₀/mg or TCID₅₀/mg) or other appropriate methods (e.g. titration using IPT or FAT
792 detection). Quantitative PCR may be used to detect positive samples, but results should be confirmed
793 by infectious virus titration as described above. Determine virus titres in all collected samples by
794 quantitative virus isolation (HAD₅₀/ml or TCID₅₀/ml) and using a real-time PCR test. If the vaccine
795 virus is non-haemadsorbing or does not cause cytopathic effects, a real-time PCR test or other
796 appropriate method (e.g. titration using IPT or FAT detection) may be used.

797 At the end of the test period, humanely euthanise all contact piglets. Conduct gross pathology on
798 spleen, lung, tonsil, and kidney tissue samples and at least three different lymph nodes. (which should
799 include lymph node closest to site of inoculation, gastrohepatic and submandibular nodes).
800 Determine virus titres in all collected samples by quantitative virus isolation (HAD₅₀/mg or TCID₅₀/mg)
801 or other appropriate methods (e.g. titration using IPT or FAT detection). Quantitative PCR may be
802 used to detect positive samples, but results should be confirmed by infectious virus titration as
803 described above. Determine virus titres in all collected samples by quantitative virus isolation
804 (HAD₅₀/mg or TCID₅₀/mg) and real-time PCR (see Section B.1. Identification of the agent). If the
805 vaccine virus is non-haemadsorbing or does not cause cytopathic effects, a real-time PCR test or
806 other appropriate method (e.g. titration using IPT or FAT detection) may be used.

807 The test is invalid if the vaccine fails to comply with the compliance criteria described for the protected
808 dose test in vaccinated pigs (Section C.2.3.3.i above).

809 If the manufacturer claims that the vaccine induces sterilising immunity, the vaccine complies with
810 the test for a reduction in horizontal disease transmission if all the following conditions are satisfied:

- 811 • ~~No naïve, contact exposed piglet shows abnormal (local or systemic) reactions, reaches the~~
812 ~~defined humane endpoint or dies from causes attributable to ASF;~~
- 813 • ~~No naïve, contact exposed piglet displays fever accompanied by typical signs of disease,~~
814 ~~including gross pathology.~~
- 815 • ~~Naïve contact pigs show an absence of challenge virus in blood and tissues.~~
- 816 • ~~No naïve contact pigs test positive for antibodies to the challenge virus.~~
- 817 ~~Otherwise, the vaccine complies with the test for a reduction in horizontal disease transmission if:~~
- 818 • ~~Naïve contact pigs show a reduction or absence of challenge virus levels in blood and tissues.~~
- 819 • ~~None of or a reduced number of naïve contact exposed pigs test positive for antibodies to the~~
820 ~~challenge virus.~~

821 At a minimum, an efficacious MLV vaccine shall demonstrate ALL the following features (minimal
822 standards):

- 823 • Protects against mortality:
- 824 • Reduces acute or other forms of disease (fever accompanied by a reduction of typical clinical
825 and pathological signs of acute disease):
- 826 • ~~Reduces levels of viral shedding and viraemia.~~
- 827 • ~~Reduces horizontal disease transmission (no none of or a reduced number of naïve, contact~~
828 ~~exposed piglets shows abnormal [local or systemic] reactions, reaches the humane endpoint or~~
829 ~~dies from causes attributable to ASF, and displays fever accompanied by typical acute disease~~
830 ~~signs caused by ASF) and test positive for antibodies to the challenge virus.~~
- 831 • Reduces levels of viral shedding and viraemia.

832 In general, for regulatory approval, ASF MLV addition, the vaccines in their commercial presentation before
833 being authorised for general use should be tested for efficacy in the under field conditions (see chapter
834 1.1.8 Section 7.2.3). Additional Field efficacy evaluation studies may generally include but are not limited
835 to: onset of immunity, duration of immunity, and impact on disease transmission measurement of relevant
836 efficacy parameters including but limited to mortality, clinical signs, impact on disease transmission,
837 performance parameters.

838 **2.3.4. Duration of immunity**

839 Although not included in the guidance for ASF MLV first generation vaccines, manufacturers are
840 encouraged required, as part of the ~~authorisation-regulatory approval~~ procedure, to define and
841 demonstrate the duration of immunity of a given vaccine by evaluation of potency at the end of the claimed
842 period of protection.

843 **2.3.5. Stability**

844 Stability of the vaccine should be demonstrated over the shelf life recommended for the product. Although
845 not included in the standards for first generation MLV ASF vaccines, manufacturers are ~~encouraged in~~
846 general required, as part of the ~~authorisation-regulatory approval~~ procedure, to generate data supporting
847 the retention of immunogenicity over a defined period of validity-time of a lyophilised or other
848 pharmaceutical form of the ASF vaccine as part of the ~~authorisation-regulatory approval~~ procedure.

849 **REFERENCES**

- 850 ACHENBACH J.E., GALLARDO C., NIETO-PELEGRIN E., RIVERA-ARROYO B., DEGEFA-NEGI T., ARIAS M., JENBERIE S., MULISA D.D.,
851 GIZAW D., GELAYE E., CHIBSSA T.R., BELAYE A., LOITSCH A., FORSA M., YAMI M., DIALLO A., SOLER A., LAMIEN C.E. & SÁNCHEZ-
852 VIZCAÍNO J.M. (2017). Identification of a New Genotype of African Swine Fever Virus in Domestic Pigs from Ethiopia.
853 *Transbound. Emerg. Dis.*, **64**, 1393–1404.
- 854 AGÜERO M., FERNÁNDEZ J., ROMERO L., SANCHEZ C., ARIAS M. & SÁNCHEZ-VIZCAÍNO J.M. (2003). Highly sensitive PCR assay for
855 the routine diagnosis of African swine fever virus in clinical samples, *J. Clin. Microbiol.*, **41**, 4431–4434.
- 856 AGÜERO M., FERNÁNDEZ J., ROMERO L., ZAMORA M.J., SANCHEZ C., BELÁK S., ARIAS M. & SÁNCHEZ-VIZCAÍNO J.M. (2004). A highly
857 sensitive and specific gel-based multiplex RT-PCR assay for the simultaneous and differential diagnosis of African swine
858 fever and Classical swine fever. *Vet. Res.*, **35**, 1–13.

- 859 ALEJO A., MATAMOROS T., GUERRA M. & ANDRÉS G. (2018). A Proteomic Atlas of the African Swine Fever Virus Particle. *J.*
860 *Virology*, **92**, pii: e01293-18. doi: 10.1128/JVI.01293-18.
- 861 BARASONA J.A., GALLARDO C., CADENAS-FERNÁNDEZ E., JURADO C., RIVERA B., RODRÍGUEZ-BERTOS A., ARIAS M. & SÁNCHEZ-
862 VIZCAÍNO J.M. (2019). First oral vaccination of Eurasian wild boar against African swine fever virus genotype II. *Front. Vet.*
863 *Sci.*, **6**, 137. [https://doi: 10.3389/fvets.2019.00137](https://doi.org/10.3389/fvets.2019.00137).
- 864 BASTO A.P., PORTUGAL R.S., NIX R.J., CARTAXEIRO C., BOINAS F., DIXON L.K., LEITAO A. & MARTINS C. (2006). Development of
865 a nested PCR and its internal control for the detection of African swine fever virus (ASFV) in *Ornithodoros erraticus*. *Arch.*
866 *Virology*, **151**, 819–826
- 867 BISHOP R.P., FLEISCHAUER C., DE VILLIERS E.P., OKOTH E.A., ARIAS M., GALLARDO C. & UPTON C. (2015). Comparative analysis
868 of the complete genome sequences of Kenyan African swine fever virus isolates within p72 genotypes IX and X. *Virus Genes*,
869 **50**, 303–309.
- 870 BORCA M.V., RAI A., RAMÍREZ-MEDINA E., SILVA E., VELÁZQUEZ-SALINAS L., VUONO E., PRUITT S., ESPINOZA N. & GLADUE D.P.
871 (2021). A Cell Culture-Adapted Vaccine Virus against the Current African Swine Fever Virus Pandemic Strain. *J. Virology*, **95**,
872 e0012321. [https://doi: 10.1128/JVI.00123-21](https://doi.org/10.1128/JVI.00123-21).
- 873 BORCA M.V., RAMÍREZ-MEDINA E., ESPINOZA N., RAI A., SPINARD E., VELÁZQUEZ-SALINAS L., VALLADARES A., SILVA E., BURTON L.,
874 MEYERS A., CLARK J., WU P., GAY C.G. & GLADUE D.P. (2024). Deletion of the EP402R Gene from the Genome of African
875 Swine Fever Vaccine Strain ASFV-G-Δ1177L Provides the Potential Capability of Differentiating between Infected and
876 Vaccinated Animals. *Viruses*, **16**, 376. doi: 10.3390/v16030376.
- 877 BOSHOF C.I., BASTOS A.D., GERBER L.J. & VOSLOO W. (2007). Genetic characterisation of African swine fever viruses from
878 outbreaks in southern Africa (1973–1999). *Vet. Microbiology*, **121**, 45–55.
- 879 BOURRY O., HUTET E., LE DIMNA M., LUCAS P., BLANCHARD Y., CHASTAGNER A., PABOEUF F. & LE POTIER M.F. (2022). Oronasal
880 or Intramuscular Immunization with a Thermo-Attenuated ASFV Strain Provides Full Clinical Protection against Georgia
881 2007/1 Challenge. *Viruses*, **14**, 2777. doi: 10.3390/v14122777
- 882 BRAKE D.A. (2022). African Swine Fever Modified Live Vaccine Candidates: Transitioning from Discovery to Product
883 Development through Harmonized Standards and Guidelines. *Viruses*, **14**, 2619. doi: 10.3390/v14122619
- 884 CADENAS-FERNÁNDEZ E., SÁNCHEZ-VIZCAÍNO J.M., KOSOWSKA A., RIVERA B., MAYORAL-ALEGRE F., RODRÍGUEZ-BERTOS A., YAO
885 J., BRAY J., LOKHANDWALA S., MWANGI W. & BARASONA J.A. (2020). Adenovirus-vectored African Swine Fever Virus Antigens
886 Cocktail Is Not Protective against Virulent Arm07 Isolate in Eurasian Wild Boar. *Pathogens*, **9**, 171. doi:
887 10.3390/pathogens9030171.
- 888 CHAPMAN D.A., DARBY A.C., DA SILVA M., UPTON C., RADFORD A.D. & DIXON L.K. (2011). Genomic analysis of highly virulent
889 Georgia 2007/1 isolate of African swine fever virus. *Emerg. Infect. Dis.*, **17**, 599–605.
- 890 CHEN W., ZHAO D., HE X., LIU R., WANG Z., ZHANG X., LI F., SHAN D., CHEN H., ZHANG J., WANG L., WEN Z., WANG X., GUAN Y.,
891 LIU J. & BU Z. (2020). A seven-gene-deleted African swine fever virus is safe and effective as a live attenuated vaccine in
892 pigs. *Sci. China Life Sci.*, **63**, 623. [https://doi: 10.1007/s11427-020-1657-9](https://doi.org/10.1007/s11427-020-1657-9).
- 893 COSTARD S., MUR L., LUBROTH J., SANCHEZ-VIZCAINO J.M. & PFEIFFER D.U. (2013). Epidemiology of African swine fever virus.
894 *Virus Res.*, **173**, 191–197.
- 895 DE LEÓN P., BUSTOS M.J. & CARRASCOSA A.L. (2013). Laboratory methods to study African swine fever virus. *Virus Res.*, **173**,
896 168–179.
- 897 DE VILLIER E.P., GALLARDO C., ARIAS M., DA SILVA M., UPTON C., MARTIN R. & BISHOP R.P. (2010). Phylogenomic analysis of 11
898 complete African swine fever virus genome sequences. *Virology*, **400**, 128–136.
- 899 DIXON L.K., ESCRIBANO J.M., MARTINS C., ROCK D.L., SALAS M.L. & WILKINSON P.J. (2005). *In: Virus Taxonomy, VIIIth Report*
900 *of the ICTV, Fauquet C.M., Mayo M.A., Maniloff J, Desselberger U. & Ball L.A., eds. Elsevier/Academic Press, London, UK,*
901 *135–143.*
- 902 ESCRIBANO J.M., PASTOR M.J. & SANCHEZ VIZCAINO J.M. (1989). Antibodies to bovine serum albumin in swine sera: implications
903 for false positive reactions in the sero diagnosis of African swine fever. *Am. J. Vet. Res.*, **50**, 1118–1122.
- 904 FERNÁNDEZ-PACHECO P., NIETO R., SIMÓN A., GARCÍA CASTEY T.A., MARTÍN E., ARIAS M. & GALLARDO C. (2016). Comparative
905 evaluation of the performance of six ELISA tests for the detection of antibodies against African swine fever virus (ASFV).

-
- 906 EPIZONE 10th Annual Meeting, Madrid, Spain, 27–29 September 2016, p. [https://www.epizone-](https://www.epizone-eu.net/en/Home/Downloads.htm)
907 [eu.net/en/Home/Downloads.htm](https://www.epizone-eu.net/en/Home/Downloads.htm)
- 908 FERNÁNDEZ-PINERO J., GALLARDO C., ELIZALDE M., RASMUSSEN T.B., STAHL K., LOEFFEN W., BLOME S., BATTEN C., CROOKE H.,
909 LE POTIER M.F., UTTENTHAL Å., LEBLANC N., ALBINA E., KOWALCZYK A., MARKOWSKA-DANIEL I., TIGNON M., DE MIA G.M.,
910 GIAMMARIOLI M., ARIAS M. & HOFFMANN B. (2010). EPIZONE ring trial on ASFV real-time PCR. Annual Meeting of National
911 African swine fever Laboratories, 18 May 2010, Pulawy, Poland.
- 912 FERNÁNDEZ-PINERO J., GALLARDO C., ELIZALDE M., ROBLES A., GÓMEZ C., BISHOP R., HEATH L., COUACY-HYMAN E., FASINA F.O.,
913 PELAYO V., SOLER A & ARIAS M. (2013). Molecular diagnosis of African Swine Fever by a new real-time PCR using universal
914 probe library. *Transbound. Emerg. Dis.*, **60**, 48–58.
- 915 FORTH J.H., CALVELAGE S., FISCHER M., HELLERT J., SEHL-EWERT J., ROSZYK H., DEUTSCHMANN P., REICHOLD A., LANGE M.,
916 THULKE H.-H., SAUTER-LOUIS C., HÖPER D., MANDYHRA S., SAPACHOVA M., BEER M. & BLOME S. (2023). African swine fever virus
917 - variants on the rise. *Emerg. Microbes infect.*, **12**, 2146537.
- 918 GALLARDO C., FERNÁNDEZ-PINERO J., PELAYO V., GAZAEV I., MARKOWSKA-DANIEL I., PRIDOTKAS G., NIETO R., FERNÁNDEZ-
919 PACHECO P., BOKHAN S., NEVOLKO O., DROZHZE Z., PÉREZ C., SOLER A., KOLVASOV D. & ARIAS M. (2014). Genetic variation
920 among African swine fever genotype II viruses, eastern and central Europe. *Emerg. Infect. Dis.*, **20**, 1544–1547.
- 921 GALLARDO C., MWAENGO D.M., MACHARIA J.M., ARIAS M., TARACHA E.A., SOLER A., OKOTH E., MARTÍN E., KASITI J. & BISHOP R.P.
922 (2009). Enhanced discrimination of African swine fever virus isolates through nucleotide sequencing of the p54, p72, and
923 pB602L (CVR) genes. *Virus Genes*, **38** 85–95.
- 924 GALLARDO C., NIETO R., SOLER A., PELAYO V., FERNÁNDEZ-PINERO J., MARKOWSKA-DANIEL I., PRIDOTKAS G., NURMOJA I., GRANTA
925 R., SIMÓN A., PÉREZ C., MARTÍN E., FERNÁNDEZ-PACHECO P. & ARIAS M. (2015b). Assessment of African swine fever diagnostic
926 techniques as a response to the epidemic outbreaks in Eastern European Union countries: How to improve surveillance and
927 control programs. *J. Clin. Microbiol.*, **53**, 2555–2565.
- 928 GALLARDO C., SOLER A., NIETO R., CARRASCOSA A.L., DE MIA G.M., BISHOP R.P., MARTINS C., FASINA F.O., COUACY-HYMAN E.,
929 HEATH L., PELAYO V., MARTIN E., SIMON A., MARTIN R., OKURUT A.R., LEKOLOL I., OKOTH E. & ARIAS M. (2013). Comparative
930 evaluation of novel African swine fever virus (ASF) antibody detection techniques derived from specific ASF viral genotypes
931 with the OIE internationally prescribed serological tests. *Vet. Microbiol.*, **162**, 32–43.
- 932 GALLARDO C., SOLER A., NIETO R., SÁNCHEZ M.A.S., MARTINS E., PELAYO V., CARRASCOSA A., REVILLA Y., SIMON A., BRIONES V.,
933 SÁNCHEZ-VIZCAÍNO J.M. & ARIAS M. (2015a). Experimental Transmission of African Swine Fever (ASF) Low Virulent Isolate
934 NH/P68 by Surviving Pigs. *Transbound. Emerg. Dis.*, **62**, 612–622.
- 935 GLADUE D.P. & BORCA M.V. (2022). Recombinant ASF Live Attenuated Virus Strains as Experimental Vaccine Candidates.
936 *Viruses*, **14**, 878. <http://doi:10.3390/v14050878>.
- 937 GLADUE D.P., RAMIREZ-MEDINA E., VUONO E., SILVA E., RAI A., PRUITT S., ESPINOZA N., VELAZQUEZ-SALINAS L. & BORCA M.V.
938 (2021). Deletion of the A137R Gene from the Pandemic Strain of African Swine Fever Virus Attenuates the Strain and Offers
939 Protection against the Virulent Pandemic Virus. *J. Virol.*, **95** (21):e01113921. doi: 10.1128/JVI.011139-21. Epub 2021 Aug 18.
940 PMID: 34406865; PMCID: PMC8513468.
- 941 HAINES F.J., HOFMANN M.A., KING D.P., DREW T.W. & CROOKE H.R. (2013). Development and validation of a multiplex, real-
942 time RT PCR assay for the simultaneous detection of classical and African swine fever viruses. *PLoS One*, **8** (7).
- 943 HAYES B.H., ANDRAUD M., SALAZAR L.G., ROSE N. & VERGNE T. (2021). Mechanistic modelling of African swine fever: A
944 systematic review. *Prev. Vet. Med.*, **191**, 105358. doi: 10.1016/j.prevetmed.2021.105358.
- 945 KITAMURA T., MASUJIN K., YAMAZOE R., KAMEYAMA K.I., WATANABE M., IKEZAWA M., YAMADA M. & KOKUHO T. (2023). A
946 Spontaneously Occurring African Swine Fever Virus with 11 Gene Deletions Partially Protects Pigs Challenged with the
947 Parental Strain. *Viruses*, **15**, 311. doi: 10.3390/v15020311. PMID: 36851524; PMCID: PMC9966947.
- 948 KING K., CHAPMAN D., ARGILAGUET J.M., FISHBOURNE E., HUTET E., CARIOLET R., HUTCHINGS G., OURA C.A., NETHERTON C.,
949 MOFFAT K., TAYLOR G., LE POTIER M.-F., DIXON L.K. & TAKAMATSU H.-H. (2011). Protection of European domestic pigs from
950 virulent African isolates of African swine fever virus by experimental immunisation. *Vaccine*, **29**, 4593–4600. [https://doi:](https://doi:10.1016/j.vaccine.2011.04.052)
951 [10.1016/j.vaccine.2011.04.052](https://doi:10.1016/j.vaccine.2011.04.052)
- 952 KING D.P., REID S.M., HUTCHINGS G.H., GRIERSON S.S., WILKINSON P.J., DIXON L.K., BASTOS A.D.S. & DREW T.W. (2003).
953 Development of a TaqMan® PCR assay with internal amplification control for the detection of African swine fever virus. *J.*
954 *Virol. Methods*, **107**, 53–61.
-

- 955 LIU Y., XIE Z., LI Y., SONG Y., DI D., LIU J., GONG L., CHEN Z., WU J., YE Z., LIU J., YU W., LV L., ZHONG Q., TIAN C., SONG Q.,
956 WANG H. & CHEN H. (2023). Evaluation of an I177L gene-based five-gene-deleted African swine fever virus as a live
957 attenuated vaccine in pigs. *Emerg. Microbes Infect.*, **12**, 2148560. doi: 10.1080/22221751.2022.2148560. PMID: 36378022;
958 PMCID: PMC9769145.
- 959 LUBISI B.A., BASTOS A.D., DWARKA R.M. & VOSLOO W. (2005). Molecular epidemiology of African swine fever in East Africa.
960 *Arch Virol.*, **150**, 2439–2452.
- 961 MASUJIN K., KITAMURA K., KAMEYAMA K.I., OKADERA K., NISHI T., TAKENOUCI T., KITANI H. & KOKUHO T. (2021). An immortalized
962 porcine macrophage cell line competent for the isolation of African swine fever virus. *Sci. Rep.*, **11**, 4759.
963 doi.org/10.1038/s41598-021-84237-2.
- 964 MONTEAGUDO P.L., LACASTA A., LOPEZ L., BOSCH J., COLLADO J., PINA-PEDRERO S., CORREA-FIZ F., ACCENSI F., NAVAS M.J.,
965 VIDAL E., BUSTOS M.J., RODRÍGUEZ J.M., GALLEI A., NIKOLIN V., SALAS M.L. & RODRÍGUEZ F. (2017). BA71deltaCD2: A new
966 recombinant live attenuated African swine fever virus with cross-protective capabilities. *J. Virol.*, **91**, e1058–e1117.
967 https://doi: 10.1128/JVI.01058-17.
- 968 NCBI (NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION) (2020). <https://www.ncbi.nlm.nih.gov/nuccore/FR682468>.
969 Accessed 4/4/2023.
- 970 NIX R.J., GALLARDO C., HUTCHINGS G., BLANCO E. & DIXON L.K. (2006). Molecular epidemiology of African swine fever virus
971 studied by analysis of four variable genome regions. *Arch. Virol.*, **151**, 2475–244.
- 972 O'DONNELL V., HOLINKA L.G., GLADUE D.P., SANFORD B., KRUG P.W., LU X., ARZT J., REESE B., CARRILLO C., RISATTI G.R. &
973 BORCA M.V. (2015). African swine fever virus Georgia isolate harboring deletions of MGF360 and MGF505 genes is
974 attenuated in swine and confers protection against challenge with virulent parental virus. *J. Virol.*, **89**, 6048. [https://doi:](https://doi: 10.1128/JVI.00554-15)
975 10.1128/JVI.00554-15.
- 976 O'DONNELL V., RISATTI G.R., HOLINKA L.G., KRUG P.W., CARLSON J., VELAZQUEZ-SALINAS L., AZZINARO P.A., GLADUE D.P. &
977 BORCA M.V. (2016). Simultaneous Deletion of the 9GL and UK Genes from the African Swine Fever Virus Georgia 2007
978 Isolate Offers In-creased Safety and Protection against Homologous Challenge. *J. Virol.*, **91**, e01760-16. [https://doi:](https://doi: 10.1128/JVI.01760-16)
979 10.1128/JVI.01760-16.
- 980 PASTOR M.J., ARIAS M. & ESCRIBANO J.M. (1990). Comparison of two antigens for use in an enzyme-linked immunosorbent
981 assay to detect African swine fever antibody. *Am. J. Vet. Res.*, **51**, 1540–1543.
- 982 PASTOR M.J., LAVIADA M.D., SANCHEZ VIZCAINO J.M. & ESCRIBANO J.M. (1989). Detection of African swine fever virus antibodies
983 by immunoblotting assay. *Can. J. Vet. Res.*, **53**, 105–107.
- 984 PENRITH M.L., VAN HEERDEN J., HEATH L., ABWORO E.O. & BASTOS A.D.S. (2022). Review of the Pig-Adapted African Swine
985 Fever Viruses in and Outside Africa. *Pathogens*, **11**, 1190. doi: 10.3390/pathogens11101190.
- 986 PÉREZ-NÚÑEZ D., SUNWOO S.-Y., GARCÍA-BELMONTE R., KIM C., VIGARA-ASTILLERO G., RIERA E., KIM D.-M., JEONG J., TARK D.,
987 KO Y.-S., YOU Y.-K. & REVILLA Y. (2022). Recombinant African Swine Fever Virus Arm/07/CBM/c2 Lacking CD2v and A238L
988 Is Attenuated and Protects Pigs against Virulent Korean Paju Strain. *Vaccines*, **10**, 1992.
989 <https://doi.org/10.3390/vaccines10121992>.
- 990 PORTUGAL R., COELHO J., HÖPER D., LITTLE N.S., SMITHSON C., UPTON C., MARTINS C., LEITÃO A. & KEIL G.M. (2015). Related
991 strains of African swine fever virus with different virulence: genome comparison and analysis. *J. Gen. Virol.*, **96** (Pt 2), 408–
992 419.
- 993 PORTUGAL R., GOATLEY L.C., HUSMANN R., ZUCKERMANN F.A. & DIXON L.K. (2020). A porcine macrophage cell line that supports
994 high levels of replication of OURT88/3, an attenuated strain of African swine fever virus. *Emerg. Microbes Infect.*, **9**, 1245–
995 1253. doi.org/10.1080/22221751.2020.1772675.
- 996 QUEMBO C.J., JORI F., VOSLOO W. & HEATH L. (2018). Genetic characterization of African swine fever virus isolates from soft
997 ticks at the wildlife/domestic interface in Mozambique and identification of a novel genotype. *Transbound. Emerg. Dis.*, **65**,
998 420–431.
- 999 SÁNCHEZ-VIZCAÍNO J.M. (1987). African swine fever diagnosis. In: African Swine Fever, Becker Y., ed. Martinus Nijhoff,
1000 Boston, USA, 63–71.
- 1001 SÁNCHEZ-VIZCAÍNO J.M. & ARIAS M. (2012). African swine fever. In: Diseases of Swine, tenth Edition, Straw B., D'Allaire S.,
1002 Mengeling W., Taylor D., eds. Iowa State University, USA, pp.396–404.

1003 SÁNCHEZ-VIZCAÍNO J.M., MARTINEZ-LÓPEZ B., MARTINEZ-AVILÉS M., MARTINS C., BOINAS B., VIAL L., MICHAUD V., JORI F., ETTER
1004 E., ALBINA E. & ROGER F. (2009). Scientific Review on African swine fever. CFP/EFSA/AHAW/2007/02, pp: 1–141.

1005 SÁNCHEZ-VIZCAÍNO J.M., MUR L., GOMEZ-VILLAMANDOS J.C. & CARRASCO L. (2015). An update on the epidemiology and
1006 pathology of African swine fever. *J. Comp. Pathol.*, **152**, 9–21.

1007 TEKLUE T., WANG T., LUO Y., HU R., SUN Y. & QIU H.J. (2020). Generation and Evaluation of an African Swine Fever Virus
1008 Mutant with Deletion of the CD2v and UK Genes. *Vaccines*, **8**, 763. <https://doi:10.3390/vaccines8040763>.

1009 TIGNON M., GALLARDO C., ISCARO C., HUTET E., VAN DER STEDE Y., KOLBASOV D., DE MIA G.M., LE POTIER M.F., BISHOP R.P.,
1010 ARIAS M. & KOENEN F. (2011). Development and inter-laboratory validation study of an improved new real-time PCR assay
1011 with internal control for detection and laboratory diagnosis of African swine fever virus. *J. Virol. Methods*, **178**, 161–167.

1012 VELAZQUEZ-SALINAS L., RAMIREZ-MEDINA E., RAI A., PRUITT S., VUONO E.A., ESPINOZA N., GLADUE D.P. & BORCA M.V. (2021).
1013 Development Real-Time PCR Assays to Genetically Differentiate Vaccinated Pigs from Infected Pigs with the Eurasian Strain
1014 of African Swine Fever Virus. *Front. Vet. Sci.* **8**, 768869. doi: 10.3389/fvets.2021.768869.

1015 WANG N., ZHAO D., WANG J., ZHANG Y., WANG M., GAO Y., LI F., WANG J., BU Z., RAO Z. & WANG X. (2019). Architecture of
1016 African swine fever virus and implications for viral assembly. *Science*, **366**, 640–644. doi: 10.1126/science.aaz1439. Epub
1017 2019 Oct 17.

1018 ZHANG Y., KE J., ZHANG J., YANG J., YUE H., ZHOU X., QI Y., ZHU R., MIAO F. & LI Q. (2021). African Swine Fever Virus Bearing
1019 an I226R Gene Deletion Elicits Robust Immunity in Pigs to African Swine Fever. *J. Virol.*, **95**, e0119921. [https://doi:
1020 10.1128/JVI.01199-21](https://doi:10.1128/JVI.01199-21).

1021 ZHAO D., SUN E., HUANG L., DING L., ZHU Y., ZHANG J., SHEN D., ZHANG X., ZHANG Z., REN T., WANG W., LI F., HE X. & BU Z.
1022 (2023). Highly lethal genotype I and II recombinant African swine fever viruses detected in pigs. *Nat. Commun.*, **14**, 3096.

1023 *
1024 * *

1025 **NB:** There are WOAHA Reference Laboratories for African swine fever
1026 (please consult the WOAHA Web site:
1027 <https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>).
1028 Please contact the WOAHA Reference Laboratories for any further information on
1029 diagnostic tests and reagents for African swine fever

1030 **NB:** FIRST ADOPTED IN 1990. MOST RECENT UPDATES ADOPTED IN 2021.

© **Organización Mundial de Sanidad Animal (OMSA), 2024**

Este documento ha sido elaborado por especialistas convocados por la Organización Mundial de Sanidad Animal (OMSA). A la espera de su adopción por la Asamblea Mundial de Delegados, las opiniones aquí expresadas sólo pueden interpretarse como las de dichos especialistas.

Todas las publicaciones de la OMSA están protegidas por la legislación internacional sobre derechos de autor. Pueden copiarse, reproducirse, traducirse, adaptarse o publicarse extractos en revistas, documentos, libros, medios electrónicos y cualquier otro medio destinado al público, con fines informativos, educativos o comerciales, siempre que se cuente con la autorización previa por escrito de la OMSA.

Las denominaciones empleadas en esta publicación y la forma en que aparecen presentados los datos que contiene no implican, por parte de la OMSA, juicio alguno sobre la condición jurídica de países, territorios, ciudades o zonas, o de sus autoridades, ni respecto del trazado de sus fronteras o límites.

Las opiniones expresadas en los artículos firmados son responsabilidad exclusiva de sus autores. La mención de determinadas sociedades mercantiles o de nombres comerciales de ciertos productos, estén o no patentados, no implica que la OMSA los apruebe o recomiende con preferencia a otros análogos.
